data_2mhg_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mhg _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.3 p . . . . . 0 C--O 1.233 0.223 0 CA-C-O 121.525 0.679 . . . . 75.25 111.333 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 150.45 -76.48 0.24 Allowed Glycine 0 N--CA 1.443 -0.879 0 N-CA-C 110.521 -1.032 . . . . 72.030000000000001 110.521 -175.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 56.35 75.5 0.57 Allowed Pre-proline 0 N--CA 1.469 0.492 0 O-C-N 124.185 0.58 . . . . 70.5 112.473 173.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.663 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 71.6 Cg_endo -87.0 116.53 1.27 Allowed 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.507 2.138 . . . . 73.299999999999997 112.544 177.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -139.21 167.21 22.58 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.485 -0.561 . . . . 64.049999999999997 109.485 176.074 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.53 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 11.3 p -114.46 124.03 70.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.505 0.669 . . . . 71.329999999999998 111.502 -175.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.7 m -89.83 106.14 18.27 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.6 -0.727 . . . . 74.450000000000003 109.249 174.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.439 HG21 ' HG2' ' A' ' 24' ' ' GLN . 57.6 mt -93.89 107.84 19.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 120.908 0.385 . . . . 71.230000000000004 111.0 -175.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 4.8 mtm180 -116.13 174.77 5.87 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.225 -0.443 . . . . 75.109999999999999 110.537 177.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -129.98 104.87 7.61 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.782 -0.644 . . . . 65.109999999999999 109.823 175.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -97.32 83.56 3.31 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.563 -0.744 . . . . 72.510000000000005 109.338 -177.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.72 -115.17 4.12 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.429 -0.891 . . . . 73.310000000000002 111.413 -176.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.978 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 23.0 m-20 -110.73 24.95 12.31 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.099 0.476 . . . . 72.5 110.267 178.548 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.5 pttm -132.3 118.52 19.56 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 121.297 0.57 . . . . 71.340000000000003 110.782 178.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.422 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 35.8 m -80.06 101.42 8.71 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.421 -0.809 . . . . 54.43 109.374 177.047 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.528 HG12 HG23 ' A' ' 37' ' ' VAL . 16.4 mt -98.53 113.31 32.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.236 0.541 . . . . 72.25 110.388 -174.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.53 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 21.4 mt-30 -96.5 110.18 22.62 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.404 -0.816 . . . . 74.129999999999995 110.552 -178.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 30.0 mt-10 -84.3 103.24 13.32 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.681 -0.691 . . . . 74.140000000000001 110.828 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.41 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 85.2 m-85 -83.4 97.48 8.97 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.521 -0.548 . . . . 73.230000000000004 109.521 174.251 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 94.0 mtt180 -110.44 129.59 55.74 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.869 -0.605 . . . . 72.409999999999997 109.744 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.849 HG12 ' H ' ' A' ' 29' ' ' ASN . 2.7 p -91.98 -82.7 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 C-N-CA 120.322 -0.551 . . . . 65.239999999999995 109.812 175.182 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.849 ' H ' HG12 ' A' ' 28' ' ' VAL . 5.6 t-20 -123.36 77.7 1.51 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.023 0.439 . . . . 73.5 110.325 -176.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 70.72 20.51 77.46 Favored Glycine 0 N--CA 1.448 -0.528 0 CA-C-N 115.456 -0.793 . . . . 73.319999999999993 113.144 177.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.452 ' CD2' HG22 ' B' ' 128' ' ' VAL . 32.2 t80 -148.12 129.3 14.62 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.125 0.488 . . . . 73.450000000000003 110.42 177.653 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.947 HD12 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -69.51 116.69 10.21 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 114.945 -1.025 . . . . 75.219999999999999 109.174 175.427 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . 0.41 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 36.7 p90 -105.1 -20.49 13.5 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.299 -0.56 . . . . 73.329999999999998 111.562 -178.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -157.43 143.41 17.61 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.947 0.403 . . . . 72.349999999999994 111.13 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.947 HG13 HD12 ' A' ' 32' ' ' LEU . 72.4 mt -120.86 120.25 61.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.171 -0.468 . . . . 71.329999999999998 110.148 175.377 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.403 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 86.6 tttt -103.04 97.78 7.83 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.849 -0.797 . . . . 73.010000000000005 108.849 171.103 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.528 HG23 HG12 ' A' ' 23' ' ' ILE . 2.1 p -100.2 128.61 51.99 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 CA-C-N 116.112 -0.495 . . . . 75.319999999999993 110.18 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.562 HG21 ' HB3' ' A' ' 44' ' ' PRO . 34.7 t -107.93 87.16 3.54 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 115.428 -0.805 . . . . 73.319999999999993 109.646 178.417 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 66.9 Cg_endo -83.48 132.9 6.01 Favored 'Trans proline' 0 N--CA 1.448 -1.171 0 C-N-CA 122.206 1.937 . . . . 73.239999999999995 111.905 178.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.978 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 58.6 mtpt -63.72 -24.0 67.6 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.648 -0.705 . . . . 71.329999999999998 109.93 176.35 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 59.3 m-70 -120.07 85.11 2.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.367 -0.833 . . . . 74.510000000000005 109.671 177.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 145.04 -20.07 1.95 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.286 -0.959 . . . . 74.349999999999994 113.205 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 94.0 mttt 73.42 144.42 0.1 Allowed Pre-proline 0 N--CA 1.474 0.743 0 C-N-CA 123.153 0.581 . . . . 74.239999999999995 111.373 178.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.562 ' HB3' HG21 ' A' ' 38' ' ' VAL . 41.7 Cg_endo -67.8 156.43 65.98 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.803 2.335 . . . . 75.549999999999997 113.361 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.412 ' CE1' HG11 ' A' ' 37' ' ' VAL . 6.8 p90 -165.3 167.16 18.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.581 -0.736 . . . . 73.310000000000002 109.516 178.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.55 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 64.4 m-85 -100.24 134.19 43.54 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.871 0.367 . . . . 74.409999999999997 110.591 176.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.421 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 20.2 tp -118.87 102.93 9.16 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.264 -0.643 . . . . 74.219999999999999 109.264 176.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.4 t -96.85 135.17 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.802 0.334 . . . . 72.219999999999999 111.663 -173.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.9 111.13 6.89 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.862 -0.608 . . . . 74.329999999999998 109.816 178.521 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.54 168.51 16.14 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.446 -0.343 . . . . 74.340000000000003 110.739 178.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -64.91 137.25 57.64 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.321 -0.4 . . . . 72.129999999999995 110.084 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 87.22 122.3 1.58 Allowed Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.705 -0.76 . . . . 74.129999999999995 111.239 -175.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.5 t -85.51 36.62 0.65 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.207 0.527 . . . . 74.109999999999999 110.277 -175.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -66.04 -48.44 71.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.504 -0.771 . . . . 75.450000000000003 110.753 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 134.46 49.75 0.08 OUTLIER Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.861 -0.685 . . . . 53.009999999999998 111.572 -177.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.81 HD22 ' HB3' ' A' ' 66' ' ' LEU . 41.1 t-20 -136.54 134.27 37.33 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.717 -0.475 . . . . 71.239999999999995 109.717 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.477 ' HD1' HG22 ' A' ' 72' ' ' ILE . 52.5 m-85 -123.53 159.71 28.56 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.139 -0.482 . . . . 74.340000000000003 110.784 -179.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 47.9 mm -117.49 129.96 73.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 109.501 -0.555 . . . . 73.140000000000001 109.501 175.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.926 ' HG3' HG13 ' A' ' 67' ' ' ILE . 18.0 mtm180 -95.79 153.63 17.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.827 0.346 . . . . 71.219999999999999 111.198 -176.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.55 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 59.5 p -71.53 -21.25 61.93 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.788 -0.642 . . . . 73.040000000000006 109.512 172.379 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -60.7 -44.0 97.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 114.833 -1.076 . . . . 73.030000000000001 110.858 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 9.8 tt0 -160.1 98.92 1.45 Allowed Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 115.8 -0.636 . . . . 75.219999999999999 109.908 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -73.03 -6.8 19.62 Favored 'Trans proline' 0 C--O 1.23 0.099 0 C-N-CA 122.777 2.318 . . . . 73.150000000000006 111.659 177.56 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -85.11 1.62 47.09 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.961 -1.018 . . . . 73.319999999999993 110.162 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 62.0 tttp -129.03 135.91 49.58 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.153 -0.476 . . . . 75.5 110.577 -177.651 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.81 ' HB3' HD22 ' A' ' 56' ' ' ASN . 5.0 mp -90.34 132.18 35.72 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.705 -0.85 . . . . 63.109999999999999 108.705 176.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.926 HG13 ' HG3' ' A' ' 59' ' ' ARG . 45.2 mm -106.15 110.52 64.05 Favored Pre-proline 0 C--N 1.317 -0.81 0 CA-C-O 121.021 0.438 . . . . 71.230000000000004 111.362 -172.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.525 ' O ' HG23 ' A' ' 72' ' ' ILE . 73.0 Cg_endo -76.44 -179.93 5.79 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 123.337 2.691 . . . . 74.409999999999997 112.297 177.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . 1.013 ' HA ' HG12 ' A' ' 72' ' ' ILE . 27.4 mt-30 -71.38 -32.69 68.76 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 113.489 0.922 . . . . 64.400000000000006 113.489 -169.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 25.2 p90 -70.13 -15.9 63.03 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.22 -0.592 . . . . 75.299999999999997 109.961 176.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.646 ' HB3' HG21 ' A' ' 67' ' ' ILE . 3.9 mm-40 -101.16 -30.31 11.63 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.776 -0.647 . . . . 75.349999999999994 111.186 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 1.013 HG12 ' HA ' ' A' ' 69' ' ' GLN . 44.8 pt -72.43 -32.77 43.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 121.099 0.476 . . . . 75.019999999999996 110.163 177.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -101.77 39.94 1.39 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.946 -0.57 . . . . 64.430000000000007 110.125 174.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.3 t -74.76 -16.12 60.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.355 -0.839 . . . . 73.519999999999996 109.762 179.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 8.6 p-90 . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 115.944 -0.571 . . . . 70.409999999999997 110.661 175.449 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 4.3 p . . . . . 0 N--CA 1.452 -0.342 0 CA-C-O 120.796 0.331 . . . . 73.109999999999999 110.473 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 100.43 84.45 1.8 Allowed Glycine 0 CA--C 1.504 -0.651 0 N-CA-C 110.992 -0.843 . . . . 73.400000000000006 110.992 -176.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -118.27 92.6 43.36 Favored Pre-proline 0 C--N 1.315 -0.934 0 CA-C-N 114.959 -0.621 . . . . 72.150000000000006 110.258 -174.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.83 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 40.5 Cg_endo -74.08 88.1 1.13 Allowed 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 121.781 1.654 . . . . 72.310000000000002 111.486 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -104.64 147.11 28.01 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.889 -1.05 . . . . 75.409999999999997 109.785 179.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.653 HG21 ' HB3' ' B' ' 124' ' ' GLN . 9.9 p -104.05 127.55 58.16 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-O 121.316 0.579 . . . . 74.010000000000005 111.073 -177.757 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 114' ' ' THR . . . . . 0.658 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.4 m -83.9 102.65 12.55 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.607 -0.724 . . . . 71.25 109.364 175.594 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.1 mt -92.77 106.45 17.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.279 -0.419 . . . . 73.319999999999993 110.909 -174.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . 0.436 ' HG2' ' O ' ' B' ' 123' ' ' ILE . 13.3 ptm180 -118.25 171.47 8.1 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.335 -0.617 . . . . 73.109999999999999 109.335 176.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 89.7 mt-30 -139.55 113.49 8.73 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.32 0.581 . . . . 74.430000000000007 110.825 -179.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 17.9 mm-40 -101.26 97.73 8.2 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.335 -0.848 . . . . 71.219999999999999 109.569 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 70.24 -95.67 0.52 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.886 -0.673 . . . . 63.32 111.973 -177.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . 0.792 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 9.7 m-20 -127.54 26.71 5.91 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.849 0.357 . . . . 73.219999999999999 110.538 178.463 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.513 ' HE3' ' HE3' ' B' ' 175' ' ' TRP . 23.1 pttm -129.3 119.31 23.72 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.233 0.54 . . . . 64.109999999999999 110.88 175.113 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 122' ' ' THR . . . . . 0.802 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 28.0 m -80.3 105.28 11.44 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.576 -0.738 . . . . 73.420000000000002 109.53 177.387 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . 0.504 HD12 ' HE2' ' B' ' 121' ' ' LYS . 24.2 mt -96.3 106.38 18.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-O 121.27 0.557 . . . . 75.209999999999994 110.097 -177.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.653 ' HB3' HG21 ' B' ' 113' ' ' VAL . 26.1 mt-30 -97.51 103.87 15.85 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.451 -0.795 . . . . 64.450000000000003 110.892 -176.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . 0.658 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 48.3 mt-10 -84.97 102.55 13.25 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.788 -0.642 . . . . 64.099999999999994 111.049 -179.214 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . 0.447 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 39.2 m-85 -78.38 107.09 10.75 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.931 0.396 . . . . 73.420000000000002 110.67 178.115 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . 0.403 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 50.2 mtt180 -125.11 125.13 43.27 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.009 -0.542 . . . . 75.450000000000003 109.787 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.83 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 7.3 p -90.05 -25.6 5.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.202 0.525 . . . . 74.420000000000002 111.081 -174.815 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -165.94 56.35 0.1 Allowed 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.034 -0.728 . . . . 72.219999999999999 109.034 -179.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.68 -34.55 4.31 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.284 -0.871 . . . . 64.430000000000007 112.915 -178.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -94.54 133.47 38.13 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.204 0.526 . . . . 73.109999999999999 110.856 -173.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.689 HD12 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -73.95 125.82 29.08 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.983 -1.008 . . . . 73.150000000000006 110.17 179.289 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . 0.447 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 37.0 p90 -117.18 -16.97 10.35 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.617 -0.433 . . . . 73.409999999999997 111.384 177.457 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . 0.429 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -161.79 146.51 12.99 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.668 0.271 . . . . 75.099999999999994 110.87 178.029 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.689 HG13 HD12 ' B' ' 132' ' ' LEU . 71.1 mt -124.95 115.71 45.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 110.149 -0.315 . . . . 52.130000000000003 110.149 176.552 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.524 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.9 tttt -93.57 105.62 17.65 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.226 -0.657 . . . . 74.019999999999996 109.226 175.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.619 HG12 ' HD3' ' B' ' 139' ' ' PRO . 3.0 t -88.44 130.95 37.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.279 -0.637 . . . . 72.439999999999998 109.279 178.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.802 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 34.0 t -117.4 72.87 7.39 Favored Pre-proline 0 C--N 1.318 -0.795 0 CA-C-O 121.002 0.43 . . . . 71.230000000000004 109.863 173.152 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.619 ' HD3' HG12 ' B' ' 137' ' ' VAL . 44.4 Cg_endo -76.95 126.47 8.74 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.128 1.885 . . . . 71.140000000000001 112.473 176.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . 0.792 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 60.1 mtpt -66.04 -9.4 30.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.192 -0.913 . . . . 75.230000000000004 111.302 -179.046 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -129.92 21.81 5.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.772 -0.649 . . . . 75.420000000000002 110.298 -177.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . 0.491 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . -152.16 -9.21 0.1 OUTLIER Glycine 0 CA--C 1.521 0.416 0 C-N-CA 120.381 -0.914 . . . . 71.230000000000004 113.68 -178.424 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . 0.491 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 67.7 mmtt 75.69 143.98 0.1 Allowed Pre-proline 0 N--CA 1.472 0.67 0 CA-C-O 121.361 0.601 . . . . 73.530000000000001 112.128 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.608 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 59.8 Cg_endo -72.32 134.75 23.36 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 123.162 2.575 . . . . 72.239999999999995 112.887 -176.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -150.51 151.29 32.46 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.89 -0.595 . . . . 73.310000000000002 110.495 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.612 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 93.0 m-85 -89.51 128.1 35.94 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.31 -0.405 . . . . 73.340000000000003 110.103 176.403 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . 0.552 ' HG ' ' CD1' ' B' ' 157' ' ' PHE . 16.0 tp -107.39 98.35 7.99 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.852 -0.796 . . . . 71.439999999999998 108.852 175.01 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 40.8 t -87.87 133.67 29.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.028 -0.533 . . . . 75.25 111.464 -172.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.03 108.13 8.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.803 -0.635 . . . . 70.019999999999996 110.476 178.064 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.12 155.72 33.94 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.876 -0.416 . . . . 60.329999999999998 109.876 173.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -62.31 139.21 58.53 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.885 0.374 . . . . 75.140000000000001 110.803 -177.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . 0.464 ' C ' ' H ' ' B' ' 154' ' ' ASP . . . 87.87 137.14 5.43 Favored Glycine 0 N--CA 1.44 -1.07 0 C-N-CA 120.433 -0.889 . . . . 64.109999999999999 111.689 -178.614 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 14.4 t -75.61 39.58 0.17 Allowed 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.616 0.722 . . . . 75.209999999999994 110.711 178.048 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . 0.464 ' H ' ' C ' ' B' ' 152' ' ' GLY . 21.3 t70 -67.29 -27.18 66.96 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.527 -0.761 . . . . 75.25 110.293 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 99.07 18.33 24.86 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.796 -0.716 . . . . 44.219999999999999 112.185 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . 0.977 HD22 ' HB3' ' B' ' 166' ' ' LEU . 18.5 t-20 -101.13 139.15 37.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.841 0.353 . . . . 71.450000000000003 110.375 -178.26 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . 0.552 ' CD1' ' HG ' ' B' ' 147' ' ' LEU . 29.3 m-85 -127.41 156.88 41.37 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.963 -0.562 . . . . 75.310000000000002 110.404 176.449 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.2 mm -122.69 130.19 74.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.563 -0.532 . . . . 73.129999999999995 109.563 177.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.456 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 11.0 mtm180 -93.3 145.35 24.52 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.818 -0.353 . . . . 75.040000000000006 110.076 179.748 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 160' ' ' SER . . . . . 0.612 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 54.5 p -70.66 -16.71 62.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.26 -0.427 . . . . 64.209999999999994 111.383 -179.307 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -86.35 -25.13 25.54 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.972 0.415 . . . . 75.049999999999997 110.195 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 9.9 tt0 -151.72 79.54 6.46 Favored Pre-proline 0 N--CA 1.451 -0.411 0 CA-C-N 115.919 -0.582 . . . . 74.109999999999999 110.102 -177.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . 0.458 ' CG ' ' HB2' ' A' ' 60' ' ' SER . 16.1 Cg_exo -69.35 -9.57 26.6 Favored 'Trans proline' 0 C--O 1.233 0.247 0 C-N-CA 122.999 2.466 . . . . 74.439999999999998 111.398 177.081 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -78.01 -13.53 59.84 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.89 -1.05 . . . . 74.409999999999997 110.434 178.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 62.4 tttp -110.51 135.29 51.4 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.008 0.432 . . . . 73.519999999999996 110.938 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . 0.977 ' HB3' HD22 ' B' ' 156' ' ' ASN . 5.0 mp -97.85 126.22 43.11 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.616 -0.883 . . . . 70.140000000000001 108.616 175.104 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 51.2 mm -86.88 115.72 63.48 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-O 120.626 0.251 . . . . 73.120000000000005 110.611 -175.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.574 ' O ' HG22 ' B' ' 172' ' ' ILE . 49.3 Cg_endo -69.09 172.23 12.35 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.923 2.415 . . . . 75.439999999999998 112.172 178.61 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -84.49 8.8 15.28 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.926 -0.579 . . . . 71.030000000000001 111.968 -167.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . 0.539 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 31.8 p90 -108.33 -26.82 10.33 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.6 -0.519 . . . . 75.019999999999996 109.6 170.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.539 ' HG2' ' CD1' ' B' ' 170' ' ' TRP . 5.7 mm-40 -86.22 -13.49 46.74 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.932 -0.576 . . . . 60.100000000000001 111.549 -177.044 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.574 HG22 ' O ' ' B' ' 168' ' ' PRO . 24.0 pt -61.15 -27.9 42.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.568 -0.742 . . . . 74.230000000000004 111.554 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -110.15 44.01 1.29 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.299 0.571 . . . . 74.519999999999996 110.341 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 22.8 t -69.02 -22.96 64.03 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.569 -0.741 . . . . 74.439999999999998 110.446 178.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . 0.513 ' HE3' ' HE3' ' B' ' 121' ' ' LYS . 10.2 p-90 . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.383 -0.817 . . . . 70.439999999999998 110.965 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 24.8 m . . . . . 0 N--CA 1.451 -0.388 0 N-CA-C 109.825 -0.435 . . . . 73.209999999999994 109.825 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.476 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 102.93 52.85 0.93 Allowed Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 109.091 -1.604 . . . . 54.409999999999997 109.091 -168.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -88.51 103.49 5.42 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 114.233 -0.984 . . . . 75.140000000000001 109.722 -168.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.868 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 90.6 Cg_endo -87.18 101.36 0.52 Allowed 'Trans proline' 0 N--CA 1.443 -1.468 0 C-N-CA 122.539 2.16 . . . . 72.450000000000003 112.636 -172.649 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.13 149.74 20.96 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 116.067 -0.515 . . . . 74.439999999999998 109.98 -178.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.652 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 13.9 p -106.87 127.58 62.34 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.384 0.612 . . . . 75.540000000000006 110.61 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.463 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 25.3 m -91.77 112.33 24.21 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.833 -0.621 . . . . 71.299999999999997 109.44 176.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.9 mt -95.1 111.49 25.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.153 0.501 . . . . 74.420000000000002 111.54 -174.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 33.7 mmt180 -119.89 156.88 29.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.615 -0.72 . . . . 75.200000000000003 109.798 173.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -127.56 107.59 10.06 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.988 0.423 . . . . 74.25 110.795 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.432 ' HB2' ' HE2' ' A' ' 21' ' ' LYS . 54.9 mm-40 -97.57 81.72 2.98 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.012 -0.54 . . . . 73.230000000000004 109.595 178.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.47 -118.74 5.18 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.602 -0.808 . . . . 63.409999999999997 111.637 -176.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.735 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 42.7 m-20 -101.82 16.88 24.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.437 0.16 . . . . 64.310000000000002 110.962 179.048 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.496 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 23.1 pttm -123.49 122.52 38.43 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.269 0.557 . . . . 63.520000000000003 111.545 -179.261 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 36.2 m -83.73 103.98 13.47 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.273 -0.876 . . . . 65.439999999999998 109.577 174.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 51.0 mt -95.53 109.99 23.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.91 0.386 . . . . 73.129999999999995 110.03 -177.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.652 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 51.6 mt-30 -101.33 119.72 39.18 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.84 -0.618 . . . . 74.439999999999998 111.787 -175.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.463 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 29.0 mt-10 -89.77 99.98 12.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.619 -0.719 . . . . 71.019999999999996 110.36 175.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.43 ' CD2' ' HB3' ' B' ' 151' ' ' ASP . 68.3 m-85 -81.15 101.5 9.69 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.824 -0.436 . . . . 72.5 109.824 175.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 58.6 mtt180 -115.03 129.28 56.67 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.121 -0.49 . . . . 74.140000000000001 110.013 -179.064 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.868 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 2.4 p -90.0 -57.64 4.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-O 120.915 0.388 . . . . 63.310000000000002 111.541 -177.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.501 ' H ' HG12 ' A' ' 28' ' ' VAL . 5.1 t-20 -127.63 50.5 2.02 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 109.007 -0.738 . . . . 74.209999999999994 109.007 -179.246 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 92.42 -29.74 7.47 Favored Glycine 0 N--CA 1.45 -0.39 0 CA-C-N 115.484 -0.78 . . . . 71.200000000000003 112.292 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.556 ' CD2' HG21 ' B' ' 128' ' ' VAL . 57.1 t80 -92.35 134.43 34.92 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.113 0.482 . . . . 70.010000000000005 110.843 -176.247 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.834 HD13 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -72.84 118.81 16.23 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.225 -0.898 . . . . 74.329999999999998 109.965 177.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . 0.406 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 39.5 p90 -104.79 -25.54 12.61 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 120.3 -0.56 . . . . 74.400000000000006 111.263 179.528 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.423 ' O ' ' HB2' ' A' ' 26' ' ' TYR . . . -156.85 137.89 13.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.935 0.397 . . . . 73.219999999999999 111.102 178.622 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.834 HG13 HD13 ' A' ' 32' ' ' LEU . 76.4 mt -110.4 119.79 59.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.093 -0.503 . . . . 75.310000000000002 109.812 175.727 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -102.43 101.28 11.48 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.043 -0.663 . . . . 72.219999999999999 109.535 174.414 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.526 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.4 p -93.48 120.66 43.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 N-CA-C 109.525 -0.546 . . . . 73.420000000000002 109.525 176.361 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.58 HG12 ' HB3' ' A' ' 44' ' ' PRO . 41.7 t -107.34 86.25 2.57 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.365 -0.834 . . . . 73.400000000000006 109.858 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.526 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 62.3 Cg_endo -85.39 132.76 4.43 Favored 'Trans proline' 0 N--CA 1.445 -1.35 0 C-N-CA 122.347 2.031 . . . . 70.200000000000003 112.278 179.066 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.735 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 58.1 mtpt -62.61 -20.34 64.66 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.51 -0.768 . . . . 75.230000000000004 109.604 173.609 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 10.6 m-70 -123.6 96.94 5.16 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.216 -0.902 . . . . 73.120000000000005 108.942 177.067 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.464 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 133.64 -18.77 4.3 Favored Glycine 0 CA--C 1.52 0.373 0 C-N-CA 120.558 -0.83 . . . . 73.239999999999995 113.075 178.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.464 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 69.6 mmtt 75.31 136.6 0.05 OUTLIER Pre-proline 0 N--CA 1.47 0.556 0 C-N-CA 123.432 0.693 . . . . 73.530000000000001 112.39 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.58 ' HB3' HG12 ' A' ' 38' ' ' VAL . 21.8 Cg_endo -61.03 143.43 99.23 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 123.497 2.798 . . . . 75.430000000000007 113.334 -177.23 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.523 ' CE1' HG11 ' A' ' 37' ' ' VAL . 4.9 p90 -158.48 160.79 37.14 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.818 -0.628 . . . . 75.420000000000002 110.116 178.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.653 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 90.3 m-85 -100.03 142.0 32.1 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.294 -0.412 . . . . 75.430000000000007 111.073 -179.376 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 51.9 mt -113.98 103.05 10.77 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.791 -0.64 . . . . 75.209999999999994 109.367 168.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 43.0 t -86.34 133.58 29.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.129 -0.487 . . . . 75.409999999999997 110.287 -178.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . 0.414 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 33.8 tpt85 -76.71 115.54 16.57 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.958 -0.386 . . . . 73.450000000000003 109.958 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.14 154.79 18.68 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 116.094 -0.503 . . . . 71.030000000000001 111.406 -179.037 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -73.15 167.03 21.99 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.626 -0.715 . . . . 73.439999999999998 111.632 -176.022 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.54 10.22 86.08 Favored Glycine 0 N--CA 1.454 -0.131 0 CA-C-N 115.41 -0.814 . . . . 70.120000000000005 112.801 172.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.5 m 61.14 17.83 8.48 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 122.919 0.488 . . . . 72.040000000000006 111.745 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -50.39 -66.02 0.46 Allowed 'General case' 0 N--CA 1.468 0.451 0 O-C-N 123.607 0.567 . . . . 72.120000000000005 111.898 -178.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 137.4 -18.12 3.49 Favored Glycine 0 CA--C 1.508 -0.381 0 C-N-CA 120.591 -0.814 . . . . 71.230000000000004 111.759 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.414 ' ND2' ' HB3' ' A' ' 66' ' ' LEU . 13.8 t-20 -66.04 146.41 54.72 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.141 -0.53 . . . . 71.430000000000007 111.036 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.487 ' HB2' HG21 ' A' ' 72' ' ' ILE . 35.4 m-85 -119.35 141.46 49.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.256 -0.429 . . . . 73.219999999999999 110.082 175.686 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.4 ' CG2' ' HA ' ' A' ' 63' ' ' PRO . 49.6 mm -108.18 124.36 64.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.993 -0.549 . . . . 74.239999999999995 110.521 -177.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.428 HH11 ' HD3' ' A' ' 59' ' ' ARG . 42.4 mtp-105 -77.7 137.78 38.69 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.92 -0.4 . . . . 74.299999999999997 109.92 177.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.653 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 63.6 p -67.51 -23.95 65.52 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.403 0.62 . . . . 74.329999999999998 110.082 175.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -70.17 -43.08 71.54 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.217 -0.901 . . . . 64.400000000000006 110.569 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.9 mm100 -134.9 76.19 59.77 Favored Pre-proline 0 N--CA 1.441 -0.899 0 CA-C-N 115.95 -0.568 . . . . 73.540000000000006 111.193 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . 0.4 ' HA ' ' CG2' ' A' ' 58' ' ' ILE . 26.5 Cg_exo -63.47 -15.88 51.19 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 123.011 2.474 . . . . 74.420000000000002 112.533 177.019 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -75.24 -20.85 58.99 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.882 -0.599 . . . . 74.439999999999998 110.683 178.765 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 22.7 tptm -109.37 129.03 55.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.192 0.52 . . . . 71.040000000000006 111.495 -176.225 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.414 ' HB3' ' ND2' ' A' ' 56' ' ' ASN . 5.9 mp -89.93 128.8 36.3 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.43 -0.804 . . . . 75.329999999999998 109.965 176.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 50.5 mm -96.31 124.89 49.78 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 116.353 -0.385 . . . . 72.230000000000004 111.597 -173.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.562 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 38.1 Cg_endo -65.22 174.39 5.06 Favored 'Trans proline' 0 C--N 1.348 0.509 0 C-N-CA 123.13 2.553 . . . . 73.319999999999993 112.887 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 16.4 tt0 -83.82 -9.01 59.08 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.804 -0.635 . . . . 75.439999999999998 111.924 -168.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 38.4 p90 -96.88 -5.09 38.96 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.296 0.57 . . . . 74.120000000000005 109.927 175.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.562 ' HB2' ' HG2' ' A' ' 68' ' ' PRO . 4.8 mm-40 -115.63 10.76 15.62 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.42 -0.809 . . . . 75.329999999999998 111.145 -176.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.532 HG23 ' O ' ' A' ' 68' ' ' PRO . 18.9 pt -90.33 -11.25 9.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-O 121.096 0.474 . . . . 75.109999999999999 110.811 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 33.8 p90 -128.5 27.25 5.57 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.954 -0.566 . . . . 74.319999999999993 110.419 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 4.8 m -49.76 -41.33 43.8 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.692 -0.686 . . . . 73.030000000000001 111.041 -179.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . 0.496 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 10.3 p-90 . . . . . 0 C--N 1.326 -0.439 0 CA-C-N 115.787 -0.642 . . . . 75.120000000000005 111.043 175.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 42.7 m . . . . . 0 N--CA 1.454 -0.25 0 CA-C-O 120.994 0.426 . . . . 51.210000000000001 110.238 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 128.14 82.04 0.34 Allowed Glycine 0 N--CA 1.446 -0.65 0 N-CA-C 110.577 -1.009 . . . . 70.25 110.577 -173.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . 0.414 ' HA ' ' HD3' ' B' ' 111' ' ' PRO . 13.4 mt-10 -123.38 114.13 29.04 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-O 121.327 0.584 . . . . 74.299999999999997 109.975 -172.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.814 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 19.2 Cg_endo -89.01 102.29 0.38 Allowed 'Trans proline' 0 N--CA 1.438 -1.766 0 C-N-CA 122.832 2.355 . . . . 70.439999999999998 112.397 -176.241 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -101.57 115.28 30.16 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.188 -0.671 . . . . 72.239999999999995 109.188 178.274 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . . . . . . . . . 7.9 p -72.71 132.64 33.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.625 -0.716 . . . . 74.439999999999998 111.082 -176.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 27.4 m -93.22 99.17 11.78 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.464 -0.789 . . . . 74.120000000000005 109.742 174.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.594 HG21 ' HG2' ' B' ' 124' ' ' GLN . 71.3 mt -96.06 106.03 17.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.838 -0.619 . . . . 72.340000000000003 110.286 -177.252 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 39.1 mmt180 -118.75 149.6 41.19 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.192 0.52 . . . . 72.299999999999997 110.485 178.279 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -100.6 113.64 26.64 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-O 121.596 0.712 . . . . 75.450000000000003 110.865 -179.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . 0.529 ' HB3' ' HE2' ' B' ' 121' ' ' LYS . 0.7 OUTLIER -102.83 48.92 0.85 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.003 -0.999 . . . . 71.430000000000007 109.851 -176.785 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 97.74 -117.35 5.78 Favored Glycine 0 N--CA 1.446 -0.652 0 N-CA-C 111.223 -0.751 . . . . 63.130000000000003 111.223 -176.266 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . 0.485 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 3.6 m-20 -89.13 -3.32 58.67 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.037 0.446 . . . . 73.340000000000003 110.308 177.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.674 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 25.4 pttm -111.79 120.19 41.13 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.205 0.526 . . . . 75.530000000000001 111.303 -177.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 122' ' ' THR . . . . . 0.462 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 5.5 m -84.03 111.96 19.77 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.908 -0.587 . . . . 72.400000000000006 109.611 175.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 51.4 mt -101.17 108.12 22.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-O 121.104 0.478 . . . . 74.400000000000006 110.368 -177.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.594 ' HG2' HG21 ' B' ' 115' ' ' ILE . 8.8 mt-30 -105.28 103.76 13.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.792 -0.64 . . . . 72.099999999999994 110.366 -178.427 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -88.4 108.82 19.56 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.234 -0.439 . . . . 73.450000000000003 110.766 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . 0.455 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 46.7 m-85 -82.37 106.39 14.21 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.218 -0.446 . . . . 74.400000000000006 110.47 177.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -120.86 125.31 47.16 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.508 -0.553 . . . . 72.439999999999998 109.508 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.814 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 3.5 p -93.65 -41.63 12.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 120.757 0.313 . . . . 73.510000000000005 111.497 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -158.6 70.37 0.52 Allowed 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.606 -0.438 . . . . 73.150000000000006 110.584 -175.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 78.87 -4.05 62.64 Favored Glycine 0 N--CA 1.454 -0.162 0 CA-C-N 115.692 -0.686 . . . . 65.319999999999993 113.574 175.218 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -130.0 129.32 43.57 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.097 0.475 . . . . 75.030000000000001 110.717 -178.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.876 HD12 HG13 ' B' ' 135' ' ' ILE . 3.5 tm? -73.5 118.35 16.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 114.875 -1.057 . . . . 74.230000000000004 109.462 175.223 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . 0.455 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 46.3 p90 -106.09 -23.77 12.53 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.66 -0.416 . . . . 75.450000000000003 111.528 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . 0.459 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -158.99 134.55 8.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.806 0.336 . . . . 73.109999999999999 111.282 179.005 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.876 HG13 HD12 ' B' ' 132' ' ' LEU . 74.3 mt -114.07 130.73 67.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 N-CA-C 109.634 -0.506 . . . . 73.219999999999999 109.634 174.151 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -107.79 110.41 22.21 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.679 -0.489 . . . . 74.439999999999998 109.679 174.232 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.622 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.4 t -93.67 131.14 41.44 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 108.808 -0.812 . . . . 74.010000000000005 108.808 176.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.462 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 17.2 t -117.73 72.86 8.33 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 109.961 -0.385 . . . . 73.409999999999997 109.961 173.582 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.674 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 52.4 Cg_endo -78.48 134.73 12.69 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 122.367 2.044 . . . . 70.340000000000003 112.596 176.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . 0.485 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 48.6 mtpt -60.83 -33.21 72.69 Favored 'General case' 0 CA--C 1.518 -0.262 0 CA-C-O 121.416 0.627 . . . . 73.129999999999995 109.596 173.37 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 36.6 m-70 -110.52 82.58 1.62 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.252 -0.885 . . . . 74.349999999999994 109.2 177.038 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 150.68 -26.73 1.06 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.357 -0.925 . . . . 73.549999999999997 113.054 -179.335 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . 0.484 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 70.7 mmtt 76.68 148.91 0.12 Allowed Pre-proline 0 N--CA 1.472 0.635 0 C-N-CA 123.283 0.633 . . . . 73.230000000000004 111.933 178.4 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.622 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 38.3 Cg_endo -66.27 127.6 17.79 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 123.069 2.513 . . . . 73.349999999999994 113.492 -176.098 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -143.91 150.48 38.47 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.79 -0.641 . . . . 72.049999999999997 110.734 179.327 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.669 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 77.8 m-85 -98.14 146.16 25.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.976 -0.556 . . . . 74.420000000000002 110.466 178.345 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . 0.459 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 59.9 mt -122.73 100.55 6.97 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.826 -0.625 . . . . 73.030000000000001 109.555 171.156 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 61.4 t -92.84 130.34 42.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.054 -0.521 . . . . 74.140000000000001 110.677 -178.036 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . 0.534 HH11 ' HG3' ' B' ' 149' ' ' ARG . 0.3 OUTLIER -72.2 128.07 34.53 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.913 0.387 . . . . 74.239999999999995 111.689 -179.429 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.87 155.78 38.62 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 115.738 -0.664 . . . . 75.030000000000001 110.612 176.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . 0.43 ' HB3' ' CD2' ' A' ' 26' ' ' TYR . 3.9 p-10 -77.6 162.21 27.25 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.287 0.565 . . . . 73.530000000000001 111.736 -173.08 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.93 21.73 60.77 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.284 -0.871 . . . . 72.430000000000007 112.364 173.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 25.2 m 55.87 30.11 15.31 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-O 120.969 0.414 . . . . 75.319999999999993 110.384 -177.011 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -51.37 -64.39 0.83 Allowed 'General case' 0 N--CA 1.461 0.121 0 CA-C-N 114.851 -1.068 . . . . 74.120000000000005 111.068 -178.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 132.2 -36.36 2.21 Favored Glycine 0 CA--C 1.491 -1.458 0 C-N-CA 120.569 -0.824 . . . . 62.109999999999999 111.218 175.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . 0.621 ' OD1' ' HA ' ' B' ' 168' ' ' PRO . 75.6 m-20 -68.41 152.63 45.14 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 113.964 -1.118 . . . . 74.109999999999999 111.773 -179.424 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . 0.45 ' CE2' ' HG2' ' B' ' 149' ' ' ARG . 46.2 m-85 -112.32 157.7 20.66 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.54 -0.754 . . . . 61.200000000000003 110.248 176.285 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 49.1 mm -116.03 124.92 72.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 N-CA-C 109.596 -0.52 . . . . 74.540000000000006 109.596 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.475 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 30.2 ttt180 -85.51 137.72 32.7 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.4 -0.364 . . . . 74.200000000000003 110.165 -177.131 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 160' ' ' SER . . . . . 0.669 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 6.5 p -57.18 -42.6 81.49 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.722 0.638 . . . . 64.409999999999997 112.722 -174.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -86.04 -1.06 57.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.979 0.419 . . . . 74.140000000000001 111.551 -174.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 10.9 tp60 -151.86 71.41 7.99 Favored Pre-proline 0 C--N 1.327 -0.401 0 N-CA-C 109.614 -0.513 . . . . 73.299999999999997 109.614 -178.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -67.47 -14.41 42.36 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 123.223 2.616 . . . . 75.420000000000002 113.13 -173.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -90.52 -6.39 54.81 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.169 -0.469 . . . . 71.150000000000006 110.549 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 23.1 tptm -104.74 126.17 51.55 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.163 0.506 . . . . 74.510000000000005 110.637 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.0 mp -95.19 124.68 39.36 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.326 -0.852 . . . . 74.109999999999999 109.789 178.302 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 51.5 mm -93.17 111.58 52.44 Favored Pre-proline 0 C--N 1.32 -0.7 0 CA-C-N 116.122 -0.49 . . . . 74.120000000000005 109.827 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.621 ' HA ' ' OD1' ' B' ' 156' ' ' ASN . 60.2 Cg_endo -71.63 175.17 9.92 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.664 2.243 . . . . 71.329999999999998 113.025 -176.457 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . 0.413 ' O ' HG12 ' B' ' 172' ' ' ILE . 36.3 tt0 -78.92 -8.32 58.77 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.573 -0.739 . . . . 74.349999999999994 111.518 -170.341 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 10.3 p90 -94.23 -8.04 40.36 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.088 0.47 . . . . 74.319999999999993 110.081 174.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.462 ' O ' ' HB2' ' B' ' 174' ' ' SER . 0.1 OUTLIER -110.42 -4.63 15.47 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.891 -0.595 . . . . 65.230000000000004 110.717 -177.538 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.47 HG22 ' O ' ' B' ' 168' ' ' PRO . 36.6 pt -70.15 -18.68 21.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.231 -0.44 . . . . 74.340000000000003 111.197 -179.613 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -102.01 40.62 1.31 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.593 0.711 . . . . 74.439999999999998 109.678 176.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 174' ' ' SER . . . . . 0.462 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 4.5 t -73.38 -11.13 60.37 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 114.9 -1.045 . . . . 64.400000000000006 110.211 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . 0.441 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 0.9 OUTLIER . . . . . 0 C--O 1.245 0.829 0 CA-C-O 118.353 -0.832 . . . . 74.329999999999998 110.9 179.008 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.5 p . . . . . 0 N--CA 1.449 -0.488 0 N-CA-C 109.749 -0.463 . . . . 75.430000000000007 109.749 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.03 66.33 0.53 Allowed Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.158 -1.177 . . . . 73.209999999999994 110.158 -173.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . 0.497 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -114.46 117.16 43.23 Favored Pre-proline 0 N--CA 1.44 -0.933 0 N-CA-C 107.995 -1.113 . . . . 74.150000000000006 107.995 -175.839 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.598 ' HG3' ' CZ ' ' B' ' 131' ' ' PHE . 24.7 Cg_endo -88.87 101.0 0.37 Allowed 'Trans proline' 0 N--CA 1.433 -2.049 0 C-N-CA 122.173 1.915 . . . . 73.219999999999999 111.693 -175.377 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -107.8 171.61 7.3 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 114.871 -1.059 . . . . 64.439999999999998 110.344 179.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.638 HG22 ' HB3' ' A' ' 24' ' ' GLN . 7.6 p -123.42 131.51 73.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 115.773 -0.649 . . . . 73.519999999999996 110.353 178.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.409 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 61.5 m -91.62 111.33 22.8 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.663 -0.699 . . . . 71.420000000000002 109.585 176.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 56.1 mt -88.66 103.76 14.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.942 -0.572 . . . . 74.129999999999995 110.967 -174.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.455 ' HA ' ' NE ' ' A' ' 16' ' ' ARG . 3.5 mmp_? -108.45 165.12 11.76 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.49 -0.777 . . . . 73.319999999999993 109.48 177.207 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -139.13 111.44 7.5 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.042 0.449 . . . . 73.340000000000003 110.502 174.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 30.9 mm-40 -103.77 100.57 10.38 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.448 -0.796 . . . . 75.319999999999993 109.002 178.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.25 -109.31 2.83 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.529 -0.843 . . . . 75.230000000000004 111.664 -175.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -111.02 8.46 21.91 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.788 0.294 . . . . 74.310000000000002 111.078 -177.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.702 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 0.3 OUTLIER -114.97 118.54 33.73 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.434 0.635 . . . . 74.540000000000006 111.463 179.484 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.723 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 20.7 m -76.59 98.33 4.65 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.19 -0.914 . . . . 54.340000000000003 109.618 175.213 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 38.3 mt -90.31 105.39 16.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.221 0.534 . . . . 74.329999999999998 110.234 -176.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.638 ' HB3' HG22 ' A' ' 13' ' ' VAL . 21.6 mt-30 -94.67 112.78 24.51 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.433 -0.803 . . . . 75.340000000000003 110.734 -177.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.409 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.6 mt-10 -91.99 108.85 20.23 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.03 -0.532 . . . . 65.219999999999999 110.736 -177.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.458 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 41.3 m-85 -84.72 106.06 15.98 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.349 -0.387 . . . . 75.409999999999997 110.687 178.173 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 71.3 mtm-85 -130.01 123.61 30.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.064 -0.516 . . . . 74.329999999999998 110.11 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.2 p -97.18 -41.99 11.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.313 -0.403 . . . . 75.099999999999994 111.48 -179.055 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 11.7 t-20 -153.65 73.37 0.95 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.006 0.432 . . . . 75.329999999999998 110.294 -176.087 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 67.03 18.53 69.0 Favored Glycine 0 C--N 1.33 0.207 0 CA-C-N 115.815 -0.63 . . . . 65.310000000000002 112.845 177.224 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.613 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 87.8 t80 -139.67 128.59 23.49 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.994 0.426 . . . . 70.519999999999996 111.042 -178.117 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.823 HD13 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -82.36 110.31 17.39 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.112 -0.949 . . . . 74.140000000000001 108.544 172.822 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . 0.458 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 45.5 p90 -103.92 -17.49 14.99 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.885 -0.326 . . . . 74.150000000000006 111.478 -178.39 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.454 ' O ' ' HB2' ' A' ' 26' ' ' TYR . . . -159.35 140.34 12.67 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.878 0.371 . . . . 52.100000000000001 111.105 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.823 HG13 HD13 ' A' ' 32' ' ' LEU . 66.9 mt -117.6 124.95 73.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 N-CA-C 109.653 -0.499 . . . . 74.230000000000004 109.653 174.326 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.606 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.9 tttt -106.01 103.77 13.33 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.533 -0.543 . . . . 73.409999999999997 109.533 176.11 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.734 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.6 t -88.7 127.24 41.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.839 -0.8 . . . . 75.439999999999998 108.839 177.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.723 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 22.0 t -115.14 74.0 3.64 Favored Pre-proline 0 C--N 1.318 -0.769 0 N-CA-C 109.55 -0.537 . . . . 74.340000000000003 109.55 172.492 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.702 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 39.4 Cg_endo -76.86 131.1 11.92 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.011 1.807 . . . . 75.239999999999995 112.242 177.003 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -54.83 -40.0 69.13 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.522 -0.763 . . . . 74.109999999999999 110.26 177.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -116.67 82.46 1.8 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.517 -0.765 . . . . 72.239999999999995 109.228 179.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.433 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 159.15 -29.48 0.41 Allowed Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.507 -0.769 . . . . 75.140000000000001 111.428 -175.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.433 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 71.6 mmtt 76.42 143.81 0.1 OUTLIER Pre-proline 0 N--CA 1.469 0.513 0 C-N-CA 123.738 0.815 . . . . 72.329999999999998 112.267 176.19 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.734 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 30.8 Cg_endo -64.03 132.7 35.37 Favored 'Trans proline' 0 C--N 1.347 0.469 0 C-N-CA 123.218 2.612 . . . . 74.200000000000003 113.61 -176.197 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 21.9 p90 -148.36 163.2 37.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.463 -0.79 . . . . 72.5 109.645 177.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.473 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 91.2 m-85 -107.76 137.79 45.14 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.842 0.353 . . . . 75.329999999999998 111.572 -176.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 34.7 mt -114.15 104.48 12.15 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.717 -0.674 . . . . 73.329999999999998 109.216 168.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 44.4 t -92.52 137.88 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.554 -0.294 . . . . 74.519999999999996 110.333 -178.198 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . 0.56 ' HG2' ' CE2' ' A' ' 57' ' ' PHE . 5.0 mmm180 -81.8 121.92 27.04 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.032 0.444 . . . . 72.219999999999999 110.885 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.45 167.03 19.16 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.337 -0.847 . . . . 74.230000000000004 111.22 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.466 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 9.8 p-10 -66.87 142.86 57.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.298 -0.41 . . . . 70.209999999999994 110.264 179.037 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.466 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 94.16 143.45 13.81 Favored Glycine 0 N--CA 1.433 -1.559 0 C-N-CA 120.588 -0.815 . . . . 64.329999999999998 111.566 -178.591 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 18.6 m -74.32 40.14 0.13 Allowed 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.174 0.511 . . . . 74.430000000000007 110.677 176.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.466 ' H ' ' C ' ' A' ' 52' ' ' GLY . 18.0 t70 -78.01 -39.86 40.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.779 -0.646 . . . . 53.310000000000002 110.357 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 112.02 -32.05 6.6 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.636 -0.792 . . . . 65.239999999999995 113.302 176.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -58.29 149.82 23.44 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 113.027 0.751 . . . . 72.120000000000005 113.027 -175.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.56 ' CE2' ' HG2' ' A' ' 49' ' ' ARG . 63.3 m-85 -115.5 168.3 10.12 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.096 -0.956 . . . . 73.310000000000002 110.697 -179.063 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 45.4 mm -128.27 132.16 68.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.995 -0.548 . . . . 75.540000000000006 109.649 174.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.796 ' HG3' HD11 ' A' ' 67' ' ' ILE . 70.7 mtt180 -78.59 147.88 33.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.809 0.337 . . . . 74.329999999999998 111.249 178.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.473 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 62.2 p -79.01 -29.86 43.92 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.681 -0.859 . . . . 54.32 108.681 165.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -70.27 -34.34 72.67 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.381 -1.281 . . . . 74.409999999999997 110.876 177.316 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . 0.569 ' HB3' ' HD2' ' A' ' 59' ' ' ARG . 9.9 tt0 -143.37 82.52 11.57 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 115.747 -0.66 . . . . 74.530000000000001 109.71 -174.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -79.58 -7.44 14.73 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.871 2.381 . . . . 75.030000000000001 113.13 -175.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -94.46 9.32 38.9 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.331 0.586 . . . . 73.439999999999998 110.165 178.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.4 tptt -125.63 128.23 47.56 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.85 -0.614 . . . . 74.150000000000006 110.429 -178.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.2 mp -87.36 111.85 21.51 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 108.434 -0.95 . . . . 73.319999999999993 108.434 175.118 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.796 HD11 ' HG3' ' A' ' 59' ' ' ARG . 34.6 mm -67.24 117.33 45.42 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.146 -0.479 . . . . 75.430000000000007 111.27 -172.254 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.1 175.03 8.08 Favored 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.676 2.251 . . . . 72.140000000000001 112.038 -179.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -84.36 -1.06 54.84 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.943 -0.572 . . . . 74.140000000000001 111.21 -169.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 16.5 p90 -98.89 -20.24 16.93 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.557 -0.457 . . . . 71.310000000000002 110.437 174.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.506 ' OE2' HD13 ' A' ' 67' ' ' ILE . 19.4 tt0 -90.55 -11.96 38.54 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 121.096 0.474 . . . . 72.219999999999999 110.536 -177.038 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 45.6 pt -64.88 -19.26 25.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.095 -0.502 . . . . 74.109999999999999 110.975 178.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -117.6 29.32 7.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.951 -0.568 . . . . 74.129999999999995 110.289 176.121 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 23.0 t -63.72 -26.76 68.8 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.898 -0.592 . . . . 61.240000000000002 110.15 179.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 20.8 p-90 . . . . . 0 C--N 1.324 -0.528 0 CA-C-N 115.896 -0.593 . . . . 72.409999999999997 110.579 175.069 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 21.1 m . . . . . 0 C--O 1.236 0.389 0 CA-C-O 120.779 0.324 . . . . 74.409999999999997 110.558 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 99.72 83.24 1.72 Allowed Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 120.876 -0.678 . . . . 72.439999999999998 111.924 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 50.7 mt-10 -109.51 102.94 51.57 Favored Pre-proline 0 C--N 1.323 -0.545 0 N-CA-C 109.046 -0.724 . . . . 75.400000000000006 109.046 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.613 ' HG3' ' CZ ' ' A' ' 31' ' ' PHE . 66.2 Cg_endo -83.48 85.83 1.46 Allowed 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 122.036 1.824 . . . . 73.549999999999997 112.076 -176.21 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -96.05 133.47 40.25 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.049 -0.978 . . . . 71.25 109.359 178.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.508 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 14.7 p -92.92 127.55 44.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 121.438 0.637 . . . . 73.109999999999999 110.262 179.089 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 21.9 m -91.3 105.46 17.8 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.794 -0.639 . . . . 72.209999999999994 109.699 177.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 63.6 mt -84.36 106.13 14.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.024 -0.535 . . . . 75.140000000000001 110.899 -176.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 14.4 mtp180 -105.99 173.05 6.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.928 -0.578 . . . . 74.010000000000005 111.052 178.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -148.2 101.16 3.24 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.743 -0.662 . . . . 71.430000000000007 110.891 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . 0.592 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 3.8 mp0 -104.52 90.61 3.57 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.457 -0.792 . . . . 75.420000000000002 110.399 -178.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 76.85 -89.52 0.96 Allowed Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.775 -0.726 . . . . 75.200000000000003 112.486 179.282 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -127.57 14.57 7.06 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.458 0.129 . . . . 65.310000000000002 110.899 178.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.592 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 38.4 pttt -123.6 121.36 35.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.267 0.556 . . . . 72.150000000000006 111.181 -179.085 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 122' ' ' THR . . . . . 0.513 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 20.8 m -84.13 98.31 9.83 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.488 -0.778 . . . . 75.150000000000006 109.748 176.412 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . 0.465 HD12 ' HE3' ' B' ' 121' ' ' LYS . 30.4 mt -89.68 107.52 18.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.174 0.511 . . . . 73.409999999999997 110.599 -177.231 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.508 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 20.8 mt-30 -97.95 107.6 20.12 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.783 -0.644 . . . . 74.049999999999997 110.515 -178.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -87.47 111.23 20.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.014 -0.539 . . . . 74.510000000000005 110.485 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . 0.466 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 78.5 m-85 -85.16 101.29 12.34 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.046 -0.353 . . . . 74.400000000000006 110.046 176.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 20.6 mtm180 -113.41 128.05 56.32 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.413 -0.358 . . . . 75.030000000000001 110.234 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.606 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -96.58 -50.6 11.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 C-N-CA 120.731 -0.388 . . . . 75.540000000000006 111.521 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -156.67 76.1 0.87 Allowed 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.622 -0.51 . . . . 73.040000000000006 109.622 -176.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 66.94 16.73 66.69 Favored Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.713 -0.676 . . . . 73.209999999999994 112.403 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . 0.598 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 89.4 t80 -137.33 128.34 27.52 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.038 0.447 . . . . 73.120000000000005 110.791 -179.07 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.796 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -83.2 113.35 20.6 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.175 -0.92 . . . . 75.120000000000005 108.791 173.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . 0.407 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 50.9 p90 -104.88 -14.99 15.3 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.388 -0.525 . . . . 73.430000000000007 111.665 -178.07 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -159.9 143.01 13.93 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.897 0.38 . . . . 72.209999999999994 111.278 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.796 HG13 HD11 ' B' ' 132' ' ' LEU . 80.8 mt -120.93 127.09 75.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.931 -0.577 . . . . 73.329999999999998 109.889 174.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.431 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 82.6 tttt -116.69 101.12 8.31 Favored 'General case' 0 C--N 1.321 -0.63 0 N-CA-C 109.411 -0.588 . . . . 74.319999999999993 109.411 172.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.518 ' O ' ' HD3' ' B' ' 139' ' ' PRO . 4.9 p -101.95 129.38 53.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.978 0 C-N-CA 120.231 -0.588 . . . . 73.200000000000003 109.758 178.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.513 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 37.5 t -109.07 84.91 2.94 Favored Pre-proline 0 C--N 1.322 -0.591 0 CA-C-N 115.553 -0.748 . . . . 75.230000000000004 109.976 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.518 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 69.0 Cg_endo -87.86 133.46 3.02 Favored 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 122.506 2.138 . . . . 75.239999999999995 112.365 178.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -60.97 -20.31 62.2 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.94 -0.573 . . . . 75.099999999999994 110.304 174.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 5.6 m-70 -122.66 81.88 1.91 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.425 -0.807 . . . . 73.400000000000006 109.181 -175.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 140.0 -17.44 2.98 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.736 -0.745 . . . . 73.340000000000003 112.64 -178.082 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt 70.79 145.5 0.11 Allowed Pre-proline 0 N--CA 1.472 0.639 0 C-N-CA 123.41 0.684 . . . . 75.239999999999995 111.896 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.478 ' HB3' HG23 ' B' ' 138' ' ' VAL . 43.0 Cg_endo -67.95 149.1 77.36 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.62 2.213 . . . . 72.25 113.09 -177.342 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -158.71 156.7 30.37 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.848 -0.615 . . . . 74.549999999999997 109.695 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.402 ' O ' ' HA ' ' B' ' 159' ' ' ARG . 59.9 m-85 -102.29 134.34 45.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.647 0.261 . . . . 73.430000000000007 111.117 -179.221 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 46.0 mt -114.02 105.31 13.07 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.045 -0.525 . . . . 70.439999999999998 109.704 170.036 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 46.7 t -97.79 137.27 25.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.123 -0.49 . . . . 75.209999999999994 110.147 -178.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 2.8 mmt85 -75.68 131.64 40.02 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.99 0.424 . . . . 75.439999999999998 111.458 178.235 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -87.58 169.68 11.96 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.644 -0.707 . . . . 72.129999999999995 109.215 172.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . 0.413 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 6.2 p-10 -69.99 125.52 26.99 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.374 0.606 . . . . 61.109999999999999 109.971 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 120.95 127.9 3.49 Favored Glycine 0 N--CA 1.442 -0.91 0 CA-C-N 115.505 -0.77 . . . . 73.209999999999994 112.12 -178.395 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 12.2 t -79.45 45.25 0.65 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.433 0.635 . . . . 74.109999999999999 110.08 178.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -84.88 -16.94 39.49 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.39 -0.823 . . . . 72.319999999999993 110.57 -178.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 86.39 23.56 43.25 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.825 -0.703 . . . . 74.239999999999995 111.666 -177.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 30.7 t30 -99.57 129.95 45.77 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.268 -0.466 . . . . 72.030000000000001 110.681 -177.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -116.59 151.08 36.94 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.815 -0.63 . . . . 61.020000000000003 110.004 178.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.7 mm -117.96 129.55 74.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 116.17 -0.468 . . . . 74.310000000000002 109.777 178.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.447 ' HG3' HD11 ' B' ' 167' ' ' ILE . 92.9 mtt180 -75.02 150.78 38.84 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.821 0.343 . . . . 74.510000000000005 111.136 179.362 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 64.7 p -81.29 -27.73 34.95 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 107.993 -1.114 . . . . 70.140000000000001 107.993 164.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -64.7 -35.61 81.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.019 -1.446 . . . . 65.519999999999996 110.94 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 9.3 tt0 -153.24 85.59 4.19 Favored Pre-proline 0 C--N 1.322 -0.589 0 CA-C-N 115.518 -0.764 . . . . 72.5 109.557 -177.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -79.14 8.87 3.6 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 123.106 2.537 . . . . 71.349999999999994 112.766 -176.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -107.4 3.9 25.73 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.214 0.531 . . . . 74.140000000000001 110.729 -178.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -125.23 130.65 52.51 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.855 -0.612 . . . . 74.239999999999995 110.484 -179.059 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . 0.419 HD11 ' N ' ' B' ' 166' ' ' LEU . 4.7 mp -84.67 119.81 25.66 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.695 -0.854 . . . . 75.150000000000006 108.695 176.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . 0.447 HD11 ' HG3' ' B' ' 159' ' ' ARG . 36.4 mm -80.56 119.51 76.49 Favored Pre-proline 0 C--N 1.322 -0.614 0 CA-C-O 120.995 0.426 . . . . 75.120000000000005 111.177 -172.048 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.542 ' O ' HG22 ' B' ' 172' ' ' ILE . 58.1 Cg_endo -69.73 173.0 11.58 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.803 2.335 . . . . 74.329999999999998 112.098 178.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . 0.621 ' O ' HG12 ' B' ' 172' ' ' ILE . 5.5 tt0 -73.78 -33.11 64.11 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.734 -0.666 . . . . 64.530000000000001 111.362 -168.71 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 11.6 p90 -66.4 -17.72 64.94 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.437 -0.505 . . . . 73.420000000000002 110.714 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.578 ' HA ' ' HB2' ' B' ' 174' ' ' SER . 20.1 tt0 -102.46 -17.68 15.68 Favored 'General case' 0 N--CA 1.444 -0.727 0 CA-C-N 116.428 -0.351 . . . . 72.420000000000002 111.496 -177.024 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.621 HG12 ' O ' ' B' ' 169' ' ' GLN . 30.7 pt -70.18 -27.54 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.954 0.407 . . . . 72.439999999999998 110.509 178.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -118.22 36.25 4.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.517 0.675 . . . . 73.409999999999997 109.782 173.194 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 174' ' ' SER . . . . . 0.578 ' HB2' ' HA ' ' B' ' 171' ' ' GLU . 45.3 t -62.39 -27.17 68.89 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.023 -0.99 . . . . 62.210000000000001 111.194 -179.307 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . 0.445 ' C ' ' HZ3' ' B' ' 121' ' ' LYS . 0.7 OUTLIER . . . . . 0 C--O 1.246 0.916 0 CA-C-O 118.437 -0.792 . . . . 75.400000000000006 111.263 -179.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.0 p . . . . . 0 C--O 1.236 0.355 0 CA-C-O 120.853 0.359 . . . . 64.409999999999997 110.875 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.2 -73.34 2.63 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.77 -0.729 . . . . 73.219999999999999 111.467 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 60.4 74.87 0.51 Allowed Pre-proline 0 C--N 1.329 -0.285 0 C-N-CA 123.046 0.538 . . . . 65.099999999999994 110.152 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.922 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 12.2 Cg_endo -60.32 107.33 0.41 Allowed 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.597 2.198 . . . . 74.120000000000005 112.708 -178.806 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 23.7 m-20 -90.5 154.03 19.94 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.627 -0.715 . . . . 61.43 109.876 179.163 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.478 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 12.5 p -117.99 125.74 74.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-O 121.395 0.617 . . . . 72.299999999999997 110.549 176.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.6 m -98.53 111.45 23.81 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.548 -0.751 . . . . 73.030000000000001 110.062 179.253 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.8 mt -93.2 105.86 17.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.285 -0.416 . . . . 75.209999999999994 110.945 -176.374 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -120.48 167.42 12.39 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.014 -0.735 . . . . 74.329999999999998 109.014 177.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 91.6 mt-30 -127.35 119.0 25.24 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 120.929 0.395 . . . . 73.310000000000002 111.281 177.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.427 ' HG3' HD12 ' A' ' 23' ' ' ILE . 12.4 mm-40 -97.52 82.54 3.11 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.939 -0.763 . . . . 73.230000000000004 108.939 175.151 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 79.63 -107.03 2.51 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.3 -0.952 . . . . 64.230000000000004 111.351 -173.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.561 ' HB3' ' HB2' ' A' ' 40' ' ' LYS . 10.3 m-20 -108.85 0.41 20.27 Favored 'General case' 0 C--N 1.327 -0.38 0 O-C-N 122.615 -0.344 . . . . 72.430000000000007 111.114 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.805 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 22.1 pttm -101.74 113.03 25.84 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.443 0.64 . . . . 72.420000000000002 111.022 179.085 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.694 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 21.1 m -80.0 97.87 6.97 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.222 -0.899 . . . . 63.420000000000002 109.798 177.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.561 HG12 HG13 ' A' ' 37' ' ' VAL . 55.0 mt -90.85 112.23 24.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.035 0.445 . . . . 73.439999999999998 110.566 -176.544 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.57 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 17.1 mt-30 -95.67 108.33 20.61 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.961 -0.563 . . . . 72.349999999999994 109.956 178.21 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -84.82 102.81 13.36 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.78 -0.646 . . . . 74.450000000000003 110.346 -177.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.417 ' HE1' ' HB2' ' A' ' 36' ' ' LYS . 86.3 m-85 -82.12 102.38 11.02 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.162 0.506 . . . . 64.239999999999995 109.783 176.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 88.1 mtm180 -118.12 117.52 29.39 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.853 -0.612 . . . . 73.109999999999999 109.93 -179.382 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.922 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 2.6 p -69.4 -43.19 81.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.924 -0.58 . . . . 71.310000000000002 111.14 -174.356 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 33.9 t-20 -169.85 75.35 0.08 Allowed 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.644 -0.873 . . . . 65.400000000000006 108.644 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 85.22 -23.54 8.1 Favored Glycine 0 N--CA 1.45 -0.416 0 CA-C-N 115.443 -0.799 . . . . 70.340000000000003 112.676 -177.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 51.2 t80 -112.25 131.24 55.6 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.215 0.531 . . . . 75.120000000000005 110.749 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.493 HD22 ' CG1' ' A' ' 35' ' ' ILE . 27.2 tp -76.66 126.21 30.59 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 114.974 -1.012 . . . . 72.239999999999995 110.463 178.471 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . 0.41 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 49.6 p90 -115.23 -14.3 11.71 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.764 -0.374 . . . . 75.329999999999998 111.173 179.068 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -161.72 143.81 11.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.998 0.428 . . . . 74.310000000000002 111.142 -177.602 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.6 ' HB ' ' HB2' ' A' ' 47' ' ' LEU . 63.7 mt -121.84 121.35 64.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.992 -0.549 . . . . 64.239999999999995 109.87 176.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.57 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 88.2 tttt -102.19 99.62 9.76 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.244 -0.651 . . . . 75.430000000000007 109.244 172.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.704 HG11 ' HD3' ' A' ' 39' ' ' PRO . 3.5 t -86.18 126.63 40.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 108.568 -0.901 . . . . 72.0 108.568 178.132 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.694 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.6 t -115.73 72.87 4.19 Favored Pre-proline 0 C--N 1.318 -0.761 0 N-CA-C 109.753 -0.462 . . . . 72.349999999999994 109.753 172.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.805 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 43.2 Cg_endo -77.08 129.4 10.5 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 122.041 1.827 . . . . 75.120000000000005 112.413 177.179 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.561 ' HB2' ' HB3' ' A' ' 20' ' ' ASP . 55.7 mtpt -59.05 -32.13 69.47 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.043 -0.981 . . . . 74.400000000000006 110.285 176.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 67.9 m-70 -115.36 95.93 5.41 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.365 -0.834 . . . . 65.209999999999994 109.314 178.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 132.46 -23.06 4.08 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 121.009 -0.615 . . . . 71.439999999999998 111.99 -176.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.496 ' HD3' ' HA ' ' A' ' 43' ' ' LYS . 68.8 mmtt 72.99 148.94 0.12 Allowed Pre-proline 0 N--CA 1.467 0.389 0 C-N-CA 123.86 0.864 . . . . 74.340000000000003 112.651 177.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.652 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 27.9 Cg_endo -62.59 141.86 87.68 Favored 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 123.04 2.493 . . . . 62.340000000000003 113.921 -174.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.417 ' CE2' ' HG2' ' A' ' 59' ' ' ARG . 25.1 p90 -151.43 149.42 29.26 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-N 115.361 -0.836 . . . . 74.030000000000001 109.855 176.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.576 ' HB2' ' HB2' ' A' ' 60' ' ' SER . 88.6 m-85 -92.35 150.4 20.86 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.286 -0.416 . . . . 75.439999999999998 111.14 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.6 ' HB2' ' HB ' ' A' ' 35' ' ' ILE . 23.0 mt -123.37 96.46 4.99 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.711 -0.677 . . . . 74.030000000000001 109.674 171.252 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 45.8 t -90.16 122.24 41.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.438 -0.346 . . . . 63.399999999999999 110.519 -178.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -62.25 128.98 38.64 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 120.974 0.416 . . . . 74.510000000000005 111.303 176.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.9 152.33 19.44 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.452 -0.573 . . . . 74.420000000000002 109.452 172.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -57.85 144.07 40.12 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.332 -0.395 . . . . 72.409999999999997 110.58 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 118.45 148.31 8.46 Favored Glycine 0 N--CA 1.431 -1.684 0 C-N-CA 120.198 -1.001 . . . . 51.240000000000002 112.402 -179.664 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 16.6 m -76.67 -2.63 33.76 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 114.947 -0.626 . . . . 74.400000000000006 110.779 175.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -57.91 -43.66 86.34 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.142 -0.481 . . . . 70.319999999999993 112.048 -178.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 98.79 32.76 5.8 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.419 -0.896 . . . . 62.310000000000002 111.63 -179.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.78 HD22 HD21 ' A' ' 66' ' ' LEU . 32.1 t30 -87.06 132.82 33.7 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.367 -0.416 . . . . 74.299999999999997 110.417 -178.342 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -122.17 160.17 25.7 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.994 -0.548 . . . . 71.019999999999996 110.211 177.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.806 HD11 HD23 ' A' ' 66' ' ' LEU . 43.9 mm -120.22 115.32 46.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 116.279 -0.419 . . . . 74.439999999999998 109.972 177.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.673 ' HG3' HG13 ' A' ' 67' ' ' ILE . 18.7 mtp180 -75.95 130.1 37.94 Favored 'General case' 0 C--O 1.22 -0.492 0 CA-C-N 115.785 -0.643 . . . . 74.420000000000002 109.797 177.366 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.576 ' HB2' ' HB2' ' A' ' 46' ' ' PHE . 17.4 t -70.48 -17.53 62.97 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.894 0.854 . . . . 75.530000000000001 108.79 172.504 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -67.76 -27.38 66.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 114.384 -1.28 . . . . 75.319999999999993 110.453 173.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 -158.88 78.84 3.01 Favored Pre-proline 0 C--N 1.327 -0.404 0 CA-C-N 115.664 -0.698 . . . . 75.420000000000002 109.484 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_endo -78.76 -1.24 11.43 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.725 2.284 . . . . 71.209999999999994 112.375 -174.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -92.52 0.09 57.39 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.406 -0.816 . . . . 72.430000000000007 110.205 -178.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.427 ' HE3' ' O ' ' A' ' 66' ' ' LEU . 52.4 tptt -128.48 134.29 48.68 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.732 -0.667 . . . . 74.109999999999999 110.539 -179.078 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.806 HD23 HD11 ' A' ' 58' ' ' ILE . 26.2 mt -80.29 123.48 28.01 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.129 -0.693 . . . . 75.409999999999997 109.129 175.182 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.673 HG13 ' HG3' ' A' ' 59' ' ' ARG . 44.1 mm -92.43 113.76 60.32 Favored Pre-proline 0 C--N 1.32 -0.681 0 CA-C-O 120.941 0.401 . . . . 75.340000000000003 111.277 -173.08 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -72.62 177.99 6.82 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.887 2.392 . . . . 74.239999999999995 112.961 -177.288 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . 0.52 ' O ' HG12 ' A' ' 72' ' ' ILE . 19.4 tt0 -77.58 -17.14 58.13 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.493 -0.776 . . . . 73.340000000000003 112.067 -168.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 10.4 p90 -83.16 -18.32 39.83 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.251 -0.58 . . . . 74.329999999999998 110.281 176.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.547 ' HB3' HG21 ' A' ' 67' ' ' ILE . 1.4 tm-20 -90.35 -24.49 20.82 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 115.933 -0.576 . . . . 75.329999999999998 109.966 -178.304 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.52 HG12 ' O ' ' A' ' 69' ' ' GLN . 31.5 pt -70.28 -20.89 23.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 121.223 0.535 . . . . 74.420000000000002 110.396 177.766 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 46.2 m-85 -111.62 33.67 4.6 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.787 -0.642 . . . . 75.010000000000005 109.822 174.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 19.0 t -67.0 -33.17 74.98 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.384 -0.825 . . . . 70.109999999999999 110.171 178.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . 0.442 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 8.2 p-90 . . . . . 0 C--N 1.327 -0.398 0 CA-C-N 116.003 -0.544 . . . . 74.340000000000003 110.602 175.386 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 5.2 p . . . . . 0 N--CA 1.453 -0.289 0 CA-C-O 121.014 0.435 . . . . 74.239999999999995 111.065 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 108.75 -77.21 0.22 Allowed Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.588 -1.005 . . . . 73.329999999999998 110.588 -177.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 68.85 86.68 0.12 Allowed Pre-proline 0 CA--C 1.521 -0.171 0 CA-C-O 121.274 0.559 . . . . 74.209999999999994 110.558 173.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.679 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 3.0 Cg_exo -69.95 118.04 5.45 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 122.298 1.999 . . . . 74.439999999999998 111.731 -174.493 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -118.44 161.38 20.07 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.091 -0.958 . . . . 62.5 109.763 -174.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . . . . . . . . . 14.6 p -133.3 132.63 58.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.428 0.632 . . . . 72.430000000000007 111.5 -178.012 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 31.4 m -97.17 105.07 17.16 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.527 -0.76 . . . . 75.099999999999994 109.266 174.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 65.6 mt -95.59 104.66 16.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.369 0.604 . . . . 72.450000000000003 110.703 -176.369 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 57.1 mtm180 -123.55 176.06 6.42 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.247 -0.888 . . . . 73.109999999999999 109.354 176.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . 0.715 ' HG2' ' HA ' ' B' ' 122' ' ' THR . 37.7 mt-30 -134.17 139.73 46.05 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.411 0.624 . . . . 73.120000000000005 111.389 178.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . 0.558 ' HB3' ' HE2' ' B' ' 121' ' ' LYS . 0.9 OUTLIER -120.15 72.85 0.95 Allowed 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.954 -1.021 . . . . 74.340000000000003 109.679 -177.075 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 87.93 -108.87 3.44 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.611 -0.804 . . . . 71.409999999999997 111.703 -175.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . 0.712 ' HB3' ' HD2' ' B' ' 140' ' ' LYS . 39.5 m-20 -109.9 13.24 23.55 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.932 0.396 . . . . 75.140000000000001 110.616 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.558 ' HE2' ' HB3' ' B' ' 118' ' ' GLU . 23.7 pttm -120.02 116.49 25.85 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.868 -0.606 . . . . 74.129999999999995 110.664 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 122' ' ' THR . . . . . 0.715 ' HA ' ' HG2' ' B' ' 117' ' ' GLN . 20.0 m -77.4 122.16 24.78 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.598 -0.728 . . . . 75.200000000000003 109.495 176.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 55.7 mt -112.4 107.79 23.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.328 0.585 . . . . 75.439999999999998 110.819 -176.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.49 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 12.4 mt-30 -100.5 102.9 14.19 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.724 -0.671 . . . . 75.430000000000007 109.935 178.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . 0.4 ' HB3' HD11 ' B' ' 132' ' ' LEU . 48.3 mt-10 -82.92 104.58 13.24 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.005 -0.543 . . . . 73.120000000000005 110.521 -179.612 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . 0.416 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 79.2 m-85 -82.15 108.9 15.98 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.165 0.507 . . . . 74.430000000000007 110.147 178.356 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 82.9 mtt180 -118.97 121.41 39.86 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.806 -0.634 . . . . 75.329999999999998 109.342 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.878 HG12 HG12 ' A' ' 28' ' ' VAL . 2.1 p -70.68 -46.44 69.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 C-N-CA 120.761 -0.376 . . . . 74.430000000000007 110.719 -178.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -158.34 56.96 0.46 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.482 0.658 . . . . 63.210000000000001 109.427 -177.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 98.04 -23.74 34.76 Favored Glycine 0 N--CA 1.449 -0.452 0 CA-C-N 115.589 -0.732 . . . . 74.0 112.86 -178.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -104.28 129.82 52.11 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 121.062 0.458 . . . . 74.530000000000001 110.46 -178.064 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.543 HD22 ' CG1' ' B' ' 135' ' ' ILE . 28.7 tp -74.46 120.86 20.6 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.107 -0.952 . . . . 72.219999999999999 110.6 177.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . 0.416 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 54.1 p90 -110.86 -12.96 14.21 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.845 -0.342 . . . . 74.510000000000005 111.204 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . 0.555 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -167.1 137.1 2.96 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.974 0.416 . . . . 71.25 111.141 -177.337 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.543 ' CG1' HD22 ' B' ' 132' ' ' LEU . 56.9 mt -114.58 122.78 69.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.02 -0.536 . . . . 73.200000000000003 109.821 175.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.49 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.3 tttt -96.0 101.51 13.19 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.089 -0.708 . . . . 64.430000000000007 109.089 172.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.67 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.0 t -91.62 125.84 44.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 108.493 -0.929 . . . . 72.209999999999994 108.493 177.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.53 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.3 t -115.48 72.91 3.81 Favored Pre-proline 0 C--N 1.316 -0.867 0 N-CA-C 109.672 -0.492 . . . . 54.409999999999997 109.672 173.791 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.624 ' HD3' HG13 ' B' ' 137' ' ' VAL . 56.8 Cg_endo -80.21 133.32 9.76 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 122.153 1.902 . . . . 73.040000000000006 112.005 175.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . 0.712 ' HD2' ' HB3' ' B' ' 120' ' ' ASP . 93.0 mttt -52.05 -40.93 61.88 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.527 0.68 . . . . 60.210000000000001 110.219 175.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 8.6 m-70 -112.26 91.9 3.82 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.108 -0.951 . . . . 75.530000000000001 109.429 -175.056 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . 0.403 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 140.66 -21.65 2.7 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.819 -0.628 . . . . 61.420000000000002 111.832 -177.014 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . 0.403 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 74.6 mmtt 75.3 150.62 0.13 Allowed Pre-proline 0 N--CA 1.469 0.491 0 C-N-CA 123.544 0.738 . . . . 73.319999999999993 111.708 178.271 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.67 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 36.5 Cg_endo -66.9 137.39 44.8 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 122.461 2.107 . . . . 63.549999999999997 112.791 -177.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . 0.404 ' CD2' ' HD2' ' B' ' 159' ' ' ARG . 50.8 p90 -149.51 150.28 32.06 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.751 -0.659 . . . . 73.129999999999995 110.352 179.276 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.539 ' O ' ' HA ' ' B' ' 159' ' ' ARG . 92.4 m-85 -95.74 130.35 42.68 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.778 -0.646 . . . . 75.519999999999996 110.375 176.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . 0.555 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 15.0 mt -99.77 99.29 10.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.119 -0.491 . . . . 74.310000000000002 109.908 170.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.0 t -83.97 127.99 39.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 116.311 -0.404 . . . . 75.430000000000007 110.246 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.99 108.72 2.7 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.124 -0.695 . . . . 74.209999999999994 109.124 176.418 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.24 166.38 9.95 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.207 -0.451 . . . . 72.510000000000005 110.97 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -53.5 129.03 31.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.7 0.762 . . . . 75.450000000000003 112.52 -175.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 83.11 -115.99 4.13 Favored Glycine 0 N--CA 1.429 -1.816 0 CA-C-N 114.447 -1.251 . . . . 70.310000000000002 111.509 178.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 17.0 m -169.41 34.51 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 113.803 -1.198 . . . . 65.540000000000006 109.384 -178.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -78.79 35.7 0.25 Allowed 'General case' 0 CA--C 1.535 0.365 0 CA-C-N 115.4 -0.818 . . . . 72.25 111.405 -173.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 58.12 43.23 95.35 Favored Glycine 0 C--O 1.229 -0.212 0 CA-C-N 115.789 -0.641 . . . . 73.310000000000002 113.21 177.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 47.1 t30 -137.3 137.83 39.39 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.185 0.516 . . . . 74.319999999999993 111.085 -177.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . 0.484 ' HB3' HD22 ' B' ' 147' ' ' LEU . 39.0 m-85 -131.09 154.25 48.48 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.189 -0.914 . . . . 75.129999999999995 108.697 172.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 49.2 mm -120.65 122.79 68.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 N-CA-C 110.183 -0.303 . . . . 73.109999999999999 110.183 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.935 ' HG3' HG13 ' B' ' 167' ' ' ILE . 31.5 mtm-85 -88.9 137.28 32.46 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-N 116.338 -0.392 . . . . 72.439999999999998 110.126 178.067 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 35.1 t -64.69 -18.94 65.44 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.445 0.64 . . . . 73.319999999999993 109.334 171.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -59.37 -52.13 66.95 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 114.942 -1.027 . . . . 71.150000000000006 110.878 174.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 26.2 mt-30 -143.71 79.6 13.45 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 74.409999999999997 110.442 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -68.21 -0.58 5.87 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 123.292 2.661 . . . . 73.530000000000001 112.329 177.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -81.44 -18.48 45.16 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.639 -0.71 . . . . 64.25 110.233 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -119.95 140.11 51.42 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.856 -0.611 . . . . 61.549999999999997 110.885 -177.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.0 mp -81.87 126.87 32.4 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 107.898 -1.149 . . . . 74.319999999999993 107.898 171.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . 0.935 HG13 ' HG3' ' B' ' 159' ' ' ARG . 44.7 mm -87.81 119.66 70.63 Favored Pre-proline 0 C--N 1.318 -0.794 0 CA-C-O 120.882 0.372 . . . . 75.340000000000003 111.267 -170.425 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.437 ' O ' HG23 ' B' ' 172' ' ' ILE . 58.8 Cg_endo -71.09 174.3 10.85 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 123.27 2.647 . . . . 73.140000000000001 112.655 -179.187 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . 0.805 ' HA ' HG12 ' B' ' 172' ' ' ILE . 8.5 tt0 -72.75 -32.62 65.79 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.58 -0.736 . . . . 61.439999999999998 111.963 -168.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 36.9 p90 -73.56 -17.86 61.14 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.165 0.507 . . . . 74.439999999999998 110.326 178.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -94.28 -30.86 14.33 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.847 -0.615 . . . . 63.229999999999997 110.964 178.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.805 HG12 ' HA ' ' B' ' 169' ' ' GLN . 37.6 pt -74.45 -29.3 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.985 0.421 . . . . 73.400000000000006 110.381 176.312 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -104.76 37.86 2.04 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.184 0.516 . . . . 73.140000000000001 110.13 175.256 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 15.9 t -73.78 -22.88 59.69 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.827 -0.624 . . . . 71.219999999999999 110.262 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . 0.533 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 60.3 p-90 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.243 -0.884 . . . . 75.209999999999994 110.656 -178.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 28.5 p . . . . . 0 N--CA 1.452 -0.325 0 CA-C-O 120.883 0.373 . . . . 74.430000000000007 110.043 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.79 105.63 3.02 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 110.2 -1.16 . . . . 72.439999999999998 110.2 -173.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -116.76 95.74 47.06 Favored Pre-proline 0 C--N 1.317 -0.823 0 N-CA-C 109.516 -0.55 . . . . 74.409999999999997 109.516 -171.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.29 100.35 1.36 Allowed 'Trans proline' 0 N--CA 1.445 -1.372 0 C-N-CA 121.797 1.664 . . . . 63.530000000000001 111.422 -177.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -132.12 145.28 51.28 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.222 -0.899 . . . . 75.329999999999998 109.546 178.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.7 HG21 ' HB3' ' A' ' 24' ' ' GLN . 12.8 p -98.63 131.5 45.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 CA-C-O 121.297 0.57 . . . . 75.239999999999995 111.674 -172.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.488 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 25.0 m -83.69 103.79 13.28 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.686 -0.688 . . . . 75.219999999999999 109.211 176.527 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 61.3 mt -93.44 105.66 17.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 116.246 -0.434 . . . . 74.099999999999994 110.474 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 28.4 mmm180 -121.41 153.74 37.43 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.99 -0.55 . . . . 73.299999999999997 110.29 177.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 23.3 mp0 -113.49 107.66 16.12 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-O 121.355 0.598 . . . . 75.510000000000005 110.522 -178.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.596 ' HG3' HD12 ' A' ' 23' ' ' ILE . 24.1 mm-40 -106.21 88.4 2.78 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.204 -0.907 . . . . 72.510000000000005 109.8 -177.115 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 74.11 -109.57 2.83 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.702 -0.761 . . . . 64.340000000000003 112.201 -179.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.668 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 25.4 m-20 -109.31 22.4 15.87 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.752 0.311 . . . . 72.010000000000005 110.507 -177.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.584 ' HE2' HD13 ' A' ' 23' ' ' ILE . 22.2 pttm -138.41 127.05 23.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.307 0.575 . . . . 64.409999999999997 111.175 -178.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.579 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 26.4 m -85.13 103.9 14.54 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.623 -0.717 . . . . 62.329999999999998 109.232 174.423 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.596 HD12 ' HG3' ' A' ' 18' ' ' GLU . 41.7 mt -95.61 112.54 28.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.162 0.505 . . . . 72.420000000000002 110.294 -176.029 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.7 ' HB3' HG21 ' A' ' 13' ' ' VAL . 23.9 mt-30 -103.82 109.78 21.65 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.413 -0.812 . . . . 75.040000000000006 111.111 -176.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.488 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 24.7 mt-10 -94.61 106.67 18.66 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.032 -0.531 . . . . 72.409999999999997 111.137 -179.113 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.477 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 54.5 m-85 -76.69 109.52 10.53 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.276 -0.42 . . . . 74.120000000000005 110.508 178.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 74.7 mtt180 -124.06 140.49 52.92 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.337 -0.392 . . . . 75.099999999999994 110.115 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.496 HG23 ' CG ' ' B' ' 131' ' ' PHE . 12.3 p -109.03 -19.47 6.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.422 0.63 . . . . 72.530000000000001 111.28 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -159.82 24.54 0.18 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.237 -0.653 . . . . 73.420000000000002 109.237 -176.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 99.62 -31.18 8.65 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 110.984 -0.846 . . . . 75.319999999999993 110.984 -169.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 89.3 t80 -66.87 130.1 42.04 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.178 -0.511 . . . . 75.299999999999997 110.811 178.004 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.724 HD12 HG13 ' A' ' 35' ' ' ILE . 3.3 tm? -88.38 114.47 25.03 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.554 -0.748 . . . . 71.010000000000005 109.231 178.19 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . 0.477 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 43.2 p90 -110.98 -13.27 14.13 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.664 -0.414 . . . . 74.299999999999997 111.682 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -163.21 144.42 9.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.723 0.296 . . . . 73.140000000000001 111.34 179.588 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.724 HG13 HD12 ' A' ' 32' ' ' LEU . 71.3 mt -126.1 123.71 64.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.111 -0.495 . . . . 72.430000000000007 109.768 176.07 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -108.81 107.22 17.56 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.628 -0.508 . . . . 70.310000000000002 109.628 176.029 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.653 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.7 t -89.92 132.31 34.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.189 -0.671 . . . . 63.310000000000002 109.189 178.38 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.579 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 18.9 t -116.57 73.97 6.05 Favored Pre-proline 0 C--N 1.322 -0.623 0 N-CA-C 109.433 -0.58 . . . . 73.200000000000003 109.433 171.194 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.472 ' HD3' HG11 ' A' ' 37' ' ' VAL . 61.0 Cg_endo -78.71 145.87 20.69 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.642 2.228 . . . . 75.420000000000002 112.977 179.212 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.668 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 30.5 mtpp -68.07 -28.0 66.99 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.514 -0.766 . . . . 73.530000000000001 109.932 174.043 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 66.5 m-70 -122.52 96.2 4.94 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.55 -0.75 . . . . 70.010000000000005 109.745 178.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.415 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 139.51 -21.5 2.9 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.73 -0.747 . . . . 75.420000000000002 112.422 -179.649 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.422 ' HD3' ' HA ' ' A' ' 43' ' ' LYS . 69.4 mmtt 71.89 150.38 0.13 Allowed Pre-proline 0 N--CA 1.47 0.56 0 C-N-CA 123.201 0.6 . . . . 75.549999999999997 111.956 -179.593 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.653 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 39.4 Cg_endo -67.0 137.18 43.72 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.564 2.176 . . . . 73.530000000000001 112.683 -178.359 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 42.0 p90 -149.52 163.95 36.41 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.738 -0.664 . . . . 73.329999999999998 110.294 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.47 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 96.3 m-85 -108.22 126.44 52.81 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.484 -0.325 . . . . 75.109999999999999 111.429 -176.797 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.436 ' HB3' ' HD2' ' A' ' 57' ' ' PHE . 36.9 mt -107.22 100.14 9.62 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.131 -0.486 . . . . 72.510000000000005 109.977 171.253 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.6 t -84.74 126.72 40.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.245 -0.434 . . . . 73.349999999999994 109.901 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.45 111.39 18.43 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.236 -0.653 . . . . 73.420000000000002 109.236 -178.542 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.05 168.89 19.01 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.8 -0.636 . . . . 64.420000000000002 111.411 -172.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -64.14 145.19 56.37 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.765 -0.652 . . . . 74.329999999999998 109.904 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.413 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 113.83 135.95 6.26 Favored Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.452 -0.88 . . . . 74.340000000000003 112.373 -179.785 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.2 m -79.24 19.68 0.56 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.931 0.396 . . . . 61.539999999999999 110.832 178.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.413 ' H ' ' C ' ' A' ' 52' ' ' GLY . 21.6 t70 -78.91 -42.61 26.7 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.026 0.441 . . . . 64.219999999999999 111.137 -177.313 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.84 36.4 2.99 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.698 -0.763 . . . . 75.319999999999993 111.919 -178.404 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.2 t30 -95.45 129.49 42.59 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.821 0.343 . . . . 74.049999999999997 110.539 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.436 ' HD2' ' HB3' ' A' ' 47' ' ' LEU . 34.7 m-85 -111.51 149.38 31.43 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.227 -0.442 . . . . 74.340000000000003 110.153 177.016 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 51.0 mm -121.57 125.73 73.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.22 -0.445 . . . . 74.430000000000007 109.98 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.568 ' HG3' HG13 ' A' ' 67' ' ' ILE . 27.4 mtp180 -81.6 141.08 34.05 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.438 -0.346 . . . . 72.120000000000005 110.66 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 33.7 t -70.0 -16.21 63.14 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.229 0.538 . . . . 74.140000000000001 109.894 176.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.453 ' OD1' ' HB3' ' A' ' 59' ' ' ARG . 0.4 OUTLIER -76.03 -34.41 59.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.4 -0.818 . . . . 73.310000000000002 109.945 178.169 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 47.7 mt-30 -143.26 70.36 18.01 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.443 -0.799 . . . . 74.329999999999998 109.786 -174.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -72.88 -2.35 11.83 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 123.325 2.684 . . . . 74.310000000000002 113.476 -175.067 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -94.06 -13.63 26.67 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.608 0.242 . . . . 71.450000000000003 111.332 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.406 ' HE2' ' HB2' ' A' ' 65' ' ' LYS . 0.0 OUTLIER -117.02 168.76 9.97 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-O 120.549 0.214 . . . . 73.049999999999997 110.943 -179.567 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.438 ' N ' HD13 ' A' ' 66' ' ' LEU . 4.1 mp -106.3 151.84 24.31 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 120.831 0.348 . . . . 74.109999999999999 111.032 -175.228 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.568 HG13 ' HG3' ' A' ' 59' ' ' ARG . 37.9 mm -119.54 104.98 44.43 Favored Pre-proline 0 C--N 1.325 -0.463 0 CA-C-N 116.192 -0.458 . . . . 74.510000000000005 109.98 177.519 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.548 ' O ' HG23 ' A' ' 72' ' ' ILE . 61.3 Cg_endo -73.77 177.42 8.11 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.822 2.348 . . . . 62.219999999999999 113.004 -178.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . 0.62 ' HA ' HG12 ' A' ' 72' ' ' ILE . 28.5 tt0 -65.32 -32.05 73.5 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 113.029 0.751 . . . . 72.329999999999998 113.029 -168.159 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 3.9 p90 -71.34 -18.95 62.36 Favored 'General case' 0 C--N 1.323 -0.545 0 O-C-N 121.517 -0.739 . . . . 74.430000000000007 110.592 178.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.481 ' HB3' HG21 ' A' ' 67' ' ' ILE . 4.8 tp10 -102.38 -17.76 15.7 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 115.749 -0.66 . . . . 72.430000000000007 110.549 -177.117 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.62 HG12 ' HA ' ' A' ' 69' ' ' GLN . 35.3 pt -74.26 -21.77 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.147 0 CA-C-O 121.256 0.55 . . . . 74.239999999999995 109.863 174.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -107.21 26.59 9.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.417 -0.81 . . . . 73.540000000000006 109.664 174.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.2 t -61.42 -29.84 70.19 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.197 -0.91 . . . . 65.540000000000006 110.234 179.295 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . 0.514 ' O ' ' HE3' ' A' ' 21' ' ' LYS . 28.3 p-90 . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.135 -0.484 . . . . 72.219999999999999 110.757 175.399 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 15.0 m . . . . . 0 C--O 1.233 0.236 0 CA-C-O 121.108 0.48 . . . . 72.430000000000007 110.737 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 124.49 -65.6 0.54 Allowed Glycine 0 N--CA 1.442 -0.953 0 N-CA-C 109.983 -1.247 . . . . 74.049999999999997 109.983 -174.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 66.82 86.4 0.13 Allowed Pre-proline 0 N--CA 1.463 0.178 0 O-C-N 124.334 0.667 . . . . 65.319999999999993 111.736 173.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.584 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 11.2 Cg_endo -77.58 97.16 1.13 Allowed 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 121.913 1.742 . . . . 72.549999999999997 110.775 177.441 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -128.81 150.82 50.15 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.407 -0.815 . . . . 75.310000000000002 109.67 -175.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.529 HG21 ' HB3' ' B' ' 124' ' ' GLN . 12.0 p -100.7 131.31 48.56 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 121.417 0.627 . . . . 75.109999999999999 111.748 -174.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 114' ' ' THR . . . . . 0.579 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 15.6 m -87.77 102.43 14.66 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.5 -0.773 . . . . 74.140000000000001 109.772 175.585 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 55.1 mt -91.03 105.82 16.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-O 120.829 0.347 . . . . 75.040000000000006 110.495 -176.291 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 28.7 mmm180 -112.85 157.89 20.84 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.259 -0.428 . . . . 74.340000000000003 110.464 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -121.22 99.32 6.42 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.23 -0.441 . . . . 61.140000000000001 109.961 178.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 57.5 mm-40 -109.59 80.86 1.36 Allowed 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.981 -0.554 . . . . 74.230000000000004 110.515 -176.353 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 82.26 -121.43 5.43 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 121.008 -0.615 . . . . 73.209999999999994 112.32 -179.351 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . 0.486 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 5.9 m-20 -88.57 0.89 55.88 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.914 0.388 . . . . 74.109999999999999 110.527 -176.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.615 ' HE2' ' HB2' ' B' ' 175' ' ' TRP . 15.6 pttp -125.47 124.67 41.9 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.349 0.595 . . . . 75.120000000000005 112.373 -172.54 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 122' ' ' THR . . . . . 0.44 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 33.4 m -83.97 109.7 17.84 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.044 -0.98 . . . . 75.25 108.595 172.114 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 53.2 mt -100.3 107.83 21.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.107 0.48 . . . . 75.450000000000003 110.627 -173.45 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.663 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 17.0 mt-30 -95.5 102.26 14.05 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.67 -0.695 . . . . 75.329999999999998 110.45 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . 0.579 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 43.3 mt-10 -86.87 102.31 14.2 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.265 -0.425 . . . . 73.5 110.365 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -78.54 104.83 9.4 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.122 0.487 . . . . 75.299999999999997 110.017 178.101 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . 0.508 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 82.6 mtm180 -126.14 136.76 53.26 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.653 -0.703 . . . . 71.519999999999996 110.141 -179.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.677 HG11 ' H ' ' B' ' 129' ' ' ASN . 2.4 p -84.81 -67.87 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 C-N-CA 120.32 -0.552 . . . . 72.109999999999999 109.658 175.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . 0.677 ' H ' HG11 ' B' ' 128' ' ' VAL . 2.2 t-20 -138.64 75.84 1.54 Allowed 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.56 -0.533 . . . . 72.019999999999996 109.56 178.332 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.7 -27.55 5.29 Favored Glycine 0 CA--C 1.518 0.231 0 CA-C-N 115.771 -0.65 . . . . 75.439999999999998 112.223 -178.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . 0.496 ' CG ' HG23 ' A' ' 28' ' ' VAL . 82.9 t80 -86.19 124.75 32.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.902 0.382 . . . . 65.530000000000001 111.225 -177.176 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.836 HD13 HG13 ' B' ' 135' ' ' ILE . 3.5 tm? -85.6 119.38 25.88 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.893 -0.78 . . . . 75.409999999999997 108.893 175.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 44.1 p90 -112.94 -17.11 12.55 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.495 -0.482 . . . . 75.420000000000002 111.787 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.46 133.22 6.43 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.717 0.294 . . . . 72.209999999999994 111.059 178.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.836 HG13 HD13 ' B' ' 132' ' ' LEU . 69.8 mt -113.28 120.34 62.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.453 -0.339 . . . . 74.409999999999997 110.174 174.4 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.663 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.9 tttt -101.0 104.64 15.81 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.682 -0.488 . . . . 74.519999999999996 109.682 176.213 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.61 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 2.7 t -90.91 128.67 42.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 108.928 -0.767 . . . . 74.409999999999997 108.928 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.44 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 20.3 t -112.96 73.34 1.57 Allowed Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.771 -0.455 . . . . 75.450000000000003 109.771 171.253 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.473 ' HD3' HG12 ' B' ' 137' ' ' VAL . 72.9 Cg_endo -80.66 143.84 15.24 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 122.438 2.092 . . . . 71.340000000000003 112.76 178.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . 0.486 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 30.0 mtpp -65.75 -23.77 66.81 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.483 -0.78 . . . . 74.209999999999994 110.383 174.04 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 72.6 m-70 -115.91 95.07 4.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.574 -0.739 . . . . 63.329999999999998 110.025 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . 0.452 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 127.58 -9.93 6.83 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.178 -1.011 . . . . 51.43 113.638 177.093 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 73.1 mmtt 70.64 155.9 0.15 Allowed Pre-proline 0 N--CA 1.472 0.644 0 CA-C-O 120.755 0.312 . . . . 75.329999999999998 111.164 -178.488 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.61 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 33.6 Cg_endo -66.48 135.13 38.17 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.192 1.928 . . . . 70.540000000000006 112.84 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . 0.471 ' HE1' ' HG3' ' B' ' 139' ' ' PRO . 14.7 p90 -146.4 161.28 40.71 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.768 -0.651 . . . . 73.099999999999994 110.205 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -106.75 138.46 42.88 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.27 -0.423 . . . . 72.439999999999998 111.758 -176.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . 0.463 ' HB2' ' HB ' ' B' ' 135' ' ' ILE . 18.7 mt -110.38 95.73 5.76 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.447 -0.797 . . . . 75.299999999999997 109.72 168.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 41.6 t -82.14 126.39 39.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 109.692 -0.484 . . . . 72.409999999999997 109.692 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . 0.463 HH11 ' HG3' ' B' ' 149' ' ' ARG . 0.0 OUTLIER -80.86 114.66 19.89 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.439 -0.578 . . . . 73.209999999999994 109.439 -179.228 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.75 165.18 25.65 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.627 -0.715 . . . . 70.420000000000002 111.005 -174.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -70.44 147.57 49.32 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.581 -0.526 . . . . 71.420000000000002 109.581 178.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 105.01 131.26 7.03 Favored Glycine 0 N--CA 1.436 -1.347 0 C-N-CA 120.61 -0.805 . . . . 61.340000000000003 111.357 -175.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 21.6 m -82.77 17.8 1.75 Allowed 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.286 0.565 . . . . 75.010000000000005 110.587 -178.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -64.77 -52.96 54.14 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.488 -0.778 . . . . 73.239999999999995 110.958 -178.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 125.86 50.36 0.18 Allowed Glycine 0 CA--C 1.505 -0.588 0 C-N-CA 120.657 -0.782 . . . . 74.109999999999999 112.025 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 4.9 m120 -119.06 134.29 55.28 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.356 -0.422 . . . . 74.239999999999995 111.484 -177.305 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . 0.439 ' HB2' HG23 ' B' ' 172' ' ' ILE . 29.6 m-85 -117.31 159.19 23.1 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.541 -0.754 . . . . 73.319999999999993 109.735 174.357 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . 0.823 HD13 HD22 ' B' ' 166' ' ' LEU . 47.4 mm -120.7 122.79 68.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 116.256 -0.429 . . . . 74.5 110.008 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.616 ' HG3' HG13 ' B' ' 167' ' ' ILE . 52.2 mtp180 -87.81 147.18 25.26 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.375 -0.375 . . . . 73.209999999999994 110.379 178.028 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 33.8 t -67.38 -20.64 65.57 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.337 0.589 . . . . 74.450000000000003 109.466 174.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . 0.462 ' OD1' ' HB3' ' B' ' 159' ' ' ARG . 0.5 OUTLIER -71.93 -34.19 68.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.221 -0.9 . . . . 71.140000000000001 109.869 177.248 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -141.47 76.88 20.31 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.448 -0.796 . . . . 75.010000000000005 109.709 -174.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -82.18 4.53 6.99 Favored 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 122.746 2.297 . . . . 73.510000000000005 113.326 -173.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -109.07 -11.07 14.99 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.804 0.335 . . . . 73.349999999999994 111.084 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -122.93 137.25 55.0 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.75 0.31 . . . . 75.549999999999997 110.907 -176.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . 0.823 HD22 HD13 ' B' ' 158' ' ' ILE . 93.6 mt -73.96 130.65 40.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.018 -0.537 . . . . 74.340000000000003 109.986 177.122 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . 0.616 HG13 ' HG3' ' B' ' 159' ' ' ARG . 42.3 mm -81.48 128.5 69.54 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 116.366 -0.379 . . . . 73.219999999999999 110.393 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.511 ' O ' HG22 ' B' ' 172' ' ' ILE . 40.0 Cg_endo -65.75 173.01 7.37 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 123.163 2.575 . . . . 74.409999999999997 112.789 -179.344 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 33.8 tt0 -86.11 3.76 41.21 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.825 -0.625 . . . . 74.129999999999995 112.181 -168.271 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . 0.452 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 33.7 p90 -104.05 -18.89 14.38 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.377 -0.529 . . . . 73.420000000000002 109.872 172.799 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.452 ' HG2' ' CD1' ' B' ' 170' ' ' TRP . 2.8 mm-40 -97.65 -10.47 24.98 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.566 -0.743 . . . . 74.310000000000002 111.393 -176.631 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.511 HG22 ' O ' ' B' ' 168' ' ' PRO . 30.7 pt -71.68 -21.52 21.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.877 -0.601 . . . . 75.450000000000003 110.171 175.537 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -112.09 46.49 1.15 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.41 -0.814 . . . . 74.219999999999999 108.995 174.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 174' ' ' SER . . . . . 0.45 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 2.1 t -74.89 -13.84 60.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.402 -0.817 . . . . 74.219999999999999 110.163 -178.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . 0.615 ' HB2' ' HE2' ' B' ' 121' ' ' LYS . 49.1 p-90 . . . . . 0 C--O 1.248 0.998 0 CA-C-N 115.502 -0.772 . . . . 74.129999999999995 109.85 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 41.6 m . . . . . 0 C--O 1.233 0.193 0 CA-C-O 121.112 0.482 . . . . 73.319999999999993 111.022 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -177.69 -38.72 0.06 OUTLIER Glycine 0 N--CA 1.446 -0.663 0 N-CA-C 110.71 -0.956 . . . . 72.239999999999995 110.71 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 54.05 66.29 4.52 Favored Pre-proline 0 N--CA 1.464 0.254 0 C-N-CA 123.556 0.742 . . . . 71.049999999999997 112.15 175.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.535 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 53.8 Cg_endo -76.97 137.49 17.53 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.169 1.912 . . . . 73.140000000000001 112.516 -178.317 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -141.4 155.83 45.86 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.968 -0.56 . . . . 74.439999999999998 109.738 179.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.8 p -110.88 129.75 65.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.273 0.559 . . . . 65.25 110.842 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.6 m -93.86 104.38 16.45 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.728 -0.669 . . . . 75.319999999999993 109.563 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 67.1 mt -90.1 106.82 17.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 116.301 -0.409 . . . . 75.109999999999999 110.351 -177.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 23.6 mmm180 -115.57 156.96 24.83 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.143 -0.48 . . . . 73.430000000000007 110.212 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 26.1 mp0 -121.58 127.17 50.64 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 121.098 0.475 . . . . 70.219999999999999 110.057 178.047 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -105.08 -60.58 1.59 Allowed 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.35 -0.841 . . . . 75.209999999999994 111.0 -172.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.55 ' C ' ' H ' ' A' ' 21' ' ' LYS . . . -156.95 76.58 0.2 Allowed Glycine 0 CA--C 1.507 -0.433 0 N-CA-C 110.353 -1.099 . . . . 73.430000000000007 110.353 178.741 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.53 ' HB3' ' HG3' ' A' ' 40' ' ' LYS . 19.2 m-20 70.07 -26.76 0.16 Allowed 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 123.519 0.728 . . . . 64.129999999999995 111.017 -170.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.55 ' H ' ' C ' ' A' ' 19' ' ' GLY . 22.7 pttm -83.42 120.21 25.61 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 121.198 0.523 . . . . 63.329999999999998 110.42 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.59 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 33.2 m -82.48 121.62 26.99 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.375 -0.83 . . . . 72.530000000000001 109.641 176.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 56.0 mt -111.33 106.77 21.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-O 121.036 0.446 . . . . 75.329999999999998 110.333 -178.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.651 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 19.2 mt-30 -100.53 111.04 23.24 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.788 -0.642 . . . . 75.409999999999997 110.756 -177.642 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 33.0 mt-10 -92.57 108.77 20.23 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.768 -0.651 . . . . 63.439999999999998 110.85 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.555 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 95.6 m-85 -83.0 104.65 13.37 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.968 0.414 . . . . 71.030000000000001 110.151 178.317 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -115.12 119.25 35.77 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.947 -0.569 . . . . 74.310000000000002 109.617 -179.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.802 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.7 p -73.26 -73.32 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 C-N-CA 120.786 -0.366 . . . . 74.409999999999997 110.879 -178.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.802 ' H ' HG13 ' A' ' 28' ' ' VAL . 7.6 t-20 -127.53 68.28 1.3 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.291 -0.633 . . . . 65.340000000000003 109.291 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 73.19 12.52 79.62 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.452 -0.795 . . . . 72.530000000000001 111.784 -175.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 29.5 t80 -129.33 124.08 33.42 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.818 0.342 . . . . 75.439999999999998 110.202 -175.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -72.41 132.76 44.35 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.611 -0.722 . . . . 74.409999999999997 109.781 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . 0.555 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 45.4 p90 -125.76 -22.81 4.13 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.127 0.417 . . . . 74.340000000000003 112.127 176.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.18 148.23 24.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.661 0.267 . . . . 75.230000000000004 111.022 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 61.6 mt -125.23 124.37 67.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 116.412 -0.358 . . . . 75.299999999999997 110.215 177.49 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.651 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.6 tttt -103.72 106.24 16.7 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.631 -0.507 . . . . 74.519999999999996 109.631 177.121 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.706 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.7 t -94.65 129.7 44.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 N-CA-C 109.226 -0.657 . . . . 75.129999999999995 109.226 177.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.59 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.4 t -117.6 72.57 7.81 Favored Pre-proline 0 C--N 1.317 -0.808 0 N-CA-C 109.845 -0.428 . . . . 72.329999999999998 109.845 173.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.594 ' HD3' HG13 ' A' ' 37' ' ' VAL . 54.1 Cg_endo -78.62 137.31 14.37 Favored 'Trans proline' 0 N--CA 1.456 -0.735 0 C-N-CA 122.197 1.932 . . . . 70.439999999999998 112.297 176.213 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.53 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 26.3 mtpp -68.76 -20.46 64.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.451 0.643 . . . . 62.130000000000003 109.868 178.333 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 84.7 m-70 -117.69 83.57 2.01 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.392 -0.822 . . . . 71.040000000000006 109.423 178.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.445 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 141.33 -22.0 2.58 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.945 -0.645 . . . . 64.510000000000005 112.339 -178.562 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.445 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 98.6 mttt 74.78 152.72 0.14 Allowed Pre-proline 0 N--CA 1.469 0.477 0 C-N-CA 123.579 0.752 . . . . 74.319999999999993 111.889 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.706 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 35.1 Cg_endo -66.73 136.37 41.9 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.651 2.234 . . . . 74.519999999999996 113.247 -178.139 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -142.33 162.32 35.77 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.511 -0.768 . . . . 62.140000000000001 109.589 176.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -106.11 123.19 47.63 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.397 -0.365 . . . . 72.349999999999994 110.244 178.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.451 HD13 HG13 ' A' ' 67' ' ' ILE . 28.5 tp -102.27 96.1 6.74 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 108.792 -0.818 . . . . 74.430000000000007 108.792 172.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.5 t -93.63 120.63 43.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.749 -0.659 . . . . 73.400000000000006 110.181 -175.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.7 tmm_? -77.88 121.47 24.18 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 109.065 -0.717 . . . . 74.239999999999995 109.065 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.15 -162.98 0.26 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.913 -0.585 . . . . 75.299999999999997 111.269 -173.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.41 ' OD2' ' HB2' ' A' ' 53' ' ' SER . 5.7 p-10 -73.76 154.78 39.43 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.161 0.505 . . . . 73.530000000000001 110.805 -177.443 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -65.29 -22.35 69.14 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.641 -0.709 . . . . 62.109999999999999 113.28 -177.422 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.41 ' HB2' ' OD2' ' A' ' 51' ' ' ASP . 14.5 m -73.52 -39.9 64.43 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.089 0.471 . . . . 63.210000000000001 109.958 178.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.514 ' OD2' ' HB3' ' A' ' 56' ' ' ASN . 31.2 t70 -71.66 -39.76 70.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.506 -0.77 . . . . 54.240000000000002 109.835 175.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 58.95 63.49 5.15 Favored Glycine 0 C--N 1.336 0.557 0 CA-C-N 115.78 -0.646 . . . . 74.430000000000007 111.663 178.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.514 ' HB3' ' OD2' ' A' ' 54' ' ' ASP . 14.6 t30 -165.36 155.76 13.51 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.685 -0.257 . . . . 73.310000000000002 110.331 -168.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.545 ' HB2' ' HB ' ' A' ' 67' ' ' ILE . 2.4 m-85 -108.68 143.11 38.2 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.162 -0.681 . . . . 75.439999999999998 109.162 174.448 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 48.1 mm -113.53 127.46 70.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.436 0.636 . . . . 74.549999999999997 110.319 177.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.456 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 58.5 ttt180 -93.63 124.09 37.39 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.309 -0.86 . . . . 73.0 109.685 -176.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 87.9 p -59.67 -26.77 65.82 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.242 0.544 . . . . 75.019999999999996 110.788 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.456 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 16.5 t70 -60.22 -39.71 87.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.211 -0.904 . . . . 64.230000000000004 110.711 177.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 29.3 mt-30 -144.67 89.01 6.85 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 115.947 -0.569 . . . . 71.109999999999999 109.863 -179.018 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -62.58 -24.71 75.22 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 123.1 2.533 . . . . 75.129999999999995 113.261 -175.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -78.84 -14.27 59.34 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 120.747 0.308 . . . . 75.040000000000006 110.73 178.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.2 tptm -93.71 123.42 37.02 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.459 0.647 . . . . 62.119999999999997 110.892 -177.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.406 HD13 ' N ' ' A' ' 66' ' ' LEU . 5.5 mp -90.24 128.48 36.41 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 114.798 -1.092 . . . . 61.399999999999999 108.688 175.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.737 HG21 ' HB3' ' A' ' 71' ' ' GLU . 47.0 mm -87.9 112.67 50.6 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-O 120.854 0.359 . . . . 72.209999999999994 111.373 -172.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.561 ' O ' HG23 ' A' ' 72' ' ' ILE . 60.0 Cg_endo -71.44 174.97 10.07 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.833 2.355 . . . . 74.400000000000006 112.036 179.163 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -79.15 1.85 22.96 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 112.987 0.736 . . . . 64.319999999999993 112.987 -166.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 42.4 p90 -107.04 -19.62 13.56 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.437 0.637 . . . . 71.420000000000002 109.953 172.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.737 ' HB3' HG21 ' A' ' 67' ' ' ILE . 2.8 mm-40 -87.41 -17.46 32.23 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.462 -0.79 . . . . 74.299999999999997 110.332 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.561 HG23 ' O ' ' A' ' 68' ' ' PRO . 42.3 pt -63.23 -28.39 44.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.885 -0.598 . . . . 74.540000000000006 111.412 -179.005 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.467 ' HD1' HG13 ' A' ' 72' ' ' ILE . 41.0 p90 -117.25 42.77 2.47 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.581 0.705 . . . . 74.319999999999993 109.584 175.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 4.7 t -59.27 -25.2 63.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.05 -0.977 . . . . 64.540000000000006 110.801 -179.567 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 26.6 p-90 . . . . . 0 C--N 1.327 -0.397 0 CA-C-N 115.925 -0.579 . . . . 74.329999999999998 111.267 177.479 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 57.1 m . . . . . 0 C--O 1.234 0.268 0 CA-C-O 121.451 0.643 . . . . 74.120000000000005 111.089 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 125.24 -60.8 0.62 Allowed Glycine 0 N--CA 1.44 -1.073 0 N-CA-C 109.129 -1.588 . . . . 61.219999999999999 109.129 -169.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 61.08 88.34 0.12 Allowed Pre-proline 0 CA--C 1.52 -0.209 0 O-C-N 124.322 0.66 . . . . 73.310000000000002 111.27 171.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.895 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 7.3 Cg_endo -76.41 102.83 1.66 Allowed 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.173 1.915 . . . . 74.230000000000004 111.098 -178.497 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -102.89 150.36 23.59 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.037 -0.528 . . . . 61.43 109.838 -177.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.638 HG23 ' HB3' ' B' ' 124' ' ' GLN . 14.9 p -113.05 131.58 64.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 121.401 0.62 . . . . 72.349999999999994 111.617 -175.153 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 48.1 m -89.46 118.86 29.42 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.314 -0.857 . . . . 71.200000000000003 109.373 174.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 63.5 mt -92.54 105.25 16.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.07 0.462 . . . . 74.319999999999993 111.175 -174.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . 0.54 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 11.0 mmm180 -99.12 153.0 19.23 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.952 -0.567 . . . . 74.409999999999997 110.459 177.224 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 76.0 mt-30 -134.81 99.19 4.24 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.537 -0.912 . . . . 75.450000000000003 108.537 176.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . 0.443 ' HG3' HD11 ' B' ' 123' ' ' ILE . 43.2 mm-40 -103.6 9.25 37.47 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.125 -0.489 . . . . 74.200000000000003 112.205 -169.333 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . 0.424 ' C ' ' H ' ' B' ' 121' ' ' LYS . . . 109.45 100.81 2.64 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.37 -0.919 . . . . 64.129999999999995 111.92 -178.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . 0.573 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 9.5 m-20 66.66 -9.57 0.33 Allowed 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 124.085 0.954 . . . . 73.549999999999997 111.672 -176.515 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.478 ' HB3' ' HB3' ' B' ' 139' ' ' PRO . 27.1 pttt -131.56 115.71 16.47 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 121.243 0.544 . . . . 75.25 112.074 -176.618 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 59.4 m -82.39 114.03 20.57 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.08 -0.964 . . . . 72.5 109.243 172.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . 0.68 HG12 HG12 ' B' ' 137' ' ' VAL . 49.8 mt -101.51 105.94 18.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 CA-C-O 121.326 0.584 . . . . 74.519999999999996 110.377 -176.114 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.638 ' HB3' HG23 ' B' ' 113' ' ' VAL . 49.7 mt-30 -96.01 106.89 19.11 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.444 -0.798 . . . . 75.120000000000005 110.974 -176.571 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -90.06 106.09 18.24 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.841 -0.618 . . . . 74.109999999999999 110.631 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -85.1 107.06 17.01 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.994 0.426 . . . . 75.200000000000003 110.698 -179.586 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . 0.497 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 79.0 mtm180 -120.39 120.52 36.22 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.137 0.494 . . . . 75.310000000000002 110.204 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.895 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -76.79 -62.5 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.893 -0.594 . . . . 72.219999999999999 111.021 -178.177 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . 0.568 ' H ' HG11 ' B' ' 128' ' ' VAL . 1.2 t-20 -149.21 76.82 1.34 Allowed 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.638 -0.504 . . . . 64.010000000000005 109.638 -178.54 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.75 -7.34 66.11 Favored Glycine 0 CA--C 1.521 0.438 0 CA-C-N 115.817 -0.629 . . . . 45.43 113.058 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 54.4 t80 -122.31 123.25 40.98 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.151 0.5 . . . . 71.450000000000003 111.27 -176.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.687 HD12 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -76.6 117.84 18.64 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.09 -0.959 . . . . 75.120000000000005 108.888 173.431 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -108.06 -22.85 12.23 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.478 -0.489 . . . . 71.049999999999997 111.525 -178.233 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -157.62 143.05 17.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.929 0.395 . . . . 75.0 111.329 -178.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.687 HG13 HD12 ' B' ' 132' ' ' LEU . 76.5 mt -121.77 121.75 65.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 115.895 -0.593 . . . . 72.140000000000001 110.067 176.333 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.469 ' HD2' ' CZ ' ' B' ' 146' ' ' PHE . 82.2 tttt -102.79 105.06 15.41 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.928 0.394 . . . . 71.200000000000003 109.99 177.373 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.68 HG12 HG12 ' B' ' 123' ' ' ILE . 5.0 t -90.46 132.37 35.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 108.653 -0.869 . . . . 74.420000000000002 108.653 176.08 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.497 HG11 ' HB3' ' B' ' 144' ' ' PRO . 20.6 t -114.21 71.73 2.21 Favored Pre-proline 0 C--N 1.317 -0.822 0 N-CA-C 109.907 -0.405 . . . . 72.319999999999993 109.907 173.345 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.564 ' HD3' HG13 ' B' ' 137' ' ' VAL . 74.3 Cg_endo -81.13 134.42 9.24 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.082 1.855 . . . . 73.420000000000002 113.243 178.534 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . 0.573 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 28.8 mtpp -60.04 -26.85 66.45 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.291 -0.868 . . . . 65.019999999999996 109.84 171.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 89.4 m-70 -116.8 89.5 3.12 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.282 -0.872 . . . . 73.420000000000002 109.492 177.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 138.36 -19.14 3.23 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.482 -0.866 . . . . 62.350000000000001 112.536 -179.294 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 47.0 mtmt 71.62 147.21 0.12 Allowed Pre-proline 0 N--CA 1.469 0.522 0 C-N-CA 123.309 0.643 . . . . 73.040000000000006 111.637 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.674 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 29.6 Cg_endo -64.8 125.81 15.48 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.584 2.189 . . . . 74.239999999999995 112.626 -179.356 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . 0.41 ' HH ' ' HD1' ' B' ' 175' ' ' TRP . 25.7 p90 -139.88 160.29 40.23 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.076 -0.511 . . . . 74.420000000000002 110.383 179.404 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.469 ' CZ ' ' HD2' ' B' ' 136' ' ' LYS . 70.4 m-85 -104.54 122.18 45.02 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.091 -0.504 . . . . 73.019999999999996 110.04 178.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 26.0 tp -97.86 93.33 6.28 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 108.248 -1.019 . . . . 74.409999999999997 108.248 171.329 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.6 t -95.39 129.11 45.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.755 -0.657 . . . . 74.319999999999993 110.55 -173.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . 0.597 HH11 ' HG3' ' B' ' 149' ' ' ARG . 0.0 OUTLIER -79.45 123.22 27.33 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 116.217 -0.447 . . . . 75.510000000000005 109.871 177.462 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -77.41 -168.32 1.12 Allowed 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.815 -0.63 . . . . 72.400000000000006 110.034 177.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -56.94 147.13 24.63 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.174 -0.466 . . . . 75.129999999999995 110.792 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -75.14 -10.32 84.2 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.541 -0.838 . . . . 60.240000000000002 112.745 -177.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 1.6 m -67.67 -38.33 83.59 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.888 0.851 . . . . 71.349999999999994 108.729 172.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 15.1 t0 -80.36 -42.08 23.56 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.335 -1.302 . . . . 74.140000000000001 109.627 175.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 69.38 18.8 73.78 Favored Glycine 0 C--N 1.331 0.27 0 CA-C-N 115.17 -0.923 . . . . 72.340000000000003 112.139 -177.132 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 39.2 t30 -104.63 155.43 18.86 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 122.453 0.301 . . . . 74.340000000000003 111.656 -169.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . 0.63 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 8.3 m-85 -110.28 146.63 35.35 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.922 -0.77 . . . . 73.430000000000007 108.922 173.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.7 mm -118.31 133.39 65.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.038 0.447 . . . . 54.020000000000003 110.341 178.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.516 ' HD2' HD13 ' B' ' 167' ' ' ILE . 9.5 ttt180 -88.69 122.24 31.91 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.208 -0.664 . . . . 75.439999999999998 109.208 -179.001 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 66.5 p -57.66 -30.56 65.53 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 112.141 0.423 . . . . 61.240000000000002 112.141 -174.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -69.66 -40.45 76.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.068 0.461 . . . . 62.210000000000001 111.244 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 12.4 tt0 -130.33 88.84 46.41 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-N 116.139 -0.482 . . . . 73.219999999999999 110.178 -175.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -67.8 -12.76 36.49 Favored 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.917 2.411 . . . . 63.0 112.29 -179.083 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -84.58 -6.32 59.36 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.735 -0.666 . . . . 64.209999999999994 110.144 176.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 22.2 tptm -109.26 123.67 49.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.547 0.689 . . . . 73.219999999999999 110.998 -177.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . 0.473 HD11 ' N ' ' B' ' 166' ' ' LEU . 4.0 mp -91.21 135.2 33.95 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 114.731 -1.122 . . . . 75.129999999999995 108.204 175.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . 0.63 ' HB ' ' HB2' ' B' ' 157' ' ' PHE . 48.1 mm -95.93 113.11 61.46 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-O 121.037 0.446 . . . . 75.430000000000007 111.303 -173.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.478 ' O ' HG22 ' B' ' 172' ' ' ILE . 55.9 Cg_endo -69.91 177.95 5.17 Favored 'Trans proline' 0 N--CA 1.464 -0.253 0 C-N-CA 123.15 2.566 . . . . 73.329999999999998 112.479 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -85.86 6.39 28.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.976 -0.557 . . . . 74.129999999999995 112.269 -168.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 30.4 p90 -107.7 -25.32 11.35 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.207 0.527 . . . . 75.239999999999995 110.007 171.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . . . . . . . . . 21.0 mm-40 -80.77 -14.7 57.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.753 -0.658 . . . . 75.519999999999996 110.9 -179.051 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.524 HG13 ' CD2' ' B' ' 173' ' ' PHE . 26.5 pt -72.64 -12.02 15.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.86 -0.609 . . . . 72.420000000000002 112.291 -176.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . 0.524 ' CD2' HG13 ' B' ' 172' ' ' ILE . 88.4 m-85 -126.83 21.03 7.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.44 0.638 . . . . 72.409999999999997 109.785 176.323 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 7.8 t -95.76 28.77 2.91 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.115 -0.948 . . . . 62.039999999999999 110.925 -175.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . 0.41 ' HD1' ' HH ' ' B' ' 145' ' ' TYR . 6.3 m0 . . . . . 0 C--O 1.244 0.794 0 CA-C-O 118.201 -0.904 . . . . 73.409999999999997 111.679 -176.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 18.2 m . . . . . 0 C--O 1.234 0.266 0 CA-C-O 120.908 0.385 . . . . 73.299999999999997 111.256 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 83.34 -60.54 4.87 Favored Glycine 0 N--CA 1.447 -0.619 0 N-CA-C 110.763 -0.935 . . . . 73.120000000000005 110.763 -173.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 60.19 88.35 0.12 Allowed Pre-proline 0 N--CA 1.463 0.214 0 C-N-CA 123.818 0.847 . . . . 74.129999999999995 112.235 176.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.611 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 37.5 Cg_endo -83.75 102.31 0.97 Allowed 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.344 2.03 . . . . 73.049999999999997 111.145 175.537 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.538 ' HA ' ' HB2' ' B' ' 151' ' ' ASP . 5.8 p-10 -130.06 140.91 50.77 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.186 0.517 . . . . 71.519999999999996 110.026 179.09 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.659 HG22 ' HB3' ' A' ' 24' ' ' GLN . 14.1 p -85.05 130.8 35.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.864 -0.607 . . . . 75.340000000000003 110.958 -176.392 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.477 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 34.3 m -88.26 105.07 17.3 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 109.674 -0.491 . . . . 74.519999999999996 109.674 177.359 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 72.2 mt -87.82 111.24 21.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.938 -0.574 . . . . 71.140000000000001 110.51 -177.091 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.46 ' HG2' ' O ' ' A' ' 23' ' ' ILE . 12.9 ptm180 -126.4 173.78 9.1 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.438 -0.578 . . . . 74.549999999999997 109.438 178.15 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -138.3 101.23 4.33 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.834 0.349 . . . . 75.409999999999997 110.222 -176.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.555 ' HG3' HD12 ' A' ' 23' ' ' ILE . 11.3 mm-40 -97.83 90.17 4.86 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.793 -0.64 . . . . 75.209999999999994 109.969 -176.278 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 75.51 -92.78 0.89 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.788 -0.72 . . . . 64.319999999999993 112.183 -178.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.588 ' HB2' ' HB2' ' A' ' 40' ' ' LYS . 7.3 p-10 -102.85 -36.73 8.14 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.438 0.637 . . . . 74.319999999999993 110.592 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.469 ' HB3' ' HA ' ' A' ' 39' ' ' PRO . 5.8 pttm -92.94 127.27 38.39 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.602 -0.727 . . . . 72.540000000000006 112.38 -167.226 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.455 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 46.6 m -82.67 96.01 8.0 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 114.771 -1.104 . . . . 64.200000000000003 108.326 174.162 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.712 HG12 HG21 ' A' ' 37' ' ' VAL . 48.5 mt -86.37 112.25 22.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.854 -0.612 . . . . 74.549999999999997 110.349 -175.336 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.659 ' HB3' HG22 ' A' ' 13' ' ' VAL . 47.7 mt-30 -94.01 104.63 16.67 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.738 -0.664 . . . . 73.219999999999999 110.464 179.456 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.477 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 26.7 mt-10 -87.48 100.6 12.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.673 -0.694 . . . . 74.400000000000006 110.868 -178.256 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -75.33 97.83 3.68 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.812 -0.44 . . . . 75.099999999999994 109.812 176.212 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.474 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 71.8 mtm180 -120.49 127.02 51.81 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.158 -0.474 . . . . 65.329999999999998 109.882 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.611 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 2.5 p -83.08 -64.26 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.643 -0.423 . . . . 75.310000000000002 110.843 178.675 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.586 ' H ' HG12 ' A' ' 28' ' ' VAL . 4.8 t-20 -142.72 69.25 1.31 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.175 0.512 . . . . 72.219999999999999 110.292 -176.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 88.18 1.87 81.14 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.562 -0.745 . . . . 70.439999999999998 113.474 176.223 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.403 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 60.7 t80 -131.24 127.01 36.97 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 117.151 0.476 . . . . 75.540000000000006 111.356 179.861 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.827 HD12 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -72.48 120.27 17.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.284 -0.871 . . . . 74.230000000000004 109.545 174.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -111.88 -19.51 12.37 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.396 -0.522 . . . . 73.150000000000006 111.746 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.44 141.56 18.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.832 0.349 . . . . 75.109999999999999 111.216 178.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.827 HG13 HD12 ' A' ' 32' ' ' LEU . 93.7 mt -119.73 117.36 53.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.36 -0.382 . . . . 72.310000000000002 110.723 176.706 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 45' ' ' TYR . 85.7 tttt -102.14 100.23 10.44 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.536 -0.913 . . . . 74.340000000000003 108.536 172.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.712 HG21 HG12 ' A' ' 23' ' ' ILE . 8.4 p -95.38 131.57 41.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 CA-C-N 116.174 -0.466 . . . . 74.439999999999998 110.045 -176.679 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.632 HG13 ' HG3' ' A' ' 44' ' ' PRO . 40.7 t -108.05 88.54 4.75 Favored Pre-proline 0 C--N 1.323 -0.559 0 N-CA-C 109.496 -0.557 . . . . 74.310000000000002 109.496 175.057 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.469 ' HA ' ' HB3' ' A' ' 21' ' ' LYS . 73.7 Cg_endo -82.39 141.26 11.23 Favored 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 122.51 2.14 . . . . 70.340000000000003 112.314 -178.395 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.588 ' HB2' ' HB2' ' A' ' 20' ' ' ASP . 27.9 mtpp -77.92 -14.93 59.38 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.346 0.593 . . . . 75.239999999999995 109.935 179.301 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 -116.43 25.63 10.48 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.342 -0.844 . . . . 72.400000000000006 110.203 -176.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -164.41 -148.64 5.51 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.28 -0.873 . . . . 44.219999999999999 111.128 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.1 pttp -131.9 142.63 45.87 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 117.238 0.519 . . . . 73.239999999999995 110.081 175.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.644 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 50.2 Cg_exo -53.15 135.53 59.67 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 123.55 2.833 . . . . 64.040000000000006 112.926 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.489 ' O ' ' HA ' ' A' ' 36' ' ' LYS . 4.6 p90 -142.32 160.44 40.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.163 -0.471 . . . . 74.040000000000006 110.69 177.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.658 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 92.0 m-85 -99.97 121.87 42.01 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.862 -0.608 . . . . 65.129999999999995 109.416 173.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 18.1 tp -108.36 97.43 7.11 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.913 -0.773 . . . . 74.349999999999994 108.913 175.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.419 HG22 HG23 ' B' ' 148' ' ' VAL . 38.4 t -93.94 135.41 28.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.255 -0.429 . . . . 74.129999999999995 111.282 -172.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . 0.625 HH21 ' HA ' ' A' ' 53' ' ' SER . 13.3 tpt180 -73.1 124.59 25.86 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.876 -0.602 . . . . 74.219999999999999 111.112 176.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.42 174.47 10.79 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.884 -0.598 . . . . 64.519999999999996 109.928 173.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -70.65 145.27 50.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.764 0.316 . . . . 71.200000000000003 110.596 -178.194 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.479 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 86.27 158.45 31.29 Favored Glycine 0 N--CA 1.428 -1.868 0 CA-C-O 122.133 0.852 . . . . 74.439999999999998 112.844 175.57 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.625 ' HA ' HH21 ' A' ' 49' ' ' ARG . 49.5 m -80.65 26.71 0.39 Allowed 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 114.604 -0.798 . . . . 72.420000000000002 110.113 170.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.479 ' H ' ' C ' ' A' ' 52' ' ' GLY . 22.6 t70 -56.77 -39.24 73.68 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.123 -0.944 . . . . 74.200000000000003 111.611 -178.149 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.48 16.41 20.32 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.511 -0.852 . . . . 52.229999999999997 113.068 176.325 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -112.63 148.39 34.71 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.049 0.452 . . . . 73.230000000000004 110.31 177.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -124.1 163.06 22.27 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.739 -0.664 . . . . 72.319999999999993 109.656 176.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.771 HD11 HD23 ' A' ' 66' ' ' LEU . 46.1 mm -121.27 123.81 70.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 N-CA-C 109.538 -0.541 . . . . 73.209999999999994 109.538 177.211 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.655 ' HD2' ' HB3' ' A' ' 61' ' ' ASP . 11.6 ttm180 -92.2 145.63 24.35 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.806 -0.442 . . . . 73.450000000000003 109.806 -176.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.729 ' HB2' ' HB3' ' B' ' 163' ' ' PRO . 23.8 p -61.13 -39.89 91.76 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.573 0.702 . . . . 74.109999999999999 110.133 174.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.655 ' HB3' ' HD2' ' A' ' 59' ' ' ARG . 27.7 t70 -68.34 -28.28 67.0 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 114.808 -1.087 . . . . 73.200000000000003 110.817 178.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . 0.416 ' HB3' ' HB3' ' A' ' 65' ' ' LYS . 86.7 mm-40 -133.52 73.14 73.46 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.022 -0.535 . . . . 61.130000000000003 110.254 -175.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -75.81 -17.2 18.01 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.568 2.179 . . . . 74.329999999999998 112.703 -174.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -101.62 7.32 42.19 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.03 -0.532 . . . . 71.310000000000002 110.697 -178.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.416 ' HB3' ' HB3' ' A' ' 62' ' ' GLN . 83.4 tttt -123.32 135.27 54.12 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.013 -0.539 . . . . 74.120000000000005 110.74 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.771 HD23 HD11 ' A' ' 58' ' ' ILE . 40.7 mt -84.75 112.21 20.29 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.882 -0.784 . . . . 72.150000000000006 108.882 175.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 51.4 mm -70.68 117.85 59.36 Favored Pre-proline 0 C--N 1.322 -0.629 0 CA-C-N 116.142 -0.481 . . . . 71.319999999999993 110.841 -176.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.91 178.62 6.99 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 123.28 2.653 . . . . 74.510000000000005 112.86 -178.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . 0.631 ' HA ' HG12 ' A' ' 72' ' ' ILE . 27.7 tt0 -74.76 -34.62 62.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.853 -0.612 . . . . 72.5 111.521 -170.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 16.0 p90 -67.66 -20.51 65.32 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.39 -0.524 . . . . 75.040000000000006 110.279 178.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -91.4 -28.42 17.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.334 -0.394 . . . . 71.519999999999996 111.404 -179.177 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.631 HG12 ' HA ' ' A' ' 69' ' ' GLN . 37.4 pt -74.81 -23.49 17.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.103 0.478 . . . . 75.319999999999993 110.274 176.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.495 ' HE2' HE21 ' A' ' 69' ' ' GLN . 38.1 m-85 -105.33 29.51 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.006 -0.543 . . . . 73.530000000000001 110.637 176.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 22.8 t -82.25 32.25 0.39 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.261 0.553 . . . . 54.439999999999998 110.863 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 54.3 m0 . . . . . 0 C--N 1.323 -0.552 0 CA-C-N 116.128 -0.487 . . . . 73.340000000000003 110.852 179.923 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 5.2 p . . . . . 0 C--O 1.234 0.282 0 CA-C-O 121.305 0.574 . . . . 75.540000000000006 111.534 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 100.98 -73.48 0.39 Allowed Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 109.999 -1.24 . . . . 74.140000000000001 109.999 -172.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 54.17 74.47 0.74 Allowed Pre-proline 0 C--N 1.329 -0.317 0 O-C-N 124.154 0.561 . . . . 75.439999999999998 111.259 175.459 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.94 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 18.0 Cg_endo -63.01 99.47 0.22 Allowed 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 122.106 1.871 . . . . 64.310000000000002 110.594 178.339 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -106.81 155.04 20.14 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.335 -0.848 . . . . 71.400000000000006 110.635 -173.217 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.619 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 12.4 p -111.54 124.68 68.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 CA-C-O 121.557 0.694 . . . . 73.319999999999993 110.421 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 114' ' ' THR . . . . . 0.569 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 26.2 m -87.47 105.03 17.01 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.591 -0.731 . . . . 74.219999999999999 110.094 178.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.7 mt -83.48 106.07 13.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.955 -0.566 . . . . 72.010000000000005 110.375 -178.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . 0.405 ' HG3' HG22 ' B' ' 114' ' ' THR . 44.0 mtm105 -124.09 -178.9 4.22 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.403 -0.362 . . . . 74.230000000000004 110.465 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 64.0 mt-30 -144.76 115.21 7.61 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.205 -0.452 . . . . 72.209999999999994 111.056 -178.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . 0.456 ' O ' ' HE2' ' B' ' 121' ' ' LYS . 76.7 mm-40 -101.52 81.98 2.24 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.563 -0.532 . . . . 70.329999999999998 109.563 175.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 91.11 -110.83 3.88 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.657 -0.782 . . . . 64.530000000000001 111.4 -175.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . 0.814 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 18.2 m-20 -115.06 24.01 12.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.786 0.327 . . . . 74.030000000000001 110.488 178.178 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.469 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 22.5 pttt -124.55 120.1 30.98 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.232 0.539 . . . . 71.420000000000002 110.833 178.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 49.1 m -79.38 104.9 10.31 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.414 -0.812 . . . . 72.230000000000004 109.588 177.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . 0.473 HD12 ' CE3' ' B' ' 175' ' ' TRP . 52.8 mt -97.52 112.54 29.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.122 0.487 . . . . 74.329999999999998 110.408 -176.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.619 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 51.2 mt-30 -92.29 105.7 17.85 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.449 -0.796 . . . . 74.25 110.552 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . 0.569 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 41.7 mt-10 -88.3 100.78 13.27 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.774 -0.648 . . . . 74.040000000000006 110.421 -178.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . 0.462 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 63.4 m-85 -78.25 110.28 13.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.528 -0.305 . . . . 74.239999999999995 110.538 179.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . 0.419 ' HA ' ' O ' ' B' ' 131' ' ' PHE . 84.6 mtm180 -132.99 120.23 21.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.295 -0.411 . . . . 75.25 110.258 -179.622 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.94 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.5 p -83.51 -54.37 9.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.234 -0.439 . . . . 74.25 111.181 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 32.8 t-20 -150.08 79.25 1.36 Allowed 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.958 -0.386 . . . . 73.230000000000004 109.958 -175.136 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.65 30.36 74.55 Favored Glycine 0 N--CA 1.452 -0.234 0 CA-C-N 115.537 -0.756 . . . . 72.430000000000007 112.867 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . 0.419 ' O ' ' HA ' ' B' ' 127' ' ' ARG . 87.2 t80 -147.86 127.22 13.09 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.856 0.36 . . . . 70.519999999999996 111.256 179.594 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.725 HD12 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -81.25 111.47 17.69 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.467 -0.788 . . . . 75.439999999999998 108.948 174.758 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . 0.462 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 51.6 p90 -106.98 -15.53 14.67 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.68 -0.408 . . . . 73.450000000000003 111.57 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . 0.52 ' HB1' ' CE2' ' B' ' 146' ' ' PHE . . . -159.07 145.18 16.61 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.947 0.403 . . . . 62.210000000000001 111.576 -178.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.725 HG13 HD12 ' B' ' 132' ' ' LEU . 75.7 mt -125.47 123.66 65.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.936 -0.574 . . . . 74.129999999999995 110.162 176.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.434 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 88.5 tttt -116.15 102.32 9.5 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.396 -0.594 . . . . 74.319999999999993 109.396 174.374 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.523 HG12 ' CE1' ' B' ' 145' ' ' TYR . 0.9 OUTLIER -102.36 127.07 56.31 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.088 0.471 . . . . 75.349999999999994 110.947 -177.603 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.794 HG23 ' HB3' ' B' ' 144' ' ' PRO . 22.8 t -112.55 88.83 11.74 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 115.235 -0.893 . . . . 71.310000000000002 109.73 -179.309 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.469 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 67.0 Cg_endo -77.95 134.54 13.31 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.137 1.891 . . . . 63.409999999999997 112.717 178.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . 0.814 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 58.2 mtpt -62.75 -28.18 69.79 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.577 -0.738 . . . . 72.200000000000003 110.251 173.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -96.43 43.84 1.07 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.996 -1.002 . . . . 75.420000000000002 110.187 -177.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 164.2 -146.71 11.75 Favored Glycine 0 N--CA 1.446 -0.645 0 CA-C-N 115.531 -0.759 . . . . 75.019999999999996 111.766 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 34.1 mmtp -126.68 150.0 69.87 Favored Pre-proline 0 C--N 1.322 -0.63 0 N-CA-C 110.206 -0.294 . . . . 74.299999999999997 110.206 177.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.794 ' HB3' HG23 ' B' ' 138' ' ' VAL . 18.6 Cg_endo -61.37 145.16 98.51 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.827 2.351 . . . . 75.109999999999999 112.22 178.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . 0.543 ' HH ' ' HB3' ' B' ' 175' ' ' TRP . 12.6 p90 -148.89 164.05 35.63 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.205 -0.452 . . . . 75.409999999999997 110.15 177.11 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.52 ' CE2' ' HB1' ' B' ' 134' ' ' ALA . 0.8 OUTLIER -113.14 142.13 46.12 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.901 -0.591 . . . . 75.340000000000003 111.17 -172.437 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . 0.432 ' HB3' ' CD2' ' B' ' 157' ' ' PHE . 20.7 mt -126.65 108.74 11.37 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.972 -0.558 . . . . 75.040000000000006 109.659 170.074 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . 0.419 HG23 HG22 ' A' ' 48' ' ' VAL . 38.8 t -90.86 130.59 39.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.262 -0.426 . . . . 75.340000000000003 110.274 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . 0.452 ' HD3' ' CZ ' ' B' ' 157' ' ' PHE . 45.5 tpt85 -85.1 104.38 14.95 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.53 -0.544 . . . . 73.099999999999994 109.53 179.134 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.1 -178.85 0.85 Allowed 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.049 -0.523 . . . . 72.329999999999998 110.496 179.096 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . 0.538 ' HB2' ' HA ' ' A' ' 12' ' ' ASP . 2.2 p-10 -84.21 158.62 21.22 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.846 -0.427 . . . . 73.019999999999996 109.846 179.343 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 96.68 139.19 10.41 Favored Glycine 0 N--CA 1.439 -1.152 0 C-N-CA 120.049 -1.072 . . . . 70.200000000000003 112.609 176.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 16.3 m -77.6 43.12 0.39 Allowed 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.357 0.599 . . . . 72.420000000000002 110.97 176.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -89.15 -28.35 20.09 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.522 -0.763 . . . . 72.129999999999995 110.467 -178.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 88.79 31.39 12.73 Favored Glycine 0 N--CA 1.451 -0.36 0 N-CA-C 111.067 -0.813 . . . . 64.310000000000002 111.067 -174.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . 0.764 HD22 HD22 ' B' ' 166' ' ' LEU . 26.9 t30 -100.46 130.94 46.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.147 -0.526 . . . . 74.209999999999994 111.606 -172.571 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . 0.452 ' CZ ' ' HD3' ' B' ' 149' ' ' ARG . 29.2 m-85 -121.02 160.61 23.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.639 -0.71 . . . . 73.519999999999996 109.572 175.134 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . 0.796 HD12 HD21 ' B' ' 166' ' ' LEU . 46.0 mm -119.74 118.27 56.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.492 -0.558 . . . . 65.219999999999999 109.492 174.206 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.545 ' HG2' ' H ' ' B' ' 161' ' ' ASP . 20.0 ttm-85 -84.09 142.38 30.44 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 110.034 -0.358 . . . . 75.340000000000003 110.034 -177.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 42.3 p -63.08 -29.16 70.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.174 0.512 . . . . 70.400000000000006 110.836 178.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . 0.545 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 16.1 t70 -77.76 -27.49 50.36 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.477 -0.783 . . . . 72.230000000000004 110.81 178.808 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . 0.555 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 28.0 mm-40 -135.35 68.98 68.61 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 115.889 -0.596 . . . . 74.439999999999998 110.185 -177.608 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . 0.729 ' HB3' ' HB2' ' A' ' 60' ' ' SER . 12.9 Cg_exo -70.1 -26.33 26.1 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.71 2.274 . . . . 73.450000000000003 112.191 -177.479 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -84.0 1.31 44.38 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.451 -0.795 . . . . 72.510000000000005 110.27 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . 0.555 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 57.8 tttp -116.9 134.94 54.14 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.814 -0.63 . . . . 75.030000000000001 110.82 -177.498 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . 0.796 HD21 HD12 ' B' ' 158' ' ' ILE . 39.0 mt -89.53 115.4 26.91 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.643 -0.873 . . . . 74.400000000000006 108.643 175.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . 0.572 HG22 ' HB3' ' B' ' 171' ' ' GLU . 43.0 mm -75.04 123.87 89.14 Favored Pre-proline 0 C--N 1.32 -0.705 0 CA-C-N 116.147 -0.479 . . . . 74.540000000000006 110.896 -172.537 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.402 ' O ' HG22 ' B' ' 172' ' ' ILE . 72.5 Cg_endo -72.75 173.65 13.08 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.825 2.35 . . . . 74.329999999999998 112.225 -178.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . 0.441 ' O ' HG12 ' B' ' 172' ' ' ILE . 30.4 tt0 -77.79 -8.22 57.7 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.665 -0.698 . . . . 75.420000000000002 111.811 -169.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 8.4 p90 -95.33 -12.23 26.46 Favored 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 120.457 -0.497 . . . . 73.310000000000002 110.583 176.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.572 ' HB3' HG22 ' B' ' 167' ' ' ILE . 12.9 tt0 -104.07 -1.87 26.75 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 121.039 0.447 . . . . 65.450000000000003 110.409 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.441 HG12 ' O ' ' B' ' 169' ' ' GLN . 46.8 pt -71.75 -24.5 23.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.017 0.437 . . . . 72.319999999999993 110.689 179.399 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -104.85 35.93 2.62 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.42 0.629 . . . . 70.150000000000006 109.745 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 174' ' ' SER . . . . . 0.418 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 23.2 t -63.74 -20.4 65.72 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 114.993 -1.003 . . . . 53.25 110.792 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . 0.543 ' HB3' ' HH ' ' B' ' 145' ' ' TYR . 8.9 p-90 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.255 -0.879 . . . . 73.430000000000007 110.388 174.259 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 57.8 m . . . . . 0 C--O 1.234 0.279 0 CA-C-O 121.732 0.777 . . . . 75.319999999999993 112.361 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 138.64 -74.62 0.39 Allowed Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 109.197 -1.561 . . . . 71.439999999999998 109.197 -171.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 33.3 mt-10 58.68 92.49 0.06 OUTLIER Pre-proline 0 N--CA 1.463 0.197 0 CA-C-O 121.539 0.685 . . . . 74.319999999999993 112.052 170.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.543 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 9.6 Cg_endo -80.46 136.31 11.05 Favored 'Trans proline' 0 N--CA 1.451 -1.001 0 C-N-CA 122.833 2.355 . . . . 70.420000000000002 112.604 -173.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -124.8 170.84 10.64 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.173 -0.677 . . . . 73.519999999999996 109.173 177.069 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.461 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 14.0 p -127.72 124.29 62.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 121.481 0.657 . . . . 75.430000000000007 110.76 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.58 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 76.4 m -87.9 104.25 16.43 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.629 -0.714 . . . . 74.310000000000002 109.664 177.27 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 52.3 mt -98.45 117.66 43.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.064 -0.516 . . . . 73.549999999999997 110.388 -175.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -141.4 178.23 7.57 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.707 -0.679 . . . . 73.319999999999993 110.273 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 17.4 mp0 -133.45 126.15 30.56 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.922 0.392 . . . . 73.340000000000003 110.828 -178.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 52.0 mm-40 -95.58 -16.1 22.34 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.851 -0.613 . . . . 72.099999999999994 111.493 -178.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.43 104.91 1.3 Allowed Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.619 -0.8 . . . . 74.099999999999994 111.468 -176.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 1.048 ' HB3' ' HG3' ' A' ' 40' ' ' LYS . 35.3 m-20 61.81 13.89 5.8 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 123.226 0.61 . . . . 73.219999999999999 111.482 -175.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.426 ' HB3' ' HA ' ' A' ' 39' ' ' PRO . 40.2 pttt -154.52 114.97 3.9 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.229 0.538 . . . . 70.019999999999996 110.907 176.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 34.1 m -83.08 117.74 23.07 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.375 -0.83 . . . . 73.219999999999999 109.298 174.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.476 HG12 HG23 ' A' ' 37' ' ' VAL . 24.9 mt -108.61 120.33 59.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 120.906 0.384 . . . . 71.049999999999997 110.633 -174.13 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.461 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 20.1 mt-30 -105.27 111.31 24.01 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.819 -0.628 . . . . 74.209999999999994 110.758 -179.23 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.58 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 31.6 mt-10 -89.62 102.55 15.23 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.62 -0.718 . . . . 72.129999999999995 110.673 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.435 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 80.6 m-85 -79.38 108.19 12.71 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.965 0.412 . . . . 73.239999999999995 109.957 177.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.423 HH21 ' CD ' ' A' ' 25' ' ' GLU . 90.1 mtt180 -116.98 126.56 53.09 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.979 -0.555 . . . . 74.319999999999993 109.852 -178.449 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.678 HG11 HG13 ' B' ' 128' ' ' VAL . 3.7 p -78.77 -35.96 18.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.326 0.584 . . . . 73.5 110.027 179.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -168.92 64.68 0.06 Allowed 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.31 -0.996 . . . . 60.43 108.31 -179.045 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.76 -29.75 3.29 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-N 115.477 -0.783 . . . . 64.129999999999995 112.036 -174.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -86.26 130.92 34.36 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.941 0.401 . . . . 73.329999999999998 110.455 -176.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.856 HD12 HG13 ' A' ' 35' ' ' ILE . 3.2 tm? -81.96 119.21 23.67 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.436 -0.802 . . . . 74.439999999999998 109.847 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . 0.435 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 54.8 p90 -112.9 -17.54 12.47 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.937 -0.305 . . . . 74.200000000000003 111.218 177.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.537 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -157.28 142.21 16.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.812 0.339 . . . . 75.450000000000003 111.181 179.327 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.856 HG13 HD12 ' A' ' 32' ' ' LEU . 78.8 mt -125.14 120.21 57.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 116.329 -0.396 . . . . 75.25 110.01 175.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.47 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 86.0 tttt -108.53 101.15 10.33 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 120.381 -0.528 . . . . 75.129999999999995 109.697 173.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.538 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.8 p -101.02 131.78 48.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.973 0 CA-C-N 116.243 -0.435 . . . . 75.510000000000005 109.917 175.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.802 HG21 ' HB3' ' A' ' 44' ' ' PRO . 29.6 t -106.0 84.85 1.4 Allowed Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.396 -0.82 . . . . 74.430000000000007 109.51 177.469 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.538 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 97.3 Cg_endo -87.65 151.21 7.5 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.615 2.21 . . . . 73.329999999999998 113.143 -177.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 1.048 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 1.0 OUTLIER -55.06 -38.53 68.14 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.202 -0.908 . . . . 74.409999999999997 110.578 173.715 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 95.1 m-70 -123.56 120.9 34.21 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.814 -0.63 . . . . 75.239999999999995 110.181 179.428 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 117.46 -32.63 5.31 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.002 -0.839 . . . . 52.149999999999999 111.002 -173.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.457 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 67.0 mttm 67.97 155.61 0.14 Allowed Pre-proline 0 N--CA 1.465 0.282 0 C-N-CA 123.39 0.676 . . . . 75.420000000000002 111.97 178.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.802 ' HB3' HG21 ' A' ' 38' ' ' VAL . 11.4 Cg_endo -54.57 126.43 22.3 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 123.136 2.557 . . . . 74.219999999999999 113.179 -174.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.506 ' CE1' HG11 ' A' ' 37' ' ' VAL . 5.8 p90 -144.51 151.76 39.61 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.009 -0.541 . . . . 75.099999999999994 110.543 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.621 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 86.8 m-85 -96.18 133.27 40.69 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.097 -0.501 . . . . 75.120000000000005 110.804 178.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.537 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 21.2 mt -101.69 93.41 5.32 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.59 -0.522 . . . . 64.219999999999999 109.59 167.884 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.42 128.96 38.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 116.168 -0.469 . . . . 73.140000000000001 109.799 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . 0.484 HH21 ' HA ' ' A' ' 53' ' ' SER . 15.6 tpt180 -63.05 127.23 30.3 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.21 0.529 . . . . 75.310000000000002 111.87 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.05 113.84 21.31 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.114 -1.069 . . . . 74.519999999999996 108.114 166.281 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.539 ' OD2' ' HA ' ' B' ' 126' ' ' TYR . 37.8 m-20 -49.07 142.54 6.67 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.216 0.531 . . . . 72.329999999999998 111.715 -176.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.23 133.61 8.16 Favored Glycine 0 N--CA 1.437 -1.257 0 N-CA-C 110.508 -1.037 . . . . 54.210000000000001 110.508 -169.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.484 ' HA ' HH21 ' A' ' 49' ' ' ARG . 19.6 m -84.87 43.16 0.97 Allowed 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.128 0.49 . . . . 74.25 110.997 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -73.41 -33.95 65.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.682 -0.69 . . . . 73.420000000000002 109.769 -179.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 113.46 38.97 1.15 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.911 -0.661 . . . . 45.130000000000003 113.089 176.022 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -135.31 146.42 48.46 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.209 0.528 . . . . 71.349999999999994 111.688 -176.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.571 ' HB2' HG21 ' A' ' 72' ' ' ILE . 31.5 m-85 -127.74 167.04 17.04 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.318 -0.856 . . . . 72.519999999999996 109.494 175.499 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.88 HD12 HD23 ' A' ' 66' ' ' LEU . 39.4 mm -122.83 123.22 67.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 109.981 -0.378 . . . . 74.0 109.981 179.111 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.961 ' HG3' HG13 ' A' ' 67' ' ' ILE . 28.8 mtm180 -88.89 140.06 29.82 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.124 -0.324 . . . . 72.219999999999999 110.124 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 7.2 p -60.8 -20.95 62.58 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.222 0.534 . . . . 71.150000000000006 110.933 177.211 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -76.0 -31.43 58.95 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.422 -0.808 . . . . 75.530000000000001 110.67 178.256 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 82.0 mm-40 -141.75 71.21 24.92 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.346 -0.388 . . . . 71.430000000000007 110.433 -175.102 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo -71.14 -11.58 29.14 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 122.771 2.314 . . . . 72.510000000000005 112.427 -178.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -89.54 -14.56 34.87 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.699 -0.682 . . . . 72.5 110.799 -178.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -112.0 133.8 53.95 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.919 0.39 . . . . 71.230000000000004 110.86 -178.207 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.88 HD23 HD12 ' A' ' 58' ' ' ILE . 85.2 mt -80.74 110.18 16.0 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.114 -0.699 . . . . 72.430000000000007 109.114 176.101 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.961 HG13 ' HG3' ' A' ' 59' ' ' ARG . 50.6 mm -72.32 116.77 52.53 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 115.986 -0.552 . . . . 72.109999999999999 110.502 -175.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.451 ' O ' HG23 ' A' ' 72' ' ' ILE . 58.6 Cg_endo -70.39 177.56 5.89 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 123.315 2.676 . . . . 64.409999999999997 112.881 -177.491 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . 0.674 ' HA ' HG12 ' A' ' 72' ' ' ILE . 25.3 tt0 -73.5 -30.66 63.27 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.903 -0.589 . . . . 72.219999999999999 111.654 -171.013 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 21.5 p90 -73.06 -15.68 61.5 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.168 0.509 . . . . 73.219999999999999 110.234 177.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.43 ' HB3' HG21 ' A' ' 67' ' ' ILE . 3.2 mm-40 -103.08 -16.14 15.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.649 -0.705 . . . . 72.120000000000005 111.808 -176.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.674 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.4 pt -80.91 -20.26 11.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.179 0.514 . . . . 72.219999999999999 110.262 176.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -107.88 22.79 15.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.601 -0.727 . . . . 75.430000000000007 109.678 174.134 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.1 t -61.26 -34.08 74.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.195 -0.911 . . . . 75.209999999999994 110.622 -178.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 65.9 p-90 . . . . . 0 C--N 1.327 -0.372 0 CA-C-N 116.352 -0.385 . . . . 74.439999999999998 110.608 177.217 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 13.9 m . . . . . 0 N--CA 1.452 -0.374 0 CA-C-O 121.078 0.466 . . . . 75.329999999999998 111.05 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.65 -45.88 1.25 Allowed Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 110.249 -1.141 . . . . 72.299999999999997 110.249 -175.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 40.3 83.14 0.21 Allowed Pre-proline 0 N--CA 1.47 0.564 0 C-N-CA 124.755 1.222 . . . . 73.329999999999998 113.473 170.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.655 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 43.5 Cg_endo -90.56 124.58 1.06 Allowed 'Trans proline' 0 N--CA 1.446 -1.323 0 C-N-CA 123.009 2.473 . . . . 55.450000000000003 111.667 178.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -122.87 127.87 49.59 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.475 0.655 . . . . 73.430000000000007 110.008 -178.586 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.486 ' HB ' ' HB2' ' A' ' 51' ' ' ASP . 7.3 p -79.45 127.82 38.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-O 121.508 0.67 . . . . 71.120000000000005 110.459 -178.311 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 114' ' ' THR . . . . . 0.898 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 25.8 m -80.62 101.69 9.36 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 115.386 -0.824 . . . . 74.420000000000002 109.605 178.676 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 51.1 mt -91.02 103.83 14.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.033 -0.53 . . . . 72.430000000000007 110.445 -175.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . 0.461 ' HG2' ' O ' ' B' ' 123' ' ' ILE . 14.0 ptm180 -124.94 178.87 5.28 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.949 -0.76 . . . . 73.409999999999997 108.949 178.763 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -138.88 158.74 43.67 Favored 'General case' 0 CA--C 1.502 -0.886 0 CA-C-O 122.189 0.995 . . . . 74.120000000000005 112.661 -178.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . 0.561 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 26.5 mt-10 -135.44 168.62 18.88 Favored 'General case' 0 N--CA 1.432 -1.365 0 CA-C-N 112.968 -1.924 . . . . 75.239999999999995 107.166 159.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . -42.29 107.92 0.12 Allowed Glycine 0 CA--C 1.526 0.722 0 O-C-N 123.718 0.636 . . . . 74.219999999999999 114.34 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 43.3 m-20 61.67 24.62 14.69 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.893 0.877 . . . . 71.030000000000001 112.508 176.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.664 ' HZ2' ' HB2' ' B' ' 175' ' ' TRP . 58.7 pttt -147.81 115.02 6.21 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.616 0.722 . . . . 74.099999999999994 111.286 174.312 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 23.4 m -80.03 117.11 20.57 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.404 -0.817 . . . . 74.25 109.374 175.003 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . 0.497 HG12 HG12 ' B' ' 137' ' ' VAL . 40.2 mt -105.53 108.96 26.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.25 0.548 . . . . 63.329999999999998 110.457 -175.744 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.469 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 13.6 mt-30 -103.13 109.52 21.12 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.658 -0.701 . . . . 74.340000000000003 110.538 -176.21 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . 0.898 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 70.8 mt-10 -88.9 98.74 11.91 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.014 -0.539 . . . . 74.239999999999995 110.43 178.655 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . 0.539 ' HA ' ' OD2' ' A' ' 51' ' ' ASP . 67.7 m-85 -71.32 114.34 9.29 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.045 0.45 . . . . 73.200000000000003 110.295 179.18 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . 0.558 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 59.1 mtt-85 -135.36 131.12 35.97 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.709 -0.678 . . . . 72.340000000000003 110.989 -173.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.678 HG13 HG11 ' A' ' 28' ' ' VAL . 14.0 p -85.39 -132.76 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 108.689 -0.856 . . . . 71.530000000000001 108.689 172.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . 0.63 ' H ' HG22 ' B' ' 128' ' ' VAL . 2.3 t-20 -80.62 65.87 5.92 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.164 0.506 . . . . 75.239999999999995 110.812 -177.445 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.65 26.63 22.18 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.756 -0.735 . . . . 41.039999999999999 113.285 174.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 62.1 t80 -142.11 126.74 17.95 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 117.262 0.531 . . . . 72.450000000000003 111.31 175.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.558 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 3.5 tm? -77.15 117.49 18.75 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.992 -0.744 . . . . 72.230000000000004 108.992 175.505 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 39.6 p90 -119.15 -6.3 10.42 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.257 -0.577 . . . . 75.319999999999993 112.261 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . 0.526 ' HB3' ' HB2' ' B' ' 126' ' ' TYR . . . -164.21 143.35 7.54 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.699 0.285 . . . . 74.200000000000003 111.031 177.697 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.418 HG13 HD12 ' B' ' 132' ' ' LEU . 61.9 mt -122.84 121.06 62.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 109.924 -0.398 . . . . 74.420000000000002 109.924 175.403 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.484 ' CB ' ' HE1' ' B' ' 126' ' ' TYR . 83.6 tttt -107.84 107.03 17.59 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.835 -0.431 . . . . 74.200000000000003 109.835 177.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.749 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.5 t -94.81 131.6 41.16 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 N-CA-C 108.641 -0.874 . . . . 74.099999999999994 108.641 176.585 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.518 HG22 ' HB3' ' B' ' 144' ' ' PRO . 18.0 t -114.72 72.7 2.78 Favored Pre-proline 0 C--N 1.318 -0.769 0 N-CA-C 109.78 -0.452 . . . . 73.120000000000005 109.78 172.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.53 ' HD3' HG13 ' B' ' 137' ' ' VAL . 94.1 Cg_endo -83.2 142.16 10.67 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.235 1.957 . . . . 73.109999999999999 112.563 177.105 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 49.6 mttp -54.56 -44.56 73.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.596 0.712 . . . . 72.120000000000005 110.348 173.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 26.1 m-70 -102.8 92.1 4.45 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.836 -1.074 . . . . 72.150000000000006 109.474 -174.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 132.54 -27.35 3.56 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.357 -0.838 . . . . 64.450000000000003 111.712 -176.294 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . 0.528 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 71.2 mttt 69.1 159.66 0.15 Allowed Pre-proline 0 N--CA 1.464 0.255 0 C-N-CA 123.622 0.769 . . . . 72.230000000000004 112.367 -178.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.749 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 21.6 Cg_endo -61.09 134.5 53.16 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 122.873 2.382 . . . . 71.239999999999995 113.525 -177.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -143.32 147.21 34.37 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.68 -0.691 . . . . 74.109999999999999 110.291 175.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.62 ' HB2' ' HB2' ' B' ' 160' ' ' SER . 86.0 m-85 -93.61 125.93 38.49 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.231 -0.441 . . . . 61.509999999999998 110.392 176.629 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . 0.507 HD12 HG23 ' B' ' 167' ' ' ILE . 25.0 tp -109.12 97.44 7.06 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.64 -0.874 . . . . 71.349999999999994 108.64 172.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.7 t -91.77 139.3 18.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.155 -0.475 . . . . 73.349999999999994 111.311 -172.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . 0.412 ' HD3' ' CZ ' ' B' ' 157' ' ' PHE . 42.4 tpt85 -80.36 113.73 18.75 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.278 -0.638 . . . . 75.040000000000006 109.278 176.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.89 175.6 6.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.825 0.345 . . . . 75.329999999999998 111.104 -176.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -71.47 147.8 47.46 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.163 -0.471 . . . . 74.120000000000005 110.94 -178.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . 0.525 ' C ' ' H ' ' B' ' 154' ' ' ASP . . . 89.85 145.4 12.74 Favored Glycine 0 N--CA 1.436 -1.365 0 C-N-CA 120.723 -0.751 . . . . 74.140000000000001 112.561 175.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 44.9 m -72.59 21.93 0.06 Allowed 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 121.022 0.439 . . . . 74.010000000000005 111.083 173.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . 0.525 ' H ' ' C ' ' B' ' 152' ' ' GLY . 14.5 t70 -60.86 -35.82 77.56 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.777 -0.647 . . . . 73.329999999999998 110.618 177.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 97.92 17.13 31.12 Favored Glycine 0 CA--C 1.507 -0.451 0 CA-C-N 115.734 -0.666 . . . . 75.310000000000002 111.89 -179.383 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -90.97 137.52 32.3 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.019 -0.59 . . . . 65.299999999999997 111.566 -175.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . 0.412 ' CZ ' ' HD3' ' B' ' 149' ' ' ARG . 39.0 m-85 -118.21 154.04 32.87 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.751 -0.658 . . . . 74.409999999999997 109.533 174.299 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.3 mm -121.46 119.91 60.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.817 -0.438 . . . . 75.400000000000006 109.817 177.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.718 ' HE ' ' HB3' ' B' ' 161' ' ' ASP . 37.2 ttp180 -85.02 129.05 34.86 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.444 -0.576 . . . . 74.329999999999998 109.444 -179.706 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 160' ' ' SER . . . . . 0.62 ' HB2' ' HB2' ' B' ' 146' ' ' PHE . 36.6 t -59.84 -18.34 43.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.774 0.321 . . . . 64.430000000000007 111.318 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . 0.718 ' HB3' ' HE ' ' B' ' 159' ' ' ARG . 22.8 t70 -69.24 -39.77 78.31 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.031 -0.531 . . . . 74.319999999999993 110.29 176.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . 0.417 ' HG2' ' OD2' ' B' ' 161' ' ' ASP . 84.1 mm-40 -133.53 86.33 40.37 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 115.674 -0.693 . . . . 75.409999999999997 109.692 179.546 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.01 -14.37 40.86 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.56 2.173 . . . . 74.019999999999996 112.47 -178.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -100.49 21.09 13.76 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.817 -0.628 . . . . 72.150000000000006 110.421 178.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -133.3 136.06 45.24 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.365 -0.38 . . . . 74.049999999999997 110.732 -179.487 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . 0.42 HD11 ' N ' ' B' ' 166' ' ' LEU . 4.6 mp -90.54 134.94 34.02 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.027 -0.731 . . . . 75.409999999999997 109.027 176.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . 0.52 HG21 ' HB3' ' B' ' 171' ' ' GLU . 46.2 mm -94.15 117.02 67.11 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-O 120.917 0.389 . . . . 74.319999999999993 111.771 -172.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.4 ' O ' HG22 ' B' ' 172' ' ' ILE . 59.5 Cg_endo -72.37 -179.55 4.14 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.305 2.67 . . . . 74.430000000000007 112.615 177.084 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . 0.587 ' HA ' HG12 ' B' ' 172' ' ' ILE . 33.0 tt0 -77.1 -36.09 55.94 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.258 -0.428 . . . . 72.129999999999995 112.136 -170.211 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . 0.407 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 35.9 p90 -66.99 -21.16 65.97 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 121.648 -0.658 . . . . 74.430000000000007 109.622 177.251 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.52 ' HB3' HG21 ' B' ' 167' ' ' ILE . 9.3 mm-40 -88.22 -26.05 22.57 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 115.156 -0.929 . . . . 75.129999999999995 111.647 -178.078 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.587 HG12 ' HA ' ' B' ' 169' ' ' GLN . 40.9 pt -77.97 -17.42 13.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.146 0.498 . . . . 74.530000000000001 109.971 177.118 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -108.05 34.61 3.5 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.574 -0.739 . . . . 72.519999999999996 109.748 174.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.9 t -65.13 -35.27 80.58 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.203 -0.908 . . . . 71.019999999999996 111.03 -179.182 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . 0.664 ' HB2' ' HZ2' ' B' ' 121' ' ' LYS . 25.6 p-90 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.018 -0.991 . . . . 74.450000000000003 111.023 -178.133 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 39.8 m . . . . . 0 N--CA 1.453 -0.312 0 N-CA-C 109.947 -0.39 . . . . 75.200000000000003 109.947 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 87.27 -34.01 3.72 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 110.977 -0.849 . . . . 75.200000000000003 110.977 -173.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 55.37 63.69 6.31 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 123.998 0.919 . . . . 64.329999999999998 111.73 177.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.713 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 18.2 Cg_endo -78.95 121.65 5.06 Favored 'Trans proline' 0 N--CA 1.45 -1.064 0 C-N-CA 122.091 1.861 . . . . 73.219999999999999 111.584 -179.612 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -148.36 122.42 9.47 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.654 0.74 . . . . 72.140000000000001 110.357 177.515 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.8 p -82.65 129.16 37.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-N 114.366 -1.288 . . . . 74.230000000000004 110.682 -178.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 59.2 m -93.64 102.51 14.69 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.592 -0.731 . . . . 55.219999999999999 109.735 178.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.1 mt -90.63 104.06 14.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.967 -0.561 . . . . 74.109999999999999 110.037 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -122.83 174.07 7.37 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.533 -0.758 . . . . 72.219999999999999 109.734 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -122.98 133.36 54.37 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 121.285 0.564 . . . . 74.430000000000007 111.059 -177.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.502 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 1.0 OUTLIER -115.81 84.9 2.19 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.318 -0.855 . . . . 64.420000000000002 109.336 -179.411 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 80.88 -106.11 2.51 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 110.827 -0.909 . . . . 73.450000000000003 110.827 -172.481 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.408 ' HB3' ' CD ' ' A' ' 40' ' ' LYS . 11.7 m-20 -110.49 -14.47 14.09 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.761 0.315 . . . . 71.409999999999997 110.93 176.323 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.502 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 24.6 pttm -89.41 136.57 32.95 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.98 0.419 . . . . 74.010000000000005 110.918 -176.28 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 13.0 m -83.8 130.33 34.93 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.781 -0.645 . . . . 74.109999999999999 110.205 178.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 26.4 mm -116.65 106.82 21.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 120.93 0.395 . . . . 75.5 110.128 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 16.1 mt-30 -100.02 102.5 13.87 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.225 -0.443 . . . . 73.510000000000005 109.828 178.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.403 ' HB3' HD11 ' A' ' 32' ' ' LEU . 26.4 mt-10 -89.67 100.68 13.43 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.519 -0.764 . . . . 65.450000000000003 110.937 -176.302 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.595 ' HD2' ' HB2' ' B' ' 151' ' ' ASP . 44.2 m-85 -75.41 100.21 4.39 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.086 -0.507 . . . . 74.519999999999996 110.32 179.257 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 51.2 mtm180 -115.89 124.45 50.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.311 -0.404 . . . . 74.019999999999996 110.418 178.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.86 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.9 p -87.24 -93.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 C-N-CA 120.564 -0.454 . . . . 70.510000000000005 110.091 175.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.86 ' H ' HG13 ' A' ' 28' ' ' VAL . 3.4 t-20 -107.49 70.07 0.77 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 121.562 -0.712 . . . . 74.519999999999996 109.997 -176.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 77.57 9.08 87.09 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.714 -0.755 . . . . 75.230000000000004 112.344 179.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 85.6 t80 -127.55 123.06 34.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.676 0.274 . . . . 75.049999999999997 110.643 -177.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.528 HD21 HD13 ' A' ' 35' ' ' ILE . 27.6 tp -78.65 115.5 18.4 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.025 -0.534 . . . . 72.329999999999998 109.762 173.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -103.51 -14.68 16.11 Favored 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 120.253 -0.579 . . . . 74.299999999999997 111.481 -176.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.439 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -167.61 146.34 4.81 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.889 0.376 . . . . 71.310000000000002 111.475 -177.206 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.528 HD13 HD21 ' A' ' 32' ' ' LEU . 71.4 mt -122.59 131.4 73.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 116.084 -0.507 . . . . 75.219999999999999 109.77 175.167 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -104.49 100.75 10.43 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.948 -0.76 . . . . 74.310000000000002 108.948 170.195 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.486 HG21 ' HD3' ' A' ' 39' ' ' PRO . 0.9 OUTLIER -97.75 123.56 50.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 115.663 -0.699 . . . . 75.530000000000001 110.283 -179.483 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.717 HG21 ' HB3' ' A' ' 44' ' ' PRO . 22.0 t -113.73 87.65 12.55 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 115.384 -0.825 . . . . 73.530000000000001 110.3 -178.489 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.486 ' HD3' HG21 ' A' ' 37' ' ' VAL . 74.5 Cg_endo -77.83 141.71 19.46 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.406 2.071 . . . . 74.409999999999997 111.33 176.568 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.408 ' CD ' ' HB3' ' A' ' 20' ' ' ASP . 35.2 mtmt -58.89 -32.95 69.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.197 0.523 . . . . 64.239999999999995 110.603 179.346 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -130.6 100.51 5.34 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.74 -0.664 . . . . 74.150000000000006 109.297 177.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 149.54 -16.0 1.1 Allowed Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.884 -0.674 . . . . 61.43 112.277 -177.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.5 mttt 72.76 140.84 0.08 OUTLIER Pre-proline 0 N--CA 1.467 0.393 0 C-N-CA 123.383 0.673 . . . . 74.219999999999999 112.237 178.29 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.717 ' HB3' HG21 ' A' ' 38' ' ' VAL . 29.1 Cg_endo -64.18 133.6 38.77 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 123.103 2.535 . . . . 74.120000000000005 112.476 179.04 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 11.2 p90 -144.15 156.18 44.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.107 -0.497 . . . . 72.109999999999999 110.57 -179.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.491 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 20.0 m-85 -99.54 142.38 31.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.084 -0.507 . . . . 75.430000000000007 111.484 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.439 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 72.0 mt -124.88 104.51 8.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.608 -0.724 . . . . 74.510000000000005 109.747 171.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 43.2 t -93.24 136.36 25.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.184 -0.462 . . . . 75.319999999999993 110.047 -178.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . 0.556 HH11 ' HG3' ' A' ' 49' ' ' ARG . 0.5 OUTLIER -76.06 132.06 39.87 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.94 0.4 . . . . 71.430000000000007 111.621 -178.504 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.12 158.31 35.98 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.565 -0.743 . . . . 74.329999999999998 111.707 179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -79.18 171.86 14.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.647 -0.706 . . . . 72.209999999999994 111.771 -176.265 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 70.33 21.49 77.35 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.657 -0.701 . . . . 73.329999999999998 113.035 171.147 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.9 m 57.28 30.66 18.83 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.024 0.44 . . . . 73.319999999999993 110.526 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -55.98 -63.93 1.02 Allowed 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.468 -0.787 . . . . 74.129999999999995 111.501 -179.278 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 131.1 -39.2 1.81 Allowed Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.273 -0.965 . . . . 74.349999999999994 112.794 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -68.57 164.55 21.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.43 0.633 . . . . 64.219999999999999 111.507 -176.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.417 ' CE2' ' HG2' ' A' ' 49' ' ' ARG . 67.9 m-85 -113.29 155.28 25.41 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.209 -0.905 . . . . 74.209999999999994 109.587 175.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.622 HD11 HD23 ' A' ' 66' ' ' LEU . 27.5 mm -113.27 119.87 61.8 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 108.883 -0.784 . . . . 75.299999999999997 108.883 177.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.567 ' HB2' HG13 ' A' ' 67' ' ' ILE . 8.1 ttm180 -82.7 149.43 27.32 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.951 -0.3 . . . . 75.450000000000003 110.403 -175.273 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.491 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 4.3 p -62.82 -27.14 69.11 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.282 -0.417 . . . . 64.109999999999999 111.452 178.266 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.46 ' HB2' ' HD2' ' A' ' 59' ' ' ARG . 1.3 m-20 -64.41 -29.13 70.19 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.131 -0.486 . . . . 72.040000000000006 111.537 -179.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.9 tp-100 -150.79 93.0 3.79 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-O 121.034 0.445 . . . . 71.239999999999995 109.992 -179.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . 0.473 ' HB2' ' HD2' ' B' ' 146' ' ' PHE . 72.7 Cg_endo -74.35 15.06 0.67 Allowed 'Trans proline' 0 C--O 1.233 0.24 0 C-N-CA 123.396 2.73 . . . . 72.349999999999994 113.151 -176.429 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -128.25 8.33 6.04 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.161 0.505 . . . . 74.140000000000001 110.338 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 12.5 mmmt -121.75 145.43 48.04 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.101 -0.5 . . . . 74.140000000000001 111.925 -177.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.622 HD23 HD11 ' A' ' 58' ' ' ILE . 65.6 mt -92.41 109.11 20.49 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.342 -0.844 . . . . 74.519999999999996 109.754 178.071 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.567 HG13 ' HB2' ' A' ' 59' ' ' ARG . 46.6 mm -72.67 119.54 75.77 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 116.323 -0.398 . . . . 72.299999999999997 110.408 -178.697 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.53 178.95 3.91 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 123.274 2.649 . . . . 74.530000000000001 113.363 -177.184 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . 0.809 ' HA ' HG12 ' A' ' 72' ' ' ILE . 34.9 tt0 -75.19 -34.58 61.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.513 -0.767 . . . . 74.209999999999994 111.515 -170.486 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 3.7 p90 -64.32 -23.89 67.46 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.349 -0.541 . . . . 75.340000000000003 110.916 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.445 ' HA ' ' HB2' ' A' ' 74' ' ' SER . 4.2 tp10 -92.99 -27.79 16.8 Favored 'General case' 0 N--CA 1.438 -1.052 0 CA-C-N 116.086 -0.507 . . . . 73.239999999999995 110.639 -176.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.809 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.3 pt -80.14 -16.95 12.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.039 0.447 . . . . 73.109999999999999 110.66 177.547 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.444 ' CD1' HG13 ' A' ' 72' ' ' ILE . 46.5 m-85 -108.37 15.37 24.04 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.825 -0.625 . . . . 73.439999999999998 110.118 174.04 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.445 ' HB2' ' HA ' ' A' ' 71' ' ' GLU . 8.3 t -74.43 -28.81 61.23 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.755 -0.657 . . . . 71.109999999999999 110.396 -177.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . 0.404 ' O ' ' HE3' ' A' ' 21' ' ' LYS . 65.3 p-90 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.515 -0.311 . . . . 73.129999999999995 110.935 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 35.0 m . . . . . 0 N--CA 1.453 -0.295 0 CA-C-O 121.087 0.47 . . . . 72.420000000000002 110.861 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.49 -68.3 0.22 Allowed Glycine 0 N--CA 1.446 -0.691 0 N-CA-C 111.595 -0.602 . . . . 72.409999999999997 111.595 -177.408 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 57.8 mm-40 69.21 77.12 0.24 Allowed Pre-proline 0 N--CA 1.468 0.463 0 C-N-CA 123.537 0.735 . . . . 74.439999999999998 111.807 -178.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.613 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 10.8 Cg_endo -80.93 85.22 1.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.087 0 C-N-CA 122.455 2.103 . . . . 62.049999999999997 111.049 174.792 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -97.01 150.52 20.69 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.208 0.528 . . . . 75.349999999999994 110.448 -178.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.423 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 13.5 p -105.46 123.75 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.906 0 CA-C-N 115.653 -0.703 . . . . 73.400000000000006 109.417 174.282 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 114' ' ' THR . . . . . 0.518 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 19.6 m -89.22 99.52 12.49 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 115.658 -0.701 . . . . 72.219999999999999 109.472 177.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 59.8 mt -88.86 106.19 16.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.919 -0.582 . . . . 74.439999999999998 110.093 -177.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 32.1 mtp-105 -122.28 -174.36 2.88 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.408 -0.815 . . . . 75.239999999999995 110.34 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 23.6 mp0 -136.16 132.55 36.13 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.839 -0.619 . . . . 74.5 110.431 179.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . 0.439 ' HG2' HG13 ' B' ' 123' ' ' ILE . 79.4 mm-40 -112.56 82.26 1.61 Allowed 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.062 -0.718 . . . . 75.430000000000007 109.062 173.687 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 81.05 -92.06 1.45 Allowed Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.743 -0.741 . . . . 75.450000000000003 111.387 -175.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 29.9 m-20 -117.61 -20.49 8.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.767 0.318 . . . . 71.200000000000003 111.205 178.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.757 ' HE3' ' HE3' ' B' ' 175' ' ' TRP . 23.6 pttt -86.62 126.0 34.21 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.273 0.559 . . . . 74.310000000000002 111.076 -177.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 43.9 m -80.72 124.32 28.93 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.502 -0.772 . . . . 70.140000000000001 109.986 178.592 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . 0.439 HG13 ' HG2' ' B' ' 118' ' ' GLU . 27.3 mm -108.98 108.59 25.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.552 -0.295 . . . . 74.400000000000006 110.393 -175.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.423 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 16.5 mt-30 -100.65 100.52 11.24 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.917 0.389 . . . . 74.299999999999997 110.254 178.256 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . 0.518 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 43.7 mt-10 -86.77 107.43 18.26 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.034 -0.53 . . . . 75.450000000000003 111.116 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . 0.472 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 78.0 m-85 -86.99 113.39 22.71 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.976 0.417 . . . . 74.109999999999999 110.422 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 60.5 mtm180 -117.22 178.7 4.27 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.124 -0.489 . . . . 74.510000000000005 109.957 179.145 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.613 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -140.58 -65.21 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 116.279 -0.419 . . . . 74.209999999999994 110.884 173.055 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . 0.601 ' H ' HG13 ' B' ' 128' ' ' VAL . 3.7 t-20 -141.79 75.99 1.52 Allowed 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.438 -0.505 . . . . 74.040000000000006 110.194 -179.64 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.04 25.75 73.32 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.346 -0.843 . . . . 74.340000000000003 111.782 -179.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 67.7 t80 -146.01 121.7 10.5 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.685 -0.487 . . . . 73.400000000000006 109.685 -179.498 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.428 HD21 HD11 ' B' ' 135' ' ' ILE . 24.5 tp -80.14 123.93 28.33 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.724 -0.671 . . . . 75.519999999999996 109.318 176.048 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . 0.472 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 37.2 p90 -108.85 -15.72 14.32 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.969 -0.692 . . . . 75.310000000000002 111.849 -176.883 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . 0.402 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -168.03 148.85 5.07 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.928 0.394 . . . . 75.319999999999993 111.6 -178.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.428 HD11 HD21 ' B' ' 132' ' ' LEU . 62.9 mt -125.39 126.18 70.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.118 -0.492 . . . . 63.210000000000001 109.842 174.337 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.417 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 88.6 tttt -105.04 101.19 10.77 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.957 -0.757 . . . . 73.439999999999998 108.957 172.254 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 1.4 p -99.23 133.64 41.22 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.855 -0.611 . . . . 72.239999999999995 110.196 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.855 HG23 ' HB3' ' B' ' 144' ' ' PRO . 24.4 t -107.85 84.61 2.11 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 115.384 -0.826 . . . . 75.420000000000002 109.536 177.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.413 ' HG3' ' HE1' ' B' ' 145' ' ' TYR . 92.3 Cg_endo -79.86 150.01 20.78 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 122.407 2.072 . . . . 70.200000000000003 111.969 -179.175 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 4.1 mmpt? -62.2 -35.71 79.7 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.77 -0.65 . . . . 74.439999999999998 110.123 177.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 86.2 m-70 -124.73 90.67 3.29 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 115.789 -0.642 . . . . 72.310000000000002 109.913 -178.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . 0.406 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 150.49 -29.18 1.07 Allowed Glycine 0 N--CA 1.448 -0.549 0 CA-C-N 115.191 -0.913 . . . . 70.25 111.675 -176.035 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . 0.454 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 87.0 mttt 70.34 155.73 0.15 Allowed Pre-proline 0 N--CA 1.467 0.421 0 C-N-CA 123.427 0.691 . . . . 74.140000000000001 112.01 -178.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.855 ' HB3' HG23 ' B' ' 138' ' ' VAL . 18.9 Cg_endo -58.25 124.07 15.06 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 123.224 2.616 . . . . 74.299999999999997 113.47 -175.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . 0.486 ' CE1' HG12 ' B' ' 137' ' ' VAL . 5.1 p90 -139.65 168.23 20.3 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.636 -0.711 . . . . 74.140000000000001 110.137 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.473 ' HD2' ' HB2' ' A' ' 63' ' ' PRO . 1.2 m-85 -108.84 139.32 43.83 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.954 0.407 . . . . 73.420000000000002 111.882 -176.506 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . 0.402 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 25.6 mt -118.75 101.28 7.97 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.448 -0.796 . . . . 75.219999999999999 109.653 169.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 42.7 t -86.46 137.91 20.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 116.225 -0.443 . . . . 73.409999999999997 110.077 -179.101 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 5.1 mmt85 -74.85 130.38 39.32 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.884 0.373 . . . . 72.5 111.285 178.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -71.03 122.14 19.5 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.769 -0.65 . . . . 43.100000000000001 111.08 177.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . 0.595 ' HB2' ' HD2' ' A' ' 26' ' ' TYR . 15.7 t70 -61.31 140.0 58.06 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.648 -0.705 . . . . 73.239999999999995 110.981 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 73.47 -56.61 2.03 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.955 -0.566 . . . . 71.400000000000006 113.237 179.323 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 153' ' ' SER . . . . . 0.43 ' O ' ' HB3' ' B' ' 154' ' ' ASP . 19.7 m -61.2 -46.07 91.96 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 122.43 0.292 . . . . 75.549999999999997 110.868 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . 0.43 ' HB3' ' O ' ' B' ' 153' ' ' SER . 18.0 t70 71.47 -48.27 0.67 Allowed 'General case' 0 N--CA 1.464 0.237 0 C-N-CA 123.743 0.817 . . . . 74.329999999999998 111.859 178.107 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . -88.13 50.07 3.84 Favored Glycine 0 N--CA 1.448 -0.502 0 CA-C-N 116.122 -0.49 . . . . 72.439999999999998 112.601 -178.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . 0.452 HD22 ' HB3' ' B' ' 166' ' ' LEU . 25.9 t-20 -162.54 144.59 10.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.457 -0.571 . . . . 75.549999999999997 109.457 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . 0.506 ' HB2' HG21 ' B' ' 172' ' ' ILE . 72.4 m-85 -118.99 150.71 39.48 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.909 0.385 . . . . 74.040000000000006 110.463 178.108 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.0 mm -113.43 114.44 46.86 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 N-CA-C 108.82 -0.807 . . . . 74.540000000000006 108.82 175.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.532 ' HB2' HG13 ' B' ' 167' ' ' ILE . 15.0 ttp180 -88.03 146.92 25.24 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 110.046 -0.353 . . . . 72.340000000000003 110.046 -174.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 4.0 p -60.03 -36.31 76.99 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 112.779 0.659 . . . . 74.310000000000002 112.779 -174.101 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -78.28 -14.65 59.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.973 0.416 . . . . 73.219999999999999 110.908 -177.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . 0.804 ' HG3' ' HB2' ' B' ' 165' ' ' LYS . 5.4 tp-100 -138.03 72.02 47.57 Favored Pre-proline 0 N--CA 1.45 -0.438 0 CA-C-N 116.219 -0.446 . . . . 73.010000000000005 110.894 -177.334 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -85.09 -1.57 9.38 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.674 2.249 . . . . 73.400000000000006 111.775 179.18 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -91.74 -17.99 24.59 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.25 -0.886 . . . . 75.200000000000003 110.14 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . 0.804 ' HB2' ' HG3' ' B' ' 162' ' ' GLN . 0.7 OUTLIER -122.79 158.83 29.35 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.124 -0.944 . . . . 73.109999999999999 111.134 -175.133 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . 0.452 ' HB3' HD22 ' B' ' 156' ' ' ASN . 5.1 mp -94.74 134.02 37.79 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.064 -1.087 . . . . 73.420000000000002 108.064 172.577 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . 0.532 HG13 ' HB2' ' B' ' 159' ' ' ARG . 50.2 mm -84.69 125.11 72.07 Favored Pre-proline 0 C--N 1.32 -0.695 0 C-N-CA 120.91 -0.316 . . . . 75.409999999999997 111.041 -171.552 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.466 ' HG2' ' HB2' ' B' ' 171' ' ' GLU . 49.6 Cg_endo -67.7 172.77 10.02 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.762 2.308 . . . . 74.299999999999997 112.429 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . 0.507 ' HA ' HG12 ' B' ' 172' ' ' ILE . 20.4 tt0 -79.56 -16.93 55.05 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.766 -0.652 . . . . 74.540000000000006 111.626 -167.464 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . 0.402 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 24.4 p90 -86.75 -8.01 57.76 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.234 0.54 . . . . 71.409999999999997 110.019 176.043 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.541 ' O ' ' HB2' ' B' ' 174' ' ' SER . 1.9 mm-40 -113.32 -11.89 13.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.816 -0.629 . . . . 74.209999999999994 111.961 -176.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.507 HG12 ' HA ' ' B' ' 169' ' ' GLN . 31.8 pt -76.82 -16.87 14.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 121.264 0.554 . . . . 70.5 110.277 175.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -109.14 39.09 2.13 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.356 -0.838 . . . . 75.219999999999999 108.874 174.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 174' ' ' SER . . . . . 0.541 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 0.5 OUTLIER -70.15 -14.48 62.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 114.981 -1.009 . . . . 60.340000000000003 110.916 -176.181 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . 0.757 ' HE3' ' HE3' ' B' ' 121' ' ' LYS . 59.7 p-90 . . . . . 0 C--O 1.245 0.842 0 CA-C-O 118.286 -0.864 . . . . 74.230000000000004 110.204 177.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 15.0 m . . . . . 0 N--CA 1.453 -0.286 0 N-CA-C 109.03 -0.73 . . . . 75.219999999999999 109.03 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 116.17 102.8 2.33 Favored Glycine 0 N--CA 1.439 -1.111 0 N-CA-C 108.79 -1.724 . . . . 74.439999999999998 108.79 -166.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . 0.484 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 10.1 pt-20 -141.03 113.99 6.96 Favored Pre-proline 0 N--CA 1.437 -1.12 0 N-CA-C 108.089 -1.078 . . . . 63.409999999999997 108.089 -167.773 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.484 ' HD3' ' HA ' ' A' ' 10' ' ' GLU . 4.9 Cg_exo -77.12 81.47 2.61 Favored 'Trans proline' 0 N--CA 1.437 -1.803 0 C-N-CA 121.873 1.715 . . . . 73.340000000000003 110.531 -176.451 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -86.26 155.37 20.71 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.564 -1.198 . . . . 72.120000000000005 109.869 -177.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.57 HG22 ' HB3' ' A' ' 24' ' ' GLN . 10.1 p -121.23 123.79 70.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 CA-C-O 121.512 0.673 . . . . 64.420000000000002 111.143 -178.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.54 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 88.8 m -86.03 104.21 15.43 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.521 -0.763 . . . . 71.239999999999995 108.944 177.011 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.3 mt -91.44 105.5 16.61 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 CA-C-N 116.093 -0.503 . . . . 74.5 110.598 -175.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.3 mtm180 -117.86 172.99 7.02 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.787 -0.642 . . . . 73.209999999999994 109.993 177.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . 0.471 ' HG2' ' HA ' ' A' ' 22' ' ' THR . 82.6 mt-30 -136.93 122.17 19.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.172 0.51 . . . . 64.519999999999996 111.024 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.443 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 31.5 mm-40 -106.96 87.35 2.49 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.398 -0.819 . . . . 75.430000000000007 110.018 178.188 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 79.17 -95.13 1.4 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.633 -0.794 . . . . 74.430000000000007 111.678 -178.26 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -124.09 12.5 8.97 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.83 0.347 . . . . 72.420000000000002 110.871 -179.228 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.703 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 21.3 pttm -117.27 117.29 29.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.019 0.438 . . . . 74.549999999999997 110.987 178.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.687 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 23.6 m -79.25 101.91 8.27 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.736 -0.665 . . . . 72.030000000000001 109.679 176.047 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.441 HG12 HG11 ' A' ' 37' ' ' VAL . 57.0 mt -92.64 106.85 18.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 120.996 0.427 . . . . 75.120000000000005 110.14 -176.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.588 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 20.2 mt-30 -91.4 110.7 22.01 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.801 -0.636 . . . . 75.120000000000005 110.3 178.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.617 ' HB3' HD12 ' A' ' 32' ' ' LEU . 26.4 mt-10 -93.83 103.48 15.6 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.469 -0.787 . . . . 62.329999999999998 111.109 -177.142 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.407 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 86.8 m-85 -77.83 109.13 11.58 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.985 0.421 . . . . 73.519999999999996 110.228 178.692 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 83.8 mtt180 -127.58 127.3 43.65 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.581 -0.736 . . . . 75.439999999999998 109.459 -179.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.596 HG22 ' CD2' ' B' ' 131' ' ' PHE . 11.9 p -90.49 -28.25 4.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 C-N-CA 120.37 -0.532 . . . . 71.519999999999996 110.628 -177.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -172.26 68.06 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.707 -0.679 . . . . 73.109999999999999 109.631 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 95.77 -37.97 3.26 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.773 -0.727 . . . . 62.32 113.414 178.262 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.451 ' CD2' HG21 ' B' ' 128' ' ' VAL . 80.1 t80 -94.82 133.5 38.46 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.239 0.542 . . . . 74.299999999999997 111.405 -174.058 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.617 HD12 ' HB3' ' A' ' 25' ' ' GLU . 50.1 tp -82.38 112.86 19.73 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.941 -1.027 . . . . 75.219999999999999 110.156 174.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . 0.45 ' O ' ' HB2' ' A' ' 49' ' ' ARG . 44.3 p90 -108.62 -4.99 16.65 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.895 -0.322 . . . . 74.219999999999999 111.72 -176.614 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -168.3 136.97 2.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.891 0.377 . . . . 73.510000000000005 110.889 -176.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.403 ' CG1' HD21 ' A' ' 32' ' ' LEU . 61.4 mt -118.97 126.12 75.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.0 -0.546 . . . . 75.319999999999993 110.542 178.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.588 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 83.1 tttt -108.69 100.78 9.98 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.003 -0.74 . . . . 63.340000000000003 109.003 171.366 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.716 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.8 t -87.91 128.79 40.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 109.153 -0.684 . . . . 75.150000000000006 109.153 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.773 HG13 ' HG3' ' A' ' 44' ' ' PRO . 24.2 t -115.74 72.71 4.16 Favored Pre-proline 0 C--N 1.32 -0.709 0 N-CA-C 109.75 -0.463 . . . . 65.049999999999997 109.75 172.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.703 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 57.1 Cg_endo -78.76 134.43 12.09 Favored 'Trans proline' 0 N--CA 1.458 -0.615 0 C-N-CA 122.18 1.92 . . . . 72.439999999999998 112.433 176.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.651 ' HB3' ' HZ3' ' A' ' 40' ' ' LYS . 9.4 mtpm? -59.78 -33.06 71.21 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-O 121.29 0.566 . . . . 74.200000000000003 109.948 175.275 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 62.4 m-70 -115.77 103.58 10.8 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.244 -0.889 . . . . 73.340000000000003 109.148 178.009 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 130.11 -25.18 4.39 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.943 -0.646 . . . . 61.409999999999997 112.096 -177.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.0 mttm 69.57 147.79 0.12 Allowed Pre-proline 0 N--CA 1.466 0.363 0 C-N-CA 123.342 0.657 . . . . 74.319999999999993 112.323 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.773 ' HG3' HG13 ' A' ' 38' ' ' VAL . 31.0 Cg_exo -58.51 145.97 92.59 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 123.222 2.615 . . . . 74.349999999999994 113.561 -177.03 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 30.6 p90 -156.39 164.91 37.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.314 -0.857 . . . . 74.310000000000002 109.304 174.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.542 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 85.1 m-85 -106.62 136.44 46.4 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.021 0.438 . . . . 72.120000000000005 110.7 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 16.9 tp -125.14 98.96 5.88 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.695 -0.854 . . . . 73.140000000000001 108.695 176.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.422 HG22 HG23 ' B' ' 148' ' ' VAL . 28.7 t -96.32 140.59 16.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.421 -0.354 . . . . 74.239999999999995 111.548 -171.036 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . 0.45 ' HB2' ' O ' ' A' ' 33' ' ' TYR . 0.7 OUTLIER -66.85 122.38 17.57 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.213 -0.449 . . . . 73.430000000000007 111.32 176.66 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.44 172.39 13.7 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.921 -0.581 . . . . 72.439999999999998 109.503 172.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -68.04 125.04 25.07 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.22 0.533 . . . . 75.25 109.781 176.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.41 125.57 5.49 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.783 -0.723 . . . . 63.229999999999997 111.899 -176.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.5 t -87.45 23.1 1.99 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.347 0.594 . . . . 74.349999999999994 110.24 -177.027 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -58.12 -60.43 3.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.432 -0.804 . . . . 71.409999999999997 110.206 177.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 156.61 21.87 0.03 OUTLIER Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 115.546 -0.752 . . . . 72.349999999999994 112.453 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.47 ' OD1' ' HB3' ' A' ' 66' ' ' LEU . 7.4 t30 -102.91 137.18 41.44 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.963 0.411 . . . . 74.099999999999994 110.867 -176.562 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -123.56 174.42 7.43 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.942 -0.572 . . . . 74.319999999999993 110.47 177.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 49.8 mm -123.97 122.08 63.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.893 -0.78 . . . . 71.010000000000005 108.893 171.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.646 ' HB2' HG13 ' A' ' 67' ' ' ILE . 74.6 ttt180 -93.34 131.97 38.0 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.07 -0.514 . . . . 73.409999999999997 110.309 -175.386 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.542 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 67.9 p -62.8 -22.77 66.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.86 0.362 . . . . 75.340000000000003 111.343 -178.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 16.4 t70 -64.23 -46.37 84.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.778 -0.647 . . . . 65.019999999999996 109.981 178.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . 0.42 ' C ' ' H ' ' A' ' 64' ' ' ASP . 78.0 mm-40 -132.14 82.66 58.1 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.479 -0.782 . . . . 72.450000000000003 109.383 178.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -76.34 30.9 0.4 Allowed 'Trans proline' 0 CA--C 1.529 0.254 0 C-N-CA 123.28 2.653 . . . . 62.140000000000001 112.5 -177.052 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.42 ' H ' ' C ' ' A' ' 62' ' ' GLN . 15.4 t70 -119.57 -39.89 2.83 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.433 -0.803 . . . . 72.219999999999999 110.462 -177.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.7 pttt -97.53 160.22 14.45 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.999 -0.546 . . . . 75.420000000000002 110.501 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.47 ' HB3' ' OD1' ' A' ' 56' ' ' ASN . 5.4 mp -92.96 140.25 29.67 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.668 -0.696 . . . . 72.510000000000005 109.335 179.214 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.685 HG21 ' HB3' ' A' ' 71' ' ' GLU . 47.1 mm -96.84 109.03 46.79 Favored Pre-proline 0 C--N 1.322 -0.593 0 CA-C-O 121.235 0.54 . . . . 75.310000000000002 111.307 -176.453 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.479 ' O ' HG23 ' A' ' 72' ' ' ILE . 93.0 Cg_endo -81.61 -176.92 3.3 Favored 'Trans proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.505 2.803 . . . . 61.140000000000001 111.983 177.499 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . 0.629 ' O ' HG12 ' A' ' 72' ' ' ILE . 6.3 tt0 -67.99 -40.42 83.09 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.225 0.454 . . . . 72.420000000000002 112.225 -171.122 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . 0.635 ' HA ' ' CZ ' ' A' ' 73' ' ' PHE . 17.4 p90 -63.38 -17.76 62.95 Favored 'General case' 0 C--N 1.326 -0.441 0 O-C-N 121.723 -0.61 . . . . 72.349999999999994 110.981 -178.591 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.685 ' HB3' HG21 ' A' ' 67' ' ' ILE . 2.5 mm-40 -94.45 -18.45 21.49 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.041 -0.527 . . . . 74.25 111.117 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.629 HG12 ' O ' ' A' ' 69' ' ' GLN . 39.9 pt -83.61 -36.03 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 C-N-CA 120.723 -0.391 . . . . 74.340000000000003 111.625 -177.199 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.635 ' CZ ' ' HA ' ' A' ' 70' ' ' TRP . 10.7 p90 -90.82 26.09 2.18 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.262 0.554 . . . . 75.109999999999999 110.722 178.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.3 t -78.72 9.03 4.49 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.767 -0.652 . . . . 73.420000000000002 111.102 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . 0.673 ' HB3' ' HE3' ' A' ' 21' ' ' LYS . 38.8 m0 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.459 -0.337 . . . . 72.519999999999996 111.176 177.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 31.8 m . . . . . 0 C--O 1.233 0.221 0 CA-C-O 121.154 0.502 . . . . 72.239999999999995 110.366 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 122.61 42.89 0.4 Allowed Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 110.491 -1.043 . . . . 63.049999999999997 110.491 -170.397 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -106.59 100.56 31.25 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-O 121.658 0.742 . . . . 74.340000000000003 109.286 -179.463 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.548 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 58.0 Cg_endo -79.43 121.04 4.61 Favored 'Trans proline' 0 N--CA 1.448 -1.148 0 C-N-CA 122.382 2.054 . . . . 61.100000000000001 113.195 -169.645 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -122.84 144.19 49.36 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.814 -1.084 . . . . 74.340000000000003 108.599 174.583 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.722 HG21 ' HB3' ' B' ' 124' ' ' GLN . 7.9 p -92.37 132.01 37.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-O 121.396 0.617 . . . . 75.409999999999997 111.543 -172.112 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 114' ' ' THR . . . . . 0.737 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.4 m -82.84 103.39 12.28 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.167 -0.924 . . . . 71.409999999999997 109.177 174.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 59.2 mt -88.67 104.61 14.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.096 0.474 . . . . 72.510000000000005 111.066 -176.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . 0.427 HH21 ' CD ' ' B' ' 125' ' ' GLU . 38.1 mtm180 -108.88 167.86 9.78 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.721 -0.672 . . . . 72.430000000000007 109.627 174.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 91.5 mt-30 -139.55 112.03 7.73 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.068 0.461 . . . . 74.340000000000003 110.585 177.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 81.6 mm-40 -108.48 85.35 2.09 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.669 -0.696 . . . . 74.099999999999994 110.384 -178.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 88.38 -111.94 3.84 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.624 -0.798 . . . . 55.130000000000003 111.589 -178.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . 0.504 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 4.3 m-20 -116.0 23.24 12.37 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.059 0.457 . . . . 74.209999999999994 110.041 177.141 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.951 ' HE3' ' HB3' ' B' ' 175' ' ' TRP . 21.2 pttm -127.5 115.56 19.04 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.236 0.541 . . . . 73.219999999999999 110.307 177.311 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 122' ' ' THR . . . . . 0.729 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 62.5 m -76.22 113.0 13.29 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.611 -0.722 . . . . 74.209999999999994 109.675 177.172 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 14.2 mm -92.8 102.51 13.7 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-N 115.948 -0.569 . . . . 75.129999999999995 109.999 -178.222 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.761 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 15.5 mt-30 -94.77 102.89 14.79 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.093 0.473 . . . . 73.25 110.327 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . 0.737 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 38.9 mt-10 -84.62 102.72 13.13 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.556 -0.747 . . . . 75.409999999999997 110.603 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . 0.479 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 41.4 m-85 -78.8 106.0 10.51 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.137 0.494 . . . . 71.530000000000001 110.377 178.061 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 65.6 mtt-85 -124.08 134.55 53.36 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.61 -0.723 . . . . 74.150000000000006 109.468 -178.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.548 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 5.6 p -96.08 -30.91 3.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-O 120.966 0.412 . . . . 73.439999999999998 111.407 -176.374 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -160.45 45.99 0.22 Allowed 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.872 -0.788 . . . . 72.340000000000003 108.872 -176.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 95.54 -32.08 6.58 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.425 -0.807 . . . . 64.519999999999996 112.186 -177.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . 0.596 ' CD2' HG22 ' A' ' 28' ' ' VAL . 38.2 t80 -86.49 133.6 33.74 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.99 0.424 . . . . 74.310000000000002 110.445 -177.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.439 HD22 HD11 ' B' ' 135' ' ' ILE . 41.4 tp -82.83 120.5 25.73 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.354 -0.839 . . . . 74.230000000000004 110.645 179.328 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . 0.479 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 36.2 p90 -110.4 -10.43 14.58 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.498 -0.481 . . . . 74.019999999999996 111.658 -179.101 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -170.14 148.13 3.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.806 0.336 . . . . 75.150000000000006 110.913 -178.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.439 HD11 HD22 ' B' ' 132' ' ' LEU . 63.5 mt -122.44 125.89 73.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.332 -0.395 . . . . 73.319999999999993 110.17 177.456 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.761 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 75.9 tttt -102.43 102.39 12.7 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 109.07 -0.715 . . . . 75.450000000000003 109.07 173.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.621 HG13 ' HD3' ' B' ' 139' ' ' PRO . 3.4 t -86.52 128.94 39.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 N-CA-C 108.559 -0.904 . . . . 75.299999999999997 108.559 178.151 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.729 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.5 t -115.35 72.1 3.39 Favored Pre-proline 0 C--N 1.317 -0.841 0 N-CA-C 109.956 -0.387 . . . . 75.409999999999997 109.956 173.525 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.621 ' HD3' HG13 ' B' ' 137' ' ' VAL . 45.1 Cg_endo -77.12 130.5 11.23 Favored 'Trans proline' 0 N--CA 1.455 -0.754 0 C-N-CA 121.992 1.794 . . . . 64.109999999999999 111.868 176.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . 0.504 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 22.9 mtpp -64.76 -27.43 68.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.442 -0.799 . . . . 73.450000000000003 110.199 177.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -114.43 86.57 2.46 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.132 -0.94 . . . . 75.109999999999999 109.149 176.293 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 140.96 -13.88 2.85 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.593 -0.813 . . . . 74.230000000000004 112.678 -177.576 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 67.1 mttm 70.03 149.01 0.12 Allowed Pre-proline 0 N--CA 1.469 0.525 0 C-N-CA 123.134 0.574 . . . . 74.209999999999994 112.183 178.266 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.559 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 56.3 Cg_endo -70.64 143.1 45.7 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.674 2.249 . . . . 74.219999999999999 113.146 -178.279 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 44.7 p90 -150.99 154.77 37.72 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.789 -0.641 . . . . 74.230000000000004 110.199 178.207 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.626 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 93.4 m-85 -96.64 130.5 43.84 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.838 -0.43 . . . . 75.25 109.838 177.255 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 15.7 tp -117.21 98.81 6.64 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.134 -0.691 . . . . 73.439999999999998 109.134 176.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . 0.422 HG23 HG22 ' A' ' 48' ' ' VAL . 39.0 t -83.92 135.73 24.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.05 -0.523 . . . . 72.140000000000001 110.837 -175.294 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.29 119.44 24.59 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.58 -0.526 . . . . 74.420000000000002 109.58 -177.722 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.14 166.75 22.88 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 121.321 0.581 . . . . 71.209999999999994 111.74 -174.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . 0.407 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 5.6 p-10 -67.77 157.59 34.38 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 114.964 -1.017 . . . . 71.239999999999995 111.99 -175.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.41 -8.93 57.24 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.301 -0.863 . . . . 71.230000000000004 113.28 173.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 23.3 t 59.3 31.1 20.9 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-O 121.513 0.673 . . . . 71.209999999999994 110.007 -178.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -64.43 -26.18 68.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.597 -0.729 . . . . 74.450000000000003 111.841 -178.139 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 106.15 25.17 6.53 Favored Glycine 0 CA--C 1.506 -0.525 0 N-CA-C 111.169 -0.772 . . . . 64.319999999999993 111.169 -175.044 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . 0.402 HD22 HD22 ' B' ' 166' ' ' LEU . 38.0 t30 -111.95 144.26 41.59 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.461 -0.57 . . . . 75.109999999999999 109.461 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . 0.507 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 55.8 m-85 -130.62 149.56 52.22 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.305 -0.407 . . . . 75.450000000000003 110.083 179.587 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.2 mm -112.44 117.19 54.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.444 -0.576 . . . . 74.120000000000005 109.444 176.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . . . . . . . . . 46.1 ttt180 -85.95 135.05 33.82 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.48 -0.782 . . . . 75.400000000000006 110.075 -175.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 160' ' ' SER . . . . . 0.626 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 61.3 p -60.46 -33.07 72.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.406 0.622 . . . . 74.200000000000003 110.412 178.66 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -75.94 -24.59 55.51 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.15 -0.932 . . . . 71.310000000000002 110.921 178.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . 0.419 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 84.3 mm-40 -139.98 70.97 35.44 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 71.319999999999993 110.197 -175.235 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -73.11 -15.37 25.8 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.431 2.087 . . . . 72.230000000000004 112.007 -178.032 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -89.2 -7.2 56.06 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.41 -0.814 . . . . 72.140000000000001 109.641 177.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . 0.419 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 51.3 tptt -110.68 123.98 51.06 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.444 -0.798 . . . . 75.099999999999994 110.447 -176.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . 0.402 HD22 HD22 ' B' ' 156' ' ' ASN . 5.3 mp -89.64 117.5 28.56 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.515 -0.766 . . . . 72.530000000000001 108.989 177.096 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . 0.507 ' HB ' ' HB2' ' B' ' 157' ' ' PHE . 49.3 mm -77.73 119.56 77.91 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.185 -0.462 . . . . 72.25 111.272 -171.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.471 ' O ' HG22 ' B' ' 172' ' ' ILE . 73.7 Cg_endo -73.3 177.26 8.1 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 123.049 2.5 . . . . 73.409999999999997 111.998 178.492 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 -84.25 0.88 47.2 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.347 -0.388 . . . . 71.319999999999993 111.468 -172.127 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 7.8 p90 -100.46 -18.89 16.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.987 0.423 . . . . 73.549999999999997 110.89 175.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.417 ' HB2' ' HG2' ' B' ' 168' ' ' PRO . 2.0 mm-40 -94.29 -11.43 30.15 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.194 -0.457 . . . . 74.519999999999996 110.76 -177.232 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.471 HG22 ' O ' ' B' ' 168' ' ' PRO . 37.0 pt -65.56 -29.65 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.991 -0.55 . . . . 75.219999999999999 111.432 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . 0.484 ' C ' ' H ' ' B' ' 175' ' ' TRP . 33.8 p90 -107.79 43.96 1.15 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.525 0.678 . . . . 71.140000000000001 110.447 178.742 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 174' ' ' SER . . . . . 0.401 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 1.9 t -78.59 21.97 0.37 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.05 -0.977 . . . . 72.439999999999998 110.036 178.183 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . 0.951 ' HB3' ' HE3' ' B' ' 121' ' ' LYS . 39.3 m0 . . . . . 0 C--O 1.25 1.129 0 CA-C-N 115.223 -0.898 . . . . 75.209999999999994 110.928 -176.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.6 m . . . . . 0 C--O 1.233 0.22 0 N-CA-C 109.518 -0.549 . . . . 65.109999999999999 109.518 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.657 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 74.03 73.02 0.95 Allowed Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.02 -1.086 . . . . 61.329999999999998 110.621 -173.727 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -96.22 99.1 4.77 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-O 121.417 0.627 . . . . 74.299999999999997 110.667 -174.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.728 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 98.2 Cg_endo -93.73 94.72 0.14 Allowed 'Trans proline' 0 N--CA 1.445 -1.368 0 C-N-CA 122.926 2.417 . . . . 64.109999999999999 112.747 -176.524 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -86.96 147.1 25.89 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 108.932 -0.766 . . . . 60.210000000000001 108.932 177.069 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.612 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 8.1 p -90.63 122.41 41.98 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 CA-C-O 121.629 0.728 . . . . 70.319999999999993 110.261 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.626 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 21.6 m -83.31 102.59 12.08 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.264 -0.88 . . . . 72.400000000000006 109.196 179.226 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 53.2 mt -84.72 103.98 12.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-N 115.978 -0.555 . . . . 74.340000000000003 110.308 -175.449 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -108.8 161.24 15.3 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.621 -0.718 . . . . 74.219999999999999 109.32 176.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -137.87 98.25 3.61 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-O 121.351 0.596 . . . . 72.439999999999998 110.232 176.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -93.88 96.84 9.99 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 114.982 -1.008 . . . . 75.420000000000002 109.849 -177.313 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 71.06 -101.84 1.0 Allowed Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.837 -0.697 . . . . 64.239999999999995 112.077 -178.105 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.748 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 16.5 m-20 -120.76 30.42 6.91 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.635 0.255 . . . . 71.340000000000003 110.951 -178.364 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.431 ' HB3' ' HA ' ' A' ' 39' ' ' PRO . 48.0 pttt -143.55 127.69 17.58 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.382 0.61 . . . . 75.25 111.624 175.72 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.437 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 75.0 m -81.66 107.18 14.2 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.189 -0.914 . . . . 72.219999999999999 109.936 177.073 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 50.2 mt -94.63 104.35 15.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.088 -0.505 . . . . 72.310000000000002 109.721 178.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.612 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 24.0 mt-30 -95.15 106.38 18.39 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.871 -0.604 . . . . 74.299999999999997 110.654 -177.725 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.626 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.7 mt-10 -89.86 104.51 17.06 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.874 -0.603 . . . . 53.509999999999998 111.355 -177.437 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.565 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 71.7 m-85 -76.94 103.57 6.95 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.393 -0.595 . . . . 74.340000000000003 109.393 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 55.5 mtt180 -120.39 128.05 52.86 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.259 -0.428 . . . . 74.230000000000004 110.362 -177.312 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.728 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 2.3 p -93.49 -66.73 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.543 -0.298 . . . . 73.519999999999996 111.232 179.58 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.692 ' H ' HG12 ' A' ' 28' ' ' VAL . 74.2 m-20 -133.53 77.5 1.73 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.85 0.357 . . . . 71.010000000000005 110.158 179.513 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 69.21 13.49 67.38 Favored Glycine 0 C--N 1.331 0.267 0 CA-C-N 115.792 -0.64 . . . . 75.209999999999994 112.868 179.042 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.604 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 83.3 t80 -129.86 128.04 41.45 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.888 0.375 . . . . 72.120000000000005 111.12 -175.431 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.728 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -85.98 116.25 24.09 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.559 -0.746 . . . . 72.209999999999994 109.327 173.571 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -110.89 -19.71 12.71 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.622 -0.431 . . . . 74.040000000000006 111.729 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -156.08 141.21 17.39 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.656 0.265 . . . . 61.219999999999999 111.031 -179.338 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.728 HG13 HD11 ' A' ' 32' ' ' LEU . 77.0 mt -124.31 125.9 71.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 116.055 -0.521 . . . . 72.319999999999993 110.612 176.867 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.433 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 82.1 tttt -102.99 102.56 12.61 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.104 -0.702 . . . . 72.299999999999997 109.104 170.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.437 ' HA ' ' O ' ' A' ' 22' ' ' THR . 0.5 OUTLIER -101.84 119.93 50.78 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 116.119 -0.491 . . . . 72.519999999999996 110.337 -179.538 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.559 HG13 ' HB3' ' A' ' 44' ' ' PRO . 22.3 t -109.17 89.71 7.19 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.445 -0.798 . . . . 73.439999999999998 110.135 -179.826 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.431 ' HA ' ' HB3' ' A' ' 21' ' ' LYS . 63.6 Cg_endo -79.37 135.92 12.24 Favored 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 122.282 1.988 . . . . 73.019999999999996 112.133 178.001 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.748 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 56.5 mtpt -63.43 -36.27 83.19 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.362 0.601 . . . . 74.439999999999998 109.518 174.622 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -97.81 92.63 5.94 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.222 -0.899 . . . . 70.319999999999993 109.114 177.269 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 126.0 -151.39 17.82 Favored Glycine 0 N--CA 1.448 -0.549 0 N-CA-C 111.478 -0.649 . . . . 74.319999999999993 111.478 -176.529 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -129.29 143.76 50.11 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.801 0.301 . . . . 73.420000000000002 110.601 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.559 ' HB3' HG13 ' A' ' 38' ' ' VAL . 32.1 Cg_endo -65.29 128.94 21.49 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.679 2.253 . . . . 74.400000000000006 112.077 177.758 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -133.86 156.73 47.54 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.267 -0.424 . . . . 74.120000000000005 110.343 -178.151 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -95.71 131.62 41.77 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.778 -0.647 . . . . 74.140000000000001 109.792 177.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.559 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 17.0 tp -115.63 94.11 4.56 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.827 -0.805 . . . . 72.120000000000005 108.827 178.102 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.7 t -87.29 138.27 19.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.064 -0.517 . . . . 72.200000000000003 110.872 -174.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . 0.421 ' HE ' ' HA ' ' A' ' 53' ' ' SER . 0.0 OUTLIER -100.89 121.6 42.0 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.926 -0.398 . . . . 75.120000000000005 109.926 -177.3 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.98 172.06 13.79 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.01 0.433 . . . . 71.299999999999997 112.076 -173.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.43 ' HB3' ' CD2' ' B' ' 126' ' ' TYR . 4.3 p-10 -72.13 167.73 19.64 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 115.793 -0.64 . . . . 74.310000000000002 111.09 -175.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 81.2 -17.17 13.42 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.831 -0.622 . . . . 74.349999999999994 112.798 177.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.421 ' HA ' ' HE ' ' A' ' 49' ' ' ARG . 20.9 t 61.64 33.46 18.13 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-O 120.894 0.378 . . . . 63.530000000000001 110.148 -178.075 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -55.89 -42.02 75.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.714 -0.675 . . . . 75.310000000000002 111.363 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 119.17 25.52 2.7 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.834 -0.698 . . . . 72.109999999999999 111.392 -177.167 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 11.2 p30 -118.74 147.24 44.07 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.178 0.513 . . . . 75.239999999999995 110.633 -177.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.559 ' CD2' ' HG ' ' A' ' 47' ' ' LEU . 46.6 m-85 -128.17 154.33 45.91 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.684 -0.689 . . . . 75.400000000000006 110.501 -178.729 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 45.3 mm -113.1 122.89 68.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.987 -0.551 . . . . 73.409999999999997 109.519 177.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.465 ' HB3' ' HB3' ' A' ' 61' ' ' ASP . 67.2 mtt180 -86.17 144.79 27.3 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.56 -0.291 . . . . 75.519999999999996 110.61 178.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 77.6 p -76.02 -21.85 56.41 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.407 -0.961 . . . . 75.299999999999997 108.407 166.396 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.465 ' HB3' ' HB3' ' A' ' 59' ' ' ARG . 19.2 t70 -57.62 -49.17 77.33 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.519 -1.219 . . . . 74.349999999999994 110.092 172.746 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 24.1 mm-40 -144.78 86.38 7.9 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.151 -0.932 . . . . 71.540000000000006 110.25 178.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_endo -78.79 13.0 2.03 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.89 2.394 . . . . 75.439999999999998 112.24 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -83.65 -30.7 26.65 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.418 -0.81 . . . . 71.329999999999998 110.529 -178.59 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.25 178.1 6.02 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-O 121.196 0.522 . . . . 74.340000000000003 111.614 -176.664 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.5 mp -111.16 138.19 47.91 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.206 -0.906 . . . . 75.409999999999997 109.607 177.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 33.7 mm -76.55 124.86 87.95 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 116.448 -0.342 . . . . 75.430000000000007 110.145 178.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.43 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 44.3 Cg_endo -66.98 173.84 7.72 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.903 2.402 . . . . 75.010000000000005 112.759 -177.855 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 19.5 tt0 -88.63 -1.44 58.07 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.54 -0.755 . . . . 74.109999999999999 111.907 -168.684 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . 0.583 ' HA ' ' CE2' ' A' ' 73' ' ' PHE . 33.4 p90 -97.39 -22.61 16.51 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.265 0.555 . . . . 74.530000000000001 109.727 172.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.43 ' HB2' ' HG2' ' A' ' 68' ' ' PRO . 4.4 mm-40 -84.25 -12.71 54.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.448 -0.796 . . . . 72.420000000000002 111.522 -176.745 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 31.9 pt -77.67 -15.88 14.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.125 -0.489 . . . . 75.109999999999999 111.875 -177.496 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CE2' ' HA ' ' A' ' 70' ' ' TRP . 42.4 p90 -119.45 23.83 11.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.42 0.629 . . . . 74.420000000000002 110.189 177.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 56.2 m -80.23 -1.34 40.25 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.712 -0.676 . . . . 71.340000000000003 110.875 177.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . 0.528 ' HH2' HG23 ' A' ' 35' ' ' ILE . 0.3 OUTLIER . . . . . 0 C--N 1.327 -0.38 0 CA-C-N 116.149 -0.478 . . . . 73.129999999999995 110.58 178.275 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 58.8 m . . . . . 0 N--CA 1.45 -0.449 0 N-CA-C 109.292 -0.632 . . . . 75.340000000000003 109.292 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.45 52.66 0.55 Allowed Glycine 0 N--CA 1.445 -0.715 0 N-CA-C 110.551 -1.02 . . . . 73.230000000000004 110.551 -170.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . 0.402 ' O ' ' HG3' ' B' ' 110' ' ' GLU . 10.1 pt-20 -97.92 105.33 26.84 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.365 -0.976 . . . . 73.239999999999995 108.365 -179.316 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.642 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 73.7 Cg_endo -83.11 113.42 2.11 Favored 'Trans proline' 0 N--CA 1.443 -1.489 0 C-N-CA 122.143 1.895 . . . . 74.109999999999999 112.418 -170.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 16.5 p-10 -109.72 133.46 53.1 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 115.066 -0.97 . . . . 75.409999999999997 109.444 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.616 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 11.7 p -83.55 127.89 39.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 121.42 0.629 . . . . 65.040000000000006 110.734 -177.396 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 114' ' ' THR . . . . . 0.635 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 27.0 m -81.72 108.85 15.6 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.456 -0.793 . . . . 74.0 109.964 179.349 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.474 HG12 ' HG2' ' B' ' 124' ' ' GLN . 66.4 mt -93.26 106.05 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.074 0.464 . . . . 73.329999999999998 110.907 -176.439 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . 0.467 ' HA ' ' NE ' ' B' ' 116' ' ' ARG . 3.5 mmp_? -116.24 164.98 13.69 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.657 -0.701 . . . . 73.120000000000005 109.457 176.824 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -138.39 107.46 6.03 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.099 0.476 . . . . 72.219999999999999 110.962 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -100.36 97.29 8.07 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.584 -0.734 . . . . 74.430000000000007 110.297 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 74.89 -97.01 0.98 Allowed Glycine 0 N--CA 1.444 -0.797 0 C-N-CA 121.011 -0.614 . . . . 74.209999999999994 112.256 178.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . 0.773 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 5.8 m-20 -125.06 32.07 5.48 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.702 0.287 . . . . 72.109999999999999 110.664 -178.702 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.432 ' HB3' ' HA ' ' B' ' 139' ' ' PRO . 41.9 pttt -145.83 125.43 13.28 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.273 0.559 . . . . 74.5 111.806 177.754 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 59.8 m -79.91 107.74 12.93 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.073 -0.967 . . . . 74.530000000000001 109.828 175.413 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 42.6 mt -100.13 109.46 24.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-O 121.209 0.528 . . . . 73.310000000000002 110.096 -178.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.616 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 55.0 mt-30 -96.19 111.23 23.34 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.573 -0.74 . . . . 74.010000000000005 111.135 -178.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . 0.635 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 42.9 mt-10 -90.0 104.94 17.46 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.874 -0.603 . . . . 74.439999999999998 110.669 177.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . 0.43 ' CD2' ' HB3' ' A' ' 51' ' ' ASP . 56.8 m-85 -76.82 110.8 11.72 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.486 -0.324 . . . . 74.019999999999996 110.487 178.002 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . 0.598 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 48.0 mtt180 -130.93 137.7 49.41 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.971 -0.381 . . . . 74.040000000000006 109.971 178.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.642 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.5 p -98.8 -41.21 9.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.273 0.558 . . . . 70.010000000000005 110.797 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 -157.36 72.92 0.71 Allowed 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.848 -0.797 . . . . 75.299999999999997 108.848 -177.751 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.47 -38.16 2.77 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.819 -0.628 . . . . 53.149999999999999 112.889 -178.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -88.97 132.62 34.64 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.039 0.447 . . . . 75.219999999999999 111.573 -172.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.598 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 45.1 tp -85.16 117.96 24.43 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.317 -0.856 . . . . 72.439999999999998 110.085 175.091 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -109.67 -9.39 14.86 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.428 -0.509 . . . . 75.209999999999994 111.948 -177.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -167.51 141.52 3.61 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.735 0.302 . . . . 52.310000000000002 111.294 -177.188 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 57.9 mt -118.13 126.29 74.85 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 116.271 -0.422 . . . . 73.209999999999994 110.121 176.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.447 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 84.7 tttt -112.7 101.19 9.31 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.367 -0.605 . . . . 72.340000000000003 109.367 174.453 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.507 HG12 ' CE1' ' B' ' 145' ' ' TYR . 0.7 OUTLIER -103.57 126.46 58.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 CA-C-O 121.03 0.443 . . . . 73.329999999999998 110.715 -178.844 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.777 HG23 ' HB3' ' B' ' 144' ' ' PRO . 21.9 t -110.2 89.53 8.54 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.366 -0.834 . . . . 74.239999999999995 109.62 178.748 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.432 ' HA ' ' HB3' ' B' ' 121' ' ' LYS . 61.0 Cg_endo -77.35 136.52 15.94 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 122.508 2.139 . . . . 74.25 112.701 -179.436 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . 0.773 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 56.2 mtpt -61.13 -38.08 85.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.6 0.714 . . . . 64.420000000000002 109.62 171.598 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 94.9 m-70 -99.3 84.25 2.97 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.832 -1.076 . . . . 75.140000000000001 108.889 177.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 130.59 -162.55 23.33 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 110.322 -1.111 . . . . 73.450000000000003 110.322 -172.316 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -138.83 153.24 71.82 Favored Pre-proline 0 C--N 1.321 -0.652 0 CA-C-N 117.336 0.568 . . . . 75.310000000000002 110.715 178.169 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.777 ' HB3' HG23 ' B' ' 138' ' ' VAL . 21.8 Cg_endo -60.47 140.72 92.93 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 123.226 2.617 . . . . 74.510000000000005 113.29 -174.235 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . 0.507 ' CE1' HG12 ' B' ' 137' ' ' VAL . 23.3 p90 -143.44 155.67 44.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.53 -0.759 . . . . 74.120000000000005 109.481 177.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.461 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 96.4 m-85 -97.22 133.14 42.25 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.754 0.312 . . . . 74.129999999999995 110.431 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . 0.515 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 17.5 tp -122.29 98.53 5.97 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.864 -0.791 . . . . 72.409999999999997 108.864 177.508 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 39.0 t -99.31 144.72 11.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.431 -0.349 . . . . 73.129999999999995 111.186 -172.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 5.2 mmt85 -76.91 145.25 38.36 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-O 120.962 0.41 . . . . 75.409999999999997 111.932 179.194 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.96 169.95 12.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.807 -0.633 . . . . 72.239999999999995 109.823 171.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . 0.565 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 6.2 p-10 -67.64 157.23 34.99 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.373 0.606 . . . . 74.510000000000005 112.155 -174.479 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 84.76 -5.68 81.09 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.481 -0.781 . . . . 71.129999999999995 113.268 174.384 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 153' ' ' SER . . . . . 0.406 ' HB2' ' CD ' ' A' ' 11' ' ' PRO . 3.5 t 62.22 27.99 16.78 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.487 0.66 . . . . 71.109999999999999 109.664 -177.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -56.59 -27.56 58.29 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 114.782 -1.099 . . . . 65.540000000000006 111.885 -178.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 112.09 -22.11 18.96 Favored Glycine 0 CA--C 1.498 -1.0 0 C-N-CA 120.617 -0.802 . . . . 73.230000000000004 111.19 -178.593 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . 0.983 HD22 HD23 ' B' ' 166' ' ' LEU . 52.2 t30 -63.8 132.96 52.51 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 114.203 -0.998 . . . . 74.230000000000004 111.507 179.446 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . 0.515 ' CD2' ' HG ' ' B' ' 147' ' ' LEU . 27.2 m-85 -115.0 159.17 21.09 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.828 -0.623 . . . . 74.329999999999998 110.538 178.04 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . 0.804 HD13 HD22 ' B' ' 166' ' ' LEU . 48.6 mm -127.75 132.71 68.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.992 -0.549 . . . . 73.409999999999997 109.558 174.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.49 ' HB2' ' HB2' ' B' ' 162' ' ' GLN . 70.2 mtt180 -85.26 156.89 20.76 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.885 0.374 . . . . 73.109999999999999 111.249 -179.829 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 160' ' ' SER . . . . . 0.461 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 49.4 p -80.01 -19.48 47.64 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.885 0.85 . . . . 60.549999999999997 108.777 166.37 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -86.84 -26.04 24.23 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 114.461 -1.245 . . . . 71.019999999999996 110.46 176.549 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . 0.49 ' HB2' ' HB2' ' B' ' 159' ' ' ARG . 25.4 mm-40 -136.68 74.94 51.27 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.518 -0.764 . . . . 74.519999999999996 109.346 -179.691 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -89.24 11.68 2.89 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.897 2.398 . . . . 64.540000000000006 113.183 -176.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -107.87 -45.42 3.99 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 120.992 -0.283 . . . . 74.230000000000004 111.013 -178.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.25 172.79 7.89 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.029 0.442 . . . . 75.519999999999996 111.26 178.581 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . 0.983 HD23 HD22 ' B' ' 156' ' ' ASN . 15.8 mt -105.35 150.27 25.36 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.851 -0.613 . . . . 72.140000000000001 109.948 -175.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 40.8 mm -101.31 111.67 63.98 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 116.389 -0.369 . . . . 72.219999999999999 110.183 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.59 ' O ' HG22 ' B' ' 172' ' ' ILE . 59.7 Cg_endo -70.05 174.52 9.64 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 123.075 2.516 . . . . 75.120000000000005 112.593 -178.511 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . 0.604 ' O ' HG12 ' B' ' 172' ' ' ILE . 6.3 tt0 -72.45 -35.7 68.35 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.877 -0.601 . . . . 75.120000000000005 111.969 -167.816 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 33.4 p90 -69.02 -14.66 63.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.168 0.509 . . . . 65.420000000000002 110.222 177.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.425 ' HA ' ' HB2' ' B' ' 174' ' ' SER . 7.0 mm-40 -96.51 -29.54 13.83 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.569 -0.741 . . . . 71.150000000000006 111.671 -178.029 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.604 HG12 ' O ' ' B' ' 169' ' ' GLN . 43.4 pt -67.66 -26.21 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 N-CA-C 111.876 0.324 . . . . 73.040000000000006 111.876 -175.309 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -124.09 36.3 4.65 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.353 0.597 . . . . 74.519999999999996 110.256 176.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 174' ' ' SER . . . . . 0.425 ' HB2' ' HA ' ' B' ' 171' ' ' GLU . 22.1 t -85.66 10.73 12.56 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.342 -0.845 . . . . 71.219999999999999 111.369 -176.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 11.9 p-90 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.619 -0.705 . . . . 72.5 111.599 -178.364 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 25.3 p . . . . . 0 N--CA 1.451 -0.389 0 N-CA-C 110.342 -0.244 . . . . 75.239999999999995 110.342 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 145.07 -53.16 0.57 Allowed Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.848 -0.691 . . . . 54.450000000000003 111.622 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 64.6 100.96 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.542 0.686 . . . . 73.310000000000002 111.624 177.041 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.668 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 18.8 Cg_endo -91.62 122.05 0.67 Allowed 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 123.58 2.853 . . . . 74.340000000000003 112.595 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -139.62 138.58 36.26 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.148 -0.478 . . . . 73.129999999999995 109.749 178.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.525 ' HB ' ' HB2' ' B' ' 151' ' ' ASP . 13.7 p -101.94 132.8 47.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.331 0.586 . . . . 74.129999999999995 111.215 -171.594 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.7 m -92.77 104.06 16.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.738 -0.665 . . . . 72.140000000000001 109.722 176.055 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 66.4 mt -94.23 107.83 19.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.167 -0.469 . . . . 74.5 110.5 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.9 mtp180 -115.83 -179.2 3.59 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.242 -0.435 . . . . 71.430000000000007 110.505 177.065 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 70.9 mt-30 -140.1 106.24 5.23 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.937 -0.574 . . . . 71.010000000000005 110.763 178.211 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -99.62 107.08 19.13 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.912 -0.585 . . . . 75.129999999999995 109.846 176.716 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 62.61 -111.15 3.8 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.752 -0.737 . . . . 71.439999999999998 112.215 -178.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.506 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 7.7 m-20 -105.81 7.62 32.43 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 111.49 0.181 . . . . 74.340000000000003 111.49 -177.847 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.63 ' HE3' ' HE3' ' A' ' 75' ' ' TRP . 0.0 OUTLIER -121.06 131.68 54.42 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 119.951 -0.7 . . . . 73.519999999999996 112.259 179.951 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.516 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 6.2 m -80.68 124.08 28.71 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.162 -0.926 . . . . 72.209999999999994 109.313 174.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 23.7 mm -108.45 107.32 22.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 110.141 -0.318 . . . . 64.219999999999999 110.141 -175.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 14.6 mt-30 -102.23 105.26 15.9 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.91 0.386 . . . . 65.319999999999993 110.273 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -88.92 100.38 13.14 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.447 -0.797 . . . . 71.549999999999997 110.606 -178.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.547 ' HA ' ' OD2' ' B' ' 151' ' ' ASP . 96.3 m-85 -76.22 118.39 18.9 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.011 -0.541 . . . . 75.200000000000003 110.3 179.561 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.453 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 50.6 mtt180 -139.2 121.17 15.6 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.161 0.505 . . . . 75.200000000000003 112.014 -173.174 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.668 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 3.8 p -97.45 120.5 46.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 108.751 -0.833 . . . . 75.400000000000006 108.751 169.722 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 73.85 -34.39 0.28 Allowed 'General case' 0 N--CA 1.47 0.562 0 O-C-N 123.456 0.473 . . . . 72.019999999999996 111.085 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.457 ' H ' ' C ' ' A' ' 28' ' ' VAL . . . 157.32 -16.39 0.34 Allowed Glycine 0 N--CA 1.45 -0.431 0 N-CA-C 111.859 -0.496 . . . . 72.319999999999993 111.859 178.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.45 ' O ' ' HA ' ' A' ' 27' ' ' ARG . 81.3 t80 -79.47 125.73 29.94 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.69 0.281 . . . . 74.219999999999999 111.003 -177.782 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.668 HD12 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -73.21 112.33 9.15 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.281 -0.637 . . . . 74.329999999999998 109.281 175.821 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 25.7 p90 -111.66 -14.3 13.64 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 120.402 -0.519 . . . . 74.519999999999996 111.83 -178.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -159.54 142.86 14.37 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.732 0.301 . . . . 73.299999999999997 110.94 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.668 HG13 HD12 ' A' ' 32' ' ' LEU . 68.2 mt -123.91 122.86 65.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.233 -0.44 . . . . 74.129999999999995 110.14 175.521 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.439 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 53.2 tttp -107.66 106.57 16.98 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.003 -0.74 . . . . 71.430000000000007 109.003 172.152 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.577 HG22 ' HB2' ' A' ' 21' ' ' LYS . 1.5 p -102.58 126.85 56.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-N 116.111 -0.495 . . . . 72.319999999999993 110.26 178.28 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.689 HG23 ' HB3' ' A' ' 44' ' ' PRO . 23.5 t -109.3 85.66 3.66 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.273 -0.876 . . . . 73.099999999999994 109.99 178.397 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.505 ' HD2' ' C ' ' A' ' 43' ' ' LYS . 36.6 Cg_endo -86.36 132.9 3.79 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 122.572 2.182 . . . . 75.25 112.557 179.539 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.506 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 56.2 mtpt -60.35 -26.01 66.28 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.619 0.724 . . . . 75.430000000000007 109.884 175.188 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -122.54 88.25 2.9 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 115.194 -0.912 . . . . 74.349999999999994 108.818 176.414 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 145.28 -34.7 1.5 Allowed Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.442 -0.799 . . . . 72.299999999999997 111.702 -175.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.505 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 97.4 mttt 72.22 145.97 0.11 Allowed Pre-proline 0 N--CA 1.468 0.451 0 C-N-CA 123.565 0.746 . . . . 73.0 112.152 176.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.689 ' HB3' HG23 ' A' ' 38' ' ' VAL . 34.3 Cg_endo -63.25 137.49 61.31 Favored 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 123.454 2.769 . . . . 72.219999999999999 114.362 -170.019 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 8.6 p90 -148.21 165.96 29.37 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.577 -0.738 . . . . 72.219999999999999 109.243 174.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.716 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 38.6 m-85 -104.93 134.19 48.46 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.904 0.383 . . . . 74.510000000000005 110.774 177.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.507 HD23 HG21 ' A' ' 72' ' ' ILE . 16.6 tp -120.41 102.7 8.64 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.574 -0.899 . . . . 75.439999999999998 108.574 172.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.4 t -97.61 138.68 21.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.143 -0.481 . . . . 74.409999999999997 110.886 -173.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 7.4 tpt180 -66.57 128.02 34.62 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.89 -0.595 . . . . 74.120000000000005 110.131 175.634 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.09 116.84 18.85 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.736 -0.468 . . . . 62.420000000000002 109.736 174.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.617 ' HB2' ' CD2' ' B' ' 126' ' ' TYR . 0.4 OUTLIER -53.38 138.74 32.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.969 -0.56 . . . . 72.239999999999995 110.165 177.325 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 109.39 -32.48 6.78 Favored Glycine 0 N--CA 1.442 -0.963 0 N-CA-C 110.453 -1.059 . . . . 64.310000000000002 110.453 -171.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.4 t 56.99 50.36 12.28 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-O 121.253 0.549 . . . . 73.219999999999999 110.838 176.445 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -92.46 18.29 8.73 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.206 -0.452 . . . . 70.209999999999994 111.012 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.97 52.62 4.25 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.752 -0.737 . . . . 54.420000000000002 111.507 -176.591 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 30.2 t30 -147.76 141.81 25.99 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.804 0.335 . . . . 62.399999999999999 110.999 -174.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -129.42 147.1 51.2 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.898 -0.592 . . . . 74.040000000000006 109.529 175.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 43.7 mm -111.16 137.0 45.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.041 0.448 . . . . 75.010000000000005 110.394 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.722 ' HB2' HG13 ' A' ' 67' ' ' ILE . 24.0 ttt180 -103.22 142.18 34.61 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.826 -0.624 . . . . 73.519999999999996 110.5 -172.351 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.716 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 76.9 p -70.11 -30.81 68.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.41 0.624 . . . . 73.200000000000003 110.157 176.011 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -70.81 -27.86 64.2 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 114.845 -1.07 . . . . 73.230000000000004 110.631 176.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . 0.682 ' HG2' ' HB3' ' A' ' 65' ' ' LYS . 5.5 tt0 -146.05 77.04 12.2 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.685 -0.689 . . . . 70.230000000000004 109.598 -175.241 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.2 -35.38 8.72 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.836 2.357 . . . . 73.310000000000002 113.842 -172.175 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -95.07 41.02 1.1 Allowed 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.888 0.851 . . . . 63.439999999999998 109.953 -177.657 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.682 ' HB3' ' HG2' ' A' ' 62' ' ' GLN . 22.9 tptm -150.46 128.38 11.78 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.185 -0.916 . . . . 75.310000000000002 109.93 175.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.455 ' H ' HD11 ' A' ' 66' ' ' LEU . 4.5 mp -73.32 120.35 18.82 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.324 -0.853 . . . . 71.129999999999995 109.045 176.654 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.722 HG13 ' HB2' ' A' ' 59' ' ' ARG . 47.4 mm -85.75 125.39 69.12 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-O 120.861 0.362 . . . . 62.310000000000002 110.639 -176.265 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -66.54 175.73 4.87 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.876 2.384 . . . . 72.310000000000002 112.778 -178.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 16.4 tt0 -93.9 14.35 19.82 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.588 -0.733 . . . . 70.019999999999996 111.834 -168.506 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 18.7 p90 -109.24 -26.35 10.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.147 0.499 . . . . 75.439999999999998 110.151 173.246 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -81.12 -11.89 59.37 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.998 -0.546 . . . . 65.400000000000006 110.672 -178.653 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.507 HG21 HD23 ' A' ' 47' ' ' LEU . 44.9 pt -69.59 -22.84 25.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.915 -0.584 . . . . 71.319999999999993 110.91 177.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -112.6 25.26 11.64 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-N 115.808 -0.633 . . . . 64.140000000000001 109.822 -178.587 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 4.5 t -60.22 -37.78 81.37 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.873 -1.058 . . . . 72.219999999999999 109.906 -179.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . 0.63 ' HE3' ' HE3' ' A' ' 21' ' ' LYS . 43.2 p-90 . . . . . 0 C--N 1.326 -0.434 0 CA-C-N 115.884 -0.598 . . . . 74.129999999999995 110.454 176.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 55.0 m . . . . . 0 N--CA 1.452 -0.326 0 CA-C-O 120.904 0.383 . . . . 55.340000000000003 110.542 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 117.06 -63.25 0.38 Allowed Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 110.524 -1.031 . . . . 42.219999999999999 110.524 -175.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 62.3 88.19 0.12 Allowed Pre-proline 0 C--O 1.232 0.138 0 C-N-CA 123.157 0.583 . . . . 72.310000000000002 111.056 175.032 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.646 ' HB3' ' HA ' ' B' ' 128' ' ' VAL . 56.4 Cg_endo -86.67 140.08 5.94 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.982 2.454 . . . . 75.439999999999998 112.713 -176.701 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -148.13 122.42 9.62 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.751 -0.659 . . . . 73.140000000000001 109.28 177.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.456 ' N ' ' HB3' ' A' ' 51' ' ' ASP . 7.5 p -71.6 134.21 30.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.391 0.615 . . . . 70.129999999999995 111.739 -172.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 85.1 m -95.04 104.78 16.66 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.474 -0.785 . . . . 72.010000000000005 109.854 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 65.2 mt -88.19 106.56 16.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.893 -0.594 . . . . 72.219999999999999 110.143 -177.642 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 25.3 mtp-105 -108.75 171.59 7.34 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.166 0.508 . . . . 75.010000000000005 111.569 -178.241 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 70.4 mt-30 -132.34 114.7 14.7 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.581 -0.736 . . . . 74.420000000000002 109.989 176.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . 0.594 ' HG3' HD12 ' B' ' 123' ' ' ILE . 22.1 mm-40 -99.61 23.25 9.75 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.94 -0.573 . . . . 73.430000000000007 110.672 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 123.45 -90.47 0.42 Allowed Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.692 -0.563 . . . . 52.450000000000003 111.692 -178.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . 0.67 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 72.0 m-20 -105.35 -16.51 14.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.14 0.495 . . . . 71.310000000000002 110.077 177.51 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.683 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 27.4 pttt -99.96 120.09 39.26 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.434 0.635 . . . . 74.329999999999998 111.15 -178.761 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 122' ' ' THR . . . . . 0.45 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 25.0 m -83.22 104.29 13.28 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.376 -0.829 . . . . 64.25 109.193 174.471 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . 0.594 HD12 ' HG3' ' B' ' 118' ' ' GLU . 23.4 mt -98.39 107.26 20.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.181 0.515 . . . . 74.400000000000006 110.887 -174.118 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.569 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 17.9 mt-30 -93.62 107.07 18.98 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.431 -0.804 . . . . 75.230000000000004 110.061 179.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -87.95 111.08 21.09 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.097 -0.501 . . . . 74.239999999999995 110.687 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . 0.617 ' CD2' ' HB2' ' A' ' 51' ' ' ASP . 37.8 m-85 -86.4 113.6 22.49 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.013 -0.54 . . . . 64.420000000000002 110.131 177.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . 0.636 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 63.7 mtt180 -138.12 132.95 32.78 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.663 -0.699 . . . . 73.150000000000006 109.675 -176.791 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.646 ' HA ' ' HB3' ' B' ' 111' ' ' PRO . 2.7 p -96.32 -39.39 9.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 120.944 0.402 . . . . 62.130000000000003 110.991 -178.341 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -153.1 64.79 0.77 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.322 -0.622 . . . . 75.040000000000006 109.322 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.07 -36.01 3.35 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.489 -0.778 . . . . 72.310000000000002 112.597 -179.261 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . 0.456 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 80.8 t80 -83.84 124.79 31.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.084 0.468 . . . . 74.099999999999994 111.233 -173.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.779 HD13 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -77.12 115.6 17.05 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.312 -0.858 . . . . 71.519999999999996 109.251 175.169 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 22.5 p90 -109.11 -19.03 13.5 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.268 -0.573 . . . . 73.430000000000007 111.901 -178.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -155.98 141.47 17.72 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.024 0.44 . . . . 73.0 111.057 179.065 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.779 HG13 HD13 ' B' ' 132' ' ' LEU . 81.8 mt -119.2 123.82 72.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.859 -0.609 . . . . 73.150000000000006 110.286 177.127 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.569 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.6 tttt -105.62 99.68 9.27 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.274 -0.639 . . . . 72.310000000000002 109.274 172.007 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.449 HG22 ' HB2' ' B' ' 121' ' ' LYS . 2.0 p -101.4 121.8 52.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-O 121.194 0.521 . . . . 74.439999999999998 110.361 -178.602 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.819 HG23 ' HB3' ' B' ' 144' ' ' PRO . 24.6 t -109.03 85.51 3.29 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 115.086 -0.961 . . . . 73.129999999999995 110.21 179.614 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.683 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 71.6 Cg_endo -84.3 134.08 5.73 Favored 'Trans proline' 0 N--CA 1.451 -0.979 0 C-N-CA 122.375 2.05 . . . . 72.319999999999993 112.545 179.525 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . 0.67 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 57.8 mtpt -57.92 -31.56 66.91 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.448 0.642 . . . . 70.439999999999998 109.889 174.436 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 82.7 m-70 -111.14 83.18 1.72 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.201 -0.909 . . . . 62.240000000000002 109.292 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . 0.415 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 148.71 -32.03 1.21 Allowed Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.684 -0.77 . . . . 63.210000000000001 112.785 -178.87 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . 0.442 ' C ' ' HD2' ' B' ' 139' ' ' PRO . 98.9 mttt 73.44 151.43 0.14 Allowed Pre-proline 0 N--CA 1.471 0.604 0 C-N-CA 123.452 0.701 . . . . 70.230000000000004 111.704 -178.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.819 ' HB3' HG23 ' B' ' 138' ' ' VAL . 26.7 Cg_endo -62.0 135.24 54.04 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 123.197 2.598 . . . . 70.510000000000005 113.952 -171.129 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . 0.428 ' CE1' HG12 ' B' ' 137' ' ' VAL . 6.2 p90 -150.99 152.19 33.17 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.356 -0.838 . . . . 74.409999999999997 109.852 176.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.681 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 50.7 m-85 -97.29 141.89 29.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.475 -0.33 . . . . 74.349999999999994 111.366 -178.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . 0.448 HD21 ' HA ' ' B' ' 147' ' ' LEU . 15.3 mt -124.42 101.78 7.33 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.45 -0.795 . . . . 74.239999999999995 109.208 166.543 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . 0.437 HG13 ' HB ' ' B' ' 158' ' ' ILE . 6.0 p -104.65 139.2 26.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.724 -0.671 . . . . 73.409999999999997 111.015 -175.766 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 19.4 tpt180 -63.65 136.8 57.77 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.551 -0.75 . . . . 75.310000000000002 111.754 -178.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -90.19 123.95 34.43 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.275 -0.639 . . . . 74.109999999999999 109.275 169.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . 0.547 ' OD2' ' HA ' ' A' ' 26' ' ' TYR . 72.2 m-20 -57.33 142.91 41.79 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.285 0.564 . . . . 64.420000000000002 111.159 -178.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 109.91 -29.11 9.64 Favored Glycine 0 N--CA 1.444 -0.827 0 N-CA-C 110.468 -1.053 . . . . 73.239999999999995 110.468 -170.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 5.4 t 65.05 37.4 6.77 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-O 121.231 0.538 . . . . 64.530000000000001 111.009 174.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -65.11 -14.4 60.43 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.798 -0.637 . . . . 72.209999999999994 111.326 178.542 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 98.11 23.69 12.7 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 110.634 -0.986 . . . . 62.109999999999999 110.634 -173.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 42.1 t30 -110.71 140.18 45.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.916 -0.642 . . . . 71.150000000000006 110.494 -176.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -121.36 160.35 24.21 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.797 -0.638 . . . . 74.409999999999997 109.574 175.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . 0.437 ' HB ' HG13 ' B' ' 148' ' ' VAL . 46.2 mm -116.66 121.15 67.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 109.405 -0.591 . . . . 74.230000000000004 109.405 174.694 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.487 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 73.0 ttt180 -92.2 127.47 37.69 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.699 -0.682 . . . . 74.549999999999997 109.82 -177.61 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 160' ' ' SER . . . . . 0.681 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 80.4 p -65.88 -9.22 27.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.513 -0.312 . . . . 71.450000000000003 111.78 -175.06 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -64.06 -42.67 96.92 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.325 -0.621 . . . . 75.319999999999993 109.325 174.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . 0.417 ' HA ' ' HD2' ' B' ' 163' ' ' PRO . 23.1 mt-30 -141.86 92.6 7.79 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 115.146 -0.933 . . . . 71.209999999999994 108.766 177.518 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . 0.417 ' HD2' ' HA ' ' B' ' 162' ' ' GLN . 36.6 Cg_endo -64.0 -10.59 23.58 Favored 'Trans proline' 0 N--CA 1.475 0.441 0 C-N-CA 123.767 2.978 . . . . 70.010000000000005 114.103 -172.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -98.39 -6.18 31.16 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.088 0.471 . . . . 75.109999999999999 109.925 179.066 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 24.4 tptm -97.21 127.94 43.63 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.743 -0.662 . . . . 73.310000000000002 110.872 -175.216 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . 0.451 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.7 mp -86.68 134.66 33.58 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.565 -0.743 . . . . 72.040000000000006 109.107 177.439 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . 0.882 HG22 ' HB3' ' B' ' 171' ' ' GLU . 27.3 mm -91.71 118.94 68.59 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-O 121.149 0.5 . . . . 74.219999999999999 112.052 -172.519 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.485 ' O ' HG22 ' B' ' 172' ' ' ILE . 74.5 Cg_endo -74.71 -179.39 4.84 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 123.451 2.767 . . . . 74.120000000000005 112.284 177.15 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . 0.618 ' HA ' HG12 ' B' ' 172' ' ' ILE . 34.6 tt0 -73.56 -30.95 63.36 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.873 0.368 . . . . 74.439999999999998 111.761 -170.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 22.7 p90 -75.74 -7.3 54.05 Favored 'General case' 0 C--N 1.324 -0.525 0 O-C-N 121.886 -0.509 . . . . 74.25 110.15 177.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.882 ' HB3' HG22 ' B' ' 167' ' ' ILE . 3.2 mm-40 -109.74 -18.81 13.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.791 -0.641 . . . . 70.340000000000003 111.472 -179.47 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.618 HG12 ' HA ' ' B' ' 169' ' ' GLN . 42.5 pt -73.51 -28.59 25.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.292 0.568 . . . . 73.299999999999997 109.932 176.329 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 62.1 m-85 -101.63 39.75 1.4 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.509 -0.769 . . . . 70.540000000000006 109.364 173.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 174' ' ' SER . . . . . 0.586 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 5.7 t -66.7 -29.22 69.16 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.134 -0.939 . . . . 73.0 110.827 -176.39 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 20.8 p-90 . . . . . 0 C--O 1.242 0.677 0 CA-C-O 118.916 -0.564 . . . . 75.150000000000006 110.217 178.206 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 25.0 m . . . . . 0 C--O 1.234 0.25 0 CA-C-O 121.306 0.574 . . . . 74.109999999999999 111.034 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 157.33 40.89 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.727 0 N-CA-C 111.218 -0.753 . . . . 73.239999999999995 111.218 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . 0.425 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -114.99 101.59 54.59 Favored Pre-proline 0 N--CA 1.445 -0.681 0 N-CA-C 108.208 -1.034 . . . . 75.099999999999994 108.208 179.493 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.658 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 11.3 Cg_endo -79.32 104.65 1.78 Allowed 'Trans proline' 0 N--CA 1.44 -1.635 0 C-N-CA 122.064 1.843 . . . . 73.120000000000005 111.69 -171.552 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -123.13 149.59 44.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.502 -0.772 . . . . 74.450000000000003 109.21 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.643 HG21 ' HB3' ' A' ' 24' ' ' GLN . 9.3 p -99.74 126.97 53.04 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-O 121.595 0.712 . . . . 74.310000000000002 111.772 -172.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.533 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 7.0 m -83.36 103.51 12.79 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.513 -0.767 . . . . 75.310000000000002 109.334 176.706 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.5 mt -94.14 108.79 21.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 120.932 0.396 . . . . 75.420000000000002 111.127 -174.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 19.1 mmt180 -120.72 159.32 25.61 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.202 -0.454 . . . . 73.129999999999995 109.826 175.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -117.58 124.88 49.72 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.331 0.586 . . . . 72.420000000000002 110.677 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -111.42 59.67 0.62 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.9 -1.046 . . . . 72.030000000000001 110.061 -174.225 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 83.47 -107.67 2.95 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.843 -0.694 . . . . 65.099999999999994 111.943 -178.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -94.85 20.21 9.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.886 0.374 . . . . 74.209999999999994 110.652 -177.286 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.724 ' HD2' HD13 ' A' ' 23' ' ' ILE . 4.0 pttp -143.93 134.38 24.7 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.228 0.537 . . . . 74.019999999999996 111.89 -178.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 27.3 m -94.06 107.98 19.85 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.055 -0.72 . . . . 75.329999999999998 109.055 172.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.724 HD13 ' HD2' ' A' ' 21' ' ' LYS . 19.8 mt -101.61 113.54 38.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.269 0.556 . . . . 73.319999999999993 110.353 -175.098 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.643 ' HB3' HG21 ' A' ' 13' ' ' VAL . 23.2 mt-30 -104.89 117.86 35.1 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.497 -0.774 . . . . 75.019999999999996 111.356 -175.162 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.533 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 25.2 mt-10 -90.52 103.01 15.75 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.051 -0.522 . . . . 75.120000000000005 110.983 177.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 -81.27 103.5 11.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.897 0.379 . . . . 75.310000000000002 110.051 175.199 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.518 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 53.2 mtt180 -120.25 138.11 53.84 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.916 -0.402 . . . . 74.540000000000006 109.916 178.083 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.658 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 11.8 p -105.79 -27.89 2.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.288 0.566 . . . . 74.400000000000006 110.947 -175.82 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -162.64 59.05 0.21 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.758 -0.83 . . . . 75.340000000000003 108.758 -177.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.93 -36.95 3.23 Favored Glycine 0 N--CA 1.45 -0.427 0 CA-C-N 115.355 -0.839 . . . . 72.140000000000001 112.635 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.568 ' CD2' HG22 ' B' ' 128' ' ' VAL . 50.4 t80 -90.28 133.74 34.75 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.145 0.498 . . . . 74.519999999999996 110.723 -173.658 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.882 HD13 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -76.11 116.13 16.5 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.229 -0.896 . . . . 73.209999999999994 109.317 176.656 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 40.0 p90 -106.93 -17.8 14.09 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.431 -0.508 . . . . 75.040000000000006 111.218 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.441 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -157.58 137.9 12.76 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.014 0.435 . . . . 63.43 111.532 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.882 HG13 HD13 ' A' ' 32' ' ' LEU . 73.2 mt -118.02 117.08 53.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.159 -0.473 . . . . 74.540000000000006 110.102 175.262 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 84.9 tttt -100.69 101.53 12.43 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.022 -0.733 . . . . 74.030000000000001 109.022 173.296 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.65 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.5 p -102.77 124.5 56.84 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 N-CA-C 109.777 -0.453 . . . . 74.230000000000004 109.777 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.628 HG23 ' HB3' ' A' ' 44' ' ' PRO . 35.9 t -105.27 84.9 1.18 Allowed Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.206 -0.907 . . . . 71.099999999999994 109.525 177.391 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.65 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 89.2 Cg_endo -95.93 147.05 1.26 Allowed 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 123.04 2.493 . . . . 72.430000000000007 113.279 -178.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -68.73 -11.11 59.89 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.519 -0.764 . . . . 73.129999999999995 109.623 170.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 80.6 m-70 -121.85 92.85 3.83 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 115.022 -0.99 . . . . 74.140000000000001 109.468 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 121.54 -19.76 8.46 Favored Glycine 0 CA--C 1.519 0.338 0 C-N-CA 120.757 -0.735 . . . . 61.130000000000003 113.176 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.422 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 99.3 mttt 68.9 151.61 0.13 Allowed Pre-proline 0 N--CA 1.473 0.69 0 C-N-CA 123.026 0.53 . . . . 72.409999999999997 110.943 -178.166 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.628 ' HB3' HG23 ' A' ' 38' ' ' VAL . 18.3 Cg_endo -59.88 133.05 48.36 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.364 2.043 . . . . 74.439999999999998 112.816 -175.047 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.533 ' CE1' HG11 ' A' ' 37' ' ' VAL . 5.4 p90 -150.32 155.9 40.53 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.655 -0.702 . . . . 71.129999999999995 110.432 -179.072 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.447 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 87.7 m-85 -99.75 127.64 45.88 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.076 -0.511 . . . . 73.239999999999995 110.901 -179.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.441 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 53.1 mt -102.12 97.35 7.67 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.146 -0.479 . . . . 74.230000000000004 109.761 171.052 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 60.8 t -90.58 137.43 21.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.065 -0.516 . . . . 74.140000000000001 110.578 -178.046 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 5.3 mmt180 -79.13 119.6 22.47 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.984 0.421 . . . . 75.230000000000004 111.108 175.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -72.15 167.22 20.74 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.603 -0.726 . . . . 73.239999999999995 109.555 172.722 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -69.74 128.92 38.12 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.416 0.627 . . . . 75.450000000000003 109.577 178.615 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.42 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 100.22 116.04 3.87 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 111.105 -0.798 . . . . 71.519999999999996 111.105 -171.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 39.1 p -78.02 36.7 0.23 Allowed 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.05 0.452 . . . . 75.439999999999998 111.311 -176.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.42 ' H ' ' C ' ' A' ' 52' ' ' GLY . 22.5 t70 -63.33 -29.6 70.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.801 -0.636 . . . . 65.450000000000003 111.588 -175.423 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 131.01 -13.21 5.53 Favored Glycine 0 CA--C 1.508 -0.404 0 C-N-CA 120.318 -0.944 . . . . 73.219999999999999 113.214 177.504 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -83.63 138.82 33.17 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.144 0.497 . . . . 75.409999999999997 111.544 -173.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.437 ' CD1' ' HB3' ' A' ' 47' ' ' LEU . 38.2 m-85 -109.38 162.46 14.32 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.762 -0.654 . . . . 74.519999999999996 110.02 174.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.4 mm -120.64 123.86 71.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.35 -0.611 . . . . 72.349999999999994 109.35 175.762 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.773 ' HG3' HG13 ' A' ' 67' ' ' ILE . 53.7 mtm180 -88.34 149.77 23.58 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.221 0.534 . . . . 73.200000000000003 111.826 -177.79 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 5.7 p -69.12 -24.53 64.12 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.379 -0.828 . . . . 72.319999999999993 109.84 171.365 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.73 -37.46 84.29 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-N 115.517 -0.765 . . . . 72.430000000000007 110.152 176.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -156.64 96.91 2.17 Favored Pre-proline 0 N--CA 1.451 -0.4 0 CA-C-N 115.835 -0.62 . . . . 75.25 110.612 -175.421 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.19 -10.07 23.94 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.433 2.089 . . . . 72.310000000000002 111.233 175.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -81.22 -15.86 54.4 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 114.895 -1.048 . . . . 72.209999999999994 110.774 178.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.6 tptt -114.9 132.34 56.57 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.2 -0.454 . . . . 72.099999999999994 111.252 -175.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.6 mp -90.31 125.79 35.64 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.333 -0.617 . . . . 73.120000000000005 109.333 174.218 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.773 HG13 ' HG3' ' A' ' 59' ' ' ARG . 49.4 mm -84.78 112.59 43.82 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 116.111 -0.495 . . . . 73.219999999999999 110.491 -177.25 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -74.63 179.69 5.71 Favored 'Trans proline' 0 N--CA 1.464 -0.264 0 C-N-CA 123.289 2.659 . . . . 61.210000000000001 112.937 -177.155 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . 0.463 ' CG ' HD12 ' A' ' 72' ' ' ILE . 31.4 tt0 -80.86 -4.27 54.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.581 -0.736 . . . . 73.340000000000003 112.519 -171.083 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 15.9 p90 -96.24 -19.97 18.91 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.234 -0.586 . . . . 75.430000000000007 110.312 175.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -99.99 8.04 44.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.93 -0.577 . . . . 74.400000000000006 111.042 -177.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.463 HD12 ' CG ' ' A' ' 69' ' ' GLN . 21.6 pt -98.71 -7.06 9.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.249 0.547 . . . . 74.219999999999999 110.21 175.251 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -104.91 16.17 26.43 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.632 -0.713 . . . . 71.420000000000002 109.486 177.041 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 12.9 m -73.59 -7.78 53.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.185 -0.916 . . . . 72.120000000000005 111.309 -178.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 57.9 p-90 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.442 -0.344 . . . . 73.400000000000006 110.459 176.222 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 44.3 m . . . . . 0 C--O 1.233 0.22 0 CA-C-O 121.021 0.439 . . . . 74.409999999999997 110.046 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 121.1 102.34 1.81 Allowed Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.914 -0.66 . . . . 61.409999999999997 111.764 -178.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -122.15 92.57 48.86 Favored Pre-proline 0 C--N 1.324 -0.532 0 N-CA-C 109.382 -0.599 . . . . 75.310000000000002 109.382 -178.081 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.429 ' HA ' ' O ' ' B' ' 127' ' ' ARG . 8.4 Cg_endo -77.98 82.85 2.32 Favored 'Trans proline' 0 N--CA 1.443 -1.451 0 C-N-CA 121.917 1.745 . . . . 73.430000000000007 111.633 -178.559 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -108.71 141.84 40.11 Favored 'General case' 0 CA--C 1.51 -0.566 0 CA-C-N 115.194 -0.912 . . . . 65.409999999999997 109.558 177.649 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.493 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 10.3 p -101.84 125.7 55.91 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 CA-C-N 115.627 -0.715 . . . . 73.409999999999997 110.807 -176.637 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 10.1 m -88.55 103.57 16.01 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.34 -0.846 . . . . 74.040000000000006 109.609 177.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.5 HG12 ' HG2' ' B' ' 124' ' ' GLN . 54.6 mt -94.59 105.94 17.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 116.164 -0.471 . . . . 73.420000000000002 110.358 -176.568 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 27.0 mmm180 -122.27 153.44 38.9 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.242 -0.435 . . . . 74.099999999999994 110.541 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -111.19 103.09 11.49 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.002 0.43 . . . . 73.519999999999996 110.701 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 49.8 mm-40 -99.67 81.51 2.49 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.778 -0.646 . . . . 73.430000000000007 109.294 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 81.94 -128.69 8.6 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.805 -0.712 . . . . 71.25 111.382 -174.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . 0.574 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 67.8 m-20 -91.84 9.92 30.79 Favored 'General case' 0 C--N 1.328 -0.349 0 O-C-N 122.699 -0.295 . . . . 73.239999999999995 111.088 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.521 ' HE2' HD12 ' B' ' 123' ' ' ILE . 24.6 pttm -119.27 116.58 26.55 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.576 0.703 . . . . 75.120000000000005 111.073 179.371 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 26.1 m -84.97 108.43 17.58 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.292 -0.867 . . . . 64.5 109.502 176.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . 0.521 HD12 ' HE2' ' B' ' 121' ' ' LYS . 52.1 mt -101.14 117.12 45.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.973 -0.558 . . . . 73.5 110.604 -173.788 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.511 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 23.0 mt-30 -102.61 104.49 14.87 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.649 -0.705 . . . . 74.319999999999993 110.35 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -85.27 107.25 17.21 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.06 -0.518 . . . . 74.530000000000001 111.071 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 59.6 m-85 -80.71 103.67 10.72 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.947 0.403 . . . . 74.420000000000002 109.945 175.333 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . 0.429 ' O ' ' HA ' ' B' ' 111' ' ' PRO . 65.5 mtt180 -114.14 152.78 30.62 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.857 -0.611 . . . . 72.049999999999997 109.389 178.587 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.568 HG22 ' CD2' ' A' ' 31' ' ' PHE . 7.0 p -120.36 -37.41 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.078 0.466 . . . . 72.239999999999995 111.73 179.385 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -140.83 35.8 1.78 Allowed 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.035 -0.728 . . . . 74.530000000000001 109.035 -178.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 98.26 -29.5 11.25 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 114.992 -1.004 . . . . 72.439999999999998 111.746 -177.498 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . 0.528 ' HD2' HG21 ' A' ' 28' ' ' VAL . 26.9 t80 -93.39 132.86 37.23 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.917 0.389 . . . . 74.439999999999998 110.261 -176.19 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.762 HD12 HG13 ' B' ' 135' ' ' ILE . 3.3 tm? -69.49 134.44 48.91 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.104 -0.953 . . . . 73.530000000000001 110.43 179.042 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . 0.417 ' N ' HD13 ' B' ' 132' ' ' LEU . 42.6 p90 -124.24 -23.51 4.51 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 121.026 -0.27 . . . . 64.150000000000006 111.361 174.608 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -149.92 143.19 25.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.784 0.326 . . . . 71.109999999999999 111.055 179.068 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.762 HG13 HD12 ' B' ' 132' ' ' LEU . 77.5 mt -125.08 129.56 73.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.507 -0.315 . . . . 75.530000000000001 110.804 178.648 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.511 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.2 tttt -112.69 102.51 10.56 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.128 -0.693 . . . . 75.340000000000003 109.128 172.485 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.44 HG12 ' CE1' ' B' ' 145' ' ' TYR . 1.8 p -106.52 127.99 61.47 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-O 121.271 0.558 . . . . 62.329999999999998 110.744 -177.665 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.862 HG22 ' HB3' ' B' ' 144' ' ' PRO . 22.6 t -113.21 87.72 11.4 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.138 -0.937 . . . . 65.310000000000002 110.282 -179.299 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 73.5 Cg_endo -83.66 134.87 6.62 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.283 1.988 . . . . 71.439999999999998 112.309 176.127 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . 0.574 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 56.2 mtpt -67.62 -9.48 43.44 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.773 -0.649 . . . . 71.219999999999999 110.954 176.668 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 31.6 m-70 -126.68 54.14 1.62 Allowed 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.574 -0.739 . . . . 64.310000000000002 109.524 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 167.45 -17.09 0.08 OUTLIER Glycine 0 CA--C 1.52 0.391 0 C-N-CA 120.59 -0.815 . . . . 73.400000000000006 113.39 -177.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 93.6 mttt 71.59 150.88 0.14 Allowed Pre-proline 0 N--CA 1.473 0.688 0 C-N-CA 123.235 0.614 . . . . 74.420000000000002 111.438 179.428 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.862 ' HB3' HG22 ' B' ' 138' ' ' VAL . 24.5 Cg_endo -62.42 140.68 83.56 Favored 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.77 2.313 . . . . 73.219999999999999 113.357 -176.154 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . 0.44 ' CE1' HG12 ' B' ' 137' ' ' VAL . 8.7 p90 -150.59 155.26 39.06 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.655 -0.702 . . . . 75.200000000000003 109.969 177.107 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.571 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 83.6 m-85 -101.56 141.29 34.66 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.286 -0.415 . . . . 73.439999999999998 111.37 -177.503 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 27.6 mt -124.88 95.74 4.62 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.559 -0.746 . . . . 70.349999999999994 109.885 169.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 48.9 t -94.02 122.81 45.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.02 -0.733 . . . . 73.400000000000006 109.02 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 15.6 ttm-85 -67.94 143.54 55.61 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.468 0.651 . . . . 73.109999999999999 111.975 -174.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.03 175.4 10.67 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.664 -1.153 . . . . 64.430000000000007 110.586 176.128 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -84.94 138.27 32.6 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 109.01 -0.737 . . . . 75.219999999999999 109.01 173.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 110.07 132.07 6.24 Favored Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 120.654 -0.784 . . . . 71.430000000000007 111.655 -177.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 18.8 m -82.33 30.5 0.4 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.921 0.391 . . . . 74.109999999999999 110.983 -177.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -73.59 -47.29 41.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.052 0.453 . . . . 72.450000000000003 110.56 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 121.38 46.75 0.31 Allowed Glycine 0 CA--C 1.503 -0.714 0 C-N-CA 120.774 -0.727 . . . . 71.439999999999998 112.417 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 -122.17 135.53 54.79 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 120.964 0.411 . . . . 74.209999999999994 110.705 -179.178 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -113.01 159.4 19.17 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.764 -0.653 . . . . 73.5 109.381 173.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . 0.8 HD12 HD23 ' B' ' 166' ' ' LEU . 48.7 mm -114.34 115.84 50.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 N-CA-C 109.341 -0.614 . . . . 73.310000000000002 109.341 176.079 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.47 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 40.2 ttm180 -85.39 145.16 27.61 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.75 -0.659 . . . . 74.129999999999995 110.376 -174.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 160' ' ' SER . . . . . 0.571 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 5.2 p -58.89 -31.87 68.99 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.447 0.641 . . . . 72.340000000000003 110.862 178.211 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . 0.443 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 3.5 m-20 -76.03 -31.26 58.79 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.192 -0.913 . . . . 72.230000000000004 110.902 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . 0.641 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 13.9 mm100 -132.37 71.07 79.66 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 115.944 -0.571 . . . . 72.299999999999997 110.808 -176.358 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -73.37 -12.79 25.29 Favored 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.187 1.925 . . . . 75.430000000000007 111.432 178.462 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -93.24 -4.91 51.07 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.012 -0.995 . . . . 73.409999999999997 110.253 179.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . 0.641 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 60.7 tptt -122.72 126.54 47.74 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.918 -0.583 . . . . 64.430000000000007 111.074 -174.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . 0.8 HD23 HD12 ' B' ' 158' ' ' ILE . 61.0 mt -74.41 110.43 8.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.398 -0.819 . . . . 72.140000000000001 109.087 174.477 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . 0.415 HG13 ' HB2' ' B' ' 159' ' ' ARG . 43.3 mm -70.56 116.37 44.74 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 109.92 -0.4 . . . . 75.319999999999993 109.92 -176.569 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.498 ' O ' HG21 ' B' ' 172' ' ' ILE . 38.3 Cg_endo -64.95 172.57 7.01 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 123.251 2.634 . . . . 71.420000000000002 113.416 -174.231 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -76.98 -9.9 59.0 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.92 -1.036 . . . . 74.409999999999997 111.978 -168.142 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 31.8 p90 -96.22 -10.8 27.16 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.461 0.648 . . . . 74.099999999999994 109.924 175.079 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.487 ' HB2' ' HG2' ' B' ' 168' ' ' PRO . 6.8 mm-40 -106.58 -7.06 17.6 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.454 -0.794 . . . . 71.129999999999995 111.215 -176.872 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.498 HG21 ' O ' ' B' ' 168' ' ' PRO . 29.0 pt -71.04 -30.01 39.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.121 -0.491 . . . . 75.409999999999997 110.723 178.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -102.32 41.54 1.22 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.304 0.574 . . . . 74.040000000000006 109.772 174.263 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 31.1 t -55.08 -31.86 61.52 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.992 -1.004 . . . . 74.299999999999997 110.847 179.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . 0.502 ' CE3' HD13 ' B' ' 123' ' ' ILE . 4.0 p-90 . . . . . 0 C--O 1.251 1.169 0 CA-C-O 118.044 -0.979 . . . . 75.349999999999994 110.462 176.765 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.8 m . . . . . 0 N--CA 1.453 -0.309 0 N-CA-C 109.896 -0.409 . . . . 74.310000000000002 109.896 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.483 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 95.27 63.52 0.98 Allowed Glycine 0 N--CA 1.442 -0.918 0 C-N-CA 120.664 -0.779 . . . . 64.129999999999995 111.191 -175.489 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -100.3 98.94 8.55 Favored Pre-proline 0 C--N 1.324 -0.537 0 N-CA-C 108.845 -0.798 . . . . 73.420000000000002 108.845 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.663 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 88.5 Cg_endo -80.25 102.8 1.46 Allowed 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.247 1.964 . . . . 75.310000000000002 112.29 -173.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -80.88 141.5 34.53 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.062 -0.972 . . . . 71.430000000000007 109.939 -178.45 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.432 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 11.2 p -103.3 120.29 53.04 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 CA-C-O 121.638 0.732 . . . . 65.030000000000001 109.88 179.461 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.4 m -93.47 103.11 15.34 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 115.449 -0.796 . . . . 71.230000000000004 109.564 -179.547 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.525 HG23 ' HG2' ' A' ' 24' ' ' GLN . 63.9 mt -85.61 105.2 14.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.82 -0.627 . . . . 73.219999999999999 110.517 -175.297 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -101.61 160.92 14.04 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.681 -0.69 . . . . 73.109999999999999 110.565 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -127.11 98.04 5.16 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.617 -0.512 . . . . 73.540000000000006 109.617 175.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.634 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 43.6 mm-40 -103.49 93.32 4.88 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.819 -0.628 . . . . 64.439999999999998 109.618 -178.064 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 66.06 -106.36 1.56 Allowed Glycine 0 N--CA 1.444 -0.83 0 C-N-CA 120.764 -0.731 . . . . 43.130000000000003 111.832 -176.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.647 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 4.0 m-20 -102.05 -5.34 24.67 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.566 0.222 . . . . 73.319999999999993 110.819 -177.197 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.634 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 12.3 ptmt -110.77 121.03 44.33 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 121.471 0.653 . . . . 73.230000000000004 111.934 -173.449 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.4 m -82.41 97.56 8.43 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.276 -0.875 . . . . 74.310000000000002 109.212 174.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 54.1 mt -93.99 106.88 18.57 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-O 121.117 0.485 . . . . 73.209999999999994 110.812 -175.574 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.525 ' HG2' HG23 ' A' ' 15' ' ' ILE . 12.7 mt-30 -94.55 109.39 21.29 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.019 -0.537 . . . . 74.019999999999996 110.029 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.428 ' HB3' HD23 ' A' ' 32' ' ' LEU . 27.5 mt-10 -89.2 111.38 22.15 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.134 -0.484 . . . . 74.129999999999995 110.84 -178.539 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.505 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 50.5 m-85 -84.59 103.88 14.09 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.635 -0.506 . . . . 72.450000000000003 109.635 176.268 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -116.04 133.72 55.72 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.062 -0.517 . . . . 74.530000000000001 109.923 -179.552 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.663 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 3.4 p -92.05 -60.37 2.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 C-N-CA 120.272 -0.571 . . . . 63.420000000000002 110.443 176.684 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.554 ' H ' HG12 ' A' ' 28' ' ' VAL . 88.5 m-20 -138.47 72.6 1.41 Allowed 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.045 0.45 . . . . 75.430000000000007 110.213 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 90.46 -27.94 8.09 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.914 -0.585 . . . . 74.400000000000006 113.676 175.248 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.47 ' HD2' HG22 ' B' ' 128' ' ' VAL . 35.8 t80 -112.08 134.52 53.58 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.376 0.608 . . . . 73.420000000000002 111.469 -173.756 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.863 HD12 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -67.21 123.64 20.87 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.495 -1.229 . . . . 62.32 110.441 176.268 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . 0.474 ' CD1' ' HB2' ' B' ' 133' ' ' TYR . 24.2 p90 -108.23 -24.82 11.35 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.369 -0.533 . . . . 71.430000000000007 111.345 177.172 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -156.19 142.72 18.56 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.685 0.278 . . . . 64.0 110.965 179.342 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.863 HG13 HD12 ' A' ' 32' ' ' LEU . 81.4 mt -120.8 132.41 70.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.537 -0.301 . . . . 72.140000000000001 110.589 178.062 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.49 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 88.3 tttt -115.16 100.43 8.15 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 108.953 -0.758 . . . . 74.430000000000007 108.953 169.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.561 HG23 ' HB2' ' A' ' 21' ' ' LYS . 1.1 p -98.39 126.17 51.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 116.092 -0.503 . . . . 74.319999999999993 110.124 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.525 HG23 ' HB3' ' A' ' 44' ' ' PRO . 25.0 t -111.64 88.28 9.24 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 115.544 -0.753 . . . . 74.510000000000005 110.109 -179.789 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 57.8 Cg_endo -73.67 142.42 32.35 Favored 'Trans proline' 0 N--CA 1.457 -0.663 0 C-N-CA 122.48 2.12 . . . . 71.219999999999999 111.975 177.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.647 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 28.9 mtpp -70.09 -10.55 59.11 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.944 -0.571 . . . . 73.219999999999999 110.978 176.329 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 38.7 m-70 -131.04 80.64 1.95 Allowed 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.848 -0.615 . . . . 71.140000000000001 109.78 -178.532 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 151.3 -117.23 0.81 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.128 -0.558 . . . . 73.340000000000003 112.306 179.499 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 14.3 ptpt -152.79 151.76 27.18 Favored Pre-proline 0 C--N 1.328 -0.344 0 N-CA-C 110.179 -0.304 . . . . 73.120000000000005 110.179 178.467 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.525 ' HB3' HG23 ' A' ' 38' ' ' VAL . 48.5 Cg_endo -74.28 124.09 8.73 Favored 'Trans proline' 0 N--CA 1.46 -0.492 0 C-N-CA 122.262 1.975 . . . . 73.120000000000005 110.987 170.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.516 ' CE1' HG11 ' A' ' 37' ' ' VAL . 11.4 p90 -139.86 158.57 43.88 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.803 0.335 . . . . 75.150000000000006 110.988 -175.185 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.516 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 73.1 m-85 -103.93 141.64 35.81 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.828 -0.624 . . . . 73.430000000000007 111.258 -176.498 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 83.8 mt -123.71 105.02 9.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.535 -0.757 . . . . 75.510000000000005 109.907 172.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.568 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 43.8 t -85.79 139.66 17.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.098 -0.501 . . . . 74.349999999999994 109.917 179.355 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 4.5 tpt180 -75.06 115.09 14.31 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.846 -0.428 . . . . 75.319999999999993 109.846 179.222 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.33 149.83 41.14 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.023 -0.535 . . . . 73.040000000000006 111.399 -178.204 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.585 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 4.9 p-10 -57.44 132.07 52.01 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.269 0.557 . . . . 73.340000000000003 110.981 -178.265 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.57 -24.13 24.76 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.41 -0.814 . . . . 74.319999999999993 111.86 -179.025 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.5 t 58.15 37.57 26.34 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 121.192 0.52 . . . . 65.030000000000001 109.985 -176.56 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -53.57 -38.61 64.05 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.425 -0.807 . . . . 74.420000000000002 111.44 -179.03 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 150.44 24.4 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.365 -0.921 . . . . 65.120000000000005 113.261 176.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.4 ' OD1' ' HA ' ' A' ' 68' ' ' PRO . 93.5 m-20 -134.79 162.7 31.62 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.79 0.329 . . . . 74.409999999999997 110.579 -176.764 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 73.2 m-85 -121.73 158.57 28.47 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.078 -0.51 . . . . 75.549999999999997 110.15 177.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.568 ' HB ' ' HB ' ' A' ' 48' ' ' VAL . 39.5 mm -106.74 110.54 32.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 N-CA-C 109.35 -0.611 . . . . 62.420000000000002 109.35 175.566 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.561 ' HG2' ' H ' ' A' ' 61' ' ' ASP . 74.3 ttt180 -83.99 140.42 31.9 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.276 -0.42 . . . . 74.540000000000006 110.682 -176.253 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.516 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 9.7 p -64.08 -25.06 67.94 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.901 -0.59 . . . . 72.219999999999999 112.204 -177.775 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.561 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 5.5 m-20 -72.78 -24.99 61.01 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.768 0.318 . . . . 71.439999999999998 111.649 -178.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.5 tp60 -155.0 88.36 3.21 Favored Pre-proline 0 C--N 1.327 -0.399 0 CA-C-O 120.73 0.3 . . . . 75.310000000000002 110.616 -176.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -82.05 6.5 5.66 Favored 'Trans proline' 0 C--O 1.233 0.231 0 C-N-CA 122.915 2.41 . . . . 55.240000000000002 112.455 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -62.34 -44.22 96.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.646 -0.706 . . . . 75.409999999999997 111.059 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.55 -178.37 4.9 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-N 115.6 -0.727 . . . . 74.140000000000001 111.458 -176.054 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.0 mp -95.51 135.04 37.66 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.078 -0.964 . . . . 75.420000000000002 108.846 177.424 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 41.0 mm -78.64 112.85 29.85 Favored Pre-proline 0 C--N 1.319 -0.743 0 N-CA-C 109.85 -0.426 . . . . 71.530000000000001 109.85 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.453 ' O ' HG23 ' A' ' 72' ' ' ILE . 46.6 Cg_endo -67.1 174.48 6.89 Favored 'Trans proline' 0 CA--C 1.519 -0.268 0 C-N-CA 123.188 2.592 . . . . 75.209999999999994 113.311 -173.336 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . 0.739 ' HA ' HG12 ' A' ' 72' ' ' ILE . 9.5 tt0 -68.16 -42.39 80.11 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.516 -0.765 . . . . 71.430000000000007 111.567 -170.624 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . 0.78 ' HA ' ' CZ ' ' A' ' 73' ' ' PHE . 29.6 p90 -63.19 -16.38 59.95 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.339 0.59 . . . . 74.319999999999993 110.395 -179.117 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 16.0 mm-40 -94.94 -28.75 15.01 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.527 -0.76 . . . . 74.0 111.579 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.739 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.0 pt -76.63 -38.6 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.148 0 N-CA-C 111.882 0.327 . . . . 72.150000000000006 111.882 -178.199 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.78 ' CZ ' ' HA ' ' A' ' 70' ' ' TRP . 6.6 p90 -85.67 30.65 0.63 Allowed 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.727 0.775 . . . . 75.140000000000001 110.847 179.55 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 32.5 t -74.23 -11.77 60.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.103 -0.953 . . . . 71.420000000000002 108.64 170.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . 0.426 ' HH2' HD13 ' A' ' 35' ' ' ILE . 36.6 m0 . . . . . 0 C--O 1.233 0.218 0 CA-C-N 115.465 -0.789 . . . . 72.549999999999997 110.6 173.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 33.1 m . . . . . 0 N--CA 1.455 -0.185 0 CA-C-O 121.06 0.457 . . . . 74.010000000000005 109.774 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 112.5 95.0 2.19 Favored Glycine 0 N--CA 1.441 -0.985 0 N-CA-C 110.838 -0.905 . . . . 72.129999999999995 110.838 -172.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -110.43 98.33 35.83 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-O 121.424 0.631 . . . . 73.319999999999993 109.899 -178.322 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.776 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 82.7 Cg_endo -81.83 76.57 4.25 Favored 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 122.484 2.123 . . . . 74.120000000000005 112.68 -175.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -91.38 149.86 21.53 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.092 -0.707 . . . . 73.129999999999995 109.092 176.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.643 HG21 ' HB3' ' B' ' 124' ' ' GLN . 7.2 p -102.96 130.52 52.93 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-O 121.555 0.693 . . . . 74.129999999999995 111.307 -176.085 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 114' ' ' THR . . . . . 0.439 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 30.4 m -91.84 111.2 22.64 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.234 -0.894 . . . . 73.219999999999999 109.139 176.027 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.6 mt -88.69 107.69 18.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 120.957 0.408 . . . . 72.400000000000006 111.06 -174.148 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . 0.486 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 20.2 mmt180 -94.84 160.46 14.59 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.447 -0.575 . . . . 64.530000000000001 109.447 175.619 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -136.99 86.84 2.24 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 115.774 -0.648 . . . . 62.439999999999998 109.574 174.138 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -100.35 87.81 3.51 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.475 -0.784 . . . . 74.420000000000002 109.395 -173.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 78.97 -111.56 3.27 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.791 -0.719 . . . . 63.399999999999999 111.968 -177.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . 0.65 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 20.4 m-20 -109.11 12.16 25.24 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.855 0.36 . . . . 75.299999999999997 111.189 -177.572 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.938 ' HE3' ' HB3' ' B' ' 175' ' ' TRP . 20.8 pttm -125.27 123.24 39.06 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.483 0.659 . . . . 75.420000000000002 111.481 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 65.9 m -81.75 103.31 11.35 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.249 -0.887 . . . . 70.299999999999997 109.472 174.629 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . 0.486 ' HB ' ' HB2' ' B' ' 116' ' ' ARG . 64.7 mt -93.58 105.87 17.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.076 0.465 . . . . 73.219999999999999 110.378 -177.284 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.643 ' HB3' HG21 ' B' ' 113' ' ' VAL . 21.1 mt-30 -96.23 109.72 22.14 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.167 -0.47 . . . . 74.209999999999994 110.897 -177.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . 0.439 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 45.8 mt-10 -86.47 106.48 17.51 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.778 -0.647 . . . . 73.129999999999995 110.799 179.471 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . 0.585 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 21.6 m-85 -82.07 106.36 13.92 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.88 -0.415 . . . . 74.439999999999998 109.88 174.297 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 95.2 mtt180 -119.97 126.38 50.7 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.842 -0.429 . . . . 75.010000000000005 109.842 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.776 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 3.0 p -99.0 -34.77 4.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.32 0.581 . . . . 74.299999999999997 111.268 -177.422 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -143.15 40.71 1.49 Allowed 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.596 0.712 . . . . 74.120000000000005 109.166 -175.43 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.15 -23.69 10.82 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.324 -0.853 . . . . 74.420000000000002 111.83 -176.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 58.3 t80 -93.83 132.26 38.4 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.98 0.419 . . . . 73.329999999999998 110.435 -177.647 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.836 HD13 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -70.66 117.29 12.0 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.359 -0.837 . . . . 74.129999999999995 109.261 176.368 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . 0.546 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 41.9 p90 -105.39 -24.69 12.61 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.384 -0.527 . . . . 73.329999999999998 111.18 179.533 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . 0.48 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -156.56 134.96 11.43 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.762 0.315 . . . . 74.140000000000001 110.734 179.224 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.836 HG13 HD13 ' B' ' 132' ' ' LEU . 74.3 mt -107.71 125.7 64.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 N-CA-C 110.031 -0.359 . . . . 73.299999999999997 110.031 175.492 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.536 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.9 tttt -107.53 99.92 9.38 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.038 -0.727 . . . . 74.120000000000005 109.038 174.142 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.516 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 1.1 p -103.85 124.45 58.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-O 121.074 0.464 . . . . 73.319999999999993 110.356 -178.519 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.751 HG23 ' HB3' ' B' ' 144' ' ' PRO . 21.2 t -108.89 88.12 5.18 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 115.224 -0.898 . . . . 65.040000000000006 109.732 179.706 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.437 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 72.4 Cg_endo -83.13 135.96 7.67 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.539 2.159 . . . . 74.400000000000006 112.459 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . 0.65 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 59.1 mtpt -60.32 -34.53 73.93 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.605 -0.725 . . . . 75.049999999999997 110.088 173.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -102.09 77.06 1.65 Allowed 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.461 -0.79 . . . . 74.439999999999998 108.925 177.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 144.38 -158.14 27.4 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.215 -0.902 . . . . 65.349999999999994 110.988 -174.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -131.13 150.03 75.39 Favored Pre-proline 0 C--N 1.324 -0.515 0 N-CA-C 110.026 -0.361 . . . . 73.540000000000006 110.026 177.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.751 ' HB3' HG23 ' B' ' 138' ' ' VAL . 17.7 Cg_endo -61.58 122.88 11.71 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.426 2.084 . . . . 65.209999999999994 112.124 178.064 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . 0.455 ' CE1' HG12 ' B' ' 137' ' ' VAL . 5.7 p90 -136.49 152.86 51.0 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.144 -0.48 . . . . 75.099999999999994 110.964 -177.005 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.523 ' O ' ' HA ' ' B' ' 159' ' ' ARG . 88.2 m-85 -101.97 138.33 39.08 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.88 -0.6 . . . . 72.230000000000004 111.114 -178.268 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . 0.46 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 56.9 mt -117.5 104.19 10.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.992 -0.549 . . . . 74.219999999999999 109.965 172.016 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . 0.486 ' HB ' ' HB ' ' B' ' 158' ' ' ILE . 49.1 t -91.33 128.02 43.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 116.339 -0.391 . . . . 75.140000000000001 110.888 -177.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 23.8 tpt180 -63.11 120.45 11.48 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 116.47 -0.332 . . . . 74.530000000000001 110.975 176.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.09 154.62 37.35 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-N 115.987 -0.551 . . . . 72.5 110.933 177.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . 0.505 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 8.0 p-10 -59.64 147.06 38.78 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.83 -0.623 . . . . 74.25 111.574 -176.667 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 73.63 2.59 60.83 Favored Glycine 0 N--CA 1.452 -0.247 0 CA-C-N 115.389 -0.823 . . . . 71.340000000000003 112.391 178.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 7.9 t 59.73 49.2 8.4 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 109.137 -0.69 . . . . 75.030000000000001 109.137 -175.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -48.64 -43.74 36.8 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 114.84 -1.073 . . . . 72.510000000000005 111.251 -179.326 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 131.13 -18.38 5.02 Favored Glycine 0 CA--C 1.492 -1.346 0 N-CA-C 110.718 -0.953 . . . . 71.230000000000004 110.718 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 -97.89 166.78 11.29 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 113.719 -1.241 . . . . 72.030000000000001 110.816 -176.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -121.22 153.39 37.67 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.817 -0.629 . . . . 72.120000000000005 110.206 178.314 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . 0.486 ' HB ' ' HB ' ' B' ' 148' ' ' VAL . 48.5 mm -106.31 114.77 46.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 N-CA-C 109.266 -0.642 . . . . 75.430000000000007 109.266 176.712 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.523 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 68.0 ttt180 -89.33 138.58 31.31 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.25 -0.432 . . . . 71.129999999999995 110.87 -175.505 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 5.6 p -62.59 -22.4 66.34 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.821 -0.627 . . . . 73.400000000000006 112.301 -177.191 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . 0.462 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 5.5 m-20 -76.22 -16.95 59.72 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.731 0.301 . . . . 74.120000000000005 111.237 -177.772 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 21.9 tp60 -166.06 84.81 0.97 Allowed Pre-proline 0 C--N 1.328 -0.34 0 N-CA-C 109.44 -0.578 . . . . 75.019999999999996 109.44 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . 0.474 ' HG2' ' HB2' ' A' ' 60' ' ' SER . 23.7 Cg_exo -64.86 -9.36 20.96 Favored 'Trans proline' 0 N--CA 1.474 0.337 0 C-N-CA 123.16 2.573 . . . . 63.25 112.929 -178.682 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -90.6 -5.63 55.66 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.962 -0.563 . . . . 74.409999999999997 110.768 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.8 tptt -114.83 123.29 48.81 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.25 0.548 . . . . 75.239999999999995 110.419 -178.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.3 mp -85.34 113.57 21.76 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.169 -0.923 . . . . 74.150000000000006 109.229 177.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . 0.523 HG22 ' HB3' ' B' ' 171' ' ' GLU . 50.5 mm -64.41 110.58 4.15 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 123.608 0.567 . . . . 74.209999999999994 110.681 -177.347 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.544 ' O ' HG22 ' B' ' 172' ' ' ILE . 80.5 Cg_endo -76.06 176.81 9.55 Favored 'Trans proline' 0 N--CA 1.461 -0.386 0 C-N-CA 122.933 2.422 . . . . 60.43 112.472 -176.711 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -76.26 -5.42 46.89 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.711 -0.677 . . . . 71.430000000000007 112.707 -170.453 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 27.9 p90 -97.64 -12.88 21.93 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.497 -0.481 . . . . 74.209999999999994 110.254 173.395 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.523 ' HB3' HG22 ' B' ' 167' ' ' ILE . 1.7 mm-40 -105.95 -15.05 15.01 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.37 -0.377 . . . . 54.509999999999998 111.465 -177.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.544 HG22 ' O ' ' B' ' 168' ' ' PRO . 43.1 pt -66.73 -21.28 28.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.083 0.468 . . . . 75.140000000000001 110.693 177.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -88.87 41.88 1.05 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.797 -0.638 . . . . 71.299999999999997 109.99 177.43 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 22.8 t -86.1 17.22 3.7 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.393 -0.821 . . . . 75.310000000000002 110.247 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . 0.938 ' HB3' ' HE3' ' B' ' 121' ' ' LYS . 45.9 m0 . . . . . 0 C--O 1.246 0.921 0 CA-C-O 118.471 -0.776 . . . . 72.519999999999996 110.421 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 20.9 m . . . . . 0 C--O 1.235 0.319 0 CA-C-O 120.643 0.258 . . . . 75.430000000000007 110.543 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 80.22 -86.77 1.29 Allowed Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 110.903 -0.879 . . . . 70.319999999999993 110.903 -176.164 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 70.87 97.94 0.04 OUTLIER Pre-proline 0 CA--C 1.516 -0.347 0 C-N-CA 123.138 0.575 . . . . 74.340000000000003 110.89 175.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.534 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 5.5 Cg_endo -78.82 85.03 1.92 Allowed 'Trans proline' 0 N--CA 1.443 -1.451 0 C-N-CA 122.378 2.052 . . . . 74.329999999999998 110.041 178.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -95.7 152.05 18.81 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.284 -0.871 . . . . 73.510000000000005 110.179 -175.372 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.709 HG21 ' HB3' ' A' ' 24' ' ' GLN . 7.3 p -121.67 131.52 72.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-O 121.378 0.609 . . . . 73.439999999999998 111.158 -176.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.2 m -92.05 115.55 28.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.437 -0.801 . . . . 72.510000000000005 109.488 176.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 50.3 mt -94.13 107.73 19.7 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.101 0.477 . . . . 73.340000000000003 111.344 -173.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.705 ' HB2' ' HB ' ' A' ' 23' ' ' ILE . 33.5 mmt180 -100.41 169.31 9.18 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.701 -0.681 . . . . 71.329999999999998 109.424 175.688 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 69.2 mt-30 -139.61 102.78 4.53 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.878 0.37 . . . . 73.230000000000004 110.301 175.537 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 60.2 mm-40 -101.51 80.15 2.03 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.031 -0.532 . . . . 72.310000000000002 110.18 -178.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.41 -111.06 3.49 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.794 -0.717 . . . . 74.019999999999996 111.51 -176.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.57 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 5.8 m-20 -112.47 4.23 17.33 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.239 0.542 . . . . 61.210000000000001 109.837 178.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.519 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 23.9 pttm -107.08 119.99 40.88 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.492 0.663 . . . . 74.0 110.379 175.581 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.684 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 8.5 m -80.21 127.15 32.01 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.499 -0.773 . . . . 74.150000000000006 109.488 177.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.705 ' HB ' ' HB2' ' A' ' 16' ' ' ARG . 26.0 mm -108.08 104.99 17.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 120.677 0.275 . . . . 74.200000000000003 110.296 -175.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.737 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 16.2 mt-30 -99.35 109.34 21.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.887 0.375 . . . . 73.150000000000006 110.827 -178.109 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -91.69 110.9 22.24 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.978 -0.556 . . . . 60.200000000000003 110.311 -179.161 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.535 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 28.1 m-85 -88.69 108.91 19.72 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.877 0.37 . . . . 74.329999999999998 111.531 -178.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 46.4 mtm105 -121.44 123.68 42.67 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.713 -0.477 . . . . 65.219999999999999 109.713 175.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.534 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.4 p -91.83 -27.88 4.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 121.11 0.481 . . . . 75.400000000000006 110.728 -177.719 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -172.3 72.5 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.015 -0.539 . . . . 73.340000000000003 109.905 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.31 -24.97 4.52 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.795 -0.639 . . . . 55.409999999999997 113.202 177.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -108.17 130.11 55.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.969 0.384 . . . . 72.340000000000003 111.097 -174.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.482 HD12 HG13 ' A' ' 35' ' ' ILE . 3.1 tm? -74.51 112.76 11.02 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.345 -0.843 . . . . 74.450000000000003 109.037 175.031 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -105.44 -16.33 14.76 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.614 -0.434 . . . . 63.329999999999998 111.696 -177.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -160.47 145.75 14.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.032 0.444 . . . . 64.230000000000004 111.522 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.482 HG13 HD12 ' A' ' 32' ' ' LEU . 63.6 mt -118.32 125.68 74.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 115.909 -0.587 . . . . 64.329999999999998 109.461 174.084 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.737 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 82.6 tttt -109.78 105.66 14.97 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.881 -0.415 . . . . 75.040000000000006 109.881 179.163 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.663 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 3.5 t -89.52 134.38 28.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 108.965 -0.754 . . . . 74.140000000000001 108.965 178.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.684 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.4 t -120.32 73.22 20.61 Favored Pre-proline 0 C--N 1.317 -0.839 0 N-CA-C 109.731 -0.47 . . . . 73.109999999999999 109.731 173.693 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.657 ' HD3' HG11 ' A' ' 37' ' ' VAL . 49.6 Cg_endo -76.96 132.46 12.9 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.286 1.991 . . . . 75.109999999999999 111.489 175.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.57 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 21.9 mtpp -57.77 -34.41 69.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 74.040000000000006 111.11 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -119.11 109.69 16.19 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.331 -0.618 . . . . 73.109999999999999 109.331 175.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 128.53 -27.6 4.4 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 110.79 -0.924 . . . . 55.149999999999999 110.79 -173.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 58.6 mtmt 70.97 152.0 0.14 Allowed Pre-proline 0 CA--C 1.532 0.255 0 C-N-CA 123.593 0.757 . . . . 73.400000000000006 112.496 175.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.663 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 43.3 Cg_endo -67.63 145.2 69.15 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.138 2.559 . . . . 73.530000000000001 114.159 -174.434 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 29.2 p90 -148.93 158.92 44.54 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.497 -0.774 . . . . 74.319999999999993 109.801 176.363 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.547 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 72.7 m-85 -101.71 129.14 47.81 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.276 -0.42 . . . . 74.430000000000007 110.701 178.7 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.572 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 29.7 tp -109.67 96.2 6.11 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.898 -0.779 . . . . 74.329999999999998 108.898 173.034 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 32.3 t -94.61 142.38 13.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 116.239 -0.437 . . . . 75.450000000000003 111.293 -172.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . 0.442 HH11 ' HZ ' ' A' ' 57' ' ' PHE . 1.6 mmt-85 -66.93 137.57 56.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.962 -0.563 . . . . 74.219999999999999 111.046 177.075 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.73 153.84 21.04 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.056 -0.52 . . . . 74.230000000000004 109.701 172.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.415 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 4.3 p-10 -60.64 130.37 46.17 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.264 0.554 . . . . 65.420000000000002 111.289 -177.793 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 81.17 -15.0 24.94 Favored Glycine 0 CA--C 1.518 0.257 0 CA-C-N 115.637 -0.711 . . . . 63.43 112.39 -178.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.7 p 43.52 72.46 0.18 Allowed 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 123.721 0.808 . . . . 73.329999999999998 112.503 -175.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -80.09 42.08 0.55 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.612 0.72 . . . . 65.150000000000006 109.435 177.164 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 62.35 37.16 94.14 Favored Glycine 0 N--CA 1.451 -0.362 0 N-CA-C 110.359 -1.097 . . . . 75.340000000000003 110.359 -170.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.856 HD22 HD21 ' A' ' 66' ' ' LEU . 51.1 t30 -133.08 141.68 48.34 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.937 0.399 . . . . 72.450000000000003 110.766 -169.397 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.572 ' CD2' ' HG ' ' A' ' 47' ' ' LEU . 29.7 m-85 -132.09 168.36 18.12 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.767 -0.651 . . . . 73.530000000000001 109.879 177.03 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.879 HD12 HD23 ' A' ' 66' ' ' LEU . 42.4 mm -129.16 120.79 52.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.482 -0.562 . . . . 73.329999999999998 109.482 174.679 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.61 ' HG3' HG13 ' A' ' 67' ' ' ILE . 41.6 mtp180 -88.03 150.66 23.28 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.271 -0.422 . . . . 72.530000000000001 110.655 -179.085 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.638 ' HB2' ' HB3' ' B' ' 163' ' ' PRO . 34.2 p -66.71 -30.43 70.66 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.283 0.564 . . . . 74.319999999999993 110.363 177.082 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.496 ' OD1' ' HB3' ' A' ' 59' ' ' ARG . 4.2 p-10 -78.51 -23.23 46.42 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.709 -0.678 . . . . 72.310000000000002 110.971 177.048 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -137.33 70.58 54.29 Favored Pre-proline 0 C--N 1.316 -0.868 0 CA-C-N 115.719 -0.673 . . . . 73.319999999999993 110.808 -172.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . 0.478 ' HG3' ' HB2' ' B' ' 160' ' ' SER . 84.2 Cg_endo -84.47 -19.83 4.22 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.662 2.242 . . . . 74.019999999999996 112.587 -178.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 14.7 p-10 -90.61 3.76 53.2 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.935 -0.575 . . . . 74.409999999999997 109.975 -179.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 81.5 tttt -127.04 137.39 53.05 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.412 -0.813 . . . . 75.430000000000007 109.972 179.018 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.879 HD23 HD12 ' A' ' 58' ' ' ILE . 48.1 mt -86.22 116.54 24.46 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.916 -0.772 . . . . 74.129999999999995 108.916 176.08 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.656 HG23 ' HB3' ' A' ' 71' ' ' GLU . 41.5 mm -69.71 120.15 75.69 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 115.905 -0.589 . . . . 75.340000000000003 111.2 -172.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.54 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 51.3 Cg_endo -68.82 172.98 10.78 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.561 2.174 . . . . 62.450000000000003 112.574 -178.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 10.9 tt0 -80.1 -4.03 51.19 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.503 -0.771 . . . . 64.040000000000006 112.091 -166.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 39.1 p90 -100.78 -17.86 16.72 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.196 0.522 . . . . 75.420000000000002 110.214 174.002 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.656 ' HB3' HG23 ' A' ' 67' ' ' ILE . 1.2 mm-40 -90.73 -13.1 34.71 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.682 -0.69 . . . . 74.329999999999998 110.037 -178.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.522 HG21 ' O ' ' A' ' 68' ' ' PRO . 41.2 pt -70.34 -21.49 23.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.738 -0.665 . . . . 70.25 110.218 176.514 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -108.0 38.42 2.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.643 -0.708 . . . . 64.319999999999993 109.211 175.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.541 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 7.7 t -62.85 -32.77 74.06 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.192 -0.913 . . . . 71.409999999999997 111.187 -175.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 66.9 p-90 . . . . . 0 C--N 1.327 -0.383 0 CA-C-O 120.887 0.375 . . . . 74.040000000000006 110.838 179.19 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 14.1 m . . . . . 0 C--O 1.236 0.352 0 CA-C-O 120.937 0.398 . . . . 61.43 110.699 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.9 -58.28 4.98 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.72 -0.752 . . . . 73.219999999999999 111.362 -178.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 58.43 77.11 0.42 Allowed Pre-proline 0 C--N 1.329 -0.298 0 C-N-CA 122.941 0.497 . . . . 73.140000000000001 111.363 177.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.613 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 46.3 Cg_endo -72.84 80.12 1.84 Allowed 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 121.914 1.743 . . . . 73.129999999999995 110.745 175.159 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -97.77 164.33 12.44 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.197 -0.911 . . . . 75.409999999999997 110.255 -176.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.619 HG23 ' HB3' ' B' ' 124' ' ' GLN . 9.7 p -125.09 132.7 70.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-O 121.395 0.617 . . . . 62.350000000000001 111.195 -177.622 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 114' ' ' THR . . . . . 0.561 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 21.6 m -93.4 110.48 22.04 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.469 -0.787 . . . . 64.129999999999995 109.534 175.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.5 mt -84.37 105.35 13.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.062 0.458 . . . . 75.400000000000006 111.051 -176.039 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . 0.739 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 30.2 mmt180 -100.81 171.93 7.37 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.733 -0.667 . . . . 75.109999999999999 109.551 176.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 -145.59 125.18 13.25 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.512 0.672 . . . . 75.209999999999994 110.49 172.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.13 61.27 0.81 Allowed 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 115.008 -0.996 . . . . 71.230000000000004 110.223 -175.178 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 94.14 -111.94 4.25 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.685 -0.769 . . . . 71.430000000000007 111.638 -179.035 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -100.23 9.45 42.73 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.036 0.446 . . . . 73.040000000000006 109.837 178.215 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.681 ' HD2' ' HB2' ' B' ' 175' ' ' TRP . 25.0 pttm -123.81 119.59 30.15 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.9 -0.591 . . . . 74.310000000000002 110.791 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 122' ' ' THR . . . . . 0.637 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 35.0 m -80.07 133.38 36.11 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.755 -0.657 . . . . 74.109999999999999 109.543 175.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . 0.739 ' HB ' ' HB2' ' B' ' 116' ' ' ARG . 32.5 mm -114.89 103.39 15.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 120.753 0.311 . . . . 72.400000000000006 110.41 -177.403 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.734 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 14.5 mt-30 -95.7 105.69 17.72 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 120.644 -0.422 . . . . 74.450000000000003 110.452 -178.055 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . 0.561 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 41.1 mt-10 -81.63 101.7 10.19 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.865 -0.607 . . . . 75.510000000000005 110.831 179.137 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . 0.46 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 55.6 m-85 -81.03 105.72 12.46 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.916 0.388 . . . . 75.430000000000007 110.253 176.362 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . 0.479 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 86.8 mtm180 -127.67 118.03 23.08 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.956 -0.566 . . . . 73.439999999999998 110.262 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.751 HG11 ' H ' ' B' ' 129' ' ' ASN . 2.4 p -84.44 -72.06 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-N 116.114 -0.494 . . . . 74.319999999999993 110.246 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . 0.751 ' H ' HG11 ' B' ' 128' ' ' VAL . 18.3 t-20 -122.28 69.44 0.96 Allowed 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.122 0.487 . . . . 70.409999999999997 110.252 -177.091 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.79 -18.74 37.41 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.501 -0.772 . . . . 53.329999999999998 113.684 175.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . 0.446 ' CD2' HG22 ' A' ' 28' ' ' VAL . 38.0 t80 -114.68 132.13 56.5 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.138 0.494 . . . . 73.329999999999998 111.189 -171.721 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.753 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -73.24 113.6 10.5 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.967 -1.015 . . . . 75.140000000000001 109.358 174.668 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . 0.46 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 52.5 p90 -106.01 -20.04 13.54 Favored 'General case' 0 C--N 1.326 -0.415 0 C-N-CA 120.72 -0.392 . . . . 74.420000000000002 111.456 -179.072 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -157.44 142.11 16.6 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.816 0.341 . . . . 75.310000000000002 111.361 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.753 HG13 HD11 ' B' ' 132' ' ' LEU . 73.5 mt -119.14 117.44 54.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 116.145 -0.48 . . . . 75.349999999999994 109.958 175.028 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.734 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 78.9 tttt -93.8 104.64 16.71 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.399 -0.593 . . . . 73.019999999999996 109.399 175.611 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.687 HG13 ' HD3' ' B' ' 139' ' ' PRO . 4.1 t -88.71 131.04 37.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 N-CA-C 108.985 -0.746 . . . . 74.099999999999994 108.985 177.529 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.637 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.4 t -118.18 73.03 9.76 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.703 -0.481 . . . . 73.120000000000005 109.703 173.016 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.687 ' HD3' HG13 ' B' ' 137' ' ' VAL . 61.2 Cg_endo -81.27 134.04 8.9 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 122.047 1.831 . . . . 75.400000000000006 112.161 175.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 63.4 mttm -57.07 -42.91 81.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.592 0.71 . . . . 74.150000000000006 110.083 174.659 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 18.0 m-70 -98.95 83.77 2.97 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.088 -0.96 . . . . 73.109999999999999 109.406 -173.165 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 136.28 -21.5 3.46 Favored Glycine 0 N--CA 1.45 -0.372 0 CA-C-N 115.51 -0.768 . . . . 52.549999999999997 111.848 -177.402 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . 0.505 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 53.7 mtmt 72.46 154.88 0.15 Allowed Pre-proline 0 N--CA 1.466 0.354 0 C-N-CA 123.682 0.793 . . . . 73.319999999999993 111.893 179.639 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.53 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 36.4 Cg_endo -65.49 146.85 86.06 Favored 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 123.017 2.478 . . . . 72.109999999999999 114.12 -174.334 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 27.3 p90 -151.19 171.26 17.67 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.402 -0.817 . . . . 75.439999999999998 109.472 175.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -111.67 126.54 55.14 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.94 0.4 . . . . 65.439999999999998 111.163 -179.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . 0.424 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 26.7 tp -107.79 99.18 8.67 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.601 -0.727 . . . . 72.209999999999994 109.121 175.503 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 39.2 t -99.87 138.06 25.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 120.805 0.336 . . . . 64.409999999999997 111.152 -174.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . 0.463 ' HD3' ' CE2' ' B' ' 157' ' ' PHE . 0.4 OUTLIER -65.46 123.77 20.51 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 121.049 0.452 . . . . 72.409999999999997 111.469 174.509 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.05 156.54 37.37 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.228 -0.897 . . . . 72.400000000000006 110.705 177.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . 0.535 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 5.7 p-10 -64.51 133.85 53.25 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.144 0.497 . . . . 74.420000000000002 110.427 -179.364 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 89.72 -30.76 5.58 Favored Glycine 0 N--CA 1.453 -0.217 0 CA-C-N 115.831 -0.622 . . . . 55.229999999999997 111.808 -175.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 59.8 p 46.21 56.4 6.26 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.126 0.97 . . . . 75.230000000000004 113.13 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -77.64 40.79 0.31 Allowed 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.837 0.827 . . . . 71.530000000000001 110.417 176.623 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 73.08 28.73 65.91 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 111.362 -0.695 . . . . 51.100000000000001 111.362 -173.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . 0.516 ' ND2' HD22 ' B' ' 166' ' ' LEU . 34.0 t30 -122.02 141.57 51.22 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.393 -0.403 . . . . 64.409999999999997 110.364 -175.424 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . 0.463 ' CE2' ' HD3' ' B' ' 149' ' ' ARG . 43.1 m-85 -125.93 162.63 24.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.026 -0.533 . . . . 71.510000000000005 110.025 179.283 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 46.4 mm -122.07 130.14 74.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 109.088 -0.708 . . . . 73.420000000000002 109.088 175.382 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.497 ' HB3' ' OD1' ' B' ' 161' ' ' ASP . 23.6 mtp180 -104.92 158.79 16.29 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.193 0.52 . . . . 74.519999999999996 111.382 -175.762 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 160' ' ' SER . . . . . 0.478 ' HB2' ' HG3' ' A' ' 63' ' ' PRO . 11.5 p -74.86 -26.06 59.42 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.907 -0.588 . . . . 62.229999999999997 110.689 178.808 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . 0.497 ' OD1' ' HB3' ' B' ' 159' ' ' ARG . 11.3 p-10 -86.68 -15.4 39.69 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.883 -0.598 . . . . 62.340000000000003 110.428 177.274 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . 0.423 ' OE1' ' HD3' ' B' ' 165' ' ' LYS . 39.4 mt-30 -143.24 74.45 17.48 Favored Pre-proline 0 C--N 1.319 -0.718 0 CA-C-N 115.243 -0.89 . . . . 74.239999999999995 109.38 -176.095 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . 0.638 ' HB3' ' HB2' ' A' ' 60' ' ' SER . 74.0 Cg_endo -83.05 -44.23 0.07 OUTLIER 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.966 2.444 . . . . 74.219999999999999 114.133 -172.155 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -80.8 -6.8 59.01 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.443 0.64 . . . . 73.310000000000002 109.631 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . 0.423 ' HD3' ' OE1' ' B' ' 162' ' ' GLN . 88.1 tttt -103.92 135.98 44.43 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.18 -0.918 . . . . 71.319999999999993 110.27 -178.04 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . 0.516 HD22 ' ND2' ' B' ' 156' ' ' ASN . 5.3 mp -87.41 124.21 33.16 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 108.994 -0.743 . . . . 73.040000000000006 108.994 178.374 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 46.5 mm -83.44 117.73 69.47 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.114 -0.494 . . . . 74.530000000000001 111.686 -170.635 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.5 ' O ' HG21 ' B' ' 172' ' ' ILE . 70.4 Cg_endo -72.95 175.93 9.74 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.957 2.438 . . . . 64.209999999999994 112.874 -178.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -82.75 15.16 2.77 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.45 -0.795 . . . . 63.420000000000002 112.944 -168.469 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 26.3 p90 -115.67 -14.98 11.41 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.144 0.497 . . . . 75.319999999999993 110.424 171.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -107.32 0.81 23.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.967 -0.561 . . . . 73.400000000000006 111.017 -176.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.5 HG21 ' O ' ' B' ' 168' ' ' PRO . 21.6 pt -80.79 -31.3 12.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.914 -0.585 . . . . 74.420000000000002 111.217 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -111.5 39.4 2.34 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.422 0.63 . . . . 72.129999999999995 110.376 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.9 t -61.19 -26.03 67.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.378 -0.828 . . . . 74.019999999999996 110.933 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . 0.681 ' HB2' ' HD2' ' B' ' 121' ' ' LYS . 4.0 p-90 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.126 -0.94 . . . . 73.219999999999999 110.981 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 14.6 m . . . . . 0 C--O 1.235 0.325 0 N-CA-C 110.213 -0.291 . . . . 71.540000000000006 110.213 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.506 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 85.43 87.69 0.94 Allowed Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 110.437 -1.065 . . . . 73.129999999999995 110.437 -171.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -106.06 101.91 36.68 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-O 120.834 0.35 . . . . 72.420000000000002 110.938 -169.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.749 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 71.7 Cg_endo -92.07 122.41 0.62 Allowed 'Trans proline' 0 N--CA 1.445 -1.363 0 C-N-CA 122.864 2.376 . . . . 75.230000000000004 112.314 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -128.19 111.56 13.57 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.526 0.679 . . . . 71.510000000000005 110.321 176.508 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.588 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 9.1 p -67.33 130.0 32.31 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.085 0 CA-C-N 114.723 -1.126 . . . . 74.430000000000007 110.806 179.412 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.534 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 51.8 m -86.23 103.34 14.76 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.671 -0.695 . . . . 75.219999999999999 109.561 175.763 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 63.5 mt -86.8 104.47 14.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.159 -0.473 . . . . 73.530000000000001 110.482 -177.427 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 10.1 mmm-85 -106.0 156.34 18.49 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.682 -0.69 . . . . 74.519999999999996 110.766 -178.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -129.23 98.21 4.83 Favored 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 108.873 -0.788 . . . . 73.109999999999999 108.873 173.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.56 ' HG3' HD12 ' A' ' 23' ' ' ILE . 8.0 mm-40 -91.47 15.7 11.8 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.475 -0.784 . . . . 74.310000000000002 110.723 -171.773 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.41 -98.96 0.64 Allowed Glycine 0 N--CA 1.445 -0.727 0 C-N-CA 120.998 -0.62 . . . . 52.140000000000001 111.899 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.454 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 11.5 p-10 -85.45 4.57 35.02 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.632 0.253 . . . . 72.540000000000006 111.568 -178.129 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.628 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 14.1 pttm -148.44 130.54 15.41 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 112.664 0.616 . . . . 72.340000000000003 112.664 -176.553 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.8 m -84.87 103.31 13.82 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 114.925 -1.034 . . . . 74.519999999999996 108.997 172.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.56 HD12 ' HG3' ' A' ' 18' ' ' GLU . 55.7 mt -100.33 112.23 32.36 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.013 0.435 . . . . 73.239999999999995 110.393 -175.264 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.588 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 21.4 mt-30 -101.43 117.36 34.78 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.96 -0.564 . . . . 75.439999999999998 111.576 -177.16 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.534 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.1 mt-10 -91.05 100.5 13.34 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.551 -0.75 . . . . 73.209999999999994 110.322 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.545 ' CD2' ' HB2' ' B' ' 151' ' ' ASP . 63.2 m-85 -78.12 104.73 8.88 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.676 0.274 . . . . 74.140000000000001 110.682 179.327 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 94.0 mtt180 -122.69 132.9 54.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.313 -0.403 . . . . 75.340000000000003 110.687 -178.423 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.788 HG12 ' H ' ' A' ' 29' ' ' ASN . 3.0 p -98.59 -73.98 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 C-N-CA 120.725 -0.39 . . . . 74.310000000000002 110.898 176.222 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.788 ' H ' HG12 ' A' ' 28' ' ' VAL . 7.4 m-20 -128.38 68.62 1.36 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.05 0.453 . . . . 74.030000000000001 110.51 -177.308 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 77.42 12.56 84.44 Favored Glycine 0 N--CA 1.451 -0.331 0 CA-C-N 115.679 -0.691 . . . . 71.310000000000002 112.019 -179.052 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 79.9 t80 -130.07 127.36 39.72 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.921 0.391 . . . . 75.450000000000003 110.785 -176.183 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 30.2 tp -85.91 114.8 23.1 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.393 -0.821 . . . . 74.420000000000002 109.413 174.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . 0.472 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 50.8 p90 -104.47 -10.3 17.78 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.669 -0.412 . . . . 75.540000000000006 111.938 -176.782 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -167.44 145.05 4.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.081 0.467 . . . . 63.310000000000002 111.361 -177.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 66.9 mt -121.14 115.77 47.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.872 -0.604 . . . . 73.209999999999994 109.615 174.3 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.453 ' CB ' ' HE1' ' A' ' 26' ' ' TYR . 83.5 tttt -104.69 105.25 15.26 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.666 -0.494 . . . . 72.019999999999996 109.666 177.326 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.536 HG12 ' CE1' ' A' ' 45' ' ' TYR . 1.6 p -104.24 127.05 58.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.996 0.427 . . . . 74.129999999999995 110.512 178.3 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.805 HG21 ' HB3' ' A' ' 44' ' ' PRO . 16.1 t -103.0 88.01 1.41 Allowed Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 115.312 -0.858 . . . . 74.129999999999995 109.463 175.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.486 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 90.0 Cg_endo -81.65 150.09 16.57 Favored 'Trans proline' 0 N--CA 1.461 -0.423 0 C-N-CA 122.714 2.276 . . . . 71.230000000000004 113.432 -176.734 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.454 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 29.0 mtpp -74.36 -10.48 59.63 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.368 -0.833 . . . . 75.5 110.556 174.175 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 52.9 m-70 -113.43 21.01 15.58 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.766 -0.652 . . . . 74.150000000000006 110.277 -173.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.26 -155.85 15.33 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 115.675 -0.693 . . . . 72.209999999999994 111.661 -178.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.483 ' HB2' ' HZ1' ' A' ' 43' ' ' LYS . 9.5 mtmp? -112.09 150.53 42.57 Favored Pre-proline 0 C--N 1.324 -0.506 0 N-CA-C 109.89 -0.411 . . . . 73.129999999999995 109.89 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.805 ' HB3' HG21 ' A' ' 38' ' ' VAL . 19.8 Cg_endo -60.18 121.03 9.15 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.37 2.046 . . . . 64.349999999999994 111.8 175.774 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.536 ' CE1' HG12 ' A' ' 37' ' ' VAL . 9.4 p90 -136.53 155.73 49.56 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.0 -0.546 . . . . 74.230000000000004 111.039 -176.227 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -99.7 137.07 38.69 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.621 -0.718 . . . . 72.510000000000005 110.787 -179.805 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 31.8 mt -104.7 98.13 7.92 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.865 -0.791 . . . . 71.040000000000006 108.865 164.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 39.7 t -83.54 129.12 38.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.117 -0.492 . . . . 73.329999999999998 110.083 -176.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.19 125.64 29.65 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.303 -0.408 . . . . 75.209999999999994 110.435 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.409 ' HB3' ' HB3' ' A' ' 54' ' ' ASP . . . -67.43 135.72 53.58 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 120.953 0.406 . . . . 65.25 110.899 178.181 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.713 ' OD1' ' HB2' ' B' ' 111' ' ' PRO . 31.3 t0 -80.01 168.58 19.0 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.594 -0.73 . . . . 74.209999999999994 110.942 -174.743 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.65 24.51 45.88 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.269 -0.732 . . . . 75.510000000000005 111.269 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 14.2 m 58.66 28.01 16.61 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.118 0.485 . . . . 74.530000000000001 110.592 -177.054 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.409 ' HB3' ' HB3' ' A' ' 50' ' ' ALA . 17.5 t70 -60.09 -47.95 83.75 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 115.349 -0.841 . . . . 74.329999999999998 111.325 -177.213 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 101.34 -36.73 4.01 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.679 -0.772 . . . . 63.340000000000003 112.946 176.386 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -70.93 150.95 45.2 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.967 0.413 . . . . 65.140000000000001 111.619 -175.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.452 ' CD1' HG22 ' A' ' 72' ' ' ILE . 37.7 m-85 -108.95 148.88 30.02 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.271 -0.422 . . . . 74.430000000000007 110.685 179.429 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 50.2 mm -111.26 129.07 67.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 109.641 -0.503 . . . . 74.430000000000007 109.641 176.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 43.2 ttm180 -89.91 135.69 33.49 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.541 -0.299 . . . . 75.510000000000005 110.59 -176.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 35.0 t -63.2 -33.27 75.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.33 -0.396 . . . . 73.340000000000003 111.704 -178.194 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -62.3 -42.64 99.53 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.248 0.547 . . . . 72.299999999999997 110.5 178.475 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 62.4 mt-30 -135.04 89.6 23.68 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 115.491 -0.777 . . . . 74.120000000000005 110.355 -174.015 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -68.97 -6.19 17.58 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.892 2.395 . . . . 74.109999999999999 112.416 -178.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -95.7 -8.44 34.6 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.086 -0.506 . . . . 71.219999999999999 110.241 178.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.3 tptt -105.84 123.12 47.45 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.869 -0.605 . . . . 63.329999999999998 110.737 -177.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.412 ' N ' HD12 ' A' ' 66' ' ' LEU . 5.1 mp -90.45 119.64 30.9 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.108 -0.951 . . . . 74.530000000000001 109.075 177.787 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 49.6 mm -90.07 113.92 58.97 Favored Pre-proline 0 C--N 1.323 -0.573 0 CA-C-N 116.263 -0.426 . . . . 75.310000000000002 110.729 -175.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.461 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 56.9 Cg_endo -69.43 174.03 9.81 Favored 'Trans proline' 0 N--CA 1.46 -0.5 0 C-N-CA 122.498 2.132 . . . . 71.530000000000001 112.371 -179.304 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 29.4 tt0 -83.14 -5.17 59.02 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.806 -0.633 . . . . 74.409999999999997 111.857 -168.233 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 35.7 p90 -100.45 -2.02 34.33 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.287 0.565 . . . . 75.400000000000006 109.902 176.468 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.461 ' HB2' ' HG2' ' A' ' 68' ' ' PRO . 2.8 mm-40 -121.72 17.02 11.12 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.391 -0.822 . . . . 71.299999999999997 111.03 -177.016 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.452 HG22 ' CD1' ' A' ' 57' ' ' PHE . 12.1 pt -98.18 -22.55 4.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.944 -0.571 . . . . 72.430000000000007 111.457 -179.569 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -113.58 20.78 15.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.185 0.517 . . . . 71.549999999999997 110.427 -178.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.1 m -57.75 -32.69 67.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.246 -0.888 . . . . 71.409999999999997 111.489 -177.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . 0.628 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 10.2 p-90 . . . . . 0 C--N 1.325 -0.467 0 CA-C-N 116.23 -0.441 . . . . 75.439999999999998 111.088 176.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 26.3 m . . . . . 0 N--CA 1.45 -0.437 0 CA-C-O 121.369 0.604 . . . . 70.209999999999994 109.763 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . 0.433 ' O ' ' HD3' ' B' ' 111' ' ' PRO . . . 151.59 54.14 0.01 OUTLIER Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 110.485 -1.046 . . . . 70.219999999999999 110.485 -175.058 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 -92.41 104.03 10.07 Favored Pre-proline 0 C--N 1.323 -0.578 0 CA-C-N 115.182 -0.509 . . . . 64.200000000000003 109.851 -176.065 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.713 ' HB2' ' OD1' ' A' ' 51' ' ' ASP . 68.4 Cg_endo -98.61 158.37 0.73 Allowed 'Trans proline' 0 N--CA 1.444 -1.437 0 C-N-CA 123.156 2.571 . . . . 74.150000000000006 112.768 -174.621 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -156.26 126.28 6.49 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 115.544 -0.753 . . . . 71.099999999999994 109.766 177.151 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.449 ' HB ' ' HB3' ' A' ' 51' ' ' ASP . 5.4 p -84.88 132.79 30.82 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 CA-C-N 114.979 -1.01 . . . . 74.439999999999998 110.801 -174.124 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 114' ' ' THR . . . . . 0.578 HG21 ' HG3' ' B' ' 116' ' ' ARG . 28.6 m -95.78 104.76 16.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.463 -0.79 . . . . 73.019999999999996 110.184 179.077 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.507 HG12 ' HG2' ' B' ' 124' ' ' GLN . 60.7 mt -90.64 102.98 13.92 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 116.073 -0.512 . . . . 74.019999999999996 109.928 -179.593 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . 0.578 ' HG3' HG21 ' B' ' 114' ' ' THR . 71.7 mtm180 -121.24 169.71 10.3 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.162 -0.472 . . . . 74.430000000000007 110.847 -178.41 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -125.24 117.49 23.95 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.045 -0.525 . . . . 75.109999999999999 110.537 179.016 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . 0.563 ' HG3' HD12 ' B' ' 123' ' ' ILE . 22.8 mm-40 -95.36 25.66 4.26 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.577 -0.738 . . . . 74.549999999999997 110.911 -177.225 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 121.45 -107.95 1.28 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.897 -0.668 . . . . 62.140000000000001 111.638 -177.379 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . 0.54 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 28.4 m-20 -95.39 29.21 2.61 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.911 0.386 . . . . 70.430000000000007 110.027 179.519 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . . . . . . . . . 20.7 pttm -151.88 127.52 10.14 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.032 0.444 . . . . 75.219999999999999 111.292 179.121 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 21.7 m -90.14 113.24 24.96 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.599 -0.728 . . . . 74.400000000000006 109.19 174.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . 0.563 HD12 ' HG3' ' B' ' 118' ' ' GLU . 51.8 mt -109.84 114.79 47.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.198 0.523 . . . . 70.140000000000001 110.634 -173.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.507 ' HG2' HG12 ' B' ' 115' ' ' ILE . 19.6 mt-30 -95.3 105.89 17.88 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.552 -0.749 . . . . 73.519999999999996 109.569 178.067 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . 0.415 ' CD ' HH21 ' B' ' 116' ' ' ARG . 28.8 mt-10 -84.53 98.82 10.34 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.541 -0.754 . . . . 74.329999999999998 110.34 -177.482 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . 0.6 ' CD2' ' HB2' ' A' ' 51' ' ' ASP . 6.5 m-85 -76.51 103.3 6.43 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.595 -0.52 . . . . 71.450000000000003 109.595 178.361 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 56.9 mtt-85 -132.43 126.34 32.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.108 0.48 . . . . 73.349999999999994 111.553 -172.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.696 ' HB ' ' HB3' ' B' ' 111' ' ' PRO . 4.3 p -115.7 119.44 61.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.675 -0.693 . . . . 75.400000000000006 109.827 175.105 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 60.29 27.14 16.66 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.284 -0.416 . . . . 75.340000000000003 111.545 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.36 21.13 52.92 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.509 -0.853 . . . . 71.519999999999996 112.576 179.544 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . 0.459 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 90.0 t80 -122.27 119.43 31.16 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.933 0.396 . . . . 72.5 110.235 175.443 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.535 HD23 HD11 ' B' ' 135' ' ' ILE . 24.4 tp -83.06 114.24 21.16 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.694 -0.684 . . . . 72.540000000000006 109.928 178.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 45.6 p90 -110.06 -6.93 15.0 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.618 -0.433 . . . . 71.400000000000006 111.296 -178.107 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -165.83 146.88 6.89 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.027 0.441 . . . . 73.019999999999996 111.207 -177.148 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.535 HD11 HD23 ' B' ' 132' ' ' LEU . 59.3 mt -130.57 118.05 41.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.932 -0.576 . . . . 73.420000000000002 109.946 177.582 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.506 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.1 tttt -101.3 98.32 8.72 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 120.092 -0.643 . . . . 75.209999999999994 109.477 172.354 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.523 HG12 ' CE1' ' B' ' 145' ' ' TYR . 1.9 p -101.4 125.38 55.43 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.125 0.488 . . . . 73.310000000000002 110.537 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.646 HG23 ' HB3' ' B' ' 144' ' ' PRO . 23.2 t -104.98 88.67 2.48 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.169 -0.923 . . . . 72.219999999999999 109.451 175.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.456 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 72.6 Cg_endo -83.51 132.69 5.92 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.54 2.16 . . . . 75.099999999999994 112.708 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . 0.54 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 29.1 mtpp -56.65 -33.38 66.28 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.454 -0.794 . . . . 72.140000000000001 111.006 176.742 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -97.11 17.42 17.14 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.705 -0.679 . . . . 74.540000000000006 111.029 -174.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . -155.76 -149.99 5.48 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 121.001 -0.619 . . . . 65.230000000000004 111.742 178.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . 0.529 ' HB2' ' HZ3' ' B' ' 143' ' ' LYS . 9.5 mtmp? -119.08 147.42 42.66 Favored Pre-proline 0 C--N 1.327 -0.395 0 N-CA-C 109.611 -0.514 . . . . 74.219999999999999 109.611 176.495 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.646 ' HB3' HG23 ' B' ' 138' ' ' VAL . 25.3 Cg_endo -64.29 123.85 12.47 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.362 2.041 . . . . 75.549999999999997 111.492 175.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . 0.523 ' CE1' HG12 ' B' ' 137' ' ' VAL . 5.8 p90 -144.88 151.79 39.25 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.874 0.368 . . . . 70.329999999999998 111.418 -175.614 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.468 ' HB2' ' OG ' ' B' ' 160' ' ' SER . 74.9 m-85 -96.83 136.81 36.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.675 -0.693 . . . . 72.030000000000001 110.393 177.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . 0.496 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 56.9 mt -109.53 102.62 11.46 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.163 -0.471 . . . . 75.450000000000003 109.884 169.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.9 t -81.83 130.35 35.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 109.836 -0.431 . . . . 74.129999999999995 109.836 178.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . 0.577 ' NH1' ' HA ' ' B' ' 153' ' ' SER . 0.0 OUTLIER -81.31 128.06 33.41 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.703 -0.226 . . . . 71.510000000000005 110.447 -177.149 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -68.58 150.7 47.7 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 120.963 0.411 . . . . 74.409999999999997 110.631 176.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . 0.545 ' HB2' ' CD2' ' A' ' 26' ' ' TYR . 22.7 t70 -70.77 165.88 22.14 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.598 -0.728 . . . . 71.299999999999997 111.115 -175.148 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.08 0.66 70.97 Favored Glycine 0 C--N 1.331 0.3 0 CA-C-N 116.206 -0.452 . . . . 74.5 112.34 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 153' ' ' SER . . . . . 0.577 ' HA ' ' NH1' ' B' ' 149' ' ' ARG . 5.9 t 60.6 31.91 20.29 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.078 0.466 . . . . 61.229999999999997 109.836 -176.441 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -52.39 -49.4 64.53 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.126 -0.943 . . . . 71.340000000000003 111.54 -179.521 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 124.61 -17.87 7.28 Favored Glycine 0 CA--C 1.499 -0.918 0 C-N-CA 120.762 -0.732 . . . . 73.120000000000005 111.565 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -70.33 140.35 52.21 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 114.851 -0.675 . . . . 63.520000000000003 111.281 178.037 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . 0.486 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 53.9 m-85 -118.28 151.47 37.61 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.071 -0.513 . . . . 73.120000000000005 109.673 174.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 46.7 mm -119.35 121.91 67.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 N-CA-C 109.743 -0.465 . . . . 64.219999999999999 109.743 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.552 ' HB3' ' H ' ' B' ' 162' ' ' GLN . 54.5 mtt180 -76.2 137.07 39.78 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.318 -0.401 . . . . 71.019999999999996 110.941 179.434 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 160' ' ' SER . . . . . 0.468 ' OG ' ' HB2' ' B' ' 146' ' ' PHE . 19.9 m -80.88 -13.68 58.7 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.252 -1.018 . . . . 74.239999999999995 108.252 165.096 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -73.66 -45.85 50.13 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.251 -1.34 . . . . 75.319999999999993 109.859 173.033 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . 0.552 ' H ' ' HB3' ' B' ' 159' ' ' ARG . 77.6 mt-30 -137.63 86.19 19.28 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-N 115.364 -0.835 . . . . 75.430000000000007 109.444 176.456 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -68.19 -13.99 39.39 Favored 'Trans proline' 0 N--CA 1.473 0.282 0 C-N-CA 122.905 2.403 . . . . 72.450000000000003 112.936 -176.436 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -92.29 10.68 28.67 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.976 0.417 . . . . 72.239999999999995 110.453 -179.028 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -127.09 125.81 41.91 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.33 0.586 . . . . 75.319999999999993 111.075 -179.589 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . 0.429 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.9 mp -87.87 125.06 34.27 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.036 -0.984 . . . . 64.510000000000005 108.93 176.573 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . 0.817 HG21 ' HB3' ' B' ' 171' ' ' GLU . 39.4 mm -87.26 117.43 68.58 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 116.18 -0.463 . . . . 64.120000000000005 111.64 -172.396 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.452 ' HG2' ' HB2' ' B' ' 171' ' ' GLU . 72.4 Cg_endo -75.59 -179.75 5.42 Favored 'Trans proline' 0 N--CA 1.463 -0.287 0 C-N-CA 123.088 2.525 . . . . 63.25 112.043 175.539 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . 0.75 ' O ' HG12 ' B' ' 172' ' ' ILE . 35.4 tt0 -76.34 -29.51 57.28 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.727 -0.389 . . . . 74.019999999999996 111.68 -172.261 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 36.5 p90 -75.06 -14.11 60.56 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 119.92 -0.712 . . . . 74.450000000000003 110.313 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.817 ' HB3' HG21 ' B' ' 167' ' ' ILE . 0.8 OUTLIER -89.68 -21.1 22.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.885 -0.598 . . . . 73.150000000000006 110.185 -179.257 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.75 HG12 ' O ' ' B' ' 169' ' ' GLN . 21.9 pt -73.59 -18.44 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 121.27 0.557 . . . . 74.200000000000003 110.24 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 80.0 m-85 -93.65 15.23 16.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.663 -0.699 . . . . 74.319999999999993 110.168 176.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.7 t -56.96 -37.06 71.04 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-N 115.817 -0.629 . . . . 72.019999999999996 109.777 175.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 54.7 p-90 . . . . . 0 C--O 1.247 0.927 0 CA-C-O 118.203 -0.903 . . . . 74.420000000000002 109.828 175.02 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 19.6 m . . . . . 0 N--CA 1.45 -0.461 0 N-CA-C 109.504 -0.554 . . . . 71.430000000000007 109.504 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 72.41 74.78 0.74 Allowed Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 110.005 -1.238 . . . . 64.510000000000005 110.005 -168.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . 0.441 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 7.1 pt-20 -112.31 107.74 55.26 Favored Pre-proline 0 C--N 1.317 -0.809 0 CA-C-O 121.375 0.607 . . . . 73.430000000000007 109.712 -169.83 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.639 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 32.5 Cg_endo -84.67 108.94 1.28 Allowed 'Trans proline' 0 N--CA 1.442 -1.541 0 C-N-CA 122.445 2.097 . . . . 63.109999999999999 112.371 -174.006 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -118.79 164.2 15.75 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.127 -0.942 . . . . 52.109999999999999 109.674 -179.437 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.577 HG21 ' HB3' ' A' ' 24' ' ' GLN . 13.1 p -115.34 131.24 68.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.237 0.541 . . . . 74.510000000000005 111.41 -177.315 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 52.9 m -93.16 107.09 18.96 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.244 -0.65 . . . . 73.420000000000002 109.244 174.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 53.5 mt -92.09 107.96 19.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 120.963 0.411 . . . . 71.209999999999994 111.217 -174.559 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 66.7 mtt180 -103.65 167.85 9.53 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.736 -0.665 . . . . 75.129999999999995 110.252 176.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 62.6 mt-30 -134.16 97.31 3.82 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.438 -0.579 . . . . 72.219999999999999 109.438 170.317 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 22.1 mm-40 -96.29 82.42 3.42 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.823 -0.626 . . . . 74.209999999999994 110.093 -175.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.86 -109.02 3.31 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.798 -0.715 . . . . 62.200000000000003 111.927 -178.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.91 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 7.1 m-20 -111.22 17.53 20.2 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.899 0.381 . . . . 65.239999999999995 110.326 -179.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.584 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 22.9 pttm -130.84 123.79 29.84 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.294 0.569 . . . . 74.120000000000005 111.398 -179.151 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.454 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 24.5 m -82.83 109.75 17.24 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.603 -0.726 . . . . 71.340000000000003 109.682 176.265 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 48.7 mt -102.55 112.83 37.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-O 121.117 0.484 . . . . 73.340000000000003 110.654 -176.335 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.577 ' HB3' HG21 ' A' ' 13' ' ' VAL . 25.2 mt-30 -102.48 110.92 23.02 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.67 -0.695 . . . . 74.310000000000002 110.996 -177.562 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -92.26 107.51 19.27 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.795 -0.639 . . . . 73.019999999999996 110.837 -178.42 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -84.87 112.42 20.54 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.893 0.378 . . . . 75.219999999999999 110.599 178.392 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.418 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 87.9 mtt180 -117.39 137.56 52.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.924 -0.58 . . . . 75.109999999999999 109.905 178.756 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.639 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 6.2 p -96.82 -34.82 5.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-O 121.346 0.593 . . . . 72.239999999999995 110.489 177.714 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 30.9 t-20 -161.78 59.8 0.26 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.641 -0.874 . . . . 64.329999999999998 108.641 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.07 -34.69 3.36 Favored Glycine 0 CA--C 1.519 0.297 0 CA-C-N 115.482 -0.781 . . . . 64.120000000000005 112.058 -176.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.536 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 81.9 t80 -78.28 129.25 34.82 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.021 0.438 . . . . 73.219999999999999 111.047 -177.328 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.759 HD12 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -81.44 114.04 19.91 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.196 -0.911 . . . . 72.340000000000003 109.094 174.59 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 52.1 p90 -107.86 -19.4 13.53 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.634 -0.426 . . . . 74.340000000000003 111.682 -179.057 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -154.85 136.15 14.05 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.785 0.326 . . . . 62.219999999999999 111.244 -179.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.759 HG13 HD12 ' A' ' 32' ' ' LEU . 75.0 mt -116.26 122.81 70.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 116.064 -0.516 . . . . 75.450000000000003 109.91 175.378 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.4 tmtp? -110.21 114.49 28.02 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 108.732 -0.84 . . . . 72.299999999999997 108.732 173.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.558 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 0.9 OUTLIER -120.46 129.72 75.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 CA-C-N 115.796 -0.638 . . . . 74.549999999999997 110.692 -174.011 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.739 HG23 ' HB3' ' A' ' 44' ' ' PRO . 21.2 t -112.8 86.96 9.38 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.313 -0.858 . . . . 75.400000000000006 110.097 -179.378 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.462 ' HD2' ' C ' ' A' ' 43' ' ' LYS . 70.4 Cg_endo -86.49 134.45 4.05 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 122.503 2.135 . . . . 74.219999999999999 112.496 176.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.91 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 59.4 mtpt -56.31 -31.19 63.46 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.664 -0.698 . . . . 74.239999999999995 110.168 174.149 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 61.4 m-70 -116.95 91.18 3.51 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.338 -0.846 . . . . 73.340000000000003 109.156 176.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 141.31 -31.31 2.16 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.837 -0.619 . . . . 65.329999999999998 111.977 -177.019 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.462 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 98.5 mttt 70.52 151.12 0.13 Allowed Pre-proline 0 N--CA 1.469 0.477 0 C-N-CA 123.508 0.723 . . . . 73.530000000000001 111.872 178.577 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.739 ' HB3' HG23 ' A' ' 38' ' ' VAL . 18.8 Cg_endo -59.26 139.44 90.09 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 123.013 2.476 . . . . 74.010000000000005 113.798 -174.01 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.527 ' CE1' HG11 ' A' ' 37' ' ' VAL . 22.5 p90 -152.34 163.65 39.04 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.62 -0.718 . . . . 73.140000000000001 109.548 176.594 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . 0.481 ' HB2' ' HB2' ' A' ' 60' ' ' SER . 60.1 m-85 -107.6 120.66 42.84 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.704 0.288 . . . . 74.120000000000005 110.712 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 28.1 tp -107.15 99.14 8.7 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.16 -0.681 . . . . 73.109999999999999 109.16 176.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 37.3 t -95.38 140.76 16.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.26 -0.427 . . . . 63.409999999999997 111.436 -173.52 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . 0.486 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 43.8 tpt85 -81.82 110.97 17.61 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.495 -0.557 . . . . 73.109999999999999 109.495 178.23 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.425 ' HB2' HG12 ' A' ' 58' ' ' ILE . . . -70.03 -177.96 1.48 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.994 -0.548 . . . . 73.519999999999996 111.111 -177.286 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.733 ' HB2' ' HA ' ' B' ' 112' ' ' ASP . 9.1 p-10 -79.01 148.42 32.53 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.154 -0.475 . . . . 72.049999999999997 110.17 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 103.27 140.16 10.69 Favored Glycine 0 N--CA 1.439 -1.16 0 C-N-CA 120.571 -0.823 . . . . 64.010000000000005 112.675 174.026 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 20.7 m -69.13 -4.93 19.3 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.675 -0.262 . . . . 75.409999999999997 110.919 174.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -43.03 -48.07 5.97 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 123.556 0.743 . . . . 73.0 112.012 176.711 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.25 53.86 1.32 Allowed Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.608 -0.806 . . . . 65.329999999999998 112.46 178.275 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -127.17 148.96 50.17 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.095 0.474 . . . . 71.430000000000007 110.538 176.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.486 ' CZ ' ' HD3' ' A' ' 49' ' ' ARG . 40.2 m-85 -117.75 152.64 34.87 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.594 -0.73 . . . . 75.010000000000005 110.322 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.425 HG12 ' HB2' ' A' ' 50' ' ' ALA . 50.6 mm -121.26 127.07 75.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 109.914 -0.402 . . . . 73.230000000000004 109.914 179.753 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 65.0 mtp180 -78.55 139.2 38.64 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 110.144 -0.317 . . . . 70.5 110.144 175.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.481 ' HB2' ' HB2' ' A' ' 46' ' ' PHE . 63.2 m -73.05 -23.19 60.55 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.495 -0.321 . . . . 74.030000000000001 110.448 176.109 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.447 ' OD1' ' HB2' ' A' ' 45' ' ' TYR . 0.8 OUTLIER -61.79 -60.58 3.44 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 121.74 0.781 . . . . 74.010000000000005 109.414 175.918 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 -122.65 88.62 49.85 Favored Pre-proline 0 N--CA 1.445 -0.724 0 CA-C-N 114.538 -1.21 . . . . 75.120000000000005 109.817 -179.524 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.84 -9.19 20.24 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 123.165 2.577 . . . . 65.239999999999995 112.626 -178.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -78.37 -24.84 46.19 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.926 -0.579 . . . . 73.239999999999995 110.599 177.393 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.406 ' HA ' ' HD2' ' A' ' 65' ' ' LYS . 42.6 tptt -91.82 122.92 34.8 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.388 0.613 . . . . 74.519999999999996 111.395 -175.14 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.5 mp -96.59 119.38 34.98 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.09 -0.959 . . . . 74.510000000000005 109.642 176.243 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 50.7 mm -88.11 111.42 42.85 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 116.273 -0.421 . . . . 73.409999999999997 110.023 178.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.418 ' O ' HG23 ' A' ' 72' ' ' ILE . 72.7 Cg_endo -74.16 176.72 9.18 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.563 2.175 . . . . 74.299999999999997 112.367 -177.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 28.4 tt0 -80.41 -6.24 57.76 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.859 -0.61 . . . . 71.219999999999999 111.334 -169.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -95.24 -12.14 26.76 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.409 -0.516 . . . . 73.420000000000002 110.433 176.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -103.12 -7.6 21.17 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.839 0.352 . . . . 71.340000000000003 110.795 -178.167 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.418 HG23 ' O ' ' A' ' 68' ' ' PRO . 45.7 pt -67.72 -27.74 39.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.846 0.355 . . . . 75.230000000000004 111.573 -178.24 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 24.3 p90 -101.27 34.49 2.54 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.372 0.605 . . . . 74.129999999999995 110.528 178.101 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 42.4 t -64.75 -26.98 68.59 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.43 -0.805 . . . . 73.349999999999994 110.212 176.161 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . 0.584 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 26.0 p-90 . . . . . 0 C--O 1.235 0.327 0 CA-C-N 116.436 -0.347 . . . . 74.439999999999998 111.048 177.309 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 16.9 m . . . . . 0 C--O 1.233 0.223 0 CA-C-O 120.833 0.349 . . . . 72.209999999999994 110.072 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 114.58 85.05 1.28 Allowed Glycine 0 N--CA 1.443 -0.864 0 C-N-CA 120.578 -0.82 . . . . 63.340000000000003 111.437 -176.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . 0.462 ' HA ' ' HD3' ' B' ' 111' ' ' PRO . 11.1 pt-20 -124.08 110.73 28.99 Favored Pre-proline 0 C--N 1.322 -0.618 0 CA-C-O 121.322 0.582 . . . . 72.049999999999997 109.558 -176.384 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.749 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 19.1 Cg_endo -89.52 131.35 2.01 Favored 'Trans proline' 0 N--CA 1.444 -1.4 0 C-N-CA 122.63 2.22 . . . . 75.329999999999998 112.604 -176.393 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . 0.733 ' HA ' ' HB2' ' A' ' 51' ' ' ASP . 4.2 p-10 -144.9 171.17 14.82 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.188 -0.671 . . . . 74.109999999999999 109.188 175.272 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.527 HG22 ' HB3' ' B' ' 124' ' ' GLN . 10.9 p -118.44 131.6 70.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.653 0.739 . . . . 75.140000000000001 112.096 -172.461 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 30.3 m -94.86 103.44 15.32 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.435 -0.802 . . . . 74.340000000000003 109.31 173.161 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.458 HG12 ' HG2' ' B' ' 124' ' ' GLN . 65.2 mt -90.57 106.44 17.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.245 -0.434 . . . . 72.099999999999994 110.823 -176.15 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -113.74 165.08 12.91 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.126 -0.488 . . . . 72.439999999999998 110.603 177.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -133.14 105.57 7.11 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.094 0.474 . . . . 74.310000000000002 110.468 178.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -109.85 88.75 2.82 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.904 -0.589 . . . . 72.430000000000007 110.191 -178.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 88.47 -119.8 5.47 Favored Glycine 0 N--CA 1.445 -0.734 0 CA-C-N 115.439 -0.8 . . . . 53.530000000000001 111.742 -177.377 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . 0.51 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 90.5 m-20 -101.37 6.29 42.57 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.73 0.3 . . . . 63.340000000000003 110.573 178.84 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.698 ' HE3' ' HB2' ' B' ' 175' ' ' TRP . 25.1 pttm -117.42 120.69 38.92 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.47 0.652 . . . . 72.420000000000002 111.692 -177.806 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 122' ' ' THR . . . . . 0.572 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 69.7 m -84.86 105.0 15.31 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.163 -0.926 . . . . 75.150000000000006 109.478 174.183 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . 0.647 HD13 ' HE2' ' B' ' 121' ' ' LYS . 33.2 mt -95.02 108.08 20.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 121.049 0.452 . . . . 74.310000000000002 110.531 -176.366 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.527 ' HB3' HG22 ' B' ' 113' ' ' VAL . 22.1 mt-30 -98.65 105.15 17.26 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.825 -0.625 . . . . 72.120000000000005 110.319 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -87.37 112.77 22.46 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.125 -0.488 . . . . 71.450000000000003 110.926 -179.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -90.09 111.14 22.16 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.205 -0.452 . . . . 72.230000000000004 110.028 176.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . 0.405 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 52.8 mtt-85 -128.33 138.1 52.23 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.313 -0.403 . . . . 75.340000000000003 110.346 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.749 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -101.86 -56.17 5.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.065 0.459 . . . . 71.510000000000005 111.201 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . 0.469 ' H ' HG11 ' B' ' 128' ' ' VAL . 6.7 t-20 -122.66 42.03 3.28 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.761 0.791 . . . . 65.340000000000003 109.103 -178.029 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 92.31 -28.72 8.51 Favored Glycine 0 N--CA 1.448 -0.563 0 CA-C-N 115.086 -0.961 . . . . 64.319999999999993 112.099 -178.087 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 33.8 t80 -84.59 135.57 34.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.934 0.397 . . . . 74.439999999999998 110.318 -175.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.825 HD12 HG13 ' B' ' 135' ' ' ILE . 3.3 tm? -76.75 117.59 18.53 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.327 -0.851 . . . . 75.140000000000001 109.966 179.068 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 40.0 p90 -112.26 -14.96 13.27 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.521 -0.471 . . . . 72.010000000000005 111.571 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.11 141.61 12.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.848 0.356 . . . . 70.510000000000005 111.169 178.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.825 HG13 HD12 ' B' ' 132' ' ' LEU . 75.3 mt -125.14 121.61 61.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.188 -0.46 . . . . 73.230000000000004 109.935 175.713 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -104.37 98.5 8.28 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 108.821 -0.807 . . . . 74.430000000000007 108.821 171.512 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.525 ' O ' ' HD3' ' B' ' 139' ' ' PRO . 3.5 p -98.21 128.67 49.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-O 121.142 0.496 . . . . 74.409999999999997 109.916 179.374 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.572 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 40.8 t -108.03 84.82 2.28 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.31 -0.859 . . . . 72.129999999999995 109.69 179.083 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.525 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 62.5 Cg_endo -88.7 132.33 2.45 Favored 'Trans proline' 0 N--CA 1.443 -1.464 0 C-N-CA 122.459 2.106 . . . . 75.140000000000001 111.885 178.411 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . 0.51 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 55.0 mtpt -65.37 -15.81 62.96 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.701 -0.681 . . . . 74.409999999999997 109.808 176.229 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 64.4 m-70 -117.47 89.52 3.13 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-N 115.174 -0.921 . . . . 75.540000000000006 109.289 178.413 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 127.87 -18.35 5.94 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.724 -0.751 . . . . 74.019999999999996 112.555 -178.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 89.1 mttt 72.98 148.94 0.12 Allowed Pre-proline 0 N--CA 1.472 0.649 0 C-N-CA 123.557 0.743 . . . . 73.299999999999997 111.736 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.509 ' HB3' HG22 ' B' ' 138' ' ' VAL . 34.9 Cg_endo -65.12 149.26 89.24 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.936 2.424 . . . . 74.400000000000006 113.375 -176.433 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . 0.421 ' HE2' HD12 ' B' ' 147' ' ' LEU . 3.9 p90 -160.3 160.43 32.51 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.534 -0.757 . . . . 72.150000000000006 109.59 178.178 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.546 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 55.0 m-85 -94.55 128.84 41.42 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.457 -0.338 . . . . 74.439999999999998 110.216 176.687 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . 0.43 ' HG ' ' HB3' ' B' ' 157' ' ' PHE . 15.8 tp -110.36 99.8 8.76 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 108.931 -0.766 . . . . 74.420000000000002 108.931 174.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.3 t -93.77 139.28 18.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.988 -0.551 . . . . 73.5 111.047 -173.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 11.6 tpt180 -72.02 131.06 42.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.199 -0.455 . . . . 72.319999999999993 111.245 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -93.34 162.22 14.08 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.372 -0.603 . . . . 75.140000000000001 109.372 171.306 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -68.69 138.24 54.78 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.966 0.412 . . . . 72.299999999999997 110.537 -177.548 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.1 147.45 15.01 Favored Glycine 0 N--CA 1.437 -1.28 0 C-N-CA 120.491 -0.861 . . . . 72.25 112.048 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 11.1 t -87.0 23.88 1.66 Allowed 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 121.253 0.549 . . . . 63.140000000000001 110.015 175.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -65.17 -29.45 70.28 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.571 -0.74 . . . . 72.150000000000006 110.59 179.01 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 94.44 37.92 5.18 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.891 -0.671 . . . . 71.049999999999997 111.641 -177.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . 0.89 HD22 HD21 ' B' ' 166' ' ' LEU . 40.7 t30 -110.85 130.51 55.56 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.836 0.351 . . . . 75.219999999999999 110.69 -177.457 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . 0.43 ' HB3' ' HG ' ' B' ' 147' ' ' LEU . 27.1 m-85 -126.71 161.0 29.15 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.002 -0.545 . . . . 72.239999999999995 110.269 178.198 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . 0.763 HD13 HD23 ' B' ' 166' ' ' LEU . 39.9 mm -118.38 141.05 39.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.458 -0.337 . . . . 73.120000000000005 110.603 -179.63 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.769 ' HD2' HD12 ' B' ' 167' ' ' ILE . 34.1 mtp-105 -96.23 145.68 25.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.394 -0.366 . . . . 75.400000000000006 110.925 -178.098 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 160' ' ' SER . . . . . 0.546 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 25.8 p -74.96 -15.16 60.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.26 0.552 . . . . 74.239999999999995 110.679 175.098 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -78.66 -30.79 46.47 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.118 -0.492 . . . . 72.530000000000001 110.38 177.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -159.19 98.02 1.63 Allowed Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.781 -0.645 . . . . 75.420000000000002 110.224 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.62 -13.03 34.41 Favored 'Trans proline' 0 CA--C 1.529 0.231 0 C-N-CA 122.991 2.461 . . . . 73.329999999999998 112.844 -179.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -77.66 -19.38 55.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.86 0.362 . . . . 71.329999999999998 111.022 177.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 51.7 tptt -94.07 122.61 36.76 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.409 0.623 . . . . 71.120000000000005 111.132 -177.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . 0.89 HD21 HD22 ' B' ' 156' ' ' ASN . 20.4 mt -90.57 128.02 36.45 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.598 -1.183 . . . . 73.400000000000006 108.832 176.734 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . 0.769 HD12 ' HD2' ' B' ' 159' ' ' ARG . 46.1 mm -98.77 112.08 61.89 Favored Pre-proline 0 C--N 1.318 -0.778 0 CA-C-O 120.65 0.262 . . . . 72.049999999999997 110.832 -178.151 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.528 ' O ' HG22 ' B' ' 172' ' ' ILE . 68.6 Cg_endo -73.5 175.23 10.94 Favored 'Trans proline' 0 N--CA 1.464 -0.263 0 C-N-CA 122.775 2.317 . . . . 75.340000000000003 112.611 -179.421 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . 0.501 ' O ' HG12 ' B' ' 172' ' ' ILE . 28.0 tt0 -69.65 -25.48 63.94 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.703 -0.681 . . . . 74.439999999999998 112.325 -168.488 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 30.6 p90 -81.09 -12.07 59.36 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 120.182 -0.607 . . . . 74.439999999999998 110.303 178.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.527 ' HB3' HG23 ' B' ' 167' ' ' ILE . 3.9 mt-10 -106.79 -19.27 13.7 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.157 -0.474 . . . . 73.430000000000007 111.892 -178.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.528 HG22 ' O ' ' B' ' 168' ' ' PRO . 43.6 pt -64.51 -26.36 40.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.244 0.545 . . . . 73.409999999999997 110.681 177.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -105.3 48.56 0.83 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.612 -0.722 . . . . 72.129999999999995 109.782 174.4 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 16.6 t -71.06 -15.39 62.54 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.806 -0.634 . . . . 73.409999999999997 110.17 179.379 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . 0.698 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 4.5 p-90 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.249 -0.882 . . . . 73.25 110.519 178.305 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 27.0 m . . . . . 0 C--O 1.23 0.059 0 CA-C-O 121.66 0.743 . . . . 73.239999999999995 110.374 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -135.18 102.99 0.45 Allowed Glycine 0 N--CA 1.442 -0.957 0 N-CA-C 110.108 -1.197 . . . . 75.109999999999999 110.108 177.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -119.99 94.71 48.81 Favored Pre-proline 0 C--N 1.319 -0.743 0 CA-C-O 121.261 0.553 . . . . 74.329999999999998 110.401 -175.069 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.869 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 51.6 Cg_endo -77.56 81.79 2.57 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 121.913 1.742 . . . . 74.340000000000003 111.265 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -100.48 168.26 9.85 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.339 -0.615 . . . . 73.450000000000003 109.339 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.66 HG21 ' HB3' ' A' ' 24' ' ' GLN . 8.3 p -125.65 131.41 72.06 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-O 121.253 0.549 . . . . 55.140000000000001 111.387 -175.177 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.5 m -89.51 121.14 31.44 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.679 -0.691 . . . . 72.540000000000006 109.423 176.34 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 52.9 mt -91.58 109.09 20.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 120.834 0.349 . . . . 72.040000000000006 111.161 -175.382 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 38.3 mmt180 -105.51 165.7 10.96 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 73.319999999999993 109.867 176.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 40.1 mt-30 -138.95 122.57 17.43 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.768 0.318 . . . . 75.349999999999994 111.147 177.007 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -124.97 96.93 5.05 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.793 -0.639 . . . . 73.040000000000006 109.524 176.212 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.24 -106.49 1.8 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.476 -0.869 . . . . 75.349999999999994 111.719 -178.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.58 ' HB3' ' HB2' ' A' ' 40' ' ' LYS . 7.0 m-20 -111.35 6.26 20.31 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 121.156 -0.217 . . . . 62.310000000000002 111.537 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.656 ' HB3' ' HB3' ' A' ' 39' ' ' PRO . 0.0 OUTLIER -110.94 122.49 48.01 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 119.917 -0.713 . . . . 74.329999999999998 111.472 177.422 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.44 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 42.4 m -83.42 101.28 11.26 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 114.961 -1.018 . . . . 70.150000000000006 108.983 173.174 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.455 HG12 HG11 ' A' ' 37' ' ' VAL . 61.3 mt -90.82 109.86 21.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.153 0.502 . . . . 74.209999999999994 110.291 -175.789 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.66 ' HB3' HG21 ' A' ' 13' ' ' VAL . 14.6 mt-30 -99.78 119.45 38.18 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.787 -0.642 . . . . 73.219999999999999 111.021 -175.562 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -94.31 108.73 20.6 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.825 -0.625 . . . . 75.129999999999995 110.559 -178.001 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.521 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 33.5 m-85 -86.62 114.82 23.65 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.923 0.392 . . . . 75.120000000000005 111.051 -179.587 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.421 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 68.3 mtm180 -131.03 126.64 36.43 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.018 -0.537 . . . . 73.120000000000005 110.416 179.295 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.869 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.3 p -91.07 -28.83 4.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.063 -0.517 . . . . 74.219999999999999 111.242 -176.52 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -173.61 69.68 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.626 -0.509 . . . . 73.209999999999994 109.626 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.98 -24.59 5.19 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.817 -0.629 . . . . 74.409999999999997 112.642 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.63 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 88.4 t80 -97.26 128.43 44.11 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.869 0.366 . . . . 75.25 111.057 -176.2 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.599 HD12 HG13 ' A' ' 35' ' ' ILE . 3.2 tm? -79.24 109.73 13.85 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.803 -0.814 . . . . 72.400000000000006 108.803 175.194 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 41.7 p90 -106.0 -13.87 15.35 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.513 -0.475 . . . . 63.32 111.467 -176.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -162.11 149.49 14.12 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.069 0.461 . . . . 74.319999999999993 111.62 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.599 HG13 HD12 ' A' ' 32' ' ' LEU . 70.1 mt -126.07 128.12 71.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.659 -0.701 . . . . 72.510000000000005 109.681 174.669 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.61 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 81.5 tttt -112.01 105.15 13.47 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.306 -0.406 . . . . 74.530000000000001 110.084 179.159 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.708 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 4.4 t -89.64 126.71 42.55 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 108.765 -0.828 . . . . 74.140000000000001 108.765 177.379 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.44 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 20.1 t -114.43 73.98 2.91 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 109.883 -0.414 . . . . 75.450000000000003 109.883 172.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.689 ' HD3' HG12 ' A' ' 37' ' ' VAL . 39.8 Cg_endo -77.52 132.11 11.99 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.094 1.862 . . . . 65.420000000000002 112.648 176.377 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.58 ' HB2' ' HB3' ' A' ' 20' ' ' ASP . 50.4 mtpt -60.76 -28.22 68.55 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.535 -0.757 . . . . 73.340000000000003 110.316 175.24 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 74.2 m-70 -118.03 94.63 4.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.325 -0.852 . . . . 75.150000000000006 108.763 178.026 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.418 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 134.04 -31.22 2.84 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.492 -0.776 . . . . 73.319999999999993 111.544 -175.038 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.469 ' HA ' ' HD3' ' A' ' 43' ' ' LYS . 31.5 mmtp 74.23 153.65 0.15 Allowed Pre-proline 0 N--CA 1.469 0.501 0 C-N-CA 123.557 0.743 . . . . 72.430000000000007 112.254 177.243 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.708 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 28.3 Cg_endo -62.86 132.52 37.54 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 123.074 2.516 . . . . 74.340000000000003 114.2 -173.485 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -140.0 154.55 47.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.456 -0.793 . . . . 72.129999999999995 109.884 175.364 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -107.01 136.98 45.95 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-O 120.763 0.316 . . . . 73.420000000000002 111.574 -175.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.582 HD23 ' HA ' ' A' ' 59' ' ' ARG . 47.7 mt -118.38 107.78 14.25 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.851 -0.613 . . . . 75.030000000000001 109.858 171.431 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 47.3 t -95.46 134.92 31.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.628 -0.26 . . . . 63.43 110.398 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . 0.626 ' HD2' ' HA ' ' A' ' 53' ' ' SER . 16.1 tpp85 -68.7 122.04 17.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.808 0.337 . . . . 75.140000000000001 110.123 177.211 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -73.6 158.35 34.95 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.136 -0.483 . . . . 74.25 110.784 179.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -53.49 143.55 19.26 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 115.765 -0.652 . . . . 63.140000000000001 111.194 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.28 -33.84 5.36 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.772 -0.728 . . . . 73.219999999999999 111.99 -178.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.626 ' HA ' ' HD2' ' A' ' 49' ' ' ARG . 17.4 t 63.02 38.3 11.06 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-O 121.009 0.433 . . . . 75.129999999999995 110.992 178.776 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -76.44 -3.67 38.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.526 0.679 . . . . 73.349999999999994 110.815 -178.468 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 111.54 2.53 27.46 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.617 -0.801 . . . . 54.200000000000003 111.692 -179.038 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -85.89 134.59 33.89 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.051 0.453 . . . . 73.219999999999999 110.497 178.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -116.04 144.19 44.45 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.82 -0.627 . . . . 72.409999999999997 110.109 176.095 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.2 mm -105.75 105.43 18.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 CA-C-O 121.564 0.697 . . . . 73.219999999999999 109.368 176.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.699 ' HB2' HG13 ' A' ' 67' ' ' ILE . 24.0 ttt180 -69.56 119.78 14.34 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 114.631 -1.168 . . . . 71.540000000000006 109.461 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.5 t -63.05 -18.56 63.49 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.396 0.617 . . . . 71.219999999999999 110.404 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.674 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 24.7 t70 -73.96 -28.42 61.48 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.449 -0.796 . . . . 74.5 110.489 175.61 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -142.79 68.5 19.09 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-N 115.424 -0.807 . . . . 65.140000000000001 109.191 -177.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . 0.487 ' HG3' ' HG ' ' B' ' 160' ' ' SER . 7.3 Cg_exo -71.06 -11.5 29.18 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 123.256 2.637 . . . . 75.230000000000004 112.998 -171.757 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -95.47 4.76 52.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.493 0.663 . . . . 73.219999999999999 109.758 -178.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -131.96 137.35 47.88 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.6 -0.727 . . . . 70.549999999999997 110.753 -178.038 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.475 ' N ' HD13 ' A' ' 66' ' ' LEU . 4.5 mp -85.02 131.44 34.46 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.049 -0.523 . . . . 75.120000000000005 109.65 179.678 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.699 HG13 ' HB2' ' A' ' 59' ' ' ARG . 40.6 mm -89.71 129.1 47.95 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-O 120.933 0.397 . . . . 71.510000000000005 111.305 -174.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -76.28 176.59 9.86 Favored 'Trans proline' 0 N--CA 1.459 -0.505 0 C-N-CA 122.862 2.374 . . . . 71.439999999999998 112.514 178.15 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . 0.671 ' HA ' HG12 ' A' ' 72' ' ' ILE . 6.4 tt0 -79.41 -31.62 42.72 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.61 -0.723 . . . . 74.109999999999999 112.184 -170.653 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 28.3 p90 -69.42 -19.39 63.8 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 120.184 -0.607 . . . . 71.530000000000001 110.384 178.421 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -84.84 -35.45 22.26 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.852 -0.613 . . . . 73.239999999999995 110.179 178.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.671 HG12 ' HA ' ' A' ' 69' ' ' GLN . 41.2 pt -76.24 -21.79 15.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.116 0 CA-C-O 120.965 0.412 . . . . 74.420000000000002 110.878 179.843 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 31.4 m-85 -103.63 28.47 6.52 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.077 -0.511 . . . . 74.120000000000005 110.926 176.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 11.1 t -84.93 45.22 1.14 Allowed 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.864 0.84 . . . . 71.219999999999999 109.616 178.352 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 11.3 m0 . . . . . 0 C--N 1.324 -0.521 0 CA-C-N 115.124 -0.944 . . . . 74.450000000000003 110.729 -178.83 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 6.3 p . . . . . 0 N--CA 1.452 -0.358 0 CA-C-O 121.041 0.448 . . . . 74.420000000000002 109.998 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 128.05 76.89 0.21 Allowed Glycine 0 N--CA 1.445 -0.701 0 N-CA-C 110.891 -0.884 . . . . 74.049999999999997 110.891 -175.555 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -110.16 105.77 57.47 Favored Pre-proline 0 C--N 1.32 -0.703 0 N-CA-C 109.138 -0.69 . . . . 71.040000000000006 109.138 -175.371 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.758 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 46.1 Cg_endo -82.23 86.35 1.54 Allowed 'Trans proline' 0 N--CA 1.439 -1.734 0 C-N-CA 121.898 1.732 . . . . 70.230000000000004 110.959 -178.021 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -101.81 155.63 18.02 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 114.258 -1.337 . . . . 74.010000000000005 109.92 -175.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.594 ' HA ' ' O ' ' B' ' 125' ' ' GLU . 7.6 p -117.65 130.71 72.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.474 0.655 . . . . 75.430000000000007 111.104 -177.707 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 52.0 m -104.7 122.05 44.85 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.401 -0.818 . . . . 65.420000000000002 109.996 178.636 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 47.3 mt -87.09 108.03 17.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 116.145 -0.479 . . . . 72.129999999999995 111.443 -174.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -101.15 170.73 8.06 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.469 -0.567 . . . . 65.409999999999997 109.469 175.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -142.76 138.76 30.7 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.782 0.325 . . . . 75.109999999999999 110.786 175.532 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -135.52 104.58 5.87 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.638 -0.71 . . . . 75.109999999999999 109.754 176.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.62 -110.14 3.31 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.908 -0.663 . . . . 73.129999999999995 111.898 -177.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . 0.598 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 9.5 m-20 -97.06 -19.33 18.79 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.705 0.288 . . . . 74.200000000000003 110.977 -179.147 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.586 ' HB3' ' HA ' ' B' ' 139' ' ' PRO . 49.3 pttt -100.88 141.75 33.33 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.6 0.714 . . . . 74.120000000000005 112.503 -170.088 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 122' ' ' THR . . . . . 0.588 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 47.9 m -91.77 138.43 31.56 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 114.828 -1.078 . . . . 73.409999999999997 109.646 176.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 65.9 mt -124.89 106.56 16.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 120.984 0.421 . . . . 71.430000000000007 110.276 -178.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.542 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 18.7 mt-30 -96.91 117.19 30.57 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.918 0.39 . . . . 64.25 111.092 -176.081 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . 0.594 ' O ' ' HA ' ' B' ' 113' ' ' VAL . 43.2 mt-10 -83.02 114.15 21.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.736 -0.665 . . . . 74.230000000000004 110.947 179.299 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . 0.433 ' HB2' ' O ' ' B' ' 134' ' ' ALA . 41.2 m-85 -92.75 97.33 10.71 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.493 -0.558 . . . . 70.239999999999995 109.493 170.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . 0.445 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 21.8 mtm105 -121.08 127.41 51.63 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.803 -0.635 . . . . 74.040000000000006 110.071 179.375 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.758 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 6.0 p -87.97 -37.5 10.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.097 0.475 . . . . 71.540000000000006 110.834 -176.541 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -160.27 62.86 0.33 Allowed 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.292 0.568 . . . . 73.099999999999994 109.69 -178.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.0 -26.57 6.63 Favored Glycine 0 N--CA 1.446 -0.664 0 CA-C-N 115.404 -0.816 . . . . 70.409999999999997 112.734 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -99.12 130.81 45.46 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.014 0.435 . . . . 72.129999999999995 110.56 -175.342 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.766 HD12 HG13 ' B' ' 135' ' ' ILE . 3.2 tm? -78.06 118.62 20.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.263 -0.881 . . . . 72.409999999999997 109.615 178.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . 0.402 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 51.4 p90 -109.3 -22.27 12.14 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 120.748 -0.381 . . . . 75.319999999999993 111.34 178.24 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . 0.433 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -156.14 147.81 22.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.39 . . . . 75.239999999999995 111.12 179.517 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.766 HG13 HD12 ' B' ' 132' ' ' LEU . 75.4 mt -125.47 130.68 72.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.152 -0.476 . . . . 65.239999999999995 109.723 175.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.542 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 46.6 tttp -106.46 106.82 17.52 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.383 -0.599 . . . . 74.349999999999994 109.383 174.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.676 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.0 t -91.51 136.05 25.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 N-CA-C 109.024 -0.732 . . . . 74.129999999999995 109.024 178.583 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.588 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 22.0 t -121.85 73.33 34.29 Favored Pre-proline 0 C--N 1.318 -0.762 0 N-CA-C 109.483 -0.562 . . . . 75.109999999999999 109.483 173.298 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.591 ' HD3' HG13 ' B' ' 137' ' ' VAL . 53.2 Cg_endo -78.52 134.64 12.57 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 122.183 1.922 . . . . 74.450000000000003 112.931 176.601 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . 0.598 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 30.8 mtpp -62.94 -30.93 71.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.638 0.732 . . . . 71.430000000000007 109.547 174.222 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 72.8 m-70 -112.99 89.89 3.2 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.043 -0.981 . . . . 75.120000000000005 109.392 176.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 138.7 -21.52 3.04 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.621 -0.8 . . . . 75.299999999999997 112.328 -178.207 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 33.4 mmtp 69.59 150.8 0.13 Allowed Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 123.2 0.6 . . . . 73.409999999999997 111.524 178.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.676 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 19.3 Cg_endo -59.8 140.3 92.6 Favored 'Trans proline' 0 C--O 1.235 0.336 0 C-N-CA 122.575 2.183 . . . . 75.540000000000006 113.278 -177.244 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 38.9 p90 -155.33 151.06 27.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.924 -0.58 . . . . 74.310000000000002 110.307 178.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.485 ' HB2' ' HB2' ' B' ' 160' ' ' SER . 87.2 m-85 -95.35 139.32 31.82 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.171 -0.468 . . . . 75.319999999999993 111.166 179.453 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . 0.404 ' HB3' ' CD2' ' B' ' 157' ' ' PHE . 39.5 mt -116.27 110.29 18.55 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.634 -0.712 . . . . 74.439999999999998 109.693 170.316 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 41.7 t -95.23 132.91 37.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.579 -0.282 . . . . 74.219999999999999 110.953 -178.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . 0.405 HH11 ' HG2' ' B' ' 149' ' ' ARG . 17.0 tpp85 -70.46 113.63 7.77 Favored 'General case' 0 N--CA 1.452 -0.338 0 N-CA-C 109.895 -0.409 . . . . 74.319999999999993 109.895 175.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.65 155.44 35.91 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 116.094 -0.503 . . . . 74.239999999999995 111.202 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . 0.521 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 3.4 p-10 -56.9 138.79 53.31 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.551 -0.749 . . . . 72.0 112.132 -177.418 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 93.74 -11.24 71.46 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.213 -0.903 . . . . 65.5 112.648 176.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 2.3 t 57.58 50.33 11.19 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-O 121.692 0.758 . . . . 72.400000000000006 109.391 -177.618 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -73.51 -8.45 55.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 114.885 -1.052 . . . . 72.450000000000003 111.876 -175.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 90.96 18.32 47.66 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.5 -0.857 . . . . 63.439999999999998 111.175 -174.089 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . 0.633 HD22 HD21 ' B' ' 166' ' ' LEU . 36.5 t30 -119.88 137.47 54.0 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.914 -0.643 . . . . 73.400000000000006 110.058 -178.322 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . 0.404 ' CD2' ' HB3' ' B' ' 147' ' ' LEU . 42.3 m-85 -113.56 159.93 19.07 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.167 -0.469 . . . . 75.439999999999998 110.166 177.666 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . 0.684 HD13 HD23 ' B' ' 166' ' ' LEU . 45.7 mm -121.9 119.07 57.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 109.442 -0.577 . . . . 75.310000000000002 109.442 175.061 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . . . . . . . . . 36.2 mtt180 -71.14 140.16 50.49 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.213 -0.448 . . . . 75.040000000000006 110.09 176.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 160' ' ' SER . . . . . 0.487 ' HG ' ' HG3' ' A' ' 63' ' ' PRO . 7.4 t -80.82 1.06 32.21 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.617 -0.883 . . . . 64.549999999999997 108.617 169.702 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.53 -23.12 15.65 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.561 -1.199 . . . . 73.219999999999999 109.884 174.567 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -144.71 67.83 14.24 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 115.099 -0.955 . . . . 73.109999999999999 109.559 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -75.34 -12.97 20.86 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 123.162 2.575 . . . . 73.319999999999993 113.346 -173.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -87.89 -12.5 44.6 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.581 0.705 . . . . 65.519999999999996 109.504 178.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 48.8 mtpt -105.46 170.45 7.88 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.406 -0.815 . . . . 75.099999999999994 111.459 -177.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . 0.684 HD23 HD13 ' B' ' 158' ' ' ILE . 17.8 mt -117.48 125.46 50.93 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.423 -0.954 . . . . 73.439999999999998 108.423 177.21 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . 0.529 ' CG2' ' HB3' ' B' ' 171' ' ' GLU . 36.5 mm -80.95 116.37 62.01 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-O 121.275 0.56 . . . . 75.450000000000003 111.835 -169.798 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.53 -179.46 2.82 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.58 2.853 . . . . 74.239999999999995 112.781 -178.227 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . 0.795 ' HA ' HG12 ' B' ' 172' ' ' ILE . 3.7 tt0 -79.23 -32.35 43.87 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.07 -0.514 . . . . 71.099999999999994 111.386 -170.367 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 11.4 p90 -68.21 -17.09 64.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.088 0.471 . . . . 74.140000000000001 110.231 178.09 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.529 ' HB3' ' CG2' ' B' ' 167' ' ' ILE . 1.2 tm-20 -91.12 -43.69 9.73 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.577 -0.738 . . . . 73.530000000000001 110.211 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.795 HG12 ' HA ' ' B' ' 169' ' ' GLN . 44.1 pt -68.61 -25.35 30.62 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.168 -0.469 . . . . 74.540000000000006 111.06 -179.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . 0.458 ' C ' ' H ' ' B' ' 175' ' ' TRP . 30.9 m-85 -111.14 30.45 6.88 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.18 0.514 . . . . 73.099999999999994 110.563 176.617 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 25.1 t -79.03 22.44 0.39 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.866 -0.607 . . . . 73.040000000000006 110.652 178.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . 0.458 ' H ' ' C ' ' B' ' 173' ' ' PHE . 12.9 m95 . . . . . 0 C--O 1.248 1.018 0 CA-C-O 118.271 -0.871 . . . . 73.409999999999997 110.509 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 20.3 m . . . . . 0 N--CA 1.453 -0.319 0 N-CA-C 109.567 -0.531 . . . . 72.420000000000002 109.567 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.461 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 95.42 70.19 1.06 Allowed Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 110.53 -1.028 . . . . 74.5 110.53 -173.129 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -98.48 102.65 15.12 Favored Pre-proline 0 C--N 1.325 -0.482 0 N-CA-C 109.348 -0.612 . . . . 64.420000000000002 109.348 -177.321 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.546 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 53.4 Cg_endo -91.14 97.24 0.23 Allowed 'Trans proline' 0 N--CA 1.441 -1.571 0 C-N-CA 122.572 2.181 . . . . 64.0 112.135 -175.008 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -103.05 114.18 28.27 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-N 115.365 -0.834 . . . . 74.109999999999999 109.859 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.621 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 9.1 p -77.1 127.12 38.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 CA-C-N 115.681 -0.69 . . . . 74.409999999999997 109.97 179.478 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.638 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 24.5 m -84.22 103.1 13.14 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.848 -0.614 . . . . 72.030000000000001 110.078 -178.063 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 65.5 mt -90.84 107.95 19.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.06 -0.518 . . . . 74.019999999999996 110.571 -176.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . 0.499 ' HG2' ' O ' ' A' ' 23' ' ' ILE . 12.7 ptm180 -121.96 174.4 6.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.871 -0.604 . . . . 75.299999999999997 109.786 179.066 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -133.08 104.38 6.49 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 116.223 -0.444 . . . . 72.540000000000006 110.089 -177.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 58.5 mm-40 -103.49 80.1 1.77 Allowed 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 120.969 0.414 . . . . 75.099999999999994 110.205 -178.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 78.35 -106.16 2.27 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.797 -0.716 . . . . 72.549999999999997 112.428 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.891 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 6.9 m-20 -108.63 34.88 3.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.792 0.329 . . . . 74.120000000000005 110.831 -178.249 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.817 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 20.5 pttm -154.2 124.04 6.73 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.157 0.503 . . . . 75.140000000000001 111.46 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.436 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 62.3 m -82.02 105.89 13.49 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.624 -0.716 . . . . 74.340000000000003 109.36 174.036 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.572 HG12 HG11 ' A' ' 37' ' ' VAL . 61.1 mt -97.59 113.68 32.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.046 0.45 . . . . 72.439999999999998 110.687 -176.484 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.672 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 17.9 mt-30 -100.58 109.19 21.26 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.738 -0.664 . . . . 71.230000000000004 110.329 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.638 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.1 mt-10 -91.69 104.25 16.74 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.064 -0.517 . . . . 74.329999999999998 110.853 -178.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.541 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 54.0 m-85 -73.26 106.73 5.22 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.174 -0.467 . . . . 74.230000000000004 110.753 179.463 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.44 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 59.9 mtt180 -129.24 133.7 47.64 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.552 -0.536 . . . . 74.230000000000004 109.552 177.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.546 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 6.4 p -104.34 -41.47 6.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 121.272 0.558 . . . . 74.340000000000003 110.721 -179.105 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 54.5 m-20 -140.94 56.83 1.56 Allowed 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.708 -0.678 . . . . 74.040000000000006 109.626 178.463 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.21 -32.67 4.04 Favored Glycine 0 N--CA 1.451 -0.322 0 CA-C-N 115.385 -0.825 . . . . 72.430000000000007 113.242 177.614 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -90.32 132.2 35.69 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.001 0.429 . . . . 74.430000000000007 110.654 -174.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.556 HD11 ' HB3' ' A' ' 25' ' ' GLU . 33.2 tp -77.92 114.3 16.64 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.395 -0.82 . . . . 63.43 110.599 179.306 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . 0.517 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 35.4 p90 -106.34 -6.64 18.18 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.774 -0.37 . . . . 74.129999999999995 111.809 -178.376 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -171.84 142.91 1.57 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.842 0.353 . . . . 74.439999999999998 111.256 -178.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.444 HD11 HD21 ' A' ' 47' ' ' LEU . 61.9 mt -117.77 127.4 75.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.249 -0.432 . . . . 72.420000000000002 110.179 176.089 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.672 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.8 tttt -111.65 103.48 11.79 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 109.446 -0.576 . . . . 73.329999999999998 109.446 175.036 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.754 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 3.7 t -96.77 134.52 34.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 N-CA-C 109.309 -0.626 . . . . 53.310000000000002 109.309 -178.551 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.625 HG23 ' HB3' ' A' ' 44' ' ' PRO . 21.7 t -114.22 74.21 2.8 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 109.317 -0.623 . . . . 75.299999999999997 109.317 170.759 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.478 ' HD3' HG12 ' A' ' 37' ' ' VAL . 42.4 Cg_endo -74.0 142.81 31.79 Favored 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 122.039 1.826 . . . . 74.129999999999995 112.764 179.118 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.891 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 61.0 mtpt -64.39 -17.13 63.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.134 -0.939 . . . . 71.129999999999995 110.913 176.72 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -128.99 88.3 2.69 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.662 -0.699 . . . . 74.540000000000006 110.215 -178.643 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.404 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 135.23 -16.06 4.18 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.288 -0.958 . . . . 74.430000000000007 113.203 179.202 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.54 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 99.5 mttt 71.79 160.03 0.16 Allowed Pre-proline 0 N--CA 1.472 0.626 0 C-N-CA 122.755 0.422 . . . . 74.319999999999993 111.469 179.507 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.754 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 26.2 Cg_endo -63.57 141.62 80.82 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 122.491 2.127 . . . . 64.340000000000003 113.716 -176.48 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -145.71 155.23 42.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.717 -0.674 . . . . 75.129999999999995 110.212 177.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -99.72 132.91 44.76 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.305 -0.407 . . . . 74.120000000000005 110.994 178.144 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.444 HD21 HD11 ' A' ' 35' ' ' ILE . 40.1 tp -121.07 98.81 6.16 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.686 -0.688 . . . . 74.030000000000001 109.345 176.171 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 25.0 t -87.98 146.99 5.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.396 -0.366 . . . . 74.150000000000006 111.358 -172.205 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 10.0 tpt180 -81.23 122.92 28.01 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.848 -0.427 . . . . 73.319999999999993 109.848 177.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.417 ' HB1' ' OD1' ' A' ' 56' ' ' ASN . . . -74.86 161.94 29.1 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.208 -0.451 . . . . 73.230000000000004 110.862 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -66.78 145.54 55.4 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.135 0.493 . . . . 72.439999999999998 110.957 -177.6 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 88.67 -25.17 9.94 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.863 -0.608 . . . . 64.540000000000006 112.487 177.6 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 57.2 p 47.75 43.9 17.29 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.459 0.704 . . . . 74.420000000000002 112.058 -179.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -68.0 -33.0 73.79 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.453 0.644 . . . . 74.420000000000002 110.919 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 147.99 41.58 0.04 OUTLIER Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.582 -1.007 . . . . 61.409999999999997 110.582 -178.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . 0.417 ' OD1' ' HB1' ' A' ' 50' ' ' ALA . 11.5 p30 -140.52 152.65 45.73 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.18 0.514 . . . . 75.049999999999997 111.078 -172.805 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 36.3 m-85 -134.23 157.5 46.11 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.511 -0.768 . . . . 74.010000000000005 109.566 175.444 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.807 HD11 HD22 ' A' ' 66' ' ' LEU . 45.2 mm -115.23 108.07 24.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.253 0.549 . . . . 74.510000000000005 109.668 176.324 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.588 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 50.2 ttp180 -89.31 133.37 34.51 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.811 -0.631 . . . . 73.099999999999994 109.952 -177.057 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.1 p -58.21 -25.57 61.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.15 0.5 . . . . 74.219999999999999 111.168 178.644 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.588 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 0.6 OUTLIER -59.55 -39.13 83.0 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.508 -0.769 . . . . 75.230000000000004 111.379 174.275 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 21.5 tp60 -147.91 79.68 9.16 Favored Pre-proline 0 C--N 1.326 -0.454 0 N-CA-C 109.827 -0.434 . . . . 64.319999999999993 109.827 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -73.8 -8.0 20.81 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.381 2.054 . . . . 75.230000000000004 111.52 179.553 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.05 3.06 36.24 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.118 -0.946 . . . . 71.340000000000003 110.084 178.382 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -139.37 140.06 37.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.043 -0.526 . . . . 73.400000000000006 111.022 -174.291 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.807 HD22 HD11 ' A' ' 58' ' ' ILE . 38.1 mt -82.08 113.1 19.72 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 108.581 -0.896 . . . . 75.030000000000001 108.581 171.807 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.484 HG13 ' HB2' ' A' ' 59' ' ' ARG . 50.1 mm -65.34 122.76 81.78 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 116.271 -0.422 . . . . 73.109999999999999 110.964 -175.566 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.49 ' O ' HG23 ' A' ' 72' ' ' ILE . 72.8 Cg_endo -73.27 175.12 11.0 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 123.106 2.537 . . . . 73.209999999999994 113.014 -177.695 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . 0.722 ' HA ' HG12 ' A' ' 72' ' ' ILE . 6.7 tt0 -74.65 -29.5 61.28 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.693 -0.685 . . . . 75.25 112.323 -168.07 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 33.6 p90 -74.45 -16.23 60.87 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.598 -0.441 . . . . 74.510000000000005 110.23 178.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.463 ' HA ' ' HB2' ' A' ' 74' ' ' SER . 8.3 mm-40 -100.0 -29.29 12.63 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.727 -0.67 . . . . 74.430000000000007 111.615 -178.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.722 HG12 ' HA ' ' A' ' 69' ' ' GLN . 42.0 pt -68.22 -29.44 44.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.148 0.499 . . . . 73.140000000000001 110.595 177.188 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 48.5 m-85 -118.82 38.69 3.71 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.735 -0.666 . . . . 73.340000000000003 109.267 174.27 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.463 ' HB2' ' HA ' ' A' ' 71' ' ' GLU . 6.1 t -62.49 -36.38 82.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.35 -0.841 . . . . 74.239999999999995 110.461 -178.758 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . 0.817 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 6.1 p-90 . . . . . 0 C--N 1.326 -0.443 0 CA-C-N 115.93 -0.577 . . . . 72.310000000000002 110.948 177.289 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 35.0 m . . . . . 0 N--CA 1.454 -0.251 0 CA-C-O 121.605 0.717 . . . . 74.439999999999998 109.128 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 140.07 78.08 0.06 OUTLIER Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 109.965 -1.254 . . . . 60.409999999999997 109.965 -172.108 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -109.72 94.77 17.71 Favored Pre-proline 0 C--N 1.322 -0.6 0 N-CA-C 109.693 -0.484 . . . . 65.349999999999994 109.693 -172.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.594 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 54.9 Cg_endo -77.36 79.01 3.29 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 C-N-CA 121.538 1.492 . . . . 73.209999999999994 111.031 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -100.24 156.37 17.26 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 114.747 -1.115 . . . . 74.400000000000006 109.184 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.702 HG21 ' HB3' ' B' ' 124' ' ' GLN . 8.8 p -112.94 127.76 70.02 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.812 0 CA-C-O 121.72 0.771 . . . . 74.109999999999999 111.738 -175.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 114' ' ' THR . . . . . 0.523 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.3 m -92.01 106.94 18.85 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.022 -0.99 . . . . 75.129999999999995 109.529 175.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.8 mt -90.8 115.5 30.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 120.699 0.285 . . . . 62.539999999999999 111.274 -175.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 41.4 mtm180 -115.39 165.81 12.56 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.178 -0.465 . . . . 74.349999999999994 110.712 175.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 96.8 mt-30 -129.44 108.79 10.55 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.197 -0.456 . . . . 74.299999999999997 110.18 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . 0.441 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 45.8 mm-40 -108.4 89.88 3.13 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.551 -0.536 . . . . 65.109999999999999 109.551 -178.441 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 83.68 -102.95 2.5 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 110.929 -0.869 . . . . 72.129999999999995 110.929 -172.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . 0.546 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 30.8 m-20 -117.73 -18.17 9.69 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.756 0.312 . . . . 74.230000000000004 110.784 175.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.441 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 23.4 pttm -78.36 126.73 31.19 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.257 0.551 . . . . 71.310000000000002 110.861 -175.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 122' ' ' THR . . . . . 0.581 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 22.8 m -84.72 106.34 16.19 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.502 -0.772 . . . . 72.430000000000007 109.468 178.085 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . 0.429 HG12 HG12 ' B' ' 137' ' ' VAL . 28.4 mt -101.42 110.37 28.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 121.374 0.607 . . . . 74.450000000000003 110.631 -174.685 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.702 ' HB3' HG21 ' B' ' 113' ' ' VAL . 19.9 mt-30 -102.29 111.54 23.87 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.354 -0.839 . . . . 75.040000000000006 111.144 -175.511 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . 0.557 ' HB3' HD12 ' B' ' 132' ' ' LEU . 43.0 mt-10 -89.79 107.84 19.34 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.13 -0.486 . . . . 64.530000000000001 110.948 179.764 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . 0.439 ' HE1' ' HB2' ' B' ' 136' ' ' LYS . 58.3 m-85 -84.44 110.9 19.0 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.767 0.318 . . . . 74.299999999999997 110.338 177.553 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 69.6 mtt180 -123.42 116.13 22.73 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.844 0.354 . . . . 74.120000000000005 110.31 -178.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.594 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.4 p -82.83 -45.71 19.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.065 -0.516 . . . . 75.540000000000006 111.904 -177.434 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -158.99 74.08 0.63 Allowed 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 120.742 -0.383 . . . . 74.239999999999995 110.319 -174.243 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 64.2 23.81 68.36 Favored Glycine 0 C--N 1.33 0.232 0 C-N-CA 121.028 -0.606 . . . . 41.240000000000002 112.065 -178.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -145.91 124.93 12.78 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.876 -0.416 . . . . 72.430000000000007 109.876 -179.236 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.557 HD12 ' HB3' ' B' ' 125' ' ' GLU . 50.0 tp -83.06 113.01 20.31 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.791 -0.64 . . . . 74.299999999999997 109.569 175.781 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -103.12 -13.73 16.69 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.32 -0.552 . . . . 72.409999999999997 111.728 -175.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -164.94 139.81 5.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.087 0.47 . . . . 74.5 111.397 -175.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.402 ' CG1' HD22 ' B' ' 132' ' ' LEU . 63.6 mt -118.02 117.85 56.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.693 -0.685 . . . . 63.539999999999999 109.846 175.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.598 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 81.3 tttt -93.62 103.92 16.06 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.184 -0.673 . . . . 75.349999999999994 109.184 175.481 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.643 HG13 ' HD3' ' B' ' 139' ' ' PRO . 3.5 t -89.12 126.51 42.12 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 N-CA-C 108.785 -0.82 . . . . 64.430000000000007 108.785 177.299 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.581 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.5 t -113.67 74.47 2.38 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 109.543 -0.54 . . . . 72.219999999999999 109.543 171.647 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.643 ' HD3' HG13 ' B' ' 137' ' ' VAL . 43.3 Cg_endo -77.17 130.01 10.85 Favored 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.105 1.87 . . . . 75.0 111.892 175.815 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . 0.546 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 59.2 mtpt -58.36 -38.58 77.53 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.661 -0.699 . . . . 74.239999999999995 109.776 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 70.3 m-70 -111.81 90.32 3.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.282 -0.872 . . . . 73.299999999999997 109.385 175.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . 0.423 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 151.98 -22.71 0.89 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.54 -0.838 . . . . 61.240000000000002 112.704 -178.587 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . 0.423 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 95.2 mttt 76.48 144.65 0.1 Allowed Pre-proline 0 N--CA 1.472 0.638 0 C-N-CA 123.419 0.688 . . . . 75.340000000000003 111.258 179.177 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.598 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 55.5 Cg_endo -70.57 139.05 36.56 Favored 'Trans proline' 0 N--CA 1.463 -0.285 0 C-N-CA 122.865 2.376 . . . . 74.430000000000007 112.983 -177.059 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 45.4 p90 -152.39 160.03 43.34 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.895 -0.593 . . . . 75.319999999999993 110.322 179.114 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . 0.659 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 96.5 m-85 -100.59 133.29 45.26 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.192 -0.458 . . . . 73.310000000000002 109.959 177.786 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . 0.498 ' HG ' ' HB3' ' B' ' 157' ' ' PHE . 14.1 tp -115.46 100.84 8.37 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.386 -0.598 . . . . 72.200000000000003 109.386 175.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 49.1 t -92.55 140.56 16.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 116.061 -0.518 . . . . 72.519999999999996 111.347 -173.185 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -80.37 116.37 20.4 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.549 -0.296 . . . . 64.430000000000007 110.261 177.376 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.56 157.55 32.04 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-N 116.218 -0.447 . . . . 71.319999999999993 111.201 -179.423 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . 0.541 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 3.8 p-10 -57.45 143.48 40.28 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.96 -0.564 . . . . 74.329999999999998 110.855 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.43 -33.73 4.03 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.773 -0.727 . . . . 75.109999999999999 111.373 -175.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 50.8 m 57.3 33.17 22.91 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 123.008 0.523 . . . . 61.020000000000003 111.919 177.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -53.81 -68.77 0.15 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 115.712 -0.676 . . . . 74.409999999999997 111.145 -178.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . -173.43 30.58 0.1 OUTLIER Glycine 0 CA--C 1.505 -0.579 0 C-N-CA 120.338 -0.934 . . . . 73.030000000000001 112.456 178.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 79.5 m-20 -133.32 145.83 50.78 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.784 0.326 . . . . 64.510000000000005 110.799 -177.166 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . 0.498 ' HB3' ' HG ' ' B' ' 147' ' ' LEU . 32.6 m-85 -118.34 157.03 27.87 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.875 -0.602 . . . . 73.329999999999998 110.034 176.201 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.1 mm -113.91 122.66 68.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 109.676 -0.49 . . . . 74.430000000000007 109.676 178.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . . . . . . . . . 44.8 ttp180 -86.36 135.92 33.33 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.028 -0.36 . . . . 74.349999999999994 110.028 -178.386 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 160' ' ' SER . . . . . 0.659 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 23.5 p -56.97 -34.78 68.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.064 0.459 . . . . 71.310000000000002 111.118 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -69.39 -37.93 77.75 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.448 -0.796 . . . . 70.310000000000002 111.346 177.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 8.6 tp60 -134.03 83.6 45.35 Favored Pre-proline 0 C--N 1.324 -0.527 0 C-N-CA 121.04 -0.264 . . . . 74.510000000000005 110.715 -176.297 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -77.59 0.27 9.96 Favored 'Trans proline' 0 C--O 1.234 0.282 0 C-N-CA 122.577 2.184 . . . . 60.130000000000003 111.616 177.15 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -79.19 -33.31 43.99 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.178 -0.919 . . . . 64.400000000000006 110.768 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -116.64 138.13 51.67 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.857 -0.61 . . . . 74.209999999999994 111.173 -172.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.5 mp -85.27 121.31 27.83 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 108.795 -0.817 . . . . 75.010000000000005 108.795 175.083 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 50.3 mm -71.24 117.7 59.16 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 116.129 -0.487 . . . . 74.420000000000002 109.778 -177.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.518 ' HG2' ' HB2' ' B' ' 171' ' ' GLU . 59.6 Cg_endo -70.39 173.61 11.28 Favored 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 122.843 2.362 . . . . 73.519999999999996 113.008 -175.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . 0.445 ' HA ' HG12 ' B' ' 172' ' ' ILE . 5.4 tt0 -74.95 -17.66 60.51 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.524 -0.762 . . . . 65.349999999999994 112.224 -168.156 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 42.4 p90 -90.24 -10.1 45.55 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.122 0.487 . . . . 74.310000000000002 110.013 176.374 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.563 ' O ' ' HB2' ' B' ' 174' ' ' SER . 19.6 mm-40 -109.42 -12.63 14.7 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.736 -0.665 . . . . 75.299999999999997 111.708 -178.282 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.506 HG22 ' O ' ' B' ' 168' ' ' PRO . 26.1 pt -72.7 -12.35 15.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.254 0.549 . . . . 71.420000000000002 110.435 176.177 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -115.9 32.76 5.89 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.442 -0.799 . . . . 62.409999999999997 109.148 175.094 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 174' ' ' SER . . . . . 0.563 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 3.0 t -66.97 -25.22 66.22 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 114.915 -1.039 . . . . 72.510000000000005 110.575 -177.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 7.1 p-90 . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.295 -0.86 . . . . 75.230000000000004 110.788 -179.936 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.7 p . . . . . 0 N--CA 1.454 -0.265 0 CA-C-O 121.269 0.557 . . . . 72.430000000000007 110.513 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 136.63 106.28 0.8 Allowed Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 111.12 -0.792 . . . . 63.219999999999999 111.12 -174.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -124.3 97.29 40.29 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-O 121.357 0.599 . . . . 72.209999999999994 110.113 -175.301 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.613 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 9.9 Cg_endo -85.17 93.97 0.66 Allowed 'Trans proline' 0 N--CA 1.444 -1.421 0 C-N-CA 122.867 2.378 . . . . 71.239999999999995 111.817 -178.102 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -116.72 153.96 31.45 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.952 -1.022 . . . . 72.209999999999994 109.373 -179.276 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.491 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 13.4 p -119.42 130.35 74.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.497 0.665 . . . . 74.420000000000002 111.639 -177.782 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.516 ' O ' ' HA ' ' A' ' 24' ' ' GLN . 9.3 m -90.68 111.85 23.36 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.369 -0.832 . . . . 73.150000000000006 109.693 176.372 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.435 HG12 ' HG2' ' A' ' 24' ' ' GLN . 60.9 mt -106.74 107.33 22.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.791 0.329 . . . . 74.200000000000003 110.865 -176.23 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -125.51 166.02 17.41 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.178 -0.465 . . . . 74.209999999999994 110.594 178.252 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -118.52 108.63 15.22 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.768 0.318 . . . . 72.530000000000001 110.761 -179.322 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.432 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 25.7 mm-40 -108.42 99.54 8.92 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.162 -0.472 . . . . 72.439999999999998 109.97 178.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 71.09 -114.27 5.15 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.786 -0.721 . . . . 73.439999999999998 112.298 -179.611 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.426 ' HB3' ' HD2' ' A' ' 40' ' ' LYS . 13.6 m-20 -106.43 13.33 28.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.771 0.32 . . . . 61.32 110.476 -178.735 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.432 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 14.2 ptmt -133.29 123.18 25.03 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.464 0.649 . . . . 74.209999999999994 111.949 -176.049 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' THR . . . . . 0.43 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 25.6 m -83.07 115.31 21.81 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.36 -0.836 . . . . 75.25 109.675 176.517 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 68.3 mt -100.77 120.43 50.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 120.716 0.293 . . . . 75.209999999999994 110.65 -175.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLN . . . . . 0.516 ' HA ' ' O ' ' A' ' 14' ' ' THR . 16.7 mt-30 -112.05 111.77 22.92 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.102 -0.499 . . . . 72.310000000000002 110.723 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -90.08 109.59 20.63 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.222 -0.444 . . . . 75.239999999999995 110.312 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 73.4 m-85 -87.68 110.55 20.5 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.763 0.315 . . . . 74.409999999999997 110.374 177.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ARG . . . . . 0.551 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 65.5 mtt180 -116.91 139.91 50.08 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.508 -0.553 . . . . 75.409999999999997 109.508 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.613 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 14.2 p -112.83 -11.96 11.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.509 0.671 . . . . 71.310000000000002 111.002 -177.641 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -166.77 38.4 0.04 OUTLIER 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 108.757 -0.831 . . . . 75.420000000000002 108.757 -177.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 85.17 -28.73 4.53 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.308 -0.86 . . . . 72.219999999999999 111.824 -174.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . 0.408 ' CD2' HG21 ' B' ' 128' ' ' VAL . 15.4 t80 -88.24 125.85 34.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.106 0.479 . . . . 71.420000000000002 110.29 -177.055 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.647 HD13 HG13 ' A' ' 35' ' ' ILE . 3.3 tm? -68.24 134.27 50.15 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.201 -0.909 . . . . 74.209999999999994 110.141 178.74 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' TYR . . . . . 0.49 ' CE1' ' HB ' ' A' ' 28' ' ' VAL . 53.3 p90 -128.55 -24.56 3.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.594 -0.276 . . . . 75.409999999999997 111.584 176.275 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -149.54 139.82 22.26 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.815 0.34 . . . . 64.0 110.895 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.647 HG13 HD13 ' A' ' 32' ' ' LEU . 78.4 mt -122.72 122.35 65.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 116.17 -0.468 . . . . 73.030000000000001 110.239 178.07 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.493 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.4 tttt -101.18 102.05 12.89 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.406 -0.591 . . . . 70.140000000000001 109.406 174.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.551 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.7 p -99.39 124.44 52.71 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.98 0 CA-C-O 121.163 0.506 . . . . 72.439999999999998 110.005 176.485 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.606 HG21 ' HB3' ' A' ' 44' ' ' PRO . 40.0 t -106.91 85.01 1.72 Allowed Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 115.096 -0.956 . . . . 71.120000000000005 109.873 179.199 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.551 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 85.4 Cg_endo -91.08 144.01 3.33 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 122.762 2.308 . . . . 71.400000000000006 112.41 179.206 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.426 ' HD2' ' HB3' ' A' ' 20' ' ' ASP . 97.0 mttt -60.46 -27.02 67.21 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.186 0.517 . . . . 74.140000000000001 110.128 173.784 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 6.5 m-70 -118.99 85.4 2.36 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.568 -0.742 . . . . 74.430000000000007 109.947 -174.203 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 139.15 -18.76 3.1 Favored Glycine 0 N--CA 1.449 -0.444 0 CA-C-N 115.876 -0.602 . . . . 71.010000000000005 111.982 -176.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 42.5 mtpt 69.4 150.86 0.13 Allowed Pre-proline 0 N--CA 1.469 0.48 0 C-N-CA 123.727 0.811 . . . . 72.439999999999998 112.235 -179.035 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.606 ' HB3' HG21 ' A' ' 38' ' ' VAL . 16.0 Cg_endo -59.7 123.64 13.71 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.878 2.385 . . . . 74.150000000000006 112.474 -179.647 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' TYR . . . . . 0.499 ' CE1' HG11 ' A' ' 37' ' ' VAL . 16.4 p90 -142.28 151.18 41.77 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.865 -0.607 . . . . 74.140000000000001 110.258 179.551 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -90.74 125.0 35.55 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.17 -0.468 . . . . 74.150000000000006 109.981 176.085 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 18.9 tp -103.34 100.91 10.81 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 108.42 -0.956 . . . . 73.400000000000006 108.42 174.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.3 t -90.75 132.27 35.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.979 -0.555 . . . . 75.040000000000006 111.029 -173.675 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -86.04 121.16 28.26 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.069 -0.715 . . . . 74.099999999999994 109.069 178.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.11 174.78 9.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.924 0.392 . . . . 73.5 111.574 -173.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.59 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 7.0 p-10 -68.94 135.66 51.34 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.301 -0.409 . . . . 75.109999999999999 110.405 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.475 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 94.54 146.05 19.66 Favored Glycine 0 N--CA 1.433 -1.562 0 C-N-CA 120.422 -0.895 . . . . 45.399999999999999 112.042 179.067 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 27.8 t -80.57 28.55 0.33 Allowed 'General case' 0 C--N 1.312 -1.05 0 CA-C-O 121.436 0.636 . . . . 75.019999999999996 109.866 175.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.475 ' H ' ' C ' ' A' ' 52' ' ' GLY . 30.0 t70 -63.89 -32.43 73.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.159 -0.928 . . . . 64.200000000000003 111.26 -177.629 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.86 37.49 4.42 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.41 -0.9 . . . . 63.32 113.138 177.426 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -126.06 139.53 53.33 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.05 0.452 . . . . 74.109999999999999 110.052 176.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -117.47 155.16 30.18 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.711 -0.677 . . . . 74.120000000000005 109.864 179.207 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 44.9 mm -113.86 116.59 53.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.137 -0.483 . . . . 64.340000000000003 109.7 177.341 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . 0.496 ' HB2' HD13 ' A' ' 67' ' ' ILE . 55.5 ttt180 -83.82 124.06 30.54 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.121 -0.49 . . . . 75.239999999999995 109.846 -178.791 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.471 ' HA ' ' HG ' ' B' ' 160' ' ' SER . 30.9 t -63.71 -8.3 9.97 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.342 -0.39 . . . . 61.130000000000003 111.615 -177.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . 0.402 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 15.6 t70 -70.03 -36.0 74.72 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.231 0.538 . . . . 72.349999999999994 109.701 175.578 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -159.08 88.87 2.1 Favored Pre-proline 0 N--CA 1.451 -0.383 0 CA-C-N 115.515 -0.766 . . . . 72.200000000000003 109.589 -177.492 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . 0.437 ' HG3' ' OG ' ' B' ' 160' ' ' SER . 35.7 Cg_exo -58.98 -16.42 32.36 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 123.335 2.69 . . . . 73.150000000000006 112.699 178.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . 0.473 ' CG ' ' HZ2' ' B' ' 143' ' ' LYS . 8.7 m-20 -66.62 -22.43 66.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.899 -0.591 . . . . 73.439999999999998 111.255 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.16 141.12 48.56 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 121.404 0.621 . . . . 63.329999999999998 111.892 -177.077 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.7 mp -88.54 141.43 28.53 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.689 -1.142 . . . . 71.329999999999998 109.306 174.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ILE . . . . . 0.73 HG23 ' HB3' ' A' ' 71' ' ' GLU . 25.2 mm -83.41 121.87 76.84 Favored Pre-proline 0 C--N 1.317 -0.818 0 CA-C-N 116.167 -0.47 . . . . 74.439999999999998 111.709 -176.77 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.498 ' O ' HG21 ' A' ' 72' ' ' ILE . 68.2 Cg_endo -74.05 179.45 5.74 Favored 'Trans proline' 0 C--O 1.233 0.264 0 C-N-CA 123.211 2.607 . . . . 75.099999999999994 112.488 178.631 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' GLN . . . . . 0.71 ' HA ' HG12 ' A' ' 72' ' ' ILE . 4.2 tt0 -71.99 -33.11 67.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.171 -0.468 . . . . 75.409999999999997 111.701 -168.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 7.2 p90 -69.23 -16.97 63.72 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.411 -0.516 . . . . 75.230000000000004 110.799 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.73 ' HB3' HG23 ' A' ' 67' ' ' ILE . 2.6 mm-40 -103.44 -20.22 14.13 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.329 -0.396 . . . . 63.25 111.233 -178.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.71 HG12 ' HA ' ' A' ' 69' ' ' GLN . 42.6 pt -75.61 -24.17 16.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 121.162 0.506 . . . . 72.099999999999994 109.922 174.752 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -103.69 39.21 1.65 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.467 -0.788 . . . . 75.340000000000003 109.371 173.353 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.483 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 11.5 t -71.17 -20.03 62.34 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.293 -0.867 . . . . 64.120000000000005 110.94 -177.141 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' TRP . . . . . 0.569 ' HZ2' HD12 ' A' ' 35' ' ' ILE . 69.6 p-90 . . . . . 0 C--O 1.235 0.312 0 CA-C-O 120.861 0.362 . . . . 73.450000000000003 110.835 177.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 8.6 p . . . . . 0 N--CA 1.452 -0.332 0 CA-C-O 121.26 0.552 . . . . 74.430000000000007 110.594 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 92.25 116.29 2.25 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 111.063 -0.815 . . . . 61.210000000000001 111.063 -174.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -119.87 93.33 47.62 Favored Pre-proline 0 C--N 1.319 -0.739 0 CA-C-O 121.14 0.495 . . . . 71.409999999999997 110.58 -175.137 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 111' ' ' PRO . . . . . 0.719 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 55.7 Cg_endo -77.44 68.45 7.52 Favored 'Trans proline' 0 N--CA 1.449 -1.115 0 C-N-CA 121.943 1.762 . . . . 74.319999999999993 110.891 176.086 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -91.05 157.46 17.24 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 114.411 -1.268 . . . . 72.040000000000006 109.553 -178.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 113' ' ' VAL . . . . . 0.666 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 12.4 p -122.78 127.25 74.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-O 121.477 0.656 . . . . 73.450000000000003 111.19 -178.419 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 114' ' ' THR . . . . . 0.421 ' O ' ' HA ' ' B' ' 124' ' ' GLN . 13.7 m -84.61 111.26 19.38 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.435 -0.802 . . . . 74.219999999999999 109.439 178.749 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.6 mt -99.09 116.45 42.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 120.955 0.407 . . . . 75.140000000000001 111.527 -172.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 45.7 mtt180 -126.87 170.64 12.01 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.947 -0.57 . . . . 74.209999999999994 110.606 175.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 69.7 mt-30 -132.54 98.23 4.3 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.18 0.514 . . . . 71.120000000000005 110.204 176.536 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 118' ' ' GLU . . . . . 0.583 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 20.9 mm-40 -96.66 100.8 12.34 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.657 -0.701 . . . . 61.0 109.317 -178.433 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 73.37 -117.89 6.03 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.434 -0.889 . . . . 74.420000000000002 111.36 -175.44 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 120' ' ' ASP . . . . . 0.51 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 5.2 m-20 -104.26 11.58 34.7 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.94 0.37 . . . . 71.040000000000006 110.493 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 121' ' ' LYS . . . . . 0.583 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 10.1 ptmt -124.96 121.59 34.89 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.567 0.699 . . . . 62.240000000000002 111.73 -175.456 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 122' ' ' THR . . . . . 0.832 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 35.9 m -76.96 104.15 7.29 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.243 -0.89 . . . . 63.100000000000001 109.798 175.387 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 46.6 mt -94.01 119.89 42.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.218 0.532 . . . . 73.150000000000006 110.301 -179.311 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 124' ' ' GLN . . . . . 0.666 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 25.4 mt-30 -115.23 113.06 23.4 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.322 -0.854 . . . . 65.209999999999994 110.914 -177.043 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -88.16 111.98 22.21 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.173 -0.467 . . . . 74.430000000000007 110.678 -179.505 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 126' ' ' TYR . . . . . 0.59 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 29.1 m-85 -88.65 112.73 23.44 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.938 0.399 . . . . 74.349999999999994 111.07 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 127' ' ' ARG . . . . . 0.518 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 89.6 mtm180 -132.22 128.67 38.42 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.071 -0.513 . . . . 73.209999999999994 110.109 -179.218 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 128' ' ' VAL . . . . . 0.719 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 9.7 p -99.86 -27.84 3.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.071 0.462 . . . . 73.349999999999994 111.862 -174.367 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -152.74 47.61 0.72 Allowed 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.574 -0.528 . . . . 74.400000000000006 109.574 -179.032 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.19 -21.33 12.69 Favored Glycine 0 CA--C 1.518 0.235 0 CA-C-N 115.567 -0.742 . . . . 75.439999999999998 112.731 -178.447 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 131' ' ' PHE . . . . . 0.457 ' HD2' HG22 ' A' ' 28' ' ' VAL . 26.5 t80 -98.22 130.12 44.95 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.712 0.291 . . . . 75.099999999999994 110.374 -176.584 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 132' ' ' LEU . . . . . 0.518 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 3.1 tm? -71.0 132.55 45.32 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.812 -0.631 . . . . 74.5 109.967 179.214 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 46.1 p90 -129.32 -15.55 4.1 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.582 -0.447 . . . . 75.409999999999997 112.04 177.715 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.31 149.97 17.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.719 0.295 . . . . 75.040000000000006 111.079 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 135' ' ' ILE . . . . . 0.401 HG13 HD11 ' B' ' 132' ' ' LEU . 67.5 mt -130.69 125.42 58.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.963 -0.384 . . . . 74.140000000000001 109.963 176.863 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 136' ' ' LYS . . . . . 0.61 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 85.5 tttt -104.11 114.55 28.87 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.107 -0.331 . . . . 75.230000000000004 110.107 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 137' ' ' VAL . . . . . 0.612 HG11 ' HD3' ' B' ' 139' ' ' PRO . 3.4 t -96.49 130.94 44.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.126 -0.694 . . . . 73.239999999999995 109.126 175.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 138' ' ' VAL . . . . . 0.832 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 24.1 t -115.65 74.65 4.77 Favored Pre-proline 0 C--N 1.318 -0.798 0 N-CA-C 109.875 -0.417 . . . . 74.239999999999995 109.875 171.723 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 139' ' ' PRO . . . . . 0.612 ' HD3' HG11 ' B' ' 137' ' ' VAL . 37.1 Cg_endo -74.22 131.89 15.84 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.186 1.924 . . . . 74.010000000000005 112.276 176.445 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 140' ' ' LYS . . . . . 0.51 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 59.2 mtpt -60.63 -19.49 58.18 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.399 -0.818 . . . . 72.549999999999997 111.111 178.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 80.8 m-70 -130.72 105.4 7.78 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.703 -0.68 . . . . 63.140000000000001 109.379 178.492 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 142' ' ' GLY . . . . . 0.425 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 125.36 -11.02 7.65 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.75 -0.738 . . . . 61.140000000000001 112.432 -177.142 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 143' ' ' LYS . . . . . 0.473 ' HZ2' ' CG ' ' A' ' 64' ' ' ASP . 45.7 mtpt 72.77 150.84 0.14 Allowed Pre-proline 0 N--CA 1.468 0.433 0 C-N-CA 123.603 0.761 . . . . 74.319999999999993 112.353 179.105 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 144' ' ' PRO . . . . . 0.561 ' HB3' HG11 ' B' ' 138' ' ' VAL . 44.3 Cg_endo -68.76 137.75 39.34 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.795 2.33 . . . . 72.040000000000006 112.552 178.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -143.75 147.99 34.99 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 120.954 0.407 . . . . 73.299999999999997 110.638 179.114 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -90.47 129.27 36.66 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.88 -0.6 . . . . 74.439999999999998 110.032 175.506 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 147' ' ' LEU . . . . . 0.441 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 25.5 tp -108.59 93.27 4.43 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.621 -0.881 . . . . 74.409999999999997 108.621 173.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 40.3 t -83.53 135.91 23.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.602 -0.727 . . . . 74.230000000000004 110.499 -174.395 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 3.0 tmm_? -89.25 120.83 30.96 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 108.573 -0.899 . . . . 74.140000000000001 108.573 178.616 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -76.16 -173.94 2.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.978 0.418 . . . . 63.299999999999997 111.655 -173.123 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -75.33 146.26 41.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.369 -0.378 . . . . 71.400000000000006 110.288 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 91.63 136.8 7.26 Favored Glycine 0 N--CA 1.44 -1.076 0 C-N-CA 120.571 -0.823 . . . . 50.310000000000002 111.823 -177.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 18.4 t -87.22 35.67 0.71 Allowed 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.226 0.536 . . . . 55.149999999999999 110.212 178.425 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -74.68 -47.49 31.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.513 -0.767 . . . . 64.239999999999995 111.185 -178.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 123.08 36.6 0.65 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.868 -0.682 . . . . 63.109999999999999 111.97 -176.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -119.73 126.75 51.84 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.974 0.416 . . . . 75.420000000000002 110.596 -178.322 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 157' ' ' PHE . . . . . 0.441 ' CD2' ' HG ' ' B' ' 147' ' ' LEU . 13.4 m-85 -109.97 164.0 13.02 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.196 -0.456 . . . . 72.420000000000002 110.487 179.541 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.7 mm -121.79 109.22 24.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.789 -0.819 . . . . 73.329999999999998 108.789 173.128 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 159' ' ' ARG . . . . . 0.529 ' HE ' ' HB3' ' B' ' 161' ' ' ASP . 43.3 ttp180 -75.07 125.94 29.98 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 109.027 -0.731 . . . . 72.150000000000006 109.027 178.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 160' ' ' SER . . . . . 0.471 ' HG ' ' HA ' ' A' ' 60' ' ' SER . 23.8 t -58.64 -22.06 55.55 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.187 0.518 . . . . 72.0 110.755 -178.75 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 161' ' ' ASP . . . . . 0.529 ' HB3' ' HE ' ' B' ' 159' ' ' ARG . 1.5 t70 -68.81 -30.24 68.76 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.797 -0.638 . . . . 73.400000000000006 111.104 175.547 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 162' ' ' GLN . . . . . 0.668 HE21 ' HA ' ' B' ' 162' ' ' GLN . 0.0 OUTLIER -140.95 81.34 16.31 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.271 -0.422 . . . . 74.400000000000006 110.409 -174.198 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.41 -8.67 17.36 Favored 'Trans proline' 0 C--N 1.343 0.264 0 C-N-CA 122.498 2.132 . . . . 72.150000000000006 112.318 -178.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -81.87 -21.52 37.45 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.665 -0.698 . . . . 63.329999999999998 110.502 178.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 19.1 ttmm -114.57 134.32 55.13 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.017 -0.538 . . . . 75.319999999999993 110.894 -175.006 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.1 mp -82.98 129.31 35.02 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.22 -1.03 . . . . 75.400000000000006 108.22 171.449 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 45.2 mm -87.84 110.31 34.05 Favored Pre-proline 0 C--N 1.321 -0.651 0 N-CA-C 110.177 -0.305 . . . . 65.329999999999998 110.177 -174.21 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 168' ' ' PRO . . . . . 0.48 ' O ' HG21 ' B' ' 172' ' ' ILE . 42.9 Cg_endo -66.57 172.89 8.59 Favored 'Trans proline' 0 N--CA 1.462 -0.332 0 C-N-CA 122.94 2.426 . . . . 73.239999999999995 112.768 -175.595 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 5.1 tt0 -75.44 -5.44 45.01 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.304 -0.862 . . . . 74.439999999999998 111.665 -169.097 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -96.04 -13.24 23.87 Favored 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 120.495 -0.482 . . . . 71.530000000000001 110.73 176.471 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 171' ' ' GLU . . . . . 0.6 ' O ' ' HB2' ' B' ' 174' ' ' SER . 1.5 mm-40 -107.24 -9.61 16.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.988 0.423 . . . . 72.319999999999993 110.817 -178.386 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 172' ' ' ILE . . . . . 0.48 HG21 ' O ' ' B' ' 168' ' ' PRO . 47.9 pt -68.08 -19.15 24.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.423 0.63 . . . . 73.439999999999998 110.262 176.365 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -99.45 39.24 1.32 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.293 -0.867 . . . . 71.049999999999997 108.823 175.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 174' ' ' SER . . . . . 0.6 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 1.7 t -72.84 -15.31 61.62 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.358 -0.837 . . . . 62.340000000000003 110.305 -178.375 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 65.4 p-90 . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.817 -0.611 . . . . 74.099999999999994 109.371 174.38 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.682 0 N-CA-C 111.635 -0.586 . . . . 61.520000000000003 111.635 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -74.32 -71.9 0.31 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.139 0.495 . . . . 73.549999999999997 110.143 176.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -99.98 153.46 19.17 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.712 -0.676 . . . . 73.420000000000002 109.591 176.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -134.0 151.97 51.66 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.766 0.317 . . . . 73.239999999999995 110.822 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -153.19 83.4 1.2 Allowed 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.067 -0.716 . . . . 73.209999999999994 109.067 177.704 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -80.41 135.44 53.61 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 115.862 -0.608 . . . . 72.519999999999996 111.274 -175.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -73.96 175.34 10.96 Favored 'Trans proline' 0 CA--C 1.527 0.174 0 C-N-CA 122.798 2.332 . . . . 72.109999999999999 112.06 177.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.3 p -57.32 107.43 0.43 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.525 0.679 . . . . 75.25 111.333 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 150.45 -76.48 0.24 Allowed Glycine 0 N--CA 1.443 -0.879 0 N-CA-C 110.521 -1.032 . . . . 72.030000000000001 110.521 -175.022 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 56.35 75.5 0.57 Allowed Pre-proline 0 N--CA 1.469 0.492 0 O-C-N 124.185 0.58 . . . . 70.5 112.473 173.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.663 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 71.6 Cg_endo -87.0 116.53 1.27 Allowed 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.507 2.138 . . . . 73.299999999999997 112.544 177.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -139.21 167.21 22.58 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.485 -0.561 . . . . 64.049999999999997 109.485 176.074 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.53 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 11.3 p -114.46 124.03 70.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.505 0.669 . . . . 71.329999999999998 111.502 -175.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.7 m -89.83 106.14 18.27 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.6 -0.727 . . . . 74.450000000000003 109.249 174.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.439 HG21 ' HG2' ' A' ' 24' ' ' GLN . 57.6 mt -93.89 107.84 19.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 120.908 0.385 . . . . 71.230000000000004 111.0 -175.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 4.8 mtm180 -116.13 174.77 5.87 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.225 -0.443 . . . . 75.109999999999999 110.537 177.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -129.98 104.87 7.61 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.782 -0.644 . . . . 65.109999999999999 109.823 175.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -97.32 83.56 3.31 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.563 -0.744 . . . . 72.510000000000005 109.338 -177.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.72 -115.17 4.12 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.429 -0.891 . . . . 73.310000000000002 111.413 -176.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.978 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 23.0 m-20 -110.73 24.95 12.31 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.099 0.476 . . . . 72.5 110.267 178.548 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.5 pttm -132.3 118.52 19.56 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 121.297 0.57 . . . . 71.340000000000003 110.782 178.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.422 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 35.8 m -80.06 101.42 8.71 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.421 -0.809 . . . . 54.43 109.374 177.047 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.528 HG12 HG23 ' A' ' 37' ' ' VAL . 16.4 mt -98.53 113.31 32.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.236 0.541 . . . . 72.25 110.388 -174.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.53 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 21.4 mt-30 -96.5 110.18 22.62 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.404 -0.816 . . . . 74.129999999999995 110.552 -178.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 30.0 mt-10 -84.3 103.24 13.32 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.681 -0.691 . . . . 74.140000000000001 110.828 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.41 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 85.2 m-85 -83.4 97.48 8.97 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.521 -0.548 . . . . 73.230000000000004 109.521 174.251 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 94.0 mtt180 -110.44 129.59 55.74 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.869 -0.605 . . . . 72.409999999999997 109.744 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.849 HG12 ' H ' ' A' ' 29' ' ' ASN . 2.7 p -91.98 -82.7 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 C-N-CA 120.322 -0.551 . . . . 65.239999999999995 109.812 175.182 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.849 ' H ' HG12 ' A' ' 28' ' ' VAL . 5.6 t-20 -123.36 77.7 1.51 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.023 0.439 . . . . 73.5 110.325 -176.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 70.72 20.51 77.46 Favored Glycine 0 N--CA 1.448 -0.528 0 CA-C-N 115.456 -0.793 . . . . 73.319999999999993 113.144 177.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.452 ' CD2' HG22 ' B' ' 128' ' ' VAL . 32.2 t80 -148.12 129.3 14.62 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.125 0.488 . . . . 73.450000000000003 110.42 177.653 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.947 HD12 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -69.51 116.69 10.21 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 114.945 -1.025 . . . . 75.219999999999999 109.174 175.427 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . 0.41 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 36.7 p90 -105.1 -20.49 13.5 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.299 -0.56 . . . . 73.329999999999998 111.562 -178.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -157.43 143.41 17.61 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.947 0.403 . . . . 72.349999999999994 111.13 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.947 HG13 HD12 ' A' ' 32' ' ' LEU . 72.4 mt -120.86 120.25 61.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.171 -0.468 . . . . 71.329999999999998 110.148 175.377 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.403 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 86.6 tttt -103.04 97.78 7.83 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.849 -0.797 . . . . 73.010000000000005 108.849 171.103 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.528 HG23 HG12 ' A' ' 23' ' ' ILE . 2.1 p -100.2 128.61 51.99 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 CA-C-N 116.112 -0.495 . . . . 75.319999999999993 110.18 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.562 HG21 ' HB3' ' A' ' 44' ' ' PRO . 34.7 t -107.93 87.16 3.54 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 115.428 -0.805 . . . . 73.319999999999993 109.646 178.417 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 66.9 Cg_endo -83.48 132.9 6.01 Favored 'Trans proline' 0 N--CA 1.448 -1.171 0 C-N-CA 122.206 1.937 . . . . 73.239999999999995 111.905 178.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.978 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 58.6 mtpt -63.72 -24.0 67.6 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.648 -0.705 . . . . 71.329999999999998 109.93 176.35 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 59.3 m-70 -120.07 85.11 2.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.367 -0.833 . . . . 74.510000000000005 109.671 177.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 145.04 -20.07 1.95 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.286 -0.959 . . . . 74.349999999999994 113.205 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 94.0 mttt 73.42 144.42 0.1 Allowed Pre-proline 0 N--CA 1.474 0.743 0 C-N-CA 123.153 0.581 . . . . 74.239999999999995 111.373 178.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.562 ' HB3' HG21 ' A' ' 38' ' ' VAL . 41.7 Cg_endo -67.8 156.43 65.98 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.803 2.335 . . . . 75.549999999999997 113.361 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.412 ' CE1' HG11 ' A' ' 37' ' ' VAL . 6.8 p90 -165.3 167.16 18.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.581 -0.736 . . . . 73.310000000000002 109.516 178.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.55 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 64.4 m-85 -100.24 134.19 43.54 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.871 0.367 . . . . 74.409999999999997 110.591 176.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.421 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 20.2 tp -118.87 102.93 9.16 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.264 -0.643 . . . . 74.219999999999999 109.264 176.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.4 t -96.85 135.17 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.802 0.334 . . . . 72.219999999999999 111.663 -173.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.9 111.13 6.89 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.862 -0.608 . . . . 74.329999999999998 109.816 178.521 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.54 168.51 16.14 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.446 -0.343 . . . . 74.340000000000003 110.739 178.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -64.91 137.25 57.64 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.321 -0.4 . . . . 72.129999999999995 110.084 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 87.22 122.3 1.58 Allowed Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.705 -0.76 . . . . 74.129999999999995 111.239 -175.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.5 t -85.51 36.62 0.65 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.207 0.527 . . . . 74.109999999999999 110.277 -175.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -66.04 -48.44 71.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.504 -0.771 . . . . 75.450000000000003 110.753 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 134.46 49.75 0.08 OUTLIER Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.861 -0.685 . . . . 53.009999999999998 111.572 -177.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.81 HD22 ' HB3' ' A' ' 66' ' ' LEU . 41.1 t-20 -136.54 134.27 37.33 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.717 -0.475 . . . . 71.239999999999995 109.717 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.477 ' HD1' HG22 ' A' ' 72' ' ' ILE . 52.5 m-85 -123.53 159.71 28.56 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.139 -0.482 . . . . 74.340000000000003 110.784 -179.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 47.9 mm -117.49 129.96 73.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 109.501 -0.555 . . . . 73.140000000000001 109.501 175.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.926 ' HG3' HG13 ' A' ' 67' ' ' ILE . 18.0 mtm180 -95.79 153.63 17.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.827 0.346 . . . . 71.219999999999999 111.198 -176.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.55 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 59.5 p -71.53 -21.25 61.93 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.788 -0.642 . . . . 73.040000000000006 109.512 172.379 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -60.7 -44.0 97.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 114.833 -1.076 . . . . 73.030000000000001 110.858 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 9.8 tt0 -160.1 98.92 1.45 Allowed Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 115.8 -0.636 . . . . 75.219999999999999 109.908 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -73.03 -6.8 19.62 Favored 'Trans proline' 0 C--O 1.23 0.099 0 C-N-CA 122.777 2.318 . . . . 73.150000000000006 111.659 177.56 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -85.11 1.62 47.09 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.961 -1.018 . . . . 73.319999999999993 110.162 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 62.0 tttp -129.03 135.91 49.58 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.153 -0.476 . . . . 75.5 110.577 -177.651 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.81 ' HB3' HD22 ' A' ' 56' ' ' ASN . 5.0 mp -90.34 132.18 35.72 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.705 -0.85 . . . . 63.109999999999999 108.705 176.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.926 HG13 ' HG3' ' A' ' 59' ' ' ARG . 45.2 mm -106.15 110.52 64.05 Favored Pre-proline 0 C--N 1.317 -0.81 0 CA-C-O 121.021 0.438 . . . . 71.230000000000004 111.362 -172.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.525 ' O ' HG23 ' A' ' 72' ' ' ILE . 73.0 Cg_endo -76.44 -179.93 5.79 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 123.337 2.691 . . . . 74.409999999999997 112.297 177.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . 1.013 ' HA ' HG12 ' A' ' 72' ' ' ILE . 27.4 mt-30 -71.38 -32.69 68.76 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 113.489 0.922 . . . . 64.400000000000006 113.489 -169.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 25.2 p90 -70.13 -15.9 63.03 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.22 -0.592 . . . . 75.299999999999997 109.961 176.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.646 ' HB3' HG21 ' A' ' 67' ' ' ILE . 3.9 mm-40 -101.16 -30.31 11.63 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.776 -0.647 . . . . 75.349999999999994 111.186 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 1.013 HG12 ' HA ' ' A' ' 69' ' ' GLN . 44.8 pt -72.43 -32.77 43.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 121.099 0.476 . . . . 75.019999999999996 110.163 177.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -101.77 39.94 1.39 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.946 -0.57 . . . . 64.430000000000007 110.125 174.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.3 t -74.76 -16.12 60.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.355 -0.839 . . . . 73.519999999999996 109.762 179.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 8.6 p-90 . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 115.944 -0.571 . . . . 70.409999999999997 110.661 175.449 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.384 0 N-CA-C 112.174 -0.37 . . . . 64.439999999999998 112.174 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -157.7 -41.3 0.07 Allowed 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.808 0.337 . . . . 73.349999999999994 111.327 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -92.12 37.45 0.98 Allowed 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 112.171 0.434 . . . . 72.030000000000001 112.171 -173.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -88.91 33.42 0.78 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.251 0.548 . . . . 75.150000000000006 110.482 175.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -54.34 132.45 43.98 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.054 -0.975 . . . . 74.450000000000003 111.862 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -90.24 120.13 69.17 Favored Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.1 -0.5 . . . . 65.0 110.502 178.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.32 -166.29 0.34 Allowed 'Trans proline' 0 N--CA 1.464 -0.264 0 C-N-CA 123.171 2.581 . . . . 64.430000000000007 112.581 -178.613 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 4.3 p -72.75 117.03 13.95 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.802 -0.635 . . . . 73.109999999999999 110.473 178.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 100.43 84.45 1.8 Allowed Glycine 0 CA--C 1.504 -0.651 0 N-CA-C 110.992 -0.843 . . . . 73.400000000000006 110.992 -176.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -118.27 92.6 43.36 Favored Pre-proline 0 C--N 1.315 -0.934 0 CA-C-N 114.959 -0.621 . . . . 72.150000000000006 110.258 -174.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.83 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 40.5 Cg_endo -74.08 88.1 1.13 Allowed 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 121.781 1.654 . . . . 72.310000000000002 111.486 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -104.64 147.11 28.01 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.889 -1.05 . . . . 75.409999999999997 109.785 179.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.653 HG21 ' HB3' ' B' ' 124' ' ' GLN . 9.9 p -104.05 127.55 58.16 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-O 121.316 0.579 . . . . 74.010000000000005 111.073 -177.757 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 114' ' ' THR . . . . . 0.658 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.4 m -83.9 102.65 12.55 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.607 -0.724 . . . . 71.25 109.364 175.594 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.1 mt -92.77 106.45 17.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.279 -0.419 . . . . 73.319999999999993 110.909 -174.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . 0.436 ' HG2' ' O ' ' B' ' 123' ' ' ILE . 13.3 ptm180 -118.25 171.47 8.1 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.335 -0.617 . . . . 73.109999999999999 109.335 176.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 89.7 mt-30 -139.55 113.49 8.73 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.32 0.581 . . . . 74.430000000000007 110.825 -179.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 17.9 mm-40 -101.26 97.73 8.2 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.335 -0.848 . . . . 71.219999999999999 109.569 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 70.24 -95.67 0.52 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.886 -0.673 . . . . 63.32 111.973 -177.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . 0.792 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 9.7 m-20 -127.54 26.71 5.91 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.849 0.357 . . . . 73.219999999999999 110.538 178.463 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.513 ' HE3' ' HE3' ' B' ' 175' ' ' TRP . 23.1 pttm -129.3 119.31 23.72 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.233 0.54 . . . . 64.109999999999999 110.88 175.113 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 122' ' ' THR . . . . . 0.802 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 28.0 m -80.3 105.28 11.44 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.576 -0.738 . . . . 73.420000000000002 109.53 177.387 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . 0.504 HD12 ' HE2' ' B' ' 121' ' ' LYS . 24.2 mt -96.3 106.38 18.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-O 121.27 0.557 . . . . 75.209999999999994 110.097 -177.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.653 ' HB3' HG21 ' B' ' 113' ' ' VAL . 26.1 mt-30 -97.51 103.87 15.85 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.451 -0.795 . . . . 64.450000000000003 110.892 -176.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . 0.658 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 48.3 mt-10 -84.97 102.55 13.25 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.788 -0.642 . . . . 64.099999999999994 111.049 -179.214 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . 0.447 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 39.2 m-85 -78.38 107.09 10.75 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.931 0.396 . . . . 73.420000000000002 110.67 178.115 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . 0.403 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 50.2 mtt180 -125.11 125.13 43.27 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.009 -0.542 . . . . 75.450000000000003 109.787 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.83 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 7.3 p -90.05 -25.6 5.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.202 0.525 . . . . 74.420000000000002 111.081 -174.815 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -165.94 56.35 0.1 Allowed 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.034 -0.728 . . . . 72.219999999999999 109.034 -179.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.68 -34.55 4.31 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.284 -0.871 . . . . 64.430000000000007 112.915 -178.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -94.54 133.47 38.13 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.204 0.526 . . . . 73.109999999999999 110.856 -173.524 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.689 HD12 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -73.95 125.82 29.08 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.983 -1.008 . . . . 73.150000000000006 110.17 179.289 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . 0.447 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 37.0 p90 -117.18 -16.97 10.35 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.617 -0.433 . . . . 73.409999999999997 111.384 177.457 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . 0.429 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -161.79 146.51 12.99 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.668 0.271 . . . . 75.099999999999994 110.87 178.029 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.689 HG13 HD12 ' B' ' 132' ' ' LEU . 71.1 mt -124.95 115.71 45.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 110.149 -0.315 . . . . 52.130000000000003 110.149 176.552 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.524 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.9 tttt -93.57 105.62 17.65 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.226 -0.657 . . . . 74.019999999999996 109.226 175.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.619 HG12 ' HD3' ' B' ' 139' ' ' PRO . 3.0 t -88.44 130.95 37.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.279 -0.637 . . . . 72.439999999999998 109.279 178.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.802 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 34.0 t -117.4 72.87 7.39 Favored Pre-proline 0 C--N 1.318 -0.795 0 CA-C-O 121.002 0.43 . . . . 71.230000000000004 109.863 173.152 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.619 ' HD3' HG12 ' B' ' 137' ' ' VAL . 44.4 Cg_endo -76.95 126.47 8.74 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.128 1.885 . . . . 71.140000000000001 112.473 176.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . 0.792 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 60.1 mtpt -66.04 -9.4 30.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.192 -0.913 . . . . 75.230000000000004 111.302 -179.046 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -129.92 21.81 5.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.772 -0.649 . . . . 75.420000000000002 110.298 -177.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . 0.491 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . -152.16 -9.21 0.1 OUTLIER Glycine 0 CA--C 1.521 0.416 0 C-N-CA 120.381 -0.914 . . . . 71.230000000000004 113.68 -178.424 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . 0.491 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 67.7 mmtt 75.69 143.98 0.1 Allowed Pre-proline 0 N--CA 1.472 0.67 0 CA-C-O 121.361 0.601 . . . . 73.530000000000001 112.128 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.608 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 59.8 Cg_endo -72.32 134.75 23.36 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 123.162 2.575 . . . . 72.239999999999995 112.887 -176.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -150.51 151.29 32.46 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.89 -0.595 . . . . 73.310000000000002 110.495 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.612 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 93.0 m-85 -89.51 128.1 35.94 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.31 -0.405 . . . . 73.340000000000003 110.103 176.403 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . 0.552 ' HG ' ' CD1' ' B' ' 157' ' ' PHE . 16.0 tp -107.39 98.35 7.99 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.852 -0.796 . . . . 71.439999999999998 108.852 175.01 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 40.8 t -87.87 133.67 29.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.028 -0.533 . . . . 75.25 111.464 -172.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.03 108.13 8.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.803 -0.635 . . . . 70.019999999999996 110.476 178.064 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.12 155.72 33.94 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.876 -0.416 . . . . 60.329999999999998 109.876 173.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -62.31 139.21 58.53 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.885 0.374 . . . . 75.140000000000001 110.803 -177.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . 0.464 ' C ' ' H ' ' B' ' 154' ' ' ASP . . . 87.87 137.14 5.43 Favored Glycine 0 N--CA 1.44 -1.07 0 C-N-CA 120.433 -0.889 . . . . 64.109999999999999 111.689 -178.614 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 14.4 t -75.61 39.58 0.17 Allowed 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.616 0.722 . . . . 75.209999999999994 110.711 178.048 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . 0.464 ' H ' ' C ' ' B' ' 152' ' ' GLY . 21.3 t70 -67.29 -27.18 66.96 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.527 -0.761 . . . . 75.25 110.293 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 99.07 18.33 24.86 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.796 -0.716 . . . . 44.219999999999999 112.185 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . 0.977 HD22 ' HB3' ' B' ' 166' ' ' LEU . 18.5 t-20 -101.13 139.15 37.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.841 0.353 . . . . 71.450000000000003 110.375 -178.26 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . 0.552 ' CD1' ' HG ' ' B' ' 147' ' ' LEU . 29.3 m-85 -127.41 156.88 41.37 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.963 -0.562 . . . . 75.310000000000002 110.404 176.449 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.2 mm -122.69 130.19 74.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.563 -0.532 . . . . 73.129999999999995 109.563 177.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.456 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 11.0 mtm180 -93.3 145.35 24.52 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.818 -0.353 . . . . 75.040000000000006 110.076 179.748 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 160' ' ' SER . . . . . 0.612 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 54.5 p -70.66 -16.71 62.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.26 -0.427 . . . . 64.209999999999994 111.383 -179.307 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -86.35 -25.13 25.54 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.972 0.415 . . . . 75.049999999999997 110.195 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 9.9 tt0 -151.72 79.54 6.46 Favored Pre-proline 0 N--CA 1.451 -0.411 0 CA-C-N 115.919 -0.582 . . . . 74.109999999999999 110.102 -177.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . 0.458 ' CG ' ' HB2' ' A' ' 60' ' ' SER . 16.1 Cg_exo -69.35 -9.57 26.6 Favored 'Trans proline' 0 C--O 1.233 0.247 0 C-N-CA 122.999 2.466 . . . . 74.439999999999998 111.398 177.081 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -78.01 -13.53 59.84 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.89 -1.05 . . . . 74.409999999999997 110.434 178.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 62.4 tttp -110.51 135.29 51.4 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.008 0.432 . . . . 73.519999999999996 110.938 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . 0.977 ' HB3' HD22 ' B' ' 156' ' ' ASN . 5.0 mp -97.85 126.22 43.11 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.616 -0.883 . . . . 70.140000000000001 108.616 175.104 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 51.2 mm -86.88 115.72 63.48 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-O 120.626 0.251 . . . . 73.120000000000005 110.611 -175.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.574 ' O ' HG22 ' B' ' 172' ' ' ILE . 49.3 Cg_endo -69.09 172.23 12.35 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.923 2.415 . . . . 75.439999999999998 112.172 178.61 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -84.49 8.8 15.28 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.926 -0.579 . . . . 71.030000000000001 111.968 -167.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . 0.539 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 31.8 p90 -108.33 -26.82 10.33 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.6 -0.519 . . . . 75.019999999999996 109.6 170.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.539 ' HG2' ' CD1' ' B' ' 170' ' ' TRP . 5.7 mm-40 -86.22 -13.49 46.74 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.932 -0.576 . . . . 60.100000000000001 111.549 -177.044 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.574 HG22 ' O ' ' B' ' 168' ' ' PRO . 24.0 pt -61.15 -27.9 42.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.568 -0.742 . . . . 74.230000000000004 111.554 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -110.15 44.01 1.29 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.299 0.571 . . . . 74.519999999999996 110.341 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 22.8 t -69.02 -22.96 64.03 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.569 -0.741 . . . . 74.439999999999998 110.446 178.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . 0.513 ' HE3' ' HE3' ' B' ' 121' ' ' LYS . 10.2 p-90 . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.383 -0.817 . . . . 70.439999999999998 110.965 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.796 0 N-CA-C 111.848 -0.501 . . . . 73.200000000000003 111.848 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -83.68 92.5 7.71 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.043 0.449 . . . . 72.420000000000002 110.221 176.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -123.47 123.72 41.28 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.989 -0.55 . . . . 75.319999999999993 110.605 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -158.37 -166.81 2.01 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.532 -0.914 . . . . 73.120000000000005 108.532 178.021 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -82.54 110.7 17.87 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.824 0.345 . . . . 74.409999999999997 110.326 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -68.1 120.83 77.13 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.014 -0.539 . . . . 64.340000000000003 111.253 -177.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_endo -78.38 174.88 11.75 Favored 'Trans proline' 0 C--O 1.233 0.252 0 C-N-CA 122.998 2.465 . . . . 74.319999999999993 112.461 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 24.8 m -77.72 141.63 39.2 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.176 -0.466 . . . . 73.209999999999994 109.825 178.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.476 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 102.93 52.85 0.93 Allowed Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 109.091 -1.604 . . . . 54.409999999999997 109.091 -168.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -88.51 103.49 5.42 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 114.233 -0.984 . . . . 75.140000000000001 109.722 -168.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.868 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 90.6 Cg_endo -87.18 101.36 0.52 Allowed 'Trans proline' 0 N--CA 1.443 -1.468 0 C-N-CA 122.539 2.16 . . . . 72.450000000000003 112.636 -172.649 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.13 149.74 20.96 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 116.067 -0.515 . . . . 74.439999999999998 109.98 -178.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.652 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 13.9 p -106.87 127.58 62.34 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.384 0.612 . . . . 75.540000000000006 110.61 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.463 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 25.3 m -91.77 112.33 24.21 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.833 -0.621 . . . . 71.299999999999997 109.44 176.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.9 mt -95.1 111.49 25.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.153 0.501 . . . . 74.420000000000002 111.54 -174.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 33.7 mmt180 -119.89 156.88 29.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.615 -0.72 . . . . 75.200000000000003 109.798 173.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -127.56 107.59 10.06 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.988 0.423 . . . . 74.25 110.795 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.432 ' HB2' ' HE2' ' A' ' 21' ' ' LYS . 54.9 mm-40 -97.57 81.72 2.98 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.012 -0.54 . . . . 73.230000000000004 109.595 178.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.47 -118.74 5.18 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.602 -0.808 . . . . 63.409999999999997 111.637 -176.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.735 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 42.7 m-20 -101.82 16.88 24.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.437 0.16 . . . . 64.310000000000002 110.962 179.048 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.496 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 23.1 pttm -123.49 122.52 38.43 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.269 0.557 . . . . 63.520000000000003 111.545 -179.261 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 36.2 m -83.73 103.98 13.47 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.273 -0.876 . . . . 65.439999999999998 109.577 174.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 51.0 mt -95.53 109.99 23.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.91 0.386 . . . . 73.129999999999995 110.03 -177.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.652 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 51.6 mt-30 -101.33 119.72 39.18 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.84 -0.618 . . . . 74.439999999999998 111.787 -175.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.463 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 29.0 mt-10 -89.77 99.98 12.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.619 -0.719 . . . . 71.019999999999996 110.36 175.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.43 ' CD2' ' HB3' ' B' ' 151' ' ' ASP . 68.3 m-85 -81.15 101.5 9.69 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.824 -0.436 . . . . 72.5 109.824 175.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 58.6 mtt180 -115.03 129.28 56.67 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.121 -0.49 . . . . 74.140000000000001 110.013 -179.064 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.868 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 2.4 p -90.0 -57.64 4.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-O 120.915 0.388 . . . . 63.310000000000002 111.541 -177.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.501 ' H ' HG12 ' A' ' 28' ' ' VAL . 5.1 t-20 -127.63 50.5 2.02 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 109.007 -0.738 . . . . 74.209999999999994 109.007 -179.246 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 92.42 -29.74 7.47 Favored Glycine 0 N--CA 1.45 -0.39 0 CA-C-N 115.484 -0.78 . . . . 71.200000000000003 112.292 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.556 ' CD2' HG21 ' B' ' 128' ' ' VAL . 57.1 t80 -92.35 134.43 34.92 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.113 0.482 . . . . 70.010000000000005 110.843 -176.247 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.834 HD13 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -72.84 118.81 16.23 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.225 -0.898 . . . . 74.329999999999998 109.965 177.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . 0.406 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 39.5 p90 -104.79 -25.54 12.61 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 120.3 -0.56 . . . . 74.400000000000006 111.263 179.528 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.423 ' O ' ' HB2' ' A' ' 26' ' ' TYR . . . -156.85 137.89 13.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.935 0.397 . . . . 73.219999999999999 111.102 178.622 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.834 HG13 HD13 ' A' ' 32' ' ' LEU . 76.4 mt -110.4 119.79 59.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.093 -0.503 . . . . 75.310000000000002 109.812 175.727 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -102.43 101.28 11.48 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.043 -0.663 . . . . 72.219999999999999 109.535 174.414 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.526 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.4 p -93.48 120.66 43.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 N-CA-C 109.525 -0.546 . . . . 73.420000000000002 109.525 176.361 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.58 HG12 ' HB3' ' A' ' 44' ' ' PRO . 41.7 t -107.34 86.25 2.57 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.365 -0.834 . . . . 73.400000000000006 109.858 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.526 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 62.3 Cg_endo -85.39 132.76 4.43 Favored 'Trans proline' 0 N--CA 1.445 -1.35 0 C-N-CA 122.347 2.031 . . . . 70.200000000000003 112.278 179.066 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.735 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 58.1 mtpt -62.61 -20.34 64.66 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.51 -0.768 . . . . 75.230000000000004 109.604 173.609 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 10.6 m-70 -123.6 96.94 5.16 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.216 -0.902 . . . . 73.120000000000005 108.942 177.067 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.464 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 133.64 -18.77 4.3 Favored Glycine 0 CA--C 1.52 0.373 0 C-N-CA 120.558 -0.83 . . . . 73.239999999999995 113.075 178.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.464 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 69.6 mmtt 75.31 136.6 0.05 OUTLIER Pre-proline 0 N--CA 1.47 0.556 0 C-N-CA 123.432 0.693 . . . . 73.530000000000001 112.39 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.58 ' HB3' HG12 ' A' ' 38' ' ' VAL . 21.8 Cg_endo -61.03 143.43 99.23 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 123.497 2.798 . . . . 75.430000000000007 113.334 -177.23 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.523 ' CE1' HG11 ' A' ' 37' ' ' VAL . 4.9 p90 -158.48 160.79 37.14 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.818 -0.628 . . . . 75.420000000000002 110.116 178.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.653 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 90.3 m-85 -100.03 142.0 32.1 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.294 -0.412 . . . . 75.430000000000007 111.073 -179.376 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 51.9 mt -113.98 103.05 10.77 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.791 -0.64 . . . . 75.209999999999994 109.367 168.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 43.0 t -86.34 133.58 29.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.129 -0.487 . . . . 75.409999999999997 110.287 -178.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.414 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 33.8 tpt85 -76.71 115.54 16.57 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.958 -0.386 . . . . 73.450000000000003 109.958 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.14 154.79 18.68 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 116.094 -0.503 . . . . 71.030000000000001 111.406 -179.037 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -73.15 167.03 21.99 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.626 -0.715 . . . . 73.439999999999998 111.632 -176.022 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.54 10.22 86.08 Favored Glycine 0 N--CA 1.454 -0.131 0 CA-C-N 115.41 -0.814 . . . . 70.120000000000005 112.801 172.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.5 m 61.14 17.83 8.48 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 122.919 0.488 . . . . 72.040000000000006 111.745 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -50.39 -66.02 0.46 Allowed 'General case' 0 N--CA 1.468 0.451 0 O-C-N 123.607 0.567 . . . . 72.120000000000005 111.898 -178.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 137.4 -18.12 3.49 Favored Glycine 0 CA--C 1.508 -0.381 0 C-N-CA 120.591 -0.814 . . . . 71.230000000000004 111.759 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.414 ' ND2' ' HB3' ' A' ' 66' ' ' LEU . 13.8 t-20 -66.04 146.41 54.72 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.141 -0.53 . . . . 71.430000000000007 111.036 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.487 ' HB2' HG21 ' A' ' 72' ' ' ILE . 35.4 m-85 -119.35 141.46 49.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.256 -0.429 . . . . 73.219999999999999 110.082 175.686 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.4 ' CG2' ' HA ' ' A' ' 63' ' ' PRO . 49.6 mm -108.18 124.36 64.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.993 -0.549 . . . . 74.239999999999995 110.521 -177.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.428 HH11 ' HD3' ' A' ' 59' ' ' ARG . 42.4 mtp-105 -77.7 137.78 38.69 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.92 -0.4 . . . . 74.299999999999997 109.92 177.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.653 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 63.6 p -67.51 -23.95 65.52 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.403 0.62 . . . . 74.329999999999998 110.082 175.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -70.17 -43.08 71.54 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.217 -0.901 . . . . 64.400000000000006 110.569 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.9 mm100 -134.9 76.19 59.77 Favored Pre-proline 0 N--CA 1.441 -0.899 0 CA-C-N 115.95 -0.568 . . . . 73.540000000000006 111.193 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.4 ' HA ' ' CG2' ' A' ' 58' ' ' ILE . 26.5 Cg_exo -63.47 -15.88 51.19 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 123.011 2.474 . . . . 74.420000000000002 112.533 177.019 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -75.24 -20.85 58.99 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.882 -0.599 . . . . 74.439999999999998 110.683 178.765 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 22.7 tptm -109.37 129.03 55.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.192 0.52 . . . . 71.040000000000006 111.495 -176.225 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.414 ' HB3' ' ND2' ' A' ' 56' ' ' ASN . 5.9 mp -89.93 128.8 36.3 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.43 -0.804 . . . . 75.329999999999998 109.965 176.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 50.5 mm -96.31 124.89 49.78 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 116.353 -0.385 . . . . 72.230000000000004 111.597 -173.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.562 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 38.1 Cg_endo -65.22 174.39 5.06 Favored 'Trans proline' 0 C--N 1.348 0.509 0 C-N-CA 123.13 2.553 . . . . 73.319999999999993 112.887 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 16.4 tt0 -83.82 -9.01 59.08 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.804 -0.635 . . . . 75.439999999999998 111.924 -168.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 38.4 p90 -96.88 -5.09 38.96 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.296 0.57 . . . . 74.120000000000005 109.927 175.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.562 ' HB2' ' HG2' ' A' ' 68' ' ' PRO . 4.8 mm-40 -115.63 10.76 15.62 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.42 -0.809 . . . . 75.329999999999998 111.145 -176.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.532 HG23 ' O ' ' A' ' 68' ' ' PRO . 18.9 pt -90.33 -11.25 9.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-O 121.096 0.474 . . . . 75.109999999999999 110.811 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 33.8 p90 -128.5 27.25 5.57 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.954 -0.566 . . . . 74.319999999999993 110.419 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 4.8 m -49.76 -41.33 43.8 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.692 -0.686 . . . . 73.030000000000001 111.041 -179.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . 0.496 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 10.3 p-90 . . . . . 0 C--N 1.326 -0.439 0 CA-C-N 115.787 -0.642 . . . . 75.120000000000005 111.043 175.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.434 0 N-CA-C 112.334 -0.307 . . . . 64.519999999999996 112.334 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -86.19 144.14 27.62 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.881 -0.414 . . . . 71.239999999999995 109.881 176.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -100.12 110.22 22.5 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.866 0.841 . . . . 73.409999999999997 111.664 -176.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -127.65 127.83 44.44 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 107.166 -1.42 . . . . 74.109999999999999 107.166 169.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -48.28 107.32 0.12 Allowed 'General case' 0 N--CA 1.468 0.471 0 O-C-N 123.678 0.611 . . . . 75.439999999999998 112.115 -170.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . 0.4 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -107.07 148.55 37.21 Favored Pre-proline 0 C--N 1.32 -0.689 0 CA-C-N 115.328 -0.851 . . . . 62.340000000000003 110.351 -179.122 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 24.8 Cg_exo -64.95 175.86 3.46 Favored 'Trans proline' 0 C--O 1.233 0.252 0 C-N-CA 122.943 2.429 . . . . 72.109999999999999 112.352 177.018 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 42.7 m -60.32 129.51 42.05 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.197 -0.456 . . . . 51.210000000000001 110.238 176.607 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 128.14 82.04 0.34 Allowed Glycine 0 N--CA 1.446 -0.65 0 N-CA-C 110.577 -1.009 . . . . 70.25 110.577 -173.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . 0.414 ' HA ' ' HD3' ' B' ' 111' ' ' PRO . 13.4 mt-10 -123.38 114.13 29.04 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-O 121.327 0.584 . . . . 74.299999999999997 109.975 -172.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.814 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 19.2 Cg_endo -89.01 102.29 0.38 Allowed 'Trans proline' 0 N--CA 1.438 -1.766 0 C-N-CA 122.832 2.355 . . . . 70.439999999999998 112.397 -176.241 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -101.57 115.28 30.16 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.188 -0.671 . . . . 72.239999999999995 109.188 178.274 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . . . . . . . . . 7.9 p -72.71 132.64 33.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.625 -0.716 . . . . 74.439999999999998 111.082 -176.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 27.4 m -93.22 99.17 11.78 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.464 -0.789 . . . . 74.120000000000005 109.742 174.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.594 HG21 ' HG2' ' B' ' 124' ' ' GLN . 71.3 mt -96.06 106.03 17.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.838 -0.619 . . . . 72.340000000000003 110.286 -177.252 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 39.1 mmt180 -118.75 149.6 41.19 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.192 0.52 . . . . 72.299999999999997 110.485 178.279 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -100.6 113.64 26.64 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-O 121.596 0.712 . . . . 75.450000000000003 110.865 -179.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . 0.529 ' HB3' ' HE2' ' B' ' 121' ' ' LYS . 0.7 OUTLIER -102.83 48.92 0.85 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.003 -0.999 . . . . 71.430000000000007 109.851 -176.785 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 97.74 -117.35 5.78 Favored Glycine 0 N--CA 1.446 -0.652 0 N-CA-C 111.223 -0.751 . . . . 63.130000000000003 111.223 -176.266 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . 0.485 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 3.6 m-20 -89.13 -3.32 58.67 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.037 0.446 . . . . 73.340000000000003 110.308 177.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.674 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 25.4 pttm -111.79 120.19 41.13 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.205 0.526 . . . . 75.530000000000001 111.303 -177.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 122' ' ' THR . . . . . 0.462 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 5.5 m -84.03 111.96 19.77 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.908 -0.587 . . . . 72.400000000000006 109.611 175.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 51.4 mt -101.17 108.12 22.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-O 121.104 0.478 . . . . 74.400000000000006 110.368 -177.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.594 ' HG2' HG21 ' B' ' 115' ' ' ILE . 8.8 mt-30 -105.28 103.76 13.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.792 -0.64 . . . . 72.099999999999994 110.366 -178.427 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -88.4 108.82 19.56 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.234 -0.439 . . . . 73.450000000000003 110.766 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . 0.455 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 46.7 m-85 -82.37 106.39 14.21 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.218 -0.446 . . . . 74.400000000000006 110.47 177.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -120.86 125.31 47.16 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.508 -0.553 . . . . 72.439999999999998 109.508 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.814 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 3.5 p -93.65 -41.63 12.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 120.757 0.313 . . . . 73.510000000000005 111.497 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -158.6 70.37 0.52 Allowed 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.606 -0.438 . . . . 73.150000000000006 110.584 -175.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 78.87 -4.05 62.64 Favored Glycine 0 N--CA 1.454 -0.162 0 CA-C-N 115.692 -0.686 . . . . 65.319999999999993 113.574 175.218 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -130.0 129.32 43.57 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.097 0.475 . . . . 75.030000000000001 110.717 -178.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.876 HD12 HG13 ' B' ' 135' ' ' ILE . 3.5 tm? -73.5 118.35 16.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 114.875 -1.057 . . . . 74.230000000000004 109.462 175.223 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . 0.455 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 46.3 p90 -106.09 -23.77 12.53 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.66 -0.416 . . . . 75.450000000000003 111.528 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . 0.459 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -158.99 134.55 8.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.806 0.336 . . . . 73.109999999999999 111.282 179.005 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.876 HG13 HD12 ' B' ' 132' ' ' LEU . 74.3 mt -114.07 130.73 67.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 N-CA-C 109.634 -0.506 . . . . 73.219999999999999 109.634 174.151 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -107.79 110.41 22.21 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.679 -0.489 . . . . 74.439999999999998 109.679 174.232 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.622 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.4 t -93.67 131.14 41.44 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 108.808 -0.812 . . . . 74.010000000000005 108.808 176.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.462 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 17.2 t -117.73 72.86 8.33 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 109.961 -0.385 . . . . 73.409999999999997 109.961 173.582 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.674 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 52.4 Cg_endo -78.48 134.73 12.69 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 122.367 2.044 . . . . 70.340000000000003 112.596 176.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . 0.485 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 48.6 mtpt -60.83 -33.21 72.69 Favored 'General case' 0 CA--C 1.518 -0.262 0 CA-C-O 121.416 0.627 . . . . 73.129999999999995 109.596 173.37 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 36.6 m-70 -110.52 82.58 1.62 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.252 -0.885 . . . . 74.349999999999994 109.2 177.038 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 150.68 -26.73 1.06 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.357 -0.925 . . . . 73.549999999999997 113.054 -179.335 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . 0.484 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 70.7 mmtt 76.68 148.91 0.12 Allowed Pre-proline 0 N--CA 1.472 0.635 0 C-N-CA 123.283 0.633 . . . . 73.230000000000004 111.933 178.4 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.622 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 38.3 Cg_endo -66.27 127.6 17.79 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 123.069 2.513 . . . . 73.349999999999994 113.492 -176.098 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -143.91 150.48 38.47 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.79 -0.641 . . . . 72.049999999999997 110.734 179.327 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.669 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 77.8 m-85 -98.14 146.16 25.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.976 -0.556 . . . . 74.420000000000002 110.466 178.345 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . 0.459 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 59.9 mt -122.73 100.55 6.97 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.826 -0.625 . . . . 73.030000000000001 109.555 171.156 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 61.4 t -92.84 130.34 42.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.054 -0.521 . . . . 74.140000000000001 110.677 -178.036 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . 0.534 HH11 ' HG3' ' B' ' 149' ' ' ARG . 0.3 OUTLIER -72.2 128.07 34.53 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.913 0.387 . . . . 74.239999999999995 111.689 -179.429 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.87 155.78 38.62 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 115.738 -0.664 . . . . 75.030000000000001 110.612 176.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . 0.43 ' HB3' ' CD2' ' A' ' 26' ' ' TYR . 3.9 p-10 -77.6 162.21 27.25 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.287 0.565 . . . . 73.530000000000001 111.736 -173.08 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.93 21.73 60.77 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.284 -0.871 . . . . 72.430000000000007 112.364 173.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 25.2 m 55.87 30.11 15.31 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-O 120.969 0.414 . . . . 75.319999999999993 110.384 -177.011 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -51.37 -64.39 0.83 Allowed 'General case' 0 N--CA 1.461 0.121 0 CA-C-N 114.851 -1.068 . . . . 74.120000000000005 111.068 -178.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 132.2 -36.36 2.21 Favored Glycine 0 CA--C 1.491 -1.458 0 C-N-CA 120.569 -0.824 . . . . 62.109999999999999 111.218 175.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . 0.621 ' OD1' ' HA ' ' B' ' 168' ' ' PRO . 75.6 m-20 -68.41 152.63 45.14 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 113.964 -1.118 . . . . 74.109999999999999 111.773 -179.424 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . 0.45 ' CE2' ' HG2' ' B' ' 149' ' ' ARG . 46.2 m-85 -112.32 157.7 20.66 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.54 -0.754 . . . . 61.200000000000003 110.248 176.285 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 49.1 mm -116.03 124.92 72.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 N-CA-C 109.596 -0.52 . . . . 74.540000000000006 109.596 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.475 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 30.2 ttt180 -85.51 137.72 32.7 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.4 -0.364 . . . . 74.200000000000003 110.165 -177.131 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 160' ' ' SER . . . . . 0.669 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 6.5 p -57.18 -42.6 81.49 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.722 0.638 . . . . 64.409999999999997 112.722 -174.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -86.04 -1.06 57.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.979 0.419 . . . . 74.140000000000001 111.551 -174.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 10.9 tp60 -151.86 71.41 7.99 Favored Pre-proline 0 C--N 1.327 -0.401 0 N-CA-C 109.614 -0.513 . . . . 73.299999999999997 109.614 -178.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -67.47 -14.41 42.36 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 123.223 2.616 . . . . 75.420000000000002 113.13 -173.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -90.52 -6.39 54.81 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.169 -0.469 . . . . 71.150000000000006 110.549 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 23.1 tptm -104.74 126.17 51.55 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.163 0.506 . . . . 74.510000000000005 110.637 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.0 mp -95.19 124.68 39.36 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.326 -0.852 . . . . 74.109999999999999 109.789 178.302 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 51.5 mm -93.17 111.58 52.44 Favored Pre-proline 0 C--N 1.32 -0.7 0 CA-C-N 116.122 -0.49 . . . . 74.120000000000005 109.827 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.621 ' HA ' ' OD1' ' B' ' 156' ' ' ASN . 60.2 Cg_endo -71.63 175.17 9.92 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.664 2.243 . . . . 71.329999999999998 113.025 -176.457 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . 0.413 ' O ' HG12 ' B' ' 172' ' ' ILE . 36.3 tt0 -78.92 -8.32 58.77 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.573 -0.739 . . . . 74.349999999999994 111.518 -170.341 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 10.3 p90 -94.23 -8.04 40.36 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.088 0.47 . . . . 74.319999999999993 110.081 174.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.462 ' O ' ' HB2' ' B' ' 174' ' ' SER . 0.1 OUTLIER -110.42 -4.63 15.47 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.891 -0.595 . . . . 65.230000000000004 110.717 -177.538 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.47 HG22 ' O ' ' B' ' 168' ' ' PRO . 36.6 pt -70.15 -18.68 21.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.231 -0.44 . . . . 74.340000000000003 111.197 -179.613 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -102.01 40.62 1.31 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.593 0.711 . . . . 74.439999999999998 109.678 176.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 174' ' ' SER . . . . . 0.462 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 4.5 t -73.38 -11.13 60.37 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 114.9 -1.045 . . . . 64.400000000000006 110.211 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . 0.441 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 0.9 OUTLIER . . . . . 0 C--O 1.245 0.829 0 CA-C-O 118.353 -0.832 . . . . 74.329999999999998 110.9 179.008 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.609 0 N-CA-C 111.987 -0.445 . . . . 72.329999999999998 111.987 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -135.69 -39.4 0.72 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.744 0.306 . . . . 72.019999999999996 111.262 -178.051 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -100.83 17.76 21.27 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.425 -0.352 . . . . 73.310000000000002 111.258 -177.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -64.5 131.09 46.13 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.244 -0.435 . . . . 65.140000000000001 110.653 177.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 61.61 68.18 0.72 Allowed 'General case' 0 C--N 1.329 -0.318 0 O-C-N 123.856 0.723 . . . . 74.439999999999998 110.752 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -109.85 149.54 40.12 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 115.325 -0.852 . . . . 72.549999999999997 110.302 -179.123 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -78.46 153.56 27.23 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.384 2.056 . . . . 74.329999999999998 112.546 179.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.5 p -94.53 119.06 32.63 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.965 -0.561 . . . . 75.430000000000007 109.749 175.025 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.03 66.33 0.53 Allowed Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.158 -1.177 . . . . 73.209999999999994 110.158 -173.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . 0.497 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -114.46 117.16 43.23 Favored Pre-proline 0 N--CA 1.44 -0.933 0 N-CA-C 107.995 -1.113 . . . . 74.150000000000006 107.995 -175.839 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.598 ' HG3' ' CZ ' ' B' ' 131' ' ' PHE . 24.7 Cg_endo -88.87 101.0 0.37 Allowed 'Trans proline' 0 N--CA 1.433 -2.049 0 C-N-CA 122.173 1.915 . . . . 73.219999999999999 111.693 -175.377 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -107.8 171.61 7.3 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 114.871 -1.059 . . . . 64.439999999999998 110.344 179.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.638 HG22 ' HB3' ' A' ' 24' ' ' GLN . 7.6 p -123.42 131.51 73.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 115.773 -0.649 . . . . 73.519999999999996 110.353 178.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.409 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 61.5 m -91.62 111.33 22.8 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.663 -0.699 . . . . 71.420000000000002 109.585 176.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 56.1 mt -88.66 103.76 14.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.942 -0.572 . . . . 74.129999999999995 110.967 -174.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.455 ' HA ' ' NE ' ' A' ' 16' ' ' ARG . 3.5 mmp_? -108.45 165.12 11.76 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.49 -0.777 . . . . 73.319999999999993 109.48 177.207 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -139.13 111.44 7.5 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.042 0.449 . . . . 73.340000000000003 110.502 174.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 30.9 mm-40 -103.77 100.57 10.38 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.448 -0.796 . . . . 75.319999999999993 109.002 178.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.25 -109.31 2.83 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.529 -0.843 . . . . 75.230000000000004 111.664 -175.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -111.02 8.46 21.91 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.788 0.294 . . . . 74.310000000000002 111.078 -177.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.702 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 0.3 OUTLIER -114.97 118.54 33.73 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.434 0.635 . . . . 74.540000000000006 111.463 179.484 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.723 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 20.7 m -76.59 98.33 4.65 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.19 -0.914 . . . . 54.340000000000003 109.618 175.213 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 38.3 mt -90.31 105.39 16.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.221 0.534 . . . . 74.329999999999998 110.234 -176.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.638 ' HB3' HG22 ' A' ' 13' ' ' VAL . 21.6 mt-30 -94.67 112.78 24.51 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.433 -0.803 . . . . 75.340000000000003 110.734 -177.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.409 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.6 mt-10 -91.99 108.85 20.23 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.03 -0.532 . . . . 65.219999999999999 110.736 -177.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.458 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 41.3 m-85 -84.72 106.06 15.98 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.349 -0.387 . . . . 75.409999999999997 110.687 178.173 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 71.3 mtm-85 -130.01 123.61 30.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.064 -0.516 . . . . 74.329999999999998 110.11 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.2 p -97.18 -41.99 11.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.313 -0.403 . . . . 75.099999999999994 111.48 -179.055 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 11.7 t-20 -153.65 73.37 0.95 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.006 0.432 . . . . 75.329999999999998 110.294 -176.087 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 67.03 18.53 69.0 Favored Glycine 0 C--N 1.33 0.207 0 CA-C-N 115.815 -0.63 . . . . 65.310000000000002 112.845 177.224 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.613 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 87.8 t80 -139.67 128.59 23.49 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.994 0.426 . . . . 70.519999999999996 111.042 -178.117 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.823 HD13 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -82.36 110.31 17.39 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.112 -0.949 . . . . 74.140000000000001 108.544 172.822 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . 0.458 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 45.5 p90 -103.92 -17.49 14.99 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.885 -0.326 . . . . 74.150000000000006 111.478 -178.39 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.454 ' O ' ' HB2' ' A' ' 26' ' ' TYR . . . -159.35 140.34 12.67 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.878 0.371 . . . . 52.100000000000001 111.105 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.823 HG13 HD13 ' A' ' 32' ' ' LEU . 66.9 mt -117.6 124.95 73.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 N-CA-C 109.653 -0.499 . . . . 74.230000000000004 109.653 174.326 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.606 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.9 tttt -106.01 103.77 13.33 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.533 -0.543 . . . . 73.409999999999997 109.533 176.11 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.734 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.6 t -88.7 127.24 41.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.839 -0.8 . . . . 75.439999999999998 108.839 177.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.723 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 22.0 t -115.14 74.0 3.64 Favored Pre-proline 0 C--N 1.318 -0.769 0 N-CA-C 109.55 -0.537 . . . . 74.340000000000003 109.55 172.492 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.702 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 39.4 Cg_endo -76.86 131.1 11.92 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.011 1.807 . . . . 75.239999999999995 112.242 177.003 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -54.83 -40.0 69.13 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.522 -0.763 . . . . 74.109999999999999 110.26 177.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -116.67 82.46 1.8 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.517 -0.765 . . . . 72.239999999999995 109.228 179.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.433 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 159.15 -29.48 0.41 Allowed Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.507 -0.769 . . . . 75.140000000000001 111.428 -175.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.433 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 71.6 mmtt 76.42 143.81 0.1 OUTLIER Pre-proline 0 N--CA 1.469 0.513 0 C-N-CA 123.738 0.815 . . . . 72.329999999999998 112.267 176.19 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.734 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 30.8 Cg_endo -64.03 132.7 35.37 Favored 'Trans proline' 0 C--N 1.347 0.469 0 C-N-CA 123.218 2.612 . . . . 74.200000000000003 113.61 -176.197 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 21.9 p90 -148.36 163.2 37.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.463 -0.79 . . . . 72.5 109.645 177.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.473 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 91.2 m-85 -107.76 137.79 45.14 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.842 0.353 . . . . 75.329999999999998 111.572 -176.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 34.7 mt -114.15 104.48 12.15 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.717 -0.674 . . . . 73.329999999999998 109.216 168.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 44.4 t -92.52 137.88 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.554 -0.294 . . . . 74.519999999999996 110.333 -178.198 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.56 ' HG2' ' CE2' ' A' ' 57' ' ' PHE . 5.0 mmm180 -81.8 121.92 27.04 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.032 0.444 . . . . 72.219999999999999 110.885 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.45 167.03 19.16 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.337 -0.847 . . . . 74.230000000000004 111.22 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.466 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 9.8 p-10 -66.87 142.86 57.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.298 -0.41 . . . . 70.209999999999994 110.264 179.037 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.466 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 94.16 143.45 13.81 Favored Glycine 0 N--CA 1.433 -1.559 0 C-N-CA 120.588 -0.815 . . . . 64.329999999999998 111.566 -178.591 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 18.6 m -74.32 40.14 0.13 Allowed 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.174 0.511 . . . . 74.430000000000007 110.677 176.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.466 ' H ' ' C ' ' A' ' 52' ' ' GLY . 18.0 t70 -78.01 -39.86 40.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.779 -0.646 . . . . 53.310000000000002 110.357 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 112.02 -32.05 6.6 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.636 -0.792 . . . . 65.239999999999995 113.302 176.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -58.29 149.82 23.44 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 113.027 0.751 . . . . 72.120000000000005 113.027 -175.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.56 ' CE2' ' HG2' ' A' ' 49' ' ' ARG . 63.3 m-85 -115.5 168.3 10.12 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.096 -0.956 . . . . 73.310000000000002 110.697 -179.063 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 45.4 mm -128.27 132.16 68.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.995 -0.548 . . . . 75.540000000000006 109.649 174.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.796 ' HG3' HD11 ' A' ' 67' ' ' ILE . 70.7 mtt180 -78.59 147.88 33.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.809 0.337 . . . . 74.329999999999998 111.249 178.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.473 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 62.2 p -79.01 -29.86 43.92 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.681 -0.859 . . . . 54.32 108.681 165.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -70.27 -34.34 72.67 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.381 -1.281 . . . . 74.409999999999997 110.876 177.316 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . 0.569 ' HB3' ' HD2' ' A' ' 59' ' ' ARG . 9.9 tt0 -143.37 82.52 11.57 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 115.747 -0.66 . . . . 74.530000000000001 109.71 -174.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -79.58 -7.44 14.73 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.871 2.381 . . . . 75.030000000000001 113.13 -175.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -94.46 9.32 38.9 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.331 0.586 . . . . 73.439999999999998 110.165 178.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.4 tptt -125.63 128.23 47.56 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.85 -0.614 . . . . 74.150000000000006 110.429 -178.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.2 mp -87.36 111.85 21.51 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 108.434 -0.95 . . . . 73.319999999999993 108.434 175.118 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.796 HD11 ' HG3' ' A' ' 59' ' ' ARG . 34.6 mm -67.24 117.33 45.42 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.146 -0.479 . . . . 75.430000000000007 111.27 -172.254 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.1 175.03 8.08 Favored 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.676 2.251 . . . . 72.140000000000001 112.038 -179.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -84.36 -1.06 54.84 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.943 -0.572 . . . . 74.140000000000001 111.21 -169.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 16.5 p90 -98.89 -20.24 16.93 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.557 -0.457 . . . . 71.310000000000002 110.437 174.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.506 ' OE2' HD13 ' A' ' 67' ' ' ILE . 19.4 tt0 -90.55 -11.96 38.54 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 121.096 0.474 . . . . 72.219999999999999 110.536 -177.038 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 45.6 pt -64.88 -19.26 25.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.095 -0.502 . . . . 74.109999999999999 110.975 178.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -117.6 29.32 7.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.951 -0.568 . . . . 74.129999999999995 110.289 176.121 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 23.0 t -63.72 -26.76 68.8 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.898 -0.592 . . . . 61.240000000000002 110.15 179.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 20.8 p-90 . . . . . 0 C--N 1.324 -0.528 0 CA-C-N 115.896 -0.593 . . . . 72.409999999999997 110.579 175.069 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.163 -0.375 . . . . 74.510000000000005 112.163 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -92.13 -31.34 15.54 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.343 0.592 . . . . 74.409999999999997 110.19 178.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -120.71 166.43 13.72 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.416 -0.811 . . . . 75.540000000000006 109.968 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -137.86 104.14 5.19 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.261 -0.427 . . . . 63.240000000000002 109.978 178.106 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 38.9 t70 67.28 97.13 0.06 Allowed 'General case' 0 N--CA 1.465 0.296 0 O-C-N 123.936 0.772 . . . . 75.219999999999999 110.709 -177.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . 0.436 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -68.29 133.49 91.36 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 115.332 -0.849 . . . . 74.439999999999998 111.693 -174.832 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 8.0 Cg_exo -72.68 155.87 53.9 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 123.246 2.631 . . . . 74.319999999999993 112.109 178.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 21.1 m -72.72 107.71 5.32 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.385 -0.371 . . . . 74.409999999999997 110.558 178.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 99.72 83.24 1.72 Allowed Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 120.876 -0.678 . . . . 72.439999999999998 111.924 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 50.7 mt-10 -109.51 102.94 51.57 Favored Pre-proline 0 C--N 1.323 -0.545 0 N-CA-C 109.046 -0.724 . . . . 75.400000000000006 109.046 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.613 ' HG3' ' CZ ' ' A' ' 31' ' ' PHE . 66.2 Cg_endo -83.48 85.83 1.46 Allowed 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 122.036 1.824 . . . . 73.549999999999997 112.076 -176.21 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -96.05 133.47 40.25 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.049 -0.978 . . . . 71.25 109.359 178.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.508 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 14.7 p -92.92 127.55 44.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 121.438 0.637 . . . . 73.109999999999999 110.262 179.089 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 21.9 m -91.3 105.46 17.8 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.794 -0.639 . . . . 72.209999999999994 109.699 177.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 63.6 mt -84.36 106.13 14.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.024 -0.535 . . . . 75.140000000000001 110.899 -176.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 14.4 mtp180 -105.99 173.05 6.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.928 -0.578 . . . . 74.010000000000005 111.052 178.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -148.2 101.16 3.24 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.743 -0.662 . . . . 71.430000000000007 110.891 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . 0.592 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 3.8 mp0 -104.52 90.61 3.57 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.457 -0.792 . . . . 75.420000000000002 110.399 -178.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 76.85 -89.52 0.96 Allowed Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.775 -0.726 . . . . 75.200000000000003 112.486 179.282 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -127.57 14.57 7.06 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.458 0.129 . . . . 65.310000000000002 110.899 178.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.592 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 38.4 pttt -123.6 121.36 35.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.267 0.556 . . . . 72.150000000000006 111.181 -179.085 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 122' ' ' THR . . . . . 0.513 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 20.8 m -84.13 98.31 9.83 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.488 -0.778 . . . . 75.150000000000006 109.748 176.412 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . 0.465 HD12 ' HE3' ' B' ' 121' ' ' LYS . 30.4 mt -89.68 107.52 18.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.174 0.511 . . . . 73.409999999999997 110.599 -177.231 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.508 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 20.8 mt-30 -97.95 107.6 20.12 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.783 -0.644 . . . . 74.049999999999997 110.515 -178.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -87.47 111.23 20.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.014 -0.539 . . . . 74.510000000000005 110.485 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . 0.466 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 78.5 m-85 -85.16 101.29 12.34 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.046 -0.353 . . . . 74.400000000000006 110.046 176.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 20.6 mtm180 -113.41 128.05 56.32 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.413 -0.358 . . . . 75.030000000000001 110.234 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.606 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -96.58 -50.6 11.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 C-N-CA 120.731 -0.388 . . . . 75.540000000000006 111.521 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -156.67 76.1 0.87 Allowed 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.622 -0.51 . . . . 73.040000000000006 109.622 -176.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 66.94 16.73 66.69 Favored Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.713 -0.676 . . . . 73.209999999999994 112.403 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . 0.598 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 89.4 t80 -137.33 128.34 27.52 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.038 0.447 . . . . 73.120000000000005 110.791 -179.07 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.796 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -83.2 113.35 20.6 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.175 -0.92 . . . . 75.120000000000005 108.791 173.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . 0.407 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 50.9 p90 -104.88 -14.99 15.3 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.388 -0.525 . . . . 73.430000000000007 111.665 -178.07 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -159.9 143.01 13.93 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.897 0.38 . . . . 72.209999999999994 111.278 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.796 HG13 HD11 ' B' ' 132' ' ' LEU . 80.8 mt -120.93 127.09 75.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.931 -0.577 . . . . 73.329999999999998 109.889 174.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.431 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 82.6 tttt -116.69 101.12 8.31 Favored 'General case' 0 C--N 1.321 -0.63 0 N-CA-C 109.411 -0.588 . . . . 74.319999999999993 109.411 172.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.518 ' O ' ' HD3' ' B' ' 139' ' ' PRO . 4.9 p -101.95 129.38 53.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.978 0 C-N-CA 120.231 -0.588 . . . . 73.200000000000003 109.758 178.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.513 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 37.5 t -109.07 84.91 2.94 Favored Pre-proline 0 C--N 1.322 -0.591 0 CA-C-N 115.553 -0.748 . . . . 75.230000000000004 109.976 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.518 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 69.0 Cg_endo -87.86 133.46 3.02 Favored 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 122.506 2.138 . . . . 75.239999999999995 112.365 178.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -60.97 -20.31 62.2 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.94 -0.573 . . . . 75.099999999999994 110.304 174.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 5.6 m-70 -122.66 81.88 1.91 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.425 -0.807 . . . . 73.400000000000006 109.181 -175.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 140.0 -17.44 2.98 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.736 -0.745 . . . . 73.340000000000003 112.64 -178.082 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt 70.79 145.5 0.11 Allowed Pre-proline 0 N--CA 1.472 0.639 0 C-N-CA 123.41 0.684 . . . . 75.239999999999995 111.896 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.478 ' HB3' HG23 ' B' ' 138' ' ' VAL . 43.0 Cg_endo -67.95 149.1 77.36 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.62 2.213 . . . . 72.25 113.09 -177.342 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -158.71 156.7 30.37 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.848 -0.615 . . . . 74.549999999999997 109.695 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.402 ' O ' ' HA ' ' B' ' 159' ' ' ARG . 59.9 m-85 -102.29 134.34 45.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.647 0.261 . . . . 73.430000000000007 111.117 -179.221 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 46.0 mt -114.02 105.31 13.07 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.045 -0.525 . . . . 70.439999999999998 109.704 170.036 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 46.7 t -97.79 137.27 25.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.123 -0.49 . . . . 75.209999999999994 110.147 -178.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 2.8 mmt85 -75.68 131.64 40.02 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.99 0.424 . . . . 75.439999999999998 111.458 178.235 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -87.58 169.68 11.96 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.644 -0.707 . . . . 72.129999999999995 109.215 172.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . 0.413 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 6.2 p-10 -69.99 125.52 26.99 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.374 0.606 . . . . 61.109999999999999 109.971 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 120.95 127.9 3.49 Favored Glycine 0 N--CA 1.442 -0.91 0 CA-C-N 115.505 -0.77 . . . . 73.209999999999994 112.12 -178.395 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 12.2 t -79.45 45.25 0.65 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.433 0.635 . . . . 74.109999999999999 110.08 178.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -84.88 -16.94 39.49 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.39 -0.823 . . . . 72.319999999999993 110.57 -178.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 86.39 23.56 43.25 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.825 -0.703 . . . . 74.239999999999995 111.666 -177.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 30.7 t30 -99.57 129.95 45.77 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.268 -0.466 . . . . 72.030000000000001 110.681 -177.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -116.59 151.08 36.94 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.815 -0.63 . . . . 61.020000000000003 110.004 178.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.7 mm -117.96 129.55 74.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 116.17 -0.468 . . . . 74.310000000000002 109.777 178.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.447 ' HG3' HD11 ' B' ' 167' ' ' ILE . 92.9 mtt180 -75.02 150.78 38.84 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.821 0.343 . . . . 74.510000000000005 111.136 179.362 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 64.7 p -81.29 -27.73 34.95 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 107.993 -1.114 . . . . 70.140000000000001 107.993 164.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -64.7 -35.61 81.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.019 -1.446 . . . . 65.519999999999996 110.94 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 9.3 tt0 -153.24 85.59 4.19 Favored Pre-proline 0 C--N 1.322 -0.589 0 CA-C-N 115.518 -0.764 . . . . 72.5 109.557 -177.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -79.14 8.87 3.6 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 123.106 2.537 . . . . 71.349999999999994 112.766 -176.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -107.4 3.9 25.73 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.214 0.531 . . . . 74.140000000000001 110.729 -178.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -125.23 130.65 52.51 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.855 -0.612 . . . . 74.239999999999995 110.484 -179.059 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . 0.419 HD11 ' N ' ' B' ' 166' ' ' LEU . 4.7 mp -84.67 119.81 25.66 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.695 -0.854 . . . . 75.150000000000006 108.695 176.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . 0.447 HD11 ' HG3' ' B' ' 159' ' ' ARG . 36.4 mm -80.56 119.51 76.49 Favored Pre-proline 0 C--N 1.322 -0.614 0 CA-C-O 120.995 0.426 . . . . 75.120000000000005 111.177 -172.048 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.542 ' O ' HG22 ' B' ' 172' ' ' ILE . 58.1 Cg_endo -69.73 173.0 11.58 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.803 2.335 . . . . 74.329999999999998 112.098 178.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . 0.621 ' O ' HG12 ' B' ' 172' ' ' ILE . 5.5 tt0 -73.78 -33.11 64.11 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.734 -0.666 . . . . 64.530000000000001 111.362 -168.71 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 11.6 p90 -66.4 -17.72 64.94 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.437 -0.505 . . . . 73.420000000000002 110.714 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.578 ' HA ' ' HB2' ' B' ' 174' ' ' SER . 20.1 tt0 -102.46 -17.68 15.68 Favored 'General case' 0 N--CA 1.444 -0.727 0 CA-C-N 116.428 -0.351 . . . . 72.420000000000002 111.496 -177.024 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.621 HG12 ' O ' ' B' ' 169' ' ' GLN . 30.7 pt -70.18 -27.54 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.954 0.407 . . . . 72.439999999999998 110.509 178.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -118.22 36.25 4.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.517 0.675 . . . . 73.409999999999997 109.782 173.194 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 174' ' ' SER . . . . . 0.578 ' HB2' ' HA ' ' B' ' 171' ' ' GLU . 45.3 t -62.39 -27.17 68.89 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.023 -0.99 . . . . 62.210000000000001 111.194 -179.307 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . 0.445 ' C ' ' HZ3' ' B' ' 121' ' ' LYS . 0.7 OUTLIER . . . . . 0 C--O 1.246 0.916 0 CA-C-O 118.437 -0.792 . . . . 75.400000000000006 111.263 -179.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.669 0 N-CA-C 112.076 -0.41 . . . . 54.329999999999998 112.076 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.45 -22.84 21.21 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.73 0.3 . . . . 70.409999999999997 111.242 -176.681 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 14.3 p-10 -83.77 -44.44 14.4 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.467 -0.333 . . . . 43.219999999999999 110.497 -178.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -166.24 -167.25 1.01 Allowed 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.094 -0.706 . . . . 73.239999999999995 109.094 175.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -126.09 111.78 15.08 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.905 0.383 . . . . 73.319999999999993 110.5 -178.374 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -98.91 115.1 65.95 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 115.989 -0.551 . . . . 71.510000000000005 111.142 -177.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -84.37 -160.25 0.11 Allowed 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 123.053 2.502 . . . . 74.340000000000003 112.228 177.092 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.0 p -79.41 178.05 8.4 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.305 -0.407 . . . . 64.409999999999997 110.875 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.2 -73.34 2.63 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.77 -0.729 . . . . 73.219999999999999 111.467 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 60.4 74.87 0.51 Allowed Pre-proline 0 C--N 1.329 -0.285 0 C-N-CA 123.046 0.538 . . . . 65.099999999999994 110.152 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.922 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 12.2 Cg_endo -60.32 107.33 0.41 Allowed 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.597 2.198 . . . . 74.120000000000005 112.708 -178.806 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 23.7 m-20 -90.5 154.03 19.94 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.627 -0.715 . . . . 61.43 109.876 179.163 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.478 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 12.5 p -117.99 125.74 74.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-O 121.395 0.617 . . . . 72.299999999999997 110.549 176.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.6 m -98.53 111.45 23.81 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.548 -0.751 . . . . 73.030000000000001 110.062 179.253 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.8 mt -93.2 105.86 17.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.285 -0.416 . . . . 75.209999999999994 110.945 -176.374 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -120.48 167.42 12.39 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.014 -0.735 . . . . 74.329999999999998 109.014 177.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 91.6 mt-30 -127.35 119.0 25.24 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 120.929 0.395 . . . . 73.310000000000002 111.281 177.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.427 ' HG3' HD12 ' A' ' 23' ' ' ILE . 12.4 mm-40 -97.52 82.54 3.11 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.939 -0.763 . . . . 73.230000000000004 108.939 175.151 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 79.63 -107.03 2.51 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.3 -0.952 . . . . 64.230000000000004 111.351 -173.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.561 ' HB3' ' HB2' ' A' ' 40' ' ' LYS . 10.3 m-20 -108.85 0.41 20.27 Favored 'General case' 0 C--N 1.327 -0.38 0 O-C-N 122.615 -0.344 . . . . 72.430000000000007 111.114 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.805 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 22.1 pttm -101.74 113.03 25.84 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.443 0.64 . . . . 72.420000000000002 111.022 179.085 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.694 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 21.1 m -80.0 97.87 6.97 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.222 -0.899 . . . . 63.420000000000002 109.798 177.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.561 HG12 HG13 ' A' ' 37' ' ' VAL . 55.0 mt -90.85 112.23 24.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.035 0.445 . . . . 73.439999999999998 110.566 -176.544 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.57 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 17.1 mt-30 -95.67 108.33 20.61 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.961 -0.563 . . . . 72.349999999999994 109.956 178.21 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -84.82 102.81 13.36 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.78 -0.646 . . . . 74.450000000000003 110.346 -177.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.417 ' HE1' ' HB2' ' A' ' 36' ' ' LYS . 86.3 m-85 -82.12 102.38 11.02 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.162 0.506 . . . . 64.239999999999995 109.783 176.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 88.1 mtm180 -118.12 117.52 29.39 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.853 -0.612 . . . . 73.109999999999999 109.93 -179.382 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.922 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 2.6 p -69.4 -43.19 81.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.924 -0.58 . . . . 71.310000000000002 111.14 -174.356 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 33.9 t-20 -169.85 75.35 0.08 Allowed 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.644 -0.873 . . . . 65.400000000000006 108.644 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 85.22 -23.54 8.1 Favored Glycine 0 N--CA 1.45 -0.416 0 CA-C-N 115.443 -0.799 . . . . 70.340000000000003 112.676 -177.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 51.2 t80 -112.25 131.24 55.6 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.215 0.531 . . . . 75.120000000000005 110.749 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.493 HD22 ' CG1' ' A' ' 35' ' ' ILE . 27.2 tp -76.66 126.21 30.59 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 114.974 -1.012 . . . . 72.239999999999995 110.463 178.471 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . 0.41 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 49.6 p90 -115.23 -14.3 11.71 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.764 -0.374 . . . . 75.329999999999998 111.173 179.068 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -161.72 143.81 11.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.998 0.428 . . . . 74.310000000000002 111.142 -177.602 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.6 ' HB ' ' HB2' ' A' ' 47' ' ' LEU . 63.7 mt -121.84 121.35 64.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.992 -0.549 . . . . 64.239999999999995 109.87 176.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.57 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 88.2 tttt -102.19 99.62 9.76 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.244 -0.651 . . . . 75.430000000000007 109.244 172.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.704 HG11 ' HD3' ' A' ' 39' ' ' PRO . 3.5 t -86.18 126.63 40.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 108.568 -0.901 . . . . 72.0 108.568 178.132 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.694 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.6 t -115.73 72.87 4.19 Favored Pre-proline 0 C--N 1.318 -0.761 0 N-CA-C 109.753 -0.462 . . . . 72.349999999999994 109.753 172.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.805 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 43.2 Cg_endo -77.08 129.4 10.5 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 122.041 1.827 . . . . 75.120000000000005 112.413 177.179 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.561 ' HB2' ' HB3' ' A' ' 20' ' ' ASP . 55.7 mtpt -59.05 -32.13 69.47 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.043 -0.981 . . . . 74.400000000000006 110.285 176.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 67.9 m-70 -115.36 95.93 5.41 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.365 -0.834 . . . . 65.209999999999994 109.314 178.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 132.46 -23.06 4.08 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 121.009 -0.615 . . . . 71.439999999999998 111.99 -176.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.496 ' HD3' ' HA ' ' A' ' 43' ' ' LYS . 68.8 mmtt 72.99 148.94 0.12 Allowed Pre-proline 0 N--CA 1.467 0.389 0 C-N-CA 123.86 0.864 . . . . 74.340000000000003 112.651 177.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.652 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 27.9 Cg_endo -62.59 141.86 87.68 Favored 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 123.04 2.493 . . . . 62.340000000000003 113.921 -174.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.417 ' CE2' ' HG2' ' A' ' 59' ' ' ARG . 25.1 p90 -151.43 149.42 29.26 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-N 115.361 -0.836 . . . . 74.030000000000001 109.855 176.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.576 ' HB2' ' HB2' ' A' ' 60' ' ' SER . 88.6 m-85 -92.35 150.4 20.86 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.286 -0.416 . . . . 75.439999999999998 111.14 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.6 ' HB2' ' HB ' ' A' ' 35' ' ' ILE . 23.0 mt -123.37 96.46 4.99 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.711 -0.677 . . . . 74.030000000000001 109.674 171.252 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 45.8 t -90.16 122.24 41.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.438 -0.346 . . . . 63.399999999999999 110.519 -178.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -62.25 128.98 38.64 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 120.974 0.416 . . . . 74.510000000000005 111.303 176.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.9 152.33 19.44 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.452 -0.573 . . . . 74.420000000000002 109.452 172.601 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -57.85 144.07 40.12 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.332 -0.395 . . . . 72.409999999999997 110.58 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 118.45 148.31 8.46 Favored Glycine 0 N--CA 1.431 -1.684 0 C-N-CA 120.198 -1.001 . . . . 51.240000000000002 112.402 -179.664 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 16.6 m -76.67 -2.63 33.76 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 114.947 -0.626 . . . . 74.400000000000006 110.779 175.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -57.91 -43.66 86.34 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.142 -0.481 . . . . 70.319999999999993 112.048 -178.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 98.79 32.76 5.8 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.419 -0.896 . . . . 62.310000000000002 111.63 -179.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.78 HD22 HD21 ' A' ' 66' ' ' LEU . 32.1 t30 -87.06 132.82 33.7 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.367 -0.416 . . . . 74.299999999999997 110.417 -178.342 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -122.17 160.17 25.7 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.994 -0.548 . . . . 71.019999999999996 110.211 177.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.806 HD11 HD23 ' A' ' 66' ' ' LEU . 43.9 mm -120.22 115.32 46.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 116.279 -0.419 . . . . 74.439999999999998 109.972 177.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.673 ' HG3' HG13 ' A' ' 67' ' ' ILE . 18.7 mtp180 -75.95 130.1 37.94 Favored 'General case' 0 C--O 1.22 -0.492 0 CA-C-N 115.785 -0.643 . . . . 74.420000000000002 109.797 177.366 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.576 ' HB2' ' HB2' ' A' ' 46' ' ' PHE . 17.4 t -70.48 -17.53 62.97 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.894 0.854 . . . . 75.530000000000001 108.79 172.504 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -67.76 -27.38 66.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 114.384 -1.28 . . . . 75.319999999999993 110.453 173.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 -158.88 78.84 3.01 Favored Pre-proline 0 C--N 1.327 -0.404 0 CA-C-N 115.664 -0.698 . . . . 75.420000000000002 109.484 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_endo -78.76 -1.24 11.43 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.725 2.284 . . . . 71.209999999999994 112.375 -174.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -92.52 0.09 57.39 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.406 -0.816 . . . . 72.430000000000007 110.205 -178.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.427 ' HE3' ' O ' ' A' ' 66' ' ' LEU . 52.4 tptt -128.48 134.29 48.68 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.732 -0.667 . . . . 74.109999999999999 110.539 -179.078 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.806 HD23 HD11 ' A' ' 58' ' ' ILE . 26.2 mt -80.29 123.48 28.01 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.129 -0.693 . . . . 75.409999999999997 109.129 175.182 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.673 HG13 ' HG3' ' A' ' 59' ' ' ARG . 44.1 mm -92.43 113.76 60.32 Favored Pre-proline 0 C--N 1.32 -0.681 0 CA-C-O 120.941 0.401 . . . . 75.340000000000003 111.277 -173.08 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -72.62 177.99 6.82 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.887 2.392 . . . . 74.239999999999995 112.961 -177.288 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . 0.52 ' O ' HG12 ' A' ' 72' ' ' ILE . 19.4 tt0 -77.58 -17.14 58.13 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.493 -0.776 . . . . 73.340000000000003 112.067 -168.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 10.4 p90 -83.16 -18.32 39.83 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.251 -0.58 . . . . 74.329999999999998 110.281 176.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.547 ' HB3' HG21 ' A' ' 67' ' ' ILE . 1.4 tm-20 -90.35 -24.49 20.82 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 115.933 -0.576 . . . . 75.329999999999998 109.966 -178.304 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.52 HG12 ' O ' ' A' ' 69' ' ' GLN . 31.5 pt -70.28 -20.89 23.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 121.223 0.535 . . . . 74.420000000000002 110.396 177.766 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 46.2 m-85 -111.62 33.67 4.6 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.787 -0.642 . . . . 75.010000000000005 109.822 174.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 19.0 t -67.0 -33.17 74.98 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.384 -0.825 . . . . 70.109999999999999 110.171 178.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . 0.442 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 8.2 p-90 . . . . . 0 C--N 1.327 -0.398 0 CA-C-N 116.003 -0.544 . . . . 74.340000000000003 110.602 175.386 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.405 0 N-CA-C 112.186 -0.366 . . . . 74.329999999999998 112.186 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -78.59 -39.31 37.79 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.198 0.523 . . . . 63.109999999999999 110.368 178.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . 0.419 ' O ' ' HB3' ' B' ' 104' ' ' ASP . 6.4 p-10 -109.14 117.34 33.89 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.079 -0.711 . . . . 74.329999999999998 109.079 173.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . 0.419 ' HB3' ' O ' ' B' ' 103' ' ' ASP . 8.4 t70 70.18 136.59 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 121.522 0.677 . . . . 64.409999999999997 111.615 -177.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -121.4 128.65 52.42 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.829 -0.623 . . . . 72.129999999999995 110.991 -178.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . 0.489 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -115.36 135.09 22.52 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.199 -0.455 . . . . 71.209999999999994 110.516 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . 0.489 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 15.1 Cg_endo -90.71 -161.25 0.1 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 123.408 2.739 . . . . 64.540000000000006 112.698 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 5.2 p -73.37 162.33 29.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.777 -0.647 . . . . 74.239999999999995 111.065 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 108.75 -77.21 0.22 Allowed Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.588 -1.005 . . . . 73.329999999999998 110.588 -177.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 68.85 86.68 0.12 Allowed Pre-proline 0 CA--C 1.521 -0.171 0 CA-C-O 121.274 0.559 . . . . 74.209999999999994 110.558 173.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.679 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 3.0 Cg_exo -69.95 118.04 5.45 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 122.298 1.999 . . . . 74.439999999999998 111.731 -174.493 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -118.44 161.38 20.07 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.091 -0.958 . . . . 62.5 109.763 -174.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . . . . . . . . . 14.6 p -133.3 132.63 58.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.428 0.632 . . . . 72.430000000000007 111.5 -178.012 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 31.4 m -97.17 105.07 17.16 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.527 -0.76 . . . . 75.099999999999994 109.266 174.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 65.6 mt -95.59 104.66 16.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.369 0.604 . . . . 72.450000000000003 110.703 -176.369 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 57.1 mtm180 -123.55 176.06 6.42 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.247 -0.888 . . . . 73.109999999999999 109.354 176.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . 0.715 ' HG2' ' HA ' ' B' ' 122' ' ' THR . 37.7 mt-30 -134.17 139.73 46.05 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.411 0.624 . . . . 73.120000000000005 111.389 178.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . 0.558 ' HB3' ' HE2' ' B' ' 121' ' ' LYS . 0.9 OUTLIER -120.15 72.85 0.95 Allowed 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.954 -1.021 . . . . 74.340000000000003 109.679 -177.075 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 87.93 -108.87 3.44 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.611 -0.804 . . . . 71.409999999999997 111.703 -175.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . 0.712 ' HB3' ' HD2' ' B' ' 140' ' ' LYS . 39.5 m-20 -109.9 13.24 23.55 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.932 0.396 . . . . 75.140000000000001 110.616 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.558 ' HE2' ' HB3' ' B' ' 118' ' ' GLU . 23.7 pttm -120.02 116.49 25.85 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.868 -0.606 . . . . 74.129999999999995 110.664 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 122' ' ' THR . . . . . 0.715 ' HA ' ' HG2' ' B' ' 117' ' ' GLN . 20.0 m -77.4 122.16 24.78 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.598 -0.728 . . . . 75.200000000000003 109.495 176.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 55.7 mt -112.4 107.79 23.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.328 0.585 . . . . 75.439999999999998 110.819 -176.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.49 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 12.4 mt-30 -100.5 102.9 14.19 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.724 -0.671 . . . . 75.430000000000007 109.935 178.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . 0.4 ' HB3' HD11 ' B' ' 132' ' ' LEU . 48.3 mt-10 -82.92 104.58 13.24 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.005 -0.543 . . . . 73.120000000000005 110.521 -179.612 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . 0.416 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 79.2 m-85 -82.15 108.9 15.98 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.165 0.507 . . . . 74.430000000000007 110.147 178.356 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 82.9 mtt180 -118.97 121.41 39.86 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.806 -0.634 . . . . 75.329999999999998 109.342 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.878 HG12 HG12 ' A' ' 28' ' ' VAL . 2.1 p -70.68 -46.44 69.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 C-N-CA 120.761 -0.376 . . . . 74.430000000000007 110.719 -178.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -158.34 56.96 0.46 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.482 0.658 . . . . 63.210000000000001 109.427 -177.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 98.04 -23.74 34.76 Favored Glycine 0 N--CA 1.449 -0.452 0 CA-C-N 115.589 -0.732 . . . . 74.0 112.86 -178.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -104.28 129.82 52.11 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 121.062 0.458 . . . . 74.530000000000001 110.46 -178.064 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.543 HD22 ' CG1' ' B' ' 135' ' ' ILE . 28.7 tp -74.46 120.86 20.6 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.107 -0.952 . . . . 72.219999999999999 110.6 177.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . 0.416 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 54.1 p90 -110.86 -12.96 14.21 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.845 -0.342 . . . . 74.510000000000005 111.204 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . 0.555 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -167.1 137.1 2.96 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.974 0.416 . . . . 71.25 111.141 -177.337 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.543 ' CG1' HD22 ' B' ' 132' ' ' LEU . 56.9 mt -114.58 122.78 69.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.02 -0.536 . . . . 73.200000000000003 109.821 175.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.49 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.3 tttt -96.0 101.51 13.19 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.089 -0.708 . . . . 64.430000000000007 109.089 172.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.67 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.0 t -91.62 125.84 44.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 108.493 -0.929 . . . . 72.209999999999994 108.493 177.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.53 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.3 t -115.48 72.91 3.81 Favored Pre-proline 0 C--N 1.316 -0.867 0 N-CA-C 109.672 -0.492 . . . . 54.409999999999997 109.672 173.791 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.624 ' HD3' HG13 ' B' ' 137' ' ' VAL . 56.8 Cg_endo -80.21 133.32 9.76 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 122.153 1.902 . . . . 73.040000000000006 112.005 175.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . 0.712 ' HD2' ' HB3' ' B' ' 120' ' ' ASP . 93.0 mttt -52.05 -40.93 61.88 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.527 0.68 . . . . 60.210000000000001 110.219 175.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 8.6 m-70 -112.26 91.9 3.82 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.108 -0.951 . . . . 75.530000000000001 109.429 -175.056 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . 0.403 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 140.66 -21.65 2.7 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.819 -0.628 . . . . 61.420000000000002 111.832 -177.014 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . 0.403 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 74.6 mmtt 75.3 150.62 0.13 Allowed Pre-proline 0 N--CA 1.469 0.491 0 C-N-CA 123.544 0.738 . . . . 73.319999999999993 111.708 178.271 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.67 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 36.5 Cg_endo -66.9 137.39 44.8 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 122.461 2.107 . . . . 63.549999999999997 112.791 -177.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . 0.404 ' CD2' ' HD2' ' B' ' 159' ' ' ARG . 50.8 p90 -149.51 150.28 32.06 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.751 -0.659 . . . . 73.129999999999995 110.352 179.276 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.539 ' O ' ' HA ' ' B' ' 159' ' ' ARG . 92.4 m-85 -95.74 130.35 42.68 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.778 -0.646 . . . . 75.519999999999996 110.375 176.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . 0.555 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 15.0 mt -99.77 99.29 10.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.119 -0.491 . . . . 74.310000000000002 109.908 170.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.0 t -83.97 127.99 39.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 116.311 -0.404 . . . . 75.430000000000007 110.246 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.99 108.72 2.7 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.124 -0.695 . . . . 74.209999999999994 109.124 176.418 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.24 166.38 9.95 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.207 -0.451 . . . . 72.510000000000005 110.97 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -53.5 129.03 31.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.7 0.762 . . . . 75.450000000000003 112.52 -175.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 83.11 -115.99 4.13 Favored Glycine 0 N--CA 1.429 -1.816 0 CA-C-N 114.447 -1.251 . . . . 70.310000000000002 111.509 178.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 17.0 m -169.41 34.51 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 113.803 -1.198 . . . . 65.540000000000006 109.384 -178.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -78.79 35.7 0.25 Allowed 'General case' 0 CA--C 1.535 0.365 0 CA-C-N 115.4 -0.818 . . . . 72.25 111.405 -173.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 58.12 43.23 95.35 Favored Glycine 0 C--O 1.229 -0.212 0 CA-C-N 115.789 -0.641 . . . . 73.310000000000002 113.21 177.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 47.1 t30 -137.3 137.83 39.39 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.185 0.516 . . . . 74.319999999999993 111.085 -177.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . 0.484 ' HB3' HD22 ' B' ' 147' ' ' LEU . 39.0 m-85 -131.09 154.25 48.48 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.189 -0.914 . . . . 75.129999999999995 108.697 172.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 49.2 mm -120.65 122.79 68.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 N-CA-C 110.183 -0.303 . . . . 73.109999999999999 110.183 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.935 ' HG3' HG13 ' B' ' 167' ' ' ILE . 31.5 mtm-85 -88.9 137.28 32.46 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-N 116.338 -0.392 . . . . 72.439999999999998 110.126 178.067 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 35.1 t -64.69 -18.94 65.44 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.445 0.64 . . . . 73.319999999999993 109.334 171.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -59.37 -52.13 66.95 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 114.942 -1.027 . . . . 71.150000000000006 110.878 174.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 26.2 mt-30 -143.71 79.6 13.45 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 74.409999999999997 110.442 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -68.21 -0.58 5.87 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 123.292 2.661 . . . . 73.530000000000001 112.329 177.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -81.44 -18.48 45.16 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.639 -0.71 . . . . 64.25 110.233 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -119.95 140.11 51.42 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.856 -0.611 . . . . 61.549999999999997 110.885 -177.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.0 mp -81.87 126.87 32.4 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 107.898 -1.149 . . . . 74.319999999999993 107.898 171.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . 0.935 HG13 ' HG3' ' B' ' 159' ' ' ARG . 44.7 mm -87.81 119.66 70.63 Favored Pre-proline 0 C--N 1.318 -0.794 0 CA-C-O 120.882 0.372 . . . . 75.340000000000003 111.267 -170.425 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.437 ' O ' HG23 ' B' ' 172' ' ' ILE . 58.8 Cg_endo -71.09 174.3 10.85 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 123.27 2.647 . . . . 73.140000000000001 112.655 -179.187 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . 0.805 ' HA ' HG12 ' B' ' 172' ' ' ILE . 8.5 tt0 -72.75 -32.62 65.79 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.58 -0.736 . . . . 61.439999999999998 111.963 -168.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 36.9 p90 -73.56 -17.86 61.14 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.165 0.507 . . . . 74.439999999999998 110.326 178.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -94.28 -30.86 14.33 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.847 -0.615 . . . . 63.229999999999997 110.964 178.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.805 HG12 ' HA ' ' B' ' 169' ' ' GLN . 37.6 pt -74.45 -29.3 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.985 0.421 . . . . 73.400000000000006 110.381 176.312 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -104.76 37.86 2.04 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.184 0.516 . . . . 73.140000000000001 110.13 175.256 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 15.9 t -73.78 -22.88 59.69 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.827 -0.624 . . . . 71.219999999999999 110.262 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . 0.533 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 60.3 p-90 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.243 -0.884 . . . . 75.209999999999994 110.656 -178.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.84 0 N-CA-C 112.195 -0.362 . . . . 72.230000000000004 112.195 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -144.72 79.74 1.61 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.719 0.295 . . . . 72.349999999999994 110.801 179.398 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 62.11 20.87 11.98 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.721 -0.672 . . . . 72.299999999999997 111.963 178.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -95.62 155.35 16.78 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.146 0.498 . . . . 75.109999999999999 110.588 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 34.8 t70 -93.29 133.1 36.87 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.768 -0.651 . . . . 63.539999999999999 110.972 -177.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -87.63 138.23 31.74 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-N 115.845 -0.616 . . . . 70.329999999999998 111.096 -177.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -82.24 179.46 5.49 Favored 'Trans proline' 0 N--CA 1.464 -0.261 0 C-N-CA 122.954 2.436 . . . . 74.319999999999993 112.938 -177.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 28.5 p -72.42 110.43 6.82 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-N 116.135 -0.484 . . . . 74.430000000000007 110.043 176.122 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.79 105.63 3.02 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 110.2 -1.16 . . . . 72.439999999999998 110.2 -173.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -116.76 95.74 47.06 Favored Pre-proline 0 C--N 1.317 -0.823 0 N-CA-C 109.516 -0.55 . . . . 74.409999999999997 109.516 -171.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.29 100.35 1.36 Allowed 'Trans proline' 0 N--CA 1.445 -1.372 0 C-N-CA 121.797 1.664 . . . . 63.530000000000001 111.422 -177.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -132.12 145.28 51.28 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.222 -0.899 . . . . 75.329999999999998 109.546 178.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.7 HG21 ' HB3' ' A' ' 24' ' ' GLN . 12.8 p -98.63 131.5 45.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 CA-C-O 121.297 0.57 . . . . 75.239999999999995 111.674 -172.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.488 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 25.0 m -83.69 103.79 13.28 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.686 -0.688 . . . . 75.219999999999999 109.211 176.527 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 61.3 mt -93.44 105.66 17.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 116.246 -0.434 . . . . 74.099999999999994 110.474 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 28.4 mmm180 -121.41 153.74 37.43 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.99 -0.55 . . . . 73.299999999999997 110.29 177.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 23.3 mp0 -113.49 107.66 16.12 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-O 121.355 0.598 . . . . 75.510000000000005 110.522 -178.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.596 ' HG3' HD12 ' A' ' 23' ' ' ILE . 24.1 mm-40 -106.21 88.4 2.78 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.204 -0.907 . . . . 72.510000000000005 109.8 -177.115 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 74.11 -109.57 2.83 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.702 -0.761 . . . . 64.340000000000003 112.201 -179.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.668 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 25.4 m-20 -109.31 22.4 15.87 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.752 0.311 . . . . 72.010000000000005 110.507 -177.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.584 ' HE2' HD13 ' A' ' 23' ' ' ILE . 22.2 pttm -138.41 127.05 23.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.307 0.575 . . . . 64.409999999999997 111.175 -178.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.579 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 26.4 m -85.13 103.9 14.54 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.623 -0.717 . . . . 62.329999999999998 109.232 174.423 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.596 HD12 ' HG3' ' A' ' 18' ' ' GLU . 41.7 mt -95.61 112.54 28.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.162 0.505 . . . . 72.420000000000002 110.294 -176.029 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.7 ' HB3' HG21 ' A' ' 13' ' ' VAL . 23.9 mt-30 -103.82 109.78 21.65 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.413 -0.812 . . . . 75.040000000000006 111.111 -176.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.488 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 24.7 mt-10 -94.61 106.67 18.66 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.032 -0.531 . . . . 72.409999999999997 111.137 -179.113 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.477 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 54.5 m-85 -76.69 109.52 10.53 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.276 -0.42 . . . . 74.120000000000005 110.508 178.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 74.7 mtt180 -124.06 140.49 52.92 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.337 -0.392 . . . . 75.099999999999994 110.115 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.496 HG23 ' CG ' ' B' ' 131' ' ' PHE . 12.3 p -109.03 -19.47 6.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.422 0.63 . . . . 72.530000000000001 111.28 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -159.82 24.54 0.18 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.237 -0.653 . . . . 73.420000000000002 109.237 -176.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 99.62 -31.18 8.65 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 110.984 -0.846 . . . . 75.319999999999993 110.984 -169.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 89.3 t80 -66.87 130.1 42.04 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.178 -0.511 . . . . 75.299999999999997 110.811 178.004 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.724 HD12 HG13 ' A' ' 35' ' ' ILE . 3.3 tm? -88.38 114.47 25.03 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.554 -0.748 . . . . 71.010000000000005 109.231 178.19 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . 0.477 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 43.2 p90 -110.98 -13.27 14.13 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.664 -0.414 . . . . 74.299999999999997 111.682 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -163.21 144.42 9.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.723 0.296 . . . . 73.140000000000001 111.34 179.588 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.724 HG13 HD12 ' A' ' 32' ' ' LEU . 71.3 mt -126.1 123.71 64.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.111 -0.495 . . . . 72.430000000000007 109.768 176.07 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -108.81 107.22 17.56 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.628 -0.508 . . . . 70.310000000000002 109.628 176.029 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.653 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.7 t -89.92 132.31 34.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.189 -0.671 . . . . 63.310000000000002 109.189 178.38 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.579 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 18.9 t -116.57 73.97 6.05 Favored Pre-proline 0 C--N 1.322 -0.623 0 N-CA-C 109.433 -0.58 . . . . 73.200000000000003 109.433 171.194 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.472 ' HD3' HG11 ' A' ' 37' ' ' VAL . 61.0 Cg_endo -78.71 145.87 20.69 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.642 2.228 . . . . 75.420000000000002 112.977 179.212 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.668 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 30.5 mtpp -68.07 -28.0 66.99 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.514 -0.766 . . . . 73.530000000000001 109.932 174.043 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 66.5 m-70 -122.52 96.2 4.94 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.55 -0.75 . . . . 70.010000000000005 109.745 178.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.415 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 139.51 -21.5 2.9 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.73 -0.747 . . . . 75.420000000000002 112.422 -179.649 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.422 ' HD3' ' HA ' ' A' ' 43' ' ' LYS . 69.4 mmtt 71.89 150.38 0.13 Allowed Pre-proline 0 N--CA 1.47 0.56 0 C-N-CA 123.201 0.6 . . . . 75.549999999999997 111.956 -179.593 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.653 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 39.4 Cg_endo -67.0 137.18 43.72 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.564 2.176 . . . . 73.530000000000001 112.683 -178.359 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 42.0 p90 -149.52 163.95 36.41 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.738 -0.664 . . . . 73.329999999999998 110.294 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.47 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 96.3 m-85 -108.22 126.44 52.81 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.484 -0.325 . . . . 75.109999999999999 111.429 -176.797 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.436 ' HB3' ' HD2' ' A' ' 57' ' ' PHE . 36.9 mt -107.22 100.14 9.62 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.131 -0.486 . . . . 72.510000000000005 109.977 171.253 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.6 t -84.74 126.72 40.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.245 -0.434 . . . . 73.349999999999994 109.901 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.45 111.39 18.43 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.236 -0.653 . . . . 73.420000000000002 109.236 -178.542 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.05 168.89 19.01 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.8 -0.636 . . . . 64.420000000000002 111.411 -172.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -64.14 145.19 56.37 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.765 -0.652 . . . . 74.329999999999998 109.904 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.413 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 113.83 135.95 6.26 Favored Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.452 -0.88 . . . . 74.340000000000003 112.373 -179.785 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.2 m -79.24 19.68 0.56 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.931 0.396 . . . . 61.539999999999999 110.832 178.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.413 ' H ' ' C ' ' A' ' 52' ' ' GLY . 21.6 t70 -78.91 -42.61 26.7 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.026 0.441 . . . . 64.219999999999999 111.137 -177.313 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.84 36.4 2.99 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.698 -0.763 . . . . 75.319999999999993 111.919 -178.404 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.2 t30 -95.45 129.49 42.59 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.821 0.343 . . . . 74.049999999999997 110.539 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.436 ' HD2' ' HB3' ' A' ' 47' ' ' LEU . 34.7 m-85 -111.51 149.38 31.43 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.227 -0.442 . . . . 74.340000000000003 110.153 177.016 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 51.0 mm -121.57 125.73 73.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.22 -0.445 . . . . 74.430000000000007 109.98 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.568 ' HG3' HG13 ' A' ' 67' ' ' ILE . 27.4 mtp180 -81.6 141.08 34.05 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.438 -0.346 . . . . 72.120000000000005 110.66 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 33.7 t -70.0 -16.21 63.14 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.229 0.538 . . . . 74.140000000000001 109.894 176.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.453 ' OD1' ' HB3' ' A' ' 59' ' ' ARG . 0.4 OUTLIER -76.03 -34.41 59.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.4 -0.818 . . . . 73.310000000000002 109.945 178.169 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 47.7 mt-30 -143.26 70.36 18.01 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.443 -0.799 . . . . 74.329999999999998 109.786 -174.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -72.88 -2.35 11.83 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 123.325 2.684 . . . . 74.310000000000002 113.476 -175.067 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -94.06 -13.63 26.67 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.608 0.242 . . . . 71.450000000000003 111.332 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.406 ' HE2' ' HB2' ' A' ' 65' ' ' LYS . 0.0 OUTLIER -117.02 168.76 9.97 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-O 120.549 0.214 . . . . 73.049999999999997 110.943 -179.567 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.438 ' N ' HD13 ' A' ' 66' ' ' LEU . 4.1 mp -106.3 151.84 24.31 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 120.831 0.348 . . . . 74.109999999999999 111.032 -175.228 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.568 HG13 ' HG3' ' A' ' 59' ' ' ARG . 37.9 mm -119.54 104.98 44.43 Favored Pre-proline 0 C--N 1.325 -0.463 0 CA-C-N 116.192 -0.458 . . . . 74.510000000000005 109.98 177.519 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.548 ' O ' HG23 ' A' ' 72' ' ' ILE . 61.3 Cg_endo -73.77 177.42 8.11 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.822 2.348 . . . . 62.219999999999999 113.004 -178.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . 0.62 ' HA ' HG12 ' A' ' 72' ' ' ILE . 28.5 tt0 -65.32 -32.05 73.5 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 113.029 0.751 . . . . 72.329999999999998 113.029 -168.159 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 3.9 p90 -71.34 -18.95 62.36 Favored 'General case' 0 C--N 1.323 -0.545 0 O-C-N 121.517 -0.739 . . . . 74.430000000000007 110.592 178.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.481 ' HB3' HG21 ' A' ' 67' ' ' ILE . 4.8 tp10 -102.38 -17.76 15.7 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 115.749 -0.66 . . . . 72.430000000000007 110.549 -177.117 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.62 HG12 ' HA ' ' A' ' 69' ' ' GLN . 35.3 pt -74.26 -21.77 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.147 0 CA-C-O 121.256 0.55 . . . . 74.239999999999995 109.863 174.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -107.21 26.59 9.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.417 -0.81 . . . . 73.540000000000006 109.664 174.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.2 t -61.42 -29.84 70.19 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.197 -0.91 . . . . 65.540000000000006 110.234 179.295 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . 0.514 ' O ' ' HE3' ' A' ' 21' ' ' LYS . 28.3 p-90 . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.135 -0.484 . . . . 72.219999999999999 110.757 175.399 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 N-CA-C 112.128 -0.389 . . . . 73.230000000000004 112.128 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -140.67 -59.99 0.51 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.086 0.469 . . . . 75.219999999999999 110.117 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -139.08 81.84 1.86 Allowed 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 108.703 -0.851 . . . . 74.200000000000003 108.703 173.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -173.21 177.92 2.57 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.468 -0.787 . . . . 71.510000000000005 110.208 -172.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -114.95 161.97 17.58 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.113 -0.494 . . . . 74.439999999999998 110.832 -177.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -118.21 139.18 26.39 Favored Pre-proline 0 C--N 1.321 -0.638 0 CA-C-N 115.652 -0.704 . . . . 74.219999999999999 109.428 172.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.2 148.95 87.84 Favored 'Trans proline' 0 C--O 1.236 0.39 0 C-N-CA 122.451 2.101 . . . . 72.420000000000002 111.798 178.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 15.0 m -51.5 130.27 27.3 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-O 121.108 0.48 . . . . 72.430000000000007 110.737 -178.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 124.49 -65.6 0.54 Allowed Glycine 0 N--CA 1.442 -0.953 0 N-CA-C 109.983 -1.247 . . . . 74.049999999999997 109.983 -174.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 66.82 86.4 0.13 Allowed Pre-proline 0 N--CA 1.463 0.178 0 O-C-N 124.334 0.667 . . . . 65.319999999999993 111.736 173.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.584 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 11.2 Cg_endo -77.58 97.16 1.13 Allowed 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 121.913 1.742 . . . . 72.549999999999997 110.775 177.441 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -128.81 150.82 50.15 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.407 -0.815 . . . . 75.310000000000002 109.67 -175.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.529 HG21 ' HB3' ' B' ' 124' ' ' GLN . 12.0 p -100.7 131.31 48.56 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 121.417 0.627 . . . . 75.109999999999999 111.748 -174.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 114' ' ' THR . . . . . 0.579 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 15.6 m -87.77 102.43 14.66 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.5 -0.773 . . . . 74.140000000000001 109.772 175.585 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 55.1 mt -91.03 105.82 16.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-O 120.829 0.347 . . . . 75.040000000000006 110.495 -176.291 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 28.7 mmm180 -112.85 157.89 20.84 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.259 -0.428 . . . . 74.340000000000003 110.464 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -121.22 99.32 6.42 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.23 -0.441 . . . . 61.140000000000001 109.961 178.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 57.5 mm-40 -109.59 80.86 1.36 Allowed 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.981 -0.554 . . . . 74.230000000000004 110.515 -176.353 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 82.26 -121.43 5.43 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 121.008 -0.615 . . . . 73.209999999999994 112.32 -179.351 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . 0.486 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 5.9 m-20 -88.57 0.89 55.88 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.914 0.388 . . . . 74.109999999999999 110.527 -176.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.615 ' HE2' ' HB2' ' B' ' 175' ' ' TRP . 15.6 pttp -125.47 124.67 41.9 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.349 0.595 . . . . 75.120000000000005 112.373 -172.54 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 122' ' ' THR . . . . . 0.44 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 33.4 m -83.97 109.7 17.84 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.044 -0.98 . . . . 75.25 108.595 172.114 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 53.2 mt -100.3 107.83 21.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.107 0.48 . . . . 75.450000000000003 110.627 -173.45 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.663 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 17.0 mt-30 -95.5 102.26 14.05 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.67 -0.695 . . . . 75.329999999999998 110.45 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . 0.579 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 43.3 mt-10 -86.87 102.31 14.2 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.265 -0.425 . . . . 73.5 110.365 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -78.54 104.83 9.4 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.122 0.487 . . . . 75.299999999999997 110.017 178.101 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . 0.508 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 82.6 mtm180 -126.14 136.76 53.26 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.653 -0.703 . . . . 71.519999999999996 110.141 -179.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.677 HG11 ' H ' ' B' ' 129' ' ' ASN . 2.4 p -84.81 -67.87 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 C-N-CA 120.32 -0.552 . . . . 72.109999999999999 109.658 175.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . 0.677 ' H ' HG11 ' B' ' 128' ' ' VAL . 2.2 t-20 -138.64 75.84 1.54 Allowed 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.56 -0.533 . . . . 72.019999999999996 109.56 178.332 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.7 -27.55 5.29 Favored Glycine 0 CA--C 1.518 0.231 0 CA-C-N 115.771 -0.65 . . . . 75.439999999999998 112.223 -178.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . 0.496 ' CG ' HG23 ' A' ' 28' ' ' VAL . 82.9 t80 -86.19 124.75 32.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.902 0.382 . . . . 65.530000000000001 111.225 -177.176 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.836 HD13 HG13 ' B' ' 135' ' ' ILE . 3.5 tm? -85.6 119.38 25.88 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.893 -0.78 . . . . 75.409999999999997 108.893 175.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 44.1 p90 -112.94 -17.11 12.55 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.495 -0.482 . . . . 75.420000000000002 111.787 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.46 133.22 6.43 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.717 0.294 . . . . 72.209999999999994 111.059 178.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.836 HG13 HD13 ' B' ' 132' ' ' LEU . 69.8 mt -113.28 120.34 62.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.453 -0.339 . . . . 74.409999999999997 110.174 174.4 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.663 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.9 tttt -101.0 104.64 15.81 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.682 -0.488 . . . . 74.519999999999996 109.682 176.213 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.61 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 2.7 t -90.91 128.67 42.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 108.928 -0.767 . . . . 74.409999999999997 108.928 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.44 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 20.3 t -112.96 73.34 1.57 Allowed Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.771 -0.455 . . . . 75.450000000000003 109.771 171.253 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.473 ' HD3' HG12 ' B' ' 137' ' ' VAL . 72.9 Cg_endo -80.66 143.84 15.24 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 122.438 2.092 . . . . 71.340000000000003 112.76 178.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . 0.486 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 30.0 mtpp -65.75 -23.77 66.81 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.483 -0.78 . . . . 74.209999999999994 110.383 174.04 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 72.6 m-70 -115.91 95.07 4.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.574 -0.739 . . . . 63.329999999999998 110.025 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . 0.452 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 127.58 -9.93 6.83 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.178 -1.011 . . . . 51.43 113.638 177.093 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 73.1 mmtt 70.64 155.9 0.15 Allowed Pre-proline 0 N--CA 1.472 0.644 0 CA-C-O 120.755 0.312 . . . . 75.329999999999998 111.164 -178.488 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.61 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 33.6 Cg_endo -66.48 135.13 38.17 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.192 1.928 . . . . 70.540000000000006 112.84 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . 0.471 ' HE1' ' HG3' ' B' ' 139' ' ' PRO . 14.7 p90 -146.4 161.28 40.71 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.768 -0.651 . . . . 73.099999999999994 110.205 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -106.75 138.46 42.88 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.27 -0.423 . . . . 72.439999999999998 111.758 -176.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . 0.463 ' HB2' ' HB ' ' B' ' 135' ' ' ILE . 18.7 mt -110.38 95.73 5.76 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.447 -0.797 . . . . 75.299999999999997 109.72 168.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 41.6 t -82.14 126.39 39.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 109.692 -0.484 . . . . 72.409999999999997 109.692 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . 0.463 HH11 ' HG3' ' B' ' 149' ' ' ARG . 0.0 OUTLIER -80.86 114.66 19.89 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.439 -0.578 . . . . 73.209999999999994 109.439 -179.228 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.75 165.18 25.65 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.627 -0.715 . . . . 70.420000000000002 111.005 -174.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -70.44 147.57 49.32 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.581 -0.526 . . . . 71.420000000000002 109.581 178.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 105.01 131.26 7.03 Favored Glycine 0 N--CA 1.436 -1.347 0 C-N-CA 120.61 -0.805 . . . . 61.340000000000003 111.357 -175.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 21.6 m -82.77 17.8 1.75 Allowed 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.286 0.565 . . . . 75.010000000000005 110.587 -178.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -64.77 -52.96 54.14 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.488 -0.778 . . . . 73.239999999999995 110.958 -178.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 125.86 50.36 0.18 Allowed Glycine 0 CA--C 1.505 -0.588 0 C-N-CA 120.657 -0.782 . . . . 74.109999999999999 112.025 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 4.9 m120 -119.06 134.29 55.28 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.356 -0.422 . . . . 74.239999999999995 111.484 -177.305 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . 0.439 ' HB2' HG23 ' B' ' 172' ' ' ILE . 29.6 m-85 -117.31 159.19 23.1 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.541 -0.754 . . . . 73.319999999999993 109.735 174.357 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . 0.823 HD13 HD22 ' B' ' 166' ' ' LEU . 47.4 mm -120.7 122.79 68.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 116.256 -0.429 . . . . 74.5 110.008 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.616 ' HG3' HG13 ' B' ' 167' ' ' ILE . 52.2 mtp180 -87.81 147.18 25.26 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.375 -0.375 . . . . 73.209999999999994 110.379 178.028 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 33.8 t -67.38 -20.64 65.57 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.337 0.589 . . . . 74.450000000000003 109.466 174.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . 0.462 ' OD1' ' HB3' ' B' ' 159' ' ' ARG . 0.5 OUTLIER -71.93 -34.19 68.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.221 -0.9 . . . . 71.140000000000001 109.869 177.248 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -141.47 76.88 20.31 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.448 -0.796 . . . . 75.010000000000005 109.709 -174.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -82.18 4.53 6.99 Favored 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 122.746 2.297 . . . . 73.510000000000005 113.326 -173.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -109.07 -11.07 14.99 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.804 0.335 . . . . 73.349999999999994 111.084 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -122.93 137.25 55.0 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.75 0.31 . . . . 75.549999999999997 110.907 -176.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . 0.823 HD22 HD13 ' B' ' 158' ' ' ILE . 93.6 mt -73.96 130.65 40.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.018 -0.537 . . . . 74.340000000000003 109.986 177.122 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . 0.616 HG13 ' HG3' ' B' ' 159' ' ' ARG . 42.3 mm -81.48 128.5 69.54 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 116.366 -0.379 . . . . 73.219999999999999 110.393 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.511 ' O ' HG22 ' B' ' 172' ' ' ILE . 40.0 Cg_endo -65.75 173.01 7.37 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 123.163 2.575 . . . . 74.409999999999997 112.789 -179.344 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 33.8 tt0 -86.11 3.76 41.21 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.825 -0.625 . . . . 74.129999999999995 112.181 -168.271 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . 0.452 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 33.7 p90 -104.05 -18.89 14.38 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.377 -0.529 . . . . 73.420000000000002 109.872 172.799 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.452 ' HG2' ' CD1' ' B' ' 170' ' ' TRP . 2.8 mm-40 -97.65 -10.47 24.98 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.566 -0.743 . . . . 74.310000000000002 111.393 -176.631 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.511 HG22 ' O ' ' B' ' 168' ' ' PRO . 30.7 pt -71.68 -21.52 21.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.877 -0.601 . . . . 75.450000000000003 110.171 175.537 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -112.09 46.49 1.15 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.41 -0.814 . . . . 74.219999999999999 108.995 174.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 174' ' ' SER . . . . . 0.45 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 2.1 t -74.89 -13.84 60.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.402 -0.817 . . . . 74.219999999999999 110.163 -178.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . 0.615 ' HB2' ' HE2' ' B' ' 121' ' ' LYS . 49.1 p-90 . . . . . 0 C--O 1.248 0.998 0 CA-C-N 115.502 -0.772 . . . . 74.129999999999995 109.85 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.798 0 N-CA-C 111.607 -0.597 . . . . 62.200000000000003 111.607 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -75.3 -54.75 6.57 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.201 -0.666 . . . . 72.420000000000002 109.201 175.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 44.5 m-20 52.4 68.59 0.8 Allowed 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.286 -0.87 . . . . 74.120000000000005 111.49 174.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -132.96 161.8 33.34 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.477 -0.783 . . . . 74.230000000000004 109.521 178.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -87.46 116.47 25.59 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.342 -0.39 . . . . 75.010000000000005 110.415 -179.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -89.05 156.12 49.3 Favored Pre-proline 0 C--N 1.32 -0.703 0 CA-C-N 116.109 -0.496 . . . . 52.409999999999997 109.889 178.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.44 ' HB2' ' HD1' ' B' ' 131' ' ' PHE . 51.9 Cg_exo -53.68 150.07 29.97 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.643 2.229 . . . . 73.319999999999993 112.186 178.457 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 41.6 m -60.93 115.63 3.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.112 0.482 . . . . 73.319999999999993 111.022 -177.089 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -177.69 -38.72 0.06 OUTLIER Glycine 0 N--CA 1.446 -0.663 0 N-CA-C 110.71 -0.956 . . . . 72.239999999999995 110.71 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 54.05 66.29 4.52 Favored Pre-proline 0 N--CA 1.464 0.254 0 C-N-CA 123.556 0.742 . . . . 71.049999999999997 112.15 175.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.535 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 53.8 Cg_endo -76.97 137.49 17.53 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.169 1.912 . . . . 73.140000000000001 112.516 -178.317 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -141.4 155.83 45.86 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.968 -0.56 . . . . 74.439999999999998 109.738 179.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.8 p -110.88 129.75 65.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.273 0.559 . . . . 65.25 110.842 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.6 m -93.86 104.38 16.45 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.728 -0.669 . . . . 75.319999999999993 109.563 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 67.1 mt -90.1 106.82 17.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 116.301 -0.409 . . . . 75.109999999999999 110.351 -177.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 23.6 mmm180 -115.57 156.96 24.83 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.143 -0.48 . . . . 73.430000000000007 110.212 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 26.1 mp0 -121.58 127.17 50.64 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 121.098 0.475 . . . . 70.219999999999999 110.057 178.047 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -105.08 -60.58 1.59 Allowed 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.35 -0.841 . . . . 75.209999999999994 111.0 -172.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.55 ' C ' ' H ' ' A' ' 21' ' ' LYS . . . -156.95 76.58 0.2 Allowed Glycine 0 CA--C 1.507 -0.433 0 N-CA-C 110.353 -1.099 . . . . 73.430000000000007 110.353 178.741 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.53 ' HB3' ' HG3' ' A' ' 40' ' ' LYS . 19.2 m-20 70.07 -26.76 0.16 Allowed 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 123.519 0.728 . . . . 64.129999999999995 111.017 -170.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.55 ' H ' ' C ' ' A' ' 19' ' ' GLY . 22.7 pttm -83.42 120.21 25.61 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 121.198 0.523 . . . . 63.329999999999998 110.42 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.59 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 33.2 m -82.48 121.62 26.99 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.375 -0.83 . . . . 72.530000000000001 109.641 176.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 56.0 mt -111.33 106.77 21.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-O 121.036 0.446 . . . . 75.329999999999998 110.333 -178.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.651 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 19.2 mt-30 -100.53 111.04 23.24 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.788 -0.642 . . . . 75.409999999999997 110.756 -177.642 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 33.0 mt-10 -92.57 108.77 20.23 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.768 -0.651 . . . . 63.439999999999998 110.85 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.555 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 95.6 m-85 -83.0 104.65 13.37 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.968 0.414 . . . . 71.030000000000001 110.151 178.317 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -115.12 119.25 35.77 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.947 -0.569 . . . . 74.310000000000002 109.617 -179.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.802 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.7 p -73.26 -73.32 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 C-N-CA 120.786 -0.366 . . . . 74.409999999999997 110.879 -178.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.802 ' H ' HG13 ' A' ' 28' ' ' VAL . 7.6 t-20 -127.53 68.28 1.3 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.291 -0.633 . . . . 65.340000000000003 109.291 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 73.19 12.52 79.62 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.452 -0.795 . . . . 72.530000000000001 111.784 -175.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.766 ' HE1' ' HB2' ' B' ' 107' ' ' PRO . 29.5 t80 -129.33 124.08 33.42 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.818 0.342 . . . . 75.439999999999998 110.202 -175.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -72.41 132.76 44.35 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.611 -0.722 . . . . 74.409999999999997 109.781 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . 0.555 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 45.4 p90 -125.76 -22.81 4.13 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.127 0.417 . . . . 74.340000000000003 112.127 176.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.18 148.23 24.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.661 0.267 . . . . 75.230000000000004 111.022 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 61.6 mt -125.23 124.37 67.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 116.412 -0.358 . . . . 75.299999999999997 110.215 177.49 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.651 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.6 tttt -103.72 106.24 16.7 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.631 -0.507 . . . . 74.519999999999996 109.631 177.121 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.706 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.7 t -94.65 129.7 44.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 N-CA-C 109.226 -0.657 . . . . 75.129999999999995 109.226 177.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.59 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.4 t -117.6 72.57 7.81 Favored Pre-proline 0 C--N 1.317 -0.808 0 N-CA-C 109.845 -0.428 . . . . 72.329999999999998 109.845 173.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.594 ' HD3' HG13 ' A' ' 37' ' ' VAL . 54.1 Cg_endo -78.62 137.31 14.37 Favored 'Trans proline' 0 N--CA 1.456 -0.735 0 C-N-CA 122.197 1.932 . . . . 70.439999999999998 112.297 176.213 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.53 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 26.3 mtpp -68.76 -20.46 64.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.451 0.643 . . . . 62.130000000000003 109.868 178.333 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 84.7 m-70 -117.69 83.57 2.01 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.392 -0.822 . . . . 71.040000000000006 109.423 178.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.445 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 141.33 -22.0 2.58 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.945 -0.645 . . . . 64.510000000000005 112.339 -178.562 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.445 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 98.6 mttt 74.78 152.72 0.14 Allowed Pre-proline 0 N--CA 1.469 0.477 0 C-N-CA 123.579 0.752 . . . . 74.319999999999993 111.889 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.706 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 35.1 Cg_endo -66.73 136.37 41.9 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.651 2.234 . . . . 74.519999999999996 113.247 -178.139 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -142.33 162.32 35.77 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.511 -0.768 . . . . 62.140000000000001 109.589 176.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -106.11 123.19 47.63 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.397 -0.365 . . . . 72.349999999999994 110.244 178.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.451 HD13 HG13 ' A' ' 67' ' ' ILE . 28.5 tp -102.27 96.1 6.74 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 108.792 -0.818 . . . . 74.430000000000007 108.792 172.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.5 t -93.63 120.63 43.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.749 -0.659 . . . . 73.400000000000006 110.181 -175.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.7 tmm_? -77.88 121.47 24.18 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 109.065 -0.717 . . . . 74.239999999999995 109.065 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.15 -162.98 0.26 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.913 -0.585 . . . . 75.299999999999997 111.269 -173.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.41 ' OD2' ' HB2' ' A' ' 53' ' ' SER . 5.7 p-10 -73.76 154.78 39.43 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.161 0.505 . . . . 73.530000000000001 110.805 -177.443 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -65.29 -22.35 69.14 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.641 -0.709 . . . . 62.109999999999999 113.28 -177.422 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.41 ' HB2' ' OD2' ' A' ' 51' ' ' ASP . 14.5 m -73.52 -39.9 64.43 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.089 0.471 . . . . 63.210000000000001 109.958 178.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.514 ' OD2' ' HB3' ' A' ' 56' ' ' ASN . 31.2 t70 -71.66 -39.76 70.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.506 -0.77 . . . . 54.240000000000002 109.835 175.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 58.95 63.49 5.15 Favored Glycine 0 C--N 1.336 0.557 0 CA-C-N 115.78 -0.646 . . . . 74.430000000000007 111.663 178.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.514 ' HB3' ' OD2' ' A' ' 54' ' ' ASP . 14.6 t30 -165.36 155.76 13.51 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.685 -0.257 . . . . 73.310000000000002 110.331 -168.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.545 ' HB2' ' HB ' ' A' ' 67' ' ' ILE . 2.4 m-85 -108.68 143.11 38.2 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.162 -0.681 . . . . 75.439999999999998 109.162 174.448 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 48.1 mm -113.53 127.46 70.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.436 0.636 . . . . 74.549999999999997 110.319 177.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.456 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 58.5 ttt180 -93.63 124.09 37.39 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.309 -0.86 . . . . 73.0 109.685 -176.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 87.9 p -59.67 -26.77 65.82 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.242 0.544 . . . . 75.019999999999996 110.788 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.456 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 16.5 t70 -60.22 -39.71 87.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.211 -0.904 . . . . 64.230000000000004 110.711 177.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 29.3 mt-30 -144.67 89.01 6.85 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 115.947 -0.569 . . . . 71.109999999999999 109.863 -179.018 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -62.58 -24.71 75.22 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 123.1 2.533 . . . . 75.129999999999995 113.261 -175.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -78.84 -14.27 59.34 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 120.747 0.308 . . . . 75.040000000000006 110.73 178.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.2 tptm -93.71 123.42 37.02 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.459 0.647 . . . . 62.119999999999997 110.892 -177.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.406 HD13 ' N ' ' A' ' 66' ' ' LEU . 5.5 mp -90.24 128.48 36.41 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 114.798 -1.092 . . . . 61.399999999999999 108.688 175.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.737 HG21 ' HB3' ' A' ' 71' ' ' GLU . 47.0 mm -87.9 112.67 50.6 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-O 120.854 0.359 . . . . 72.209999999999994 111.373 -172.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.561 ' O ' HG23 ' A' ' 72' ' ' ILE . 60.0 Cg_endo -71.44 174.97 10.07 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.833 2.355 . . . . 74.400000000000006 112.036 179.163 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -79.15 1.85 22.96 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 112.987 0.736 . . . . 64.319999999999993 112.987 -166.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 42.4 p90 -107.04 -19.62 13.56 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.437 0.637 . . . . 71.420000000000002 109.953 172.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.737 ' HB3' HG21 ' A' ' 67' ' ' ILE . 2.8 mm-40 -87.41 -17.46 32.23 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.462 -0.79 . . . . 74.299999999999997 110.332 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.561 HG23 ' O ' ' A' ' 68' ' ' PRO . 42.3 pt -63.23 -28.39 44.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.885 -0.598 . . . . 74.540000000000006 111.412 -179.005 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.467 ' HD1' HG13 ' A' ' 72' ' ' ILE . 41.0 p90 -117.25 42.77 2.47 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.581 0.705 . . . . 74.319999999999993 109.584 175.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 4.7 t -59.27 -25.2 63.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.05 -0.977 . . . . 64.540000000000006 110.801 -179.567 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 26.6 p-90 . . . . . 0 C--N 1.327 -0.397 0 CA-C-N 115.925 -0.579 . . . . 74.329999999999998 111.267 177.479 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.435 0 N-CA-C 112.346 -0.302 . . . . 73.209999999999994 112.346 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -132.44 -62.18 0.84 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.564 0.221 . . . . 75.400000000000006 110.479 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 62.98 22.22 13.34 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 115.696 -0.684 . . . . 72.409999999999997 112.703 176.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -105.09 160.96 14.65 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.716 0.294 . . . . 75.040000000000006 110.324 178.319 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -75.35 134.02 41.09 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.185 -0.461 . . . . 73.540000000000006 111.229 -177.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . 0.429 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -82.11 130.41 60.16 Favored Pre-proline 0 C--N 1.322 -0.63 0 CA-C-N 115.902 -0.59 . . . . 70.310000000000002 109.798 174.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . 0.766 ' HB2' ' HE1' ' A' ' 31' ' ' PHE . 34.3 Cg_exo -59.69 147.07 93.62 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.746 2.297 . . . . 74.530000000000001 112.101 -178.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 57.1 m -54.53 144.4 21.47 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-O 121.451 0.643 . . . . 74.120000000000005 111.089 -179.197 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 125.24 -60.8 0.62 Allowed Glycine 0 N--CA 1.44 -1.073 0 N-CA-C 109.129 -1.588 . . . . 61.219999999999999 109.129 -169.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 61.08 88.34 0.12 Allowed Pre-proline 0 CA--C 1.52 -0.209 0 O-C-N 124.322 0.66 . . . . 73.310000000000002 111.27 171.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.895 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 7.3 Cg_endo -76.41 102.83 1.66 Allowed 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.173 1.915 . . . . 74.230000000000004 111.098 -178.497 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -102.89 150.36 23.59 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.037 -0.528 . . . . 61.43 109.838 -177.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.638 HG23 ' HB3' ' B' ' 124' ' ' GLN . 14.9 p -113.05 131.58 64.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 121.401 0.62 . . . . 72.349999999999994 111.617 -175.153 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 48.1 m -89.46 118.86 29.42 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.314 -0.857 . . . . 71.200000000000003 109.373 174.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 63.5 mt -92.54 105.25 16.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.07 0.462 . . . . 74.319999999999993 111.175 -174.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . 0.54 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 11.0 mmm180 -99.12 153.0 19.23 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.952 -0.567 . . . . 74.409999999999997 110.459 177.224 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 76.0 mt-30 -134.81 99.19 4.24 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.537 -0.912 . . . . 75.450000000000003 108.537 176.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . 0.443 ' HG3' HD11 ' B' ' 123' ' ' ILE . 43.2 mm-40 -103.6 9.25 37.47 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.125 -0.489 . . . . 74.200000000000003 112.205 -169.333 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . 0.424 ' C ' ' H ' ' B' ' 121' ' ' LYS . . . 109.45 100.81 2.64 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.37 -0.919 . . . . 64.129999999999995 111.92 -178.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . 0.573 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 9.5 m-20 66.66 -9.57 0.33 Allowed 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 124.085 0.954 . . . . 73.549999999999997 111.672 -176.515 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.478 ' HB3' ' HB3' ' B' ' 139' ' ' PRO . 27.1 pttt -131.56 115.71 16.47 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 121.243 0.544 . . . . 75.25 112.074 -176.618 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 59.4 m -82.39 114.03 20.57 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.08 -0.964 . . . . 72.5 109.243 172.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . 0.68 HG12 HG12 ' B' ' 137' ' ' VAL . 49.8 mt -101.51 105.94 18.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 CA-C-O 121.326 0.584 . . . . 74.519999999999996 110.377 -176.114 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.638 ' HB3' HG23 ' B' ' 113' ' ' VAL . 49.7 mt-30 -96.01 106.89 19.11 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.444 -0.798 . . . . 75.120000000000005 110.974 -176.571 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -90.06 106.09 18.24 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.841 -0.618 . . . . 74.109999999999999 110.631 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -85.1 107.06 17.01 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.994 0.426 . . . . 75.200000000000003 110.698 -179.586 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . 0.497 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 79.0 mtm180 -120.39 120.52 36.22 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.137 0.494 . . . . 75.310000000000002 110.204 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.895 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -76.79 -62.5 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.893 -0.594 . . . . 72.219999999999999 111.021 -178.177 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . 0.568 ' H ' HG11 ' B' ' 128' ' ' VAL . 1.2 t-20 -149.21 76.82 1.34 Allowed 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.638 -0.504 . . . . 64.010000000000005 109.638 -178.54 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.75 -7.34 66.11 Favored Glycine 0 CA--C 1.521 0.438 0 CA-C-N 115.817 -0.629 . . . . 45.43 113.058 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . 0.44 ' HD1' ' HB2' ' A' ' 7' ' ' PRO . 54.4 t80 -122.31 123.25 40.98 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.151 0.5 . . . . 71.450000000000003 111.27 -176.625 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.687 HD12 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -76.6 117.84 18.64 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.09 -0.959 . . . . 75.120000000000005 108.888 173.431 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -108.06 -22.85 12.23 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.478 -0.489 . . . . 71.049999999999997 111.525 -178.233 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -157.62 143.05 17.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.929 0.395 . . . . 75.0 111.329 -178.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.687 HG13 HD12 ' B' ' 132' ' ' LEU . 76.5 mt -121.77 121.75 65.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 115.895 -0.593 . . . . 72.140000000000001 110.067 176.333 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.469 ' HD2' ' CZ ' ' B' ' 146' ' ' PHE . 82.2 tttt -102.79 105.06 15.41 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.928 0.394 . . . . 71.200000000000003 109.99 177.373 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.68 HG12 HG12 ' B' ' 123' ' ' ILE . 5.0 t -90.46 132.37 35.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 108.653 -0.869 . . . . 74.420000000000002 108.653 176.08 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.497 HG11 ' HB3' ' B' ' 144' ' ' PRO . 20.6 t -114.21 71.73 2.21 Favored Pre-proline 0 C--N 1.317 -0.822 0 N-CA-C 109.907 -0.405 . . . . 72.319999999999993 109.907 173.345 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.564 ' HD3' HG13 ' B' ' 137' ' ' VAL . 74.3 Cg_endo -81.13 134.42 9.24 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.082 1.855 . . . . 73.420000000000002 113.243 178.534 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . 0.573 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 28.8 mtpp -60.04 -26.85 66.45 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.291 -0.868 . . . . 65.019999999999996 109.84 171.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 89.4 m-70 -116.8 89.5 3.12 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.282 -0.872 . . . . 73.420000000000002 109.492 177.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 138.36 -19.14 3.23 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.482 -0.866 . . . . 62.350000000000001 112.536 -179.294 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 47.0 mtmt 71.62 147.21 0.12 Allowed Pre-proline 0 N--CA 1.469 0.522 0 C-N-CA 123.309 0.643 . . . . 73.040000000000006 111.637 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.674 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 29.6 Cg_endo -64.8 125.81 15.48 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.584 2.189 . . . . 74.239999999999995 112.626 -179.356 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . 0.41 ' HH ' ' HD1' ' B' ' 175' ' ' TRP . 25.7 p90 -139.88 160.29 40.23 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.076 -0.511 . . . . 74.420000000000002 110.383 179.404 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.469 ' CZ ' ' HD2' ' B' ' 136' ' ' LYS . 70.4 m-85 -104.54 122.18 45.02 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.091 -0.504 . . . . 73.019999999999996 110.04 178.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 26.0 tp -97.86 93.33 6.28 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 108.248 -1.019 . . . . 74.409999999999997 108.248 171.329 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.6 t -95.39 129.11 45.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.755 -0.657 . . . . 74.319999999999993 110.55 -173.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . 0.597 HH11 ' HG3' ' B' ' 149' ' ' ARG . 0.0 OUTLIER -79.45 123.22 27.33 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 116.217 -0.447 . . . . 75.510000000000005 109.871 177.462 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -77.41 -168.32 1.12 Allowed 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.815 -0.63 . . . . 72.400000000000006 110.034 177.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -56.94 147.13 24.63 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.174 -0.466 . . . . 75.129999999999995 110.792 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -75.14 -10.32 84.2 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.541 -0.838 . . . . 60.240000000000002 112.745 -177.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 1.6 m -67.67 -38.33 83.59 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.888 0.851 . . . . 71.349999999999994 108.729 172.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 15.1 t0 -80.36 -42.08 23.56 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.335 -1.302 . . . . 74.140000000000001 109.627 175.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 69.38 18.8 73.78 Favored Glycine 0 C--N 1.331 0.27 0 CA-C-N 115.17 -0.923 . . . . 72.340000000000003 112.139 -177.132 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 39.2 t30 -104.63 155.43 18.86 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 122.453 0.301 . . . . 74.340000000000003 111.656 -169.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . 0.63 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 8.3 m-85 -110.28 146.63 35.35 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.922 -0.77 . . . . 73.430000000000007 108.922 173.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.7 mm -118.31 133.39 65.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.038 0.447 . . . . 54.020000000000003 110.341 178.308 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.516 ' HD2' HD13 ' B' ' 167' ' ' ILE . 9.5 ttt180 -88.69 122.24 31.91 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.208 -0.664 . . . . 75.439999999999998 109.208 -179.001 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 66.5 p -57.66 -30.56 65.53 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 112.141 0.423 . . . . 61.240000000000002 112.141 -174.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -69.66 -40.45 76.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.068 0.461 . . . . 62.210000000000001 111.244 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 12.4 tt0 -130.33 88.84 46.41 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-N 116.139 -0.482 . . . . 73.219999999999999 110.178 -175.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -67.8 -12.76 36.49 Favored 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.917 2.411 . . . . 63.0 112.29 -179.083 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -84.58 -6.32 59.36 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.735 -0.666 . . . . 64.209999999999994 110.144 176.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 22.2 tptm -109.26 123.67 49.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.547 0.689 . . . . 73.219999999999999 110.998 -177.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . 0.473 HD11 ' N ' ' B' ' 166' ' ' LEU . 4.0 mp -91.21 135.2 33.95 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 114.731 -1.122 . . . . 75.129999999999995 108.204 175.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . 0.63 ' HB ' ' HB2' ' B' ' 157' ' ' PHE . 48.1 mm -95.93 113.11 61.46 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-O 121.037 0.446 . . . . 75.430000000000007 111.303 -173.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.478 ' O ' HG22 ' B' ' 172' ' ' ILE . 55.9 Cg_endo -69.91 177.95 5.17 Favored 'Trans proline' 0 N--CA 1.464 -0.253 0 C-N-CA 123.15 2.566 . . . . 73.329999999999998 112.479 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -85.86 6.39 28.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.976 -0.557 . . . . 74.129999999999995 112.269 -168.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 30.4 p90 -107.7 -25.32 11.35 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.207 0.527 . . . . 75.239999999999995 110.007 171.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . . . . . . . . . 21.0 mm-40 -80.77 -14.7 57.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.753 -0.658 . . . . 75.519999999999996 110.9 -179.051 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.524 HG13 ' CD2' ' B' ' 173' ' ' PHE . 26.5 pt -72.64 -12.02 15.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.86 -0.609 . . . . 72.420000000000002 112.291 -176.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . 0.524 ' CD2' HG13 ' B' ' 172' ' ' ILE . 88.4 m-85 -126.83 21.03 7.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.44 0.638 . . . . 72.409999999999997 109.785 176.323 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 7.8 t -95.76 28.77 2.91 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.115 -0.948 . . . . 62.039999999999999 110.925 -175.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . 0.41 ' HD1' ' HH ' ' B' ' 145' ' ' TYR . 6.3 m0 . . . . . 0 C--O 1.244 0.794 0 CA-C-O 118.201 -0.904 . . . . 73.409999999999997 111.679 -176.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.596 0 N-CA-C 111.865 -0.494 . . . . 71.109999999999999 111.865 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.03 85.9 2.2 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.129 0.49 . . . . 74.430000000000007 110.524 178.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -134.75 -41.02 0.77 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.674 -0.693 . . . . 74.519999999999996 110.063 179.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -76.06 153.62 36.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.974 -0.557 . . . . 64.400000000000006 109.89 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -84.83 129.67 34.78 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.849 0.357 . . . . 72.439999999999998 111.208 -174.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.448 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -79.49 140.48 55.87 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.944 -0.571 . . . . 63.229999999999997 110.902 -178.757 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.448 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 17.0 Cg_exo -67.35 179.21 2.58 Favored 'Trans proline' 0 CA--C 1.531 0.334 0 C-N-CA 123.048 2.499 . . . . 75.030000000000001 112.594 179.764 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 18.2 m -63.9 169.78 3.96 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.139 -0.482 . . . . 73.299999999999997 111.256 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 83.34 -60.54 4.87 Favored Glycine 0 N--CA 1.447 -0.619 0 N-CA-C 110.763 -0.935 . . . . 73.120000000000005 110.763 -173.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 60.19 88.35 0.12 Allowed Pre-proline 0 N--CA 1.463 0.214 0 C-N-CA 123.818 0.847 . . . . 74.129999999999995 112.235 176.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.611 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 37.5 Cg_endo -83.75 102.31 0.97 Allowed 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.344 2.03 . . . . 73.049999999999997 111.145 175.537 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.538 ' HA ' ' HB2' ' B' ' 151' ' ' ASP . 5.8 p-10 -130.06 140.91 50.77 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.186 0.517 . . . . 71.519999999999996 110.026 179.09 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.659 HG22 ' HB3' ' A' ' 24' ' ' GLN . 14.1 p -85.05 130.8 35.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.864 -0.607 . . . . 75.340000000000003 110.958 -176.392 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.477 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 34.3 m -88.26 105.07 17.3 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 109.674 -0.491 . . . . 74.519999999999996 109.674 177.359 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 72.2 mt -87.82 111.24 21.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.938 -0.574 . . . . 71.140000000000001 110.51 -177.091 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.46 ' HG2' ' O ' ' A' ' 23' ' ' ILE . 12.9 ptm180 -126.4 173.78 9.1 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.438 -0.578 . . . . 74.549999999999997 109.438 178.15 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -138.3 101.23 4.33 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.834 0.349 . . . . 75.409999999999997 110.222 -176.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.555 ' HG3' HD12 ' A' ' 23' ' ' ILE . 11.3 mm-40 -97.83 90.17 4.86 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.793 -0.64 . . . . 75.209999999999994 109.969 -176.278 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 75.51 -92.78 0.89 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.788 -0.72 . . . . 64.319999999999993 112.183 -178.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.588 ' HB2' ' HB2' ' A' ' 40' ' ' LYS . 7.3 p-10 -102.85 -36.73 8.14 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.438 0.637 . . . . 74.319999999999993 110.592 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.469 ' HB3' ' HA ' ' A' ' 39' ' ' PRO . 5.8 pttm -92.94 127.27 38.39 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.602 -0.727 . . . . 72.540000000000006 112.38 -167.226 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.455 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 46.6 m -82.67 96.01 8.0 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 114.771 -1.104 . . . . 64.200000000000003 108.326 174.162 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.712 HG12 HG21 ' A' ' 37' ' ' VAL . 48.5 mt -86.37 112.25 22.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.854 -0.612 . . . . 74.549999999999997 110.349 -175.336 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.659 ' HB3' HG22 ' A' ' 13' ' ' VAL . 47.7 mt-30 -94.01 104.63 16.67 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.738 -0.664 . . . . 73.219999999999999 110.464 179.456 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.477 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 26.7 mt-10 -87.48 100.6 12.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.673 -0.694 . . . . 74.400000000000006 110.868 -178.256 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -75.33 97.83 3.68 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.812 -0.44 . . . . 75.099999999999994 109.812 176.212 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.474 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 71.8 mtm180 -120.49 127.02 51.81 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.158 -0.474 . . . . 65.329999999999998 109.882 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.611 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 2.5 p -83.08 -64.26 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.643 -0.423 . . . . 75.310000000000002 110.843 178.675 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.586 ' H ' HG12 ' A' ' 28' ' ' VAL . 4.8 t-20 -142.72 69.25 1.31 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.175 0.512 . . . . 72.219999999999999 110.292 -176.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 88.18 1.87 81.14 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.562 -0.745 . . . . 70.439999999999998 113.474 176.223 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.403 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 60.7 t80 -131.24 127.01 36.97 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 117.151 0.476 . . . . 75.540000000000006 111.356 179.861 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.827 HD12 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -72.48 120.27 17.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.284 -0.871 . . . . 74.230000000000004 109.545 174.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -111.88 -19.51 12.37 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.396 -0.522 . . . . 73.150000000000006 111.746 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.44 141.56 18.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.832 0.349 . . . . 75.109999999999999 111.216 178.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.827 HG13 HD12 ' A' ' 32' ' ' LEU . 93.7 mt -119.73 117.36 53.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.36 -0.382 . . . . 72.310000000000002 110.723 176.706 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 45' ' ' TYR . 85.7 tttt -102.14 100.23 10.44 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.536 -0.913 . . . . 74.340000000000003 108.536 172.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.712 HG21 HG12 ' A' ' 23' ' ' ILE . 8.4 p -95.38 131.57 41.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 CA-C-N 116.174 -0.466 . . . . 74.439999999999998 110.045 -176.679 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.632 HG13 ' HG3' ' A' ' 44' ' ' PRO . 40.7 t -108.05 88.54 4.75 Favored Pre-proline 0 C--N 1.323 -0.559 0 N-CA-C 109.496 -0.557 . . . . 74.310000000000002 109.496 175.057 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.469 ' HA ' ' HB3' ' A' ' 21' ' ' LYS . 73.7 Cg_endo -82.39 141.26 11.23 Favored 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 122.51 2.14 . . . . 70.340000000000003 112.314 -178.395 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.588 ' HB2' ' HB2' ' A' ' 20' ' ' ASP . 27.9 mtpp -77.92 -14.93 59.38 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.346 0.593 . . . . 75.239999999999995 109.935 179.301 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 -116.43 25.63 10.48 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.342 -0.844 . . . . 72.400000000000006 110.203 -176.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -164.41 -148.64 5.51 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.28 -0.873 . . . . 44.219999999999999 111.128 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.1 pttp -131.9 142.63 45.87 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 117.238 0.519 . . . . 73.239999999999995 110.081 175.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.644 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 50.2 Cg_exo -53.15 135.53 59.67 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 123.55 2.833 . . . . 64.040000000000006 112.926 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.489 ' O ' ' HA ' ' A' ' 36' ' ' LYS . 4.6 p90 -142.32 160.44 40.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.163 -0.471 . . . . 74.040000000000006 110.69 177.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.658 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 92.0 m-85 -99.97 121.87 42.01 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.862 -0.608 . . . . 65.129999999999995 109.416 173.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 18.1 tp -108.36 97.43 7.11 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.913 -0.773 . . . . 74.349999999999994 108.913 175.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.419 HG22 HG23 ' B' ' 148' ' ' VAL . 38.4 t -93.94 135.41 28.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.255 -0.429 . . . . 74.129999999999995 111.282 -172.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.625 HH21 ' HA ' ' A' ' 53' ' ' SER . 13.3 tpt180 -73.1 124.59 25.86 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.876 -0.602 . . . . 74.219999999999999 111.112 176.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.42 174.47 10.79 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.884 -0.598 . . . . 64.519999999999996 109.928 173.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -70.65 145.27 50.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.764 0.316 . . . . 71.200000000000003 110.596 -178.194 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.479 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 86.27 158.45 31.29 Favored Glycine 0 N--CA 1.428 -1.868 0 CA-C-O 122.133 0.852 . . . . 74.439999999999998 112.844 175.57 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.625 ' HA ' HH21 ' A' ' 49' ' ' ARG . 49.5 m -80.65 26.71 0.39 Allowed 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 114.604 -0.798 . . . . 72.420000000000002 110.113 170.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.479 ' H ' ' C ' ' A' ' 52' ' ' GLY . 22.6 t70 -56.77 -39.24 73.68 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.123 -0.944 . . . . 74.200000000000003 111.611 -178.149 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.48 16.41 20.32 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.511 -0.852 . . . . 52.229999999999997 113.068 176.325 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -112.63 148.39 34.71 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.049 0.452 . . . . 73.230000000000004 110.31 177.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -124.1 163.06 22.27 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.739 -0.664 . . . . 72.319999999999993 109.656 176.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.771 HD11 HD23 ' A' ' 66' ' ' LEU . 46.1 mm -121.27 123.81 70.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 N-CA-C 109.538 -0.541 . . . . 73.209999999999994 109.538 177.211 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.655 ' HD2' ' HB3' ' A' ' 61' ' ' ASP . 11.6 ttm180 -92.2 145.63 24.35 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.806 -0.442 . . . . 73.450000000000003 109.806 -176.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.729 ' HB2' ' HB3' ' B' ' 163' ' ' PRO . 23.8 p -61.13 -39.89 91.76 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.573 0.702 . . . . 74.109999999999999 110.133 174.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.655 ' HB3' ' HD2' ' A' ' 59' ' ' ARG . 27.7 t70 -68.34 -28.28 67.0 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 114.808 -1.087 . . . . 73.200000000000003 110.817 178.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . 0.416 ' HB3' ' HB3' ' A' ' 65' ' ' LYS . 86.7 mm-40 -133.52 73.14 73.46 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.022 -0.535 . . . . 61.130000000000003 110.254 -175.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -75.81 -17.2 18.01 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.568 2.179 . . . . 74.329999999999998 112.703 -174.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -101.62 7.32 42.19 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.03 -0.532 . . . . 71.310000000000002 110.697 -178.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.416 ' HB3' ' HB3' ' A' ' 62' ' ' GLN . 83.4 tttt -123.32 135.27 54.12 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.013 -0.539 . . . . 74.120000000000005 110.74 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.771 HD23 HD11 ' A' ' 58' ' ' ILE . 40.7 mt -84.75 112.21 20.29 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.882 -0.784 . . . . 72.150000000000006 108.882 175.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 51.4 mm -70.68 117.85 59.36 Favored Pre-proline 0 C--N 1.322 -0.629 0 CA-C-N 116.142 -0.481 . . . . 71.319999999999993 110.841 -176.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.91 178.62 6.99 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 123.28 2.653 . . . . 74.510000000000005 112.86 -178.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . 0.631 ' HA ' HG12 ' A' ' 72' ' ' ILE . 27.7 tt0 -74.76 -34.62 62.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.853 -0.612 . . . . 72.5 111.521 -170.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 16.0 p90 -67.66 -20.51 65.32 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.39 -0.524 . . . . 75.040000000000006 110.279 178.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -91.4 -28.42 17.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.334 -0.394 . . . . 71.519999999999996 111.404 -179.177 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.631 HG12 ' HA ' ' A' ' 69' ' ' GLN . 37.4 pt -74.81 -23.49 17.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.103 0.478 . . . . 75.319999999999993 110.274 176.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.495 ' HE2' HE21 ' A' ' 69' ' ' GLN . 38.1 m-85 -105.33 29.51 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.006 -0.543 . . . . 73.530000000000001 110.637 176.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 22.8 t -82.25 32.25 0.39 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.261 0.553 . . . . 54.439999999999998 110.863 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 54.3 m0 . . . . . 0 C--N 1.323 -0.552 0 CA-C-N 116.128 -0.487 . . . . 73.340000000000003 110.852 179.923 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.492 0 N-CA-C 111.993 -0.443 . . . . 60.340000000000003 111.993 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -81.45 76.0 8.39 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.103 0.478 . . . . 63.149999999999999 110.998 -179.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -98.9 4.18 47.37 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.035 -0.529 . . . . 65.219999999999999 110.942 178.132 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -142.57 148.23 37.19 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.441 -0.345 . . . . 74.549999999999997 110.157 -178.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -82.22 147.06 29.17 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.198 -0.455 . . . . 74.420000000000002 111.132 -176.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -105.78 133.04 20.39 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 120.873 0.368 . . . . 71.120000000000005 111.989 -175.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -73.15 -176.17 2.3 Favored 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 123.059 2.506 . . . . 73.439999999999998 112.132 176.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 5.2 p -62.83 158.43 18.91 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-O 121.305 0.574 . . . . 75.540000000000006 111.534 -178.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 100.98 -73.48 0.39 Allowed Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 109.999 -1.24 . . . . 74.140000000000001 109.999 -172.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 54.17 74.47 0.74 Allowed Pre-proline 0 C--N 1.329 -0.317 0 O-C-N 124.154 0.561 . . . . 75.439999999999998 111.259 175.459 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.94 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 18.0 Cg_endo -63.01 99.47 0.22 Allowed 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 122.106 1.871 . . . . 64.310000000000002 110.594 178.339 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -106.81 155.04 20.14 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.335 -0.848 . . . . 71.400000000000006 110.635 -173.217 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.619 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 12.4 p -111.54 124.68 68.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 CA-C-O 121.557 0.694 . . . . 73.319999999999993 110.421 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 114' ' ' THR . . . . . 0.569 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 26.2 m -87.47 105.03 17.01 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.591 -0.731 . . . . 74.219999999999999 110.094 178.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.7 mt -83.48 106.07 13.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.955 -0.566 . . . . 72.010000000000005 110.375 -178.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . 0.405 ' HG3' HG22 ' B' ' 114' ' ' THR . 44.0 mtm105 -124.09 -178.9 4.22 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.403 -0.362 . . . . 74.230000000000004 110.465 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 64.0 mt-30 -144.76 115.21 7.61 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.205 -0.452 . . . . 72.209999999999994 111.056 -178.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . 0.456 ' O ' ' HE2' ' B' ' 121' ' ' LYS . 76.7 mm-40 -101.52 81.98 2.24 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.563 -0.532 . . . . 70.329999999999998 109.563 175.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 91.11 -110.83 3.88 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.657 -0.782 . . . . 64.530000000000001 111.4 -175.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . 0.814 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 18.2 m-20 -115.06 24.01 12.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.786 0.327 . . . . 74.030000000000001 110.488 178.178 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.469 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 22.5 pttt -124.55 120.1 30.98 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.232 0.539 . . . . 71.420000000000002 110.833 178.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 49.1 m -79.38 104.9 10.31 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.414 -0.812 . . . . 72.230000000000004 109.588 177.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . 0.473 HD12 ' CE3' ' B' ' 175' ' ' TRP . 52.8 mt -97.52 112.54 29.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.122 0.487 . . . . 74.329999999999998 110.408 -176.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.619 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 51.2 mt-30 -92.29 105.7 17.85 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.449 -0.796 . . . . 74.25 110.552 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . 0.569 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 41.7 mt-10 -88.3 100.78 13.27 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.774 -0.648 . . . . 74.040000000000006 110.421 -178.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . 0.462 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 63.4 m-85 -78.25 110.28 13.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.528 -0.305 . . . . 74.239999999999995 110.538 179.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . 0.419 ' HA ' ' O ' ' B' ' 131' ' ' PHE . 84.6 mtm180 -132.99 120.23 21.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.295 -0.411 . . . . 75.25 110.258 -179.622 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.94 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.5 p -83.51 -54.37 9.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.234 -0.439 . . . . 74.25 111.181 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 32.8 t-20 -150.08 79.25 1.36 Allowed 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.958 -0.386 . . . . 73.230000000000004 109.958 -175.136 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.65 30.36 74.55 Favored Glycine 0 N--CA 1.452 -0.234 0 CA-C-N 115.537 -0.756 . . . . 72.430000000000007 112.867 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . 0.419 ' O ' ' HA ' ' B' ' 127' ' ' ARG . 87.2 t80 -147.86 127.22 13.09 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.856 0.36 . . . . 70.519999999999996 111.256 179.594 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.725 HD12 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -81.25 111.47 17.69 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.467 -0.788 . . . . 75.439999999999998 108.948 174.758 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . 0.462 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 51.6 p90 -106.98 -15.53 14.67 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.68 -0.408 . . . . 73.450000000000003 111.57 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . 0.52 ' HB1' ' CE2' ' B' ' 146' ' ' PHE . . . -159.07 145.18 16.61 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.947 0.403 . . . . 62.210000000000001 111.576 -178.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.725 HG13 HD12 ' B' ' 132' ' ' LEU . 75.7 mt -125.47 123.66 65.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.936 -0.574 . . . . 74.129999999999995 110.162 176.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.434 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 88.5 tttt -116.15 102.32 9.5 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.396 -0.594 . . . . 74.319999999999993 109.396 174.374 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.523 HG12 ' CE1' ' B' ' 145' ' ' TYR . 0.9 OUTLIER -102.36 127.07 56.31 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.088 0.471 . . . . 75.349999999999994 110.947 -177.603 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.794 HG23 ' HB3' ' B' ' 144' ' ' PRO . 22.8 t -112.55 88.83 11.74 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 115.235 -0.893 . . . . 71.310000000000002 109.73 -179.309 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.469 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 67.0 Cg_endo -77.95 134.54 13.31 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.137 1.891 . . . . 63.409999999999997 112.717 178.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . 0.814 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 58.2 mtpt -62.75 -28.18 69.79 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.577 -0.738 . . . . 72.200000000000003 110.251 173.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -96.43 43.84 1.07 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.996 -1.002 . . . . 75.420000000000002 110.187 -177.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 164.2 -146.71 11.75 Favored Glycine 0 N--CA 1.446 -0.645 0 CA-C-N 115.531 -0.759 . . . . 75.019999999999996 111.766 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 34.1 mmtp -126.68 150.0 69.87 Favored Pre-proline 0 C--N 1.322 -0.63 0 N-CA-C 110.206 -0.294 . . . . 74.299999999999997 110.206 177.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.794 ' HB3' HG23 ' B' ' 138' ' ' VAL . 18.6 Cg_endo -61.37 145.16 98.51 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.827 2.351 . . . . 75.109999999999999 112.22 178.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . 0.543 ' HH ' ' HB3' ' B' ' 175' ' ' TRP . 12.6 p90 -148.89 164.05 35.63 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.205 -0.452 . . . . 75.409999999999997 110.15 177.11 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.52 ' CE2' ' HB1' ' B' ' 134' ' ' ALA . 0.8 OUTLIER -113.14 142.13 46.12 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.901 -0.591 . . . . 75.340000000000003 111.17 -172.437 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . 0.432 ' HB3' ' CD2' ' B' ' 157' ' ' PHE . 20.7 mt -126.65 108.74 11.37 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.972 -0.558 . . . . 75.040000000000006 109.659 170.074 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . 0.419 HG23 HG22 ' A' ' 48' ' ' VAL . 38.8 t -90.86 130.59 39.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.262 -0.426 . . . . 75.340000000000003 110.274 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . 0.452 ' HD3' ' CZ ' ' B' ' 157' ' ' PHE . 45.5 tpt85 -85.1 104.38 14.95 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.53 -0.544 . . . . 73.099999999999994 109.53 179.134 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.1 -178.85 0.85 Allowed 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.049 -0.523 . . . . 72.329999999999998 110.496 179.096 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . 0.538 ' HB2' ' HA ' ' A' ' 12' ' ' ASP . 2.2 p-10 -84.21 158.62 21.22 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.846 -0.427 . . . . 73.019999999999996 109.846 179.343 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 96.68 139.19 10.41 Favored Glycine 0 N--CA 1.439 -1.152 0 C-N-CA 120.049 -1.072 . . . . 70.200000000000003 112.609 176.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 16.3 m -77.6 43.12 0.39 Allowed 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.357 0.599 . . . . 72.420000000000002 110.97 176.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -89.15 -28.35 20.09 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.522 -0.763 . . . . 72.129999999999995 110.467 -178.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 88.79 31.39 12.73 Favored Glycine 0 N--CA 1.451 -0.36 0 N-CA-C 111.067 -0.813 . . . . 64.310000000000002 111.067 -174.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . 0.764 HD22 HD22 ' B' ' 166' ' ' LEU . 26.9 t30 -100.46 130.94 46.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.147 -0.526 . . . . 74.209999999999994 111.606 -172.571 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . 0.452 ' CZ ' ' HD3' ' B' ' 149' ' ' ARG . 29.2 m-85 -121.02 160.61 23.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.639 -0.71 . . . . 73.519999999999996 109.572 175.134 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . 0.796 HD12 HD21 ' B' ' 166' ' ' LEU . 46.0 mm -119.74 118.27 56.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.492 -0.558 . . . . 65.219999999999999 109.492 174.206 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.545 ' HG2' ' H ' ' B' ' 161' ' ' ASP . 20.0 ttm-85 -84.09 142.38 30.44 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 110.034 -0.358 . . . . 75.340000000000003 110.034 -177.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 42.3 p -63.08 -29.16 70.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.174 0.512 . . . . 70.400000000000006 110.836 178.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . 0.545 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 16.1 t70 -77.76 -27.49 50.36 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.477 -0.783 . . . . 72.230000000000004 110.81 178.808 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . 0.555 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 28.0 mm-40 -135.35 68.98 68.61 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 115.889 -0.596 . . . . 74.439999999999998 110.185 -177.608 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . 0.729 ' HB3' ' HB2' ' A' ' 60' ' ' SER . 12.9 Cg_exo -70.1 -26.33 26.1 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.71 2.274 . . . . 73.450000000000003 112.191 -177.479 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -84.0 1.31 44.38 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.451 -0.795 . . . . 72.510000000000005 110.27 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . 0.555 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 57.8 tttp -116.9 134.94 54.14 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.814 -0.63 . . . . 75.030000000000001 110.82 -177.498 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . 0.796 HD21 HD12 ' B' ' 158' ' ' ILE . 39.0 mt -89.53 115.4 26.91 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.643 -0.873 . . . . 74.400000000000006 108.643 175.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . 0.572 HG22 ' HB3' ' B' ' 171' ' ' GLU . 43.0 mm -75.04 123.87 89.14 Favored Pre-proline 0 C--N 1.32 -0.705 0 CA-C-N 116.147 -0.479 . . . . 74.540000000000006 110.896 -172.537 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.402 ' O ' HG22 ' B' ' 172' ' ' ILE . 72.5 Cg_endo -72.75 173.65 13.08 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.825 2.35 . . . . 74.329999999999998 112.225 -178.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . 0.441 ' O ' HG12 ' B' ' 172' ' ' ILE . 30.4 tt0 -77.79 -8.22 57.7 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.665 -0.698 . . . . 75.420000000000002 111.811 -169.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 8.4 p90 -95.33 -12.23 26.46 Favored 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 120.457 -0.497 . . . . 73.310000000000002 110.583 176.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.572 ' HB3' HG22 ' B' ' 167' ' ' ILE . 12.9 tt0 -104.07 -1.87 26.75 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 121.039 0.447 . . . . 65.450000000000003 110.409 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.441 HG12 ' O ' ' B' ' 169' ' ' GLN . 46.8 pt -71.75 -24.5 23.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.017 0.437 . . . . 72.319999999999993 110.689 179.399 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -104.85 35.93 2.62 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.42 0.629 . . . . 70.150000000000006 109.745 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 174' ' ' SER . . . . . 0.418 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 23.2 t -63.74 -20.4 65.72 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 114.993 -1.003 . . . . 53.25 110.792 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . 0.543 ' HB3' ' HH ' ' B' ' 145' ' ' TYR . 8.9 p-90 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.255 -0.879 . . . . 73.430000000000007 110.388 174.259 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 2.007 0 N-CA-C 112.414 -0.275 . . . . 37.869999999999997 112.414 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' B' ' 154' ' ' ASP . . . -138.08 155.26 48.95 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.89 0.376 . . . . 43.399999999999999 110.048 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -135.32 104.38 5.85 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.568 0.699 . . . . 73.109999999999999 111.094 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -133.78 -168.67 2.15 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 107.806 -1.183 . . . . 71.209999999999994 107.806 173.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -121.61 140.73 51.88 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.025 0.441 . . . . 73.010000000000005 110.853 -176.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -119.95 164.08 24.28 Favored Pre-proline 0 C--N 1.32 -0.692 0 CA-C-N 115.882 -0.599 . . . . 65.120000000000005 110.198 -177.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.36 164.28 13.24 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.419 2.079 . . . . 74.209999999999994 111.961 175.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 57.8 m -56.91 142.95 39.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.732 0.777 . . . . 75.319999999999993 112.361 -175.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 138.64 -74.62 0.39 Allowed Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 109.197 -1.561 . . . . 71.439999999999998 109.197 -171.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 33.3 mt-10 58.68 92.49 0.06 OUTLIER Pre-proline 0 N--CA 1.463 0.197 0 CA-C-O 121.539 0.685 . . . . 74.319999999999993 112.052 170.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.543 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 9.6 Cg_endo -80.46 136.31 11.05 Favored 'Trans proline' 0 N--CA 1.451 -1.001 0 C-N-CA 122.833 2.355 . . . . 70.420000000000002 112.604 -173.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -124.8 170.84 10.64 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.173 -0.677 . . . . 73.519999999999996 109.173 177.069 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.461 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 14.0 p -127.72 124.29 62.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 121.481 0.657 . . . . 75.430000000000007 110.76 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.58 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 76.4 m -87.9 104.25 16.43 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.629 -0.714 . . . . 74.310000000000002 109.664 177.27 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 52.3 mt -98.45 117.66 43.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.064 -0.516 . . . . 73.549999999999997 110.388 -175.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -141.4 178.23 7.57 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.707 -0.679 . . . . 73.319999999999993 110.273 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 17.4 mp0 -133.45 126.15 30.56 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.922 0.392 . . . . 73.340000000000003 110.828 -178.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 52.0 mm-40 -95.58 -16.1 22.34 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.851 -0.613 . . . . 72.099999999999994 111.493 -178.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.43 104.91 1.3 Allowed Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.619 -0.8 . . . . 74.099999999999994 111.468 -176.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 1.048 ' HB3' ' HG3' ' A' ' 40' ' ' LYS . 35.3 m-20 61.81 13.89 5.8 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 123.226 0.61 . . . . 73.219999999999999 111.482 -175.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.426 ' HB3' ' HA ' ' A' ' 39' ' ' PRO . 40.2 pttt -154.52 114.97 3.9 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.229 0.538 . . . . 70.019999999999996 110.907 176.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 34.1 m -83.08 117.74 23.07 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.375 -0.83 . . . . 73.219999999999999 109.298 174.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.476 HG12 HG23 ' A' ' 37' ' ' VAL . 24.9 mt -108.61 120.33 59.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 120.906 0.384 . . . . 71.049999999999997 110.633 -174.13 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.461 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 20.1 mt-30 -105.27 111.31 24.01 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.819 -0.628 . . . . 74.209999999999994 110.758 -179.23 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.58 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 31.6 mt-10 -89.62 102.55 15.23 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.62 -0.718 . . . . 72.129999999999995 110.673 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.435 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 80.6 m-85 -79.38 108.19 12.71 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.965 0.412 . . . . 73.239999999999995 109.957 177.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.423 HH21 ' CD ' ' A' ' 25' ' ' GLU . 90.1 mtt180 -116.98 126.56 53.09 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.979 -0.555 . . . . 74.319999999999993 109.852 -178.449 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.678 HG11 HG13 ' B' ' 128' ' ' VAL . 3.7 p -78.77 -35.96 18.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.326 0.584 . . . . 73.5 110.027 179.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -168.92 64.68 0.06 Allowed 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.31 -0.996 . . . . 60.43 108.31 -179.045 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.76 -29.75 3.29 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-N 115.477 -0.783 . . . . 64.129999999999995 112.036 -174.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -86.26 130.92 34.36 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.941 0.401 . . . . 73.329999999999998 110.455 -176.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.856 HD12 HG13 ' A' ' 35' ' ' ILE . 3.2 tm? -81.96 119.21 23.67 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.436 -0.802 . . . . 74.439999999999998 109.847 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . 0.435 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 54.8 p90 -112.9 -17.54 12.47 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.937 -0.305 . . . . 74.200000000000003 111.218 177.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.537 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -157.28 142.21 16.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.812 0.339 . . . . 75.450000000000003 111.181 179.327 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.856 HG13 HD12 ' A' ' 32' ' ' LEU . 78.8 mt -125.14 120.21 57.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 116.329 -0.396 . . . . 75.25 110.01 175.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.47 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 86.0 tttt -108.53 101.15 10.33 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 120.381 -0.528 . . . . 75.129999999999995 109.697 173.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.538 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.8 p -101.02 131.78 48.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.973 0 CA-C-N 116.243 -0.435 . . . . 75.510000000000005 109.917 175.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.802 HG21 ' HB3' ' A' ' 44' ' ' PRO . 29.6 t -106.0 84.85 1.4 Allowed Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.396 -0.82 . . . . 74.430000000000007 109.51 177.469 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.538 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 97.3 Cg_endo -87.65 151.21 7.5 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.615 2.21 . . . . 73.329999999999998 113.143 -177.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 1.048 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 1.0 OUTLIER -55.06 -38.53 68.14 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.202 -0.908 . . . . 74.409999999999997 110.578 173.715 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 95.1 m-70 -123.56 120.9 34.21 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.814 -0.63 . . . . 75.239999999999995 110.181 179.428 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 117.46 -32.63 5.31 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.002 -0.839 . . . . 52.149999999999999 111.002 -173.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.457 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 67.0 mttm 67.97 155.61 0.14 Allowed Pre-proline 0 N--CA 1.465 0.282 0 C-N-CA 123.39 0.676 . . . . 75.420000000000002 111.97 178.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.802 ' HB3' HG21 ' A' ' 38' ' ' VAL . 11.4 Cg_endo -54.57 126.43 22.3 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 123.136 2.557 . . . . 74.219999999999999 113.179 -174.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.506 ' CE1' HG11 ' A' ' 37' ' ' VAL . 5.8 p90 -144.51 151.76 39.61 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.009 -0.541 . . . . 75.099999999999994 110.543 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.621 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 86.8 m-85 -96.18 133.27 40.69 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.097 -0.501 . . . . 75.120000000000005 110.804 178.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.537 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 21.2 mt -101.69 93.41 5.32 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.59 -0.522 . . . . 64.219999999999999 109.59 167.884 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.42 128.96 38.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 116.168 -0.469 . . . . 73.140000000000001 109.799 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.484 HH21 ' HA ' ' A' ' 53' ' ' SER . 15.6 tpt180 -63.05 127.23 30.3 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.21 0.529 . . . . 75.310000000000002 111.87 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.05 113.84 21.31 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.114 -1.069 . . . . 74.519999999999996 108.114 166.281 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.539 ' OD2' ' HA ' ' B' ' 126' ' ' TYR . 37.8 m-20 -49.07 142.54 6.67 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.216 0.531 . . . . 72.329999999999998 111.715 -176.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.23 133.61 8.16 Favored Glycine 0 N--CA 1.437 -1.257 0 N-CA-C 110.508 -1.037 . . . . 54.210000000000001 110.508 -169.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.484 ' HA ' HH21 ' A' ' 49' ' ' ARG . 19.6 m -84.87 43.16 0.97 Allowed 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.128 0.49 . . . . 74.25 110.997 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -73.41 -33.95 65.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.682 -0.69 . . . . 73.420000000000002 109.769 -179.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 113.46 38.97 1.15 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.911 -0.661 . . . . 45.130000000000003 113.089 176.022 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -135.31 146.42 48.46 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.209 0.528 . . . . 71.349999999999994 111.688 -176.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.571 ' HB2' HG21 ' A' ' 72' ' ' ILE . 31.5 m-85 -127.74 167.04 17.04 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.318 -0.856 . . . . 72.519999999999996 109.494 175.499 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.88 HD12 HD23 ' A' ' 66' ' ' LEU . 39.4 mm -122.83 123.22 67.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 109.981 -0.378 . . . . 74.0 109.981 179.111 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.961 ' HG3' HG13 ' A' ' 67' ' ' ILE . 28.8 mtm180 -88.89 140.06 29.82 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.124 -0.324 . . . . 72.219999999999999 110.124 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 7.2 p -60.8 -20.95 62.58 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.222 0.534 . . . . 71.150000000000006 110.933 177.211 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -76.0 -31.43 58.95 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.422 -0.808 . . . . 75.530000000000001 110.67 178.256 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 82.0 mm-40 -141.75 71.21 24.92 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.346 -0.388 . . . . 71.430000000000007 110.433 -175.102 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo -71.14 -11.58 29.14 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 122.771 2.314 . . . . 72.510000000000005 112.427 -178.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -89.54 -14.56 34.87 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.699 -0.682 . . . . 72.5 110.799 -178.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -112.0 133.8 53.95 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.919 0.39 . . . . 71.230000000000004 110.86 -178.207 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.88 HD23 HD12 ' A' ' 58' ' ' ILE . 85.2 mt -80.74 110.18 16.0 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.114 -0.699 . . . . 72.430000000000007 109.114 176.101 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.961 HG13 ' HG3' ' A' ' 59' ' ' ARG . 50.6 mm -72.32 116.77 52.53 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 115.986 -0.552 . . . . 72.109999999999999 110.502 -175.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.451 ' O ' HG23 ' A' ' 72' ' ' ILE . 58.6 Cg_endo -70.39 177.56 5.89 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 123.315 2.676 . . . . 64.409999999999997 112.881 -177.491 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . 0.674 ' HA ' HG12 ' A' ' 72' ' ' ILE . 25.3 tt0 -73.5 -30.66 63.27 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.903 -0.589 . . . . 72.219999999999999 111.654 -171.013 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 21.5 p90 -73.06 -15.68 61.5 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.168 0.509 . . . . 73.219999999999999 110.234 177.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.43 ' HB3' HG21 ' A' ' 67' ' ' ILE . 3.2 mm-40 -103.08 -16.14 15.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.649 -0.705 . . . . 72.120000000000005 111.808 -176.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.674 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.4 pt -80.91 -20.26 11.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.179 0.514 . . . . 72.219999999999999 110.262 176.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -107.88 22.79 15.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.601 -0.727 . . . . 75.430000000000007 109.678 174.134 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.1 t -61.26 -34.08 74.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.195 -0.911 . . . . 75.209999999999994 110.622 -178.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 65.9 p-90 . . . . . 0 C--N 1.327 -0.372 0 CA-C-N 116.352 -0.385 . . . . 74.439999999999998 110.608 177.217 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.103 -0.399 . . . . 60.25 112.103 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -146.02 156.55 43.56 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.225 -0.287 . . . . 71.030000000000001 110.225 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -162.0 131.78 4.65 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.427 0.632 . . . . 70.239999999999995 110.793 176.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -152.41 151.92 31.39 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 107.269 -1.382 . . . . 73.040000000000006 107.269 173.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -62.08 127.01 29.34 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 120.473 -0.491 . . . . 72.439999999999998 110.442 -174.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . 0.404 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -59.92 118.57 33.53 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 115.667 -0.697 . . . . 72.329999999999998 111.998 -173.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 7.4 Cg_exo -73.63 176.75 8.92 Favored 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 123.102 2.535 . . . . 75.319999999999993 111.938 178.722 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 13.9 m -71.88 157.44 37.86 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.905 -0.588 . . . . 75.329999999999998 111.05 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.65 -45.88 1.25 Allowed Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 110.249 -1.141 . . . . 72.299999999999997 110.249 -175.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 40.3 83.14 0.21 Allowed Pre-proline 0 N--CA 1.47 0.564 0 C-N-CA 124.755 1.222 . . . . 73.329999999999998 113.473 170.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.655 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 43.5 Cg_endo -90.56 124.58 1.06 Allowed 'Trans proline' 0 N--CA 1.446 -1.323 0 C-N-CA 123.009 2.473 . . . . 55.450000000000003 111.667 178.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -122.87 127.87 49.59 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.475 0.655 . . . . 73.430000000000007 110.008 -178.586 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.486 ' HB ' ' HB2' ' A' ' 51' ' ' ASP . 7.3 p -79.45 127.82 38.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-O 121.508 0.67 . . . . 71.120000000000005 110.459 -178.311 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 114' ' ' THR . . . . . 0.898 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 25.8 m -80.62 101.69 9.36 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 115.386 -0.824 . . . . 74.420000000000002 109.605 178.676 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 51.1 mt -91.02 103.83 14.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.033 -0.53 . . . . 72.430000000000007 110.445 -175.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . 0.461 ' HG2' ' O ' ' B' ' 123' ' ' ILE . 14.0 ptm180 -124.94 178.87 5.28 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.949 -0.76 . . . . 73.409999999999997 108.949 178.763 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -138.88 158.74 43.67 Favored 'General case' 0 CA--C 1.502 -0.886 0 CA-C-O 122.189 0.995 . . . . 74.120000000000005 112.661 -178.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . 0.561 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 26.5 mt-10 -135.44 168.62 18.88 Favored 'General case' 0 N--CA 1.432 -1.365 0 CA-C-N 112.968 -1.924 . . . . 75.239999999999995 107.166 159.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . -42.29 107.92 0.12 Allowed Glycine 0 CA--C 1.526 0.722 0 O-C-N 123.718 0.636 . . . . 74.219999999999999 114.34 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 43.3 m-20 61.67 24.62 14.69 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.893 0.877 . . . . 71.030000000000001 112.508 176.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.664 ' HZ2' ' HB2' ' B' ' 175' ' ' TRP . 58.7 pttt -147.81 115.02 6.21 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.616 0.722 . . . . 74.099999999999994 111.286 174.312 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 23.4 m -80.03 117.11 20.57 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.404 -0.817 . . . . 74.25 109.374 175.003 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . 0.497 HG12 HG12 ' B' ' 137' ' ' VAL . 40.2 mt -105.53 108.96 26.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.25 0.548 . . . . 63.329999999999998 110.457 -175.744 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.469 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 13.6 mt-30 -103.13 109.52 21.12 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.658 -0.701 . . . . 74.340000000000003 110.538 -176.21 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . 0.898 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 70.8 mt-10 -88.9 98.74 11.91 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.014 -0.539 . . . . 74.239999999999995 110.43 178.655 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . 0.539 ' HA ' ' OD2' ' A' ' 51' ' ' ASP . 67.7 m-85 -71.32 114.34 9.29 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.045 0.45 . . . . 73.200000000000003 110.295 179.18 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . 0.558 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 59.1 mtt-85 -135.36 131.12 35.97 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.709 -0.678 . . . . 72.340000000000003 110.989 -173.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.678 HG13 HG11 ' A' ' 28' ' ' VAL . 14.0 p -85.39 -132.76 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 108.689 -0.856 . . . . 71.530000000000001 108.689 172.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . 0.63 ' H ' HG22 ' B' ' 128' ' ' VAL . 2.3 t-20 -80.62 65.87 5.92 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.164 0.506 . . . . 75.239999999999995 110.812 -177.445 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.65 26.63 22.18 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.756 -0.735 . . . . 41.039999999999999 113.285 174.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 62.1 t80 -142.11 126.74 17.95 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 117.262 0.531 . . . . 72.450000000000003 111.31 175.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.558 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 3.5 tm? -77.15 117.49 18.75 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.992 -0.744 . . . . 72.230000000000004 108.992 175.505 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 39.6 p90 -119.15 -6.3 10.42 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.257 -0.577 . . . . 75.319999999999993 112.261 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . 0.526 ' HB3' ' HB2' ' B' ' 126' ' ' TYR . . . -164.21 143.35 7.54 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.699 0.285 . . . . 74.200000000000003 111.031 177.697 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.418 HG13 HD12 ' B' ' 132' ' ' LEU . 61.9 mt -122.84 121.06 62.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 109.924 -0.398 . . . . 74.420000000000002 109.924 175.403 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.484 ' CB ' ' HE1' ' B' ' 126' ' ' TYR . 83.6 tttt -107.84 107.03 17.59 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.835 -0.431 . . . . 74.200000000000003 109.835 177.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.749 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.5 t -94.81 131.6 41.16 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 N-CA-C 108.641 -0.874 . . . . 74.099999999999994 108.641 176.585 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.518 HG22 ' HB3' ' B' ' 144' ' ' PRO . 18.0 t -114.72 72.7 2.78 Favored Pre-proline 0 C--N 1.318 -0.769 0 N-CA-C 109.78 -0.452 . . . . 73.120000000000005 109.78 172.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.53 ' HD3' HG13 ' B' ' 137' ' ' VAL . 94.1 Cg_endo -83.2 142.16 10.67 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.235 1.957 . . . . 73.109999999999999 112.563 177.105 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 49.6 mttp -54.56 -44.56 73.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.596 0.712 . . . . 72.120000000000005 110.348 173.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 26.1 m-70 -102.8 92.1 4.45 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.836 -1.074 . . . . 72.150000000000006 109.474 -174.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 132.54 -27.35 3.56 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.357 -0.838 . . . . 64.450000000000003 111.712 -176.294 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . 0.528 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 71.2 mttt 69.1 159.66 0.15 Allowed Pre-proline 0 N--CA 1.464 0.255 0 C-N-CA 123.622 0.769 . . . . 72.230000000000004 112.367 -178.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.749 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 21.6 Cg_endo -61.09 134.5 53.16 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 122.873 2.382 . . . . 71.239999999999995 113.525 -177.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -143.32 147.21 34.37 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.68 -0.691 . . . . 74.109999999999999 110.291 175.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.62 ' HB2' ' HB2' ' B' ' 160' ' ' SER . 86.0 m-85 -93.61 125.93 38.49 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.231 -0.441 . . . . 61.509999999999998 110.392 176.629 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . 0.507 HD12 HG23 ' B' ' 167' ' ' ILE . 25.0 tp -109.12 97.44 7.06 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.64 -0.874 . . . . 71.349999999999994 108.64 172.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.7 t -91.77 139.3 18.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.155 -0.475 . . . . 73.349999999999994 111.311 -172.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . 0.412 ' HD3' ' CZ ' ' B' ' 157' ' ' PHE . 42.4 tpt85 -80.36 113.73 18.75 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.278 -0.638 . . . . 75.040000000000006 109.278 176.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.89 175.6 6.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.825 0.345 . . . . 75.329999999999998 111.104 -176.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -71.47 147.8 47.46 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.163 -0.471 . . . . 74.120000000000005 110.94 -178.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . 0.525 ' C ' ' H ' ' B' ' 154' ' ' ASP . . . 89.85 145.4 12.74 Favored Glycine 0 N--CA 1.436 -1.365 0 C-N-CA 120.723 -0.751 . . . . 74.140000000000001 112.561 175.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 44.9 m -72.59 21.93 0.06 Allowed 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 121.022 0.439 . . . . 74.010000000000005 111.083 173.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . 0.525 ' H ' ' C ' ' B' ' 152' ' ' GLY . 14.5 t70 -60.86 -35.82 77.56 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.777 -0.647 . . . . 73.329999999999998 110.618 177.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 97.92 17.13 31.12 Favored Glycine 0 CA--C 1.507 -0.451 0 CA-C-N 115.734 -0.666 . . . . 75.310000000000002 111.89 -179.383 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -90.97 137.52 32.3 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.019 -0.59 . . . . 65.299999999999997 111.566 -175.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . 0.412 ' CZ ' ' HD3' ' B' ' 149' ' ' ARG . 39.0 m-85 -118.21 154.04 32.87 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.751 -0.658 . . . . 74.409999999999997 109.533 174.299 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.3 mm -121.46 119.91 60.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.817 -0.438 . . . . 75.400000000000006 109.817 177.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.718 ' HE ' ' HB3' ' B' ' 161' ' ' ASP . 37.2 ttp180 -85.02 129.05 34.86 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.444 -0.576 . . . . 74.329999999999998 109.444 -179.706 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 160' ' ' SER . . . . . 0.62 ' HB2' ' HB2' ' B' ' 146' ' ' PHE . 36.6 t -59.84 -18.34 43.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.774 0.321 . . . . 64.430000000000007 111.318 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . 0.718 ' HB3' ' HE ' ' B' ' 159' ' ' ARG . 22.8 t70 -69.24 -39.77 78.31 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.031 -0.531 . . . . 74.319999999999993 110.29 176.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . 0.417 ' HG2' ' OD2' ' B' ' 161' ' ' ASP . 84.1 mm-40 -133.53 86.33 40.37 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 115.674 -0.693 . . . . 75.409999999999997 109.692 179.546 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.01 -14.37 40.86 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.56 2.173 . . . . 74.019999999999996 112.47 -178.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -100.49 21.09 13.76 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.817 -0.628 . . . . 72.150000000000006 110.421 178.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -133.3 136.06 45.24 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.365 -0.38 . . . . 74.049999999999997 110.732 -179.487 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . 0.42 HD11 ' N ' ' B' ' 166' ' ' LEU . 4.6 mp -90.54 134.94 34.02 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.027 -0.731 . . . . 75.409999999999997 109.027 176.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . 0.52 HG21 ' HB3' ' B' ' 171' ' ' GLU . 46.2 mm -94.15 117.02 67.11 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-O 120.917 0.389 . . . . 74.319999999999993 111.771 -172.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.4 ' O ' HG22 ' B' ' 172' ' ' ILE . 59.5 Cg_endo -72.37 -179.55 4.14 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.305 2.67 . . . . 74.430000000000007 112.615 177.084 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . 0.587 ' HA ' HG12 ' B' ' 172' ' ' ILE . 33.0 tt0 -77.1 -36.09 55.94 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.258 -0.428 . . . . 72.129999999999995 112.136 -170.211 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . 0.407 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 35.9 p90 -66.99 -21.16 65.97 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 121.648 -0.658 . . . . 74.430000000000007 109.622 177.251 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.52 ' HB3' HG21 ' B' ' 167' ' ' ILE . 9.3 mm-40 -88.22 -26.05 22.57 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 115.156 -0.929 . . . . 75.129999999999995 111.647 -178.078 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.587 HG12 ' HA ' ' B' ' 169' ' ' GLN . 40.9 pt -77.97 -17.42 13.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.146 0.498 . . . . 74.530000000000001 109.971 177.118 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -108.05 34.61 3.5 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.574 -0.739 . . . . 72.519999999999996 109.748 174.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.9 t -65.13 -35.27 80.58 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.203 -0.908 . . . . 71.019999999999996 111.03 -179.182 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . 0.664 ' HB2' ' HZ2' ' B' ' 121' ' ' LYS . 25.6 p-90 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.018 -0.991 . . . . 74.450000000000003 111.023 -178.133 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.855 0 N-CA-C 112.152 -0.379 . . . . 52.43 112.152 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.74 131.71 38.83 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.289 -0.263 . . . . 74.319999999999993 110.289 178.251 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -59.05 -48.19 82.5 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.96 0.41 . . . . 73.340000000000003 110.406 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -157.87 139.61 13.92 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.95 -0.759 . . . . 73.329999999999998 108.95 171.764 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -169.13 137.71 2.0 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 110.158 -0.312 . . . . 71.430000000000007 110.158 -178.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -83.35 125.56 73.92 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.485 -0.325 . . . . 72.340000000000003 110.504 178.086 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -82.91 -160.01 0.12 Allowed 'Trans proline' 0 N--CA 1.463 -0.285 0 C-N-CA 123.063 2.508 . . . . 73.519999999999996 112.426 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 39.8 m -131.35 168.71 17.1 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.947 -0.39 . . . . 75.200000000000003 109.947 176.012 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 87.27 -34.01 3.72 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 110.977 -0.849 . . . . 75.200000000000003 110.977 -173.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 55.37 63.69 6.31 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 123.998 0.919 . . . . 64.329999999999998 111.73 177.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.713 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 18.2 Cg_endo -78.95 121.65 5.06 Favored 'Trans proline' 0 N--CA 1.45 -1.064 0 C-N-CA 122.091 1.861 . . . . 73.219999999999999 111.584 -179.612 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -148.36 122.42 9.47 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.654 0.74 . . . . 72.140000000000001 110.357 177.515 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.8 p -82.65 129.16 37.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-N 114.366 -1.288 . . . . 74.230000000000004 110.682 -178.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 59.2 m -93.64 102.51 14.69 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.592 -0.731 . . . . 55.219999999999999 109.735 178.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.1 mt -90.63 104.06 14.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.967 -0.561 . . . . 74.109999999999999 110.037 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -122.83 174.07 7.37 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.533 -0.758 . . . . 72.219999999999999 109.734 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -122.98 133.36 54.37 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 121.285 0.564 . . . . 74.430000000000007 111.059 -177.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.502 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 1.0 OUTLIER -115.81 84.9 2.19 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.318 -0.855 . . . . 64.420000000000002 109.336 -179.411 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 80.88 -106.11 2.51 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 110.827 -0.909 . . . . 73.450000000000003 110.827 -172.481 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.408 ' HB3' ' CD ' ' A' ' 40' ' ' LYS . 11.7 m-20 -110.49 -14.47 14.09 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.761 0.315 . . . . 71.409999999999997 110.93 176.323 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.502 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 24.6 pttm -89.41 136.57 32.95 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.98 0.419 . . . . 74.010000000000005 110.918 -176.28 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 13.0 m -83.8 130.33 34.93 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.781 -0.645 . . . . 74.109999999999999 110.205 178.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 26.4 mm -116.65 106.82 21.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 120.93 0.395 . . . . 75.5 110.128 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 16.1 mt-30 -100.02 102.5 13.87 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.225 -0.443 . . . . 73.510000000000005 109.828 178.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.403 ' HB3' HD11 ' A' ' 32' ' ' LEU . 26.4 mt-10 -89.67 100.68 13.43 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.519 -0.764 . . . . 65.450000000000003 110.937 -176.302 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.595 ' HD2' ' HB2' ' B' ' 151' ' ' ASP . 44.2 m-85 -75.41 100.21 4.39 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.086 -0.507 . . . . 74.519999999999996 110.32 179.257 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 51.2 mtm180 -115.89 124.45 50.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.311 -0.404 . . . . 74.019999999999996 110.418 178.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.86 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.9 p -87.24 -93.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 C-N-CA 120.564 -0.454 . . . . 70.510000000000005 110.091 175.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.86 ' H ' HG13 ' A' ' 28' ' ' VAL . 3.4 t-20 -107.49 70.07 0.77 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 121.562 -0.712 . . . . 74.519999999999996 109.997 -176.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 77.57 9.08 87.09 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.714 -0.755 . . . . 75.230000000000004 112.344 179.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 85.6 t80 -127.55 123.06 34.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.676 0.274 . . . . 75.049999999999997 110.643 -177.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.528 HD21 HD13 ' A' ' 35' ' ' ILE . 27.6 tp -78.65 115.5 18.4 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.025 -0.534 . . . . 72.329999999999998 109.762 173.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -103.51 -14.68 16.11 Favored 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 120.253 -0.579 . . . . 74.299999999999997 111.481 -176.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.439 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -167.61 146.34 4.81 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.889 0.376 . . . . 71.310000000000002 111.475 -177.206 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.528 HD13 HD21 ' A' ' 32' ' ' LEU . 71.4 mt -122.59 131.4 73.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 116.084 -0.507 . . . . 75.219999999999999 109.77 175.167 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -104.49 100.75 10.43 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.948 -0.76 . . . . 74.310000000000002 108.948 170.195 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.486 HG21 ' HD3' ' A' ' 39' ' ' PRO . 0.9 OUTLIER -97.75 123.56 50.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 115.663 -0.699 . . . . 75.530000000000001 110.283 -179.483 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.717 HG21 ' HB3' ' A' ' 44' ' ' PRO . 22.0 t -113.73 87.65 12.55 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 115.384 -0.825 . . . . 73.530000000000001 110.3 -178.489 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.486 ' HD3' HG21 ' A' ' 37' ' ' VAL . 74.5 Cg_endo -77.83 141.71 19.46 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.406 2.071 . . . . 74.409999999999997 111.33 176.568 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.408 ' CD ' ' HB3' ' A' ' 20' ' ' ASP . 35.2 mtmt -58.89 -32.95 69.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.197 0.523 . . . . 64.239999999999995 110.603 179.346 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -130.6 100.51 5.34 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.74 -0.664 . . . . 74.150000000000006 109.297 177.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 149.54 -16.0 1.1 Allowed Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.884 -0.674 . . . . 61.43 112.277 -177.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.5 mttt 72.76 140.84 0.08 OUTLIER Pre-proline 0 N--CA 1.467 0.393 0 C-N-CA 123.383 0.673 . . . . 74.219999999999999 112.237 178.29 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.717 ' HB3' HG21 ' A' ' 38' ' ' VAL . 29.1 Cg_endo -64.18 133.6 38.77 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 123.103 2.535 . . . . 74.120000000000005 112.476 179.04 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 11.2 p90 -144.15 156.18 44.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.107 -0.497 . . . . 72.109999999999999 110.57 -179.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.491 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 20.0 m-85 -99.54 142.38 31.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.084 -0.507 . . . . 75.430000000000007 111.484 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.439 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 72.0 mt -124.88 104.51 8.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.608 -0.724 . . . . 74.510000000000005 109.747 171.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 43.2 t -93.24 136.36 25.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.184 -0.462 . . . . 75.319999999999993 110.047 -178.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.556 HH11 ' HG3' ' A' ' 49' ' ' ARG . 0.5 OUTLIER -76.06 132.06 39.87 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.94 0.4 . . . . 71.430000000000007 111.621 -178.504 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.12 158.31 35.98 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.565 -0.743 . . . . 74.329999999999998 111.707 179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -79.18 171.86 14.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.647 -0.706 . . . . 72.209999999999994 111.771 -176.265 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 70.33 21.49 77.35 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.657 -0.701 . . . . 73.329999999999998 113.035 171.147 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.9 m 57.28 30.66 18.83 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.024 0.44 . . . . 73.319999999999993 110.526 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -55.98 -63.93 1.02 Allowed 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.468 -0.787 . . . . 74.129999999999995 111.501 -179.278 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 131.1 -39.2 1.81 Allowed Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.273 -0.965 . . . . 74.349999999999994 112.794 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -68.57 164.55 21.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.43 0.633 . . . . 64.219999999999999 111.507 -176.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.417 ' CE2' ' HG2' ' A' ' 49' ' ' ARG . 67.9 m-85 -113.29 155.28 25.41 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.209 -0.905 . . . . 74.209999999999994 109.587 175.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.622 HD11 HD23 ' A' ' 66' ' ' LEU . 27.5 mm -113.27 119.87 61.8 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 108.883 -0.784 . . . . 75.299999999999997 108.883 177.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.567 ' HB2' HG13 ' A' ' 67' ' ' ILE . 8.1 ttm180 -82.7 149.43 27.32 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.951 -0.3 . . . . 75.450000000000003 110.403 -175.273 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.491 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 4.3 p -62.82 -27.14 69.11 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.282 -0.417 . . . . 64.109999999999999 111.452 178.266 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.46 ' HB2' ' HD2' ' A' ' 59' ' ' ARG . 1.3 m-20 -64.41 -29.13 70.19 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.131 -0.486 . . . . 72.040000000000006 111.537 -179.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.9 tp-100 -150.79 93.0 3.79 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-O 121.034 0.445 . . . . 71.239999999999995 109.992 -179.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.473 ' HB2' ' HD2' ' B' ' 146' ' ' PHE . 72.7 Cg_endo -74.35 15.06 0.67 Allowed 'Trans proline' 0 C--O 1.233 0.24 0 C-N-CA 123.396 2.73 . . . . 72.349999999999994 113.151 -176.429 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -128.25 8.33 6.04 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.161 0.505 . . . . 74.140000000000001 110.338 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 12.5 mmmt -121.75 145.43 48.04 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.101 -0.5 . . . . 74.140000000000001 111.925 -177.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.622 HD23 HD11 ' A' ' 58' ' ' ILE . 65.6 mt -92.41 109.11 20.49 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.342 -0.844 . . . . 74.519999999999996 109.754 178.071 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.567 HG13 ' HB2' ' A' ' 59' ' ' ARG . 46.6 mm -72.67 119.54 75.77 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 116.323 -0.398 . . . . 72.299999999999997 110.408 -178.697 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.53 178.95 3.91 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 123.274 2.649 . . . . 74.530000000000001 113.363 -177.184 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . 0.809 ' HA ' HG12 ' A' ' 72' ' ' ILE . 34.9 tt0 -75.19 -34.58 61.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.513 -0.767 . . . . 74.209999999999994 111.515 -170.486 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 3.7 p90 -64.32 -23.89 67.46 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.349 -0.541 . . . . 75.340000000000003 110.916 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.445 ' HA ' ' HB2' ' A' ' 74' ' ' SER . 4.2 tp10 -92.99 -27.79 16.8 Favored 'General case' 0 N--CA 1.438 -1.052 0 CA-C-N 116.086 -0.507 . . . . 73.239999999999995 110.639 -176.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.809 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.3 pt -80.14 -16.95 12.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.039 0.447 . . . . 73.109999999999999 110.66 177.547 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.444 ' CD1' HG13 ' A' ' 72' ' ' ILE . 46.5 m-85 -108.37 15.37 24.04 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.825 -0.625 . . . . 73.439999999999998 110.118 174.04 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.445 ' HB2' ' HA ' ' A' ' 71' ' ' GLU . 8.3 t -74.43 -28.81 61.23 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.755 -0.657 . . . . 71.109999999999999 110.396 -177.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . 0.404 ' O ' ' HE3' ' A' ' 21' ' ' LYS . 65.3 p-90 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.515 -0.311 . . . . 73.129999999999995 110.935 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.45 0 N-CA-C 111.67 -0.572 . . . . 71.209999999999994 111.67 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -99.58 116.29 31.37 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.1 0.476 . . . . 75.409999999999997 111.118 -176.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -101.83 -52.74 3.12 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.449 0.643 . . . . 72.040000000000006 109.463 177.34 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -136.49 26.4 3.13 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 107.79 -1.189 . . . . 73.420000000000002 107.79 174.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -87.32 91.09 8.6 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 114.257 -1.338 . . . . 71.439999999999998 110.611 -173.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -90.5 116.28 66.04 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.194 -0.457 . . . . 71.310000000000002 111.02 -178.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -68.28 176.49 5.52 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.902 2.401 . . . . 62.25 111.805 178.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 35.0 m -107.56 159.22 16.6 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.087 0.47 . . . . 72.420000000000002 110.861 -179.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.49 -68.3 0.22 Allowed Glycine 0 N--CA 1.446 -0.691 0 N-CA-C 111.595 -0.602 . . . . 72.409999999999997 111.595 -177.408 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 57.8 mm-40 69.21 77.12 0.24 Allowed Pre-proline 0 N--CA 1.468 0.463 0 C-N-CA 123.537 0.735 . . . . 74.439999999999998 111.807 -178.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.613 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 10.8 Cg_endo -80.93 85.22 1.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.087 0 C-N-CA 122.455 2.103 . . . . 62.049999999999997 111.049 174.792 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -97.01 150.52 20.69 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.208 0.528 . . . . 75.349999999999994 110.448 -178.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.423 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 13.5 p -105.46 123.75 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.906 0 CA-C-N 115.653 -0.703 . . . . 73.400000000000006 109.417 174.282 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 114' ' ' THR . . . . . 0.518 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 19.6 m -89.22 99.52 12.49 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 115.658 -0.701 . . . . 72.219999999999999 109.472 177.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 59.8 mt -88.86 106.19 16.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.919 -0.582 . . . . 74.439999999999998 110.093 -177.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 32.1 mtp-105 -122.28 -174.36 2.88 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.408 -0.815 . . . . 75.239999999999995 110.34 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 23.6 mp0 -136.16 132.55 36.13 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.839 -0.619 . . . . 74.5 110.431 179.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . 0.439 ' HG2' HG13 ' B' ' 123' ' ' ILE . 79.4 mm-40 -112.56 82.26 1.61 Allowed 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.062 -0.718 . . . . 75.430000000000007 109.062 173.687 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 81.05 -92.06 1.45 Allowed Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.743 -0.741 . . . . 75.450000000000003 111.387 -175.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 29.9 m-20 -117.61 -20.49 8.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.767 0.318 . . . . 71.200000000000003 111.205 178.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.757 ' HE3' ' HE3' ' B' ' 175' ' ' TRP . 23.6 pttt -86.62 126.0 34.21 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.273 0.559 . . . . 74.310000000000002 111.076 -177.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 43.9 m -80.72 124.32 28.93 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.502 -0.772 . . . . 70.140000000000001 109.986 178.592 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . 0.439 HG13 ' HG2' ' B' ' 118' ' ' GLU . 27.3 mm -108.98 108.59 25.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.552 -0.295 . . . . 74.400000000000006 110.393 -175.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.423 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 16.5 mt-30 -100.65 100.52 11.24 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.917 0.389 . . . . 74.299999999999997 110.254 178.256 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . 0.518 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 43.7 mt-10 -86.77 107.43 18.26 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.034 -0.53 . . . . 75.450000000000003 111.116 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . 0.472 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 78.0 m-85 -86.99 113.39 22.71 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.976 0.417 . . . . 74.109999999999999 110.422 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 60.5 mtm180 -117.22 178.7 4.27 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.124 -0.489 . . . . 74.510000000000005 109.957 179.145 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.613 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -140.58 -65.21 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 116.279 -0.419 . . . . 74.209999999999994 110.884 173.055 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . 0.601 ' H ' HG13 ' B' ' 128' ' ' VAL . 3.7 t-20 -141.79 75.99 1.52 Allowed 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.438 -0.505 . . . . 74.040000000000006 110.194 -179.64 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.04 25.75 73.32 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.346 -0.843 . . . . 74.340000000000003 111.782 -179.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 67.7 t80 -146.01 121.7 10.5 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.685 -0.487 . . . . 73.400000000000006 109.685 -179.498 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.428 HD21 HD11 ' B' ' 135' ' ' ILE . 24.5 tp -80.14 123.93 28.33 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.724 -0.671 . . . . 75.519999999999996 109.318 176.048 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . 0.472 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 37.2 p90 -108.85 -15.72 14.32 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.969 -0.692 . . . . 75.310000000000002 111.849 -176.883 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . 0.402 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -168.03 148.85 5.07 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.928 0.394 . . . . 75.319999999999993 111.6 -178.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.428 HD11 HD21 ' B' ' 132' ' ' LEU . 62.9 mt -125.39 126.18 70.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.118 -0.492 . . . . 63.210000000000001 109.842 174.337 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.417 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 88.6 tttt -105.04 101.19 10.77 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.957 -0.757 . . . . 73.439999999999998 108.957 172.254 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 1.4 p -99.23 133.64 41.22 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.855 -0.611 . . . . 72.239999999999995 110.196 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.855 HG23 ' HB3' ' B' ' 144' ' ' PRO . 24.4 t -107.85 84.61 2.11 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 115.384 -0.826 . . . . 75.420000000000002 109.536 177.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.413 ' HG3' ' HE1' ' B' ' 145' ' ' TYR . 92.3 Cg_endo -79.86 150.01 20.78 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 122.407 2.072 . . . . 70.200000000000003 111.969 -179.175 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 4.1 mmpt? -62.2 -35.71 79.7 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.77 -0.65 . . . . 74.439999999999998 110.123 177.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 86.2 m-70 -124.73 90.67 3.29 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 115.789 -0.642 . . . . 72.310000000000002 109.913 -178.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . 0.406 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 150.49 -29.18 1.07 Allowed Glycine 0 N--CA 1.448 -0.549 0 CA-C-N 115.191 -0.913 . . . . 70.25 111.675 -176.035 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . 0.454 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 87.0 mttt 70.34 155.73 0.15 Allowed Pre-proline 0 N--CA 1.467 0.421 0 C-N-CA 123.427 0.691 . . . . 74.140000000000001 112.01 -178.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.855 ' HB3' HG23 ' B' ' 138' ' ' VAL . 18.9 Cg_endo -58.25 124.07 15.06 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 123.224 2.616 . . . . 74.299999999999997 113.47 -175.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . 0.486 ' CE1' HG12 ' B' ' 137' ' ' VAL . 5.1 p90 -139.65 168.23 20.3 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.636 -0.711 . . . . 74.140000000000001 110.137 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.473 ' HD2' ' HB2' ' A' ' 63' ' ' PRO . 1.2 m-85 -108.84 139.32 43.83 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.954 0.407 . . . . 73.420000000000002 111.882 -176.506 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . 0.402 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 25.6 mt -118.75 101.28 7.97 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.448 -0.796 . . . . 75.219999999999999 109.653 169.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 42.7 t -86.46 137.91 20.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 116.225 -0.443 . . . . 73.409999999999997 110.077 -179.101 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 5.1 mmt85 -74.85 130.38 39.32 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.884 0.373 . . . . 72.5 111.285 178.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -71.03 122.14 19.5 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.769 -0.65 . . . . 43.100000000000001 111.08 177.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . 0.595 ' HB2' ' HD2' ' A' ' 26' ' ' TYR . 15.7 t70 -61.31 140.0 58.06 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.648 -0.705 . . . . 73.239999999999995 110.981 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 73.47 -56.61 2.03 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.955 -0.566 . . . . 71.400000000000006 113.237 179.323 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 153' ' ' SER . . . . . 0.43 ' O ' ' HB3' ' B' ' 154' ' ' ASP . 19.7 m -61.2 -46.07 91.96 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 122.43 0.292 . . . . 75.549999999999997 110.868 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . 0.43 ' HB3' ' O ' ' B' ' 153' ' ' SER . 18.0 t70 71.47 -48.27 0.67 Allowed 'General case' 0 N--CA 1.464 0.237 0 C-N-CA 123.743 0.817 . . . . 74.329999999999998 111.859 178.107 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . -88.13 50.07 3.84 Favored Glycine 0 N--CA 1.448 -0.502 0 CA-C-N 116.122 -0.49 . . . . 72.439999999999998 112.601 -178.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . 0.452 HD22 ' HB3' ' B' ' 166' ' ' LEU . 25.9 t-20 -162.54 144.59 10.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.457 -0.571 . . . . 75.549999999999997 109.457 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . 0.506 ' HB2' HG21 ' B' ' 172' ' ' ILE . 72.4 m-85 -118.99 150.71 39.48 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.909 0.385 . . . . 74.040000000000006 110.463 178.108 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.0 mm -113.43 114.44 46.86 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 N-CA-C 108.82 -0.807 . . . . 74.540000000000006 108.82 175.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.532 ' HB2' HG13 ' B' ' 167' ' ' ILE . 15.0 ttp180 -88.03 146.92 25.24 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 110.046 -0.353 . . . . 72.340000000000003 110.046 -174.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 4.0 p -60.03 -36.31 76.99 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 112.779 0.659 . . . . 74.310000000000002 112.779 -174.101 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -78.28 -14.65 59.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.973 0.416 . . . . 73.219999999999999 110.908 -177.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . 0.804 ' HG3' ' HB2' ' B' ' 165' ' ' LYS . 5.4 tp-100 -138.03 72.02 47.57 Favored Pre-proline 0 N--CA 1.45 -0.438 0 CA-C-N 116.219 -0.446 . . . . 73.010000000000005 110.894 -177.334 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -85.09 -1.57 9.38 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.674 2.249 . . . . 73.400000000000006 111.775 179.18 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -91.74 -17.99 24.59 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.25 -0.886 . . . . 75.200000000000003 110.14 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . 0.804 ' HB2' ' HG3' ' B' ' 162' ' ' GLN . 0.7 OUTLIER -122.79 158.83 29.35 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.124 -0.944 . . . . 73.109999999999999 111.134 -175.133 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . 0.452 ' HB3' HD22 ' B' ' 156' ' ' ASN . 5.1 mp -94.74 134.02 37.79 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.064 -1.087 . . . . 73.420000000000002 108.064 172.577 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . 0.532 HG13 ' HB2' ' B' ' 159' ' ' ARG . 50.2 mm -84.69 125.11 72.07 Favored Pre-proline 0 C--N 1.32 -0.695 0 C-N-CA 120.91 -0.316 . . . . 75.409999999999997 111.041 -171.552 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.466 ' HG2' ' HB2' ' B' ' 171' ' ' GLU . 49.6 Cg_endo -67.7 172.77 10.02 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.762 2.308 . . . . 74.299999999999997 112.429 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . 0.507 ' HA ' HG12 ' B' ' 172' ' ' ILE . 20.4 tt0 -79.56 -16.93 55.05 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.766 -0.652 . . . . 74.540000000000006 111.626 -167.464 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . 0.402 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 24.4 p90 -86.75 -8.01 57.76 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.234 0.54 . . . . 71.409999999999997 110.019 176.043 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.541 ' O ' ' HB2' ' B' ' 174' ' ' SER . 1.9 mm-40 -113.32 -11.89 13.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.816 -0.629 . . . . 74.209999999999994 111.961 -176.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.507 HG12 ' HA ' ' B' ' 169' ' ' GLN . 31.8 pt -76.82 -16.87 14.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 121.264 0.554 . . . . 70.5 110.277 175.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -109.14 39.09 2.13 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.356 -0.838 . . . . 75.219999999999999 108.874 174.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 174' ' ' SER . . . . . 0.541 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 0.5 OUTLIER -70.15 -14.48 62.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 114.981 -1.009 . . . . 60.340000000000003 110.916 -176.181 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . 0.757 ' HE3' ' HE3' ' B' ' 121' ' ' LYS . 59.7 p-90 . . . . . 0 C--O 1.245 0.842 0 CA-C-O 118.286 -0.864 . . . . 74.230000000000004 110.204 177.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.659 0 N-CA-C 111.328 -0.709 . . . . 63.32 111.328 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -78.74 73.56 5.28 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.447 0.641 . . . . 73.030000000000001 110.518 175.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -121.17 131.39 54.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.31 -0.859 . . . . 73.409999999999997 109.909 178.096 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -82.05 -60.89 2.07 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.88 -0.6 . . . . 70.099999999999994 111.964 -173.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -83.77 111.88 19.58 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.272 -0.422 . . . . 72.400000000000006 111.124 -175.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -86.97 131.36 45.14 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-N 115.677 -0.692 . . . . 74.030000000000001 109.798 176.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -68.69 165.68 28.68 Favored 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.671 2.248 . . . . 63.439999999999998 112.386 -178.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 15.0 m -81.03 111.58 17.64 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.03 -0.73 . . . . 75.219999999999999 109.03 175.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 116.17 102.8 2.33 Favored Glycine 0 N--CA 1.439 -1.111 0 N-CA-C 108.79 -1.724 . . . . 74.439999999999998 108.79 -166.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . 0.484 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 10.1 pt-20 -141.03 113.99 6.96 Favored Pre-proline 0 N--CA 1.437 -1.12 0 N-CA-C 108.089 -1.078 . . . . 63.409999999999997 108.089 -167.773 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.484 ' HD3' ' HA ' ' A' ' 10' ' ' GLU . 4.9 Cg_exo -77.12 81.47 2.61 Favored 'Trans proline' 0 N--CA 1.437 -1.803 0 C-N-CA 121.873 1.715 . . . . 73.340000000000003 110.531 -176.451 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -86.26 155.37 20.71 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.564 -1.198 . . . . 72.120000000000005 109.869 -177.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.57 HG22 ' HB3' ' A' ' 24' ' ' GLN . 10.1 p -121.23 123.79 70.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 CA-C-O 121.512 0.673 . . . . 64.420000000000002 111.143 -178.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.54 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 88.8 m -86.03 104.21 15.43 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.521 -0.763 . . . . 71.239999999999995 108.944 177.011 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.3 mt -91.44 105.5 16.61 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 CA-C-N 116.093 -0.503 . . . . 74.5 110.598 -175.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.3 mtm180 -117.86 172.99 7.02 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.787 -0.642 . . . . 73.209999999999994 109.993 177.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . 0.471 ' HG2' ' HA ' ' A' ' 22' ' ' THR . 82.6 mt-30 -136.93 122.17 19.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.172 0.51 . . . . 64.519999999999996 111.024 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.443 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 31.5 mm-40 -106.96 87.35 2.49 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.398 -0.819 . . . . 75.430000000000007 110.018 178.188 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 79.17 -95.13 1.4 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.633 -0.794 . . . . 74.430000000000007 111.678 -178.26 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -124.09 12.5 8.97 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.83 0.347 . . . . 72.420000000000002 110.871 -179.228 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.703 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 21.3 pttm -117.27 117.29 29.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.019 0.438 . . . . 74.549999999999997 110.987 178.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.687 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 23.6 m -79.25 101.91 8.27 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.736 -0.665 . . . . 72.030000000000001 109.679 176.047 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.441 HG12 HG11 ' A' ' 37' ' ' VAL . 57.0 mt -92.64 106.85 18.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 120.996 0.427 . . . . 75.120000000000005 110.14 -176.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.588 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 20.2 mt-30 -91.4 110.7 22.01 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.801 -0.636 . . . . 75.120000000000005 110.3 178.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.617 ' HB3' HD12 ' A' ' 32' ' ' LEU . 26.4 mt-10 -93.83 103.48 15.6 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.469 -0.787 . . . . 62.329999999999998 111.109 -177.142 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.407 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 86.8 m-85 -77.83 109.13 11.58 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.985 0.421 . . . . 73.519999999999996 110.228 178.692 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 83.8 mtt180 -127.58 127.3 43.65 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.581 -0.736 . . . . 75.439999999999998 109.459 -179.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.596 HG22 ' CD2' ' B' ' 131' ' ' PHE . 11.9 p -90.49 -28.25 4.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 C-N-CA 120.37 -0.532 . . . . 71.519999999999996 110.628 -177.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -172.26 68.06 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.707 -0.679 . . . . 73.109999999999999 109.631 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 95.77 -37.97 3.26 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.773 -0.727 . . . . 62.32 113.414 178.262 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.451 ' CD2' HG21 ' B' ' 128' ' ' VAL . 80.1 t80 -94.82 133.5 38.46 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.239 0.542 . . . . 74.299999999999997 111.405 -174.058 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.617 HD12 ' HB3' ' A' ' 25' ' ' GLU . 50.1 tp -82.38 112.86 19.73 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.941 -1.027 . . . . 75.219999999999999 110.156 174.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . 0.45 ' O ' ' HB2' ' A' ' 49' ' ' ARG . 44.3 p90 -108.62 -4.99 16.65 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.895 -0.322 . . . . 74.219999999999999 111.72 -176.614 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -168.3 136.97 2.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.891 0.377 . . . . 73.510000000000005 110.889 -176.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.403 ' CG1' HD21 ' A' ' 32' ' ' LEU . 61.4 mt -118.97 126.12 75.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.0 -0.546 . . . . 75.319999999999993 110.542 178.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.588 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 83.1 tttt -108.69 100.78 9.98 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.003 -0.74 . . . . 63.340000000000003 109.003 171.366 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.716 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.8 t -87.91 128.79 40.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 109.153 -0.684 . . . . 75.150000000000006 109.153 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.773 HG13 ' HG3' ' A' ' 44' ' ' PRO . 24.2 t -115.74 72.71 4.16 Favored Pre-proline 0 C--N 1.32 -0.709 0 N-CA-C 109.75 -0.463 . . . . 65.049999999999997 109.75 172.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.703 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 57.1 Cg_endo -78.76 134.43 12.09 Favored 'Trans proline' 0 N--CA 1.458 -0.615 0 C-N-CA 122.18 1.92 . . . . 72.439999999999998 112.433 176.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.651 ' HB3' ' HZ3' ' A' ' 40' ' ' LYS . 9.4 mtpm? -59.78 -33.06 71.21 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-O 121.29 0.566 . . . . 74.200000000000003 109.948 175.275 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 62.4 m-70 -115.77 103.58 10.8 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.244 -0.889 . . . . 73.340000000000003 109.148 178.009 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 130.11 -25.18 4.39 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.943 -0.646 . . . . 61.409999999999997 112.096 -177.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.0 mttm 69.57 147.79 0.12 Allowed Pre-proline 0 N--CA 1.466 0.363 0 C-N-CA 123.342 0.657 . . . . 74.319999999999993 112.323 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.773 ' HG3' HG13 ' A' ' 38' ' ' VAL . 31.0 Cg_exo -58.51 145.97 92.59 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 123.222 2.615 . . . . 74.349999999999994 113.561 -177.03 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 30.6 p90 -156.39 164.91 37.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.314 -0.857 . . . . 74.310000000000002 109.304 174.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.542 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 85.1 m-85 -106.62 136.44 46.4 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.021 0.438 . . . . 72.120000000000005 110.7 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 16.9 tp -125.14 98.96 5.88 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.695 -0.854 . . . . 73.140000000000001 108.695 176.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.422 HG22 HG23 ' B' ' 148' ' ' VAL . 28.7 t -96.32 140.59 16.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.421 -0.354 . . . . 74.239999999999995 111.548 -171.036 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.45 ' HB2' ' O ' ' A' ' 33' ' ' TYR . 0.7 OUTLIER -66.85 122.38 17.57 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.213 -0.449 . . . . 73.430000000000007 111.32 176.66 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.44 172.39 13.7 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.921 -0.581 . . . . 72.439999999999998 109.503 172.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -68.04 125.04 25.07 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.22 0.533 . . . . 75.25 109.781 176.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.41 125.57 5.49 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.783 -0.723 . . . . 63.229999999999997 111.899 -176.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.5 t -87.45 23.1 1.99 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.347 0.594 . . . . 74.349999999999994 110.24 -177.027 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -58.12 -60.43 3.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.432 -0.804 . . . . 71.409999999999997 110.206 177.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 156.61 21.87 0.03 OUTLIER Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 115.546 -0.752 . . . . 72.349999999999994 112.453 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.47 ' OD1' ' HB3' ' A' ' 66' ' ' LEU . 7.4 t30 -102.91 137.18 41.44 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.963 0.411 . . . . 74.099999999999994 110.867 -176.562 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -123.56 174.42 7.43 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.942 -0.572 . . . . 74.319999999999993 110.47 177.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 49.8 mm -123.97 122.08 63.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.893 -0.78 . . . . 71.010000000000005 108.893 171.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.646 ' HB2' HG13 ' A' ' 67' ' ' ILE . 74.6 ttt180 -93.34 131.97 38.0 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.07 -0.514 . . . . 73.409999999999997 110.309 -175.386 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.542 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 67.9 p -62.8 -22.77 66.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.86 0.362 . . . . 75.340000000000003 111.343 -178.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 16.4 t70 -64.23 -46.37 84.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.778 -0.647 . . . . 65.019999999999996 109.981 178.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . 0.42 ' C ' ' H ' ' A' ' 64' ' ' ASP . 78.0 mm-40 -132.14 82.66 58.1 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.479 -0.782 . . . . 72.450000000000003 109.383 178.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -76.34 30.9 0.4 Allowed 'Trans proline' 0 CA--C 1.529 0.254 0 C-N-CA 123.28 2.653 . . . . 62.140000000000001 112.5 -177.052 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.42 ' H ' ' C ' ' A' ' 62' ' ' GLN . 15.4 t70 -119.57 -39.89 2.83 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.433 -0.803 . . . . 72.219999999999999 110.462 -177.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.7 pttt -97.53 160.22 14.45 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.999 -0.546 . . . . 75.420000000000002 110.501 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.47 ' HB3' ' OD1' ' A' ' 56' ' ' ASN . 5.4 mp -92.96 140.25 29.67 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.668 -0.696 . . . . 72.510000000000005 109.335 179.214 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.685 HG21 ' HB3' ' A' ' 71' ' ' GLU . 47.1 mm -96.84 109.03 46.79 Favored Pre-proline 0 C--N 1.322 -0.593 0 CA-C-O 121.235 0.54 . . . . 75.310000000000002 111.307 -176.453 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.479 ' O ' HG23 ' A' ' 72' ' ' ILE . 93.0 Cg_endo -81.61 -176.92 3.3 Favored 'Trans proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.505 2.803 . . . . 61.140000000000001 111.983 177.499 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . 0.629 ' O ' HG12 ' A' ' 72' ' ' ILE . 6.3 tt0 -67.99 -40.42 83.09 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.225 0.454 . . . . 72.420000000000002 112.225 -171.122 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . 0.635 ' HA ' ' CZ ' ' A' ' 73' ' ' PHE . 17.4 p90 -63.38 -17.76 62.95 Favored 'General case' 0 C--N 1.326 -0.441 0 O-C-N 121.723 -0.61 . . . . 72.349999999999994 110.981 -178.591 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.685 ' HB3' HG21 ' A' ' 67' ' ' ILE . 2.5 mm-40 -94.45 -18.45 21.49 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.041 -0.527 . . . . 74.25 111.117 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.629 HG12 ' O ' ' A' ' 69' ' ' GLN . 39.9 pt -83.61 -36.03 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 C-N-CA 120.723 -0.391 . . . . 74.340000000000003 111.625 -177.199 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.635 ' CZ ' ' HA ' ' A' ' 70' ' ' TRP . 10.7 p90 -90.82 26.09 2.18 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.262 0.554 . . . . 75.109999999999999 110.722 178.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.3 t -78.72 9.03 4.49 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.767 -0.652 . . . . 73.420000000000002 111.102 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . 0.673 ' HB3' ' HE3' ' A' ' 21' ' ' LYS . 38.8 m0 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.459 -0.337 . . . . 72.519999999999996 111.176 177.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 N-CA-C 111.876 -0.49 . . . . 55.32 111.876 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -103.66 0.36 30.56 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.228 0.537 . . . . 72.239999999999995 110.319 178.163 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -88.94 168.38 12.44 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.679 -0.692 . . . . 62.32 110.456 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -81.94 -48.25 11.71 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.145 0.498 . . . . 71.140000000000001 110.612 178.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -114.03 134.68 54.7 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.611 -0.722 . . . . 73.239999999999995 110.528 -178.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -120.75 128.58 25.71 Favored Pre-proline 0 C--N 1.319 -0.747 0 CA-C-N 115.883 -0.599 . . . . 72.140000000000001 109.979 177.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -52.89 144.08 46.14 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.833 2.355 . . . . 73.25 112.183 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 31.8 m -58.77 115.72 3.26 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.872 -0.603 . . . . 72.239999999999995 110.366 -179.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 122.61 42.89 0.4 Allowed Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 110.491 -1.043 . . . . 63.049999999999997 110.491 -170.397 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -106.59 100.56 31.25 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-O 121.658 0.742 . . . . 74.340000000000003 109.286 -179.463 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.548 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 58.0 Cg_endo -79.43 121.04 4.61 Favored 'Trans proline' 0 N--CA 1.448 -1.148 0 C-N-CA 122.382 2.054 . . . . 61.100000000000001 113.195 -169.645 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -122.84 144.19 49.36 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.814 -1.084 . . . . 74.340000000000003 108.599 174.583 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.722 HG21 ' HB3' ' B' ' 124' ' ' GLN . 7.9 p -92.37 132.01 37.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-O 121.396 0.617 . . . . 75.409999999999997 111.543 -172.112 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 114' ' ' THR . . . . . 0.737 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.4 m -82.84 103.39 12.28 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.167 -0.924 . . . . 71.409999999999997 109.177 174.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 59.2 mt -88.67 104.61 14.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.096 0.474 . . . . 72.510000000000005 111.066 -176.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . 0.427 HH21 ' CD ' ' B' ' 125' ' ' GLU . 38.1 mtm180 -108.88 167.86 9.78 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.721 -0.672 . . . . 72.430000000000007 109.627 174.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 91.5 mt-30 -139.55 112.03 7.73 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.068 0.461 . . . . 74.340000000000003 110.585 177.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 81.6 mm-40 -108.48 85.35 2.09 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.669 -0.696 . . . . 74.099999999999994 110.384 -178.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 88.38 -111.94 3.84 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.624 -0.798 . . . . 55.130000000000003 111.589 -178.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . 0.504 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 4.3 m-20 -116.0 23.24 12.37 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.059 0.457 . . . . 74.209999999999994 110.041 177.141 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.951 ' HE3' ' HB3' ' B' ' 175' ' ' TRP . 21.2 pttm -127.5 115.56 19.04 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.236 0.541 . . . . 73.219999999999999 110.307 177.311 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 122' ' ' THR . . . . . 0.729 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 62.5 m -76.22 113.0 13.29 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.611 -0.722 . . . . 74.209999999999994 109.675 177.172 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 14.2 mm -92.8 102.51 13.7 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-N 115.948 -0.569 . . . . 75.129999999999995 109.999 -178.222 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.761 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 15.5 mt-30 -94.77 102.89 14.79 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.093 0.473 . . . . 73.25 110.327 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . 0.737 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 38.9 mt-10 -84.62 102.72 13.13 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.556 -0.747 . . . . 75.409999999999997 110.603 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . 0.479 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 41.4 m-85 -78.8 106.0 10.51 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.137 0.494 . . . . 71.530000000000001 110.377 178.061 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 65.6 mtt-85 -124.08 134.55 53.36 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.61 -0.723 . . . . 74.150000000000006 109.468 -178.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.548 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 5.6 p -96.08 -30.91 3.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-O 120.966 0.412 . . . . 73.439999999999998 111.407 -176.374 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -160.45 45.99 0.22 Allowed 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.872 -0.788 . . . . 72.340000000000003 108.872 -176.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 95.54 -32.08 6.58 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.425 -0.807 . . . . 64.519999999999996 112.186 -177.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . 0.596 ' CD2' HG22 ' A' ' 28' ' ' VAL . 38.2 t80 -86.49 133.6 33.74 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.99 0.424 . . . . 74.310000000000002 110.445 -177.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.439 HD22 HD11 ' B' ' 135' ' ' ILE . 41.4 tp -82.83 120.5 25.73 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.354 -0.839 . . . . 74.230000000000004 110.645 179.328 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . 0.479 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 36.2 p90 -110.4 -10.43 14.58 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.498 -0.481 . . . . 74.019999999999996 111.658 -179.101 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -170.14 148.13 3.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.806 0.336 . . . . 75.150000000000006 110.913 -178.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.439 HD11 HD22 ' B' ' 132' ' ' LEU . 63.5 mt -122.44 125.89 73.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.332 -0.395 . . . . 73.319999999999993 110.17 177.456 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.761 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 75.9 tttt -102.43 102.39 12.7 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 109.07 -0.715 . . . . 75.450000000000003 109.07 173.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.621 HG13 ' HD3' ' B' ' 139' ' ' PRO . 3.4 t -86.52 128.94 39.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 N-CA-C 108.559 -0.904 . . . . 75.299999999999997 108.559 178.151 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.729 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.5 t -115.35 72.1 3.39 Favored Pre-proline 0 C--N 1.317 -0.841 0 N-CA-C 109.956 -0.387 . . . . 75.409999999999997 109.956 173.525 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.621 ' HD3' HG13 ' B' ' 137' ' ' VAL . 45.1 Cg_endo -77.12 130.5 11.23 Favored 'Trans proline' 0 N--CA 1.455 -0.754 0 C-N-CA 121.992 1.794 . . . . 64.109999999999999 111.868 176.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . 0.504 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 22.9 mtpp -64.76 -27.43 68.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.442 -0.799 . . . . 73.450000000000003 110.199 177.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -114.43 86.57 2.46 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.132 -0.94 . . . . 75.109999999999999 109.149 176.293 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 140.96 -13.88 2.85 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.593 -0.813 . . . . 74.230000000000004 112.678 -177.576 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 67.1 mttm 70.03 149.01 0.12 Allowed Pre-proline 0 N--CA 1.469 0.525 0 C-N-CA 123.134 0.574 . . . . 74.209999999999994 112.183 178.266 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.559 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 56.3 Cg_endo -70.64 143.1 45.7 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.674 2.249 . . . . 74.219999999999999 113.146 -178.279 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 44.7 p90 -150.99 154.77 37.72 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.789 -0.641 . . . . 74.230000000000004 110.199 178.207 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.626 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 93.4 m-85 -96.64 130.5 43.84 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.838 -0.43 . . . . 75.25 109.838 177.255 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 15.7 tp -117.21 98.81 6.64 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.134 -0.691 . . . . 73.439999999999998 109.134 176.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . 0.422 HG23 HG22 ' A' ' 48' ' ' VAL . 39.0 t -83.92 135.73 24.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.05 -0.523 . . . . 72.140000000000001 110.837 -175.294 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.29 119.44 24.59 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.58 -0.526 . . . . 74.420000000000002 109.58 -177.722 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.14 166.75 22.88 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 121.321 0.581 . . . . 71.209999999999994 111.74 -174.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . 0.407 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 5.6 p-10 -67.77 157.59 34.38 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 114.964 -1.017 . . . . 71.239999999999995 111.99 -175.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.41 -8.93 57.24 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.301 -0.863 . . . . 71.230000000000004 113.28 173.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 23.3 t 59.3 31.1 20.9 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-O 121.513 0.673 . . . . 71.209999999999994 110.007 -178.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -64.43 -26.18 68.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.597 -0.729 . . . . 74.450000000000003 111.841 -178.139 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 106.15 25.17 6.53 Favored Glycine 0 CA--C 1.506 -0.525 0 N-CA-C 111.169 -0.772 . . . . 64.319999999999993 111.169 -175.044 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . 0.402 HD22 HD22 ' B' ' 166' ' ' LEU . 38.0 t30 -111.95 144.26 41.59 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.461 -0.57 . . . . 75.109999999999999 109.461 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . 0.507 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 55.8 m-85 -130.62 149.56 52.22 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.305 -0.407 . . . . 75.450000000000003 110.083 179.587 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.2 mm -112.44 117.19 54.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.444 -0.576 . . . . 74.120000000000005 109.444 176.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . . . . . . . . . 46.1 ttt180 -85.95 135.05 33.82 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.48 -0.782 . . . . 75.400000000000006 110.075 -175.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 160' ' ' SER . . . . . 0.626 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 61.3 p -60.46 -33.07 72.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.406 0.622 . . . . 74.200000000000003 110.412 178.66 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 26.6 t70 -75.94 -24.59 55.51 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.15 -0.932 . . . . 71.310000000000002 110.921 178.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . 0.419 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 84.3 mm-40 -139.98 70.97 35.44 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 71.319999999999993 110.197 -175.235 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -73.11 -15.37 25.8 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.431 2.087 . . . . 72.230000000000004 112.007 -178.032 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -89.2 -7.2 56.06 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.41 -0.814 . . . . 72.140000000000001 109.641 177.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . 0.419 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 51.3 tptt -110.68 123.98 51.06 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.444 -0.798 . . . . 75.099999999999994 110.447 -176.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . 0.402 HD22 HD22 ' B' ' 156' ' ' ASN . 5.3 mp -89.64 117.5 28.56 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.515 -0.766 . . . . 72.530000000000001 108.989 177.096 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . 0.507 ' HB ' ' HB2' ' B' ' 157' ' ' PHE . 49.3 mm -77.73 119.56 77.91 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.185 -0.462 . . . . 72.25 111.272 -171.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.471 ' O ' HG22 ' B' ' 172' ' ' ILE . 73.7 Cg_endo -73.3 177.26 8.1 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 123.049 2.5 . . . . 73.409999999999997 111.998 178.492 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 -84.25 0.88 47.2 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.347 -0.388 . . . . 71.319999999999993 111.468 -172.127 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 7.8 p90 -100.46 -18.89 16.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.987 0.423 . . . . 73.549999999999997 110.89 175.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.417 ' HB2' ' HG2' ' B' ' 168' ' ' PRO . 2.0 mm-40 -94.29 -11.43 30.15 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.194 -0.457 . . . . 74.519999999999996 110.76 -177.232 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.471 HG22 ' O ' ' B' ' 168' ' ' PRO . 37.0 pt -65.56 -29.65 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.991 -0.55 . . . . 75.219999999999999 111.432 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . 0.484 ' C ' ' H ' ' B' ' 175' ' ' TRP . 33.8 p90 -107.79 43.96 1.15 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.525 0.678 . . . . 71.140000000000001 110.447 178.742 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 174' ' ' SER . . . . . 0.401 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 1.9 t -78.59 21.97 0.37 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.05 -0.977 . . . . 72.439999999999998 110.036 178.183 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . 0.951 ' HB3' ' HE3' ' B' ' 121' ' ' LYS . 39.3 m0 . . . . . 0 C--O 1.25 1.129 0 CA-C-N 115.223 -0.898 . . . . 75.209999999999994 110.928 -176.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.884 0 N-CA-C 112.028 -0.429 . . . . 45.030000000000001 112.028 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -154.0 95.74 1.89 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.627 0.251 . . . . 71.349999999999994 110.681 -179.195 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -96.46 75.48 2.88 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.447 0.642 . . . . 75.140000000000001 109.318 178.296 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -116.83 112.82 21.65 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.282 -0.872 . . . . 74.349999999999994 110.278 -176.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -103.7 154.81 19.12 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.675 0.274 . . . . 74.209999999999994 110.482 -179.318 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.408 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -99.74 130.55 26.33 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-N 116.239 -0.437 . . . . 52.439999999999998 110.692 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 16.7 Cg_exo -68.13 171.42 12.62 Favored 'Trans proline' 0 CA--C 1.529 0.242 0 C-N-CA 122.955 2.436 . . . . 71.010000000000005 112.369 -179.513 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.6 m -65.67 143.25 57.69 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.518 -0.549 . . . . 65.109999999999999 109.518 176.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.657 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 74.03 73.02 0.95 Allowed Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.02 -1.086 . . . . 61.329999999999998 110.621 -173.727 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -96.22 99.1 4.77 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-O 121.417 0.627 . . . . 74.299999999999997 110.667 -174.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.728 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 98.2 Cg_endo -93.73 94.72 0.14 Allowed 'Trans proline' 0 N--CA 1.445 -1.368 0 C-N-CA 122.926 2.417 . . . . 64.109999999999999 112.747 -176.524 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -86.96 147.1 25.89 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 108.932 -0.766 . . . . 60.210000000000001 108.932 177.069 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.612 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 8.1 p -90.63 122.41 41.98 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 CA-C-O 121.629 0.728 . . . . 70.319999999999993 110.261 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.626 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 21.6 m -83.31 102.59 12.08 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.264 -0.88 . . . . 72.400000000000006 109.196 179.226 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 53.2 mt -84.72 103.98 12.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-N 115.978 -0.555 . . . . 74.340000000000003 110.308 -175.449 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -108.8 161.24 15.3 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.621 -0.718 . . . . 74.219999999999999 109.32 176.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -137.87 98.25 3.61 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-O 121.351 0.596 . . . . 72.439999999999998 110.232 176.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -93.88 96.84 9.99 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 114.982 -1.008 . . . . 75.420000000000002 109.849 -177.313 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 71.06 -101.84 1.0 Allowed Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.837 -0.697 . . . . 64.239999999999995 112.077 -178.105 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.748 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 16.5 m-20 -120.76 30.42 6.91 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.635 0.255 . . . . 71.340000000000003 110.951 -178.364 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.431 ' HB3' ' HA ' ' A' ' 39' ' ' PRO . 48.0 pttt -143.55 127.69 17.58 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.382 0.61 . . . . 75.25 111.624 175.72 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.437 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 75.0 m -81.66 107.18 14.2 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.189 -0.914 . . . . 72.219999999999999 109.936 177.073 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 50.2 mt -94.63 104.35 15.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.088 -0.505 . . . . 72.310000000000002 109.721 178.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.612 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 24.0 mt-30 -95.15 106.38 18.39 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.871 -0.604 . . . . 74.299999999999997 110.654 -177.725 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.626 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.7 mt-10 -89.86 104.51 17.06 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.874 -0.603 . . . . 53.509999999999998 111.355 -177.437 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.565 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 71.7 m-85 -76.94 103.57 6.95 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.393 -0.595 . . . . 74.340000000000003 109.393 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 55.5 mtt180 -120.39 128.05 52.86 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.259 -0.428 . . . . 74.230000000000004 110.362 -177.312 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.728 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 2.3 p -93.49 -66.73 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.543 -0.298 . . . . 73.519999999999996 111.232 179.58 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.692 ' H ' HG12 ' A' ' 28' ' ' VAL . 74.2 m-20 -133.53 77.5 1.73 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.85 0.357 . . . . 71.010000000000005 110.158 179.513 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 69.21 13.49 67.38 Favored Glycine 0 C--N 1.331 0.267 0 CA-C-N 115.792 -0.64 . . . . 75.209999999999994 112.868 179.042 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.604 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 83.3 t80 -129.86 128.04 41.45 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.888 0.375 . . . . 72.120000000000005 111.12 -175.431 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.728 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -85.98 116.25 24.09 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.559 -0.746 . . . . 72.209999999999994 109.327 173.571 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -110.89 -19.71 12.71 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.622 -0.431 . . . . 74.040000000000006 111.729 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -156.08 141.21 17.39 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.656 0.265 . . . . 61.219999999999999 111.031 -179.338 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.728 HG13 HD11 ' A' ' 32' ' ' LEU . 77.0 mt -124.31 125.9 71.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 116.055 -0.521 . . . . 72.319999999999993 110.612 176.867 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.433 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 82.1 tttt -102.99 102.56 12.61 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.104 -0.702 . . . . 72.299999999999997 109.104 170.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.437 ' HA ' ' O ' ' A' ' 22' ' ' THR . 0.5 OUTLIER -101.84 119.93 50.78 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 116.119 -0.491 . . . . 72.519999999999996 110.337 -179.538 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.559 HG13 ' HB3' ' A' ' 44' ' ' PRO . 22.3 t -109.17 89.71 7.19 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.445 -0.798 . . . . 73.439999999999998 110.135 -179.826 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.431 ' HA ' ' HB3' ' A' ' 21' ' ' LYS . 63.6 Cg_endo -79.37 135.92 12.24 Favored 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 122.282 1.988 . . . . 73.019999999999996 112.133 178.001 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.748 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 56.5 mtpt -63.43 -36.27 83.19 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.362 0.601 . . . . 74.439999999999998 109.518 174.622 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -97.81 92.63 5.94 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.222 -0.899 . . . . 70.319999999999993 109.114 177.269 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 126.0 -151.39 17.82 Favored Glycine 0 N--CA 1.448 -0.549 0 N-CA-C 111.478 -0.649 . . . . 74.319999999999993 111.478 -176.529 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -129.29 143.76 50.11 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.801 0.301 . . . . 73.420000000000002 110.601 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.559 ' HB3' HG13 ' A' ' 38' ' ' VAL . 32.1 Cg_endo -65.29 128.94 21.49 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.679 2.253 . . . . 74.400000000000006 112.077 177.758 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -133.86 156.73 47.54 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.267 -0.424 . . . . 74.120000000000005 110.343 -178.151 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -95.71 131.62 41.77 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.778 -0.647 . . . . 74.140000000000001 109.792 177.514 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.559 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 17.0 tp -115.63 94.11 4.56 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.827 -0.805 . . . . 72.120000000000005 108.827 178.102 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.7 t -87.29 138.27 19.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.064 -0.517 . . . . 72.200000000000003 110.872 -174.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.421 ' HE ' ' HA ' ' A' ' 53' ' ' SER . 0.0 OUTLIER -100.89 121.6 42.0 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.926 -0.398 . . . . 75.120000000000005 109.926 -177.3 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.98 172.06 13.79 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.01 0.433 . . . . 71.299999999999997 112.076 -173.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.43 ' HB3' ' CD2' ' B' ' 126' ' ' TYR . 4.3 p-10 -72.13 167.73 19.64 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 115.793 -0.64 . . . . 74.310000000000002 111.09 -175.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 81.2 -17.17 13.42 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.831 -0.622 . . . . 74.349999999999994 112.798 177.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.421 ' HA ' ' HE ' ' A' ' 49' ' ' ARG . 20.9 t 61.64 33.46 18.13 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-O 120.894 0.378 . . . . 63.530000000000001 110.148 -178.075 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -55.89 -42.02 75.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.714 -0.675 . . . . 75.310000000000002 111.363 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 119.17 25.52 2.7 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.834 -0.698 . . . . 72.109999999999999 111.392 -177.167 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 11.2 p30 -118.74 147.24 44.07 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.178 0.513 . . . . 75.239999999999995 110.633 -177.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.559 ' CD2' ' HG ' ' A' ' 47' ' ' LEU . 46.6 m-85 -128.17 154.33 45.91 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.684 -0.689 . . . . 75.400000000000006 110.501 -178.729 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 45.3 mm -113.1 122.89 68.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.987 -0.551 . . . . 73.409999999999997 109.519 177.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.465 ' HB3' ' HB3' ' A' ' 61' ' ' ASP . 67.2 mtt180 -86.17 144.79 27.3 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.56 -0.291 . . . . 75.519999999999996 110.61 178.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 77.6 p -76.02 -21.85 56.41 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.407 -0.961 . . . . 75.299999999999997 108.407 166.396 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.465 ' HB3' ' HB3' ' A' ' 59' ' ' ARG . 19.2 t70 -57.62 -49.17 77.33 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.519 -1.219 . . . . 74.349999999999994 110.092 172.746 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 24.1 mm-40 -144.78 86.38 7.9 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.151 -0.932 . . . . 71.540000000000006 110.25 178.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_endo -78.79 13.0 2.03 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.89 2.394 . . . . 75.439999999999998 112.24 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -83.65 -30.7 26.65 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.418 -0.81 . . . . 71.329999999999998 110.529 -178.59 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.25 178.1 6.02 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-O 121.196 0.522 . . . . 74.340000000000003 111.614 -176.664 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.5 mp -111.16 138.19 47.91 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.206 -0.906 . . . . 75.409999999999997 109.607 177.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 33.7 mm -76.55 124.86 87.95 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 116.448 -0.342 . . . . 75.430000000000007 110.145 178.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.43 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 44.3 Cg_endo -66.98 173.84 7.72 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.903 2.402 . . . . 75.010000000000005 112.759 -177.855 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 19.5 tt0 -88.63 -1.44 58.07 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.54 -0.755 . . . . 74.109999999999999 111.907 -168.684 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . 0.583 ' HA ' ' CE2' ' A' ' 73' ' ' PHE . 33.4 p90 -97.39 -22.61 16.51 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.265 0.555 . . . . 74.530000000000001 109.727 172.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.43 ' HB2' ' HG2' ' A' ' 68' ' ' PRO . 4.4 mm-40 -84.25 -12.71 54.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.448 -0.796 . . . . 72.420000000000002 111.522 -176.745 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 31.9 pt -77.67 -15.88 14.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.125 -0.489 . . . . 75.109999999999999 111.875 -177.496 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CE2' ' HA ' ' A' ' 70' ' ' TRP . 42.4 p90 -119.45 23.83 11.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.42 0.629 . . . . 74.420000000000002 110.189 177.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 56.2 m -80.23 -1.34 40.25 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.712 -0.676 . . . . 71.340000000000003 110.875 177.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . 0.528 ' HH2' HG23 ' A' ' 35' ' ' ILE . 0.3 OUTLIER . . . . . 0 C--N 1.327 -0.38 0 CA-C-N 116.149 -0.478 . . . . 73.129999999999995 110.58 178.275 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.253 0 N-CA-C 112.093 -0.403 . . . . 75.450000000000003 112.093 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -94.71 155.4 16.86 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.48 0.181 . . . . 61.140000000000001 110.595 179.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -135.3 95.85 3.36 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.142 0.496 . . . . 72.439999999999998 110.576 -179.281 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -118.18 118.89 33.08 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.08 -0.711 . . . . 71.25 109.08 177.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -71.97 127.15 31.65 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.154 0.502 . . . . 71.209999999999994 110.184 -178.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -107.9 109.3 62.1 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 115.755 -0.657 . . . . 64.310000000000002 110.757 -177.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -65.48 161.87 36.35 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 123.178 2.585 . . . . 74.25 112.256 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 58.8 m -71.12 111.34 6.4 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.292 -0.632 . . . . 75.340000000000003 109.292 175.088 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.45 52.66 0.55 Allowed Glycine 0 N--CA 1.445 -0.715 0 N-CA-C 110.551 -1.02 . . . . 73.230000000000004 110.551 -170.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . 0.402 ' O ' ' HG3' ' B' ' 110' ' ' GLU . 10.1 pt-20 -97.92 105.33 26.84 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.365 -0.976 . . . . 73.239999999999995 108.365 -179.316 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.642 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 73.7 Cg_endo -83.11 113.42 2.11 Favored 'Trans proline' 0 N--CA 1.443 -1.489 0 C-N-CA 122.143 1.895 . . . . 74.109999999999999 112.418 -170.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 16.5 p-10 -109.72 133.46 53.1 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 115.066 -0.97 . . . . 75.409999999999997 109.444 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.616 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 11.7 p -83.55 127.89 39.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 121.42 0.629 . . . . 65.040000000000006 110.734 -177.396 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 114' ' ' THR . . . . . 0.635 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 27.0 m -81.72 108.85 15.6 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.456 -0.793 . . . . 74.0 109.964 179.349 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.474 HG12 ' HG2' ' B' ' 124' ' ' GLN . 66.4 mt -93.26 106.05 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.074 0.464 . . . . 73.329999999999998 110.907 -176.439 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . 0.467 ' HA ' ' NE ' ' B' ' 116' ' ' ARG . 3.5 mmp_? -116.24 164.98 13.69 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.657 -0.701 . . . . 73.120000000000005 109.457 176.824 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -138.39 107.46 6.03 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.099 0.476 . . . . 72.219999999999999 110.962 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -100.36 97.29 8.07 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.584 -0.734 . . . . 74.430000000000007 110.297 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 74.89 -97.01 0.98 Allowed Glycine 0 N--CA 1.444 -0.797 0 C-N-CA 121.011 -0.614 . . . . 74.209999999999994 112.256 178.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . 0.773 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 5.8 m-20 -125.06 32.07 5.48 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.702 0.287 . . . . 72.109999999999999 110.664 -178.702 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.432 ' HB3' ' HA ' ' B' ' 139' ' ' PRO . 41.9 pttt -145.83 125.43 13.28 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.273 0.559 . . . . 74.5 111.806 177.754 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 59.8 m -79.91 107.74 12.93 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.073 -0.967 . . . . 74.530000000000001 109.828 175.413 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 42.6 mt -100.13 109.46 24.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-O 121.209 0.528 . . . . 73.310000000000002 110.096 -178.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.616 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 55.0 mt-30 -96.19 111.23 23.34 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.573 -0.74 . . . . 74.010000000000005 111.135 -178.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . 0.635 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 42.9 mt-10 -90.0 104.94 17.46 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.874 -0.603 . . . . 74.439999999999998 110.669 177.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . 0.43 ' CD2' ' HB3' ' A' ' 51' ' ' ASP . 56.8 m-85 -76.82 110.8 11.72 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.486 -0.324 . . . . 74.019999999999996 110.487 178.002 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . 0.598 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 48.0 mtt180 -130.93 137.7 49.41 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.971 -0.381 . . . . 74.040000000000006 109.971 178.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.642 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.5 p -98.8 -41.21 9.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.273 0.558 . . . . 70.010000000000005 110.797 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 -157.36 72.92 0.71 Allowed 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.848 -0.797 . . . . 75.299999999999997 108.848 -177.751 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.47 -38.16 2.77 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.819 -0.628 . . . . 53.149999999999999 112.889 -178.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -88.97 132.62 34.64 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.039 0.447 . . . . 75.219999999999999 111.573 -172.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.598 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 45.1 tp -85.16 117.96 24.43 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.317 -0.856 . . . . 72.439999999999998 110.085 175.091 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -109.67 -9.39 14.86 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.428 -0.509 . . . . 75.209999999999994 111.948 -177.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -167.51 141.52 3.61 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.735 0.302 . . . . 52.310000000000002 111.294 -177.188 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 57.9 mt -118.13 126.29 74.85 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 116.271 -0.422 . . . . 73.209999999999994 110.121 176.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.447 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 84.7 tttt -112.7 101.19 9.31 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.367 -0.605 . . . . 72.340000000000003 109.367 174.453 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.507 HG12 ' CE1' ' B' ' 145' ' ' TYR . 0.7 OUTLIER -103.57 126.46 58.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 CA-C-O 121.03 0.443 . . . . 73.329999999999998 110.715 -178.844 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.777 HG23 ' HB3' ' B' ' 144' ' ' PRO . 21.9 t -110.2 89.53 8.54 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.366 -0.834 . . . . 74.239999999999995 109.62 178.748 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.432 ' HA ' ' HB3' ' B' ' 121' ' ' LYS . 61.0 Cg_endo -77.35 136.52 15.94 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 122.508 2.139 . . . . 74.25 112.701 -179.436 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . 0.773 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 56.2 mtpt -61.13 -38.08 85.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.6 0.714 . . . . 64.420000000000002 109.62 171.598 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 94.9 m-70 -99.3 84.25 2.97 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.832 -1.076 . . . . 75.140000000000001 108.889 177.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 130.59 -162.55 23.33 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 110.322 -1.111 . . . . 73.450000000000003 110.322 -172.316 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -138.83 153.24 71.82 Favored Pre-proline 0 C--N 1.321 -0.652 0 CA-C-N 117.336 0.568 . . . . 75.310000000000002 110.715 178.169 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.777 ' HB3' HG23 ' B' ' 138' ' ' VAL . 21.8 Cg_endo -60.47 140.72 92.93 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 123.226 2.617 . . . . 74.510000000000005 113.29 -174.235 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . 0.507 ' CE1' HG12 ' B' ' 137' ' ' VAL . 23.3 p90 -143.44 155.67 44.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.53 -0.759 . . . . 74.120000000000005 109.481 177.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.461 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 96.4 m-85 -97.22 133.14 42.25 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.754 0.312 . . . . 74.129999999999995 110.431 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . 0.515 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 17.5 tp -122.29 98.53 5.97 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.864 -0.791 . . . . 72.409999999999997 108.864 177.508 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 39.0 t -99.31 144.72 11.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.431 -0.349 . . . . 73.129999999999995 111.186 -172.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 5.2 mmt85 -76.91 145.25 38.36 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-O 120.962 0.41 . . . . 75.409999999999997 111.932 179.194 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.96 169.95 12.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.807 -0.633 . . . . 72.239999999999995 109.823 171.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . 0.565 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 6.2 p-10 -67.64 157.23 34.99 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.373 0.606 . . . . 74.510000000000005 112.155 -174.479 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 84.76 -5.68 81.09 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.481 -0.781 . . . . 71.129999999999995 113.268 174.384 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 153' ' ' SER . . . . . 0.406 ' HB2' ' CD ' ' A' ' 11' ' ' PRO . 3.5 t 62.22 27.99 16.78 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.487 0.66 . . . . 71.109999999999999 109.664 -177.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -56.59 -27.56 58.29 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 114.782 -1.099 . . . . 65.540000000000006 111.885 -178.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 112.09 -22.11 18.96 Favored Glycine 0 CA--C 1.498 -1.0 0 C-N-CA 120.617 -0.802 . . . . 73.230000000000004 111.19 -178.593 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . 0.983 HD22 HD23 ' B' ' 166' ' ' LEU . 52.2 t30 -63.8 132.96 52.51 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 114.203 -0.998 . . . . 74.230000000000004 111.507 179.446 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . 0.515 ' CD2' ' HG ' ' B' ' 147' ' ' LEU . 27.2 m-85 -115.0 159.17 21.09 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.828 -0.623 . . . . 74.329999999999998 110.538 178.04 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . 0.804 HD13 HD22 ' B' ' 166' ' ' LEU . 48.6 mm -127.75 132.71 68.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.992 -0.549 . . . . 73.409999999999997 109.558 174.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.49 ' HB2' ' HB2' ' B' ' 162' ' ' GLN . 70.2 mtt180 -85.26 156.89 20.76 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.885 0.374 . . . . 73.109999999999999 111.249 -179.829 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 160' ' ' SER . . . . . 0.461 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 49.4 p -80.01 -19.48 47.64 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.885 0.85 . . . . 60.549999999999997 108.777 166.37 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -86.84 -26.04 24.23 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 114.461 -1.245 . . . . 71.019999999999996 110.46 176.549 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . 0.49 ' HB2' ' HB2' ' B' ' 159' ' ' ARG . 25.4 mm-40 -136.68 74.94 51.27 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.518 -0.764 . . . . 74.519999999999996 109.346 -179.691 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -89.24 11.68 2.89 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.897 2.398 . . . . 64.540000000000006 113.183 -176.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -107.87 -45.42 3.99 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 120.992 -0.283 . . . . 74.230000000000004 111.013 -178.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.25 172.79 7.89 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.029 0.442 . . . . 75.519999999999996 111.26 178.581 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . 0.983 HD23 HD22 ' B' ' 156' ' ' ASN . 15.8 mt -105.35 150.27 25.36 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.851 -0.613 . . . . 72.140000000000001 109.948 -175.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 40.8 mm -101.31 111.67 63.98 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 116.389 -0.369 . . . . 72.219999999999999 110.183 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.59 ' O ' HG22 ' B' ' 172' ' ' ILE . 59.7 Cg_endo -70.05 174.52 9.64 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 123.075 2.516 . . . . 75.120000000000005 112.593 -178.511 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . 0.604 ' O ' HG12 ' B' ' 172' ' ' ILE . 6.3 tt0 -72.45 -35.7 68.35 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.877 -0.601 . . . . 75.120000000000005 111.969 -167.816 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 33.4 p90 -69.02 -14.66 63.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.168 0.509 . . . . 65.420000000000002 110.222 177.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.425 ' HA ' ' HB2' ' B' ' 174' ' ' SER . 7.0 mm-40 -96.51 -29.54 13.83 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.569 -0.741 . . . . 71.150000000000006 111.671 -178.029 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.604 HG12 ' O ' ' B' ' 169' ' ' GLN . 43.4 pt -67.66 -26.21 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 N-CA-C 111.876 0.324 . . . . 73.040000000000006 111.876 -175.309 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -124.09 36.3 4.65 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.353 0.597 . . . . 74.519999999999996 110.256 176.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 174' ' ' SER . . . . . 0.425 ' HB2' ' HA ' ' B' ' 171' ' ' GLU . 22.1 t -85.66 10.73 12.56 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.342 -0.845 . . . . 71.219999999999999 111.369 -176.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 11.9 p-90 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.619 -0.705 . . . . 72.5 111.599 -178.364 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.886 0 N-CA-C 111.72 -0.552 . . . . 74.540000000000006 111.72 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -98.97 -45.93 5.79 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.627 -0.508 . . . . 75.400000000000006 109.627 176.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -132.0 130.84 41.93 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.434 -0.803 . . . . 75.439999999999998 109.526 176.591 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.45 ' CG ' ' H ' ' A' ' 5' ' ' ASP . 3.6 p-10 -112.7 -93.09 0.47 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.705 -0.225 . . . . 74.519999999999996 111.348 -177.722 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.45 ' H ' ' CG ' ' A' ' 4' ' ' ASP . 32.7 t70 -154.06 124.09 6.84 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.914 0.388 . . . . 74.239999999999995 110.567 -178.491 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.442 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -133.71 134.68 23.73 Favored Pre-proline 0 C--N 1.323 -0.565 0 CA-C-N 115.937 -0.574 . . . . 74.010000000000005 110.106 179.406 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 19.4 Cg_exo -66.04 110.2 1.68 Allowed 'Trans proline' 0 N--CA 1.462 -0.327 0 C-N-CA 122.745 2.296 . . . . 75.549999999999997 112.281 -179.429 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 25.3 p -103.56 156.12 18.02 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.099 -0.501 . . . . 75.239999999999995 110.342 177.502 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 145.07 -53.16 0.57 Allowed Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.848 -0.691 . . . . 54.450000000000003 111.622 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 64.6 100.96 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.542 0.686 . . . . 73.310000000000002 111.624 177.041 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.668 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 18.8 Cg_endo -91.62 122.05 0.67 Allowed 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 123.58 2.853 . . . . 74.340000000000003 112.595 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -139.62 138.58 36.26 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.148 -0.478 . . . . 73.129999999999995 109.749 178.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.525 ' HB ' ' HB2' ' B' ' 151' ' ' ASP . 13.7 p -101.94 132.8 47.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.331 0.586 . . . . 74.129999999999995 111.215 -171.594 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.7 m -92.77 104.06 16.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.738 -0.665 . . . . 72.140000000000001 109.722 176.055 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 66.4 mt -94.23 107.83 19.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.167 -0.469 . . . . 74.5 110.5 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.9 mtp180 -115.83 -179.2 3.59 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.242 -0.435 . . . . 71.430000000000007 110.505 177.065 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 70.9 mt-30 -140.1 106.24 5.23 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.937 -0.574 . . . . 71.010000000000005 110.763 178.211 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -99.62 107.08 19.13 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.912 -0.585 . . . . 75.129999999999995 109.846 176.716 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 62.61 -111.15 3.8 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.752 -0.737 . . . . 71.439999999999998 112.215 -178.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.506 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 7.7 m-20 -105.81 7.62 32.43 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 111.49 0.181 . . . . 74.340000000000003 111.49 -177.847 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.63 ' HE3' ' HE3' ' A' ' 75' ' ' TRP . 0.0 OUTLIER -121.06 131.68 54.42 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 119.951 -0.7 . . . . 73.519999999999996 112.259 179.951 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.516 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 6.2 m -80.68 124.08 28.71 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.162 -0.926 . . . . 72.209999999999994 109.313 174.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 23.7 mm -108.45 107.32 22.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 110.141 -0.318 . . . . 64.219999999999999 110.141 -175.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 14.6 mt-30 -102.23 105.26 15.9 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.91 0.386 . . . . 65.319999999999993 110.273 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 29.7 mt-10 -88.92 100.38 13.14 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.447 -0.797 . . . . 71.549999999999997 110.606 -178.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.547 ' HA ' ' OD2' ' B' ' 151' ' ' ASP . 96.3 m-85 -76.22 118.39 18.9 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.011 -0.541 . . . . 75.200000000000003 110.3 179.561 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.453 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 50.6 mtt180 -139.2 121.17 15.6 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.161 0.505 . . . . 75.200000000000003 112.014 -173.174 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.668 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 3.8 p -97.45 120.5 46.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 108.751 -0.833 . . . . 75.400000000000006 108.751 169.722 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 73.85 -34.39 0.28 Allowed 'General case' 0 N--CA 1.47 0.562 0 O-C-N 123.456 0.473 . . . . 72.019999999999996 111.085 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.457 ' H ' ' C ' ' A' ' 28' ' ' VAL . . . 157.32 -16.39 0.34 Allowed Glycine 0 N--CA 1.45 -0.431 0 N-CA-C 111.859 -0.496 . . . . 72.319999999999993 111.859 178.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.45 ' O ' ' HA ' ' A' ' 27' ' ' ARG . 81.3 t80 -79.47 125.73 29.94 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.69 0.281 . . . . 74.219999999999999 111.003 -177.782 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.668 HD12 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -73.21 112.33 9.15 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.281 -0.637 . . . . 74.329999999999998 109.281 175.821 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 25.7 p90 -111.66 -14.3 13.64 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 120.402 -0.519 . . . . 74.519999999999996 111.83 -178.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -159.54 142.86 14.37 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.732 0.301 . . . . 73.299999999999997 110.94 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.668 HG13 HD12 ' A' ' 32' ' ' LEU . 68.2 mt -123.91 122.86 65.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.233 -0.44 . . . . 74.129999999999995 110.14 175.521 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.439 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 53.2 tttp -107.66 106.57 16.98 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.003 -0.74 . . . . 71.430000000000007 109.003 172.152 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.577 HG22 ' HB2' ' A' ' 21' ' ' LYS . 1.5 p -102.58 126.85 56.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-N 116.111 -0.495 . . . . 72.319999999999993 110.26 178.28 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.689 HG23 ' HB3' ' A' ' 44' ' ' PRO . 23.5 t -109.3 85.66 3.66 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.273 -0.876 . . . . 73.099999999999994 109.99 178.397 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.505 ' HD2' ' C ' ' A' ' 43' ' ' LYS . 36.6 Cg_endo -86.36 132.9 3.79 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 122.572 2.182 . . . . 75.25 112.557 179.539 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.506 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 56.2 mtpt -60.35 -26.01 66.28 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.619 0.724 . . . . 75.430000000000007 109.884 175.188 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -122.54 88.25 2.9 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 115.194 -0.912 . . . . 74.349999999999994 108.818 176.414 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 145.28 -34.7 1.5 Allowed Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.442 -0.799 . . . . 72.299999999999997 111.702 -175.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.505 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 97.4 mttt 72.22 145.97 0.11 Allowed Pre-proline 0 N--CA 1.468 0.451 0 C-N-CA 123.565 0.746 . . . . 73.0 112.152 176.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.689 ' HB3' HG23 ' A' ' 38' ' ' VAL . 34.3 Cg_endo -63.25 137.49 61.31 Favored 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 123.454 2.769 . . . . 72.219999999999999 114.362 -170.019 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 8.6 p90 -148.21 165.96 29.37 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.577 -0.738 . . . . 72.219999999999999 109.243 174.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.716 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 38.6 m-85 -104.93 134.19 48.46 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.904 0.383 . . . . 74.510000000000005 110.774 177.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.507 HD23 HG21 ' A' ' 72' ' ' ILE . 16.6 tp -120.41 102.7 8.64 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.574 -0.899 . . . . 75.439999999999998 108.574 172.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.4 t -97.61 138.68 21.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.143 -0.481 . . . . 74.409999999999997 110.886 -173.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 7.4 tpt180 -66.57 128.02 34.62 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.89 -0.595 . . . . 74.120000000000005 110.131 175.634 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.09 116.84 18.85 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.736 -0.468 . . . . 62.420000000000002 109.736 174.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.617 ' HB2' ' CD2' ' B' ' 126' ' ' TYR . 0.4 OUTLIER -53.38 138.74 32.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.969 -0.56 . . . . 72.239999999999995 110.165 177.325 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 109.39 -32.48 6.78 Favored Glycine 0 N--CA 1.442 -0.963 0 N-CA-C 110.453 -1.059 . . . . 64.310000000000002 110.453 -171.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.4 t 56.99 50.36 12.28 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-O 121.253 0.549 . . . . 73.219999999999999 110.838 176.445 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -92.46 18.29 8.73 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.206 -0.452 . . . . 70.209999999999994 111.012 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.97 52.62 4.25 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.752 -0.737 . . . . 54.420000000000002 111.507 -176.591 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 30.2 t30 -147.76 141.81 25.99 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.804 0.335 . . . . 62.399999999999999 110.999 -174.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -129.42 147.1 51.2 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.898 -0.592 . . . . 74.040000000000006 109.529 175.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 43.7 mm -111.16 137.0 45.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.041 0.448 . . . . 75.010000000000005 110.394 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.722 ' HB2' HG13 ' A' ' 67' ' ' ILE . 24.0 ttt180 -103.22 142.18 34.61 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.826 -0.624 . . . . 73.519999999999996 110.5 -172.351 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.716 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 76.9 p -70.11 -30.81 68.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.41 0.624 . . . . 73.200000000000003 110.157 176.011 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -70.81 -27.86 64.2 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 114.845 -1.07 . . . . 73.230000000000004 110.631 176.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . 0.682 ' HG2' ' HB3' ' A' ' 65' ' ' LYS . 5.5 tt0 -146.05 77.04 12.2 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.685 -0.689 . . . . 70.230000000000004 109.598 -175.241 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.2 -35.38 8.72 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.836 2.357 . . . . 73.310000000000002 113.842 -172.175 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -95.07 41.02 1.1 Allowed 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.888 0.851 . . . . 63.439999999999998 109.953 -177.657 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.682 ' HB3' ' HG2' ' A' ' 62' ' ' GLN . 22.9 tptm -150.46 128.38 11.78 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.185 -0.916 . . . . 75.310000000000002 109.93 175.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.455 ' H ' HD11 ' A' ' 66' ' ' LEU . 4.5 mp -73.32 120.35 18.82 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.324 -0.853 . . . . 71.129999999999995 109.045 176.654 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.722 HG13 ' HB2' ' A' ' 59' ' ' ARG . 47.4 mm -85.75 125.39 69.12 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-O 120.861 0.362 . . . . 62.310000000000002 110.639 -176.265 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -66.54 175.73 4.87 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.876 2.384 . . . . 72.310000000000002 112.778 -178.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 16.4 tt0 -93.9 14.35 19.82 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.588 -0.733 . . . . 70.019999999999996 111.834 -168.506 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 18.7 p90 -109.24 -26.35 10.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.147 0.499 . . . . 75.439999999999998 110.151 173.246 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -81.12 -11.89 59.37 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.998 -0.546 . . . . 65.400000000000006 110.672 -178.653 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.507 HG21 HD23 ' A' ' 47' ' ' LEU . 44.9 pt -69.59 -22.84 25.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.915 -0.584 . . . . 71.319999999999993 110.91 177.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -112.6 25.26 11.64 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-N 115.808 -0.633 . . . . 64.140000000000001 109.822 -178.587 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 4.5 t -60.22 -37.78 81.37 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.873 -1.058 . . . . 72.219999999999999 109.906 -179.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . 0.63 ' HE3' ' HE3' ' A' ' 21' ' ' LYS . 43.2 p-90 . . . . . 0 C--N 1.326 -0.434 0 CA-C-N 115.884 -0.598 . . . . 74.129999999999995 110.454 176.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.404 0 N-CA-C 112.155 -0.378 . . . . 51.340000000000003 112.155 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -119.55 -1.67 10.62 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.938 0.399 . . . . 73.010000000000005 110.623 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -131.4 117.07 18.36 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.002 -0.544 . . . . 75.200000000000003 111.107 -177.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 -108.36 -71.64 0.75 Allowed 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.258 -0.645 . . . . 75.329999999999998 109.258 173.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -160.6 139.95 10.72 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.315 -0.857 . . . . 71.349999999999994 109.238 178.096 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . 0.46 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -137.37 126.99 15.39 Favored Pre-proline 0 C--N 1.32 -0.688 0 N-CA-C 110.176 -0.305 . . . . 61.439999999999998 110.176 179.173 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . 0.46 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 5.2 Cg_exo -79.38 69.16 8.05 Favored 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 123.041 2.494 . . . . 75.340000000000003 112.069 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 55.0 m -76.18 158.89 31.22 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.18 -0.464 . . . . 55.340000000000003 110.542 178.274 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 117.06 -63.25 0.38 Allowed Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 110.524 -1.031 . . . . 42.219999999999999 110.524 -175.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 62.3 88.19 0.12 Allowed Pre-proline 0 C--O 1.232 0.138 0 C-N-CA 123.157 0.583 . . . . 72.310000000000002 111.056 175.032 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.646 ' HB3' ' HA ' ' B' ' 128' ' ' VAL . 56.4 Cg_endo -86.67 140.08 5.94 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.982 2.454 . . . . 75.439999999999998 112.713 -176.701 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -148.13 122.42 9.62 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.751 -0.659 . . . . 73.140000000000001 109.28 177.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.456 ' N ' ' HB3' ' A' ' 51' ' ' ASP . 7.5 p -71.6 134.21 30.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.391 0.615 . . . . 70.129999999999995 111.739 -172.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 85.1 m -95.04 104.78 16.66 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.474 -0.785 . . . . 72.010000000000005 109.854 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 65.2 mt -88.19 106.56 16.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.893 -0.594 . . . . 72.219999999999999 110.143 -177.642 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 25.3 mtp-105 -108.75 171.59 7.34 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.166 0.508 . . . . 75.010000000000005 111.569 -178.241 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 70.4 mt-30 -132.34 114.7 14.7 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.581 -0.736 . . . . 74.420000000000002 109.989 176.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . 0.594 ' HG3' HD12 ' B' ' 123' ' ' ILE . 22.1 mm-40 -99.61 23.25 9.75 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.94 -0.573 . . . . 73.430000000000007 110.672 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 123.45 -90.47 0.42 Allowed Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.692 -0.563 . . . . 52.450000000000003 111.692 -178.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . 0.67 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 72.0 m-20 -105.35 -16.51 14.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.14 0.495 . . . . 71.310000000000002 110.077 177.51 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.683 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 27.4 pttt -99.96 120.09 39.26 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.434 0.635 . . . . 74.329999999999998 111.15 -178.761 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 122' ' ' THR . . . . . 0.45 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 25.0 m -83.22 104.29 13.28 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.376 -0.829 . . . . 64.25 109.193 174.471 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . 0.594 HD12 ' HG3' ' B' ' 118' ' ' GLU . 23.4 mt -98.39 107.26 20.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.181 0.515 . . . . 74.400000000000006 110.887 -174.118 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.569 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 17.9 mt-30 -93.62 107.07 18.98 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.431 -0.804 . . . . 75.230000000000004 110.061 179.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -87.95 111.08 21.09 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.097 -0.501 . . . . 74.239999999999995 110.687 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . 0.617 ' CD2' ' HB2' ' A' ' 51' ' ' ASP . 37.8 m-85 -86.4 113.6 22.49 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.013 -0.54 . . . . 64.420000000000002 110.131 177.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . 0.636 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 63.7 mtt180 -138.12 132.95 32.78 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.663 -0.699 . . . . 73.150000000000006 109.675 -176.791 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.646 ' HA ' ' HB3' ' B' ' 111' ' ' PRO . 2.7 p -96.32 -39.39 9.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 120.944 0.402 . . . . 62.130000000000003 110.991 -178.341 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -153.1 64.79 0.77 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.322 -0.622 . . . . 75.040000000000006 109.322 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.07 -36.01 3.35 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.489 -0.778 . . . . 72.310000000000002 112.597 -179.261 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . 0.456 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 80.8 t80 -83.84 124.79 31.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.084 0.468 . . . . 74.099999999999994 111.233 -173.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.779 HD13 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -77.12 115.6 17.05 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.312 -0.858 . . . . 71.519999999999996 109.251 175.169 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 22.5 p90 -109.11 -19.03 13.5 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.268 -0.573 . . . . 73.430000000000007 111.901 -178.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -155.98 141.47 17.72 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.024 0.44 . . . . 73.0 111.057 179.065 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.779 HG13 HD13 ' B' ' 132' ' ' LEU . 81.8 mt -119.2 123.82 72.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.859 -0.609 . . . . 73.150000000000006 110.286 177.127 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.569 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.6 tttt -105.62 99.68 9.27 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.274 -0.639 . . . . 72.310000000000002 109.274 172.007 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.449 HG22 ' HB2' ' B' ' 121' ' ' LYS . 2.0 p -101.4 121.8 52.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-O 121.194 0.521 . . . . 74.439999999999998 110.361 -178.602 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.819 HG23 ' HB3' ' B' ' 144' ' ' PRO . 24.6 t -109.03 85.51 3.29 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 115.086 -0.961 . . . . 73.129999999999995 110.21 179.614 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.683 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 71.6 Cg_endo -84.3 134.08 5.73 Favored 'Trans proline' 0 N--CA 1.451 -0.979 0 C-N-CA 122.375 2.05 . . . . 72.319999999999993 112.545 179.525 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . 0.67 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 57.8 mtpt -57.92 -31.56 66.91 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.448 0.642 . . . . 70.439999999999998 109.889 174.436 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 82.7 m-70 -111.14 83.18 1.72 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.201 -0.909 . . . . 62.240000000000002 109.292 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . 0.415 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 148.71 -32.03 1.21 Allowed Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.684 -0.77 . . . . 63.210000000000001 112.785 -178.87 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . 0.442 ' C ' ' HD2' ' B' ' 139' ' ' PRO . 98.9 mttt 73.44 151.43 0.14 Allowed Pre-proline 0 N--CA 1.471 0.604 0 C-N-CA 123.452 0.701 . . . . 70.230000000000004 111.704 -178.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.819 ' HB3' HG23 ' B' ' 138' ' ' VAL . 26.7 Cg_endo -62.0 135.24 54.04 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 123.197 2.598 . . . . 70.510000000000005 113.952 -171.129 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . 0.428 ' CE1' HG12 ' B' ' 137' ' ' VAL . 6.2 p90 -150.99 152.19 33.17 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.356 -0.838 . . . . 74.409999999999997 109.852 176.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.681 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 50.7 m-85 -97.29 141.89 29.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.475 -0.33 . . . . 74.349999999999994 111.366 -178.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . 0.448 HD21 ' HA ' ' B' ' 147' ' ' LEU . 15.3 mt -124.42 101.78 7.33 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.45 -0.795 . . . . 74.239999999999995 109.208 166.543 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . 0.437 HG13 ' HB ' ' B' ' 158' ' ' ILE . 6.0 p -104.65 139.2 26.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.724 -0.671 . . . . 73.409999999999997 111.015 -175.766 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 19.4 tpt180 -63.65 136.8 57.77 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.551 -0.75 . . . . 75.310000000000002 111.754 -178.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -90.19 123.95 34.43 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.275 -0.639 . . . . 74.109999999999999 109.275 169.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . 0.547 ' OD2' ' HA ' ' A' ' 26' ' ' TYR . 72.2 m-20 -57.33 142.91 41.79 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.285 0.564 . . . . 64.420000000000002 111.159 -178.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 109.91 -29.11 9.64 Favored Glycine 0 N--CA 1.444 -0.827 0 N-CA-C 110.468 -1.053 . . . . 73.239999999999995 110.468 -170.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 5.4 t 65.05 37.4 6.77 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-O 121.231 0.538 . . . . 64.530000000000001 111.009 174.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -65.11 -14.4 60.43 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.798 -0.637 . . . . 72.209999999999994 111.326 178.542 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 98.11 23.69 12.7 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 110.634 -0.986 . . . . 62.109999999999999 110.634 -173.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 42.1 t30 -110.71 140.18 45.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.916 -0.642 . . . . 71.150000000000006 110.494 -176.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -121.36 160.35 24.21 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.797 -0.638 . . . . 74.409999999999997 109.574 175.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . 0.437 ' HB ' HG13 ' B' ' 148' ' ' VAL . 46.2 mm -116.66 121.15 67.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 109.405 -0.591 . . . . 74.230000000000004 109.405 174.694 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.487 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 73.0 ttt180 -92.2 127.47 37.69 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.699 -0.682 . . . . 74.549999999999997 109.82 -177.61 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 160' ' ' SER . . . . . 0.681 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 80.4 p -65.88 -9.22 27.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.513 -0.312 . . . . 71.450000000000003 111.78 -175.06 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -64.06 -42.67 96.92 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.325 -0.621 . . . . 75.319999999999993 109.325 174.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . 0.417 ' HA ' ' HD2' ' B' ' 163' ' ' PRO . 23.1 mt-30 -141.86 92.6 7.79 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 115.146 -0.933 . . . . 71.209999999999994 108.766 177.518 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . 0.417 ' HD2' ' HA ' ' B' ' 162' ' ' GLN . 36.6 Cg_endo -64.0 -10.59 23.58 Favored 'Trans proline' 0 N--CA 1.475 0.441 0 C-N-CA 123.767 2.978 . . . . 70.010000000000005 114.103 -172.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -98.39 -6.18 31.16 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.088 0.471 . . . . 75.109999999999999 109.925 179.066 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 24.4 tptm -97.21 127.94 43.63 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.743 -0.662 . . . . 73.310000000000002 110.872 -175.216 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . 0.451 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.7 mp -86.68 134.66 33.58 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.565 -0.743 . . . . 72.040000000000006 109.107 177.439 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . 0.882 HG22 ' HB3' ' B' ' 171' ' ' GLU . 27.3 mm -91.71 118.94 68.59 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-O 121.149 0.5 . . . . 74.219999999999999 112.052 -172.519 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.485 ' O ' HG22 ' B' ' 172' ' ' ILE . 74.5 Cg_endo -74.71 -179.39 4.84 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 123.451 2.767 . . . . 74.120000000000005 112.284 177.15 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . 0.618 ' HA ' HG12 ' B' ' 172' ' ' ILE . 34.6 tt0 -73.56 -30.95 63.36 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.873 0.368 . . . . 74.439999999999998 111.761 -170.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 22.7 p90 -75.74 -7.3 54.05 Favored 'General case' 0 C--N 1.324 -0.525 0 O-C-N 121.886 -0.509 . . . . 74.25 110.15 177.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.882 ' HB3' HG22 ' B' ' 167' ' ' ILE . 3.2 mm-40 -109.74 -18.81 13.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.791 -0.641 . . . . 70.340000000000003 111.472 -179.47 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.618 HG12 ' HA ' ' B' ' 169' ' ' GLN . 42.5 pt -73.51 -28.59 25.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.292 0.568 . . . . 73.299999999999997 109.932 176.329 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 62.1 m-85 -101.63 39.75 1.4 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.509 -0.769 . . . . 70.540000000000006 109.364 173.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 174' ' ' SER . . . . . 0.586 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 5.7 t -66.7 -29.22 69.16 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.134 -0.939 . . . . 73.0 110.827 -176.39 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 20.8 p-90 . . . . . 0 C--O 1.242 0.677 0 CA-C-O 118.916 -0.564 . . . . 75.150000000000006 110.217 178.206 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.723 0 N-CA-C 111.515 -0.634 . . . . 70.329999999999998 111.515 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -77.76 129.35 35.37 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.699 -0.482 . . . . 75.040000000000006 109.699 176.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -65.54 136.91 56.99 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.067 0.461 . . . . 70.430000000000007 111.163 -176.666 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -95.08 -30.19 14.2 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.551 -0.749 . . . . 72.409999999999997 111.857 -174.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -88.66 68.94 8.74 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.153 0.501 . . . . 73.340000000000003 110.599 -175.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.419 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -163.02 138.7 5.36 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 115.76 -0.655 . . . . 71.409999999999997 110.367 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 6.8 Cg_exo -73.82 -170.64 0.72 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 123.184 2.59 . . . . 73.430000000000007 112.083 178.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 25.0 m -70.37 92.5 0.81 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.306 0.574 . . . . 74.109999999999999 111.034 -179.481 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 157.33 40.89 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.727 0 N-CA-C 111.218 -0.753 . . . . 73.239999999999995 111.218 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . 0.425 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -114.99 101.59 54.59 Favored Pre-proline 0 N--CA 1.445 -0.681 0 N-CA-C 108.208 -1.034 . . . . 75.099999999999994 108.208 179.493 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.658 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 11.3 Cg_endo -79.32 104.65 1.78 Allowed 'Trans proline' 0 N--CA 1.44 -1.635 0 C-N-CA 122.064 1.843 . . . . 73.120000000000005 111.69 -171.552 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -123.13 149.59 44.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.502 -0.772 . . . . 74.450000000000003 109.21 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.643 HG21 ' HB3' ' A' ' 24' ' ' GLN . 9.3 p -99.74 126.97 53.04 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-O 121.595 0.712 . . . . 74.310000000000002 111.772 -172.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.533 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 7.0 m -83.36 103.51 12.79 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.513 -0.767 . . . . 75.310000000000002 109.334 176.706 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.5 mt -94.14 108.79 21.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 120.932 0.396 . . . . 75.420000000000002 111.127 -174.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 19.1 mmt180 -120.72 159.32 25.61 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.202 -0.454 . . . . 73.129999999999995 109.826 175.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -117.58 124.88 49.72 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.331 0.586 . . . . 72.420000000000002 110.677 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -111.42 59.67 0.62 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.9 -1.046 . . . . 72.030000000000001 110.061 -174.225 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 83.47 -107.67 2.95 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.843 -0.694 . . . . 65.099999999999994 111.943 -178.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -94.85 20.21 9.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.886 0.374 . . . . 74.209999999999994 110.652 -177.286 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.724 ' HD2' HD13 ' A' ' 23' ' ' ILE . 4.0 pttp -143.93 134.38 24.7 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.228 0.537 . . . . 74.019999999999996 111.89 -178.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 27.3 m -94.06 107.98 19.85 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.055 -0.72 . . . . 75.329999999999998 109.055 172.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.724 HD13 ' HD2' ' A' ' 21' ' ' LYS . 19.8 mt -101.61 113.54 38.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.269 0.556 . . . . 73.319999999999993 110.353 -175.098 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.643 ' HB3' HG21 ' A' ' 13' ' ' VAL . 23.2 mt-30 -104.89 117.86 35.1 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.497 -0.774 . . . . 75.019999999999996 111.356 -175.162 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.533 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 25.2 mt-10 -90.52 103.01 15.75 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.051 -0.522 . . . . 75.120000000000005 110.983 177.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 -81.27 103.5 11.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.897 0.379 . . . . 75.310000000000002 110.051 175.199 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.518 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 53.2 mtt180 -120.25 138.11 53.84 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.916 -0.402 . . . . 74.540000000000006 109.916 178.083 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.658 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 11.8 p -105.79 -27.89 2.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.288 0.566 . . . . 74.400000000000006 110.947 -175.82 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -162.64 59.05 0.21 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.758 -0.83 . . . . 75.340000000000003 108.758 -177.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.93 -36.95 3.23 Favored Glycine 0 N--CA 1.45 -0.427 0 CA-C-N 115.355 -0.839 . . . . 72.140000000000001 112.635 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.568 ' CD2' HG22 ' B' ' 128' ' ' VAL . 50.4 t80 -90.28 133.74 34.75 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.145 0.498 . . . . 74.519999999999996 110.723 -173.658 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.882 HD13 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -76.11 116.13 16.5 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.229 -0.896 . . . . 73.209999999999994 109.317 176.656 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 40.0 p90 -106.93 -17.8 14.09 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.431 -0.508 . . . . 75.040000000000006 111.218 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.441 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -157.58 137.9 12.76 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.014 0.435 . . . . 63.43 111.532 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.882 HG13 HD13 ' A' ' 32' ' ' LEU . 73.2 mt -118.02 117.08 53.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.159 -0.473 . . . . 74.540000000000006 110.102 175.262 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 84.9 tttt -100.69 101.53 12.43 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.022 -0.733 . . . . 74.030000000000001 109.022 173.296 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.65 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.5 p -102.77 124.5 56.84 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 N-CA-C 109.777 -0.453 . . . . 74.230000000000004 109.777 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.628 HG23 ' HB3' ' A' ' 44' ' ' PRO . 35.9 t -105.27 84.9 1.18 Allowed Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.206 -0.907 . . . . 71.099999999999994 109.525 177.391 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.65 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 89.2 Cg_endo -95.93 147.05 1.26 Allowed 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 123.04 2.493 . . . . 72.430000000000007 113.279 -178.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -68.73 -11.11 59.89 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.519 -0.764 . . . . 73.129999999999995 109.623 170.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 80.6 m-70 -121.85 92.85 3.83 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 115.022 -0.99 . . . . 74.140000000000001 109.468 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 121.54 -19.76 8.46 Favored Glycine 0 CA--C 1.519 0.338 0 C-N-CA 120.757 -0.735 . . . . 61.130000000000003 113.176 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.422 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 99.3 mttt 68.9 151.61 0.13 Allowed Pre-proline 0 N--CA 1.473 0.69 0 C-N-CA 123.026 0.53 . . . . 72.409999999999997 110.943 -178.166 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.628 ' HB3' HG23 ' A' ' 38' ' ' VAL . 18.3 Cg_endo -59.88 133.05 48.36 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.364 2.043 . . . . 74.439999999999998 112.816 -175.047 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.533 ' CE1' HG11 ' A' ' 37' ' ' VAL . 5.4 p90 -150.32 155.9 40.53 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.655 -0.702 . . . . 71.129999999999995 110.432 -179.072 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.447 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 87.7 m-85 -99.75 127.64 45.88 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.076 -0.511 . . . . 73.239999999999995 110.901 -179.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.441 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 53.1 mt -102.12 97.35 7.67 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.146 -0.479 . . . . 74.230000000000004 109.761 171.052 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 60.8 t -90.58 137.43 21.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.065 -0.516 . . . . 74.140000000000001 110.578 -178.046 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 5.3 mmt180 -79.13 119.6 22.47 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.984 0.421 . . . . 75.230000000000004 111.108 175.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -72.15 167.22 20.74 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.603 -0.726 . . . . 73.239999999999995 109.555 172.722 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -69.74 128.92 38.12 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.416 0.627 . . . . 75.450000000000003 109.577 178.615 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.42 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 100.22 116.04 3.87 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 111.105 -0.798 . . . . 71.519999999999996 111.105 -171.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 39.1 p -78.02 36.7 0.23 Allowed 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.05 0.452 . . . . 75.439999999999998 111.311 -176.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.42 ' H ' ' C ' ' A' ' 52' ' ' GLY . 22.5 t70 -63.33 -29.6 70.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.801 -0.636 . . . . 65.450000000000003 111.588 -175.423 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 131.01 -13.21 5.53 Favored Glycine 0 CA--C 1.508 -0.404 0 C-N-CA 120.318 -0.944 . . . . 73.219999999999999 113.214 177.504 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -83.63 138.82 33.17 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.144 0.497 . . . . 75.409999999999997 111.544 -173.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.437 ' CD1' ' HB3' ' A' ' 47' ' ' LEU . 38.2 m-85 -109.38 162.46 14.32 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.762 -0.654 . . . . 74.519999999999996 110.02 174.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.4 mm -120.64 123.86 71.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.35 -0.611 . . . . 72.349999999999994 109.35 175.762 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.773 ' HG3' HG13 ' A' ' 67' ' ' ILE . 53.7 mtm180 -88.34 149.77 23.58 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.221 0.534 . . . . 73.200000000000003 111.826 -177.79 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 5.7 p -69.12 -24.53 64.12 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.379 -0.828 . . . . 72.319999999999993 109.84 171.365 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.73 -37.46 84.29 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-N 115.517 -0.765 . . . . 72.430000000000007 110.152 176.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -156.64 96.91 2.17 Favored Pre-proline 0 N--CA 1.451 -0.4 0 CA-C-N 115.835 -0.62 . . . . 75.25 110.612 -175.421 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.19 -10.07 23.94 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.433 2.089 . . . . 72.310000000000002 111.233 175.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -81.22 -15.86 54.4 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 114.895 -1.048 . . . . 72.209999999999994 110.774 178.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.6 tptt -114.9 132.34 56.57 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.2 -0.454 . . . . 72.099999999999994 111.252 -175.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.6 mp -90.31 125.79 35.64 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.333 -0.617 . . . . 73.120000000000005 109.333 174.218 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.773 HG13 ' HG3' ' A' ' 59' ' ' ARG . 49.4 mm -84.78 112.59 43.82 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 116.111 -0.495 . . . . 73.219999999999999 110.491 -177.25 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -74.63 179.69 5.71 Favored 'Trans proline' 0 N--CA 1.464 -0.264 0 C-N-CA 123.289 2.659 . . . . 61.210000000000001 112.937 -177.155 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . 0.463 ' CG ' HD12 ' A' ' 72' ' ' ILE . 31.4 tt0 -80.86 -4.27 54.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.581 -0.736 . . . . 73.340000000000003 112.519 -171.083 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 15.9 p90 -96.24 -19.97 18.91 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.234 -0.586 . . . . 75.430000000000007 110.312 175.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -99.99 8.04 44.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.93 -0.577 . . . . 74.400000000000006 111.042 -177.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.463 HD12 ' CG ' ' A' ' 69' ' ' GLN . 21.6 pt -98.71 -7.06 9.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.249 0.547 . . . . 74.219999999999999 110.21 175.251 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -104.91 16.17 26.43 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.632 -0.713 . . . . 71.420000000000002 109.486 177.041 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 12.9 m -73.59 -7.78 53.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.185 -0.916 . . . . 72.120000000000005 111.309 -178.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 57.9 p-90 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.442 -0.344 . . . . 73.400000000000006 110.459 176.222 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 N-CA-C 112.116 -0.394 . . . . 62.200000000000003 112.116 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -159.07 124.66 4.32 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.677 0.275 . . . . 71.409999999999997 110.617 179.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -138.31 129.21 26.86 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.216 -0.447 . . . . 55.43 109.92 176.569 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -85.34 -16.45 39.93 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.449 0.642 . . . . 54.32 110.247 -177.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -88.83 11.07 18.91 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.598 -0.728 . . . . 64.310000000000002 110.536 178.764 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -63.8 138.58 97.43 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.15 -0.477 . . . . 74.420000000000002 110.822 179.054 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_endo -90.1 -164.14 0.15 Allowed 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 123.037 2.491 . . . . 75.310000000000002 112.261 178.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 44.3 m -75.22 99.24 3.96 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.021 0.439 . . . . 74.409999999999997 110.046 176.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 121.1 102.34 1.81 Allowed Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.914 -0.66 . . . . 61.409999999999997 111.764 -178.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -122.15 92.57 48.86 Favored Pre-proline 0 C--N 1.324 -0.532 0 N-CA-C 109.382 -0.599 . . . . 75.310000000000002 109.382 -178.081 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.429 ' HA ' ' O ' ' B' ' 127' ' ' ARG . 8.4 Cg_endo -77.98 82.85 2.32 Favored 'Trans proline' 0 N--CA 1.443 -1.451 0 C-N-CA 121.917 1.745 . . . . 73.430000000000007 111.633 -178.559 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -108.71 141.84 40.11 Favored 'General case' 0 CA--C 1.51 -0.566 0 CA-C-N 115.194 -0.912 . . . . 65.409999999999997 109.558 177.649 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.493 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 10.3 p -101.84 125.7 55.91 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 CA-C-N 115.627 -0.715 . . . . 73.409999999999997 110.807 -176.637 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 10.1 m -88.55 103.57 16.01 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.34 -0.846 . . . . 74.040000000000006 109.609 177.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.5 HG12 ' HG2' ' B' ' 124' ' ' GLN . 54.6 mt -94.59 105.94 17.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 116.164 -0.471 . . . . 73.420000000000002 110.358 -176.568 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 27.0 mmm180 -122.27 153.44 38.9 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.242 -0.435 . . . . 74.099999999999994 110.541 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -111.19 103.09 11.49 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.002 0.43 . . . . 73.519999999999996 110.701 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 49.8 mm-40 -99.67 81.51 2.49 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.778 -0.646 . . . . 73.430000000000007 109.294 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 81.94 -128.69 8.6 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.805 -0.712 . . . . 71.25 111.382 -174.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . 0.574 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 67.8 m-20 -91.84 9.92 30.79 Favored 'General case' 0 C--N 1.328 -0.349 0 O-C-N 122.699 -0.295 . . . . 73.239999999999995 111.088 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.521 ' HE2' HD12 ' B' ' 123' ' ' ILE . 24.6 pttm -119.27 116.58 26.55 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.576 0.703 . . . . 75.120000000000005 111.073 179.371 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 26.1 m -84.97 108.43 17.58 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.292 -0.867 . . . . 64.5 109.502 176.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . 0.521 HD12 ' HE2' ' B' ' 121' ' ' LYS . 52.1 mt -101.14 117.12 45.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.973 -0.558 . . . . 73.5 110.604 -173.788 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.511 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 23.0 mt-30 -102.61 104.49 14.87 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.649 -0.705 . . . . 74.319999999999993 110.35 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -85.27 107.25 17.21 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.06 -0.518 . . . . 74.530000000000001 111.071 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 59.6 m-85 -80.71 103.67 10.72 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.947 0.403 . . . . 74.420000000000002 109.945 175.333 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . 0.429 ' O ' ' HA ' ' B' ' 111' ' ' PRO . 65.5 mtt180 -114.14 152.78 30.62 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.857 -0.611 . . . . 72.049999999999997 109.389 178.587 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.568 HG22 ' CD2' ' A' ' 31' ' ' PHE . 7.0 p -120.36 -37.41 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.078 0.466 . . . . 72.239999999999995 111.73 179.385 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -140.83 35.8 1.78 Allowed 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.035 -0.728 . . . . 74.530000000000001 109.035 -178.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 98.26 -29.5 11.25 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 114.992 -1.004 . . . . 72.439999999999998 111.746 -177.498 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . 0.528 ' HD2' HG21 ' A' ' 28' ' ' VAL . 26.9 t80 -93.39 132.86 37.23 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.917 0.389 . . . . 74.439999999999998 110.261 -176.19 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.762 HD12 HG13 ' B' ' 135' ' ' ILE . 3.3 tm? -69.49 134.44 48.91 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.104 -0.953 . . . . 73.530000000000001 110.43 179.042 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . 0.417 ' N ' HD13 ' B' ' 132' ' ' LEU . 42.6 p90 -124.24 -23.51 4.51 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 121.026 -0.27 . . . . 64.150000000000006 111.361 174.608 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -149.92 143.19 25.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.784 0.326 . . . . 71.109999999999999 111.055 179.068 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.762 HG13 HD12 ' B' ' 132' ' ' LEU . 77.5 mt -125.08 129.56 73.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.507 -0.315 . . . . 75.530000000000001 110.804 178.648 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.511 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.2 tttt -112.69 102.51 10.56 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.128 -0.693 . . . . 75.340000000000003 109.128 172.485 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.44 HG12 ' CE1' ' B' ' 145' ' ' TYR . 1.8 p -106.52 127.99 61.47 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-O 121.271 0.558 . . . . 62.329999999999998 110.744 -177.665 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.862 HG22 ' HB3' ' B' ' 144' ' ' PRO . 22.6 t -113.21 87.72 11.4 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.138 -0.937 . . . . 65.310000000000002 110.282 -179.299 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 73.5 Cg_endo -83.66 134.87 6.62 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.283 1.988 . . . . 71.439999999999998 112.309 176.127 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . 0.574 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 56.2 mtpt -67.62 -9.48 43.44 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.773 -0.649 . . . . 71.219999999999999 110.954 176.668 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 31.6 m-70 -126.68 54.14 1.62 Allowed 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.574 -0.739 . . . . 64.310000000000002 109.524 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 167.45 -17.09 0.08 OUTLIER Glycine 0 CA--C 1.52 0.391 0 C-N-CA 120.59 -0.815 . . . . 73.400000000000006 113.39 -177.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 93.6 mttt 71.59 150.88 0.14 Allowed Pre-proline 0 N--CA 1.473 0.688 0 C-N-CA 123.235 0.614 . . . . 74.420000000000002 111.438 179.428 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.862 ' HB3' HG22 ' B' ' 138' ' ' VAL . 24.5 Cg_endo -62.42 140.68 83.56 Favored 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.77 2.313 . . . . 73.219999999999999 113.357 -176.154 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . 0.44 ' CE1' HG12 ' B' ' 137' ' ' VAL . 8.7 p90 -150.59 155.26 39.06 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.655 -0.702 . . . . 75.200000000000003 109.969 177.107 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.571 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 83.6 m-85 -101.56 141.29 34.66 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.286 -0.415 . . . . 73.439999999999998 111.37 -177.503 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 27.6 mt -124.88 95.74 4.62 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.559 -0.746 . . . . 70.349999999999994 109.885 169.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 48.9 t -94.02 122.81 45.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.02 -0.733 . . . . 73.400000000000006 109.02 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 15.6 ttm-85 -67.94 143.54 55.61 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.468 0.651 . . . . 73.109999999999999 111.975 -174.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.03 175.4 10.67 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.664 -1.153 . . . . 64.430000000000007 110.586 176.128 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -84.94 138.27 32.6 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 109.01 -0.737 . . . . 75.219999999999999 109.01 173.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 110.07 132.07 6.24 Favored Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 120.654 -0.784 . . . . 71.430000000000007 111.655 -177.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 18.8 m -82.33 30.5 0.4 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.921 0.391 . . . . 74.109999999999999 110.983 -177.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -73.59 -47.29 41.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.052 0.453 . . . . 72.450000000000003 110.56 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 121.38 46.75 0.31 Allowed Glycine 0 CA--C 1.503 -0.714 0 C-N-CA 120.774 -0.727 . . . . 71.439999999999998 112.417 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 -122.17 135.53 54.79 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 120.964 0.411 . . . . 74.209999999999994 110.705 -179.178 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -113.01 159.4 19.17 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.764 -0.653 . . . . 73.5 109.381 173.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . 0.8 HD12 HD23 ' B' ' 166' ' ' LEU . 48.7 mm -114.34 115.84 50.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 N-CA-C 109.341 -0.614 . . . . 73.310000000000002 109.341 176.079 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.47 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 40.2 ttm180 -85.39 145.16 27.61 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.75 -0.659 . . . . 74.129999999999995 110.376 -174.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 160' ' ' SER . . . . . 0.571 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 5.2 p -58.89 -31.87 68.99 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.447 0.641 . . . . 72.340000000000003 110.862 178.211 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . 0.443 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 3.5 m-20 -76.03 -31.26 58.79 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.192 -0.913 . . . . 72.230000000000004 110.902 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . 0.641 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 13.9 mm100 -132.37 71.07 79.66 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 115.944 -0.571 . . . . 72.299999999999997 110.808 -176.358 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -73.37 -12.79 25.29 Favored 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.187 1.925 . . . . 75.430000000000007 111.432 178.462 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -93.24 -4.91 51.07 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.012 -0.995 . . . . 73.409999999999997 110.253 179.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . 0.641 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 60.7 tptt -122.72 126.54 47.74 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.918 -0.583 . . . . 64.430000000000007 111.074 -174.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . 0.8 HD23 HD12 ' B' ' 158' ' ' ILE . 61.0 mt -74.41 110.43 8.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.398 -0.819 . . . . 72.140000000000001 109.087 174.477 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . 0.415 HG13 ' HB2' ' B' ' 159' ' ' ARG . 43.3 mm -70.56 116.37 44.74 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 109.92 -0.4 . . . . 75.319999999999993 109.92 -176.569 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.498 ' O ' HG21 ' B' ' 172' ' ' ILE . 38.3 Cg_endo -64.95 172.57 7.01 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 123.251 2.634 . . . . 71.420000000000002 113.416 -174.231 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -76.98 -9.9 59.0 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.92 -1.036 . . . . 74.409999999999997 111.978 -168.142 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 31.8 p90 -96.22 -10.8 27.16 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.461 0.648 . . . . 74.099999999999994 109.924 175.079 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.487 ' HB2' ' HG2' ' B' ' 168' ' ' PRO . 6.8 mm-40 -106.58 -7.06 17.6 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.454 -0.794 . . . . 71.129999999999995 111.215 -176.872 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.498 HG21 ' O ' ' B' ' 168' ' ' PRO . 29.0 pt -71.04 -30.01 39.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.121 -0.491 . . . . 75.409999999999997 110.723 178.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -102.32 41.54 1.22 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.304 0.574 . . . . 74.040000000000006 109.772 174.263 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 31.1 t -55.08 -31.86 61.52 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.992 -1.004 . . . . 74.299999999999997 110.847 179.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . 0.502 ' CE3' HD13 ' B' ' 123' ' ' ILE . 4.0 p-90 . . . . . 0 C--O 1.251 1.169 0 CA-C-O 118.044 -0.979 . . . . 75.349999999999994 110.462 176.765 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.624 0 N-CA-C 112.116 -0.393 . . . . 64.230000000000004 112.116 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -72.99 -62.05 1.6 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.687 0.28 . . . . 74.25 111.172 -178.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -83.67 119.94 25.39 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.42 -0.355 . . . . 72.129999999999995 110.295 -178.413 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -114.37 153.29 30.09 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.249 0.547 . . . . 74.109999999999999 111.041 -177.236 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -146.05 90.32 1.96 Allowed 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.389 -0.823 . . . . 74.140000000000001 109.222 175.019 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.22 128.37 84.75 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 116.156 -0.475 . . . . 72.230000000000004 111.597 -175.234 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -80.64 179.21 6.25 Favored 'Trans proline' 0 N--CA 1.461 -0.398 0 C-N-CA 122.865 2.377 . . . . 74.430000000000007 111.985 176.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.8 m -71.9 120.72 17.89 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.896 -0.409 . . . . 74.310000000000002 109.896 177.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.483 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 95.27 63.52 0.98 Allowed Glycine 0 N--CA 1.442 -0.918 0 C-N-CA 120.664 -0.779 . . . . 64.129999999999995 111.191 -175.489 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -100.3 98.94 8.55 Favored Pre-proline 0 C--N 1.324 -0.537 0 N-CA-C 108.845 -0.798 . . . . 73.420000000000002 108.845 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.663 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 88.5 Cg_endo -80.25 102.8 1.46 Allowed 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.247 1.964 . . . . 75.310000000000002 112.29 -173.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -80.88 141.5 34.53 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.062 -0.972 . . . . 71.430000000000007 109.939 -178.45 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.432 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 11.2 p -103.3 120.29 53.04 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 CA-C-O 121.638 0.732 . . . . 65.030000000000001 109.88 179.461 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.4 m -93.47 103.11 15.34 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 115.449 -0.796 . . . . 71.230000000000004 109.564 -179.547 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.525 HG23 ' HG2' ' A' ' 24' ' ' GLN . 63.9 mt -85.61 105.2 14.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.82 -0.627 . . . . 73.219999999999999 110.517 -175.297 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -101.61 160.92 14.04 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.681 -0.69 . . . . 73.109999999999999 110.565 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -127.11 98.04 5.16 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.617 -0.512 . . . . 73.540000000000006 109.617 175.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.634 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 43.6 mm-40 -103.49 93.32 4.88 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.819 -0.628 . . . . 64.439999999999998 109.618 -178.064 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 66.06 -106.36 1.56 Allowed Glycine 0 N--CA 1.444 -0.83 0 C-N-CA 120.764 -0.731 . . . . 43.130000000000003 111.832 -176.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.647 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 4.0 m-20 -102.05 -5.34 24.67 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.566 0.222 . . . . 73.319999999999993 110.819 -177.197 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.634 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 12.3 ptmt -110.77 121.03 44.33 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 121.471 0.653 . . . . 73.230000000000004 111.934 -173.449 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.4 m -82.41 97.56 8.43 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.276 -0.875 . . . . 74.310000000000002 109.212 174.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 54.1 mt -93.99 106.88 18.57 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-O 121.117 0.485 . . . . 73.209999999999994 110.812 -175.574 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.525 ' HG2' HG23 ' A' ' 15' ' ' ILE . 12.7 mt-30 -94.55 109.39 21.29 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.019 -0.537 . . . . 74.019999999999996 110.029 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.428 ' HB3' HD23 ' A' ' 32' ' ' LEU . 27.5 mt-10 -89.2 111.38 22.15 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.134 -0.484 . . . . 74.129999999999995 110.84 -178.539 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.505 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 50.5 m-85 -84.59 103.88 14.09 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.635 -0.506 . . . . 72.450000000000003 109.635 176.268 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -116.04 133.72 55.72 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.062 -0.517 . . . . 74.530000000000001 109.923 -179.552 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.663 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 3.4 p -92.05 -60.37 2.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 C-N-CA 120.272 -0.571 . . . . 63.420000000000002 110.443 176.684 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.554 ' H ' HG12 ' A' ' 28' ' ' VAL . 88.5 m-20 -138.47 72.6 1.41 Allowed 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.045 0.45 . . . . 75.430000000000007 110.213 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 90.46 -27.94 8.09 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.914 -0.585 . . . . 74.400000000000006 113.676 175.248 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.47 ' HD2' HG22 ' B' ' 128' ' ' VAL . 35.8 t80 -112.08 134.52 53.58 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.376 0.608 . . . . 73.420000000000002 111.469 -173.756 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.863 HD12 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -67.21 123.64 20.87 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.495 -1.229 . . . . 62.32 110.441 176.268 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . 0.474 ' CD1' ' HB2' ' B' ' 133' ' ' TYR . 24.2 p90 -108.23 -24.82 11.35 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.369 -0.533 . . . . 71.430000000000007 111.345 177.172 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -156.19 142.72 18.56 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.685 0.278 . . . . 64.0 110.965 179.342 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.863 HG13 HD12 ' A' ' 32' ' ' LEU . 81.4 mt -120.8 132.41 70.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.537 -0.301 . . . . 72.140000000000001 110.589 178.062 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.49 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 88.3 tttt -115.16 100.43 8.15 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 108.953 -0.758 . . . . 74.430000000000007 108.953 169.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.561 HG23 ' HB2' ' A' ' 21' ' ' LYS . 1.1 p -98.39 126.17 51.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 116.092 -0.503 . . . . 74.319999999999993 110.124 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.525 HG23 ' HB3' ' A' ' 44' ' ' PRO . 25.0 t -111.64 88.28 9.24 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 115.544 -0.753 . . . . 74.510000000000005 110.109 -179.789 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 57.8 Cg_endo -73.67 142.42 32.35 Favored 'Trans proline' 0 N--CA 1.457 -0.663 0 C-N-CA 122.48 2.12 . . . . 71.219999999999999 111.975 177.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.647 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 28.9 mtpp -70.09 -10.55 59.11 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.944 -0.571 . . . . 73.219999999999999 110.978 176.329 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 38.7 m-70 -131.04 80.64 1.95 Allowed 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.848 -0.615 . . . . 71.140000000000001 109.78 -178.532 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 151.3 -117.23 0.81 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.128 -0.558 . . . . 73.340000000000003 112.306 179.499 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 14.3 ptpt -152.79 151.76 27.18 Favored Pre-proline 0 C--N 1.328 -0.344 0 N-CA-C 110.179 -0.304 . . . . 73.120000000000005 110.179 178.467 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.525 ' HB3' HG23 ' A' ' 38' ' ' VAL . 48.5 Cg_endo -74.28 124.09 8.73 Favored 'Trans proline' 0 N--CA 1.46 -0.492 0 C-N-CA 122.262 1.975 . . . . 73.120000000000005 110.987 170.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.516 ' CE1' HG11 ' A' ' 37' ' ' VAL . 11.4 p90 -139.86 158.57 43.88 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.803 0.335 . . . . 75.150000000000006 110.988 -175.185 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.516 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 73.1 m-85 -103.93 141.64 35.81 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.828 -0.624 . . . . 73.430000000000007 111.258 -176.498 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 83.8 mt -123.71 105.02 9.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.535 -0.757 . . . . 75.510000000000005 109.907 172.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.568 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 43.8 t -85.79 139.66 17.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.098 -0.501 . . . . 74.349999999999994 109.917 179.355 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 4.5 tpt180 -75.06 115.09 14.31 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.846 -0.428 . . . . 75.319999999999993 109.846 179.222 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.33 149.83 41.14 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.023 -0.535 . . . . 73.040000000000006 111.399 -178.204 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.585 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 4.9 p-10 -57.44 132.07 52.01 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.269 0.557 . . . . 73.340000000000003 110.981 -178.265 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.57 -24.13 24.76 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.41 -0.814 . . . . 74.319999999999993 111.86 -179.025 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.5 t 58.15 37.57 26.34 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 121.192 0.52 . . . . 65.030000000000001 109.985 -176.56 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -53.57 -38.61 64.05 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.425 -0.807 . . . . 74.420000000000002 111.44 -179.03 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 150.44 24.4 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.365 -0.921 . . . . 65.120000000000005 113.261 176.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.4 ' OD1' ' HA ' ' A' ' 68' ' ' PRO . 93.5 m-20 -134.79 162.7 31.62 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.79 0.329 . . . . 74.409999999999997 110.579 -176.764 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 73.2 m-85 -121.73 158.57 28.47 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.078 -0.51 . . . . 75.549999999999997 110.15 177.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.568 ' HB ' ' HB ' ' A' ' 48' ' ' VAL . 39.5 mm -106.74 110.54 32.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 N-CA-C 109.35 -0.611 . . . . 62.420000000000002 109.35 175.566 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.561 ' HG2' ' H ' ' A' ' 61' ' ' ASP . 74.3 ttt180 -83.99 140.42 31.9 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.276 -0.42 . . . . 74.540000000000006 110.682 -176.253 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.516 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 9.7 p -64.08 -25.06 67.94 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.901 -0.59 . . . . 72.219999999999999 112.204 -177.775 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.561 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 5.5 m-20 -72.78 -24.99 61.01 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.768 0.318 . . . . 71.439999999999998 111.649 -178.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.5 tp60 -155.0 88.36 3.21 Favored Pre-proline 0 C--N 1.327 -0.399 0 CA-C-O 120.73 0.3 . . . . 75.310000000000002 110.616 -176.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -82.05 6.5 5.66 Favored 'Trans proline' 0 C--O 1.233 0.231 0 C-N-CA 122.915 2.41 . . . . 55.240000000000002 112.455 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -62.34 -44.22 96.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.646 -0.706 . . . . 75.409999999999997 111.059 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.55 -178.37 4.9 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-N 115.6 -0.727 . . . . 74.140000000000001 111.458 -176.054 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.0 mp -95.51 135.04 37.66 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.078 -0.964 . . . . 75.420000000000002 108.846 177.424 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 41.0 mm -78.64 112.85 29.85 Favored Pre-proline 0 C--N 1.319 -0.743 0 N-CA-C 109.85 -0.426 . . . . 71.530000000000001 109.85 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.453 ' O ' HG23 ' A' ' 72' ' ' ILE . 46.6 Cg_endo -67.1 174.48 6.89 Favored 'Trans proline' 0 CA--C 1.519 -0.268 0 C-N-CA 123.188 2.592 . . . . 75.209999999999994 113.311 -173.336 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . 0.739 ' HA ' HG12 ' A' ' 72' ' ' ILE . 9.5 tt0 -68.16 -42.39 80.11 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.516 -0.765 . . . . 71.430000000000007 111.567 -170.624 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . 0.78 ' HA ' ' CZ ' ' A' ' 73' ' ' PHE . 29.6 p90 -63.19 -16.38 59.95 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.339 0.59 . . . . 74.319999999999993 110.395 -179.117 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 16.0 mm-40 -94.94 -28.75 15.01 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.527 -0.76 . . . . 74.0 111.579 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.739 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.0 pt -76.63 -38.6 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.148 0 N-CA-C 111.882 0.327 . . . . 72.150000000000006 111.882 -178.199 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.78 ' CZ ' ' HA ' ' A' ' 70' ' ' TRP . 6.6 p90 -85.67 30.65 0.63 Allowed 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.727 0.775 . . . . 75.140000000000001 110.847 179.55 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 32.5 t -74.23 -11.77 60.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.103 -0.953 . . . . 71.420000000000002 108.64 170.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . 0.426 ' HH2' HD13 ' A' ' 35' ' ' ILE . 36.6 m0 . . . . . 0 C--O 1.233 0.218 0 CA-C-N 115.465 -0.789 . . . . 72.549999999999997 110.6 173.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.255 0 N-CA-C 112.329 -0.309 . . . . 64.219999999999999 112.329 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -158.79 -54.35 0.06 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.097 0.475 . . . . 72.420000000000002 110.435 -178.731 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -141.99 116.4 9.58 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.701 -0.681 . . . . 63.43 109.851 179.258 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -118.99 145.58 45.71 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.185 -0.672 . . . . 72.120000000000005 109.185 178.014 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -134.27 123.19 23.82 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.914 0.388 . . . . 63.140000000000001 111.594 -174.471 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -106.37 134.41 19.8 Favored Pre-proline 0 C--N 1.322 -0.625 0 CA-C-N 115.778 -0.646 . . . . 63.539999999999999 110.688 178.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -80.84 -160.77 0.13 Allowed 'Trans proline' 0 C--O 1.235 0.354 0 C-N-CA 122.955 2.437 . . . . 75.439999999999998 112.156 179.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 33.1 m -65.41 96.91 0.26 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.06 0.457 . . . . 74.010000000000005 109.774 174.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 112.5 95.0 2.19 Favored Glycine 0 N--CA 1.441 -0.985 0 N-CA-C 110.838 -0.905 . . . . 72.129999999999995 110.838 -172.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -110.43 98.33 35.83 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-O 121.424 0.631 . . . . 73.319999999999993 109.899 -178.322 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.776 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 82.7 Cg_endo -81.83 76.57 4.25 Favored 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 122.484 2.123 . . . . 74.120000000000005 112.68 -175.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -91.38 149.86 21.53 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.092 -0.707 . . . . 73.129999999999995 109.092 176.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.643 HG21 ' HB3' ' B' ' 124' ' ' GLN . 7.2 p -102.96 130.52 52.93 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-O 121.555 0.693 . . . . 74.129999999999995 111.307 -176.085 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 114' ' ' THR . . . . . 0.439 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 30.4 m -91.84 111.2 22.64 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.234 -0.894 . . . . 73.219999999999999 109.139 176.027 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.6 mt -88.69 107.69 18.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 120.957 0.408 . . . . 72.400000000000006 111.06 -174.148 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . 0.486 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 20.2 mmt180 -94.84 160.46 14.59 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.447 -0.575 . . . . 64.530000000000001 109.447 175.619 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -136.99 86.84 2.24 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 115.774 -0.648 . . . . 62.439999999999998 109.574 174.138 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -100.35 87.81 3.51 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.475 -0.784 . . . . 74.420000000000002 109.395 -173.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 78.97 -111.56 3.27 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.791 -0.719 . . . . 63.399999999999999 111.968 -177.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . 0.65 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 20.4 m-20 -109.11 12.16 25.24 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.855 0.36 . . . . 75.299999999999997 111.189 -177.572 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.938 ' HE3' ' HB3' ' B' ' 175' ' ' TRP . 20.8 pttm -125.27 123.24 39.06 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.483 0.659 . . . . 75.420000000000002 111.481 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 65.9 m -81.75 103.31 11.35 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.249 -0.887 . . . . 70.299999999999997 109.472 174.629 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . 0.486 ' HB ' ' HB2' ' B' ' 116' ' ' ARG . 64.7 mt -93.58 105.87 17.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.076 0.465 . . . . 73.219999999999999 110.378 -177.284 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.643 ' HB3' HG21 ' B' ' 113' ' ' VAL . 21.1 mt-30 -96.23 109.72 22.14 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.167 -0.47 . . . . 74.209999999999994 110.897 -177.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . 0.439 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 45.8 mt-10 -86.47 106.48 17.51 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.778 -0.647 . . . . 73.129999999999995 110.799 179.471 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . 0.585 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 21.6 m-85 -82.07 106.36 13.92 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.88 -0.415 . . . . 74.439999999999998 109.88 174.297 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 95.2 mtt180 -119.97 126.38 50.7 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.842 -0.429 . . . . 75.010000000000005 109.842 179.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.776 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 3.0 p -99.0 -34.77 4.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.32 0.581 . . . . 74.299999999999997 111.268 -177.422 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -143.15 40.71 1.49 Allowed 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.596 0.712 . . . . 74.120000000000005 109.166 -175.43 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.15 -23.69 10.82 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.324 -0.853 . . . . 74.420000000000002 111.83 -176.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 58.3 t80 -93.83 132.26 38.4 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.98 0.419 . . . . 73.329999999999998 110.435 -177.647 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.836 HD13 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -70.66 117.29 12.0 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.359 -0.837 . . . . 74.129999999999995 109.261 176.368 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . 0.546 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 41.9 p90 -105.39 -24.69 12.61 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.384 -0.527 . . . . 73.329999999999998 111.18 179.533 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . 0.48 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -156.56 134.96 11.43 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.762 0.315 . . . . 74.140000000000001 110.734 179.224 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.836 HG13 HD13 ' B' ' 132' ' ' LEU . 74.3 mt -107.71 125.7 64.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 N-CA-C 110.031 -0.359 . . . . 73.299999999999997 110.031 175.492 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.536 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.9 tttt -107.53 99.92 9.38 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.038 -0.727 . . . . 74.120000000000005 109.038 174.142 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.516 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 1.1 p -103.85 124.45 58.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-O 121.074 0.464 . . . . 73.319999999999993 110.356 -178.519 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.751 HG23 ' HB3' ' B' ' 144' ' ' PRO . 21.2 t -108.89 88.12 5.18 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 115.224 -0.898 . . . . 65.040000000000006 109.732 179.706 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.437 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 72.4 Cg_endo -83.13 135.96 7.67 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.539 2.159 . . . . 74.400000000000006 112.459 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . 0.65 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 59.1 mtpt -60.32 -34.53 73.93 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.605 -0.725 . . . . 75.049999999999997 110.088 173.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -102.09 77.06 1.65 Allowed 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.461 -0.79 . . . . 74.439999999999998 108.925 177.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 144.38 -158.14 27.4 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.215 -0.902 . . . . 65.349999999999994 110.988 -174.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -131.13 150.03 75.39 Favored Pre-proline 0 C--N 1.324 -0.515 0 N-CA-C 110.026 -0.361 . . . . 73.540000000000006 110.026 177.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.751 ' HB3' HG23 ' B' ' 138' ' ' VAL . 17.7 Cg_endo -61.58 122.88 11.71 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.426 2.084 . . . . 65.209999999999994 112.124 178.064 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . 0.455 ' CE1' HG12 ' B' ' 137' ' ' VAL . 5.7 p90 -136.49 152.86 51.0 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.144 -0.48 . . . . 75.099999999999994 110.964 -177.005 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.523 ' O ' ' HA ' ' B' ' 159' ' ' ARG . 88.2 m-85 -101.97 138.33 39.08 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.88 -0.6 . . . . 72.230000000000004 111.114 -178.268 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . 0.46 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 56.9 mt -117.5 104.19 10.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.992 -0.549 . . . . 74.219999999999999 109.965 172.016 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . 0.486 ' HB ' ' HB ' ' B' ' 158' ' ' ILE . 49.1 t -91.33 128.02 43.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 116.339 -0.391 . . . . 75.140000000000001 110.888 -177.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 23.8 tpt180 -63.11 120.45 11.48 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 116.47 -0.332 . . . . 74.530000000000001 110.975 176.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.09 154.62 37.35 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-N 115.987 -0.551 . . . . 72.5 110.933 177.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . 0.505 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 8.0 p-10 -59.64 147.06 38.78 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.83 -0.623 . . . . 74.25 111.574 -176.667 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 73.63 2.59 60.83 Favored Glycine 0 N--CA 1.452 -0.247 0 CA-C-N 115.389 -0.823 . . . . 71.340000000000003 112.391 178.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 7.9 t 59.73 49.2 8.4 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 109.137 -0.69 . . . . 75.030000000000001 109.137 -175.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -48.64 -43.74 36.8 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 114.84 -1.073 . . . . 72.510000000000005 111.251 -179.326 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 131.13 -18.38 5.02 Favored Glycine 0 CA--C 1.492 -1.346 0 N-CA-C 110.718 -0.953 . . . . 71.230000000000004 110.718 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 -97.89 166.78 11.29 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 113.719 -1.241 . . . . 72.030000000000001 110.816 -176.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -121.22 153.39 37.67 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.817 -0.629 . . . . 72.120000000000005 110.206 178.314 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . 0.486 ' HB ' ' HB ' ' B' ' 148' ' ' VAL . 48.5 mm -106.31 114.77 46.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 N-CA-C 109.266 -0.642 . . . . 75.430000000000007 109.266 176.712 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.523 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 68.0 ttt180 -89.33 138.58 31.31 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.25 -0.432 . . . . 71.129999999999995 110.87 -175.505 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 5.6 p -62.59 -22.4 66.34 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.821 -0.627 . . . . 73.400000000000006 112.301 -177.191 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . 0.462 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 5.5 m-20 -76.22 -16.95 59.72 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.731 0.301 . . . . 74.120000000000005 111.237 -177.772 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 21.9 tp60 -166.06 84.81 0.97 Allowed Pre-proline 0 C--N 1.328 -0.34 0 N-CA-C 109.44 -0.578 . . . . 75.019999999999996 109.44 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . 0.474 ' HG2' ' HB2' ' A' ' 60' ' ' SER . 23.7 Cg_exo -64.86 -9.36 20.96 Favored 'Trans proline' 0 N--CA 1.474 0.337 0 C-N-CA 123.16 2.573 . . . . 63.25 112.929 -178.682 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -90.6 -5.63 55.66 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.962 -0.563 . . . . 74.409999999999997 110.768 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.8 tptt -114.83 123.29 48.81 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.25 0.548 . . . . 75.239999999999995 110.419 -178.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.3 mp -85.34 113.57 21.76 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.169 -0.923 . . . . 74.150000000000006 109.229 177.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . 0.523 HG22 ' HB3' ' B' ' 171' ' ' GLU . 50.5 mm -64.41 110.58 4.15 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 123.608 0.567 . . . . 74.209999999999994 110.681 -177.347 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.544 ' O ' HG22 ' B' ' 172' ' ' ILE . 80.5 Cg_endo -76.06 176.81 9.55 Favored 'Trans proline' 0 N--CA 1.461 -0.386 0 C-N-CA 122.933 2.422 . . . . 60.43 112.472 -176.711 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -76.26 -5.42 46.89 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.711 -0.677 . . . . 71.430000000000007 112.707 -170.453 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 27.9 p90 -97.64 -12.88 21.93 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.497 -0.481 . . . . 74.209999999999994 110.254 173.395 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.523 ' HB3' HG22 ' B' ' 167' ' ' ILE . 1.7 mm-40 -105.95 -15.05 15.01 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.37 -0.377 . . . . 54.509999999999998 111.465 -177.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.544 HG22 ' O ' ' B' ' 168' ' ' PRO . 43.1 pt -66.73 -21.28 28.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.083 0.468 . . . . 75.140000000000001 110.693 177.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -88.87 41.88 1.05 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.797 -0.638 . . . . 71.299999999999997 109.99 177.43 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 22.8 t -86.1 17.22 3.7 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.393 -0.821 . . . . 75.310000000000002 110.247 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . 0.938 ' HB3' ' HE3' ' B' ' 121' ' ' LYS . 45.9 m0 . . . . . 0 C--O 1.246 0.921 0 CA-C-O 118.471 -0.776 . . . . 72.519999999999996 110.421 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.718 0 N-CA-C 111.809 -0.517 . . . . 75.120000000000005 111.809 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 64.91 15.19 9.78 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 123.348 0.659 . . . . 75.409999999999997 111.854 177.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -103.64 105.31 15.51 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.936 0.398 . . . . 65.129999999999995 110.004 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -145.89 -43.24 0.21 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.045 -0.525 . . . . 74.140000000000001 110.382 -178.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -89.9 113.23 24.81 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.907 -0.588 . . . . 71.140000000000001 109.938 -178.692 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.46 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -83.26 124.59 75.92 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 116.095 -0.502 . . . . 74.349999999999994 112.009 -175.107 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.46 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 6.7 Cg_exo -74.7 172.68 15.76 Favored 'Trans proline' 0 C--O 1.235 0.338 0 C-N-CA 123.317 2.678 . . . . 73.109999999999999 112.098 176.794 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 20.9 m -89.15 -178.72 5.73 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.391 -0.368 . . . . 75.430000000000007 110.543 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 80.22 -86.77 1.29 Allowed Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 110.903 -0.879 . . . . 70.319999999999993 110.903 -176.164 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 70.87 97.94 0.04 OUTLIER Pre-proline 0 CA--C 1.516 -0.347 0 C-N-CA 123.138 0.575 . . . . 74.340000000000003 110.89 175.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.534 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 5.5 Cg_endo -78.82 85.03 1.92 Allowed 'Trans proline' 0 N--CA 1.443 -1.451 0 C-N-CA 122.378 2.052 . . . . 74.329999999999998 110.041 178.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -95.7 152.05 18.81 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.284 -0.871 . . . . 73.510000000000005 110.179 -175.372 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.709 HG21 ' HB3' ' A' ' 24' ' ' GLN . 7.3 p -121.67 131.52 72.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-O 121.378 0.609 . . . . 73.439999999999998 111.158 -176.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.2 m -92.05 115.55 28.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.437 -0.801 . . . . 72.510000000000005 109.488 176.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 50.3 mt -94.13 107.73 19.7 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.101 0.477 . . . . 73.340000000000003 111.344 -173.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.705 ' HB2' ' HB ' ' A' ' 23' ' ' ILE . 33.5 mmt180 -100.41 169.31 9.18 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.701 -0.681 . . . . 71.329999999999998 109.424 175.688 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 69.2 mt-30 -139.61 102.78 4.53 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.878 0.37 . . . . 73.230000000000004 110.301 175.537 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 60.2 mm-40 -101.51 80.15 2.03 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.031 -0.532 . . . . 72.310000000000002 110.18 -178.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.41 -111.06 3.49 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.794 -0.717 . . . . 74.019999999999996 111.51 -176.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.57 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 5.8 m-20 -112.47 4.23 17.33 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.239 0.542 . . . . 61.210000000000001 109.837 178.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.519 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 23.9 pttm -107.08 119.99 40.88 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.492 0.663 . . . . 74.0 110.379 175.581 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.684 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 8.5 m -80.21 127.15 32.01 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.499 -0.773 . . . . 74.150000000000006 109.488 177.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.705 ' HB ' ' HB2' ' A' ' 16' ' ' ARG . 26.0 mm -108.08 104.99 17.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 120.677 0.275 . . . . 74.200000000000003 110.296 -175.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.737 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 16.2 mt-30 -99.35 109.34 21.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.887 0.375 . . . . 73.150000000000006 110.827 -178.109 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -91.69 110.9 22.24 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.978 -0.556 . . . . 60.200000000000003 110.311 -179.161 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.535 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 28.1 m-85 -88.69 108.91 19.72 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.877 0.37 . . . . 74.329999999999998 111.531 -178.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 46.4 mtm105 -121.44 123.68 42.67 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.713 -0.477 . . . . 65.219999999999999 109.713 175.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.534 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.4 p -91.83 -27.88 4.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 121.11 0.481 . . . . 75.400000000000006 110.728 -177.719 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -172.3 72.5 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.015 -0.539 . . . . 73.340000000000003 109.905 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.31 -24.97 4.52 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.795 -0.639 . . . . 55.409999999999997 113.202 177.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -108.17 130.11 55.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.969 0.384 . . . . 72.340000000000003 111.097 -174.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.482 HD12 HG13 ' A' ' 35' ' ' ILE . 3.1 tm? -74.51 112.76 11.02 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.345 -0.843 . . . . 74.450000000000003 109.037 175.031 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -105.44 -16.33 14.76 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.614 -0.434 . . . . 63.329999999999998 111.696 -177.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -160.47 145.75 14.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.032 0.444 . . . . 64.230000000000004 111.522 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.482 HG13 HD12 ' A' ' 32' ' ' LEU . 63.6 mt -118.32 125.68 74.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 115.909 -0.587 . . . . 64.329999999999998 109.461 174.084 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.737 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 82.6 tttt -109.78 105.66 14.97 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.881 -0.415 . . . . 75.040000000000006 109.881 179.163 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.663 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 3.5 t -89.52 134.38 28.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 108.965 -0.754 . . . . 74.140000000000001 108.965 178.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.684 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.4 t -120.32 73.22 20.61 Favored Pre-proline 0 C--N 1.317 -0.839 0 N-CA-C 109.731 -0.47 . . . . 73.109999999999999 109.731 173.693 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.657 ' HD3' HG11 ' A' ' 37' ' ' VAL . 49.6 Cg_endo -76.96 132.46 12.9 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.286 1.991 . . . . 75.109999999999999 111.489 175.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.57 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 21.9 mtpp -57.77 -34.41 69.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 74.040000000000006 111.11 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -119.11 109.69 16.19 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.331 -0.618 . . . . 73.109999999999999 109.331 175.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 128.53 -27.6 4.4 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 110.79 -0.924 . . . . 55.149999999999999 110.79 -173.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 58.6 mtmt 70.97 152.0 0.14 Allowed Pre-proline 0 CA--C 1.532 0.255 0 C-N-CA 123.593 0.757 . . . . 73.400000000000006 112.496 175.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.663 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 43.3 Cg_endo -67.63 145.2 69.15 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.138 2.559 . . . . 73.530000000000001 114.159 -174.434 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 29.2 p90 -148.93 158.92 44.54 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.497 -0.774 . . . . 74.319999999999993 109.801 176.363 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.547 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 72.7 m-85 -101.71 129.14 47.81 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.276 -0.42 . . . . 74.430000000000007 110.701 178.7 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.572 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 29.7 tp -109.67 96.2 6.11 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.898 -0.779 . . . . 74.329999999999998 108.898 173.034 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 32.3 t -94.61 142.38 13.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 116.239 -0.437 . . . . 75.450000000000003 111.293 -172.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.442 HH11 ' HZ ' ' A' ' 57' ' ' PHE . 1.6 mmt-85 -66.93 137.57 56.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.962 -0.563 . . . . 74.219999999999999 111.046 177.075 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.73 153.84 21.04 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.056 -0.52 . . . . 74.230000000000004 109.701 172.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.415 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 4.3 p-10 -60.64 130.37 46.17 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.264 0.554 . . . . 65.420000000000002 111.289 -177.793 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 81.17 -15.0 24.94 Favored Glycine 0 CA--C 1.518 0.257 0 CA-C-N 115.637 -0.711 . . . . 63.43 112.39 -178.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.7 p 43.52 72.46 0.18 Allowed 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 123.721 0.808 . . . . 73.329999999999998 112.503 -175.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -80.09 42.08 0.55 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.612 0.72 . . . . 65.150000000000006 109.435 177.164 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 62.35 37.16 94.14 Favored Glycine 0 N--CA 1.451 -0.362 0 N-CA-C 110.359 -1.097 . . . . 75.340000000000003 110.359 -170.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.856 HD22 HD21 ' A' ' 66' ' ' LEU . 51.1 t30 -133.08 141.68 48.34 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.937 0.399 . . . . 72.450000000000003 110.766 -169.397 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.572 ' CD2' ' HG ' ' A' ' 47' ' ' LEU . 29.7 m-85 -132.09 168.36 18.12 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.767 -0.651 . . . . 73.530000000000001 109.879 177.03 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.879 HD12 HD23 ' A' ' 66' ' ' LEU . 42.4 mm -129.16 120.79 52.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.482 -0.562 . . . . 73.329999999999998 109.482 174.679 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.61 ' HG3' HG13 ' A' ' 67' ' ' ILE . 41.6 mtp180 -88.03 150.66 23.28 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.271 -0.422 . . . . 72.530000000000001 110.655 -179.085 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.638 ' HB2' ' HB3' ' B' ' 163' ' ' PRO . 34.2 p -66.71 -30.43 70.66 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.283 0.564 . . . . 74.319999999999993 110.363 177.082 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.496 ' OD1' ' HB3' ' A' ' 59' ' ' ARG . 4.2 p-10 -78.51 -23.23 46.42 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.709 -0.678 . . . . 72.310000000000002 110.971 177.048 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -137.33 70.58 54.29 Favored Pre-proline 0 C--N 1.316 -0.868 0 CA-C-N 115.719 -0.673 . . . . 73.319999999999993 110.808 -172.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.478 ' HG3' ' HB2' ' B' ' 160' ' ' SER . 84.2 Cg_endo -84.47 -19.83 4.22 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.662 2.242 . . . . 74.019999999999996 112.587 -178.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 14.7 p-10 -90.61 3.76 53.2 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.935 -0.575 . . . . 74.409999999999997 109.975 -179.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 81.5 tttt -127.04 137.39 53.05 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.412 -0.813 . . . . 75.430000000000007 109.972 179.018 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.879 HD23 HD12 ' A' ' 58' ' ' ILE . 48.1 mt -86.22 116.54 24.46 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.916 -0.772 . . . . 74.129999999999995 108.916 176.08 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.656 HG23 ' HB3' ' A' ' 71' ' ' GLU . 41.5 mm -69.71 120.15 75.69 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 115.905 -0.589 . . . . 75.340000000000003 111.2 -172.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.54 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 51.3 Cg_endo -68.82 172.98 10.78 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.561 2.174 . . . . 62.450000000000003 112.574 -178.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 10.9 tt0 -80.1 -4.03 51.19 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.503 -0.771 . . . . 64.040000000000006 112.091 -166.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 39.1 p90 -100.78 -17.86 16.72 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.196 0.522 . . . . 75.420000000000002 110.214 174.002 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.656 ' HB3' HG23 ' A' ' 67' ' ' ILE . 1.2 mm-40 -90.73 -13.1 34.71 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.682 -0.69 . . . . 74.329999999999998 110.037 -178.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.522 HG21 ' O ' ' A' ' 68' ' ' PRO . 41.2 pt -70.34 -21.49 23.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.738 -0.665 . . . . 70.25 110.218 176.514 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -108.0 38.42 2.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.643 -0.708 . . . . 64.319999999999993 109.211 175.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.541 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 7.7 t -62.85 -32.77 74.06 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.192 -0.913 . . . . 71.409999999999997 111.187 -175.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 66.9 p-90 . . . . . 0 C--N 1.327 -0.383 0 CA-C-O 120.887 0.375 . . . . 74.040000000000006 110.838 179.19 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.469 0 N-CA-C 111.975 -0.45 . . . . 72.329999999999998 111.975 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -139.5 123.27 17.54 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.564 0.221 . . . . 73.340000000000003 110.59 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -91.61 129.58 37.56 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.53 -0.545 . . . . 73.319999999999993 109.53 178.234 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -96.35 3.7 52.75 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.19 0.441 . . . . 72.25 112.19 -170.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -78.08 137.41 38.21 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.877 0.37 . . . . 75.540000000000006 111.068 -178.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . 0.444 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -112.98 117.36 46.19 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 115.879 -0.601 . . . . 71.230000000000004 110.216 178.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 2.9 Cg_exo -75.27 165.45 30.89 Favored 'Trans proline' 0 N--CA 1.462 -0.329 0 C-N-CA 123.302 2.668 . . . . 75.230000000000004 112.845 -178.003 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 14.1 m -77.6 179.19 6.72 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.826 -0.625 . . . . 61.43 110.699 178.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.9 -58.28 4.98 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.72 -0.752 . . . . 73.219999999999999 111.362 -178.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 58.43 77.11 0.42 Allowed Pre-proline 0 C--N 1.329 -0.298 0 C-N-CA 122.941 0.497 . . . . 73.140000000000001 111.363 177.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.613 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 46.3 Cg_endo -72.84 80.12 1.84 Allowed 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 121.914 1.743 . . . . 73.129999999999995 110.745 175.159 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -97.77 164.33 12.44 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.197 -0.911 . . . . 75.409999999999997 110.255 -176.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.619 HG23 ' HB3' ' B' ' 124' ' ' GLN . 9.7 p -125.09 132.7 70.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-O 121.395 0.617 . . . . 62.350000000000001 111.195 -177.622 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 114' ' ' THR . . . . . 0.561 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 21.6 m -93.4 110.48 22.04 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.469 -0.787 . . . . 64.129999999999995 109.534 175.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.5 mt -84.37 105.35 13.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.062 0.458 . . . . 75.400000000000006 111.051 -176.039 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . 0.739 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 30.2 mmt180 -100.81 171.93 7.37 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.733 -0.667 . . . . 75.109999999999999 109.551 176.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 -145.59 125.18 13.25 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.512 0.672 . . . . 75.209999999999994 110.49 172.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.13 61.27 0.81 Allowed 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 115.008 -0.996 . . . . 71.230000000000004 110.223 -175.178 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 94.14 -111.94 4.25 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.685 -0.769 . . . . 71.430000000000007 111.638 -179.035 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -100.23 9.45 42.73 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.036 0.446 . . . . 73.040000000000006 109.837 178.215 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.681 ' HD2' ' HB2' ' B' ' 175' ' ' TRP . 25.0 pttm -123.81 119.59 30.15 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.9 -0.591 . . . . 74.310000000000002 110.791 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 122' ' ' THR . . . . . 0.637 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 35.0 m -80.07 133.38 36.11 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.755 -0.657 . . . . 74.109999999999999 109.543 175.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . 0.739 ' HB ' ' HB2' ' B' ' 116' ' ' ARG . 32.5 mm -114.89 103.39 15.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 120.753 0.311 . . . . 72.400000000000006 110.41 -177.403 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.734 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 14.5 mt-30 -95.7 105.69 17.72 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 120.644 -0.422 . . . . 74.450000000000003 110.452 -178.055 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . 0.561 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 41.1 mt-10 -81.63 101.7 10.19 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.865 -0.607 . . . . 75.510000000000005 110.831 179.137 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . 0.46 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 55.6 m-85 -81.03 105.72 12.46 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.916 0.388 . . . . 75.430000000000007 110.253 176.362 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . 0.479 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 86.8 mtm180 -127.67 118.03 23.08 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.956 -0.566 . . . . 73.439999999999998 110.262 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.751 HG11 ' H ' ' B' ' 129' ' ' ASN . 2.4 p -84.44 -72.06 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-N 116.114 -0.494 . . . . 74.319999999999993 110.246 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . 0.751 ' H ' HG11 ' B' ' 128' ' ' VAL . 18.3 t-20 -122.28 69.44 0.96 Allowed 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.122 0.487 . . . . 70.409999999999997 110.252 -177.091 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.79 -18.74 37.41 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.501 -0.772 . . . . 53.329999999999998 113.684 175.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . 0.446 ' CD2' HG22 ' A' ' 28' ' ' VAL . 38.0 t80 -114.68 132.13 56.5 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.138 0.494 . . . . 73.329999999999998 111.189 -171.721 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.753 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -73.24 113.6 10.5 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.967 -1.015 . . . . 75.140000000000001 109.358 174.668 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . 0.46 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 52.5 p90 -106.01 -20.04 13.54 Favored 'General case' 0 C--N 1.326 -0.415 0 C-N-CA 120.72 -0.392 . . . . 74.420000000000002 111.456 -179.072 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -157.44 142.11 16.6 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.816 0.341 . . . . 75.310000000000002 111.361 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.753 HG13 HD11 ' B' ' 132' ' ' LEU . 73.5 mt -119.14 117.44 54.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 116.145 -0.48 . . . . 75.349999999999994 109.958 175.028 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.734 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 78.9 tttt -93.8 104.64 16.71 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.399 -0.593 . . . . 73.019999999999996 109.399 175.611 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.687 HG13 ' HD3' ' B' ' 139' ' ' PRO . 4.1 t -88.71 131.04 37.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 N-CA-C 108.985 -0.746 . . . . 74.099999999999994 108.985 177.529 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.637 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.4 t -118.18 73.03 9.76 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.703 -0.481 . . . . 73.120000000000005 109.703 173.016 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.687 ' HD3' HG13 ' B' ' 137' ' ' VAL . 61.2 Cg_endo -81.27 134.04 8.9 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 122.047 1.831 . . . . 75.400000000000006 112.161 175.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 63.4 mttm -57.07 -42.91 81.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.592 0.71 . . . . 74.150000000000006 110.083 174.659 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 18.0 m-70 -98.95 83.77 2.97 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.088 -0.96 . . . . 73.109999999999999 109.406 -173.165 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 136.28 -21.5 3.46 Favored Glycine 0 N--CA 1.45 -0.372 0 CA-C-N 115.51 -0.768 . . . . 52.549999999999997 111.848 -177.402 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . 0.505 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 53.7 mtmt 72.46 154.88 0.15 Allowed Pre-proline 0 N--CA 1.466 0.354 0 C-N-CA 123.682 0.793 . . . . 73.319999999999993 111.893 179.639 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.53 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 36.4 Cg_endo -65.49 146.85 86.06 Favored 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 123.017 2.478 . . . . 72.109999999999999 114.12 -174.334 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 27.3 p90 -151.19 171.26 17.67 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.402 -0.817 . . . . 75.439999999999998 109.472 175.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -111.67 126.54 55.14 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.94 0.4 . . . . 65.439999999999998 111.163 -179.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . 0.424 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 26.7 tp -107.79 99.18 8.67 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.601 -0.727 . . . . 72.209999999999994 109.121 175.503 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 39.2 t -99.87 138.06 25.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 120.805 0.336 . . . . 64.409999999999997 111.152 -174.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . 0.463 ' HD3' ' CE2' ' B' ' 157' ' ' PHE . 0.4 OUTLIER -65.46 123.77 20.51 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 121.049 0.452 . . . . 72.409999999999997 111.469 174.509 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.05 156.54 37.37 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.228 -0.897 . . . . 72.400000000000006 110.705 177.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . 0.535 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 5.7 p-10 -64.51 133.85 53.25 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.144 0.497 . . . . 74.420000000000002 110.427 -179.364 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 89.72 -30.76 5.58 Favored Glycine 0 N--CA 1.453 -0.217 0 CA-C-N 115.831 -0.622 . . . . 55.229999999999997 111.808 -175.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 59.8 p 46.21 56.4 6.26 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.126 0.97 . . . . 75.230000000000004 113.13 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -77.64 40.79 0.31 Allowed 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.837 0.827 . . . . 71.530000000000001 110.417 176.623 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 73.08 28.73 65.91 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 111.362 -0.695 . . . . 51.100000000000001 111.362 -173.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . 0.516 ' ND2' HD22 ' B' ' 166' ' ' LEU . 34.0 t30 -122.02 141.57 51.22 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.393 -0.403 . . . . 64.409999999999997 110.364 -175.424 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . 0.463 ' CE2' ' HD3' ' B' ' 149' ' ' ARG . 43.1 m-85 -125.93 162.63 24.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.026 -0.533 . . . . 71.510000000000005 110.025 179.283 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 46.4 mm -122.07 130.14 74.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 109.088 -0.708 . . . . 73.420000000000002 109.088 175.382 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.497 ' HB3' ' OD1' ' B' ' 161' ' ' ASP . 23.6 mtp180 -104.92 158.79 16.29 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.193 0.52 . . . . 74.519999999999996 111.382 -175.762 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 160' ' ' SER . . . . . 0.478 ' HB2' ' HG3' ' A' ' 63' ' ' PRO . 11.5 p -74.86 -26.06 59.42 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.907 -0.588 . . . . 62.229999999999997 110.689 178.808 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . 0.497 ' OD1' ' HB3' ' B' ' 159' ' ' ARG . 11.3 p-10 -86.68 -15.4 39.69 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.883 -0.598 . . . . 62.340000000000003 110.428 177.274 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . 0.423 ' OE1' ' HD3' ' B' ' 165' ' ' LYS . 39.4 mt-30 -143.24 74.45 17.48 Favored Pre-proline 0 C--N 1.319 -0.718 0 CA-C-N 115.243 -0.89 . . . . 74.239999999999995 109.38 -176.095 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . 0.638 ' HB3' ' HB2' ' A' ' 60' ' ' SER . 74.0 Cg_endo -83.05 -44.23 0.07 OUTLIER 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.966 2.444 . . . . 74.219999999999999 114.133 -172.155 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -80.8 -6.8 59.01 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.443 0.64 . . . . 73.310000000000002 109.631 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . 0.423 ' HD3' ' OE1' ' B' ' 162' ' ' GLN . 88.1 tttt -103.92 135.98 44.43 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.18 -0.918 . . . . 71.319999999999993 110.27 -178.04 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . 0.516 HD22 ' ND2' ' B' ' 156' ' ' ASN . 5.3 mp -87.41 124.21 33.16 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 108.994 -0.743 . . . . 73.040000000000006 108.994 178.374 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 46.5 mm -83.44 117.73 69.47 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.114 -0.494 . . . . 74.530000000000001 111.686 -170.635 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.5 ' O ' HG21 ' B' ' 172' ' ' ILE . 70.4 Cg_endo -72.95 175.93 9.74 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.957 2.438 . . . . 64.209999999999994 112.874 -178.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -82.75 15.16 2.77 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.45 -0.795 . . . . 63.420000000000002 112.944 -168.469 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 26.3 p90 -115.67 -14.98 11.41 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.144 0.497 . . . . 75.319999999999993 110.424 171.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -107.32 0.81 23.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.967 -0.561 . . . . 73.400000000000006 111.017 -176.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.5 HG21 ' O ' ' B' ' 168' ' ' PRO . 21.6 pt -80.79 -31.3 12.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.914 -0.585 . . . . 74.420000000000002 111.217 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -111.5 39.4 2.34 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.422 0.63 . . . . 72.129999999999995 110.376 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.9 t -61.19 -26.03 67.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.378 -0.828 . . . . 74.019999999999996 110.933 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . 0.681 ' HB2' ' HD2' ' B' ' 121' ' ' LYS . 4.0 p-90 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.126 -0.94 . . . . 73.219999999999999 110.981 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.63 0 N-CA-C 111.712 -0.555 . . . . 74.549999999999997 111.712 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -139.42 133.5 31.1 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.922 0.392 . . . . 74.519999999999996 111.192 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -86.2 97.96 10.65 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.119 -0.697 . . . . 75.219999999999999 109.119 174.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.427 ' CG ' ' H ' ' A' ' 5' ' ' ASP . 6.0 t70 -144.06 -171.85 3.64 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.489 -0.323 . . . . 74.040000000000006 110.764 -175.757 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.427 ' H ' ' CG ' ' A' ' 4' ' ' ASP . 22.9 t70 -107.83 113.68 27.09 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.395 -0.366 . . . . 72.430000000000007 111.347 -173.333 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.482 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -72.33 122.5 87.6 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 116.202 -0.454 . . . . 75.540000000000006 110.572 176.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.482 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 1.6 Cg_endo -83.26 -153.03 0.04 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.454 0 C-N-CA 123.341 2.694 . . . . 74.319999999999993 112.279 -179.084 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 14.6 m -66.81 143.96 56.58 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.083 -0.508 . . . . 71.540000000000006 110.213 178.192 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.506 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 85.43 87.69 0.94 Allowed Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 110.437 -1.065 . . . . 73.129999999999995 110.437 -171.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -106.06 101.91 36.68 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-O 120.834 0.35 . . . . 72.420000000000002 110.938 -169.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.749 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 71.7 Cg_endo -92.07 122.41 0.62 Allowed 'Trans proline' 0 N--CA 1.445 -1.363 0 C-N-CA 122.864 2.376 . . . . 75.230000000000004 112.314 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -128.19 111.56 13.57 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.526 0.679 . . . . 71.510000000000005 110.321 176.508 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.588 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 9.1 p -67.33 130.0 32.31 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.085 0 CA-C-N 114.723 -1.126 . . . . 74.430000000000007 110.806 179.412 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.534 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 51.8 m -86.23 103.34 14.76 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.671 -0.695 . . . . 75.219999999999999 109.561 175.763 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 63.5 mt -86.8 104.47 14.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.159 -0.473 . . . . 73.530000000000001 110.482 -177.427 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 10.1 mmm-85 -106.0 156.34 18.49 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.682 -0.69 . . . . 74.519999999999996 110.766 -178.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -129.23 98.21 4.83 Favored 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 108.873 -0.788 . . . . 73.109999999999999 108.873 173.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.56 ' HG3' HD12 ' A' ' 23' ' ' ILE . 8.0 mm-40 -91.47 15.7 11.8 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.475 -0.784 . . . . 74.310000000000002 110.723 -171.773 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.41 -98.96 0.64 Allowed Glycine 0 N--CA 1.445 -0.727 0 C-N-CA 120.998 -0.62 . . . . 52.140000000000001 111.899 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.454 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 11.5 p-10 -85.45 4.57 35.02 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.632 0.253 . . . . 72.540000000000006 111.568 -178.129 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.628 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 14.1 pttm -148.44 130.54 15.41 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 112.664 0.616 . . . . 72.340000000000003 112.664 -176.553 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.8 m -84.87 103.31 13.82 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 114.925 -1.034 . . . . 74.519999999999996 108.997 172.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.56 HD12 ' HG3' ' A' ' 18' ' ' GLU . 55.7 mt -100.33 112.23 32.36 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.013 0.435 . . . . 73.239999999999995 110.393 -175.264 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.588 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 21.4 mt-30 -101.43 117.36 34.78 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.96 -0.564 . . . . 75.439999999999998 111.576 -177.16 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.534 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.1 mt-10 -91.05 100.5 13.34 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.551 -0.75 . . . . 73.209999999999994 110.322 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.545 ' CD2' ' HB2' ' B' ' 151' ' ' ASP . 63.2 m-85 -78.12 104.73 8.88 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.676 0.274 . . . . 74.140000000000001 110.682 179.327 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 94.0 mtt180 -122.69 132.9 54.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.313 -0.403 . . . . 75.340000000000003 110.687 -178.423 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.788 HG12 ' H ' ' A' ' 29' ' ' ASN . 3.0 p -98.59 -73.98 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 C-N-CA 120.725 -0.39 . . . . 74.310000000000002 110.898 176.222 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.788 ' H ' HG12 ' A' ' 28' ' ' VAL . 7.4 m-20 -128.38 68.62 1.36 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.05 0.453 . . . . 74.030000000000001 110.51 -177.308 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 77.42 12.56 84.44 Favored Glycine 0 N--CA 1.451 -0.331 0 CA-C-N 115.679 -0.691 . . . . 71.310000000000002 112.019 -179.052 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 79.9 t80 -130.07 127.36 39.72 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.921 0.391 . . . . 75.450000000000003 110.785 -176.183 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 30.2 tp -85.91 114.8 23.1 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.393 -0.821 . . . . 74.420000000000002 109.413 174.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . 0.472 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 50.8 p90 -104.47 -10.3 17.78 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.669 -0.412 . . . . 75.540000000000006 111.938 -176.782 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -167.44 145.05 4.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.081 0.467 . . . . 63.310000000000002 111.361 -177.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 66.9 mt -121.14 115.77 47.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.872 -0.604 . . . . 73.209999999999994 109.615 174.3 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.453 ' CB ' ' HE1' ' A' ' 26' ' ' TYR . 83.5 tttt -104.69 105.25 15.26 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.666 -0.494 . . . . 72.019999999999996 109.666 177.326 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.536 HG12 ' CE1' ' A' ' 45' ' ' TYR . 1.6 p -104.24 127.05 58.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.996 0.427 . . . . 74.129999999999995 110.512 178.3 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.805 HG21 ' HB3' ' A' ' 44' ' ' PRO . 16.1 t -103.0 88.01 1.41 Allowed Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 115.312 -0.858 . . . . 74.129999999999995 109.463 175.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.486 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 90.0 Cg_endo -81.65 150.09 16.57 Favored 'Trans proline' 0 N--CA 1.461 -0.423 0 C-N-CA 122.714 2.276 . . . . 71.230000000000004 113.432 -176.734 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.454 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 29.0 mtpp -74.36 -10.48 59.63 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.368 -0.833 . . . . 75.5 110.556 174.175 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 52.9 m-70 -113.43 21.01 15.58 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.766 -0.652 . . . . 74.150000000000006 110.277 -173.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.26 -155.85 15.33 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 115.675 -0.693 . . . . 72.209999999999994 111.661 -178.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.483 ' HB2' ' HZ1' ' A' ' 43' ' ' LYS . 9.5 mtmp? -112.09 150.53 42.57 Favored Pre-proline 0 C--N 1.324 -0.506 0 N-CA-C 109.89 -0.411 . . . . 73.129999999999995 109.89 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.805 ' HB3' HG21 ' A' ' 38' ' ' VAL . 19.8 Cg_endo -60.18 121.03 9.15 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.37 2.046 . . . . 64.349999999999994 111.8 175.774 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.536 ' CE1' HG12 ' A' ' 37' ' ' VAL . 9.4 p90 -136.53 155.73 49.56 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.0 -0.546 . . . . 74.230000000000004 111.039 -176.227 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -99.7 137.07 38.69 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.621 -0.718 . . . . 72.510000000000005 110.787 -179.805 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 31.8 mt -104.7 98.13 7.92 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.865 -0.791 . . . . 71.040000000000006 108.865 164.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 39.7 t -83.54 129.12 38.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.117 -0.492 . . . . 73.329999999999998 110.083 -176.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.19 125.64 29.65 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.303 -0.408 . . . . 75.209999999999994 110.435 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.409 ' HB3' ' HB3' ' A' ' 54' ' ' ASP . . . -67.43 135.72 53.58 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 120.953 0.406 . . . . 65.25 110.899 178.181 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.713 ' OD1' ' HB2' ' B' ' 111' ' ' PRO . 31.3 t0 -80.01 168.58 19.0 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.594 -0.73 . . . . 74.209999999999994 110.942 -174.743 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.65 24.51 45.88 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.269 -0.732 . . . . 75.510000000000005 111.269 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 14.2 m 58.66 28.01 16.61 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.118 0.485 . . . . 74.530000000000001 110.592 -177.054 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.409 ' HB3' ' HB3' ' A' ' 50' ' ' ALA . 17.5 t70 -60.09 -47.95 83.75 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 115.349 -0.841 . . . . 74.329999999999998 111.325 -177.213 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 101.34 -36.73 4.01 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.679 -0.772 . . . . 63.340000000000003 112.946 176.386 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -70.93 150.95 45.2 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.967 0.413 . . . . 65.140000000000001 111.619 -175.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.452 ' CD1' HG22 ' A' ' 72' ' ' ILE . 37.7 m-85 -108.95 148.88 30.02 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.271 -0.422 . . . . 74.430000000000007 110.685 179.429 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 50.2 mm -111.26 129.07 67.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 109.641 -0.503 . . . . 74.430000000000007 109.641 176.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 43.2 ttm180 -89.91 135.69 33.49 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.541 -0.299 . . . . 75.510000000000005 110.59 -176.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 35.0 t -63.2 -33.27 75.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.33 -0.396 . . . . 73.340000000000003 111.704 -178.194 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -62.3 -42.64 99.53 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.248 0.547 . . . . 72.299999999999997 110.5 178.475 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 62.4 mt-30 -135.04 89.6 23.68 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 115.491 -0.777 . . . . 74.120000000000005 110.355 -174.015 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -68.97 -6.19 17.58 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.892 2.395 . . . . 74.109999999999999 112.416 -178.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -95.7 -8.44 34.6 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.086 -0.506 . . . . 71.219999999999999 110.241 178.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.3 tptt -105.84 123.12 47.45 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.869 -0.605 . . . . 63.329999999999998 110.737 -177.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.412 ' N ' HD12 ' A' ' 66' ' ' LEU . 5.1 mp -90.45 119.64 30.9 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.108 -0.951 . . . . 74.530000000000001 109.075 177.787 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 49.6 mm -90.07 113.92 58.97 Favored Pre-proline 0 C--N 1.323 -0.573 0 CA-C-N 116.263 -0.426 . . . . 75.310000000000002 110.729 -175.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.461 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 56.9 Cg_endo -69.43 174.03 9.81 Favored 'Trans proline' 0 N--CA 1.46 -0.5 0 C-N-CA 122.498 2.132 . . . . 71.530000000000001 112.371 -179.304 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 29.4 tt0 -83.14 -5.17 59.02 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.806 -0.633 . . . . 74.409999999999997 111.857 -168.233 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 35.7 p90 -100.45 -2.02 34.33 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.287 0.565 . . . . 75.400000000000006 109.902 176.468 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.461 ' HB2' ' HG2' ' A' ' 68' ' ' PRO . 2.8 mm-40 -121.72 17.02 11.12 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.391 -0.822 . . . . 71.299999999999997 111.03 -177.016 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.452 HG22 ' CD1' ' A' ' 57' ' ' PHE . 12.1 pt -98.18 -22.55 4.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.944 -0.571 . . . . 72.430000000000007 111.457 -179.569 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -113.58 20.78 15.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.185 0.517 . . . . 71.549999999999997 110.427 -178.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.1 m -57.75 -32.69 67.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.246 -0.888 . . . . 71.409999999999997 111.489 -177.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . 0.628 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 10.2 p-90 . . . . . 0 C--N 1.325 -0.467 0 CA-C-N 116.23 -0.441 . . . . 75.439999999999998 111.088 176.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.419 0 N-CA-C 112.039 -0.424 . . . . 65.219999999999999 112.039 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -98.58 78.69 2.4 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 120.903 0.383 . . . . 73.230000000000004 110.691 -179.278 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -74.11 140.84 45.53 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.713 -0.476 . . . . 74.409999999999997 109.713 179.226 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -145.73 179.65 7.3 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.122 -0.325 . . . . 63.109999999999999 110.122 -176.008 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -98.67 113.32 25.34 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.934 -0.395 . . . . 75.120000000000005 109.934 179.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -70.15 123.67 89.27 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.99 -0.55 . . . . 75.019999999999996 110.811 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_endo -77.31 -155.34 0.05 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.281 0 C-N-CA 122.792 2.328 . . . . 73.200000000000003 111.435 176.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 26.3 m -74.62 90.78 2.29 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.369 0.604 . . . . 70.209999999999994 109.763 177.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . 0.433 ' O ' ' HD3' ' B' ' 111' ' ' PRO . . . 151.59 54.14 0.01 OUTLIER Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 110.485 -1.046 . . . . 70.219999999999999 110.485 -175.058 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 -92.41 104.03 10.07 Favored Pre-proline 0 C--N 1.323 -0.578 0 CA-C-N 115.182 -0.509 . . . . 64.200000000000003 109.851 -176.065 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.713 ' HB2' ' OD1' ' A' ' 51' ' ' ASP . 68.4 Cg_endo -98.61 158.37 0.73 Allowed 'Trans proline' 0 N--CA 1.444 -1.437 0 C-N-CA 123.156 2.571 . . . . 74.150000000000006 112.768 -174.621 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -156.26 126.28 6.49 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 115.544 -0.753 . . . . 71.099999999999994 109.766 177.151 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.449 ' HB ' ' HB3' ' A' ' 51' ' ' ASP . 5.4 p -84.88 132.79 30.82 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 CA-C-N 114.979 -1.01 . . . . 74.439999999999998 110.801 -174.124 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 114' ' ' THR . . . . . 0.578 HG21 ' HG3' ' B' ' 116' ' ' ARG . 28.6 m -95.78 104.76 16.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.463 -0.79 . . . . 73.019999999999996 110.184 179.077 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.507 HG12 ' HG2' ' B' ' 124' ' ' GLN . 60.7 mt -90.64 102.98 13.92 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 116.073 -0.512 . . . . 74.019999999999996 109.928 -179.593 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . 0.578 ' HG3' HG21 ' B' ' 114' ' ' THR . 71.7 mtm180 -121.24 169.71 10.3 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.162 -0.472 . . . . 74.430000000000007 110.847 -178.41 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -125.24 117.49 23.95 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.045 -0.525 . . . . 75.109999999999999 110.537 179.016 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . 0.563 ' HG3' HD12 ' B' ' 123' ' ' ILE . 22.8 mm-40 -95.36 25.66 4.26 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.577 -0.738 . . . . 74.549999999999997 110.911 -177.225 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 121.45 -107.95 1.28 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.897 -0.668 . . . . 62.140000000000001 111.638 -177.379 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . 0.54 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 28.4 m-20 -95.39 29.21 2.61 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.911 0.386 . . . . 70.430000000000007 110.027 179.519 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . . . . . . . . . 20.7 pttm -151.88 127.52 10.14 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.032 0.444 . . . . 75.219999999999999 111.292 179.121 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 21.7 m -90.14 113.24 24.96 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.599 -0.728 . . . . 74.400000000000006 109.19 174.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . 0.563 HD12 ' HG3' ' B' ' 118' ' ' GLU . 51.8 mt -109.84 114.79 47.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.198 0.523 . . . . 70.140000000000001 110.634 -173.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.507 ' HG2' HG12 ' B' ' 115' ' ' ILE . 19.6 mt-30 -95.3 105.89 17.88 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.552 -0.749 . . . . 73.519999999999996 109.569 178.067 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . 0.415 ' CD ' HH21 ' B' ' 116' ' ' ARG . 28.8 mt-10 -84.53 98.82 10.34 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.541 -0.754 . . . . 74.329999999999998 110.34 -177.482 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . 0.6 ' CD2' ' HB2' ' A' ' 51' ' ' ASP . 6.5 m-85 -76.51 103.3 6.43 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.595 -0.52 . . . . 71.450000000000003 109.595 178.361 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 56.9 mtt-85 -132.43 126.34 32.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.108 0.48 . . . . 73.349999999999994 111.553 -172.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.696 ' HB ' ' HB3' ' B' ' 111' ' ' PRO . 4.3 p -115.7 119.44 61.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.675 -0.693 . . . . 75.400000000000006 109.827 175.105 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 60.29 27.14 16.66 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.284 -0.416 . . . . 75.340000000000003 111.545 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.36 21.13 52.92 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.509 -0.853 . . . . 71.519999999999996 112.576 179.544 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . 0.459 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 90.0 t80 -122.27 119.43 31.16 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.933 0.396 . . . . 72.5 110.235 175.443 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.535 HD23 HD11 ' B' ' 135' ' ' ILE . 24.4 tp -83.06 114.24 21.16 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.694 -0.684 . . . . 72.540000000000006 109.928 178.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 45.6 p90 -110.06 -6.93 15.0 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.618 -0.433 . . . . 71.400000000000006 111.296 -178.107 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -165.83 146.88 6.89 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.027 0.441 . . . . 73.019999999999996 111.207 -177.148 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.535 HD11 HD23 ' B' ' 132' ' ' LEU . 59.3 mt -130.57 118.05 41.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.932 -0.576 . . . . 73.420000000000002 109.946 177.582 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.506 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.1 tttt -101.3 98.32 8.72 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 120.092 -0.643 . . . . 75.209999999999994 109.477 172.354 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.523 HG12 ' CE1' ' B' ' 145' ' ' TYR . 1.9 p -101.4 125.38 55.43 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.125 0.488 . . . . 73.310000000000002 110.537 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.646 HG23 ' HB3' ' B' ' 144' ' ' PRO . 23.2 t -104.98 88.67 2.48 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.169 -0.923 . . . . 72.219999999999999 109.451 175.896 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.456 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 72.6 Cg_endo -83.51 132.69 5.92 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.54 2.16 . . . . 75.099999999999994 112.708 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . 0.54 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 29.1 mtpp -56.65 -33.38 66.28 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.454 -0.794 . . . . 72.140000000000001 111.006 176.742 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -97.11 17.42 17.14 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.705 -0.679 . . . . 74.540000000000006 111.029 -174.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . -155.76 -149.99 5.48 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 121.001 -0.619 . . . . 65.230000000000004 111.742 178.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . 0.529 ' HB2' ' HZ3' ' B' ' 143' ' ' LYS . 9.5 mtmp? -119.08 147.42 42.66 Favored Pre-proline 0 C--N 1.327 -0.395 0 N-CA-C 109.611 -0.514 . . . . 74.219999999999999 109.611 176.495 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.646 ' HB3' HG23 ' B' ' 138' ' ' VAL . 25.3 Cg_endo -64.29 123.85 12.47 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.362 2.041 . . . . 75.549999999999997 111.492 175.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . 0.523 ' CE1' HG12 ' B' ' 137' ' ' VAL . 5.8 p90 -144.88 151.79 39.25 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.874 0.368 . . . . 70.329999999999998 111.418 -175.614 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.468 ' HB2' ' OG ' ' B' ' 160' ' ' SER . 74.9 m-85 -96.83 136.81 36.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.675 -0.693 . . . . 72.030000000000001 110.393 177.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . 0.496 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 56.9 mt -109.53 102.62 11.46 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.163 -0.471 . . . . 75.450000000000003 109.884 169.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.9 t -81.83 130.35 35.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 109.836 -0.431 . . . . 74.129999999999995 109.836 178.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . 0.577 ' NH1' ' HA ' ' B' ' 153' ' ' SER . 0.0 OUTLIER -81.31 128.06 33.41 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.703 -0.226 . . . . 71.510000000000005 110.447 -177.149 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -68.58 150.7 47.7 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 120.963 0.411 . . . . 74.409999999999997 110.631 176.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . 0.545 ' HB2' ' CD2' ' A' ' 26' ' ' TYR . 22.7 t70 -70.77 165.88 22.14 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.598 -0.728 . . . . 71.299999999999997 111.115 -175.148 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.08 0.66 70.97 Favored Glycine 0 C--N 1.331 0.3 0 CA-C-N 116.206 -0.452 . . . . 74.5 112.34 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 153' ' ' SER . . . . . 0.577 ' HA ' ' NH1' ' B' ' 149' ' ' ARG . 5.9 t 60.6 31.91 20.29 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.078 0.466 . . . . 61.229999999999997 109.836 -176.441 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -52.39 -49.4 64.53 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.126 -0.943 . . . . 71.340000000000003 111.54 -179.521 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 124.61 -17.87 7.28 Favored Glycine 0 CA--C 1.499 -0.918 0 C-N-CA 120.762 -0.732 . . . . 73.120000000000005 111.565 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -70.33 140.35 52.21 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 114.851 -0.675 . . . . 63.520000000000003 111.281 178.037 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . 0.486 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 53.9 m-85 -118.28 151.47 37.61 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.071 -0.513 . . . . 73.120000000000005 109.673 174.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 46.7 mm -119.35 121.91 67.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 N-CA-C 109.743 -0.465 . . . . 64.219999999999999 109.743 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.552 ' HB3' ' H ' ' B' ' 162' ' ' GLN . 54.5 mtt180 -76.2 137.07 39.78 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.318 -0.401 . . . . 71.019999999999996 110.941 179.434 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 160' ' ' SER . . . . . 0.468 ' OG ' ' HB2' ' B' ' 146' ' ' PHE . 19.9 m -80.88 -13.68 58.7 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.252 -1.018 . . . . 74.239999999999995 108.252 165.096 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -73.66 -45.85 50.13 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.251 -1.34 . . . . 75.319999999999993 109.859 173.033 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . 0.552 ' H ' ' HB3' ' B' ' 159' ' ' ARG . 77.6 mt-30 -137.63 86.19 19.28 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-N 115.364 -0.835 . . . . 75.430000000000007 109.444 176.456 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -68.19 -13.99 39.39 Favored 'Trans proline' 0 N--CA 1.473 0.282 0 C-N-CA 122.905 2.403 . . . . 72.450000000000003 112.936 -176.436 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -92.29 10.68 28.67 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.976 0.417 . . . . 72.239999999999995 110.453 -179.028 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -127.09 125.81 41.91 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.33 0.586 . . . . 75.319999999999993 111.075 -179.589 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . 0.429 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.9 mp -87.87 125.06 34.27 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.036 -0.984 . . . . 64.510000000000005 108.93 176.573 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . 0.817 HG21 ' HB3' ' B' ' 171' ' ' GLU . 39.4 mm -87.26 117.43 68.58 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 116.18 -0.463 . . . . 64.120000000000005 111.64 -172.396 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.452 ' HG2' ' HB2' ' B' ' 171' ' ' GLU . 72.4 Cg_endo -75.59 -179.75 5.42 Favored 'Trans proline' 0 N--CA 1.463 -0.287 0 C-N-CA 123.088 2.525 . . . . 63.25 112.043 175.539 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . 0.75 ' O ' HG12 ' B' ' 172' ' ' ILE . 35.4 tt0 -76.34 -29.51 57.28 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.727 -0.389 . . . . 74.019999999999996 111.68 -172.261 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 36.5 p90 -75.06 -14.11 60.56 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 119.92 -0.712 . . . . 74.450000000000003 110.313 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.817 ' HB3' HG21 ' B' ' 167' ' ' ILE . 0.8 OUTLIER -89.68 -21.1 22.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.885 -0.598 . . . . 73.150000000000006 110.185 -179.257 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.75 HG12 ' O ' ' B' ' 169' ' ' GLN . 21.9 pt -73.59 -18.44 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 121.27 0.557 . . . . 74.200000000000003 110.24 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 80.0 m-85 -93.65 15.23 16.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.663 -0.699 . . . . 74.319999999999993 110.168 176.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.7 t -56.96 -37.06 71.04 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-N 115.817 -0.629 . . . . 72.019999999999996 109.777 175.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 54.7 p-90 . . . . . 0 C--O 1.247 0.927 0 CA-C-O 118.203 -0.903 . . . . 74.420000000000002 109.828 175.02 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.565 0 N-CA-C 111.912 -0.475 . . . . 54.310000000000002 111.912 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -142.4 -75.13 0.28 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.941 0.401 . . . . 73.129999999999995 110.002 178.505 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -155.75 126.92 7.1 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.833 -0.622 . . . . 73.329999999999998 109.524 176.501 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -138.0 111.41 8.04 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.909 -0.587 . . . . 75.019999999999996 110.943 -177.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -95.98 107.51 19.8 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.002 -0.545 . . . . 74.439999999999998 110.488 178.31 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -83.84 149.33 56.41 Favored Pre-proline 0 C--N 1.324 -0.506 0 CA-C-N 115.923 -0.581 . . . . 72.109999999999999 110.27 177.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -74.58 178.85 6.56 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.418 2.079 . . . . 74.040000000000006 112.138 178.454 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 19.6 m -72.09 167.24 20.64 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.504 -0.554 . . . . 71.430000000000007 109.504 175.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 72.41 74.78 0.74 Allowed Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 110.005 -1.238 . . . . 64.510000000000005 110.005 -168.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . 0.441 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 7.1 pt-20 -112.31 107.74 55.26 Favored Pre-proline 0 C--N 1.317 -0.809 0 CA-C-O 121.375 0.607 . . . . 73.430000000000007 109.712 -169.83 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.639 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 32.5 Cg_endo -84.67 108.94 1.28 Allowed 'Trans proline' 0 N--CA 1.442 -1.541 0 C-N-CA 122.445 2.097 . . . . 63.109999999999999 112.371 -174.006 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -118.79 164.2 15.75 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.127 -0.942 . . . . 52.109999999999999 109.674 -179.437 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.577 HG21 ' HB3' ' A' ' 24' ' ' GLN . 13.1 p -115.34 131.24 68.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.237 0.541 . . . . 74.510000000000005 111.41 -177.315 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 52.9 m -93.16 107.09 18.96 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.244 -0.65 . . . . 73.420000000000002 109.244 174.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 53.5 mt -92.09 107.96 19.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 120.963 0.411 . . . . 71.209999999999994 111.217 -174.559 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 66.7 mtt180 -103.65 167.85 9.53 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.736 -0.665 . . . . 75.129999999999995 110.252 176.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 62.6 mt-30 -134.16 97.31 3.82 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.438 -0.579 . . . . 72.219999999999999 109.438 170.317 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 22.1 mm-40 -96.29 82.42 3.42 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.823 -0.626 . . . . 74.209999999999994 110.093 -175.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.86 -109.02 3.31 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.798 -0.715 . . . . 62.200000000000003 111.927 -178.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.91 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 7.1 m-20 -111.22 17.53 20.2 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.899 0.381 . . . . 65.239999999999995 110.326 -179.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.584 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 22.9 pttm -130.84 123.79 29.84 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.294 0.569 . . . . 74.120000000000005 111.398 -179.151 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.454 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 24.5 m -82.83 109.75 17.24 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.603 -0.726 . . . . 71.340000000000003 109.682 176.265 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 48.7 mt -102.55 112.83 37.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-O 121.117 0.484 . . . . 73.340000000000003 110.654 -176.335 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.577 ' HB3' HG21 ' A' ' 13' ' ' VAL . 25.2 mt-30 -102.48 110.92 23.02 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.67 -0.695 . . . . 74.310000000000002 110.996 -177.562 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -92.26 107.51 19.27 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.795 -0.639 . . . . 73.019999999999996 110.837 -178.42 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -84.87 112.42 20.54 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.893 0.378 . . . . 75.219999999999999 110.599 178.392 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.418 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 87.9 mtt180 -117.39 137.56 52.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.924 -0.58 . . . . 75.109999999999999 109.905 178.756 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.639 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 6.2 p -96.82 -34.82 5.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-O 121.346 0.593 . . . . 72.239999999999995 110.489 177.714 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 30.9 t-20 -161.78 59.8 0.26 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.641 -0.874 . . . . 64.329999999999998 108.641 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.07 -34.69 3.36 Favored Glycine 0 CA--C 1.519 0.297 0 CA-C-N 115.482 -0.781 . . . . 64.120000000000005 112.058 -176.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.536 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 81.9 t80 -78.28 129.25 34.82 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.021 0.438 . . . . 73.219999999999999 111.047 -177.328 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.759 HD12 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -81.44 114.04 19.91 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.196 -0.911 . . . . 72.340000000000003 109.094 174.59 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 52.1 p90 -107.86 -19.4 13.53 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.634 -0.426 . . . . 74.340000000000003 111.682 -179.057 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -154.85 136.15 14.05 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.785 0.326 . . . . 62.219999999999999 111.244 -179.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.759 HG13 HD12 ' A' ' 32' ' ' LEU . 75.0 mt -116.26 122.81 70.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 116.064 -0.516 . . . . 75.450000000000003 109.91 175.378 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.4 tmtp? -110.21 114.49 28.02 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 108.732 -0.84 . . . . 72.299999999999997 108.732 173.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.558 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 0.9 OUTLIER -120.46 129.72 75.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 CA-C-N 115.796 -0.638 . . . . 74.549999999999997 110.692 -174.011 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.739 HG23 ' HB3' ' A' ' 44' ' ' PRO . 21.2 t -112.8 86.96 9.38 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.313 -0.858 . . . . 75.400000000000006 110.097 -179.378 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.462 ' HD2' ' C ' ' A' ' 43' ' ' LYS . 70.4 Cg_endo -86.49 134.45 4.05 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 122.503 2.135 . . . . 74.219999999999999 112.496 176.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.91 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 59.4 mtpt -56.31 -31.19 63.46 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.664 -0.698 . . . . 74.239999999999995 110.168 174.149 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 61.4 m-70 -116.95 91.18 3.51 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.338 -0.846 . . . . 73.340000000000003 109.156 176.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 141.31 -31.31 2.16 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.837 -0.619 . . . . 65.329999999999998 111.977 -177.019 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.462 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 98.5 mttt 70.52 151.12 0.13 Allowed Pre-proline 0 N--CA 1.469 0.477 0 C-N-CA 123.508 0.723 . . . . 73.530000000000001 111.872 178.577 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.739 ' HB3' HG23 ' A' ' 38' ' ' VAL . 18.8 Cg_endo -59.26 139.44 90.09 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 123.013 2.476 . . . . 74.010000000000005 113.798 -174.01 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.527 ' CE1' HG11 ' A' ' 37' ' ' VAL . 22.5 p90 -152.34 163.65 39.04 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.62 -0.718 . . . . 73.140000000000001 109.548 176.594 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . 0.481 ' HB2' ' HB2' ' A' ' 60' ' ' SER . 60.1 m-85 -107.6 120.66 42.84 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.704 0.288 . . . . 74.120000000000005 110.712 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 28.1 tp -107.15 99.14 8.7 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.16 -0.681 . . . . 73.109999999999999 109.16 176.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 37.3 t -95.38 140.76 16.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.26 -0.427 . . . . 63.409999999999997 111.436 -173.52 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.486 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 43.8 tpt85 -81.82 110.97 17.61 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.495 -0.557 . . . . 73.109999999999999 109.495 178.23 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.425 ' HB2' HG12 ' A' ' 58' ' ' ILE . . . -70.03 -177.96 1.48 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.994 -0.548 . . . . 73.519999999999996 111.111 -177.286 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.733 ' HB2' ' HA ' ' B' ' 112' ' ' ASP . 9.1 p-10 -79.01 148.42 32.53 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.154 -0.475 . . . . 72.049999999999997 110.17 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 103.27 140.16 10.69 Favored Glycine 0 N--CA 1.439 -1.16 0 C-N-CA 120.571 -0.823 . . . . 64.010000000000005 112.675 174.026 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 20.7 m -69.13 -4.93 19.3 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.675 -0.262 . . . . 75.409999999999997 110.919 174.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -43.03 -48.07 5.97 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 123.556 0.743 . . . . 73.0 112.012 176.711 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.25 53.86 1.32 Allowed Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.608 -0.806 . . . . 65.329999999999998 112.46 178.275 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -127.17 148.96 50.17 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.095 0.474 . . . . 71.430000000000007 110.538 176.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.486 ' CZ ' ' HD3' ' A' ' 49' ' ' ARG . 40.2 m-85 -117.75 152.64 34.87 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.594 -0.73 . . . . 75.010000000000005 110.322 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.425 HG12 ' HB2' ' A' ' 50' ' ' ALA . 50.6 mm -121.26 127.07 75.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 109.914 -0.402 . . . . 73.230000000000004 109.914 179.753 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 65.0 mtp180 -78.55 139.2 38.64 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 110.144 -0.317 . . . . 70.5 110.144 175.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.481 ' HB2' ' HB2' ' A' ' 46' ' ' PHE . 63.2 m -73.05 -23.19 60.55 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.495 -0.321 . . . . 74.030000000000001 110.448 176.109 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.447 ' OD1' ' HB2' ' A' ' 45' ' ' TYR . 0.8 OUTLIER -61.79 -60.58 3.44 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 121.74 0.781 . . . . 74.010000000000005 109.414 175.918 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 -122.65 88.62 49.85 Favored Pre-proline 0 N--CA 1.445 -0.724 0 CA-C-N 114.538 -1.21 . . . . 75.120000000000005 109.817 -179.524 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.84 -9.19 20.24 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 123.165 2.577 . . . . 65.239999999999995 112.626 -178.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -78.37 -24.84 46.19 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.926 -0.579 . . . . 73.239999999999995 110.599 177.393 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.406 ' HA ' ' HD2' ' A' ' 65' ' ' LYS . 42.6 tptt -91.82 122.92 34.8 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.388 0.613 . . . . 74.519999999999996 111.395 -175.14 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.5 mp -96.59 119.38 34.98 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.09 -0.959 . . . . 74.510000000000005 109.642 176.243 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 50.7 mm -88.11 111.42 42.85 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 116.273 -0.421 . . . . 73.409999999999997 110.023 178.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.418 ' O ' HG23 ' A' ' 72' ' ' ILE . 72.7 Cg_endo -74.16 176.72 9.18 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.563 2.175 . . . . 74.299999999999997 112.367 -177.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 28.4 tt0 -80.41 -6.24 57.76 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.859 -0.61 . . . . 71.219999999999999 111.334 -169.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -95.24 -12.14 26.76 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.409 -0.516 . . . . 73.420000000000002 110.433 176.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -103.12 -7.6 21.17 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.839 0.352 . . . . 71.340000000000003 110.795 -178.167 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.418 HG23 ' O ' ' A' ' 68' ' ' PRO . 45.7 pt -67.72 -27.74 39.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.846 0.355 . . . . 75.230000000000004 111.573 -178.24 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 24.3 p90 -101.27 34.49 2.54 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.372 0.605 . . . . 74.129999999999995 110.528 178.101 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 42.4 t -64.75 -26.98 68.59 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.43 -0.805 . . . . 73.349999999999994 110.212 176.161 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . 0.584 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 26.0 p-90 . . . . . 0 C--O 1.235 0.327 0 CA-C-N 116.436 -0.347 . . . . 74.439999999999998 111.048 177.309 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.249 0 N-CA-C 112.689 -0.164 . . . . 74.019999999999996 112.689 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -167.87 -78.68 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.048 0.452 . . . . 61.049999999999997 110.417 178.093 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -147.52 130.99 16.7 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.731 -0.668 . . . . 65.329999999999998 109.821 179.688 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -156.56 155.97 32.81 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.021 -0.536 . . . . 74.420000000000002 110.119 -179.592 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -92.16 146.82 23.42 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.01 -0.541 . . . . 71.099999999999994 111.377 -177.041 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . 0.47 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -90.63 129.94 42.97 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-N 115.531 -0.759 . . . . 71.540000000000006 110.203 178.43 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . 0.47 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 7.6 Cg_exo -73.33 171.03 18.49 Favored 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.736 2.291 . . . . 54.25 111.643 177.429 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 16.9 m -60.27 109.3 0.95 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.414 -0.357 . . . . 72.209999999999994 110.072 175.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 114.58 85.05 1.28 Allowed Glycine 0 N--CA 1.443 -0.864 0 C-N-CA 120.578 -0.82 . . . . 63.340000000000003 111.437 -176.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . 0.462 ' HA ' ' HD3' ' B' ' 111' ' ' PRO . 11.1 pt-20 -124.08 110.73 28.99 Favored Pre-proline 0 C--N 1.322 -0.618 0 CA-C-O 121.322 0.582 . . . . 72.049999999999997 109.558 -176.384 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.749 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 19.1 Cg_endo -89.52 131.35 2.01 Favored 'Trans proline' 0 N--CA 1.444 -1.4 0 C-N-CA 122.63 2.22 . . . . 75.329999999999998 112.604 -176.393 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . 0.733 ' HA ' ' HB2' ' A' ' 51' ' ' ASP . 4.2 p-10 -144.9 171.17 14.82 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.188 -0.671 . . . . 74.109999999999999 109.188 175.272 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.527 HG22 ' HB3' ' B' ' 124' ' ' GLN . 10.9 p -118.44 131.6 70.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.653 0.739 . . . . 75.140000000000001 112.096 -172.461 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 30.3 m -94.86 103.44 15.32 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.435 -0.802 . . . . 74.340000000000003 109.31 173.161 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.458 HG12 ' HG2' ' B' ' 124' ' ' GLN . 65.2 mt -90.57 106.44 17.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.245 -0.434 . . . . 72.099999999999994 110.823 -176.15 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -113.74 165.08 12.91 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.126 -0.488 . . . . 72.439999999999998 110.603 177.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -133.14 105.57 7.11 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.094 0.474 . . . . 74.310000000000002 110.468 178.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -109.85 88.75 2.82 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.904 -0.589 . . . . 72.430000000000007 110.191 -178.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 88.47 -119.8 5.47 Favored Glycine 0 N--CA 1.445 -0.734 0 CA-C-N 115.439 -0.8 . . . . 53.530000000000001 111.742 -177.377 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . 0.51 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 90.5 m-20 -101.37 6.29 42.57 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.73 0.3 . . . . 63.340000000000003 110.573 178.84 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.698 ' HE3' ' HB2' ' B' ' 175' ' ' TRP . 25.1 pttm -117.42 120.69 38.92 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.47 0.652 . . . . 72.420000000000002 111.692 -177.806 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 122' ' ' THR . . . . . 0.572 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 69.7 m -84.86 105.0 15.31 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.163 -0.926 . . . . 75.150000000000006 109.478 174.183 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . 0.647 HD13 ' HE2' ' B' ' 121' ' ' LYS . 33.2 mt -95.02 108.08 20.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 121.049 0.452 . . . . 74.310000000000002 110.531 -176.366 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.527 ' HB3' HG22 ' B' ' 113' ' ' VAL . 22.1 mt-30 -98.65 105.15 17.26 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.825 -0.625 . . . . 72.120000000000005 110.319 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -87.37 112.77 22.46 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.125 -0.488 . . . . 71.450000000000003 110.926 -179.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -90.09 111.14 22.16 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.205 -0.452 . . . . 72.230000000000004 110.028 176.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . 0.405 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 52.8 mtt-85 -128.33 138.1 52.23 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.313 -0.403 . . . . 75.340000000000003 110.346 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.749 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -101.86 -56.17 5.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.065 0.459 . . . . 71.510000000000005 111.201 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . 0.469 ' H ' HG11 ' B' ' 128' ' ' VAL . 6.7 t-20 -122.66 42.03 3.28 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.761 0.791 . . . . 65.340000000000003 109.103 -178.029 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 92.31 -28.72 8.51 Favored Glycine 0 N--CA 1.448 -0.563 0 CA-C-N 115.086 -0.961 . . . . 64.319999999999993 112.099 -178.087 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 33.8 t80 -84.59 135.57 34.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.934 0.397 . . . . 74.439999999999998 110.318 -175.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.825 HD12 HG13 ' B' ' 135' ' ' ILE . 3.3 tm? -76.75 117.59 18.53 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.327 -0.851 . . . . 75.140000000000001 109.966 179.068 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 40.0 p90 -112.26 -14.96 13.27 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.521 -0.471 . . . . 72.010000000000005 111.571 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.11 141.61 12.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.848 0.356 . . . . 70.510000000000005 111.169 178.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.825 HG13 HD12 ' B' ' 132' ' ' LEU . 75.3 mt -125.14 121.61 61.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.188 -0.46 . . . . 73.230000000000004 109.935 175.713 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -104.37 98.5 8.28 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 108.821 -0.807 . . . . 74.430000000000007 108.821 171.512 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.525 ' O ' ' HD3' ' B' ' 139' ' ' PRO . 3.5 p -98.21 128.67 49.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-O 121.142 0.496 . . . . 74.409999999999997 109.916 179.374 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.572 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 40.8 t -108.03 84.82 2.28 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.31 -0.859 . . . . 72.129999999999995 109.69 179.083 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.525 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 62.5 Cg_endo -88.7 132.33 2.45 Favored 'Trans proline' 0 N--CA 1.443 -1.464 0 C-N-CA 122.459 2.106 . . . . 75.140000000000001 111.885 178.411 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . 0.51 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 55.0 mtpt -65.37 -15.81 62.96 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.701 -0.681 . . . . 74.409999999999997 109.808 176.229 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 64.4 m-70 -117.47 89.52 3.13 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-N 115.174 -0.921 . . . . 75.540000000000006 109.289 178.413 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 127.87 -18.35 5.94 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.724 -0.751 . . . . 74.019999999999996 112.555 -178.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 89.1 mttt 72.98 148.94 0.12 Allowed Pre-proline 0 N--CA 1.472 0.649 0 C-N-CA 123.557 0.743 . . . . 73.299999999999997 111.736 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.509 ' HB3' HG22 ' B' ' 138' ' ' VAL . 34.9 Cg_endo -65.12 149.26 89.24 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.936 2.424 . . . . 74.400000000000006 113.375 -176.433 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . 0.421 ' HE2' HD12 ' B' ' 147' ' ' LEU . 3.9 p90 -160.3 160.43 32.51 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.534 -0.757 . . . . 72.150000000000006 109.59 178.178 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.546 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 55.0 m-85 -94.55 128.84 41.42 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.457 -0.338 . . . . 74.439999999999998 110.216 176.687 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . 0.43 ' HG ' ' HB3' ' B' ' 157' ' ' PHE . 15.8 tp -110.36 99.8 8.76 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 108.931 -0.766 . . . . 74.420000000000002 108.931 174.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.3 t -93.77 139.28 18.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.988 -0.551 . . . . 73.5 111.047 -173.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 11.6 tpt180 -72.02 131.06 42.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.199 -0.455 . . . . 72.319999999999993 111.245 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -93.34 162.22 14.08 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.372 -0.603 . . . . 75.140000000000001 109.372 171.306 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -68.69 138.24 54.78 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.966 0.412 . . . . 72.299999999999997 110.537 -177.548 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.1 147.45 15.01 Favored Glycine 0 N--CA 1.437 -1.28 0 C-N-CA 120.491 -0.861 . . . . 72.25 112.048 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 11.1 t -87.0 23.88 1.66 Allowed 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 121.253 0.549 . . . . 63.140000000000001 110.015 175.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -65.17 -29.45 70.28 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.571 -0.74 . . . . 72.150000000000006 110.59 179.01 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 94.44 37.92 5.18 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.891 -0.671 . . . . 71.049999999999997 111.641 -177.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . 0.89 HD22 HD21 ' B' ' 166' ' ' LEU . 40.7 t30 -110.85 130.51 55.56 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.836 0.351 . . . . 75.219999999999999 110.69 -177.457 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . 0.43 ' HB3' ' HG ' ' B' ' 147' ' ' LEU . 27.1 m-85 -126.71 161.0 29.15 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.002 -0.545 . . . . 72.239999999999995 110.269 178.198 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . 0.763 HD13 HD23 ' B' ' 166' ' ' LEU . 39.9 mm -118.38 141.05 39.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.458 -0.337 . . . . 73.120000000000005 110.603 -179.63 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.769 ' HD2' HD12 ' B' ' 167' ' ' ILE . 34.1 mtp-105 -96.23 145.68 25.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.394 -0.366 . . . . 75.400000000000006 110.925 -178.098 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 160' ' ' SER . . . . . 0.546 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 25.8 p -74.96 -15.16 60.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.26 0.552 . . . . 74.239999999999995 110.679 175.098 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -78.66 -30.79 46.47 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.118 -0.492 . . . . 72.530000000000001 110.38 177.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -159.19 98.02 1.63 Allowed Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.781 -0.645 . . . . 75.420000000000002 110.224 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.62 -13.03 34.41 Favored 'Trans proline' 0 CA--C 1.529 0.231 0 C-N-CA 122.991 2.461 . . . . 73.329999999999998 112.844 -179.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -77.66 -19.38 55.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.86 0.362 . . . . 71.329999999999998 111.022 177.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 51.7 tptt -94.07 122.61 36.76 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.409 0.623 . . . . 71.120000000000005 111.132 -177.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . 0.89 HD21 HD22 ' B' ' 156' ' ' ASN . 20.4 mt -90.57 128.02 36.45 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.598 -1.183 . . . . 73.400000000000006 108.832 176.734 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . 0.769 HD12 ' HD2' ' B' ' 159' ' ' ARG . 46.1 mm -98.77 112.08 61.89 Favored Pre-proline 0 C--N 1.318 -0.778 0 CA-C-O 120.65 0.262 . . . . 72.049999999999997 110.832 -178.151 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.528 ' O ' HG22 ' B' ' 172' ' ' ILE . 68.6 Cg_endo -73.5 175.23 10.94 Favored 'Trans proline' 0 N--CA 1.464 -0.263 0 C-N-CA 122.775 2.317 . . . . 75.340000000000003 112.611 -179.421 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . 0.501 ' O ' HG12 ' B' ' 172' ' ' ILE . 28.0 tt0 -69.65 -25.48 63.94 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.703 -0.681 . . . . 74.439999999999998 112.325 -168.488 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 30.6 p90 -81.09 -12.07 59.36 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 120.182 -0.607 . . . . 74.439999999999998 110.303 178.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.527 ' HB3' HG23 ' B' ' 167' ' ' ILE . 3.9 mt-10 -106.79 -19.27 13.7 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.157 -0.474 . . . . 73.430000000000007 111.892 -178.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.528 HG22 ' O ' ' B' ' 168' ' ' PRO . 43.6 pt -64.51 -26.36 40.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.244 0.545 . . . . 73.409999999999997 110.681 177.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -105.3 48.56 0.83 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.612 -0.722 . . . . 72.129999999999995 109.782 174.4 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 16.6 t -71.06 -15.39 62.54 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.806 -0.634 . . . . 73.409999999999997 110.17 179.379 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . 0.698 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 4.5 p-90 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.249 -0.882 . . . . 73.25 110.519 178.305 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.661 0 N-CA-C 112.198 -0.361 . . . . 74.349999999999994 112.198 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -91.21 90.25 7.7 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.164 0.507 . . . . 72.319999999999993 109.933 178.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -156.56 134.62 11.19 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.534 -0.757 . . . . 74.109999999999999 109.667 -177.414 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -136.63 100.39 4.32 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.076 0.465 . . . . 74.420000000000002 112.031 -178.55 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -128.27 136.03 50.46 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 108.19 -1.041 . . . . 73.340000000000003 108.19 169.356 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.409 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -146.54 142.78 17.75 Favored Pre-proline 0 C--N 1.319 -0.724 0 C-N-CA 121.011 -0.275 . . . . 73.329999999999998 111.335 -174.803 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 18.8 Cg_exo -67.25 172.67 9.72 Favored 'Trans proline' 0 CA--C 1.53 0.306 0 C-N-CA 122.841 2.361 . . . . 70.099999999999994 112.239 178.269 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 27.0 m -89.68 11.47 19.76 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.66 0.743 . . . . 73.239999999999995 110.374 179.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -135.18 102.99 0.45 Allowed Glycine 0 N--CA 1.442 -0.957 0 N-CA-C 110.108 -1.197 . . . . 75.109999999999999 110.108 177.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -119.99 94.71 48.81 Favored Pre-proline 0 C--N 1.319 -0.743 0 CA-C-O 121.261 0.553 . . . . 74.329999999999998 110.401 -175.069 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.869 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 51.6 Cg_endo -77.56 81.79 2.57 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 121.913 1.742 . . . . 74.340000000000003 111.265 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -100.48 168.26 9.85 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.339 -0.615 . . . . 73.450000000000003 109.339 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.66 HG21 ' HB3' ' A' ' 24' ' ' GLN . 8.3 p -125.65 131.41 72.06 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-O 121.253 0.549 . . . . 55.140000000000001 111.387 -175.177 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.5 m -89.51 121.14 31.44 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.679 -0.691 . . . . 72.540000000000006 109.423 176.34 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 52.9 mt -91.58 109.09 20.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 120.834 0.349 . . . . 72.040000000000006 111.161 -175.382 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 38.3 mmt180 -105.51 165.7 10.96 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 73.319999999999993 109.867 176.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 40.1 mt-30 -138.95 122.57 17.43 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.768 0.318 . . . . 75.349999999999994 111.147 177.007 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -124.97 96.93 5.05 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.793 -0.639 . . . . 73.040000000000006 109.524 176.212 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.24 -106.49 1.8 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.476 -0.869 . . . . 75.349999999999994 111.719 -178.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.58 ' HB3' ' HB2' ' A' ' 40' ' ' LYS . 7.0 m-20 -111.35 6.26 20.31 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 121.156 -0.217 . . . . 62.310000000000002 111.537 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.656 ' HB3' ' HB3' ' A' ' 39' ' ' PRO . 0.0 OUTLIER -110.94 122.49 48.01 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 119.917 -0.713 . . . . 74.329999999999998 111.472 177.422 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.44 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 42.4 m -83.42 101.28 11.26 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 114.961 -1.018 . . . . 70.150000000000006 108.983 173.174 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.455 HG12 HG11 ' A' ' 37' ' ' VAL . 61.3 mt -90.82 109.86 21.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.153 0.502 . . . . 74.209999999999994 110.291 -175.789 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.66 ' HB3' HG21 ' A' ' 13' ' ' VAL . 14.6 mt-30 -99.78 119.45 38.18 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.787 -0.642 . . . . 73.219999999999999 111.021 -175.562 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -94.31 108.73 20.6 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.825 -0.625 . . . . 75.129999999999995 110.559 -178.001 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.521 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 33.5 m-85 -86.62 114.82 23.65 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.923 0.392 . . . . 75.120000000000005 111.051 -179.587 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.421 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 68.3 mtm180 -131.03 126.64 36.43 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.018 -0.537 . . . . 73.120000000000005 110.416 179.295 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.869 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.3 p -91.07 -28.83 4.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.063 -0.517 . . . . 74.219999999999999 111.242 -176.52 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -173.61 69.68 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.626 -0.509 . . . . 73.209999999999994 109.626 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.98 -24.59 5.19 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.817 -0.629 . . . . 74.409999999999997 112.642 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.63 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 88.4 t80 -97.26 128.43 44.11 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.869 0.366 . . . . 75.25 111.057 -176.2 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.599 HD12 HG13 ' A' ' 35' ' ' ILE . 3.2 tm? -79.24 109.73 13.85 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.803 -0.814 . . . . 72.400000000000006 108.803 175.194 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 41.7 p90 -106.0 -13.87 15.35 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.513 -0.475 . . . . 63.32 111.467 -176.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -162.11 149.49 14.12 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.069 0.461 . . . . 74.319999999999993 111.62 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.599 HG13 HD12 ' A' ' 32' ' ' LEU . 70.1 mt -126.07 128.12 71.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.659 -0.701 . . . . 72.510000000000005 109.681 174.669 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.61 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 81.5 tttt -112.01 105.15 13.47 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.306 -0.406 . . . . 74.530000000000001 110.084 179.159 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.708 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 4.4 t -89.64 126.71 42.55 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 108.765 -0.828 . . . . 74.140000000000001 108.765 177.379 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.44 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 20.1 t -114.43 73.98 2.91 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 109.883 -0.414 . . . . 75.450000000000003 109.883 172.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.689 ' HD3' HG12 ' A' ' 37' ' ' VAL . 39.8 Cg_endo -77.52 132.11 11.99 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.094 1.862 . . . . 65.420000000000002 112.648 176.377 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.58 ' HB2' ' HB3' ' A' ' 20' ' ' ASP . 50.4 mtpt -60.76 -28.22 68.55 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.535 -0.757 . . . . 73.340000000000003 110.316 175.24 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 74.2 m-70 -118.03 94.63 4.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.325 -0.852 . . . . 75.150000000000006 108.763 178.026 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.418 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 134.04 -31.22 2.84 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.492 -0.776 . . . . 73.319999999999993 111.544 -175.038 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.469 ' HA ' ' HD3' ' A' ' 43' ' ' LYS . 31.5 mmtp 74.23 153.65 0.15 Allowed Pre-proline 0 N--CA 1.469 0.501 0 C-N-CA 123.557 0.743 . . . . 72.430000000000007 112.254 177.243 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.708 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 28.3 Cg_endo -62.86 132.52 37.54 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 123.074 2.516 . . . . 74.340000000000003 114.2 -173.485 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -140.0 154.55 47.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.456 -0.793 . . . . 72.129999999999995 109.884 175.364 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -107.01 136.98 45.95 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-O 120.763 0.316 . . . . 73.420000000000002 111.574 -175.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.582 HD23 ' HA ' ' A' ' 59' ' ' ARG . 47.7 mt -118.38 107.78 14.25 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.851 -0.613 . . . . 75.030000000000001 109.858 171.431 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 47.3 t -95.46 134.92 31.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.628 -0.26 . . . . 63.43 110.398 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.626 ' HD2' ' HA ' ' A' ' 53' ' ' SER . 16.1 tpp85 -68.7 122.04 17.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.808 0.337 . . . . 75.140000000000001 110.123 177.211 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -73.6 158.35 34.95 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.136 -0.483 . . . . 74.25 110.784 179.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -53.49 143.55 19.26 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 115.765 -0.652 . . . . 63.140000000000001 111.194 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.28 -33.84 5.36 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.772 -0.728 . . . . 73.219999999999999 111.99 -178.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.626 ' HA ' ' HD2' ' A' ' 49' ' ' ARG . 17.4 t 63.02 38.3 11.06 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-O 121.009 0.433 . . . . 75.129999999999995 110.992 178.776 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -76.44 -3.67 38.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.526 0.679 . . . . 73.349999999999994 110.815 -178.468 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 111.54 2.53 27.46 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.617 -0.801 . . . . 54.200000000000003 111.692 -179.038 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -85.89 134.59 33.89 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.051 0.453 . . . . 73.219999999999999 110.497 178.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -116.04 144.19 44.45 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.82 -0.627 . . . . 72.409999999999997 110.109 176.095 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.2 mm -105.75 105.43 18.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 CA-C-O 121.564 0.697 . . . . 73.219999999999999 109.368 176.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.699 ' HB2' HG13 ' A' ' 67' ' ' ILE . 24.0 ttt180 -69.56 119.78 14.34 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 114.631 -1.168 . . . . 71.540000000000006 109.461 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.5 t -63.05 -18.56 63.49 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.396 0.617 . . . . 71.219999999999999 110.404 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.674 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 24.7 t70 -73.96 -28.42 61.48 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.449 -0.796 . . . . 74.5 110.489 175.61 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -142.79 68.5 19.09 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-N 115.424 -0.807 . . . . 65.140000000000001 109.191 -177.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.487 ' HG3' ' HG ' ' B' ' 160' ' ' SER . 7.3 Cg_exo -71.06 -11.5 29.18 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 123.256 2.637 . . . . 75.230000000000004 112.998 -171.757 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -95.47 4.76 52.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.493 0.663 . . . . 73.219999999999999 109.758 -178.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -131.96 137.35 47.88 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.6 -0.727 . . . . 70.549999999999997 110.753 -178.038 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.475 ' N ' HD13 ' A' ' 66' ' ' LEU . 4.5 mp -85.02 131.44 34.46 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.049 -0.523 . . . . 75.120000000000005 109.65 179.678 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.699 HG13 ' HB2' ' A' ' 59' ' ' ARG . 40.6 mm -89.71 129.1 47.95 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-O 120.933 0.397 . . . . 71.510000000000005 111.305 -174.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -76.28 176.59 9.86 Favored 'Trans proline' 0 N--CA 1.459 -0.505 0 C-N-CA 122.862 2.374 . . . . 71.439999999999998 112.514 178.15 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . 0.671 ' HA ' HG12 ' A' ' 72' ' ' ILE . 6.4 tt0 -79.41 -31.62 42.72 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.61 -0.723 . . . . 74.109999999999999 112.184 -170.653 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 28.3 p90 -69.42 -19.39 63.8 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 120.184 -0.607 . . . . 71.530000000000001 110.384 178.421 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -84.84 -35.45 22.26 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.852 -0.613 . . . . 73.239999999999995 110.179 178.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.671 HG12 ' HA ' ' A' ' 69' ' ' GLN . 41.2 pt -76.24 -21.79 15.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.116 0 CA-C-O 120.965 0.412 . . . . 74.420000000000002 110.878 179.843 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 31.4 m-85 -103.63 28.47 6.52 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.077 -0.511 . . . . 74.120000000000005 110.926 176.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 11.1 t -84.93 45.22 1.14 Allowed 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.864 0.84 . . . . 71.219999999999999 109.616 178.352 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 11.3 m0 . . . . . 0 C--N 1.324 -0.521 0 CA-C-N 115.124 -0.944 . . . . 74.450000000000003 110.729 -178.83 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 112.439 -0.264 . . . . 65.209999999999994 112.439 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -86.78 96.67 10.26 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 120.698 0.285 . . . . 72.439999999999998 111.099 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -73.89 110.91 8.56 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.75 -0.463 . . . . 53.219999999999999 109.75 175.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -100.72 32.86 2.96 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.598 0.713 . . . . 70.019999999999996 110.828 -174.507 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -84.75 95.55 8.98 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.191 -0.67 . . . . 72.319999999999993 109.191 176.146 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -108.68 111.13 61.23 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-O 120.926 0.393 . . . . 71.120000000000005 111.329 -175.199 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -83.8 159.08 14.04 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.638 2.225 . . . . 65.349999999999994 111.61 176.171 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 6.3 p -75.75 96.47 3.65 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.041 0.448 . . . . 74.420000000000002 109.998 176.721 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 128.05 76.89 0.21 Allowed Glycine 0 N--CA 1.445 -0.701 0 N-CA-C 110.891 -0.884 . . . . 74.049999999999997 110.891 -175.555 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -110.16 105.77 57.47 Favored Pre-proline 0 C--N 1.32 -0.703 0 N-CA-C 109.138 -0.69 . . . . 71.040000000000006 109.138 -175.371 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.758 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 46.1 Cg_endo -82.23 86.35 1.54 Allowed 'Trans proline' 0 N--CA 1.439 -1.734 0 C-N-CA 121.898 1.732 . . . . 70.230000000000004 110.959 -178.021 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -101.81 155.63 18.02 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 114.258 -1.337 . . . . 74.010000000000005 109.92 -175.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.594 ' HA ' ' O ' ' B' ' 125' ' ' GLU . 7.6 p -117.65 130.71 72.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.474 0.655 . . . . 75.430000000000007 111.104 -177.707 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 52.0 m -104.7 122.05 44.85 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.401 -0.818 . . . . 65.420000000000002 109.996 178.636 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 47.3 mt -87.09 108.03 17.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 116.145 -0.479 . . . . 72.129999999999995 111.443 -174.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -101.15 170.73 8.06 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.469 -0.567 . . . . 65.409999999999997 109.469 175.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -142.76 138.76 30.7 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.782 0.325 . . . . 75.109999999999999 110.786 175.532 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -135.52 104.58 5.87 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.638 -0.71 . . . . 75.109999999999999 109.754 176.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.62 -110.14 3.31 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.908 -0.663 . . . . 73.129999999999995 111.898 -177.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . 0.598 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 9.5 m-20 -97.06 -19.33 18.79 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.705 0.288 . . . . 74.200000000000003 110.977 -179.147 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.586 ' HB3' ' HA ' ' B' ' 139' ' ' PRO . 49.3 pttt -100.88 141.75 33.33 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.6 0.714 . . . . 74.120000000000005 112.503 -170.088 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 122' ' ' THR . . . . . 0.588 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 47.9 m -91.77 138.43 31.56 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 114.828 -1.078 . . . . 73.409999999999997 109.646 176.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 65.9 mt -124.89 106.56 16.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 120.984 0.421 . . . . 71.430000000000007 110.276 -178.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.542 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 18.7 mt-30 -96.91 117.19 30.57 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.918 0.39 . . . . 64.25 111.092 -176.081 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . 0.594 ' O ' ' HA ' ' B' ' 113' ' ' VAL . 43.2 mt-10 -83.02 114.15 21.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.736 -0.665 . . . . 74.230000000000004 110.947 179.299 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . 0.433 ' HB2' ' O ' ' B' ' 134' ' ' ALA . 41.2 m-85 -92.75 97.33 10.71 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.493 -0.558 . . . . 70.239999999999995 109.493 170.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . 0.445 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 21.8 mtm105 -121.08 127.41 51.63 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.803 -0.635 . . . . 74.040000000000006 110.071 179.375 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.758 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 6.0 p -87.97 -37.5 10.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.097 0.475 . . . . 71.540000000000006 110.834 -176.541 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -160.27 62.86 0.33 Allowed 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.292 0.568 . . . . 73.099999999999994 109.69 -178.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.0 -26.57 6.63 Favored Glycine 0 N--CA 1.446 -0.664 0 CA-C-N 115.404 -0.816 . . . . 70.409999999999997 112.734 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -99.12 130.81 45.46 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.014 0.435 . . . . 72.129999999999995 110.56 -175.342 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.766 HD12 HG13 ' B' ' 135' ' ' ILE . 3.2 tm? -78.06 118.62 20.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.263 -0.881 . . . . 72.409999999999997 109.615 178.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . 0.402 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 51.4 p90 -109.3 -22.27 12.14 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 120.748 -0.381 . . . . 75.319999999999993 111.34 178.24 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . 0.433 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -156.14 147.81 22.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.39 . . . . 75.239999999999995 111.12 179.517 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.766 HG13 HD12 ' B' ' 132' ' ' LEU . 75.4 mt -125.47 130.68 72.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.152 -0.476 . . . . 65.239999999999995 109.723 175.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.542 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 46.6 tttp -106.46 106.82 17.52 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.383 -0.599 . . . . 74.349999999999994 109.383 174.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.676 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.0 t -91.51 136.05 25.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 N-CA-C 109.024 -0.732 . . . . 74.129999999999995 109.024 178.583 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.588 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 22.0 t -121.85 73.33 34.29 Favored Pre-proline 0 C--N 1.318 -0.762 0 N-CA-C 109.483 -0.562 . . . . 75.109999999999999 109.483 173.298 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.591 ' HD3' HG13 ' B' ' 137' ' ' VAL . 53.2 Cg_endo -78.52 134.64 12.57 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 122.183 1.922 . . . . 74.450000000000003 112.931 176.601 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . 0.598 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 30.8 mtpp -62.94 -30.93 71.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.638 0.732 . . . . 71.430000000000007 109.547 174.222 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 72.8 m-70 -112.99 89.89 3.2 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.043 -0.981 . . . . 75.120000000000005 109.392 176.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 138.7 -21.52 3.04 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.621 -0.8 . . . . 75.299999999999997 112.328 -178.207 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 33.4 mmtp 69.59 150.8 0.13 Allowed Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 123.2 0.6 . . . . 73.409999999999997 111.524 178.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.676 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 19.3 Cg_endo -59.8 140.3 92.6 Favored 'Trans proline' 0 C--O 1.235 0.336 0 C-N-CA 122.575 2.183 . . . . 75.540000000000006 113.278 -177.244 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 38.9 p90 -155.33 151.06 27.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.924 -0.58 . . . . 74.310000000000002 110.307 178.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.485 ' HB2' ' HB2' ' B' ' 160' ' ' SER . 87.2 m-85 -95.35 139.32 31.82 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.171 -0.468 . . . . 75.319999999999993 111.166 179.453 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . 0.404 ' HB3' ' CD2' ' B' ' 157' ' ' PHE . 39.5 mt -116.27 110.29 18.55 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.634 -0.712 . . . . 74.439999999999998 109.693 170.316 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 41.7 t -95.23 132.91 37.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.579 -0.282 . . . . 74.219999999999999 110.953 -178.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . 0.405 HH11 ' HG2' ' B' ' 149' ' ' ARG . 17.0 tpp85 -70.46 113.63 7.77 Favored 'General case' 0 N--CA 1.452 -0.338 0 N-CA-C 109.895 -0.409 . . . . 74.319999999999993 109.895 175.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.65 155.44 35.91 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 116.094 -0.503 . . . . 74.239999999999995 111.202 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . 0.521 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 3.4 p-10 -56.9 138.79 53.31 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.551 -0.749 . . . . 72.0 112.132 -177.418 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 93.74 -11.24 71.46 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.213 -0.903 . . . . 65.5 112.648 176.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 2.3 t 57.58 50.33 11.19 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-O 121.692 0.758 . . . . 72.400000000000006 109.391 -177.618 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -73.51 -8.45 55.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 114.885 -1.052 . . . . 72.450000000000003 111.876 -175.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 90.96 18.32 47.66 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.5 -0.857 . . . . 63.439999999999998 111.175 -174.089 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . 0.633 HD22 HD21 ' B' ' 166' ' ' LEU . 36.5 t30 -119.88 137.47 54.0 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.914 -0.643 . . . . 73.400000000000006 110.058 -178.322 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . 0.404 ' CD2' ' HB3' ' B' ' 147' ' ' LEU . 42.3 m-85 -113.56 159.93 19.07 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.167 -0.469 . . . . 75.439999999999998 110.166 177.666 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . 0.684 HD13 HD23 ' B' ' 166' ' ' LEU . 45.7 mm -121.9 119.07 57.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 109.442 -0.577 . . . . 75.310000000000002 109.442 175.061 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . . . . . . . . . 36.2 mtt180 -71.14 140.16 50.49 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.213 -0.448 . . . . 75.040000000000006 110.09 176.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 160' ' ' SER . . . . . 0.487 ' HG ' ' HG3' ' A' ' 63' ' ' PRO . 7.4 t -80.82 1.06 32.21 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.617 -0.883 . . . . 64.549999999999997 108.617 169.702 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -98.53 -23.12 15.65 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.561 -1.199 . . . . 73.219999999999999 109.884 174.567 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -144.71 67.83 14.24 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 115.099 -0.955 . . . . 73.109999999999999 109.559 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -75.34 -12.97 20.86 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 123.162 2.575 . . . . 73.319999999999993 113.346 -173.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -87.89 -12.5 44.6 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.581 0.705 . . . . 65.519999999999996 109.504 178.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 48.8 mtpt -105.46 170.45 7.88 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.406 -0.815 . . . . 75.099999999999994 111.459 -177.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . 0.684 HD23 HD13 ' B' ' 158' ' ' ILE . 17.8 mt -117.48 125.46 50.93 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.423 -0.954 . . . . 73.439999999999998 108.423 177.21 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . 0.529 ' CG2' ' HB3' ' B' ' 171' ' ' GLU . 36.5 mm -80.95 116.37 62.01 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-O 121.275 0.56 . . . . 75.450000000000003 111.835 -169.798 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.53 -179.46 2.82 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.58 2.853 . . . . 74.239999999999995 112.781 -178.227 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . 0.795 ' HA ' HG12 ' B' ' 172' ' ' ILE . 3.7 tt0 -79.23 -32.35 43.87 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.07 -0.514 . . . . 71.099999999999994 111.386 -170.367 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 11.4 p90 -68.21 -17.09 64.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.088 0.471 . . . . 74.140000000000001 110.231 178.09 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.529 ' HB3' ' CG2' ' B' ' 167' ' ' ILE . 1.2 tm-20 -91.12 -43.69 9.73 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.577 -0.738 . . . . 73.530000000000001 110.211 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.795 HG12 ' HA ' ' B' ' 169' ' ' GLN . 44.1 pt -68.61 -25.35 30.62 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.168 -0.469 . . . . 74.540000000000006 111.06 -179.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . 0.458 ' C ' ' H ' ' B' ' 175' ' ' TRP . 30.9 m-85 -111.14 30.45 6.88 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.18 0.514 . . . . 73.099999999999994 110.563 176.617 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 25.1 t -79.03 22.44 0.39 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.866 -0.607 . . . . 73.040000000000006 110.652 178.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . 0.458 ' H ' ' C ' ' B' ' 173' ' ' PHE . 12.9 m95 . . . . . 0 C--O 1.248 1.018 0 CA-C-O 118.271 -0.871 . . . . 73.409999999999997 110.509 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.622 0 N-CA-C 112.043 -0.423 . . . . 71.329999999999998 112.043 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -157.18 123.54 4.92 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.806 0.303 . . . . 74.230000000000004 111.255 -178.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 33.4 t70 74.43 -49.84 0.67 Allowed 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 123.868 0.867 . . . . 62.530000000000001 111.999 174.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -78.4 109.76 12.84 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.808 -0.441 . . . . 71.019999999999996 109.808 177.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.606 ' O ' ' HD3' ' A' ' 7' ' ' PRO . 24.1 m-20 -87.57 -163.26 0.91 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.459 -0.337 . . . . 72.349999999999994 110.659 179.673 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.407 ' H ' ' HB3' ' A' ' 5' ' ' ASP . . . -106.5 96.15 13.35 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-O 120.753 0.311 . . . . 73.519999999999996 111.686 -176.225 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.606 ' HD3' ' O ' ' A' ' 5' ' ' ASP . 12.4 Cg_endo -92.38 117.38 0.4 Allowed 'Trans proline' 0 N--CA 1.45 -1.066 0 C-N-CA 123.301 2.667 . . . . 74.340000000000003 112.209 177.0 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 20.3 m -71.35 119.35 15.36 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.567 -0.531 . . . . 72.420000000000002 109.567 174.804 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.461 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 95.42 70.19 1.06 Allowed Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 110.53 -1.028 . . . . 74.5 110.53 -173.129 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -98.48 102.65 15.12 Favored Pre-proline 0 C--N 1.325 -0.482 0 N-CA-C 109.348 -0.612 . . . . 64.420000000000002 109.348 -177.321 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.546 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 53.4 Cg_endo -91.14 97.24 0.23 Allowed 'Trans proline' 0 N--CA 1.441 -1.571 0 C-N-CA 122.572 2.181 . . . . 64.0 112.135 -175.008 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -103.05 114.18 28.27 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-N 115.365 -0.834 . . . . 74.109999999999999 109.859 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.621 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 9.1 p -77.1 127.12 38.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 CA-C-N 115.681 -0.69 . . . . 74.409999999999997 109.97 179.478 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.638 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 24.5 m -84.22 103.1 13.14 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.848 -0.614 . . . . 72.030000000000001 110.078 -178.063 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 65.5 mt -90.84 107.95 19.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.06 -0.518 . . . . 74.019999999999996 110.571 -176.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . 0.499 ' HG2' ' O ' ' A' ' 23' ' ' ILE . 12.7 ptm180 -121.96 174.4 6.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.871 -0.604 . . . . 75.299999999999997 109.786 179.066 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -133.08 104.38 6.49 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 116.223 -0.444 . . . . 72.540000000000006 110.089 -177.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 58.5 mm-40 -103.49 80.1 1.77 Allowed 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 120.969 0.414 . . . . 75.099999999999994 110.205 -178.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 78.35 -106.16 2.27 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.797 -0.716 . . . . 72.549999999999997 112.428 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.891 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 6.9 m-20 -108.63 34.88 3.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.792 0.329 . . . . 74.120000000000005 110.831 -178.249 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.817 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 20.5 pttm -154.2 124.04 6.73 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.157 0.503 . . . . 75.140000000000001 111.46 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.436 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 62.3 m -82.02 105.89 13.49 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.624 -0.716 . . . . 74.340000000000003 109.36 174.036 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.572 HG12 HG11 ' A' ' 37' ' ' VAL . 61.1 mt -97.59 113.68 32.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.046 0.45 . . . . 72.439999999999998 110.687 -176.484 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.672 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 17.9 mt-30 -100.58 109.19 21.26 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.738 -0.664 . . . . 71.230000000000004 110.329 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.638 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.1 mt-10 -91.69 104.25 16.74 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.064 -0.517 . . . . 74.329999999999998 110.853 -178.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.541 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 54.0 m-85 -73.26 106.73 5.22 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.174 -0.467 . . . . 74.230000000000004 110.753 179.463 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.44 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 59.9 mtt180 -129.24 133.7 47.64 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.552 -0.536 . . . . 74.230000000000004 109.552 177.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.546 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 6.4 p -104.34 -41.47 6.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 121.272 0.558 . . . . 74.340000000000003 110.721 -179.105 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 54.5 m-20 -140.94 56.83 1.56 Allowed 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.708 -0.678 . . . . 74.040000000000006 109.626 178.463 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.21 -32.67 4.04 Favored Glycine 0 N--CA 1.451 -0.322 0 CA-C-N 115.385 -0.825 . . . . 72.430000000000007 113.242 177.614 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -90.32 132.2 35.69 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.001 0.429 . . . . 74.430000000000007 110.654 -174.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.556 HD11 ' HB3' ' A' ' 25' ' ' GLU . 33.2 tp -77.92 114.3 16.64 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.395 -0.82 . . . . 63.43 110.599 179.306 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . 0.517 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 35.4 p90 -106.34 -6.64 18.18 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.774 -0.37 . . . . 74.129999999999995 111.809 -178.376 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -171.84 142.91 1.57 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.842 0.353 . . . . 74.439999999999998 111.256 -178.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.444 HD11 HD21 ' A' ' 47' ' ' LEU . 61.9 mt -117.77 127.4 75.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.249 -0.432 . . . . 72.420000000000002 110.179 176.089 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.672 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.8 tttt -111.65 103.48 11.79 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 109.446 -0.576 . . . . 73.329999999999998 109.446 175.036 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.754 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 3.7 t -96.77 134.52 34.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 N-CA-C 109.309 -0.626 . . . . 53.310000000000002 109.309 -178.551 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.625 HG23 ' HB3' ' A' ' 44' ' ' PRO . 21.7 t -114.22 74.21 2.8 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 109.317 -0.623 . . . . 75.299999999999997 109.317 170.759 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.478 ' HD3' HG12 ' A' ' 37' ' ' VAL . 42.4 Cg_endo -74.0 142.81 31.79 Favored 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 122.039 1.826 . . . . 74.129999999999995 112.764 179.118 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.891 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 61.0 mtpt -64.39 -17.13 63.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.134 -0.939 . . . . 71.129999999999995 110.913 176.72 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -128.99 88.3 2.69 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.662 -0.699 . . . . 74.540000000000006 110.215 -178.643 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.404 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 135.23 -16.06 4.18 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.288 -0.958 . . . . 74.430000000000007 113.203 179.202 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.54 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 99.5 mttt 71.79 160.03 0.16 Allowed Pre-proline 0 N--CA 1.472 0.626 0 C-N-CA 122.755 0.422 . . . . 74.319999999999993 111.469 179.507 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.754 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 26.2 Cg_endo -63.57 141.62 80.82 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 122.491 2.127 . . . . 64.340000000000003 113.716 -176.48 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -145.71 155.23 42.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.717 -0.674 . . . . 75.129999999999995 110.212 177.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -99.72 132.91 44.76 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.305 -0.407 . . . . 74.120000000000005 110.994 178.144 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.444 HD21 HD11 ' A' ' 35' ' ' ILE . 40.1 tp -121.07 98.81 6.16 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.686 -0.688 . . . . 74.030000000000001 109.345 176.171 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 25.0 t -87.98 146.99 5.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.396 -0.366 . . . . 74.150000000000006 111.358 -172.205 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 10.0 tpt180 -81.23 122.92 28.01 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.848 -0.427 . . . . 73.319999999999993 109.848 177.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.417 ' HB1' ' OD1' ' A' ' 56' ' ' ASN . . . -74.86 161.94 29.1 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.208 -0.451 . . . . 73.230000000000004 110.862 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -66.78 145.54 55.4 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.135 0.493 . . . . 72.439999999999998 110.957 -177.6 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 88.67 -25.17 9.94 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.863 -0.608 . . . . 64.540000000000006 112.487 177.6 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 57.2 p 47.75 43.9 17.29 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.459 0.704 . . . . 74.420000000000002 112.058 -179.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -68.0 -33.0 73.79 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.453 0.644 . . . . 74.420000000000002 110.919 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 147.99 41.58 0.04 OUTLIER Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.582 -1.007 . . . . 61.409999999999997 110.582 -178.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . 0.417 ' OD1' ' HB1' ' A' ' 50' ' ' ALA . 11.5 p30 -140.52 152.65 45.73 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.18 0.514 . . . . 75.049999999999997 111.078 -172.805 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 36.3 m-85 -134.23 157.5 46.11 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.511 -0.768 . . . . 74.010000000000005 109.566 175.444 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.807 HD11 HD22 ' A' ' 66' ' ' LEU . 45.2 mm -115.23 108.07 24.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.253 0.549 . . . . 74.510000000000005 109.668 176.324 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.588 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 50.2 ttp180 -89.31 133.37 34.51 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.811 -0.631 . . . . 73.099999999999994 109.952 -177.057 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.1 p -58.21 -25.57 61.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.15 0.5 . . . . 74.219999999999999 111.168 178.644 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.588 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 0.6 OUTLIER -59.55 -39.13 83.0 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.508 -0.769 . . . . 75.230000000000004 111.379 174.275 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 21.5 tp60 -147.91 79.68 9.16 Favored Pre-proline 0 C--N 1.326 -0.454 0 N-CA-C 109.827 -0.434 . . . . 64.319999999999993 109.827 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -73.8 -8.0 20.81 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.381 2.054 . . . . 75.230000000000004 111.52 179.553 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.05 3.06 36.24 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.118 -0.946 . . . . 71.340000000000003 110.084 178.382 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -139.37 140.06 37.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.043 -0.526 . . . . 73.400000000000006 111.022 -174.291 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.807 HD22 HD11 ' A' ' 58' ' ' ILE . 38.1 mt -82.08 113.1 19.72 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 108.581 -0.896 . . . . 75.030000000000001 108.581 171.807 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.484 HG13 ' HB2' ' A' ' 59' ' ' ARG . 50.1 mm -65.34 122.76 81.78 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 116.271 -0.422 . . . . 73.109999999999999 110.964 -175.566 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.49 ' O ' HG23 ' A' ' 72' ' ' ILE . 72.8 Cg_endo -73.27 175.12 11.0 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 123.106 2.537 . . . . 73.209999999999994 113.014 -177.695 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . 0.722 ' HA ' HG12 ' A' ' 72' ' ' ILE . 6.7 tt0 -74.65 -29.5 61.28 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.693 -0.685 . . . . 75.25 112.323 -168.07 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 33.6 p90 -74.45 -16.23 60.87 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.598 -0.441 . . . . 74.510000000000005 110.23 178.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.463 ' HA ' ' HB2' ' A' ' 74' ' ' SER . 8.3 mm-40 -100.0 -29.29 12.63 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.727 -0.67 . . . . 74.430000000000007 111.615 -178.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.722 HG12 ' HA ' ' A' ' 69' ' ' GLN . 42.0 pt -68.22 -29.44 44.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.148 0.499 . . . . 73.140000000000001 110.595 177.188 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 48.5 m-85 -118.82 38.69 3.71 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.735 -0.666 . . . . 73.340000000000003 109.267 174.27 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.463 ' HB2' ' HA ' ' A' ' 71' ' ' GLU . 6.1 t -62.49 -36.38 82.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.35 -0.841 . . . . 74.239999999999995 110.461 -178.758 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . 0.817 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 6.1 p-90 . . . . . 0 C--N 1.326 -0.443 0 CA-C-N 115.93 -0.577 . . . . 72.310000000000002 110.948 177.289 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.282 0 N-CA-C 112.22 -0.352 . . . . 74.439999999999998 112.22 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -132.14 157.22 44.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.717 0.294 . . . . 74.230000000000004 110.776 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -87.41 37.58 0.79 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.081 0.467 . . . . 74.430000000000007 110.968 -178.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -97.16 151.24 20.0 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.77 -0.65 . . . . 75.140000000000001 109.977 -179.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -144.98 48.94 1.29 Allowed 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.246 0.546 . . . . 62.530000000000001 109.968 -179.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -65.94 127.01 92.85 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.653 -0.703 . . . . 71.409999999999997 111.877 -177.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -91.41 -178.84 1.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.487 0 C-N-CA 123.237 2.624 . . . . 74.209999999999994 112.355 177.493 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 35.0 m -81.77 83.43 7.14 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.605 0.717 . . . . 74.439999999999998 109.128 174.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 140.07 78.08 0.06 OUTLIER Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 109.965 -1.254 . . . . 60.409999999999997 109.965 -172.108 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -109.72 94.77 17.71 Favored Pre-proline 0 C--N 1.322 -0.6 0 N-CA-C 109.693 -0.484 . . . . 65.349999999999994 109.693 -172.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.594 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 54.9 Cg_endo -77.36 79.01 3.29 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 C-N-CA 121.538 1.492 . . . . 73.209999999999994 111.031 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -100.24 156.37 17.26 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 114.747 -1.115 . . . . 74.400000000000006 109.184 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.702 HG21 ' HB3' ' B' ' 124' ' ' GLN . 8.8 p -112.94 127.76 70.02 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.812 0 CA-C-O 121.72 0.771 . . . . 74.109999999999999 111.738 -175.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 114' ' ' THR . . . . . 0.523 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.3 m -92.01 106.94 18.85 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.022 -0.99 . . . . 75.129999999999995 109.529 175.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.8 mt -90.8 115.5 30.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 120.699 0.285 . . . . 62.539999999999999 111.274 -175.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 41.4 mtm180 -115.39 165.81 12.56 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.178 -0.465 . . . . 74.349999999999994 110.712 175.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 96.8 mt-30 -129.44 108.79 10.55 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.197 -0.456 . . . . 74.299999999999997 110.18 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . 0.441 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 45.8 mm-40 -108.4 89.88 3.13 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.551 -0.536 . . . . 65.109999999999999 109.551 -178.441 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 83.68 -102.95 2.5 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 110.929 -0.869 . . . . 72.129999999999995 110.929 -172.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . 0.546 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 30.8 m-20 -117.73 -18.17 9.69 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.756 0.312 . . . . 74.230000000000004 110.784 175.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.441 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 23.4 pttm -78.36 126.73 31.19 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.257 0.551 . . . . 71.310000000000002 110.861 -175.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 122' ' ' THR . . . . . 0.581 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 22.8 m -84.72 106.34 16.19 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.502 -0.772 . . . . 72.430000000000007 109.468 178.085 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . 0.429 HG12 HG12 ' B' ' 137' ' ' VAL . 28.4 mt -101.42 110.37 28.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 121.374 0.607 . . . . 74.450000000000003 110.631 -174.685 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.702 ' HB3' HG21 ' B' ' 113' ' ' VAL . 19.9 mt-30 -102.29 111.54 23.87 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.354 -0.839 . . . . 75.040000000000006 111.144 -175.511 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . 0.557 ' HB3' HD12 ' B' ' 132' ' ' LEU . 43.0 mt-10 -89.79 107.84 19.34 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.13 -0.486 . . . . 64.530000000000001 110.948 179.764 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . 0.439 ' HE1' ' HB2' ' B' ' 136' ' ' LYS . 58.3 m-85 -84.44 110.9 19.0 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.767 0.318 . . . . 74.299999999999997 110.338 177.553 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 69.6 mtt180 -123.42 116.13 22.73 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.844 0.354 . . . . 74.120000000000005 110.31 -178.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.594 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.4 p -82.83 -45.71 19.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.065 -0.516 . . . . 75.540000000000006 111.904 -177.434 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -158.99 74.08 0.63 Allowed 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 120.742 -0.383 . . . . 74.239999999999995 110.319 -174.243 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 64.2 23.81 68.36 Favored Glycine 0 C--N 1.33 0.232 0 C-N-CA 121.028 -0.606 . . . . 41.240000000000002 112.065 -178.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -145.91 124.93 12.78 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.876 -0.416 . . . . 72.430000000000007 109.876 -179.236 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.557 HD12 ' HB3' ' B' ' 125' ' ' GLU . 50.0 tp -83.06 113.01 20.31 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.791 -0.64 . . . . 74.299999999999997 109.569 175.781 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -103.12 -13.73 16.69 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.32 -0.552 . . . . 72.409999999999997 111.728 -175.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -164.94 139.81 5.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.087 0.47 . . . . 74.5 111.397 -175.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.402 ' CG1' HD22 ' B' ' 132' ' ' LEU . 63.6 mt -118.02 117.85 56.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.693 -0.685 . . . . 63.539999999999999 109.846 175.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.598 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 81.3 tttt -93.62 103.92 16.06 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.184 -0.673 . . . . 75.349999999999994 109.184 175.481 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.643 HG13 ' HD3' ' B' ' 139' ' ' PRO . 3.5 t -89.12 126.51 42.12 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 N-CA-C 108.785 -0.82 . . . . 64.430000000000007 108.785 177.299 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.581 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.5 t -113.67 74.47 2.38 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 109.543 -0.54 . . . . 72.219999999999999 109.543 171.647 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.643 ' HD3' HG13 ' B' ' 137' ' ' VAL . 43.3 Cg_endo -77.17 130.01 10.85 Favored 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.105 1.87 . . . . 75.0 111.892 175.815 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . 0.546 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 59.2 mtpt -58.36 -38.58 77.53 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.661 -0.699 . . . . 74.239999999999995 109.776 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 70.3 m-70 -111.81 90.32 3.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.282 -0.872 . . . . 73.299999999999997 109.385 175.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . 0.423 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 151.98 -22.71 0.89 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.54 -0.838 . . . . 61.240000000000002 112.704 -178.587 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . 0.423 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 95.2 mttt 76.48 144.65 0.1 Allowed Pre-proline 0 N--CA 1.472 0.638 0 C-N-CA 123.419 0.688 . . . . 75.340000000000003 111.258 179.177 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.598 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 55.5 Cg_endo -70.57 139.05 36.56 Favored 'Trans proline' 0 N--CA 1.463 -0.285 0 C-N-CA 122.865 2.376 . . . . 74.430000000000007 112.983 -177.059 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 45.4 p90 -152.39 160.03 43.34 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.895 -0.593 . . . . 75.319999999999993 110.322 179.114 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . 0.659 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 96.5 m-85 -100.59 133.29 45.26 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.192 -0.458 . . . . 73.310000000000002 109.959 177.786 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . 0.498 ' HG ' ' HB3' ' B' ' 157' ' ' PHE . 14.1 tp -115.46 100.84 8.37 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.386 -0.598 . . . . 72.200000000000003 109.386 175.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 49.1 t -92.55 140.56 16.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 116.061 -0.518 . . . . 72.519999999999996 111.347 -173.185 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -80.37 116.37 20.4 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.549 -0.296 . . . . 64.430000000000007 110.261 177.376 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.56 157.55 32.04 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-N 116.218 -0.447 . . . . 71.319999999999993 111.201 -179.423 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . 0.541 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 3.8 p-10 -57.45 143.48 40.28 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.96 -0.564 . . . . 74.329999999999998 110.855 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.43 -33.73 4.03 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.773 -0.727 . . . . 75.109999999999999 111.373 -175.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 50.8 m 57.3 33.17 22.91 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 123.008 0.523 . . . . 61.020000000000003 111.919 177.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -53.81 -68.77 0.15 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 115.712 -0.676 . . . . 74.409999999999997 111.145 -178.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . -173.43 30.58 0.1 OUTLIER Glycine 0 CA--C 1.505 -0.579 0 C-N-CA 120.338 -0.934 . . . . 73.030000000000001 112.456 178.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 79.5 m-20 -133.32 145.83 50.78 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.784 0.326 . . . . 64.510000000000005 110.799 -177.166 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . 0.498 ' HB3' ' HG ' ' B' ' 147' ' ' LEU . 32.6 m-85 -118.34 157.03 27.87 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.875 -0.602 . . . . 73.329999999999998 110.034 176.201 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.1 mm -113.91 122.66 68.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 109.676 -0.49 . . . . 74.430000000000007 109.676 178.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . . . . . . . . . 44.8 ttp180 -86.36 135.92 33.33 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.028 -0.36 . . . . 74.349999999999994 110.028 -178.386 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 160' ' ' SER . . . . . 0.659 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 23.5 p -56.97 -34.78 68.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.064 0.459 . . . . 71.310000000000002 111.118 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -69.39 -37.93 77.75 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.448 -0.796 . . . . 70.310000000000002 111.346 177.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 8.6 tp60 -134.03 83.6 45.35 Favored Pre-proline 0 C--N 1.324 -0.527 0 C-N-CA 121.04 -0.264 . . . . 74.510000000000005 110.715 -176.297 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -77.59 0.27 9.96 Favored 'Trans proline' 0 C--O 1.234 0.282 0 C-N-CA 122.577 2.184 . . . . 60.130000000000003 111.616 177.15 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -79.19 -33.31 43.99 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.178 -0.919 . . . . 64.400000000000006 110.768 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -116.64 138.13 51.67 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.857 -0.61 . . . . 74.209999999999994 111.173 -172.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.5 mp -85.27 121.31 27.83 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 108.795 -0.817 . . . . 75.010000000000005 108.795 175.083 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 50.3 mm -71.24 117.7 59.16 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 116.129 -0.487 . . . . 74.420000000000002 109.778 -177.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.518 ' HG2' ' HB2' ' B' ' 171' ' ' GLU . 59.6 Cg_endo -70.39 173.61 11.28 Favored 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 122.843 2.362 . . . . 73.519999999999996 113.008 -175.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . 0.445 ' HA ' HG12 ' B' ' 172' ' ' ILE . 5.4 tt0 -74.95 -17.66 60.51 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.524 -0.762 . . . . 65.349999999999994 112.224 -168.156 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 42.4 p90 -90.24 -10.1 45.55 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.122 0.487 . . . . 74.310000000000002 110.013 176.374 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.563 ' O ' ' HB2' ' B' ' 174' ' ' SER . 19.6 mm-40 -109.42 -12.63 14.7 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.736 -0.665 . . . . 75.299999999999997 111.708 -178.282 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.506 HG22 ' O ' ' B' ' 168' ' ' PRO . 26.1 pt -72.7 -12.35 15.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.254 0.549 . . . . 71.420000000000002 110.435 176.177 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -115.9 32.76 5.89 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.442 -0.799 . . . . 62.409999999999997 109.148 175.094 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 174' ' ' SER . . . . . 0.563 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 3.0 t -66.97 -25.22 66.22 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 114.915 -1.039 . . . . 72.510000000000005 110.575 -177.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 7.1 p-90 . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.295 -0.86 . . . . 75.230000000000004 110.788 -179.936 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.683 0 N-CA-C 111.987 -0.445 . . . . 65.120000000000005 111.987 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.9 112.89 20.97 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.036 -0.357 . . . . 73.120000000000005 110.036 179.08 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 60.97 79.85 0.24 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.679 -0.691 . . . . 75.239999999999995 111.019 -177.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.42 ' CG ' ' H ' ' A' ' 5' ' ' ASP . 9.3 t70 -104.06 -162.68 0.91 Allowed 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 108.615 -0.883 . . . . 70.129999999999995 108.615 178.804 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.42 ' H ' ' CG ' ' A' ' 4' ' ' ASP . 23.5 t70 -138.57 -30.07 0.78 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 121.039 0.447 . . . . 73.120000000000005 111.031 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -171.0 97.12 0.42 Allowed Pre-proline 0 C--N 1.316 -0.869 0 CA-C-N 115.416 -0.811 . . . . 60.229999999999997 111.203 -177.081 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -89.2 97.63 0.34 Allowed 'Trans proline' 0 N--CA 1.449 -1.115 0 C-N-CA 122.812 2.341 . . . . 74.120000000000005 111.361 175.285 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.7 p -84.17 94.2 8.33 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.269 0.557 . . . . 72.430000000000007 110.513 178.11 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 136.63 106.28 0.8 Allowed Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 111.12 -0.792 . . . . 63.219999999999999 111.12 -174.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -124.3 97.29 40.29 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-O 121.357 0.599 . . . . 72.209999999999994 110.113 -175.301 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.613 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 9.9 Cg_endo -85.17 93.97 0.66 Allowed 'Trans proline' 0 N--CA 1.444 -1.421 0 C-N-CA 122.867 2.378 . . . . 71.239999999999995 111.817 -178.102 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -116.72 153.96 31.45 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.952 -1.022 . . . . 72.209999999999994 109.373 -179.276 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.491 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 13.4 p -119.42 130.35 74.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.497 0.665 . . . . 74.420000000000002 111.639 -177.782 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.516 ' O ' ' HA ' ' A' ' 24' ' ' GLN . 9.3 m -90.68 111.85 23.36 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.369 -0.832 . . . . 73.150000000000006 109.693 176.372 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.435 HG12 ' HG2' ' A' ' 24' ' ' GLN . 60.9 mt -106.74 107.33 22.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.791 0.329 . . . . 74.200000000000003 110.865 -176.23 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -125.51 166.02 17.41 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.178 -0.465 . . . . 74.209999999999994 110.594 178.252 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -118.52 108.63 15.22 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.768 0.318 . . . . 72.530000000000001 110.761 -179.322 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.432 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 25.7 mm-40 -108.42 99.54 8.92 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.162 -0.472 . . . . 72.439999999999998 109.97 178.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 71.09 -114.27 5.15 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.786 -0.721 . . . . 73.439999999999998 112.298 -179.611 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.426 ' HB3' ' HD2' ' A' ' 40' ' ' LYS . 13.6 m-20 -106.43 13.33 28.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.771 0.32 . . . . 61.32 110.476 -178.735 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.432 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 14.2 ptmt -133.29 123.18 25.03 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.464 0.649 . . . . 74.209999999999994 111.949 -176.049 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' THR . . . . . 0.43 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 25.6 m -83.07 115.31 21.81 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.36 -0.836 . . . . 75.25 109.675 176.517 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 68.3 mt -100.77 120.43 50.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 120.716 0.293 . . . . 75.209999999999994 110.65 -175.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLN . . . . . 0.516 ' HA ' ' O ' ' A' ' 14' ' ' THR . 16.7 mt-30 -112.05 111.77 22.92 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.102 -0.499 . . . . 72.310000000000002 110.723 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -90.08 109.59 20.63 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.222 -0.444 . . . . 75.239999999999995 110.312 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 73.4 m-85 -87.68 110.55 20.5 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.763 0.315 . . . . 74.409999999999997 110.374 177.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ARG . . . . . 0.551 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 65.5 mtt180 -116.91 139.91 50.08 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.508 -0.553 . . . . 75.409999999999997 109.508 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.613 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 14.2 p -112.83 -11.96 11.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.509 0.671 . . . . 71.310000000000002 111.002 -177.641 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -166.77 38.4 0.04 OUTLIER 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 108.757 -0.831 . . . . 75.420000000000002 108.757 -177.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 85.17 -28.73 4.53 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.308 -0.86 . . . . 72.219999999999999 111.824 -174.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . 0.408 ' CD2' HG21 ' B' ' 128' ' ' VAL . 15.4 t80 -88.24 125.85 34.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.106 0.479 . . . . 71.420000000000002 110.29 -177.055 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.647 HD13 HG13 ' A' ' 35' ' ' ILE . 3.3 tm? -68.24 134.27 50.15 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.201 -0.909 . . . . 74.209999999999994 110.141 178.74 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' TYR . . . . . 0.49 ' CE1' ' HB ' ' A' ' 28' ' ' VAL . 53.3 p90 -128.55 -24.56 3.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.594 -0.276 . . . . 75.409999999999997 111.584 176.275 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -149.54 139.82 22.26 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.815 0.34 . . . . 64.0 110.895 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.647 HG13 HD13 ' A' ' 32' ' ' LEU . 78.4 mt -122.72 122.35 65.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 116.17 -0.468 . . . . 73.030000000000001 110.239 178.07 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.493 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.4 tttt -101.18 102.05 12.89 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.406 -0.591 . . . . 70.140000000000001 109.406 174.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.551 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.7 p -99.39 124.44 52.71 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.98 0 CA-C-O 121.163 0.506 . . . . 72.439999999999998 110.005 176.485 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.606 HG21 ' HB3' ' A' ' 44' ' ' PRO . 40.0 t -106.91 85.01 1.72 Allowed Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 115.096 -0.956 . . . . 71.120000000000005 109.873 179.199 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.551 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 85.4 Cg_endo -91.08 144.01 3.33 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 122.762 2.308 . . . . 71.400000000000006 112.41 179.206 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.426 ' HD2' ' HB3' ' A' ' 20' ' ' ASP . 97.0 mttt -60.46 -27.02 67.21 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.186 0.517 . . . . 74.140000000000001 110.128 173.784 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 6.5 m-70 -118.99 85.4 2.36 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.568 -0.742 . . . . 74.430000000000007 109.947 -174.203 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 139.15 -18.76 3.1 Favored Glycine 0 N--CA 1.449 -0.444 0 CA-C-N 115.876 -0.602 . . . . 71.010000000000005 111.982 -176.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 42.5 mtpt 69.4 150.86 0.13 Allowed Pre-proline 0 N--CA 1.469 0.48 0 C-N-CA 123.727 0.811 . . . . 72.439999999999998 112.235 -179.035 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.606 ' HB3' HG21 ' A' ' 38' ' ' VAL . 16.0 Cg_endo -59.7 123.64 13.71 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.878 2.385 . . . . 74.150000000000006 112.474 -179.647 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' TYR . . . . . 0.499 ' CE1' HG11 ' A' ' 37' ' ' VAL . 16.4 p90 -142.28 151.18 41.77 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.865 -0.607 . . . . 74.140000000000001 110.258 179.551 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -90.74 125.0 35.55 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.17 -0.468 . . . . 74.150000000000006 109.981 176.085 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 18.9 tp -103.34 100.91 10.81 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 108.42 -0.956 . . . . 73.400000000000006 108.42 174.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.3 t -90.75 132.27 35.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.979 -0.555 . . . . 75.040000000000006 111.029 -173.675 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -86.04 121.16 28.26 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.069 -0.715 . . . . 74.099999999999994 109.069 178.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.11 174.78 9.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.924 0.392 . . . . 73.5 111.574 -173.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.59 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 7.0 p-10 -68.94 135.66 51.34 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.301 -0.409 . . . . 75.109999999999999 110.405 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.475 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 94.54 146.05 19.66 Favored Glycine 0 N--CA 1.433 -1.562 0 C-N-CA 120.422 -0.895 . . . . 45.399999999999999 112.042 179.067 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 27.8 t -80.57 28.55 0.33 Allowed 'General case' 0 C--N 1.312 -1.05 0 CA-C-O 121.436 0.636 . . . . 75.019999999999996 109.866 175.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.475 ' H ' ' C ' ' A' ' 52' ' ' GLY . 30.0 t70 -63.89 -32.43 73.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.159 -0.928 . . . . 64.200000000000003 111.26 -177.629 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.86 37.49 4.42 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.41 -0.9 . . . . 63.32 113.138 177.426 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -126.06 139.53 53.33 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.05 0.452 . . . . 74.109999999999999 110.052 176.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -117.47 155.16 30.18 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.711 -0.677 . . . . 74.120000000000005 109.864 179.207 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 44.9 mm -113.86 116.59 53.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.137 -0.483 . . . . 64.340000000000003 109.7 177.341 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . 0.496 ' HB2' HD13 ' A' ' 67' ' ' ILE . 55.5 ttt180 -83.82 124.06 30.54 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.121 -0.49 . . . . 75.239999999999995 109.846 -178.791 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.471 ' HA ' ' HG ' ' B' ' 160' ' ' SER . 30.9 t -63.71 -8.3 9.97 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.342 -0.39 . . . . 61.130000000000003 111.615 -177.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.402 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 15.6 t70 -70.03 -36.0 74.72 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.231 0.538 . . . . 72.349999999999994 109.701 175.578 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -159.08 88.87 2.1 Favored Pre-proline 0 N--CA 1.451 -0.383 0 CA-C-N 115.515 -0.766 . . . . 72.200000000000003 109.589 -177.492 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.437 ' HG3' ' OG ' ' B' ' 160' ' ' SER . 35.7 Cg_exo -58.98 -16.42 32.36 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 123.335 2.69 . . . . 73.150000000000006 112.699 178.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.473 ' CG ' ' HZ2' ' B' ' 143' ' ' LYS . 8.7 m-20 -66.62 -22.43 66.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.899 -0.591 . . . . 73.439999999999998 111.255 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.16 141.12 48.56 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 121.404 0.621 . . . . 63.329999999999998 111.892 -177.077 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.7 mp -88.54 141.43 28.53 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.689 -1.142 . . . . 71.329999999999998 109.306 174.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ILE . . . . . 0.73 HG23 ' HB3' ' A' ' 71' ' ' GLU . 25.2 mm -83.41 121.87 76.84 Favored Pre-proline 0 C--N 1.317 -0.818 0 CA-C-N 116.167 -0.47 . . . . 74.439999999999998 111.709 -176.77 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.498 ' O ' HG21 ' A' ' 72' ' ' ILE . 68.2 Cg_endo -74.05 179.45 5.74 Favored 'Trans proline' 0 C--O 1.233 0.264 0 C-N-CA 123.211 2.607 . . . . 75.099999999999994 112.488 178.631 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' GLN . . . . . 0.71 ' HA ' HG12 ' A' ' 72' ' ' ILE . 4.2 tt0 -71.99 -33.11 67.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.171 -0.468 . . . . 75.409999999999997 111.701 -168.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 7.2 p90 -69.23 -16.97 63.72 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.411 -0.516 . . . . 75.230000000000004 110.799 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.73 ' HB3' HG23 ' A' ' 67' ' ' ILE . 2.6 mm-40 -103.44 -20.22 14.13 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.329 -0.396 . . . . 63.25 111.233 -178.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.71 HG12 ' HA ' ' A' ' 69' ' ' GLN . 42.6 pt -75.61 -24.17 16.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 121.162 0.506 . . . . 72.099999999999994 109.922 174.752 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -103.69 39.21 1.65 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.467 -0.788 . . . . 75.340000000000003 109.371 173.353 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.483 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 11.5 t -71.17 -20.03 62.34 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.293 -0.867 . . . . 64.120000000000005 110.94 -177.141 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' TRP . . . . . 0.569 ' HZ2' HD12 ' A' ' 35' ' ' ILE . 69.6 p-90 . . . . . 0 C--O 1.235 0.312 0 CA-C-O 120.861 0.362 . . . . 73.450000000000003 110.835 177.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.508 0 N-CA-C 111.854 -0.498 . . . . 74.150000000000006 111.854 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -84.59 159.42 20.64 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 110.544 -0.169 . . . . 74.140000000000001 110.544 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 64.94 89.16 0.1 Allowed 'General case' 0 C--O 1.234 0.263 0 O-C-N 123.859 0.725 . . . . 75.420000000000002 111.309 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -123.02 169.53 11.08 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.448 -0.796 . . . . 70.129999999999995 109.899 178.364 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -97.26 -47.48 5.72 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.827 0.822 . . . . 73.540000000000006 109.844 178.198 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -161.35 144.1 9.28 Favored Pre-proline 0 C--N 1.309 -1.155 0 CA-C-N 114.125 -1.398 . . . . 73.310000000000002 109.609 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -70.97 95.74 0.67 Allowed 'Trans proline' 0 N--CA 1.463 -0.295 0 C-N-CA 122.147 1.898 . . . . 74.340000000000003 111.892 176.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 8.6 p -75.57 100.58 4.62 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.26 0.552 . . . . 74.430000000000007 110.594 179.06 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 92.25 116.29 2.25 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 111.063 -0.815 . . . . 61.210000000000001 111.063 -174.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -119.87 93.33 47.62 Favored Pre-proline 0 C--N 1.319 -0.739 0 CA-C-O 121.14 0.495 . . . . 71.409999999999997 110.58 -175.137 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 111' ' ' PRO . . . . . 0.719 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 55.7 Cg_endo -77.44 68.45 7.52 Favored 'Trans proline' 0 N--CA 1.449 -1.115 0 C-N-CA 121.943 1.762 . . . . 74.319999999999993 110.891 176.086 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -91.05 157.46 17.24 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 114.411 -1.268 . . . . 72.040000000000006 109.553 -178.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 113' ' ' VAL . . . . . 0.666 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 12.4 p -122.78 127.25 74.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-O 121.477 0.656 . . . . 73.450000000000003 111.19 -178.419 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 114' ' ' THR . . . . . 0.421 ' O ' ' HA ' ' B' ' 124' ' ' GLN . 13.7 m -84.61 111.26 19.38 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.435 -0.802 . . . . 74.219999999999999 109.439 178.749 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.6 mt -99.09 116.45 42.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 120.955 0.407 . . . . 75.140000000000001 111.527 -172.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 45.7 mtt180 -126.87 170.64 12.01 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.947 -0.57 . . . . 74.209999999999994 110.606 175.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 69.7 mt-30 -132.54 98.23 4.3 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.18 0.514 . . . . 71.120000000000005 110.204 176.536 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 118' ' ' GLU . . . . . 0.583 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 20.9 mm-40 -96.66 100.8 12.34 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.657 -0.701 . . . . 61.0 109.317 -178.433 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 73.37 -117.89 6.03 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.434 -0.889 . . . . 74.420000000000002 111.36 -175.44 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 120' ' ' ASP . . . . . 0.51 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 5.2 m-20 -104.26 11.58 34.7 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.94 0.37 . . . . 71.040000000000006 110.493 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 121' ' ' LYS . . . . . 0.583 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 10.1 ptmt -124.96 121.59 34.89 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.567 0.699 . . . . 62.240000000000002 111.73 -175.456 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 122' ' ' THR . . . . . 0.832 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 35.9 m -76.96 104.15 7.29 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.243 -0.89 . . . . 63.100000000000001 109.798 175.387 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 46.6 mt -94.01 119.89 42.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.218 0.532 . . . . 73.150000000000006 110.301 -179.311 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 124' ' ' GLN . . . . . 0.666 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 25.4 mt-30 -115.23 113.06 23.4 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.322 -0.854 . . . . 65.209999999999994 110.914 -177.043 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -88.16 111.98 22.21 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.173 -0.467 . . . . 74.430000000000007 110.678 -179.505 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 126' ' ' TYR . . . . . 0.59 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 29.1 m-85 -88.65 112.73 23.44 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.938 0.399 . . . . 74.349999999999994 111.07 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 127' ' ' ARG . . . . . 0.518 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 89.6 mtm180 -132.22 128.67 38.42 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.071 -0.513 . . . . 73.209999999999994 110.109 -179.218 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 128' ' ' VAL . . . . . 0.719 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 9.7 p -99.86 -27.84 3.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.071 0.462 . . . . 73.349999999999994 111.862 -174.367 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -152.74 47.61 0.72 Allowed 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.574 -0.528 . . . . 74.400000000000006 109.574 -179.032 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.19 -21.33 12.69 Favored Glycine 0 CA--C 1.518 0.235 0 CA-C-N 115.567 -0.742 . . . . 75.439999999999998 112.731 -178.447 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 131' ' ' PHE . . . . . 0.457 ' HD2' HG22 ' A' ' 28' ' ' VAL . 26.5 t80 -98.22 130.12 44.95 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.712 0.291 . . . . 75.099999999999994 110.374 -176.584 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 132' ' ' LEU . . . . . 0.518 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 3.1 tm? -71.0 132.55 45.32 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.812 -0.631 . . . . 74.5 109.967 179.214 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 46.1 p90 -129.32 -15.55 4.1 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.582 -0.447 . . . . 75.409999999999997 112.04 177.715 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.31 149.97 17.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.719 0.295 . . . . 75.040000000000006 111.079 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 135' ' ' ILE . . . . . 0.401 HG13 HD11 ' B' ' 132' ' ' LEU . 67.5 mt -130.69 125.42 58.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.963 -0.384 . . . . 74.140000000000001 109.963 176.863 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 136' ' ' LYS . . . . . 0.61 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 85.5 tttt -104.11 114.55 28.87 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.107 -0.331 . . . . 75.230000000000004 110.107 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 137' ' ' VAL . . . . . 0.612 HG11 ' HD3' ' B' ' 139' ' ' PRO . 3.4 t -96.49 130.94 44.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.126 -0.694 . . . . 73.239999999999995 109.126 175.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 138' ' ' VAL . . . . . 0.832 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 24.1 t -115.65 74.65 4.77 Favored Pre-proline 0 C--N 1.318 -0.798 0 N-CA-C 109.875 -0.417 . . . . 74.239999999999995 109.875 171.723 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 139' ' ' PRO . . . . . 0.612 ' HD3' HG11 ' B' ' 137' ' ' VAL . 37.1 Cg_endo -74.22 131.89 15.84 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.186 1.924 . . . . 74.010000000000005 112.276 176.445 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 140' ' ' LYS . . . . . 0.51 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 59.2 mtpt -60.63 -19.49 58.18 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.399 -0.818 . . . . 72.549999999999997 111.111 178.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 80.8 m-70 -130.72 105.4 7.78 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.703 -0.68 . . . . 63.140000000000001 109.379 178.492 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 142' ' ' GLY . . . . . 0.425 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 125.36 -11.02 7.65 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.75 -0.738 . . . . 61.140000000000001 112.432 -177.142 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 143' ' ' LYS . . . . . 0.473 ' HZ2' ' CG ' ' A' ' 64' ' ' ASP . 45.7 mtpt 72.77 150.84 0.14 Allowed Pre-proline 0 N--CA 1.468 0.433 0 C-N-CA 123.603 0.761 . . . . 74.319999999999993 112.353 179.105 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 144' ' ' PRO . . . . . 0.561 ' HB3' HG11 ' B' ' 138' ' ' VAL . 44.3 Cg_endo -68.76 137.75 39.34 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.795 2.33 . . . . 72.040000000000006 112.552 178.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -143.75 147.99 34.99 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 120.954 0.407 . . . . 73.299999999999997 110.638 179.114 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -90.47 129.27 36.66 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.88 -0.6 . . . . 74.439999999999998 110.032 175.506 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 147' ' ' LEU . . . . . 0.441 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 25.5 tp -108.59 93.27 4.43 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.621 -0.881 . . . . 74.409999999999997 108.621 173.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 40.3 t -83.53 135.91 23.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.602 -0.727 . . . . 74.230000000000004 110.499 -174.395 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 3.0 tmm_? -89.25 120.83 30.96 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 108.573 -0.899 . . . . 74.140000000000001 108.573 178.616 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -76.16 -173.94 2.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.978 0.418 . . . . 63.299999999999997 111.655 -173.123 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -75.33 146.26 41.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.369 -0.378 . . . . 71.400000000000006 110.288 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 91.63 136.8 7.26 Favored Glycine 0 N--CA 1.44 -1.076 0 C-N-CA 120.571 -0.823 . . . . 50.310000000000002 111.823 -177.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 18.4 t -87.22 35.67 0.71 Allowed 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.226 0.536 . . . . 55.149999999999999 110.212 178.425 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -74.68 -47.49 31.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.513 -0.767 . . . . 64.239999999999995 111.185 -178.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 123.08 36.6 0.65 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.868 -0.682 . . . . 63.109999999999999 111.97 -176.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -119.73 126.75 51.84 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.974 0.416 . . . . 75.420000000000002 110.596 -178.322 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 157' ' ' PHE . . . . . 0.441 ' CD2' ' HG ' ' B' ' 147' ' ' LEU . 13.4 m-85 -109.97 164.0 13.02 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.196 -0.456 . . . . 72.420000000000002 110.487 179.541 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.7 mm -121.79 109.22 24.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.789 -0.819 . . . . 73.329999999999998 108.789 173.128 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 159' ' ' ARG . . . . . 0.529 ' HE ' ' HB3' ' B' ' 161' ' ' ASP . 43.3 ttp180 -75.07 125.94 29.98 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 109.027 -0.731 . . . . 72.150000000000006 109.027 178.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 160' ' ' SER . . . . . 0.471 ' HG ' ' HA ' ' A' ' 60' ' ' SER . 23.8 t -58.64 -22.06 55.55 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.187 0.518 . . . . 72.0 110.755 -178.75 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 161' ' ' ASP . . . . . 0.529 ' HB3' ' HE ' ' B' ' 159' ' ' ARG . 1.5 t70 -68.81 -30.24 68.76 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.797 -0.638 . . . . 73.400000000000006 111.104 175.547 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 162' ' ' GLN . . . . . 0.668 HE21 ' HA ' ' B' ' 162' ' ' GLN . 0.0 OUTLIER -140.95 81.34 16.31 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.271 -0.422 . . . . 74.400000000000006 110.409 -174.198 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.41 -8.67 17.36 Favored 'Trans proline' 0 C--N 1.343 0.264 0 C-N-CA 122.498 2.132 . . . . 72.150000000000006 112.318 -178.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -81.87 -21.52 37.45 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.665 -0.698 . . . . 63.329999999999998 110.502 178.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 19.1 ttmm -114.57 134.32 55.13 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.017 -0.538 . . . . 75.319999999999993 110.894 -175.006 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.1 mp -82.98 129.31 35.02 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.22 -1.03 . . . . 75.400000000000006 108.22 171.449 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 45.2 mm -87.84 110.31 34.05 Favored Pre-proline 0 C--N 1.321 -0.651 0 N-CA-C 110.177 -0.305 . . . . 65.329999999999998 110.177 -174.21 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 168' ' ' PRO . . . . . 0.48 ' O ' HG21 ' B' ' 172' ' ' ILE . 42.9 Cg_endo -66.57 172.89 8.59 Favored 'Trans proline' 0 N--CA 1.462 -0.332 0 C-N-CA 122.94 2.426 . . . . 73.239999999999995 112.768 -175.595 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 5.1 tt0 -75.44 -5.44 45.01 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.304 -0.862 . . . . 74.439999999999998 111.665 -169.097 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -96.04 -13.24 23.87 Favored 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 120.495 -0.482 . . . . 71.530000000000001 110.73 176.471 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 171' ' ' GLU . . . . . 0.6 ' O ' ' HB2' ' B' ' 174' ' ' SER . 1.5 mm-40 -107.24 -9.61 16.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.988 0.423 . . . . 72.319999999999993 110.817 -178.386 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 172' ' ' ILE . . . . . 0.48 HG21 ' O ' ' B' ' 168' ' ' PRO . 47.9 pt -68.08 -19.15 24.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.423 0.63 . . . . 73.439999999999998 110.262 176.365 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -99.45 39.24 1.32 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.293 -0.867 . . . . 71.049999999999997 108.823 175.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 174' ' ' SER . . . . . 0.6 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 1.7 t -72.84 -15.31 61.62 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.358 -0.837 . . . . 62.340000000000003 110.305 -178.375 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 65.4 p-90 . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.817 -0.611 . . . . 74.099999999999994 109.371 174.38 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.3 p . . . . . 0 C--O 1.233 0.223 0 CA-C-O 121.525 0.679 . . . . 70.12 111.333 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 150.45 -76.48 0.24 Allowed Glycine 0 N--CA 1.443 -0.879 0 N-CA-C 110.521 -1.032 . . . . 72.03 110.521 -175.022 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 56.35 75.5 0.57 Allowed Pre-proline 0 N--CA 1.469 0.492 0 O-C-N 124.185 0.58 . . . . 70.5 112.473 173.695 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.619 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 71.6 Cg_endo -87.0 116.53 1.27 Allowed 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.507 2.138 . . . . 72.22 112.544 177.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -139.21 167.21 22.58 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.485 -0.561 . . . . 64.05 109.485 176.074 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.542 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 11.3 p -114.46 124.03 70.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.505 0.669 . . . . 64.34 111.502 -175.527 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.7 m -89.83 106.14 18.27 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.6 -0.727 . . . . 71.23 109.249 174.74 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.481 HG23 ' HG2' ' A' ' 24' ' ' GLN . 57.6 mt -93.89 107.84 19.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 120.908 0.385 . . . . 64.3 111.0 -175.768 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.41 HH11 ' HD3' ' A' ' 16' ' ' ARG . 4.8 mtm180 -116.13 174.77 5.87 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.225 -0.443 . . . . 75.11 110.537 177.114 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -129.98 104.87 7.61 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.782 -0.644 . . . . 62.35 109.823 175.508 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -97.32 83.56 3.31 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.563 -0.744 . . . . 52.33 109.338 -177.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.72 -115.17 4.12 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.429 -0.891 . . . . 73.31 111.413 -176.241 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.989 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 23.0 m-20 -110.73 24.95 12.31 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.099 0.476 . . . . 72.5 110.267 178.548 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.5 pttm -132.3 118.52 19.56 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 121.297 0.57 . . . . 71.34 110.782 178.256 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.433 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 35.8 m -80.06 101.42 8.71 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.421 -0.809 . . . . 54.43 109.374 177.047 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.554 HG12 HG23 ' A' ' 37' ' ' VAL . 16.4 mt -98.53 113.31 32.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.236 0.541 . . . . 72.25 110.388 -174.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.542 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 69.7 mt-30 -96.5 110.18 22.62 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.404 -0.816 . . . . 71.43 110.552 -178.774 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 30.0 mt-10 -84.3 103.24 13.32 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.681 -0.691 . . . . 65.4 110.828 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.426 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 85.2 m-85 -83.4 97.48 8.97 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.521 -0.548 . . . . 62.45 109.521 174.251 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 94.0 mtt180 -110.44 129.59 55.74 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.869 -0.605 . . . . 72.41 109.744 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.88 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.7 p -91.98 -82.7 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 C-N-CA 120.322 -0.551 . . . . 65.15 109.812 175.182 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.88 ' H ' HG13 ' A' ' 28' ' ' VAL . 5.6 t-20 -123.36 77.7 1.51 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.023 0.439 . . . . 73.5 110.325 -176.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 70.72 20.51 77.46 Favored Glycine 0 N--CA 1.448 -0.528 0 CA-C-N 115.456 -0.793 . . . . 61.45 113.144 177.453 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.48 ' CD2' HG21 ' B' ' 128' ' ' VAL . 32.2 t80 -148.12 129.3 14.62 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.125 0.488 . . . . 62.22 110.42 177.653 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.969 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -69.51 116.69 10.21 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 114.945 -1.025 . . . . 75.22 109.174 175.427 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' TYR . . . . . 0.426 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 36.7 p90 -105.1 -20.49 13.5 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.299 -0.56 . . . . 73.33 111.562 -178.785 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -157.43 143.41 17.61 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.947 0.403 . . . . 71.05 111.13 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.969 HG13 HD11 ' A' ' 32' ' ' LEU . 72.4 mt -120.86 120.25 61.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.171 -0.468 . . . . 61.2 110.148 175.377 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.417 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 86.6 tttt -103.04 97.78 7.83 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.849 -0.797 . . . . 71.14 108.849 171.103 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.554 HG23 HG12 ' A' ' 23' ' ' ILE . 2.1 p -100.2 128.61 51.99 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 CA-C-N 116.112 -0.495 . . . . 75.32 110.18 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.597 HG22 ' HB3' ' A' ' 44' ' ' PRO . 34.7 t -107.93 87.16 3.54 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 115.428 -0.805 . . . . 73.32 109.646 178.417 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 66.9 Cg_endo -83.48 132.9 6.01 Favored 'Trans proline' 0 N--CA 1.448 -1.171 0 C-N-CA 122.206 1.937 . . . . 73.24 111.905 178.447 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.989 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 58.6 mtpt -63.72 -24.0 67.6 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.648 -0.705 . . . . 61.54 109.93 176.35 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 59.3 m-70 -120.07 85.11 2.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.367 -0.833 . . . . 74.51 109.671 177.223 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 145.04 -20.07 1.95 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.286 -0.959 . . . . 74.35 113.205 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 94.0 mttt 73.42 144.42 0.1 Allowed Pre-proline 0 N--CA 1.474 0.743 0 C-N-CA 123.153 0.581 . . . . 65.32 111.373 178.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.597 ' HB3' HG22 ' A' ' 38' ' ' VAL . 41.7 Cg_endo -67.8 156.43 65.98 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.803 2.335 . . . . 52.44 113.361 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.421 ' CE2' ' HD2' ' A' ' 59' ' ' ARG . 6.8 p90 -165.3 167.16 18.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.581 -0.736 . . . . 71.03 109.516 178.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.543 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 64.4 m-85 -100.24 134.19 43.54 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.871 0.367 . . . . 74.41 110.591 176.859 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.429 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 20.2 tp -118.87 102.93 9.16 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.264 -0.643 . . . . 73.14 109.264 176.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.4 t -96.85 135.17 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.802 0.334 . . . . 72.22 111.663 -173.391 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.9 111.13 6.89 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.862 -0.608 . . . . 72.0 109.816 178.521 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.54 168.51 16.14 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.446 -0.343 . . . . 74.34 110.739 178.677 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -64.91 137.25 57.64 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.321 -0.4 . . . . 62.54 110.084 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 87.22 122.3 1.58 Allowed Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.705 -0.76 . . . . 74.13 111.239 -175.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.5 t -85.51 36.62 0.65 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.207 0.527 . . . . 70.41 110.277 -175.058 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -66.04 -48.44 71.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.504 -0.771 . . . . 75.45 110.753 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 134.46 49.75 0.08 OUTLIER Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.861 -0.685 . . . . 53.01 111.572 -177.241 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.831 HD21 ' HB3' ' A' ' 66' ' ' LEU . 41.1 t-20 -136.54 134.27 37.33 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.717 -0.475 . . . . 52.13 109.717 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.496 ' HD1' HG21 ' A' ' 72' ' ' ILE . 52.5 m-85 -123.53 159.71 28.56 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.139 -0.482 . . . . 74.34 110.784 -179.354 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 47.9 mm -117.49 129.96 73.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 109.501 -0.555 . . . . 42.34 109.501 175.67 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.946 ' HG3' HG13 ' A' ' 67' ' ' ILE . 18.0 mtm180 -95.79 153.63 17.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.827 0.346 . . . . 71.22 111.198 -176.465 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.543 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 59.5 p -71.53 -21.25 61.93 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.788 -0.642 . . . . 71.44 109.512 172.379 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -60.7 -44.0 97.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 114.833 -1.076 . . . . 73.03 110.858 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 65.3 tt0 -160.1 98.92 1.45 Allowed Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 115.8 -0.636 . . . . 64.45 109.908 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -73.03 -6.8 19.62 Favored 'Trans proline' 0 C--O 1.23 0.099 0 C-N-CA 122.777 2.318 . . . . 73.15 111.659 177.56 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -85.11 1.62 47.09 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.961 -1.018 . . . . 72.23 110.162 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 62.0 tttp -129.03 135.91 49.58 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.153 -0.476 . . . . 71.53 110.577 -177.651 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.831 ' HB3' HD21 ' A' ' 56' ' ' ASN . 5.0 mp -90.34 132.18 35.72 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.705 -0.85 . . . . 53.21 108.705 176.509 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.946 HG13 ' HG3' ' A' ' 59' ' ' ARG . 45.2 mm -106.15 110.52 64.05 Favored Pre-proline 0 C--N 1.317 -0.81 0 CA-C-O 121.021 0.438 . . . . 65.51 111.362 -172.743 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.536 ' O ' HG23 ' A' ' 72' ' ' ILE . 73.0 Cg_endo -76.44 -179.93 5.79 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 123.337 2.691 . . . . 74.04 112.297 177.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' GLN . . . . . 1.046 ' HA ' HG12 ' A' ' 72' ' ' ILE . 27.4 mt-30 -71.38 -32.69 68.76 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 113.489 0.922 . . . . 63.44 113.489 -169.52 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 25.2 p90 -70.13 -15.9 63.03 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.22 -0.592 . . . . 75.3 109.961 176.363 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.655 ' HB3' HG23 ' A' ' 67' ' ' ILE . 3.9 mm-40 -101.16 -30.31 11.63 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.776 -0.647 . . . . 74.2 111.186 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 1.046 HG12 ' HA ' ' A' ' 69' ' ' GLN . 44.8 pt -72.43 -32.77 43.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 121.099 0.476 . . . . 74.21 110.163 177.632 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -101.77 39.94 1.39 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.946 -0.57 . . . . 60.21 110.125 174.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.3 t -74.76 -16.12 60.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.355 -0.839 . . . . 73.52 109.762 179.297 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 8.6 p-90 . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 115.944 -0.571 . . . . 65.33 110.661 175.449 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 4.3 p . . . . . 0 N--CA 1.452 -0.342 0 CA-C-O 120.796 0.331 . . . . 73.11 110.473 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 100.43 84.45 1.8 Allowed Glycine 0 CA--C 1.504 -0.651 0 N-CA-C 110.992 -0.843 . . . . 73.4 110.992 -176.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -118.27 92.6 43.36 Favored Pre-proline 0 C--N 1.315 -0.934 0 CA-C-N 114.959 -0.621 . . . . 72.01 110.258 -174.401 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.827 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 40.5 Cg_endo -74.08 88.1 1.13 Allowed 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 121.781 1.654 . . . . 72.31 111.486 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -104.64 147.11 28.01 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.889 -1.05 . . . . 75.41 109.785 179.774 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.681 HG21 ' HB3' ' B' ' 124' ' ' GLN . 9.9 p -104.05 127.55 58.16 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-O 121.316 0.579 . . . . 62.52 111.073 -177.757 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 114' ' ' THR . . . . . 0.67 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.4 m -83.9 102.65 12.55 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.607 -0.724 . . . . 71.01 109.364 175.594 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.1 mt -92.77 106.45 17.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.279 -0.419 . . . . 64.13 110.909 -174.538 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 116' ' ' ARG . . . . . 0.454 ' HG2' ' O ' ' B' ' 123' ' ' ILE . 13.3 ptm180 -118.25 171.47 8.1 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.335 -0.617 . . . . 72.11 109.335 176.846 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 89.7 mt-30 -139.55 113.49 8.73 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.32 0.581 . . . . 74.43 110.825 -179.297 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 17.9 mm-40 -101.26 97.73 8.2 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.335 -0.848 . . . . 71.22 109.569 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 70.24 -95.67 0.52 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.886 -0.673 . . . . 63.32 111.973 -177.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 120' ' ' ASP . . . . . 0.781 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 9.7 m-20 -127.54 26.71 5.91 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.849 0.357 . . . . 73.22 110.538 178.463 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.536 ' HE3' ' HE3' ' B' ' 175' ' ' TRP . 23.1 pttm -129.3 119.31 23.72 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.233 0.54 . . . . 53.24 110.88 175.113 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 122' ' ' THR . . . . . 0.815 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 28.0 m -80.3 105.28 11.44 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.576 -0.738 . . . . 73.42 109.53 177.387 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 123' ' ' ILE . . . . . 0.473 HD11 ' HE2' ' B' ' 121' ' ' LYS . 24.2 mt -96.3 106.38 18.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-O 121.27 0.557 . . . . 75.21 110.097 -177.209 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.681 ' HB3' HG21 ' B' ' 113' ' ' VAL . 76.9 mt-30 -97.51 103.87 15.85 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.451 -0.795 . . . . 63.43 110.892 -176.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 125' ' ' GLU . . . . . 0.67 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 48.3 mt-10 -84.97 102.55 13.25 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.788 -0.642 . . . . 61.42 111.049 -179.214 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 126' ' ' TYR . . . . . 0.454 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 39.2 m-85 -78.38 107.09 10.75 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.931 0.396 . . . . 72.14 110.67 178.115 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 50.2 mtt180 -125.11 125.13 43.27 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.009 -0.542 . . . . 71.32 109.787 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.827 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 7.3 p -90.05 -25.6 5.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.202 0.525 . . . . 74.42 111.081 -174.815 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -165.94 56.35 0.1 Allowed 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.034 -0.728 . . . . 64.32 109.034 -179.244 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.68 -34.55 4.31 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.284 -0.871 . . . . 64.43 112.915 -178.903 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -94.54 133.47 38.13 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.204 0.526 . . . . 62.43 110.856 -173.524 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.709 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -73.95 125.82 29.08 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.983 -1.008 . . . . 73.15 110.17 179.289 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 133' ' ' TYR . . . . . 0.454 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 37.0 p90 -117.18 -16.97 10.35 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.617 -0.433 . . . . 71.25 111.384 177.457 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 134' ' ' ALA . . . . . 0.433 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -161.79 146.51 12.99 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.668 0.271 . . . . 72.34 110.87 178.029 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.709 HG13 HD11 ' B' ' 132' ' ' LEU . 71.1 mt -124.95 115.71 45.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 110.149 -0.315 . . . . 45.54 110.149 176.552 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.542 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.9 tttt -93.57 105.62 17.65 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.226 -0.657 . . . . 74.02 109.226 175.89 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.637 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.0 t -88.44 130.95 37.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.279 -0.637 . . . . 72.33 109.279 178.716 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.815 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 34.0 t -117.4 72.87 7.39 Favored Pre-proline 0 C--N 1.318 -0.795 0 CA-C-O 121.002 0.43 . . . . 42.43 109.863 173.152 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.597 ' HD3' HG12 ' B' ' 137' ' ' VAL . 44.4 Cg_endo -76.95 126.47 8.74 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.128 1.885 . . . . 71.14 112.473 176.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 140' ' ' LYS . . . . . 0.781 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 60.1 mtpt -66.04 -9.4 30.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.192 -0.913 . . . . 74.1 111.302 -179.046 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -129.92 21.81 5.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.772 -0.649 . . . . 72.1 110.298 -177.854 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 142' ' ' GLY . . . . . 0.497 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . -152.16 -9.21 0.1 OUTLIER Glycine 0 CA--C 1.521 0.416 0 C-N-CA 120.381 -0.914 . . . . 64.11 113.68 -178.424 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 143' ' ' LYS . . . . . 0.497 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 67.7 mmtt 75.69 143.98 0.1 Allowed Pre-proline 0 N--CA 1.472 0.67 0 CA-C-O 121.361 0.601 . . . . 72.45 112.128 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.637 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 59.8 Cg_endo -72.32 134.75 23.36 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 123.162 2.575 . . . . 72.22 112.887 -176.84 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -150.51 151.29 32.46 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.89 -0.595 . . . . 73.31 110.495 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.611 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 93.0 m-85 -89.51 128.1 35.94 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.31 -0.405 . . . . 73.34 110.103 176.403 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.561 ' HG ' ' CD1' ' B' ' 157' ' ' PHE . 16.0 tp -107.39 98.35 7.99 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.852 -0.796 . . . . 71.44 108.852 175.01 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 40.8 t -87.87 133.67 29.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.028 -0.533 . . . . 74.34 111.464 -172.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.03 108.13 8.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.803 -0.635 . . . . 52.02 110.476 178.064 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.12 155.72 33.94 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.876 -0.416 . . . . 60.33 109.876 173.869 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -62.31 139.21 58.53 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.885 0.374 . . . . 75.14 110.803 -177.522 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 152' ' ' GLY . . . . . 0.425 ' C ' ' H ' ' B' ' 154' ' ' ASP . . . 87.87 137.14 5.43 Favored Glycine 0 N--CA 1.44 -1.07 0 C-N-CA 120.433 -0.889 . . . . 44.43 111.689 -178.614 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 14.4 t -75.61 39.58 0.17 Allowed 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.616 0.722 . . . . 74.42 110.711 178.048 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 154' ' ' ASP . . . . . 0.425 ' H ' ' C ' ' B' ' 152' ' ' GLY . 21.3 t70 -67.29 -27.18 66.96 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.527 -0.761 . . . . 73.34 110.293 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 99.07 18.33 24.86 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.796 -0.716 . . . . 44.22 112.185 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 156' ' ' ASN . . . . . 0.451 ' OD1' ' HB3' ' B' ' 166' ' ' LEU . 1.9 t30 -101.13 139.15 37.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.841 0.353 . . . . 71.45 110.375 -178.26 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 157' ' ' PHE . . . . . 0.561 ' CD1' ' HG ' ' B' ' 147' ' ' LEU . 29.3 m-85 -127.41 156.88 41.37 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.963 -0.562 . . . . 63.45 110.404 176.449 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.2 mm -122.69 130.19 74.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.563 -0.532 . . . . 72.33 109.563 177.593 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.456 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 11.0 mtm180 -93.3 145.35 24.52 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.818 -0.353 . . . . 75.04 110.076 179.748 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 160' ' ' SER . . . . . 0.611 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 54.5 p -70.66 -16.71 62.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.26 -0.427 . . . . 64.21 111.383 -179.307 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -86.35 -25.13 25.54 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.972 0.415 . . . . 64.55 110.195 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 64.9 tt0 -151.72 79.54 6.46 Favored Pre-proline 0 N--CA 1.451 -0.411 0 CA-C-N 115.919 -0.582 . . . . 74.11 110.102 -177.53 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 163' ' ' PRO . . . . . 0.472 ' CG ' ' HB2' ' A' ' 60' ' ' SER . 16.1 Cg_exo -69.35 -9.57 26.6 Favored 'Trans proline' 0 C--O 1.233 0.247 0 C-N-CA 122.999 2.466 . . . . 74.44 111.398 177.081 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -78.01 -13.53 59.84 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.89 -1.05 . . . . 74.41 110.434 178.538 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 62.4 tttp -110.51 135.29 51.4 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.008 0.432 . . . . 73.52 110.938 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 166' ' ' LEU . . . . . 0.451 ' HB3' ' OD1' ' B' ' 156' ' ' ASN . 5.0 mp -97.85 126.22 43.11 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.616 -0.883 . . . . 61.13 108.616 175.104 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 51.2 mm -86.88 115.72 63.48 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-O 120.626 0.251 . . . . 73.12 110.611 -175.145 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.589 ' O ' HG23 ' B' ' 172' ' ' ILE . 49.3 Cg_endo -69.09 172.23 12.35 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.923 2.415 . . . . 43.11 112.172 178.61 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -84.49 8.8 15.28 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.926 -0.579 . . . . 71.03 111.968 -167.097 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 170' ' ' TRP . . . . . 0.54 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 31.8 p90 -108.33 -26.82 10.33 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.6 -0.519 . . . . 73.22 109.6 170.407 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.54 ' HG2' ' CD1' ' B' ' 170' ' ' TRP . 5.7 mm-40 -86.22 -13.49 46.74 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.932 -0.576 . . . . 60.1 111.549 -177.044 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.589 HG23 ' O ' ' B' ' 168' ' ' PRO . 24.0 pt -61.15 -27.9 42.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.568 -0.742 . . . . 72.42 111.554 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -110.15 44.01 1.29 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.299 0.571 . . . . 74.42 110.341 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 22.8 t -69.02 -22.96 64.03 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.569 -0.741 . . . . 50.41 110.446 178.721 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 175' ' ' TRP . . . . . 0.536 ' HE3' ' HE3' ' B' ' 121' ' ' LYS . 10.2 p-90 . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.383 -0.817 . . . . 70.44 110.965 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 24.8 m . . . . . 0 N--CA 1.451 -0.388 0 N-CA-C 109.825 -0.435 . . . . 73.21 109.825 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.47 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 102.93 52.85 0.93 Allowed Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 109.091 -1.604 . . . . 54.41 109.091 -168.886 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -88.51 103.49 5.42 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 114.233 -0.984 . . . . 71.43 109.722 -168.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.792 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 90.6 Cg_endo -87.18 101.36 0.52 Allowed 'Trans proline' 0 N--CA 1.443 -1.468 0 C-N-CA 122.539 2.16 . . . . 72.45 112.636 -172.649 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.13 149.74 20.96 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 116.067 -0.515 . . . . 74.11 109.98 -178.439 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.662 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 13.9 p -106.87 127.58 62.34 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.384 0.612 . . . . 75.54 110.61 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.455 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 25.3 m -91.77 112.33 24.21 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.833 -0.621 . . . . 71.3 109.44 176.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.409 HG12 ' HG2' ' A' ' 24' ' ' GLN . 62.9 mt -95.1 111.49 25.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.153 0.501 . . . . 53.25 111.54 -174.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 33.7 mmt180 -119.89 156.88 29.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.615 -0.72 . . . . 75.2 109.798 173.035 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -127.56 107.59 10.06 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.988 0.423 . . . . 74.25 110.795 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.446 ' HB2' ' HE2' ' A' ' 21' ' ' LYS . 54.9 mm-40 -97.57 81.72 2.98 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.012 -0.54 . . . . 73.23 109.595 178.89 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.47 -118.74 5.18 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.602 -0.808 . . . . 63.41 111.637 -176.361 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.707 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 42.7 m-20 -101.82 16.88 24.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.437 0.16 . . . . 64.1 110.962 179.048 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.492 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 23.1 pttm -123.49 122.52 38.43 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.269 0.557 . . . . 63.05 111.545 -179.261 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.403 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 36.2 m -83.73 103.98 13.47 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.273 -0.876 . . . . 61.3 109.577 174.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 51.0 mt -95.53 109.99 23.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.91 0.386 . . . . 65.34 110.03 -177.73 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.662 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 51.6 mt-30 -101.33 119.72 39.18 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.84 -0.618 . . . . 53.21 111.787 -175.768 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.455 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 29.0 mt-10 -89.77 99.98 12.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.619 -0.719 . . . . 71.02 110.36 175.55 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.441 ' CD2' ' HB3' ' B' ' 151' ' ' ASP . 68.3 m-85 -81.15 101.5 9.69 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.824 -0.436 . . . . 72.5 109.824 175.387 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.447 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 58.6 mtt180 -115.03 129.28 56.67 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.121 -0.49 . . . . 72.12 110.013 -179.064 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.792 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 2.4 p -90.0 -57.64 4.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-O 120.915 0.388 . . . . 55.3 111.541 -177.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.462 ' H ' HG13 ' A' ' 28' ' ' VAL . 5.1 t-20 -127.63 50.5 2.02 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 109.007 -0.738 . . . . 74.21 109.007 -179.246 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 92.42 -29.74 7.47 Favored Glycine 0 N--CA 1.45 -0.39 0 CA-C-N 115.484 -0.78 . . . . 71.2 112.292 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.574 ' CD2' HG21 ' B' ' 128' ' ' VAL . 57.1 t80 -92.35 134.43 34.92 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.113 0.482 . . . . 70.01 110.843 -176.247 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.864 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -72.84 118.81 16.23 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.225 -0.898 . . . . 55.53 109.965 177.604 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' TYR . . . . . 0.421 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 39.5 p90 -104.79 -25.54 12.61 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 120.3 -0.56 . . . . 74.4 111.263 179.528 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.427 ' O ' ' HB2' ' A' ' 26' ' ' TYR . . . -156.85 137.89 13.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.935 0.397 . . . . 73.22 111.102 178.622 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.864 HG13 HD11 ' A' ' 32' ' ' LEU . 76.4 mt -110.4 119.79 59.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.093 -0.503 . . . . 75.31 109.812 175.727 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -102.43 101.28 11.48 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.043 -0.663 . . . . 72.22 109.535 174.414 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.55 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.4 p -93.48 120.66 43.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 N-CA-C 109.525 -0.546 . . . . 73.42 109.525 176.361 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.595 HG13 ' HB3' ' A' ' 44' ' ' PRO . 41.7 t -107.34 86.25 2.57 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.365 -0.834 . . . . 73.4 109.858 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.55 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 62.3 Cg_endo -85.39 132.76 4.43 Favored 'Trans proline' 0 N--CA 1.445 -1.35 0 C-N-CA 122.347 2.031 . . . . 70.2 112.278 179.066 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.707 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 58.1 mtpt -62.61 -20.34 64.66 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.51 -0.768 . . . . 74.32 109.604 173.609 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 10.6 m-70 -123.6 96.94 5.16 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.216 -0.902 . . . . 50.15 108.942 177.067 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.467 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 133.64 -18.77 4.3 Favored Glycine 0 CA--C 1.52 0.373 0 C-N-CA 120.558 -0.83 . . . . 73.24 113.075 178.323 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 69.6 mmtt 75.31 136.6 0.05 OUTLIER Pre-proline 0 N--CA 1.47 0.556 0 C-N-CA 123.432 0.693 . . . . 73.53 112.39 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.595 ' HB3' HG13 ' A' ' 38' ' ' VAL . 21.8 Cg_endo -61.03 143.43 99.23 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 123.497 2.798 . . . . 73.22 113.334 -177.23 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.52 ' CE1' HG13 ' A' ' 37' ' ' VAL . 4.9 p90 -158.48 160.79 37.14 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.818 -0.628 . . . . 74.04 110.116 178.747 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.647 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 90.3 m-85 -100.03 142.0 32.1 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.294 -0.412 . . . . 75.43 111.073 -179.376 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 51.9 mt -113.98 103.05 10.77 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.791 -0.64 . . . . 75.21 109.367 168.455 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 43.0 t -86.34 133.58 29.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.129 -0.487 . . . . 75.41 110.287 -178.722 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ARG . . . . . 0.427 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 33.8 tpt85 -76.71 115.54 16.57 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.958 -0.386 . . . . 72.32 109.958 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.14 154.79 18.68 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 116.094 -0.503 . . . . 71.03 111.406 -179.037 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -73.15 167.03 21.99 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.626 -0.715 . . . . 71.2 111.632 -176.022 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.54 10.22 86.08 Favored Glycine 0 N--CA 1.454 -0.131 0 CA-C-N 115.41 -0.814 . . . . 70.12 112.801 172.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.5 m 61.14 17.83 8.48 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 122.919 0.488 . . . . 72.04 111.745 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -50.39 -66.02 0.46 Allowed 'General case' 0 N--CA 1.468 0.451 0 O-C-N 123.607 0.567 . . . . 72.02 111.898 -178.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 137.4 -18.12 3.49 Favored Glycine 0 CA--C 1.508 -0.381 0 C-N-CA 120.591 -0.814 . . . . 71.23 111.759 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.428 ' ND2' ' HB3' ' A' ' 66' ' ' LEU . 13.8 t-20 -66.04 146.41 54.72 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.141 -0.53 . . . . 64.4 111.036 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.502 ' HB2' HG22 ' A' ' 72' ' ' ILE . 35.4 m-85 -119.35 141.46 49.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.256 -0.429 . . . . 73.22 110.082 175.686 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.404 ' CG2' ' HA ' ' A' ' 63' ' ' PRO . 49.6 mm -108.18 124.36 64.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.993 -0.549 . . . . 74.24 110.521 -177.853 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.436 HH11 ' HD3' ' A' ' 59' ' ' ARG . 42.4 mtp-105 -77.7 137.78 38.69 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.92 -0.4 . . . . 74.3 109.92 177.749 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.647 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 63.6 p -67.51 -23.95 65.52 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.403 0.62 . . . . 32.23 110.082 175.462 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -70.17 -43.08 71.54 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.217 -0.901 . . . . 64.4 110.569 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.9 mm100 -134.9 76.19 59.77 Favored Pre-proline 0 N--CA 1.441 -0.899 0 CA-C-N 115.95 -0.568 . . . . 63.45 111.193 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' PRO . . . . . 0.404 ' HA ' ' CG2' ' A' ' 58' ' ' ILE . 26.5 Cg_exo -63.47 -15.88 51.19 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 123.011 2.474 . . . . 74.42 112.533 177.019 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -75.24 -20.85 58.99 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.882 -0.599 . . . . 74.44 110.683 178.765 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 22.7 tptm -109.37 129.03 55.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.192 0.52 . . . . 71.04 111.495 -176.225 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.428 ' HB3' ' ND2' ' A' ' 56' ' ' ASN . 5.9 mp -89.93 128.8 36.3 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.43 -0.804 . . . . 74.52 109.965 176.545 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.405 HG13 ' HG3' ' A' ' 59' ' ' ARG . 50.5 mm -96.31 124.89 49.78 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 116.353 -0.385 . . . . 72.23 111.597 -173.709 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.56 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 38.1 Cg_endo -65.22 174.39 5.06 Favored 'Trans proline' 0 C--N 1.348 0.509 0 C-N-CA 123.13 2.553 . . . . 73.32 112.887 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 16.4 tt0 -83.82 -9.01 59.08 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.804 -0.635 . . . . 75.44 111.924 -168.551 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 38.4 p90 -96.88 -5.09 38.96 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.296 0.57 . . . . 72.14 109.927 175.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.56 ' HB2' ' HG2' ' A' ' 68' ' ' PRO . 4.8 mm-40 -115.63 10.76 15.62 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.42 -0.809 . . . . 75.33 111.145 -176.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.541 HG23 ' O ' ' A' ' 68' ' ' PRO . 18.9 pt -90.33 -11.25 9.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-O 121.096 0.474 . . . . 75.11 110.811 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 33.8 p90 -128.5 27.25 5.57 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.954 -0.566 . . . . 74.32 110.419 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 4.8 m -49.76 -41.33 43.8 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.692 -0.686 . . . . 73.03 111.041 -179.496 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' TRP . . . . . 0.492 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 10.3 p-90 . . . . . 0 C--N 1.326 -0.439 0 CA-C-N 115.787 -0.642 . . . . 75.12 111.043 175.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 42.7 m . . . . . 0 N--CA 1.454 -0.25 0 CA-C-O 120.994 0.426 . . . . 44.21 110.238 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 128.14 82.04 0.34 Allowed Glycine 0 N--CA 1.446 -0.65 0 N-CA-C 110.577 -1.009 . . . . 63.44 110.577 -173.035 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 110' ' ' GLU . . . . . 0.415 ' HA ' ' HD3' ' B' ' 111' ' ' PRO . 13.4 mt-10 -123.38 114.13 29.04 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-O 121.327 0.584 . . . . 74.3 109.975 -172.296 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.765 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 19.2 Cg_endo -89.01 102.29 0.38 Allowed 'Trans proline' 0 N--CA 1.438 -1.766 0 C-N-CA 122.832 2.355 . . . . 70.44 112.397 -176.241 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -101.57 115.28 30.16 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.188 -0.671 . . . . 71.34 109.188 178.274 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 113' ' ' VAL . . . . . . . . . . . . . 7.9 p -72.71 132.64 33.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.625 -0.716 . . . . 61.21 111.082 -176.759 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 27.4 m -93.22 99.17 11.78 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.464 -0.789 . . . . 71.24 109.742 174.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.608 HG23 ' HG2' ' B' ' 124' ' ' GLN . 71.3 mt -96.06 106.03 17.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.838 -0.619 . . . . 72.34 110.286 -177.252 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 39.1 mmt180 -118.75 149.6 41.19 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.192 0.52 . . . . 72.3 110.485 178.279 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -100.6 113.64 26.64 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-O 121.596 0.712 . . . . 75.45 110.865 -179.643 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 118' ' ' GLU . . . . . 0.517 ' HB3' ' HE2' ' B' ' 121' ' ' LYS . 0.7 OUTLIER -102.83 48.92 0.85 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.003 -0.999 . . . . 71.43 109.851 -176.785 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 97.74 -117.35 5.78 Favored Glycine 0 N--CA 1.446 -0.652 0 N-CA-C 111.223 -0.751 . . . . 63.13 111.223 -176.266 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 120' ' ' ASP . . . . . 0.497 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 3.6 m-20 -89.13 -3.32 58.67 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.037 0.446 . . . . 73.34 110.308 177.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.675 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 25.4 pttm -111.79 120.19 41.13 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.205 0.526 . . . . 75.53 111.303 -177.549 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 122' ' ' THR . . . . . 0.474 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 5.5 m -84.03 111.96 19.77 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.908 -0.587 . . . . 72.4 109.611 175.146 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 51.4 mt -101.17 108.12 22.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-O 121.104 0.478 . . . . 72.24 110.368 -177.781 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.608 ' HG2' HG23 ' B' ' 115' ' ' ILE . 40.4 mt-30 -105.28 103.76 13.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.792 -0.64 . . . . 63.05 110.366 -178.427 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -88.4 108.82 19.56 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.234 -0.439 . . . . 73.43 110.766 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 126' ' ' TYR . . . . . 0.471 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 46.7 m-85 -82.37 106.39 14.21 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.218 -0.446 . . . . 74.4 110.47 177.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -120.86 125.31 47.16 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.508 -0.553 . . . . 62.25 109.508 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.765 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 3.5 p -93.65 -41.63 12.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 120.757 0.313 . . . . 73.51 111.497 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -158.6 70.37 0.52 Allowed 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.606 -0.438 . . . . 73.15 110.584 -175.663 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 78.87 -4.05 62.64 Favored Glycine 0 N--CA 1.454 -0.162 0 CA-C-N 115.692 -0.686 . . . . 65.32 113.574 175.218 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -130.0 129.32 43.57 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.097 0.475 . . . . 75.03 110.717 -178.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.892 HD11 HG13 ' B' ' 135' ' ' ILE . 3.5 tm? -73.5 118.35 16.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 114.875 -1.057 . . . . 74.23 109.462 175.223 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 133' ' ' TYR . . . . . 0.471 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 46.3 p90 -106.09 -23.77 12.53 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.66 -0.416 . . . . 75.45 111.528 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 134' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -158.99 134.55 8.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.806 0.336 . . . . 73.11 111.282 179.005 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.892 HG13 HD11 ' B' ' 132' ' ' LEU . 74.3 mt -114.07 130.73 67.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 N-CA-C 109.634 -0.506 . . . . 65.53 109.634 174.151 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -107.79 110.41 22.21 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.679 -0.489 . . . . 73.32 109.679 174.232 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.646 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.4 t -93.67 131.14 41.44 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 108.808 -0.812 . . . . 44.34 108.808 176.296 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.474 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 17.2 t -117.73 72.86 8.33 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 109.961 -0.385 . . . . 71.12 109.961 173.582 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.675 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 52.4 Cg_endo -78.48 134.73 12.69 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 122.367 2.044 . . . . 70.34 112.596 176.819 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 140' ' ' LYS . . . . . 0.497 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 48.6 mtpt -60.83 -33.21 72.69 Favored 'General case' 0 CA--C 1.518 -0.262 0 CA-C-O 121.416 0.627 . . . . 73.13 109.596 173.37 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 36.6 m-70 -110.52 82.58 1.62 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.252 -0.885 . . . . 74.35 109.2 177.038 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 142' ' ' GLY . . . . . 0.483 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 150.68 -26.73 1.06 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.357 -0.925 . . . . 73.55 113.054 -179.335 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 143' ' ' LYS . . . . . 0.483 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 70.7 mmtt 76.68 148.91 0.12 Allowed Pre-proline 0 N--CA 1.472 0.635 0 C-N-CA 123.283 0.633 . . . . 73.23 111.933 178.4 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.646 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 38.3 Cg_endo -66.27 127.6 17.79 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 123.069 2.513 . . . . 73.35 113.492 -176.098 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -143.91 150.48 38.47 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.79 -0.641 . . . . 72.05 110.734 179.327 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.666 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 77.8 m-85 -98.14 146.16 25.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.976 -0.556 . . . . 71.23 110.466 178.345 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 59.9 mt -122.73 100.55 6.97 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.826 -0.625 . . . . 73.03 109.555 171.156 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 61.4 t -92.84 130.34 42.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.054 -0.521 . . . . 74.14 110.677 -178.036 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 149' ' ' ARG . . . . . 0.544 ' HG3' HH11 ' B' ' 149' ' ' ARG . 0.3 OUTLIER -72.2 128.07 34.53 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.913 0.387 . . . . 74.24 111.689 -179.429 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.87 155.78 38.62 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 115.738 -0.664 . . . . 75.03 110.612 176.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 151' ' ' ASP . . . . . 0.441 ' HB3' ' CD2' ' A' ' 26' ' ' TYR . 3.9 p-10 -77.6 162.21 27.25 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.287 0.565 . . . . 73.53 111.736 -173.08 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.93 21.73 60.77 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.284 -0.871 . . . . 62.34 112.364 173.61 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 153' ' ' SER . . . . . 0.433 ' H ' ' HD2' ' A' ' 11' ' ' PRO . 25.2 m 55.87 30.11 15.31 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-O 120.969 0.414 . . . . 75.32 110.384 -177.011 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -51.37 -64.39 0.83 Allowed 'General case' 0 N--CA 1.461 0.121 0 CA-C-N 114.851 -1.068 . . . . 64.22 111.068 -178.206 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 132.2 -36.36 2.21 Favored Glycine 0 CA--C 1.491 -1.458 0 C-N-CA 120.569 -0.824 . . . . 62.11 111.218 175.441 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 156' ' ' ASN . . . . . 0.607 ' OD1' ' HA ' ' B' ' 168' ' ' PRO . 75.6 m-20 -68.41 152.63 45.14 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 113.964 -1.118 . . . . 74.11 111.773 -179.424 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 157' ' ' PHE . . . . . 0.464 ' CE2' ' HG2' ' B' ' 149' ' ' ARG . 46.2 m-85 -112.32 157.7 20.66 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.54 -0.754 . . . . 61.2 110.248 176.285 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 49.1 mm -116.03 124.92 72.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 N-CA-C 109.596 -0.52 . . . . 73.35 109.596 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.491 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 30.2 ttt180 -85.51 137.72 32.7 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.4 -0.364 . . . . 74.2 110.165 -177.131 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 160' ' ' SER . . . . . 0.666 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 6.5 p -57.18 -42.6 81.49 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.722 0.638 . . . . 64.41 112.722 -174.765 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -86.04 -1.06 57.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.979 0.419 . . . . 61.43 111.551 -174.909 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 10.9 tp60 -151.86 71.41 7.99 Favored Pre-proline 0 C--N 1.327 -0.401 0 N-CA-C 109.614 -0.513 . . . . 73.3 109.614 -178.263 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -67.47 -14.41 42.36 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 123.223 2.616 . . . . 63.45 113.13 -173.771 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -90.52 -6.39 54.81 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.169 -0.469 . . . . 64.43 110.549 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 23.1 tptm -104.74 126.17 51.55 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.163 0.506 . . . . 74.51 110.637 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.0 mp -95.19 124.68 39.36 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.326 -0.852 . . . . 62.43 109.789 178.302 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 167' ' ' ILE . . . . . 0.404 HG23 ' HB3' ' B' ' 171' ' ' GLU . 51.5 mm -93.17 111.58 52.44 Favored Pre-proline 0 C--N 1.32 -0.7 0 CA-C-N 116.122 -0.49 . . . . 74.12 109.827 179.029 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.607 ' HA ' ' OD1' ' B' ' 156' ' ' ASN . 60.2 Cg_endo -71.63 175.17 9.92 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.664 2.243 . . . . 71.15 113.025 -176.457 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 169' ' ' GLN . . . . . 0.415 ' O ' HG12 ' B' ' 172' ' ' ILE . 36.3 tt0 -78.92 -8.32 58.77 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.573 -0.739 . . . . 74.35 111.518 -170.341 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 10.3 p90 -94.23 -8.04 40.36 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.088 0.47 . . . . 71.4 110.081 174.71 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.476 ' O ' ' HB2' ' B' ' 174' ' ' SER . 0.1 OUTLIER -110.42 -4.63 15.47 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.891 -0.595 . . . . 54.41 110.717 -177.538 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.474 HG23 ' O ' ' B' ' 168' ' ' PRO . 36.6 pt -70.15 -18.68 21.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.231 -0.44 . . . . 74.34 111.197 -179.613 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -102.01 40.62 1.31 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.593 0.711 . . . . 74.44 109.678 176.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 174' ' ' SER . . . . . 0.476 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 4.5 t -73.38 -11.13 60.37 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 114.9 -1.045 . . . . 64.4 110.211 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 175' ' ' TRP . . . . . 0.454 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 0.9 OUTLIER . . . . . 0 C--O 1.245 0.829 0 CA-C-O 118.353 -0.832 . . . . 74.23 110.9 179.008 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.5 p . . . . . 0 N--CA 1.449 -0.488 0 N-CA-C 109.749 -0.463 . . . . 75.43 109.749 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.03 66.33 0.53 Allowed Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.158 -1.177 . . . . 73.21 110.158 -173.533 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLU . . . . . 0.49 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -114.46 117.16 43.23 Favored Pre-proline 0 N--CA 1.44 -0.933 0 N-CA-C 107.995 -1.113 . . . . 72.31 107.995 -175.839 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.613 ' HG3' ' CZ ' ' B' ' 131' ' ' PHE . 24.7 Cg_endo -88.87 101.0 0.37 Allowed 'Trans proline' 0 N--CA 1.433 -2.049 0 C-N-CA 122.173 1.915 . . . . 73.22 111.693 -175.377 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -107.8 171.61 7.3 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 114.871 -1.059 . . . . 64.44 110.344 179.55 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.653 HG21 ' HB3' ' A' ' 24' ' ' GLN . 7.6 p -123.42 131.51 73.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 115.773 -0.649 . . . . 65.03 110.353 178.658 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.418 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 61.5 m -91.62 111.33 22.8 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.663 -0.699 . . . . 71.11 109.585 176.825 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 56.1 mt -88.66 103.76 14.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.942 -0.572 . . . . 63.25 110.967 -174.725 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.471 ' NE ' ' HA ' ' A' ' 16' ' ' ARG . 3.5 mmp_? -108.45 165.12 11.76 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.49 -0.777 . . . . 71.14 109.48 177.207 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -139.13 111.44 7.5 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.042 0.449 . . . . 73.34 110.502 174.444 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 30.9 mm-40 -103.77 100.57 10.38 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.448 -0.796 . . . . 75.32 109.002 178.035 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.25 -109.31 2.83 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.529 -0.843 . . . . 41.42 111.664 -175.476 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -111.02 8.46 21.91 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.788 0.294 . . . . 74.31 111.078 -177.366 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.705 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 0.3 OUTLIER -114.97 118.54 33.73 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.434 0.635 . . . . 72.35 111.463 179.484 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.739 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 20.7 m -76.59 98.33 4.65 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.19 -0.914 . . . . 31.35 109.618 175.213 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.427 HG12 HG13 ' A' ' 37' ' ' VAL . 38.3 mt -90.31 105.39 16.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.221 0.534 . . . . 74.33 110.234 -176.672 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.653 ' HB3' HG21 ' A' ' 13' ' ' VAL . 72.5 mt-30 -94.67 112.78 24.51 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.433 -0.803 . . . . 75.13 110.734 -177.836 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.418 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.6 mt-10 -91.99 108.85 20.23 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.03 -0.532 . . . . 65.22 110.736 -177.815 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.467 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 41.3 m-85 -84.72 106.06 15.98 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.349 -0.387 . . . . 75.33 110.687 178.173 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 71.3 mtm-85 -130.01 123.61 30.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.064 -0.516 . . . . 71.33 110.11 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.2 p -97.18 -41.99 11.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.313 -0.403 . . . . 75.1 111.48 -179.055 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 11.7 t-20 -153.65 73.37 0.95 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.006 0.432 . . . . 75.33 110.294 -176.087 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 67.03 18.53 69.0 Favored Glycine 0 C--N 1.33 0.207 0 CA-C-N 115.815 -0.63 . . . . 65.31 112.845 177.224 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.616 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 87.8 t80 -139.67 128.59 23.49 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.994 0.426 . . . . 64.45 111.042 -178.117 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.844 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -82.36 110.31 17.39 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.112 -0.949 . . . . 62.21 108.544 172.822 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' TYR . . . . . 0.467 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 45.5 p90 -103.92 -17.49 14.99 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.885 -0.326 . . . . 72.42 111.478 -178.39 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.456 ' O ' ' HB2' ' A' ' 26' ' ' TYR . . . -159.35 140.34 12.67 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.878 0.371 . . . . 31.11 111.105 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.844 HG13 HD11 ' A' ' 32' ' ' LEU . 66.9 mt -117.6 124.95 73.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 N-CA-C 109.653 -0.499 . . . . 54.42 109.653 174.326 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.623 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.9 tttt -106.01 103.77 13.33 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.533 -0.543 . . . . 73.41 109.533 176.11 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.725 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.6 t -88.7 127.24 41.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.839 -0.8 . . . . 73.34 108.839 177.854 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.739 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 22.0 t -115.14 74.0 3.64 Favored Pre-proline 0 C--N 1.318 -0.769 0 N-CA-C 109.55 -0.537 . . . . 53.45 109.55 172.492 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.705 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 39.4 Cg_endo -76.86 131.1 11.92 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.011 1.807 . . . . 45.1 112.242 177.003 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -54.83 -40.0 69.13 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.522 -0.763 . . . . 74.11 110.26 177.208 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -116.67 82.46 1.8 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.517 -0.765 . . . . 72.24 109.228 179.485 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.43 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 159.15 -29.48 0.41 Allowed Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.507 -0.769 . . . . 61.12 111.428 -175.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.43 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 71.6 mmtt 76.42 143.81 0.1 OUTLIER Pre-proline 0 N--CA 1.469 0.513 0 C-N-CA 123.738 0.815 . . . . 72.23 112.267 176.19 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.725 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 30.8 Cg_endo -64.03 132.7 35.37 Favored 'Trans proline' 0 C--N 1.347 0.469 0 C-N-CA 123.218 2.612 . . . . 73.55 113.61 -176.197 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 21.9 p90 -148.36 163.2 37.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.463 -0.79 . . . . 72.5 109.645 177.032 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.475 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 91.2 m-85 -107.76 137.79 45.14 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.842 0.353 . . . . 75.33 111.572 -176.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.407 ' HB3' ' CD2' ' A' ' 57' ' ' PHE . 34.7 mt -114.15 104.48 12.15 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.717 -0.674 . . . . 73.33 109.216 168.487 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 44.4 t -92.52 137.88 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.554 -0.294 . . . . 74.52 110.333 -178.198 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ARG . . . . . 0.574 ' HG2' ' CE2' ' A' ' 57' ' ' PHE . 5.0 mmm180 -81.8 121.92 27.04 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.032 0.444 . . . . 72.22 110.885 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.45 167.03 19.16 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.337 -0.847 . . . . 74.23 111.22 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.463 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 9.8 p-10 -66.87 142.86 57.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.298 -0.41 . . . . 70.15 110.264 179.037 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.432 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 94.16 143.45 13.81 Favored Glycine 0 N--CA 1.433 -1.559 0 C-N-CA 120.588 -0.815 . . . . 53.13 111.566 -178.591 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 18.6 m -74.32 40.14 0.13 Allowed 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.174 0.511 . . . . 74.43 110.677 176.186 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.432 ' H ' ' C ' ' A' ' 52' ' ' GLY . 18.0 t70 -78.01 -39.86 40.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.779 -0.646 . . . . 53.31 110.357 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 112.02 -32.05 6.6 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.636 -0.792 . . . . 41.02 113.302 176.873 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -58.29 149.82 23.44 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 113.027 0.751 . . . . 71.35 113.027 -175.797 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.574 ' CE2' ' HG2' ' A' ' 49' ' ' ARG . 63.3 m-85 -115.5 168.3 10.12 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.096 -0.956 . . . . 72.25 110.697 -179.063 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 45.4 mm -128.27 132.16 68.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.995 -0.548 . . . . 75.54 109.649 174.244 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.789 ' HG3' HD11 ' A' ' 67' ' ' ILE . 70.7 mtt180 -78.59 147.88 33.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.809 0.337 . . . . 74.33 111.249 178.817 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.475 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 62.2 p -79.01 -29.86 43.92 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.681 -0.859 . . . . 54.32 108.681 165.812 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -70.27 -34.34 72.67 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.381 -1.281 . . . . 74.41 110.876 177.316 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLN . . . . . 0.6 ' HB3' ' HD2' ' A' ' 59' ' ' ARG . 63.2 tt0 -143.37 82.52 11.57 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 115.747 -0.66 . . . . 63.34 109.71 -174.745 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -79.58 -7.44 14.73 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.871 2.381 . . . . 63.01 113.13 -175.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -94.46 9.32 38.9 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.331 0.586 . . . . 73.44 110.165 178.522 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.4 tptt -125.63 128.23 47.56 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.85 -0.614 . . . . 74.15 110.429 -178.588 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.404 ' N ' HD12 ' A' ' 66' ' ' LEU . 5.2 mp -87.36 111.85 21.51 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 108.434 -0.95 . . . . 73.32 108.434 175.118 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.789 HD11 ' HG3' ' A' ' 59' ' ' ARG . 34.6 mm -67.24 117.33 45.42 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.146 -0.479 . . . . 74.14 111.27 -172.254 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.403 ' O ' HG23 ' A' ' 72' ' ' ILE . 55.8 Cg_endo -69.1 175.03 8.08 Favored 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.676 2.251 . . . . 72.14 112.038 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 21.9 tt0 -84.36 -1.06 54.84 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.943 -0.572 . . . . 73.25 111.21 -169.385 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 16.5 p90 -98.89 -20.24 16.93 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.557 -0.457 . . . . 71.31 110.437 174.583 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.519 ' OE2' HD12 ' A' ' 67' ' ' ILE . 19.4 tt0 -90.55 -11.96 38.54 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 121.096 0.474 . . . . 72.11 110.536 -177.038 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.403 HG23 ' O ' ' A' ' 68' ' ' PRO . 45.6 pt -64.88 -19.26 25.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.095 -0.502 . . . . 62.14 110.975 178.891 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -117.6 29.32 7.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.951 -0.568 . . . . 71.3 110.289 176.121 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 23.0 t -63.72 -26.76 68.8 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.898 -0.592 . . . . 61.24 110.15 179.333 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 20.8 p-90 . . . . . 0 C--N 1.324 -0.528 0 CA-C-N 115.896 -0.593 . . . . 72.41 110.579 175.069 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 21.1 m . . . . . 0 C--O 1.236 0.389 0 CA-C-O 120.779 0.324 . . . . 74.41 110.558 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 99.72 83.24 1.72 Allowed Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 120.876 -0.678 . . . . 62.04 111.924 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 50.7 mt-10 -109.51 102.94 51.57 Favored Pre-proline 0 C--N 1.323 -0.545 0 N-CA-C 109.046 -0.724 . . . . 75.4 109.046 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.616 ' HG3' ' CZ ' ' A' ' 31' ' ' PHE . 66.2 Cg_endo -83.48 85.83 1.46 Allowed 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 122.036 1.824 . . . . 54.11 112.076 -176.21 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -96.05 133.47 40.25 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.049 -0.978 . . . . 71.12 109.359 178.764 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.521 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 14.7 p -92.92 127.55 44.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 121.438 0.637 . . . . 64.4 110.262 179.089 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 21.9 m -91.3 105.46 17.8 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.794 -0.639 . . . . 72.21 109.699 177.916 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 63.6 mt -84.36 106.13 14.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.024 -0.535 . . . . 65.45 110.899 -176.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 14.4 mtp180 -105.99 173.05 6.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.928 -0.578 . . . . 74.01 111.052 178.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -148.2 101.16 3.24 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.743 -0.662 . . . . 71.43 110.891 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 118' ' ' GLU . . . . . 0.607 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 3.8 mp0 -104.52 90.61 3.57 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.457 -0.792 . . . . 75.42 110.399 -178.572 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 76.85 -89.52 0.96 Allowed Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.775 -0.726 . . . . 72.05 112.486 179.282 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -127.57 14.57 7.06 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.458 0.129 . . . . 65.31 110.899 178.669 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.607 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 38.4 pttt -123.6 121.36 35.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.267 0.556 . . . . 72.15 111.181 -179.085 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 122' ' ' THR . . . . . 0.519 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 20.8 m -84.13 98.31 9.83 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.488 -0.778 . . . . 73.42 109.748 176.412 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 123' ' ' ILE . . . . . 0.476 HG12 HG23 ' B' ' 137' ' ' VAL . 30.4 mt -89.68 107.52 18.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.174 0.511 . . . . 65.44 110.599 -177.231 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.521 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 69.6 mt-30 -97.95 107.6 20.12 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.783 -0.644 . . . . 54.31 110.515 -178.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -87.47 111.23 20.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.014 -0.539 . . . . 74.45 110.485 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 126' ' ' TYR . . . . . 0.463 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 78.5 m-85 -85.16 101.29 12.34 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.046 -0.353 . . . . 74.4 110.046 176.612 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 20.6 mtm180 -113.41 128.05 56.32 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.413 -0.358 . . . . 73.22 110.234 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.594 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -96.58 -50.6 11.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 C-N-CA 120.731 -0.388 . . . . 51.15 111.521 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -156.67 76.1 0.87 Allowed 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.622 -0.51 . . . . 71.34 109.622 -176.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 66.94 16.73 66.69 Favored Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.713 -0.676 . . . . 50.34 112.403 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.613 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 89.4 t80 -137.33 128.34 27.52 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.038 0.447 . . . . 71.31 110.791 -179.07 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.827 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -83.2 113.35 20.6 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.175 -0.92 . . . . 74.55 108.791 173.879 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 133' ' ' TYR . . . . . 0.421 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 50.9 p90 -104.88 -14.99 15.3 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.388 -0.525 . . . . 73.43 111.665 -178.07 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -159.9 143.01 13.93 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.897 0.38 . . . . 72.21 111.278 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.827 HG13 HD11 ' B' ' 132' ' ' LEU . 80.8 mt -120.93 127.09 75.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.931 -0.577 . . . . 73.33 109.889 174.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.443 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 82.6 tttt -116.69 101.12 8.31 Favored 'General case' 0 C--N 1.321 -0.63 0 N-CA-C 109.411 -0.588 . . . . 70.55 109.411 172.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.542 ' O ' ' HD3' ' B' ' 139' ' ' PRO . 4.9 p -101.95 129.38 53.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.978 0 C-N-CA 120.231 -0.588 . . . . 70.34 109.758 178.715 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.519 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 37.5 t -109.07 84.91 2.94 Favored Pre-proline 0 C--N 1.322 -0.591 0 CA-C-N 115.553 -0.748 . . . . 75.23 109.976 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.542 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 69.0 Cg_endo -87.86 133.46 3.02 Favored 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 122.506 2.138 . . . . 73.44 112.365 178.855 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -60.97 -20.31 62.2 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.94 -0.573 . . . . 75.1 110.304 174.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 5.6 m-70 -122.66 81.88 1.91 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.425 -0.807 . . . . 64.13 109.181 -175.66 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 140.0 -17.44 2.98 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.736 -0.745 . . . . 73.34 112.64 -178.082 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt 70.79 145.5 0.11 Allowed Pre-proline 0 N--CA 1.472 0.639 0 C-N-CA 123.41 0.684 . . . . 75.24 111.896 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.513 ' HB3' HG22 ' B' ' 138' ' ' VAL . 43.0 Cg_endo -67.95 149.1 77.36 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.62 2.213 . . . . 53.44 113.09 -177.342 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -158.71 156.7 30.37 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.848 -0.615 . . . . 73.13 109.695 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -102.29 134.34 45.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.647 0.261 . . . . 60.31 111.117 -179.221 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 46.0 mt -114.02 105.31 13.07 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.045 -0.525 . . . . 64.11 109.704 170.036 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 46.7 t -97.79 137.27 25.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.123 -0.49 . . . . 72.15 110.147 -178.742 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 2.8 mmt85 -75.68 131.64 40.02 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.99 0.424 . . . . 75.44 111.458 178.235 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -87.58 169.68 11.96 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.644 -0.707 . . . . 72.13 109.215 172.264 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 151' ' ' ASP . . . . . 0.449 ' H ' ' HE2' ' A' ' 26' ' ' TYR . 6.2 p-10 -69.99 125.52 26.99 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.374 0.606 . . . . 61.11 109.971 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 120.95 127.9 3.49 Favored Glycine 0 N--CA 1.442 -0.91 0 CA-C-N 115.505 -0.77 . . . . 73.21 112.12 -178.395 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 12.2 t -79.45 45.25 0.65 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.433 0.635 . . . . 53.43 110.08 178.885 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -84.88 -16.94 39.49 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.39 -0.823 . . . . 71.22 110.57 -178.339 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 86.39 23.56 43.25 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.825 -0.703 . . . . 70.15 111.666 -177.061 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 30.7 t30 -99.57 129.95 45.77 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.268 -0.466 . . . . 71.24 110.681 -177.556 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -116.59 151.08 36.94 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.815 -0.63 . . . . 61.02 110.004 178.84 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.7 mm -117.96 129.55 74.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 116.17 -0.468 . . . . 74.31 109.777 178.404 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.449 ' HG3' HD11 ' B' ' 167' ' ' ILE . 92.9 mtt180 -75.02 150.78 38.84 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.821 0.343 . . . . 74.51 111.136 179.362 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 64.7 p -81.29 -27.73 34.95 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 107.993 -1.114 . . . . 70.14 107.993 164.26 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -64.7 -35.61 81.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.019 -1.446 . . . . 65.52 110.94 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -153.24 85.59 4.19 Favored Pre-proline 0 C--N 1.322 -0.589 0 CA-C-N 115.518 -0.764 . . . . 72.5 109.557 -177.137 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -79.14 8.87 3.6 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 123.106 2.537 . . . . 70.35 112.766 -176.299 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -107.4 3.9 25.73 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.214 0.531 . . . . 74.14 110.729 -178.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -125.23 130.65 52.51 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.855 -0.612 . . . . 73.14 110.484 -179.059 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 166' ' ' LEU . . . . . 0.44 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.7 mp -84.67 119.81 25.66 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.695 -0.854 . . . . 75.15 108.695 176.848 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 167' ' ' ILE . . . . . 0.449 HD11 ' HG3' ' B' ' 159' ' ' ARG . 36.4 mm -80.56 119.51 76.49 Favored Pre-proline 0 C--N 1.322 -0.614 0 CA-C-O 120.995 0.426 . . . . 72.45 111.177 -172.048 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.551 ' O ' HG23 ' B' ' 172' ' ' ILE . 58.1 Cg_endo -69.73 173.0 11.58 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.803 2.335 . . . . 72.33 112.098 178.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 169' ' ' GLN . . . . . 0.64 ' O ' HG12 ' B' ' 172' ' ' ILE . 33.9 tt0 -73.78 -33.11 64.11 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.734 -0.666 . . . . 64.53 111.362 -168.71 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 11.6 p90 -66.4 -17.72 64.94 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.437 -0.505 . . . . 72.04 110.714 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.614 ' HA ' ' HB2' ' B' ' 174' ' ' SER . 20.1 tt0 -102.46 -17.68 15.68 Favored 'General case' 0 N--CA 1.444 -0.727 0 CA-C-N 116.428 -0.351 . . . . 72.42 111.496 -177.024 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.64 HG12 ' O ' ' B' ' 169' ' ' GLN . 30.7 pt -70.18 -27.54 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.954 0.407 . . . . 72.22 110.509 178.782 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -118.22 36.25 4.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.517 0.675 . . . . 71.54 109.782 173.194 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 174' ' ' SER . . . . . 0.614 ' HB2' ' HA ' ' B' ' 171' ' ' GLU . 45.3 t -62.39 -27.17 68.89 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.023 -0.99 . . . . 61.21 111.194 -179.307 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.246 0.916 0 CA-C-O 118.437 -0.792 . . . . 70.42 111.263 -179.675 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.0 p . . . . . 0 C--O 1.236 0.355 0 CA-C-O 120.853 0.359 . . . . 64.41 110.875 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.2 -73.34 2.63 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.77 -0.729 . . . . 72.42 111.467 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 60.4 74.87 0.51 Allowed Pre-proline 0 C--N 1.329 -0.285 0 C-N-CA 123.046 0.538 . . . . 65.1 110.152 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.856 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 12.2 Cg_endo -60.32 107.33 0.41 Allowed 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.597 2.198 . . . . 74.02 112.708 -178.806 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 23.7 m-20 -90.5 154.03 19.94 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.627 -0.715 . . . . 61.43 109.876 179.163 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.493 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 12.5 p -117.99 125.74 74.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-O 121.395 0.617 . . . . 64.33 110.549 176.126 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.6 m -98.53 111.45 23.81 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.548 -0.751 . . . . 73.03 110.062 179.253 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.8 mt -93.2 105.86 17.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.285 -0.416 . . . . 42.15 110.945 -176.374 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -120.48 167.42 12.39 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.014 -0.735 . . . . 64.0 109.014 177.244 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 91.6 mt-30 -127.35 119.0 25.24 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 120.929 0.395 . . . . 73.31 111.281 177.173 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.452 ' HG3' HD12 ' A' ' 23' ' ' ILE . 12.4 mm-40 -97.52 82.54 3.11 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.939 -0.763 . . . . 62.41 108.939 175.151 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 79.63 -107.03 2.51 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.3 -0.952 . . . . 62.34 111.351 -173.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.574 ' HB3' ' HB2' ' A' ' 40' ' ' LYS . 10.3 m-20 -108.85 0.41 20.27 Favored 'General case' 0 C--N 1.327 -0.38 0 O-C-N 122.615 -0.344 . . . . 72.43 111.114 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.81 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 22.1 pttm -101.74 113.03 25.84 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.443 0.64 . . . . 72.42 111.022 179.085 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.705 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 21.1 m -80.0 97.87 6.97 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.222 -0.899 . . . . 63.42 109.798 177.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.586 HG12 HG13 ' A' ' 37' ' ' VAL . 55.0 mt -90.85 112.23 24.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.035 0.445 . . . . 73.44 110.566 -176.544 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.588 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 63.8 mt-30 -95.67 108.33 20.61 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.961 -0.563 . . . . 72.35 109.956 178.21 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -84.82 102.81 13.36 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.78 -0.646 . . . . 64.42 110.346 -177.78 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.44 ' HE1' ' HB2' ' A' ' 36' ' ' LYS . 86.3 m-85 -82.12 102.38 11.02 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.162 0.506 . . . . 54.45 109.783 176.626 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 88.1 mtm180 -118.12 117.52 29.39 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.853 -0.612 . . . . 70.45 109.93 -179.382 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.892 HG11 HG11 ' B' ' 128' ' ' VAL . 2.6 p -69.4 -43.19 81.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.924 -0.58 . . . . 63.02 111.14 -174.356 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 33.9 t-20 -169.85 75.35 0.08 Allowed 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.644 -0.873 . . . . 65.4 108.644 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 85.22 -23.54 8.1 Favored Glycine 0 N--CA 1.45 -0.416 0 CA-C-N 115.443 -0.799 . . . . 34.13 112.676 -177.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 51.2 t80 -112.25 131.24 55.6 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.215 0.531 . . . . 60.23 110.749 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.505 HD21 ' CG1' ' A' ' 35' ' ' ILE . 27.2 tp -76.66 126.21 30.59 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 114.974 -1.012 . . . . 72.24 110.463 178.471 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' TYR . . . . . 0.425 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 49.6 p90 -115.23 -14.3 11.71 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.764 -0.374 . . . . 75.33 111.173 179.068 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.508 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -161.72 143.81 11.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.998 0.428 . . . . 74.31 111.142 -177.602 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.624 ' HB ' ' HB2' ' A' ' 47' ' ' LEU . 63.7 mt -121.84 121.35 64.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.992 -0.549 . . . . 52.24 109.87 176.626 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.588 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 88.2 tttt -102.19 99.62 9.76 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.244 -0.651 . . . . 75.43 109.244 172.839 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.69 HG12 ' HD3' ' A' ' 39' ' ' PRO . 3.5 t -86.18 126.63 40.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 108.568 -0.901 . . . . 71.24 108.568 178.132 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.705 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.6 t -115.73 72.87 4.19 Favored Pre-proline 0 C--N 1.318 -0.761 0 N-CA-C 109.753 -0.462 . . . . 64.1 109.753 172.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.81 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 43.2 Cg_endo -77.08 129.4 10.5 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 122.041 1.827 . . . . 75.12 112.413 177.179 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.574 ' HB2' ' HB3' ' A' ' 20' ' ' ASP . 55.7 mtpt -59.05 -32.13 69.47 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.043 -0.981 . . . . 43.54 110.285 176.555 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 67.9 m-70 -115.36 95.93 5.41 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.365 -0.834 . . . . 65.21 109.314 178.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 132.46 -23.06 4.08 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 121.009 -0.615 . . . . 71.44 111.99 -176.779 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.498 ' HD3' ' HA ' ' A' ' 43' ' ' LYS . 68.8 mmtt 72.99 148.94 0.12 Allowed Pre-proline 0 N--CA 1.467 0.389 0 C-N-CA 123.86 0.864 . . . . 74.34 112.651 177.515 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.646 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 27.9 Cg_endo -62.59 141.86 87.68 Favored 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 123.04 2.493 . . . . 62.34 113.921 -174.74 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.422 ' CE2' ' HG2' ' A' ' 59' ' ' ARG . 25.1 p90 -151.43 149.42 29.26 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-N 115.361 -0.836 . . . . 74.03 109.855 176.548 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.597 ' HB2' ' HB2' ' A' ' 60' ' ' SER . 88.6 m-85 -92.35 150.4 20.86 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.286 -0.416 . . . . 75.44 111.14 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.624 ' HB2' ' HB ' ' A' ' 35' ' ' ILE . 23.0 mt -123.37 96.46 4.99 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.711 -0.677 . . . . 43.34 109.674 171.252 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 45.8 t -90.16 122.24 41.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.438 -0.346 . . . . 55.44 110.519 -178.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -62.25 128.98 38.64 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 120.974 0.416 . . . . 74.51 111.303 176.069 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.9 152.33 19.44 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.452 -0.573 . . . . 74.42 109.452 172.601 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -57.85 144.07 40.12 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.332 -0.395 . . . . 71.4 110.58 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 118.45 148.31 8.46 Favored Glycine 0 N--CA 1.431 -1.684 0 C-N-CA 120.198 -1.001 . . . . 51.24 112.402 -179.664 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 16.6 m -76.67 -2.63 33.76 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 114.947 -0.626 . . . . 73.0 110.779 175.306 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -57.91 -43.66 86.34 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.142 -0.481 . . . . 70.32 112.048 -178.057 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 98.79 32.76 5.8 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.419 -0.896 . . . . 45.43 111.63 -179.465 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -87.06 132.82 33.7 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.367 -0.416 . . . . 74.3 110.417 -178.342 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -122.17 160.17 25.7 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.994 -0.548 . . . . 71.02 110.211 177.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.817 HD11 HD23 ' A' ' 66' ' ' LEU . 43.9 mm -120.22 115.32 46.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 116.279 -0.419 . . . . 74.44 109.972 177.661 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.676 ' HG3' HG13 ' A' ' 67' ' ' ILE . 18.7 mtp180 -75.95 130.1 37.94 Favored 'General case' 0 C--O 1.22 -0.492 0 CA-C-N 115.785 -0.643 . . . . 74.42 109.797 177.366 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.597 ' HB2' ' HB2' ' A' ' 46' ' ' PHE . 17.4 t -70.48 -17.53 62.97 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.894 0.854 . . . . 75.53 108.79 172.504 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -67.76 -27.38 66.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 114.384 -1.28 . . . . 61.21 110.453 173.21 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 65.3 tt0 -158.88 78.84 3.01 Favored Pre-proline 0 C--N 1.327 -0.404 0 CA-C-N 115.664 -0.698 . . . . 73.01 109.484 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_endo -78.76 -1.24 11.43 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.725 2.284 . . . . 71.13 112.375 -174.023 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -92.52 0.09 57.39 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.406 -0.816 . . . . 72.43 110.205 -178.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.429 ' HE3' ' O ' ' A' ' 66' ' ' LEU . 52.4 tptt -128.48 134.29 48.68 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.732 -0.667 . . . . 74.11 110.539 -179.078 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.817 HD23 HD11 ' A' ' 58' ' ' ILE . 26.2 mt -80.29 123.48 28.01 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.129 -0.693 . . . . 75.41 109.129 175.182 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.676 HG13 ' HG3' ' A' ' 59' ' ' ARG . 44.1 mm -92.43 113.76 60.32 Favored Pre-proline 0 C--N 1.32 -0.681 0 CA-C-O 120.941 0.401 . . . . 75.34 111.277 -173.08 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -72.62 177.99 6.82 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.887 2.392 . . . . 74.24 112.961 -177.288 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' GLN . . . . . 0.535 ' O ' HG12 ' A' ' 72' ' ' ILE . 19.4 tt0 -77.58 -17.14 58.13 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.493 -0.776 . . . . 73.34 112.067 -168.506 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 10.4 p90 -83.16 -18.32 39.83 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.251 -0.58 . . . . 74.33 110.281 176.76 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.553 ' HB3' HG23 ' A' ' 67' ' ' ILE . 1.4 tm-20 -90.35 -24.49 20.82 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 115.933 -0.576 . . . . 63.14 109.966 -178.304 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.535 HG12 ' O ' ' A' ' 69' ' ' GLN . 31.5 pt -70.28 -20.89 23.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 121.223 0.535 . . . . 62.44 110.396 177.766 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 46.2 m-85 -111.62 33.67 4.6 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.787 -0.642 . . . . 74.22 109.822 174.765 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 19.0 t -67.0 -33.17 74.98 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.384 -0.825 . . . . 62.21 110.171 178.703 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' TRP . . . . . 0.458 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 8.2 p-90 . . . . . 0 C--N 1.327 -0.398 0 CA-C-N 116.003 -0.544 . . . . 74.34 110.602 175.386 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 5.2 p . . . . . 0 N--CA 1.453 -0.289 0 CA-C-O 121.014 0.435 . . . . 63.02 111.065 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 108.75 -77.21 0.22 Allowed Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.588 -1.005 . . . . 73.33 110.588 -177.702 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 68.85 86.68 0.12 Allowed Pre-proline 0 CA--C 1.521 -0.171 0 CA-C-O 121.274 0.559 . . . . 70.02 110.558 173.072 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.668 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 3.0 Cg_exo -69.95 118.04 5.45 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 122.298 1.999 . . . . 74.44 111.731 -174.493 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -118.44 161.38 20.07 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.091 -0.958 . . . . 62.5 109.763 -174.591 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 113' ' ' VAL . . . . . . . . . . . . . 14.6 p -133.3 132.63 58.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.428 0.632 . . . . 61.13 111.5 -178.012 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 31.4 m -97.17 105.07 17.16 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.527 -0.76 . . . . 75.1 109.266 174.191 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 65.6 mt -95.59 104.66 16.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.369 0.604 . . . . 65.23 110.703 -176.369 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 57.1 mtm180 -123.55 176.06 6.42 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.247 -0.888 . . . . 54.34 109.354 176.766 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 117' ' ' GLN . . . . . 0.738 ' HG2' ' HA ' ' B' ' 122' ' ' THR . 37.7 mt-30 -134.17 139.73 46.05 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.411 0.624 . . . . 73.12 111.389 178.712 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 118' ' ' GLU . . . . . 0.565 ' HB3' ' HE2' ' B' ' 121' ' ' LYS . 0.9 OUTLIER -120.15 72.85 0.95 Allowed 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.954 -1.021 . . . . 73.33 109.679 -177.075 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 87.93 -108.87 3.44 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.611 -0.804 . . . . 71.21 111.703 -175.733 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 120' ' ' ASP . . . . . 0.687 ' HB3' ' HD2' ' B' ' 140' ' ' LYS . 39.5 m-20 -109.9 13.24 23.55 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.932 0.396 . . . . 75.14 110.616 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.573 ' HE3' ' HB2' ' B' ' 175' ' ' TRP . 23.7 pttm -120.02 116.49 25.85 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.868 -0.606 . . . . 74.13 110.664 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 122' ' ' THR . . . . . 0.738 ' HA ' ' HG2' ' B' ' 117' ' ' GLN . 20.0 m -77.4 122.16 24.78 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.598 -0.728 . . . . 64.44 109.495 176.489 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 55.7 mt -112.4 107.79 23.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.328 0.585 . . . . 75.44 110.819 -176.356 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.509 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 51.2 mt-30 -100.5 102.9 14.19 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.724 -0.671 . . . . 75.43 109.935 178.476 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 125' ' ' GLU . . . . . 0.407 ' HB3' HD13 ' B' ' 132' ' ' LEU . 48.3 mt-10 -82.92 104.58 13.24 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.005 -0.543 . . . . 73.12 110.521 -179.612 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 126' ' ' TYR . . . . . 0.43 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 79.2 m-85 -82.15 108.9 15.98 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.165 0.507 . . . . 74.43 110.147 178.356 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 82.9 mtt180 -118.97 121.41 39.86 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.806 -0.634 . . . . 74.13 109.342 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.892 HG11 HG11 ' A' ' 28' ' ' VAL . 2.1 p -70.68 -46.44 69.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 C-N-CA 120.761 -0.376 . . . . 72.24 110.719 -178.424 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -158.34 56.96 0.46 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.482 0.658 . . . . 63.12 109.427 -177.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 98.04 -23.74 34.76 Favored Glycine 0 N--CA 1.449 -0.452 0 CA-C-N 115.589 -0.732 . . . . 72.35 112.86 -178.801 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -104.28 129.82 52.11 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 121.062 0.458 . . . . 72.22 110.46 -178.064 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.558 HD21 ' CG1' ' B' ' 135' ' ' ILE . 28.7 tp -74.46 120.86 20.6 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.107 -0.952 . . . . 72.14 110.6 177.777 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 133' ' ' TYR . . . . . 0.43 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 54.1 p90 -110.86 -12.96 14.21 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.845 -0.342 . . . . 74.51 111.204 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 134' ' ' ALA . . . . . 0.565 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -167.1 137.1 2.96 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.974 0.416 . . . . 65.45 111.141 -177.337 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.558 ' CG1' HD21 ' B' ' 132' ' ' LEU . 56.9 mt -114.58 122.78 69.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.02 -0.536 . . . . 73.2 109.821 175.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.509 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.3 tttt -96.0 101.51 13.19 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.089 -0.708 . . . . 51.44 109.089 172.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.681 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.0 t -91.62 125.84 44.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 108.493 -0.929 . . . . 72.21 108.493 177.821 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.536 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.3 t -115.48 72.91 3.81 Favored Pre-proline 0 C--N 1.316 -0.867 0 N-CA-C 109.672 -0.492 . . . . 54.25 109.672 173.791 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.611 ' HD3' HG12 ' B' ' 137' ' ' VAL . 56.8 Cg_endo -80.21 133.32 9.76 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 122.153 1.902 . . . . 64.31 112.005 175.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 140' ' ' LYS . . . . . 0.687 ' HD2' ' HB3' ' B' ' 120' ' ' ASP . 93.0 mttt -52.05 -40.93 61.88 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.527 0.68 . . . . 60.21 110.219 175.378 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 8.6 m-70 -112.26 91.9 3.82 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.108 -0.951 . . . . 75.53 109.429 -175.056 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 140.66 -21.65 2.7 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.819 -0.628 . . . . 51.2 111.832 -177.014 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt 75.3 150.62 0.13 Allowed Pre-proline 0 N--CA 1.469 0.491 0 C-N-CA 123.544 0.738 . . . . 54.33 111.708 178.271 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.681 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 36.5 Cg_endo -66.9 137.39 44.8 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 122.461 2.107 . . . . 62.14 112.791 -177.8 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 145' ' ' TYR . . . . . 0.413 ' CD2' ' HD2' ' B' ' 159' ' ' ARG . 50.8 p90 -149.51 150.28 32.06 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.751 -0.659 . . . . 72.04 110.352 179.276 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.534 ' O ' ' HA ' ' B' ' 159' ' ' ARG . 92.4 m-85 -95.74 130.35 42.68 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.778 -0.646 . . . . 73.14 110.375 176.857 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.565 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 15.0 mt -99.77 99.29 10.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.119 -0.491 . . . . 74.31 109.908 170.68 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.0 t -83.97 127.99 39.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 116.311 -0.404 . . . . 75.43 110.246 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.99 108.72 2.7 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.124 -0.695 . . . . 72.41 109.124 176.418 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.24 166.38 9.95 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.207 -0.451 . . . . 52.35 110.97 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -53.5 129.03 31.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.7 0.762 . . . . 75.45 112.52 -175.624 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 83.11 -115.99 4.13 Favored Glycine 0 N--CA 1.429 -1.816 0 CA-C-N 114.447 -1.251 . . . . 64.22 111.509 178.653 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 17.0 m -169.41 34.51 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 113.803 -1.198 . . . . 65.54 109.384 -178.732 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -78.79 35.7 0.25 Allowed 'General case' 0 CA--C 1.535 0.365 0 CA-C-N 115.4 -0.818 . . . . 72.25 111.405 -173.492 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 58.12 43.23 95.35 Favored Glycine 0 C--O 1.229 -0.212 0 CA-C-N 115.789 -0.641 . . . . 62.14 113.21 177.502 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 47.1 t30 -137.3 137.83 39.39 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.185 0.516 . . . . 74.32 111.085 -177.36 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 157' ' ' PHE . . . . . 0.527 ' HB3' HD22 ' B' ' 147' ' ' LEU . 39.0 m-85 -131.09 154.25 48.48 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.189 -0.914 . . . . 75.13 108.697 172.481 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 49.2 mm -120.65 122.79 68.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 N-CA-C 110.183 -0.303 . . . . 61.45 110.183 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.955 ' HG3' HG13 ' B' ' 167' ' ' ILE . 31.5 mtm-85 -88.9 137.28 32.46 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-N 116.338 -0.392 . . . . 72.44 110.126 178.067 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 35.1 t -64.69 -18.94 65.44 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.445 0.64 . . . . 73.32 109.334 171.347 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -59.37 -52.13 66.95 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 114.942 -1.027 . . . . 71.15 110.878 174.4 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 75.6 mt-30 -143.71 79.6 13.45 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 74.41 110.442 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -68.21 -0.58 5.87 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 123.292 2.661 . . . . 60.1 112.329 177.115 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -81.44 -18.48 45.16 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.639 -0.71 . . . . 64.25 110.233 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -119.95 140.11 51.42 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.856 -0.611 . . . . 61.34 110.885 -177.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.0 mp -81.87 126.87 32.4 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 107.898 -1.149 . . . . 74.32 107.898 171.007 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 167' ' ' ILE . . . . . 0.955 HG13 ' HG3' ' B' ' 159' ' ' ARG . 44.7 mm -87.81 119.66 70.63 Favored Pre-proline 0 C--N 1.318 -0.794 0 CA-C-O 120.882 0.372 . . . . 75.34 111.267 -170.425 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.449 ' O ' HG23 ' B' ' 172' ' ' ILE . 58.8 Cg_endo -71.09 174.3 10.85 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 123.27 2.647 . . . . 65.44 112.655 -179.187 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 169' ' ' GLN . . . . . 0.813 ' HA ' HG12 ' B' ' 172' ' ' ILE . 8.5 tt0 -72.75 -32.62 65.79 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.58 -0.736 . . . . 61.44 111.963 -168.592 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 36.9 p90 -73.56 -17.86 61.14 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.165 0.507 . . . . 74.33 110.326 178.103 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 171' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -94.28 -30.86 14.33 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.847 -0.615 . . . . 63.23 110.964 178.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.813 HG12 ' HA ' ' B' ' 169' ' ' GLN . 37.6 pt -74.45 -29.3 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.985 0.421 . . . . 73.13 110.381 176.312 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -104.76 37.86 2.04 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.184 0.516 . . . . 73.14 110.13 175.256 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 15.9 t -73.78 -22.88 59.69 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.827 -0.624 . . . . 65.3 110.262 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 175' ' ' TRP . . . . . 0.573 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 60.3 p-90 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.243 -0.884 . . . . 75.21 110.656 -178.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 28.5 p . . . . . 0 N--CA 1.452 -0.325 0 CA-C-O 120.883 0.373 . . . . 74.43 110.043 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.79 105.63 3.02 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 110.2 -1.16 . . . . 65.24 110.2 -173.749 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -116.76 95.74 47.06 Favored Pre-proline 0 C--N 1.317 -0.823 0 N-CA-C 109.516 -0.55 . . . . 74.41 109.516 -171.437 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.29 100.35 1.36 Allowed 'Trans proline' 0 N--CA 1.445 -1.372 0 C-N-CA 121.797 1.664 . . . . 43.05 111.422 -177.831 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -132.12 145.28 51.28 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.222 -0.899 . . . . 75.33 109.546 178.541 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.705 HG21 ' HB3' ' A' ' 24' ' ' GLN . 12.8 p -98.63 131.5 45.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 CA-C-O 121.297 0.57 . . . . 75.24 111.674 -172.628 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.49 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 25.0 m -83.69 103.79 13.28 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.686 -0.688 . . . . 75.22 109.211 176.527 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 61.3 mt -93.44 105.66 17.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 116.246 -0.434 . . . . 74.1 110.474 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 28.4 mmm180 -121.41 153.74 37.43 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.99 -0.55 . . . . 73.3 110.29 177.401 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 23.3 mp0 -113.49 107.66 16.12 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-O 121.355 0.598 . . . . 75.51 110.522 -178.069 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.653 ' HG3' HD12 ' A' ' 23' ' ' ILE . 24.1 mm-40 -106.21 88.4 2.78 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.204 -0.907 . . . . 62.11 109.8 -177.115 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 74.11 -109.57 2.83 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.702 -0.761 . . . . 64.34 112.201 -179.55 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.672 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 25.4 m-20 -109.31 22.4 15.87 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.752 0.311 . . . . 72.01 110.507 -177.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.56 ' HE2' HD11 ' A' ' 23' ' ' ILE . 22.2 pttm -138.41 127.05 23.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.307 0.575 . . . . 60.15 111.175 -178.663 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.591 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 26.4 m -85.13 103.9 14.54 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.623 -0.717 . . . . 62.33 109.232 174.423 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.653 HD12 ' HG3' ' A' ' 18' ' ' GLU . 41.7 mt -95.61 112.54 28.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.162 0.505 . . . . 72.42 110.294 -176.029 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.705 ' HB3' HG21 ' A' ' 13' ' ' VAL . 76.4 mt-30 -103.82 109.78 21.65 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.413 -0.812 . . . . 72.33 111.111 -176.86 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.49 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 24.7 mt-10 -94.61 106.67 18.66 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.032 -0.531 . . . . 72.34 111.137 -179.113 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.493 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 54.5 m-85 -76.69 109.52 10.53 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.276 -0.42 . . . . 52.53 110.508 178.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 74.7 mtt180 -124.06 140.49 52.92 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.337 -0.392 . . . . 74.11 110.115 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.505 HG21 ' CG ' ' B' ' 131' ' ' PHE . 12.3 p -109.03 -19.47 6.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.422 0.63 . . . . 72.53 111.28 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -159.82 24.54 0.18 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.237 -0.653 . . . . 72.45 109.237 -176.321 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 99.62 -31.18 8.65 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 110.984 -0.846 . . . . 75.32 110.984 -169.745 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 89.3 t80 -66.87 130.1 42.04 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.178 -0.511 . . . . 75.3 110.811 178.004 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.757 HD11 HG13 ' A' ' 35' ' ' ILE . 3.3 tm? -88.38 114.47 25.03 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.554 -0.748 . . . . 41.53 109.231 178.19 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' TYR . . . . . 0.493 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 43.2 p90 -110.98 -13.27 14.13 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.664 -0.414 . . . . 74.24 111.682 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -163.21 144.42 9.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.723 0.296 . . . . 65.01 111.34 179.588 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.757 HG13 HD11 ' A' ' 32' ' ' LEU . 71.3 mt -126.1 123.71 64.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.111 -0.495 . . . . 62.31 109.768 176.07 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.419 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 87.0 tttt -108.81 107.22 17.56 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.628 -0.508 . . . . 63.15 109.628 176.029 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.649 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.7 t -89.92 132.31 34.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.189 -0.671 . . . . 53.04 109.189 178.38 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.591 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 18.9 t -116.57 73.97 6.05 Favored Pre-proline 0 C--N 1.322 -0.623 0 N-CA-C 109.433 -0.58 . . . . 41.24 109.433 171.194 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.47 ' HD3' HG12 ' A' ' 37' ' ' VAL . 61.0 Cg_endo -78.71 145.87 20.69 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.642 2.228 . . . . 74.1 112.977 179.212 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.672 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 30.5 mtpp -68.07 -28.0 66.99 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.514 -0.766 . . . . 73.53 109.932 174.043 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 66.5 m-70 -122.52 96.2 4.94 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.55 -0.75 . . . . 54.44 109.745 178.674 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.418 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 139.51 -21.5 2.9 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.73 -0.747 . . . . 54.52 112.422 -179.649 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.422 ' HD3' ' HA ' ' A' ' 43' ' ' LYS . 69.4 mmtt 71.89 150.38 0.13 Allowed Pre-proline 0 N--CA 1.47 0.56 0 C-N-CA 123.201 0.6 . . . . 71.44 111.956 -179.593 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.649 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 39.4 Cg_endo -67.0 137.18 43.72 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.564 2.176 . . . . 73.53 112.683 -178.359 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 42.0 p90 -149.52 163.95 36.41 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.738 -0.664 . . . . 73.33 110.294 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.472 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 96.3 m-85 -108.22 126.44 52.81 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.484 -0.325 . . . . 72.53 111.429 -176.797 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.449 ' HB3' ' HD2' ' A' ' 57' ' ' PHE . 36.9 mt -107.22 100.14 9.62 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.131 -0.486 . . . . 72.51 109.977 171.253 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.6 t -84.74 126.72 40.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.245 -0.434 . . . . 73.35 109.901 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.45 111.39 18.43 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.236 -0.653 . . . . 73.42 109.236 -178.542 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.05 168.89 19.01 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.8 -0.636 . . . . 60.41 111.411 -172.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -64.14 145.19 56.37 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.765 -0.652 . . . . 74.33 109.904 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 113.83 135.95 6.26 Favored Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.452 -0.88 . . . . 44.3 112.373 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.2 m -79.24 19.68 0.56 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.931 0.396 . . . . 61.54 110.832 178.857 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -78.91 -42.61 26.7 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.026 0.441 . . . . 64.22 111.137 -177.313 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.84 36.4 2.99 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.698 -0.763 . . . . 75.32 111.919 -178.404 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.2 t30 -95.45 129.49 42.59 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.821 0.343 . . . . 74.05 110.539 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.449 ' HD2' ' HB3' ' A' ' 47' ' ' LEU . 34.7 m-85 -111.51 149.38 31.43 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.227 -0.442 . . . . 72.41 110.153 177.016 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 51.0 mm -121.57 125.73 73.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.22 -0.445 . . . . 72.12 109.98 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.581 ' HG3' HG13 ' A' ' 67' ' ' ILE . 27.4 mtp180 -81.6 141.08 34.05 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.438 -0.346 . . . . 72.12 110.66 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 33.7 t -70.0 -16.21 63.14 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.229 0.538 . . . . 74.14 109.894 176.441 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.46 ' OD1' ' HB3' ' A' ' 59' ' ' ARG . 0.4 OUTLIER -76.03 -34.41 59.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.4 -0.818 . . . . 73.31 109.945 178.169 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 47.7 mt-30 -143.26 70.36 18.01 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.443 -0.799 . . . . 74.33 109.786 -174.683 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -72.88 -2.35 11.83 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 123.325 2.684 . . . . 73.45 113.476 -175.067 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -94.06 -13.63 26.67 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.608 0.242 . . . . 71.45 111.332 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.419 ' HE2' ' HB2' ' A' ' 65' ' ' LYS . 0.0 OUTLIER -117.02 168.76 9.97 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-O 120.549 0.214 . . . . 73.05 110.943 -179.567 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.429 ' N ' HD12 ' A' ' 66' ' ' LEU . 4.1 mp -106.3 151.84 24.31 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 120.831 0.348 . . . . 74.11 111.032 -175.228 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.581 HG13 ' HG3' ' A' ' 59' ' ' ARG . 37.9 mm -119.54 104.98 44.43 Favored Pre-proline 0 C--N 1.325 -0.463 0 CA-C-N 116.192 -0.458 . . . . 52.05 109.98 177.519 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.558 ' O ' HG23 ' A' ' 72' ' ' ILE . 61.3 Cg_endo -73.77 177.42 8.11 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.822 2.348 . . . . 62.22 113.004 -178.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' GLN . . . . . 0.626 ' HA ' HG12 ' A' ' 72' ' ' ILE . 28.5 tt0 -65.32 -32.05 73.5 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 113.029 0.751 . . . . 64.12 113.029 -168.159 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 3.9 p90 -71.34 -18.95 62.36 Favored 'General case' 0 C--N 1.323 -0.545 0 O-C-N 121.517 -0.739 . . . . 74.43 110.592 178.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.47 ' HB3' HG23 ' A' ' 67' ' ' ILE . 4.8 tp10 -102.38 -17.76 15.7 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 115.749 -0.66 . . . . 72.35 110.549 -177.117 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.626 HG12 ' HA ' ' A' ' 69' ' ' GLN . 35.3 pt -74.26 -21.77 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.147 0 CA-C-O 121.256 0.55 . . . . 63.0 109.863 174.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -107.21 26.59 9.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.417 -0.81 . . . . 73.54 109.664 174.575 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.2 t -61.42 -29.84 70.19 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.197 -0.91 . . . . 65.54 110.234 179.295 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' TRP . . . . . 0.517 ' O ' ' HE3' ' A' ' 21' ' ' LYS . 28.3 p-90 . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.135 -0.484 . . . . 72.22 110.757 175.399 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 15.0 m . . . . . 0 C--O 1.233 0.236 0 CA-C-O 121.108 0.48 . . . . 72.43 110.737 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 124.49 -65.6 0.54 Allowed Glycine 0 N--CA 1.442 -0.953 0 N-CA-C 109.983 -1.247 . . . . 74.05 109.983 -174.593 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 66.82 86.4 0.13 Allowed Pre-proline 0 N--CA 1.463 0.178 0 O-C-N 124.334 0.667 . . . . 65.3 111.736 173.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.579 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 11.2 Cg_endo -77.58 97.16 1.13 Allowed 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 121.913 1.742 . . . . 72.55 110.775 177.441 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -128.81 150.82 50.15 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.407 -0.815 . . . . 75.31 109.67 -175.081 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.539 HG21 ' HB3' ' B' ' 124' ' ' GLN . 12.0 p -100.7 131.31 48.56 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 121.417 0.627 . . . . 75.11 111.748 -174.108 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 114' ' ' THR . . . . . 0.587 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 15.6 m -87.77 102.43 14.66 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.5 -0.773 . . . . 73.15 109.772 175.585 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 55.1 mt -91.03 105.82 16.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-O 120.829 0.347 . . . . 73.51 110.495 -176.291 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 28.7 mmm180 -112.85 157.89 20.84 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.259 -0.428 . . . . 65.32 110.464 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -121.22 99.32 6.42 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.23 -0.441 . . . . 33.11 109.961 178.139 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 57.5 mm-40 -109.59 80.86 1.36 Allowed 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.981 -0.554 . . . . 65.41 110.515 -176.353 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 82.26 -121.43 5.43 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 121.008 -0.615 . . . . 73.21 112.32 -179.351 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 120' ' ' ASP . . . . . 0.493 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 5.9 m-20 -88.57 0.89 55.88 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.914 0.388 . . . . 74.11 110.527 -176.697 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.617 ' HE2' ' HB2' ' B' ' 175' ' ' TRP . 15.6 pttp -125.47 124.67 41.9 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.349 0.595 . . . . 75.12 112.373 -172.54 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 122' ' ' THR . . . . . 0.454 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 33.4 m -83.97 109.7 17.84 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.044 -0.98 . . . . 75.25 108.595 172.114 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 53.2 mt -100.3 107.83 21.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.107 0.48 . . . . 61.51 110.627 -173.45 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.678 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 63.9 mt-30 -95.5 102.26 14.05 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.67 -0.695 . . . . 63.43 110.45 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 125' ' ' GLU . . . . . 0.587 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 43.3 mt-10 -86.87 102.31 14.2 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.265 -0.425 . . . . 71.23 110.365 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -78.54 104.83 9.4 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.122 0.487 . . . . 75.3 110.017 178.101 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 127' ' ' ARG . . . . . 0.513 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 82.6 mtm180 -126.14 136.76 53.26 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.653 -0.703 . . . . 71.52 110.141 -179.186 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.677 HG13 ' H ' ' B' ' 129' ' ' ASN . 2.4 p -84.81 -67.87 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 C-N-CA 120.32 -0.552 . . . . 61.33 109.658 175.677 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 129' ' ' ASN . . . . . 0.677 ' H ' HG13 ' B' ' 128' ' ' VAL . 2.2 t-20 -138.64 75.84 1.54 Allowed 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.56 -0.533 . . . . 71.3 109.56 178.332 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.7 -27.55 5.29 Favored Glycine 0 CA--C 1.518 0.231 0 CA-C-N 115.771 -0.65 . . . . 62.23 112.223 -178.462 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.505 ' CG ' HG21 ' A' ' 28' ' ' VAL . 82.9 t80 -86.19 124.75 32.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.902 0.382 . . . . 60.41 111.225 -177.176 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.857 HD11 HG13 ' B' ' 135' ' ' ILE . 3.5 tm? -85.6 119.38 25.88 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.893 -0.78 . . . . 52.25 108.893 175.462 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 44.1 p90 -112.94 -17.11 12.55 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.495 -0.482 . . . . 63.3 111.787 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.46 133.22 6.43 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.717 0.294 . . . . 63.22 111.059 178.552 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.857 HG13 HD11 ' B' ' 132' ' ' LEU . 69.8 mt -113.28 120.34 62.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.453 -0.339 . . . . 74.41 110.174 174.4 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.678 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.9 tttt -101.0 104.64 15.81 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.682 -0.488 . . . . 65.43 109.682 176.213 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.609 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 2.7 t -90.91 128.67 42.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 108.928 -0.767 . . . . 63.34 108.928 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.454 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 20.3 t -112.96 73.34 1.57 Allowed Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.771 -0.455 . . . . 75.45 109.771 171.253 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.491 ' HG3' ' HE1' ' B' ' 145' ' ' TYR . 72.9 Cg_endo -80.66 143.84 15.24 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 122.438 2.092 . . . . 71.34 112.76 178.886 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 140' ' ' LYS . . . . . 0.493 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 30.0 mtpp -65.75 -23.77 66.81 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.483 -0.78 . . . . 74.21 110.383 174.04 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 72.6 m-70 -115.91 95.07 4.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.574 -0.739 . . . . 54.04 110.025 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 142' ' ' GLY . . . . . 0.449 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 127.58 -9.93 6.83 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.178 -1.011 . . . . 51.41 113.638 177.093 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 143' ' ' LYS . . . . . 0.449 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 73.1 mmtt 70.64 155.9 0.15 Allowed Pre-proline 0 N--CA 1.472 0.644 0 CA-C-O 120.755 0.312 . . . . 44.02 111.164 -178.488 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.609 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 33.6 Cg_endo -66.48 135.13 38.17 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.192 1.928 . . . . 54.51 112.84 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 145' ' ' TYR . . . . . 0.491 ' HE1' ' HG3' ' B' ' 139' ' ' PRO . 14.7 p90 -146.4 161.28 40.71 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.768 -0.651 . . . . 73.1 110.205 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -106.75 138.46 42.88 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.27 -0.423 . . . . 72.44 111.758 -176.721 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.486 ' HB2' ' HB ' ' B' ' 135' ' ' ILE . 18.7 mt -110.38 95.73 5.76 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.447 -0.797 . . . . 75.3 109.72 168.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 41.6 t -82.14 126.39 39.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 109.692 -0.484 . . . . 72.41 109.692 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 149' ' ' ARG . . . . . 0.47 ' HG3' HH11 ' B' ' 149' ' ' ARG . 0.0 OUTLIER -80.86 114.66 19.89 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.439 -0.578 . . . . 62.11 109.439 -179.228 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.75 165.18 25.65 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.627 -0.715 . . . . 42.41 111.005 -174.226 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -70.44 147.57 49.32 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.581 -0.526 . . . . 71.42 109.581 178.235 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 105.01 131.26 7.03 Favored Glycine 0 N--CA 1.436 -1.347 0 C-N-CA 120.61 -0.805 . . . . 61.34 111.357 -175.554 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 21.6 m -82.77 17.8 1.75 Allowed 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.286 0.565 . . . . 75.01 110.587 -178.733 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -64.77 -52.96 54.14 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.488 -0.778 . . . . 61.43 110.958 -178.884 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 125.86 50.36 0.18 Allowed Glycine 0 CA--C 1.505 -0.588 0 C-N-CA 120.657 -0.782 . . . . 50.43 112.025 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 4.9 m120 -119.06 134.29 55.28 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.356 -0.422 . . . . 54.34 111.484 -177.305 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 157' ' ' PHE . . . . . 0.434 ' HB2' HG22 ' B' ' 172' ' ' ILE . 29.6 m-85 -117.31 159.19 23.1 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.541 -0.754 . . . . 63.23 109.735 174.357 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 158' ' ' ILE . . . . . 0.9 HD11 HD23 ' B' ' 166' ' ' LEU . 47.4 mm -120.7 122.79 68.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 116.256 -0.429 . . . . 74.5 110.008 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.627 ' HG3' HG13 ' B' ' 167' ' ' ILE . 52.2 mtp180 -87.81 147.18 25.26 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.375 -0.375 . . . . 73.21 110.379 178.028 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 33.8 t -67.38 -20.64 65.57 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.337 0.589 . . . . 74.45 109.466 174.713 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 161' ' ' ASP . . . . . 0.471 ' OD1' ' HB3' ' B' ' 159' ' ' ARG . 0.5 OUTLIER -71.93 -34.19 68.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.221 -0.9 . . . . 71.14 109.869 177.248 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -141.47 76.88 20.31 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.448 -0.796 . . . . 73.42 109.709 -174.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -82.18 4.53 6.99 Favored 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 122.746 2.297 . . . . 71.54 113.326 -173.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -109.07 -11.07 14.99 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.804 0.335 . . . . 73.35 111.084 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -122.93 137.25 55.0 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.75 0.31 . . . . 75.55 110.907 -176.59 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 166' ' ' LEU . . . . . 0.9 HD23 HD11 ' B' ' 158' ' ' ILE . 93.6 mt -73.96 130.65 40.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.018 -0.537 . . . . 74.34 109.986 177.122 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 167' ' ' ILE . . . . . 0.627 HG13 ' HG3' ' B' ' 159' ' ' ARG . 42.3 mm -81.48 128.5 69.54 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 116.366 -0.379 . . . . 73.22 110.393 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.527 ' O ' HG23 ' B' ' 172' ' ' ILE . 40.0 Cg_endo -65.75 173.01 7.37 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 123.163 2.575 . . . . 63.31 112.789 -179.344 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 33.8 tt0 -86.11 3.76 41.21 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.825 -0.625 . . . . 73.41 112.181 -168.271 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 170' ' ' TRP . . . . . 0.464 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 33.7 p90 -104.05 -18.89 14.38 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.377 -0.529 . . . . 73.42 109.872 172.799 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.464 ' HG2' ' CD1' ' B' ' 170' ' ' TRP . 2.8 mm-40 -97.65 -10.47 24.98 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.566 -0.743 . . . . 71.14 111.393 -176.631 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.527 HG23 ' O ' ' B' ' 168' ' ' PRO . 30.7 pt -71.68 -21.52 21.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.877 -0.601 . . . . 71.2 110.171 175.537 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -112.09 46.49 1.15 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.41 -0.814 . . . . 64.2 108.995 174.568 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 174' ' ' SER . . . . . 0.464 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 2.1 t -74.89 -13.84 60.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.402 -0.817 . . . . 74.22 110.163 -178.403 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 175' ' ' TRP . . . . . 0.617 ' HB2' ' HE2' ' B' ' 121' ' ' LYS . 49.1 p-90 . . . . . 0 C--O 1.248 0.998 0 CA-C-N 115.502 -0.772 . . . . 74.13 109.85 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 41.6 m . . . . . 0 C--O 1.233 0.193 0 CA-C-O 121.112 0.482 . . . . 73.32 111.022 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -177.69 -38.72 0.06 OUTLIER Glycine 0 N--CA 1.446 -0.663 0 N-CA-C 110.71 -0.956 . . . . 54.24 110.71 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 54.05 66.29 4.52 Favored Pre-proline 0 N--CA 1.464 0.254 0 C-N-CA 123.556 0.742 . . . . 71.05 112.15 175.81 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 53.8 Cg_endo -76.97 137.49 17.53 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.169 1.912 . . . . 73.11 112.516 -178.317 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -141.4 155.83 45.86 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.968 -0.56 . . . . 71.5 109.738 179.755 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.8 p -110.88 129.75 65.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.273 0.559 . . . . 64.12 110.842 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.6 m -93.86 104.38 16.45 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.728 -0.669 . . . . 71.44 109.563 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 67.1 mt -90.1 106.82 17.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 116.301 -0.409 . . . . 72.41 110.351 -177.878 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 23.6 mmm180 -115.57 156.96 24.83 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.143 -0.48 . . . . 73.43 110.212 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 26.1 mp0 -121.58 127.17 50.64 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 121.098 0.475 . . . . 70.22 110.057 178.047 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -105.08 -60.58 1.59 Allowed 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.35 -0.841 . . . . 63.13 111.0 -172.12 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.519 ' C ' ' H ' ' A' ' 21' ' ' LYS . . . -156.95 76.58 0.2 Allowed Glycine 0 CA--C 1.507 -0.433 0 N-CA-C 110.353 -1.099 . . . . 51.42 110.353 178.741 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.538 ' HB3' ' HG3' ' A' ' 40' ' ' LYS . 19.2 m-20 70.07 -26.76 0.16 Allowed 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 123.519 0.728 . . . . 63.33 111.017 -170.907 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.519 ' H ' ' C ' ' A' ' 19' ' ' GLY . 22.7 pttm -83.42 120.21 25.61 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 121.198 0.523 . . . . 60.14 110.42 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.594 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 33.2 m -82.48 121.62 26.99 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.375 -0.83 . . . . 72.31 109.641 176.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 56.0 mt -111.33 106.77 21.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-O 121.036 0.446 . . . . 61.44 110.333 -178.188 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.67 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 67.5 mt-30 -100.53 111.04 23.24 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.788 -0.642 . . . . 55.1 110.756 -177.642 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 33.0 mt-10 -92.57 108.77 20.23 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.768 -0.651 . . . . 63.1 110.85 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.57 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 95.6 m-85 -83.0 104.65 13.37 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.968 0.414 . . . . 63.01 110.151 178.317 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -115.12 119.25 35.77 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.947 -0.569 . . . . 74.31 109.617 -179.24 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.781 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.7 p -73.26 -73.32 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 C-N-CA 120.786 -0.366 . . . . 61.32 110.879 -178.834 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.781 ' H ' HG13 ' A' ' 28' ' ' VAL . 7.6 t-20 -127.53 68.28 1.3 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.291 -0.633 . . . . 62.51 109.291 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 73.19 12.52 79.62 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.452 -0.795 . . . . 72.53 111.784 -175.763 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 29.5 t80 -129.33 124.08 33.42 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.818 0.342 . . . . 64.11 110.202 -175.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.419 HD11 HG13 ' A' ' 35' ' ' ILE . 3.2 tm? -72.41 132.76 44.35 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.611 -0.722 . . . . 74.41 109.781 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' TYR . . . . . 0.57 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 45.4 p90 -125.76 -22.81 4.13 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.127 0.417 . . . . 74.34 112.127 176.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.18 148.23 24.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.661 0.267 . . . . 75.23 111.022 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.419 HG13 HD11 ' A' ' 32' ' ' LEU . 61.6 mt -125.23 124.37 67.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 116.412 -0.358 . . . . 73.51 110.215 177.49 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.67 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.6 tttt -103.72 106.24 16.7 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.631 -0.507 . . . . 74.52 109.631 177.121 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.698 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.7 t -94.65 129.7 44.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 N-CA-C 109.226 -0.657 . . . . 34.5 109.226 177.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.594 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.4 t -117.6 72.57 7.81 Favored Pre-proline 0 C--N 1.317 -0.808 0 N-CA-C 109.845 -0.428 . . . . 45.43 109.845 173.646 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.581 ' HD3' HG12 ' A' ' 37' ' ' VAL . 54.1 Cg_endo -78.62 137.31 14.37 Favored 'Trans proline' 0 N--CA 1.456 -0.735 0 C-N-CA 122.197 1.932 . . . . 61.24 112.297 176.213 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.538 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 26.3 mtpp -68.76 -20.46 64.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.451 0.643 . . . . 44.04 109.868 178.333 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 84.7 m-70 -117.69 83.57 2.01 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.392 -0.822 . . . . 71.04 109.423 178.27 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.443 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 141.33 -22.0 2.58 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.945 -0.645 . . . . 52.4 112.339 -178.562 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.443 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 98.6 mttt 74.78 152.72 0.14 Allowed Pre-proline 0 N--CA 1.469 0.477 0 C-N-CA 123.579 0.752 . . . . 74.32 111.889 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.698 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 35.1 Cg_endo -66.73 136.37 41.9 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.651 2.234 . . . . 73.12 113.247 -178.139 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -142.33 162.32 35.77 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.511 -0.768 . . . . 62.14 109.589 176.505 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -106.11 123.19 47.63 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.397 -0.365 . . . . 72.35 110.244 178.183 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.465 HD11 HG13 ' A' ' 67' ' ' ILE . 28.5 tp -102.27 96.1 6.74 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 108.792 -0.818 . . . . 74.43 108.792 172.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.5 t -93.63 120.63 43.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.749 -0.659 . . . . 73.4 110.181 -175.311 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.7 tmm_? -77.88 121.47 24.18 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 109.065 -0.717 . . . . 74.15 109.065 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.15 -162.98 0.26 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.913 -0.585 . . . . 62.35 111.269 -173.754 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.404 ' OD2' ' HB2' ' A' ' 53' ' ' SER . 5.7 p-10 -73.76 154.78 39.43 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.161 0.505 . . . . 63.23 110.805 -177.443 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -65.29 -22.35 69.14 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.641 -0.709 . . . . 50.11 113.28 -177.422 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.404 ' HB2' ' OD2' ' A' ' 51' ' ' ASP . 14.5 m -73.52 -39.9 64.43 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.089 0.471 . . . . 40.03 109.958 178.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.521 ' OD2' ' HB3' ' A' ' 56' ' ' ASN . 31.2 t70 -71.66 -39.76 70.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.506 -0.77 . . . . 54.24 109.835 175.834 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 58.95 63.49 5.15 Favored Glycine 0 C--N 1.336 0.557 0 CA-C-N 115.78 -0.646 . . . . 74.43 111.663 178.312 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.521 ' HB3' ' OD2' ' A' ' 54' ' ' ASP . 14.6 t30 -165.36 155.76 13.51 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.685 -0.257 . . . . 72.12 110.331 -168.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.572 ' HB2' ' HB ' ' A' ' 67' ' ' ILE . 2.4 m-85 -108.68 143.11 38.2 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.162 -0.681 . . . . 75.44 109.162 174.448 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 48.1 mm -113.53 127.46 70.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.436 0.636 . . . . 74.55 110.319 177.468 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.469 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 58.5 ttt180 -93.63 124.09 37.39 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.309 -0.86 . . . . 73.0 109.685 -176.805 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 87.9 p -59.67 -26.77 65.82 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.242 0.544 . . . . 41.12 110.788 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.469 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 16.5 t70 -60.22 -39.71 87.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.211 -0.904 . . . . 62.45 110.711 177.575 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 29.3 mt-30 -144.67 89.01 6.85 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 115.947 -0.569 . . . . 71.11 109.863 -179.018 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -62.58 -24.71 75.22 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 123.1 2.533 . . . . 75.13 113.261 -175.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -78.84 -14.27 59.34 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 120.747 0.308 . . . . 73.51 110.73 178.254 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.2 tptm -93.71 123.42 37.02 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.459 0.647 . . . . 52.51 110.892 -177.258 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.412 ' N ' HD12 ' A' ' 66' ' ' LEU . 5.5 mp -90.24 128.48 36.41 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 114.798 -1.092 . . . . 61.4 108.688 175.523 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.757 HG23 ' HB3' ' A' ' 71' ' ' GLU . 47.0 mm -87.9 112.67 50.6 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-O 120.854 0.359 . . . . 72.21 111.373 -172.883 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.571 ' O ' HG23 ' A' ' 72' ' ' ILE . 60.0 Cg_endo -71.44 174.97 10.07 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.833 2.355 . . . . 53.14 112.036 179.163 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -79.15 1.85 22.96 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 112.987 0.736 . . . . 64.32 112.987 -166.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 42.4 p90 -107.04 -19.62 13.56 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.437 0.637 . . . . 70.42 109.953 172.881 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.757 ' HB3' HG23 ' A' ' 67' ' ' ILE . 2.8 mm-40 -87.41 -17.46 32.23 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.462 -0.79 . . . . 74.3 110.332 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.571 HG23 ' O ' ' A' ' 68' ' ' PRO . 42.3 pt -63.23 -28.39 44.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.885 -0.598 . . . . 65.21 111.412 -179.005 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.477 ' HD1' HG13 ' A' ' 72' ' ' ILE . 41.0 p90 -117.25 42.77 2.47 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.581 0.705 . . . . 74.32 109.584 175.634 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.424 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 4.7 t -59.27 -25.2 63.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.05 -0.977 . . . . 64.54 110.801 -179.567 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 26.6 p-90 . . . . . 0 C--N 1.327 -0.397 0 CA-C-N 115.925 -0.579 . . . . 70.15 111.267 177.479 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 57.1 m . . . . . 0 C--O 1.234 0.268 0 CA-C-O 121.451 0.643 . . . . 63.42 111.089 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 125.24 -60.8 0.62 Allowed Glycine 0 N--CA 1.44 -1.073 0 N-CA-C 109.129 -1.588 . . . . 61.22 109.129 -169.692 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 61.08 88.34 0.12 Allowed Pre-proline 0 CA--C 1.52 -0.209 0 O-C-N 124.322 0.66 . . . . 73.31 111.27 171.416 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.888 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 7.3 Cg_endo -76.41 102.83 1.66 Allowed 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.173 1.915 . . . . 74.23 111.098 -178.497 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -102.89 150.36 23.59 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.037 -0.528 . . . . 61.43 109.838 -177.712 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.644 HG21 ' HB3' ' B' ' 124' ' ' GLN . 14.9 p -113.05 131.58 64.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 121.401 0.62 . . . . 61.43 111.617 -175.153 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 48.1 m -89.46 118.86 29.42 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.314 -0.857 . . . . 61.1 109.373 174.498 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 63.5 mt -92.54 105.25 16.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.07 0.462 . . . . 74.32 111.175 -174.519 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 116' ' ' ARG . . . . . 0.562 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 11.0 mmm180 -99.12 153.0 19.23 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.952 -0.567 . . . . 74.41 110.459 177.224 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 76.0 mt-30 -134.81 99.19 4.24 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.537 -0.912 . . . . 75.12 108.537 176.163 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 118' ' ' GLU . . . . . 0.49 ' HG3' HD12 ' B' ' 123' ' ' ILE . 43.2 mm-40 -103.6 9.25 37.47 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.125 -0.489 . . . . 64.04 112.205 -169.333 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 109.45 100.81 2.64 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.37 -0.919 . . . . 64.13 111.92 -178.744 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 120' ' ' ASP . . . . . 0.573 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 9.5 m-20 66.66 -9.57 0.33 Allowed 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 124.085 0.954 . . . . 73.55 111.672 -176.515 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.491 ' HA ' ' O ' ' B' ' 138' ' ' VAL . 27.1 pttt -131.56 115.71 16.47 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 121.243 0.544 . . . . 75.01 112.074 -176.618 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 59.4 m -82.39 114.03 20.57 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.08 -0.964 . . . . 72.5 109.243 172.408 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 123' ' ' ILE . . . . . 0.708 HG12 HG13 ' B' ' 137' ' ' VAL . 49.8 mt -101.51 105.94 18.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 CA-C-O 121.326 0.584 . . . . 74.52 110.377 -176.114 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.644 ' HB3' HG21 ' B' ' 113' ' ' VAL . 49.7 mt-30 -96.01 106.89 19.11 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.444 -0.798 . . . . 71.23 110.974 -176.571 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -90.06 106.09 18.24 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.841 -0.618 . . . . 74.11 110.631 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -85.1 107.06 17.01 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.994 0.426 . . . . 75.2 110.698 -179.586 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 127' ' ' ARG . . . . . 0.502 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 79.0 mtm180 -120.39 120.52 36.22 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.137 0.494 . . . . 61.2 110.204 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.888 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -76.79 -62.5 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.893 -0.594 . . . . 72.22 111.021 -178.177 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 129' ' ' ASN . . . . . 0.574 ' H ' HG13 ' B' ' 128' ' ' VAL . 1.2 t-20 -149.21 76.82 1.34 Allowed 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.638 -0.504 . . . . 64.01 109.638 -178.54 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.75 -7.34 66.11 Favored Glycine 0 CA--C 1.521 0.438 0 CA-C-N 115.817 -0.629 . . . . 45.43 113.058 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.407 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 54.4 t80 -122.31 123.25 40.98 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.151 0.5 . . . . 71.45 111.27 -176.625 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.703 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -76.6 117.84 18.64 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.09 -0.959 . . . . 63.54 108.888 173.431 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -108.06 -22.85 12.23 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.478 -0.489 . . . . 71.05 111.525 -178.233 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -157.62 143.05 17.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.929 0.395 . . . . 75.0 111.329 -178.776 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.703 HG13 HD11 ' B' ' 132' ' ' LEU . 76.5 mt -121.77 121.75 65.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 115.895 -0.593 . . . . 65.55 110.067 176.333 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.467 ' HD2' ' CZ ' ' B' ' 146' ' ' PHE . 82.2 tttt -102.79 105.06 15.41 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.928 0.394 . . . . 70.2 109.99 177.373 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.708 HG13 HG12 ' B' ' 123' ' ' ILE . 5.0 t -90.46 132.37 35.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 108.653 -0.869 . . . . 74.42 108.653 176.08 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.511 HG13 ' HB3' ' B' ' 144' ' ' PRO . 20.6 t -114.21 71.73 2.21 Favored Pre-proline 0 C--N 1.317 -0.822 0 N-CA-C 109.907 -0.405 . . . . 64.03 109.907 173.345 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.534 ' HD3' HG12 ' B' ' 137' ' ' VAL . 74.3 Cg_endo -81.13 134.42 9.24 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.082 1.855 . . . . 73.42 113.243 178.534 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 140' ' ' LYS . . . . . 0.573 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 28.8 mtpp -60.04 -26.85 66.45 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.291 -0.868 . . . . 65.02 109.84 171.83 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 89.4 m-70 -116.8 89.5 3.12 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.282 -0.872 . . . . 73.42 109.492 177.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 138.36 -19.14 3.23 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.482 -0.866 . . . . 54.13 112.536 -179.294 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 47.0 mtmt 71.62 147.21 0.12 Allowed Pre-proline 0 N--CA 1.469 0.522 0 C-N-CA 123.309 0.643 . . . . 64.52 111.637 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.697 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 29.6 Cg_endo -64.8 125.81 15.48 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.584 2.189 . . . . 53.22 112.626 -179.356 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 25.7 p90 -139.88 160.29 40.23 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.076 -0.511 . . . . 71.33 110.383 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.467 ' CZ ' ' HD2' ' B' ' 136' ' ' LYS . 70.4 m-85 -104.54 122.18 45.02 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.091 -0.504 . . . . 73.02 110.04 178.312 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 26.0 tp -97.86 93.33 6.28 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 108.248 -1.019 . . . . 73.03 108.248 171.329 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.6 t -95.39 129.11 45.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.755 -0.657 . . . . 74.32 110.55 -173.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 149' ' ' ARG . . . . . 0.598 ' HG3' HH11 ' B' ' 149' ' ' ARG . 0.0 OUTLIER -79.45 123.22 27.33 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 116.217 -0.447 . . . . 75.51 109.871 177.462 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -77.41 -168.32 1.12 Allowed 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.815 -0.63 . . . . 72.4 110.034 177.801 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -56.94 147.13 24.63 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.174 -0.466 . . . . 52.13 110.792 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -75.14 -10.32 84.2 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.541 -0.838 . . . . 60.24 112.745 -177.006 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 1.6 m -67.67 -38.33 83.59 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.888 0.851 . . . . 71.35 108.729 172.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 15.1 t0 -80.36 -42.08 23.56 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.335 -1.302 . . . . 74.14 109.627 175.36 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 69.38 18.8 73.78 Favored Glycine 0 C--N 1.331 0.27 0 CA-C-N 115.17 -0.923 . . . . 72.34 112.139 -177.132 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 39.2 t30 -104.63 155.43 18.86 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 122.453 0.301 . . . . 62.31 111.656 -169.79 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 157' ' ' PHE . . . . . 0.662 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 8.3 m-85 -110.28 146.63 35.35 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.922 -0.77 . . . . 63.44 108.922 173.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.7 mm -118.31 133.39 65.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.038 0.447 . . . . 54.02 110.341 178.308 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.525 ' HD2' HD11 ' B' ' 167' ' ' ILE . 9.5 ttt180 -88.69 122.24 31.91 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.208 -0.664 . . . . 72.02 109.208 -179.001 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 66.5 p -57.66 -30.56 65.53 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 112.141 0.423 . . . . 61.24 112.141 -174.879 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -69.66 -40.45 76.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.068 0.461 . . . . 60.2 111.244 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 12.4 tt0 -130.33 88.84 46.41 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-N 116.139 -0.482 . . . . 73.22 110.178 -175.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -67.8 -12.76 36.49 Favored 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.917 2.411 . . . . 63.0 112.29 -179.083 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -84.58 -6.32 59.36 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.735 -0.666 . . . . 64.21 110.144 176.473 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 22.2 tptm -109.26 123.67 49.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.547 0.689 . . . . 73.22 110.998 -177.63 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 166' ' ' LEU . . . . . 0.471 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.0 mp -91.21 135.2 33.95 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 114.731 -1.122 . . . . 75.13 108.204 175.205 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 167' ' ' ILE . . . . . 0.662 ' HB ' ' HB2' ' B' ' 157' ' ' PHE . 48.1 mm -95.93 113.11 61.46 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-O 121.037 0.446 . . . . 74.12 111.303 -173.555 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.497 ' O ' HG23 ' B' ' 172' ' ' ILE . 55.9 Cg_endo -69.91 177.95 5.17 Favored 'Trans proline' 0 N--CA 1.464 -0.253 0 C-N-CA 123.15 2.566 . . . . 73.33 112.479 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -85.86 6.39 28.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.976 -0.557 . . . . 70.11 112.269 -168.83 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 30.4 p90 -107.7 -25.32 11.35 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.207 0.527 . . . . 75.24 110.007 171.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.415 ' HA ' ' HB2' ' B' ' 174' ' ' SER . 21.0 mm-40 -80.77 -14.7 57.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.753 -0.658 . . . . 64.32 110.9 -179.051 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.526 HG13 ' CD2' ' B' ' 173' ' ' PHE . 26.5 pt -72.64 -12.02 15.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.86 -0.609 . . . . 72.42 112.291 -176.732 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 173' ' ' PHE . . . . . 0.526 ' CD2' HG13 ' B' ' 172' ' ' ILE . 88.4 m-85 -126.83 21.03 7.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.44 0.638 . . . . 62.34 109.785 176.323 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 174' ' ' SER . . . . . 0.415 ' HB2' ' HA ' ' B' ' 171' ' ' GLU . 7.8 t -95.76 28.77 2.91 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.115 -0.948 . . . . 60.5 110.925 -175.16 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 6.3 m0 . . . . . 0 C--O 1.244 0.794 0 CA-C-O 118.201 -0.904 . . . . 73.41 111.679 -176.671 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 18.2 m . . . . . 0 C--O 1.234 0.266 0 CA-C-O 120.908 0.385 . . . . 73.3 111.256 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 83.34 -60.54 4.87 Favored Glycine 0 N--CA 1.447 -0.619 0 N-CA-C 110.763 -0.935 . . . . 73.12 110.763 -173.665 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 60.19 88.35 0.12 Allowed Pre-proline 0 N--CA 1.463 0.214 0 C-N-CA 123.818 0.847 . . . . 74.13 112.235 176.783 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.608 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 37.5 Cg_endo -83.75 102.31 0.97 Allowed 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.344 2.03 . . . . 73.05 111.145 175.537 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.52 ' HA ' ' HB2' ' B' ' 151' ' ' ASP . 5.8 p-10 -130.06 140.91 50.77 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.186 0.517 . . . . 52.33 110.026 179.09 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.669 HG21 ' HB3' ' A' ' 24' ' ' GLN . 14.1 p -85.05 130.8 35.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.864 -0.607 . . . . 75.34 110.958 -176.392 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 34.3 m -88.26 105.07 17.3 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 109.674 -0.491 . . . . 73.35 109.674 177.359 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 72.2 mt -87.82 111.24 21.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.938 -0.574 . . . . 55.42 110.51 -177.091 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.476 ' HG2' ' O ' ' A' ' 23' ' ' ILE . 12.9 ptm180 -126.4 173.78 9.1 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.438 -0.578 . . . . 74.55 109.438 178.15 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -138.3 101.23 4.33 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.834 0.349 . . . . 72.21 110.222 -176.511 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.604 ' HG3' HD12 ' A' ' 23' ' ' ILE . 11.3 mm-40 -97.83 90.17 4.86 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.793 -0.64 . . . . 72.24 109.969 -176.278 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 75.51 -92.78 0.89 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.788 -0.72 . . . . 64.32 112.183 -178.573 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.588 ' HB2' ' HB2' ' A' ' 40' ' ' LYS . 7.3 p-10 -102.85 -36.73 8.14 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.438 0.637 . . . . 65.3 110.592 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.436 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 5.8 pttm -92.94 127.27 38.39 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.602 -0.727 . . . . 70.23 112.38 -167.226 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.467 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 46.6 m -82.67 96.01 8.0 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 114.771 -1.104 . . . . 62.33 108.326 174.162 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.742 HG12 HG23 ' A' ' 37' ' ' VAL . 48.5 mt -86.37 112.25 22.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.854 -0.612 . . . . 70.43 110.349 -175.336 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.669 ' HB3' HG21 ' A' ' 13' ' ' VAL . 47.7 mt-30 -94.01 104.63 16.67 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.738 -0.664 . . . . 73.22 110.464 179.456 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.486 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 26.7 mt-10 -87.48 100.6 12.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.673 -0.694 . . . . 71.11 110.868 -178.256 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -75.33 97.83 3.68 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.812 -0.44 . . . . 74.31 109.812 176.212 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.472 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 71.8 mtm180 -120.49 127.02 51.81 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.158 -0.474 . . . . 61.54 109.882 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.608 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 2.5 p -83.08 -64.26 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.643 -0.423 . . . . 75.21 110.843 178.675 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.578 ' H ' HG13 ' A' ' 28' ' ' VAL . 4.8 t-20 -142.72 69.25 1.31 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.175 0.512 . . . . 72.22 110.292 -176.832 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 88.18 1.87 81.14 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.562 -0.745 . . . . 54.55 113.474 176.223 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.408 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 60.7 t80 -131.24 127.01 36.97 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 117.151 0.476 . . . . 75.54 111.356 179.861 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.842 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -72.48 120.27 17.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.284 -0.871 . . . . 73.23 109.545 174.379 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -111.88 -19.51 12.37 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.396 -0.522 . . . . 73.15 111.746 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.44 141.56 18.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.832 0.349 . . . . 70.24 111.216 178.209 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.842 HG13 HD11 ' A' ' 32' ' ' LEU . 93.7 mt -119.73 117.36 53.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.36 -0.382 . . . . 72.31 110.723 176.706 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.495 ' HA ' ' O ' ' A' ' 45' ' ' TYR . 85.7 tttt -102.14 100.23 10.44 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.536 -0.913 . . . . 60.0 108.536 172.243 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.742 HG23 HG12 ' A' ' 23' ' ' ILE . 8.4 p -95.38 131.57 41.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 CA-C-N 116.174 -0.466 . . . . 74.44 110.045 -176.679 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.66 HG13 ' HG3' ' A' ' 44' ' ' PRO . 40.7 t -108.05 88.54 4.75 Favored Pre-proline 0 C--N 1.323 -0.559 0 N-CA-C 109.496 -0.557 . . . . 63.04 109.496 175.057 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.417 ' HA ' ' HB3' ' A' ' 21' ' ' LYS . 73.7 Cg_endo -82.39 141.26 11.23 Favored 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 122.51 2.14 . . . . 70.34 112.314 -178.395 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.588 ' HB2' ' HB2' ' A' ' 20' ' ' ASP . 27.9 mtpp -77.92 -14.93 59.38 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.346 0.593 . . . . 61.13 109.935 179.301 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 -116.43 25.63 10.48 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.342 -0.844 . . . . 62.13 110.203 -176.62 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -164.41 -148.64 5.51 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.28 -0.873 . . . . 44.22 111.128 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.1 pttp -131.9 142.63 45.87 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 117.238 0.519 . . . . 73.21 110.081 175.781 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.66 ' HG3' HG13 ' A' ' 38' ' ' VAL . 50.2 Cg_exo -53.15 135.53 59.67 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 123.55 2.833 . . . . 64.04 112.926 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.495 ' O ' ' HA ' ' A' ' 36' ' ' LYS . 4.6 p90 -142.32 160.44 40.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.163 -0.471 . . . . 72.3 110.69 177.403 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.656 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 92.0 m-85 -99.97 121.87 42.01 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.862 -0.608 . . . . 65.13 109.416 173.695 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 18.1 tp -108.36 97.43 7.11 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.913 -0.773 . . . . 74.35 108.913 175.626 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.47 HG21 HG21 ' B' ' 148' ' ' VAL . 38.4 t -93.94 135.41 28.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.255 -0.429 . . . . 73.3 111.282 -172.883 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ARG . . . . . 0.627 HH21 ' HA ' ' A' ' 53' ' ' SER . 13.3 tpt180 -73.1 124.59 25.86 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.876 -0.602 . . . . 52.44 111.112 176.853 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.42 174.47 10.79 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.884 -0.598 . . . . 64.52 109.928 173.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -70.65 145.27 50.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.764 0.316 . . . . 52.4 110.596 -178.194 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.448 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 86.27 158.45 31.29 Favored Glycine 0 N--CA 1.428 -1.868 0 CA-C-O 122.133 0.852 . . . . 63.11 112.844 175.57 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.627 ' HA ' HH21 ' A' ' 49' ' ' ARG . 49.5 m -80.65 26.71 0.39 Allowed 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 114.604 -0.798 . . . . 72.42 110.113 170.722 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.448 ' H ' ' C ' ' A' ' 52' ' ' GLY . 22.6 t70 -56.77 -39.24 73.68 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.123 -0.944 . . . . 52.5 111.611 -178.149 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.48 16.41 20.32 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.511 -0.852 . . . . 52.23 113.068 176.325 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -112.63 148.39 34.71 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.049 0.452 . . . . 72.3 110.31 177.873 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -124.1 163.06 22.27 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.739 -0.664 . . . . 63.13 109.656 176.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.79 HD11 HD23 ' A' ' 66' ' ' LEU . 46.1 mm -121.27 123.81 70.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 N-CA-C 109.538 -0.541 . . . . 73.21 109.538 177.211 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.675 ' HD2' ' HB3' ' A' ' 61' ' ' ASP . 11.6 ttm180 -92.2 145.63 24.35 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.806 -0.442 . . . . 73.25 109.806 -176.627 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.777 ' HB2' ' HB3' ' B' ' 163' ' ' PRO . 23.8 p -61.13 -39.89 91.76 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.573 0.702 . . . . 61.42 110.133 174.906 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.675 ' HB3' ' HD2' ' A' ' 59' ' ' ARG . 27.7 t70 -68.34 -28.28 67.0 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 114.808 -1.087 . . . . 71.21 110.817 178.262 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLN . . . . . 0.46 ' HB3' ' HB3' ' A' ' 65' ' ' LYS . 86.7 mm-40 -133.52 73.14 73.46 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.022 -0.535 . . . . 44.43 110.254 -175.79 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -75.81 -17.2 18.01 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.568 2.179 . . . . 71.13 112.703 -174.697 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -101.62 7.32 42.19 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.03 -0.532 . . . . 71.31 110.697 -178.452 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.46 ' HB3' ' HB3' ' A' ' 62' ' ' GLN . 83.4 tttt -123.32 135.27 54.12 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.013 -0.539 . . . . 71.31 110.74 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.79 HD23 HD11 ' A' ' 58' ' ' ILE . 40.7 mt -84.75 112.21 20.29 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.882 -0.784 . . . . 72.15 108.882 175.775 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 51.4 mm -70.68 117.85 59.36 Favored Pre-proline 0 C--N 1.322 -0.629 0 CA-C-N 116.142 -0.481 . . . . 52.22 110.841 -176.211 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.91 178.62 6.99 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 123.28 2.653 . . . . 74.51 112.86 -178.686 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' GLN . . . . . 0.623 ' HA ' HG12 ' A' ' 72' ' ' ILE . 6.1 tt0 -74.76 -34.62 62.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.853 -0.612 . . . . 72.5 111.521 -170.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 16.0 p90 -67.66 -20.51 65.32 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.39 -0.524 . . . . 72.22 110.279 178.259 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -91.4 -28.42 17.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.334 -0.394 . . . . 60.11 111.404 -179.177 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.623 HG12 ' HA ' ' A' ' 69' ' ' GLN . 37.4 pt -74.81 -23.49 17.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.103 0.478 . . . . 71.43 110.274 176.86 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 38.1 m-85 -105.33 29.51 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.006 -0.543 . . . . 73.53 110.637 176.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 22.8 t -82.25 32.25 0.39 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.261 0.553 . . . . 54.44 110.863 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 54.3 m0 . . . . . 0 C--N 1.323 -0.552 0 CA-C-N 116.128 -0.487 . . . . 72.35 110.852 179.923 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 5.2 p . . . . . 0 C--O 1.234 0.282 0 CA-C-O 121.305 0.574 . . . . 75.54 111.534 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 100.98 -73.48 0.39 Allowed Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 109.999 -1.24 . . . . 74.14 109.999 -172.14 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 54.17 74.47 0.74 Allowed Pre-proline 0 C--N 1.329 -0.317 0 O-C-N 124.154 0.561 . . . . 73.2 111.259 175.459 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.928 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 18.0 Cg_endo -63.01 99.47 0.22 Allowed 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 122.106 1.871 . . . . 35.22 110.594 178.339 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -106.81 155.04 20.14 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.335 -0.848 . . . . 63.24 110.635 -173.217 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.624 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 12.4 p -111.54 124.68 68.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 CA-C-O 121.557 0.694 . . . . 73.32 110.421 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 114' ' ' THR . . . . . 0.572 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 26.2 m -87.47 105.03 17.01 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.591 -0.731 . . . . 64.23 110.094 178.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.7 mt -83.48 106.07 13.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.955 -0.566 . . . . 72.01 110.375 -178.73 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 116' ' ' ARG . . . . . 0.437 ' HG3' HG22 ' B' ' 114' ' ' THR . 44.0 mtm105 -124.09 -178.9 4.22 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.403 -0.362 . . . . 74.23 110.465 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 64.0 mt-30 -144.76 115.21 7.61 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.205 -0.452 . . . . 72.21 111.056 -178.875 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 118' ' ' GLU . . . . . 0.461 ' O ' ' HE2' ' B' ' 121' ' ' LYS . 76.7 mm-40 -101.52 81.98 2.24 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.563 -0.532 . . . . 65.52 109.563 175.922 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 91.11 -110.83 3.88 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.657 -0.782 . . . . 61.41 111.4 -175.506 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 120' ' ' ASP . . . . . 0.79 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 18.2 m-20 -115.06 24.01 12.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.786 0.327 . . . . 74.03 110.488 178.178 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.496 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 22.5 pttt -124.55 120.1 30.98 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.232 0.539 . . . . 60.21 110.833 178.556 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 49.1 m -79.38 104.9 10.31 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.414 -0.812 . . . . 53.25 109.588 177.385 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 123' ' ' ILE . . . . . 0.439 HD13 ' CE3' ' B' ' 175' ' ' TRP . 52.8 mt -97.52 112.54 29.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.122 0.487 . . . . 73.52 110.408 -176.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.624 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 51.2 mt-30 -92.29 105.7 17.85 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.449 -0.796 . . . . 73.21 110.552 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 125' ' ' GLU . . . . . 0.572 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 41.7 mt-10 -88.3 100.78 13.27 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.774 -0.648 . . . . 63.32 110.421 -178.793 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 126' ' ' TYR . . . . . 0.474 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 63.4 m-85 -78.25 110.28 13.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.528 -0.305 . . . . 61.24 110.538 179.403 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 127' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' B' ' 131' ' ' PHE . 84.6 mtm180 -132.99 120.23 21.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.295 -0.411 . . . . 73.11 110.258 -179.622 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.928 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.5 p -83.51 -54.37 9.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.234 -0.439 . . . . 74.12 111.181 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 32.8 t-20 -150.08 79.25 1.36 Allowed 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.958 -0.386 . . . . 73.23 109.958 -175.136 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.65 30.36 74.55 Favored Glycine 0 N--CA 1.452 -0.234 0 CA-C-N 115.537 -0.756 . . . . 64.33 112.867 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.43 ' O ' ' HA ' ' B' ' 127' ' ' ARG . 87.2 t80 -147.86 127.22 13.09 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.856 0.36 . . . . 70.52 111.256 179.594 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.743 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -81.25 111.47 17.69 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.467 -0.788 . . . . 75.44 108.948 174.758 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 133' ' ' TYR . . . . . 0.474 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 51.6 p90 -106.98 -15.53 14.67 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.68 -0.408 . . . . 73.45 111.57 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 134' ' ' ALA . . . . . 0.51 ' HB1' ' CE2' ' B' ' 146' ' ' PHE . . . -159.07 145.18 16.61 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.947 0.403 . . . . 61.24 111.576 -178.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.743 HG13 HD11 ' B' ' 132' ' ' LEU . 75.7 mt -125.47 123.66 65.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.936 -0.574 . . . . 45.12 110.162 176.448 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.452 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 88.5 tttt -116.15 102.32 9.5 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.396 -0.594 . . . . 74.32 109.396 174.374 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.51 HG13 ' CE1' ' B' ' 145' ' ' TYR . 0.9 OUTLIER -102.36 127.07 56.31 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.088 0.471 . . . . 73.03 110.947 -177.603 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.816 HG22 ' HB3' ' B' ' 144' ' ' PRO . 22.8 t -112.55 88.83 11.74 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 115.235 -0.893 . . . . 71.1 109.73 -179.309 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.496 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 67.0 Cg_endo -77.95 134.54 13.31 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.137 1.891 . . . . 60.32 112.717 178.671 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 140' ' ' LYS . . . . . 0.79 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 58.2 mtpt -62.75 -28.18 69.79 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.577 -0.738 . . . . 64.12 110.251 173.546 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -96.43 43.84 1.07 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.996 -1.002 . . . . 75.42 110.187 -177.638 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 164.2 -146.71 11.75 Favored Glycine 0 N--CA 1.446 -0.645 0 CA-C-N 115.531 -0.759 . . . . 72.52 111.766 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 34.1 mmtp -126.68 150.0 69.87 Favored Pre-proline 0 C--N 1.322 -0.63 0 N-CA-C 110.206 -0.294 . . . . 73.2 110.206 177.379 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.816 ' HB3' HG22 ' B' ' 138' ' ' VAL . 18.6 Cg_endo -61.37 145.16 98.51 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.827 2.351 . . . . 74.32 112.22 178.72 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 145' ' ' TYR . . . . . 0.51 ' CE1' HG13 ' B' ' 137' ' ' VAL . 12.6 p90 -148.89 164.05 35.63 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.205 -0.452 . . . . 75.41 110.15 177.11 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.51 ' CE2' ' HB1' ' B' ' 134' ' ' ALA . 0.8 OUTLIER -113.14 142.13 46.12 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.901 -0.591 . . . . 75.34 111.17 -172.437 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.444 ' HB3' ' CD2' ' B' ' 157' ' ' PHE . 20.7 mt -126.65 108.74 11.37 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.972 -0.558 . . . . 75.04 109.659 170.074 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 148' ' ' VAL . . . . . 0.47 HG21 HG21 ' A' ' 48' ' ' VAL . 38.8 t -90.86 130.59 39.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.262 -0.426 . . . . 75.34 110.274 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 149' ' ' ARG . . . . . 0.463 ' HD3' ' CZ ' ' B' ' 157' ' ' PHE . 45.5 tpt85 -85.1 104.38 14.95 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.53 -0.544 . . . . 60.41 109.53 179.134 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.1 -178.85 0.85 Allowed 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.049 -0.523 . . . . 63.51 110.496 179.096 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 151' ' ' ASP . . . . . 0.52 ' HB2' ' HA ' ' A' ' 12' ' ' ASP . 2.2 p-10 -84.21 158.62 21.22 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.846 -0.427 . . . . 73.02 109.846 179.343 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 96.68 139.19 10.41 Favored Glycine 0 N--CA 1.439 -1.152 0 C-N-CA 120.049 -1.072 . . . . 70.2 112.609 176.721 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 16.3 m -77.6 43.12 0.39 Allowed 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.357 0.599 . . . . 62.23 110.97 176.413 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -89.15 -28.35 20.09 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.522 -0.763 . . . . 72.13 110.467 -178.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 88.79 31.39 12.73 Favored Glycine 0 N--CA 1.451 -0.36 0 N-CA-C 111.067 -0.813 . . . . 64.31 111.067 -174.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -100.46 130.94 46.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.147 -0.526 . . . . 74.21 111.606 -172.571 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 157' ' ' PHE . . . . . 0.463 ' CZ ' ' HD3' ' B' ' 149' ' ' ARG . 29.2 m-85 -121.02 160.61 23.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.639 -0.71 . . . . 73.52 109.572 175.134 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 158' ' ' ILE . . . . . 0.8 HD11 HD23 ' B' ' 166' ' ' LEU . 46.0 mm -119.74 118.27 56.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.492 -0.558 . . . . 65.22 109.492 174.206 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.59 ' HG2' ' H ' ' B' ' 161' ' ' ASP . 20.0 ttm-85 -84.09 142.38 30.44 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 110.034 -0.358 . . . . 75.34 110.034 -177.8 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 42.3 p -63.08 -29.16 70.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.174 0.512 . . . . 70.4 110.836 178.187 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 161' ' ' ASP . . . . . 0.59 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 16.1 t70 -77.76 -27.49 50.36 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.477 -0.783 . . . . 72.23 110.81 178.808 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 162' ' ' GLN . . . . . 0.596 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 28.0 mm-40 -135.35 68.98 68.61 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 115.889 -0.596 . . . . 70.0 110.185 -177.608 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 163' ' ' PRO . . . . . 0.777 ' HB3' ' HB2' ' A' ' 60' ' ' SER . 12.9 Cg_exo -70.1 -26.33 26.1 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.71 2.274 . . . . 73.45 112.191 -177.479 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -84.0 1.31 44.38 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.451 -0.795 . . . . 72.51 110.27 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 165' ' ' LYS . . . . . 0.596 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 57.8 tttp -116.9 134.94 54.14 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.814 -0.63 . . . . 72.22 110.82 -177.498 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 166' ' ' LEU . . . . . 0.8 HD23 HD11 ' B' ' 158' ' ' ILE . 39.0 mt -89.53 115.4 26.91 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.643 -0.873 . . . . 74.4 108.643 175.651 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 167' ' ' ILE . . . . . 0.581 HG23 ' HB3' ' B' ' 171' ' ' GLU . 43.0 mm -75.04 123.87 89.14 Favored Pre-proline 0 C--N 1.32 -0.705 0 CA-C-N 116.147 -0.479 . . . . 74.54 110.896 -172.537 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.414 ' O ' HG23 ' B' ' 172' ' ' ILE . 72.5 Cg_endo -72.75 173.65 13.08 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.825 2.35 . . . . 74.33 112.225 -178.829 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 169' ' ' GLN . . . . . 0.444 ' O ' HG12 ' B' ' 172' ' ' ILE . 30.4 tt0 -77.79 -8.22 57.7 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.665 -0.698 . . . . 75.11 111.811 -169.403 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 8.4 p90 -95.33 -12.23 26.46 Favored 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 120.457 -0.497 . . . . 71.21 110.583 176.799 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.581 ' HB3' HG23 ' B' ' 167' ' ' ILE . 12.9 tt0 -104.07 -1.87 26.75 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 121.039 0.447 . . . . 65.45 110.409 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.444 HG12 ' O ' ' B' ' 169' ' ' GLN . 46.8 pt -71.75 -24.5 23.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.017 0.437 . . . . 63.53 110.689 179.399 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -104.85 35.93 2.62 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.42 0.629 . . . . 70.15 109.745 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 174' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 23.2 t -63.74 -20.4 65.72 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 114.993 -1.003 . . . . 53.25 110.792 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 175' ' ' TRP . . . . . 0.439 ' CE3' HD13 ' B' ' 123' ' ' ILE . 8.9 p-90 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.255 -0.879 . . . . 73.43 110.388 174.259 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 57.8 m . . . . . 0 C--O 1.234 0.279 0 CA-C-O 121.732 0.777 . . . . 75.32 112.361 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 138.64 -74.62 0.39 Allowed Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 109.197 -1.561 . . . . 71.44 109.197 -171.596 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 33.3 mt-10 58.68 92.49 0.06 OUTLIER Pre-proline 0 N--CA 1.463 0.197 0 CA-C-O 121.539 0.685 . . . . 72.41 112.052 170.782 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 9.6 Cg_endo -80.46 136.31 11.05 Favored 'Trans proline' 0 N--CA 1.451 -1.001 0 C-N-CA 122.833 2.355 . . . . 55.24 112.604 -173.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -124.8 170.84 10.64 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.173 -0.677 . . . . 73.52 109.173 177.069 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.471 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 14.0 p -127.72 124.29 62.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 121.481 0.657 . . . . 75.43 110.76 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.586 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 76.4 m -87.9 104.25 16.43 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.629 -0.714 . . . . 72.34 109.664 177.27 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 52.3 mt -98.45 117.66 43.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.064 -0.516 . . . . 65.13 110.388 -175.845 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -141.4 178.23 7.57 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.707 -0.679 . . . . 73.32 110.273 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 17.4 mp0 -133.45 126.15 30.56 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.922 0.392 . . . . 70.31 110.828 -178.131 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 52.0 mm-40 -95.58 -16.1 22.34 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.851 -0.613 . . . . 72.1 111.493 -178.502 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.43 104.91 1.3 Allowed Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.619 -0.8 . . . . 54.23 111.468 -176.457 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 1.093 ' HB3' ' HG3' ' A' ' 40' ' ' LYS . 35.3 m-20 61.81 13.89 5.8 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 123.226 0.61 . . . . 73.22 111.482 -175.677 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.428 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 40.2 pttt -154.52 114.97 3.9 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.229 0.538 . . . . 64.13 110.907 176.326 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 34.1 m -83.08 117.74 23.07 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.375 -0.83 . . . . 63.24 109.298 174.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.461 HG12 HG23 ' A' ' 37' ' ' VAL . 24.9 mt -108.61 120.33 59.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 120.906 0.384 . . . . 71.05 110.633 -174.13 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.471 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 68.3 mt-30 -105.27 111.31 24.01 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.819 -0.628 . . . . 74.21 110.758 -179.23 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.586 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 31.6 mt-10 -89.62 102.55 15.23 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.62 -0.718 . . . . 72.13 110.673 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.452 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 80.6 m-85 -79.38 108.19 12.71 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.965 0.412 . . . . 72.35 109.957 177.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.427 HH21 ' CD ' ' A' ' 25' ' ' GLU . 90.1 mtt180 -116.98 126.56 53.09 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.979 -0.555 . . . . 61.32 109.852 -178.449 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.68 HG11 HG11 ' B' ' 128' ' ' VAL . 3.7 p -78.77 -35.96 18.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.326 0.584 . . . . 41.22 110.027 179.192 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -168.92 64.68 0.06 Allowed 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.31 -0.996 . . . . 60.43 108.31 -179.045 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.76 -29.75 3.29 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-N 115.477 -0.783 . . . . 64.13 112.036 -174.608 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -86.26 130.92 34.36 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.941 0.401 . . . . 72.34 110.455 -176.606 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.888 HD11 HG13 ' A' ' 35' ' ' ILE . 3.2 tm? -81.96 119.21 23.67 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.436 -0.802 . . . . 74.44 109.847 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' TYR . . . . . 0.452 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 54.8 p90 -112.9 -17.54 12.47 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.937 -0.305 . . . . 74.2 111.218 177.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.544 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -157.28 142.21 16.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.812 0.339 . . . . 75.45 111.181 179.327 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.888 HG13 HD11 ' A' ' 32' ' ' LEU . 78.8 mt -125.14 120.21 57.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 116.329 -0.396 . . . . 63.32 110.01 175.502 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.469 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 86.0 tttt -108.53 101.15 10.33 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 120.381 -0.528 . . . . 63.34 109.697 173.658 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.565 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.8 p -101.02 131.78 48.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.973 0 CA-C-N 116.243 -0.435 . . . . 73.04 109.917 175.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.829 HG22 ' HB3' ' A' ' 44' ' ' PRO . 29.6 t -106.0 84.85 1.4 Allowed Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.396 -0.82 . . . . 73.22 109.51 177.469 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.565 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 97.3 Cg_endo -87.65 151.21 7.5 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.615 2.21 . . . . 72.32 113.143 -177.513 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 1.093 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 1.0 OUTLIER -55.06 -38.53 68.14 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.202 -0.908 . . . . 74.41 110.578 173.715 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 95.1 m-70 -123.56 120.9 34.21 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.814 -0.63 . . . . 71.53 110.181 179.428 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 117.46 -32.63 5.31 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.002 -0.839 . . . . 52.15 111.002 -173.418 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.469 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 67.0 mttm 67.97 155.61 0.14 Allowed Pre-proline 0 N--CA 1.465 0.282 0 C-N-CA 123.39 0.676 . . . . 74.41 111.97 178.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.829 ' HB3' HG22 ' A' ' 38' ' ' VAL . 11.4 Cg_endo -54.57 126.43 22.3 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 123.136 2.557 . . . . 71.23 113.179 -174.828 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.516 ' CE1' HG13 ' A' ' 37' ' ' VAL . 5.8 p90 -144.51 151.76 39.61 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.009 -0.541 . . . . 63.52 110.543 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.625 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 86.8 m-85 -96.18 133.27 40.69 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.097 -0.501 . . . . 72.44 110.804 178.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.544 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 21.2 mt -101.69 93.41 5.32 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.59 -0.522 . . . . 64.22 109.59 167.884 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.42 128.96 38.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 116.168 -0.469 . . . . 73.14 109.799 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ARG . . . . . 0.474 HH21 ' HA ' ' A' ' 53' ' ' SER . 15.6 tpt180 -63.05 127.23 30.3 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.21 0.529 . . . . 74.54 111.87 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.05 113.84 21.31 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.114 -1.069 . . . . 74.52 108.114 166.281 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.556 ' OD2' ' HA ' ' B' ' 126' ' ' TYR . 37.8 m-20 -49.07 142.54 6.67 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.216 0.531 . . . . 72.33 111.715 -176.832 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.23 133.61 8.16 Favored Glycine 0 N--CA 1.437 -1.257 0 N-CA-C 110.508 -1.037 . . . . 54.21 110.508 -169.15 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.474 ' HA ' HH21 ' A' ' 49' ' ' ARG . 19.6 m -84.87 43.16 0.97 Allowed 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.128 0.49 . . . . 74.25 110.997 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -73.41 -33.95 65.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.682 -0.69 . . . . 73.42 109.769 -179.523 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 113.46 38.97 1.15 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.911 -0.661 . . . . 45.13 113.089 176.022 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -135.31 146.42 48.46 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.209 0.528 . . . . 70.05 111.688 -176.815 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.566 ' HB2' HG22 ' A' ' 72' ' ' ILE . 31.5 m-85 -127.74 167.04 17.04 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.318 -0.856 . . . . 63.2 109.494 175.499 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.898 HD11 HD23 ' A' ' 66' ' ' LEU . 39.4 mm -122.83 123.22 67.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 109.981 -0.378 . . . . 74.0 109.981 179.111 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.978 ' HG3' HG13 ' A' ' 67' ' ' ILE . 28.8 mtm180 -88.89 140.06 29.82 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.124 -0.324 . . . . 72.22 110.124 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 7.2 p -60.8 -20.95 62.58 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.222 0.534 . . . . 65.34 110.933 177.211 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -76.0 -31.43 58.95 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.422 -0.808 . . . . 75.53 110.67 178.256 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 82.0 mm-40 -141.75 71.21 24.92 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.346 -0.388 . . . . 71.43 110.433 -175.102 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo -71.14 -11.58 29.14 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 122.771 2.314 . . . . 72.51 112.427 -178.539 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -89.54 -14.56 34.87 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.699 -0.682 . . . . 72.5 110.799 -178.719 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -112.0 133.8 53.95 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.919 0.39 . . . . 70.34 110.86 -178.207 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.898 HD23 HD11 ' A' ' 58' ' ' ILE . 85.2 mt -80.74 110.18 16.0 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.114 -0.699 . . . . 72.43 109.114 176.101 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.978 HG13 ' HG3' ' A' ' 59' ' ' ARG . 50.6 mm -72.32 116.77 52.53 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 115.986 -0.552 . . . . 70.21 110.502 -175.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.462 ' O ' HG23 ' A' ' 72' ' ' ILE . 58.6 Cg_endo -70.39 177.56 5.89 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 123.315 2.676 . . . . 64.41 112.881 -177.491 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' GLN . . . . . 0.67 ' HA ' HG12 ' A' ' 72' ' ' ILE . 25.3 tt0 -73.5 -30.66 63.27 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.903 -0.589 . . . . 72.22 111.654 -171.013 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 21.5 p90 -73.06 -15.68 61.5 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.168 0.509 . . . . 73.22 110.234 177.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.459 ' HB3' HG23 ' A' ' 67' ' ' ILE . 3.2 mm-40 -103.08 -16.14 15.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.649 -0.705 . . . . 71.44 111.808 -176.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.67 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.4 pt -80.91 -20.26 11.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.179 0.514 . . . . 65.14 110.262 176.647 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -107.88 22.79 15.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.601 -0.727 . . . . 75.43 109.678 174.134 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.1 t -61.26 -34.08 74.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.195 -0.911 . . . . 75.21 110.622 -178.565 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 65.9 p-90 . . . . . 0 C--N 1.327 -0.372 0 CA-C-N 116.352 -0.385 . . . . 74.44 110.608 177.217 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 13.9 m . . . . . 0 N--CA 1.452 -0.374 0 CA-C-O 121.078 0.466 . . . . 75.33 111.05 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.65 -45.88 1.25 Allowed Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 110.249 -1.141 . . . . 71.14 110.249 -175.682 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 40.3 83.14 0.21 Allowed Pre-proline 0 N--CA 1.47 0.564 0 C-N-CA 124.755 1.222 . . . . 73.33 113.473 170.194 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.6 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 43.5 Cg_endo -90.56 124.58 1.06 Allowed 'Trans proline' 0 N--CA 1.446 -1.323 0 C-N-CA 123.009 2.473 . . . . 55.45 111.667 178.444 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -122.87 127.87 49.59 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.475 0.655 . . . . 53.31 110.008 -178.586 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.495 ' HB ' ' HB2' ' A' ' 51' ' ' ASP . 7.3 p -79.45 127.82 38.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-O 121.508 0.67 . . . . 52.24 110.459 -178.311 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 114' ' ' THR . . . . . 0.907 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 25.8 m -80.62 101.69 9.36 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 115.386 -0.824 . . . . 74.42 109.605 178.676 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 51.1 mt -91.02 103.83 14.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.033 -0.53 . . . . 52.35 110.445 -175.22 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 116' ' ' ARG . . . . . 0.483 ' HG2' ' O ' ' B' ' 123' ' ' ILE . 14.0 ptm180 -124.94 178.87 5.28 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.949 -0.76 . . . . 73.24 108.949 178.763 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -138.88 158.74 43.67 Favored 'General case' 0 CA--C 1.502 -0.886 0 CA-C-O 122.189 0.995 . . . . 74.12 112.661 -178.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 118' ' ' GLU . . . . . 0.591 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 26.5 mt-10 -135.44 168.62 18.88 Favored 'General case' 0 N--CA 1.432 -1.365 0 CA-C-N 112.968 -1.924 . . . . 75.24 107.166 159.662 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . -42.29 107.92 0.12 Allowed Glycine 0 CA--C 1.526 0.722 0 O-C-N 123.718 0.636 . . . . 61.15 114.34 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 43.3 m-20 61.67 24.62 14.69 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.893 0.877 . . . . 53.1 112.508 176.811 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.591 ' HE3' ' HB2' ' B' ' 118' ' ' GLU . 58.7 pttt -147.81 115.02 6.21 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.616 0.722 . . . . 44.31 111.286 174.312 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 23.4 m -80.03 117.11 20.57 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.404 -0.817 . . . . 74.25 109.374 175.003 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 123' ' ' ILE . . . . . 0.517 HG12 HG13 ' B' ' 137' ' ' VAL . 40.2 mt -105.53 108.96 26.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.25 0.548 . . . . 63.33 110.457 -175.744 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.481 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 52.2 mt-30 -103.13 109.52 21.12 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.658 -0.701 . . . . 53.44 110.538 -176.21 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 125' ' ' GLU . . . . . 0.907 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 70.8 mt-10 -88.9 98.74 11.91 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.014 -0.539 . . . . 74.24 110.43 178.655 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 126' ' ' TYR . . . . . 0.556 ' HA ' ' OD2' ' A' ' 51' ' ' ASP . 67.7 m-85 -71.32 114.34 9.29 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.045 0.45 . . . . 73.2 110.295 179.18 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 127' ' ' ARG . . . . . 0.569 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 59.1 mtt-85 -135.36 131.12 35.97 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.709 -0.678 . . . . 72.34 110.989 -173.826 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.68 HG11 HG11 ' A' ' 28' ' ' VAL . 14.0 p -85.39 -132.76 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 108.689 -0.856 . . . . 71.53 108.689 172.785 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 129' ' ' ASN . . . . . 0.629 ' H ' HG22 ' B' ' 128' ' ' VAL . 2.3 t-20 -80.62 65.87 5.92 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.164 0.506 . . . . 63.12 110.812 -177.445 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.65 26.63 22.18 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.756 -0.735 . . . . 41.04 113.285 174.263 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 62.1 t80 -142.11 126.74 17.95 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 117.262 0.531 . . . . 72.41 111.31 175.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.569 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 3.5 tm? -77.15 117.49 18.75 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.992 -0.744 . . . . 72.23 108.992 175.505 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 39.6 p90 -119.15 -6.3 10.42 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.257 -0.577 . . . . 75.32 112.261 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 134' ' ' ALA . . . . . 0.525 ' HB3' ' HB2' ' B' ' 126' ' ' TYR . . . -164.21 143.35 7.54 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.699 0.285 . . . . 74.2 111.031 177.697 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.442 HG13 HD11 ' B' ' 132' ' ' LEU . 61.9 mt -122.84 121.06 62.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 109.924 -0.398 . . . . 53.31 109.924 175.403 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.485 ' CB ' ' HE1' ' B' ' 126' ' ' TYR . 83.6 tttt -107.84 107.03 17.59 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.835 -0.431 . . . . 74.2 109.835 177.803 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.762 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.5 t -94.81 131.6 41.16 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 N-CA-C 108.641 -0.874 . . . . 74.1 108.641 176.585 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.553 HG22 ' HB3' ' B' ' 144' ' ' PRO . 18.0 t -114.72 72.7 2.78 Favored Pre-proline 0 C--N 1.318 -0.769 0 N-CA-C 109.78 -0.452 . . . . 73.12 109.78 172.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.524 ' HD3' HG12 ' B' ' 137' ' ' VAL . 94.1 Cg_endo -83.2 142.16 10.67 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.235 1.957 . . . . 60.53 112.563 177.105 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 49.6 mttp -54.56 -44.56 73.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.596 0.712 . . . . 70.11 110.348 173.016 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 26.1 m-70 -102.8 92.1 4.45 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.836 -1.074 . . . . 72.15 109.474 -174.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 132.54 -27.35 3.56 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.357 -0.838 . . . . 64.45 111.712 -176.294 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 143' ' ' LYS . . . . . 0.51 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 71.2 mttt 69.1 159.66 0.15 Allowed Pre-proline 0 N--CA 1.464 0.255 0 C-N-CA 123.622 0.769 . . . . 72.21 112.367 -178.885 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.762 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 21.6 Cg_endo -61.09 134.5 53.16 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 122.873 2.382 . . . . 71.24 113.525 -177.541 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -143.32 147.21 34.37 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.68 -0.691 . . . . 74.11 110.291 175.376 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.65 ' HB2' ' HB2' ' B' ' 160' ' ' SER . 86.0 m-85 -93.61 125.93 38.49 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.231 -0.441 . . . . 61.51 110.392 176.629 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.507 HD11 HG21 ' B' ' 167' ' ' ILE . 25.0 tp -109.12 97.44 7.06 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.64 -0.874 . . . . 50.52 108.64 172.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.7 t -91.77 139.3 18.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.155 -0.475 . . . . 52.41 111.311 -172.321 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 149' ' ' ARG . . . . . 0.427 ' HD3' ' CZ ' ' B' ' 157' ' ' PHE . 42.4 tpt85 -80.36 113.73 18.75 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.278 -0.638 . . . . 74.14 109.278 176.82 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.89 175.6 6.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.825 0.345 . . . . 75.33 111.104 -176.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -71.47 147.8 47.46 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.163 -0.471 . . . . 74.12 110.94 -178.668 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 152' ' ' GLY . . . . . 0.492 ' C ' ' H ' ' B' ' 154' ' ' ASP . . . 89.85 145.4 12.74 Favored Glycine 0 N--CA 1.436 -1.365 0 C-N-CA 120.723 -0.751 . . . . 74.14 112.561 175.319 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 44.9 m -72.59 21.93 0.06 Allowed 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 121.022 0.439 . . . . 74.01 111.083 173.664 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 154' ' ' ASP . . . . . 0.492 ' H ' ' C ' ' B' ' 152' ' ' GLY . 14.5 t70 -60.86 -35.82 77.56 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.777 -0.647 . . . . 73.33 110.618 177.584 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 97.92 17.13 31.12 Favored Glycine 0 CA--C 1.507 -0.451 0 CA-C-N 115.734 -0.666 . . . . 75.31 111.89 -179.383 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -90.97 137.52 32.3 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.019 -0.59 . . . . 55.54 111.566 -175.744 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 157' ' ' PHE . . . . . 0.427 ' CZ ' ' HD3' ' B' ' 149' ' ' ARG . 39.0 m-85 -118.21 154.04 32.87 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.751 -0.658 . . . . 74.41 109.533 174.299 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.3 mm -121.46 119.91 60.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.817 -0.438 . . . . 65.53 109.817 177.596 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.727 ' HE ' ' HB3' ' B' ' 161' ' ' ASP . 37.2 ttp180 -85.02 129.05 34.86 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.444 -0.576 . . . . 74.33 109.444 -179.706 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 160' ' ' SER . . . . . 0.65 ' HB2' ' HB2' ' B' ' 146' ' ' PHE . 36.6 t -59.84 -18.34 43.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.774 0.321 . . . . 54.31 111.318 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 161' ' ' ASP . . . . . 0.727 ' HB3' ' HE ' ' B' ' 159' ' ' ARG . 22.8 t70 -69.24 -39.77 78.31 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.031 -0.531 . . . . 74.32 110.29 176.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 162' ' ' GLN . . . . . 0.427 ' HG2' ' OD2' ' B' ' 161' ' ' ASP . 84.1 mm-40 -133.53 86.33 40.37 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 115.674 -0.693 . . . . 61.54 109.692 179.546 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.01 -14.37 40.86 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.56 2.173 . . . . 73.33 112.47 -178.07 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -100.49 21.09 13.76 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.817 -0.628 . . . . 72.15 110.421 178.615 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -133.3 136.06 45.24 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.365 -0.38 . . . . 74.05 110.732 -179.487 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 166' ' ' LEU . . . . . 0.435 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.6 mp -90.54 134.94 34.02 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.027 -0.731 . . . . 71.52 109.027 176.658 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 167' ' ' ILE . . . . . 0.538 HG23 ' HB3' ' B' ' 171' ' ' GLU . 46.2 mm -94.15 117.02 67.11 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-O 120.917 0.389 . . . . 74.32 111.771 -172.764 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.409 ' O ' HG23 ' B' ' 172' ' ' ILE . 59.5 Cg_endo -72.37 -179.55 4.14 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.305 2.67 . . . . 74.43 112.615 177.084 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 169' ' ' GLN . . . . . 0.59 ' HA ' HG12 ' B' ' 172' ' ' ILE . 33.0 tt0 -77.1 -36.09 55.94 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.258 -0.428 . . . . 65.43 112.136 -170.211 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 170' ' ' TRP . . . . . 0.409 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 35.9 p90 -66.99 -21.16 65.97 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 121.648 -0.658 . . . . 74.43 109.622 177.251 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.538 ' HB3' HG23 ' B' ' 167' ' ' ILE . 9.3 mm-40 -88.22 -26.05 22.57 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 115.156 -0.929 . . . . 75.13 111.647 -178.078 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.59 HG12 ' HA ' ' B' ' 169' ' ' GLN . 40.9 pt -77.97 -17.42 13.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.146 0.498 . . . . 74.53 109.971 177.118 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -108.05 34.61 3.5 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.574 -0.739 . . . . 70.32 109.748 174.264 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.9 t -65.13 -35.27 80.58 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.203 -0.908 . . . . 71.02 111.03 -179.182 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 25.6 p-90 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.018 -0.991 . . . . 73.1 111.023 -178.133 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 39.8 m . . . . . 0 N--CA 1.453 -0.312 0 N-CA-C 109.947 -0.39 . . . . 70.32 109.947 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 87.27 -34.01 3.72 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 110.977 -0.849 . . . . 50.32 110.977 -173.677 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 55.37 63.69 6.31 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 123.998 0.919 . . . . 62.44 111.73 177.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.699 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 18.2 Cg_endo -78.95 121.65 5.06 Favored 'Trans proline' 0 N--CA 1.45 -1.064 0 C-N-CA 122.091 1.861 . . . . 73.22 111.584 -179.612 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -148.36 122.42 9.47 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.654 0.74 . . . . 72.14 110.357 177.515 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.8 p -82.65 129.16 37.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-N 114.366 -1.288 . . . . 51.14 110.682 -178.113 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 59.2 m -93.64 102.51 14.69 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.592 -0.731 . . . . 53.11 109.735 178.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.1 mt -90.63 104.06 14.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.967 -0.561 . . . . 74.11 110.037 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -122.83 174.07 7.37 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.533 -0.758 . . . . 72.22 109.734 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -122.98 133.36 54.37 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 121.285 0.564 . . . . 74.43 111.059 -177.703 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.527 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 1.0 OUTLIER -115.81 84.9 2.19 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.318 -0.855 . . . . 64.42 109.336 -179.411 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 80.88 -106.11 2.51 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 110.827 -0.909 . . . . 73.45 110.827 -172.481 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.434 ' HB3' ' HG3' ' A' ' 40' ' ' LYS . 11.7 m-20 -110.49 -14.47 14.09 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.761 0.315 . . . . 71.41 110.93 176.323 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.527 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 24.6 pttm -89.41 136.57 32.95 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.98 0.419 . . . . 74.01 110.918 -176.28 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 13.0 m -83.8 130.33 34.93 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.781 -0.645 . . . . 73.51 110.205 178.665 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 26.4 mm -116.65 106.82 21.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 120.93 0.395 . . . . 75.5 110.128 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 60.8 mt-30 -100.02 102.5 13.87 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.225 -0.443 . . . . 73.51 109.828 178.492 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.417 ' HB3' HD13 ' A' ' 32' ' ' LEU . 26.4 mt-10 -89.67 100.68 13.43 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.519 -0.764 . . . . 65.45 110.937 -176.302 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.622 ' HD2' ' HB2' ' B' ' 151' ' ' ASP . 44.2 m-85 -75.41 100.21 4.39 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.086 -0.507 . . . . 74.52 110.32 179.257 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 51.2 mtm180 -115.89 124.45 50.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.311 -0.404 . . . . 71.11 110.418 178.758 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.849 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.9 p -87.24 -93.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 C-N-CA 120.564 -0.454 . . . . 70.51 110.091 175.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.849 ' H ' HG13 ' A' ' 28' ' ' VAL . 2.8 t30 -107.49 70.07 0.77 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 121.562 -0.712 . . . . 64.33 109.997 -176.569 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 77.57 9.08 87.09 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.714 -0.755 . . . . 75.23 112.344 179.128 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 85.6 t80 -127.55 123.06 34.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.676 0.274 . . . . 73.43 110.643 -177.253 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.537 HD21 HD11 ' A' ' 35' ' ' ILE . 27.6 tp -78.65 115.5 18.4 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.025 -0.534 . . . . 72.33 109.762 173.668 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -103.51 -14.68 16.11 Favored 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 120.253 -0.579 . . . . 61.43 111.481 -176.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.446 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -167.61 146.34 4.81 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.889 0.376 . . . . 71.31 111.475 -177.206 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.537 HD11 HD21 ' A' ' 32' ' ' LEU . 71.4 mt -122.59 131.4 73.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 116.084 -0.507 . . . . 71.13 109.77 175.167 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -104.49 100.75 10.43 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.948 -0.76 . . . . 72.34 108.948 170.195 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 0.9 OUTLIER -97.75 123.56 50.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 115.663 -0.699 . . . . 64.32 110.283 -179.483 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.731 HG22 ' HB3' ' A' ' 44' ' ' PRO . 22.0 t -113.73 87.65 12.55 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 115.384 -0.825 . . . . 73.53 110.3 -178.489 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.489 ' HD3' HG22 ' A' ' 37' ' ' VAL . 74.5 Cg_endo -77.83 141.71 19.46 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.406 2.071 . . . . 62.43 111.33 176.568 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.434 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 35.2 mtmt -58.89 -32.95 69.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.197 0.523 . . . . 63.34 110.603 179.346 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -130.6 100.51 5.34 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.74 -0.664 . . . . 74.15 109.297 177.263 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 149.54 -16.0 1.1 Allowed Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.884 -0.674 . . . . 45.34 112.277 -177.417 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.5 mttt 72.76 140.84 0.08 OUTLIER Pre-proline 0 N--CA 1.467 0.393 0 C-N-CA 123.383 0.673 . . . . 74.22 112.237 178.29 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.731 ' HB3' HG22 ' A' ' 38' ' ' VAL . 29.1 Cg_endo -64.18 133.6 38.77 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 123.103 2.535 . . . . 71.12 112.476 179.04 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 11.2 p90 -144.15 156.18 44.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.107 -0.497 . . . . 70.13 110.57 -179.318 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.492 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 20.0 m-85 -99.54 142.38 31.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.084 -0.507 . . . . 75.43 111.484 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.446 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 72.0 mt -124.88 104.51 8.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.608 -0.724 . . . . 74.51 109.747 171.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 43.2 t -93.24 136.36 25.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.184 -0.462 . . . . 74.42 110.047 -178.756 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ARG . . . . . 0.562 ' HG3' HH11 ' A' ' 49' ' ' ARG . 0.5 OUTLIER -76.06 132.06 39.87 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.94 0.4 . . . . 71.43 111.621 -178.504 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.12 158.31 35.98 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.565 -0.743 . . . . 74.25 111.707 179.546 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -79.18 171.86 14.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.647 -0.706 . . . . 72.21 111.771 -176.265 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 70.33 21.49 77.35 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.657 -0.701 . . . . 70.41 113.035 171.147 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.9 m 57.28 30.66 18.83 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.024 0.44 . . . . 73.32 110.526 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -55.98 -63.93 1.02 Allowed 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.468 -0.787 . . . . 74.13 111.501 -179.278 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 131.1 -39.2 1.81 Allowed Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.273 -0.965 . . . . 74.35 112.794 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -68.57 164.55 21.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.43 0.633 . . . . 64.22 111.507 -176.1 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.43 ' CE2' ' HG2' ' A' ' 49' ' ' ARG . 67.9 m-85 -113.29 155.28 25.41 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.209 -0.905 . . . . 74.21 109.587 175.022 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.624 HD11 HD23 ' A' ' 66' ' ' LEU . 27.5 mm -113.27 119.87 61.8 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 108.883 -0.784 . . . . 75.3 108.883 177.868 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.571 ' HB2' HG13 ' A' ' 67' ' ' ILE . 8.1 ttm180 -82.7 149.43 27.32 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.951 -0.3 . . . . 75.42 110.403 -175.273 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.492 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 4.3 p -62.82 -27.14 69.11 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.282 -0.417 . . . . 61.24 111.452 178.266 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.449 ' HB2' ' HD2' ' A' ' 59' ' ' ARG . 1.3 m-20 -64.41 -29.13 70.19 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.131 -0.486 . . . . 72.04 111.537 -179.843 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.9 tp-100 -150.79 93.0 3.79 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-O 121.034 0.445 . . . . 71.24 109.992 -179.115 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' PRO . . . . . 0.481 ' HB2' ' HD2' ' B' ' 146' ' ' PHE . 72.7 Cg_endo -74.35 15.06 0.67 Allowed 'Trans proline' 0 C--O 1.233 0.24 0 C-N-CA 123.396 2.73 . . . . 72.35 113.151 -176.429 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -128.25 8.33 6.04 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.161 0.505 . . . . 74.14 110.338 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 12.5 mmmt -121.75 145.43 48.04 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.101 -0.5 . . . . 65.1 111.925 -177.407 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.624 HD23 HD11 ' A' ' 58' ' ' ILE . 65.6 mt -92.41 109.11 20.49 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.342 -0.844 . . . . 64.24 109.754 178.071 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.571 HG13 ' HB2' ' A' ' 59' ' ' ARG . 46.6 mm -72.67 119.54 75.77 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 116.323 -0.398 . . . . 72.3 110.408 -178.697 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.53 178.95 3.91 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 123.274 2.649 . . . . 74.53 113.363 -177.184 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' GLN . . . . . 0.822 ' HA ' HG12 ' A' ' 72' ' ' ILE . 34.9 tt0 -75.19 -34.58 61.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.513 -0.767 . . . . 74.21 111.515 -170.486 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 3.7 p90 -64.32 -23.89 67.46 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.349 -0.541 . . . . 75.34 110.916 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.483 ' HA ' ' HB2' ' A' ' 74' ' ' SER . 4.2 tp10 -92.99 -27.79 16.8 Favored 'General case' 0 N--CA 1.438 -1.052 0 CA-C-N 116.086 -0.507 . . . . 72.41 110.639 -176.591 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.822 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.3 pt -80.14 -16.95 12.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.039 0.447 . . . . 70.55 110.66 177.547 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.452 ' CD1' HG13 ' A' ' 72' ' ' ILE . 46.5 m-85 -108.37 15.37 24.04 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.825 -0.625 . . . . 73.44 110.118 174.04 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.483 ' HB2' ' HA ' ' A' ' 71' ' ' GLU . 8.3 t -74.43 -28.81 61.23 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.755 -0.657 . . . . 71.11 110.396 -177.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' TRP . . . . . 0.405 ' O ' ' HE3' ' A' ' 21' ' ' LYS . 65.3 p-90 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.515 -0.311 . . . . 72.53 110.935 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 35.0 m . . . . . 0 N--CA 1.453 -0.295 0 CA-C-O 121.087 0.47 . . . . 64.03 110.861 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.49 -68.3 0.22 Allowed Glycine 0 N--CA 1.446 -0.691 0 N-CA-C 111.595 -0.602 . . . . 63.5 111.595 -177.408 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 57.8 mm-40 69.21 77.12 0.24 Allowed Pre-proline 0 N--CA 1.468 0.463 0 C-N-CA 123.537 0.735 . . . . 74.44 111.807 -178.394 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.617 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 10.8 Cg_endo -80.93 85.22 1.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.087 0 C-N-CA 122.455 2.103 . . . . 52.13 111.049 174.792 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -97.01 150.52 20.69 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.208 0.528 . . . . 61.21 110.448 -178.218 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.434 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 13.5 p -105.46 123.75 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.906 0 CA-C-N 115.653 -0.703 . . . . 54.05 109.417 174.282 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 114' ' ' THR . . . . . 0.528 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 19.6 m -89.22 99.52 12.49 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 115.658 -0.701 . . . . 61.22 109.472 177.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 59.8 mt -88.86 106.19 16.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.919 -0.582 . . . . 52.31 110.093 -177.732 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 32.1 mtp-105 -122.28 -174.36 2.88 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.408 -0.815 . . . . 75.24 110.34 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 23.6 mp0 -136.16 132.55 36.13 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.839 -0.619 . . . . 74.5 110.431 179.201 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 118' ' ' GLU . . . . . 0.48 ' HG2' HG13 ' B' ' 123' ' ' ILE . 79.4 mm-40 -112.56 82.26 1.61 Allowed 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.062 -0.718 . . . . 75.43 109.062 173.687 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 81.05 -92.06 1.45 Allowed Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.743 -0.741 . . . . 75.45 111.387 -175.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 29.9 m-20 -117.61 -20.49 8.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.767 0.318 . . . . 70.33 111.205 178.815 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.745 ' HE3' ' HE3' ' B' ' 175' ' ' TRP . 23.6 pttt -86.62 126.0 34.21 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.273 0.559 . . . . 72.14 111.076 -177.391 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 43.9 m -80.72 124.32 28.93 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.502 -0.772 . . . . 70.14 109.986 178.592 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 123' ' ' ILE . . . . . 0.48 HG13 ' HG2' ' B' ' 118' ' ' GLU . 27.3 mm -108.98 108.59 25.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.552 -0.295 . . . . 72.01 110.393 -175.729 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.434 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 61.6 mt-30 -100.65 100.52 11.24 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.917 0.389 . . . . 73.52 110.254 178.256 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 125' ' ' GLU . . . . . 0.528 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 43.7 mt-10 -86.77 107.43 18.26 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.034 -0.53 . . . . 72.5 111.116 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 126' ' ' TYR . . . . . 0.487 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 78.0 m-85 -86.99 113.39 22.71 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.976 0.417 . . . . 74.11 110.422 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 127' ' ' ARG . . . . . 0.423 ' O ' ' HA ' ' B' ' 111' ' ' PRO . 60.5 mtm180 -117.22 178.7 4.27 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.124 -0.489 . . . . 71.31 109.957 179.145 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.624 HG13 ' H ' ' B' ' 129' ' ' ASN . 2.6 p -140.58 -65.21 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 116.279 -0.419 . . . . 64.52 110.884 173.055 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 129' ' ' ASN . . . . . 0.624 ' H ' HG13 ' B' ' 128' ' ' VAL . 3.7 t-20 -141.79 75.99 1.52 Allowed 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.438 -0.505 . . . . 61.15 110.194 -179.64 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.04 25.75 73.32 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.346 -0.843 . . . . 74.34 111.782 -179.053 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 67.7 t80 -146.01 121.7 10.5 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.685 -0.487 . . . . 73.02 109.685 -179.498 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.465 HD21 HD11 ' B' ' 135' ' ' ILE . 24.5 tp -80.14 123.93 28.33 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.724 -0.671 . . . . 75.52 109.318 176.048 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 133' ' ' TYR . . . . . 0.487 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 37.2 p90 -108.85 -15.72 14.32 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.969 -0.692 . . . . 75.31 111.849 -176.883 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 134' ' ' ALA . . . . . 0.41 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -168.03 148.85 5.07 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.928 0.394 . . . . 75.32 111.6 -178.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.465 HD11 HD21 ' B' ' 132' ' ' LEU . 62.9 mt -125.39 126.18 70.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.118 -0.492 . . . . 43.15 109.842 174.337 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.434 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 88.6 tttt -105.04 101.19 10.77 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.957 -0.757 . . . . 62.35 108.957 172.254 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.568 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 1.4 p -99.23 133.64 41.22 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.855 -0.611 . . . . 72.14 110.196 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.883 HG22 ' HB3' ' B' ' 144' ' ' PRO . 24.4 t -107.85 84.61 2.11 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 115.384 -0.826 . . . . 75.42 109.536 177.849 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.415 ' HG3' ' HE1' ' B' ' 145' ' ' TYR . 92.3 Cg_endo -79.86 150.01 20.78 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 122.407 2.072 . . . . 55.15 111.969 -179.175 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 4.1 mmpt? -62.2 -35.71 79.7 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.77 -0.65 . . . . 62.44 110.123 177.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 86.2 m-70 -124.73 90.67 3.29 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 115.789 -0.642 . . . . 72.31 109.913 -178.28 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 142' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 150.49 -29.18 1.07 Allowed Glycine 0 N--CA 1.448 -0.549 0 CA-C-N 115.191 -0.913 . . . . 70.25 111.675 -176.035 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 143' ' ' LYS . . . . . 0.446 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 87.0 mttt 70.34 155.73 0.15 Allowed Pre-proline 0 N--CA 1.467 0.421 0 C-N-CA 123.427 0.691 . . . . 74.14 112.01 -178.777 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.883 ' HB3' HG22 ' B' ' 138' ' ' VAL . 18.9 Cg_endo -58.25 124.07 15.06 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 123.224 2.616 . . . . 71.21 113.47 -175.692 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 145' ' ' TYR . . . . . 0.511 ' CE1' HG13 ' B' ' 137' ' ' VAL . 5.1 p90 -139.65 168.23 20.3 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.636 -0.711 . . . . 72.22 110.137 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.481 ' HD2' ' HB2' ' A' ' 63' ' ' PRO . 1.2 m-85 -108.84 139.32 43.83 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.954 0.407 . . . . 73.42 111.882 -176.506 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.41 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 25.6 mt -118.75 101.28 7.97 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.448 -0.796 . . . . 75.22 109.653 169.479 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 42.7 t -86.46 137.91 20.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 116.225 -0.443 . . . . 73.41 110.077 -179.101 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 5.1 mmt85 -74.85 130.38 39.32 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.884 0.373 . . . . 72.24 111.285 178.615 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -71.03 122.14 19.5 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.769 -0.65 . . . . 34.52 111.08 177.822 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 151' ' ' ASP . . . . . 0.622 ' HB2' ' HD2' ' A' ' 26' ' ' TYR . 15.7 t70 -61.31 140.0 58.06 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.648 -0.705 . . . . 73.24 110.981 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 73.47 -56.61 2.03 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.955 -0.566 . . . . 71.4 113.237 179.323 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 153' ' ' SER . . . . . 0.433 ' O ' ' HB3' ' B' ' 154' ' ' ASP . 19.7 m -61.2 -46.07 91.96 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 122.43 0.292 . . . . 73.41 110.868 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 154' ' ' ASP . . . . . 0.433 ' HB3' ' O ' ' B' ' 153' ' ' SER . 18.0 t70 71.47 -48.27 0.67 Allowed 'General case' 0 N--CA 1.464 0.237 0 C-N-CA 123.743 0.817 . . . . 74.33 111.859 178.107 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . -88.13 50.07 3.84 Favored Glycine 0 N--CA 1.448 -0.502 0 CA-C-N 116.122 -0.49 . . . . 54.43 112.601 -178.083 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -162.54 144.59 10.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.457 -0.571 . . . . 75.55 109.457 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 157' ' ' PHE . . . . . 0.506 ' HB2' HG22 ' B' ' 172' ' ' ILE . 72.4 m-85 -118.99 150.71 39.48 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.909 0.385 . . . . 74.04 110.463 178.108 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.0 mm -113.43 114.44 46.86 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 N-CA-C 108.82 -0.807 . . . . 64.14 108.82 175.45 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.535 ' HB2' HG13 ' B' ' 167' ' ' ILE . 15.0 ttp180 -88.03 146.92 25.24 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 110.046 -0.353 . . . . 72.34 110.046 -174.815 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 4.0 p -60.03 -36.31 76.99 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 112.779 0.659 . . . . 61.11 112.779 -174.101 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -78.28 -14.65 59.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.973 0.416 . . . . 70.12 110.908 -177.679 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 162' ' ' GLN . . . . . 0.838 ' HG3' ' HB2' ' B' ' 165' ' ' LYS . 5.4 tp-100 -138.03 72.02 47.57 Favored Pre-proline 0 N--CA 1.45 -0.438 0 CA-C-N 116.219 -0.446 . . . . 54.31 110.894 -177.334 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -85.09 -1.57 9.38 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.674 2.249 . . . . 72.53 111.775 179.18 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -91.74 -17.99 24.59 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.25 -0.886 . . . . 75.2 110.14 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 165' ' ' LYS . . . . . 0.838 ' HB2' ' HG3' ' B' ' 162' ' ' GLN . 0.7 OUTLIER -122.79 158.83 29.35 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.124 -0.944 . . . . 72.42 111.134 -175.133 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.1 mp -94.74 134.02 37.79 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.064 -1.087 . . . . 55.14 108.064 172.577 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 167' ' ' ILE . . . . . 0.535 HG13 ' HB2' ' B' ' 159' ' ' ARG . 50.2 mm -84.69 125.11 72.07 Favored Pre-proline 0 C--N 1.32 -0.695 0 C-N-CA 120.91 -0.316 . . . . 73.43 111.041 -171.552 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.455 ' O ' HG23 ' B' ' 172' ' ' ILE . 49.6 Cg_endo -67.7 172.77 10.02 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.762 2.308 . . . . 74.3 112.429 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 169' ' ' GLN . . . . . 0.516 ' HA ' HG12 ' B' ' 172' ' ' ILE . 20.4 tt0 -79.56 -16.93 55.05 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.766 -0.652 . . . . 74.54 111.626 -167.464 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 170' ' ' TRP . . . . . 0.417 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 24.4 p90 -86.75 -8.01 57.76 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.234 0.54 . . . . 62.5 110.019 176.043 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.55 ' O ' ' HB2' ' B' ' 174' ' ' SER . 1.9 mm-40 -113.32 -11.89 13.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.816 -0.629 . . . . 73.12 111.961 -176.657 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.516 HG12 ' HA ' ' B' ' 169' ' ' GLN . 31.8 pt -76.82 -16.87 14.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 121.264 0.554 . . . . 70.5 110.277 175.848 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -109.14 39.09 2.13 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.356 -0.838 . . . . 75.22 108.874 174.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 174' ' ' SER . . . . . 0.55 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 0.5 OUTLIER -70.15 -14.48 62.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 114.981 -1.009 . . . . 60.34 110.916 -176.181 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 175' ' ' TRP . . . . . 0.745 ' HE3' ' HE3' ' B' ' 121' ' ' LYS . 59.7 p-90 . . . . . 0 C--O 1.245 0.842 0 CA-C-O 118.286 -0.864 . . . . 64.24 110.204 177.573 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 15.0 m . . . . . 0 N--CA 1.453 -0.286 0 N-CA-C 109.03 -0.73 . . . . 75.22 109.03 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 116.17 102.8 2.33 Favored Glycine 0 N--CA 1.439 -1.111 0 N-CA-C 108.79 -1.724 . . . . 74.44 108.79 -166.103 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLU . . . . . 0.476 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 10.1 pt-20 -141.03 113.99 6.96 Favored Pre-proline 0 N--CA 1.437 -1.12 0 N-CA-C 108.089 -1.078 . . . . 63.41 108.089 -167.773 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.476 ' HD3' ' HA ' ' A' ' 10' ' ' GLU . 4.9 Cg_exo -77.12 81.47 2.61 Favored 'Trans proline' 0 N--CA 1.437 -1.803 0 C-N-CA 121.873 1.715 . . . . 73.12 110.531 -176.451 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -86.26 155.37 20.71 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.564 -1.198 . . . . 72.12 109.869 -177.452 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.592 HG21 ' HB3' ' A' ' 24' ' ' GLN . 10.1 p -121.23 123.79 70.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 CA-C-O 121.512 0.673 . . . . 64.42 111.143 -178.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.558 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 88.8 m -86.03 104.21 15.43 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.521 -0.763 . . . . 71.0 108.944 177.011 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.3 mt -91.44 105.5 16.61 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 CA-C-N 116.093 -0.503 . . . . 44.43 110.598 -175.698 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.405 HH21 ' CD ' ' A' ' 25' ' ' GLU . 62.3 mtm180 -117.86 172.99 7.02 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.787 -0.642 . . . . 72.54 109.993 177.766 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.499 ' HG2' ' HA ' ' A' ' 22' ' ' THR . 82.6 mt-30 -136.93 122.17 19.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.172 0.51 . . . . 64.52 111.024 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.469 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 31.5 mm-40 -106.96 87.35 2.49 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.398 -0.819 . . . . 75.43 110.018 178.188 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 79.17 -95.13 1.4 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.633 -0.794 . . . . 74.43 111.678 -178.26 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -124.09 12.5 8.97 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.83 0.347 . . . . 72.42 110.871 -179.228 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.714 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 21.3 pttm -117.27 117.29 29.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.019 0.438 . . . . 74.55 110.987 178.797 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.702 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 23.6 m -79.25 101.91 8.27 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.736 -0.665 . . . . 72.03 109.679 176.047 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.469 HG12 HG13 ' A' ' 37' ' ' VAL . 57.0 mt -92.64 106.85 18.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 120.996 0.427 . . . . 63.43 110.14 -176.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.604 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 72.6 mt-30 -91.4 110.7 22.01 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.801 -0.636 . . . . 75.12 110.3 178.784 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.622 ' HB3' HD13 ' A' ' 32' ' ' LEU . 26.4 mt-10 -93.83 103.48 15.6 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.469 -0.787 . . . . 62.33 111.109 -177.142 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.413 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 86.8 m-85 -77.83 109.13 11.58 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.985 0.421 . . . . 73.52 110.228 178.692 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 31' ' ' PHE . 83.8 mtt180 -127.58 127.3 43.65 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.581 -0.736 . . . . 74.42 109.459 -179.681 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.604 HG21 ' CD2' ' B' ' 131' ' ' PHE . 11.9 p -90.49 -28.25 4.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 C-N-CA 120.37 -0.532 . . . . 61.02 110.628 -177.754 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -172.26 68.06 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.707 -0.679 . . . . 73.11 109.631 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 95.77 -37.97 3.26 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.773 -0.727 . . . . 62.32 113.414 178.262 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.416 ' CD2' HG21 ' B' ' 128' ' ' VAL . 80.1 t80 -94.82 133.5 38.46 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.239 0.542 . . . . 71.15 111.405 -174.058 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.622 HD13 ' HB3' ' A' ' 25' ' ' GLU . 50.1 tp -82.38 112.86 19.73 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.941 -1.027 . . . . 54.1 110.156 174.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' TYR . . . . . 0.455 ' O ' ' HB2' ' A' ' 49' ' ' ARG . 44.3 p90 -108.62 -4.99 16.65 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.895 -0.322 . . . . 73.4 111.72 -176.614 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.405 ' HB3' ' HB2' ' A' ' 26' ' ' TYR . . . -168.3 136.97 2.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.891 0.377 . . . . 71.42 110.889 -176.141 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.414 ' CG1' HD21 ' A' ' 32' ' ' LEU . 61.4 mt -118.97 126.12 75.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.0 -0.546 . . . . 75.32 110.542 178.852 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.604 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 83.1 tttt -108.69 100.78 9.98 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.003 -0.74 . . . . 62.25 109.003 171.366 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.706 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.8 t -87.91 128.79 40.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 109.153 -0.684 . . . . 63.32 109.153 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.817 HG13 ' HG3' ' A' ' 44' ' ' PRO . 24.2 t -115.74 72.71 4.16 Favored Pre-proline 0 C--N 1.32 -0.709 0 N-CA-C 109.75 -0.463 . . . . 65.05 109.75 172.869 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.714 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 57.1 Cg_endo -78.76 134.43 12.09 Favored 'Trans proline' 0 N--CA 1.458 -0.615 0 C-N-CA 122.18 1.92 . . . . 63.11 112.433 176.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 9.4 mtpm? -59.78 -33.06 71.21 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-O 121.29 0.566 . . . . 74.2 109.948 175.275 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 62.4 m-70 -115.77 103.58 10.8 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.244 -0.889 . . . . 54.3 109.148 178.009 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 130.11 -25.18 4.39 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.943 -0.646 . . . . 31.44 112.096 -177.552 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.0 mttm 69.57 147.79 0.12 Allowed Pre-proline 0 N--CA 1.466 0.363 0 C-N-CA 123.342 0.657 . . . . 73.43 112.323 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.817 ' HG3' HG13 ' A' ' 38' ' ' VAL . 31.0 Cg_exo -58.51 145.97 92.59 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 123.222 2.615 . . . . 74.35 113.561 -177.03 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 30.6 p90 -156.39 164.91 37.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.314 -0.857 . . . . 74.31 109.304 174.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.557 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 85.1 m-85 -106.62 136.44 46.4 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.021 0.438 . . . . 72.12 110.7 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 16.9 tp -125.14 98.96 5.88 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.695 -0.854 . . . . 54.3 108.695 176.408 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.438 HG21 HG21 ' B' ' 148' ' ' VAL . 28.7 t -96.32 140.59 16.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.421 -0.354 . . . . 74.24 111.548 -171.036 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ARG . . . . . 0.455 ' HB2' ' O ' ' A' ' 33' ' ' TYR . 0.7 OUTLIER -66.85 122.38 17.57 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.213 -0.449 . . . . 72.35 111.32 176.66 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.44 172.39 13.7 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.921 -0.581 . . . . 72.44 109.503 172.498 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -68.04 125.04 25.07 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.22 0.533 . . . . 71.51 109.781 176.807 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.41 125.57 5.49 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.783 -0.723 . . . . 63.23 111.899 -176.351 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.5 t -87.45 23.1 1.99 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.347 0.594 . . . . 74.35 110.24 -177.027 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -58.12 -60.43 3.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.432 -0.804 . . . . 54.51 110.206 177.673 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 156.61 21.87 0.03 OUTLIER Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 115.546 -0.752 . . . . 72.35 112.453 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.485 ' OD1' ' HB3' ' A' ' 66' ' ' LEU . 7.4 t30 -102.91 137.18 41.44 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.963 0.411 . . . . 65.34 110.867 -176.562 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -123.56 174.42 7.43 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.942 -0.572 . . . . 72.11 110.47 177.659 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 49.8 mm -123.97 122.08 63.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.893 -0.78 . . . . 42.41 108.893 171.506 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.668 ' HB2' HG13 ' A' ' 67' ' ' ILE . 74.6 ttt180 -93.34 131.97 38.0 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.07 -0.514 . . . . 71.15 110.309 -175.386 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.557 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 67.9 p -62.8 -22.77 66.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.86 0.362 . . . . 74.35 111.343 -178.592 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.468 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 16.4 t70 -64.23 -46.37 84.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.778 -0.647 . . . . 64.34 109.981 178.479 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 78.0 mm-40 -132.14 82.66 58.1 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.479 -0.782 . . . . 71.32 109.383 178.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -76.34 30.9 0.4 Allowed 'Trans proline' 0 CA--C 1.529 0.254 0 C-N-CA 123.28 2.653 . . . . 62.14 112.5 -177.052 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -119.57 -39.89 2.83 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.433 -0.803 . . . . 72.22 110.462 -177.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.7 pttt -97.53 160.22 14.45 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.999 -0.546 . . . . 74.53 110.501 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.485 ' HB3' ' OD1' ' A' ' 56' ' ' ASN . 5.4 mp -92.96 140.25 29.67 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.668 -0.696 . . . . 71.14 109.335 179.214 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.711 HG23 ' HB3' ' A' ' 71' ' ' GLU . 47.1 mm -96.84 109.03 46.79 Favored Pre-proline 0 C--N 1.322 -0.593 0 CA-C-O 121.235 0.54 . . . . 75.31 111.307 -176.453 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.49 ' O ' HG23 ' A' ' 72' ' ' ILE . 93.0 Cg_endo -81.61 -176.92 3.3 Favored 'Trans proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.505 2.803 . . . . 61.14 111.983 177.499 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' GLN . . . . . 0.651 ' O ' HG12 ' A' ' 72' ' ' ILE . 45.6 tt0 -67.99 -40.42 83.09 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.225 0.454 . . . . 72.42 112.225 -171.122 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' TRP . . . . . 0.644 ' HA ' ' CZ ' ' A' ' 73' ' ' PHE . 17.4 p90 -63.38 -17.76 62.95 Favored 'General case' 0 C--N 1.326 -0.441 0 O-C-N 121.723 -0.61 . . . . 72.35 110.981 -178.591 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.711 ' HB3' HG23 ' A' ' 67' ' ' ILE . 2.5 mm-40 -94.45 -18.45 21.49 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.041 -0.527 . . . . 71.03 111.117 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.651 HG12 ' O ' ' A' ' 69' ' ' GLN . 39.9 pt -83.61 -36.03 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 C-N-CA 120.723 -0.391 . . . . 53.3 111.625 -177.199 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.644 ' CZ ' ' HA ' ' A' ' 70' ' ' TRP . 10.7 p90 -90.82 26.09 2.18 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.262 0.554 . . . . 75.11 110.722 178.839 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.3 t -78.72 9.03 4.49 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.767 -0.652 . . . . 73.42 111.102 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' TRP . . . . . 0.681 ' HB3' ' HE3' ' A' ' 21' ' ' LYS . 38.8 m0 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.459 -0.337 . . . . 72.52 111.176 177.652 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 31.8 m . . . . . 0 C--O 1.233 0.221 0 CA-C-O 121.154 0.502 . . . . 72.24 110.366 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 122.61 42.89 0.4 Allowed Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 110.491 -1.043 . . . . 63.05 110.491 -170.397 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -106.59 100.56 31.25 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-O 121.658 0.742 . . . . 74.34 109.286 -179.463 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 58.0 Cg_endo -79.43 121.04 4.61 Favored 'Trans proline' 0 N--CA 1.448 -1.148 0 C-N-CA 122.382 2.054 . . . . 54.13 113.195 -169.645 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -122.84 144.19 49.36 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.814 -1.084 . . . . 74.34 108.599 174.583 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.75 HG21 ' HB3' ' B' ' 124' ' ' GLN . 7.9 p -92.37 132.01 37.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-O 121.396 0.617 . . . . 75.0 111.543 -172.112 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 114' ' ' THR . . . . . 0.747 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.4 m -82.84 103.39 12.28 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.167 -0.924 . . . . 71.41 109.177 174.885 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 59.2 mt -88.67 104.61 14.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.096 0.474 . . . . 72.43 111.066 -176.124 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 116' ' ' ARG . . . . . 0.434 HH21 ' CD ' ' B' ' 125' ' ' GLU . 38.1 mtm180 -108.88 167.86 9.78 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.721 -0.672 . . . . 72.22 109.627 174.901 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 91.5 mt-30 -139.55 112.03 7.73 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.068 0.461 . . . . 74.34 110.585 177.447 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 81.6 mm-40 -108.48 85.35 2.09 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.669 -0.696 . . . . 74.1 110.384 -178.621 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 88.38 -111.94 3.84 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.624 -0.798 . . . . 51.42 111.589 -178.138 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 120' ' ' ASP . . . . . 0.507 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 4.3 m-20 -116.0 23.24 12.37 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.059 0.457 . . . . 42.23 110.041 177.141 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.962 ' HE3' ' HB3' ' B' ' 175' ' ' TRP . 21.2 pttm -127.5 115.56 19.04 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.236 0.541 . . . . 63.31 110.307 177.311 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 122' ' ' THR . . . . . 0.747 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 62.5 m -76.22 113.0 13.29 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.611 -0.722 . . . . 73.24 109.675 177.172 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 14.2 mm -92.8 102.51 13.7 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-N 115.948 -0.569 . . . . 75.13 109.999 -178.222 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.776 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 63.2 mt-30 -94.77 102.89 14.79 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.093 0.473 . . . . 63.13 110.327 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 125' ' ' GLU . . . . . 0.747 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 38.9 mt-10 -84.62 102.72 13.13 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.556 -0.747 . . . . 71.12 110.603 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 126' ' ' TYR . . . . . 0.493 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 41.4 m-85 -78.8 106.0 10.51 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.137 0.494 . . . . 55.11 110.377 178.061 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 65.6 mtt-85 -124.08 134.55 53.36 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.61 -0.723 . . . . 74.1 109.468 -178.367 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 5.6 p -96.08 -30.91 3.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-O 120.966 0.412 . . . . 54.02 111.407 -176.374 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -160.45 45.99 0.22 Allowed 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.872 -0.788 . . . . 72.34 108.872 -176.563 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 95.54 -32.08 6.58 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.425 -0.807 . . . . 23.51 112.186 -177.124 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.604 ' CD2' HG21 ' A' ' 28' ' ' VAL . 38.2 t80 -86.49 133.6 33.74 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.99 0.424 . . . . 74.31 110.445 -177.848 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.449 HD21 HD11 ' B' ' 135' ' ' ILE . 41.4 tp -82.83 120.5 25.73 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.354 -0.839 . . . . 62.21 110.645 179.328 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 133' ' ' TYR . . . . . 0.493 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 36.2 p90 -110.4 -10.43 14.58 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.498 -0.481 . . . . 74.02 111.658 -179.101 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -170.14 148.13 3.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.806 0.336 . . . . 44.21 110.913 -178.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.449 HD11 HD21 ' B' ' 132' ' ' LEU . 63.5 mt -122.44 125.89 73.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.332 -0.395 . . . . 71.11 110.17 177.456 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.776 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 75.9 tttt -102.43 102.39 12.7 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 109.07 -0.715 . . . . 72.13 109.07 173.851 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.589 HG12 ' HD3' ' B' ' 139' ' ' PRO . 3.4 t -86.52 128.94 39.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 N-CA-C 108.559 -0.904 . . . . 70.41 108.559 178.151 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.747 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.5 t -115.35 72.1 3.39 Favored Pre-proline 0 C--N 1.317 -0.841 0 N-CA-C 109.956 -0.387 . . . . 75.12 109.956 173.525 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.589 ' HD3' HG12 ' B' ' 137' ' ' VAL . 45.1 Cg_endo -77.12 130.5 11.23 Favored 'Trans proline' 0 N--CA 1.455 -0.754 0 C-N-CA 121.992 1.794 . . . . 64.11 111.868 176.719 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 140' ' ' LYS . . . . . 0.507 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 22.9 mtpp -64.76 -27.43 68.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.442 -0.799 . . . . 73.45 110.199 177.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -114.43 86.57 2.46 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.132 -0.94 . . . . 73.02 109.149 176.293 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 140.96 -13.88 2.85 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.593 -0.813 . . . . 60.52 112.678 -177.576 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 67.1 mttm 70.03 149.01 0.12 Allowed Pre-proline 0 N--CA 1.469 0.525 0 C-N-CA 123.134 0.574 . . . . 74.21 112.183 178.266 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.554 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 56.3 Cg_endo -70.64 143.1 45.7 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.674 2.249 . . . . 74.22 113.146 -178.279 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 44.7 p90 -150.99 154.77 37.72 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.789 -0.641 . . . . 74.23 110.199 178.207 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.636 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 93.4 m-85 -96.64 130.5 43.84 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.838 -0.43 . . . . 75.25 109.838 177.255 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.402 HD11 HG13 ' B' ' 167' ' ' ILE . 15.7 tp -117.21 98.81 6.64 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.134 -0.691 . . . . 73.44 109.134 176.479 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 148' ' ' VAL . . . . . 0.438 HG21 HG21 ' A' ' 48' ' ' VAL . 39.0 t -83.92 135.73 24.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.05 -0.523 . . . . 72.14 110.837 -175.294 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.29 119.44 24.59 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.58 -0.526 . . . . 64.35 109.58 -177.722 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.14 166.75 22.88 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 121.321 0.581 . . . . 71.21 111.74 -174.704 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 151' ' ' ASP . . . . . 0.404 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 5.6 p-10 -67.77 157.59 34.38 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 114.964 -1.017 . . . . 71.24 111.99 -175.603 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.41 -8.93 57.24 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.301 -0.863 . . . . 52.22 113.28 173.179 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 23.3 t 59.3 31.1 20.9 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-O 121.513 0.673 . . . . 71.21 110.007 -178.155 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -64.43 -26.18 68.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.597 -0.729 . . . . 64.33 111.841 -178.139 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 106.15 25.17 6.53 Favored Glycine 0 CA--C 1.506 -0.525 0 N-CA-C 111.169 -0.772 . . . . 62.23 111.169 -175.044 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 156' ' ' ASN . . . . . 0.444 HD21 HD23 ' B' ' 166' ' ' LEU . 38.0 t30 -111.95 144.26 41.59 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.461 -0.57 . . . . 75.11 109.461 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 157' ' ' PHE . . . . . 0.531 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 55.8 m-85 -130.62 149.56 52.22 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.305 -0.407 . . . . 75.45 110.083 179.587 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.2 mm -112.44 117.19 54.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.444 -0.576 . . . . 72.15 109.444 176.306 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.443 ' HG2' ' H ' ' B' ' 161' ' ' ASP . 46.1 ttt180 -85.95 135.05 33.82 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.48 -0.782 . . . . 74.01 110.075 -175.824 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 160' ' ' SER . . . . . 0.636 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 61.3 p -60.46 -33.07 72.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.406 0.622 . . . . 74.2 110.412 178.66 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 161' ' ' ASP . . . . . 0.443 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 26.6 t70 -75.94 -24.59 55.51 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.15 -0.932 . . . . 71.31 110.921 178.701 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 162' ' ' GLN . . . . . 0.453 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 84.3 mm-40 -139.98 70.97 35.44 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 71.32 110.197 -175.235 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -73.11 -15.37 25.8 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.431 2.087 . . . . 72.23 112.007 -178.032 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -89.2 -7.2 56.06 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.41 -0.814 . . . . 72.14 109.641 177.02 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 165' ' ' LYS . . . . . 0.453 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 51.3 tptt -110.68 123.98 51.06 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.444 -0.798 . . . . 75.1 110.447 -176.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 166' ' ' LEU . . . . . 0.444 HD23 HD21 ' B' ' 156' ' ' ASN . 5.3 mp -89.64 117.5 28.56 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.515 -0.766 . . . . 62.41 108.989 177.096 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 167' ' ' ILE . . . . . 0.531 ' HB ' ' HB2' ' B' ' 157' ' ' PHE . 49.3 mm -77.73 119.56 77.91 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.185 -0.462 . . . . 72.25 111.272 -171.31 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.481 ' O ' HG23 ' B' ' 172' ' ' ILE . 73.7 Cg_endo -73.3 177.26 8.1 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 123.049 2.5 . . . . 73.41 111.998 178.492 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 28.5 tt0 -84.25 0.88 47.2 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.347 -0.388 . . . . 71.32 111.468 -172.127 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 7.8 p90 -100.46 -18.89 16.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.987 0.423 . . . . 73.55 110.89 175.259 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.418 ' HB2' ' HG2' ' B' ' 168' ' ' PRO . 2.0 mm-40 -94.29 -11.43 30.15 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.194 -0.457 . . . . 74.52 110.76 -177.232 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.481 HG23 ' O ' ' B' ' 168' ' ' PRO . 37.0 pt -65.56 -29.65 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.991 -0.55 . . . . 75.22 111.432 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 173' ' ' PHE . . . . . 0.458 ' C ' ' H ' ' B' ' 175' ' ' TRP . 33.8 p90 -107.79 43.96 1.15 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.525 0.678 . . . . 71.14 110.447 178.742 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 174' ' ' SER . . . . . 0.418 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 1.9 t -78.59 21.97 0.37 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.05 -0.977 . . . . 71.35 110.036 178.183 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 175' ' ' TRP . . . . . 0.962 ' HB3' ' HE3' ' B' ' 121' ' ' LYS . 39.3 m0 . . . . . 0 C--O 1.25 1.129 0 CA-C-N 115.223 -0.898 . . . . 75.21 110.928 -176.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.6 m . . . . . 0 C--O 1.233 0.22 0 N-CA-C 109.518 -0.549 . . . . 65.11 109.518 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.663 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 74.03 73.02 0.95 Allowed Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.02 -1.086 . . . . 52.33 110.621 -173.727 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLU . . . . . 0.432 ' H ' ' HG2' ' A' ' 10' ' ' GLU . 7.6 pt-20 -96.22 99.1 4.77 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-O 121.417 0.627 . . . . 63.05 110.667 -174.844 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.673 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 98.2 Cg_endo -93.73 94.72 0.14 Allowed 'Trans proline' 0 N--CA 1.445 -1.368 0 C-N-CA 122.926 2.417 . . . . 64.04 112.747 -176.524 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -86.96 147.1 25.89 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 108.932 -0.766 . . . . 60.21 108.932 177.069 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.623 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 8.1 p -90.63 122.41 41.98 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 CA-C-O 121.629 0.728 . . . . 65.13 110.261 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.628 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 21.6 m -83.31 102.59 12.08 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.264 -0.88 . . . . 72.4 109.196 179.226 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 53.2 mt -84.72 103.98 12.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-N 115.978 -0.555 . . . . 74.34 110.308 -175.449 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -108.8 161.24 15.3 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.621 -0.718 . . . . 64.31 109.32 176.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -137.87 98.25 3.61 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-O 121.351 0.596 . . . . 71.13 110.232 176.786 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -93.88 96.84 9.99 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 114.982 -1.008 . . . . 75.42 109.849 -177.313 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 71.06 -101.84 1.0 Allowed Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.837 -0.697 . . . . 63.44 112.077 -178.105 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.745 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 16.5 m-20 -120.76 30.42 6.91 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.635 0.255 . . . . 62.43 110.951 -178.364 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 48.0 pttt -143.55 127.69 17.58 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.382 0.61 . . . . 75.25 111.624 175.72 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.447 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 75.0 m -81.66 107.18 14.2 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.189 -0.914 . . . . 71.34 109.936 177.073 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 50.2 mt -94.63 104.35 15.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.088 -0.505 . . . . 72.31 109.721 178.521 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.623 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 74.7 mt-30 -95.15 106.38 18.39 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.871 -0.604 . . . . 74.3 110.654 -177.725 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.628 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.7 mt-10 -89.86 104.51 17.06 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.874 -0.603 . . . . 53.15 111.355 -177.437 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.568 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 71.7 m-85 -76.94 103.57 6.95 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.393 -0.595 . . . . 74.34 109.393 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.43 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 55.5 mtt180 -120.39 128.05 52.86 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.259 -0.428 . . . . 73.55 110.362 -177.312 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.685 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.3 p -93.49 -66.73 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.543 -0.298 . . . . 72.45 111.232 179.58 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.685 ' H ' HG13 ' A' ' 28' ' ' VAL . 74.2 m-20 -133.53 77.5 1.73 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.85 0.357 . . . . 71.01 110.158 179.513 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 69.21 13.49 67.38 Favored Glycine 0 C--N 1.331 0.267 0 CA-C-N 115.792 -0.64 . . . . 74.21 112.868 179.042 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.614 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 83.3 t80 -129.86 128.04 41.45 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.888 0.375 . . . . 72.12 111.12 -175.431 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.74 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -85.98 116.25 24.09 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.559 -0.746 . . . . 72.12 109.327 173.571 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -110.89 -19.71 12.71 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.622 -0.431 . . . . 74.04 111.729 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -156.08 141.21 17.39 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.656 0.265 . . . . 61.01 111.031 -179.338 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.74 HG13 HD11 ' A' ' 32' ' ' LEU . 77.0 mt -124.31 125.9 71.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 116.055 -0.521 . . . . 72.32 110.612 176.867 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.444 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 82.1 tttt -102.99 102.56 12.61 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.104 -0.702 . . . . 72.3 109.104 170.787 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 22' ' ' THR . 0.5 OUTLIER -101.84 119.93 50.78 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 116.119 -0.491 . . . . 70.51 110.337 -179.538 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.571 HG13 ' HB3' ' A' ' 44' ' ' PRO . 22.3 t -109.17 89.71 7.19 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.445 -0.798 . . . . 73.44 110.135 -179.826 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.417 ' HD3' HG22 ' A' ' 37' ' ' VAL . 63.6 Cg_endo -79.37 135.92 12.24 Favored 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 122.282 1.988 . . . . 73.02 112.133 178.001 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.745 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 56.5 mtpt -63.43 -36.27 83.19 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.362 0.601 . . . . 71.33 109.518 174.622 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -97.81 92.63 5.94 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.222 -0.899 . . . . 63.3 109.114 177.269 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 126.0 -151.39 17.82 Favored Glycine 0 N--CA 1.448 -0.549 0 N-CA-C 111.478 -0.649 . . . . 63.12 111.478 -176.529 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -129.29 143.76 50.11 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.801 0.301 . . . . 73.42 110.601 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.571 ' HB3' HG13 ' A' ' 38' ' ' VAL . 32.1 Cg_endo -65.29 128.94 21.49 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.679 2.253 . . . . 74.13 112.077 177.758 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -133.86 156.73 47.54 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.267 -0.424 . . . . 74.12 110.343 -178.151 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -95.71 131.62 41.77 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.778 -0.647 . . . . 74.14 109.792 177.514 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.569 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 17.0 tp -115.63 94.11 4.56 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.827 -0.805 . . . . 72.01 108.827 178.102 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.7 t -87.29 138.27 19.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.064 -0.517 . . . . 63.25 110.872 -174.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ARG . . . . . 0.461 ' HE ' ' HA ' ' A' ' 53' ' ' SER . 0.0 OUTLIER -100.89 121.6 42.0 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.926 -0.398 . . . . 74.32 109.926 -177.3 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.431 ' HB3' ' OD1' ' A' ' 56' ' ' ASN . . . -76.98 172.06 13.79 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.01 0.433 . . . . 71.3 112.076 -173.387 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.437 ' HB3' ' CD2' ' B' ' 126' ' ' TYR . 4.3 p-10 -72.13 167.73 19.64 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 115.793 -0.64 . . . . 74.31 111.09 -175.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 81.2 -17.17 13.42 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.831 -0.622 . . . . 50.43 112.798 177.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.461 ' HA ' ' HE ' ' A' ' 49' ' ' ARG . 20.9 t 61.64 33.46 18.13 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-O 120.894 0.378 . . . . 63.53 110.148 -178.075 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -55.89 -42.02 75.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.714 -0.675 . . . . 73.32 111.363 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 119.17 25.52 2.7 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.834 -0.698 . . . . 72.11 111.392 -177.167 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.431 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 11.2 p30 -118.74 147.24 44.07 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.178 0.513 . . . . 74.14 110.633 -177.368 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.569 ' CD2' ' HG ' ' A' ' 47' ' ' LEU . 46.6 m-85 -128.17 154.33 45.91 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.684 -0.689 . . . . 75.4 110.501 -178.729 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 45.3 mm -113.1 122.89 68.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.987 -0.551 . . . . 73.41 109.519 177.705 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.491 ' HB3' ' HB3' ' A' ' 61' ' ' ASP . 67.2 mtt180 -86.17 144.79 27.3 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.56 -0.291 . . . . 71.42 110.61 178.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 77.6 p -76.02 -21.85 56.41 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.407 -0.961 . . . . 75.3 108.407 166.396 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.491 ' HB3' ' HB3' ' A' ' 59' ' ' ARG . 19.2 t70 -57.62 -49.17 77.33 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.519 -1.219 . . . . 74.35 110.092 172.746 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 24.1 mm-40 -144.78 86.38 7.9 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.151 -0.932 . . . . 63.2 110.25 178.796 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_endo -78.79 13.0 2.03 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.89 2.394 . . . . 75.44 112.24 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -83.65 -30.7 26.65 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.418 -0.81 . . . . 71.1 110.529 -178.59 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.434 ' HE3' HD11 ' A' ' 67' ' ' ILE . 0.0 OUTLIER -126.25 178.1 6.02 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-O 121.196 0.522 . . . . 72.35 111.614 -176.664 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.5 mp -111.16 138.19 47.91 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.206 -0.906 . . . . 75.41 109.607 177.357 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.434 HD11 ' HE3' ' A' ' 65' ' ' LYS . 33.7 mm -76.55 124.86 87.95 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 116.448 -0.342 . . . . 75.43 110.145 178.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.411 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 44.3 Cg_endo -66.98 173.84 7.72 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.903 2.402 . . . . 75.01 112.759 -177.855 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 19.5 tt0 -88.63 -1.44 58.07 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.54 -0.755 . . . . 74.11 111.907 -168.684 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' TRP . . . . . 0.586 ' HA ' ' CE2' ' A' ' 73' ' ' PHE . 33.4 p90 -97.39 -22.61 16.51 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.265 0.555 . . . . 74.53 109.727 172.706 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.414 ' HA ' ' OG ' ' A' ' 74' ' ' SER . 4.4 mm-40 -84.25 -12.71 54.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.448 -0.796 . . . . 44.41 111.522 -176.745 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 31.9 pt -77.67 -15.88 14.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.125 -0.489 . . . . 64.4 111.875 -177.496 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CE2' ' HA ' ' A' ' 70' ' ' TRP . 42.4 p90 -119.45 23.83 11.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.42 0.629 . . . . 74.42 110.189 177.766 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.414 ' OG ' ' HA ' ' A' ' 71' ' ' GLU . 56.2 m -80.23 -1.34 40.25 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.712 -0.676 . . . . 65.42 110.875 177.879 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' TRP . . . . . 0.553 ' HH2' HG21 ' A' ' 35' ' ' ILE . 0.3 OUTLIER . . . . . 0 C--N 1.327 -0.38 0 CA-C-N 116.149 -0.478 . . . . 73.13 110.58 178.275 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 58.8 m . . . . . 0 N--CA 1.45 -0.449 0 N-CA-C 109.292 -0.632 . . . . 75.34 109.292 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.45 52.66 0.55 Allowed Glycine 0 N--CA 1.445 -0.715 0 N-CA-C 110.551 -1.02 . . . . 73.23 110.551 -170.112 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 110' ' ' GLU . . . . . 0.407 ' O ' ' HG3' ' B' ' 110' ' ' GLU . 10.1 pt-20 -97.92 105.33 26.84 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.365 -0.976 . . . . 73.24 108.365 -179.316 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.614 ' HG3' ' CZ ' ' A' ' 31' ' ' PHE . 73.7 Cg_endo -83.11 113.42 2.11 Favored 'Trans proline' 0 N--CA 1.443 -1.489 0 C-N-CA 122.143 1.895 . . . . 72.55 112.418 -170.843 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 16.5 p-10 -109.72 133.46 53.1 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 115.066 -0.97 . . . . 75.41 109.444 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.626 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 11.7 p -83.55 127.89 39.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 121.42 0.629 . . . . 65.04 110.734 -177.396 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 114' ' ' THR . . . . . 0.646 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 27.0 m -81.72 108.85 15.6 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.456 -0.793 . . . . 71.13 109.964 179.349 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.487 HG12 ' HG2' ' B' ' 124' ' ' GLN . 66.4 mt -93.26 106.05 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.074 0.464 . . . . 61.32 110.907 -176.439 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 116' ' ' ARG . . . . . 0.485 ' NE ' ' HA ' ' B' ' 116' ' ' ARG . 3.5 mmp_? -116.24 164.98 13.69 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.657 -0.701 . . . . 73.12 109.457 176.824 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -138.39 107.46 6.03 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.099 0.476 . . . . 72.22 110.962 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -100.36 97.29 8.07 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.584 -0.734 . . . . 71.24 110.297 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 74.89 -97.01 0.98 Allowed Glycine 0 N--CA 1.444 -0.797 0 C-N-CA 121.011 -0.614 . . . . 74.21 112.256 178.925 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 120' ' ' ASP . . . . . 0.746 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 5.8 m-20 -125.06 32.07 5.48 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.702 0.287 . . . . 72.11 110.664 -178.702 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 121' ' ' LYS . . . . . . . . . . . . . 41.9 pttt -145.83 125.43 13.28 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.273 0.559 . . . . 55.41 111.806 177.754 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 59.8 m -79.91 107.74 12.93 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.073 -0.967 . . . . 71.21 109.828 175.413 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 42.6 mt -100.13 109.46 24.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-O 121.209 0.528 . . . . 61.44 110.096 -178.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.626 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 55.0 mt-30 -96.19 111.23 23.34 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.573 -0.74 . . . . 74.01 111.135 -178.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 125' ' ' GLU . . . . . 0.646 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 42.9 mt-10 -90.0 104.94 17.46 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.874 -0.603 . . . . 74.44 110.669 177.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 126' ' ' TYR . . . . . 0.437 ' CD2' ' HB3' ' A' ' 51' ' ' ASP . 56.8 m-85 -76.82 110.8 11.72 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.486 -0.324 . . . . 74.02 110.487 178.002 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 127' ' ' ARG . . . . . 0.613 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 48.0 mtt180 -130.93 137.7 49.41 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.971 -0.381 . . . . 74.04 109.971 178.87 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.5 p -98.8 -41.21 9.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.273 0.558 . . . . 54.02 110.797 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 -157.36 72.92 0.71 Allowed 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.848 -0.797 . . . . 75.3 108.848 -177.751 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.47 -38.16 2.77 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.819 -0.628 . . . . 53.15 112.889 -178.914 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -88.97 132.62 34.64 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.039 0.447 . . . . 75.22 111.573 -172.613 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.613 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 45.1 tp -85.16 117.96 24.43 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.317 -0.856 . . . . 53.12 110.085 175.091 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -109.67 -9.39 14.86 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.428 -0.509 . . . . 75.21 111.948 -177.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -167.51 141.52 3.61 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.735 0.302 . . . . 52.31 111.294 -177.188 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 57.9 mt -118.13 126.29 74.85 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 116.271 -0.422 . . . . 71.14 110.121 176.547 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.466 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 84.7 tttt -112.7 101.19 9.31 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.367 -0.605 . . . . 72.31 109.367 174.453 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.511 HG13 ' CE1' ' B' ' 145' ' ' TYR . 0.7 OUTLIER -103.57 126.46 58.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 CA-C-O 121.03 0.443 . . . . 72.03 110.715 -178.844 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.809 HG22 ' HB3' ' B' ' 144' ' ' PRO . 21.9 t -110.2 89.53 8.54 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.366 -0.834 . . . . 64.13 109.62 178.748 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 139' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -77.35 136.52 15.94 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 122.508 2.139 . . . . 74.25 112.701 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 140' ' ' LYS . . . . . 0.746 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 56.2 mtpt -61.13 -38.08 85.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.6 0.714 . . . . 51.41 109.62 171.598 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 94.9 m-70 -99.3 84.25 2.97 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.832 -1.076 . . . . 75.14 108.889 177.71 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 130.59 -162.55 23.33 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 110.322 -1.111 . . . . 73.45 110.322 -172.316 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -138.83 153.24 71.82 Favored Pre-proline 0 C--N 1.321 -0.652 0 CA-C-N 117.336 0.568 . . . . 75.31 110.715 178.169 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.809 ' HB3' HG22 ' B' ' 138' ' ' VAL . 21.8 Cg_endo -60.47 140.72 92.93 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 123.226 2.617 . . . . 55.24 113.29 -174.235 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 145' ' ' TYR . . . . . 0.511 ' CE1' HG13 ' B' ' 137' ' ' VAL . 23.3 p90 -143.44 155.67 44.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.53 -0.759 . . . . 74.12 109.481 177.84 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.463 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 96.4 m-85 -97.22 133.14 42.25 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.754 0.312 . . . . 64.23 110.431 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.528 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 17.5 tp -122.29 98.53 5.97 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.864 -0.791 . . . . 72.41 108.864 177.508 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 39.0 t -99.31 144.72 11.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.431 -0.349 . . . . 24.04 111.186 -172.729 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 5.2 mmt85 -76.91 145.25 38.36 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-O 120.962 0.41 . . . . 75.41 111.932 179.194 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.96 169.95 12.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.807 -0.633 . . . . 64.32 109.823 171.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 151' ' ' ASP . . . . . 0.568 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 6.2 p-10 -67.64 157.23 34.99 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.373 0.606 . . . . 74.51 112.155 -174.479 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 84.76 -5.68 81.09 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.481 -0.781 . . . . 71.13 113.268 174.384 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 153' ' ' SER . . . . . 0.413 ' HB2' ' CD ' ' A' ' 11' ' ' PRO . 3.5 t 62.22 27.99 16.78 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.487 0.66 . . . . 41.43 109.664 -177.773 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -56.59 -27.56 58.29 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 114.782 -1.099 . . . . 65.54 111.885 -178.748 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 112.09 -22.11 18.96 Favored Glycine 0 CA--C 1.498 -1.0 0 C-N-CA 120.617 -0.802 . . . . 73.23 111.19 -178.593 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 156' ' ' ASN . . . . . 0.698 HD22 ' HB3' ' B' ' 166' ' ' LEU . 2.3 t-20 -63.8 132.96 52.51 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 114.203 -0.998 . . . . 72.53 111.507 179.446 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 157' ' ' PHE . . . . . 0.528 ' CD2' ' HG ' ' B' ' 147' ' ' LEU . 27.2 m-85 -115.0 159.17 21.09 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.828 -0.623 . . . . 72.25 110.538 178.04 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 158' ' ' ILE . . . . . 0.831 HD11 HD23 ' B' ' 166' ' ' LEU . 48.6 mm -127.75 132.71 68.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.992 -0.549 . . . . 73.41 109.558 174.503 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.502 ' HB2' ' HB2' ' B' ' 162' ' ' GLN . 70.2 mtt180 -85.26 156.89 20.76 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.885 0.374 . . . . 73.11 111.249 -179.829 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 160' ' ' SER . . . . . 0.463 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 49.4 p -80.01 -19.48 47.64 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.885 0.85 . . . . 60.55 108.777 166.37 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 161' ' ' ASP . . . . . 0.409 ' H ' ' HB3' ' B' ' 159' ' ' ARG . 3.7 t70 -86.84 -26.04 24.23 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 114.461 -1.245 . . . . 63.22 110.46 176.549 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 162' ' ' GLN . . . . . 0.502 ' HB2' ' HB2' ' B' ' 159' ' ' ARG . 25.4 mm-40 -136.68 74.94 51.27 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.518 -0.764 . . . . 74.52 109.346 -179.691 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -89.24 11.68 2.89 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.897 2.398 . . . . 61.54 113.183 -176.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -107.87 -45.42 3.99 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 120.992 -0.283 . . . . 74.23 111.013 -178.222 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.25 172.79 7.89 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.029 0.442 . . . . 70.35 111.26 178.581 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 166' ' ' LEU . . . . . 0.831 HD23 HD11 ' B' ' 158' ' ' ILE . 15.8 mt -105.35 150.27 25.36 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.851 -0.613 . . . . 72.14 109.948 -175.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 40.8 mm -101.31 111.67 63.98 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 116.389 -0.369 . . . . 72.22 110.183 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.602 ' O ' HG23 ' B' ' 172' ' ' ILE . 59.7 Cg_endo -70.05 174.52 9.64 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 123.075 2.516 . . . . 73.01 112.593 -178.511 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 169' ' ' GLN . . . . . 0.625 ' O ' HG12 ' B' ' 172' ' ' ILE . 6.3 tt0 -72.45 -35.7 68.35 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.877 -0.601 . . . . 72.43 111.969 -167.816 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 33.4 p90 -69.02 -14.66 63.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.168 0.509 . . . . 65.42 110.222 177.956 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.467 ' HA ' ' HB2' ' B' ' 174' ' ' SER . 7.0 mm-40 -96.51 -29.54 13.83 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.569 -0.741 . . . . 71.15 111.671 -178.029 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.625 HG12 ' O ' ' B' ' 169' ' ' GLN . 43.4 pt -67.66 -26.21 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 N-CA-C 111.876 0.324 . . . . 71.2 111.876 -175.309 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -124.09 36.3 4.65 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.353 0.597 . . . . 71.41 110.256 176.379 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 174' ' ' SER . . . . . 0.467 ' HB2' ' HA ' ' B' ' 171' ' ' GLU . 22.1 t -85.66 10.73 12.56 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.342 -0.845 . . . . 71.22 111.369 -176.588 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 11.9 p-90 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.619 -0.705 . . . . 72.5 111.599 -178.364 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 25.3 p . . . . . 0 N--CA 1.451 -0.389 0 N-CA-C 110.342 -0.244 . . . . 75.04 110.342 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 145.07 -53.16 0.57 Allowed Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.848 -0.691 . . . . 54.45 111.622 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 64.6 100.96 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.542 0.686 . . . . 65.21 111.624 177.041 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.646 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 18.8 Cg_endo -91.62 122.05 0.67 Allowed 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 123.58 2.853 . . . . 74.34 112.595 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -139.62 138.58 36.26 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.148 -0.478 . . . . 73.13 109.749 178.711 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.543 ' HB ' ' HB2' ' B' ' 151' ' ' ASP . 13.7 p -101.94 132.8 47.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.331 0.586 . . . . 74.13 111.215 -171.594 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.7 m -92.77 104.06 16.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.738 -0.665 . . . . 72.14 109.722 176.055 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 66.4 mt -94.23 107.83 19.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.167 -0.469 . . . . 71.04 110.5 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.9 mtp180 -115.83 -179.2 3.59 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.242 -0.435 . . . . 64.21 110.505 177.065 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 70.9 mt-30 -140.1 106.24 5.23 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.937 -0.574 . . . . 64.04 110.763 178.211 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -99.62 107.08 19.13 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.912 -0.585 . . . . 75.13 109.846 176.716 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 62.61 -111.15 3.8 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.752 -0.737 . . . . 71.44 112.215 -178.323 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.506 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 7.7 m-20 -105.81 7.62 32.43 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 111.49 0.181 . . . . 74.34 111.49 -177.847 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.641 ' HE3' ' HE3' ' A' ' 75' ' ' TRP . 0.0 OUTLIER -121.06 131.68 54.42 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 119.951 -0.7 . . . . 73.23 112.259 179.951 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.526 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 6.2 m -80.68 124.08 28.71 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.162 -0.926 . . . . 72.21 109.313 174.814 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.415 HD11 ' HG3' ' A' ' 21' ' ' LYS . 23.7 mm -108.45 107.32 22.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 110.141 -0.318 . . . . 64.22 110.141 -175.878 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 54.4 mt-30 -102.23 105.26 15.9 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.91 0.386 . . . . 64.15 110.273 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.417 ' HB3' HD23 ' A' ' 32' ' ' LEU . 29.7 mt-10 -88.92 100.38 13.14 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.447 -0.797 . . . . 63.34 110.606 -178.772 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.558 ' HA ' ' OD2' ' B' ' 151' ' ' ASP . 96.3 m-85 -76.22 118.39 18.9 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.011 -0.541 . . . . 75.2 110.3 179.561 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.461 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 50.6 mtt180 -139.2 121.17 15.6 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.161 0.505 . . . . 75.2 112.014 -173.174 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.646 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 3.8 p -97.45 120.5 46.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 108.751 -0.833 . . . . 75.4 108.751 169.722 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 73.85 -34.39 0.28 Allowed 'General case' 0 N--CA 1.47 0.562 0 O-C-N 123.456 0.473 . . . . 64.22 111.085 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.406 ' H ' ' C ' ' A' ' 28' ' ' VAL . . . 157.32 -16.39 0.34 Allowed Glycine 0 N--CA 1.45 -0.431 0 N-CA-C 111.859 -0.496 . . . . 72.0 111.859 178.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.438 ' O ' ' HA ' ' A' ' 27' ' ' ARG . 81.3 t80 -79.47 125.73 29.94 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.69 0.281 . . . . 74.22 111.003 -177.782 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.686 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -73.21 112.33 9.15 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.281 -0.637 . . . . 74.03 109.281 175.821 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 25.7 p90 -111.66 -14.3 13.64 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 120.402 -0.519 . . . . 74.52 111.83 -178.768 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -159.54 142.86 14.37 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.732 0.301 . . . . 73.3 110.94 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.686 HG13 HD11 ' A' ' 32' ' ' LEU . 68.2 mt -123.91 122.86 65.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.233 -0.44 . . . . 73.43 110.14 175.521 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.437 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 53.2 tttp -107.66 106.57 16.98 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.003 -0.74 . . . . 55.33 109.003 172.152 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.578 HG23 ' HB2' ' A' ' 21' ' ' LYS . 1.5 p -102.58 126.85 56.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-N 116.111 -0.495 . . . . 71.14 110.26 178.28 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.716 HG22 ' HB3' ' A' ' 44' ' ' PRO . 23.5 t -109.3 85.66 3.66 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.273 -0.876 . . . . 64.03 109.99 178.397 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.518 ' HD2' ' C ' ' A' ' 43' ' ' LYS . 36.6 Cg_endo -86.36 132.9 3.79 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 122.572 2.182 . . . . 75.25 112.557 179.539 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.506 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 56.2 mtpt -60.35 -26.01 66.28 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.619 0.724 . . . . 74.21 109.884 175.188 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -122.54 88.25 2.9 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 115.194 -0.912 . . . . 74.35 108.818 176.414 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 145.28 -34.7 1.5 Allowed Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.442 -0.799 . . . . 42.11 111.702 -175.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.518 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 97.4 mttt 72.22 145.97 0.11 Allowed Pre-proline 0 N--CA 1.468 0.451 0 C-N-CA 123.565 0.746 . . . . 53.15 112.152 176.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.716 ' HB3' HG22 ' A' ' 38' ' ' VAL . 34.3 Cg_endo -63.25 137.49 61.31 Favored 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 123.454 2.769 . . . . 55.41 114.362 -170.019 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.404 ' CE1' HG13 ' A' ' 37' ' ' VAL . 8.6 p90 -148.21 165.96 29.37 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.577 -0.738 . . . . 72.22 109.243 174.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.74 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 38.6 m-85 -104.93 134.19 48.46 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.904 0.383 . . . . 74.51 110.774 177.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.523 HD21 HG22 ' A' ' 72' ' ' ILE . 16.6 tp -120.41 102.7 8.64 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.574 -0.899 . . . . 75.44 108.574 172.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.4 t -97.61 138.68 21.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.143 -0.481 . . . . 62.42 110.886 -173.148 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ARG . . . . . 0.424 ' HD3' HH11 ' A' ' 49' ' ' ARG . 7.4 tpt180 -66.57 128.02 34.62 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.89 -0.595 . . . . 72.34 110.131 175.634 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.09 116.84 18.85 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.736 -0.468 . . . . 62.42 109.736 174.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.618 ' HB2' ' CD2' ' B' ' 126' ' ' TYR . 0.4 OUTLIER -53.38 138.74 32.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.969 -0.56 . . . . 72.24 110.165 177.325 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 109.39 -32.48 6.78 Favored Glycine 0 N--CA 1.442 -0.963 0 N-CA-C 110.453 -1.059 . . . . 64.31 110.453 -171.623 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.4 t 56.99 50.36 12.28 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-O 121.253 0.549 . . . . 71.52 110.838 176.445 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -92.46 18.29 8.73 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.206 -0.452 . . . . 70.21 111.012 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.97 52.62 4.25 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.752 -0.737 . . . . 54.42 111.507 -176.591 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 30.2 t30 -147.76 141.81 25.99 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.804 0.335 . . . . 62.4 110.999 -174.586 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -129.42 147.1 51.2 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.898 -0.592 . . . . 74.04 109.529 175.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 43.7 mm -111.16 137.0 45.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.041 0.448 . . . . 75.01 110.394 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.743 ' HB2' HG13 ' A' ' 67' ' ' ILE . 24.0 ttt180 -103.22 142.18 34.61 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.826 -0.624 . . . . 73.52 110.5 -172.351 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.74 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 76.9 p -70.11 -30.81 68.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.41 0.624 . . . . 41.24 110.157 176.011 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.412 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 0.8 OUTLIER -70.81 -27.86 64.2 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 114.845 -1.07 . . . . 73.23 110.631 176.969 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLN . . . . . 0.699 ' HG2' ' HB3' ' A' ' 65' ' ' LYS . 31.0 tt0 -146.05 77.04 12.2 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.685 -0.689 . . . . 70.23 109.598 -175.241 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.2 -35.38 8.72 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.836 2.357 . . . . 65.04 113.842 -172.175 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -95.07 41.02 1.1 Allowed 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.888 0.851 . . . . 63.44 109.953 -177.657 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.699 ' HB3' ' HG2' ' A' ' 62' ' ' GLN . 22.9 tptm -150.46 128.38 11.78 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.185 -0.916 . . . . 70.54 109.93 175.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.511 ' H ' HD12 ' A' ' 66' ' ' LEU . 4.5 mp -73.32 120.35 18.82 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.324 -0.853 . . . . 65.54 109.045 176.654 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.743 HG13 ' HB2' ' A' ' 59' ' ' ARG . 47.4 mm -85.75 125.39 69.12 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-O 120.861 0.362 . . . . 62.31 110.639 -176.265 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -66.54 175.73 4.87 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.876 2.384 . . . . 72.31 112.778 -178.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 16.4 tt0 -93.9 14.35 19.82 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.588 -0.733 . . . . 70.02 111.834 -168.506 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 18.7 p90 -109.24 -26.35 10.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.147 0.499 . . . . 72.51 110.151 173.246 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -81.12 -11.89 59.37 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.998 -0.546 . . . . 64.34 110.672 -178.653 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.523 HG22 HD21 ' A' ' 47' ' ' LEU . 44.9 pt -69.59 -22.84 25.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.915 -0.584 . . . . 51.41 110.91 177.917 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -112.6 25.26 11.64 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-N 115.808 -0.633 . . . . 62.3 109.822 -178.587 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 4.5 t -60.22 -37.78 81.37 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.873 -1.058 . . . . 60.51 109.906 -179.222 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' TRP . . . . . 0.641 ' HE3' ' HE3' ' A' ' 21' ' ' LYS . 43.2 p-90 . . . . . 0 C--N 1.326 -0.434 0 CA-C-N 115.884 -0.598 . . . . 65.22 110.454 176.028 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 55.0 m . . . . . 0 N--CA 1.452 -0.326 0 CA-C-O 120.904 0.383 . . . . 55.34 110.542 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 117.06 -63.25 0.38 Allowed Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 110.524 -1.031 . . . . 42.22 110.524 -175.741 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 62.3 88.19 0.12 Allowed Pre-proline 0 C--O 1.232 0.138 0 C-N-CA 123.157 0.583 . . . . 60.14 111.056 175.032 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.633 ' HB3' ' HA ' ' B' ' 128' ' ' VAL . 56.4 Cg_endo -86.67 140.08 5.94 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.982 2.454 . . . . 72.34 112.713 -176.701 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -148.13 122.42 9.62 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.751 -0.659 . . . . 73.14 109.28 177.471 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.462 ' N ' ' HB3' ' A' ' 51' ' ' ASP . 7.5 p -71.6 134.21 30.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.391 0.615 . . . . 70.13 111.739 -172.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 85.1 m -95.04 104.78 16.66 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.474 -0.785 . . . . 72.01 109.854 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 65.2 mt -88.19 106.56 16.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.893 -0.594 . . . . 72.22 110.143 -177.642 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 25.3 mtp-105 -108.75 171.59 7.34 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.166 0.508 . . . . 75.01 111.569 -178.241 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 70.4 mt-30 -132.34 114.7 14.7 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.581 -0.736 . . . . 62.53 109.989 176.921 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 118' ' ' GLU . . . . . 0.68 ' HG3' HD12 ' B' ' 123' ' ' ILE . 22.1 mm-40 -99.61 23.25 9.75 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.94 -0.573 . . . . 73.43 110.672 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 123.45 -90.47 0.42 Allowed Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.692 -0.563 . . . . 43.53 111.692 -178.827 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 120' ' ' ASP . . . . . 0.668 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 72.0 m-20 -105.35 -16.51 14.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.14 0.495 . . . . 64.22 110.077 177.51 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.676 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 27.4 pttt -99.96 120.09 39.26 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.434 0.635 . . . . 74.33 111.15 -178.761 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 122' ' ' THR . . . . . 0.464 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 25.0 m -83.22 104.29 13.28 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.376 -0.829 . . . . 64.25 109.193 174.471 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 123' ' ' ILE . . . . . 0.68 HD12 ' HG3' ' B' ' 118' ' ' GLU . 23.4 mt -98.39 107.26 20.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.181 0.515 . . . . 73.24 110.887 -174.118 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.586 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 64.1 mt-30 -93.62 107.07 18.98 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.431 -0.804 . . . . 64.43 110.061 179.72 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -87.95 111.08 21.09 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.097 -0.501 . . . . 65.0 110.687 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 126' ' ' TYR . . . . . 0.618 ' CD2' ' HB2' ' A' ' 51' ' ' ASP . 37.8 m-85 -86.4 113.6 22.49 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.013 -0.54 . . . . 64.42 110.131 177.611 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 127' ' ' ARG . . . . . 0.638 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 63.7 mtt180 -138.12 132.95 32.78 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.663 -0.699 . . . . 72.34 109.675 -176.791 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.633 ' HA ' ' HB3' ' B' ' 111' ' ' PRO . 2.7 p -96.32 -39.39 9.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 120.944 0.402 . . . . 31.24 110.991 -178.341 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -153.1 64.79 0.77 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.322 -0.622 . . . . 75.04 109.322 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.07 -36.01 3.35 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.489 -0.778 . . . . 72.31 112.597 -179.261 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.475 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 80.8 t80 -83.84 124.79 31.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.084 0.468 . . . . 72.31 111.233 -173.382 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.799 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -77.12 115.6 17.05 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.312 -0.858 . . . . 71.52 109.251 175.169 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 22.5 p90 -109.11 -19.03 13.5 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.268 -0.573 . . . . 72.52 111.901 -178.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -155.98 141.47 17.72 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.024 0.44 . . . . 73.0 111.057 179.065 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.799 HG13 HD11 ' B' ' 132' ' ' LEU . 81.8 mt -119.2 123.82 72.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.859 -0.609 . . . . 73.15 110.286 177.127 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.586 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.6 tttt -105.62 99.68 9.27 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.274 -0.639 . . . . 71.53 109.274 172.007 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.463 HG23 ' HB2' ' B' ' 121' ' ' LYS . 2.0 p -101.4 121.8 52.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-O 121.194 0.521 . . . . 74.44 110.361 -178.602 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.841 HG22 ' HB3' ' B' ' 144' ' ' PRO . 24.6 t -109.03 85.51 3.29 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 115.086 -0.961 . . . . 55.45 110.21 179.614 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.676 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 71.6 Cg_endo -84.3 134.08 5.73 Favored 'Trans proline' 0 N--CA 1.451 -0.979 0 C-N-CA 122.375 2.05 . . . . 64.03 112.545 179.525 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 140' ' ' LYS . . . . . 0.668 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 57.8 mtpt -57.92 -31.56 66.91 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.448 0.642 . . . . 61.33 109.889 174.436 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 82.7 m-70 -111.14 83.18 1.72 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.201 -0.909 . . . . 62.24 109.292 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 142' ' ' GLY . . . . . 0.41 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 148.71 -32.03 1.21 Allowed Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.684 -0.77 . . . . 63.21 112.785 -178.87 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 143' ' ' LYS . . . . . 0.45 ' C ' ' HD2' ' B' ' 139' ' ' PRO . 98.9 mttt 73.44 151.43 0.14 Allowed Pre-proline 0 N--CA 1.471 0.604 0 C-N-CA 123.452 0.701 . . . . 45.25 111.704 -178.616 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.841 ' HB3' HG22 ' B' ' 138' ' ' VAL . 26.7 Cg_endo -62.0 135.24 54.04 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 123.197 2.598 . . . . 70.51 113.952 -171.129 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 145' ' ' TYR . . . . . 0.429 ' CE1' HG13 ' B' ' 137' ' ' VAL . 6.2 p90 -150.99 152.19 33.17 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.356 -0.838 . . . . 74.41 109.852 176.872 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.681 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 50.7 m-85 -97.29 141.89 29.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.475 -0.33 . . . . 74.35 111.366 -178.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.457 HD23 ' HA ' ' B' ' 147' ' ' LEU . 15.3 mt -124.42 101.78 7.33 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.45 -0.795 . . . . 74.22 109.208 166.543 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 148' ' ' VAL . . . . . 0.433 HG13 ' HB ' ' B' ' 158' ' ' ILE . 6.0 p -104.65 139.2 26.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.724 -0.671 . . . . 73.41 111.015 -175.766 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 19.4 tpt180 -63.65 136.8 57.77 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.551 -0.75 . . . . 75.31 111.754 -178.314 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -90.19 123.95 34.43 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.275 -0.639 . . . . 74.11 109.275 169.837 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 151' ' ' ASP . . . . . 0.558 ' OD2' ' HA ' ' A' ' 26' ' ' TYR . 72.2 m-20 -57.33 142.91 41.79 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.285 0.564 . . . . 60.43 111.159 -178.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 109.91 -29.11 9.64 Favored Glycine 0 N--CA 1.444 -0.827 0 N-CA-C 110.468 -1.053 . . . . 64.33 110.468 -170.892 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 5.4 t 65.05 37.4 6.77 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-O 121.231 0.538 . . . . 64.53 111.009 174.792 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -65.11 -14.4 60.43 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.798 -0.637 . . . . 72.21 111.326 178.542 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 98.11 23.69 12.7 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 110.634 -0.986 . . . . 62.11 110.634 -173.405 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 42.1 t30 -110.71 140.18 45.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.916 -0.642 . . . . 70.22 110.494 -176.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -121.36 160.35 24.21 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.797 -0.638 . . . . 74.41 109.574 175.824 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 158' ' ' ILE . . . . . 0.433 ' HB ' HG13 ' B' ' 148' ' ' VAL . 46.2 mm -116.66 121.15 67.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 109.405 -0.591 . . . . 74.13 109.405 174.694 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.504 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 73.0 ttt180 -92.2 127.47 37.69 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.699 -0.682 . . . . 74.55 109.82 -177.61 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 160' ' ' SER . . . . . 0.681 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 80.4 p -65.88 -9.22 27.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.513 -0.312 . . . . 71.45 111.78 -175.06 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 161' ' ' ASP . . . . . 0.457 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 21.1 t70 -64.06 -42.67 96.92 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.325 -0.621 . . . . 75.32 109.325 174.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 162' ' ' GLN . . . . . 0.423 ' HA ' ' HD2' ' B' ' 163' ' ' PRO . 96.1 mt-30 -141.86 92.6 7.79 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 115.146 -0.933 . . . . 71.21 108.766 177.518 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 163' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' B' ' 162' ' ' GLN . 36.6 Cg_endo -64.0 -10.59 23.58 Favored 'Trans proline' 0 N--CA 1.475 0.441 0 C-N-CA 123.767 2.978 . . . . 62.03 114.103 -172.914 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -98.39 -6.18 31.16 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.088 0.471 . . . . 75.11 109.925 179.066 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 24.4 tptm -97.21 127.94 43.63 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.743 -0.662 . . . . 73.0 110.872 -175.216 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 166' ' ' LEU . . . . . 0.445 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.7 mp -86.68 134.66 33.58 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.565 -0.743 . . . . 71.31 109.107 177.439 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 167' ' ' ILE . . . . . 0.906 HG23 ' HB3' ' B' ' 171' ' ' GLU . 27.3 mm -91.71 118.94 68.59 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-O 121.149 0.5 . . . . 43.04 112.052 -172.519 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.499 ' O ' HG23 ' B' ' 172' ' ' ILE . 74.5 Cg_endo -74.71 -179.39 4.84 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 123.451 2.767 . . . . 64.15 112.284 177.15 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 169' ' ' GLN . . . . . 0.612 ' HA ' HG12 ' B' ' 172' ' ' ILE . 34.6 tt0 -73.56 -30.95 63.36 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.873 0.368 . . . . 73.22 111.761 -170.888 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 22.7 p90 -75.74 -7.3 54.05 Favored 'General case' 0 C--N 1.324 -0.525 0 O-C-N 121.886 -0.509 . . . . 73.24 110.15 177.757 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.906 ' HB3' HG23 ' B' ' 167' ' ' ILE . 3.2 mm-40 -109.74 -18.81 13.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.791 -0.641 . . . . 70.22 111.472 -179.47 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.612 HG12 ' HA ' ' B' ' 169' ' ' GLN . 42.5 pt -73.51 -28.59 25.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.292 0.568 . . . . 73.3 109.932 176.329 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 62.1 m-85 -101.63 39.75 1.4 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.509 -0.769 . . . . 70.54 109.364 173.708 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 174' ' ' SER . . . . . 0.603 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 5.7 t -66.7 -29.22 69.16 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.134 -0.939 . . . . 73.0 110.827 -176.39 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 20.8 p-90 . . . . . 0 C--O 1.242 0.677 0 CA-C-O 118.916 -0.564 . . . . 74.34 110.217 178.206 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 25.0 m . . . . . 0 C--O 1.234 0.25 0 CA-C-O 121.306 0.574 . . . . 74.11 111.034 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 157.33 40.89 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.727 0 N-CA-C 111.218 -0.753 . . . . 72.04 111.218 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLU . . . . . 0.405 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -114.99 101.59 54.59 Favored Pre-proline 0 N--CA 1.445 -0.681 0 N-CA-C 108.208 -1.034 . . . . 75.1 108.208 179.493 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.61 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 11.3 Cg_endo -79.32 104.65 1.78 Allowed 'Trans proline' 0 N--CA 1.44 -1.635 0 C-N-CA 122.064 1.843 . . . . 73.12 111.69 -171.552 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -123.13 149.59 44.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.502 -0.772 . . . . 74.45 109.21 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.653 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 9.3 p -99.74 126.97 53.04 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-O 121.595 0.712 . . . . 74.31 111.772 -172.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.54 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 7.0 m -83.36 103.51 12.79 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.513 -0.767 . . . . 75.31 109.334 176.706 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.5 mt -94.14 108.79 21.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 120.932 0.396 . . . . 71.25 111.127 -174.871 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 19.1 mmt180 -120.72 159.32 25.61 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.202 -0.454 . . . . 54.11 109.826 175.55 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -117.58 124.88 49.72 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.331 0.586 . . . . 71.24 110.677 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -111.42 59.67 0.62 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.9 -1.046 . . . . 72.03 110.061 -174.225 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 83.47 -107.67 2.95 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.843 -0.694 . . . . 55.45 111.943 -178.291 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -94.85 20.21 9.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.886 0.374 . . . . 74.21 110.652 -177.286 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.746 ' HD2' HD11 ' A' ' 23' ' ' ILE . 4.0 pttp -143.93 134.38 24.7 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.228 0.537 . . . . 74.02 111.89 -178.87 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 27.3 m -94.06 107.98 19.85 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.055 -0.72 . . . . 75.33 109.055 172.383 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.746 HD11 ' HD2' ' A' ' 21' ' ' LYS . 19.8 mt -101.61 113.54 38.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.269 0.556 . . . . 73.32 110.353 -175.098 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.653 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 72.4 mt-30 -104.89 117.86 35.1 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.497 -0.774 . . . . 52.24 111.356 -175.162 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.54 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 25.2 mt-10 -90.52 103.01 15.75 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.051 -0.522 . . . . 71.11 110.983 177.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 -81.27 103.5 11.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.897 0.379 . . . . 75.31 110.051 175.199 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.508 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 53.2 mtt180 -120.25 138.11 53.84 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.916 -0.402 . . . . 74.54 109.916 178.083 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.61 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 11.8 p -105.79 -27.89 2.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.288 0.566 . . . . 62.23 110.947 -175.82 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -162.64 59.05 0.21 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.758 -0.83 . . . . 73.55 108.758 -177.846 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.93 -36.95 3.23 Favored Glycine 0 N--CA 1.45 -0.427 0 CA-C-N 115.355 -0.839 . . . . 65.11 112.635 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.56 ' CD2' HG21 ' B' ' 128' ' ' VAL . 50.4 t80 -90.28 133.74 34.75 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.145 0.498 . . . . 74.52 110.723 -173.658 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.902 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -76.11 116.13 16.5 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.229 -0.896 . . . . 73.21 109.317 176.656 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 40.0 p90 -106.93 -17.8 14.09 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.431 -0.508 . . . . 71.33 111.218 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.45 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -157.58 137.9 12.76 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.014 0.435 . . . . 63.43 111.532 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.902 HG13 HD11 ' A' ' 32' ' ' LEU . 73.2 mt -118.02 117.08 53.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.159 -0.473 . . . . 72.14 110.102 175.262 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 84.9 tttt -100.69 101.53 12.43 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.022 -0.733 . . . . 53.24 109.022 173.296 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.671 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.5 p -102.77 124.5 56.84 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 N-CA-C 109.777 -0.453 . . . . 74.23 109.777 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.647 HG22 ' HB3' ' A' ' 44' ' ' PRO . 35.9 t -105.27 84.9 1.18 Allowed Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.206 -0.907 . . . . 55.12 109.525 177.391 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.671 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 89.2 Cg_endo -95.93 147.05 1.26 Allowed 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 123.04 2.493 . . . . 72.33 113.279 -178.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -68.73 -11.11 59.89 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.519 -0.764 . . . . 70.42 109.623 170.715 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 80.6 m-70 -121.85 92.85 3.83 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 115.022 -0.99 . . . . 74.14 109.468 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 121.54 -19.76 8.46 Favored Glycine 0 CA--C 1.519 0.338 0 C-N-CA 120.757 -0.735 . . . . 55.14 113.176 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.432 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 99.3 mttt 68.9 151.61 0.13 Allowed Pre-proline 0 N--CA 1.473 0.69 0 C-N-CA 123.026 0.53 . . . . 54.12 110.943 -178.166 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.647 ' HB3' HG22 ' A' ' 38' ' ' VAL . 18.3 Cg_endo -59.88 133.05 48.36 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.364 2.043 . . . . 74.44 112.816 -175.047 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.536 ' CE1' HG13 ' A' ' 37' ' ' VAL . 5.4 p90 -150.32 155.9 40.53 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.655 -0.702 . . . . 63.1 110.432 -179.072 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.452 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 87.7 m-85 -99.75 127.64 45.88 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.076 -0.511 . . . . 73.24 110.901 -179.818 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 53.1 mt -102.12 97.35 7.67 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.146 -0.479 . . . . 64.44 109.761 171.052 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 60.8 t -90.58 137.43 21.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.065 -0.516 . . . . 74.14 110.578 -178.046 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 5.3 mmt180 -79.13 119.6 22.47 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.984 0.421 . . . . 75.23 111.108 175.715 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -72.15 167.22 20.74 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.603 -0.726 . . . . 43.25 109.555 172.722 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -69.74 128.92 38.12 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.416 0.627 . . . . 75.45 109.577 178.615 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.22 116.04 3.87 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 111.105 -0.798 . . . . 62.41 111.105 -171.854 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 39.1 p -78.02 36.7 0.23 Allowed 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.05 0.452 . . . . 75.44 111.311 -176.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -63.33 -29.6 70.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.801 -0.636 . . . . 65.45 111.588 -175.423 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 131.01 -13.21 5.53 Favored Glycine 0 CA--C 1.508 -0.404 0 C-N-CA 120.318 -0.944 . . . . 71.24 113.214 177.504 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -83.63 138.82 33.17 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.144 0.497 . . . . 75.41 111.544 -173.304 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.449 ' CD1' ' HB3' ' A' ' 47' ' ' LEU . 38.2 m-85 -109.38 162.46 14.32 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.762 -0.654 . . . . 64.3 110.02 174.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.4 mm -120.64 123.86 71.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.35 -0.611 . . . . 71.22 109.35 175.762 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.791 ' HG3' HG13 ' A' ' 67' ' ' ILE . 53.7 mtm180 -88.34 149.77 23.58 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.221 0.534 . . . . 73.2 111.826 -177.79 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 5.7 p -69.12 -24.53 64.12 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.379 -0.828 . . . . 72.32 109.84 171.365 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.73 -37.46 84.29 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-N 115.517 -0.765 . . . . 61.1 110.152 176.42 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -156.64 96.91 2.17 Favored Pre-proline 0 N--CA 1.451 -0.4 0 CA-C-N 115.835 -0.62 . . . . 74.2 110.612 -175.421 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.19 -10.07 23.94 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.433 2.089 . . . . 72.31 111.233 175.51 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -81.22 -15.86 54.4 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 114.895 -1.048 . . . . 72.21 110.774 178.013 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.6 tptt -114.9 132.34 56.57 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.2 -0.454 . . . . 70.25 111.252 -175.584 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.6 mp -90.31 125.79 35.64 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.333 -0.617 . . . . 63.24 109.333 174.218 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.791 HG13 ' HG3' ' A' ' 59' ' ' ARG . 49.4 mm -84.78 112.59 43.82 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 116.111 -0.495 . . . . 42.44 110.491 -177.25 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -74.63 179.69 5.71 Favored 'Trans proline' 0 N--CA 1.464 -0.264 0 C-N-CA 123.289 2.659 . . . . 61.21 112.937 -177.155 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' GLN . . . . . 0.463 ' CG ' HD11 ' A' ' 72' ' ' ILE . 31.4 tt0 -80.86 -4.27 54.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.581 -0.736 . . . . 72.35 112.519 -171.083 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 15.9 p90 -96.24 -19.97 18.91 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.234 -0.586 . . . . 75.43 110.312 175.821 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -99.99 8.04 44.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.93 -0.577 . . . . 72.2 111.042 -177.895 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.463 HD11 ' CG ' ' A' ' 69' ' ' GLN . 21.6 pt -98.71 -7.06 9.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.249 0.547 . . . . 74.22 110.21 175.251 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -104.91 16.17 26.43 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.632 -0.713 . . . . 71.42 109.486 177.041 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 12.9 m -73.59 -7.78 53.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.185 -0.916 . . . . 70.11 111.309 -178.637 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 57.9 p-90 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.442 -0.344 . . . . 73.4 110.459 176.222 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 44.3 m . . . . . 0 C--O 1.233 0.22 0 CA-C-O 121.021 0.439 . . . . 61.31 110.046 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 121.1 102.34 1.81 Allowed Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.914 -0.66 . . . . 61.41 111.764 -178.362 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -122.15 92.57 48.86 Favored Pre-proline 0 C--N 1.324 -0.532 0 N-CA-C 109.382 -0.599 . . . . 75.31 109.382 -178.081 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.474 ' HA ' ' O ' ' B' ' 127' ' ' ARG . 8.4 Cg_endo -77.98 82.85 2.32 Favored 'Trans proline' 0 N--CA 1.443 -1.451 0 C-N-CA 121.917 1.745 . . . . 73.43 111.633 -178.559 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -108.71 141.84 40.11 Favored 'General case' 0 CA--C 1.51 -0.566 0 CA-C-N 115.194 -0.912 . . . . 65.41 109.558 177.649 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.508 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 10.3 p -101.84 125.7 55.91 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 CA-C-N 115.627 -0.715 . . . . 73.41 110.807 -176.637 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 10.1 m -88.55 103.57 16.01 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.34 -0.846 . . . . 74.04 109.609 177.828 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.502 HG12 ' HG2' ' B' ' 124' ' ' GLN . 54.6 mt -94.59 105.94 17.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 116.164 -0.471 . . . . 70.54 110.358 -176.568 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 27.0 mmm180 -122.27 153.44 38.9 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.242 -0.435 . . . . 74.1 110.541 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -111.19 103.09 11.49 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.002 0.43 . . . . 61.3 110.701 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 49.8 mm-40 -99.67 81.51 2.49 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.778 -0.646 . . . . 73.43 109.294 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 81.94 -128.69 8.6 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.805 -0.712 . . . . 71.25 111.382 -174.877 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 120' ' ' ASP . . . . . 0.579 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 67.8 m-20 -91.84 9.92 30.79 Favored 'General case' 0 C--N 1.328 -0.349 0 O-C-N 122.699 -0.295 . . . . 73.24 111.088 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.517 ' HE2' HD11 ' B' ' 123' ' ' ILE . 24.6 pttm -119.27 116.58 26.55 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.576 0.703 . . . . 75.12 111.073 179.371 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 26.1 m -84.97 108.43 17.58 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.292 -0.867 . . . . 64.5 109.502 176.558 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 123' ' ' ILE . . . . . 0.517 HD11 ' HE2' ' B' ' 121' ' ' LYS . 52.1 mt -101.14 117.12 45.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.973 -0.558 . . . . 73.5 110.604 -173.788 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.529 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 72.2 mt-30 -102.61 104.49 14.87 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.649 -0.705 . . . . 74.32 110.35 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -85.27 107.25 17.21 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.06 -0.518 . . . . 71.43 111.071 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 59.6 m-85 -80.71 103.67 10.72 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.947 0.403 . . . . 74.21 109.945 175.333 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 127' ' ' ARG . . . . . 0.474 ' O ' ' HA ' ' B' ' 111' ' ' PRO . 65.5 mtt180 -114.14 152.78 30.62 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.857 -0.611 . . . . 70.2 109.389 178.587 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.56 HG21 ' CD2' ' A' ' 31' ' ' PHE . 7.0 p -120.36 -37.41 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.078 0.466 . . . . 72.24 111.73 179.385 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -140.83 35.8 1.78 Allowed 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.035 -0.728 . . . . 54.14 109.035 -178.856 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 98.26 -29.5 11.25 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 114.992 -1.004 . . . . 44.12 111.746 -177.498 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.524 ' HD2' HG21 ' A' ' 28' ' ' VAL . 26.9 t80 -93.39 132.86 37.23 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.917 0.389 . . . . 62.52 110.261 -176.19 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.784 HD11 HG13 ' B' ' 135' ' ' ILE . 3.3 tm? -69.49 134.44 48.91 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.104 -0.953 . . . . 71.33 110.43 179.042 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 133' ' ' TYR . . . . . 0.426 ' N ' HD13 ' B' ' 132' ' ' LEU . 42.6 p90 -124.24 -23.51 4.51 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 121.026 -0.27 . . . . 64.15 111.361 174.608 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -149.92 143.19 25.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.784 0.326 . . . . 71.11 111.055 179.068 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.784 HG13 HD11 ' B' ' 132' ' ' LEU . 77.5 mt -125.08 129.56 73.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.507 -0.315 . . . . 75.53 110.804 178.648 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.529 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.2 tttt -112.69 102.51 10.56 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.128 -0.693 . . . . 73.25 109.128 172.485 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.458 HG21 ' HB3' ' B' ' 175' ' ' TRP . 1.8 p -106.52 127.99 61.47 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-O 121.271 0.558 . . . . 43.44 110.744 -177.665 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.893 HG22 ' HB3' ' B' ' 144' ' ' PRO . 22.6 t -113.21 87.72 11.4 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.138 -0.937 . . . . 62.54 110.282 -179.299 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.48 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 73.5 Cg_endo -83.66 134.87 6.62 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.283 1.988 . . . . 63.03 112.309 176.127 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 140' ' ' LYS . . . . . 0.579 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 56.2 mtpt -67.62 -9.48 43.44 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.773 -0.649 . . . . 71.22 110.954 176.668 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 31.6 m-70 -126.68 54.14 1.62 Allowed 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.574 -0.739 . . . . 64.31 109.524 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 167.45 -17.09 0.08 OUTLIER Glycine 0 CA--C 1.52 0.391 0 C-N-CA 120.59 -0.815 . . . . 73.4 113.39 -177.843 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 93.6 mttt 71.59 150.88 0.14 Allowed Pre-proline 0 N--CA 1.473 0.688 0 C-N-CA 123.235 0.614 . . . . 74.24 111.438 179.428 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.893 ' HB3' HG22 ' B' ' 138' ' ' VAL . 24.5 Cg_endo -62.42 140.68 83.56 Favored 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.77 2.313 . . . . 73.22 113.357 -176.154 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 145' ' ' TYR . . . . . 0.448 ' CE1' HG13 ' B' ' 137' ' ' VAL . 8.7 p90 -150.59 155.26 39.06 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.655 -0.702 . . . . 75.2 109.969 177.107 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.569 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 83.6 m-85 -101.56 141.29 34.66 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.286 -0.415 . . . . 73.44 111.37 -177.503 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 27.6 mt -124.88 95.74 4.62 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.559 -0.746 . . . . 62.0 109.885 169.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 48.9 t -94.02 122.81 45.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.02 -0.733 . . . . 73.4 109.02 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 15.6 ttm-85 -67.94 143.54 55.61 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.468 0.651 . . . . 64.35 111.975 -174.873 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.03 175.4 10.67 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.664 -1.153 . . . . 64.43 110.586 176.128 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -84.94 138.27 32.6 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 109.01 -0.737 . . . . 75.22 109.01 173.007 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 110.07 132.07 6.24 Favored Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 120.654 -0.784 . . . . 71.43 111.655 -177.23 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 18.8 m -82.33 30.5 0.4 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.921 0.391 . . . . 74.11 110.983 -177.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -73.59 -47.29 41.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.052 0.453 . . . . 72.45 110.56 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 121.38 46.75 0.31 Allowed Glycine 0 CA--C 1.503 -0.714 0 C-N-CA 120.774 -0.727 . . . . 54.55 112.417 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 -122.17 135.53 54.79 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 120.964 0.411 . . . . 71.44 110.705 -179.178 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -113.01 159.4 19.17 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.764 -0.653 . . . . 73.5 109.381 173.479 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 158' ' ' ILE . . . . . 0.807 HD11 HD23 ' B' ' 166' ' ' LEU . 48.7 mm -114.34 115.84 50.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 N-CA-C 109.341 -0.614 . . . . 73.25 109.341 176.079 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.513 ' HG2' ' H ' ' B' ' 161' ' ' ASP . 40.2 ttm180 -85.39 145.16 27.61 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.75 -0.659 . . . . 74.13 110.376 -174.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 160' ' ' SER . . . . . 0.569 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 5.2 p -58.89 -31.87 68.99 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.447 0.641 . . . . 72.34 110.862 178.211 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 161' ' ' ASP . . . . . 0.513 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 3.5 m-20 -76.03 -31.26 58.79 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.192 -0.913 . . . . 72.23 110.902 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 162' ' ' GLN . . . . . 0.677 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 80.1 mm-40 -132.37 71.07 79.66 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 115.944 -0.571 . . . . 52.25 110.808 -176.358 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 163' ' ' PRO . . . . . 0.405 ' HA ' ' CG2' ' B' ' 158' ' ' ILE . 59.2 Cg_endo -73.37 -12.79 25.29 Favored 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.187 1.925 . . . . 73.32 111.432 178.462 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -93.24 -4.91 51.07 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.012 -0.995 . . . . 73.41 110.253 179.001 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 165' ' ' LYS . . . . . 0.677 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 60.7 tptt -122.72 126.54 47.74 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.918 -0.583 . . . . 64.43 111.074 -174.806 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 166' ' ' LEU . . . . . 0.807 HD23 HD11 ' B' ' 158' ' ' ILE . 61.0 mt -74.41 110.43 8.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.398 -0.819 . . . . 71.25 109.087 174.477 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 167' ' ' ILE . . . . . 0.438 HG13 ' HB2' ' B' ' 159' ' ' ARG . 43.3 mm -70.56 116.37 44.74 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 109.92 -0.4 . . . . 73.35 109.92 -176.569 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.505 ' O ' HG23 ' B' ' 172' ' ' ILE . 38.3 Cg_endo -64.95 172.57 7.01 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 123.251 2.634 . . . . 71.42 113.416 -174.231 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -76.98 -9.9 59.0 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.92 -1.036 . . . . 74.41 111.978 -168.142 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 31.8 p90 -96.22 -10.8 27.16 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.461 0.648 . . . . 74.1 109.924 175.079 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.478 ' HB2' ' HG2' ' B' ' 168' ' ' PRO . 6.8 mm-40 -106.58 -7.06 17.6 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.454 -0.794 . . . . 71.13 111.215 -176.872 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.505 HG23 ' O ' ' B' ' 168' ' ' PRO . 29.0 pt -71.04 -30.01 39.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.121 -0.491 . . . . 64.11 110.723 178.829 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -102.32 41.54 1.22 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.304 0.574 . . . . 74.04 109.772 174.263 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 31.1 t -55.08 -31.86 61.52 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.992 -1.004 . . . . 74.3 110.847 179.348 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 175' ' ' TRP . . . . . 0.515 ' HB2' ' HD2' ' B' ' 121' ' ' LYS . 4.0 p-90 . . . . . 0 C--O 1.251 1.169 0 CA-C-O 118.044 -0.979 . . . . 75.35 110.462 176.765 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.8 m . . . . . 0 N--CA 1.453 -0.309 0 N-CA-C 109.896 -0.409 . . . . 72.45 109.896 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.493 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 95.27 63.52 0.98 Allowed Glycine 0 N--CA 1.442 -0.918 0 C-N-CA 120.664 -0.779 . . . . 35.22 111.191 -175.489 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -100.3 98.94 8.55 Favored Pre-proline 0 C--N 1.324 -0.537 0 N-CA-C 108.845 -0.798 . . . . 73.42 108.845 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.613 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 88.5 Cg_endo -80.25 102.8 1.46 Allowed 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.247 1.964 . . . . 73.23 112.29 -173.669 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -80.88 141.5 34.53 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.062 -0.972 . . . . 71.43 109.939 -178.45 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.447 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 11.2 p -103.3 120.29 53.04 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 CA-C-O 121.638 0.732 . . . . 65.03 109.88 179.461 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.4 m -93.47 103.11 15.34 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 115.449 -0.796 . . . . 65.3 109.564 -179.547 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.536 HG23 ' HG2' ' A' ' 24' ' ' GLN . 63.9 mt -85.61 105.2 14.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.82 -0.627 . . . . 73.02 110.517 -175.297 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -101.61 160.92 14.04 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.681 -0.69 . . . . 73.11 110.565 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -127.11 98.04 5.16 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.617 -0.512 . . . . 73.54 109.617 175.828 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.642 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 43.6 mm-40 -103.49 93.32 4.88 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.819 -0.628 . . . . 64.44 109.618 -178.064 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 66.06 -106.36 1.56 Allowed Glycine 0 N--CA 1.444 -0.83 0 C-N-CA 120.764 -0.731 . . . . 43.13 111.832 -176.044 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.655 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 4.0 m-20 -102.05 -5.34 24.67 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.566 0.222 . . . . 73.32 110.819 -177.197 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.642 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 12.3 ptmt -110.77 121.03 44.33 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 121.471 0.653 . . . . 64.3 111.934 -173.449 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.4 m -82.41 97.56 8.43 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.276 -0.875 . . . . 74.31 109.212 174.434 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.409 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 54.1 mt -93.99 106.88 18.57 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-O 121.117 0.485 . . . . 70.32 110.812 -175.574 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.536 ' HG2' HG23 ' A' ' 15' ' ' ILE . 48.8 mt-30 -94.55 109.39 21.29 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.019 -0.537 . . . . 63.41 110.029 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.439 ' HB3' HD23 ' A' ' 32' ' ' LEU . 27.5 mt-10 -89.2 111.38 22.15 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.134 -0.484 . . . . 74.13 110.84 -178.539 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.504 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 50.5 m-85 -84.59 103.88 14.09 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.635 -0.506 . . . . 72.45 109.635 176.268 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -116.04 133.72 55.72 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.062 -0.517 . . . . 61.41 109.923 -179.552 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.613 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 3.4 p -92.05 -60.37 2.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 C-N-CA 120.272 -0.571 . . . . 45.35 110.443 176.684 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.554 ' H ' HG13 ' A' ' 28' ' ' VAL . 88.5 m-20 -138.47 72.6 1.41 Allowed 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.045 0.45 . . . . 74.55 110.213 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 90.46 -27.94 8.09 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.914 -0.585 . . . . 74.4 113.676 175.248 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.491 ' HD2' HG21 ' B' ' 128' ' ' VAL . 35.8 t80 -112.08 134.52 53.58 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.376 0.608 . . . . 73.4 111.469 -173.756 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.881 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -67.21 123.64 20.87 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.495 -1.229 . . . . 53.22 110.441 176.268 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' TYR . . . . . 0.481 ' CD1' ' HB2' ' B' ' 133' ' ' TYR . 24.2 p90 -108.23 -24.82 11.35 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.369 -0.533 . . . . 71.43 111.345 177.172 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -156.19 142.72 18.56 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.685 0.278 . . . . 64.0 110.965 179.342 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.881 HG13 HD11 ' A' ' 32' ' ' LEU . 81.4 mt -120.8 132.41 70.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.537 -0.301 . . . . 72.14 110.589 178.062 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.49 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 88.3 tttt -115.16 100.43 8.15 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 108.953 -0.758 . . . . 73.24 108.953 169.506 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.569 HG23 ' HB2' ' A' ' 21' ' ' LYS . 1.1 p -98.39 126.17 51.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 116.092 -0.503 . . . . 74.32 110.124 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.56 HG22 ' HB3' ' A' ' 44' ' ' PRO . 25.0 t -111.64 88.28 9.24 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 115.544 -0.753 . . . . 72.21 110.109 -179.789 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.534 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 57.8 Cg_endo -73.67 142.42 32.35 Favored 'Trans proline' 0 N--CA 1.457 -0.663 0 C-N-CA 122.48 2.12 . . . . 64.01 111.975 177.839 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.655 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 28.9 mtpp -70.09 -10.55 59.11 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.944 -0.571 . . . . 73.22 110.978 176.329 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 38.7 m-70 -131.04 80.64 1.95 Allowed 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.848 -0.615 . . . . 71.14 109.78 -178.532 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 151.3 -117.23 0.81 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.128 -0.558 . . . . 73.34 112.306 179.499 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 14.3 ptpt -152.79 151.76 27.18 Favored Pre-proline 0 C--N 1.328 -0.344 0 N-CA-C 110.179 -0.304 . . . . 72.33 110.179 178.467 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.56 ' HB3' HG22 ' A' ' 38' ' ' VAL . 48.5 Cg_endo -74.28 124.09 8.73 Favored 'Trans proline' 0 N--CA 1.46 -0.492 0 C-N-CA 122.262 1.975 . . . . 73.12 110.987 170.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.516 ' CE1' HG13 ' A' ' 37' ' ' VAL . 11.4 p90 -139.86 158.57 43.88 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.803 0.335 . . . . 72.1 110.988 -175.185 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.519 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 73.1 m-85 -103.93 141.64 35.81 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.828 -0.624 . . . . 53.22 111.258 -176.498 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 83.8 mt -123.71 105.02 9.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.535 -0.757 . . . . 75.51 109.907 172.155 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.593 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 43.8 t -85.79 139.66 17.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.098 -0.501 . . . . 64.14 109.917 179.355 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ARG . . . . . 0.417 HH11 ' HD3' ' A' ' 49' ' ' ARG . 4.5 tpt180 -75.06 115.09 14.31 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.846 -0.428 . . . . 73.31 109.846 179.222 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.33 149.83 41.14 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.023 -0.535 . . . . 73.04 111.399 -178.204 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.58 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 4.9 p-10 -57.44 132.07 52.01 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.269 0.557 . . . . 73.34 110.981 -178.265 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.57 -24.13 24.76 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.41 -0.814 . . . . 72.41 111.86 -179.025 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.5 t 58.15 37.57 26.34 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 121.192 0.52 . . . . 43.54 109.985 -176.56 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -53.57 -38.61 64.05 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.425 -0.807 . . . . 74.42 111.44 -179.03 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 150.44 24.4 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.365 -0.921 . . . . 64.45 113.261 176.572 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.456 ' OD1' ' HA ' ' A' ' 68' ' ' PRO . 93.5 m-20 -134.79 162.7 31.62 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.79 0.329 . . . . 74.41 110.579 -176.764 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 73.2 m-85 -121.73 158.57 28.47 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.078 -0.51 . . . . 75.55 110.15 177.72 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.593 ' HB ' ' HB ' ' A' ' 48' ' ' VAL . 39.5 mm -106.74 110.54 32.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 N-CA-C 109.35 -0.611 . . . . 62.42 109.35 175.566 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.627 ' HG2' ' H ' ' A' ' 61' ' ' ASP . 74.3 ttt180 -83.99 140.42 31.9 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.276 -0.42 . . . . 73.11 110.682 -176.253 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.519 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 9.7 p -64.08 -25.06 67.94 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.901 -0.59 . . . . 64.14 112.204 -177.775 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.627 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 5.5 m-20 -72.78 -24.99 61.01 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.768 0.318 . . . . 71.44 111.649 -178.81 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.5 tp60 -155.0 88.36 3.21 Favored Pre-proline 0 C--N 1.327 -0.399 0 CA-C-O 120.73 0.3 . . . . 71.53 110.616 -176.835 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -82.05 6.5 5.66 Favored 'Trans proline' 0 C--O 1.233 0.231 0 C-N-CA 122.915 2.41 . . . . 55.24 112.455 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -62.34 -44.22 96.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.646 -0.706 . . . . 75.41 111.059 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.55 -178.37 4.9 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-N 115.6 -0.727 . . . . 61.21 111.458 -176.054 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.0 mp -95.51 135.04 37.66 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.078 -0.964 . . . . 62.43 108.846 177.424 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.429 HG13 ' HB2' ' A' ' 59' ' ' ARG . 41.0 mm -78.64 112.85 29.85 Favored Pre-proline 0 C--N 1.319 -0.743 0 N-CA-C 109.85 -0.426 . . . . 65.0 109.85 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.463 ' O ' HG23 ' A' ' 72' ' ' ILE . 46.6 Cg_endo -67.1 174.48 6.89 Favored 'Trans proline' 0 CA--C 1.519 -0.268 0 C-N-CA 123.188 2.592 . . . . 63.44 113.311 -173.336 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' GLN . . . . . 0.732 ' HA ' HG12 ' A' ' 72' ' ' ILE . 22.2 tt0 -68.16 -42.39 80.11 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.516 -0.765 . . . . 71.43 111.567 -170.624 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' TRP . . . . . 0.792 ' HA ' ' CZ ' ' A' ' 73' ' ' PHE . 29.6 p90 -63.19 -16.38 59.95 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.339 0.59 . . . . 74.32 110.395 -179.117 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 16.0 mm-40 -94.94 -28.75 15.01 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.527 -0.76 . . . . 72.05 111.579 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.732 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.0 pt -76.63 -38.6 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.148 0 N-CA-C 111.882 0.327 . . . . 72.15 111.882 -178.199 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.792 ' CZ ' ' HA ' ' A' ' 70' ' ' TRP . 6.6 p90 -85.67 30.65 0.63 Allowed 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.727 0.775 . . . . 75.14 110.847 179.55 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 32.5 t -74.23 -11.77 60.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.103 -0.953 . . . . 23.3 108.64 170.4 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' TRP . . . . . 0.437 ' HH2' HD13 ' A' ' 35' ' ' ILE . 36.6 m0 . . . . . 0 C--O 1.233 0.218 0 CA-C-N 115.465 -0.789 . . . . 72.55 110.6 173.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 33.1 m . . . . . 0 N--CA 1.455 -0.185 0 CA-C-O 121.06 0.457 . . . . 61.21 109.774 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 112.5 95.0 2.19 Favored Glycine 0 N--CA 1.441 -0.985 0 N-CA-C 110.838 -0.905 . . . . 52.23 110.838 -172.772 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -110.43 98.33 35.83 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-O 121.424 0.631 . . . . 73.32 109.899 -178.322 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.718 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 82.7 Cg_endo -81.83 76.57 4.25 Favored 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 122.484 2.123 . . . . 65.12 112.68 -175.456 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -91.38 149.86 21.53 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.092 -0.707 . . . . 73.13 109.092 176.536 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.669 HG21 ' HB3' ' B' ' 124' ' ' GLN . 7.2 p -102.96 130.52 52.93 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-O 121.555 0.693 . . . . 71.3 111.307 -176.085 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 114' ' ' THR . . . . . 0.454 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 30.4 m -91.84 111.2 22.64 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.234 -0.894 . . . . 45.51 109.139 176.027 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.6 mt -88.69 107.69 18.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 120.957 0.408 . . . . 72.4 111.06 -174.148 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 116' ' ' ARG . . . . . 0.502 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 20.2 mmt180 -94.84 160.46 14.59 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.447 -0.575 . . . . 55.44 109.447 175.619 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -136.99 86.84 2.24 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 115.774 -0.648 . . . . 62.44 109.574 174.138 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -100.35 87.81 3.51 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.475 -0.784 . . . . 74.42 109.395 -173.356 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 78.97 -111.56 3.27 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.791 -0.719 . . . . 63.4 111.968 -177.459 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 120' ' ' ASP . . . . . 0.61 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 20.4 m-20 -109.11 12.16 25.24 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.855 0.36 . . . . 75.3 111.189 -177.572 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.95 ' HE3' ' HB3' ' B' ' 175' ' ' TRP . 20.8 pttm -125.27 123.24 39.06 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.483 0.659 . . . . 75.42 111.481 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 65.9 m -81.75 103.31 11.35 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.249 -0.887 . . . . 70.3 109.472 174.629 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 123' ' ' ILE . . . . . 0.502 ' HB ' ' HB2' ' B' ' 116' ' ' ARG . 64.7 mt -93.58 105.87 17.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.076 0.465 . . . . 73.22 110.378 -177.284 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.669 ' HB3' HG21 ' B' ' 113' ' ' VAL . 70.0 mt-30 -96.23 109.72 22.14 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.167 -0.47 . . . . 54.2 110.897 -177.467 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 125' ' ' GLU . . . . . 0.454 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 45.8 mt-10 -86.47 106.48 17.51 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.778 -0.647 . . . . 71.45 110.799 179.471 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 126' ' ' TYR . . . . . 0.58 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 21.6 m-85 -82.07 106.36 13.92 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.88 -0.415 . . . . 74.44 109.88 174.297 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 127' ' ' ARG . . . . . 0.424 ' O ' ' HA ' ' B' ' 111' ' ' PRO . 95.2 mtt180 -119.97 126.38 50.7 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.842 -0.429 . . . . 74.25 109.842 179.735 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.718 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 3.0 p -99.0 -34.77 4.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.32 0.581 . . . . 74.3 111.268 -177.422 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -143.15 40.71 1.49 Allowed 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.596 0.712 . . . . 54.21 109.166 -175.43 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.15 -23.69 10.82 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.324 -0.853 . . . . 74.42 111.83 -176.386 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 58.3 t80 -93.83 132.26 38.4 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.98 0.419 . . . . 72.31 110.435 -177.647 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.861 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -70.66 117.29 12.0 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.359 -0.837 . . . . 74.13 109.261 176.368 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 133' ' ' TYR . . . . . 0.557 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 41.9 p90 -105.39 -24.69 12.61 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.384 -0.527 . . . . 73.33 111.18 179.533 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 134' ' ' ALA . . . . . 0.483 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -156.56 134.96 11.43 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.762 0.315 . . . . 72.02 110.734 179.224 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.861 HG13 HD11 ' B' ' 132' ' ' LEU . 74.3 mt -107.71 125.7 64.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 N-CA-C 110.031 -0.359 . . . . 73.3 110.031 175.492 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.548 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.9 tttt -107.53 99.92 9.38 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.038 -0.727 . . . . 62.43 109.038 174.142 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.539 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 1.1 p -103.85 124.45 58.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-O 121.074 0.464 . . . . 71.51 110.356 -178.519 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.777 HG22 ' HB3' ' B' ' 144' ' ' PRO . 21.2 t -108.89 88.12 5.18 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 115.224 -0.898 . . . . 65.04 109.732 179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 72.4 Cg_endo -83.13 135.96 7.67 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.539 2.159 . . . . 74.4 112.459 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 140' ' ' LYS . . . . . 0.61 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 59.1 mtpt -60.32 -34.53 73.93 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.605 -0.725 . . . . 71.44 110.088 173.694 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -102.09 77.06 1.65 Allowed 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.461 -0.79 . . . . 64.23 108.925 177.477 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 144.38 -158.14 27.4 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.215 -0.902 . . . . 65.35 110.988 -174.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -131.13 150.03 75.39 Favored Pre-proline 0 C--N 1.324 -0.515 0 N-CA-C 110.026 -0.361 . . . . 73.54 110.026 177.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.777 ' HB3' HG22 ' B' ' 138' ' ' VAL . 17.7 Cg_endo -61.58 122.88 11.71 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.426 2.084 . . . . 65.21 112.124 178.064 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 145' ' ' TYR . . . . . 0.48 ' CE1' HG13 ' B' ' 137' ' ' VAL . 5.7 p90 -136.49 152.86 51.0 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.144 -0.48 . . . . 75.1 110.964 -177.005 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.541 ' O ' ' HA ' ' B' ' 159' ' ' ARG . 88.2 m-85 -101.97 138.33 39.08 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.88 -0.6 . . . . 72.23 111.114 -178.268 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.471 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 56.9 mt -117.5 104.19 10.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.992 -0.549 . . . . 65.03 109.965 172.016 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 148' ' ' VAL . . . . . 0.507 ' HB ' ' HB ' ' B' ' 158' ' ' ILE . 49.1 t -91.33 128.02 43.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 116.339 -0.391 . . . . 65.13 110.888 -177.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 23.8 tpt180 -63.11 120.45 11.48 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 116.47 -0.332 . . . . 74.53 110.975 176.456 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.09 154.62 37.35 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-N 115.987 -0.551 . . . . 63.32 110.933 177.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 151' ' ' ASP . . . . . 0.504 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 8.0 p-10 -59.64 147.06 38.78 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.83 -0.623 . . . . 70.12 111.574 -176.667 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 73.63 2.59 60.83 Favored Glycine 0 N--CA 1.452 -0.247 0 CA-C-N 115.389 -0.823 . . . . 71.34 112.391 178.868 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 7.9 t 59.73 49.2 8.4 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 109.137 -0.69 . . . . 75.03 109.137 -175.259 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -48.64 -43.74 36.8 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 114.84 -1.073 . . . . 72.51 111.251 -179.326 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 131.13 -18.38 5.02 Favored Glycine 0 CA--C 1.492 -1.346 0 N-CA-C 110.718 -0.953 . . . . 71.23 110.718 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 -97.89 166.78 11.29 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 113.719 -1.241 . . . . 65.54 110.816 -176.533 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -121.22 153.39 37.67 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.817 -0.629 . . . . 72.12 110.206 178.314 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 158' ' ' ILE . . . . . 0.507 ' HB ' ' HB ' ' B' ' 148' ' ' VAL . 48.5 mm -106.31 114.77 46.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 N-CA-C 109.266 -0.642 . . . . 75.43 109.266 176.712 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.541 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 68.0 ttt180 -89.33 138.58 31.31 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.25 -0.432 . . . . 64.15 110.87 -175.505 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 5.6 p -62.59 -22.4 66.34 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.821 -0.627 . . . . 64.42 112.301 -177.191 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 161' ' ' ASP . . . . . 0.52 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 5.5 m-20 -76.22 -16.95 59.72 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.731 0.301 . . . . 62.02 111.237 -177.772 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 21.9 tp60 -166.06 84.81 0.97 Allowed Pre-proline 0 C--N 1.328 -0.34 0 N-CA-C 109.44 -0.578 . . . . 75.02 109.44 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 163' ' ' PRO . . . . . 0.512 ' HG2' ' HB2' ' A' ' 60' ' ' SER . 23.7 Cg_exo -64.86 -9.36 20.96 Favored 'Trans proline' 0 N--CA 1.474 0.337 0 C-N-CA 123.16 2.573 . . . . 63.25 112.929 -178.682 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -90.6 -5.63 55.66 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.962 -0.563 . . . . 74.41 110.768 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.8 tptt -114.83 123.29 48.81 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.25 0.548 . . . . 73.34 110.419 -178.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.3 mp -85.34 113.57 21.76 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.169 -0.923 . . . . 74.15 109.229 177.777 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 167' ' ' ILE . . . . . 0.543 HG23 ' HB3' ' B' ' 171' ' ' GLU . 50.5 mm -64.41 110.58 4.15 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 123.608 0.567 . . . . 74.21 110.681 -177.347 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.564 ' O ' HG23 ' B' ' 172' ' ' ILE . 80.5 Cg_endo -76.06 176.81 9.55 Favored 'Trans proline' 0 N--CA 1.461 -0.386 0 C-N-CA 122.933 2.422 . . . . 60.43 112.472 -176.711 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -76.26 -5.42 46.89 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.711 -0.677 . . . . 61.25 112.707 -170.453 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 27.9 p90 -97.64 -12.88 21.93 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.497 -0.481 . . . . 64.34 110.254 173.395 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.543 ' HB3' HG23 ' B' ' 167' ' ' ILE . 1.7 mm-40 -105.95 -15.05 15.01 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.37 -0.377 . . . . 53.42 111.465 -177.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.564 HG23 ' O ' ' B' ' 168' ' ' PRO . 43.1 pt -66.73 -21.28 28.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.083 0.468 . . . . 75.14 110.693 177.67 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -88.87 41.88 1.05 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.797 -0.638 . . . . 71.3 109.99 177.43 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 22.8 t -86.1 17.22 3.7 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.393 -0.821 . . . . 75.23 110.247 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 175' ' ' TRP . . . . . 0.95 ' HB3' ' HE3' ' B' ' 121' ' ' LYS . 45.9 m0 . . . . . 0 C--O 1.246 0.921 0 CA-C-O 118.471 -0.776 . . . . 72.52 110.421 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 20.9 m . . . . . 0 C--O 1.235 0.319 0 CA-C-O 120.643 0.258 . . . . 71.01 110.543 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 80.22 -86.77 1.29 Allowed Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 110.903 -0.879 . . . . 61.53 110.903 -176.164 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 70.87 97.94 0.04 OUTLIER Pre-proline 0 CA--C 1.516 -0.347 0 C-N-CA 123.138 0.575 . . . . 74.34 110.89 175.548 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.55 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 5.5 Cg_endo -78.82 85.03 1.92 Allowed 'Trans proline' 0 N--CA 1.443 -1.451 0 C-N-CA 122.378 2.052 . . . . 50.31 110.041 178.065 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -95.7 152.05 18.81 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.284 -0.871 . . . . 73.51 110.179 -175.372 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.722 HG21 ' HB3' ' A' ' 24' ' ' GLN . 7.3 p -121.67 131.52 72.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-O 121.378 0.609 . . . . 70.31 111.158 -176.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.2 m -92.05 115.55 28.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.437 -0.801 . . . . 54.32 109.488 176.584 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 50.3 mt -94.13 107.73 19.7 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.101 0.477 . . . . 53.52 111.344 -173.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.724 ' HB2' ' HB ' ' A' ' 23' ' ' ILE . 33.5 mmt180 -100.41 169.31 9.18 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.701 -0.681 . . . . 71.33 109.424 175.688 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 69.2 mt-30 -139.61 102.78 4.53 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.878 0.37 . . . . 55.11 110.301 175.537 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 60.2 mm-40 -101.51 80.15 2.03 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.031 -0.532 . . . . 72.31 110.18 -178.39 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.41 -111.06 3.49 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.794 -0.717 . . . . 42.3 111.51 -176.062 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.587 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 5.8 m-20 -112.47 4.23 17.33 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.239 0.542 . . . . 44.2 109.837 178.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 23.9 pttm -107.08 119.99 40.88 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.492 0.663 . . . . 74.0 110.379 175.581 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.694 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 8.5 m -80.21 127.15 32.01 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.499 -0.773 . . . . 63.33 109.488 177.879 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.724 ' HB ' ' HB2' ' A' ' 16' ' ' ARG . 26.0 mm -108.08 104.99 17.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 120.677 0.275 . . . . 74.2 110.296 -175.871 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.755 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 63.7 mt-30 -99.35 109.34 21.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.887 0.375 . . . . 52.42 110.827 -178.109 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -91.69 110.9 22.24 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.978 -0.556 . . . . 60.2 110.311 -179.161 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.531 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 28.1 m-85 -88.69 108.91 19.72 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.877 0.37 . . . . 73.52 111.531 -178.894 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 46.4 mtm105 -121.44 123.68 42.67 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.713 -0.477 . . . . 64.0 109.713 175.557 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.55 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.4 p -91.83 -27.88 4.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 121.11 0.481 . . . . 65.25 110.728 -177.719 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -172.3 72.5 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.015 -0.539 . . . . 73.34 109.905 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.31 -24.97 4.52 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.795 -0.639 . . . . 55.41 113.202 177.794 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -108.17 130.11 55.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.969 0.384 . . . . 72.34 111.097 -174.72 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.514 HD11 HG13 ' A' ' 35' ' ' ILE . 3.1 tm? -74.51 112.76 11.02 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.345 -0.843 . . . . 74.45 109.037 175.031 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -105.44 -16.33 14.76 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.614 -0.434 . . . . 61.44 111.696 -177.76 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -160.47 145.75 14.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.032 0.444 . . . . 34.21 111.522 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.514 HG13 HD11 ' A' ' 32' ' ' LEU . 63.6 mt -118.32 125.68 74.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 115.909 -0.587 . . . . 64.22 109.461 174.084 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.755 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 82.6 tttt -109.78 105.66 14.97 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.881 -0.415 . . . . 71.15 109.881 179.163 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.631 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 3.5 t -89.52 134.38 28.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 108.965 -0.754 . . . . 74.14 108.965 178.729 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.694 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.4 t -120.32 73.22 20.61 Favored Pre-proline 0 C--N 1.317 -0.839 0 N-CA-C 109.731 -0.47 . . . . 73.11 109.731 173.693 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.618 ' HD3' HG12 ' A' ' 37' ' ' VAL . 49.6 Cg_endo -76.96 132.46 12.9 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.286 1.991 . . . . 75.11 111.489 175.91 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.587 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 21.9 mtpp -57.77 -34.41 69.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 65.51 111.11 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -119.11 109.69 16.19 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.331 -0.618 . . . . 73.11 109.331 175.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 128.53 -27.6 4.4 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 110.79 -0.924 . . . . 31.1 110.79 -173.89 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 58.6 mtmt 70.97 152.0 0.14 Allowed Pre-proline 0 CA--C 1.532 0.255 0 C-N-CA 123.593 0.757 . . . . 62.33 112.496 175.828 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.631 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 43.3 Cg_endo -67.63 145.2 69.15 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.138 2.559 . . . . 73.44 114.159 -174.434 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 29.2 p90 -148.93 158.92 44.54 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.497 -0.774 . . . . 74.32 109.801 176.363 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.548 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 72.7 m-85 -101.71 129.14 47.81 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.276 -0.42 . . . . 73.12 110.701 178.7 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.58 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 29.7 tp -109.67 96.2 6.11 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.898 -0.779 . . . . 73.32 108.898 173.034 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 32.3 t -94.61 142.38 13.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 116.239 -0.437 . . . . 64.14 111.293 -172.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ARG . . . . . 0.453 HH11 ' HZ ' ' A' ' 57' ' ' PHE . 1.6 mmt-85 -66.93 137.57 56.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.962 -0.563 . . . . 63.33 111.046 177.075 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.73 153.84 21.04 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.056 -0.52 . . . . 55.1 109.701 172.723 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.409 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 4.3 p-10 -60.64 130.37 46.17 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.264 0.554 . . . . 64.34 111.289 -177.793 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 81.17 -15.0 24.94 Favored Glycine 0 CA--C 1.518 0.257 0 CA-C-N 115.637 -0.711 . . . . 63.43 112.39 -178.885 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.7 p 43.52 72.46 0.18 Allowed 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 123.721 0.808 . . . . 73.33 112.503 -175.48 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -80.09 42.08 0.55 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.612 0.72 . . . . 64.32 109.435 177.164 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 62.35 37.16 94.14 Favored Glycine 0 N--CA 1.451 -0.362 0 N-CA-C 110.359 -1.097 . . . . 75.34 110.359 -170.596 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -133.08 141.68 48.34 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.937 0.399 . . . . 72.45 110.766 -169.397 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.58 ' CD2' ' HG ' ' A' ' 47' ' ' LEU . 29.7 m-85 -132.09 168.36 18.12 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.767 -0.651 . . . . 73.53 109.879 177.03 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.891 HD11 HD23 ' A' ' 66' ' ' LEU . 42.4 mm -129.16 120.79 52.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.482 -0.562 . . . . 44.44 109.482 174.679 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.615 ' HG3' HG13 ' A' ' 67' ' ' ILE . 41.6 mtp180 -88.03 150.66 23.28 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.271 -0.422 . . . . 62.43 110.655 -179.085 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.672 ' HB2' ' HB3' ' B' ' 163' ' ' PRO . 34.2 p -66.71 -30.43 70.66 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.283 0.564 . . . . 45.24 110.363 177.082 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.51 ' OD1' ' HB3' ' A' ' 59' ' ' ARG . 4.2 p-10 -78.51 -23.23 46.42 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.709 -0.678 . . . . 72.31 110.971 177.048 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -137.33 70.58 54.29 Favored Pre-proline 0 C--N 1.316 -0.868 0 CA-C-N 115.719 -0.673 . . . . 73.32 110.808 -172.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' PRO . . . . . 0.467 ' HG3' ' HB2' ' B' ' 160' ' ' SER . 84.2 Cg_endo -84.47 -19.83 4.22 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.662 2.242 . . . . 74.02 112.587 -178.923 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 14.7 p-10 -90.61 3.76 53.2 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.935 -0.575 . . . . 74.41 109.975 -179.337 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 81.5 tttt -127.04 137.39 53.05 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.412 -0.813 . . . . 75.43 109.972 179.018 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.891 HD23 HD11 ' A' ' 58' ' ' ILE . 48.1 mt -86.22 116.54 24.46 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.916 -0.772 . . . . 74.13 108.916 176.08 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.673 HG23 ' HB3' ' A' ' 71' ' ' GLU . 41.5 mm -69.71 120.15 75.69 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 115.905 -0.589 . . . . 62.3 111.2 -172.852 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.537 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 51.3 Cg_endo -68.82 172.98 10.78 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.561 2.174 . . . . 62.14 112.574 -178.789 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 10.9 tt0 -80.1 -4.03 51.19 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.503 -0.771 . . . . 61.11 112.091 -166.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 39.1 p90 -100.78 -17.86 16.72 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.196 0.522 . . . . 72.4 110.214 174.002 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.673 ' HB3' HG23 ' A' ' 67' ' ' ILE . 1.2 mm-40 -90.73 -13.1 34.71 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.682 -0.69 . . . . 74.33 110.037 -178.93 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.531 HG23 ' O ' ' A' ' 68' ' ' PRO . 41.2 pt -70.34 -21.49 23.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.738 -0.665 . . . . 53.51 110.218 176.514 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -108.0 38.42 2.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.643 -0.708 . . . . 64.12 109.211 175.029 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.558 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 7.7 t -62.85 -32.77 74.06 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.192 -0.913 . . . . 64.02 111.187 -175.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 66.9 p-90 . . . . . 0 C--N 1.327 -0.383 0 CA-C-O 120.887 0.375 . . . . 74.04 110.838 179.19 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 14.1 m . . . . . 0 C--O 1.236 0.352 0 CA-C-O 120.937 0.398 . . . . 55.25 110.699 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.9 -58.28 4.98 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.72 -0.752 . . . . 73.22 111.362 -178.268 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 58.43 77.11 0.42 Allowed Pre-proline 0 C--N 1.329 -0.298 0 C-N-CA 122.941 0.497 . . . . 73.14 111.363 177.764 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.651 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 46.3 Cg_endo -72.84 80.12 1.84 Allowed 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 121.914 1.743 . . . . 73.13 110.745 175.159 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -97.77 164.33 12.44 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.197 -0.911 . . . . 75.35 110.255 -176.275 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.632 HG21 ' HB3' ' B' ' 124' ' ' GLN . 9.7 p -125.09 132.7 70.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-O 121.395 0.617 . . . . 62.35 111.195 -177.622 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 114' ' ' THR . . . . . 0.58 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 21.6 m -93.4 110.48 22.04 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.469 -0.787 . . . . 64.13 109.534 175.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.5 mt -84.37 105.35 13.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.062 0.458 . . . . 75.4 111.051 -176.039 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 116' ' ' ARG . . . . . 0.758 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 30.2 mmt180 -100.81 171.93 7.37 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.733 -0.667 . . . . 75.03 109.551 176.883 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 -145.59 125.18 13.25 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.512 0.672 . . . . 54.14 110.49 172.781 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.13 61.27 0.81 Allowed 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 115.008 -0.996 . . . . 63.34 110.223 -175.178 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 94.14 -111.94 4.25 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.685 -0.769 . . . . 53.54 111.638 -179.035 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -100.23 9.45 42.73 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.036 0.446 . . . . 73.04 109.837 178.215 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.715 ' HD2' ' HB2' ' B' ' 175' ' ' TRP . 25.0 pttm -123.81 119.59 30.15 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.9 -0.591 . . . . 74.2 110.791 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 122' ' ' THR . . . . . 0.635 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 35.0 m -80.07 133.38 36.11 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.755 -0.657 . . . . 74.11 109.543 175.943 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 123' ' ' ILE . . . . . 0.758 ' HB ' ' HB2' ' B' ' 116' ' ' ARG . 32.5 mm -114.89 103.39 15.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 120.753 0.311 . . . . 43.43 110.41 -177.403 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.751 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 60.2 mt-30 -95.7 105.69 17.72 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 120.644 -0.422 . . . . 73.03 110.452 -178.055 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 125' ' ' GLU . . . . . 0.58 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 41.1 mt-10 -81.63 101.7 10.19 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.865 -0.607 . . . . 75.51 110.831 179.137 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 126' ' ' TYR . . . . . 0.472 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 55.6 m-85 -81.03 105.72 12.46 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.916 0.388 . . . . 72.43 110.253 176.362 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 127' ' ' ARG . . . . . 0.479 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 86.8 mtm180 -127.67 118.03 23.08 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.956 -0.566 . . . . 73.44 110.262 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.733 HG13 ' H ' ' B' ' 129' ' ' ASN . 2.4 p -84.44 -72.06 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-N 116.114 -0.494 . . . . 73.1 110.246 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 129' ' ' ASN . . . . . 0.733 ' H ' HG13 ' B' ' 128' ' ' VAL . 18.3 t-20 -122.28 69.44 0.96 Allowed 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.122 0.487 . . . . 70.41 110.252 -177.091 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.79 -18.74 37.41 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.501 -0.772 . . . . 32.53 113.684 175.359 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.477 ' CD2' HG21 ' A' ' 28' ' ' VAL . 38.0 t80 -114.68 132.13 56.5 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.138 0.494 . . . . 70.04 111.189 -171.721 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.774 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -73.24 113.6 10.5 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.967 -1.015 . . . . 55.11 109.358 174.668 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 133' ' ' TYR . . . . . 0.472 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 52.5 p90 -106.01 -20.04 13.54 Favored 'General case' 0 C--N 1.326 -0.415 0 C-N-CA 120.72 -0.392 . . . . 71.1 111.456 -179.072 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -157.44 142.11 16.6 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.816 0.341 . . . . 75.31 111.361 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.774 HG13 HD11 ' B' ' 132' ' ' LEU . 73.5 mt -119.14 117.44 54.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 116.145 -0.48 . . . . 64.23 109.958 175.028 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.751 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 78.9 tttt -93.8 104.64 16.71 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.399 -0.593 . . . . 73.02 109.399 175.611 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.685 HG12 ' HD3' ' B' ' 139' ' ' PRO . 4.1 t -88.71 131.04 37.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 N-CA-C 108.985 -0.746 . . . . 63.21 108.985 177.529 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.635 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.4 t -118.18 73.03 9.76 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.703 -0.481 . . . . 71.12 109.703 173.016 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.685 ' HD3' HG12 ' B' ' 137' ' ' VAL . 61.2 Cg_endo -81.27 134.04 8.9 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 122.047 1.831 . . . . 75.4 112.161 175.913 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 63.4 mttm -57.07 -42.91 81.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.592 0.71 . . . . 62.14 110.083 174.659 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 18.0 m-70 -98.95 83.77 2.97 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.088 -0.96 . . . . 73.11 109.406 -173.165 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 136.28 -21.5 3.46 Favored Glycine 0 N--CA 1.45 -0.372 0 CA-C-N 115.51 -0.768 . . . . 52.55 111.848 -177.402 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 143' ' ' LYS . . . . . 0.503 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 53.7 mtmt 72.46 154.88 0.15 Allowed Pre-proline 0 N--CA 1.466 0.354 0 C-N-CA 123.682 0.793 . . . . 53.41 111.893 179.639 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.514 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 36.4 Cg_endo -65.49 146.85 86.06 Favored 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 123.017 2.478 . . . . 72.11 114.12 -174.334 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 27.3 p90 -151.19 171.26 17.67 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.402 -0.817 . . . . 75.44 109.472 175.795 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -111.67 126.54 55.14 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.94 0.4 . . . . 65.44 111.163 -179.269 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.427 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 26.7 tp -107.79 99.18 8.67 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.601 -0.727 . . . . 64.12 109.121 175.503 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 39.2 t -99.87 138.06 25.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 120.805 0.336 . . . . 64.41 111.152 -174.389 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 149' ' ' ARG . . . . . 0.473 ' HD3' ' CE2' ' B' ' 157' ' ' PHE . 0.4 OUTLIER -65.46 123.77 20.51 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 121.049 0.452 . . . . 72.12 111.469 174.509 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.05 156.54 37.37 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.228 -0.897 . . . . 54.42 110.705 177.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 151' ' ' ASP . . . . . 0.531 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 5.7 p-10 -64.51 133.85 53.25 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.144 0.497 . . . . 74.42 110.427 -179.364 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 89.72 -30.76 5.58 Favored Glycine 0 N--CA 1.453 -0.217 0 CA-C-N 115.831 -0.622 . . . . 50.14 111.808 -175.694 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 59.8 p 46.21 56.4 6.26 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.126 0.97 . . . . 75.23 113.13 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -77.64 40.79 0.31 Allowed 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.837 0.827 . . . . 71.53 110.417 176.623 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 73.08 28.73 65.91 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 111.362 -0.695 . . . . 51.1 111.362 -173.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 156' ' ' ASN . . . . . 0.524 ' ND2' HD23 ' B' ' 166' ' ' LEU . 34.0 t30 -122.02 141.57 51.22 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.393 -0.403 . . . . 45.24 110.364 -175.424 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 157' ' ' PHE . . . . . 0.473 ' CE2' ' HD3' ' B' ' 149' ' ' ARG . 43.1 m-85 -125.93 162.63 24.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.026 -0.533 . . . . 63.04 110.025 179.283 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 46.4 mm -122.07 130.14 74.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 109.088 -0.708 . . . . 73.13 109.088 175.382 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.512 ' HB3' ' OD1' ' B' ' 161' ' ' ASP . 23.6 mtp180 -104.92 158.79 16.29 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.193 0.52 . . . . 71.04 111.382 -175.762 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 160' ' ' SER . . . . . 0.467 ' HB2' ' HG3' ' A' ' 63' ' ' PRO . 11.5 p -74.86 -26.06 59.42 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.907 -0.588 . . . . 52.32 110.689 178.808 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 161' ' ' ASP . . . . . 0.512 ' OD1' ' HB3' ' B' ' 159' ' ' ARG . 11.3 p-10 -86.68 -15.4 39.69 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.883 -0.598 . . . . 54.33 110.428 177.274 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 162' ' ' GLN . . . . . 0.436 ' OE1' ' HD3' ' B' ' 165' ' ' LYS . 39.4 mt-30 -143.24 74.45 17.48 Favored Pre-proline 0 C--N 1.319 -0.718 0 CA-C-N 115.243 -0.89 . . . . 74.24 109.38 -176.095 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 163' ' ' PRO . . . . . 0.672 ' HB3' ' HB2' ' A' ' 60' ' ' SER . 74.0 Cg_endo -83.05 -44.23 0.07 OUTLIER 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.966 2.444 . . . . 74.22 114.133 -172.155 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -80.8 -6.8 59.01 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.443 0.64 . . . . 72.54 109.631 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 165' ' ' LYS . . . . . 0.436 ' HD3' ' OE1' ' B' ' 162' ' ' GLN . 88.1 tttt -103.92 135.98 44.43 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.18 -0.918 . . . . 71.32 110.27 -178.04 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 166' ' ' LEU . . . . . 0.524 HD23 ' ND2' ' B' ' 156' ' ' ASN . 5.3 mp -87.41 124.21 33.16 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 108.994 -0.743 . . . . 51.14 108.994 178.374 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 46.5 mm -83.44 117.73 69.47 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.114 -0.494 . . . . 74.22 111.686 -170.635 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.522 ' O ' HG23 ' B' ' 172' ' ' ILE . 70.4 Cg_endo -72.95 175.93 9.74 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.957 2.438 . . . . 62.01 112.874 -178.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -82.75 15.16 2.77 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.45 -0.795 . . . . 61.11 112.944 -168.469 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 26.3 p90 -115.67 -14.98 11.41 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.144 0.497 . . . . 74.43 110.424 171.803 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 171' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -107.32 0.81 23.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.967 -0.561 . . . . 72.34 111.017 -176.876 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.522 HG23 ' O ' ' B' ' 168' ' ' PRO . 21.6 pt -80.79 -31.3 12.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.914 -0.585 . . . . 74.42 111.217 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -111.5 39.4 2.34 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.422 0.63 . . . . 71.23 110.376 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.9 t -61.19 -26.03 67.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.378 -0.828 . . . . 74.02 110.933 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 175' ' ' TRP . . . . . 0.715 ' HB2' ' HD2' ' B' ' 121' ' ' LYS . 4.0 p-90 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.126 -0.94 . . . . 72.24 110.981 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 14.6 m . . . . . 0 C--O 1.235 0.325 0 N-CA-C 110.213 -0.291 . . . . 71.54 110.213 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.512 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 85.43 87.69 0.94 Allowed Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 110.437 -1.065 . . . . 73.13 110.437 -171.834 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -106.06 101.91 36.68 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-O 120.834 0.35 . . . . 72.42 110.938 -169.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.664 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 71.7 Cg_endo -92.07 122.41 0.62 Allowed 'Trans proline' 0 N--CA 1.445 -1.363 0 C-N-CA 122.864 2.376 . . . . 72.0 112.314 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -128.19 111.56 13.57 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.526 0.679 . . . . 71.51 110.321 176.508 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.599 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 9.1 p -67.33 130.0 32.31 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.085 0 CA-C-N 114.723 -1.126 . . . . 73.35 110.806 179.412 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.544 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 51.8 m -86.23 103.34 14.76 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.671 -0.695 . . . . 75.22 109.561 175.763 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 63.5 mt -86.8 104.47 14.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.159 -0.473 . . . . 73.53 110.482 -177.427 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 10.1 mmm-85 -106.0 156.34 18.49 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.682 -0.69 . . . . 63.11 110.766 -178.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -129.23 98.21 4.83 Favored 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 108.873 -0.788 . . . . 72.22 108.873 173.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.592 ' HG3' HD12 ' A' ' 23' ' ' ILE . 8.0 mm-40 -91.47 15.7 11.8 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.475 -0.784 . . . . 74.31 110.723 -171.773 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.41 -98.96 0.64 Allowed Glycine 0 N--CA 1.445 -0.727 0 C-N-CA 120.998 -0.62 . . . . 52.14 111.899 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.451 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 11.5 p-10 -85.45 4.57 35.02 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.632 0.253 . . . . 72.54 111.568 -178.129 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.622 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 14.1 pttm -148.44 130.54 15.41 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 112.664 0.616 . . . . 44.35 112.664 -176.553 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.8 m -84.87 103.31 13.82 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 114.925 -1.034 . . . . 74.52 108.997 172.401 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.592 HD12 ' HG3' ' A' ' 18' ' ' GLU . 55.7 mt -100.33 112.23 32.36 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.013 0.435 . . . . 72.21 110.393 -175.264 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.599 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 71.9 mt-30 -101.43 117.36 34.78 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.96 -0.564 . . . . 75.14 111.576 -177.16 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.544 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.1 mt-10 -91.05 100.5 13.34 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.551 -0.75 . . . . 24.3 110.322 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.554 ' CD2' ' HB2' ' B' ' 151' ' ' ASP . 63.2 m-85 -78.12 104.73 8.88 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.676 0.274 . . . . 74.14 110.682 179.327 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 94.0 mtt180 -122.69 132.9 54.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.313 -0.403 . . . . 75.34 110.687 -178.423 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.81 HG13 ' H ' ' A' ' 29' ' ' ASN . 3.0 p -98.59 -73.98 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 C-N-CA 120.725 -0.39 . . . . 63.53 110.898 176.222 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.81 ' H ' HG13 ' A' ' 28' ' ' VAL . 7.4 m-20 -128.38 68.62 1.36 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.05 0.453 . . . . 73.14 110.51 -177.308 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 77.42 12.56 84.44 Favored Glycine 0 N--CA 1.451 -0.331 0 CA-C-N 115.679 -0.691 . . . . 71.31 112.019 -179.052 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 79.9 t80 -130.07 127.36 39.72 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.921 0.391 . . . . 75.45 110.785 -176.183 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 30.2 tp -85.91 114.8 23.1 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.393 -0.821 . . . . 72.51 109.413 174.745 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' TYR . . . . . 0.483 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 50.8 p90 -104.47 -10.3 17.78 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.669 -0.412 . . . . 75.54 111.938 -176.782 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -167.44 145.05 4.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.081 0.467 . . . . 63.31 111.361 -177.825 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 66.9 mt -121.14 115.77 47.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.872 -0.604 . . . . 72.01 109.615 174.3 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.455 ' CB ' ' HE1' ' A' ' 26' ' ' TYR . 83.5 tttt -104.69 105.25 15.26 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.666 -0.494 . . . . 30.44 109.666 177.326 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.543 HG13 ' CE1' ' A' ' 45' ' ' TYR . 1.6 p -104.24 127.05 58.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.996 0.427 . . . . 74.13 110.512 178.3 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.827 HG22 ' HB3' ' A' ' 44' ' ' PRO . 16.1 t -103.0 88.01 1.41 Allowed Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 115.312 -0.858 . . . . 74.12 109.463 175.943 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.511 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 90.0 Cg_endo -81.65 150.09 16.57 Favored 'Trans proline' 0 N--CA 1.461 -0.423 0 C-N-CA 122.714 2.276 . . . . 65.41 113.432 -176.734 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.451 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 29.0 mtpp -74.36 -10.48 59.63 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.368 -0.833 . . . . 75.5 110.556 174.175 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 52.9 m-70 -113.43 21.01 15.58 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.766 -0.652 . . . . 74.15 110.277 -173.865 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.26 -155.85 15.33 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 115.675 -0.693 . . . . 42.1 111.661 -178.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -112.09 150.53 42.57 Favored Pre-proline 0 C--N 1.324 -0.506 0 N-CA-C 109.89 -0.411 . . . . 72.33 109.89 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.827 ' HB3' HG22 ' A' ' 38' ' ' VAL . 19.8 Cg_endo -60.18 121.03 9.15 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.37 2.046 . . . . 64.35 111.8 175.774 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.543 ' CE1' HG13 ' A' ' 37' ' ' VAL . 9.4 p90 -136.53 155.73 49.56 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.0 -0.546 . . . . 71.34 111.039 -176.227 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -99.7 137.07 38.69 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.621 -0.718 . . . . 64.24 110.787 -179.805 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 31.8 mt -104.7 98.13 7.92 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.865 -0.791 . . . . 71.04 108.865 164.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 39.7 t -83.54 129.12 38.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.117 -0.492 . . . . 72.15 110.083 -176.878 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.19 125.64 29.65 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.303 -0.408 . . . . 64.13 110.435 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.43 135.72 53.58 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 120.953 0.406 . . . . 65.25 110.899 178.181 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.709 ' OD1' ' HB2' ' B' ' 111' ' ' PRO . 31.3 t0 -80.01 168.58 19.0 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.594 -0.73 . . . . 74.21 110.942 -174.743 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.65 24.51 45.88 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.269 -0.732 . . . . 75.51 111.269 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 14.2 m 58.66 28.01 16.61 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.118 0.485 . . . . 74.53 110.592 -177.054 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.4 ' OD1' ' HB3' ' A' ' 56' ' ' ASN . 17.5 t70 -60.09 -47.95 83.75 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 115.349 -0.841 . . . . 74.33 111.325 -177.213 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 101.34 -36.73 4.01 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.679 -0.772 . . . . 63.34 112.946 176.386 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.4 ' HB3' ' OD1' ' A' ' 54' ' ' ASP . 7.4 t30 -70.93 150.95 45.2 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.967 0.413 . . . . 65.14 111.619 -175.839 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.45 ' CD1' HG21 ' A' ' 72' ' ' ILE . 37.7 m-85 -108.95 148.88 30.02 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.271 -0.422 . . . . 74.42 110.685 179.429 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 50.2 mm -111.26 129.07 67.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 109.641 -0.503 . . . . 74.43 109.641 176.358 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.415 ' HG2' ' H ' ' A' ' 61' ' ' ASP . 43.2 ttm180 -89.91 135.69 33.49 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.541 -0.299 . . . . 74.34 110.59 -176.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.405 ' HB3' ' HB2' ' A' ' 45' ' ' TYR . 35.0 t -63.2 -33.27 75.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.33 -0.396 . . . . 73.34 111.704 -178.194 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.415 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 4.6 m-20 -62.3 -42.64 99.53 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.248 0.547 . . . . 45.55 110.5 178.475 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 62.4 mt-30 -135.04 89.6 23.68 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 115.491 -0.777 . . . . 64.14 110.355 -174.015 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -68.97 -6.19 17.58 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.892 2.395 . . . . 72.11 112.416 -178.98 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -95.7 -8.44 34.6 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.086 -0.506 . . . . 71.22 110.241 178.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.3 tptt -105.84 123.12 47.45 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.869 -0.605 . . . . 45.01 110.737 -177.842 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.413 ' N ' HD12 ' A' ' 66' ' ' LEU . 5.1 mp -90.45 119.64 30.9 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.108 -0.951 . . . . 74.53 109.075 177.787 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 49.6 mm -90.07 113.92 58.97 Favored Pre-proline 0 C--N 1.323 -0.573 0 CA-C-N 116.263 -0.426 . . . . 75.31 110.729 -175.612 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.449 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 56.9 Cg_endo -69.43 174.03 9.81 Favored 'Trans proline' 0 N--CA 1.46 -0.5 0 C-N-CA 122.498 2.132 . . . . 71.53 112.371 -179.304 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 29.4 tt0 -83.14 -5.17 59.02 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.806 -0.633 . . . . 74.41 111.857 -168.233 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 35.7 p90 -100.45 -2.02 34.33 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.287 0.565 . . . . 73.33 109.902 176.468 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.449 ' HB2' ' HG2' ' A' ' 68' ' ' PRO . 2.8 mm-40 -121.72 17.02 11.12 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.391 -0.822 . . . . 71.3 111.03 -177.016 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.45 HG21 ' CD1' ' A' ' 57' ' ' PHE . 12.1 pt -98.18 -22.55 4.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.944 -0.571 . . . . 72.43 111.457 -179.569 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -113.58 20.78 15.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.185 0.517 . . . . 71.55 110.427 -178.359 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.1 m -57.75 -32.69 67.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.246 -0.888 . . . . 71.41 111.489 -177.011 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' TRP . . . . . 0.622 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 10.2 p-90 . . . . . 0 C--N 1.325 -0.467 0 CA-C-N 116.23 -0.441 . . . . 75.44 111.088 176.575 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 26.3 m . . . . . 0 N--CA 1.45 -0.437 0 CA-C-O 121.369 0.604 . . . . 70.21 109.763 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 109' ' ' GLY . . . . . 0.433 ' O ' ' HD3' ' B' ' 111' ' ' PRO . . . 151.59 54.14 0.01 OUTLIER Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 110.485 -1.046 . . . . 70.22 110.485 -175.058 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 110' ' ' GLU . . . . . 0.414 ' HA ' ' HD3' ' B' ' 111' ' ' PRO . 11.0 mt-10 -92.41 104.03 10.07 Favored Pre-proline 0 C--N 1.323 -0.578 0 CA-C-N 115.182 -0.509 . . . . 64.2 109.851 -176.065 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.722 ' HB3' ' HB ' ' B' ' 128' ' ' VAL . 68.4 Cg_endo -98.61 158.37 0.73 Allowed 'Trans proline' 0 N--CA 1.444 -1.437 0 C-N-CA 123.156 2.571 . . . . 73.45 112.768 -174.621 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -156.26 126.28 6.49 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 115.544 -0.753 . . . . 71.1 109.766 177.151 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.455 ' HB ' ' HB3' ' A' ' 51' ' ' ASP . 5.4 p -84.88 132.79 30.82 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 CA-C-N 114.979 -1.01 . . . . 74.44 110.801 -174.124 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 114' ' ' THR . . . . . 0.592 HG22 ' HG3' ' B' ' 116' ' ' ARG . 28.6 m -95.78 104.76 16.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.463 -0.79 . . . . 53.32 110.184 179.077 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.495 HG12 ' HG2' ' B' ' 124' ' ' GLN . 60.7 mt -90.64 102.98 13.92 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 116.073 -0.512 . . . . 74.02 109.928 -179.593 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 116' ' ' ARG . . . . . 0.592 ' HG3' HG22 ' B' ' 114' ' ' THR . 71.7 mtm180 -121.24 169.71 10.3 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.162 -0.472 . . . . 74.43 110.847 -178.41 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -125.24 117.49 23.95 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.045 -0.525 . . . . 75.11 110.537 179.016 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 118' ' ' GLU . . . . . 0.611 ' HG3' HD12 ' B' ' 123' ' ' ILE . 22.8 mm-40 -95.36 25.66 4.26 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.577 -0.738 . . . . 74.55 110.911 -177.225 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 121.45 -107.95 1.28 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.897 -0.668 . . . . 33.54 111.638 -177.379 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 120' ' ' ASP . . . . . 0.522 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 28.4 m-20 -95.39 29.21 2.61 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.911 0.386 . . . . 62.41 110.027 179.519 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 121' ' ' LYS . . . . . . . . . . . . . 20.7 pttm -151.88 127.52 10.14 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.032 0.444 . . . . 75.22 111.292 179.121 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 21.7 m -90.14 113.24 24.96 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.599 -0.728 . . . . 74.4 109.19 174.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 123' ' ' ILE . . . . . 0.611 HD12 ' HG3' ' B' ' 118' ' ' GLU . 51.8 mt -109.84 114.79 47.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.198 0.523 . . . . 61.43 110.634 -173.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.523 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 19.6 mt-30 -95.3 105.89 17.88 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.552 -0.749 . . . . 73.52 109.569 178.067 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 125' ' ' GLU . . . . . 0.424 ' CD ' HH21 ' B' ' 116' ' ' ARG . 28.8 mt-10 -84.53 98.82 10.34 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.541 -0.754 . . . . 71.12 110.34 -177.482 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 126' ' ' TYR . . . . . 0.62 ' CD2' ' HB2' ' A' ' 51' ' ' ASP . 6.5 m-85 -76.51 103.3 6.43 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.595 -0.52 . . . . 71.24 109.595 178.361 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 56.9 mtt-85 -132.43 126.34 32.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.108 0.48 . . . . 64.22 111.553 -172.725 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.722 ' HB ' ' HB3' ' B' ' 111' ' ' PRO . 4.3 p -115.7 119.44 61.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.675 -0.693 . . . . 51.24 109.827 175.105 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 60.29 27.14 16.66 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.284 -0.416 . . . . 74.5 111.545 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.36 21.13 52.92 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.509 -0.853 . . . . 71.52 112.576 179.544 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.468 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 90.0 t80 -122.27 119.43 31.16 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.933 0.396 . . . . 65.4 110.235 175.443 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.536 HD21 HD11 ' B' ' 135' ' ' ILE . 24.4 tp -83.06 114.24 21.16 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.694 -0.684 . . . . 72.54 109.928 178.798 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 45.6 p90 -110.06 -6.93 15.0 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.618 -0.433 . . . . 65.31 111.296 -178.107 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 134' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -165.83 146.88 6.89 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.027 0.441 . . . . 72.14 111.207 -177.148 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.536 HD11 HD21 ' B' ' 132' ' ' LEU . 59.3 mt -130.57 118.05 41.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.932 -0.576 . . . . 64.21 109.946 177.582 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.523 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.1 tttt -101.3 98.32 8.72 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 120.092 -0.643 . . . . 73.14 109.477 172.354 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.53 HG13 ' CE1' ' B' ' 145' ' ' TYR . 1.9 p -101.4 125.38 55.43 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.125 0.488 . . . . 73.31 110.537 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.671 HG22 ' HB3' ' B' ' 144' ' ' PRO . 23.2 t -104.98 88.67 2.48 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.169 -0.923 . . . . 72.22 109.451 175.896 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.482 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 72.6 Cg_endo -83.51 132.69 5.92 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.54 2.16 . . . . 75.1 112.708 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 140' ' ' LYS . . . . . 0.522 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 29.1 mtpp -56.65 -33.38 66.28 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.454 -0.794 . . . . 72.14 111.006 176.742 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -97.11 17.42 17.14 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.705 -0.679 . . . . 73.14 111.029 -174.698 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . -155.76 -149.99 5.48 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 121.001 -0.619 . . . . 52.33 111.742 178.871 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -119.08 147.42 42.66 Favored Pre-proline 0 C--N 1.327 -0.395 0 N-CA-C 109.611 -0.514 . . . . 71.31 109.611 176.495 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.671 ' HB3' HG22 ' B' ' 138' ' ' VAL . 25.3 Cg_endo -64.29 123.85 12.47 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.362 2.041 . . . . 61.21 111.492 175.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 145' ' ' TYR . . . . . 0.53 ' CE1' HG13 ' B' ' 137' ' ' VAL . 5.8 p90 -144.88 151.79 39.25 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.874 0.368 . . . . 70.33 111.418 -175.614 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.478 ' HB2' ' OG ' ' B' ' 160' ' ' SER . 74.9 m-85 -96.83 136.81 36.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.675 -0.693 . . . . 72.03 110.393 177.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.506 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 56.9 mt -109.53 102.62 11.46 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.163 -0.471 . . . . 64.13 109.884 169.936 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.9 t -81.83 130.35 35.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 109.836 -0.431 . . . . 44.01 109.836 178.862 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 149' ' ' ARG . . . . . 0.589 ' NH1' ' HA ' ' B' ' 153' ' ' SER . 0.0 OUTLIER -81.31 128.06 33.41 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.703 -0.226 . . . . 71.51 110.447 -177.149 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -68.58 150.7 47.7 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 120.963 0.411 . . . . 74.41 110.631 176.738 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 151' ' ' ASP . . . . . 0.554 ' HB2' ' CD2' ' A' ' 26' ' ' TYR . 22.7 t70 -70.77 165.88 22.14 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.598 -0.728 . . . . 71.3 111.115 -175.148 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.08 0.66 70.97 Favored Glycine 0 C--N 1.331 0.3 0 CA-C-N 116.206 -0.452 . . . . 72.54 112.34 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 153' ' ' SER . . . . . 0.589 ' HA ' ' NH1' ' B' ' 149' ' ' ARG . 5.9 t 60.6 31.91 20.29 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.078 0.466 . . . . 61.23 109.836 -176.441 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -52.39 -49.4 64.53 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.126 -0.943 . . . . 64.23 111.54 -179.521 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 124.61 -17.87 7.28 Favored Glycine 0 CA--C 1.499 -0.918 0 C-N-CA 120.762 -0.732 . . . . 73.12 111.565 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -70.33 140.35 52.21 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 114.851 -0.675 . . . . 63.52 111.281 178.037 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 157' ' ' PHE . . . . . 0.521 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 53.9 m-85 -118.28 151.47 37.61 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.071 -0.513 . . . . 73.12 109.673 174.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 46.7 mm -119.35 121.91 67.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 N-CA-C 109.743 -0.465 . . . . 64.22 109.743 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.592 ' HB3' ' H ' ' B' ' 162' ' ' GLN . 54.5 mtt180 -76.2 137.07 39.78 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.318 -0.401 . . . . 71.02 110.941 179.434 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 160' ' ' SER . . . . . 0.478 ' OG ' ' HB2' ' B' ' 146' ' ' PHE . 19.9 m -80.88 -13.68 58.7 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.252 -1.018 . . . . 74.24 108.252 165.096 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -73.66 -45.85 50.13 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.251 -1.34 . . . . 75.32 109.859 173.033 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 162' ' ' GLN . . . . . 0.592 ' H ' ' HB3' ' B' ' 159' ' ' ARG . 77.6 mt-30 -137.63 86.19 19.28 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-N 115.364 -0.835 . . . . 74.4 109.444 176.456 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -68.19 -13.99 39.39 Favored 'Trans proline' 0 N--CA 1.473 0.282 0 C-N-CA 122.905 2.403 . . . . 72.45 112.936 -176.436 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -92.29 10.68 28.67 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.976 0.417 . . . . 64.44 110.453 -179.028 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -127.09 125.81 41.91 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.33 0.586 . . . . 75.32 111.075 -179.589 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 166' ' ' LEU . . . . . 0.429 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.9 mp -87.87 125.06 34.27 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.036 -0.984 . . . . 55.41 108.93 176.573 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 167' ' ' ILE . . . . . 0.837 HG23 ' HB3' ' B' ' 171' ' ' GLU . 39.4 mm -87.26 117.43 68.58 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 116.18 -0.463 . . . . 64.12 111.64 -172.396 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.454 ' HG2' ' HB2' ' B' ' 171' ' ' GLU . 72.4 Cg_endo -75.59 -179.75 5.42 Favored 'Trans proline' 0 N--CA 1.463 -0.287 0 C-N-CA 123.088 2.525 . . . . 61.13 112.043 175.539 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 169' ' ' GLN . . . . . 0.761 ' O ' HG12 ' B' ' 172' ' ' ILE . 35.4 tt0 -76.34 -29.51 57.28 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.727 -0.389 . . . . 62.13 111.68 -172.261 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 36.5 p90 -75.06 -14.11 60.56 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 119.92 -0.712 . . . . 74.45 110.313 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.837 ' HB3' HG23 ' B' ' 167' ' ' ILE . 0.8 OUTLIER -89.68 -21.1 22.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.885 -0.598 . . . . 73.15 110.185 -179.257 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.761 HG12 ' O ' ' B' ' 169' ' ' GLN . 21.9 pt -73.59 -18.44 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 121.27 0.557 . . . . 74.2 110.24 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 80.0 m-85 -93.65 15.23 16.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.663 -0.699 . . . . 72.44 110.168 176.217 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.7 t -56.96 -37.06 71.04 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-N 115.817 -0.629 . . . . 72.02 109.777 175.782 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 54.7 p-90 . . . . . 0 C--O 1.247 0.927 0 CA-C-O 118.203 -0.903 . . . . 74.42 109.828 175.02 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 19.6 m . . . . . 0 N--CA 1.45 -0.461 0 N-CA-C 109.504 -0.554 . . . . 71.43 109.504 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 72.41 74.78 0.74 Allowed Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 110.005 -1.238 . . . . 64.51 110.005 -168.407 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLU . . . . . 0.446 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 7.1 pt-20 -112.31 107.74 55.26 Favored Pre-proline 0 C--N 1.317 -0.809 0 CA-C-O 121.375 0.607 . . . . 73.43 109.712 -169.83 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.578 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 32.5 Cg_endo -84.67 108.94 1.28 Allowed 'Trans proline' 0 N--CA 1.442 -1.541 0 C-N-CA 122.445 2.097 . . . . 62.44 112.371 -174.006 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -118.79 164.2 15.75 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.127 -0.942 . . . . 50.25 109.674 -179.437 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.604 HG21 ' HB3' ' A' ' 24' ' ' GLN . 13.1 p -115.34 131.24 68.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.237 0.541 . . . . 64.43 111.41 -177.315 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 52.9 m -93.16 107.09 18.96 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.244 -0.65 . . . . 63.53 109.244 174.469 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 53.5 mt -92.09 107.96 19.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 120.963 0.411 . . . . 71.21 111.217 -174.559 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 66.7 mtt180 -103.65 167.85 9.53 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.736 -0.665 . . . . 72.15 110.252 176.751 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 62.6 mt-30 -134.16 97.31 3.82 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.438 -0.579 . . . . 72.22 109.438 170.317 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 22.1 mm-40 -96.29 82.42 3.42 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.823 -0.626 . . . . 74.21 110.093 -175.683 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.86 -109.02 3.31 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.798 -0.715 . . . . 62.2 111.927 -178.506 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.903 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 7.1 m-20 -111.22 17.53 20.2 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.899 0.381 . . . . 65.24 110.326 -179.789 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.599 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 22.9 pttm -130.84 123.79 29.84 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.294 0.569 . . . . 74.12 111.398 -179.151 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.474 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 24.5 m -82.83 109.75 17.24 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.603 -0.726 . . . . 33.33 109.682 176.265 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 48.7 mt -102.55 112.83 37.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-O 121.117 0.484 . . . . 71.24 110.654 -176.335 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.604 ' HB3' HG21 ' A' ' 13' ' ' VAL . 73.8 mt-30 -102.48 110.92 23.02 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.67 -0.695 . . . . 74.31 110.996 -177.562 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -92.26 107.51 19.27 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.795 -0.639 . . . . 73.02 110.837 -178.42 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -84.87 112.42 20.54 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.893 0.378 . . . . 74.02 110.599 178.392 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.466 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 87.9 mtt180 -117.39 137.56 52.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.924 -0.58 . . . . 71.02 109.905 178.756 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.578 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 6.2 p -96.82 -34.82 5.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-O 121.346 0.593 . . . . 72.24 110.489 177.714 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 30.9 t-20 -161.78 59.8 0.26 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.641 -0.874 . . . . 61.0 108.641 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.07 -34.69 3.36 Favored Glycine 0 CA--C 1.519 0.297 0 CA-C-N 115.482 -0.781 . . . . 61.04 112.058 -176.162 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.56 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 81.9 t80 -78.28 129.25 34.82 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.021 0.438 . . . . 64.42 111.047 -177.328 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.781 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -81.44 114.04 19.91 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.196 -0.911 . . . . 72.34 109.094 174.59 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 52.1 p90 -107.86 -19.4 13.53 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.634 -0.426 . . . . 74.13 111.682 -179.057 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -154.85 136.15 14.05 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.785 0.326 . . . . 51.44 111.244 -179.264 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.781 HG13 HD11 ' A' ' 32' ' ' LEU . 75.0 mt -116.26 122.81 70.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 116.064 -0.516 . . . . 75.45 109.91 175.378 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.4 tmtp? -110.21 114.49 28.02 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 108.732 -0.84 . . . . 65.43 108.732 173.827 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.571 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 0.9 OUTLIER -120.46 129.72 75.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 CA-C-N 115.796 -0.638 . . . . 74.55 110.692 -174.011 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.765 HG22 ' HB3' ' A' ' 44' ' ' PRO . 21.2 t -112.8 86.96 9.38 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.313 -0.858 . . . . 75.4 110.097 -179.378 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.469 ' HD2' ' C ' ' A' ' 43' ' ' LYS . 70.4 Cg_endo -86.49 134.45 4.05 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 122.503 2.135 . . . . 64.33 112.496 176.859 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.903 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 59.4 mtpt -56.31 -31.19 63.46 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.664 -0.698 . . . . 71.21 110.168 174.149 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 61.4 m-70 -116.95 91.18 3.51 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.338 -0.846 . . . . 73.34 109.156 176.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 141.31 -31.31 2.16 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.837 -0.619 . . . . 65.33 111.977 -177.019 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.469 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 98.5 mttt 70.52 151.12 0.13 Allowed Pre-proline 0 N--CA 1.469 0.477 0 C-N-CA 123.508 0.723 . . . . 72.33 111.872 178.577 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.765 ' HB3' HG22 ' A' ' 38' ' ' VAL . 18.8 Cg_endo -59.26 139.44 90.09 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 123.013 2.476 . . . . 74.01 113.798 -174.01 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.544 ' CE1' HG13 ' A' ' 37' ' ' VAL . 22.5 p90 -152.34 163.65 39.04 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.62 -0.718 . . . . 71.21 109.548 176.594 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' PHE . . . . . 0.472 ' HB2' ' HB2' ' A' ' 60' ' ' SER . 60.1 m-85 -107.6 120.66 42.84 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.704 0.288 . . . . 74.12 110.712 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 28.1 tp -107.15 99.14 8.7 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.16 -0.681 . . . . 44.15 109.16 176.842 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 37.3 t -95.38 140.76 16.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.26 -0.427 . . . . 63.41 111.436 -173.52 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ARG . . . . . 0.498 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 43.8 tpt85 -81.82 110.97 17.61 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.495 -0.557 . . . . 73.11 109.495 178.23 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.457 ' HB2' HG12 ' A' ' 58' ' ' ILE . . . -70.03 -177.96 1.48 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.994 -0.548 . . . . 73.52 111.111 -177.286 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.752 ' HB2' ' HA ' ' B' ' 112' ' ' ASP . 9.1 p-10 -79.01 148.42 32.53 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.154 -0.475 . . . . 72.05 110.17 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 103.27 140.16 10.69 Favored Glycine 0 N--CA 1.439 -1.16 0 C-N-CA 120.571 -0.823 . . . . 64.01 112.675 174.026 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 20.7 m -69.13 -4.93 19.3 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.675 -0.262 . . . . 52.13 110.919 174.708 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -43.03 -48.07 5.97 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 123.556 0.743 . . . . 73.0 112.012 176.711 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.25 53.86 1.32 Allowed Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.608 -0.806 . . . . 43.31 112.46 178.275 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -127.17 148.96 50.17 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.095 0.474 . . . . 65.32 110.538 176.819 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.498 ' CZ ' ' HD3' ' A' ' 49' ' ' ARG . 40.2 m-85 -117.75 152.64 34.87 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.594 -0.73 . . . . 73.02 110.322 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.457 HG12 ' HB2' ' A' ' 50' ' ' ALA . 50.6 mm -121.26 127.07 75.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 109.914 -0.402 . . . . 73.23 109.914 179.753 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 65.0 mtp180 -78.55 139.2 38.64 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 110.144 -0.317 . . . . 70.32 110.144 175.875 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.472 ' HB2' ' HB2' ' A' ' 46' ' ' PHE . 63.2 m -73.05 -23.19 60.55 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.495 -0.321 . . . . 60.31 110.448 176.109 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.46 ' OD1' ' HB2' ' A' ' 45' ' ' TYR . 0.8 OUTLIER -61.79 -60.58 3.44 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 121.74 0.781 . . . . 64.45 109.414 175.918 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 -122.65 88.62 49.85 Favored Pre-proline 0 N--CA 1.445 -0.724 0 CA-C-N 114.538 -1.21 . . . . 75.12 109.817 -179.524 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.84 -9.19 20.24 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 123.165 2.577 . . . . 65.24 112.626 -178.604 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -78.37 -24.84 46.19 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.926 -0.579 . . . . 73.22 110.599 177.393 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' A' ' 65' ' ' LYS . 42.6 tptt -91.82 122.92 34.8 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.388 0.613 . . . . 61.41 111.395 -175.14 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.5 mp -96.59 119.38 34.98 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.09 -0.959 . . . . 71.24 109.642 176.243 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 50.7 mm -88.11 111.42 42.85 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 116.273 -0.421 . . . . 73.41 110.023 178.845 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.428 ' O ' HG23 ' A' ' 72' ' ' ILE . 72.7 Cg_endo -74.16 176.72 9.18 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.563 2.175 . . . . 74.3 112.367 -177.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 28.4 tt0 -80.41 -6.24 57.76 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.859 -0.61 . . . . 54.55 111.334 -169.598 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -95.24 -12.14 26.76 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.409 -0.516 . . . . 62.5 110.433 176.367 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -103.12 -7.6 21.17 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.839 0.352 . . . . 52.44 110.795 -178.167 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.428 HG23 ' O ' ' A' ' 68' ' ' PRO . 45.7 pt -67.72 -27.74 39.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.846 0.355 . . . . 75.23 111.573 -178.24 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 24.3 p90 -101.27 34.49 2.54 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.372 0.605 . . . . 74.13 110.528 178.101 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 42.4 t -64.75 -26.98 68.59 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.43 -0.805 . . . . 52.13 110.212 176.161 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' TRP . . . . . 0.599 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 26.0 p-90 . . . . . 0 C--O 1.235 0.327 0 CA-C-N 116.436 -0.347 . . . . 65.32 111.048 177.309 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 16.9 m . . . . . 0 C--O 1.233 0.223 0 CA-C-O 120.833 0.349 . . . . 64.41 110.072 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 114.58 85.05 1.28 Allowed Glycine 0 N--CA 1.443 -0.864 0 C-N-CA 120.578 -0.82 . . . . 63.34 111.437 -176.8 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 110' ' ' GLU . . . . . 0.462 ' HA ' ' HD3' ' B' ' 111' ' ' PRO . 11.1 pt-20 -124.08 110.73 28.99 Favored Pre-proline 0 C--N 1.322 -0.618 0 CA-C-O 121.322 0.582 . . . . 72.05 109.558 -176.384 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.695 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 19.1 Cg_endo -89.52 131.35 2.01 Favored 'Trans proline' 0 N--CA 1.444 -1.4 0 C-N-CA 122.63 2.22 . . . . 60.22 112.604 -176.393 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 112' ' ' ASP . . . . . 0.752 ' HA ' ' HB2' ' A' ' 51' ' ' ASP . 4.2 p-10 -144.9 171.17 14.82 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.188 -0.671 . . . . 72.33 109.188 175.272 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.544 HG21 ' HB3' ' B' ' 124' ' ' GLN . 10.9 p -118.44 131.6 70.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.653 0.739 . . . . 72.45 112.096 -172.461 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 30.3 m -94.86 103.44 15.32 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.435 -0.802 . . . . 55.04 109.31 173.161 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.468 HG23 ' HG2' ' B' ' 124' ' ' GLN . 65.2 mt -90.57 106.44 17.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.245 -0.434 . . . . 72.1 110.823 -176.15 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -113.74 165.08 12.91 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.126 -0.488 . . . . 72.44 110.603 177.808 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -133.14 105.57 7.11 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.094 0.474 . . . . 63.45 110.468 178.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -109.85 88.75 2.82 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.904 -0.589 . . . . 71.34 110.191 -178.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 88.47 -119.8 5.47 Favored Glycine 0 N--CA 1.445 -0.734 0 CA-C-N 115.439 -0.8 . . . . 52.43 111.742 -177.377 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 120' ' ' ASP . . . . . 0.508 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 90.5 m-20 -101.37 6.29 42.57 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.73 0.3 . . . . 63.34 110.573 178.84 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.706 ' HE3' ' HB2' ' B' ' 175' ' ' TRP . 25.1 pttm -117.42 120.69 38.92 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.47 0.652 . . . . 72.42 111.692 -177.806 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 122' ' ' THR . . . . . 0.586 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 69.7 m -84.86 105.0 15.31 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.163 -0.926 . . . . 73.14 109.478 174.183 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 123' ' ' ILE . . . . . 0.655 HD11 ' HE2' ' B' ' 121' ' ' LYS . 33.2 mt -95.02 108.08 20.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 121.049 0.452 . . . . 71.11 110.531 -176.366 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.544 ' HB3' HG21 ' B' ' 113' ' ' VAL . 72.2 mt-30 -98.65 105.15 17.26 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.825 -0.625 . . . . 72.12 110.319 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -87.37 112.77 22.46 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.125 -0.488 . . . . 65.41 110.926 -179.438 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -90.09 111.14 22.16 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.205 -0.452 . . . . 72.23 110.028 176.06 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 127' ' ' ARG . . . . . 0.403 ' HD3' ' O ' ' B' ' 130' ' ' GLY . 52.8 mtt-85 -128.33 138.1 52.23 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.313 -0.403 . . . . 75.34 110.346 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.695 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -101.86 -56.17 5.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.065 0.459 . . . . 71.51 111.201 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 129' ' ' ASN . . . . . 0.449 ' H ' HG13 ' B' ' 128' ' ' VAL . 6.7 t-20 -122.66 42.03 3.28 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.761 0.791 . . . . 64.31 109.103 -178.029 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 130' ' ' GLY . . . . . 0.403 ' O ' ' HD3' ' B' ' 127' ' ' ARG . . . 92.31 -28.72 8.51 Favored Glycine 0 N--CA 1.448 -0.563 0 CA-C-N 115.086 -0.961 . . . . 64.32 112.099 -178.087 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 33.8 t80 -84.59 135.57 34.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.934 0.397 . . . . 72.33 110.318 -175.627 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.843 HD11 HG13 ' B' ' 135' ' ' ILE . 3.3 tm? -76.75 117.59 18.53 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.327 -0.851 . . . . 75.14 109.966 179.068 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 40.0 p90 -112.26 -14.96 13.27 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.521 -0.471 . . . . 72.01 111.571 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.11 141.61 12.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.848 0.356 . . . . 51.21 111.169 178.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.843 HG13 HD11 ' B' ' 132' ' ' LEU . 75.3 mt -125.14 121.61 61.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.188 -0.46 . . . . 72.13 109.935 175.713 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.407 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 83.7 tttt -104.37 98.5 8.28 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 108.821 -0.807 . . . . 73.01 108.821 171.512 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.55 ' O ' ' HD3' ' B' ' 139' ' ' PRO . 3.5 p -98.21 128.67 49.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-O 121.142 0.496 . . . . 74.12 109.916 179.374 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.586 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 40.8 t -108.03 84.82 2.28 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.31 -0.859 . . . . 72.13 109.69 179.083 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.55 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 62.5 Cg_endo -88.7 132.33 2.45 Favored 'Trans proline' 0 N--CA 1.443 -1.464 0 C-N-CA 122.459 2.106 . . . . 75.14 111.885 178.411 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 140' ' ' LYS . . . . . 0.508 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 55.0 mtpt -65.37 -15.81 62.96 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.701 -0.681 . . . . 54.33 109.808 176.229 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 64.4 m-70 -117.47 89.52 3.13 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-N 115.174 -0.921 . . . . 63.24 109.289 178.413 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 127.87 -18.35 5.94 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.724 -0.751 . . . . 63.25 112.555 -178.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 89.1 mttt 72.98 148.94 0.12 Allowed Pre-proline 0 N--CA 1.472 0.649 0 C-N-CA 123.557 0.743 . . . . 73.3 111.736 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.545 ' HB3' HG22 ' B' ' 138' ' ' VAL . 34.9 Cg_endo -65.12 149.26 89.24 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.936 2.424 . . . . 74.4 113.375 -176.433 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 145' ' ' TYR . . . . . 0.43 ' HE2' HD13 ' B' ' 147' ' ' LEU . 3.9 p90 -160.3 160.43 32.51 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.534 -0.757 . . . . 71.23 109.59 178.178 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.547 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 55.0 m-85 -94.55 128.84 41.42 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.457 -0.338 . . . . 74.44 110.216 176.687 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.43 HD13 ' HE2' ' B' ' 145' ' ' TYR . 15.8 tp -110.36 99.8 8.76 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 108.931 -0.766 . . . . 74.42 108.931 174.837 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.3 t -93.77 139.28 18.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.988 -0.551 . . . . 73.5 111.047 -173.656 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 11.6 tpt180 -72.02 131.06 42.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.199 -0.455 . . . . 72.32 111.245 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -93.34 162.22 14.08 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.372 -0.603 . . . . 75.14 109.372 171.306 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -68.69 138.24 54.78 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.966 0.412 . . . . 72.3 110.537 -177.548 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.1 147.45 15.01 Favored Glycine 0 N--CA 1.437 -1.28 0 C-N-CA 120.491 -0.861 . . . . 72.25 112.048 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 11.1 t -87.0 23.88 1.66 Allowed 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 121.253 0.549 . . . . 63.14 110.015 175.68 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -65.17 -29.45 70.28 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.571 -0.74 . . . . 72.15 110.59 179.01 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 94.44 37.92 5.18 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.891 -0.671 . . . . 71.05 111.641 -177.681 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 156' ' ' ASN . . . . . 0.481 ' HA ' ' O ' ' B' ' 167' ' ' ILE . 2.4 t-20 -110.85 130.51 55.56 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.836 0.351 . . . . 65.11 110.69 -177.457 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 157' ' ' PHE . . . . . 0.428 ' HB3' ' HG ' ' B' ' 147' ' ' LEU . 27.1 m-85 -126.71 161.0 29.15 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.002 -0.545 . . . . 72.24 110.269 178.198 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 158' ' ' ILE . . . . . 0.775 HD11 HD23 ' B' ' 166' ' ' LEU . 39.9 mm -118.38 141.05 39.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.458 -0.337 . . . . 73.12 110.603 -179.63 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.817 ' HD2' HD11 ' B' ' 167' ' ' ILE . 34.1 mtp-105 -96.23 145.68 25.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.394 -0.366 . . . . 75.4 110.925 -178.098 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 160' ' ' SER . . . . . 0.547 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 25.8 p -74.96 -15.16 60.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.26 0.552 . . . . 74.24 110.679 175.098 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -78.66 -30.79 46.47 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.118 -0.492 . . . . 72.53 110.38 177.629 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 52.8 tt0 -159.19 98.02 1.63 Allowed Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.781 -0.645 . . . . 75.42 110.224 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 163' ' ' PRO . . . . . 0.418 ' HA ' HG23 ' B' ' 158' ' ' ILE . 48.6 Cg_endo -69.62 -13.03 34.41 Favored 'Trans proline' 0 CA--C 1.529 0.231 0 C-N-CA 122.991 2.461 . . . . 61.04 112.844 -179.343 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -77.66 -19.38 55.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.86 0.362 . . . . 62.54 111.022 177.732 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 51.7 tptt -94.07 122.61 36.76 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.409 0.623 . . . . 71.12 111.132 -177.236 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 166' ' ' LEU . . . . . 0.775 HD23 HD11 ' B' ' 158' ' ' ILE . 20.4 mt -90.57 128.02 36.45 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.598 -1.183 . . . . 73.4 108.832 176.734 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 167' ' ' ILE . . . . . 0.817 HD11 ' HD2' ' B' ' 159' ' ' ARG . 46.1 mm -98.77 112.08 61.89 Favored Pre-proline 0 C--N 1.318 -0.778 0 CA-C-O 120.65 0.262 . . . . 70.31 110.832 -178.151 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.539 ' O ' HG23 ' B' ' 172' ' ' ILE . 68.6 Cg_endo -73.5 175.23 10.94 Favored 'Trans proline' 0 N--CA 1.464 -0.263 0 C-N-CA 122.775 2.317 . . . . 75.34 112.611 -179.421 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 169' ' ' GLN . . . . . 0.517 ' O ' HG12 ' B' ' 172' ' ' ILE . 28.0 tt0 -69.65 -25.48 63.94 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.703 -0.681 . . . . 73.32 112.325 -168.488 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 30.6 p90 -81.09 -12.07 59.36 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 120.182 -0.607 . . . . 74.42 110.303 178.732 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.548 ' HB3' HG23 ' B' ' 167' ' ' ILE . 3.9 mt-10 -106.79 -19.27 13.7 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.157 -0.474 . . . . 71.33 111.892 -178.703 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.539 HG23 ' O ' ' B' ' 168' ' ' PRO . 43.6 pt -64.51 -26.36 40.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.244 0.545 . . . . 72.13 110.681 177.579 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -105.3 48.56 0.83 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.612 -0.722 . . . . 70.44 109.782 174.4 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 16.6 t -71.06 -15.39 62.54 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.806 -0.634 . . . . 73.41 110.17 179.379 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 175' ' ' TRP . . . . . 0.706 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 4.5 p-90 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.249 -0.882 . . . . 73.12 110.519 178.305 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 27.0 m . . . . . 0 C--O 1.23 0.059 0 CA-C-O 121.66 0.743 . . . . 53.12 110.374 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -135.18 102.99 0.45 Allowed Glycine 0 N--CA 1.442 -0.957 0 N-CA-C 110.108 -1.197 . . . . 75.11 110.108 177.381 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -119.99 94.71 48.81 Favored Pre-proline 0 C--N 1.319 -0.743 0 CA-C-O 121.261 0.553 . . . . 74.33 110.401 -175.069 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.848 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 51.6 Cg_endo -77.56 81.79 2.57 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 121.913 1.742 . . . . 73.12 111.265 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -100.48 168.26 9.85 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.339 -0.615 . . . . 73.45 109.339 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.673 HG21 ' HB3' ' A' ' 24' ' ' GLN . 8.3 p -125.65 131.41 72.06 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-O 121.253 0.549 . . . . 44.45 111.387 -175.177 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.5 m -89.51 121.14 31.44 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.679 -0.691 . . . . 71.15 109.423 176.34 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 52.9 mt -91.58 109.09 20.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 120.834 0.349 . . . . 71.43 111.161 -175.382 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 38.3 mmt180 -105.51 165.7 10.96 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 72.11 109.867 176.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 40.1 mt-30 -138.95 122.57 17.43 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.768 0.318 . . . . 75.35 111.147 177.007 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -124.97 96.93 5.05 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.793 -0.639 . . . . 73.04 109.524 176.212 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.24 -106.49 1.8 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.476 -0.869 . . . . 75.35 111.719 -178.829 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.588 ' HB3' ' HB2' ' A' ' 40' ' ' LYS . 7.0 m-20 -111.35 6.26 20.31 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 121.156 -0.217 . . . . 41.31 111.537 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.652 ' HB3' ' HB3' ' A' ' 39' ' ' PRO . 0.0 OUTLIER -110.94 122.49 48.01 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 119.917 -0.713 . . . . 72.03 111.472 177.422 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.448 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 42.4 m -83.42 101.28 11.26 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 114.961 -1.018 . . . . 61.41 108.983 173.174 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.475 HG12 HG13 ' A' ' 37' ' ' VAL . 61.3 mt -90.82 109.86 21.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.153 0.502 . . . . 71.44 110.291 -175.789 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.673 ' HB3' HG21 ' A' ' 13' ' ' VAL . 60.2 mt-30 -99.78 119.45 38.18 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.787 -0.642 . . . . 73.22 111.021 -175.562 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -94.31 108.73 20.6 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.825 -0.625 . . . . 74.24 110.559 -178.001 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.516 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 33.5 m-85 -86.62 114.82 23.65 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.923 0.392 . . . . 75.12 111.051 -179.587 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.427 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 68.3 mtm180 -131.03 126.64 36.43 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.018 -0.537 . . . . 73.12 110.416 179.295 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.848 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.3 p -91.07 -28.83 4.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.063 -0.517 . . . . 70.11 111.242 -176.52 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -173.61 69.68 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.626 -0.509 . . . . 62.31 109.626 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.98 -24.59 5.19 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.817 -0.629 . . . . 63.12 112.642 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.645 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 88.4 t80 -97.26 128.43 44.11 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.869 0.366 . . . . 75.25 111.057 -176.2 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.622 HD11 HG13 ' A' ' 35' ' ' ILE . 3.2 tm? -79.24 109.73 13.85 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.803 -0.814 . . . . 54.11 108.803 175.194 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 41.7 p90 -106.0 -13.87 15.35 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.513 -0.475 . . . . 63.32 111.467 -176.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -162.11 149.49 14.12 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.069 0.461 . . . . 31.21 111.62 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.622 HG13 HD11 ' A' ' 32' ' ' LEU . 70.1 mt -126.07 128.12 71.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.659 -0.701 . . . . 72.51 109.681 174.669 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.622 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 81.5 tttt -112.01 105.15 13.47 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.306 -0.406 . . . . 74.53 110.084 179.159 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.696 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 4.4 t -89.64 126.71 42.55 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 108.765 -0.828 . . . . 62.23 108.765 177.379 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.448 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 20.1 t -114.43 73.98 2.91 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 109.883 -0.414 . . . . 73.22 109.883 172.904 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.679 ' HD3' HG12 ' A' ' 37' ' ' VAL . 39.8 Cg_endo -77.52 132.11 11.99 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.094 1.862 . . . . 65.42 112.648 176.377 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.588 ' HB2' ' HB3' ' A' ' 20' ' ' ASP . 50.4 mtpt -60.76 -28.22 68.55 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.535 -0.757 . . . . 70.2 110.316 175.24 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 74.2 m-70 -118.03 94.63 4.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.325 -0.852 . . . . 74.53 108.763 178.026 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.413 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 134.04 -31.22 2.84 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.492 -0.776 . . . . 73.32 111.544 -175.038 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.472 ' HD3' ' HA ' ' A' ' 43' ' ' LYS . 31.5 mmtp 74.23 153.65 0.15 Allowed Pre-proline 0 N--CA 1.469 0.501 0 C-N-CA 123.557 0.743 . . . . 60.21 112.254 177.243 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.696 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 28.3 Cg_endo -62.86 132.52 37.54 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 123.074 2.516 . . . . 74.34 114.2 -173.485 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -140.0 154.55 47.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.456 -0.793 . . . . 72.13 109.884 175.364 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -107.01 136.98 45.95 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-O 120.763 0.316 . . . . 73.42 111.574 -175.709 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.585 HD23 ' HA ' ' A' ' 59' ' ' ARG . 47.7 mt -118.38 107.78 14.25 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.851 -0.613 . . . . 60.14 109.858 171.431 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 47.3 t -95.46 134.92 31.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.628 -0.26 . . . . 61.5 110.398 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ARG . . . . . 0.656 ' HD2' ' HA ' ' A' ' 53' ' ' SER . 16.1 tpp85 -68.7 122.04 17.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.808 0.337 . . . . 75.14 110.123 177.211 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -73.6 158.35 34.95 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.136 -0.483 . . . . 72.23 110.784 179.69 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -53.49 143.55 19.26 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 115.765 -0.652 . . . . 63.14 111.194 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.28 -33.84 5.36 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.772 -0.728 . . . . 73.22 111.99 -178.835 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.656 ' HA ' ' HD2' ' A' ' 49' ' ' ARG . 17.4 t 63.02 38.3 11.06 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-O 121.009 0.433 . . . . 75.13 110.992 178.776 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -76.44 -3.67 38.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.526 0.679 . . . . 73.35 110.815 -178.468 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 111.54 2.53 27.46 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.617 -0.801 . . . . 54.2 111.692 -179.038 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -85.89 134.59 33.89 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.051 0.453 . . . . 73.22 110.497 178.884 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -116.04 144.19 44.45 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.82 -0.627 . . . . 70.45 110.109 176.095 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.2 mm -105.75 105.43 18.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 CA-C-O 121.564 0.697 . . . . 73.22 109.368 176.874 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.719 ' HB2' HG13 ' A' ' 67' ' ' ILE . 24.0 ttt180 -69.56 119.78 14.34 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 114.631 -1.168 . . . . 71.54 109.461 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.5 t -63.05 -18.56 63.49 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.396 0.617 . . . . 71.22 110.404 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.696 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 24.7 t70 -73.96 -28.42 61.48 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.449 -0.796 . . . . 74.5 110.489 175.61 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -142.79 68.5 19.09 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-N 115.424 -0.807 . . . . 65.14 109.191 -177.328 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_exo -71.06 -11.5 29.18 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 123.256 2.637 . . . . 53.33 112.998 -171.757 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -95.47 4.76 52.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.493 0.663 . . . . 72.51 109.758 -178.804 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -131.96 137.35 47.88 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.6 -0.727 . . . . 63.33 110.753 -178.038 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.488 ' N ' HD12 ' A' ' 66' ' ' LEU . 4.5 mp -85.02 131.44 34.46 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.049 -0.523 . . . . 61.03 109.65 179.678 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.719 HG13 ' HB2' ' A' ' 59' ' ' ARG . 40.6 mm -89.71 129.1 47.95 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-O 120.933 0.397 . . . . 71.51 111.305 -174.395 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -76.28 176.59 9.86 Favored 'Trans proline' 0 N--CA 1.459 -0.505 0 C-N-CA 122.862 2.374 . . . . 71.44 112.514 178.15 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' GLN . . . . . 0.685 ' HA ' HG12 ' A' ' 72' ' ' ILE . 45.1 tt0 -79.41 -31.62 42.72 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.61 -0.723 . . . . 64.33 112.184 -170.653 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 28.3 p90 -69.42 -19.39 63.8 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 120.184 -0.607 . . . . 71.53 110.384 178.421 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -84.84 -35.45 22.26 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.852 -0.613 . . . . 70.1 110.179 178.789 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.685 HG12 ' HA ' ' A' ' 69' ' ' GLN . 41.2 pt -76.24 -21.79 15.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.116 0 CA-C-O 120.965 0.412 . . . . 64.44 110.878 179.843 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 31.4 m-85 -103.63 28.47 6.52 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.077 -0.511 . . . . 74.12 110.926 176.852 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 11.1 t -84.93 45.22 1.14 Allowed 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.864 0.84 . . . . 71.22 109.616 178.352 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 11.3 m0 . . . . . 0 C--N 1.324 -0.521 0 CA-C-N 115.124 -0.944 . . . . 73.33 110.729 -178.83 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 6.3 p . . . . . 0 N--CA 1.452 -0.358 0 CA-C-O 121.041 0.448 . . . . 74.42 109.998 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 128.05 76.89 0.21 Allowed Glycine 0 N--CA 1.445 -0.701 0 N-CA-C 110.891 -0.884 . . . . 74.05 110.891 -175.555 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -110.16 105.77 57.47 Favored Pre-proline 0 C--N 1.32 -0.703 0 N-CA-C 109.138 -0.69 . . . . 71.04 109.138 -175.371 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.745 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 46.1 Cg_endo -82.23 86.35 1.54 Allowed 'Trans proline' 0 N--CA 1.439 -1.734 0 C-N-CA 121.898 1.732 . . . . 70.23 110.959 -178.021 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -101.81 155.63 18.02 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 114.258 -1.337 . . . . 74.01 109.92 -175.811 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.603 ' HA ' ' O ' ' B' ' 125' ' ' GLU . 7.6 p -117.65 130.71 72.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.474 0.655 . . . . 75.43 111.104 -177.707 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 52.0 m -104.7 122.05 44.85 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.401 -0.818 . . . . 65.42 109.996 178.636 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 47.3 mt -87.09 108.03 17.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 116.145 -0.479 . . . . 54.52 111.443 -174.783 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -101.15 170.73 8.06 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.469 -0.567 . . . . 54.25 109.469 175.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -142.76 138.76 30.7 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.782 0.325 . . . . 75.11 110.786 175.532 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -135.52 104.58 5.87 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.638 -0.71 . . . . 75.11 109.754 176.872 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.62 -110.14 3.31 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.908 -0.663 . . . . 51.11 111.898 -177.263 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 120' ' ' ASP . . . . . 0.615 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 9.5 m-20 -97.06 -19.33 18.79 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.705 0.288 . . . . 74.2 110.977 -179.147 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.533 ' HB3' ' HA ' ' B' ' 139' ' ' PRO . 49.3 pttt -100.88 141.75 33.33 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.6 0.714 . . . . 71.25 112.503 -170.088 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 122' ' ' THR . . . . . 0.594 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 47.9 m -91.77 138.43 31.56 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 114.828 -1.078 . . . . 73.41 109.646 176.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 65.9 mt -124.89 106.56 16.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 120.984 0.421 . . . . 71.43 110.276 -178.709 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.56 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 67.1 mt-30 -96.91 117.19 30.57 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.918 0.39 . . . . 64.25 111.092 -176.081 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 125' ' ' GLU . . . . . 0.603 ' O ' ' HA ' ' B' ' 113' ' ' VAL . 43.2 mt-10 -83.02 114.15 21.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.736 -0.665 . . . . 74.23 110.947 179.299 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 126' ' ' TYR . . . . . 0.444 ' HB2' ' O ' ' B' ' 134' ' ' ALA . 41.2 m-85 -92.75 97.33 10.71 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.493 -0.558 . . . . 53.43 109.493 170.815 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 127' ' ' ARG . . . . . 0.439 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 21.8 mtm105 -121.08 127.41 51.63 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.803 -0.635 . . . . 74.04 110.071 179.375 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.745 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 6.0 p -87.97 -37.5 10.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.097 0.475 . . . . 71.54 110.834 -176.541 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -160.27 62.86 0.33 Allowed 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.292 0.568 . . . . 72.23 109.69 -178.464 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.0 -26.57 6.63 Favored Glycine 0 N--CA 1.446 -0.664 0 CA-C-N 115.404 -0.816 . . . . 62.31 112.734 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -99.12 130.81 45.46 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.014 0.435 . . . . 72.13 110.56 -175.342 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.783 HD11 HG13 ' B' ' 135' ' ' ILE . 3.2 tm? -78.06 118.62 20.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.263 -0.881 . . . . 72.41 109.615 178.95 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 133' ' ' TYR . . . . . 0.415 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 51.4 p90 -109.3 -22.27 12.14 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 120.748 -0.381 . . . . 72.34 111.34 178.24 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 134' ' ' ALA . . . . . 0.444 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -156.14 147.81 22.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.39 . . . . 54.25 111.12 179.517 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.783 HG13 HD11 ' B' ' 132' ' ' LEU . 75.4 mt -125.47 130.68 72.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.152 -0.476 . . . . 55.23 109.723 175.976 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.56 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 46.6 tttp -106.46 106.82 17.52 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.383 -0.599 . . . . 64.14 109.383 174.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.685 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.0 t -91.51 136.05 25.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 N-CA-C 109.024 -0.732 . . . . 70.34 109.024 178.583 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.594 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 22.0 t -121.85 73.33 34.29 Favored Pre-proline 0 C--N 1.318 -0.762 0 N-CA-C 109.483 -0.562 . . . . 75.11 109.483 173.298 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.576 ' HD3' HG12 ' B' ' 137' ' ' VAL . 53.2 Cg_endo -78.52 134.64 12.57 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 122.183 1.922 . . . . 72.23 112.931 176.601 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 140' ' ' LYS . . . . . 0.615 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 30.8 mtpp -62.94 -30.93 71.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.638 0.732 . . . . 71.43 109.547 174.222 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 72.8 m-70 -112.99 89.89 3.2 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.043 -0.981 . . . . 75.12 109.392 176.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 138.7 -21.52 3.04 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.621 -0.8 . . . . 75.3 112.328 -178.207 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 33.4 mmtp 69.59 150.8 0.13 Allowed Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 123.2 0.6 . . . . 65.32 111.524 178.484 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.685 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 19.3 Cg_endo -59.8 140.3 92.6 Favored 'Trans proline' 0 C--O 1.235 0.336 0 C-N-CA 122.575 2.183 . . . . 75.54 113.278 -177.244 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 38.9 p90 -155.33 151.06 27.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.924 -0.58 . . . . 74.31 110.307 178.441 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.522 ' HB2' ' HB2' ' B' ' 160' ' ' SER . 87.2 m-85 -95.35 139.32 31.82 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.171 -0.468 . . . . 75.14 111.166 179.453 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.419 ' HB3' ' CD2' ' B' ' 157' ' ' PHE . 39.5 mt -116.27 110.29 18.55 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.634 -0.712 . . . . 73.32 109.693 170.316 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 41.7 t -95.23 132.91 37.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.579 -0.282 . . . . 70.45 110.953 -178.622 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 149' ' ' ARG . . . . . 0.415 ' HG2' HH11 ' B' ' 149' ' ' ARG . 17.0 tpp85 -70.46 113.63 7.77 Favored 'General case' 0 N--CA 1.452 -0.338 0 N-CA-C 109.895 -0.409 . . . . 74.04 109.895 175.879 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.65 155.44 35.91 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 116.094 -0.503 . . . . 74.24 111.202 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 151' ' ' ASP . . . . . 0.516 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 3.4 p-10 -56.9 138.79 53.31 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.551 -0.749 . . . . 72.0 112.132 -177.418 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 93.74 -11.24 71.46 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.213 -0.903 . . . . 62.13 112.648 176.705 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 2.3 t 57.58 50.33 11.19 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-O 121.692 0.758 . . . . 62.01 109.391 -177.618 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -73.51 -8.45 55.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 114.885 -1.052 . . . . 72.45 111.876 -175.037 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 90.96 18.32 47.66 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.5 -0.857 . . . . 33.12 111.175 -174.089 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -119.88 137.47 54.0 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.914 -0.643 . . . . 73.4 110.058 -178.322 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 157' ' ' PHE . . . . . 0.419 ' CD2' ' HB3' ' B' ' 147' ' ' LEU . 42.3 m-85 -113.56 159.93 19.07 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.167 -0.469 . . . . 75.44 110.166 177.666 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 158' ' ' ILE . . . . . 0.693 HD11 HD23 ' B' ' 166' ' ' LEU . 45.7 mm -121.9 119.07 57.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 109.442 -0.577 . . . . 75.31 109.442 175.061 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.418 ' HB3' ' H ' ' B' ' 161' ' ' ASP . 36.2 mtt180 -71.14 140.16 50.49 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.213 -0.448 . . . . 44.23 110.09 176.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 160' ' ' SER . . . . . 0.522 ' HB2' ' HB2' ' B' ' 146' ' ' PHE . 7.4 t -80.82 1.06 32.21 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.617 -0.883 . . . . 64.55 108.617 169.702 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 161' ' ' ASP . . . . . 0.418 ' H ' ' HB3' ' B' ' 159' ' ' ARG . 0.2 OUTLIER -98.53 -23.12 15.65 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.561 -1.199 . . . . 73.22 109.884 174.567 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -144.71 67.83 14.24 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 115.099 -0.955 . . . . 72.13 109.559 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -75.34 -12.97 20.86 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 123.162 2.575 . . . . 73.32 113.346 -173.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -87.89 -12.5 44.6 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.581 0.705 . . . . 65.52 109.504 178.418 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 48.8 mtpt -105.46 170.45 7.88 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.406 -0.815 . . . . 71.41 111.459 -177.779 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 166' ' ' LEU . . . . . 0.693 HD23 HD11 ' B' ' 158' ' ' ILE . 17.8 mt -117.48 125.46 50.93 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.423 -0.954 . . . . 71.22 108.423 177.21 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 167' ' ' ILE . . . . . 0.542 ' CG2' ' HB3' ' B' ' 171' ' ' GLU . 36.5 mm -80.95 116.37 62.01 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-O 121.275 0.56 . . . . 72.32 111.835 -169.798 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 168' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.53 -179.46 2.82 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.58 2.853 . . . . 74.24 112.781 -178.227 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 169' ' ' GLN . . . . . 0.804 ' HA ' HG12 ' B' ' 172' ' ' ILE . 28.3 tt0 -79.23 -32.35 43.87 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.07 -0.514 . . . . 52.41 111.386 -170.367 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 11.4 p90 -68.21 -17.09 64.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.088 0.471 . . . . 73.14 110.231 178.09 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.542 ' HB3' ' CG2' ' B' ' 167' ' ' ILE . 1.2 tm-20 -91.12 -43.69 9.73 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.577 -0.738 . . . . 62.13 110.211 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.804 HG12 ' HA ' ' B' ' 169' ' ' GLN . 44.1 pt -68.61 -25.35 30.62 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.168 -0.469 . . . . 55.44 111.06 -179.395 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 173' ' ' PHE . . . . . 0.42 ' C ' ' H ' ' B' ' 175' ' ' TRP . 30.9 m-85 -111.14 30.45 6.88 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.18 0.514 . . . . 72.34 110.563 176.617 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 25.1 t -79.03 22.44 0.39 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.866 -0.607 . . . . 73.04 110.652 178.558 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 175' ' ' TRP . . . . . 0.42 ' H ' ' C ' ' B' ' 173' ' ' PHE . 12.9 m95 . . . . . 0 C--O 1.248 1.018 0 CA-C-O 118.271 -0.871 . . . . 73.41 110.509 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 20.3 m . . . . . 0 N--CA 1.453 -0.319 0 N-CA-C 109.567 -0.531 . . . . 25.51 109.567 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.456 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 95.42 70.19 1.06 Allowed Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 110.53 -1.028 . . . . 74.5 110.53 -173.129 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLU . . . . . 0.415 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 11.9 pt-20 -98.48 102.65 15.12 Favored Pre-proline 0 C--N 1.325 -0.482 0 N-CA-C 109.348 -0.612 . . . . 64.42 109.348 -177.321 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.554 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 53.4 Cg_endo -91.14 97.24 0.23 Allowed 'Trans proline' 0 N--CA 1.441 -1.571 0 C-N-CA 122.572 2.181 . . . . 64.0 112.135 -175.008 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -103.05 114.18 28.27 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-N 115.365 -0.834 . . . . 74.11 109.859 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.634 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 9.1 p -77.1 127.12 38.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 CA-C-N 115.681 -0.69 . . . . 72.53 109.97 179.478 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.643 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 24.5 m -84.22 103.1 13.14 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.848 -0.614 . . . . 71.24 110.078 -178.063 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 65.5 mt -90.84 107.95 19.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.06 -0.518 . . . . 71.53 110.571 -176.055 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.507 ' HG2' ' O ' ' A' ' 23' ' ' ILE . 12.7 ptm180 -121.96 174.4 6.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.871 -0.604 . . . . 75.3 109.786 179.066 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -133.08 104.38 6.49 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 116.223 -0.444 . . . . 72.54 110.089 -177.567 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 58.5 mm-40 -103.49 80.1 1.77 Allowed 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 120.969 0.414 . . . . 75.1 110.205 -178.814 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 78.35 -106.16 2.27 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.797 -0.716 . . . . 54.42 112.428 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.859 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 6.9 m-20 -108.63 34.88 3.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.792 0.329 . . . . 73.11 110.831 -178.249 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.844 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 20.5 pttm -154.2 124.04 6.73 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.157 0.503 . . . . 75.13 111.46 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.446 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 62.3 m -82.02 105.89 13.49 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.624 -0.716 . . . . 74.34 109.36 174.036 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.599 HG12 HG13 ' A' ' 37' ' ' VAL . 61.1 mt -97.59 113.68 32.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.046 0.45 . . . . 54.42 110.687 -176.484 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.687 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 65.7 mt-30 -100.58 109.19 21.26 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.738 -0.664 . . . . 71.23 110.329 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.643 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.1 mt-10 -91.69 104.25 16.74 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.064 -0.517 . . . . 74.33 110.853 -178.912 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.539 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 54.0 m-85 -73.26 106.73 5.22 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.174 -0.467 . . . . 74.23 110.753 179.463 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.454 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 59.9 mtt180 -129.24 133.7 47.64 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.552 -0.536 . . . . 74.23 109.552 177.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 6.4 p -104.34 -41.47 6.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 121.272 0.558 . . . . 55.44 110.721 -179.105 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 54.5 m-20 -140.94 56.83 1.56 Allowed 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.708 -0.678 . . . . 71.43 109.626 178.463 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.21 -32.67 4.04 Favored Glycine 0 N--CA 1.451 -0.322 0 CA-C-N 115.385 -0.825 . . . . 72.43 113.242 177.614 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -90.32 132.2 35.69 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.001 0.429 . . . . 74.41 110.654 -174.092 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.555 HD13 ' HB3' ' A' ' 25' ' ' GLU . 33.2 tp -77.92 114.3 16.64 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.395 -0.82 . . . . 63.43 110.599 179.306 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' TYR . . . . . 0.527 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 35.4 p90 -106.34 -6.64 18.18 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.774 -0.37 . . . . 62.32 111.809 -178.376 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -171.84 142.91 1.57 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.842 0.353 . . . . 74.44 111.256 -178.747 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.459 HD12 HD23 ' A' ' 47' ' ' LEU . 61.9 mt -117.77 127.4 75.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.249 -0.432 . . . . 71.02 110.179 176.089 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.687 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.8 tttt -111.65 103.48 11.79 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 109.446 -0.576 . . . . 72.42 109.446 175.036 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.731 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 3.7 t -96.77 134.52 34.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 N-CA-C 109.309 -0.626 . . . . 53.31 109.309 -178.551 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.649 HG22 ' HB3' ' A' ' 44' ' ' PRO . 21.7 t -114.22 74.21 2.8 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 109.317 -0.623 . . . . 75.3 109.317 170.759 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.465 ' HD3' HG12 ' A' ' 37' ' ' VAL . 42.4 Cg_endo -74.0 142.81 31.79 Favored 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 122.039 1.826 . . . . 73.12 112.764 179.118 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.859 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 61.0 mtpt -64.39 -17.13 63.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.134 -0.939 . . . . 54.12 110.913 176.72 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -128.99 88.3 2.69 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.662 -0.699 . . . . 74.54 110.215 -178.643 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.403 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 135.23 -16.06 4.18 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.288 -0.958 . . . . 74.43 113.203 179.202 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.541 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 99.5 mttt 71.79 160.03 0.16 Allowed Pre-proline 0 N--CA 1.472 0.626 0 C-N-CA 122.755 0.422 . . . . 74.32 111.469 179.507 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.731 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 26.2 Cg_endo -63.57 141.62 80.82 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 122.491 2.127 . . . . 64.34 113.716 -176.48 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -145.71 155.23 42.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.717 -0.674 . . . . 75.13 110.212 177.671 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -99.72 132.91 44.76 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.305 -0.407 . . . . 74.12 110.994 178.144 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.459 HD23 HD12 ' A' ' 35' ' ' ILE . 40.1 tp -121.07 98.81 6.16 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.686 -0.688 . . . . 64.32 109.345 176.171 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 25.0 t -87.98 146.99 5.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.396 -0.366 . . . . 62.25 111.358 -172.205 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 10.0 tpt180 -81.23 122.92 28.01 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.848 -0.427 . . . . 73.32 109.848 177.659 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.426 ' HB3' ' OD1' ' A' ' 56' ' ' ASN . . . -74.86 161.94 29.1 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.208 -0.451 . . . . 73.23 110.862 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -66.78 145.54 55.4 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.135 0.493 . . . . 72.44 110.957 -177.6 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 88.67 -25.17 9.94 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.863 -0.608 . . . . 64.54 112.487 177.6 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 57.2 p 47.75 43.9 17.29 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.459 0.704 . . . . 74.42 112.058 -179.737 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -68.0 -33.0 73.79 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.453 0.644 . . . . 72.23 110.919 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 147.99 41.58 0.04 OUTLIER Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.582 -1.007 . . . . 61.41 110.582 -178.393 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ASN . . . . . 0.426 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 11.5 p30 -140.52 152.65 45.73 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.18 0.514 . . . . 75.05 111.078 -172.805 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 36.3 m-85 -134.23 157.5 46.11 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.511 -0.768 . . . . 74.01 109.566 175.444 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.809 HD11 HD23 ' A' ' 66' ' ' LEU . 45.2 mm -115.23 108.07 24.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.253 0.549 . . . . 62.25 109.668 176.324 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.592 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 50.2 ttp180 -89.31 133.37 34.51 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.811 -0.631 . . . . 62.44 109.952 -177.057 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.1 p -58.21 -25.57 61.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.15 0.5 . . . . 74.22 111.168 178.644 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.592 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 0.6 OUTLIER -59.55 -39.13 83.0 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.508 -0.769 . . . . 75.23 111.379 174.275 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 21.5 tp60 -147.91 79.68 9.16 Favored Pre-proline 0 C--N 1.326 -0.454 0 N-CA-C 109.827 -0.434 . . . . 33.55 109.827 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -73.8 -8.0 20.81 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.381 2.054 . . . . 75.23 111.52 179.553 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.05 3.06 36.24 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.118 -0.946 . . . . 62.43 110.084 178.382 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -139.37 140.06 37.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.043 -0.526 . . . . 72.31 111.022 -174.291 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.809 HD23 HD11 ' A' ' 58' ' ' ILE . 38.1 mt -82.08 113.1 19.72 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 108.581 -0.896 . . . . 75.03 108.581 171.807 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.508 HG13 ' HB2' ' A' ' 59' ' ' ARG . 50.1 mm -65.34 122.76 81.78 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 116.271 -0.422 . . . . 73.11 110.964 -175.566 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.496 ' O ' HG23 ' A' ' 72' ' ' ILE . 72.8 Cg_endo -73.27 175.12 11.0 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 123.106 2.537 . . . . 72.1 113.014 -177.695 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' GLN . . . . . 0.726 ' HA ' HG12 ' A' ' 72' ' ' ILE . 6.7 tt0 -74.65 -29.5 61.28 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.693 -0.685 . . . . 53.02 112.323 -168.07 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 33.6 p90 -74.45 -16.23 60.87 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.598 -0.441 . . . . 74.51 110.23 178.53 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.476 ' HA ' ' HB2' ' A' ' 74' ' ' SER . 8.3 mm-40 -100.0 -29.29 12.63 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.727 -0.67 . . . . 72.4 111.615 -178.86 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.726 HG12 ' HA ' ' A' ' 69' ' ' GLN . 42.0 pt -68.22 -29.44 44.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.148 0.499 . . . . 73.14 110.595 177.188 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 48.5 m-85 -118.82 38.69 3.71 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.735 -0.666 . . . . 70.2 109.267 174.27 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.476 ' HB2' ' HA ' ' A' ' 71' ' ' GLU . 6.1 t -62.49 -36.38 82.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.35 -0.841 . . . . 74.24 110.461 -178.758 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' TRP . . . . . 0.844 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 6.1 p-90 . . . . . 0 C--N 1.326 -0.443 0 CA-C-N 115.93 -0.577 . . . . 65.32 110.948 177.289 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 35.0 m . . . . . 0 N--CA 1.454 -0.251 0 CA-C-O 121.605 0.717 . . . . 74.44 109.128 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 109' ' ' GLY . . . . . 0.403 ' O ' ' HD3' ' B' ' 111' ' ' PRO . . . 140.07 78.08 0.06 OUTLIER Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 109.965 -1.254 . . . . 42.13 109.965 -172.108 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -109.72 94.77 17.71 Favored Pre-proline 0 C--N 1.322 -0.6 0 N-CA-C 109.693 -0.484 . . . . 64.32 109.693 -172.978 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.57 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 54.9 Cg_endo -77.36 79.01 3.29 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 C-N-CA 121.538 1.492 . . . . 72.23 111.031 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -100.24 156.37 17.26 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 114.747 -1.115 . . . . 74.4 109.184 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.716 HG21 ' HB3' ' B' ' 124' ' ' GLN . 8.8 p -112.94 127.76 70.02 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.812 0 CA-C-O 121.72 0.771 . . . . 74.11 111.738 -175.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 114' ' ' THR . . . . . 0.54 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.3 m -92.01 106.94 18.85 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.022 -0.99 . . . . 75.13 109.529 175.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.8 mt -90.8 115.5 30.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 120.699 0.285 . . . . 54.34 111.274 -175.234 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 41.4 mtm180 -115.39 165.81 12.56 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.178 -0.465 . . . . 72.14 110.712 175.126 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 96.8 mt-30 -129.44 108.79 10.55 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.197 -0.456 . . . . 74.3 110.18 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 118' ' ' GLU . . . . . 0.463 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 45.8 mm-40 -108.4 89.88 3.13 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.551 -0.536 . . . . 55.41 109.551 -178.441 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 83.68 -102.95 2.5 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 110.929 -0.869 . . . . 72.13 110.929 -172.75 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 120' ' ' ASP . . . . . 0.58 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 30.8 m-20 -117.73 -18.17 9.69 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.756 0.312 . . . . 74.23 110.784 175.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.463 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 23.4 pttm -78.36 126.73 31.19 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.257 0.551 . . . . 71.11 110.861 -175.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 122' ' ' THR . . . . . 0.585 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 22.8 m -84.72 106.34 16.19 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.502 -0.772 . . . . 72.43 109.468 178.085 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 123' ' ' ILE . . . . . 0.449 HG12 HG13 ' B' ' 137' ' ' VAL . 28.4 mt -101.42 110.37 28.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 121.374 0.607 . . . . 74.32 110.631 -174.685 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.716 ' HB3' HG21 ' B' ' 113' ' ' VAL . 69.0 mt-30 -102.29 111.54 23.87 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.354 -0.839 . . . . 73.15 111.144 -175.511 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 125' ' ' GLU . . . . . 0.541 ' HB3' HD13 ' B' ' 132' ' ' LEU . 43.0 mt-10 -89.79 107.84 19.34 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.13 -0.486 . . . . 61.34 110.948 179.764 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 126' ' ' TYR . . . . . 0.457 ' HE1' ' HB2' ' B' ' 136' ' ' LYS . 58.3 m-85 -84.44 110.9 19.0 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.767 0.318 . . . . 74.3 110.338 177.553 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 69.6 mtt180 -123.42 116.13 22.73 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.844 0.354 . . . . 72.42 110.31 -178.803 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.57 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.4 p -82.83 -45.71 19.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.065 -0.516 . . . . 61.53 111.904 -177.434 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -158.99 74.08 0.63 Allowed 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 120.742 -0.383 . . . . 74.24 110.319 -174.243 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 64.2 23.81 68.36 Favored Glycine 0 C--N 1.33 0.232 0 C-N-CA 121.028 -0.606 . . . . 41.24 112.065 -178.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -145.91 124.93 12.78 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.876 -0.416 . . . . 70.04 109.876 -179.236 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.541 HD13 ' HB3' ' B' ' 125' ' ' GLU . 50.0 tp -83.06 113.01 20.31 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.791 -0.64 . . . . 72.1 109.569 175.781 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -103.12 -13.73 16.69 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.32 -0.552 . . . . 62.0 111.728 -175.793 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -164.94 139.81 5.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.087 0.47 . . . . 74.5 111.397 -175.716 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.405 ' CG1' HD21 ' B' ' 132' ' ' LEU . 63.6 mt -118.02 117.85 56.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.693 -0.685 . . . . 63.54 109.846 175.882 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.618 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 81.3 tttt -93.62 103.92 16.06 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.184 -0.673 . . . . 63.33 109.184 175.481 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.65 HG12 ' HD3' ' B' ' 139' ' ' PRO . 3.5 t -89.12 126.51 42.12 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 N-CA-C 108.785 -0.82 . . . . 62.43 108.785 177.299 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.585 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.5 t -113.67 74.47 2.38 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 109.543 -0.54 . . . . 61.42 109.543 171.647 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.65 ' HD3' HG12 ' B' ' 137' ' ' VAL . 43.3 Cg_endo -77.17 130.01 10.85 Favored 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.105 1.87 . . . . 75.0 111.892 175.815 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 140' ' ' LYS . . . . . 0.58 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 59.2 mtpt -58.36 -38.58 77.53 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.661 -0.699 . . . . 62.14 109.776 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 70.3 m-70 -111.81 90.32 3.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.282 -0.872 . . . . 71.02 109.385 175.163 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 142' ' ' GLY . . . . . 0.418 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 151.98 -22.71 0.89 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.54 -0.838 . . . . 53.11 112.704 -178.587 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 143' ' ' LYS . . . . . 0.418 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 95.2 mttt 76.48 144.65 0.1 Allowed Pre-proline 0 N--CA 1.472 0.638 0 C-N-CA 123.419 0.688 . . . . 75.34 111.258 179.177 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.613 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 55.5 Cg_endo -70.57 139.05 36.56 Favored 'Trans proline' 0 N--CA 1.463 -0.285 0 C-N-CA 122.865 2.376 . . . . 74.43 112.983 -177.059 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 45.4 p90 -152.39 160.03 43.34 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.895 -0.593 . . . . 75.32 110.322 179.114 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.666 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 96.5 m-85 -100.59 133.29 45.26 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.192 -0.458 . . . . 71.14 109.959 177.786 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.502 ' HG ' ' HB3' ' B' ' 157' ' ' PHE . 14.1 tp -115.46 100.84 8.37 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.386 -0.598 . . . . 72.2 109.386 175.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 49.1 t -92.55 140.56 16.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 116.061 -0.518 . . . . 72.52 111.347 -173.185 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -80.37 116.37 20.4 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.549 -0.296 . . . . 63.53 110.261 177.376 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.56 157.55 32.04 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-N 116.218 -0.447 . . . . 71.32 111.201 -179.423 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 151' ' ' ASP . . . . . 0.539 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 3.8 p-10 -57.45 143.48 40.28 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.96 -0.564 . . . . 74.33 110.855 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.43 -33.73 4.03 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.773 -0.727 . . . . 75.11 111.373 -175.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 50.8 m 57.3 33.17 22.91 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 123.008 0.523 . . . . 54.12 111.919 177.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -53.81 -68.77 0.15 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 115.712 -0.676 . . . . 72.41 111.145 -178.707 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . -173.43 30.58 0.1 OUTLIER Glycine 0 CA--C 1.505 -0.579 0 C-N-CA 120.338 -0.934 . . . . 73.03 112.456 178.601 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 79.5 m-20 -133.32 145.83 50.78 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.784 0.326 . . . . 52.34 110.799 -177.166 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 157' ' ' PHE . . . . . 0.502 ' HB3' ' HG ' ' B' ' 147' ' ' LEU . 32.6 m-85 -118.34 157.03 27.87 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.875 -0.602 . . . . 73.33 110.034 176.201 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.1 mm -113.91 122.66 68.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 109.676 -0.49 . . . . 74.43 109.676 178.499 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 159' ' ' ARG . . . . . . . . . . . . . 44.8 ttp180 -86.36 135.92 33.33 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.028 -0.36 . . . . 73.24 110.028 -178.386 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 160' ' ' SER . . . . . 0.666 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 23.5 p -56.97 -34.78 68.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.064 0.459 . . . . 65.22 111.118 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -69.39 -37.93 77.75 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.448 -0.796 . . . . 70.31 111.346 177.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 8.6 tp60 -134.03 83.6 45.35 Favored Pre-proline 0 C--N 1.324 -0.527 0 C-N-CA 121.04 -0.264 . . . . 74.51 110.715 -176.297 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -77.59 0.27 9.96 Favored 'Trans proline' 0 C--O 1.234 0.282 0 C-N-CA 122.577 2.184 . . . . 60.13 111.616 177.15 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -79.19 -33.31 43.99 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.178 -0.919 . . . . 43.13 110.768 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -116.64 138.13 51.67 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.857 -0.61 . . . . 70.34 111.173 -172.528 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.5 mp -85.27 121.31 27.83 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 108.795 -0.817 . . . . 75.01 108.795 175.083 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 50.3 mm -71.24 117.7 59.16 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 116.129 -0.487 . . . . 74.42 109.778 -177.928 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.521 ' O ' HG23 ' B' ' 172' ' ' ILE . 59.6 Cg_endo -70.39 173.61 11.28 Favored 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 122.843 2.362 . . . . 73.52 113.008 -175.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 169' ' ' GLN . . . . . 0.449 ' HA ' HG12 ' B' ' 172' ' ' ILE . 5.4 tt0 -74.95 -17.66 60.51 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.524 -0.762 . . . . 65.35 112.224 -168.156 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 42.4 p90 -90.24 -10.1 45.55 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.122 0.487 . . . . 74.31 110.013 176.374 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.579 ' O ' ' HB2' ' B' ' 174' ' ' SER . 19.6 mm-40 -109.42 -12.63 14.7 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.736 -0.665 . . . . 70.44 111.708 -178.282 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.521 HG23 ' O ' ' B' ' 168' ' ' PRO . 26.1 pt -72.7 -12.35 15.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.254 0.549 . . . . 71.42 110.435 176.177 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -115.9 32.76 5.89 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.442 -0.799 . . . . 62.14 109.148 175.094 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 174' ' ' SER . . . . . 0.579 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 3.0 t -66.97 -25.22 66.22 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 114.915 -1.039 . . . . 72.51 110.575 -177.657 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 7.1 p-90 . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.295 -0.86 . . . . 75.23 110.788 -179.936 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.7 p . . . . . 0 N--CA 1.454 -0.265 0 CA-C-O 121.269 0.557 . . . . 72.43 110.513 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 136.63 106.28 0.8 Allowed Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 111.12 -0.792 . . . . 53.33 111.12 -174.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -124.3 97.29 40.29 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-O 121.357 0.599 . . . . 44.22 110.113 -175.301 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.599 ' HA ' ' O ' ' A' ' 27' ' ' ARG . 9.9 Cg_endo -85.17 93.97 0.66 Allowed 'Trans proline' 0 N--CA 1.444 -1.421 0 C-N-CA 122.867 2.378 . . . . 71.24 111.817 -178.102 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -116.72 153.96 31.45 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.952 -1.022 . . . . 61.14 109.373 -179.276 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.503 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 13.4 p -119.42 130.35 74.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.497 0.665 . . . . 74.42 111.639 -177.782 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.528 ' O ' ' HA ' ' A' ' 24' ' ' GLN . 9.3 m -90.68 111.85 23.36 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.369 -0.832 . . . . 71.31 109.693 176.372 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.429 HG12 ' HG2' ' A' ' 24' ' ' GLN . 60.9 mt -106.74 107.33 22.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.791 0.329 . . . . 63.54 110.865 -176.23 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -125.51 166.02 17.41 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.178 -0.465 . . . . 74.21 110.594 178.252 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -118.52 108.63 15.22 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.768 0.318 . . . . 72.53 110.761 -179.322 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.453 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 25.7 mm-40 -108.42 99.54 8.92 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.162 -0.472 . . . . 72.44 109.97 178.946 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 71.09 -114.27 5.15 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.786 -0.721 . . . . 42.4 112.298 -179.611 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ASP . . . . . 0.409 ' HB3' ' HD2' ' A' ' 40' ' ' LYS . 13.6 m-20 -106.43 13.33 28.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.771 0.32 . . . . 61.32 110.476 -178.735 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.453 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 14.2 ptmt -133.29 123.18 25.03 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.464 0.649 . . . . 74.21 111.949 -176.049 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' THR . . . . . 0.441 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 25.6 m -83.07 115.31 21.81 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.36 -0.836 . . . . 75.25 109.675 176.517 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 68.3 mt -100.77 120.43 50.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 120.716 0.293 . . . . 53.13 110.65 -175.885 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLN . . . . . 0.528 ' HA ' ' O ' ' A' ' 14' ' ' THR . 63.5 mt-30 -112.05 111.77 22.92 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.102 -0.499 . . . . 54.53 110.723 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -90.08 109.59 20.63 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.222 -0.444 . . . . 75.24 110.312 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 73.4 m-85 -87.68 110.55 20.5 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.763 0.315 . . . . 74.41 110.374 177.854 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ARG . . . . . 0.599 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 65.5 mtt180 -116.91 139.91 50.08 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.508 -0.553 . . . . 71.35 109.508 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.581 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 14.2 p -112.83 -11.96 11.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.509 0.671 . . . . 54.13 111.002 -177.641 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -166.77 38.4 0.04 OUTLIER 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 108.757 -0.831 . . . . 75.42 108.757 -177.918 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 85.17 -28.73 4.53 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.308 -0.86 . . . . 72.22 111.824 -174.926 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.418 ' CD2' HG21 ' B' ' 128' ' ' VAL . 15.4 t80 -88.24 125.85 34.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.106 0.479 . . . . 71.42 110.29 -177.055 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.662 HD11 HG13 ' A' ' 35' ' ' ILE . 3.3 tm? -68.24 134.27 50.15 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.201 -0.909 . . . . 74.21 110.141 178.74 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' TYR . . . . . 0.504 ' CE1' ' HB ' ' A' ' 28' ' ' VAL . 53.3 p90 -128.55 -24.56 3.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.594 -0.276 . . . . 70.22 111.584 176.275 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -149.54 139.82 22.26 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.815 0.34 . . . . 33.32 110.895 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.662 HG13 HD11 ' A' ' 32' ' ' LEU . 78.4 mt -122.72 122.35 65.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 116.17 -0.468 . . . . 70.44 110.239 178.07 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.512 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.4 tttt -101.18 102.05 12.89 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.406 -0.591 . . . . 70.14 109.406 174.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.572 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.7 p -99.39 124.44 52.71 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.98 0 CA-C-O 121.163 0.506 . . . . 64.35 110.005 176.485 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.633 HG22 ' HB3' ' A' ' 44' ' ' PRO . 40.0 t -106.91 85.01 1.72 Allowed Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 115.096 -0.956 . . . . 71.12 109.873 179.199 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.572 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 85.4 Cg_endo -91.08 144.01 3.33 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 122.762 2.308 . . . . 64.34 112.41 179.206 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' LYS . . . . . 0.409 ' HD2' ' HB3' ' A' ' 20' ' ' ASP . 97.0 mttt -60.46 -27.02 67.21 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.186 0.517 . . . . 71.51 110.128 173.784 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 6.5 m-70 -118.99 85.4 2.36 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.568 -0.742 . . . . 74.43 109.947 -174.203 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 139.15 -18.76 3.1 Favored Glycine 0 N--CA 1.449 -0.444 0 CA-C-N 115.876 -0.602 . . . . 71.01 111.982 -176.373 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 42.5 mtpt 69.4 150.86 0.13 Allowed Pre-proline 0 N--CA 1.469 0.48 0 C-N-CA 123.727 0.811 . . . . 61.32 112.235 -179.035 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.633 ' HB3' HG22 ' A' ' 38' ' ' VAL . 16.0 Cg_endo -59.7 123.64 13.71 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.878 2.385 . . . . 74.15 112.474 -179.647 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' TYR . . . . . 0.523 ' CE1' HG13 ' A' ' 37' ' ' VAL . 16.4 p90 -142.28 151.18 41.77 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.865 -0.607 . . . . 74.14 110.258 179.551 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -90.74 125.0 35.55 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.17 -0.468 . . . . 72.3 109.981 176.085 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.406 HD11 HG13 ' A' ' 67' ' ' ILE . 18.9 tp -103.34 100.91 10.81 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 108.42 -0.956 . . . . 73.4 108.42 174.502 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.3 t -90.75 132.27 35.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.979 -0.555 . . . . 70.12 111.029 -173.675 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -86.04 121.16 28.26 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.069 -0.715 . . . . 73.52 109.069 178.84 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.11 174.78 9.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.924 0.392 . . . . 44.02 111.574 -173.598 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.585 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 7.0 p-10 -68.94 135.66 51.34 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.301 -0.409 . . . . 75.11 110.405 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.439 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 94.54 146.05 19.66 Favored Glycine 0 N--CA 1.433 -1.562 0 C-N-CA 120.422 -0.895 . . . . 45.4 112.042 179.067 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 27.8 t -80.57 28.55 0.33 Allowed 'General case' 0 C--N 1.312 -1.05 0 CA-C-O 121.436 0.636 . . . . 71.23 109.866 175.468 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.439 ' H ' ' C ' ' A' ' 52' ' ' GLY . 30.0 t70 -63.89 -32.43 73.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.159 -0.928 . . . . 64.15 111.26 -177.629 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.86 37.49 4.42 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.41 -0.9 . . . . 63.32 113.138 177.426 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -126.06 139.53 53.33 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.05 0.452 . . . . 74.11 110.052 176.429 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -117.47 155.16 30.18 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.711 -0.677 . . . . 62.24 109.864 179.207 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 44.9 mm -113.86 116.59 53.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.137 -0.483 . . . . 64.12 109.7 177.341 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ARG . . . . . 0.519 ' HB2' HD11 ' A' ' 67' ' ' ILE . 55.5 ttt180 -83.82 124.06 30.54 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.121 -0.49 . . . . 75.24 109.846 -178.791 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 30.9 t -63.71 -8.3 9.97 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.342 -0.39 . . . . 61.13 111.615 -177.771 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ASP . . . . . 0.487 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 15.6 t70 -70.03 -36.0 74.72 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.231 0.538 . . . . 71.53 109.701 175.578 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 61.6 tt0 -159.08 88.87 2.1 Favored Pre-proline 0 N--CA 1.451 -0.383 0 CA-C-N 115.515 -0.766 . . . . 54.3 109.589 -177.492 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' PRO . . . . . 0.453 ' HG3' ' OG ' ' B' ' 160' ' ' SER . 35.7 Cg_exo -58.98 -16.42 32.36 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 123.335 2.69 . . . . 64.42 112.699 178.942 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -66.62 -22.43 66.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.899 -0.591 . . . . 70.35 111.255 179.454 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.16 141.12 48.56 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 121.404 0.621 . . . . 53.4 111.892 -177.077 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.7 mp -88.54 141.43 28.53 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.689 -1.142 . . . . 71.33 109.306 174.365 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ILE . . . . . 0.755 HG23 ' HB3' ' A' ' 71' ' ' GLU . 25.2 mm -83.41 121.87 76.84 Favored Pre-proline 0 C--N 1.317 -0.818 0 CA-C-N 116.167 -0.47 . . . . 74.44 111.709 -176.77 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.51 ' O ' HG23 ' A' ' 72' ' ' ILE . 68.2 Cg_endo -74.05 179.45 5.74 Favored 'Trans proline' 0 C--O 1.233 0.264 0 C-N-CA 123.211 2.607 . . . . 75.1 112.488 178.631 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' GLN . . . . . 0.719 ' HA ' HG12 ' A' ' 72' ' ' ILE . 33.2 tt0 -71.99 -33.11 67.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.171 -0.468 . . . . 75.41 111.701 -168.897 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 7.2 p90 -69.23 -16.97 63.72 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.411 -0.516 . . . . 75.23 110.799 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.755 ' HB3' HG23 ' A' ' 67' ' ' ILE . 2.6 mm-40 -103.44 -20.22 14.13 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.329 -0.396 . . . . 63.22 111.233 -178.882 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.719 HG12 ' HA ' ' A' ' 69' ' ' GLN . 42.6 pt -75.61 -24.17 16.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 121.162 0.506 . . . . 72.1 109.922 174.752 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -103.69 39.21 1.65 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.467 -0.788 . . . . 53.24 109.371 173.353 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.506 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 11.5 t -71.17 -20.03 62.34 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.293 -0.867 . . . . 64.12 110.94 -177.141 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' TRP . . . . . 0.575 ' HZ2' HD13 ' A' ' 35' ' ' ILE . 69.6 p-90 . . . . . 0 C--O 1.235 0.312 0 CA-C-O 120.861 0.362 . . . . 73.45 110.835 177.6 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 8.6 p . . . . . 0 N--CA 1.452 -0.332 0 CA-C-O 121.26 0.552 . . . . 74.43 110.594 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 92.25 116.29 2.25 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 111.063 -0.815 . . . . 61.21 111.063 -174.708 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -119.87 93.33 47.62 Favored Pre-proline 0 C--N 1.319 -0.739 0 CA-C-O 121.14 0.495 . . . . 71.41 110.58 -175.137 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 111' ' ' PRO . . . . . 0.684 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 55.7 Cg_endo -77.44 68.45 7.52 Favored 'Trans proline' 0 N--CA 1.449 -1.115 0 C-N-CA 121.943 1.762 . . . . 74.32 110.891 176.086 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -91.05 157.46 17.24 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 114.411 -1.268 . . . . 53.24 109.553 -178.723 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 113' ' ' VAL . . . . . 0.679 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 12.4 p -122.78 127.25 74.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-O 121.477 0.656 . . . . 73.25 111.19 -178.419 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 114' ' ' THR . . . . . 0.442 ' O ' ' HA ' ' B' ' 124' ' ' GLN . 13.7 m -84.61 111.26 19.38 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.435 -0.802 . . . . 72.34 109.439 178.749 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.6 mt -99.09 116.45 42.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 120.955 0.407 . . . . 75.14 111.527 -172.968 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 45.7 mtt180 -126.87 170.64 12.01 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.947 -0.57 . . . . 74.21 110.606 175.501 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 69.7 mt-30 -132.54 98.23 4.3 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.18 0.514 . . . . 61.02 110.204 176.536 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 118' ' ' GLU . . . . . 0.591 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 20.9 mm-40 -96.66 100.8 12.34 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.657 -0.701 . . . . 53.14 109.317 -178.433 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 73.37 -117.89 6.03 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.434 -0.889 . . . . 74.42 111.36 -175.44 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 120' ' ' ASP . . . . . 0.507 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 5.2 m-20 -104.26 11.58 34.7 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.94 0.37 . . . . 71.04 110.493 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 121' ' ' LYS . . . . . 0.591 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 10.1 ptmt -124.96 121.59 34.89 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.567 0.699 . . . . 62.24 111.73 -175.456 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 122' ' ' THR . . . . . 0.842 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 35.9 m -76.96 104.15 7.29 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.243 -0.89 . . . . 63.1 109.798 175.387 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 46.6 mt -94.01 119.89 42.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.218 0.532 . . . . 72.13 110.301 -179.311 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 124' ' ' GLN . . . . . 0.679 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 77.7 mt-30 -115.23 113.06 23.4 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.322 -0.854 . . . . 63.4 110.914 -177.043 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -88.16 111.98 22.21 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.173 -0.467 . . . . 72.13 110.678 -179.505 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 126' ' ' TYR . . . . . 0.585 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 29.1 m-85 -88.65 112.73 23.44 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.938 0.399 . . . . 73.43 111.07 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 127' ' ' ARG . . . . . 0.519 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 89.6 mtm180 -132.22 128.67 38.42 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.071 -0.513 . . . . 73.04 110.109 -179.218 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 128' ' ' VAL . . . . . 0.684 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 9.7 p -99.86 -27.84 3.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.071 0.462 . . . . 61.51 111.862 -174.367 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -152.74 47.61 0.72 Allowed 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.574 -0.528 . . . . 71.43 109.574 -179.032 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.19 -21.33 12.69 Favored Glycine 0 CA--C 1.518 0.235 0 CA-C-N 115.567 -0.742 . . . . 63.52 112.731 -178.447 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 131' ' ' PHE . . . . . 0.46 ' HD2' HG21 ' A' ' 28' ' ' VAL . 26.5 t80 -98.22 130.12 44.95 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.712 0.291 . . . . 72.41 110.374 -176.584 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 132' ' ' LEU . . . . . 0.519 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 3.1 tm? -71.0 132.55 45.32 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.812 -0.631 . . . . 74.5 109.967 179.214 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 133' ' ' TYR . . . . . 0.407 ' N ' HD13 ' B' ' 132' ' ' LEU . 46.1 p90 -129.32 -15.55 4.1 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.582 -0.447 . . . . 75.41 112.04 177.715 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.31 149.97 17.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.719 0.295 . . . . 60.3 111.079 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 135' ' ' ILE . . . . . 0.415 HG13 HD11 ' B' ' 132' ' ' LEU . 67.5 mt -130.69 125.42 58.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.963 -0.384 . . . . 62.2 109.963 176.863 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 136' ' ' LYS . . . . . 0.627 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 85.5 tttt -104.11 114.55 28.87 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.107 -0.331 . . . . 72.42 110.107 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 137' ' ' VAL . . . . . 0.589 HG12 ' HD3' ' B' ' 139' ' ' PRO . 3.4 t -96.49 130.94 44.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.126 -0.694 . . . . 55.1 109.126 175.577 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 138' ' ' VAL . . . . . 0.842 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 24.1 t -115.65 74.65 4.77 Favored Pre-proline 0 C--N 1.318 -0.798 0 N-CA-C 109.875 -0.417 . . . . 62.53 109.875 171.723 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 139' ' ' PRO . . . . . 0.589 ' HD3' HG12 ' B' ' 137' ' ' VAL . 37.1 Cg_endo -74.22 131.89 15.84 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.186 1.924 . . . . 54.01 112.276 176.445 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 140' ' ' LYS . . . . . 0.507 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 59.2 mtpt -60.63 -19.49 58.18 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.399 -0.818 . . . . 72.55 111.111 178.918 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 80.8 m-70 -130.72 105.4 7.78 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.703 -0.68 . . . . 63.14 109.379 178.492 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 142' ' ' GLY . . . . . 0.425 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 125.36 -11.02 7.65 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.75 -0.738 . . . . 61.14 112.432 -177.142 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 143' ' ' LYS . . . . . 0.463 ' HB3' ' HE2' ' B' ' 143' ' ' LYS . 45.7 mtpt 72.77 150.84 0.14 Allowed Pre-proline 0 N--CA 1.468 0.433 0 C-N-CA 123.603 0.761 . . . . 74.32 112.353 179.105 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 144' ' ' PRO . . . . . 0.58 ' HB3' HG13 ' B' ' 138' ' ' VAL . 44.3 Cg_endo -68.76 137.75 39.34 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.795 2.33 . . . . 60.31 112.552 178.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -143.75 147.99 34.99 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 120.954 0.407 . . . . 73.3 110.638 179.114 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 146' ' ' PHE . . . . . 0.408 ' HB2' ' HB2' ' B' ' 160' ' ' SER . 69.6 m-85 -90.47 129.27 36.66 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.88 -0.6 . . . . 74.44 110.032 175.506 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 147' ' ' LEU . . . . . 0.451 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 25.5 tp -108.59 93.27 4.43 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.621 -0.881 . . . . 74.41 108.621 173.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 40.3 t -83.53 135.91 23.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.602 -0.727 . . . . 74.23 110.499 -174.395 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 3.0 tmm_? -89.25 120.83 30.96 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 108.573 -0.899 . . . . 72.31 108.573 178.616 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -76.16 -173.94 2.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.978 0.418 . . . . 62.34 111.655 -173.123 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -75.33 146.26 41.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.369 -0.378 . . . . 71.4 110.288 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 91.63 136.8 7.26 Favored Glycine 0 N--CA 1.44 -1.076 0 C-N-CA 120.571 -0.823 . . . . 50.31 111.823 -177.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 18.4 t -87.22 35.67 0.71 Allowed 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.226 0.536 . . . . 52.12 110.212 178.425 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -74.68 -47.49 31.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.513 -0.767 . . . . 64.24 111.185 -178.922 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 123.08 36.6 0.65 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.868 -0.682 . . . . 24.11 111.97 -176.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 156' ' ' ASN . . . . . 0.401 ' OD1' ' HB3' ' B' ' 166' ' ' LEU . 6.8 t30 -119.73 126.75 51.84 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.974 0.416 . . . . 75.42 110.596 -178.322 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 157' ' ' PHE . . . . . 0.451 ' CD2' ' HG ' ' B' ' 147' ' ' LEU . 13.4 m-85 -109.97 164.0 13.02 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.196 -0.456 . . . . 71.41 110.487 179.541 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.7 mm -121.79 109.22 24.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.789 -0.819 . . . . 73.33 108.789 173.128 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 159' ' ' ARG . . . . . 0.543 ' HE ' ' HB3' ' B' ' 161' ' ' ASP . 43.3 ttp180 -75.07 125.94 29.98 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 109.027 -0.731 . . . . 72.15 109.027 178.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 160' ' ' SER . . . . . 0.453 ' OG ' ' HG3' ' A' ' 63' ' ' PRO . 23.8 t -58.64 -22.06 55.55 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.187 0.518 . . . . 32.33 110.755 -178.75 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 161' ' ' ASP . . . . . 0.543 ' HB3' ' HE ' ' B' ' 159' ' ' ARG . 1.5 t70 -68.81 -30.24 68.76 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.797 -0.638 . . . . 73.4 111.104 175.547 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 7.1 tp60 -140.95 81.34 16.31 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.271 -0.422 . . . . 71.14 110.409 -174.198 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.41 -8.67 17.36 Favored 'Trans proline' 0 C--N 1.343 0.264 0 C-N-CA 122.498 2.132 . . . . 72.15 112.318 -178.598 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -81.87 -21.52 37.45 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.665 -0.698 . . . . 62.04 110.502 178.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 19.1 ttmm -114.57 134.32 55.13 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.017 -0.538 . . . . 73.21 110.894 -175.006 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 166' ' ' LEU . . . . . 0.401 ' HB3' ' OD1' ' B' ' 156' ' ' ASN . 5.1 mp -82.98 129.31 35.02 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.22 -1.03 . . . . 75.4 108.22 171.449 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 45.2 mm -87.84 110.31 34.05 Favored Pre-proline 0 C--N 1.321 -0.651 0 N-CA-C 110.177 -0.305 . . . . 63.41 110.177 -174.21 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 168' ' ' PRO . . . . . 0.49 ' O ' HG23 ' B' ' 172' ' ' ILE . 42.9 Cg_endo -66.57 172.89 8.59 Favored 'Trans proline' 0 N--CA 1.462 -0.332 0 C-N-CA 122.94 2.426 . . . . 73.24 112.768 -175.595 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -75.44 -5.44 45.01 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.304 -0.862 . . . . 62.24 111.665 -169.097 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -96.04 -13.24 23.87 Favored 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 120.495 -0.482 . . . . 71.53 110.73 176.471 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 171' ' ' GLU . . . . . 0.614 ' O ' ' HB2' ' B' ' 174' ' ' SER . 1.5 mm-40 -107.24 -9.61 16.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.988 0.423 . . . . 72.32 110.817 -178.386 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 172' ' ' ILE . . . . . 0.49 HG23 ' O ' ' B' ' 168' ' ' PRO . 47.9 pt -68.08 -19.15 24.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.423 0.63 . . . . 64.14 110.262 176.365 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -99.45 39.24 1.32 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.293 -0.867 . . . . 71.05 108.823 175.757 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 174' ' ' SER . . . . . 0.614 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 1.7 t -72.84 -15.31 61.62 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.358 -0.837 . . . . 60.42 110.305 -178.375 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 65.4 p-90 . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.817 -0.611 . . . . 71.3 109.371 174.38 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.682 0 N-CA-C 111.635 -0.586 . . . . 61.52 111.635 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -74.32 -71.9 0.31 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.139 0.495 . . . . 73.12 110.143 176.485 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -99.98 153.46 19.17 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.712 -0.676 . . . . 73.42 109.591 176.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -134.0 151.97 51.66 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.766 0.317 . . . . 73.24 110.822 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -153.19 83.4 1.2 Allowed 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.067 -0.716 . . . . 73.21 109.067 177.704 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -80.41 135.44 53.61 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 115.862 -0.608 . . . . 53.01 111.274 -175.046 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -73.96 175.34 10.96 Favored 'Trans proline' 0 CA--C 1.527 0.174 0 C-N-CA 122.798 2.332 . . . . 72.11 112.06 177.559 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.3 p -57.32 107.43 0.43 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.525 0.679 . . . . 70.12 111.333 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 150.45 -76.48 0.24 Allowed Glycine 0 N--CA 1.443 -0.879 0 N-CA-C 110.521 -1.032 . . . . 72.03 110.521 -175.022 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 56.35 75.5 0.57 Allowed Pre-proline 0 N--CA 1.469 0.492 0 O-C-N 124.185 0.58 . . . . 70.5 112.473 173.695 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.619 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 71.6 Cg_endo -87.0 116.53 1.27 Allowed 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.507 2.138 . . . . 72.22 112.544 177.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -139.21 167.21 22.58 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.485 -0.561 . . . . 64.05 109.485 176.074 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.542 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 11.3 p -114.46 124.03 70.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.505 0.669 . . . . 64.34 111.502 -175.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.7 m -89.83 106.14 18.27 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.6 -0.727 . . . . 71.23 109.249 174.74 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.481 HG23 ' HG2' ' A' ' 24' ' ' GLN . 57.6 mt -93.89 107.84 19.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 120.908 0.385 . . . . 64.3 111.0 -175.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.41 HH11 ' HD3' ' A' ' 16' ' ' ARG . 4.8 mtm180 -116.13 174.77 5.87 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.225 -0.443 . . . . 75.11 110.537 177.114 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -129.98 104.87 7.61 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.782 -0.644 . . . . 62.35 109.823 175.508 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -97.32 83.56 3.31 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.563 -0.744 . . . . 52.33 109.338 -177.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.72 -115.17 4.12 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.429 -0.891 . . . . 73.31 111.413 -176.241 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.989 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 23.0 m-20 -110.73 24.95 12.31 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.099 0.476 . . . . 72.5 110.267 178.548 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.5 pttm -132.3 118.52 19.56 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 121.297 0.57 . . . . 71.34 110.782 178.256 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.433 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 35.8 m -80.06 101.42 8.71 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.421 -0.809 . . . . 54.43 109.374 177.047 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.554 HG12 HG23 ' A' ' 37' ' ' VAL . 16.4 mt -98.53 113.31 32.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.236 0.541 . . . . 72.25 110.388 -174.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.542 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 69.7 mt-30 -96.5 110.18 22.62 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.404 -0.816 . . . . 71.43 110.552 -178.774 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 30.0 mt-10 -84.3 103.24 13.32 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.681 -0.691 . . . . 65.4 110.828 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.426 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 85.2 m-85 -83.4 97.48 8.97 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.521 -0.548 . . . . 62.45 109.521 174.251 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 94.0 mtt180 -110.44 129.59 55.74 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.869 -0.605 . . . . 72.41 109.744 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.88 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.7 p -91.98 -82.7 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 C-N-CA 120.322 -0.551 . . . . 65.15 109.812 175.182 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.88 ' H ' HG13 ' A' ' 28' ' ' VAL . 5.6 t-20 -123.36 77.7 1.51 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.023 0.439 . . . . 73.5 110.325 -176.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 70.72 20.51 77.46 Favored Glycine 0 N--CA 1.448 -0.528 0 CA-C-N 115.456 -0.793 . . . . 61.45 113.144 177.453 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.48 ' CD2' HG21 ' B' ' 128' ' ' VAL . 32.2 t80 -148.12 129.3 14.62 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.125 0.488 . . . . 62.22 110.42 177.653 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.969 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -69.51 116.69 10.21 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 114.945 -1.025 . . . . 75.22 109.174 175.427 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' TYR . . . . . 0.426 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 36.7 p90 -105.1 -20.49 13.5 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.299 -0.56 . . . . 73.33 111.562 -178.785 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -157.43 143.41 17.61 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.947 0.403 . . . . 71.05 111.13 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.969 HG13 HD11 ' A' ' 32' ' ' LEU . 72.4 mt -120.86 120.25 61.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.171 -0.468 . . . . 61.2 110.148 175.377 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.417 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 86.6 tttt -103.04 97.78 7.83 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.849 -0.797 . . . . 71.14 108.849 171.103 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.554 HG23 HG12 ' A' ' 23' ' ' ILE . 2.1 p -100.2 128.61 51.99 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 CA-C-N 116.112 -0.495 . . . . 75.32 110.18 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.597 HG22 ' HB3' ' A' ' 44' ' ' PRO . 34.7 t -107.93 87.16 3.54 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 115.428 -0.805 . . . . 73.32 109.646 178.417 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 66.9 Cg_endo -83.48 132.9 6.01 Favored 'Trans proline' 0 N--CA 1.448 -1.171 0 C-N-CA 122.206 1.937 . . . . 73.24 111.905 178.447 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.989 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 58.6 mtpt -63.72 -24.0 67.6 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.648 -0.705 . . . . 61.54 109.93 176.35 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 59.3 m-70 -120.07 85.11 2.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.367 -0.833 . . . . 74.51 109.671 177.223 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 145.04 -20.07 1.95 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.286 -0.959 . . . . 74.35 113.205 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 94.0 mttt 73.42 144.42 0.1 Allowed Pre-proline 0 N--CA 1.474 0.743 0 C-N-CA 123.153 0.581 . . . . 65.32 111.373 178.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.597 ' HB3' HG22 ' A' ' 38' ' ' VAL . 41.7 Cg_endo -67.8 156.43 65.98 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.803 2.335 . . . . 52.44 113.361 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.421 ' CE2' ' HD2' ' A' ' 59' ' ' ARG . 6.8 p90 -165.3 167.16 18.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.581 -0.736 . . . . 71.03 109.516 178.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.543 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 64.4 m-85 -100.24 134.19 43.54 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.871 0.367 . . . . 74.41 110.591 176.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.429 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 20.2 tp -118.87 102.93 9.16 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.264 -0.643 . . . . 73.14 109.264 176.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.4 t -96.85 135.17 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.802 0.334 . . . . 72.22 111.663 -173.391 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.9 111.13 6.89 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.862 -0.608 . . . . 72.0 109.816 178.521 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.54 168.51 16.14 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.446 -0.343 . . . . 74.34 110.739 178.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -64.91 137.25 57.64 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.321 -0.4 . . . . 62.54 110.084 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 87.22 122.3 1.58 Allowed Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.705 -0.76 . . . . 74.13 111.239 -175.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.5 t -85.51 36.62 0.65 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.207 0.527 . . . . 70.41 110.277 -175.058 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -66.04 -48.44 71.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.504 -0.771 . . . . 75.45 110.753 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 134.46 49.75 0.08 OUTLIER Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.861 -0.685 . . . . 53.01 111.572 -177.241 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.831 HD21 ' HB3' ' A' ' 66' ' ' LEU . 41.1 t-20 -136.54 134.27 37.33 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.717 -0.475 . . . . 52.13 109.717 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.496 ' HD1' HG21 ' A' ' 72' ' ' ILE . 52.5 m-85 -123.53 159.71 28.56 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.139 -0.482 . . . . 74.34 110.784 -179.354 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 47.9 mm -117.49 129.96 73.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 109.501 -0.555 . . . . 42.34 109.501 175.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.946 ' HG3' HG13 ' A' ' 67' ' ' ILE . 18.0 mtm180 -95.79 153.63 17.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.827 0.346 . . . . 71.22 111.198 -176.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.543 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 59.5 p -71.53 -21.25 61.93 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.788 -0.642 . . . . 71.44 109.512 172.379 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -60.7 -44.0 97.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 114.833 -1.076 . . . . 73.03 110.858 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 65.3 tt0 -160.1 98.92 1.45 Allowed Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 115.8 -0.636 . . . . 64.45 109.908 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -73.03 -6.8 19.62 Favored 'Trans proline' 0 C--O 1.23 0.099 0 C-N-CA 122.777 2.318 . . . . 73.15 111.659 177.56 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -85.11 1.62 47.09 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.961 -1.018 . . . . 72.23 110.162 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 62.0 tttp -129.03 135.91 49.58 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.153 -0.476 . . . . 71.53 110.577 -177.651 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.831 ' HB3' HD21 ' A' ' 56' ' ' ASN . 5.0 mp -90.34 132.18 35.72 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.705 -0.85 . . . . 53.21 108.705 176.509 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.946 HG13 ' HG3' ' A' ' 59' ' ' ARG . 45.2 mm -106.15 110.52 64.05 Favored Pre-proline 0 C--N 1.317 -0.81 0 CA-C-O 121.021 0.438 . . . . 65.51 111.362 -172.743 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.536 ' O ' HG23 ' A' ' 72' ' ' ILE . 73.0 Cg_endo -76.44 -179.93 5.79 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 123.337 2.691 . . . . 74.04 112.297 177.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLN . . . . . 1.046 ' HA ' HG12 ' A' ' 72' ' ' ILE . 27.4 mt-30 -71.38 -32.69 68.76 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 113.489 0.922 . . . . 63.44 113.489 -169.52 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 25.2 p90 -70.13 -15.9 63.03 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.22 -0.592 . . . . 75.3 109.961 176.363 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.655 ' HB3' HG23 ' A' ' 67' ' ' ILE . 3.9 mm-40 -101.16 -30.31 11.63 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.776 -0.647 . . . . 74.2 111.186 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 1.046 HG12 ' HA ' ' A' ' 69' ' ' GLN . 44.8 pt -72.43 -32.77 43.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 121.099 0.476 . . . . 74.21 110.163 177.632 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -101.77 39.94 1.39 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.946 -0.57 . . . . 60.21 110.125 174.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.3 t -74.76 -16.12 60.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.355 -0.839 . . . . 73.52 109.762 179.297 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 8.6 p-90 . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 115.944 -0.571 . . . . 65.33 110.661 175.449 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.384 0 N-CA-C 112.174 -0.37 . . . . 64.44 112.174 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -157.7 -41.3 0.07 Allowed 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.808 0.337 . . . . 72.42 111.327 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -92.12 37.45 0.98 Allowed 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 112.171 0.434 . . . . 61.3 112.171 -173.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -88.91 33.42 0.78 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.251 0.548 . . . . 75.15 110.482 175.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -54.34 132.45 43.98 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.054 -0.975 . . . . 73.11 111.862 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -90.24 120.13 69.17 Favored Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.1 -0.5 . . . . 65.0 110.502 178.132 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.32 -166.29 0.34 Allowed 'Trans proline' 0 N--CA 1.464 -0.264 0 C-N-CA 123.171 2.581 . . . . 62.02 112.581 -178.613 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 4.3 p -72.75 117.03 13.95 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.802 -0.635 . . . . 73.11 110.473 178.154 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 100.43 84.45 1.8 Allowed Glycine 0 CA--C 1.504 -0.651 0 N-CA-C 110.992 -0.843 . . . . 73.4 110.992 -176.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -118.27 92.6 43.36 Favored Pre-proline 0 C--N 1.315 -0.934 0 CA-C-N 114.959 -0.621 . . . . 72.01 110.258 -174.401 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.827 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 40.5 Cg_endo -74.08 88.1 1.13 Allowed 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 121.781 1.654 . . . . 72.31 111.486 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -104.64 147.11 28.01 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.889 -1.05 . . . . 75.41 109.785 179.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.681 HG21 ' HB3' ' B' ' 124' ' ' GLN . 9.9 p -104.05 127.55 58.16 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-O 121.316 0.579 . . . . 62.52 111.073 -177.757 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 114' ' ' THR . . . . . 0.67 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.4 m -83.9 102.65 12.55 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.607 -0.724 . . . . 71.01 109.364 175.594 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.1 mt -92.77 106.45 17.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.279 -0.419 . . . . 64.13 110.909 -174.538 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 116' ' ' ARG . . . . . 0.454 ' HG2' ' O ' ' B' ' 123' ' ' ILE . 13.3 ptm180 -118.25 171.47 8.1 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.335 -0.617 . . . . 72.11 109.335 176.846 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 89.7 mt-30 -139.55 113.49 8.73 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.32 0.581 . . . . 74.43 110.825 -179.297 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 17.9 mm-40 -101.26 97.73 8.2 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.335 -0.848 . . . . 71.22 109.569 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 70.24 -95.67 0.52 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.886 -0.673 . . . . 63.32 111.973 -177.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.781 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 9.7 m-20 -127.54 26.71 5.91 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.849 0.357 . . . . 73.22 110.538 178.463 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.536 ' HE3' ' HE3' ' B' ' 175' ' ' TRP . 23.1 pttm -129.3 119.31 23.72 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.233 0.54 . . . . 53.24 110.88 175.113 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 122' ' ' THR . . . . . 0.815 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 28.0 m -80.3 105.28 11.44 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.576 -0.738 . . . . 73.42 109.53 177.387 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 123' ' ' ILE . . . . . 0.473 HD11 ' HE2' ' B' ' 121' ' ' LYS . 24.2 mt -96.3 106.38 18.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-O 121.27 0.557 . . . . 75.21 110.097 -177.209 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.681 ' HB3' HG21 ' B' ' 113' ' ' VAL . 76.9 mt-30 -97.51 103.87 15.85 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.451 -0.795 . . . . 63.43 110.892 -176.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 125' ' ' GLU . . . . . 0.67 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 48.3 mt-10 -84.97 102.55 13.25 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.788 -0.642 . . . . 61.42 111.049 -179.214 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 126' ' ' TYR . . . . . 0.454 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 39.2 m-85 -78.38 107.09 10.75 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.931 0.396 . . . . 72.14 110.67 178.115 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 50.2 mtt180 -125.11 125.13 43.27 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.009 -0.542 . . . . 71.32 109.787 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.827 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 7.3 p -90.05 -25.6 5.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.202 0.525 . . . . 74.42 111.081 -174.815 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -165.94 56.35 0.1 Allowed 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.034 -0.728 . . . . 64.32 109.034 -179.244 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.68 -34.55 4.31 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.284 -0.871 . . . . 64.43 112.915 -178.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -94.54 133.47 38.13 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.204 0.526 . . . . 62.43 110.856 -173.524 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.709 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -73.95 125.82 29.08 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.983 -1.008 . . . . 73.15 110.17 179.289 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 133' ' ' TYR . . . . . 0.454 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 37.0 p90 -117.18 -16.97 10.35 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.617 -0.433 . . . . 71.25 111.384 177.457 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 134' ' ' ALA . . . . . 0.433 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -161.79 146.51 12.99 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.668 0.271 . . . . 72.34 110.87 178.029 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.709 HG13 HD11 ' B' ' 132' ' ' LEU . 71.1 mt -124.95 115.71 45.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 110.149 -0.315 . . . . 45.54 110.149 176.552 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.542 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.9 tttt -93.57 105.62 17.65 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.226 -0.657 . . . . 74.02 109.226 175.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.637 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.0 t -88.44 130.95 37.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.279 -0.637 . . . . 72.33 109.279 178.716 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.815 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 34.0 t -117.4 72.87 7.39 Favored Pre-proline 0 C--N 1.318 -0.795 0 CA-C-O 121.002 0.43 . . . . 42.43 109.863 173.152 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.597 ' HD3' HG12 ' B' ' 137' ' ' VAL . 44.4 Cg_endo -76.95 126.47 8.74 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.128 1.885 . . . . 71.14 112.473 176.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 140' ' ' LYS . . . . . 0.781 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 60.1 mtpt -66.04 -9.4 30.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.192 -0.913 . . . . 74.1 111.302 -179.046 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -129.92 21.81 5.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.772 -0.649 . . . . 72.1 110.298 -177.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 142' ' ' GLY . . . . . 0.497 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . -152.16 -9.21 0.1 OUTLIER Glycine 0 CA--C 1.521 0.416 0 C-N-CA 120.381 -0.914 . . . . 64.11 113.68 -178.424 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 143' ' ' LYS . . . . . 0.497 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 67.7 mmtt 75.69 143.98 0.1 Allowed Pre-proline 0 N--CA 1.472 0.67 0 CA-C-O 121.361 0.601 . . . . 72.45 112.128 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.637 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 59.8 Cg_endo -72.32 134.75 23.36 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 123.162 2.575 . . . . 72.22 112.887 -176.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -150.51 151.29 32.46 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.89 -0.595 . . . . 73.31 110.495 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.611 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 93.0 m-85 -89.51 128.1 35.94 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.31 -0.405 . . . . 73.34 110.103 176.403 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.561 ' HG ' ' CD1' ' B' ' 157' ' ' PHE . 16.0 tp -107.39 98.35 7.99 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.852 -0.796 . . . . 71.44 108.852 175.01 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 40.8 t -87.87 133.67 29.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.028 -0.533 . . . . 74.34 111.464 -172.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.03 108.13 8.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.803 -0.635 . . . . 52.02 110.476 178.064 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.12 155.72 33.94 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.876 -0.416 . . . . 60.33 109.876 173.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -62.31 139.21 58.53 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.885 0.374 . . . . 75.14 110.803 -177.522 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 152' ' ' GLY . . . . . 0.425 ' C ' ' H ' ' B' ' 154' ' ' ASP . . . 87.87 137.14 5.43 Favored Glycine 0 N--CA 1.44 -1.07 0 C-N-CA 120.433 -0.889 . . . . 44.43 111.689 -178.614 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 14.4 t -75.61 39.58 0.17 Allowed 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.616 0.722 . . . . 74.42 110.711 178.048 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 154' ' ' ASP . . . . . 0.425 ' H ' ' C ' ' B' ' 152' ' ' GLY . 21.3 t70 -67.29 -27.18 66.96 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.527 -0.761 . . . . 73.34 110.293 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 99.07 18.33 24.86 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.796 -0.716 . . . . 44.22 112.185 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 156' ' ' ASN . . . . . 0.451 ' OD1' ' HB3' ' B' ' 166' ' ' LEU . 1.9 t30 -101.13 139.15 37.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.841 0.353 . . . . 71.45 110.375 -178.26 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 157' ' ' PHE . . . . . 0.561 ' CD1' ' HG ' ' B' ' 147' ' ' LEU . 29.3 m-85 -127.41 156.88 41.37 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.963 -0.562 . . . . 63.45 110.404 176.449 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.2 mm -122.69 130.19 74.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.563 -0.532 . . . . 72.33 109.563 177.593 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.456 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 11.0 mtm180 -93.3 145.35 24.52 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.818 -0.353 . . . . 75.04 110.076 179.748 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 160' ' ' SER . . . . . 0.611 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 54.5 p -70.66 -16.71 62.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.26 -0.427 . . . . 64.21 111.383 -179.307 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -86.35 -25.13 25.54 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.972 0.415 . . . . 64.55 110.195 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 64.9 tt0 -151.72 79.54 6.46 Favored Pre-proline 0 N--CA 1.451 -0.411 0 CA-C-N 115.919 -0.582 . . . . 74.11 110.102 -177.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 163' ' ' PRO . . . . . 0.472 ' CG ' ' HB2' ' A' ' 60' ' ' SER . 16.1 Cg_exo -69.35 -9.57 26.6 Favored 'Trans proline' 0 C--O 1.233 0.247 0 C-N-CA 122.999 2.466 . . . . 74.44 111.398 177.081 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -78.01 -13.53 59.84 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.89 -1.05 . . . . 74.41 110.434 178.538 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 62.4 tttp -110.51 135.29 51.4 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.008 0.432 . . . . 73.52 110.938 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 166' ' ' LEU . . . . . 0.451 ' HB3' ' OD1' ' B' ' 156' ' ' ASN . 5.0 mp -97.85 126.22 43.11 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.616 -0.883 . . . . 61.13 108.616 175.104 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 51.2 mm -86.88 115.72 63.48 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-O 120.626 0.251 . . . . 73.12 110.611 -175.145 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.589 ' O ' HG23 ' B' ' 172' ' ' ILE . 49.3 Cg_endo -69.09 172.23 12.35 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.923 2.415 . . . . 43.11 112.172 178.61 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -84.49 8.8 15.28 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.926 -0.579 . . . . 71.03 111.968 -167.097 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 170' ' ' TRP . . . . . 0.54 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 31.8 p90 -108.33 -26.82 10.33 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.6 -0.519 . . . . 73.22 109.6 170.407 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.54 ' HG2' ' CD1' ' B' ' 170' ' ' TRP . 5.7 mm-40 -86.22 -13.49 46.74 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.932 -0.576 . . . . 60.1 111.549 -177.044 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.589 HG23 ' O ' ' B' ' 168' ' ' PRO . 24.0 pt -61.15 -27.9 42.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.568 -0.742 . . . . 72.42 111.554 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -110.15 44.01 1.29 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.299 0.571 . . . . 74.42 110.341 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 22.8 t -69.02 -22.96 64.03 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.569 -0.741 . . . . 50.41 110.446 178.721 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 175' ' ' TRP . . . . . 0.536 ' HE3' ' HE3' ' B' ' 121' ' ' LYS . 10.2 p-90 . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.383 -0.817 . . . . 70.44 110.965 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.796 0 N-CA-C 111.848 -0.501 . . . . 73.2 111.848 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -83.68 92.5 7.71 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.043 0.449 . . . . 72.42 110.221 176.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -123.47 123.72 41.28 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.989 -0.55 . . . . 73.3 110.605 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -158.37 -166.81 2.01 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.532 -0.914 . . . . 73.12 108.532 178.021 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -82.54 110.7 17.87 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.824 0.345 . . . . 74.41 110.326 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -68.1 120.83 77.13 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.014 -0.539 . . . . 63.42 111.253 -177.664 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_endo -78.38 174.88 11.75 Favored 'Trans proline' 0 C--O 1.233 0.252 0 C-N-CA 122.998 2.465 . . . . 74.32 112.461 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 24.8 m -77.72 141.63 39.2 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.176 -0.466 . . . . 73.21 109.825 178.386 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.47 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 102.93 52.85 0.93 Allowed Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 109.091 -1.604 . . . . 54.41 109.091 -168.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -88.51 103.49 5.42 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 114.233 -0.984 . . . . 71.43 109.722 -168.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.792 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 90.6 Cg_endo -87.18 101.36 0.52 Allowed 'Trans proline' 0 N--CA 1.443 -1.468 0 C-N-CA 122.539 2.16 . . . . 72.45 112.636 -172.649 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.13 149.74 20.96 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 116.067 -0.515 . . . . 74.11 109.98 -178.439 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.662 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 13.9 p -106.87 127.58 62.34 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.384 0.612 . . . . 75.54 110.61 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.455 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 25.3 m -91.77 112.33 24.21 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.833 -0.621 . . . . 71.3 109.44 176.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.409 HG12 ' HG2' ' A' ' 24' ' ' GLN . 62.9 mt -95.1 111.49 25.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.153 0.501 . . . . 53.25 111.54 -174.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 33.7 mmt180 -119.89 156.88 29.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.615 -0.72 . . . . 75.2 109.798 173.035 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -127.56 107.59 10.06 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.988 0.423 . . . . 74.25 110.795 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.446 ' HB2' ' HE2' ' A' ' 21' ' ' LYS . 54.9 mm-40 -97.57 81.72 2.98 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.012 -0.54 . . . . 73.23 109.595 178.89 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.47 -118.74 5.18 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.602 -0.808 . . . . 63.41 111.637 -176.361 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.707 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 42.7 m-20 -101.82 16.88 24.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.437 0.16 . . . . 64.1 110.962 179.048 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.492 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 23.1 pttm -123.49 122.52 38.43 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.269 0.557 . . . . 63.05 111.545 -179.261 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.403 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 36.2 m -83.73 103.98 13.47 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.273 -0.876 . . . . 61.3 109.577 174.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 51.0 mt -95.53 109.99 23.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.91 0.386 . . . . 65.34 110.03 -177.73 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.662 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 51.6 mt-30 -101.33 119.72 39.18 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.84 -0.618 . . . . 53.21 111.787 -175.768 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.455 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 29.0 mt-10 -89.77 99.98 12.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.619 -0.719 . . . . 71.02 110.36 175.55 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.441 ' CD2' ' HB3' ' B' ' 151' ' ' ASP . 68.3 m-85 -81.15 101.5 9.69 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.824 -0.436 . . . . 72.5 109.824 175.387 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.447 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 58.6 mtt180 -115.03 129.28 56.67 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.121 -0.49 . . . . 72.12 110.013 -179.064 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.792 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 2.4 p -90.0 -57.64 4.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-O 120.915 0.388 . . . . 55.3 111.541 -177.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.462 ' H ' HG13 ' A' ' 28' ' ' VAL . 5.1 t-20 -127.63 50.5 2.02 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 109.007 -0.738 . . . . 74.21 109.007 -179.246 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 92.42 -29.74 7.47 Favored Glycine 0 N--CA 1.45 -0.39 0 CA-C-N 115.484 -0.78 . . . . 71.2 112.292 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.574 ' CD2' HG21 ' B' ' 128' ' ' VAL . 57.1 t80 -92.35 134.43 34.92 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.113 0.482 . . . . 70.01 110.843 -176.247 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.864 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -72.84 118.81 16.23 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.225 -0.898 . . . . 55.53 109.965 177.604 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' TYR . . . . . 0.421 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 39.5 p90 -104.79 -25.54 12.61 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 120.3 -0.56 . . . . 74.4 111.263 179.528 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.427 ' O ' ' HB2' ' A' ' 26' ' ' TYR . . . -156.85 137.89 13.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.935 0.397 . . . . 73.22 111.102 178.622 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.864 HG13 HD11 ' A' ' 32' ' ' LEU . 76.4 mt -110.4 119.79 59.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.093 -0.503 . . . . 75.31 109.812 175.727 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -102.43 101.28 11.48 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.043 -0.663 . . . . 72.22 109.535 174.414 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.55 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.4 p -93.48 120.66 43.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 N-CA-C 109.525 -0.546 . . . . 73.42 109.525 176.361 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.595 HG13 ' HB3' ' A' ' 44' ' ' PRO . 41.7 t -107.34 86.25 2.57 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.365 -0.834 . . . . 73.4 109.858 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.55 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 62.3 Cg_endo -85.39 132.76 4.43 Favored 'Trans proline' 0 N--CA 1.445 -1.35 0 C-N-CA 122.347 2.031 . . . . 70.2 112.278 179.066 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.707 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 58.1 mtpt -62.61 -20.34 64.66 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.51 -0.768 . . . . 74.32 109.604 173.609 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 10.6 m-70 -123.6 96.94 5.16 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.216 -0.902 . . . . 50.15 108.942 177.067 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.467 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 133.64 -18.77 4.3 Favored Glycine 0 CA--C 1.52 0.373 0 C-N-CA 120.558 -0.83 . . . . 73.24 113.075 178.323 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 69.6 mmtt 75.31 136.6 0.05 OUTLIER Pre-proline 0 N--CA 1.47 0.556 0 C-N-CA 123.432 0.693 . . . . 73.53 112.39 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.595 ' HB3' HG13 ' A' ' 38' ' ' VAL . 21.8 Cg_endo -61.03 143.43 99.23 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 123.497 2.798 . . . . 73.22 113.334 -177.23 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.52 ' CE1' HG13 ' A' ' 37' ' ' VAL . 4.9 p90 -158.48 160.79 37.14 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.818 -0.628 . . . . 74.04 110.116 178.747 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.647 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 90.3 m-85 -100.03 142.0 32.1 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.294 -0.412 . . . . 75.43 111.073 -179.376 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 51.9 mt -113.98 103.05 10.77 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.791 -0.64 . . . . 75.21 109.367 168.455 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 43.0 t -86.34 133.58 29.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.129 -0.487 . . . . 75.41 110.287 -178.722 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.427 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 33.8 tpt85 -76.71 115.54 16.57 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.958 -0.386 . . . . 72.32 109.958 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.14 154.79 18.68 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 116.094 -0.503 . . . . 71.03 111.406 -179.037 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -73.15 167.03 21.99 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.626 -0.715 . . . . 71.2 111.632 -176.022 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.54 10.22 86.08 Favored Glycine 0 N--CA 1.454 -0.131 0 CA-C-N 115.41 -0.814 . . . . 70.12 112.801 172.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.5 m 61.14 17.83 8.48 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 122.919 0.488 . . . . 72.04 111.745 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -50.39 -66.02 0.46 Allowed 'General case' 0 N--CA 1.468 0.451 0 O-C-N 123.607 0.567 . . . . 72.02 111.898 -178.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 137.4 -18.12 3.49 Favored Glycine 0 CA--C 1.508 -0.381 0 C-N-CA 120.591 -0.814 . . . . 71.23 111.759 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.428 ' ND2' ' HB3' ' A' ' 66' ' ' LEU . 13.8 t-20 -66.04 146.41 54.72 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.141 -0.53 . . . . 64.4 111.036 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.502 ' HB2' HG22 ' A' ' 72' ' ' ILE . 35.4 m-85 -119.35 141.46 49.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.256 -0.429 . . . . 73.22 110.082 175.686 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.404 ' CG2' ' HA ' ' A' ' 63' ' ' PRO . 49.6 mm -108.18 124.36 64.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.993 -0.549 . . . . 74.24 110.521 -177.853 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.436 HH11 ' HD3' ' A' ' 59' ' ' ARG . 42.4 mtp-105 -77.7 137.78 38.69 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.92 -0.4 . . . . 74.3 109.92 177.749 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.647 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 63.6 p -67.51 -23.95 65.52 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.403 0.62 . . . . 32.23 110.082 175.462 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -70.17 -43.08 71.54 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.217 -0.901 . . . . 64.4 110.569 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.9 mm100 -134.9 76.19 59.77 Favored Pre-proline 0 N--CA 1.441 -0.899 0 CA-C-N 115.95 -0.568 . . . . 63.45 111.193 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.404 ' HA ' ' CG2' ' A' ' 58' ' ' ILE . 26.5 Cg_exo -63.47 -15.88 51.19 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 123.011 2.474 . . . . 74.42 112.533 177.019 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -75.24 -20.85 58.99 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.882 -0.599 . . . . 74.44 110.683 178.765 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 22.7 tptm -109.37 129.03 55.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.192 0.52 . . . . 71.04 111.495 -176.225 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.428 ' HB3' ' ND2' ' A' ' 56' ' ' ASN . 5.9 mp -89.93 128.8 36.3 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.43 -0.804 . . . . 74.52 109.965 176.545 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.405 HG13 ' HG3' ' A' ' 59' ' ' ARG . 50.5 mm -96.31 124.89 49.78 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 116.353 -0.385 . . . . 72.23 111.597 -173.709 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.56 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 38.1 Cg_endo -65.22 174.39 5.06 Favored 'Trans proline' 0 C--N 1.348 0.509 0 C-N-CA 123.13 2.553 . . . . 73.32 112.887 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 16.4 tt0 -83.82 -9.01 59.08 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.804 -0.635 . . . . 75.44 111.924 -168.551 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 38.4 p90 -96.88 -5.09 38.96 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.296 0.57 . . . . 72.14 109.927 175.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.56 ' HB2' ' HG2' ' A' ' 68' ' ' PRO . 4.8 mm-40 -115.63 10.76 15.62 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.42 -0.809 . . . . 75.33 111.145 -176.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.541 HG23 ' O ' ' A' ' 68' ' ' PRO . 18.9 pt -90.33 -11.25 9.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-O 121.096 0.474 . . . . 75.11 110.811 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 33.8 p90 -128.5 27.25 5.57 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.954 -0.566 . . . . 74.32 110.419 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 4.8 m -49.76 -41.33 43.8 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.692 -0.686 . . . . 73.03 111.041 -179.496 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' TRP . . . . . 0.492 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 10.3 p-90 . . . . . 0 C--N 1.326 -0.439 0 CA-C-N 115.787 -0.642 . . . . 75.12 111.043 175.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.434 0 N-CA-C 112.334 -0.307 . . . . 64.52 112.334 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -86.19 144.14 27.62 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.881 -0.414 . . . . 52.41 109.881 176.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -100.12 110.22 22.5 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.866 0.841 . . . . 73.41 111.664 -176.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -127.65 127.83 44.44 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 107.166 -1.42 . . . . 74.11 107.166 169.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -48.28 107.32 0.12 Allowed 'General case' 0 N--CA 1.468 0.471 0 O-C-N 123.678 0.611 . . . . 70.52 112.115 -170.83 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 106' ' ' ALA . . . . . 0.427 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -107.07 148.55 37.21 Favored Pre-proline 0 C--N 1.32 -0.689 0 CA-C-N 115.328 -0.851 . . . . 44.14 110.351 -179.122 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 107' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 24.8 Cg_exo -64.95 175.86 3.46 Favored 'Trans proline' 0 C--O 1.233 0.252 0 C-N-CA 122.943 2.429 . . . . 72.11 112.352 177.018 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 42.7 m -60.32 129.51 42.05 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.197 -0.456 . . . . 44.21 110.238 176.607 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 128.14 82.04 0.34 Allowed Glycine 0 N--CA 1.446 -0.65 0 N-CA-C 110.577 -1.009 . . . . 63.44 110.577 -173.035 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 110' ' ' GLU . . . . . 0.415 ' HA ' ' HD3' ' B' ' 111' ' ' PRO . 13.4 mt-10 -123.38 114.13 29.04 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-O 121.327 0.584 . . . . 74.3 109.975 -172.296 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.765 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 19.2 Cg_endo -89.01 102.29 0.38 Allowed 'Trans proline' 0 N--CA 1.438 -1.766 0 C-N-CA 122.832 2.355 . . . . 70.44 112.397 -176.241 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -101.57 115.28 30.16 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.188 -0.671 . . . . 71.34 109.188 178.274 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 113' ' ' VAL . . . . . . . . . . . . . 7.9 p -72.71 132.64 33.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.625 -0.716 . . . . 61.21 111.082 -176.759 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 27.4 m -93.22 99.17 11.78 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.464 -0.789 . . . . 71.24 109.742 174.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.608 HG23 ' HG2' ' B' ' 124' ' ' GLN . 71.3 mt -96.06 106.03 17.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.838 -0.619 . . . . 72.34 110.286 -177.252 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 39.1 mmt180 -118.75 149.6 41.19 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.192 0.52 . . . . 72.3 110.485 178.279 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -100.6 113.64 26.64 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-O 121.596 0.712 . . . . 75.45 110.865 -179.643 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 118' ' ' GLU . . . . . 0.517 ' HB3' ' HE2' ' B' ' 121' ' ' LYS . 0.7 OUTLIER -102.83 48.92 0.85 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.003 -0.999 . . . . 71.43 109.851 -176.785 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 97.74 -117.35 5.78 Favored Glycine 0 N--CA 1.446 -0.652 0 N-CA-C 111.223 -0.751 . . . . 63.13 111.223 -176.266 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.497 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 3.6 m-20 -89.13 -3.32 58.67 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.037 0.446 . . . . 73.34 110.308 177.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.675 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 25.4 pttm -111.79 120.19 41.13 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.205 0.526 . . . . 75.53 111.303 -177.549 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 122' ' ' THR . . . . . 0.474 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 5.5 m -84.03 111.96 19.77 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.908 -0.587 . . . . 72.4 109.611 175.146 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 51.4 mt -101.17 108.12 22.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-O 121.104 0.478 . . . . 72.24 110.368 -177.781 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.608 ' HG2' HG23 ' B' ' 115' ' ' ILE . 40.4 mt-30 -105.28 103.76 13.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.792 -0.64 . . . . 63.05 110.366 -178.427 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -88.4 108.82 19.56 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.234 -0.439 . . . . 73.43 110.766 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 126' ' ' TYR . . . . . 0.471 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 46.7 m-85 -82.37 106.39 14.21 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.218 -0.446 . . . . 74.4 110.47 177.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -120.86 125.31 47.16 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.508 -0.553 . . . . 62.25 109.508 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.765 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 3.5 p -93.65 -41.63 12.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 120.757 0.313 . . . . 73.51 111.497 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -158.6 70.37 0.52 Allowed 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.606 -0.438 . . . . 73.15 110.584 -175.663 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 78.87 -4.05 62.64 Favored Glycine 0 N--CA 1.454 -0.162 0 CA-C-N 115.692 -0.686 . . . . 65.32 113.574 175.218 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -130.0 129.32 43.57 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.097 0.475 . . . . 75.03 110.717 -178.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.892 HD11 HG13 ' B' ' 135' ' ' ILE . 3.5 tm? -73.5 118.35 16.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 114.875 -1.057 . . . . 74.23 109.462 175.223 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 133' ' ' TYR . . . . . 0.471 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 46.3 p90 -106.09 -23.77 12.53 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.66 -0.416 . . . . 75.45 111.528 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 134' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -158.99 134.55 8.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.806 0.336 . . . . 73.11 111.282 179.005 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.892 HG13 HD11 ' B' ' 132' ' ' LEU . 74.3 mt -114.07 130.73 67.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 N-CA-C 109.634 -0.506 . . . . 65.53 109.634 174.151 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -107.79 110.41 22.21 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.679 -0.489 . . . . 73.32 109.679 174.232 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.646 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.4 t -93.67 131.14 41.44 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 108.808 -0.812 . . . . 44.34 108.808 176.296 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.474 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 17.2 t -117.73 72.86 8.33 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 109.961 -0.385 . . . . 71.12 109.961 173.582 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.675 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 52.4 Cg_endo -78.48 134.73 12.69 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 122.367 2.044 . . . . 70.34 112.596 176.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 140' ' ' LYS . . . . . 0.497 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 48.6 mtpt -60.83 -33.21 72.69 Favored 'General case' 0 CA--C 1.518 -0.262 0 CA-C-O 121.416 0.627 . . . . 73.13 109.596 173.37 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 36.6 m-70 -110.52 82.58 1.62 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.252 -0.885 . . . . 74.35 109.2 177.038 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 142' ' ' GLY . . . . . 0.483 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 150.68 -26.73 1.06 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.357 -0.925 . . . . 73.55 113.054 -179.335 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 143' ' ' LYS . . . . . 0.483 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 70.7 mmtt 76.68 148.91 0.12 Allowed Pre-proline 0 N--CA 1.472 0.635 0 C-N-CA 123.283 0.633 . . . . 73.23 111.933 178.4 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.646 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 38.3 Cg_endo -66.27 127.6 17.79 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 123.069 2.513 . . . . 73.35 113.492 -176.098 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -143.91 150.48 38.47 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.79 -0.641 . . . . 72.05 110.734 179.327 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.666 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 77.8 m-85 -98.14 146.16 25.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.976 -0.556 . . . . 71.23 110.466 178.345 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 59.9 mt -122.73 100.55 6.97 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.826 -0.625 . . . . 73.03 109.555 171.156 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 61.4 t -92.84 130.34 42.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.054 -0.521 . . . . 74.14 110.677 -178.036 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 149' ' ' ARG . . . . . 0.544 ' HG3' HH11 ' B' ' 149' ' ' ARG . 0.3 OUTLIER -72.2 128.07 34.53 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.913 0.387 . . . . 74.24 111.689 -179.429 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.87 155.78 38.62 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 115.738 -0.664 . . . . 75.03 110.612 176.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 151' ' ' ASP . . . . . 0.441 ' HB3' ' CD2' ' A' ' 26' ' ' TYR . 3.9 p-10 -77.6 162.21 27.25 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.287 0.565 . . . . 73.53 111.736 -173.08 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.93 21.73 60.77 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.284 -0.871 . . . . 62.34 112.364 173.61 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 153' ' ' SER . . . . . 0.433 ' H ' ' HD2' ' A' ' 11' ' ' PRO . 25.2 m 55.87 30.11 15.31 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-O 120.969 0.414 . . . . 75.32 110.384 -177.011 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -51.37 -64.39 0.83 Allowed 'General case' 0 N--CA 1.461 0.121 0 CA-C-N 114.851 -1.068 . . . . 64.22 111.068 -178.206 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 132.2 -36.36 2.21 Favored Glycine 0 CA--C 1.491 -1.458 0 C-N-CA 120.569 -0.824 . . . . 62.11 111.218 175.441 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 156' ' ' ASN . . . . . 0.607 ' OD1' ' HA ' ' B' ' 168' ' ' PRO . 75.6 m-20 -68.41 152.63 45.14 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 113.964 -1.118 . . . . 74.11 111.773 -179.424 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 157' ' ' PHE . . . . . 0.464 ' CE2' ' HG2' ' B' ' 149' ' ' ARG . 46.2 m-85 -112.32 157.7 20.66 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.54 -0.754 . . . . 61.2 110.248 176.285 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 49.1 mm -116.03 124.92 72.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 N-CA-C 109.596 -0.52 . . . . 73.35 109.596 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.491 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 30.2 ttt180 -85.51 137.72 32.7 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.4 -0.364 . . . . 74.2 110.165 -177.131 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 160' ' ' SER . . . . . 0.666 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 6.5 p -57.18 -42.6 81.49 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.722 0.638 . . . . 64.41 112.722 -174.765 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -86.04 -1.06 57.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.979 0.419 . . . . 61.43 111.551 -174.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 10.9 tp60 -151.86 71.41 7.99 Favored Pre-proline 0 C--N 1.327 -0.401 0 N-CA-C 109.614 -0.513 . . . . 73.3 109.614 -178.263 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -67.47 -14.41 42.36 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 123.223 2.616 . . . . 63.45 113.13 -173.771 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -90.52 -6.39 54.81 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.169 -0.469 . . . . 64.43 110.549 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 23.1 tptm -104.74 126.17 51.55 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.163 0.506 . . . . 74.51 110.637 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.0 mp -95.19 124.68 39.36 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.326 -0.852 . . . . 62.43 109.789 178.302 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 167' ' ' ILE . . . . . 0.404 HG23 ' HB3' ' B' ' 171' ' ' GLU . 51.5 mm -93.17 111.58 52.44 Favored Pre-proline 0 C--N 1.32 -0.7 0 CA-C-N 116.122 -0.49 . . . . 74.12 109.827 179.029 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.607 ' HA ' ' OD1' ' B' ' 156' ' ' ASN . 60.2 Cg_endo -71.63 175.17 9.92 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.664 2.243 . . . . 71.15 113.025 -176.457 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 169' ' ' GLN . . . . . 0.415 ' O ' HG12 ' B' ' 172' ' ' ILE . 36.3 tt0 -78.92 -8.32 58.77 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.573 -0.739 . . . . 74.35 111.518 -170.341 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 10.3 p90 -94.23 -8.04 40.36 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.088 0.47 . . . . 71.4 110.081 174.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.476 ' O ' ' HB2' ' B' ' 174' ' ' SER . 0.1 OUTLIER -110.42 -4.63 15.47 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.891 -0.595 . . . . 54.41 110.717 -177.538 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.474 HG23 ' O ' ' B' ' 168' ' ' PRO . 36.6 pt -70.15 -18.68 21.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.231 -0.44 . . . . 74.34 111.197 -179.613 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -102.01 40.62 1.31 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.593 0.711 . . . . 74.44 109.678 176.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 174' ' ' SER . . . . . 0.476 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 4.5 t -73.38 -11.13 60.37 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 114.9 -1.045 . . . . 64.4 110.211 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 175' ' ' TRP . . . . . 0.454 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 0.9 OUTLIER . . . . . 0 C--O 1.245 0.829 0 CA-C-O 118.353 -0.832 . . . . 74.23 110.9 179.008 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.609 0 N-CA-C 111.987 -0.445 . . . . 72.33 111.987 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -135.69 -39.4 0.72 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.744 0.306 . . . . 64.2 111.262 -178.051 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -100.83 17.76 21.27 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.425 -0.352 . . . . 63.13 111.258 -177.132 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -64.5 131.09 46.13 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.244 -0.435 . . . . 65.14 110.653 177.203 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 61.61 68.18 0.72 Allowed 'General case' 0 C--N 1.329 -0.318 0 O-C-N 123.856 0.723 . . . . 64.34 110.752 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -109.85 149.54 40.12 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 115.325 -0.852 . . . . 72.11 110.302 -179.123 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -78.46 153.56 27.23 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.384 2.056 . . . . 74.33 112.546 179.359 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.5 p -94.53 119.06 32.63 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.965 -0.561 . . . . 75.43 109.749 175.025 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.03 66.33 0.53 Allowed Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.158 -1.177 . . . . 73.21 110.158 -173.533 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLU . . . . . 0.49 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -114.46 117.16 43.23 Favored Pre-proline 0 N--CA 1.44 -0.933 0 N-CA-C 107.995 -1.113 . . . . 72.31 107.995 -175.839 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.613 ' HG3' ' CZ ' ' B' ' 131' ' ' PHE . 24.7 Cg_endo -88.87 101.0 0.37 Allowed 'Trans proline' 0 N--CA 1.433 -2.049 0 C-N-CA 122.173 1.915 . . . . 73.22 111.693 -175.377 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -107.8 171.61 7.3 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 114.871 -1.059 . . . . 64.44 110.344 179.55 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.653 HG21 ' HB3' ' A' ' 24' ' ' GLN . 7.6 p -123.42 131.51 73.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 115.773 -0.649 . . . . 65.03 110.353 178.658 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.418 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 61.5 m -91.62 111.33 22.8 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.663 -0.699 . . . . 71.11 109.585 176.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 56.1 mt -88.66 103.76 14.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.942 -0.572 . . . . 63.25 110.967 -174.725 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.471 ' NE ' ' HA ' ' A' ' 16' ' ' ARG . 3.5 mmp_? -108.45 165.12 11.76 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.49 -0.777 . . . . 71.14 109.48 177.207 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -139.13 111.44 7.5 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.042 0.449 . . . . 73.34 110.502 174.444 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 30.9 mm-40 -103.77 100.57 10.38 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.448 -0.796 . . . . 75.32 109.002 178.035 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.25 -109.31 2.83 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.529 -0.843 . . . . 41.42 111.664 -175.476 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -111.02 8.46 21.91 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.788 0.294 . . . . 74.31 111.078 -177.366 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.705 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 0.3 OUTLIER -114.97 118.54 33.73 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.434 0.635 . . . . 72.35 111.463 179.484 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.739 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 20.7 m -76.59 98.33 4.65 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.19 -0.914 . . . . 31.35 109.618 175.213 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.427 HG12 HG13 ' A' ' 37' ' ' VAL . 38.3 mt -90.31 105.39 16.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.221 0.534 . . . . 74.33 110.234 -176.672 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.653 ' HB3' HG21 ' A' ' 13' ' ' VAL . 72.5 mt-30 -94.67 112.78 24.51 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.433 -0.803 . . . . 75.13 110.734 -177.836 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.418 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.6 mt-10 -91.99 108.85 20.23 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.03 -0.532 . . . . 65.22 110.736 -177.815 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.467 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 41.3 m-85 -84.72 106.06 15.98 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.349 -0.387 . . . . 75.33 110.687 178.173 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 71.3 mtm-85 -130.01 123.61 30.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.064 -0.516 . . . . 71.33 110.11 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.2 p -97.18 -41.99 11.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.313 -0.403 . . . . 75.1 111.48 -179.055 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 11.7 t-20 -153.65 73.37 0.95 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.006 0.432 . . . . 75.33 110.294 -176.087 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 67.03 18.53 69.0 Favored Glycine 0 C--N 1.33 0.207 0 CA-C-N 115.815 -0.63 . . . . 65.31 112.845 177.224 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.616 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 87.8 t80 -139.67 128.59 23.49 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.994 0.426 . . . . 64.45 111.042 -178.117 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.844 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -82.36 110.31 17.39 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.112 -0.949 . . . . 62.21 108.544 172.822 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' TYR . . . . . 0.467 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 45.5 p90 -103.92 -17.49 14.99 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.885 -0.326 . . . . 72.42 111.478 -178.39 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.456 ' O ' ' HB2' ' A' ' 26' ' ' TYR . . . -159.35 140.34 12.67 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.878 0.371 . . . . 31.11 111.105 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.844 HG13 HD11 ' A' ' 32' ' ' LEU . 66.9 mt -117.6 124.95 73.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 N-CA-C 109.653 -0.499 . . . . 54.42 109.653 174.326 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.623 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.9 tttt -106.01 103.77 13.33 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.533 -0.543 . . . . 73.41 109.533 176.11 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.725 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.6 t -88.7 127.24 41.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.839 -0.8 . . . . 73.34 108.839 177.854 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.739 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 22.0 t -115.14 74.0 3.64 Favored Pre-proline 0 C--N 1.318 -0.769 0 N-CA-C 109.55 -0.537 . . . . 53.45 109.55 172.492 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.705 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 39.4 Cg_endo -76.86 131.1 11.92 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.011 1.807 . . . . 45.1 112.242 177.003 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -54.83 -40.0 69.13 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.522 -0.763 . . . . 74.11 110.26 177.208 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -116.67 82.46 1.8 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.517 -0.765 . . . . 72.24 109.228 179.485 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.43 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 159.15 -29.48 0.41 Allowed Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.507 -0.769 . . . . 61.12 111.428 -175.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.43 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 71.6 mmtt 76.42 143.81 0.1 OUTLIER Pre-proline 0 N--CA 1.469 0.513 0 C-N-CA 123.738 0.815 . . . . 72.23 112.267 176.19 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.725 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 30.8 Cg_endo -64.03 132.7 35.37 Favored 'Trans proline' 0 C--N 1.347 0.469 0 C-N-CA 123.218 2.612 . . . . 73.55 113.61 -176.197 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 21.9 p90 -148.36 163.2 37.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.463 -0.79 . . . . 72.5 109.645 177.032 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.475 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 91.2 m-85 -107.76 137.79 45.14 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.842 0.353 . . . . 75.33 111.572 -176.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.407 ' HB3' ' CD2' ' A' ' 57' ' ' PHE . 34.7 mt -114.15 104.48 12.15 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.717 -0.674 . . . . 73.33 109.216 168.487 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 44.4 t -92.52 137.88 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.554 -0.294 . . . . 74.52 110.333 -178.198 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.574 ' HG2' ' CE2' ' A' ' 57' ' ' PHE . 5.0 mmm180 -81.8 121.92 27.04 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.032 0.444 . . . . 72.22 110.885 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.45 167.03 19.16 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.337 -0.847 . . . . 74.23 111.22 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.463 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 9.8 p-10 -66.87 142.86 57.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.298 -0.41 . . . . 70.15 110.264 179.037 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.432 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 94.16 143.45 13.81 Favored Glycine 0 N--CA 1.433 -1.559 0 C-N-CA 120.588 -0.815 . . . . 53.13 111.566 -178.591 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 18.6 m -74.32 40.14 0.13 Allowed 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.174 0.511 . . . . 74.43 110.677 176.186 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.432 ' H ' ' C ' ' A' ' 52' ' ' GLY . 18.0 t70 -78.01 -39.86 40.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.779 -0.646 . . . . 53.31 110.357 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 112.02 -32.05 6.6 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.636 -0.792 . . . . 41.02 113.302 176.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -58.29 149.82 23.44 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 113.027 0.751 . . . . 71.35 113.027 -175.797 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.574 ' CE2' ' HG2' ' A' ' 49' ' ' ARG . 63.3 m-85 -115.5 168.3 10.12 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.096 -0.956 . . . . 72.25 110.697 -179.063 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 45.4 mm -128.27 132.16 68.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.995 -0.548 . . . . 75.54 109.649 174.244 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.789 ' HG3' HD11 ' A' ' 67' ' ' ILE . 70.7 mtt180 -78.59 147.88 33.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.809 0.337 . . . . 74.33 111.249 178.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.475 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 62.2 p -79.01 -29.86 43.92 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.681 -0.859 . . . . 54.32 108.681 165.812 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -70.27 -34.34 72.67 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.381 -1.281 . . . . 74.41 110.876 177.316 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLN . . . . . 0.6 ' HB3' ' HD2' ' A' ' 59' ' ' ARG . 63.2 tt0 -143.37 82.52 11.57 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 115.747 -0.66 . . . . 63.34 109.71 -174.745 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -79.58 -7.44 14.73 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.871 2.381 . . . . 63.01 113.13 -175.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -94.46 9.32 38.9 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.331 0.586 . . . . 73.44 110.165 178.522 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.4 tptt -125.63 128.23 47.56 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.85 -0.614 . . . . 74.15 110.429 -178.588 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.404 ' N ' HD12 ' A' ' 66' ' ' LEU . 5.2 mp -87.36 111.85 21.51 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 108.434 -0.95 . . . . 73.32 108.434 175.118 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.789 HD11 ' HG3' ' A' ' 59' ' ' ARG . 34.6 mm -67.24 117.33 45.42 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.146 -0.479 . . . . 74.14 111.27 -172.254 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.403 ' O ' HG23 ' A' ' 72' ' ' ILE . 55.8 Cg_endo -69.1 175.03 8.08 Favored 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.676 2.251 . . . . 72.14 112.038 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 21.9 tt0 -84.36 -1.06 54.84 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.943 -0.572 . . . . 73.25 111.21 -169.385 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 16.5 p90 -98.89 -20.24 16.93 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.557 -0.457 . . . . 71.31 110.437 174.583 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.519 ' OE2' HD12 ' A' ' 67' ' ' ILE . 19.4 tt0 -90.55 -11.96 38.54 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 121.096 0.474 . . . . 72.11 110.536 -177.038 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.403 HG23 ' O ' ' A' ' 68' ' ' PRO . 45.6 pt -64.88 -19.26 25.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.095 -0.502 . . . . 62.14 110.975 178.891 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -117.6 29.32 7.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.951 -0.568 . . . . 71.3 110.289 176.121 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 23.0 t -63.72 -26.76 68.8 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.898 -0.592 . . . . 61.24 110.15 179.333 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 20.8 p-90 . . . . . 0 C--N 1.324 -0.528 0 CA-C-N 115.896 -0.593 . . . . 72.41 110.579 175.069 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.163 -0.375 . . . . 74.51 112.163 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -92.13 -31.34 15.54 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.343 0.592 . . . . 62.23 110.19 178.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -120.71 166.43 13.72 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.416 -0.811 . . . . 74.51 109.968 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -137.86 104.14 5.19 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.261 -0.427 . . . . 63.24 109.978 178.106 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 38.9 t70 67.28 97.13 0.06 Allowed 'General case' 0 N--CA 1.465 0.296 0 O-C-N 123.936 0.772 . . . . 73.42 110.709 -177.876 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 106' ' ' ALA . . . . . 0.441 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -68.29 133.49 91.36 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 115.332 -0.849 . . . . 70.55 111.693 -174.832 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 107' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 8.0 Cg_exo -72.68 155.87 53.9 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 123.246 2.631 . . . . 74.32 112.109 178.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 21.1 m -72.72 107.71 5.32 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.385 -0.371 . . . . 74.41 110.558 178.428 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 99.72 83.24 1.72 Allowed Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 120.876 -0.678 . . . . 62.04 111.924 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 50.7 mt-10 -109.51 102.94 51.57 Favored Pre-proline 0 C--N 1.323 -0.545 0 N-CA-C 109.046 -0.724 . . . . 75.4 109.046 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.616 ' HG3' ' CZ ' ' A' ' 31' ' ' PHE . 66.2 Cg_endo -83.48 85.83 1.46 Allowed 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 122.036 1.824 . . . . 54.11 112.076 -176.21 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -96.05 133.47 40.25 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.049 -0.978 . . . . 71.12 109.359 178.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.521 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 14.7 p -92.92 127.55 44.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 121.438 0.637 . . . . 64.4 110.262 179.089 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 21.9 m -91.3 105.46 17.8 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.794 -0.639 . . . . 72.21 109.699 177.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 63.6 mt -84.36 106.13 14.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.024 -0.535 . . . . 65.45 110.899 -176.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 14.4 mtp180 -105.99 173.05 6.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.928 -0.578 . . . . 74.01 111.052 178.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -148.2 101.16 3.24 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.743 -0.662 . . . . 71.43 110.891 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 118' ' ' GLU . . . . . 0.607 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 3.8 mp0 -104.52 90.61 3.57 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.457 -0.792 . . . . 75.42 110.399 -178.572 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 76.85 -89.52 0.96 Allowed Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.775 -0.726 . . . . 72.05 112.486 179.282 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -127.57 14.57 7.06 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.458 0.129 . . . . 65.31 110.899 178.669 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.607 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 38.4 pttt -123.6 121.36 35.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.267 0.556 . . . . 72.15 111.181 -179.085 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 122' ' ' THR . . . . . 0.519 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 20.8 m -84.13 98.31 9.83 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.488 -0.778 . . . . 73.42 109.748 176.412 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 123' ' ' ILE . . . . . 0.476 HG12 HG23 ' B' ' 137' ' ' VAL . 30.4 mt -89.68 107.52 18.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.174 0.511 . . . . 65.44 110.599 -177.231 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.521 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 69.6 mt-30 -97.95 107.6 20.12 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.783 -0.644 . . . . 54.31 110.515 -178.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -87.47 111.23 20.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.014 -0.539 . . . . 74.45 110.485 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 126' ' ' TYR . . . . . 0.463 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 78.5 m-85 -85.16 101.29 12.34 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.046 -0.353 . . . . 74.4 110.046 176.612 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 20.6 mtm180 -113.41 128.05 56.32 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.413 -0.358 . . . . 73.22 110.234 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.594 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -96.58 -50.6 11.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 C-N-CA 120.731 -0.388 . . . . 51.15 111.521 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -156.67 76.1 0.87 Allowed 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.622 -0.51 . . . . 71.34 109.622 -176.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 66.94 16.73 66.69 Favored Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.713 -0.676 . . . . 50.34 112.403 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.613 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 89.4 t80 -137.33 128.34 27.52 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.038 0.447 . . . . 71.31 110.791 -179.07 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.827 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -83.2 113.35 20.6 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.175 -0.92 . . . . 74.55 108.791 173.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 133' ' ' TYR . . . . . 0.421 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 50.9 p90 -104.88 -14.99 15.3 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.388 -0.525 . . . . 73.43 111.665 -178.07 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -159.9 143.01 13.93 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.897 0.38 . . . . 72.21 111.278 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.827 HG13 HD11 ' B' ' 132' ' ' LEU . 80.8 mt -120.93 127.09 75.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.931 -0.577 . . . . 73.33 109.889 174.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.443 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 82.6 tttt -116.69 101.12 8.31 Favored 'General case' 0 C--N 1.321 -0.63 0 N-CA-C 109.411 -0.588 . . . . 70.55 109.411 172.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.542 ' O ' ' HD3' ' B' ' 139' ' ' PRO . 4.9 p -101.95 129.38 53.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.978 0 C-N-CA 120.231 -0.588 . . . . 70.34 109.758 178.715 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.519 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 37.5 t -109.07 84.91 2.94 Favored Pre-proline 0 C--N 1.322 -0.591 0 CA-C-N 115.553 -0.748 . . . . 75.23 109.976 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.542 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 69.0 Cg_endo -87.86 133.46 3.02 Favored 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 122.506 2.138 . . . . 73.44 112.365 178.855 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -60.97 -20.31 62.2 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.94 -0.573 . . . . 75.1 110.304 174.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 5.6 m-70 -122.66 81.88 1.91 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.425 -0.807 . . . . 64.13 109.181 -175.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 140.0 -17.44 2.98 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.736 -0.745 . . . . 73.34 112.64 -178.082 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt 70.79 145.5 0.11 Allowed Pre-proline 0 N--CA 1.472 0.639 0 C-N-CA 123.41 0.684 . . . . 75.24 111.896 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.513 ' HB3' HG22 ' B' ' 138' ' ' VAL . 43.0 Cg_endo -67.95 149.1 77.36 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.62 2.213 . . . . 53.44 113.09 -177.342 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -158.71 156.7 30.37 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.848 -0.615 . . . . 73.13 109.695 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -102.29 134.34 45.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.647 0.261 . . . . 60.31 111.117 -179.221 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 46.0 mt -114.02 105.31 13.07 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.045 -0.525 . . . . 64.11 109.704 170.036 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 46.7 t -97.79 137.27 25.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.123 -0.49 . . . . 72.15 110.147 -178.742 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 2.8 mmt85 -75.68 131.64 40.02 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.99 0.424 . . . . 75.44 111.458 178.235 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -87.58 169.68 11.96 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.644 -0.707 . . . . 72.13 109.215 172.264 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 151' ' ' ASP . . . . . 0.449 ' H ' ' HE2' ' A' ' 26' ' ' TYR . 6.2 p-10 -69.99 125.52 26.99 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.374 0.606 . . . . 61.11 109.971 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 120.95 127.9 3.49 Favored Glycine 0 N--CA 1.442 -0.91 0 CA-C-N 115.505 -0.77 . . . . 73.21 112.12 -178.395 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 12.2 t -79.45 45.25 0.65 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.433 0.635 . . . . 53.43 110.08 178.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -84.88 -16.94 39.49 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.39 -0.823 . . . . 71.22 110.57 -178.339 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 86.39 23.56 43.25 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.825 -0.703 . . . . 70.15 111.666 -177.061 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 30.7 t30 -99.57 129.95 45.77 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.268 -0.466 . . . . 71.24 110.681 -177.556 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -116.59 151.08 36.94 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.815 -0.63 . . . . 61.02 110.004 178.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.7 mm -117.96 129.55 74.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 116.17 -0.468 . . . . 74.31 109.777 178.404 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.449 ' HG3' HD11 ' B' ' 167' ' ' ILE . 92.9 mtt180 -75.02 150.78 38.84 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.821 0.343 . . . . 74.51 111.136 179.362 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 64.7 p -81.29 -27.73 34.95 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 107.993 -1.114 . . . . 70.14 107.993 164.26 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -64.7 -35.61 81.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.019 -1.446 . . . . 65.52 110.94 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -153.24 85.59 4.19 Favored Pre-proline 0 C--N 1.322 -0.589 0 CA-C-N 115.518 -0.764 . . . . 72.5 109.557 -177.137 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -79.14 8.87 3.6 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 123.106 2.537 . . . . 70.35 112.766 -176.299 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -107.4 3.9 25.73 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.214 0.531 . . . . 74.14 110.729 -178.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -125.23 130.65 52.51 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.855 -0.612 . . . . 73.14 110.484 -179.059 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 166' ' ' LEU . . . . . 0.44 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.7 mp -84.67 119.81 25.66 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.695 -0.854 . . . . 75.15 108.695 176.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 167' ' ' ILE . . . . . 0.449 HD11 ' HG3' ' B' ' 159' ' ' ARG . 36.4 mm -80.56 119.51 76.49 Favored Pre-proline 0 C--N 1.322 -0.614 0 CA-C-O 120.995 0.426 . . . . 72.45 111.177 -172.048 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.551 ' O ' HG23 ' B' ' 172' ' ' ILE . 58.1 Cg_endo -69.73 173.0 11.58 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.803 2.335 . . . . 72.33 112.098 178.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 169' ' ' GLN . . . . . 0.64 ' O ' HG12 ' B' ' 172' ' ' ILE . 33.9 tt0 -73.78 -33.11 64.11 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.734 -0.666 . . . . 64.53 111.362 -168.71 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 11.6 p90 -66.4 -17.72 64.94 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.437 -0.505 . . . . 72.04 110.714 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.614 ' HA ' ' HB2' ' B' ' 174' ' ' SER . 20.1 tt0 -102.46 -17.68 15.68 Favored 'General case' 0 N--CA 1.444 -0.727 0 CA-C-N 116.428 -0.351 . . . . 72.42 111.496 -177.024 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.64 HG12 ' O ' ' B' ' 169' ' ' GLN . 30.7 pt -70.18 -27.54 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.954 0.407 . . . . 72.22 110.509 178.782 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -118.22 36.25 4.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.517 0.675 . . . . 71.54 109.782 173.194 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 174' ' ' SER . . . . . 0.614 ' HB2' ' HA ' ' B' ' 171' ' ' GLU . 45.3 t -62.39 -27.17 68.89 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.023 -0.99 . . . . 61.21 111.194 -179.307 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.246 0.916 0 CA-C-O 118.437 -0.792 . . . . 70.42 111.263 -179.675 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.669 0 N-CA-C 112.076 -0.41 . . . . 54.33 112.076 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.45 -22.84 21.21 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.73 0.3 . . . . 63.44 111.242 -176.681 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 14.3 p-10 -83.77 -44.44 14.4 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.467 -0.333 . . . . 43.22 110.497 -178.869 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -166.24 -167.25 1.01 Allowed 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.094 -0.706 . . . . 73.24 109.094 175.534 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -126.09 111.78 15.08 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.905 0.383 . . . . 73.32 110.5 -178.374 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -98.91 115.1 65.95 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 115.989 -0.551 . . . . 64.11 111.142 -177.453 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -84.37 -160.25 0.11 Allowed 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 123.053 2.502 . . . . 53.41 112.228 177.092 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.0 p -79.41 178.05 8.4 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.305 -0.407 . . . . 64.41 110.875 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.2 -73.34 2.63 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.77 -0.729 . . . . 72.42 111.467 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 60.4 74.87 0.51 Allowed Pre-proline 0 C--N 1.329 -0.285 0 C-N-CA 123.046 0.538 . . . . 65.1 110.152 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.856 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 12.2 Cg_endo -60.32 107.33 0.41 Allowed 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.597 2.198 . . . . 74.02 112.708 -178.806 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 23.7 m-20 -90.5 154.03 19.94 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.627 -0.715 . . . . 61.43 109.876 179.163 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.493 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 12.5 p -117.99 125.74 74.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-O 121.395 0.617 . . . . 64.33 110.549 176.126 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.6 m -98.53 111.45 23.81 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.548 -0.751 . . . . 73.03 110.062 179.253 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.8 mt -93.2 105.86 17.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.285 -0.416 . . . . 42.15 110.945 -176.374 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -120.48 167.42 12.39 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.014 -0.735 . . . . 64.0 109.014 177.244 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 91.6 mt-30 -127.35 119.0 25.24 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 120.929 0.395 . . . . 73.31 111.281 177.173 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.452 ' HG3' HD12 ' A' ' 23' ' ' ILE . 12.4 mm-40 -97.52 82.54 3.11 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.939 -0.763 . . . . 62.41 108.939 175.151 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 79.63 -107.03 2.51 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.3 -0.952 . . . . 62.34 111.351 -173.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.574 ' HB3' ' HB2' ' A' ' 40' ' ' LYS . 10.3 m-20 -108.85 0.41 20.27 Favored 'General case' 0 C--N 1.327 -0.38 0 O-C-N 122.615 -0.344 . . . . 72.43 111.114 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.81 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 22.1 pttm -101.74 113.03 25.84 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.443 0.64 . . . . 72.42 111.022 179.085 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.705 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 21.1 m -80.0 97.87 6.97 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.222 -0.899 . . . . 63.42 109.798 177.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.586 HG12 HG13 ' A' ' 37' ' ' VAL . 55.0 mt -90.85 112.23 24.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.035 0.445 . . . . 73.44 110.566 -176.544 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.588 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 63.8 mt-30 -95.67 108.33 20.61 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.961 -0.563 . . . . 72.35 109.956 178.21 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -84.82 102.81 13.36 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.78 -0.646 . . . . 64.42 110.346 -177.78 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.44 ' HE1' ' HB2' ' A' ' 36' ' ' LYS . 86.3 m-85 -82.12 102.38 11.02 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.162 0.506 . . . . 54.45 109.783 176.626 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 88.1 mtm180 -118.12 117.52 29.39 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.853 -0.612 . . . . 70.45 109.93 -179.382 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.892 HG11 HG11 ' B' ' 128' ' ' VAL . 2.6 p -69.4 -43.19 81.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.924 -0.58 . . . . 63.02 111.14 -174.356 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 33.9 t-20 -169.85 75.35 0.08 Allowed 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.644 -0.873 . . . . 65.4 108.644 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 85.22 -23.54 8.1 Favored Glycine 0 N--CA 1.45 -0.416 0 CA-C-N 115.443 -0.799 . . . . 34.13 112.676 -177.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 51.2 t80 -112.25 131.24 55.6 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.215 0.531 . . . . 60.23 110.749 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.505 HD21 ' CG1' ' A' ' 35' ' ' ILE . 27.2 tp -76.66 126.21 30.59 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 114.974 -1.012 . . . . 72.24 110.463 178.471 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' TYR . . . . . 0.425 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 49.6 p90 -115.23 -14.3 11.71 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.764 -0.374 . . . . 75.33 111.173 179.068 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.508 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -161.72 143.81 11.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.998 0.428 . . . . 74.31 111.142 -177.602 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.624 ' HB ' ' HB2' ' A' ' 47' ' ' LEU . 63.7 mt -121.84 121.35 64.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.992 -0.549 . . . . 52.24 109.87 176.626 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.588 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 88.2 tttt -102.19 99.62 9.76 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.244 -0.651 . . . . 75.43 109.244 172.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.69 HG12 ' HD3' ' A' ' 39' ' ' PRO . 3.5 t -86.18 126.63 40.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 108.568 -0.901 . . . . 71.24 108.568 178.132 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.705 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.6 t -115.73 72.87 4.19 Favored Pre-proline 0 C--N 1.318 -0.761 0 N-CA-C 109.753 -0.462 . . . . 64.1 109.753 172.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.81 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 43.2 Cg_endo -77.08 129.4 10.5 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 122.041 1.827 . . . . 75.12 112.413 177.179 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.574 ' HB2' ' HB3' ' A' ' 20' ' ' ASP . 55.7 mtpt -59.05 -32.13 69.47 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.043 -0.981 . . . . 43.54 110.285 176.555 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 67.9 m-70 -115.36 95.93 5.41 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.365 -0.834 . . . . 65.21 109.314 178.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 132.46 -23.06 4.08 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 121.009 -0.615 . . . . 71.44 111.99 -176.779 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.498 ' HD3' ' HA ' ' A' ' 43' ' ' LYS . 68.8 mmtt 72.99 148.94 0.12 Allowed Pre-proline 0 N--CA 1.467 0.389 0 C-N-CA 123.86 0.864 . . . . 74.34 112.651 177.515 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.646 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 27.9 Cg_endo -62.59 141.86 87.68 Favored 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 123.04 2.493 . . . . 62.34 113.921 -174.74 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.422 ' CE2' ' HG2' ' A' ' 59' ' ' ARG . 25.1 p90 -151.43 149.42 29.26 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-N 115.361 -0.836 . . . . 74.03 109.855 176.548 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.597 ' HB2' ' HB2' ' A' ' 60' ' ' SER . 88.6 m-85 -92.35 150.4 20.86 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.286 -0.416 . . . . 75.44 111.14 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.624 ' HB2' ' HB ' ' A' ' 35' ' ' ILE . 23.0 mt -123.37 96.46 4.99 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.711 -0.677 . . . . 43.34 109.674 171.252 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 45.8 t -90.16 122.24 41.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.438 -0.346 . . . . 55.44 110.519 -178.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -62.25 128.98 38.64 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 120.974 0.416 . . . . 74.51 111.303 176.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.9 152.33 19.44 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.452 -0.573 . . . . 74.42 109.452 172.601 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -57.85 144.07 40.12 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.332 -0.395 . . . . 71.4 110.58 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 118.45 148.31 8.46 Favored Glycine 0 N--CA 1.431 -1.684 0 C-N-CA 120.198 -1.001 . . . . 51.24 112.402 -179.664 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 16.6 m -76.67 -2.63 33.76 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 114.947 -0.626 . . . . 73.0 110.779 175.306 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -57.91 -43.66 86.34 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.142 -0.481 . . . . 70.32 112.048 -178.057 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 98.79 32.76 5.8 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.419 -0.896 . . . . 45.43 111.63 -179.465 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -87.06 132.82 33.7 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.367 -0.416 . . . . 74.3 110.417 -178.342 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -122.17 160.17 25.7 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.994 -0.548 . . . . 71.02 110.211 177.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.817 HD11 HD23 ' A' ' 66' ' ' LEU . 43.9 mm -120.22 115.32 46.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 116.279 -0.419 . . . . 74.44 109.972 177.661 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.676 ' HG3' HG13 ' A' ' 67' ' ' ILE . 18.7 mtp180 -75.95 130.1 37.94 Favored 'General case' 0 C--O 1.22 -0.492 0 CA-C-N 115.785 -0.643 . . . . 74.42 109.797 177.366 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.597 ' HB2' ' HB2' ' A' ' 46' ' ' PHE . 17.4 t -70.48 -17.53 62.97 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.894 0.854 . . . . 75.53 108.79 172.504 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -67.76 -27.38 66.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 114.384 -1.28 . . . . 61.21 110.453 173.21 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 65.3 tt0 -158.88 78.84 3.01 Favored Pre-proline 0 C--N 1.327 -0.404 0 CA-C-N 115.664 -0.698 . . . . 73.01 109.484 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_endo -78.76 -1.24 11.43 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.725 2.284 . . . . 71.13 112.375 -174.023 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -92.52 0.09 57.39 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.406 -0.816 . . . . 72.43 110.205 -178.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.429 ' HE3' ' O ' ' A' ' 66' ' ' LEU . 52.4 tptt -128.48 134.29 48.68 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.732 -0.667 . . . . 74.11 110.539 -179.078 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.817 HD23 HD11 ' A' ' 58' ' ' ILE . 26.2 mt -80.29 123.48 28.01 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.129 -0.693 . . . . 75.41 109.129 175.182 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.676 HG13 ' HG3' ' A' ' 59' ' ' ARG . 44.1 mm -92.43 113.76 60.32 Favored Pre-proline 0 C--N 1.32 -0.681 0 CA-C-O 120.941 0.401 . . . . 75.34 111.277 -173.08 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -72.62 177.99 6.82 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.887 2.392 . . . . 74.24 112.961 -177.288 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLN . . . . . 0.535 ' O ' HG12 ' A' ' 72' ' ' ILE . 19.4 tt0 -77.58 -17.14 58.13 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.493 -0.776 . . . . 73.34 112.067 -168.506 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 10.4 p90 -83.16 -18.32 39.83 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.251 -0.58 . . . . 74.33 110.281 176.76 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.553 ' HB3' HG23 ' A' ' 67' ' ' ILE . 1.4 tm-20 -90.35 -24.49 20.82 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 115.933 -0.576 . . . . 63.14 109.966 -178.304 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.535 HG12 ' O ' ' A' ' 69' ' ' GLN . 31.5 pt -70.28 -20.89 23.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 121.223 0.535 . . . . 62.44 110.396 177.766 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 46.2 m-85 -111.62 33.67 4.6 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.787 -0.642 . . . . 74.22 109.822 174.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 19.0 t -67.0 -33.17 74.98 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.384 -0.825 . . . . 62.21 110.171 178.703 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' TRP . . . . . 0.458 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 8.2 p-90 . . . . . 0 C--N 1.327 -0.398 0 CA-C-N 116.003 -0.544 . . . . 74.34 110.602 175.386 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.405 0 N-CA-C 112.186 -0.366 . . . . 71.11 112.186 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -78.59 -39.31 37.79 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.198 0.523 . . . . 61.2 110.368 178.431 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 103' ' ' ASP . . . . . 0.425 ' O ' ' HB3' ' B' ' 104' ' ' ASP . 6.4 p-10 -109.14 117.34 33.89 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.079 -0.711 . . . . 74.33 109.079 173.519 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 104' ' ' ASP . . . . . 0.425 ' HB3' ' O ' ' B' ' 103' ' ' ASP . 8.4 t70 70.18 136.59 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 121.522 0.677 . . . . 64.41 111.615 -177.83 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -121.4 128.65 52.42 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.829 -0.623 . . . . 72.13 110.991 -178.006 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 106' ' ' ALA . . . . . 0.505 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -115.36 135.09 22.52 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.199 -0.455 . . . . 71.21 110.516 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 107' ' ' PRO . . . . . 0.505 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 15.1 Cg_endo -90.71 -161.25 0.1 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 123.408 2.739 . . . . 64.32 112.698 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 5.2 p -73.37 162.33 29.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.777 -0.647 . . . . 63.02 111.065 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 108.75 -77.21 0.22 Allowed Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.588 -1.005 . . . . 73.33 110.588 -177.702 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 68.85 86.68 0.12 Allowed Pre-proline 0 CA--C 1.521 -0.171 0 CA-C-O 121.274 0.559 . . . . 70.02 110.558 173.072 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.668 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 3.0 Cg_exo -69.95 118.04 5.45 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 122.298 1.999 . . . . 74.44 111.731 -174.493 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -118.44 161.38 20.07 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.091 -0.958 . . . . 62.5 109.763 -174.591 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 113' ' ' VAL . . . . . . . . . . . . . 14.6 p -133.3 132.63 58.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.428 0.632 . . . . 61.13 111.5 -178.012 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 31.4 m -97.17 105.07 17.16 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.527 -0.76 . . . . 75.1 109.266 174.191 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 65.6 mt -95.59 104.66 16.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.369 0.604 . . . . 65.23 110.703 -176.369 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 57.1 mtm180 -123.55 176.06 6.42 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.247 -0.888 . . . . 54.34 109.354 176.766 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 117' ' ' GLN . . . . . 0.738 ' HG2' ' HA ' ' B' ' 122' ' ' THR . 37.7 mt-30 -134.17 139.73 46.05 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.411 0.624 . . . . 73.12 111.389 178.712 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 118' ' ' GLU . . . . . 0.565 ' HB3' ' HE2' ' B' ' 121' ' ' LYS . 0.9 OUTLIER -120.15 72.85 0.95 Allowed 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.954 -1.021 . . . . 73.33 109.679 -177.075 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 87.93 -108.87 3.44 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.611 -0.804 . . . . 71.21 111.703 -175.733 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.687 ' HB3' ' HD2' ' B' ' 140' ' ' LYS . 39.5 m-20 -109.9 13.24 23.55 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.932 0.396 . . . . 75.14 110.616 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.573 ' HE3' ' HB2' ' B' ' 175' ' ' TRP . 23.7 pttm -120.02 116.49 25.85 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.868 -0.606 . . . . 74.13 110.664 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 122' ' ' THR . . . . . 0.738 ' HA ' ' HG2' ' B' ' 117' ' ' GLN . 20.0 m -77.4 122.16 24.78 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.598 -0.728 . . . . 64.44 109.495 176.489 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 55.7 mt -112.4 107.79 23.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.328 0.585 . . . . 75.44 110.819 -176.356 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.509 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 51.2 mt-30 -100.5 102.9 14.19 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.724 -0.671 . . . . 75.43 109.935 178.476 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 125' ' ' GLU . . . . . 0.407 ' HB3' HD13 ' B' ' 132' ' ' LEU . 48.3 mt-10 -82.92 104.58 13.24 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.005 -0.543 . . . . 73.12 110.521 -179.612 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 126' ' ' TYR . . . . . 0.43 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 79.2 m-85 -82.15 108.9 15.98 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.165 0.507 . . . . 74.43 110.147 178.356 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 82.9 mtt180 -118.97 121.41 39.86 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.806 -0.634 . . . . 74.13 109.342 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.892 HG11 HG11 ' A' ' 28' ' ' VAL . 2.1 p -70.68 -46.44 69.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 C-N-CA 120.761 -0.376 . . . . 72.24 110.719 -178.424 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -158.34 56.96 0.46 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.482 0.658 . . . . 63.12 109.427 -177.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 98.04 -23.74 34.76 Favored Glycine 0 N--CA 1.449 -0.452 0 CA-C-N 115.589 -0.732 . . . . 72.35 112.86 -178.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -104.28 129.82 52.11 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 121.062 0.458 . . . . 72.22 110.46 -178.064 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.558 HD21 ' CG1' ' B' ' 135' ' ' ILE . 28.7 tp -74.46 120.86 20.6 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.107 -0.952 . . . . 72.14 110.6 177.777 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 133' ' ' TYR . . . . . 0.43 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 54.1 p90 -110.86 -12.96 14.21 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.845 -0.342 . . . . 74.51 111.204 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 134' ' ' ALA . . . . . 0.565 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -167.1 137.1 2.96 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.974 0.416 . . . . 65.45 111.141 -177.337 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.558 ' CG1' HD21 ' B' ' 132' ' ' LEU . 56.9 mt -114.58 122.78 69.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.02 -0.536 . . . . 73.2 109.821 175.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.509 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.3 tttt -96.0 101.51 13.19 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.089 -0.708 . . . . 51.44 109.089 172.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.681 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.0 t -91.62 125.84 44.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 108.493 -0.929 . . . . 72.21 108.493 177.821 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.536 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.3 t -115.48 72.91 3.81 Favored Pre-proline 0 C--N 1.316 -0.867 0 N-CA-C 109.672 -0.492 . . . . 54.25 109.672 173.791 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.611 ' HD3' HG12 ' B' ' 137' ' ' VAL . 56.8 Cg_endo -80.21 133.32 9.76 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 122.153 1.902 . . . . 64.31 112.005 175.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 140' ' ' LYS . . . . . 0.687 ' HD2' ' HB3' ' B' ' 120' ' ' ASP . 93.0 mttt -52.05 -40.93 61.88 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.527 0.68 . . . . 60.21 110.219 175.378 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 8.6 m-70 -112.26 91.9 3.82 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.108 -0.951 . . . . 75.53 109.429 -175.056 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 140.66 -21.65 2.7 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.819 -0.628 . . . . 51.2 111.832 -177.014 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt 75.3 150.62 0.13 Allowed Pre-proline 0 N--CA 1.469 0.491 0 C-N-CA 123.544 0.738 . . . . 54.33 111.708 178.271 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.681 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 36.5 Cg_endo -66.9 137.39 44.8 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 122.461 2.107 . . . . 62.14 112.791 -177.8 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 145' ' ' TYR . . . . . 0.413 ' CD2' ' HD2' ' B' ' 159' ' ' ARG . 50.8 p90 -149.51 150.28 32.06 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.751 -0.659 . . . . 72.04 110.352 179.276 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.534 ' O ' ' HA ' ' B' ' 159' ' ' ARG . 92.4 m-85 -95.74 130.35 42.68 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.778 -0.646 . . . . 73.14 110.375 176.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.565 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 15.0 mt -99.77 99.29 10.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.119 -0.491 . . . . 74.31 109.908 170.68 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.0 t -83.97 127.99 39.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 116.311 -0.404 . . . . 75.43 110.246 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.99 108.72 2.7 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.124 -0.695 . . . . 72.41 109.124 176.418 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.24 166.38 9.95 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.207 -0.451 . . . . 52.35 110.97 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -53.5 129.03 31.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.7 0.762 . . . . 75.45 112.52 -175.624 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 83.11 -115.99 4.13 Favored Glycine 0 N--CA 1.429 -1.816 0 CA-C-N 114.447 -1.251 . . . . 64.22 111.509 178.653 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 17.0 m -169.41 34.51 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 113.803 -1.198 . . . . 65.54 109.384 -178.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -78.79 35.7 0.25 Allowed 'General case' 0 CA--C 1.535 0.365 0 CA-C-N 115.4 -0.818 . . . . 72.25 111.405 -173.492 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 58.12 43.23 95.35 Favored Glycine 0 C--O 1.229 -0.212 0 CA-C-N 115.789 -0.641 . . . . 62.14 113.21 177.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 47.1 t30 -137.3 137.83 39.39 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.185 0.516 . . . . 74.32 111.085 -177.36 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 157' ' ' PHE . . . . . 0.527 ' HB3' HD22 ' B' ' 147' ' ' LEU . 39.0 m-85 -131.09 154.25 48.48 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.189 -0.914 . . . . 75.13 108.697 172.481 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 49.2 mm -120.65 122.79 68.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 N-CA-C 110.183 -0.303 . . . . 61.45 110.183 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.955 ' HG3' HG13 ' B' ' 167' ' ' ILE . 31.5 mtm-85 -88.9 137.28 32.46 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-N 116.338 -0.392 . . . . 72.44 110.126 178.067 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 35.1 t -64.69 -18.94 65.44 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.445 0.64 . . . . 73.32 109.334 171.347 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -59.37 -52.13 66.95 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 114.942 -1.027 . . . . 71.15 110.878 174.4 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 75.6 mt-30 -143.71 79.6 13.45 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 74.41 110.442 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -68.21 -0.58 5.87 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 123.292 2.661 . . . . 60.1 112.329 177.115 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -81.44 -18.48 45.16 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.639 -0.71 . . . . 64.25 110.233 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -119.95 140.11 51.42 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.856 -0.611 . . . . 61.34 110.885 -177.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.0 mp -81.87 126.87 32.4 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 107.898 -1.149 . . . . 74.32 107.898 171.007 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 167' ' ' ILE . . . . . 0.955 HG13 ' HG3' ' B' ' 159' ' ' ARG . 44.7 mm -87.81 119.66 70.63 Favored Pre-proline 0 C--N 1.318 -0.794 0 CA-C-O 120.882 0.372 . . . . 75.34 111.267 -170.425 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.449 ' O ' HG23 ' B' ' 172' ' ' ILE . 58.8 Cg_endo -71.09 174.3 10.85 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 123.27 2.647 . . . . 65.44 112.655 -179.187 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 169' ' ' GLN . . . . . 0.813 ' HA ' HG12 ' B' ' 172' ' ' ILE . 8.5 tt0 -72.75 -32.62 65.79 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.58 -0.736 . . . . 61.44 111.963 -168.592 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 36.9 p90 -73.56 -17.86 61.14 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.165 0.507 . . . . 74.33 110.326 178.103 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 171' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -94.28 -30.86 14.33 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.847 -0.615 . . . . 63.23 110.964 178.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.813 HG12 ' HA ' ' B' ' 169' ' ' GLN . 37.6 pt -74.45 -29.3 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.985 0.421 . . . . 73.13 110.381 176.312 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -104.76 37.86 2.04 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.184 0.516 . . . . 73.14 110.13 175.256 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 15.9 t -73.78 -22.88 59.69 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.827 -0.624 . . . . 65.3 110.262 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 175' ' ' TRP . . . . . 0.573 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 60.3 p-90 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.243 -0.884 . . . . 75.21 110.656 -178.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.84 0 N-CA-C 112.195 -0.362 . . . . 72.23 112.195 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -144.72 79.74 1.61 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.719 0.295 . . . . 61.32 110.801 179.398 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 62.11 20.87 11.98 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.721 -0.672 . . . . 72.3 111.963 178.794 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -95.62 155.35 16.78 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.146 0.498 . . . . 75.11 110.588 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 34.8 t70 -93.29 133.1 36.87 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.768 -0.651 . . . . 63.54 110.972 -177.094 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -87.63 138.23 31.74 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-N 115.845 -0.616 . . . . 70.33 111.096 -177.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -82.24 179.46 5.49 Favored 'Trans proline' 0 N--CA 1.464 -0.261 0 C-N-CA 122.954 2.436 . . . . 74.14 112.938 -177.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 28.5 p -72.42 110.43 6.82 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-N 116.135 -0.484 . . . . 74.43 110.043 176.122 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.79 105.63 3.02 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 110.2 -1.16 . . . . 65.24 110.2 -173.749 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -116.76 95.74 47.06 Favored Pre-proline 0 C--N 1.317 -0.823 0 N-CA-C 109.516 -0.55 . . . . 74.41 109.516 -171.437 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.29 100.35 1.36 Allowed 'Trans proline' 0 N--CA 1.445 -1.372 0 C-N-CA 121.797 1.664 . . . . 43.05 111.422 -177.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -132.12 145.28 51.28 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.222 -0.899 . . . . 75.33 109.546 178.541 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.705 HG21 ' HB3' ' A' ' 24' ' ' GLN . 12.8 p -98.63 131.5 45.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 CA-C-O 121.297 0.57 . . . . 75.24 111.674 -172.628 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.49 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 25.0 m -83.69 103.79 13.28 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.686 -0.688 . . . . 75.22 109.211 176.527 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 61.3 mt -93.44 105.66 17.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 116.246 -0.434 . . . . 74.1 110.474 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 28.4 mmm180 -121.41 153.74 37.43 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.99 -0.55 . . . . 73.3 110.29 177.401 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 23.3 mp0 -113.49 107.66 16.12 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-O 121.355 0.598 . . . . 75.51 110.522 -178.069 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.653 ' HG3' HD12 ' A' ' 23' ' ' ILE . 24.1 mm-40 -106.21 88.4 2.78 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.204 -0.907 . . . . 62.11 109.8 -177.115 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 74.11 -109.57 2.83 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.702 -0.761 . . . . 64.34 112.201 -179.55 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.672 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 25.4 m-20 -109.31 22.4 15.87 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.752 0.311 . . . . 72.01 110.507 -177.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.56 ' HE2' HD11 ' A' ' 23' ' ' ILE . 22.2 pttm -138.41 127.05 23.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.307 0.575 . . . . 60.15 111.175 -178.663 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.591 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 26.4 m -85.13 103.9 14.54 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.623 -0.717 . . . . 62.33 109.232 174.423 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.653 HD12 ' HG3' ' A' ' 18' ' ' GLU . 41.7 mt -95.61 112.54 28.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.162 0.505 . . . . 72.42 110.294 -176.029 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.705 ' HB3' HG21 ' A' ' 13' ' ' VAL . 76.4 mt-30 -103.82 109.78 21.65 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.413 -0.812 . . . . 72.33 111.111 -176.86 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.49 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 24.7 mt-10 -94.61 106.67 18.66 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.032 -0.531 . . . . 72.34 111.137 -179.113 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.493 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 54.5 m-85 -76.69 109.52 10.53 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.276 -0.42 . . . . 52.53 110.508 178.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 74.7 mtt180 -124.06 140.49 52.92 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.337 -0.392 . . . . 74.11 110.115 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.505 HG21 ' CG ' ' B' ' 131' ' ' PHE . 12.3 p -109.03 -19.47 6.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.422 0.63 . . . . 72.53 111.28 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -159.82 24.54 0.18 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.237 -0.653 . . . . 72.45 109.237 -176.321 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 99.62 -31.18 8.65 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 110.984 -0.846 . . . . 75.32 110.984 -169.745 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 89.3 t80 -66.87 130.1 42.04 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.178 -0.511 . . . . 75.3 110.811 178.004 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.757 HD11 HG13 ' A' ' 35' ' ' ILE . 3.3 tm? -88.38 114.47 25.03 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.554 -0.748 . . . . 41.53 109.231 178.19 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' TYR . . . . . 0.493 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 43.2 p90 -110.98 -13.27 14.13 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.664 -0.414 . . . . 74.24 111.682 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -163.21 144.42 9.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.723 0.296 . . . . 65.01 111.34 179.588 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.757 HG13 HD11 ' A' ' 32' ' ' LEU . 71.3 mt -126.1 123.71 64.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.111 -0.495 . . . . 62.31 109.768 176.07 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.419 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 87.0 tttt -108.81 107.22 17.56 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.628 -0.508 . . . . 63.15 109.628 176.029 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.649 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.7 t -89.92 132.31 34.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.189 -0.671 . . . . 53.04 109.189 178.38 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.591 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 18.9 t -116.57 73.97 6.05 Favored Pre-proline 0 C--N 1.322 -0.623 0 N-CA-C 109.433 -0.58 . . . . 41.24 109.433 171.194 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.47 ' HD3' HG12 ' A' ' 37' ' ' VAL . 61.0 Cg_endo -78.71 145.87 20.69 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.642 2.228 . . . . 74.1 112.977 179.212 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.672 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 30.5 mtpp -68.07 -28.0 66.99 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.514 -0.766 . . . . 73.53 109.932 174.043 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 66.5 m-70 -122.52 96.2 4.94 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.55 -0.75 . . . . 54.44 109.745 178.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.418 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 139.51 -21.5 2.9 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.73 -0.747 . . . . 54.52 112.422 -179.649 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.422 ' HD3' ' HA ' ' A' ' 43' ' ' LYS . 69.4 mmtt 71.89 150.38 0.13 Allowed Pre-proline 0 N--CA 1.47 0.56 0 C-N-CA 123.201 0.6 . . . . 71.44 111.956 -179.593 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.649 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 39.4 Cg_endo -67.0 137.18 43.72 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.564 2.176 . . . . 73.53 112.683 -178.359 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 42.0 p90 -149.52 163.95 36.41 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.738 -0.664 . . . . 73.33 110.294 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.472 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 96.3 m-85 -108.22 126.44 52.81 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.484 -0.325 . . . . 72.53 111.429 -176.797 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.449 ' HB3' ' HD2' ' A' ' 57' ' ' PHE . 36.9 mt -107.22 100.14 9.62 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.131 -0.486 . . . . 72.51 109.977 171.253 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.6 t -84.74 126.72 40.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.245 -0.434 . . . . 73.35 109.901 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.45 111.39 18.43 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.236 -0.653 . . . . 73.42 109.236 -178.542 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.05 168.89 19.01 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.8 -0.636 . . . . 60.41 111.411 -172.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -64.14 145.19 56.37 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.765 -0.652 . . . . 74.33 109.904 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 113.83 135.95 6.26 Favored Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.452 -0.88 . . . . 44.3 112.373 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.2 m -79.24 19.68 0.56 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.931 0.396 . . . . 61.54 110.832 178.857 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -78.91 -42.61 26.7 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.026 0.441 . . . . 64.22 111.137 -177.313 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.84 36.4 2.99 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.698 -0.763 . . . . 75.32 111.919 -178.404 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.2 t30 -95.45 129.49 42.59 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.821 0.343 . . . . 74.05 110.539 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.449 ' HD2' ' HB3' ' A' ' 47' ' ' LEU . 34.7 m-85 -111.51 149.38 31.43 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.227 -0.442 . . . . 72.41 110.153 177.016 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 51.0 mm -121.57 125.73 73.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.22 -0.445 . . . . 72.12 109.98 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.581 ' HG3' HG13 ' A' ' 67' ' ' ILE . 27.4 mtp180 -81.6 141.08 34.05 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.438 -0.346 . . . . 72.12 110.66 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 33.7 t -70.0 -16.21 63.14 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.229 0.538 . . . . 74.14 109.894 176.441 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.46 ' OD1' ' HB3' ' A' ' 59' ' ' ARG . 0.4 OUTLIER -76.03 -34.41 59.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.4 -0.818 . . . . 73.31 109.945 178.169 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 47.7 mt-30 -143.26 70.36 18.01 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.443 -0.799 . . . . 74.33 109.786 -174.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -72.88 -2.35 11.83 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 123.325 2.684 . . . . 73.45 113.476 -175.067 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -94.06 -13.63 26.67 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.608 0.242 . . . . 71.45 111.332 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.419 ' HE2' ' HB2' ' A' ' 65' ' ' LYS . 0.0 OUTLIER -117.02 168.76 9.97 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-O 120.549 0.214 . . . . 73.05 110.943 -179.567 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.429 ' N ' HD12 ' A' ' 66' ' ' LEU . 4.1 mp -106.3 151.84 24.31 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 120.831 0.348 . . . . 74.11 111.032 -175.228 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.581 HG13 ' HG3' ' A' ' 59' ' ' ARG . 37.9 mm -119.54 104.98 44.43 Favored Pre-proline 0 C--N 1.325 -0.463 0 CA-C-N 116.192 -0.458 . . . . 52.05 109.98 177.519 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.558 ' O ' HG23 ' A' ' 72' ' ' ILE . 61.3 Cg_endo -73.77 177.42 8.11 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.822 2.348 . . . . 62.22 113.004 -178.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLN . . . . . 0.626 ' HA ' HG12 ' A' ' 72' ' ' ILE . 28.5 tt0 -65.32 -32.05 73.5 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 113.029 0.751 . . . . 64.12 113.029 -168.159 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 3.9 p90 -71.34 -18.95 62.36 Favored 'General case' 0 C--N 1.323 -0.545 0 O-C-N 121.517 -0.739 . . . . 74.43 110.592 178.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.47 ' HB3' HG23 ' A' ' 67' ' ' ILE . 4.8 tp10 -102.38 -17.76 15.7 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 115.749 -0.66 . . . . 72.35 110.549 -177.117 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.626 HG12 ' HA ' ' A' ' 69' ' ' GLN . 35.3 pt -74.26 -21.77 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.147 0 CA-C-O 121.256 0.55 . . . . 63.0 109.863 174.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -107.21 26.59 9.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.417 -0.81 . . . . 73.54 109.664 174.575 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.2 t -61.42 -29.84 70.19 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.197 -0.91 . . . . 65.54 110.234 179.295 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' TRP . . . . . 0.517 ' O ' ' HE3' ' A' ' 21' ' ' LYS . 28.3 p-90 . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.135 -0.484 . . . . 72.22 110.757 175.399 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 N-CA-C 112.128 -0.389 . . . . 73.23 112.128 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -140.67 -59.99 0.51 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.086 0.469 . . . . 75.22 110.117 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -139.08 81.84 1.86 Allowed 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 108.703 -0.851 . . . . 71.41 108.703 173.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -173.21 177.92 2.57 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.468 -0.787 . . . . 71.51 110.208 -172.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -114.95 161.97 17.58 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.113 -0.494 . . . . 74.44 110.832 -177.003 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -118.21 139.18 26.39 Favored Pre-proline 0 C--N 1.321 -0.638 0 CA-C-N 115.652 -0.704 . . . . 73.41 109.428 172.607 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.2 148.95 87.84 Favored 'Trans proline' 0 C--O 1.236 0.39 0 C-N-CA 122.451 2.101 . . . . 72.42 111.798 178.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 15.0 m -51.5 130.27 27.3 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-O 121.108 0.48 . . . . 72.43 110.737 -178.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 124.49 -65.6 0.54 Allowed Glycine 0 N--CA 1.442 -0.953 0 N-CA-C 109.983 -1.247 . . . . 74.05 109.983 -174.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 66.82 86.4 0.13 Allowed Pre-proline 0 N--CA 1.463 0.178 0 O-C-N 124.334 0.667 . . . . 65.3 111.736 173.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.579 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 11.2 Cg_endo -77.58 97.16 1.13 Allowed 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 121.913 1.742 . . . . 72.55 110.775 177.441 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -128.81 150.82 50.15 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.407 -0.815 . . . . 75.31 109.67 -175.081 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.539 HG21 ' HB3' ' B' ' 124' ' ' GLN . 12.0 p -100.7 131.31 48.56 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 121.417 0.627 . . . . 75.11 111.748 -174.108 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 114' ' ' THR . . . . . 0.587 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 15.6 m -87.77 102.43 14.66 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.5 -0.773 . . . . 73.15 109.772 175.585 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 55.1 mt -91.03 105.82 16.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-O 120.829 0.347 . . . . 73.51 110.495 -176.291 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 28.7 mmm180 -112.85 157.89 20.84 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.259 -0.428 . . . . 65.32 110.464 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -121.22 99.32 6.42 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.23 -0.441 . . . . 33.11 109.961 178.139 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 57.5 mm-40 -109.59 80.86 1.36 Allowed 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.981 -0.554 . . . . 65.41 110.515 -176.353 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 82.26 -121.43 5.43 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 121.008 -0.615 . . . . 73.21 112.32 -179.351 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.493 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 5.9 m-20 -88.57 0.89 55.88 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.914 0.388 . . . . 74.11 110.527 -176.697 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.617 ' HE2' ' HB2' ' B' ' 175' ' ' TRP . 15.6 pttp -125.47 124.67 41.9 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.349 0.595 . . . . 75.12 112.373 -172.54 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 122' ' ' THR . . . . . 0.454 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 33.4 m -83.97 109.7 17.84 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.044 -0.98 . . . . 75.25 108.595 172.114 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 53.2 mt -100.3 107.83 21.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.107 0.48 . . . . 61.51 110.627 -173.45 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.678 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 63.9 mt-30 -95.5 102.26 14.05 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.67 -0.695 . . . . 63.43 110.45 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 125' ' ' GLU . . . . . 0.587 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 43.3 mt-10 -86.87 102.31 14.2 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.265 -0.425 . . . . 71.23 110.365 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -78.54 104.83 9.4 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.122 0.487 . . . . 75.3 110.017 178.101 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 127' ' ' ARG . . . . . 0.513 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 82.6 mtm180 -126.14 136.76 53.26 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.653 -0.703 . . . . 71.52 110.141 -179.186 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.677 HG13 ' H ' ' B' ' 129' ' ' ASN . 2.4 p -84.81 -67.87 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 C-N-CA 120.32 -0.552 . . . . 61.33 109.658 175.677 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 129' ' ' ASN . . . . . 0.677 ' H ' HG13 ' B' ' 128' ' ' VAL . 2.2 t-20 -138.64 75.84 1.54 Allowed 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.56 -0.533 . . . . 71.3 109.56 178.332 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.7 -27.55 5.29 Favored Glycine 0 CA--C 1.518 0.231 0 CA-C-N 115.771 -0.65 . . . . 62.23 112.223 -178.462 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.505 ' CG ' HG21 ' A' ' 28' ' ' VAL . 82.9 t80 -86.19 124.75 32.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.902 0.382 . . . . 60.41 111.225 -177.176 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.857 HD11 HG13 ' B' ' 135' ' ' ILE . 3.5 tm? -85.6 119.38 25.88 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.893 -0.78 . . . . 52.25 108.893 175.462 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 44.1 p90 -112.94 -17.11 12.55 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.495 -0.482 . . . . 63.3 111.787 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.46 133.22 6.43 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.717 0.294 . . . . 63.22 111.059 178.552 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.857 HG13 HD11 ' B' ' 132' ' ' LEU . 69.8 mt -113.28 120.34 62.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.453 -0.339 . . . . 74.41 110.174 174.4 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.678 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.9 tttt -101.0 104.64 15.81 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.682 -0.488 . . . . 65.43 109.682 176.213 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.609 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 2.7 t -90.91 128.67 42.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 108.928 -0.767 . . . . 63.34 108.928 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.454 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 20.3 t -112.96 73.34 1.57 Allowed Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.771 -0.455 . . . . 75.45 109.771 171.253 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.491 ' HG3' ' HE1' ' B' ' 145' ' ' TYR . 72.9 Cg_endo -80.66 143.84 15.24 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 122.438 2.092 . . . . 71.34 112.76 178.886 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 140' ' ' LYS . . . . . 0.493 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 30.0 mtpp -65.75 -23.77 66.81 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.483 -0.78 . . . . 74.21 110.383 174.04 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 72.6 m-70 -115.91 95.07 4.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.574 -0.739 . . . . 54.04 110.025 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 142' ' ' GLY . . . . . 0.449 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 127.58 -9.93 6.83 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.178 -1.011 . . . . 51.41 113.638 177.093 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 143' ' ' LYS . . . . . 0.449 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 73.1 mmtt 70.64 155.9 0.15 Allowed Pre-proline 0 N--CA 1.472 0.644 0 CA-C-O 120.755 0.312 . . . . 44.02 111.164 -178.488 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.609 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 33.6 Cg_endo -66.48 135.13 38.17 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.192 1.928 . . . . 54.51 112.84 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 145' ' ' TYR . . . . . 0.491 ' HE1' ' HG3' ' B' ' 139' ' ' PRO . 14.7 p90 -146.4 161.28 40.71 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.768 -0.651 . . . . 73.1 110.205 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -106.75 138.46 42.88 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.27 -0.423 . . . . 72.44 111.758 -176.721 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.486 ' HB2' ' HB ' ' B' ' 135' ' ' ILE . 18.7 mt -110.38 95.73 5.76 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.447 -0.797 . . . . 75.3 109.72 168.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 41.6 t -82.14 126.39 39.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 109.692 -0.484 . . . . 72.41 109.692 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 149' ' ' ARG . . . . . 0.47 ' HG3' HH11 ' B' ' 149' ' ' ARG . 0.0 OUTLIER -80.86 114.66 19.89 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.439 -0.578 . . . . 62.11 109.439 -179.228 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.75 165.18 25.65 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.627 -0.715 . . . . 42.41 111.005 -174.226 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -70.44 147.57 49.32 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.581 -0.526 . . . . 71.42 109.581 178.235 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 105.01 131.26 7.03 Favored Glycine 0 N--CA 1.436 -1.347 0 C-N-CA 120.61 -0.805 . . . . 61.34 111.357 -175.554 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 21.6 m -82.77 17.8 1.75 Allowed 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.286 0.565 . . . . 75.01 110.587 -178.733 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -64.77 -52.96 54.14 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.488 -0.778 . . . . 61.43 110.958 -178.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 125.86 50.36 0.18 Allowed Glycine 0 CA--C 1.505 -0.588 0 C-N-CA 120.657 -0.782 . . . . 50.43 112.025 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 4.9 m120 -119.06 134.29 55.28 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.356 -0.422 . . . . 54.34 111.484 -177.305 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 157' ' ' PHE . . . . . 0.434 ' HB2' HG22 ' B' ' 172' ' ' ILE . 29.6 m-85 -117.31 159.19 23.1 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.541 -0.754 . . . . 63.23 109.735 174.357 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 158' ' ' ILE . . . . . 0.9 HD11 HD23 ' B' ' 166' ' ' LEU . 47.4 mm -120.7 122.79 68.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 116.256 -0.429 . . . . 74.5 110.008 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.627 ' HG3' HG13 ' B' ' 167' ' ' ILE . 52.2 mtp180 -87.81 147.18 25.26 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.375 -0.375 . . . . 73.21 110.379 178.028 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 33.8 t -67.38 -20.64 65.57 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.337 0.589 . . . . 74.45 109.466 174.713 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 161' ' ' ASP . . . . . 0.471 ' OD1' ' HB3' ' B' ' 159' ' ' ARG . 0.5 OUTLIER -71.93 -34.19 68.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.221 -0.9 . . . . 71.14 109.869 177.248 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -141.47 76.88 20.31 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.448 -0.796 . . . . 73.42 109.709 -174.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -82.18 4.53 6.99 Favored 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 122.746 2.297 . . . . 71.54 113.326 -173.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -109.07 -11.07 14.99 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.804 0.335 . . . . 73.35 111.084 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -122.93 137.25 55.0 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.75 0.31 . . . . 75.55 110.907 -176.59 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 166' ' ' LEU . . . . . 0.9 HD23 HD11 ' B' ' 158' ' ' ILE . 93.6 mt -73.96 130.65 40.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.018 -0.537 . . . . 74.34 109.986 177.122 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 167' ' ' ILE . . . . . 0.627 HG13 ' HG3' ' B' ' 159' ' ' ARG . 42.3 mm -81.48 128.5 69.54 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 116.366 -0.379 . . . . 73.22 110.393 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.527 ' O ' HG23 ' B' ' 172' ' ' ILE . 40.0 Cg_endo -65.75 173.01 7.37 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 123.163 2.575 . . . . 63.31 112.789 -179.344 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 33.8 tt0 -86.11 3.76 41.21 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.825 -0.625 . . . . 73.41 112.181 -168.271 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 170' ' ' TRP . . . . . 0.464 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 33.7 p90 -104.05 -18.89 14.38 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.377 -0.529 . . . . 73.42 109.872 172.799 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.464 ' HG2' ' CD1' ' B' ' 170' ' ' TRP . 2.8 mm-40 -97.65 -10.47 24.98 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.566 -0.743 . . . . 71.14 111.393 -176.631 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.527 HG23 ' O ' ' B' ' 168' ' ' PRO . 30.7 pt -71.68 -21.52 21.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.877 -0.601 . . . . 71.2 110.171 175.537 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -112.09 46.49 1.15 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.41 -0.814 . . . . 64.2 108.995 174.568 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 174' ' ' SER . . . . . 0.464 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 2.1 t -74.89 -13.84 60.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.402 -0.817 . . . . 74.22 110.163 -178.403 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 175' ' ' TRP . . . . . 0.617 ' HB2' ' HE2' ' B' ' 121' ' ' LYS . 49.1 p-90 . . . . . 0 C--O 1.248 0.998 0 CA-C-N 115.502 -0.772 . . . . 74.13 109.85 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.798 0 N-CA-C 111.607 -0.597 . . . . 62.2 111.607 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -75.3 -54.75 6.57 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.201 -0.666 . . . . 72.42 109.201 175.706 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 44.5 m-20 52.4 68.59 0.8 Allowed 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.286 -0.87 . . . . 74.12 111.49 174.397 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -132.96 161.8 33.34 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.477 -0.783 . . . . 74.23 109.521 178.315 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -87.46 116.47 25.59 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.342 -0.39 . . . . 72.53 110.415 -179.426 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -89.05 156.12 49.3 Favored Pre-proline 0 C--N 1.32 -0.703 0 CA-C-N 116.109 -0.496 . . . . 41.43 109.889 178.022 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.453 ' HB2' ' HD1' ' B' ' 131' ' ' PHE . 51.9 Cg_exo -53.68 150.07 29.97 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.643 2.229 . . . . 73.32 112.186 178.457 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 41.6 m -60.93 115.63 3.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.112 0.482 . . . . 73.32 111.022 -177.089 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -177.69 -38.72 0.06 OUTLIER Glycine 0 N--CA 1.446 -0.663 0 N-CA-C 110.71 -0.956 . . . . 54.24 110.71 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 54.05 66.29 4.52 Favored Pre-proline 0 N--CA 1.464 0.254 0 C-N-CA 123.556 0.742 . . . . 71.05 112.15 175.81 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 53.8 Cg_endo -76.97 137.49 17.53 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.169 1.912 . . . . 73.11 112.516 -178.317 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -141.4 155.83 45.86 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.968 -0.56 . . . . 71.5 109.738 179.755 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.8 p -110.88 129.75 65.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.273 0.559 . . . . 64.12 110.842 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.6 m -93.86 104.38 16.45 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.728 -0.669 . . . . 71.44 109.563 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 67.1 mt -90.1 106.82 17.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 116.301 -0.409 . . . . 72.41 110.351 -177.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 23.6 mmm180 -115.57 156.96 24.83 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.143 -0.48 . . . . 73.43 110.212 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 26.1 mp0 -121.58 127.17 50.64 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 121.098 0.475 . . . . 70.22 110.057 178.047 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -105.08 -60.58 1.59 Allowed 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.35 -0.841 . . . . 63.13 111.0 -172.12 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.519 ' C ' ' H ' ' A' ' 21' ' ' LYS . . . -156.95 76.58 0.2 Allowed Glycine 0 CA--C 1.507 -0.433 0 N-CA-C 110.353 -1.099 . . . . 51.42 110.353 178.741 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.538 ' HB3' ' HG3' ' A' ' 40' ' ' LYS . 19.2 m-20 70.07 -26.76 0.16 Allowed 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 123.519 0.728 . . . . 63.33 111.017 -170.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.519 ' H ' ' C ' ' A' ' 19' ' ' GLY . 22.7 pttm -83.42 120.21 25.61 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 121.198 0.523 . . . . 60.14 110.42 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.594 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 33.2 m -82.48 121.62 26.99 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.375 -0.83 . . . . 72.31 109.641 176.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 56.0 mt -111.33 106.77 21.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-O 121.036 0.446 . . . . 61.44 110.333 -178.188 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.67 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 67.5 mt-30 -100.53 111.04 23.24 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.788 -0.642 . . . . 55.1 110.756 -177.642 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 33.0 mt-10 -92.57 108.77 20.23 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.768 -0.651 . . . . 63.1 110.85 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.57 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 95.6 m-85 -83.0 104.65 13.37 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.968 0.414 . . . . 63.01 110.151 178.317 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -115.12 119.25 35.77 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.947 -0.569 . . . . 74.31 109.617 -179.24 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.781 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.7 p -73.26 -73.32 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 C-N-CA 120.786 -0.366 . . . . 61.32 110.879 -178.834 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.781 ' H ' HG13 ' A' ' 28' ' ' VAL . 7.6 t-20 -127.53 68.28 1.3 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.291 -0.633 . . . . 62.51 109.291 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 73.19 12.52 79.62 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.452 -0.795 . . . . 72.53 111.784 -175.763 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.79 ' HE1' ' HB2' ' B' ' 107' ' ' PRO . 29.5 t80 -129.33 124.08 33.42 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.818 0.342 . . . . 64.11 110.202 -175.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.419 HD11 HG13 ' A' ' 35' ' ' ILE . 3.2 tm? -72.41 132.76 44.35 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.611 -0.722 . . . . 74.41 109.781 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' TYR . . . . . 0.57 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 45.4 p90 -125.76 -22.81 4.13 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.127 0.417 . . . . 74.34 112.127 176.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.18 148.23 24.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.661 0.267 . . . . 75.23 111.022 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.419 HG13 HD11 ' A' ' 32' ' ' LEU . 61.6 mt -125.23 124.37 67.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 116.412 -0.358 . . . . 73.51 110.215 177.49 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.67 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.6 tttt -103.72 106.24 16.7 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.631 -0.507 . . . . 74.52 109.631 177.121 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.698 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.7 t -94.65 129.7 44.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 N-CA-C 109.226 -0.657 . . . . 34.5 109.226 177.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.594 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.4 t -117.6 72.57 7.81 Favored Pre-proline 0 C--N 1.317 -0.808 0 N-CA-C 109.845 -0.428 . . . . 45.43 109.845 173.646 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.581 ' HD3' HG12 ' A' ' 37' ' ' VAL . 54.1 Cg_endo -78.62 137.31 14.37 Favored 'Trans proline' 0 N--CA 1.456 -0.735 0 C-N-CA 122.197 1.932 . . . . 61.24 112.297 176.213 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.538 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 26.3 mtpp -68.76 -20.46 64.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.451 0.643 . . . . 44.04 109.868 178.333 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 84.7 m-70 -117.69 83.57 2.01 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.392 -0.822 . . . . 71.04 109.423 178.27 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.443 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 141.33 -22.0 2.58 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.945 -0.645 . . . . 52.4 112.339 -178.562 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.443 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 98.6 mttt 74.78 152.72 0.14 Allowed Pre-proline 0 N--CA 1.469 0.477 0 C-N-CA 123.579 0.752 . . . . 74.32 111.889 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.698 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 35.1 Cg_endo -66.73 136.37 41.9 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.651 2.234 . . . . 73.12 113.247 -178.139 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -142.33 162.32 35.77 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.511 -0.768 . . . . 62.14 109.589 176.505 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -106.11 123.19 47.63 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.397 -0.365 . . . . 72.35 110.244 178.183 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.465 HD11 HG13 ' A' ' 67' ' ' ILE . 28.5 tp -102.27 96.1 6.74 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 108.792 -0.818 . . . . 74.43 108.792 172.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.5 t -93.63 120.63 43.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.749 -0.659 . . . . 73.4 110.181 -175.311 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.7 tmm_? -77.88 121.47 24.18 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 109.065 -0.717 . . . . 74.15 109.065 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.15 -162.98 0.26 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.913 -0.585 . . . . 62.35 111.269 -173.754 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.404 ' OD2' ' HB2' ' A' ' 53' ' ' SER . 5.7 p-10 -73.76 154.78 39.43 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.161 0.505 . . . . 63.23 110.805 -177.443 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -65.29 -22.35 69.14 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.641 -0.709 . . . . 50.11 113.28 -177.422 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.404 ' HB2' ' OD2' ' A' ' 51' ' ' ASP . 14.5 m -73.52 -39.9 64.43 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.089 0.471 . . . . 40.03 109.958 178.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.521 ' OD2' ' HB3' ' A' ' 56' ' ' ASN . 31.2 t70 -71.66 -39.76 70.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.506 -0.77 . . . . 54.24 109.835 175.834 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 58.95 63.49 5.15 Favored Glycine 0 C--N 1.336 0.557 0 CA-C-N 115.78 -0.646 . . . . 74.43 111.663 178.312 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.521 ' HB3' ' OD2' ' A' ' 54' ' ' ASP . 14.6 t30 -165.36 155.76 13.51 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.685 -0.257 . . . . 72.12 110.331 -168.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.572 ' HB2' ' HB ' ' A' ' 67' ' ' ILE . 2.4 m-85 -108.68 143.11 38.2 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.162 -0.681 . . . . 75.44 109.162 174.448 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 48.1 mm -113.53 127.46 70.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.436 0.636 . . . . 74.55 110.319 177.468 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.469 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 58.5 ttt180 -93.63 124.09 37.39 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.309 -0.86 . . . . 73.0 109.685 -176.805 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 87.9 p -59.67 -26.77 65.82 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.242 0.544 . . . . 41.12 110.788 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.469 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 16.5 t70 -60.22 -39.71 87.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.211 -0.904 . . . . 62.45 110.711 177.575 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 29.3 mt-30 -144.67 89.01 6.85 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 115.947 -0.569 . . . . 71.11 109.863 -179.018 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -62.58 -24.71 75.22 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 123.1 2.533 . . . . 75.13 113.261 -175.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -78.84 -14.27 59.34 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 120.747 0.308 . . . . 73.51 110.73 178.254 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.2 tptm -93.71 123.42 37.02 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.459 0.647 . . . . 52.51 110.892 -177.258 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.412 ' N ' HD12 ' A' ' 66' ' ' LEU . 5.5 mp -90.24 128.48 36.41 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 114.798 -1.092 . . . . 61.4 108.688 175.523 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.757 HG23 ' HB3' ' A' ' 71' ' ' GLU . 47.0 mm -87.9 112.67 50.6 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-O 120.854 0.359 . . . . 72.21 111.373 -172.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.571 ' O ' HG23 ' A' ' 72' ' ' ILE . 60.0 Cg_endo -71.44 174.97 10.07 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.833 2.355 . . . . 53.14 112.036 179.163 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -79.15 1.85 22.96 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 112.987 0.736 . . . . 64.32 112.987 -166.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 42.4 p90 -107.04 -19.62 13.56 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.437 0.637 . . . . 70.42 109.953 172.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.757 ' HB3' HG23 ' A' ' 67' ' ' ILE . 2.8 mm-40 -87.41 -17.46 32.23 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.462 -0.79 . . . . 74.3 110.332 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.571 HG23 ' O ' ' A' ' 68' ' ' PRO . 42.3 pt -63.23 -28.39 44.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.885 -0.598 . . . . 65.21 111.412 -179.005 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.477 ' HD1' HG13 ' A' ' 72' ' ' ILE . 41.0 p90 -117.25 42.77 2.47 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.581 0.705 . . . . 74.32 109.584 175.634 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.424 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 4.7 t -59.27 -25.2 63.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.05 -0.977 . . . . 64.54 110.801 -179.567 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 26.6 p-90 . . . . . 0 C--N 1.327 -0.397 0 CA-C-N 115.925 -0.579 . . . . 70.15 111.267 177.479 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.435 0 N-CA-C 112.346 -0.302 . . . . 62.4 112.346 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -132.44 -62.18 0.84 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.564 0.221 . . . . 31.13 110.479 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 62.98 22.22 13.34 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 115.696 -0.684 . . . . 72.41 112.703 176.327 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -105.09 160.96 14.65 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.716 0.294 . . . . 75.04 110.324 178.319 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -75.35 134.02 41.09 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.185 -0.461 . . . . 73.31 111.229 -177.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 106' ' ' ALA . . . . . 0.449 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -82.11 130.41 60.16 Favored Pre-proline 0 C--N 1.322 -0.63 0 CA-C-N 115.902 -0.59 . . . . 63.23 109.798 174.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 107' ' ' PRO . . . . . 0.79 ' HB2' ' HE1' ' A' ' 31' ' ' PHE . 34.3 Cg_exo -59.69 147.07 93.62 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.746 2.297 . . . . 74.53 112.101 -178.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 57.1 m -54.53 144.4 21.47 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-O 121.451 0.643 . . . . 63.42 111.089 -179.197 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 125.24 -60.8 0.62 Allowed Glycine 0 N--CA 1.44 -1.073 0 N-CA-C 109.129 -1.588 . . . . 61.22 109.129 -169.692 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 61.08 88.34 0.12 Allowed Pre-proline 0 CA--C 1.52 -0.209 0 O-C-N 124.322 0.66 . . . . 73.31 111.27 171.416 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.888 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 7.3 Cg_endo -76.41 102.83 1.66 Allowed 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.173 1.915 . . . . 74.23 111.098 -178.497 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -102.89 150.36 23.59 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.037 -0.528 . . . . 61.43 109.838 -177.712 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.644 HG21 ' HB3' ' B' ' 124' ' ' GLN . 14.9 p -113.05 131.58 64.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 121.401 0.62 . . . . 61.43 111.617 -175.153 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 48.1 m -89.46 118.86 29.42 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.314 -0.857 . . . . 61.1 109.373 174.498 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 63.5 mt -92.54 105.25 16.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.07 0.462 . . . . 74.32 111.175 -174.519 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 116' ' ' ARG . . . . . 0.562 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 11.0 mmm180 -99.12 153.0 19.23 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.952 -0.567 . . . . 74.41 110.459 177.224 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 76.0 mt-30 -134.81 99.19 4.24 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.537 -0.912 . . . . 75.12 108.537 176.163 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 118' ' ' GLU . . . . . 0.49 ' HG3' HD12 ' B' ' 123' ' ' ILE . 43.2 mm-40 -103.6 9.25 37.47 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.125 -0.489 . . . . 64.04 112.205 -169.333 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 109.45 100.81 2.64 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.37 -0.919 . . . . 64.13 111.92 -178.744 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.573 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 9.5 m-20 66.66 -9.57 0.33 Allowed 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 124.085 0.954 . . . . 73.55 111.672 -176.515 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.491 ' HA ' ' O ' ' B' ' 138' ' ' VAL . 27.1 pttt -131.56 115.71 16.47 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 121.243 0.544 . . . . 75.01 112.074 -176.618 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 59.4 m -82.39 114.03 20.57 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.08 -0.964 . . . . 72.5 109.243 172.408 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 123' ' ' ILE . . . . . 0.708 HG12 HG13 ' B' ' 137' ' ' VAL . 49.8 mt -101.51 105.94 18.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 CA-C-O 121.326 0.584 . . . . 74.52 110.377 -176.114 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.644 ' HB3' HG21 ' B' ' 113' ' ' VAL . 49.7 mt-30 -96.01 106.89 19.11 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.444 -0.798 . . . . 71.23 110.974 -176.571 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -90.06 106.09 18.24 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.841 -0.618 . . . . 74.11 110.631 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -85.1 107.06 17.01 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.994 0.426 . . . . 75.2 110.698 -179.586 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 127' ' ' ARG . . . . . 0.502 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 79.0 mtm180 -120.39 120.52 36.22 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.137 0.494 . . . . 61.2 110.204 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.888 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -76.79 -62.5 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.893 -0.594 . . . . 72.22 111.021 -178.177 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 129' ' ' ASN . . . . . 0.574 ' H ' HG13 ' B' ' 128' ' ' VAL . 1.2 t-20 -149.21 76.82 1.34 Allowed 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.638 -0.504 . . . . 64.01 109.638 -178.54 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.75 -7.34 66.11 Favored Glycine 0 CA--C 1.521 0.438 0 CA-C-N 115.817 -0.629 . . . . 45.43 113.058 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.453 ' HD1' ' HB2' ' A' ' 7' ' ' PRO . 54.4 t80 -122.31 123.25 40.98 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.151 0.5 . . . . 71.45 111.27 -176.625 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.703 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -76.6 117.84 18.64 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.09 -0.959 . . . . 63.54 108.888 173.431 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -108.06 -22.85 12.23 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.478 -0.489 . . . . 71.05 111.525 -178.233 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -157.62 143.05 17.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.929 0.395 . . . . 75.0 111.329 -178.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.703 HG13 HD11 ' B' ' 132' ' ' LEU . 76.5 mt -121.77 121.75 65.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 115.895 -0.593 . . . . 65.55 110.067 176.333 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.467 ' HD2' ' CZ ' ' B' ' 146' ' ' PHE . 82.2 tttt -102.79 105.06 15.41 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.928 0.394 . . . . 70.2 109.99 177.373 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.708 HG13 HG12 ' B' ' 123' ' ' ILE . 5.0 t -90.46 132.37 35.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 108.653 -0.869 . . . . 74.42 108.653 176.08 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.511 HG13 ' HB3' ' B' ' 144' ' ' PRO . 20.6 t -114.21 71.73 2.21 Favored Pre-proline 0 C--N 1.317 -0.822 0 N-CA-C 109.907 -0.405 . . . . 64.03 109.907 173.345 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.534 ' HD3' HG12 ' B' ' 137' ' ' VAL . 74.3 Cg_endo -81.13 134.42 9.24 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.082 1.855 . . . . 73.42 113.243 178.534 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 140' ' ' LYS . . . . . 0.573 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 28.8 mtpp -60.04 -26.85 66.45 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.291 -0.868 . . . . 65.02 109.84 171.83 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 89.4 m-70 -116.8 89.5 3.12 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.282 -0.872 . . . . 73.42 109.492 177.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 138.36 -19.14 3.23 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.482 -0.866 . . . . 54.13 112.536 -179.294 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 47.0 mtmt 71.62 147.21 0.12 Allowed Pre-proline 0 N--CA 1.469 0.522 0 C-N-CA 123.309 0.643 . . . . 64.52 111.637 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.697 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 29.6 Cg_endo -64.8 125.81 15.48 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.584 2.189 . . . . 53.22 112.626 -179.356 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 25.7 p90 -139.88 160.29 40.23 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.076 -0.511 . . . . 71.33 110.383 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.467 ' CZ ' ' HD2' ' B' ' 136' ' ' LYS . 70.4 m-85 -104.54 122.18 45.02 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.091 -0.504 . . . . 73.02 110.04 178.312 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 26.0 tp -97.86 93.33 6.28 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 108.248 -1.019 . . . . 73.03 108.248 171.329 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.6 t -95.39 129.11 45.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.755 -0.657 . . . . 74.32 110.55 -173.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 149' ' ' ARG . . . . . 0.598 ' HG3' HH11 ' B' ' 149' ' ' ARG . 0.0 OUTLIER -79.45 123.22 27.33 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 116.217 -0.447 . . . . 75.51 109.871 177.462 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -77.41 -168.32 1.12 Allowed 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.815 -0.63 . . . . 72.4 110.034 177.801 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -56.94 147.13 24.63 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.174 -0.466 . . . . 52.13 110.792 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -75.14 -10.32 84.2 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.541 -0.838 . . . . 60.24 112.745 -177.006 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 1.6 m -67.67 -38.33 83.59 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.888 0.851 . . . . 71.35 108.729 172.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 15.1 t0 -80.36 -42.08 23.56 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.335 -1.302 . . . . 74.14 109.627 175.36 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 69.38 18.8 73.78 Favored Glycine 0 C--N 1.331 0.27 0 CA-C-N 115.17 -0.923 . . . . 72.34 112.139 -177.132 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 39.2 t30 -104.63 155.43 18.86 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 122.453 0.301 . . . . 62.31 111.656 -169.79 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 157' ' ' PHE . . . . . 0.662 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 8.3 m-85 -110.28 146.63 35.35 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.922 -0.77 . . . . 63.44 108.922 173.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.7 mm -118.31 133.39 65.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.038 0.447 . . . . 54.02 110.341 178.308 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.525 ' HD2' HD11 ' B' ' 167' ' ' ILE . 9.5 ttt180 -88.69 122.24 31.91 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.208 -0.664 . . . . 72.02 109.208 -179.001 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 66.5 p -57.66 -30.56 65.53 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 112.141 0.423 . . . . 61.24 112.141 -174.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -69.66 -40.45 76.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.068 0.461 . . . . 60.2 111.244 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 12.4 tt0 -130.33 88.84 46.41 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-N 116.139 -0.482 . . . . 73.22 110.178 -175.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -67.8 -12.76 36.49 Favored 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.917 2.411 . . . . 63.0 112.29 -179.083 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -84.58 -6.32 59.36 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.735 -0.666 . . . . 64.21 110.144 176.473 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 22.2 tptm -109.26 123.67 49.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.547 0.689 . . . . 73.22 110.998 -177.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 166' ' ' LEU . . . . . 0.471 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.0 mp -91.21 135.2 33.95 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 114.731 -1.122 . . . . 75.13 108.204 175.205 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 167' ' ' ILE . . . . . 0.662 ' HB ' ' HB2' ' B' ' 157' ' ' PHE . 48.1 mm -95.93 113.11 61.46 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-O 121.037 0.446 . . . . 74.12 111.303 -173.555 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.497 ' O ' HG23 ' B' ' 172' ' ' ILE . 55.9 Cg_endo -69.91 177.95 5.17 Favored 'Trans proline' 0 N--CA 1.464 -0.253 0 C-N-CA 123.15 2.566 . . . . 73.33 112.479 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -85.86 6.39 28.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.976 -0.557 . . . . 70.11 112.269 -168.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 30.4 p90 -107.7 -25.32 11.35 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.207 0.527 . . . . 75.24 110.007 171.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.415 ' HA ' ' HB2' ' B' ' 174' ' ' SER . 21.0 mm-40 -80.77 -14.7 57.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.753 -0.658 . . . . 64.32 110.9 -179.051 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.526 HG13 ' CD2' ' B' ' 173' ' ' PHE . 26.5 pt -72.64 -12.02 15.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.86 -0.609 . . . . 72.42 112.291 -176.732 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 173' ' ' PHE . . . . . 0.526 ' CD2' HG13 ' B' ' 172' ' ' ILE . 88.4 m-85 -126.83 21.03 7.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.44 0.638 . . . . 62.34 109.785 176.323 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 174' ' ' SER . . . . . 0.415 ' HB2' ' HA ' ' B' ' 171' ' ' GLU . 7.8 t -95.76 28.77 2.91 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.115 -0.948 . . . . 60.5 110.925 -175.16 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 6.3 m0 . . . . . 0 C--O 1.244 0.794 0 CA-C-O 118.201 -0.904 . . . . 73.41 111.679 -176.671 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.596 0 N-CA-C 111.865 -0.494 . . . . 53.54 111.865 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.03 85.9 2.2 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.129 0.49 . . . . 70.43 110.524 178.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -134.75 -41.02 0.77 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.674 -0.693 . . . . 73.54 110.063 179.482 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -76.06 153.62 36.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.974 -0.557 . . . . 64.4 109.89 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -84.83 129.67 34.78 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.849 0.357 . . . . 72.43 111.208 -174.596 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.468 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -79.49 140.48 55.87 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.944 -0.571 . . . . 63.04 110.902 -178.757 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.468 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 17.0 Cg_exo -67.35 179.21 2.58 Favored 'Trans proline' 0 CA--C 1.531 0.334 0 C-N-CA 123.048 2.499 . . . . 75.03 112.594 179.764 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 18.2 m -63.9 169.78 3.96 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.139 -0.482 . . . . 73.3 111.256 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 83.34 -60.54 4.87 Favored Glycine 0 N--CA 1.447 -0.619 0 N-CA-C 110.763 -0.935 . . . . 73.12 110.763 -173.665 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 60.19 88.35 0.12 Allowed Pre-proline 0 N--CA 1.463 0.214 0 C-N-CA 123.818 0.847 . . . . 74.13 112.235 176.783 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.608 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 37.5 Cg_endo -83.75 102.31 0.97 Allowed 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.344 2.03 . . . . 73.05 111.145 175.537 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.52 ' HA ' ' HB2' ' B' ' 151' ' ' ASP . 5.8 p-10 -130.06 140.91 50.77 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.186 0.517 . . . . 52.33 110.026 179.09 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.669 HG21 ' HB3' ' A' ' 24' ' ' GLN . 14.1 p -85.05 130.8 35.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.864 -0.607 . . . . 75.34 110.958 -176.392 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 34.3 m -88.26 105.07 17.3 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 109.674 -0.491 . . . . 73.35 109.674 177.359 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 72.2 mt -87.82 111.24 21.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.938 -0.574 . . . . 55.42 110.51 -177.091 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.476 ' HG2' ' O ' ' A' ' 23' ' ' ILE . 12.9 ptm180 -126.4 173.78 9.1 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.438 -0.578 . . . . 74.55 109.438 178.15 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -138.3 101.23 4.33 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.834 0.349 . . . . 72.21 110.222 -176.511 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.604 ' HG3' HD12 ' A' ' 23' ' ' ILE . 11.3 mm-40 -97.83 90.17 4.86 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.793 -0.64 . . . . 72.24 109.969 -176.278 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 75.51 -92.78 0.89 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.788 -0.72 . . . . 64.32 112.183 -178.573 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.588 ' HB2' ' HB2' ' A' ' 40' ' ' LYS . 7.3 p-10 -102.85 -36.73 8.14 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.438 0.637 . . . . 65.3 110.592 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.436 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 5.8 pttm -92.94 127.27 38.39 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.602 -0.727 . . . . 70.23 112.38 -167.226 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.467 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 46.6 m -82.67 96.01 8.0 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 114.771 -1.104 . . . . 62.33 108.326 174.162 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.742 HG12 HG23 ' A' ' 37' ' ' VAL . 48.5 mt -86.37 112.25 22.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.854 -0.612 . . . . 70.43 110.349 -175.336 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.669 ' HB3' HG21 ' A' ' 13' ' ' VAL . 47.7 mt-30 -94.01 104.63 16.67 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.738 -0.664 . . . . 73.22 110.464 179.456 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.486 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 26.7 mt-10 -87.48 100.6 12.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.673 -0.694 . . . . 71.11 110.868 -178.256 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -75.33 97.83 3.68 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.812 -0.44 . . . . 74.31 109.812 176.212 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.472 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 71.8 mtm180 -120.49 127.02 51.81 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.158 -0.474 . . . . 61.54 109.882 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.608 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 2.5 p -83.08 -64.26 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.643 -0.423 . . . . 75.21 110.843 178.675 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.578 ' H ' HG13 ' A' ' 28' ' ' VAL . 4.8 t-20 -142.72 69.25 1.31 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.175 0.512 . . . . 72.22 110.292 -176.832 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 88.18 1.87 81.14 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.562 -0.745 . . . . 54.55 113.474 176.223 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.408 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 60.7 t80 -131.24 127.01 36.97 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 117.151 0.476 . . . . 75.54 111.356 179.861 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.842 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -72.48 120.27 17.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.284 -0.871 . . . . 73.23 109.545 174.379 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -111.88 -19.51 12.37 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.396 -0.522 . . . . 73.15 111.746 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.44 141.56 18.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.832 0.349 . . . . 70.24 111.216 178.209 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.842 HG13 HD11 ' A' ' 32' ' ' LEU . 93.7 mt -119.73 117.36 53.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.36 -0.382 . . . . 72.31 110.723 176.706 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.495 ' HA ' ' O ' ' A' ' 45' ' ' TYR . 85.7 tttt -102.14 100.23 10.44 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.536 -0.913 . . . . 60.0 108.536 172.243 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.742 HG23 HG12 ' A' ' 23' ' ' ILE . 8.4 p -95.38 131.57 41.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 CA-C-N 116.174 -0.466 . . . . 74.44 110.045 -176.679 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.66 HG13 ' HG3' ' A' ' 44' ' ' PRO . 40.7 t -108.05 88.54 4.75 Favored Pre-proline 0 C--N 1.323 -0.559 0 N-CA-C 109.496 -0.557 . . . . 63.04 109.496 175.057 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.417 ' HA ' ' HB3' ' A' ' 21' ' ' LYS . 73.7 Cg_endo -82.39 141.26 11.23 Favored 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 122.51 2.14 . . . . 70.34 112.314 -178.395 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.588 ' HB2' ' HB2' ' A' ' 20' ' ' ASP . 27.9 mtpp -77.92 -14.93 59.38 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.346 0.593 . . . . 61.13 109.935 179.301 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 -116.43 25.63 10.48 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.342 -0.844 . . . . 62.13 110.203 -176.62 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -164.41 -148.64 5.51 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.28 -0.873 . . . . 44.22 111.128 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.1 pttp -131.9 142.63 45.87 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 117.238 0.519 . . . . 73.21 110.081 175.781 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.66 ' HG3' HG13 ' A' ' 38' ' ' VAL . 50.2 Cg_exo -53.15 135.53 59.67 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 123.55 2.833 . . . . 64.04 112.926 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.495 ' O ' ' HA ' ' A' ' 36' ' ' LYS . 4.6 p90 -142.32 160.44 40.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.163 -0.471 . . . . 72.3 110.69 177.403 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.656 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 92.0 m-85 -99.97 121.87 42.01 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.862 -0.608 . . . . 65.13 109.416 173.695 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 18.1 tp -108.36 97.43 7.11 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.913 -0.773 . . . . 74.35 108.913 175.626 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.47 HG21 HG21 ' B' ' 148' ' ' VAL . 38.4 t -93.94 135.41 28.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.255 -0.429 . . . . 73.3 111.282 -172.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.627 HH21 ' HA ' ' A' ' 53' ' ' SER . 13.3 tpt180 -73.1 124.59 25.86 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.876 -0.602 . . . . 52.44 111.112 176.853 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.42 174.47 10.79 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.884 -0.598 . . . . 64.52 109.928 173.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -70.65 145.27 50.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.764 0.316 . . . . 52.4 110.596 -178.194 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.448 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 86.27 158.45 31.29 Favored Glycine 0 N--CA 1.428 -1.868 0 CA-C-O 122.133 0.852 . . . . 63.11 112.844 175.57 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.627 ' HA ' HH21 ' A' ' 49' ' ' ARG . 49.5 m -80.65 26.71 0.39 Allowed 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 114.604 -0.798 . . . . 72.42 110.113 170.722 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.448 ' H ' ' C ' ' A' ' 52' ' ' GLY . 22.6 t70 -56.77 -39.24 73.68 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.123 -0.944 . . . . 52.5 111.611 -178.149 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.48 16.41 20.32 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.511 -0.852 . . . . 52.23 113.068 176.325 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -112.63 148.39 34.71 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.049 0.452 . . . . 72.3 110.31 177.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -124.1 163.06 22.27 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.739 -0.664 . . . . 63.13 109.656 176.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.79 HD11 HD23 ' A' ' 66' ' ' LEU . 46.1 mm -121.27 123.81 70.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 N-CA-C 109.538 -0.541 . . . . 73.21 109.538 177.211 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.675 ' HD2' ' HB3' ' A' ' 61' ' ' ASP . 11.6 ttm180 -92.2 145.63 24.35 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.806 -0.442 . . . . 73.25 109.806 -176.627 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.777 ' HB2' ' HB3' ' B' ' 163' ' ' PRO . 23.8 p -61.13 -39.89 91.76 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.573 0.702 . . . . 61.42 110.133 174.906 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.675 ' HB3' ' HD2' ' A' ' 59' ' ' ARG . 27.7 t70 -68.34 -28.28 67.0 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 114.808 -1.087 . . . . 71.21 110.817 178.262 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLN . . . . . 0.46 ' HB3' ' HB3' ' A' ' 65' ' ' LYS . 86.7 mm-40 -133.52 73.14 73.46 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.022 -0.535 . . . . 44.43 110.254 -175.79 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -75.81 -17.2 18.01 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.568 2.179 . . . . 71.13 112.703 -174.697 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -101.62 7.32 42.19 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.03 -0.532 . . . . 71.31 110.697 -178.452 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.46 ' HB3' ' HB3' ' A' ' 62' ' ' GLN . 83.4 tttt -123.32 135.27 54.12 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.013 -0.539 . . . . 71.31 110.74 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.79 HD23 HD11 ' A' ' 58' ' ' ILE . 40.7 mt -84.75 112.21 20.29 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.882 -0.784 . . . . 72.15 108.882 175.775 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 51.4 mm -70.68 117.85 59.36 Favored Pre-proline 0 C--N 1.322 -0.629 0 CA-C-N 116.142 -0.481 . . . . 52.22 110.841 -176.211 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.91 178.62 6.99 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 123.28 2.653 . . . . 74.51 112.86 -178.686 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLN . . . . . 0.623 ' HA ' HG12 ' A' ' 72' ' ' ILE . 6.1 tt0 -74.76 -34.62 62.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.853 -0.612 . . . . 72.5 111.521 -170.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 16.0 p90 -67.66 -20.51 65.32 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.39 -0.524 . . . . 72.22 110.279 178.259 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -91.4 -28.42 17.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.334 -0.394 . . . . 60.11 111.404 -179.177 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.623 HG12 ' HA ' ' A' ' 69' ' ' GLN . 37.4 pt -74.81 -23.49 17.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.103 0.478 . . . . 71.43 110.274 176.86 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 38.1 m-85 -105.33 29.51 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.006 -0.543 . . . . 73.53 110.637 176.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 22.8 t -82.25 32.25 0.39 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.261 0.553 . . . . 54.44 110.863 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 54.3 m0 . . . . . 0 C--N 1.323 -0.552 0 CA-C-N 116.128 -0.487 . . . . 72.35 110.852 179.923 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.492 0 N-CA-C 111.993 -0.443 . . . . 60.34 111.993 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -81.45 76.0 8.39 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.103 0.478 . . . . 63.15 110.998 -179.664 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -98.9 4.18 47.37 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.035 -0.529 . . . . 65.22 110.942 178.132 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -142.57 148.23 37.19 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.441 -0.345 . . . . 74.55 110.157 -178.53 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -82.22 147.06 29.17 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.198 -0.455 . . . . 74.42 111.132 -176.002 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -105.78 133.04 20.39 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 120.873 0.368 . . . . 54.25 111.989 -175.318 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -73.15 -176.17 2.3 Favored 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 123.059 2.506 . . . . 72.25 112.132 176.524 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 5.2 p -62.83 158.43 18.91 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-O 121.305 0.574 . . . . 75.54 111.534 -178.623 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 100.98 -73.48 0.39 Allowed Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 109.999 -1.24 . . . . 74.14 109.999 -172.14 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 54.17 74.47 0.74 Allowed Pre-proline 0 C--N 1.329 -0.317 0 O-C-N 124.154 0.561 . . . . 73.2 111.259 175.459 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.928 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 18.0 Cg_endo -63.01 99.47 0.22 Allowed 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 122.106 1.871 . . . . 35.22 110.594 178.339 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -106.81 155.04 20.14 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.335 -0.848 . . . . 63.24 110.635 -173.217 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.624 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 12.4 p -111.54 124.68 68.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 CA-C-O 121.557 0.694 . . . . 73.32 110.421 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 114' ' ' THR . . . . . 0.572 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 26.2 m -87.47 105.03 17.01 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.591 -0.731 . . . . 64.23 110.094 178.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.7 mt -83.48 106.07 13.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.955 -0.566 . . . . 72.01 110.375 -178.73 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 116' ' ' ARG . . . . . 0.437 ' HG3' HG22 ' B' ' 114' ' ' THR . 44.0 mtm105 -124.09 -178.9 4.22 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.403 -0.362 . . . . 74.23 110.465 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 64.0 mt-30 -144.76 115.21 7.61 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.205 -0.452 . . . . 72.21 111.056 -178.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 118' ' ' GLU . . . . . 0.461 ' O ' ' HE2' ' B' ' 121' ' ' LYS . 76.7 mm-40 -101.52 81.98 2.24 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.563 -0.532 . . . . 65.52 109.563 175.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 91.11 -110.83 3.88 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.657 -0.782 . . . . 61.41 111.4 -175.506 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.79 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 18.2 m-20 -115.06 24.01 12.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.786 0.327 . . . . 74.03 110.488 178.178 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.496 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 22.5 pttt -124.55 120.1 30.98 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.232 0.539 . . . . 60.21 110.833 178.556 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 49.1 m -79.38 104.9 10.31 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.414 -0.812 . . . . 53.25 109.588 177.385 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 123' ' ' ILE . . . . . 0.439 HD13 ' CE3' ' B' ' 175' ' ' TRP . 52.8 mt -97.52 112.54 29.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.122 0.487 . . . . 73.52 110.408 -176.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.624 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 51.2 mt-30 -92.29 105.7 17.85 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.449 -0.796 . . . . 73.21 110.552 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 125' ' ' GLU . . . . . 0.572 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 41.7 mt-10 -88.3 100.78 13.27 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.774 -0.648 . . . . 63.32 110.421 -178.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 126' ' ' TYR . . . . . 0.474 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 63.4 m-85 -78.25 110.28 13.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.528 -0.305 . . . . 61.24 110.538 179.403 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 127' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' B' ' 131' ' ' PHE . 84.6 mtm180 -132.99 120.23 21.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.295 -0.411 . . . . 73.11 110.258 -179.622 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.928 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.5 p -83.51 -54.37 9.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.234 -0.439 . . . . 74.12 111.181 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 32.8 t-20 -150.08 79.25 1.36 Allowed 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.958 -0.386 . . . . 73.23 109.958 -175.136 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.65 30.36 74.55 Favored Glycine 0 N--CA 1.452 -0.234 0 CA-C-N 115.537 -0.756 . . . . 64.33 112.867 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.43 ' O ' ' HA ' ' B' ' 127' ' ' ARG . 87.2 t80 -147.86 127.22 13.09 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.856 0.36 . . . . 70.52 111.256 179.594 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.743 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -81.25 111.47 17.69 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.467 -0.788 . . . . 75.44 108.948 174.758 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 133' ' ' TYR . . . . . 0.474 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 51.6 p90 -106.98 -15.53 14.67 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.68 -0.408 . . . . 73.45 111.57 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 134' ' ' ALA . . . . . 0.51 ' HB1' ' CE2' ' B' ' 146' ' ' PHE . . . -159.07 145.18 16.61 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.947 0.403 . . . . 61.24 111.576 -178.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.743 HG13 HD11 ' B' ' 132' ' ' LEU . 75.7 mt -125.47 123.66 65.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.936 -0.574 . . . . 45.12 110.162 176.448 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.452 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 88.5 tttt -116.15 102.32 9.5 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.396 -0.594 . . . . 74.32 109.396 174.374 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.51 HG13 ' CE1' ' B' ' 145' ' ' TYR . 0.9 OUTLIER -102.36 127.07 56.31 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.088 0.471 . . . . 73.03 110.947 -177.603 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.816 HG22 ' HB3' ' B' ' 144' ' ' PRO . 22.8 t -112.55 88.83 11.74 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 115.235 -0.893 . . . . 71.1 109.73 -179.309 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.496 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 67.0 Cg_endo -77.95 134.54 13.31 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.137 1.891 . . . . 60.32 112.717 178.671 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 140' ' ' LYS . . . . . 0.79 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 58.2 mtpt -62.75 -28.18 69.79 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.577 -0.738 . . . . 64.12 110.251 173.546 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -96.43 43.84 1.07 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.996 -1.002 . . . . 75.42 110.187 -177.638 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 164.2 -146.71 11.75 Favored Glycine 0 N--CA 1.446 -0.645 0 CA-C-N 115.531 -0.759 . . . . 72.52 111.766 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 34.1 mmtp -126.68 150.0 69.87 Favored Pre-proline 0 C--N 1.322 -0.63 0 N-CA-C 110.206 -0.294 . . . . 73.2 110.206 177.379 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.816 ' HB3' HG22 ' B' ' 138' ' ' VAL . 18.6 Cg_endo -61.37 145.16 98.51 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.827 2.351 . . . . 74.32 112.22 178.72 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 145' ' ' TYR . . . . . 0.51 ' CE1' HG13 ' B' ' 137' ' ' VAL . 12.6 p90 -148.89 164.05 35.63 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.205 -0.452 . . . . 75.41 110.15 177.11 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.51 ' CE2' ' HB1' ' B' ' 134' ' ' ALA . 0.8 OUTLIER -113.14 142.13 46.12 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.901 -0.591 . . . . 75.34 111.17 -172.437 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.444 ' HB3' ' CD2' ' B' ' 157' ' ' PHE . 20.7 mt -126.65 108.74 11.37 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.972 -0.558 . . . . 75.04 109.659 170.074 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 148' ' ' VAL . . . . . 0.47 HG21 HG21 ' A' ' 48' ' ' VAL . 38.8 t -90.86 130.59 39.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.262 -0.426 . . . . 75.34 110.274 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 149' ' ' ARG . . . . . 0.463 ' HD3' ' CZ ' ' B' ' 157' ' ' PHE . 45.5 tpt85 -85.1 104.38 14.95 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.53 -0.544 . . . . 60.41 109.53 179.134 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.1 -178.85 0.85 Allowed 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.049 -0.523 . . . . 63.51 110.496 179.096 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 151' ' ' ASP . . . . . 0.52 ' HB2' ' HA ' ' A' ' 12' ' ' ASP . 2.2 p-10 -84.21 158.62 21.22 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.846 -0.427 . . . . 73.02 109.846 179.343 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 96.68 139.19 10.41 Favored Glycine 0 N--CA 1.439 -1.152 0 C-N-CA 120.049 -1.072 . . . . 70.2 112.609 176.721 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 16.3 m -77.6 43.12 0.39 Allowed 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.357 0.599 . . . . 62.23 110.97 176.413 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -89.15 -28.35 20.09 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.522 -0.763 . . . . 72.13 110.467 -178.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 88.79 31.39 12.73 Favored Glycine 0 N--CA 1.451 -0.36 0 N-CA-C 111.067 -0.813 . . . . 64.31 111.067 -174.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -100.46 130.94 46.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.147 -0.526 . . . . 74.21 111.606 -172.571 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 157' ' ' PHE . . . . . 0.463 ' CZ ' ' HD3' ' B' ' 149' ' ' ARG . 29.2 m-85 -121.02 160.61 23.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.639 -0.71 . . . . 73.52 109.572 175.134 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 158' ' ' ILE . . . . . 0.8 HD11 HD23 ' B' ' 166' ' ' LEU . 46.0 mm -119.74 118.27 56.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.492 -0.558 . . . . 65.22 109.492 174.206 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.59 ' HG2' ' H ' ' B' ' 161' ' ' ASP . 20.0 ttm-85 -84.09 142.38 30.44 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 110.034 -0.358 . . . . 75.34 110.034 -177.8 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 42.3 p -63.08 -29.16 70.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.174 0.512 . . . . 70.4 110.836 178.187 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 161' ' ' ASP . . . . . 0.59 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 16.1 t70 -77.76 -27.49 50.36 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.477 -0.783 . . . . 72.23 110.81 178.808 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 162' ' ' GLN . . . . . 0.596 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 28.0 mm-40 -135.35 68.98 68.61 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 115.889 -0.596 . . . . 70.0 110.185 -177.608 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 163' ' ' PRO . . . . . 0.777 ' HB3' ' HB2' ' A' ' 60' ' ' SER . 12.9 Cg_exo -70.1 -26.33 26.1 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.71 2.274 . . . . 73.45 112.191 -177.479 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -84.0 1.31 44.38 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.451 -0.795 . . . . 72.51 110.27 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 165' ' ' LYS . . . . . 0.596 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 57.8 tttp -116.9 134.94 54.14 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.814 -0.63 . . . . 72.22 110.82 -177.498 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 166' ' ' LEU . . . . . 0.8 HD23 HD11 ' B' ' 158' ' ' ILE . 39.0 mt -89.53 115.4 26.91 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.643 -0.873 . . . . 74.4 108.643 175.651 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 167' ' ' ILE . . . . . 0.581 HG23 ' HB3' ' B' ' 171' ' ' GLU . 43.0 mm -75.04 123.87 89.14 Favored Pre-proline 0 C--N 1.32 -0.705 0 CA-C-N 116.147 -0.479 . . . . 74.54 110.896 -172.537 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.414 ' O ' HG23 ' B' ' 172' ' ' ILE . 72.5 Cg_endo -72.75 173.65 13.08 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.825 2.35 . . . . 74.33 112.225 -178.829 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 169' ' ' GLN . . . . . 0.444 ' O ' HG12 ' B' ' 172' ' ' ILE . 30.4 tt0 -77.79 -8.22 57.7 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.665 -0.698 . . . . 75.11 111.811 -169.403 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 8.4 p90 -95.33 -12.23 26.46 Favored 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 120.457 -0.497 . . . . 71.21 110.583 176.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.581 ' HB3' HG23 ' B' ' 167' ' ' ILE . 12.9 tt0 -104.07 -1.87 26.75 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 121.039 0.447 . . . . 65.45 110.409 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.444 HG12 ' O ' ' B' ' 169' ' ' GLN . 46.8 pt -71.75 -24.5 23.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.017 0.437 . . . . 63.53 110.689 179.399 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -104.85 35.93 2.62 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.42 0.629 . . . . 70.15 109.745 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 174' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 23.2 t -63.74 -20.4 65.72 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 114.993 -1.003 . . . . 53.25 110.792 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 175' ' ' TRP . . . . . 0.439 ' CE3' HD13 ' B' ' 123' ' ' ILE . 8.9 p-90 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.255 -0.879 . . . . 73.43 110.388 174.259 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 2.007 0 N-CA-C 112.414 -0.275 . . . . 31.01 112.414 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.493 ' O ' ' HA ' ' B' ' 154' ' ' ASP . . . -138.08 155.26 48.95 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.89 0.376 . . . . 42.55 110.048 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -135.32 104.38 5.85 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.568 0.699 . . . . 71.11 111.094 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -133.78 -168.67 2.15 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 107.806 -1.183 . . . . 53.1 107.806 173.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -121.61 140.73 51.88 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.025 0.441 . . . . 73.01 110.853 -176.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -119.95 164.08 24.28 Favored Pre-proline 0 C--N 1.32 -0.692 0 CA-C-N 115.882 -0.599 . . . . 62.32 110.198 -177.61 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.36 164.28 13.24 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.419 2.079 . . . . 63.3 111.961 175.341 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 57.8 m -56.91 142.95 39.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.732 0.777 . . . . 75.32 112.361 -175.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 138.64 -74.62 0.39 Allowed Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 109.197 -1.561 . . . . 71.44 109.197 -171.596 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 33.3 mt-10 58.68 92.49 0.06 OUTLIER Pre-proline 0 N--CA 1.463 0.197 0 CA-C-O 121.539 0.685 . . . . 72.41 112.052 170.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 9.6 Cg_endo -80.46 136.31 11.05 Favored 'Trans proline' 0 N--CA 1.451 -1.001 0 C-N-CA 122.833 2.355 . . . . 55.24 112.604 -173.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -124.8 170.84 10.64 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.173 -0.677 . . . . 73.52 109.173 177.069 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.471 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 14.0 p -127.72 124.29 62.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 121.481 0.657 . . . . 75.43 110.76 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.586 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 76.4 m -87.9 104.25 16.43 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.629 -0.714 . . . . 72.34 109.664 177.27 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 52.3 mt -98.45 117.66 43.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.064 -0.516 . . . . 65.13 110.388 -175.845 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -141.4 178.23 7.57 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.707 -0.679 . . . . 73.32 110.273 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 17.4 mp0 -133.45 126.15 30.56 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.922 0.392 . . . . 70.31 110.828 -178.131 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 52.0 mm-40 -95.58 -16.1 22.34 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.851 -0.613 . . . . 72.1 111.493 -178.502 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.43 104.91 1.3 Allowed Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.619 -0.8 . . . . 54.23 111.468 -176.457 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 1.093 ' HB3' ' HG3' ' A' ' 40' ' ' LYS . 35.3 m-20 61.81 13.89 5.8 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 123.226 0.61 . . . . 73.22 111.482 -175.677 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.428 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 40.2 pttt -154.52 114.97 3.9 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.229 0.538 . . . . 64.13 110.907 176.326 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 34.1 m -83.08 117.74 23.07 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.375 -0.83 . . . . 63.24 109.298 174.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.461 HG12 HG23 ' A' ' 37' ' ' VAL . 24.9 mt -108.61 120.33 59.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 120.906 0.384 . . . . 71.05 110.633 -174.13 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.471 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 68.3 mt-30 -105.27 111.31 24.01 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.819 -0.628 . . . . 74.21 110.758 -179.23 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.586 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 31.6 mt-10 -89.62 102.55 15.23 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.62 -0.718 . . . . 72.13 110.673 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.452 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 80.6 m-85 -79.38 108.19 12.71 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.965 0.412 . . . . 72.35 109.957 177.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.427 HH21 ' CD ' ' A' ' 25' ' ' GLU . 90.1 mtt180 -116.98 126.56 53.09 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.979 -0.555 . . . . 61.32 109.852 -178.449 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.68 HG11 HG11 ' B' ' 128' ' ' VAL . 3.7 p -78.77 -35.96 18.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.326 0.584 . . . . 41.22 110.027 179.192 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -168.92 64.68 0.06 Allowed 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.31 -0.996 . . . . 60.43 108.31 -179.045 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.76 -29.75 3.29 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-N 115.477 -0.783 . . . . 64.13 112.036 -174.608 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -86.26 130.92 34.36 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.941 0.401 . . . . 72.34 110.455 -176.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.888 HD11 HG13 ' A' ' 35' ' ' ILE . 3.2 tm? -81.96 119.21 23.67 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.436 -0.802 . . . . 74.44 109.847 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' TYR . . . . . 0.452 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 54.8 p90 -112.9 -17.54 12.47 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.937 -0.305 . . . . 74.2 111.218 177.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.544 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -157.28 142.21 16.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.812 0.339 . . . . 75.45 111.181 179.327 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.888 HG13 HD11 ' A' ' 32' ' ' LEU . 78.8 mt -125.14 120.21 57.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 116.329 -0.396 . . . . 63.32 110.01 175.502 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.469 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 86.0 tttt -108.53 101.15 10.33 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 120.381 -0.528 . . . . 63.34 109.697 173.658 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.565 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.8 p -101.02 131.78 48.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.973 0 CA-C-N 116.243 -0.435 . . . . 73.04 109.917 175.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.829 HG22 ' HB3' ' A' ' 44' ' ' PRO . 29.6 t -106.0 84.85 1.4 Allowed Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.396 -0.82 . . . . 73.22 109.51 177.469 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.565 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 97.3 Cg_endo -87.65 151.21 7.5 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.615 2.21 . . . . 72.32 113.143 -177.513 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 1.093 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 1.0 OUTLIER -55.06 -38.53 68.14 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.202 -0.908 . . . . 74.41 110.578 173.715 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 95.1 m-70 -123.56 120.9 34.21 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.814 -0.63 . . . . 71.53 110.181 179.428 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 117.46 -32.63 5.31 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.002 -0.839 . . . . 52.15 111.002 -173.418 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.469 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 67.0 mttm 67.97 155.61 0.14 Allowed Pre-proline 0 N--CA 1.465 0.282 0 C-N-CA 123.39 0.676 . . . . 74.41 111.97 178.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.829 ' HB3' HG22 ' A' ' 38' ' ' VAL . 11.4 Cg_endo -54.57 126.43 22.3 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 123.136 2.557 . . . . 71.23 113.179 -174.828 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.516 ' CE1' HG13 ' A' ' 37' ' ' VAL . 5.8 p90 -144.51 151.76 39.61 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.009 -0.541 . . . . 63.52 110.543 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.625 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 86.8 m-85 -96.18 133.27 40.69 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.097 -0.501 . . . . 72.44 110.804 178.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.544 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 21.2 mt -101.69 93.41 5.32 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.59 -0.522 . . . . 64.22 109.59 167.884 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.42 128.96 38.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 116.168 -0.469 . . . . 73.14 109.799 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.474 HH21 ' HA ' ' A' ' 53' ' ' SER . 15.6 tpt180 -63.05 127.23 30.3 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.21 0.529 . . . . 74.54 111.87 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.05 113.84 21.31 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.114 -1.069 . . . . 74.52 108.114 166.281 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.556 ' OD2' ' HA ' ' B' ' 126' ' ' TYR . 37.8 m-20 -49.07 142.54 6.67 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.216 0.531 . . . . 72.33 111.715 -176.832 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.23 133.61 8.16 Favored Glycine 0 N--CA 1.437 -1.257 0 N-CA-C 110.508 -1.037 . . . . 54.21 110.508 -169.15 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.474 ' HA ' HH21 ' A' ' 49' ' ' ARG . 19.6 m -84.87 43.16 0.97 Allowed 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.128 0.49 . . . . 74.25 110.997 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -73.41 -33.95 65.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.682 -0.69 . . . . 73.42 109.769 -179.523 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 113.46 38.97 1.15 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.911 -0.661 . . . . 45.13 113.089 176.022 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -135.31 146.42 48.46 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.209 0.528 . . . . 70.05 111.688 -176.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.566 ' HB2' HG22 ' A' ' 72' ' ' ILE . 31.5 m-85 -127.74 167.04 17.04 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.318 -0.856 . . . . 63.2 109.494 175.499 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.898 HD11 HD23 ' A' ' 66' ' ' LEU . 39.4 mm -122.83 123.22 67.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 109.981 -0.378 . . . . 74.0 109.981 179.111 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.978 ' HG3' HG13 ' A' ' 67' ' ' ILE . 28.8 mtm180 -88.89 140.06 29.82 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.124 -0.324 . . . . 72.22 110.124 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 7.2 p -60.8 -20.95 62.58 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.222 0.534 . . . . 65.34 110.933 177.211 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -76.0 -31.43 58.95 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.422 -0.808 . . . . 75.53 110.67 178.256 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 82.0 mm-40 -141.75 71.21 24.92 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.346 -0.388 . . . . 71.43 110.433 -175.102 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo -71.14 -11.58 29.14 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 122.771 2.314 . . . . 72.51 112.427 -178.539 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -89.54 -14.56 34.87 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.699 -0.682 . . . . 72.5 110.799 -178.719 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -112.0 133.8 53.95 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.919 0.39 . . . . 70.34 110.86 -178.207 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.898 HD23 HD11 ' A' ' 58' ' ' ILE . 85.2 mt -80.74 110.18 16.0 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.114 -0.699 . . . . 72.43 109.114 176.101 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.978 HG13 ' HG3' ' A' ' 59' ' ' ARG . 50.6 mm -72.32 116.77 52.53 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 115.986 -0.552 . . . . 70.21 110.502 -175.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.462 ' O ' HG23 ' A' ' 72' ' ' ILE . 58.6 Cg_endo -70.39 177.56 5.89 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 123.315 2.676 . . . . 64.41 112.881 -177.491 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLN . . . . . 0.67 ' HA ' HG12 ' A' ' 72' ' ' ILE . 25.3 tt0 -73.5 -30.66 63.27 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.903 -0.589 . . . . 72.22 111.654 -171.013 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 21.5 p90 -73.06 -15.68 61.5 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.168 0.509 . . . . 73.22 110.234 177.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.459 ' HB3' HG23 ' A' ' 67' ' ' ILE . 3.2 mm-40 -103.08 -16.14 15.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.649 -0.705 . . . . 71.44 111.808 -176.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.67 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.4 pt -80.91 -20.26 11.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.179 0.514 . . . . 65.14 110.262 176.647 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -107.88 22.79 15.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.601 -0.727 . . . . 75.43 109.678 174.134 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.1 t -61.26 -34.08 74.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.195 -0.911 . . . . 75.21 110.622 -178.565 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 65.9 p-90 . . . . . 0 C--N 1.327 -0.372 0 CA-C-N 116.352 -0.385 . . . . 74.44 110.608 177.217 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.103 -0.399 . . . . 60.25 112.103 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -146.02 156.55 43.56 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.225 -0.287 . . . . 45.42 110.225 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -162.0 131.78 4.65 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.427 0.632 . . . . 70.24 110.793 176.432 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -152.41 151.92 31.39 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 107.269 -1.382 . . . . 73.04 107.269 173.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -62.08 127.01 29.34 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 120.473 -0.491 . . . . 72.44 110.442 -174.456 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 106' ' ' ALA . . . . . 0.43 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -59.92 118.57 33.53 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 115.667 -0.697 . . . . 72.33 111.998 -173.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 107' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 7.4 Cg_exo -73.63 176.75 8.92 Favored 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 123.102 2.535 . . . . 64.12 111.938 178.722 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 13.9 m -71.88 157.44 37.86 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.905 -0.588 . . . . 75.33 111.05 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.65 -45.88 1.25 Allowed Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 110.249 -1.141 . . . . 71.14 110.249 -175.682 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 40.3 83.14 0.21 Allowed Pre-proline 0 N--CA 1.47 0.564 0 C-N-CA 124.755 1.222 . . . . 73.33 113.473 170.194 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.6 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 43.5 Cg_endo -90.56 124.58 1.06 Allowed 'Trans proline' 0 N--CA 1.446 -1.323 0 C-N-CA 123.009 2.473 . . . . 55.45 111.667 178.444 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -122.87 127.87 49.59 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.475 0.655 . . . . 53.31 110.008 -178.586 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.495 ' HB ' ' HB2' ' A' ' 51' ' ' ASP . 7.3 p -79.45 127.82 38.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-O 121.508 0.67 . . . . 52.24 110.459 -178.311 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 114' ' ' THR . . . . . 0.907 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 25.8 m -80.62 101.69 9.36 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 115.386 -0.824 . . . . 74.42 109.605 178.676 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 51.1 mt -91.02 103.83 14.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.033 -0.53 . . . . 52.35 110.445 -175.22 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 116' ' ' ARG . . . . . 0.483 ' HG2' ' O ' ' B' ' 123' ' ' ILE . 14.0 ptm180 -124.94 178.87 5.28 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.949 -0.76 . . . . 73.24 108.949 178.763 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -138.88 158.74 43.67 Favored 'General case' 0 CA--C 1.502 -0.886 0 CA-C-O 122.189 0.995 . . . . 74.12 112.661 -178.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 118' ' ' GLU . . . . . 0.591 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 26.5 mt-10 -135.44 168.62 18.88 Favored 'General case' 0 N--CA 1.432 -1.365 0 CA-C-N 112.968 -1.924 . . . . 75.24 107.166 159.662 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . -42.29 107.92 0.12 Allowed Glycine 0 CA--C 1.526 0.722 0 O-C-N 123.718 0.636 . . . . 61.15 114.34 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 43.3 m-20 61.67 24.62 14.69 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.893 0.877 . . . . 53.1 112.508 176.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.591 ' HE3' ' HB2' ' B' ' 118' ' ' GLU . 58.7 pttt -147.81 115.02 6.21 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.616 0.722 . . . . 44.31 111.286 174.312 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 23.4 m -80.03 117.11 20.57 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.404 -0.817 . . . . 74.25 109.374 175.003 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 123' ' ' ILE . . . . . 0.517 HG12 HG13 ' B' ' 137' ' ' VAL . 40.2 mt -105.53 108.96 26.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.25 0.548 . . . . 63.33 110.457 -175.744 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.481 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 52.2 mt-30 -103.13 109.52 21.12 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.658 -0.701 . . . . 53.44 110.538 -176.21 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 125' ' ' GLU . . . . . 0.907 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 70.8 mt-10 -88.9 98.74 11.91 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.014 -0.539 . . . . 74.24 110.43 178.655 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 126' ' ' TYR . . . . . 0.556 ' HA ' ' OD2' ' A' ' 51' ' ' ASP . 67.7 m-85 -71.32 114.34 9.29 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.045 0.45 . . . . 73.2 110.295 179.18 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 127' ' ' ARG . . . . . 0.569 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 59.1 mtt-85 -135.36 131.12 35.97 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.709 -0.678 . . . . 72.34 110.989 -173.826 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.68 HG11 HG11 ' A' ' 28' ' ' VAL . 14.0 p -85.39 -132.76 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 108.689 -0.856 . . . . 71.53 108.689 172.785 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 129' ' ' ASN . . . . . 0.629 ' H ' HG22 ' B' ' 128' ' ' VAL . 2.3 t-20 -80.62 65.87 5.92 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.164 0.506 . . . . 63.12 110.812 -177.445 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.65 26.63 22.18 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.756 -0.735 . . . . 41.04 113.285 174.263 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 62.1 t80 -142.11 126.74 17.95 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 117.262 0.531 . . . . 72.41 111.31 175.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.569 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 3.5 tm? -77.15 117.49 18.75 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.992 -0.744 . . . . 72.23 108.992 175.505 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 39.6 p90 -119.15 -6.3 10.42 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.257 -0.577 . . . . 75.32 112.261 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 134' ' ' ALA . . . . . 0.525 ' HB3' ' HB2' ' B' ' 126' ' ' TYR . . . -164.21 143.35 7.54 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.699 0.285 . . . . 74.2 111.031 177.697 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.442 HG13 HD11 ' B' ' 132' ' ' LEU . 61.9 mt -122.84 121.06 62.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 109.924 -0.398 . . . . 53.31 109.924 175.403 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.485 ' CB ' ' HE1' ' B' ' 126' ' ' TYR . 83.6 tttt -107.84 107.03 17.59 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.835 -0.431 . . . . 74.2 109.835 177.803 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.762 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.5 t -94.81 131.6 41.16 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 N-CA-C 108.641 -0.874 . . . . 74.1 108.641 176.585 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.553 HG22 ' HB3' ' B' ' 144' ' ' PRO . 18.0 t -114.72 72.7 2.78 Favored Pre-proline 0 C--N 1.318 -0.769 0 N-CA-C 109.78 -0.452 . . . . 73.12 109.78 172.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.524 ' HD3' HG12 ' B' ' 137' ' ' VAL . 94.1 Cg_endo -83.2 142.16 10.67 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.235 1.957 . . . . 60.53 112.563 177.105 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 49.6 mttp -54.56 -44.56 73.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.596 0.712 . . . . 70.11 110.348 173.016 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 26.1 m-70 -102.8 92.1 4.45 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.836 -1.074 . . . . 72.15 109.474 -174.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 132.54 -27.35 3.56 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.357 -0.838 . . . . 64.45 111.712 -176.294 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 143' ' ' LYS . . . . . 0.51 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 71.2 mttt 69.1 159.66 0.15 Allowed Pre-proline 0 N--CA 1.464 0.255 0 C-N-CA 123.622 0.769 . . . . 72.21 112.367 -178.885 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.762 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 21.6 Cg_endo -61.09 134.5 53.16 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 122.873 2.382 . . . . 71.24 113.525 -177.541 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -143.32 147.21 34.37 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.68 -0.691 . . . . 74.11 110.291 175.376 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.65 ' HB2' ' HB2' ' B' ' 160' ' ' SER . 86.0 m-85 -93.61 125.93 38.49 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.231 -0.441 . . . . 61.51 110.392 176.629 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.507 HD11 HG21 ' B' ' 167' ' ' ILE . 25.0 tp -109.12 97.44 7.06 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.64 -0.874 . . . . 50.52 108.64 172.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.7 t -91.77 139.3 18.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.155 -0.475 . . . . 52.41 111.311 -172.321 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 149' ' ' ARG . . . . . 0.427 ' HD3' ' CZ ' ' B' ' 157' ' ' PHE . 42.4 tpt85 -80.36 113.73 18.75 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.278 -0.638 . . . . 74.14 109.278 176.82 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.89 175.6 6.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.825 0.345 . . . . 75.33 111.104 -176.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -71.47 147.8 47.46 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.163 -0.471 . . . . 74.12 110.94 -178.668 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 152' ' ' GLY . . . . . 0.492 ' C ' ' H ' ' B' ' 154' ' ' ASP . . . 89.85 145.4 12.74 Favored Glycine 0 N--CA 1.436 -1.365 0 C-N-CA 120.723 -0.751 . . . . 74.14 112.561 175.319 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 44.9 m -72.59 21.93 0.06 Allowed 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 121.022 0.439 . . . . 74.01 111.083 173.664 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 154' ' ' ASP . . . . . 0.493 ' HA ' ' O ' ' A' ' 2' ' ' ALA . 14.5 t70 -60.86 -35.82 77.56 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.777 -0.647 . . . . 73.33 110.618 177.584 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 97.92 17.13 31.12 Favored Glycine 0 CA--C 1.507 -0.451 0 CA-C-N 115.734 -0.666 . . . . 75.31 111.89 -179.383 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -90.97 137.52 32.3 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.019 -0.59 . . . . 55.54 111.566 -175.744 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 157' ' ' PHE . . . . . 0.427 ' CZ ' ' HD3' ' B' ' 149' ' ' ARG . 39.0 m-85 -118.21 154.04 32.87 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.751 -0.658 . . . . 74.41 109.533 174.299 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.3 mm -121.46 119.91 60.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.817 -0.438 . . . . 65.53 109.817 177.596 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.727 ' HE ' ' HB3' ' B' ' 161' ' ' ASP . 37.2 ttp180 -85.02 129.05 34.86 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.444 -0.576 . . . . 74.33 109.444 -179.706 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 160' ' ' SER . . . . . 0.65 ' HB2' ' HB2' ' B' ' 146' ' ' PHE . 36.6 t -59.84 -18.34 43.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.774 0.321 . . . . 54.31 111.318 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 161' ' ' ASP . . . . . 0.727 ' HB3' ' HE ' ' B' ' 159' ' ' ARG . 22.8 t70 -69.24 -39.77 78.31 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.031 -0.531 . . . . 74.32 110.29 176.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 162' ' ' GLN . . . . . 0.427 ' HG2' ' OD2' ' B' ' 161' ' ' ASP . 84.1 mm-40 -133.53 86.33 40.37 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 115.674 -0.693 . . . . 61.54 109.692 179.546 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.01 -14.37 40.86 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.56 2.173 . . . . 73.33 112.47 -178.07 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -100.49 21.09 13.76 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.817 -0.628 . . . . 72.15 110.421 178.615 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -133.3 136.06 45.24 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.365 -0.38 . . . . 74.05 110.732 -179.487 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 166' ' ' LEU . . . . . 0.435 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.6 mp -90.54 134.94 34.02 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.027 -0.731 . . . . 71.52 109.027 176.658 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 167' ' ' ILE . . . . . 0.538 HG23 ' HB3' ' B' ' 171' ' ' GLU . 46.2 mm -94.15 117.02 67.11 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-O 120.917 0.389 . . . . 74.32 111.771 -172.764 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.409 ' O ' HG23 ' B' ' 172' ' ' ILE . 59.5 Cg_endo -72.37 -179.55 4.14 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.305 2.67 . . . . 74.43 112.615 177.084 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 169' ' ' GLN . . . . . 0.59 ' HA ' HG12 ' B' ' 172' ' ' ILE . 33.0 tt0 -77.1 -36.09 55.94 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.258 -0.428 . . . . 65.43 112.136 -170.211 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 170' ' ' TRP . . . . . 0.409 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 35.9 p90 -66.99 -21.16 65.97 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 121.648 -0.658 . . . . 74.43 109.622 177.251 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.538 ' HB3' HG23 ' B' ' 167' ' ' ILE . 9.3 mm-40 -88.22 -26.05 22.57 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 115.156 -0.929 . . . . 75.13 111.647 -178.078 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.59 HG12 ' HA ' ' B' ' 169' ' ' GLN . 40.9 pt -77.97 -17.42 13.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.146 0.498 . . . . 74.53 109.971 177.118 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -108.05 34.61 3.5 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.574 -0.739 . . . . 70.32 109.748 174.264 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.9 t -65.13 -35.27 80.58 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.203 -0.908 . . . . 71.02 111.03 -179.182 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 25.6 p-90 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.018 -0.991 . . . . 73.1 111.023 -178.133 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.855 0 N-CA-C 112.152 -0.379 . . . . 52.43 112.152 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.74 131.71 38.83 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.289 -0.263 . . . . 74.32 110.289 178.251 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -59.05 -48.19 82.5 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.96 0.41 . . . . 73.34 110.406 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -157.87 139.61 13.92 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.95 -0.759 . . . . 73.33 108.95 171.764 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -169.13 137.71 2.0 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 110.158 -0.312 . . . . 63.4 110.158 -178.307 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -83.35 125.56 73.92 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.485 -0.325 . . . . 72.34 110.504 178.086 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -82.91 -160.01 0.12 Allowed 'Trans proline' 0 N--CA 1.463 -0.285 0 C-N-CA 123.063 2.508 . . . . 73.52 112.426 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 39.8 m -131.35 168.71 17.1 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.947 -0.39 . . . . 70.32 109.947 176.012 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 87.27 -34.01 3.72 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 110.977 -0.849 . . . . 50.32 110.977 -173.677 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 55.37 63.69 6.31 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 123.998 0.919 . . . . 62.44 111.73 177.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.699 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 18.2 Cg_endo -78.95 121.65 5.06 Favored 'Trans proline' 0 N--CA 1.45 -1.064 0 C-N-CA 122.091 1.861 . . . . 73.22 111.584 -179.612 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -148.36 122.42 9.47 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.654 0.74 . . . . 72.14 110.357 177.515 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.8 p -82.65 129.16 37.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-N 114.366 -1.288 . . . . 51.14 110.682 -178.113 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 59.2 m -93.64 102.51 14.69 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.592 -0.731 . . . . 53.11 109.735 178.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.1 mt -90.63 104.06 14.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.967 -0.561 . . . . 74.11 110.037 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -122.83 174.07 7.37 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.533 -0.758 . . . . 72.22 109.734 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -122.98 133.36 54.37 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 121.285 0.564 . . . . 74.43 111.059 -177.703 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.527 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 1.0 OUTLIER -115.81 84.9 2.19 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.318 -0.855 . . . . 64.42 109.336 -179.411 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 80.88 -106.11 2.51 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 110.827 -0.909 . . . . 73.45 110.827 -172.481 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.434 ' HB3' ' HG3' ' A' ' 40' ' ' LYS . 11.7 m-20 -110.49 -14.47 14.09 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.761 0.315 . . . . 71.41 110.93 176.323 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.527 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 24.6 pttm -89.41 136.57 32.95 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.98 0.419 . . . . 74.01 110.918 -176.28 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 13.0 m -83.8 130.33 34.93 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.781 -0.645 . . . . 73.51 110.205 178.665 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 26.4 mm -116.65 106.82 21.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 120.93 0.395 . . . . 75.5 110.128 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 60.8 mt-30 -100.02 102.5 13.87 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.225 -0.443 . . . . 73.51 109.828 178.492 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.417 ' HB3' HD13 ' A' ' 32' ' ' LEU . 26.4 mt-10 -89.67 100.68 13.43 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.519 -0.764 . . . . 65.45 110.937 -176.302 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.622 ' HD2' ' HB2' ' B' ' 151' ' ' ASP . 44.2 m-85 -75.41 100.21 4.39 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.086 -0.507 . . . . 74.52 110.32 179.257 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 51.2 mtm180 -115.89 124.45 50.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.311 -0.404 . . . . 71.11 110.418 178.758 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.849 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.9 p -87.24 -93.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 C-N-CA 120.564 -0.454 . . . . 70.51 110.091 175.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.849 ' H ' HG13 ' A' ' 28' ' ' VAL . 2.8 t30 -107.49 70.07 0.77 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 121.562 -0.712 . . . . 64.33 109.997 -176.569 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 77.57 9.08 87.09 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.714 -0.755 . . . . 75.23 112.344 179.128 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 85.6 t80 -127.55 123.06 34.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.676 0.274 . . . . 73.43 110.643 -177.253 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.537 HD21 HD11 ' A' ' 35' ' ' ILE . 27.6 tp -78.65 115.5 18.4 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.025 -0.534 . . . . 72.33 109.762 173.668 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -103.51 -14.68 16.11 Favored 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 120.253 -0.579 . . . . 61.43 111.481 -176.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.446 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -167.61 146.34 4.81 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.889 0.376 . . . . 71.31 111.475 -177.206 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.537 HD11 HD21 ' A' ' 32' ' ' LEU . 71.4 mt -122.59 131.4 73.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 116.084 -0.507 . . . . 71.13 109.77 175.167 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -104.49 100.75 10.43 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.948 -0.76 . . . . 72.34 108.948 170.195 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 0.9 OUTLIER -97.75 123.56 50.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 115.663 -0.699 . . . . 64.32 110.283 -179.483 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.731 HG22 ' HB3' ' A' ' 44' ' ' PRO . 22.0 t -113.73 87.65 12.55 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 115.384 -0.825 . . . . 73.53 110.3 -178.489 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.489 ' HD3' HG22 ' A' ' 37' ' ' VAL . 74.5 Cg_endo -77.83 141.71 19.46 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.406 2.071 . . . . 62.43 111.33 176.568 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.434 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 35.2 mtmt -58.89 -32.95 69.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.197 0.523 . . . . 63.34 110.603 179.346 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -130.6 100.51 5.34 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.74 -0.664 . . . . 74.15 109.297 177.263 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 149.54 -16.0 1.1 Allowed Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.884 -0.674 . . . . 45.34 112.277 -177.417 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.5 mttt 72.76 140.84 0.08 OUTLIER Pre-proline 0 N--CA 1.467 0.393 0 C-N-CA 123.383 0.673 . . . . 74.22 112.237 178.29 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.731 ' HB3' HG22 ' A' ' 38' ' ' VAL . 29.1 Cg_endo -64.18 133.6 38.77 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 123.103 2.535 . . . . 71.12 112.476 179.04 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 11.2 p90 -144.15 156.18 44.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.107 -0.497 . . . . 70.13 110.57 -179.318 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.492 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 20.0 m-85 -99.54 142.38 31.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.084 -0.507 . . . . 75.43 111.484 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.446 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 72.0 mt -124.88 104.51 8.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.608 -0.724 . . . . 74.51 109.747 171.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 43.2 t -93.24 136.36 25.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.184 -0.462 . . . . 74.42 110.047 -178.756 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.562 ' HG3' HH11 ' A' ' 49' ' ' ARG . 0.5 OUTLIER -76.06 132.06 39.87 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.94 0.4 . . . . 71.43 111.621 -178.504 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.12 158.31 35.98 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.565 -0.743 . . . . 74.25 111.707 179.546 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -79.18 171.86 14.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.647 -0.706 . . . . 72.21 111.771 -176.265 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 70.33 21.49 77.35 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.657 -0.701 . . . . 70.41 113.035 171.147 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.9 m 57.28 30.66 18.83 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.024 0.44 . . . . 73.32 110.526 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -55.98 -63.93 1.02 Allowed 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.468 -0.787 . . . . 74.13 111.501 -179.278 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 131.1 -39.2 1.81 Allowed Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.273 -0.965 . . . . 74.35 112.794 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -68.57 164.55 21.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.43 0.633 . . . . 64.22 111.507 -176.1 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.43 ' CE2' ' HG2' ' A' ' 49' ' ' ARG . 67.9 m-85 -113.29 155.28 25.41 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.209 -0.905 . . . . 74.21 109.587 175.022 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.624 HD11 HD23 ' A' ' 66' ' ' LEU . 27.5 mm -113.27 119.87 61.8 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 108.883 -0.784 . . . . 75.3 108.883 177.868 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.571 ' HB2' HG13 ' A' ' 67' ' ' ILE . 8.1 ttm180 -82.7 149.43 27.32 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.951 -0.3 . . . . 75.42 110.403 -175.273 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.492 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 4.3 p -62.82 -27.14 69.11 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.282 -0.417 . . . . 61.24 111.452 178.266 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.449 ' HB2' ' HD2' ' A' ' 59' ' ' ARG . 1.3 m-20 -64.41 -29.13 70.19 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.131 -0.486 . . . . 72.04 111.537 -179.843 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.9 tp-100 -150.79 93.0 3.79 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-O 121.034 0.445 . . . . 71.24 109.992 -179.115 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.481 ' HB2' ' HD2' ' B' ' 146' ' ' PHE . 72.7 Cg_endo -74.35 15.06 0.67 Allowed 'Trans proline' 0 C--O 1.233 0.24 0 C-N-CA 123.396 2.73 . . . . 72.35 113.151 -176.429 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -128.25 8.33 6.04 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.161 0.505 . . . . 74.14 110.338 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 12.5 mmmt -121.75 145.43 48.04 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.101 -0.5 . . . . 65.1 111.925 -177.407 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.624 HD23 HD11 ' A' ' 58' ' ' ILE . 65.6 mt -92.41 109.11 20.49 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.342 -0.844 . . . . 64.24 109.754 178.071 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.571 HG13 ' HB2' ' A' ' 59' ' ' ARG . 46.6 mm -72.67 119.54 75.77 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 116.323 -0.398 . . . . 72.3 110.408 -178.697 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.53 178.95 3.91 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 123.274 2.649 . . . . 74.53 113.363 -177.184 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLN . . . . . 0.822 ' HA ' HG12 ' A' ' 72' ' ' ILE . 34.9 tt0 -75.19 -34.58 61.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.513 -0.767 . . . . 74.21 111.515 -170.486 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 3.7 p90 -64.32 -23.89 67.46 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.349 -0.541 . . . . 75.34 110.916 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.483 ' HA ' ' HB2' ' A' ' 74' ' ' SER . 4.2 tp10 -92.99 -27.79 16.8 Favored 'General case' 0 N--CA 1.438 -1.052 0 CA-C-N 116.086 -0.507 . . . . 72.41 110.639 -176.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.822 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.3 pt -80.14 -16.95 12.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.039 0.447 . . . . 70.55 110.66 177.547 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.452 ' CD1' HG13 ' A' ' 72' ' ' ILE . 46.5 m-85 -108.37 15.37 24.04 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.825 -0.625 . . . . 73.44 110.118 174.04 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.483 ' HB2' ' HA ' ' A' ' 71' ' ' GLU . 8.3 t -74.43 -28.81 61.23 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.755 -0.657 . . . . 71.11 110.396 -177.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' TRP . . . . . 0.405 ' O ' ' HE3' ' A' ' 21' ' ' LYS . 65.3 p-90 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.515 -0.311 . . . . 72.53 110.935 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.45 0 N-CA-C 111.67 -0.572 . . . . 43.02 111.67 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -99.58 116.29 31.37 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.1 0.476 . . . . 71.22 111.118 -176.23 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -101.83 -52.74 3.12 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.449 0.643 . . . . 72.04 109.463 177.34 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -136.49 26.4 3.13 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 107.79 -1.189 . . . . 73.42 107.79 174.64 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -87.32 91.09 8.6 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 114.257 -1.338 . . . . 71.44 110.611 -173.537 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -90.5 116.28 66.04 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.194 -0.457 . . . . 70.01 111.02 -178.423 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -68.28 176.49 5.52 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.902 2.401 . . . . 62.25 111.805 178.183 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 35.0 m -107.56 159.22 16.6 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.087 0.47 . . . . 64.03 110.861 -179.508 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.49 -68.3 0.22 Allowed Glycine 0 N--CA 1.446 -0.691 0 N-CA-C 111.595 -0.602 . . . . 63.5 111.595 -177.408 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 57.8 mm-40 69.21 77.12 0.24 Allowed Pre-proline 0 N--CA 1.468 0.463 0 C-N-CA 123.537 0.735 . . . . 74.44 111.807 -178.394 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.617 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 10.8 Cg_endo -80.93 85.22 1.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.087 0 C-N-CA 122.455 2.103 . . . . 52.13 111.049 174.792 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -97.01 150.52 20.69 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.208 0.528 . . . . 61.21 110.448 -178.218 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.434 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 13.5 p -105.46 123.75 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.906 0 CA-C-N 115.653 -0.703 . . . . 54.05 109.417 174.282 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 114' ' ' THR . . . . . 0.528 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 19.6 m -89.22 99.52 12.49 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 115.658 -0.701 . . . . 61.22 109.472 177.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 59.8 mt -88.86 106.19 16.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.919 -0.582 . . . . 52.31 110.093 -177.732 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 32.1 mtp-105 -122.28 -174.36 2.88 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.408 -0.815 . . . . 75.24 110.34 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 23.6 mp0 -136.16 132.55 36.13 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.839 -0.619 . . . . 74.5 110.431 179.201 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 118' ' ' GLU . . . . . 0.48 ' HG2' HG13 ' B' ' 123' ' ' ILE . 79.4 mm-40 -112.56 82.26 1.61 Allowed 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.062 -0.718 . . . . 75.43 109.062 173.687 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 81.05 -92.06 1.45 Allowed Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.743 -0.741 . . . . 75.45 111.387 -175.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 29.9 m-20 -117.61 -20.49 8.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.767 0.318 . . . . 70.33 111.205 178.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.745 ' HE3' ' HE3' ' B' ' 175' ' ' TRP . 23.6 pttt -86.62 126.0 34.21 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.273 0.559 . . . . 72.14 111.076 -177.391 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 43.9 m -80.72 124.32 28.93 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.502 -0.772 . . . . 70.14 109.986 178.592 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 123' ' ' ILE . . . . . 0.48 HG13 ' HG2' ' B' ' 118' ' ' GLU . 27.3 mm -108.98 108.59 25.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.552 -0.295 . . . . 72.01 110.393 -175.729 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.434 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 61.6 mt-30 -100.65 100.52 11.24 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.917 0.389 . . . . 73.52 110.254 178.256 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 125' ' ' GLU . . . . . 0.528 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 43.7 mt-10 -86.77 107.43 18.26 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.034 -0.53 . . . . 72.5 111.116 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 126' ' ' TYR . . . . . 0.487 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 78.0 m-85 -86.99 113.39 22.71 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.976 0.417 . . . . 74.11 110.422 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 127' ' ' ARG . . . . . 0.423 ' O ' ' HA ' ' B' ' 111' ' ' PRO . 60.5 mtm180 -117.22 178.7 4.27 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.124 -0.489 . . . . 71.31 109.957 179.145 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.624 HG13 ' H ' ' B' ' 129' ' ' ASN . 2.6 p -140.58 -65.21 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 116.279 -0.419 . . . . 64.52 110.884 173.055 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 129' ' ' ASN . . . . . 0.624 ' H ' HG13 ' B' ' 128' ' ' VAL . 3.7 t-20 -141.79 75.99 1.52 Allowed 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.438 -0.505 . . . . 61.15 110.194 -179.64 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.04 25.75 73.32 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.346 -0.843 . . . . 74.34 111.782 -179.053 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 67.7 t80 -146.01 121.7 10.5 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.685 -0.487 . . . . 73.02 109.685 -179.498 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.465 HD21 HD11 ' B' ' 135' ' ' ILE . 24.5 tp -80.14 123.93 28.33 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.724 -0.671 . . . . 75.52 109.318 176.048 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 133' ' ' TYR . . . . . 0.487 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 37.2 p90 -108.85 -15.72 14.32 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.969 -0.692 . . . . 75.31 111.849 -176.883 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 134' ' ' ALA . . . . . 0.41 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -168.03 148.85 5.07 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.928 0.394 . . . . 75.32 111.6 -178.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.465 HD11 HD21 ' B' ' 132' ' ' LEU . 62.9 mt -125.39 126.18 70.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.118 -0.492 . . . . 43.15 109.842 174.337 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.434 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 88.6 tttt -105.04 101.19 10.77 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.957 -0.757 . . . . 62.35 108.957 172.254 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.568 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 1.4 p -99.23 133.64 41.22 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.855 -0.611 . . . . 72.14 110.196 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.883 HG22 ' HB3' ' B' ' 144' ' ' PRO . 24.4 t -107.85 84.61 2.11 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 115.384 -0.826 . . . . 75.42 109.536 177.849 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.415 ' HG3' ' HE1' ' B' ' 145' ' ' TYR . 92.3 Cg_endo -79.86 150.01 20.78 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 122.407 2.072 . . . . 55.15 111.969 -179.175 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 4.1 mmpt? -62.2 -35.71 79.7 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.77 -0.65 . . . . 62.44 110.123 177.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 86.2 m-70 -124.73 90.67 3.29 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 115.789 -0.642 . . . . 72.31 109.913 -178.28 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 142' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 150.49 -29.18 1.07 Allowed Glycine 0 N--CA 1.448 -0.549 0 CA-C-N 115.191 -0.913 . . . . 70.25 111.675 -176.035 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 143' ' ' LYS . . . . . 0.446 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 87.0 mttt 70.34 155.73 0.15 Allowed Pre-proline 0 N--CA 1.467 0.421 0 C-N-CA 123.427 0.691 . . . . 74.14 112.01 -178.777 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.883 ' HB3' HG22 ' B' ' 138' ' ' VAL . 18.9 Cg_endo -58.25 124.07 15.06 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 123.224 2.616 . . . . 71.21 113.47 -175.692 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 145' ' ' TYR . . . . . 0.511 ' CE1' HG13 ' B' ' 137' ' ' VAL . 5.1 p90 -139.65 168.23 20.3 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.636 -0.711 . . . . 72.22 110.137 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.481 ' HD2' ' HB2' ' A' ' 63' ' ' PRO . 1.2 m-85 -108.84 139.32 43.83 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.954 0.407 . . . . 73.42 111.882 -176.506 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.41 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 25.6 mt -118.75 101.28 7.97 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.448 -0.796 . . . . 75.22 109.653 169.479 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 42.7 t -86.46 137.91 20.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 116.225 -0.443 . . . . 73.41 110.077 -179.101 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 5.1 mmt85 -74.85 130.38 39.32 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.884 0.373 . . . . 72.24 111.285 178.615 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -71.03 122.14 19.5 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.769 -0.65 . . . . 34.52 111.08 177.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 151' ' ' ASP . . . . . 0.622 ' HB2' ' HD2' ' A' ' 26' ' ' TYR . 15.7 t70 -61.31 140.0 58.06 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.648 -0.705 . . . . 73.24 110.981 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 73.47 -56.61 2.03 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.955 -0.566 . . . . 71.4 113.237 179.323 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 153' ' ' SER . . . . . 0.433 ' O ' ' HB3' ' B' ' 154' ' ' ASP . 19.7 m -61.2 -46.07 91.96 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 122.43 0.292 . . . . 73.41 110.868 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 154' ' ' ASP . . . . . 0.433 ' HB3' ' O ' ' B' ' 153' ' ' SER . 18.0 t70 71.47 -48.27 0.67 Allowed 'General case' 0 N--CA 1.464 0.237 0 C-N-CA 123.743 0.817 . . . . 74.33 111.859 178.107 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . -88.13 50.07 3.84 Favored Glycine 0 N--CA 1.448 -0.502 0 CA-C-N 116.122 -0.49 . . . . 54.43 112.601 -178.083 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -162.54 144.59 10.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.457 -0.571 . . . . 75.55 109.457 179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 157' ' ' PHE . . . . . 0.506 ' HB2' HG22 ' B' ' 172' ' ' ILE . 72.4 m-85 -118.99 150.71 39.48 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.909 0.385 . . . . 74.04 110.463 178.108 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.0 mm -113.43 114.44 46.86 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 N-CA-C 108.82 -0.807 . . . . 64.14 108.82 175.45 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.535 ' HB2' HG13 ' B' ' 167' ' ' ILE . 15.0 ttp180 -88.03 146.92 25.24 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 110.046 -0.353 . . . . 72.34 110.046 -174.815 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 4.0 p -60.03 -36.31 76.99 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 112.779 0.659 . . . . 61.11 112.779 -174.101 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -78.28 -14.65 59.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.973 0.416 . . . . 70.12 110.908 -177.679 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 162' ' ' GLN . . . . . 0.838 ' HG3' ' HB2' ' B' ' 165' ' ' LYS . 5.4 tp-100 -138.03 72.02 47.57 Favored Pre-proline 0 N--CA 1.45 -0.438 0 CA-C-N 116.219 -0.446 . . . . 54.31 110.894 -177.334 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -85.09 -1.57 9.38 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.674 2.249 . . . . 72.53 111.775 179.18 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -91.74 -17.99 24.59 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.25 -0.886 . . . . 75.2 110.14 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 165' ' ' LYS . . . . . 0.838 ' HB2' ' HG3' ' B' ' 162' ' ' GLN . 0.7 OUTLIER -122.79 158.83 29.35 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.124 -0.944 . . . . 72.42 111.134 -175.133 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.1 mp -94.74 134.02 37.79 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.064 -1.087 . . . . 55.14 108.064 172.577 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 167' ' ' ILE . . . . . 0.535 HG13 ' HB2' ' B' ' 159' ' ' ARG . 50.2 mm -84.69 125.11 72.07 Favored Pre-proline 0 C--N 1.32 -0.695 0 C-N-CA 120.91 -0.316 . . . . 73.43 111.041 -171.552 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.455 ' O ' HG23 ' B' ' 172' ' ' ILE . 49.6 Cg_endo -67.7 172.77 10.02 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.762 2.308 . . . . 74.3 112.429 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 169' ' ' GLN . . . . . 0.516 ' HA ' HG12 ' B' ' 172' ' ' ILE . 20.4 tt0 -79.56 -16.93 55.05 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.766 -0.652 . . . . 74.54 111.626 -167.464 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 170' ' ' TRP . . . . . 0.417 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 24.4 p90 -86.75 -8.01 57.76 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.234 0.54 . . . . 62.5 110.019 176.043 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.55 ' O ' ' HB2' ' B' ' 174' ' ' SER . 1.9 mm-40 -113.32 -11.89 13.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.816 -0.629 . . . . 73.12 111.961 -176.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.516 HG12 ' HA ' ' B' ' 169' ' ' GLN . 31.8 pt -76.82 -16.87 14.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 121.264 0.554 . . . . 70.5 110.277 175.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -109.14 39.09 2.13 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.356 -0.838 . . . . 75.22 108.874 174.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 174' ' ' SER . . . . . 0.55 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 0.5 OUTLIER -70.15 -14.48 62.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 114.981 -1.009 . . . . 60.34 110.916 -176.181 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 175' ' ' TRP . . . . . 0.745 ' HE3' ' HE3' ' B' ' 121' ' ' LYS . 59.7 p-90 . . . . . 0 C--O 1.245 0.842 0 CA-C-O 118.286 -0.864 . . . . 64.24 110.204 177.573 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.659 0 N-CA-C 111.328 -0.709 . . . . 63.32 111.328 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -78.74 73.56 5.28 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.447 0.641 . . . . 73.01 110.518 175.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -121.17 131.39 54.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.31 -0.859 . . . . 73.41 109.909 178.096 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -82.05 -60.89 2.07 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.88 -0.6 . . . . 62.31 111.964 -173.09 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -83.77 111.88 19.58 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.272 -0.422 . . . . 72.4 111.124 -175.613 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -86.97 131.36 45.14 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-N 115.677 -0.692 . . . . 74.03 109.798 176.152 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -68.69 165.68 28.68 Favored 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.671 2.248 . . . . 63.44 112.386 -178.528 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 15.0 m -81.03 111.58 17.64 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.03 -0.73 . . . . 75.22 109.03 175.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 116.17 102.8 2.33 Favored Glycine 0 N--CA 1.439 -1.111 0 N-CA-C 108.79 -1.724 . . . . 74.44 108.79 -166.103 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLU . . . . . 0.476 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 10.1 pt-20 -141.03 113.99 6.96 Favored Pre-proline 0 N--CA 1.437 -1.12 0 N-CA-C 108.089 -1.078 . . . . 63.41 108.089 -167.773 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.476 ' HD3' ' HA ' ' A' ' 10' ' ' GLU . 4.9 Cg_exo -77.12 81.47 2.61 Favored 'Trans proline' 0 N--CA 1.437 -1.803 0 C-N-CA 121.873 1.715 . . . . 73.12 110.531 -176.451 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -86.26 155.37 20.71 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.564 -1.198 . . . . 72.12 109.869 -177.452 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.592 HG21 ' HB3' ' A' ' 24' ' ' GLN . 10.1 p -121.23 123.79 70.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 CA-C-O 121.512 0.673 . . . . 64.42 111.143 -178.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.558 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 88.8 m -86.03 104.21 15.43 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.521 -0.763 . . . . 71.0 108.944 177.011 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.3 mt -91.44 105.5 16.61 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 CA-C-N 116.093 -0.503 . . . . 44.43 110.598 -175.698 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.405 HH21 ' CD ' ' A' ' 25' ' ' GLU . 62.3 mtm180 -117.86 172.99 7.02 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.787 -0.642 . . . . 72.54 109.993 177.766 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.499 ' HG2' ' HA ' ' A' ' 22' ' ' THR . 82.6 mt-30 -136.93 122.17 19.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.172 0.51 . . . . 64.52 111.024 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.469 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 31.5 mm-40 -106.96 87.35 2.49 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.398 -0.819 . . . . 75.43 110.018 178.188 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 79.17 -95.13 1.4 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.633 -0.794 . . . . 74.43 111.678 -178.26 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -124.09 12.5 8.97 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.83 0.347 . . . . 72.42 110.871 -179.228 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.714 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 21.3 pttm -117.27 117.29 29.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.019 0.438 . . . . 74.55 110.987 178.797 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.702 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 23.6 m -79.25 101.91 8.27 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.736 -0.665 . . . . 72.03 109.679 176.047 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.469 HG12 HG13 ' A' ' 37' ' ' VAL . 57.0 mt -92.64 106.85 18.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 120.996 0.427 . . . . 63.43 110.14 -176.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.604 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 72.6 mt-30 -91.4 110.7 22.01 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.801 -0.636 . . . . 75.12 110.3 178.784 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.622 ' HB3' HD13 ' A' ' 32' ' ' LEU . 26.4 mt-10 -93.83 103.48 15.6 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.469 -0.787 . . . . 62.33 111.109 -177.142 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.413 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 86.8 m-85 -77.83 109.13 11.58 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.985 0.421 . . . . 73.52 110.228 178.692 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 31' ' ' PHE . 83.8 mtt180 -127.58 127.3 43.65 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.581 -0.736 . . . . 74.42 109.459 -179.681 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.604 HG21 ' CD2' ' B' ' 131' ' ' PHE . 11.9 p -90.49 -28.25 4.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 C-N-CA 120.37 -0.532 . . . . 61.02 110.628 -177.754 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -172.26 68.06 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.707 -0.679 . . . . 73.11 109.631 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 95.77 -37.97 3.26 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.773 -0.727 . . . . 62.32 113.414 178.262 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.416 ' CD2' HG21 ' B' ' 128' ' ' VAL . 80.1 t80 -94.82 133.5 38.46 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.239 0.542 . . . . 71.15 111.405 -174.058 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.622 HD13 ' HB3' ' A' ' 25' ' ' GLU . 50.1 tp -82.38 112.86 19.73 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.941 -1.027 . . . . 54.1 110.156 174.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' TYR . . . . . 0.455 ' O ' ' HB2' ' A' ' 49' ' ' ARG . 44.3 p90 -108.62 -4.99 16.65 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.895 -0.322 . . . . 73.4 111.72 -176.614 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.405 ' HB3' ' HB2' ' A' ' 26' ' ' TYR . . . -168.3 136.97 2.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.891 0.377 . . . . 71.42 110.889 -176.141 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.414 ' CG1' HD21 ' A' ' 32' ' ' LEU . 61.4 mt -118.97 126.12 75.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.0 -0.546 . . . . 75.32 110.542 178.852 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.604 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 83.1 tttt -108.69 100.78 9.98 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.003 -0.74 . . . . 62.25 109.003 171.366 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.706 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.8 t -87.91 128.79 40.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 109.153 -0.684 . . . . 63.32 109.153 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.817 HG13 ' HG3' ' A' ' 44' ' ' PRO . 24.2 t -115.74 72.71 4.16 Favored Pre-proline 0 C--N 1.32 -0.709 0 N-CA-C 109.75 -0.463 . . . . 65.05 109.75 172.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.714 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 57.1 Cg_endo -78.76 134.43 12.09 Favored 'Trans proline' 0 N--CA 1.458 -0.615 0 C-N-CA 122.18 1.92 . . . . 63.11 112.433 176.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 9.4 mtpm? -59.78 -33.06 71.21 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-O 121.29 0.566 . . . . 74.2 109.948 175.275 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 62.4 m-70 -115.77 103.58 10.8 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.244 -0.889 . . . . 54.3 109.148 178.009 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 130.11 -25.18 4.39 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.943 -0.646 . . . . 31.44 112.096 -177.552 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.0 mttm 69.57 147.79 0.12 Allowed Pre-proline 0 N--CA 1.466 0.363 0 C-N-CA 123.342 0.657 . . . . 73.43 112.323 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.817 ' HG3' HG13 ' A' ' 38' ' ' VAL . 31.0 Cg_exo -58.51 145.97 92.59 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 123.222 2.615 . . . . 74.35 113.561 -177.03 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 30.6 p90 -156.39 164.91 37.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.314 -0.857 . . . . 74.31 109.304 174.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.557 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 85.1 m-85 -106.62 136.44 46.4 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.021 0.438 . . . . 72.12 110.7 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 16.9 tp -125.14 98.96 5.88 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.695 -0.854 . . . . 54.3 108.695 176.408 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.438 HG21 HG21 ' B' ' 148' ' ' VAL . 28.7 t -96.32 140.59 16.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.421 -0.354 . . . . 74.24 111.548 -171.036 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.455 ' HB2' ' O ' ' A' ' 33' ' ' TYR . 0.7 OUTLIER -66.85 122.38 17.57 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.213 -0.449 . . . . 72.35 111.32 176.66 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.44 172.39 13.7 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.921 -0.581 . . . . 72.44 109.503 172.498 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -68.04 125.04 25.07 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.22 0.533 . . . . 71.51 109.781 176.807 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.41 125.57 5.49 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.783 -0.723 . . . . 63.23 111.899 -176.351 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.5 t -87.45 23.1 1.99 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.347 0.594 . . . . 74.35 110.24 -177.027 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -58.12 -60.43 3.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.432 -0.804 . . . . 54.51 110.206 177.673 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 156.61 21.87 0.03 OUTLIER Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 115.546 -0.752 . . . . 72.35 112.453 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.485 ' OD1' ' HB3' ' A' ' 66' ' ' LEU . 7.4 t30 -102.91 137.18 41.44 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.963 0.411 . . . . 65.34 110.867 -176.562 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -123.56 174.42 7.43 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.942 -0.572 . . . . 72.11 110.47 177.659 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 49.8 mm -123.97 122.08 63.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.893 -0.78 . . . . 42.41 108.893 171.506 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.668 ' HB2' HG13 ' A' ' 67' ' ' ILE . 74.6 ttt180 -93.34 131.97 38.0 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.07 -0.514 . . . . 71.15 110.309 -175.386 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.557 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 67.9 p -62.8 -22.77 66.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.86 0.362 . . . . 74.35 111.343 -178.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.468 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 16.4 t70 -64.23 -46.37 84.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.778 -0.647 . . . . 64.34 109.981 178.479 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 78.0 mm-40 -132.14 82.66 58.1 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.479 -0.782 . . . . 71.32 109.383 178.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -76.34 30.9 0.4 Allowed 'Trans proline' 0 CA--C 1.529 0.254 0 C-N-CA 123.28 2.653 . . . . 62.14 112.5 -177.052 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -119.57 -39.89 2.83 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.433 -0.803 . . . . 72.22 110.462 -177.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.7 pttt -97.53 160.22 14.45 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.999 -0.546 . . . . 74.53 110.501 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.485 ' HB3' ' OD1' ' A' ' 56' ' ' ASN . 5.4 mp -92.96 140.25 29.67 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.668 -0.696 . . . . 71.14 109.335 179.214 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.711 HG23 ' HB3' ' A' ' 71' ' ' GLU . 47.1 mm -96.84 109.03 46.79 Favored Pre-proline 0 C--N 1.322 -0.593 0 CA-C-O 121.235 0.54 . . . . 75.31 111.307 -176.453 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.49 ' O ' HG23 ' A' ' 72' ' ' ILE . 93.0 Cg_endo -81.61 -176.92 3.3 Favored 'Trans proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.505 2.803 . . . . 61.14 111.983 177.499 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLN . . . . . 0.651 ' O ' HG12 ' A' ' 72' ' ' ILE . 45.6 tt0 -67.99 -40.42 83.09 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.225 0.454 . . . . 72.42 112.225 -171.122 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' TRP . . . . . 0.644 ' HA ' ' CZ ' ' A' ' 73' ' ' PHE . 17.4 p90 -63.38 -17.76 62.95 Favored 'General case' 0 C--N 1.326 -0.441 0 O-C-N 121.723 -0.61 . . . . 72.35 110.981 -178.591 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.711 ' HB3' HG23 ' A' ' 67' ' ' ILE . 2.5 mm-40 -94.45 -18.45 21.49 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.041 -0.527 . . . . 71.03 111.117 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.651 HG12 ' O ' ' A' ' 69' ' ' GLN . 39.9 pt -83.61 -36.03 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 C-N-CA 120.723 -0.391 . . . . 53.3 111.625 -177.199 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.644 ' CZ ' ' HA ' ' A' ' 70' ' ' TRP . 10.7 p90 -90.82 26.09 2.18 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.262 0.554 . . . . 75.11 110.722 178.839 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.3 t -78.72 9.03 4.49 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.767 -0.652 . . . . 73.42 111.102 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' TRP . . . . . 0.681 ' HB3' ' HE3' ' A' ' 21' ' ' LYS . 38.8 m0 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.459 -0.337 . . . . 72.52 111.176 177.652 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 N-CA-C 111.876 -0.49 . . . . 54.2 111.876 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -103.66 0.36 30.56 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.228 0.537 . . . . 72.24 110.319 178.163 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -88.94 168.38 12.44 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.679 -0.692 . . . . 60.34 110.456 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -81.94 -48.25 11.71 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.145 0.498 . . . . 71.14 110.612 178.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -114.03 134.68 54.7 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.611 -0.722 . . . . 73.24 110.528 -178.215 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -120.75 128.58 25.71 Favored Pre-proline 0 C--N 1.319 -0.747 0 CA-C-N 115.883 -0.599 . . . . 72.14 109.979 177.78 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -52.89 144.08 46.14 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.833 2.355 . . . . 73.21 112.183 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 31.8 m -58.77 115.72 3.26 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.872 -0.603 . . . . 72.24 110.366 -179.23 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 122.61 42.89 0.4 Allowed Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 110.491 -1.043 . . . . 63.05 110.491 -170.397 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -106.59 100.56 31.25 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-O 121.658 0.742 . . . . 74.34 109.286 -179.463 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 58.0 Cg_endo -79.43 121.04 4.61 Favored 'Trans proline' 0 N--CA 1.448 -1.148 0 C-N-CA 122.382 2.054 . . . . 54.13 113.195 -169.645 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -122.84 144.19 49.36 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.814 -1.084 . . . . 74.34 108.599 174.583 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.75 HG21 ' HB3' ' B' ' 124' ' ' GLN . 7.9 p -92.37 132.01 37.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-O 121.396 0.617 . . . . 75.0 111.543 -172.112 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 114' ' ' THR . . . . . 0.747 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.4 m -82.84 103.39 12.28 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.167 -0.924 . . . . 71.41 109.177 174.885 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 59.2 mt -88.67 104.61 14.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.096 0.474 . . . . 72.43 111.066 -176.124 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 116' ' ' ARG . . . . . 0.434 HH21 ' CD ' ' B' ' 125' ' ' GLU . 38.1 mtm180 -108.88 167.86 9.78 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.721 -0.672 . . . . 72.22 109.627 174.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 91.5 mt-30 -139.55 112.03 7.73 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.068 0.461 . . . . 74.34 110.585 177.447 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 81.6 mm-40 -108.48 85.35 2.09 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.669 -0.696 . . . . 74.1 110.384 -178.621 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 88.38 -111.94 3.84 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.624 -0.798 . . . . 51.42 111.589 -178.138 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.507 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 4.3 m-20 -116.0 23.24 12.37 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.059 0.457 . . . . 42.23 110.041 177.141 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.962 ' HE3' ' HB3' ' B' ' 175' ' ' TRP . 21.2 pttm -127.5 115.56 19.04 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.236 0.541 . . . . 63.31 110.307 177.311 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 122' ' ' THR . . . . . 0.747 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 62.5 m -76.22 113.0 13.29 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.611 -0.722 . . . . 73.24 109.675 177.172 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 14.2 mm -92.8 102.51 13.7 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-N 115.948 -0.569 . . . . 75.13 109.999 -178.222 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.776 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 63.2 mt-30 -94.77 102.89 14.79 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.093 0.473 . . . . 63.13 110.327 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 125' ' ' GLU . . . . . 0.747 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 38.9 mt-10 -84.62 102.72 13.13 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.556 -0.747 . . . . 71.12 110.603 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 126' ' ' TYR . . . . . 0.493 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 41.4 m-85 -78.8 106.0 10.51 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.137 0.494 . . . . 55.11 110.377 178.061 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 65.6 mtt-85 -124.08 134.55 53.36 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.61 -0.723 . . . . 74.1 109.468 -178.367 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 5.6 p -96.08 -30.91 3.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-O 120.966 0.412 . . . . 54.02 111.407 -176.374 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -160.45 45.99 0.22 Allowed 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.872 -0.788 . . . . 72.34 108.872 -176.563 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 95.54 -32.08 6.58 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.425 -0.807 . . . . 23.51 112.186 -177.124 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.604 ' CD2' HG21 ' A' ' 28' ' ' VAL . 38.2 t80 -86.49 133.6 33.74 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.99 0.424 . . . . 74.31 110.445 -177.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.449 HD21 HD11 ' B' ' 135' ' ' ILE . 41.4 tp -82.83 120.5 25.73 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.354 -0.839 . . . . 62.21 110.645 179.328 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 133' ' ' TYR . . . . . 0.493 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 36.2 p90 -110.4 -10.43 14.58 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.498 -0.481 . . . . 74.02 111.658 -179.101 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -170.14 148.13 3.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.806 0.336 . . . . 44.21 110.913 -178.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.449 HD11 HD21 ' B' ' 132' ' ' LEU . 63.5 mt -122.44 125.89 73.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.332 -0.395 . . . . 71.11 110.17 177.456 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.776 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 75.9 tttt -102.43 102.39 12.7 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 109.07 -0.715 . . . . 72.13 109.07 173.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.589 HG12 ' HD3' ' B' ' 139' ' ' PRO . 3.4 t -86.52 128.94 39.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 N-CA-C 108.559 -0.904 . . . . 70.41 108.559 178.151 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.747 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.5 t -115.35 72.1 3.39 Favored Pre-proline 0 C--N 1.317 -0.841 0 N-CA-C 109.956 -0.387 . . . . 75.12 109.956 173.525 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.589 ' HD3' HG12 ' B' ' 137' ' ' VAL . 45.1 Cg_endo -77.12 130.5 11.23 Favored 'Trans proline' 0 N--CA 1.455 -0.754 0 C-N-CA 121.992 1.794 . . . . 64.11 111.868 176.719 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 140' ' ' LYS . . . . . 0.507 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 22.9 mtpp -64.76 -27.43 68.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.442 -0.799 . . . . 73.45 110.199 177.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -114.43 86.57 2.46 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.132 -0.94 . . . . 73.02 109.149 176.293 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 140.96 -13.88 2.85 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.593 -0.813 . . . . 60.52 112.678 -177.576 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 67.1 mttm 70.03 149.01 0.12 Allowed Pre-proline 0 N--CA 1.469 0.525 0 C-N-CA 123.134 0.574 . . . . 74.21 112.183 178.266 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.554 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 56.3 Cg_endo -70.64 143.1 45.7 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.674 2.249 . . . . 74.22 113.146 -178.279 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 44.7 p90 -150.99 154.77 37.72 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.789 -0.641 . . . . 74.23 110.199 178.207 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.636 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 93.4 m-85 -96.64 130.5 43.84 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.838 -0.43 . . . . 75.25 109.838 177.255 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.402 HD11 HG13 ' B' ' 167' ' ' ILE . 15.7 tp -117.21 98.81 6.64 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.134 -0.691 . . . . 73.44 109.134 176.479 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 148' ' ' VAL . . . . . 0.438 HG21 HG21 ' A' ' 48' ' ' VAL . 39.0 t -83.92 135.73 24.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.05 -0.523 . . . . 72.14 110.837 -175.294 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.29 119.44 24.59 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.58 -0.526 . . . . 64.35 109.58 -177.722 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.14 166.75 22.88 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 121.321 0.581 . . . . 71.21 111.74 -174.704 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 151' ' ' ASP . . . . . 0.404 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 5.6 p-10 -67.77 157.59 34.38 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 114.964 -1.017 . . . . 71.24 111.99 -175.603 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.41 -8.93 57.24 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.301 -0.863 . . . . 52.22 113.28 173.179 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 23.3 t 59.3 31.1 20.9 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-O 121.513 0.673 . . . . 71.21 110.007 -178.155 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -64.43 -26.18 68.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.597 -0.729 . . . . 64.33 111.841 -178.139 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 106.15 25.17 6.53 Favored Glycine 0 CA--C 1.506 -0.525 0 N-CA-C 111.169 -0.772 . . . . 62.23 111.169 -175.044 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 156' ' ' ASN . . . . . 0.444 HD21 HD23 ' B' ' 166' ' ' LEU . 38.0 t30 -111.95 144.26 41.59 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.461 -0.57 . . . . 75.11 109.461 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 157' ' ' PHE . . . . . 0.531 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 55.8 m-85 -130.62 149.56 52.22 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.305 -0.407 . . . . 75.45 110.083 179.587 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.2 mm -112.44 117.19 54.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.444 -0.576 . . . . 72.15 109.444 176.306 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.443 ' HG2' ' H ' ' B' ' 161' ' ' ASP . 46.1 ttt180 -85.95 135.05 33.82 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.48 -0.782 . . . . 74.01 110.075 -175.824 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 160' ' ' SER . . . . . 0.636 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 61.3 p -60.46 -33.07 72.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.406 0.622 . . . . 74.2 110.412 178.66 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 161' ' ' ASP . . . . . 0.443 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 26.6 t70 -75.94 -24.59 55.51 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.15 -0.932 . . . . 71.31 110.921 178.701 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 162' ' ' GLN . . . . . 0.453 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 84.3 mm-40 -139.98 70.97 35.44 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 71.32 110.197 -175.235 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -73.11 -15.37 25.8 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.431 2.087 . . . . 72.23 112.007 -178.032 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -89.2 -7.2 56.06 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.41 -0.814 . . . . 72.14 109.641 177.02 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 165' ' ' LYS . . . . . 0.453 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 51.3 tptt -110.68 123.98 51.06 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.444 -0.798 . . . . 75.1 110.447 -176.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 166' ' ' LEU . . . . . 0.444 HD23 HD21 ' B' ' 156' ' ' ASN . 5.3 mp -89.64 117.5 28.56 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.515 -0.766 . . . . 62.41 108.989 177.096 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 167' ' ' ILE . . . . . 0.531 ' HB ' ' HB2' ' B' ' 157' ' ' PHE . 49.3 mm -77.73 119.56 77.91 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.185 -0.462 . . . . 72.25 111.272 -171.31 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.481 ' O ' HG23 ' B' ' 172' ' ' ILE . 73.7 Cg_endo -73.3 177.26 8.1 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 123.049 2.5 . . . . 73.41 111.998 178.492 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 28.5 tt0 -84.25 0.88 47.2 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.347 -0.388 . . . . 71.32 111.468 -172.127 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 7.8 p90 -100.46 -18.89 16.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.987 0.423 . . . . 73.55 110.89 175.259 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.418 ' HB2' ' HG2' ' B' ' 168' ' ' PRO . 2.0 mm-40 -94.29 -11.43 30.15 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.194 -0.457 . . . . 74.52 110.76 -177.232 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.481 HG23 ' O ' ' B' ' 168' ' ' PRO . 37.0 pt -65.56 -29.65 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.991 -0.55 . . . . 75.22 111.432 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 173' ' ' PHE . . . . . 0.458 ' C ' ' H ' ' B' ' 175' ' ' TRP . 33.8 p90 -107.79 43.96 1.15 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.525 0.678 . . . . 71.14 110.447 178.742 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 174' ' ' SER . . . . . 0.418 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 1.9 t -78.59 21.97 0.37 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.05 -0.977 . . . . 71.35 110.036 178.183 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 175' ' ' TRP . . . . . 0.962 ' HB3' ' HE3' ' B' ' 121' ' ' LYS . 39.3 m0 . . . . . 0 C--O 1.25 1.129 0 CA-C-N 115.223 -0.898 . . . . 75.21 110.928 -176.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.884 0 N-CA-C 112.028 -0.429 . . . . 45.03 112.028 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -154.0 95.74 1.89 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.627 0.251 . . . . 61.31 110.681 -179.195 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -96.46 75.48 2.88 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.447 0.642 . . . . 73.43 109.318 178.296 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -116.83 112.82 21.65 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.282 -0.872 . . . . 74.35 110.278 -176.618 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -103.7 154.81 19.12 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.675 0.274 . . . . 74.21 110.482 -179.318 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.426 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -99.74 130.55 26.33 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-N 116.239 -0.437 . . . . 52.13 110.692 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 16.7 Cg_exo -68.13 171.42 12.62 Favored 'Trans proline' 0 CA--C 1.529 0.242 0 C-N-CA 122.955 2.436 . . . . 71.01 112.369 -179.513 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.6 m -65.67 143.25 57.69 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.518 -0.549 . . . . 65.11 109.518 176.541 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.663 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 74.03 73.02 0.95 Allowed Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.02 -1.086 . . . . 52.33 110.621 -173.727 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLU . . . . . 0.432 ' H ' ' HG2' ' A' ' 10' ' ' GLU . 7.6 pt-20 -96.22 99.1 4.77 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-O 121.417 0.627 . . . . 63.05 110.667 -174.844 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.673 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 98.2 Cg_endo -93.73 94.72 0.14 Allowed 'Trans proline' 0 N--CA 1.445 -1.368 0 C-N-CA 122.926 2.417 . . . . 64.04 112.747 -176.524 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -86.96 147.1 25.89 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 108.932 -0.766 . . . . 60.21 108.932 177.069 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.623 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 8.1 p -90.63 122.41 41.98 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 CA-C-O 121.629 0.728 . . . . 65.13 110.261 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.628 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 21.6 m -83.31 102.59 12.08 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.264 -0.88 . . . . 72.4 109.196 179.226 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 53.2 mt -84.72 103.98 12.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-N 115.978 -0.555 . . . . 74.34 110.308 -175.449 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -108.8 161.24 15.3 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.621 -0.718 . . . . 64.31 109.32 176.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -137.87 98.25 3.61 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-O 121.351 0.596 . . . . 71.13 110.232 176.786 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -93.88 96.84 9.99 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 114.982 -1.008 . . . . 75.42 109.849 -177.313 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 71.06 -101.84 1.0 Allowed Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.837 -0.697 . . . . 63.44 112.077 -178.105 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.745 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 16.5 m-20 -120.76 30.42 6.91 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.635 0.255 . . . . 62.43 110.951 -178.364 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 48.0 pttt -143.55 127.69 17.58 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.382 0.61 . . . . 75.25 111.624 175.72 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.447 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 75.0 m -81.66 107.18 14.2 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.189 -0.914 . . . . 71.34 109.936 177.073 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 50.2 mt -94.63 104.35 15.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.088 -0.505 . . . . 72.31 109.721 178.521 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.623 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 74.7 mt-30 -95.15 106.38 18.39 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.871 -0.604 . . . . 74.3 110.654 -177.725 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.628 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.7 mt-10 -89.86 104.51 17.06 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.874 -0.603 . . . . 53.15 111.355 -177.437 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.568 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 71.7 m-85 -76.94 103.57 6.95 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.393 -0.595 . . . . 74.34 109.393 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.43 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 55.5 mtt180 -120.39 128.05 52.86 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.259 -0.428 . . . . 73.55 110.362 -177.312 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.685 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.3 p -93.49 -66.73 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.543 -0.298 . . . . 72.45 111.232 179.58 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.685 ' H ' HG13 ' A' ' 28' ' ' VAL . 74.2 m-20 -133.53 77.5 1.73 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.85 0.357 . . . . 71.01 110.158 179.513 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 69.21 13.49 67.38 Favored Glycine 0 C--N 1.331 0.267 0 CA-C-N 115.792 -0.64 . . . . 74.21 112.868 179.042 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.614 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 83.3 t80 -129.86 128.04 41.45 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.888 0.375 . . . . 72.12 111.12 -175.431 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.74 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -85.98 116.25 24.09 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.559 -0.746 . . . . 72.12 109.327 173.571 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -110.89 -19.71 12.71 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.622 -0.431 . . . . 74.04 111.729 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -156.08 141.21 17.39 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.656 0.265 . . . . 61.01 111.031 -179.338 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.74 HG13 HD11 ' A' ' 32' ' ' LEU . 77.0 mt -124.31 125.9 71.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 116.055 -0.521 . . . . 72.32 110.612 176.867 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.444 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 82.1 tttt -102.99 102.56 12.61 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.104 -0.702 . . . . 72.3 109.104 170.787 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 22' ' ' THR . 0.5 OUTLIER -101.84 119.93 50.78 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 116.119 -0.491 . . . . 70.51 110.337 -179.538 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.571 HG13 ' HB3' ' A' ' 44' ' ' PRO . 22.3 t -109.17 89.71 7.19 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.445 -0.798 . . . . 73.44 110.135 -179.826 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.417 ' HD3' HG22 ' A' ' 37' ' ' VAL . 63.6 Cg_endo -79.37 135.92 12.24 Favored 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 122.282 1.988 . . . . 73.02 112.133 178.001 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.745 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 56.5 mtpt -63.43 -36.27 83.19 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.362 0.601 . . . . 71.33 109.518 174.622 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -97.81 92.63 5.94 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.222 -0.899 . . . . 63.3 109.114 177.269 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 126.0 -151.39 17.82 Favored Glycine 0 N--CA 1.448 -0.549 0 N-CA-C 111.478 -0.649 . . . . 63.12 111.478 -176.529 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -129.29 143.76 50.11 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.801 0.301 . . . . 73.42 110.601 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.571 ' HB3' HG13 ' A' ' 38' ' ' VAL . 32.1 Cg_endo -65.29 128.94 21.49 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.679 2.253 . . . . 74.13 112.077 177.758 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -133.86 156.73 47.54 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.267 -0.424 . . . . 74.12 110.343 -178.151 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -95.71 131.62 41.77 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.778 -0.647 . . . . 74.14 109.792 177.514 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.569 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 17.0 tp -115.63 94.11 4.56 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.827 -0.805 . . . . 72.01 108.827 178.102 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.7 t -87.29 138.27 19.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.064 -0.517 . . . . 63.25 110.872 -174.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.461 ' HE ' ' HA ' ' A' ' 53' ' ' SER . 0.0 OUTLIER -100.89 121.6 42.0 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.926 -0.398 . . . . 74.32 109.926 -177.3 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.431 ' HB3' ' OD1' ' A' ' 56' ' ' ASN . . . -76.98 172.06 13.79 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.01 0.433 . . . . 71.3 112.076 -173.387 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.437 ' HB3' ' CD2' ' B' ' 126' ' ' TYR . 4.3 p-10 -72.13 167.73 19.64 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 115.793 -0.64 . . . . 74.31 111.09 -175.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 81.2 -17.17 13.42 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.831 -0.622 . . . . 50.43 112.798 177.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.461 ' HA ' ' HE ' ' A' ' 49' ' ' ARG . 20.9 t 61.64 33.46 18.13 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-O 120.894 0.378 . . . . 63.53 110.148 -178.075 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -55.89 -42.02 75.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.714 -0.675 . . . . 73.32 111.363 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 119.17 25.52 2.7 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.834 -0.698 . . . . 72.11 111.392 -177.167 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.431 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 11.2 p30 -118.74 147.24 44.07 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.178 0.513 . . . . 74.14 110.633 -177.368 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.569 ' CD2' ' HG ' ' A' ' 47' ' ' LEU . 46.6 m-85 -128.17 154.33 45.91 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.684 -0.689 . . . . 75.4 110.501 -178.729 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 45.3 mm -113.1 122.89 68.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.987 -0.551 . . . . 73.41 109.519 177.705 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.491 ' HB3' ' HB3' ' A' ' 61' ' ' ASP . 67.2 mtt180 -86.17 144.79 27.3 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.56 -0.291 . . . . 71.42 110.61 178.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 77.6 p -76.02 -21.85 56.41 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.407 -0.961 . . . . 75.3 108.407 166.396 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.491 ' HB3' ' HB3' ' A' ' 59' ' ' ARG . 19.2 t70 -57.62 -49.17 77.33 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.519 -1.219 . . . . 74.35 110.092 172.746 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 24.1 mm-40 -144.78 86.38 7.9 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.151 -0.932 . . . . 63.2 110.25 178.796 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_endo -78.79 13.0 2.03 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.89 2.394 . . . . 75.44 112.24 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -83.65 -30.7 26.65 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.418 -0.81 . . . . 71.1 110.529 -178.59 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.434 ' HE3' HD11 ' A' ' 67' ' ' ILE . 0.0 OUTLIER -126.25 178.1 6.02 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-O 121.196 0.522 . . . . 72.35 111.614 -176.664 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.5 mp -111.16 138.19 47.91 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.206 -0.906 . . . . 75.41 109.607 177.357 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.434 HD11 ' HE3' ' A' ' 65' ' ' LYS . 33.7 mm -76.55 124.86 87.95 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 116.448 -0.342 . . . . 75.43 110.145 178.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.411 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 44.3 Cg_endo -66.98 173.84 7.72 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.903 2.402 . . . . 75.01 112.759 -177.855 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 19.5 tt0 -88.63 -1.44 58.07 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.54 -0.755 . . . . 74.11 111.907 -168.684 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' TRP . . . . . 0.586 ' HA ' ' CE2' ' A' ' 73' ' ' PHE . 33.4 p90 -97.39 -22.61 16.51 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.265 0.555 . . . . 74.53 109.727 172.706 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.414 ' HA ' ' OG ' ' A' ' 74' ' ' SER . 4.4 mm-40 -84.25 -12.71 54.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.448 -0.796 . . . . 44.41 111.522 -176.745 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 31.9 pt -77.67 -15.88 14.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.125 -0.489 . . . . 64.4 111.875 -177.496 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CE2' ' HA ' ' A' ' 70' ' ' TRP . 42.4 p90 -119.45 23.83 11.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.42 0.629 . . . . 74.42 110.189 177.766 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.414 ' OG ' ' HA ' ' A' ' 71' ' ' GLU . 56.2 m -80.23 -1.34 40.25 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.712 -0.676 . . . . 65.42 110.875 177.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' TRP . . . . . 0.553 ' HH2' HG21 ' A' ' 35' ' ' ILE . 0.3 OUTLIER . . . . . 0 C--N 1.327 -0.38 0 CA-C-N 116.149 -0.478 . . . . 73.13 110.58 178.275 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.253 0 N-CA-C 112.093 -0.403 . . . . 32.31 112.093 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -94.71 155.4 16.86 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.48 0.181 . . . . 43.21 110.595 179.592 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -135.3 95.85 3.36 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.142 0.496 . . . . 72.44 110.576 -179.281 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -118.18 118.89 33.08 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.08 -0.711 . . . . 71.25 109.08 177.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -71.97 127.15 31.65 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.154 0.502 . . . . 65.13 110.184 -178.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 106' ' ' ALA . . . . . 0.406 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -107.9 109.3 62.1 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 115.755 -0.657 . . . . 55.44 110.757 -177.718 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 107' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 22.8 Cg_exo -65.48 161.87 36.35 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 123.178 2.585 . . . . 24.4 112.256 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 58.8 m -71.12 111.34 6.4 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.292 -0.632 . . . . 75.34 109.292 175.088 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.45 52.66 0.55 Allowed Glycine 0 N--CA 1.445 -0.715 0 N-CA-C 110.551 -1.02 . . . . 73.23 110.551 -170.112 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 110' ' ' GLU . . . . . 0.407 ' O ' ' HG3' ' B' ' 110' ' ' GLU . 10.1 pt-20 -97.92 105.33 26.84 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.365 -0.976 . . . . 73.24 108.365 -179.316 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.614 ' HG3' ' CZ ' ' A' ' 31' ' ' PHE . 73.7 Cg_endo -83.11 113.42 2.11 Favored 'Trans proline' 0 N--CA 1.443 -1.489 0 C-N-CA 122.143 1.895 . . . . 72.55 112.418 -170.843 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 16.5 p-10 -109.72 133.46 53.1 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 115.066 -0.97 . . . . 75.41 109.444 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.626 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 11.7 p -83.55 127.89 39.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 121.42 0.629 . . . . 65.04 110.734 -177.396 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 114' ' ' THR . . . . . 0.646 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 27.0 m -81.72 108.85 15.6 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.456 -0.793 . . . . 71.13 109.964 179.349 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.487 HG12 ' HG2' ' B' ' 124' ' ' GLN . 66.4 mt -93.26 106.05 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.074 0.464 . . . . 61.32 110.907 -176.439 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 116' ' ' ARG . . . . . 0.485 ' NE ' ' HA ' ' B' ' 116' ' ' ARG . 3.5 mmp_? -116.24 164.98 13.69 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.657 -0.701 . . . . 73.12 109.457 176.824 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -138.39 107.46 6.03 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.099 0.476 . . . . 72.22 110.962 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -100.36 97.29 8.07 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.584 -0.734 . . . . 71.24 110.297 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 74.89 -97.01 0.98 Allowed Glycine 0 N--CA 1.444 -0.797 0 C-N-CA 121.011 -0.614 . . . . 74.21 112.256 178.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.746 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 5.8 m-20 -125.06 32.07 5.48 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.702 0.287 . . . . 72.11 110.664 -178.702 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 121' ' ' LYS . . . . . . . . . . . . . 41.9 pttt -145.83 125.43 13.28 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.273 0.559 . . . . 55.41 111.806 177.754 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 59.8 m -79.91 107.74 12.93 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.073 -0.967 . . . . 71.21 109.828 175.413 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 42.6 mt -100.13 109.46 24.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-O 121.209 0.528 . . . . 61.44 110.096 -178.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.626 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 55.0 mt-30 -96.19 111.23 23.34 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.573 -0.74 . . . . 74.01 111.135 -178.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 125' ' ' GLU . . . . . 0.646 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 42.9 mt-10 -90.0 104.94 17.46 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.874 -0.603 . . . . 74.44 110.669 177.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 126' ' ' TYR . . . . . 0.437 ' CD2' ' HB3' ' A' ' 51' ' ' ASP . 56.8 m-85 -76.82 110.8 11.72 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.486 -0.324 . . . . 74.02 110.487 178.002 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 127' ' ' ARG . . . . . 0.613 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 48.0 mtt180 -130.93 137.7 49.41 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.971 -0.381 . . . . 74.04 109.971 178.87 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.5 p -98.8 -41.21 9.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.273 0.558 . . . . 54.02 110.797 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 -157.36 72.92 0.71 Allowed 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.848 -0.797 . . . . 75.3 108.848 -177.751 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.47 -38.16 2.77 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.819 -0.628 . . . . 53.15 112.889 -178.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -88.97 132.62 34.64 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.039 0.447 . . . . 75.22 111.573 -172.613 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.613 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 45.1 tp -85.16 117.96 24.43 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.317 -0.856 . . . . 53.12 110.085 175.091 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -109.67 -9.39 14.86 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.428 -0.509 . . . . 75.21 111.948 -177.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -167.51 141.52 3.61 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.735 0.302 . . . . 52.31 111.294 -177.188 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 57.9 mt -118.13 126.29 74.85 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 116.271 -0.422 . . . . 71.14 110.121 176.547 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.466 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 84.7 tttt -112.7 101.19 9.31 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.367 -0.605 . . . . 72.31 109.367 174.453 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.511 HG13 ' CE1' ' B' ' 145' ' ' TYR . 0.7 OUTLIER -103.57 126.46 58.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 CA-C-O 121.03 0.443 . . . . 72.03 110.715 -178.844 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.809 HG22 ' HB3' ' B' ' 144' ' ' PRO . 21.9 t -110.2 89.53 8.54 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.366 -0.834 . . . . 64.13 109.62 178.748 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 139' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -77.35 136.52 15.94 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 122.508 2.139 . . . . 74.25 112.701 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 140' ' ' LYS . . . . . 0.746 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 56.2 mtpt -61.13 -38.08 85.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.6 0.714 . . . . 51.41 109.62 171.598 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 94.9 m-70 -99.3 84.25 2.97 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.832 -1.076 . . . . 75.14 108.889 177.71 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 130.59 -162.55 23.33 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 110.322 -1.111 . . . . 73.45 110.322 -172.316 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -138.83 153.24 71.82 Favored Pre-proline 0 C--N 1.321 -0.652 0 CA-C-N 117.336 0.568 . . . . 75.31 110.715 178.169 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.809 ' HB3' HG22 ' B' ' 138' ' ' VAL . 21.8 Cg_endo -60.47 140.72 92.93 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 123.226 2.617 . . . . 55.24 113.29 -174.235 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 145' ' ' TYR . . . . . 0.511 ' CE1' HG13 ' B' ' 137' ' ' VAL . 23.3 p90 -143.44 155.67 44.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.53 -0.759 . . . . 74.12 109.481 177.84 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.463 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 96.4 m-85 -97.22 133.14 42.25 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.754 0.312 . . . . 64.23 110.431 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.528 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 17.5 tp -122.29 98.53 5.97 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.864 -0.791 . . . . 72.41 108.864 177.508 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 39.0 t -99.31 144.72 11.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.431 -0.349 . . . . 24.04 111.186 -172.729 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 5.2 mmt85 -76.91 145.25 38.36 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-O 120.962 0.41 . . . . 75.41 111.932 179.194 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.96 169.95 12.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.807 -0.633 . . . . 64.32 109.823 171.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 151' ' ' ASP . . . . . 0.568 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 6.2 p-10 -67.64 157.23 34.99 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.373 0.606 . . . . 74.51 112.155 -174.479 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 84.76 -5.68 81.09 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.481 -0.781 . . . . 71.13 113.268 174.384 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 153' ' ' SER . . . . . 0.413 ' HB2' ' CD ' ' A' ' 11' ' ' PRO . 3.5 t 62.22 27.99 16.78 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.487 0.66 . . . . 41.43 109.664 -177.773 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -56.59 -27.56 58.29 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 114.782 -1.099 . . . . 65.54 111.885 -178.748 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 112.09 -22.11 18.96 Favored Glycine 0 CA--C 1.498 -1.0 0 C-N-CA 120.617 -0.802 . . . . 73.23 111.19 -178.593 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 156' ' ' ASN . . . . . 0.698 HD22 ' HB3' ' B' ' 166' ' ' LEU . 2.3 t-20 -63.8 132.96 52.51 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 114.203 -0.998 . . . . 72.53 111.507 179.446 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 157' ' ' PHE . . . . . 0.528 ' CD2' ' HG ' ' B' ' 147' ' ' LEU . 27.2 m-85 -115.0 159.17 21.09 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.828 -0.623 . . . . 72.25 110.538 178.04 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 158' ' ' ILE . . . . . 0.831 HD11 HD23 ' B' ' 166' ' ' LEU . 48.6 mm -127.75 132.71 68.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.992 -0.549 . . . . 73.41 109.558 174.503 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.502 ' HB2' ' HB2' ' B' ' 162' ' ' GLN . 70.2 mtt180 -85.26 156.89 20.76 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.885 0.374 . . . . 73.11 111.249 -179.829 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 160' ' ' SER . . . . . 0.463 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 49.4 p -80.01 -19.48 47.64 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.885 0.85 . . . . 60.55 108.777 166.37 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 161' ' ' ASP . . . . . 0.409 ' H ' ' HB3' ' B' ' 159' ' ' ARG . 3.7 t70 -86.84 -26.04 24.23 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 114.461 -1.245 . . . . 63.22 110.46 176.549 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 162' ' ' GLN . . . . . 0.502 ' HB2' ' HB2' ' B' ' 159' ' ' ARG . 25.4 mm-40 -136.68 74.94 51.27 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.518 -0.764 . . . . 74.52 109.346 -179.691 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -89.24 11.68 2.89 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.897 2.398 . . . . 61.54 113.183 -176.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -107.87 -45.42 3.99 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 120.992 -0.283 . . . . 74.23 111.013 -178.222 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.25 172.79 7.89 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.029 0.442 . . . . 70.35 111.26 178.581 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 166' ' ' LEU . . . . . 0.831 HD23 HD11 ' B' ' 158' ' ' ILE . 15.8 mt -105.35 150.27 25.36 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.851 -0.613 . . . . 72.14 109.948 -175.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 40.8 mm -101.31 111.67 63.98 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 116.389 -0.369 . . . . 72.22 110.183 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.602 ' O ' HG23 ' B' ' 172' ' ' ILE . 59.7 Cg_endo -70.05 174.52 9.64 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 123.075 2.516 . . . . 73.01 112.593 -178.511 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 169' ' ' GLN . . . . . 0.625 ' O ' HG12 ' B' ' 172' ' ' ILE . 6.3 tt0 -72.45 -35.7 68.35 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.877 -0.601 . . . . 72.43 111.969 -167.816 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 33.4 p90 -69.02 -14.66 63.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.168 0.509 . . . . 65.42 110.222 177.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.467 ' HA ' ' HB2' ' B' ' 174' ' ' SER . 7.0 mm-40 -96.51 -29.54 13.83 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.569 -0.741 . . . . 71.15 111.671 -178.029 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.625 HG12 ' O ' ' B' ' 169' ' ' GLN . 43.4 pt -67.66 -26.21 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 N-CA-C 111.876 0.324 . . . . 71.2 111.876 -175.309 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -124.09 36.3 4.65 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.353 0.597 . . . . 71.41 110.256 176.379 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 174' ' ' SER . . . . . 0.467 ' HB2' ' HA ' ' B' ' 171' ' ' GLU . 22.1 t -85.66 10.73 12.56 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.342 -0.845 . . . . 71.22 111.369 -176.588 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 11.9 p-90 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.619 -0.705 . . . . 72.5 111.599 -178.364 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.886 0 N-CA-C 111.72 -0.552 . . . . 73.03 111.72 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -98.97 -45.93 5.79 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.627 -0.508 . . . . 75.4 109.627 176.381 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -132.0 130.84 41.93 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.434 -0.803 . . . . 75.44 109.526 176.591 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ASP . . . . . 0.406 ' CG ' ' H ' ' A' ' 5' ' ' ASP . 3.6 p-10 -112.7 -93.09 0.47 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.705 -0.225 . . . . 74.52 111.348 -177.722 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.406 ' H ' ' CG ' ' A' ' 4' ' ' ASP . 32.7 t70 -154.06 124.09 6.84 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.914 0.388 . . . . 74.24 110.567 -178.491 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.467 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -133.71 134.68 23.73 Favored Pre-proline 0 C--N 1.323 -0.565 0 CA-C-N 115.937 -0.574 . . . . 74.01 110.106 179.406 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.467 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 19.4 Cg_exo -66.04 110.2 1.68 Allowed 'Trans proline' 0 N--CA 1.462 -0.327 0 C-N-CA 122.745 2.296 . . . . 54.24 112.281 -179.429 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 25.3 p -103.56 156.12 18.02 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.099 -0.501 . . . . 75.04 110.342 177.502 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 145.07 -53.16 0.57 Allowed Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.848 -0.691 . . . . 54.45 111.622 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 64.6 100.96 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.542 0.686 . . . . 65.21 111.624 177.041 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.646 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 18.8 Cg_endo -91.62 122.05 0.67 Allowed 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 123.58 2.853 . . . . 74.34 112.595 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -139.62 138.58 36.26 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.148 -0.478 . . . . 73.13 109.749 178.711 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.543 ' HB ' ' HB2' ' B' ' 151' ' ' ASP . 13.7 p -101.94 132.8 47.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.331 0.586 . . . . 74.13 111.215 -171.594 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.7 m -92.77 104.06 16.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.738 -0.665 . . . . 72.14 109.722 176.055 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 66.4 mt -94.23 107.83 19.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.167 -0.469 . . . . 71.04 110.5 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.9 mtp180 -115.83 -179.2 3.59 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.242 -0.435 . . . . 64.21 110.505 177.065 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 70.9 mt-30 -140.1 106.24 5.23 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.937 -0.574 . . . . 64.04 110.763 178.211 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -99.62 107.08 19.13 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.912 -0.585 . . . . 75.13 109.846 176.716 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 62.61 -111.15 3.8 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.752 -0.737 . . . . 71.44 112.215 -178.323 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.506 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 7.7 m-20 -105.81 7.62 32.43 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 111.49 0.181 . . . . 74.34 111.49 -177.847 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.641 ' HE3' ' HE3' ' A' ' 75' ' ' TRP . 0.0 OUTLIER -121.06 131.68 54.42 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 119.951 -0.7 . . . . 73.23 112.259 179.951 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.526 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 6.2 m -80.68 124.08 28.71 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.162 -0.926 . . . . 72.21 109.313 174.814 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.415 HD11 ' HG3' ' A' ' 21' ' ' LYS . 23.7 mm -108.45 107.32 22.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 110.141 -0.318 . . . . 64.22 110.141 -175.878 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 54.4 mt-30 -102.23 105.26 15.9 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.91 0.386 . . . . 64.15 110.273 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.417 ' HB3' HD23 ' A' ' 32' ' ' LEU . 29.7 mt-10 -88.92 100.38 13.14 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.447 -0.797 . . . . 63.34 110.606 -178.772 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.558 ' HA ' ' OD2' ' B' ' 151' ' ' ASP . 96.3 m-85 -76.22 118.39 18.9 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.011 -0.541 . . . . 75.2 110.3 179.561 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.461 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 50.6 mtt180 -139.2 121.17 15.6 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.161 0.505 . . . . 75.2 112.014 -173.174 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.646 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 3.8 p -97.45 120.5 46.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 108.751 -0.833 . . . . 75.4 108.751 169.722 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 73.85 -34.39 0.28 Allowed 'General case' 0 N--CA 1.47 0.562 0 O-C-N 123.456 0.473 . . . . 64.22 111.085 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.406 ' H ' ' C ' ' A' ' 28' ' ' VAL . . . 157.32 -16.39 0.34 Allowed Glycine 0 N--CA 1.45 -0.431 0 N-CA-C 111.859 -0.496 . . . . 72.0 111.859 178.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.438 ' O ' ' HA ' ' A' ' 27' ' ' ARG . 81.3 t80 -79.47 125.73 29.94 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.69 0.281 . . . . 74.22 111.003 -177.782 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.686 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -73.21 112.33 9.15 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.281 -0.637 . . . . 74.03 109.281 175.821 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 25.7 p90 -111.66 -14.3 13.64 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 120.402 -0.519 . . . . 74.52 111.83 -178.768 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -159.54 142.86 14.37 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.732 0.301 . . . . 73.3 110.94 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.686 HG13 HD11 ' A' ' 32' ' ' LEU . 68.2 mt -123.91 122.86 65.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.233 -0.44 . . . . 73.43 110.14 175.521 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.437 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 53.2 tttp -107.66 106.57 16.98 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.003 -0.74 . . . . 55.33 109.003 172.152 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.578 HG23 ' HB2' ' A' ' 21' ' ' LYS . 1.5 p -102.58 126.85 56.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-N 116.111 -0.495 . . . . 71.14 110.26 178.28 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.716 HG22 ' HB3' ' A' ' 44' ' ' PRO . 23.5 t -109.3 85.66 3.66 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.273 -0.876 . . . . 64.03 109.99 178.397 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.518 ' HD2' ' C ' ' A' ' 43' ' ' LYS . 36.6 Cg_endo -86.36 132.9 3.79 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 122.572 2.182 . . . . 75.25 112.557 179.539 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.506 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 56.2 mtpt -60.35 -26.01 66.28 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.619 0.724 . . . . 74.21 109.884 175.188 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -122.54 88.25 2.9 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 115.194 -0.912 . . . . 74.35 108.818 176.414 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 145.28 -34.7 1.5 Allowed Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.442 -0.799 . . . . 42.11 111.702 -175.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.518 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 97.4 mttt 72.22 145.97 0.11 Allowed Pre-proline 0 N--CA 1.468 0.451 0 C-N-CA 123.565 0.746 . . . . 53.15 112.152 176.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.716 ' HB3' HG22 ' A' ' 38' ' ' VAL . 34.3 Cg_endo -63.25 137.49 61.31 Favored 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 123.454 2.769 . . . . 55.41 114.362 -170.019 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.404 ' CE1' HG13 ' A' ' 37' ' ' VAL . 8.6 p90 -148.21 165.96 29.37 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.577 -0.738 . . . . 72.22 109.243 174.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.74 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 38.6 m-85 -104.93 134.19 48.46 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.904 0.383 . . . . 74.51 110.774 177.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.523 HD21 HG22 ' A' ' 72' ' ' ILE . 16.6 tp -120.41 102.7 8.64 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.574 -0.899 . . . . 75.44 108.574 172.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.4 t -97.61 138.68 21.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.143 -0.481 . . . . 62.42 110.886 -173.148 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.424 ' HD3' HH11 ' A' ' 49' ' ' ARG . 7.4 tpt180 -66.57 128.02 34.62 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.89 -0.595 . . . . 72.34 110.131 175.634 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.09 116.84 18.85 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.736 -0.468 . . . . 62.42 109.736 174.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.618 ' HB2' ' CD2' ' B' ' 126' ' ' TYR . 0.4 OUTLIER -53.38 138.74 32.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.969 -0.56 . . . . 72.24 110.165 177.325 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 109.39 -32.48 6.78 Favored Glycine 0 N--CA 1.442 -0.963 0 N-CA-C 110.453 -1.059 . . . . 64.31 110.453 -171.623 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.4 t 56.99 50.36 12.28 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-O 121.253 0.549 . . . . 71.52 110.838 176.445 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -92.46 18.29 8.73 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.206 -0.452 . . . . 70.21 111.012 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.97 52.62 4.25 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.752 -0.737 . . . . 54.42 111.507 -176.591 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 30.2 t30 -147.76 141.81 25.99 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.804 0.335 . . . . 62.4 110.999 -174.586 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -129.42 147.1 51.2 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.898 -0.592 . . . . 74.04 109.529 175.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 43.7 mm -111.16 137.0 45.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.041 0.448 . . . . 75.01 110.394 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.743 ' HB2' HG13 ' A' ' 67' ' ' ILE . 24.0 ttt180 -103.22 142.18 34.61 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.826 -0.624 . . . . 73.52 110.5 -172.351 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.74 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 76.9 p -70.11 -30.81 68.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.41 0.624 . . . . 41.24 110.157 176.011 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.412 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 0.8 OUTLIER -70.81 -27.86 64.2 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 114.845 -1.07 . . . . 73.23 110.631 176.969 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLN . . . . . 0.699 ' HG2' ' HB3' ' A' ' 65' ' ' LYS . 31.0 tt0 -146.05 77.04 12.2 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.685 -0.689 . . . . 70.23 109.598 -175.241 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.2 -35.38 8.72 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.836 2.357 . . . . 65.04 113.842 -172.175 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -95.07 41.02 1.1 Allowed 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.888 0.851 . . . . 63.44 109.953 -177.657 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.699 ' HB3' ' HG2' ' A' ' 62' ' ' GLN . 22.9 tptm -150.46 128.38 11.78 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.185 -0.916 . . . . 70.54 109.93 175.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.511 ' H ' HD12 ' A' ' 66' ' ' LEU . 4.5 mp -73.32 120.35 18.82 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.324 -0.853 . . . . 65.54 109.045 176.654 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.743 HG13 ' HB2' ' A' ' 59' ' ' ARG . 47.4 mm -85.75 125.39 69.12 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-O 120.861 0.362 . . . . 62.31 110.639 -176.265 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -66.54 175.73 4.87 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.876 2.384 . . . . 72.31 112.778 -178.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 16.4 tt0 -93.9 14.35 19.82 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.588 -0.733 . . . . 70.02 111.834 -168.506 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 18.7 p90 -109.24 -26.35 10.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.147 0.499 . . . . 72.51 110.151 173.246 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -81.12 -11.89 59.37 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.998 -0.546 . . . . 64.34 110.672 -178.653 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.523 HG22 HD21 ' A' ' 47' ' ' LEU . 44.9 pt -69.59 -22.84 25.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.915 -0.584 . . . . 51.41 110.91 177.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -112.6 25.26 11.64 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-N 115.808 -0.633 . . . . 62.3 109.822 -178.587 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 4.5 t -60.22 -37.78 81.37 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.873 -1.058 . . . . 60.51 109.906 -179.222 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' TRP . . . . . 0.641 ' HE3' ' HE3' ' A' ' 21' ' ' LYS . 43.2 p-90 . . . . . 0 C--N 1.326 -0.434 0 CA-C-N 115.884 -0.598 . . . . 65.22 110.454 176.028 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.404 0 N-CA-C 112.155 -0.378 . . . . 41.13 112.155 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -119.55 -1.67 10.62 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.938 0.399 . . . . 73.01 110.623 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -131.4 117.07 18.36 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.002 -0.544 . . . . 73.41 111.107 -177.722 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 -108.36 -71.64 0.75 Allowed 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.258 -0.645 . . . . 71.42 109.258 173.411 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -160.6 139.95 10.72 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.315 -0.857 . . . . 71.35 109.238 178.096 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 106' ' ' ALA . . . . . 0.474 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -137.37 126.99 15.39 Favored Pre-proline 0 C--N 1.32 -0.688 0 N-CA-C 110.176 -0.305 . . . . 53.14 110.176 179.173 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 107' ' ' PRO . . . . . 0.474 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 5.2 Cg_exo -79.38 69.16 8.05 Favored 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 123.041 2.494 . . . . 72.52 112.069 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 55.0 m -76.18 158.89 31.22 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.18 -0.464 . . . . 55.34 110.542 178.274 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 117.06 -63.25 0.38 Allowed Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 110.524 -1.031 . . . . 42.22 110.524 -175.741 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 62.3 88.19 0.12 Allowed Pre-proline 0 C--O 1.232 0.138 0 C-N-CA 123.157 0.583 . . . . 60.14 111.056 175.032 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.633 ' HB3' ' HA ' ' B' ' 128' ' ' VAL . 56.4 Cg_endo -86.67 140.08 5.94 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.982 2.454 . . . . 72.34 112.713 -176.701 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -148.13 122.42 9.62 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.751 -0.659 . . . . 73.14 109.28 177.471 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.462 ' N ' ' HB3' ' A' ' 51' ' ' ASP . 7.5 p -71.6 134.21 30.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.391 0.615 . . . . 70.13 111.739 -172.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 85.1 m -95.04 104.78 16.66 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.474 -0.785 . . . . 72.01 109.854 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 65.2 mt -88.19 106.56 16.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.893 -0.594 . . . . 72.22 110.143 -177.642 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 25.3 mtp-105 -108.75 171.59 7.34 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.166 0.508 . . . . 75.01 111.569 -178.241 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 70.4 mt-30 -132.34 114.7 14.7 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.581 -0.736 . . . . 62.53 109.989 176.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 118' ' ' GLU . . . . . 0.68 ' HG3' HD12 ' B' ' 123' ' ' ILE . 22.1 mm-40 -99.61 23.25 9.75 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.94 -0.573 . . . . 73.43 110.672 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 123.45 -90.47 0.42 Allowed Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.692 -0.563 . . . . 43.53 111.692 -178.827 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.668 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 72.0 m-20 -105.35 -16.51 14.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.14 0.495 . . . . 64.22 110.077 177.51 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.676 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 27.4 pttt -99.96 120.09 39.26 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.434 0.635 . . . . 74.33 111.15 -178.761 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 122' ' ' THR . . . . . 0.464 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 25.0 m -83.22 104.29 13.28 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.376 -0.829 . . . . 64.25 109.193 174.471 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 123' ' ' ILE . . . . . 0.68 HD12 ' HG3' ' B' ' 118' ' ' GLU . 23.4 mt -98.39 107.26 20.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.181 0.515 . . . . 73.24 110.887 -174.118 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.586 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 64.1 mt-30 -93.62 107.07 18.98 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.431 -0.804 . . . . 64.43 110.061 179.72 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -87.95 111.08 21.09 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.097 -0.501 . . . . 65.0 110.687 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 126' ' ' TYR . . . . . 0.618 ' CD2' ' HB2' ' A' ' 51' ' ' ASP . 37.8 m-85 -86.4 113.6 22.49 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.013 -0.54 . . . . 64.42 110.131 177.611 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 127' ' ' ARG . . . . . 0.638 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 63.7 mtt180 -138.12 132.95 32.78 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.663 -0.699 . . . . 72.34 109.675 -176.791 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.633 ' HA ' ' HB3' ' B' ' 111' ' ' PRO . 2.7 p -96.32 -39.39 9.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 120.944 0.402 . . . . 31.24 110.991 -178.341 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -153.1 64.79 0.77 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.322 -0.622 . . . . 75.04 109.322 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.07 -36.01 3.35 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.489 -0.778 . . . . 72.31 112.597 -179.261 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.475 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 80.8 t80 -83.84 124.79 31.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.084 0.468 . . . . 72.31 111.233 -173.382 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.799 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -77.12 115.6 17.05 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.312 -0.858 . . . . 71.52 109.251 175.169 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 22.5 p90 -109.11 -19.03 13.5 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.268 -0.573 . . . . 72.52 111.901 -178.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -155.98 141.47 17.72 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.024 0.44 . . . . 73.0 111.057 179.065 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.799 HG13 HD11 ' B' ' 132' ' ' LEU . 81.8 mt -119.2 123.82 72.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.859 -0.609 . . . . 73.15 110.286 177.127 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.586 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.6 tttt -105.62 99.68 9.27 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.274 -0.639 . . . . 71.53 109.274 172.007 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.463 HG23 ' HB2' ' B' ' 121' ' ' LYS . 2.0 p -101.4 121.8 52.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-O 121.194 0.521 . . . . 74.44 110.361 -178.602 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.841 HG22 ' HB3' ' B' ' 144' ' ' PRO . 24.6 t -109.03 85.51 3.29 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 115.086 -0.961 . . . . 55.45 110.21 179.614 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.676 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 71.6 Cg_endo -84.3 134.08 5.73 Favored 'Trans proline' 0 N--CA 1.451 -0.979 0 C-N-CA 122.375 2.05 . . . . 64.03 112.545 179.525 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 140' ' ' LYS . . . . . 0.668 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 57.8 mtpt -57.92 -31.56 66.91 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.448 0.642 . . . . 61.33 109.889 174.436 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 82.7 m-70 -111.14 83.18 1.72 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.201 -0.909 . . . . 62.24 109.292 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 142' ' ' GLY . . . . . 0.41 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 148.71 -32.03 1.21 Allowed Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.684 -0.77 . . . . 63.21 112.785 -178.87 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 143' ' ' LYS . . . . . 0.45 ' C ' ' HD2' ' B' ' 139' ' ' PRO . 98.9 mttt 73.44 151.43 0.14 Allowed Pre-proline 0 N--CA 1.471 0.604 0 C-N-CA 123.452 0.701 . . . . 45.25 111.704 -178.616 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.841 ' HB3' HG22 ' B' ' 138' ' ' VAL . 26.7 Cg_endo -62.0 135.24 54.04 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 123.197 2.598 . . . . 70.51 113.952 -171.129 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 145' ' ' TYR . . . . . 0.429 ' CE1' HG13 ' B' ' 137' ' ' VAL . 6.2 p90 -150.99 152.19 33.17 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.356 -0.838 . . . . 74.41 109.852 176.872 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.681 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 50.7 m-85 -97.29 141.89 29.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.475 -0.33 . . . . 74.35 111.366 -178.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.457 HD23 ' HA ' ' B' ' 147' ' ' LEU . 15.3 mt -124.42 101.78 7.33 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.45 -0.795 . . . . 74.22 109.208 166.543 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 148' ' ' VAL . . . . . 0.433 HG13 ' HB ' ' B' ' 158' ' ' ILE . 6.0 p -104.65 139.2 26.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.724 -0.671 . . . . 73.41 111.015 -175.766 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 19.4 tpt180 -63.65 136.8 57.77 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.551 -0.75 . . . . 75.31 111.754 -178.314 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -90.19 123.95 34.43 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.275 -0.639 . . . . 74.11 109.275 169.837 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 151' ' ' ASP . . . . . 0.558 ' OD2' ' HA ' ' A' ' 26' ' ' TYR . 72.2 m-20 -57.33 142.91 41.79 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.285 0.564 . . . . 60.43 111.159 -178.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 109.91 -29.11 9.64 Favored Glycine 0 N--CA 1.444 -0.827 0 N-CA-C 110.468 -1.053 . . . . 64.33 110.468 -170.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 5.4 t 65.05 37.4 6.77 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-O 121.231 0.538 . . . . 64.53 111.009 174.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -65.11 -14.4 60.43 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.798 -0.637 . . . . 72.21 111.326 178.542 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 98.11 23.69 12.7 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 110.634 -0.986 . . . . 62.11 110.634 -173.405 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 42.1 t30 -110.71 140.18 45.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.916 -0.642 . . . . 70.22 110.494 -176.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -121.36 160.35 24.21 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.797 -0.638 . . . . 74.41 109.574 175.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 158' ' ' ILE . . . . . 0.433 ' HB ' HG13 ' B' ' 148' ' ' VAL . 46.2 mm -116.66 121.15 67.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 109.405 -0.591 . . . . 74.13 109.405 174.694 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.504 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 73.0 ttt180 -92.2 127.47 37.69 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.699 -0.682 . . . . 74.55 109.82 -177.61 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 160' ' ' SER . . . . . 0.681 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 80.4 p -65.88 -9.22 27.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.513 -0.312 . . . . 71.45 111.78 -175.06 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 161' ' ' ASP . . . . . 0.457 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 21.1 t70 -64.06 -42.67 96.92 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.325 -0.621 . . . . 75.32 109.325 174.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 162' ' ' GLN . . . . . 0.423 ' HA ' ' HD2' ' B' ' 163' ' ' PRO . 96.1 mt-30 -141.86 92.6 7.79 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 115.146 -0.933 . . . . 71.21 108.766 177.518 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 163' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' B' ' 162' ' ' GLN . 36.6 Cg_endo -64.0 -10.59 23.58 Favored 'Trans proline' 0 N--CA 1.475 0.441 0 C-N-CA 123.767 2.978 . . . . 62.03 114.103 -172.914 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -98.39 -6.18 31.16 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.088 0.471 . . . . 75.11 109.925 179.066 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 24.4 tptm -97.21 127.94 43.63 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.743 -0.662 . . . . 73.0 110.872 -175.216 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 166' ' ' LEU . . . . . 0.445 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.7 mp -86.68 134.66 33.58 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.565 -0.743 . . . . 71.31 109.107 177.439 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 167' ' ' ILE . . . . . 0.906 HG23 ' HB3' ' B' ' 171' ' ' GLU . 27.3 mm -91.71 118.94 68.59 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-O 121.149 0.5 . . . . 43.04 112.052 -172.519 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.499 ' O ' HG23 ' B' ' 172' ' ' ILE . 74.5 Cg_endo -74.71 -179.39 4.84 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 123.451 2.767 . . . . 64.15 112.284 177.15 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 169' ' ' GLN . . . . . 0.612 ' HA ' HG12 ' B' ' 172' ' ' ILE . 34.6 tt0 -73.56 -30.95 63.36 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.873 0.368 . . . . 73.22 111.761 -170.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 22.7 p90 -75.74 -7.3 54.05 Favored 'General case' 0 C--N 1.324 -0.525 0 O-C-N 121.886 -0.509 . . . . 73.24 110.15 177.757 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.906 ' HB3' HG23 ' B' ' 167' ' ' ILE . 3.2 mm-40 -109.74 -18.81 13.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.791 -0.641 . . . . 70.22 111.472 -179.47 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.612 HG12 ' HA ' ' B' ' 169' ' ' GLN . 42.5 pt -73.51 -28.59 25.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.292 0.568 . . . . 73.3 109.932 176.329 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 62.1 m-85 -101.63 39.75 1.4 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.509 -0.769 . . . . 70.54 109.364 173.708 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 174' ' ' SER . . . . . 0.603 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 5.7 t -66.7 -29.22 69.16 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.134 -0.939 . . . . 73.0 110.827 -176.39 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 20.8 p-90 . . . . . 0 C--O 1.242 0.677 0 CA-C-O 118.916 -0.564 . . . . 74.34 110.217 178.206 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.723 0 N-CA-C 111.515 -0.634 . . . . 70.33 111.515 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -77.76 129.35 35.37 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.699 -0.482 . . . . 75.04 109.699 176.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -65.54 136.91 56.99 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.067 0.461 . . . . 63.12 111.163 -176.666 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -95.08 -30.19 14.2 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.551 -0.749 . . . . 61.23 111.857 -174.807 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -88.66 68.94 8.74 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.153 0.501 . . . . 73.34 110.599 -175.102 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.437 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -163.02 138.7 5.36 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 115.76 -0.655 . . . . 53.14 110.367 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 6.8 Cg_exo -73.82 -170.64 0.72 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 123.184 2.59 . . . . 73.43 112.083 178.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 25.0 m -70.37 92.5 0.81 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.306 0.574 . . . . 74.11 111.034 -179.481 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 157.33 40.89 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.727 0 N-CA-C 111.218 -0.753 . . . . 72.04 111.218 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLU . . . . . 0.405 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -114.99 101.59 54.59 Favored Pre-proline 0 N--CA 1.445 -0.681 0 N-CA-C 108.208 -1.034 . . . . 75.1 108.208 179.493 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.61 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 11.3 Cg_endo -79.32 104.65 1.78 Allowed 'Trans proline' 0 N--CA 1.44 -1.635 0 C-N-CA 122.064 1.843 . . . . 73.12 111.69 -171.552 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -123.13 149.59 44.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.502 -0.772 . . . . 74.45 109.21 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.653 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 9.3 p -99.74 126.97 53.04 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-O 121.595 0.712 . . . . 74.31 111.772 -172.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.54 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 7.0 m -83.36 103.51 12.79 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.513 -0.767 . . . . 75.31 109.334 176.706 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.5 mt -94.14 108.79 21.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 120.932 0.396 . . . . 71.25 111.127 -174.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 19.1 mmt180 -120.72 159.32 25.61 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.202 -0.454 . . . . 54.11 109.826 175.55 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -117.58 124.88 49.72 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.331 0.586 . . . . 71.24 110.677 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -111.42 59.67 0.62 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.9 -1.046 . . . . 72.03 110.061 -174.225 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 83.47 -107.67 2.95 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.843 -0.694 . . . . 55.45 111.943 -178.291 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -94.85 20.21 9.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.886 0.374 . . . . 74.21 110.652 -177.286 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.746 ' HD2' HD11 ' A' ' 23' ' ' ILE . 4.0 pttp -143.93 134.38 24.7 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.228 0.537 . . . . 74.02 111.89 -178.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 27.3 m -94.06 107.98 19.85 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.055 -0.72 . . . . 75.33 109.055 172.383 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.746 HD11 ' HD2' ' A' ' 21' ' ' LYS . 19.8 mt -101.61 113.54 38.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.269 0.556 . . . . 73.32 110.353 -175.098 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.653 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 72.4 mt-30 -104.89 117.86 35.1 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.497 -0.774 . . . . 52.24 111.356 -175.162 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.54 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 25.2 mt-10 -90.52 103.01 15.75 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.051 -0.522 . . . . 71.11 110.983 177.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 -81.27 103.5 11.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.897 0.379 . . . . 75.31 110.051 175.199 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.508 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 53.2 mtt180 -120.25 138.11 53.84 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.916 -0.402 . . . . 74.54 109.916 178.083 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.61 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 11.8 p -105.79 -27.89 2.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.288 0.566 . . . . 62.23 110.947 -175.82 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -162.64 59.05 0.21 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.758 -0.83 . . . . 73.55 108.758 -177.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.93 -36.95 3.23 Favored Glycine 0 N--CA 1.45 -0.427 0 CA-C-N 115.355 -0.839 . . . . 65.11 112.635 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.56 ' CD2' HG21 ' B' ' 128' ' ' VAL . 50.4 t80 -90.28 133.74 34.75 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.145 0.498 . . . . 74.52 110.723 -173.658 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.902 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -76.11 116.13 16.5 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.229 -0.896 . . . . 73.21 109.317 176.656 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 40.0 p90 -106.93 -17.8 14.09 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.431 -0.508 . . . . 71.33 111.218 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.45 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -157.58 137.9 12.76 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.014 0.435 . . . . 63.43 111.532 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.902 HG13 HD11 ' A' ' 32' ' ' LEU . 73.2 mt -118.02 117.08 53.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.159 -0.473 . . . . 72.14 110.102 175.262 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 84.9 tttt -100.69 101.53 12.43 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.022 -0.733 . . . . 53.24 109.022 173.296 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.671 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.5 p -102.77 124.5 56.84 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 N-CA-C 109.777 -0.453 . . . . 74.23 109.777 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.647 HG22 ' HB3' ' A' ' 44' ' ' PRO . 35.9 t -105.27 84.9 1.18 Allowed Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.206 -0.907 . . . . 55.12 109.525 177.391 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.671 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 89.2 Cg_endo -95.93 147.05 1.26 Allowed 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 123.04 2.493 . . . . 72.33 113.279 -178.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -68.73 -11.11 59.89 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.519 -0.764 . . . . 70.42 109.623 170.715 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 80.6 m-70 -121.85 92.85 3.83 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 115.022 -0.99 . . . . 74.14 109.468 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 121.54 -19.76 8.46 Favored Glycine 0 CA--C 1.519 0.338 0 C-N-CA 120.757 -0.735 . . . . 55.14 113.176 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.432 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 99.3 mttt 68.9 151.61 0.13 Allowed Pre-proline 0 N--CA 1.473 0.69 0 C-N-CA 123.026 0.53 . . . . 54.12 110.943 -178.166 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.647 ' HB3' HG22 ' A' ' 38' ' ' VAL . 18.3 Cg_endo -59.88 133.05 48.36 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.364 2.043 . . . . 74.44 112.816 -175.047 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.536 ' CE1' HG13 ' A' ' 37' ' ' VAL . 5.4 p90 -150.32 155.9 40.53 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.655 -0.702 . . . . 63.1 110.432 -179.072 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.452 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 87.7 m-85 -99.75 127.64 45.88 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.076 -0.511 . . . . 73.24 110.901 -179.818 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 53.1 mt -102.12 97.35 7.67 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.146 -0.479 . . . . 64.44 109.761 171.052 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 60.8 t -90.58 137.43 21.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.065 -0.516 . . . . 74.14 110.578 -178.046 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 5.3 mmt180 -79.13 119.6 22.47 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.984 0.421 . . . . 75.23 111.108 175.715 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -72.15 167.22 20.74 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.603 -0.726 . . . . 43.25 109.555 172.722 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -69.74 128.92 38.12 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.416 0.627 . . . . 75.45 109.577 178.615 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.22 116.04 3.87 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 111.105 -0.798 . . . . 62.41 111.105 -171.854 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 39.1 p -78.02 36.7 0.23 Allowed 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.05 0.452 . . . . 75.44 111.311 -176.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -63.33 -29.6 70.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.801 -0.636 . . . . 65.45 111.588 -175.423 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 131.01 -13.21 5.53 Favored Glycine 0 CA--C 1.508 -0.404 0 C-N-CA 120.318 -0.944 . . . . 71.24 113.214 177.504 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -83.63 138.82 33.17 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.144 0.497 . . . . 75.41 111.544 -173.304 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.449 ' CD1' ' HB3' ' A' ' 47' ' ' LEU . 38.2 m-85 -109.38 162.46 14.32 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.762 -0.654 . . . . 64.3 110.02 174.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.4 mm -120.64 123.86 71.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.35 -0.611 . . . . 71.22 109.35 175.762 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.791 ' HG3' HG13 ' A' ' 67' ' ' ILE . 53.7 mtm180 -88.34 149.77 23.58 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.221 0.534 . . . . 73.2 111.826 -177.79 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 5.7 p -69.12 -24.53 64.12 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.379 -0.828 . . . . 72.32 109.84 171.365 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.73 -37.46 84.29 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-N 115.517 -0.765 . . . . 61.1 110.152 176.42 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -156.64 96.91 2.17 Favored Pre-proline 0 N--CA 1.451 -0.4 0 CA-C-N 115.835 -0.62 . . . . 74.2 110.612 -175.421 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.19 -10.07 23.94 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.433 2.089 . . . . 72.31 111.233 175.51 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -81.22 -15.86 54.4 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 114.895 -1.048 . . . . 72.21 110.774 178.013 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.6 tptt -114.9 132.34 56.57 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.2 -0.454 . . . . 70.25 111.252 -175.584 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.6 mp -90.31 125.79 35.64 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.333 -0.617 . . . . 63.24 109.333 174.218 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.791 HG13 ' HG3' ' A' ' 59' ' ' ARG . 49.4 mm -84.78 112.59 43.82 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 116.111 -0.495 . . . . 42.44 110.491 -177.25 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -74.63 179.69 5.71 Favored 'Trans proline' 0 N--CA 1.464 -0.264 0 C-N-CA 123.289 2.659 . . . . 61.21 112.937 -177.155 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLN . . . . . 0.463 ' CG ' HD11 ' A' ' 72' ' ' ILE . 31.4 tt0 -80.86 -4.27 54.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.581 -0.736 . . . . 72.35 112.519 -171.083 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 15.9 p90 -96.24 -19.97 18.91 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.234 -0.586 . . . . 75.43 110.312 175.821 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -99.99 8.04 44.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.93 -0.577 . . . . 72.2 111.042 -177.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.463 HD11 ' CG ' ' A' ' 69' ' ' GLN . 21.6 pt -98.71 -7.06 9.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.249 0.547 . . . . 74.22 110.21 175.251 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -104.91 16.17 26.43 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.632 -0.713 . . . . 71.42 109.486 177.041 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 12.9 m -73.59 -7.78 53.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.185 -0.916 . . . . 70.11 111.309 -178.637 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 57.9 p-90 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.442 -0.344 . . . . 73.4 110.459 176.222 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 N-CA-C 112.116 -0.394 . . . . 62.11 112.116 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -159.07 124.66 4.32 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.677 0.275 . . . . 71.41 110.617 179.757 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -138.31 129.21 26.86 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.216 -0.447 . . . . 55.43 109.92 176.569 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -85.34 -16.45 39.93 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.449 0.642 . . . . 54.32 110.247 -177.487 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -88.83 11.07 18.91 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.598 -0.728 . . . . 61.42 110.536 178.764 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 106' ' ' ALA . . . . . 0.4 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -63.8 138.58 97.43 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.15 -0.477 . . . . 33.41 110.822 179.054 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 107' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 81.1 Cg_endo -90.1 -164.14 0.15 Allowed 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 123.037 2.491 . . . . 75.31 112.261 178.467 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 44.3 m -75.22 99.24 3.96 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.021 0.439 . . . . 61.31 110.046 176.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 121.1 102.34 1.81 Allowed Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.914 -0.66 . . . . 61.41 111.764 -178.362 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -122.15 92.57 48.86 Favored Pre-proline 0 C--N 1.324 -0.532 0 N-CA-C 109.382 -0.599 . . . . 75.31 109.382 -178.081 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.474 ' HA ' ' O ' ' B' ' 127' ' ' ARG . 8.4 Cg_endo -77.98 82.85 2.32 Favored 'Trans proline' 0 N--CA 1.443 -1.451 0 C-N-CA 121.917 1.745 . . . . 73.43 111.633 -178.559 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -108.71 141.84 40.11 Favored 'General case' 0 CA--C 1.51 -0.566 0 CA-C-N 115.194 -0.912 . . . . 65.41 109.558 177.649 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.508 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 10.3 p -101.84 125.7 55.91 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 CA-C-N 115.627 -0.715 . . . . 73.41 110.807 -176.637 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 10.1 m -88.55 103.57 16.01 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.34 -0.846 . . . . 74.04 109.609 177.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.502 HG12 ' HG2' ' B' ' 124' ' ' GLN . 54.6 mt -94.59 105.94 17.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 116.164 -0.471 . . . . 70.54 110.358 -176.568 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 27.0 mmm180 -122.27 153.44 38.9 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.242 -0.435 . . . . 74.1 110.541 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -111.19 103.09 11.49 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.002 0.43 . . . . 61.3 110.701 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 49.8 mm-40 -99.67 81.51 2.49 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.778 -0.646 . . . . 73.43 109.294 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 81.94 -128.69 8.6 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.805 -0.712 . . . . 71.25 111.382 -174.877 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.579 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 67.8 m-20 -91.84 9.92 30.79 Favored 'General case' 0 C--N 1.328 -0.349 0 O-C-N 122.699 -0.295 . . . . 73.24 111.088 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.517 ' HE2' HD11 ' B' ' 123' ' ' ILE . 24.6 pttm -119.27 116.58 26.55 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.576 0.703 . . . . 75.12 111.073 179.371 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 26.1 m -84.97 108.43 17.58 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.292 -0.867 . . . . 64.5 109.502 176.558 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 123' ' ' ILE . . . . . 0.517 HD11 ' HE2' ' B' ' 121' ' ' LYS . 52.1 mt -101.14 117.12 45.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.973 -0.558 . . . . 73.5 110.604 -173.788 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.529 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 72.2 mt-30 -102.61 104.49 14.87 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.649 -0.705 . . . . 74.32 110.35 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -85.27 107.25 17.21 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.06 -0.518 . . . . 71.43 111.071 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 59.6 m-85 -80.71 103.67 10.72 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.947 0.403 . . . . 74.21 109.945 175.333 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 127' ' ' ARG . . . . . 0.474 ' O ' ' HA ' ' B' ' 111' ' ' PRO . 65.5 mtt180 -114.14 152.78 30.62 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.857 -0.611 . . . . 70.2 109.389 178.587 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.56 HG21 ' CD2' ' A' ' 31' ' ' PHE . 7.0 p -120.36 -37.41 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.078 0.466 . . . . 72.24 111.73 179.385 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -140.83 35.8 1.78 Allowed 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.035 -0.728 . . . . 54.14 109.035 -178.856 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 98.26 -29.5 11.25 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 114.992 -1.004 . . . . 44.12 111.746 -177.498 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.524 ' HD2' HG21 ' A' ' 28' ' ' VAL . 26.9 t80 -93.39 132.86 37.23 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.917 0.389 . . . . 62.52 110.261 -176.19 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.784 HD11 HG13 ' B' ' 135' ' ' ILE . 3.3 tm? -69.49 134.44 48.91 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.104 -0.953 . . . . 71.33 110.43 179.042 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 133' ' ' TYR . . . . . 0.426 ' N ' HD13 ' B' ' 132' ' ' LEU . 42.6 p90 -124.24 -23.51 4.51 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 121.026 -0.27 . . . . 64.15 111.361 174.608 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -149.92 143.19 25.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.784 0.326 . . . . 71.11 111.055 179.068 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.784 HG13 HD11 ' B' ' 132' ' ' LEU . 77.5 mt -125.08 129.56 73.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.507 -0.315 . . . . 75.53 110.804 178.648 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.529 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.2 tttt -112.69 102.51 10.56 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.128 -0.693 . . . . 73.25 109.128 172.485 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.458 HG21 ' HB3' ' B' ' 175' ' ' TRP . 1.8 p -106.52 127.99 61.47 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-O 121.271 0.558 . . . . 43.44 110.744 -177.665 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.893 HG22 ' HB3' ' B' ' 144' ' ' PRO . 22.6 t -113.21 87.72 11.4 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.138 -0.937 . . . . 62.54 110.282 -179.299 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.48 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 73.5 Cg_endo -83.66 134.87 6.62 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.283 1.988 . . . . 63.03 112.309 176.127 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 140' ' ' LYS . . . . . 0.579 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 56.2 mtpt -67.62 -9.48 43.44 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.773 -0.649 . . . . 71.22 110.954 176.668 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 31.6 m-70 -126.68 54.14 1.62 Allowed 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.574 -0.739 . . . . 64.31 109.524 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 167.45 -17.09 0.08 OUTLIER Glycine 0 CA--C 1.52 0.391 0 C-N-CA 120.59 -0.815 . . . . 73.4 113.39 -177.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 93.6 mttt 71.59 150.88 0.14 Allowed Pre-proline 0 N--CA 1.473 0.688 0 C-N-CA 123.235 0.614 . . . . 74.24 111.438 179.428 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.893 ' HB3' HG22 ' B' ' 138' ' ' VAL . 24.5 Cg_endo -62.42 140.68 83.56 Favored 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.77 2.313 . . . . 73.22 113.357 -176.154 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 145' ' ' TYR . . . . . 0.448 ' CE1' HG13 ' B' ' 137' ' ' VAL . 8.7 p90 -150.59 155.26 39.06 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.655 -0.702 . . . . 75.2 109.969 177.107 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.569 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 83.6 m-85 -101.56 141.29 34.66 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.286 -0.415 . . . . 73.44 111.37 -177.503 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 27.6 mt -124.88 95.74 4.62 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.559 -0.746 . . . . 62.0 109.885 169.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 48.9 t -94.02 122.81 45.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.02 -0.733 . . . . 73.4 109.02 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 15.6 ttm-85 -67.94 143.54 55.61 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.468 0.651 . . . . 64.35 111.975 -174.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.03 175.4 10.67 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.664 -1.153 . . . . 64.43 110.586 176.128 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -84.94 138.27 32.6 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 109.01 -0.737 . . . . 75.22 109.01 173.007 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 110.07 132.07 6.24 Favored Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 120.654 -0.784 . . . . 71.43 111.655 -177.23 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 18.8 m -82.33 30.5 0.4 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.921 0.391 . . . . 74.11 110.983 -177.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -73.59 -47.29 41.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.052 0.453 . . . . 72.45 110.56 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 121.38 46.75 0.31 Allowed Glycine 0 CA--C 1.503 -0.714 0 C-N-CA 120.774 -0.727 . . . . 54.55 112.417 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 -122.17 135.53 54.79 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 120.964 0.411 . . . . 71.44 110.705 -179.178 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -113.01 159.4 19.17 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.764 -0.653 . . . . 73.5 109.381 173.479 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 158' ' ' ILE . . . . . 0.807 HD11 HD23 ' B' ' 166' ' ' LEU . 48.7 mm -114.34 115.84 50.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 N-CA-C 109.341 -0.614 . . . . 73.25 109.341 176.079 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.513 ' HG2' ' H ' ' B' ' 161' ' ' ASP . 40.2 ttm180 -85.39 145.16 27.61 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.75 -0.659 . . . . 74.13 110.376 -174.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 160' ' ' SER . . . . . 0.569 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 5.2 p -58.89 -31.87 68.99 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.447 0.641 . . . . 72.34 110.862 178.211 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 161' ' ' ASP . . . . . 0.513 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 3.5 m-20 -76.03 -31.26 58.79 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.192 -0.913 . . . . 72.23 110.902 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 162' ' ' GLN . . . . . 0.677 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 80.1 mm-40 -132.37 71.07 79.66 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 115.944 -0.571 . . . . 52.25 110.808 -176.358 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 163' ' ' PRO . . . . . 0.405 ' HA ' ' CG2' ' B' ' 158' ' ' ILE . 59.2 Cg_endo -73.37 -12.79 25.29 Favored 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.187 1.925 . . . . 73.32 111.432 178.462 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -93.24 -4.91 51.07 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.012 -0.995 . . . . 73.41 110.253 179.001 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 165' ' ' LYS . . . . . 0.677 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 60.7 tptt -122.72 126.54 47.74 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.918 -0.583 . . . . 64.43 111.074 -174.806 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 166' ' ' LEU . . . . . 0.807 HD23 HD11 ' B' ' 158' ' ' ILE . 61.0 mt -74.41 110.43 8.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.398 -0.819 . . . . 71.25 109.087 174.477 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 167' ' ' ILE . . . . . 0.438 HG13 ' HB2' ' B' ' 159' ' ' ARG . 43.3 mm -70.56 116.37 44.74 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 109.92 -0.4 . . . . 73.35 109.92 -176.569 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.505 ' O ' HG23 ' B' ' 172' ' ' ILE . 38.3 Cg_endo -64.95 172.57 7.01 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 123.251 2.634 . . . . 71.42 113.416 -174.231 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -76.98 -9.9 59.0 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.92 -1.036 . . . . 74.41 111.978 -168.142 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 31.8 p90 -96.22 -10.8 27.16 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.461 0.648 . . . . 74.1 109.924 175.079 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.478 ' HB2' ' HG2' ' B' ' 168' ' ' PRO . 6.8 mm-40 -106.58 -7.06 17.6 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.454 -0.794 . . . . 71.13 111.215 -176.872 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.505 HG23 ' O ' ' B' ' 168' ' ' PRO . 29.0 pt -71.04 -30.01 39.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.121 -0.491 . . . . 64.11 110.723 178.829 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -102.32 41.54 1.22 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.304 0.574 . . . . 74.04 109.772 174.263 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 31.1 t -55.08 -31.86 61.52 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.992 -1.004 . . . . 74.3 110.847 179.348 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 175' ' ' TRP . . . . . 0.515 ' HB2' ' HD2' ' B' ' 121' ' ' LYS . 4.0 p-90 . . . . . 0 C--O 1.251 1.169 0 CA-C-O 118.044 -0.979 . . . . 75.35 110.462 176.765 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.624 0 N-CA-C 112.116 -0.393 . . . . 64.23 112.116 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -72.99 -62.05 1.6 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.687 0.28 . . . . 65.32 111.172 -178.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -83.67 119.94 25.39 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.42 -0.355 . . . . 72.13 110.295 -178.413 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -114.37 153.29 30.09 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.249 0.547 . . . . 74.11 111.041 -177.236 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -146.05 90.32 1.96 Allowed 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.389 -0.823 . . . . 74.14 109.222 175.019 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.22 128.37 84.75 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 116.156 -0.475 . . . . 35.34 111.597 -175.234 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -80.64 179.21 6.25 Favored 'Trans proline' 0 N--CA 1.461 -0.398 0 C-N-CA 122.865 2.377 . . . . 63.33 111.985 176.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.8 m -71.9 120.72 17.89 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.896 -0.409 . . . . 72.45 109.896 177.301 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.493 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 95.27 63.52 0.98 Allowed Glycine 0 N--CA 1.442 -0.918 0 C-N-CA 120.664 -0.779 . . . . 35.22 111.191 -175.489 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -100.3 98.94 8.55 Favored Pre-proline 0 C--N 1.324 -0.537 0 N-CA-C 108.845 -0.798 . . . . 73.42 108.845 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.613 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 88.5 Cg_endo -80.25 102.8 1.46 Allowed 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.247 1.964 . . . . 73.23 112.29 -173.669 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -80.88 141.5 34.53 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.062 -0.972 . . . . 71.43 109.939 -178.45 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.447 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 11.2 p -103.3 120.29 53.04 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 CA-C-O 121.638 0.732 . . . . 65.03 109.88 179.461 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.4 m -93.47 103.11 15.34 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 115.449 -0.796 . . . . 65.3 109.564 -179.547 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.536 HG23 ' HG2' ' A' ' 24' ' ' GLN . 63.9 mt -85.61 105.2 14.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.82 -0.627 . . . . 73.02 110.517 -175.297 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -101.61 160.92 14.04 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.681 -0.69 . . . . 73.11 110.565 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -127.11 98.04 5.16 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.617 -0.512 . . . . 73.54 109.617 175.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.642 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 43.6 mm-40 -103.49 93.32 4.88 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.819 -0.628 . . . . 64.44 109.618 -178.064 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 66.06 -106.36 1.56 Allowed Glycine 0 N--CA 1.444 -0.83 0 C-N-CA 120.764 -0.731 . . . . 43.13 111.832 -176.044 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.655 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 4.0 m-20 -102.05 -5.34 24.67 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.566 0.222 . . . . 73.32 110.819 -177.197 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.642 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 12.3 ptmt -110.77 121.03 44.33 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 121.471 0.653 . . . . 64.3 111.934 -173.449 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.4 m -82.41 97.56 8.43 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.276 -0.875 . . . . 74.31 109.212 174.434 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.409 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 54.1 mt -93.99 106.88 18.57 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-O 121.117 0.485 . . . . 70.32 110.812 -175.574 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.536 ' HG2' HG23 ' A' ' 15' ' ' ILE . 48.8 mt-30 -94.55 109.39 21.29 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.019 -0.537 . . . . 63.41 110.029 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.439 ' HB3' HD23 ' A' ' 32' ' ' LEU . 27.5 mt-10 -89.2 111.38 22.15 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.134 -0.484 . . . . 74.13 110.84 -178.539 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.504 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 50.5 m-85 -84.59 103.88 14.09 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.635 -0.506 . . . . 72.45 109.635 176.268 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -116.04 133.72 55.72 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.062 -0.517 . . . . 61.41 109.923 -179.552 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.613 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 3.4 p -92.05 -60.37 2.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 C-N-CA 120.272 -0.571 . . . . 45.35 110.443 176.684 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.554 ' H ' HG13 ' A' ' 28' ' ' VAL . 88.5 m-20 -138.47 72.6 1.41 Allowed 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.045 0.45 . . . . 74.55 110.213 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 90.46 -27.94 8.09 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.914 -0.585 . . . . 74.4 113.676 175.248 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.491 ' HD2' HG21 ' B' ' 128' ' ' VAL . 35.8 t80 -112.08 134.52 53.58 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.376 0.608 . . . . 73.4 111.469 -173.756 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.881 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -67.21 123.64 20.87 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.495 -1.229 . . . . 53.22 110.441 176.268 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' TYR . . . . . 0.481 ' CD1' ' HB2' ' B' ' 133' ' ' TYR . 24.2 p90 -108.23 -24.82 11.35 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.369 -0.533 . . . . 71.43 111.345 177.172 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -156.19 142.72 18.56 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.685 0.278 . . . . 64.0 110.965 179.342 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.881 HG13 HD11 ' A' ' 32' ' ' LEU . 81.4 mt -120.8 132.41 70.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.537 -0.301 . . . . 72.14 110.589 178.062 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.49 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 88.3 tttt -115.16 100.43 8.15 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 108.953 -0.758 . . . . 73.24 108.953 169.506 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.569 HG23 ' HB2' ' A' ' 21' ' ' LYS . 1.1 p -98.39 126.17 51.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 116.092 -0.503 . . . . 74.32 110.124 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.56 HG22 ' HB3' ' A' ' 44' ' ' PRO . 25.0 t -111.64 88.28 9.24 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 115.544 -0.753 . . . . 72.21 110.109 -179.789 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.534 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 57.8 Cg_endo -73.67 142.42 32.35 Favored 'Trans proline' 0 N--CA 1.457 -0.663 0 C-N-CA 122.48 2.12 . . . . 64.01 111.975 177.839 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.655 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 28.9 mtpp -70.09 -10.55 59.11 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.944 -0.571 . . . . 73.22 110.978 176.329 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 38.7 m-70 -131.04 80.64 1.95 Allowed 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.848 -0.615 . . . . 71.14 109.78 -178.532 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 151.3 -117.23 0.81 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.128 -0.558 . . . . 73.34 112.306 179.499 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 14.3 ptpt -152.79 151.76 27.18 Favored Pre-proline 0 C--N 1.328 -0.344 0 N-CA-C 110.179 -0.304 . . . . 72.33 110.179 178.467 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.56 ' HB3' HG22 ' A' ' 38' ' ' VAL . 48.5 Cg_endo -74.28 124.09 8.73 Favored 'Trans proline' 0 N--CA 1.46 -0.492 0 C-N-CA 122.262 1.975 . . . . 73.12 110.987 170.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.516 ' CE1' HG13 ' A' ' 37' ' ' VAL . 11.4 p90 -139.86 158.57 43.88 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.803 0.335 . . . . 72.1 110.988 -175.185 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.519 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 73.1 m-85 -103.93 141.64 35.81 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.828 -0.624 . . . . 53.22 111.258 -176.498 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 83.8 mt -123.71 105.02 9.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.535 -0.757 . . . . 75.51 109.907 172.155 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.593 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 43.8 t -85.79 139.66 17.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.098 -0.501 . . . . 64.14 109.917 179.355 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.417 HH11 ' HD3' ' A' ' 49' ' ' ARG . 4.5 tpt180 -75.06 115.09 14.31 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.846 -0.428 . . . . 73.31 109.846 179.222 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.33 149.83 41.14 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.023 -0.535 . . . . 73.04 111.399 -178.204 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.58 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 4.9 p-10 -57.44 132.07 52.01 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.269 0.557 . . . . 73.34 110.981 -178.265 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.57 -24.13 24.76 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.41 -0.814 . . . . 72.41 111.86 -179.025 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.5 t 58.15 37.57 26.34 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 121.192 0.52 . . . . 43.54 109.985 -176.56 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -53.57 -38.61 64.05 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.425 -0.807 . . . . 74.42 111.44 -179.03 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 150.44 24.4 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.365 -0.921 . . . . 64.45 113.261 176.572 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.456 ' OD1' ' HA ' ' A' ' 68' ' ' PRO . 93.5 m-20 -134.79 162.7 31.62 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.79 0.329 . . . . 74.41 110.579 -176.764 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 73.2 m-85 -121.73 158.57 28.47 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.078 -0.51 . . . . 75.55 110.15 177.72 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.593 ' HB ' ' HB ' ' A' ' 48' ' ' VAL . 39.5 mm -106.74 110.54 32.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 N-CA-C 109.35 -0.611 . . . . 62.42 109.35 175.566 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.627 ' HG2' ' H ' ' A' ' 61' ' ' ASP . 74.3 ttt180 -83.99 140.42 31.9 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.276 -0.42 . . . . 73.11 110.682 -176.253 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.519 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 9.7 p -64.08 -25.06 67.94 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.901 -0.59 . . . . 64.14 112.204 -177.775 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.627 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 5.5 m-20 -72.78 -24.99 61.01 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.768 0.318 . . . . 71.44 111.649 -178.81 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.5 tp60 -155.0 88.36 3.21 Favored Pre-proline 0 C--N 1.327 -0.399 0 CA-C-O 120.73 0.3 . . . . 71.53 110.616 -176.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -82.05 6.5 5.66 Favored 'Trans proline' 0 C--O 1.233 0.231 0 C-N-CA 122.915 2.41 . . . . 55.24 112.455 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -62.34 -44.22 96.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.646 -0.706 . . . . 75.41 111.059 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.55 -178.37 4.9 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-N 115.6 -0.727 . . . . 61.21 111.458 -176.054 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.0 mp -95.51 135.04 37.66 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.078 -0.964 . . . . 62.43 108.846 177.424 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.429 HG13 ' HB2' ' A' ' 59' ' ' ARG . 41.0 mm -78.64 112.85 29.85 Favored Pre-proline 0 C--N 1.319 -0.743 0 N-CA-C 109.85 -0.426 . . . . 65.0 109.85 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.463 ' O ' HG23 ' A' ' 72' ' ' ILE . 46.6 Cg_endo -67.1 174.48 6.89 Favored 'Trans proline' 0 CA--C 1.519 -0.268 0 C-N-CA 123.188 2.592 . . . . 63.44 113.311 -173.336 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLN . . . . . 0.732 ' HA ' HG12 ' A' ' 72' ' ' ILE . 22.2 tt0 -68.16 -42.39 80.11 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.516 -0.765 . . . . 71.43 111.567 -170.624 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' TRP . . . . . 0.792 ' HA ' ' CZ ' ' A' ' 73' ' ' PHE . 29.6 p90 -63.19 -16.38 59.95 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.339 0.59 . . . . 74.32 110.395 -179.117 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 16.0 mm-40 -94.94 -28.75 15.01 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.527 -0.76 . . . . 72.05 111.579 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.732 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.0 pt -76.63 -38.6 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.148 0 N-CA-C 111.882 0.327 . . . . 72.15 111.882 -178.199 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.792 ' CZ ' ' HA ' ' A' ' 70' ' ' TRP . 6.6 p90 -85.67 30.65 0.63 Allowed 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.727 0.775 . . . . 75.14 110.847 179.55 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 32.5 t -74.23 -11.77 60.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.103 -0.953 . . . . 23.3 108.64 170.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' TRP . . . . . 0.437 ' HH2' HD13 ' A' ' 35' ' ' ILE . 36.6 m0 . . . . . 0 C--O 1.233 0.218 0 CA-C-N 115.465 -0.789 . . . . 72.55 110.6 173.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.255 0 N-CA-C 112.329 -0.309 . . . . 64.22 112.329 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -158.79 -54.35 0.06 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.097 0.475 . . . . 72.42 110.435 -178.731 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -141.99 116.4 9.58 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.701 -0.681 . . . . 62.55 109.851 179.258 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -118.99 145.58 45.71 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.185 -0.672 . . . . 71.42 109.185 178.014 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -134.27 123.19 23.82 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.914 0.388 . . . . 63.14 111.594 -174.471 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -106.37 134.41 19.8 Favored Pre-proline 0 C--N 1.322 -0.625 0 CA-C-N 115.778 -0.646 . . . . 60.52 110.688 178.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -80.84 -160.77 0.13 Allowed 'Trans proline' 0 C--O 1.235 0.354 0 C-N-CA 122.955 2.437 . . . . 75.44 112.156 179.11 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 33.1 m -65.41 96.91 0.26 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.06 0.457 . . . . 61.21 109.774 174.664 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 112.5 95.0 2.19 Favored Glycine 0 N--CA 1.441 -0.985 0 N-CA-C 110.838 -0.905 . . . . 52.23 110.838 -172.772 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -110.43 98.33 35.83 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-O 121.424 0.631 . . . . 73.32 109.899 -178.322 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.718 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 82.7 Cg_endo -81.83 76.57 4.25 Favored 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 122.484 2.123 . . . . 65.12 112.68 -175.456 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -91.38 149.86 21.53 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.092 -0.707 . . . . 73.13 109.092 176.536 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.669 HG21 ' HB3' ' B' ' 124' ' ' GLN . 7.2 p -102.96 130.52 52.93 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-O 121.555 0.693 . . . . 71.3 111.307 -176.085 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 114' ' ' THR . . . . . 0.454 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 30.4 m -91.84 111.2 22.64 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.234 -0.894 . . . . 45.51 109.139 176.027 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.6 mt -88.69 107.69 18.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 120.957 0.408 . . . . 72.4 111.06 -174.148 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 116' ' ' ARG . . . . . 0.502 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 20.2 mmt180 -94.84 160.46 14.59 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.447 -0.575 . . . . 55.44 109.447 175.619 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -136.99 86.84 2.24 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 115.774 -0.648 . . . . 62.44 109.574 174.138 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -100.35 87.81 3.51 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.475 -0.784 . . . . 74.42 109.395 -173.356 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 78.97 -111.56 3.27 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.791 -0.719 . . . . 63.4 111.968 -177.459 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.61 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 20.4 m-20 -109.11 12.16 25.24 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.855 0.36 . . . . 75.3 111.189 -177.572 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.95 ' HE3' ' HB3' ' B' ' 175' ' ' TRP . 20.8 pttm -125.27 123.24 39.06 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.483 0.659 . . . . 75.42 111.481 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 65.9 m -81.75 103.31 11.35 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.249 -0.887 . . . . 70.3 109.472 174.629 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 123' ' ' ILE . . . . . 0.502 ' HB ' ' HB2' ' B' ' 116' ' ' ARG . 64.7 mt -93.58 105.87 17.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.076 0.465 . . . . 73.22 110.378 -177.284 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.669 ' HB3' HG21 ' B' ' 113' ' ' VAL . 70.0 mt-30 -96.23 109.72 22.14 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.167 -0.47 . . . . 54.2 110.897 -177.467 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 125' ' ' GLU . . . . . 0.454 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 45.8 mt-10 -86.47 106.48 17.51 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.778 -0.647 . . . . 71.45 110.799 179.471 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 126' ' ' TYR . . . . . 0.58 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 21.6 m-85 -82.07 106.36 13.92 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.88 -0.415 . . . . 74.44 109.88 174.297 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 127' ' ' ARG . . . . . 0.424 ' O ' ' HA ' ' B' ' 111' ' ' PRO . 95.2 mtt180 -119.97 126.38 50.7 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.842 -0.429 . . . . 74.25 109.842 179.735 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.718 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 3.0 p -99.0 -34.77 4.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.32 0.581 . . . . 74.3 111.268 -177.422 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -143.15 40.71 1.49 Allowed 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.596 0.712 . . . . 54.21 109.166 -175.43 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.15 -23.69 10.82 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.324 -0.853 . . . . 74.42 111.83 -176.386 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 58.3 t80 -93.83 132.26 38.4 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.98 0.419 . . . . 72.31 110.435 -177.647 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.861 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -70.66 117.29 12.0 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.359 -0.837 . . . . 74.13 109.261 176.368 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 133' ' ' TYR . . . . . 0.557 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 41.9 p90 -105.39 -24.69 12.61 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.384 -0.527 . . . . 73.33 111.18 179.533 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 134' ' ' ALA . . . . . 0.483 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -156.56 134.96 11.43 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.762 0.315 . . . . 72.02 110.734 179.224 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.861 HG13 HD11 ' B' ' 132' ' ' LEU . 74.3 mt -107.71 125.7 64.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 N-CA-C 110.031 -0.359 . . . . 73.3 110.031 175.492 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.548 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.9 tttt -107.53 99.92 9.38 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.038 -0.727 . . . . 62.43 109.038 174.142 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.539 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 1.1 p -103.85 124.45 58.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-O 121.074 0.464 . . . . 71.51 110.356 -178.519 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.777 HG22 ' HB3' ' B' ' 144' ' ' PRO . 21.2 t -108.89 88.12 5.18 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 115.224 -0.898 . . . . 65.04 109.732 179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 72.4 Cg_endo -83.13 135.96 7.67 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.539 2.159 . . . . 74.4 112.459 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 140' ' ' LYS . . . . . 0.61 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 59.1 mtpt -60.32 -34.53 73.93 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.605 -0.725 . . . . 71.44 110.088 173.694 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -102.09 77.06 1.65 Allowed 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.461 -0.79 . . . . 64.23 108.925 177.477 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 144.38 -158.14 27.4 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.215 -0.902 . . . . 65.35 110.988 -174.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -131.13 150.03 75.39 Favored Pre-proline 0 C--N 1.324 -0.515 0 N-CA-C 110.026 -0.361 . . . . 73.54 110.026 177.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.777 ' HB3' HG22 ' B' ' 138' ' ' VAL . 17.7 Cg_endo -61.58 122.88 11.71 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.426 2.084 . . . . 65.21 112.124 178.064 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 145' ' ' TYR . . . . . 0.48 ' CE1' HG13 ' B' ' 137' ' ' VAL . 5.7 p90 -136.49 152.86 51.0 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.144 -0.48 . . . . 75.1 110.964 -177.005 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.541 ' O ' ' HA ' ' B' ' 159' ' ' ARG . 88.2 m-85 -101.97 138.33 39.08 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.88 -0.6 . . . . 72.23 111.114 -178.268 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.471 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 56.9 mt -117.5 104.19 10.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.992 -0.549 . . . . 65.03 109.965 172.016 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 148' ' ' VAL . . . . . 0.507 ' HB ' ' HB ' ' B' ' 158' ' ' ILE . 49.1 t -91.33 128.02 43.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 116.339 -0.391 . . . . 65.13 110.888 -177.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 23.8 tpt180 -63.11 120.45 11.48 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 116.47 -0.332 . . . . 74.53 110.975 176.456 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.09 154.62 37.35 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-N 115.987 -0.551 . . . . 63.32 110.933 177.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 151' ' ' ASP . . . . . 0.504 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 8.0 p-10 -59.64 147.06 38.78 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.83 -0.623 . . . . 70.12 111.574 -176.667 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 73.63 2.59 60.83 Favored Glycine 0 N--CA 1.452 -0.247 0 CA-C-N 115.389 -0.823 . . . . 71.34 112.391 178.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 7.9 t 59.73 49.2 8.4 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 109.137 -0.69 . . . . 75.03 109.137 -175.259 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -48.64 -43.74 36.8 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 114.84 -1.073 . . . . 72.51 111.251 -179.326 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 131.13 -18.38 5.02 Favored Glycine 0 CA--C 1.492 -1.346 0 N-CA-C 110.718 -0.953 . . . . 71.23 110.718 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 -97.89 166.78 11.29 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 113.719 -1.241 . . . . 65.54 110.816 -176.533 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -121.22 153.39 37.67 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.817 -0.629 . . . . 72.12 110.206 178.314 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 158' ' ' ILE . . . . . 0.507 ' HB ' ' HB ' ' B' ' 148' ' ' VAL . 48.5 mm -106.31 114.77 46.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 N-CA-C 109.266 -0.642 . . . . 75.43 109.266 176.712 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.541 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 68.0 ttt180 -89.33 138.58 31.31 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.25 -0.432 . . . . 64.15 110.87 -175.505 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 5.6 p -62.59 -22.4 66.34 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.821 -0.627 . . . . 64.42 112.301 -177.191 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 161' ' ' ASP . . . . . 0.52 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 5.5 m-20 -76.22 -16.95 59.72 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.731 0.301 . . . . 62.02 111.237 -177.772 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 21.9 tp60 -166.06 84.81 0.97 Allowed Pre-proline 0 C--N 1.328 -0.34 0 N-CA-C 109.44 -0.578 . . . . 75.02 109.44 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 163' ' ' PRO . . . . . 0.512 ' HG2' ' HB2' ' A' ' 60' ' ' SER . 23.7 Cg_exo -64.86 -9.36 20.96 Favored 'Trans proline' 0 N--CA 1.474 0.337 0 C-N-CA 123.16 2.573 . . . . 63.25 112.929 -178.682 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -90.6 -5.63 55.66 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.962 -0.563 . . . . 74.41 110.768 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.8 tptt -114.83 123.29 48.81 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.25 0.548 . . . . 73.34 110.419 -178.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.3 mp -85.34 113.57 21.76 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.169 -0.923 . . . . 74.15 109.229 177.777 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 167' ' ' ILE . . . . . 0.543 HG23 ' HB3' ' B' ' 171' ' ' GLU . 50.5 mm -64.41 110.58 4.15 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 123.608 0.567 . . . . 74.21 110.681 -177.347 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.564 ' O ' HG23 ' B' ' 172' ' ' ILE . 80.5 Cg_endo -76.06 176.81 9.55 Favored 'Trans proline' 0 N--CA 1.461 -0.386 0 C-N-CA 122.933 2.422 . . . . 60.43 112.472 -176.711 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -76.26 -5.42 46.89 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.711 -0.677 . . . . 61.25 112.707 -170.453 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 27.9 p90 -97.64 -12.88 21.93 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.497 -0.481 . . . . 64.34 110.254 173.395 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.543 ' HB3' HG23 ' B' ' 167' ' ' ILE . 1.7 mm-40 -105.95 -15.05 15.01 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.37 -0.377 . . . . 53.42 111.465 -177.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.564 HG23 ' O ' ' B' ' 168' ' ' PRO . 43.1 pt -66.73 -21.28 28.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.083 0.468 . . . . 75.14 110.693 177.67 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -88.87 41.88 1.05 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.797 -0.638 . . . . 71.3 109.99 177.43 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 22.8 t -86.1 17.22 3.7 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.393 -0.821 . . . . 75.23 110.247 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 175' ' ' TRP . . . . . 0.95 ' HB3' ' HE3' ' B' ' 121' ' ' LYS . 45.9 m0 . . . . . 0 C--O 1.246 0.921 0 CA-C-O 118.471 -0.776 . . . . 72.52 110.421 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.718 0 N-CA-C 111.809 -0.517 . . . . 72.51 111.809 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 64.91 15.19 9.78 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 123.348 0.659 . . . . 75.41 111.854 177.604 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -103.64 105.31 15.51 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.936 0.398 . . . . 65.13 110.004 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -145.89 -43.24 0.21 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.045 -0.525 . . . . 64.25 110.382 -178.525 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -89.9 113.23 24.81 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.907 -0.588 . . . . 71.14 109.938 -178.692 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.477 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -83.26 124.59 75.92 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 116.095 -0.502 . . . . 55.33 112.009 -175.107 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.477 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 6.7 Cg_exo -74.7 172.68 15.76 Favored 'Trans proline' 0 C--O 1.235 0.338 0 C-N-CA 123.317 2.678 . . . . 64.43 112.098 176.794 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 20.9 m -89.15 -178.72 5.73 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.391 -0.368 . . . . 71.01 110.543 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 80.22 -86.77 1.29 Allowed Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 110.903 -0.879 . . . . 61.53 110.903 -176.164 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 70.87 97.94 0.04 OUTLIER Pre-proline 0 CA--C 1.516 -0.347 0 C-N-CA 123.138 0.575 . . . . 74.34 110.89 175.548 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.55 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 5.5 Cg_endo -78.82 85.03 1.92 Allowed 'Trans proline' 0 N--CA 1.443 -1.451 0 C-N-CA 122.378 2.052 . . . . 50.31 110.041 178.065 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -95.7 152.05 18.81 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.284 -0.871 . . . . 73.51 110.179 -175.372 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.722 HG21 ' HB3' ' A' ' 24' ' ' GLN . 7.3 p -121.67 131.52 72.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-O 121.378 0.609 . . . . 70.31 111.158 -176.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.2 m -92.05 115.55 28.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.437 -0.801 . . . . 54.32 109.488 176.584 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 50.3 mt -94.13 107.73 19.7 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.101 0.477 . . . . 53.52 111.344 -173.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.724 ' HB2' ' HB ' ' A' ' 23' ' ' ILE . 33.5 mmt180 -100.41 169.31 9.18 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.701 -0.681 . . . . 71.33 109.424 175.688 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 69.2 mt-30 -139.61 102.78 4.53 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.878 0.37 . . . . 55.11 110.301 175.537 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 60.2 mm-40 -101.51 80.15 2.03 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.031 -0.532 . . . . 72.31 110.18 -178.39 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.41 -111.06 3.49 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.794 -0.717 . . . . 42.3 111.51 -176.062 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.587 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 5.8 m-20 -112.47 4.23 17.33 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.239 0.542 . . . . 44.2 109.837 178.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 23.9 pttm -107.08 119.99 40.88 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.492 0.663 . . . . 74.0 110.379 175.581 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.694 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 8.5 m -80.21 127.15 32.01 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.499 -0.773 . . . . 63.33 109.488 177.879 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.724 ' HB ' ' HB2' ' A' ' 16' ' ' ARG . 26.0 mm -108.08 104.99 17.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 120.677 0.275 . . . . 74.2 110.296 -175.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.755 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 63.7 mt-30 -99.35 109.34 21.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.887 0.375 . . . . 52.42 110.827 -178.109 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -91.69 110.9 22.24 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.978 -0.556 . . . . 60.2 110.311 -179.161 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.531 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 28.1 m-85 -88.69 108.91 19.72 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.877 0.37 . . . . 73.52 111.531 -178.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 46.4 mtm105 -121.44 123.68 42.67 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.713 -0.477 . . . . 64.0 109.713 175.557 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.55 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.4 p -91.83 -27.88 4.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 121.11 0.481 . . . . 65.25 110.728 -177.719 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -172.3 72.5 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.015 -0.539 . . . . 73.34 109.905 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.31 -24.97 4.52 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.795 -0.639 . . . . 55.41 113.202 177.794 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -108.17 130.11 55.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.969 0.384 . . . . 72.34 111.097 -174.72 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.514 HD11 HG13 ' A' ' 35' ' ' ILE . 3.1 tm? -74.51 112.76 11.02 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.345 -0.843 . . . . 74.45 109.037 175.031 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -105.44 -16.33 14.76 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.614 -0.434 . . . . 61.44 111.696 -177.76 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -160.47 145.75 14.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.032 0.444 . . . . 34.21 111.522 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.514 HG13 HD11 ' A' ' 32' ' ' LEU . 63.6 mt -118.32 125.68 74.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 115.909 -0.587 . . . . 64.22 109.461 174.084 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.755 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 82.6 tttt -109.78 105.66 14.97 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.881 -0.415 . . . . 71.15 109.881 179.163 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.631 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 3.5 t -89.52 134.38 28.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 108.965 -0.754 . . . . 74.14 108.965 178.729 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.694 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.4 t -120.32 73.22 20.61 Favored Pre-proline 0 C--N 1.317 -0.839 0 N-CA-C 109.731 -0.47 . . . . 73.11 109.731 173.693 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.618 ' HD3' HG12 ' A' ' 37' ' ' VAL . 49.6 Cg_endo -76.96 132.46 12.9 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.286 1.991 . . . . 75.11 111.489 175.91 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.587 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 21.9 mtpp -57.77 -34.41 69.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 65.51 111.11 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -119.11 109.69 16.19 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.331 -0.618 . . . . 73.11 109.331 175.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 128.53 -27.6 4.4 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 110.79 -0.924 . . . . 31.1 110.79 -173.89 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 58.6 mtmt 70.97 152.0 0.14 Allowed Pre-proline 0 CA--C 1.532 0.255 0 C-N-CA 123.593 0.757 . . . . 62.33 112.496 175.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.631 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 43.3 Cg_endo -67.63 145.2 69.15 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.138 2.559 . . . . 73.44 114.159 -174.434 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 29.2 p90 -148.93 158.92 44.54 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.497 -0.774 . . . . 74.32 109.801 176.363 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.548 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 72.7 m-85 -101.71 129.14 47.81 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.276 -0.42 . . . . 73.12 110.701 178.7 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.58 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 29.7 tp -109.67 96.2 6.11 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.898 -0.779 . . . . 73.32 108.898 173.034 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 32.3 t -94.61 142.38 13.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 116.239 -0.437 . . . . 64.14 111.293 -172.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.453 HH11 ' HZ ' ' A' ' 57' ' ' PHE . 1.6 mmt-85 -66.93 137.57 56.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.962 -0.563 . . . . 63.33 111.046 177.075 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.73 153.84 21.04 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.056 -0.52 . . . . 55.1 109.701 172.723 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.409 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 4.3 p-10 -60.64 130.37 46.17 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.264 0.554 . . . . 64.34 111.289 -177.793 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 81.17 -15.0 24.94 Favored Glycine 0 CA--C 1.518 0.257 0 CA-C-N 115.637 -0.711 . . . . 63.43 112.39 -178.885 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.7 p 43.52 72.46 0.18 Allowed 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 123.721 0.808 . . . . 73.33 112.503 -175.48 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -80.09 42.08 0.55 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.612 0.72 . . . . 64.32 109.435 177.164 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 62.35 37.16 94.14 Favored Glycine 0 N--CA 1.451 -0.362 0 N-CA-C 110.359 -1.097 . . . . 75.34 110.359 -170.596 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -133.08 141.68 48.34 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.937 0.399 . . . . 72.45 110.766 -169.397 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.58 ' CD2' ' HG ' ' A' ' 47' ' ' LEU . 29.7 m-85 -132.09 168.36 18.12 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.767 -0.651 . . . . 73.53 109.879 177.03 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.891 HD11 HD23 ' A' ' 66' ' ' LEU . 42.4 mm -129.16 120.79 52.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.482 -0.562 . . . . 44.44 109.482 174.679 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.615 ' HG3' HG13 ' A' ' 67' ' ' ILE . 41.6 mtp180 -88.03 150.66 23.28 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.271 -0.422 . . . . 62.43 110.655 -179.085 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.672 ' HB2' ' HB3' ' B' ' 163' ' ' PRO . 34.2 p -66.71 -30.43 70.66 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.283 0.564 . . . . 45.24 110.363 177.082 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.51 ' OD1' ' HB3' ' A' ' 59' ' ' ARG . 4.2 p-10 -78.51 -23.23 46.42 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.709 -0.678 . . . . 72.31 110.971 177.048 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -137.33 70.58 54.29 Favored Pre-proline 0 C--N 1.316 -0.868 0 CA-C-N 115.719 -0.673 . . . . 73.32 110.808 -172.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.467 ' HG3' ' HB2' ' B' ' 160' ' ' SER . 84.2 Cg_endo -84.47 -19.83 4.22 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.662 2.242 . . . . 74.02 112.587 -178.923 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 14.7 p-10 -90.61 3.76 53.2 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.935 -0.575 . . . . 74.41 109.975 -179.337 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 81.5 tttt -127.04 137.39 53.05 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.412 -0.813 . . . . 75.43 109.972 179.018 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.891 HD23 HD11 ' A' ' 58' ' ' ILE . 48.1 mt -86.22 116.54 24.46 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.916 -0.772 . . . . 74.13 108.916 176.08 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.673 HG23 ' HB3' ' A' ' 71' ' ' GLU . 41.5 mm -69.71 120.15 75.69 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 115.905 -0.589 . . . . 62.3 111.2 -172.852 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.537 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 51.3 Cg_endo -68.82 172.98 10.78 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.561 2.174 . . . . 62.14 112.574 -178.789 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 10.9 tt0 -80.1 -4.03 51.19 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.503 -0.771 . . . . 61.11 112.091 -166.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 39.1 p90 -100.78 -17.86 16.72 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.196 0.522 . . . . 72.4 110.214 174.002 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.673 ' HB3' HG23 ' A' ' 67' ' ' ILE . 1.2 mm-40 -90.73 -13.1 34.71 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.682 -0.69 . . . . 74.33 110.037 -178.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.531 HG23 ' O ' ' A' ' 68' ' ' PRO . 41.2 pt -70.34 -21.49 23.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.738 -0.665 . . . . 53.51 110.218 176.514 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -108.0 38.42 2.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.643 -0.708 . . . . 64.12 109.211 175.029 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.558 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 7.7 t -62.85 -32.77 74.06 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.192 -0.913 . . . . 64.02 111.187 -175.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 66.9 p-90 . . . . . 0 C--N 1.327 -0.383 0 CA-C-O 120.887 0.375 . . . . 74.04 110.838 179.19 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.469 0 N-CA-C 111.975 -0.45 . . . . 72.33 111.975 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -139.5 123.27 17.54 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.564 0.221 . . . . 73.34 110.59 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -91.61 129.58 37.56 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.53 -0.545 . . . . 73.21 109.53 178.234 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -96.35 3.7 52.75 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.19 0.441 . . . . 72.25 112.19 -170.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -78.08 137.41 38.21 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.877 0.37 . . . . 75.54 111.068 -178.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 106' ' ' ALA . . . . . 0.453 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -112.98 117.36 46.19 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 115.879 -0.601 . . . . 71.23 110.216 178.896 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 107' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 2.9 Cg_exo -75.27 165.45 30.89 Favored 'Trans proline' 0 N--CA 1.462 -0.329 0 C-N-CA 123.302 2.668 . . . . 75.23 112.845 -178.003 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 14.1 m -77.6 179.19 6.72 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.826 -0.625 . . . . 55.25 110.699 178.412 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.9 -58.28 4.98 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.72 -0.752 . . . . 73.22 111.362 -178.268 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 58.43 77.11 0.42 Allowed Pre-proline 0 C--N 1.329 -0.298 0 C-N-CA 122.941 0.497 . . . . 73.14 111.363 177.764 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.651 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 46.3 Cg_endo -72.84 80.12 1.84 Allowed 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 121.914 1.743 . . . . 73.13 110.745 175.159 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -97.77 164.33 12.44 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.197 -0.911 . . . . 75.35 110.255 -176.275 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.632 HG21 ' HB3' ' B' ' 124' ' ' GLN . 9.7 p -125.09 132.7 70.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-O 121.395 0.617 . . . . 62.35 111.195 -177.622 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 114' ' ' THR . . . . . 0.58 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 21.6 m -93.4 110.48 22.04 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.469 -0.787 . . . . 64.13 109.534 175.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.5 mt -84.37 105.35 13.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.062 0.458 . . . . 75.4 111.051 -176.039 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 116' ' ' ARG . . . . . 0.758 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 30.2 mmt180 -100.81 171.93 7.37 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.733 -0.667 . . . . 75.03 109.551 176.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 -145.59 125.18 13.25 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.512 0.672 . . . . 54.14 110.49 172.781 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.13 61.27 0.81 Allowed 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 115.008 -0.996 . . . . 63.34 110.223 -175.178 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 94.14 -111.94 4.25 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.685 -0.769 . . . . 53.54 111.638 -179.035 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -100.23 9.45 42.73 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.036 0.446 . . . . 73.04 109.837 178.215 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.715 ' HD2' ' HB2' ' B' ' 175' ' ' TRP . 25.0 pttm -123.81 119.59 30.15 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.9 -0.591 . . . . 74.2 110.791 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 122' ' ' THR . . . . . 0.635 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 35.0 m -80.07 133.38 36.11 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.755 -0.657 . . . . 74.11 109.543 175.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 123' ' ' ILE . . . . . 0.758 ' HB ' ' HB2' ' B' ' 116' ' ' ARG . 32.5 mm -114.89 103.39 15.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 120.753 0.311 . . . . 43.43 110.41 -177.403 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.751 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 60.2 mt-30 -95.7 105.69 17.72 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 120.644 -0.422 . . . . 73.03 110.452 -178.055 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 125' ' ' GLU . . . . . 0.58 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 41.1 mt-10 -81.63 101.7 10.19 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.865 -0.607 . . . . 75.51 110.831 179.137 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 126' ' ' TYR . . . . . 0.472 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 55.6 m-85 -81.03 105.72 12.46 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.916 0.388 . . . . 72.43 110.253 176.362 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 127' ' ' ARG . . . . . 0.479 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 86.8 mtm180 -127.67 118.03 23.08 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.956 -0.566 . . . . 73.44 110.262 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.733 HG13 ' H ' ' B' ' 129' ' ' ASN . 2.4 p -84.44 -72.06 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-N 116.114 -0.494 . . . . 73.1 110.246 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 129' ' ' ASN . . . . . 0.733 ' H ' HG13 ' B' ' 128' ' ' VAL . 18.3 t-20 -122.28 69.44 0.96 Allowed 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.122 0.487 . . . . 70.41 110.252 -177.091 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.79 -18.74 37.41 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.501 -0.772 . . . . 32.53 113.684 175.359 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.477 ' CD2' HG21 ' A' ' 28' ' ' VAL . 38.0 t80 -114.68 132.13 56.5 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.138 0.494 . . . . 70.04 111.189 -171.721 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.774 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -73.24 113.6 10.5 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.967 -1.015 . . . . 55.11 109.358 174.668 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 133' ' ' TYR . . . . . 0.472 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 52.5 p90 -106.01 -20.04 13.54 Favored 'General case' 0 C--N 1.326 -0.415 0 C-N-CA 120.72 -0.392 . . . . 71.1 111.456 -179.072 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -157.44 142.11 16.6 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.816 0.341 . . . . 75.31 111.361 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.774 HG13 HD11 ' B' ' 132' ' ' LEU . 73.5 mt -119.14 117.44 54.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 116.145 -0.48 . . . . 64.23 109.958 175.028 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.751 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 78.9 tttt -93.8 104.64 16.71 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.399 -0.593 . . . . 73.02 109.399 175.611 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.685 HG12 ' HD3' ' B' ' 139' ' ' PRO . 4.1 t -88.71 131.04 37.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 N-CA-C 108.985 -0.746 . . . . 63.21 108.985 177.529 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.635 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.4 t -118.18 73.03 9.76 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.703 -0.481 . . . . 71.12 109.703 173.016 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.685 ' HD3' HG12 ' B' ' 137' ' ' VAL . 61.2 Cg_endo -81.27 134.04 8.9 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 122.047 1.831 . . . . 75.4 112.161 175.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 63.4 mttm -57.07 -42.91 81.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.592 0.71 . . . . 62.14 110.083 174.659 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 18.0 m-70 -98.95 83.77 2.97 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.088 -0.96 . . . . 73.11 109.406 -173.165 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 136.28 -21.5 3.46 Favored Glycine 0 N--CA 1.45 -0.372 0 CA-C-N 115.51 -0.768 . . . . 52.55 111.848 -177.402 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 143' ' ' LYS . . . . . 0.503 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 53.7 mtmt 72.46 154.88 0.15 Allowed Pre-proline 0 N--CA 1.466 0.354 0 C-N-CA 123.682 0.793 . . . . 53.41 111.893 179.639 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.514 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 36.4 Cg_endo -65.49 146.85 86.06 Favored 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 123.017 2.478 . . . . 72.11 114.12 -174.334 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 27.3 p90 -151.19 171.26 17.67 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.402 -0.817 . . . . 75.44 109.472 175.795 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -111.67 126.54 55.14 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.94 0.4 . . . . 65.44 111.163 -179.269 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.427 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 26.7 tp -107.79 99.18 8.67 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.601 -0.727 . . . . 64.12 109.121 175.503 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 39.2 t -99.87 138.06 25.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 120.805 0.336 . . . . 64.41 111.152 -174.389 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 149' ' ' ARG . . . . . 0.473 ' HD3' ' CE2' ' B' ' 157' ' ' PHE . 0.4 OUTLIER -65.46 123.77 20.51 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 121.049 0.452 . . . . 72.12 111.469 174.509 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.05 156.54 37.37 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.228 -0.897 . . . . 54.42 110.705 177.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 151' ' ' ASP . . . . . 0.531 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 5.7 p-10 -64.51 133.85 53.25 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.144 0.497 . . . . 74.42 110.427 -179.364 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 89.72 -30.76 5.58 Favored Glycine 0 N--CA 1.453 -0.217 0 CA-C-N 115.831 -0.622 . . . . 50.14 111.808 -175.694 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 59.8 p 46.21 56.4 6.26 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.126 0.97 . . . . 75.23 113.13 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -77.64 40.79 0.31 Allowed 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.837 0.827 . . . . 71.53 110.417 176.623 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 73.08 28.73 65.91 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 111.362 -0.695 . . . . 51.1 111.362 -173.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 156' ' ' ASN . . . . . 0.524 ' ND2' HD23 ' B' ' 166' ' ' LEU . 34.0 t30 -122.02 141.57 51.22 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.393 -0.403 . . . . 45.24 110.364 -175.424 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 157' ' ' PHE . . . . . 0.473 ' CE2' ' HD3' ' B' ' 149' ' ' ARG . 43.1 m-85 -125.93 162.63 24.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.026 -0.533 . . . . 63.04 110.025 179.283 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 46.4 mm -122.07 130.14 74.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 109.088 -0.708 . . . . 73.13 109.088 175.382 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.512 ' HB3' ' OD1' ' B' ' 161' ' ' ASP . 23.6 mtp180 -104.92 158.79 16.29 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.193 0.52 . . . . 71.04 111.382 -175.762 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 160' ' ' SER . . . . . 0.467 ' HB2' ' HG3' ' A' ' 63' ' ' PRO . 11.5 p -74.86 -26.06 59.42 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.907 -0.588 . . . . 52.32 110.689 178.808 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 161' ' ' ASP . . . . . 0.512 ' OD1' ' HB3' ' B' ' 159' ' ' ARG . 11.3 p-10 -86.68 -15.4 39.69 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.883 -0.598 . . . . 54.33 110.428 177.274 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 162' ' ' GLN . . . . . 0.436 ' OE1' ' HD3' ' B' ' 165' ' ' LYS . 39.4 mt-30 -143.24 74.45 17.48 Favored Pre-proline 0 C--N 1.319 -0.718 0 CA-C-N 115.243 -0.89 . . . . 74.24 109.38 -176.095 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 163' ' ' PRO . . . . . 0.672 ' HB3' ' HB2' ' A' ' 60' ' ' SER . 74.0 Cg_endo -83.05 -44.23 0.07 OUTLIER 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.966 2.444 . . . . 74.22 114.133 -172.155 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -80.8 -6.8 59.01 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.443 0.64 . . . . 72.54 109.631 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 165' ' ' LYS . . . . . 0.436 ' HD3' ' OE1' ' B' ' 162' ' ' GLN . 88.1 tttt -103.92 135.98 44.43 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.18 -0.918 . . . . 71.32 110.27 -178.04 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 166' ' ' LEU . . . . . 0.524 HD23 ' ND2' ' B' ' 156' ' ' ASN . 5.3 mp -87.41 124.21 33.16 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 108.994 -0.743 . . . . 51.14 108.994 178.374 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 46.5 mm -83.44 117.73 69.47 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.114 -0.494 . . . . 74.22 111.686 -170.635 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.522 ' O ' HG23 ' B' ' 172' ' ' ILE . 70.4 Cg_endo -72.95 175.93 9.74 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.957 2.438 . . . . 62.01 112.874 -178.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -82.75 15.16 2.77 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.45 -0.795 . . . . 61.11 112.944 -168.469 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 26.3 p90 -115.67 -14.98 11.41 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.144 0.497 . . . . 74.43 110.424 171.803 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 171' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -107.32 0.81 23.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.967 -0.561 . . . . 72.34 111.017 -176.876 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.522 HG23 ' O ' ' B' ' 168' ' ' PRO . 21.6 pt -80.79 -31.3 12.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.914 -0.585 . . . . 74.42 111.217 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -111.5 39.4 2.34 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.422 0.63 . . . . 71.23 110.376 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.9 t -61.19 -26.03 67.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.378 -0.828 . . . . 74.02 110.933 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 175' ' ' TRP . . . . . 0.715 ' HB2' ' HD2' ' B' ' 121' ' ' LYS . 4.0 p-90 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.126 -0.94 . . . . 72.24 110.981 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.63 0 N-CA-C 111.712 -0.555 . . . . 74.55 111.712 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -139.42 133.5 31.1 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.922 0.392 . . . . 62.22 111.192 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -86.2 97.96 10.65 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.119 -0.697 . . . . 64.24 109.119 174.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -144.06 -171.85 3.64 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.489 -0.323 . . . . 73.34 110.764 -175.757 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -107.83 113.68 27.09 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.395 -0.366 . . . . 44.55 111.347 -173.333 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.529 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -72.33 122.5 87.6 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 116.202 -0.454 . . . . 73.34 110.572 176.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.529 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 1.6 Cg_endo -83.26 -153.03 0.04 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.454 0 C-N-CA 123.341 2.694 . . . . 74.32 112.279 -179.084 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 14.6 m -66.81 143.96 56.58 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.083 -0.508 . . . . 71.54 110.213 178.192 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.512 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 85.43 87.69 0.94 Allowed Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 110.437 -1.065 . . . . 73.13 110.437 -171.834 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -106.06 101.91 36.68 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-O 120.834 0.35 . . . . 72.42 110.938 -169.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.664 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 71.7 Cg_endo -92.07 122.41 0.62 Allowed 'Trans proline' 0 N--CA 1.445 -1.363 0 C-N-CA 122.864 2.376 . . . . 72.0 112.314 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -128.19 111.56 13.57 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.526 0.679 . . . . 71.51 110.321 176.508 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.599 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 9.1 p -67.33 130.0 32.31 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.085 0 CA-C-N 114.723 -1.126 . . . . 73.35 110.806 179.412 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.544 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 51.8 m -86.23 103.34 14.76 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.671 -0.695 . . . . 75.22 109.561 175.763 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 63.5 mt -86.8 104.47 14.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.159 -0.473 . . . . 73.53 110.482 -177.427 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 10.1 mmm-85 -106.0 156.34 18.49 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.682 -0.69 . . . . 63.11 110.766 -178.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -129.23 98.21 4.83 Favored 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 108.873 -0.788 . . . . 72.22 108.873 173.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.592 ' HG3' HD12 ' A' ' 23' ' ' ILE . 8.0 mm-40 -91.47 15.7 11.8 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.475 -0.784 . . . . 74.31 110.723 -171.773 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.41 -98.96 0.64 Allowed Glycine 0 N--CA 1.445 -0.727 0 C-N-CA 120.998 -0.62 . . . . 52.14 111.899 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.451 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 11.5 p-10 -85.45 4.57 35.02 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.632 0.253 . . . . 72.54 111.568 -178.129 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.622 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 14.1 pttm -148.44 130.54 15.41 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 112.664 0.616 . . . . 44.35 112.664 -176.553 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.8 m -84.87 103.31 13.82 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 114.925 -1.034 . . . . 74.52 108.997 172.401 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.592 HD12 ' HG3' ' A' ' 18' ' ' GLU . 55.7 mt -100.33 112.23 32.36 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.013 0.435 . . . . 72.21 110.393 -175.264 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.599 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 71.9 mt-30 -101.43 117.36 34.78 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.96 -0.564 . . . . 75.14 111.576 -177.16 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.544 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.1 mt-10 -91.05 100.5 13.34 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.551 -0.75 . . . . 24.3 110.322 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.554 ' CD2' ' HB2' ' B' ' 151' ' ' ASP . 63.2 m-85 -78.12 104.73 8.88 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.676 0.274 . . . . 74.14 110.682 179.327 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 94.0 mtt180 -122.69 132.9 54.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.313 -0.403 . . . . 75.34 110.687 -178.423 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.81 HG13 ' H ' ' A' ' 29' ' ' ASN . 3.0 p -98.59 -73.98 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 C-N-CA 120.725 -0.39 . . . . 63.53 110.898 176.222 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.81 ' H ' HG13 ' A' ' 28' ' ' VAL . 7.4 m-20 -128.38 68.62 1.36 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.05 0.453 . . . . 73.14 110.51 -177.308 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 77.42 12.56 84.44 Favored Glycine 0 N--CA 1.451 -0.331 0 CA-C-N 115.679 -0.691 . . . . 71.31 112.019 -179.052 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 79.9 t80 -130.07 127.36 39.72 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.921 0.391 . . . . 75.45 110.785 -176.183 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 30.2 tp -85.91 114.8 23.1 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.393 -0.821 . . . . 72.51 109.413 174.745 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' TYR . . . . . 0.483 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 50.8 p90 -104.47 -10.3 17.78 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.669 -0.412 . . . . 75.54 111.938 -176.782 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -167.44 145.05 4.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.081 0.467 . . . . 63.31 111.361 -177.825 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 66.9 mt -121.14 115.77 47.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.872 -0.604 . . . . 72.01 109.615 174.3 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.455 ' CB ' ' HE1' ' A' ' 26' ' ' TYR . 83.5 tttt -104.69 105.25 15.26 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.666 -0.494 . . . . 30.44 109.666 177.326 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.543 HG13 ' CE1' ' A' ' 45' ' ' TYR . 1.6 p -104.24 127.05 58.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.996 0.427 . . . . 74.13 110.512 178.3 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.827 HG22 ' HB3' ' A' ' 44' ' ' PRO . 16.1 t -103.0 88.01 1.41 Allowed Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 115.312 -0.858 . . . . 74.12 109.463 175.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.511 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 90.0 Cg_endo -81.65 150.09 16.57 Favored 'Trans proline' 0 N--CA 1.461 -0.423 0 C-N-CA 122.714 2.276 . . . . 65.41 113.432 -176.734 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.451 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 29.0 mtpp -74.36 -10.48 59.63 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.368 -0.833 . . . . 75.5 110.556 174.175 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 52.9 m-70 -113.43 21.01 15.58 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.766 -0.652 . . . . 74.15 110.277 -173.865 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.26 -155.85 15.33 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 115.675 -0.693 . . . . 42.1 111.661 -178.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -112.09 150.53 42.57 Favored Pre-proline 0 C--N 1.324 -0.506 0 N-CA-C 109.89 -0.411 . . . . 72.33 109.89 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.827 ' HB3' HG22 ' A' ' 38' ' ' VAL . 19.8 Cg_endo -60.18 121.03 9.15 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.37 2.046 . . . . 64.35 111.8 175.774 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.543 ' CE1' HG13 ' A' ' 37' ' ' VAL . 9.4 p90 -136.53 155.73 49.56 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.0 -0.546 . . . . 71.34 111.039 -176.227 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -99.7 137.07 38.69 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.621 -0.718 . . . . 64.24 110.787 -179.805 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 31.8 mt -104.7 98.13 7.92 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.865 -0.791 . . . . 71.04 108.865 164.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 39.7 t -83.54 129.12 38.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.117 -0.492 . . . . 72.15 110.083 -176.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.19 125.64 29.65 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.303 -0.408 . . . . 64.13 110.435 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.43 135.72 53.58 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 120.953 0.406 . . . . 65.25 110.899 178.181 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.709 ' OD1' ' HB2' ' B' ' 111' ' ' PRO . 31.3 t0 -80.01 168.58 19.0 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.594 -0.73 . . . . 74.21 110.942 -174.743 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.65 24.51 45.88 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.269 -0.732 . . . . 75.51 111.269 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 14.2 m 58.66 28.01 16.61 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.118 0.485 . . . . 74.53 110.592 -177.054 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.4 ' OD1' ' HB3' ' A' ' 56' ' ' ASN . 17.5 t70 -60.09 -47.95 83.75 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 115.349 -0.841 . . . . 74.33 111.325 -177.213 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 101.34 -36.73 4.01 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.679 -0.772 . . . . 63.34 112.946 176.386 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.4 ' HB3' ' OD1' ' A' ' 54' ' ' ASP . 7.4 t30 -70.93 150.95 45.2 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.967 0.413 . . . . 65.14 111.619 -175.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.45 ' CD1' HG21 ' A' ' 72' ' ' ILE . 37.7 m-85 -108.95 148.88 30.02 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.271 -0.422 . . . . 74.42 110.685 179.429 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 50.2 mm -111.26 129.07 67.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 109.641 -0.503 . . . . 74.43 109.641 176.358 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.415 ' HG2' ' H ' ' A' ' 61' ' ' ASP . 43.2 ttm180 -89.91 135.69 33.49 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.541 -0.299 . . . . 74.34 110.59 -176.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.405 ' HB3' ' HB2' ' A' ' 45' ' ' TYR . 35.0 t -63.2 -33.27 75.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.33 -0.396 . . . . 73.34 111.704 -178.194 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.415 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 4.6 m-20 -62.3 -42.64 99.53 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.248 0.547 . . . . 45.55 110.5 178.475 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 62.4 mt-30 -135.04 89.6 23.68 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 115.491 -0.777 . . . . 64.14 110.355 -174.015 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -68.97 -6.19 17.58 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.892 2.395 . . . . 72.11 112.416 -178.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -95.7 -8.44 34.6 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.086 -0.506 . . . . 71.22 110.241 178.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.3 tptt -105.84 123.12 47.45 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.869 -0.605 . . . . 45.01 110.737 -177.842 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.413 ' N ' HD12 ' A' ' 66' ' ' LEU . 5.1 mp -90.45 119.64 30.9 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.108 -0.951 . . . . 74.53 109.075 177.787 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 49.6 mm -90.07 113.92 58.97 Favored Pre-proline 0 C--N 1.323 -0.573 0 CA-C-N 116.263 -0.426 . . . . 75.31 110.729 -175.612 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.449 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 56.9 Cg_endo -69.43 174.03 9.81 Favored 'Trans proline' 0 N--CA 1.46 -0.5 0 C-N-CA 122.498 2.132 . . . . 71.53 112.371 -179.304 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 29.4 tt0 -83.14 -5.17 59.02 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.806 -0.633 . . . . 74.41 111.857 -168.233 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 35.7 p90 -100.45 -2.02 34.33 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.287 0.565 . . . . 73.33 109.902 176.468 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.449 ' HB2' ' HG2' ' A' ' 68' ' ' PRO . 2.8 mm-40 -121.72 17.02 11.12 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.391 -0.822 . . . . 71.3 111.03 -177.016 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.45 HG21 ' CD1' ' A' ' 57' ' ' PHE . 12.1 pt -98.18 -22.55 4.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.944 -0.571 . . . . 72.43 111.457 -179.569 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -113.58 20.78 15.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.185 0.517 . . . . 71.55 110.427 -178.359 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.1 m -57.75 -32.69 67.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.246 -0.888 . . . . 71.41 111.489 -177.011 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' TRP . . . . . 0.622 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 10.2 p-90 . . . . . 0 C--N 1.325 -0.467 0 CA-C-N 116.23 -0.441 . . . . 75.44 111.088 176.575 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.419 0 N-CA-C 112.039 -0.424 . . . . 25.22 112.039 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -98.58 78.69 2.4 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 120.903 0.383 . . . . 73.23 110.691 -179.278 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -74.11 140.84 45.53 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.713 -0.476 . . . . 74.41 109.713 179.226 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -145.73 179.65 7.3 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.122 -0.325 . . . . 54.21 110.122 -176.008 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -98.67 113.32 25.34 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.934 -0.395 . . . . 75.12 109.934 179.587 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -70.15 123.67 89.27 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.99 -0.55 . . . . 70.43 110.811 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_endo -77.31 -155.34 0.05 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.281 0 C-N-CA 122.792 2.328 . . . . 61.14 111.435 176.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 26.3 m -74.62 90.78 2.29 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.369 0.604 . . . . 70.21 109.763 177.358 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 109' ' ' GLY . . . . . 0.433 ' O ' ' HD3' ' B' ' 111' ' ' PRO . . . 151.59 54.14 0.01 OUTLIER Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 110.485 -1.046 . . . . 70.22 110.485 -175.058 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 110' ' ' GLU . . . . . 0.414 ' HA ' ' HD3' ' B' ' 111' ' ' PRO . 11.0 mt-10 -92.41 104.03 10.07 Favored Pre-proline 0 C--N 1.323 -0.578 0 CA-C-N 115.182 -0.509 . . . . 64.2 109.851 -176.065 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.722 ' HB3' ' HB ' ' B' ' 128' ' ' VAL . 68.4 Cg_endo -98.61 158.37 0.73 Allowed 'Trans proline' 0 N--CA 1.444 -1.437 0 C-N-CA 123.156 2.571 . . . . 73.45 112.768 -174.621 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -156.26 126.28 6.49 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 115.544 -0.753 . . . . 71.1 109.766 177.151 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.455 ' HB ' ' HB3' ' A' ' 51' ' ' ASP . 5.4 p -84.88 132.79 30.82 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 CA-C-N 114.979 -1.01 . . . . 74.44 110.801 -174.124 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 114' ' ' THR . . . . . 0.592 HG22 ' HG3' ' B' ' 116' ' ' ARG . 28.6 m -95.78 104.76 16.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.463 -0.79 . . . . 53.32 110.184 179.077 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.495 HG12 ' HG2' ' B' ' 124' ' ' GLN . 60.7 mt -90.64 102.98 13.92 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 116.073 -0.512 . . . . 74.02 109.928 -179.593 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 116' ' ' ARG . . . . . 0.592 ' HG3' HG22 ' B' ' 114' ' ' THR . 71.7 mtm180 -121.24 169.71 10.3 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.162 -0.472 . . . . 74.43 110.847 -178.41 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -125.24 117.49 23.95 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.045 -0.525 . . . . 75.11 110.537 179.016 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 118' ' ' GLU . . . . . 0.611 ' HG3' HD12 ' B' ' 123' ' ' ILE . 22.8 mm-40 -95.36 25.66 4.26 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.577 -0.738 . . . . 74.55 110.911 -177.225 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 121.45 -107.95 1.28 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.897 -0.668 . . . . 33.54 111.638 -177.379 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.522 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 28.4 m-20 -95.39 29.21 2.61 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.911 0.386 . . . . 62.41 110.027 179.519 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 121' ' ' LYS . . . . . . . . . . . . . 20.7 pttm -151.88 127.52 10.14 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.032 0.444 . . . . 75.22 111.292 179.121 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 21.7 m -90.14 113.24 24.96 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.599 -0.728 . . . . 74.4 109.19 174.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 123' ' ' ILE . . . . . 0.611 HD12 ' HG3' ' B' ' 118' ' ' GLU . 51.8 mt -109.84 114.79 47.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.198 0.523 . . . . 61.43 110.634 -173.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.523 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 19.6 mt-30 -95.3 105.89 17.88 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.552 -0.749 . . . . 73.52 109.569 178.067 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 125' ' ' GLU . . . . . 0.424 ' CD ' HH21 ' B' ' 116' ' ' ARG . 28.8 mt-10 -84.53 98.82 10.34 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.541 -0.754 . . . . 71.12 110.34 -177.482 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 126' ' ' TYR . . . . . 0.62 ' CD2' ' HB2' ' A' ' 51' ' ' ASP . 6.5 m-85 -76.51 103.3 6.43 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.595 -0.52 . . . . 71.24 109.595 178.361 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 56.9 mtt-85 -132.43 126.34 32.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.108 0.48 . . . . 64.22 111.553 -172.725 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.722 ' HB ' ' HB3' ' B' ' 111' ' ' PRO . 4.3 p -115.7 119.44 61.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.675 -0.693 . . . . 51.24 109.827 175.105 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 60.29 27.14 16.66 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.284 -0.416 . . . . 74.5 111.545 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.36 21.13 52.92 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.509 -0.853 . . . . 71.52 112.576 179.544 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.468 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 90.0 t80 -122.27 119.43 31.16 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.933 0.396 . . . . 65.4 110.235 175.443 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.536 HD21 HD11 ' B' ' 135' ' ' ILE . 24.4 tp -83.06 114.24 21.16 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.694 -0.684 . . . . 72.54 109.928 178.798 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 45.6 p90 -110.06 -6.93 15.0 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.618 -0.433 . . . . 65.31 111.296 -178.107 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 134' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -165.83 146.88 6.89 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.027 0.441 . . . . 72.14 111.207 -177.148 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.536 HD11 HD21 ' B' ' 132' ' ' LEU . 59.3 mt -130.57 118.05 41.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.932 -0.576 . . . . 64.21 109.946 177.582 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.523 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.1 tttt -101.3 98.32 8.72 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 120.092 -0.643 . . . . 73.14 109.477 172.354 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.53 HG13 ' CE1' ' B' ' 145' ' ' TYR . 1.9 p -101.4 125.38 55.43 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.125 0.488 . . . . 73.31 110.537 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.671 HG22 ' HB3' ' B' ' 144' ' ' PRO . 23.2 t -104.98 88.67 2.48 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.169 -0.923 . . . . 72.22 109.451 175.896 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.482 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 72.6 Cg_endo -83.51 132.69 5.92 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.54 2.16 . . . . 75.1 112.708 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 140' ' ' LYS . . . . . 0.522 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 29.1 mtpp -56.65 -33.38 66.28 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.454 -0.794 . . . . 72.14 111.006 176.742 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -97.11 17.42 17.14 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.705 -0.679 . . . . 73.14 111.029 -174.698 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . -155.76 -149.99 5.48 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 121.001 -0.619 . . . . 52.33 111.742 178.871 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -119.08 147.42 42.66 Favored Pre-proline 0 C--N 1.327 -0.395 0 N-CA-C 109.611 -0.514 . . . . 71.31 109.611 176.495 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.671 ' HB3' HG22 ' B' ' 138' ' ' VAL . 25.3 Cg_endo -64.29 123.85 12.47 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.362 2.041 . . . . 61.21 111.492 175.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 145' ' ' TYR . . . . . 0.53 ' CE1' HG13 ' B' ' 137' ' ' VAL . 5.8 p90 -144.88 151.79 39.25 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.874 0.368 . . . . 70.33 111.418 -175.614 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.478 ' HB2' ' OG ' ' B' ' 160' ' ' SER . 74.9 m-85 -96.83 136.81 36.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.675 -0.693 . . . . 72.03 110.393 177.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.506 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 56.9 mt -109.53 102.62 11.46 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.163 -0.471 . . . . 64.13 109.884 169.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.9 t -81.83 130.35 35.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 109.836 -0.431 . . . . 44.01 109.836 178.862 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 149' ' ' ARG . . . . . 0.589 ' NH1' ' HA ' ' B' ' 153' ' ' SER . 0.0 OUTLIER -81.31 128.06 33.41 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.703 -0.226 . . . . 71.51 110.447 -177.149 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -68.58 150.7 47.7 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 120.963 0.411 . . . . 74.41 110.631 176.738 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 151' ' ' ASP . . . . . 0.554 ' HB2' ' CD2' ' A' ' 26' ' ' TYR . 22.7 t70 -70.77 165.88 22.14 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.598 -0.728 . . . . 71.3 111.115 -175.148 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.08 0.66 70.97 Favored Glycine 0 C--N 1.331 0.3 0 CA-C-N 116.206 -0.452 . . . . 72.54 112.34 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 153' ' ' SER . . . . . 0.589 ' HA ' ' NH1' ' B' ' 149' ' ' ARG . 5.9 t 60.6 31.91 20.29 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.078 0.466 . . . . 61.23 109.836 -176.441 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -52.39 -49.4 64.53 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.126 -0.943 . . . . 64.23 111.54 -179.521 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 124.61 -17.87 7.28 Favored Glycine 0 CA--C 1.499 -0.918 0 C-N-CA 120.762 -0.732 . . . . 73.12 111.565 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -70.33 140.35 52.21 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 114.851 -0.675 . . . . 63.52 111.281 178.037 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 157' ' ' PHE . . . . . 0.521 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 53.9 m-85 -118.28 151.47 37.61 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.071 -0.513 . . . . 73.12 109.673 174.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 46.7 mm -119.35 121.91 67.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 N-CA-C 109.743 -0.465 . . . . 64.22 109.743 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.592 ' HB3' ' H ' ' B' ' 162' ' ' GLN . 54.5 mtt180 -76.2 137.07 39.78 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.318 -0.401 . . . . 71.02 110.941 179.434 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 160' ' ' SER . . . . . 0.478 ' OG ' ' HB2' ' B' ' 146' ' ' PHE . 19.9 m -80.88 -13.68 58.7 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.252 -1.018 . . . . 74.24 108.252 165.096 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -73.66 -45.85 50.13 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.251 -1.34 . . . . 75.32 109.859 173.033 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 162' ' ' GLN . . . . . 0.592 ' H ' ' HB3' ' B' ' 159' ' ' ARG . 77.6 mt-30 -137.63 86.19 19.28 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-N 115.364 -0.835 . . . . 74.4 109.444 176.456 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -68.19 -13.99 39.39 Favored 'Trans proline' 0 N--CA 1.473 0.282 0 C-N-CA 122.905 2.403 . . . . 72.45 112.936 -176.436 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -92.29 10.68 28.67 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.976 0.417 . . . . 64.44 110.453 -179.028 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -127.09 125.81 41.91 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.33 0.586 . . . . 75.32 111.075 -179.589 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 166' ' ' LEU . . . . . 0.429 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.9 mp -87.87 125.06 34.27 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.036 -0.984 . . . . 55.41 108.93 176.573 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 167' ' ' ILE . . . . . 0.837 HG23 ' HB3' ' B' ' 171' ' ' GLU . 39.4 mm -87.26 117.43 68.58 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 116.18 -0.463 . . . . 64.12 111.64 -172.396 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.454 ' HG2' ' HB2' ' B' ' 171' ' ' GLU . 72.4 Cg_endo -75.59 -179.75 5.42 Favored 'Trans proline' 0 N--CA 1.463 -0.287 0 C-N-CA 123.088 2.525 . . . . 61.13 112.043 175.539 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 169' ' ' GLN . . . . . 0.761 ' O ' HG12 ' B' ' 172' ' ' ILE . 35.4 tt0 -76.34 -29.51 57.28 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.727 -0.389 . . . . 62.13 111.68 -172.261 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 36.5 p90 -75.06 -14.11 60.56 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 119.92 -0.712 . . . . 74.45 110.313 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.837 ' HB3' HG23 ' B' ' 167' ' ' ILE . 0.8 OUTLIER -89.68 -21.1 22.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.885 -0.598 . . . . 73.15 110.185 -179.257 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.761 HG12 ' O ' ' B' ' 169' ' ' GLN . 21.9 pt -73.59 -18.44 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 121.27 0.557 . . . . 74.2 110.24 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 80.0 m-85 -93.65 15.23 16.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.663 -0.699 . . . . 72.44 110.168 176.217 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.7 t -56.96 -37.06 71.04 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-N 115.817 -0.629 . . . . 72.02 109.777 175.782 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 54.7 p-90 . . . . . 0 C--O 1.247 0.927 0 CA-C-O 118.203 -0.903 . . . . 74.42 109.828 175.02 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.565 0 N-CA-C 111.912 -0.475 . . . . 34.41 111.912 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -142.4 -75.13 0.28 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.941 0.401 . . . . 73.13 110.002 178.505 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -155.75 126.92 7.1 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.833 -0.622 . . . . 73.33 109.524 176.501 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -138.0 111.41 8.04 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.909 -0.587 . . . . 75.02 110.943 -177.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -95.98 107.51 19.8 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.002 -0.545 . . . . 74.44 110.488 178.31 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -83.84 149.33 56.41 Favored Pre-proline 0 C--N 1.324 -0.506 0 CA-C-N 115.923 -0.581 . . . . 64.41 110.27 177.553 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -74.58 178.85 6.56 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.418 2.079 . . . . 74.04 112.138 178.454 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 19.6 m -72.09 167.24 20.64 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.504 -0.554 . . . . 71.43 109.504 175.425 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 72.41 74.78 0.74 Allowed Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 110.005 -1.238 . . . . 64.51 110.005 -168.407 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLU . . . . . 0.446 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 7.1 pt-20 -112.31 107.74 55.26 Favored Pre-proline 0 C--N 1.317 -0.809 0 CA-C-O 121.375 0.607 . . . . 73.43 109.712 -169.83 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.578 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 32.5 Cg_endo -84.67 108.94 1.28 Allowed 'Trans proline' 0 N--CA 1.442 -1.541 0 C-N-CA 122.445 2.097 . . . . 62.44 112.371 -174.006 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -118.79 164.2 15.75 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.127 -0.942 . . . . 50.25 109.674 -179.437 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.604 HG21 ' HB3' ' A' ' 24' ' ' GLN . 13.1 p -115.34 131.24 68.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.237 0.541 . . . . 64.43 111.41 -177.315 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 52.9 m -93.16 107.09 18.96 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.244 -0.65 . . . . 63.53 109.244 174.469 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 53.5 mt -92.09 107.96 19.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 120.963 0.411 . . . . 71.21 111.217 -174.559 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 66.7 mtt180 -103.65 167.85 9.53 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.736 -0.665 . . . . 72.15 110.252 176.751 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 62.6 mt-30 -134.16 97.31 3.82 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.438 -0.579 . . . . 72.22 109.438 170.317 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 22.1 mm-40 -96.29 82.42 3.42 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.823 -0.626 . . . . 74.21 110.093 -175.683 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.86 -109.02 3.31 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.798 -0.715 . . . . 62.2 111.927 -178.506 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.903 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 7.1 m-20 -111.22 17.53 20.2 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.899 0.381 . . . . 65.24 110.326 -179.789 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.599 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 22.9 pttm -130.84 123.79 29.84 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.294 0.569 . . . . 74.12 111.398 -179.151 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.474 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 24.5 m -82.83 109.75 17.24 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.603 -0.726 . . . . 33.33 109.682 176.265 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 48.7 mt -102.55 112.83 37.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-O 121.117 0.484 . . . . 71.24 110.654 -176.335 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.604 ' HB3' HG21 ' A' ' 13' ' ' VAL . 73.8 mt-30 -102.48 110.92 23.02 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.67 -0.695 . . . . 74.31 110.996 -177.562 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -92.26 107.51 19.27 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.795 -0.639 . . . . 73.02 110.837 -178.42 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -84.87 112.42 20.54 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.893 0.378 . . . . 74.02 110.599 178.392 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.466 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 87.9 mtt180 -117.39 137.56 52.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.924 -0.58 . . . . 71.02 109.905 178.756 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.578 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 6.2 p -96.82 -34.82 5.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-O 121.346 0.593 . . . . 72.24 110.489 177.714 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 30.9 t-20 -161.78 59.8 0.26 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.641 -0.874 . . . . 61.0 108.641 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.07 -34.69 3.36 Favored Glycine 0 CA--C 1.519 0.297 0 CA-C-N 115.482 -0.781 . . . . 61.04 112.058 -176.162 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.56 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 81.9 t80 -78.28 129.25 34.82 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.021 0.438 . . . . 64.42 111.047 -177.328 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.781 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -81.44 114.04 19.91 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.196 -0.911 . . . . 72.34 109.094 174.59 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 52.1 p90 -107.86 -19.4 13.53 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.634 -0.426 . . . . 74.13 111.682 -179.057 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -154.85 136.15 14.05 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.785 0.326 . . . . 51.44 111.244 -179.264 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.781 HG13 HD11 ' A' ' 32' ' ' LEU . 75.0 mt -116.26 122.81 70.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 116.064 -0.516 . . . . 75.45 109.91 175.378 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.4 tmtp? -110.21 114.49 28.02 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 108.732 -0.84 . . . . 65.43 108.732 173.827 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.571 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 0.9 OUTLIER -120.46 129.72 75.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 CA-C-N 115.796 -0.638 . . . . 74.55 110.692 -174.011 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.765 HG22 ' HB3' ' A' ' 44' ' ' PRO . 21.2 t -112.8 86.96 9.38 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.313 -0.858 . . . . 75.4 110.097 -179.378 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.469 ' HD2' ' C ' ' A' ' 43' ' ' LYS . 70.4 Cg_endo -86.49 134.45 4.05 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 122.503 2.135 . . . . 64.33 112.496 176.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.903 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 59.4 mtpt -56.31 -31.19 63.46 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.664 -0.698 . . . . 71.21 110.168 174.149 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 61.4 m-70 -116.95 91.18 3.51 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.338 -0.846 . . . . 73.34 109.156 176.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 141.31 -31.31 2.16 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.837 -0.619 . . . . 65.33 111.977 -177.019 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.469 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 98.5 mttt 70.52 151.12 0.13 Allowed Pre-proline 0 N--CA 1.469 0.477 0 C-N-CA 123.508 0.723 . . . . 72.33 111.872 178.577 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.765 ' HB3' HG22 ' A' ' 38' ' ' VAL . 18.8 Cg_endo -59.26 139.44 90.09 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 123.013 2.476 . . . . 74.01 113.798 -174.01 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.544 ' CE1' HG13 ' A' ' 37' ' ' VAL . 22.5 p90 -152.34 163.65 39.04 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.62 -0.718 . . . . 71.21 109.548 176.594 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' PHE . . . . . 0.472 ' HB2' ' HB2' ' A' ' 60' ' ' SER . 60.1 m-85 -107.6 120.66 42.84 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.704 0.288 . . . . 74.12 110.712 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 28.1 tp -107.15 99.14 8.7 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.16 -0.681 . . . . 44.15 109.16 176.842 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 37.3 t -95.38 140.76 16.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.26 -0.427 . . . . 63.41 111.436 -173.52 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.498 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 43.8 tpt85 -81.82 110.97 17.61 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.495 -0.557 . . . . 73.11 109.495 178.23 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.457 ' HB2' HG12 ' A' ' 58' ' ' ILE . . . -70.03 -177.96 1.48 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.994 -0.548 . . . . 73.52 111.111 -177.286 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.752 ' HB2' ' HA ' ' B' ' 112' ' ' ASP . 9.1 p-10 -79.01 148.42 32.53 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.154 -0.475 . . . . 72.05 110.17 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 103.27 140.16 10.69 Favored Glycine 0 N--CA 1.439 -1.16 0 C-N-CA 120.571 -0.823 . . . . 64.01 112.675 174.026 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 20.7 m -69.13 -4.93 19.3 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.675 -0.262 . . . . 52.13 110.919 174.708 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -43.03 -48.07 5.97 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 123.556 0.743 . . . . 73.0 112.012 176.711 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.25 53.86 1.32 Allowed Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.608 -0.806 . . . . 43.31 112.46 178.275 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -127.17 148.96 50.17 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.095 0.474 . . . . 65.32 110.538 176.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.498 ' CZ ' ' HD3' ' A' ' 49' ' ' ARG . 40.2 m-85 -117.75 152.64 34.87 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.594 -0.73 . . . . 73.02 110.322 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.457 HG12 ' HB2' ' A' ' 50' ' ' ALA . 50.6 mm -121.26 127.07 75.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 109.914 -0.402 . . . . 73.23 109.914 179.753 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 65.0 mtp180 -78.55 139.2 38.64 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 110.144 -0.317 . . . . 70.32 110.144 175.875 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.472 ' HB2' ' HB2' ' A' ' 46' ' ' PHE . 63.2 m -73.05 -23.19 60.55 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.495 -0.321 . . . . 60.31 110.448 176.109 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.46 ' OD1' ' HB2' ' A' ' 45' ' ' TYR . 0.8 OUTLIER -61.79 -60.58 3.44 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 121.74 0.781 . . . . 64.45 109.414 175.918 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 -122.65 88.62 49.85 Favored Pre-proline 0 N--CA 1.445 -0.724 0 CA-C-N 114.538 -1.21 . . . . 75.12 109.817 -179.524 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.84 -9.19 20.24 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 123.165 2.577 . . . . 65.24 112.626 -178.604 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -78.37 -24.84 46.19 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.926 -0.579 . . . . 73.22 110.599 177.393 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' A' ' 65' ' ' LYS . 42.6 tptt -91.82 122.92 34.8 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.388 0.613 . . . . 61.41 111.395 -175.14 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.5 mp -96.59 119.38 34.98 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.09 -0.959 . . . . 71.24 109.642 176.243 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 50.7 mm -88.11 111.42 42.85 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 116.273 -0.421 . . . . 73.41 110.023 178.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.428 ' O ' HG23 ' A' ' 72' ' ' ILE . 72.7 Cg_endo -74.16 176.72 9.18 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.563 2.175 . . . . 74.3 112.367 -177.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 28.4 tt0 -80.41 -6.24 57.76 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.859 -0.61 . . . . 54.55 111.334 -169.598 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -95.24 -12.14 26.76 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.409 -0.516 . . . . 62.5 110.433 176.367 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -103.12 -7.6 21.17 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.839 0.352 . . . . 52.44 110.795 -178.167 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.428 HG23 ' O ' ' A' ' 68' ' ' PRO . 45.7 pt -67.72 -27.74 39.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.846 0.355 . . . . 75.23 111.573 -178.24 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 24.3 p90 -101.27 34.49 2.54 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.372 0.605 . . . . 74.13 110.528 178.101 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 42.4 t -64.75 -26.98 68.59 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.43 -0.805 . . . . 52.13 110.212 176.161 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' TRP . . . . . 0.599 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 26.0 p-90 . . . . . 0 C--O 1.235 0.327 0 CA-C-N 116.436 -0.347 . . . . 65.32 111.048 177.309 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.249 0 N-CA-C 112.689 -0.164 . . . . 43.34 112.689 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -167.87 -78.68 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.048 0.452 . . . . 52.53 110.417 178.093 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -147.52 130.99 16.7 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.731 -0.668 . . . . 64.33 109.821 179.688 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -156.56 155.97 32.81 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.021 -0.536 . . . . 74.42 110.119 -179.592 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -92.16 146.82 23.42 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.01 -0.541 . . . . 71.1 111.377 -177.041 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 106' ' ' ALA . . . . . 0.487 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -90.63 129.94 42.97 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-N 115.531 -0.759 . . . . 71.54 110.203 178.43 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 107' ' ' PRO . . . . . 0.487 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 7.6 Cg_exo -73.33 171.03 18.49 Favored 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.736 2.291 . . . . 54.25 111.643 177.429 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 16.9 m -60.27 109.3 0.95 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.414 -0.357 . . . . 64.41 110.072 175.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 114.58 85.05 1.28 Allowed Glycine 0 N--CA 1.443 -0.864 0 C-N-CA 120.578 -0.82 . . . . 63.34 111.437 -176.8 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 110' ' ' GLU . . . . . 0.462 ' HA ' ' HD3' ' B' ' 111' ' ' PRO . 11.1 pt-20 -124.08 110.73 28.99 Favored Pre-proline 0 C--N 1.322 -0.618 0 CA-C-O 121.322 0.582 . . . . 72.05 109.558 -176.384 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.695 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 19.1 Cg_endo -89.52 131.35 2.01 Favored 'Trans proline' 0 N--CA 1.444 -1.4 0 C-N-CA 122.63 2.22 . . . . 60.22 112.604 -176.393 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 112' ' ' ASP . . . . . 0.752 ' HA ' ' HB2' ' A' ' 51' ' ' ASP . 4.2 p-10 -144.9 171.17 14.82 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.188 -0.671 . . . . 72.33 109.188 175.272 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.544 HG21 ' HB3' ' B' ' 124' ' ' GLN . 10.9 p -118.44 131.6 70.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.653 0.739 . . . . 72.45 112.096 -172.461 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 30.3 m -94.86 103.44 15.32 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.435 -0.802 . . . . 55.04 109.31 173.161 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.468 HG23 ' HG2' ' B' ' 124' ' ' GLN . 65.2 mt -90.57 106.44 17.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.245 -0.434 . . . . 72.1 110.823 -176.15 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -113.74 165.08 12.91 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.126 -0.488 . . . . 72.44 110.603 177.808 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -133.14 105.57 7.11 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.094 0.474 . . . . 63.45 110.468 178.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -109.85 88.75 2.82 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.904 -0.589 . . . . 71.34 110.191 -178.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 88.47 -119.8 5.47 Favored Glycine 0 N--CA 1.445 -0.734 0 CA-C-N 115.439 -0.8 . . . . 52.43 111.742 -177.377 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.508 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 90.5 m-20 -101.37 6.29 42.57 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.73 0.3 . . . . 63.34 110.573 178.84 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.706 ' HE3' ' HB2' ' B' ' 175' ' ' TRP . 25.1 pttm -117.42 120.69 38.92 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.47 0.652 . . . . 72.42 111.692 -177.806 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 122' ' ' THR . . . . . 0.586 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 69.7 m -84.86 105.0 15.31 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.163 -0.926 . . . . 73.14 109.478 174.183 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 123' ' ' ILE . . . . . 0.655 HD11 ' HE2' ' B' ' 121' ' ' LYS . 33.2 mt -95.02 108.08 20.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 121.049 0.452 . . . . 71.11 110.531 -176.366 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.544 ' HB3' HG21 ' B' ' 113' ' ' VAL . 72.2 mt-30 -98.65 105.15 17.26 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.825 -0.625 . . . . 72.12 110.319 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -87.37 112.77 22.46 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.125 -0.488 . . . . 65.41 110.926 -179.438 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -90.09 111.14 22.16 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.205 -0.452 . . . . 72.23 110.028 176.06 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 127' ' ' ARG . . . . . 0.403 ' HD3' ' O ' ' B' ' 130' ' ' GLY . 52.8 mtt-85 -128.33 138.1 52.23 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.313 -0.403 . . . . 75.34 110.346 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.695 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -101.86 -56.17 5.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.065 0.459 . . . . 71.51 111.201 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 129' ' ' ASN . . . . . 0.449 ' H ' HG13 ' B' ' 128' ' ' VAL . 6.7 t-20 -122.66 42.03 3.28 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.761 0.791 . . . . 64.31 109.103 -178.029 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 130' ' ' GLY . . . . . 0.403 ' O ' ' HD3' ' B' ' 127' ' ' ARG . . . 92.31 -28.72 8.51 Favored Glycine 0 N--CA 1.448 -0.563 0 CA-C-N 115.086 -0.961 . . . . 64.32 112.099 -178.087 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 33.8 t80 -84.59 135.57 34.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.934 0.397 . . . . 72.33 110.318 -175.627 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.843 HD11 HG13 ' B' ' 135' ' ' ILE . 3.3 tm? -76.75 117.59 18.53 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.327 -0.851 . . . . 75.14 109.966 179.068 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 40.0 p90 -112.26 -14.96 13.27 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.521 -0.471 . . . . 72.01 111.571 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.11 141.61 12.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.848 0.356 . . . . 51.21 111.169 178.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.843 HG13 HD11 ' B' ' 132' ' ' LEU . 75.3 mt -125.14 121.61 61.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.188 -0.46 . . . . 72.13 109.935 175.713 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.407 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 83.7 tttt -104.37 98.5 8.28 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 108.821 -0.807 . . . . 73.01 108.821 171.512 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.55 ' O ' ' HD3' ' B' ' 139' ' ' PRO . 3.5 p -98.21 128.67 49.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-O 121.142 0.496 . . . . 74.12 109.916 179.374 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.586 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 40.8 t -108.03 84.82 2.28 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.31 -0.859 . . . . 72.13 109.69 179.083 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.55 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 62.5 Cg_endo -88.7 132.33 2.45 Favored 'Trans proline' 0 N--CA 1.443 -1.464 0 C-N-CA 122.459 2.106 . . . . 75.14 111.885 178.411 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 140' ' ' LYS . . . . . 0.508 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 55.0 mtpt -65.37 -15.81 62.96 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.701 -0.681 . . . . 54.33 109.808 176.229 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 64.4 m-70 -117.47 89.52 3.13 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-N 115.174 -0.921 . . . . 63.24 109.289 178.413 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 127.87 -18.35 5.94 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.724 -0.751 . . . . 63.25 112.555 -178.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 89.1 mttt 72.98 148.94 0.12 Allowed Pre-proline 0 N--CA 1.472 0.649 0 C-N-CA 123.557 0.743 . . . . 73.3 111.736 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.545 ' HB3' HG22 ' B' ' 138' ' ' VAL . 34.9 Cg_endo -65.12 149.26 89.24 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.936 2.424 . . . . 74.4 113.375 -176.433 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 145' ' ' TYR . . . . . 0.43 ' HE2' HD13 ' B' ' 147' ' ' LEU . 3.9 p90 -160.3 160.43 32.51 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.534 -0.757 . . . . 71.23 109.59 178.178 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.547 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 55.0 m-85 -94.55 128.84 41.42 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.457 -0.338 . . . . 74.44 110.216 176.687 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.43 HD13 ' HE2' ' B' ' 145' ' ' TYR . 15.8 tp -110.36 99.8 8.76 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 108.931 -0.766 . . . . 74.42 108.931 174.837 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.3 t -93.77 139.28 18.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.988 -0.551 . . . . 73.5 111.047 -173.656 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 11.6 tpt180 -72.02 131.06 42.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.199 -0.455 . . . . 72.32 111.245 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -93.34 162.22 14.08 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.372 -0.603 . . . . 75.14 109.372 171.306 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -68.69 138.24 54.78 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.966 0.412 . . . . 72.3 110.537 -177.548 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.1 147.45 15.01 Favored Glycine 0 N--CA 1.437 -1.28 0 C-N-CA 120.491 -0.861 . . . . 72.25 112.048 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 11.1 t -87.0 23.88 1.66 Allowed 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 121.253 0.549 . . . . 63.14 110.015 175.68 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -65.17 -29.45 70.28 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.571 -0.74 . . . . 72.15 110.59 179.01 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 94.44 37.92 5.18 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.891 -0.671 . . . . 71.05 111.641 -177.681 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 156' ' ' ASN . . . . . 0.481 ' HA ' ' O ' ' B' ' 167' ' ' ILE . 2.4 t-20 -110.85 130.51 55.56 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.836 0.351 . . . . 65.11 110.69 -177.457 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 157' ' ' PHE . . . . . 0.428 ' HB3' ' HG ' ' B' ' 147' ' ' LEU . 27.1 m-85 -126.71 161.0 29.15 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.002 -0.545 . . . . 72.24 110.269 178.198 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 158' ' ' ILE . . . . . 0.775 HD11 HD23 ' B' ' 166' ' ' LEU . 39.9 mm -118.38 141.05 39.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.458 -0.337 . . . . 73.12 110.603 -179.63 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.817 ' HD2' HD11 ' B' ' 167' ' ' ILE . 34.1 mtp-105 -96.23 145.68 25.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.394 -0.366 . . . . 75.4 110.925 -178.098 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 160' ' ' SER . . . . . 0.547 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 25.8 p -74.96 -15.16 60.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.26 0.552 . . . . 74.24 110.679 175.098 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -78.66 -30.79 46.47 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.118 -0.492 . . . . 72.53 110.38 177.629 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 52.8 tt0 -159.19 98.02 1.63 Allowed Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.781 -0.645 . . . . 75.42 110.224 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 163' ' ' PRO . . . . . 0.418 ' HA ' HG23 ' B' ' 158' ' ' ILE . 48.6 Cg_endo -69.62 -13.03 34.41 Favored 'Trans proline' 0 CA--C 1.529 0.231 0 C-N-CA 122.991 2.461 . . . . 61.04 112.844 -179.343 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -77.66 -19.38 55.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.86 0.362 . . . . 62.54 111.022 177.732 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 51.7 tptt -94.07 122.61 36.76 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.409 0.623 . . . . 71.12 111.132 -177.236 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 166' ' ' LEU . . . . . 0.775 HD23 HD11 ' B' ' 158' ' ' ILE . 20.4 mt -90.57 128.02 36.45 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.598 -1.183 . . . . 73.4 108.832 176.734 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 167' ' ' ILE . . . . . 0.817 HD11 ' HD2' ' B' ' 159' ' ' ARG . 46.1 mm -98.77 112.08 61.89 Favored Pre-proline 0 C--N 1.318 -0.778 0 CA-C-O 120.65 0.262 . . . . 70.31 110.832 -178.151 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.539 ' O ' HG23 ' B' ' 172' ' ' ILE . 68.6 Cg_endo -73.5 175.23 10.94 Favored 'Trans proline' 0 N--CA 1.464 -0.263 0 C-N-CA 122.775 2.317 . . . . 75.34 112.611 -179.421 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 169' ' ' GLN . . . . . 0.517 ' O ' HG12 ' B' ' 172' ' ' ILE . 28.0 tt0 -69.65 -25.48 63.94 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.703 -0.681 . . . . 73.32 112.325 -168.488 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 30.6 p90 -81.09 -12.07 59.36 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 120.182 -0.607 . . . . 74.42 110.303 178.732 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.548 ' HB3' HG23 ' B' ' 167' ' ' ILE . 3.9 mt-10 -106.79 -19.27 13.7 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.157 -0.474 . . . . 71.33 111.892 -178.703 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.539 HG23 ' O ' ' B' ' 168' ' ' PRO . 43.6 pt -64.51 -26.36 40.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.244 0.545 . . . . 72.13 110.681 177.579 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -105.3 48.56 0.83 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.612 -0.722 . . . . 70.44 109.782 174.4 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 16.6 t -71.06 -15.39 62.54 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.806 -0.634 . . . . 73.41 110.17 179.379 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 175' ' ' TRP . . . . . 0.706 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 4.5 p-90 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.249 -0.882 . . . . 73.12 110.519 178.305 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.661 0 N-CA-C 112.198 -0.361 . . . . 74.35 112.198 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -91.21 90.25 7.7 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.164 0.507 . . . . 72.32 109.933 178.48 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -156.56 134.62 11.19 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.534 -0.757 . . . . 74.11 109.667 -177.414 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -136.63 100.39 4.32 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.076 0.465 . . . . 73.13 112.031 -178.55 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -128.27 136.03 50.46 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 108.19 -1.041 . . . . 73.34 108.19 169.356 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.436 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -146.54 142.78 17.75 Favored Pre-proline 0 C--N 1.319 -0.724 0 C-N-CA 121.011 -0.275 . . . . 73.12 111.335 -174.803 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 18.8 Cg_exo -67.25 172.67 9.72 Favored 'Trans proline' 0 CA--C 1.53 0.306 0 C-N-CA 122.841 2.361 . . . . 62.44 112.239 178.269 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 27.0 m -89.68 11.47 19.76 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.66 0.743 . . . . 53.12 110.374 179.825 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -135.18 102.99 0.45 Allowed Glycine 0 N--CA 1.442 -0.957 0 N-CA-C 110.108 -1.197 . . . . 75.11 110.108 177.381 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -119.99 94.71 48.81 Favored Pre-proline 0 C--N 1.319 -0.743 0 CA-C-O 121.261 0.553 . . . . 74.33 110.401 -175.069 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.848 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 51.6 Cg_endo -77.56 81.79 2.57 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 121.913 1.742 . . . . 73.12 111.265 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -100.48 168.26 9.85 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.339 -0.615 . . . . 73.45 109.339 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.673 HG21 ' HB3' ' A' ' 24' ' ' GLN . 8.3 p -125.65 131.41 72.06 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-O 121.253 0.549 . . . . 44.45 111.387 -175.177 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.5 m -89.51 121.14 31.44 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.679 -0.691 . . . . 71.15 109.423 176.34 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 52.9 mt -91.58 109.09 20.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 120.834 0.349 . . . . 71.43 111.161 -175.382 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 38.3 mmt180 -105.51 165.7 10.96 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 72.11 109.867 176.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 40.1 mt-30 -138.95 122.57 17.43 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.768 0.318 . . . . 75.35 111.147 177.007 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -124.97 96.93 5.05 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.793 -0.639 . . . . 73.04 109.524 176.212 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.24 -106.49 1.8 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.476 -0.869 . . . . 75.35 111.719 -178.829 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.588 ' HB3' ' HB2' ' A' ' 40' ' ' LYS . 7.0 m-20 -111.35 6.26 20.31 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 121.156 -0.217 . . . . 41.31 111.537 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.652 ' HB3' ' HB3' ' A' ' 39' ' ' PRO . 0.0 OUTLIER -110.94 122.49 48.01 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 119.917 -0.713 . . . . 72.03 111.472 177.422 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.448 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 42.4 m -83.42 101.28 11.26 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 114.961 -1.018 . . . . 61.41 108.983 173.174 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.475 HG12 HG13 ' A' ' 37' ' ' VAL . 61.3 mt -90.82 109.86 21.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.153 0.502 . . . . 71.44 110.291 -175.789 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.673 ' HB3' HG21 ' A' ' 13' ' ' VAL . 60.2 mt-30 -99.78 119.45 38.18 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.787 -0.642 . . . . 73.22 111.021 -175.562 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -94.31 108.73 20.6 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.825 -0.625 . . . . 74.24 110.559 -178.001 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.516 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 33.5 m-85 -86.62 114.82 23.65 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.923 0.392 . . . . 75.12 111.051 -179.587 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.427 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 68.3 mtm180 -131.03 126.64 36.43 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.018 -0.537 . . . . 73.12 110.416 179.295 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.848 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.3 p -91.07 -28.83 4.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.063 -0.517 . . . . 70.11 111.242 -176.52 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -173.61 69.68 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.626 -0.509 . . . . 62.31 109.626 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.98 -24.59 5.19 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.817 -0.629 . . . . 63.12 112.642 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.645 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 88.4 t80 -97.26 128.43 44.11 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.869 0.366 . . . . 75.25 111.057 -176.2 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.622 HD11 HG13 ' A' ' 35' ' ' ILE . 3.2 tm? -79.24 109.73 13.85 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.803 -0.814 . . . . 54.11 108.803 175.194 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 41.7 p90 -106.0 -13.87 15.35 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.513 -0.475 . . . . 63.32 111.467 -176.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -162.11 149.49 14.12 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.069 0.461 . . . . 31.21 111.62 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.622 HG13 HD11 ' A' ' 32' ' ' LEU . 70.1 mt -126.07 128.12 71.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.659 -0.701 . . . . 72.51 109.681 174.669 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.622 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 81.5 tttt -112.01 105.15 13.47 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.306 -0.406 . . . . 74.53 110.084 179.159 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.696 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 4.4 t -89.64 126.71 42.55 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 108.765 -0.828 . . . . 62.23 108.765 177.379 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.448 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 20.1 t -114.43 73.98 2.91 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 109.883 -0.414 . . . . 73.22 109.883 172.904 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.679 ' HD3' HG12 ' A' ' 37' ' ' VAL . 39.8 Cg_endo -77.52 132.11 11.99 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.094 1.862 . . . . 65.42 112.648 176.377 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.588 ' HB2' ' HB3' ' A' ' 20' ' ' ASP . 50.4 mtpt -60.76 -28.22 68.55 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.535 -0.757 . . . . 70.2 110.316 175.24 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 74.2 m-70 -118.03 94.63 4.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.325 -0.852 . . . . 74.53 108.763 178.026 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.413 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 134.04 -31.22 2.84 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.492 -0.776 . . . . 73.32 111.544 -175.038 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.472 ' HD3' ' HA ' ' A' ' 43' ' ' LYS . 31.5 mmtp 74.23 153.65 0.15 Allowed Pre-proline 0 N--CA 1.469 0.501 0 C-N-CA 123.557 0.743 . . . . 60.21 112.254 177.243 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.696 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 28.3 Cg_endo -62.86 132.52 37.54 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 123.074 2.516 . . . . 74.34 114.2 -173.485 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -140.0 154.55 47.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.456 -0.793 . . . . 72.13 109.884 175.364 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -107.01 136.98 45.95 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-O 120.763 0.316 . . . . 73.42 111.574 -175.709 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.585 HD23 ' HA ' ' A' ' 59' ' ' ARG . 47.7 mt -118.38 107.78 14.25 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.851 -0.613 . . . . 60.14 109.858 171.431 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 47.3 t -95.46 134.92 31.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.628 -0.26 . . . . 61.5 110.398 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.656 ' HD2' ' HA ' ' A' ' 53' ' ' SER . 16.1 tpp85 -68.7 122.04 17.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.808 0.337 . . . . 75.14 110.123 177.211 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -73.6 158.35 34.95 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.136 -0.483 . . . . 72.23 110.784 179.69 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -53.49 143.55 19.26 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 115.765 -0.652 . . . . 63.14 111.194 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.28 -33.84 5.36 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.772 -0.728 . . . . 73.22 111.99 -178.835 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.656 ' HA ' ' HD2' ' A' ' 49' ' ' ARG . 17.4 t 63.02 38.3 11.06 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-O 121.009 0.433 . . . . 75.13 110.992 178.776 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -76.44 -3.67 38.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.526 0.679 . . . . 73.35 110.815 -178.468 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 111.54 2.53 27.46 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.617 -0.801 . . . . 54.2 111.692 -179.038 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -85.89 134.59 33.89 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.051 0.453 . . . . 73.22 110.497 178.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -116.04 144.19 44.45 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.82 -0.627 . . . . 70.45 110.109 176.095 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.2 mm -105.75 105.43 18.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 CA-C-O 121.564 0.697 . . . . 73.22 109.368 176.874 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.719 ' HB2' HG13 ' A' ' 67' ' ' ILE . 24.0 ttt180 -69.56 119.78 14.34 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 114.631 -1.168 . . . . 71.54 109.461 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.5 t -63.05 -18.56 63.49 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.396 0.617 . . . . 71.22 110.404 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.696 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 24.7 t70 -73.96 -28.42 61.48 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.449 -0.796 . . . . 74.5 110.489 175.61 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -142.79 68.5 19.09 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-N 115.424 -0.807 . . . . 65.14 109.191 -177.328 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_exo -71.06 -11.5 29.18 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 123.256 2.637 . . . . 53.33 112.998 -171.757 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -95.47 4.76 52.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.493 0.663 . . . . 72.51 109.758 -178.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -131.96 137.35 47.88 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.6 -0.727 . . . . 63.33 110.753 -178.038 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.488 ' N ' HD12 ' A' ' 66' ' ' LEU . 4.5 mp -85.02 131.44 34.46 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.049 -0.523 . . . . 61.03 109.65 179.678 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.719 HG13 ' HB2' ' A' ' 59' ' ' ARG . 40.6 mm -89.71 129.1 47.95 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-O 120.933 0.397 . . . . 71.51 111.305 -174.395 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -76.28 176.59 9.86 Favored 'Trans proline' 0 N--CA 1.459 -0.505 0 C-N-CA 122.862 2.374 . . . . 71.44 112.514 178.15 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' GLN . . . . . 0.685 ' HA ' HG12 ' A' ' 72' ' ' ILE . 45.1 tt0 -79.41 -31.62 42.72 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.61 -0.723 . . . . 64.33 112.184 -170.653 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 28.3 p90 -69.42 -19.39 63.8 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 120.184 -0.607 . . . . 71.53 110.384 178.421 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -84.84 -35.45 22.26 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.852 -0.613 . . . . 70.1 110.179 178.789 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.685 HG12 ' HA ' ' A' ' 69' ' ' GLN . 41.2 pt -76.24 -21.79 15.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.116 0 CA-C-O 120.965 0.412 . . . . 64.44 110.878 179.843 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 31.4 m-85 -103.63 28.47 6.52 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.077 -0.511 . . . . 74.12 110.926 176.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 11.1 t -84.93 45.22 1.14 Allowed 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.864 0.84 . . . . 71.22 109.616 178.352 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 11.3 m0 . . . . . 0 C--N 1.324 -0.521 0 CA-C-N 115.124 -0.944 . . . . 73.33 110.729 -178.83 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 112.439 -0.264 . . . . 65.21 112.439 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -86.78 96.67 10.26 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 120.698 0.285 . . . . 71.34 111.099 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -73.89 110.91 8.56 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.75 -0.463 . . . . 53.22 109.75 175.168 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -100.72 32.86 2.96 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.598 0.713 . . . . 63.02 110.828 -174.507 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -84.75 95.55 8.98 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.191 -0.67 . . . . 72.23 109.191 176.146 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -108.68 111.13 61.23 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-O 120.926 0.393 . . . . 64.12 111.329 -175.199 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -83.8 159.08 14.04 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.638 2.225 . . . . 65.35 111.61 176.171 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 6.3 p -75.75 96.47 3.65 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.041 0.448 . . . . 74.42 109.998 176.721 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 128.05 76.89 0.21 Allowed Glycine 0 N--CA 1.445 -0.701 0 N-CA-C 110.891 -0.884 . . . . 74.05 110.891 -175.555 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -110.16 105.77 57.47 Favored Pre-proline 0 C--N 1.32 -0.703 0 N-CA-C 109.138 -0.69 . . . . 71.04 109.138 -175.371 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.745 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 46.1 Cg_endo -82.23 86.35 1.54 Allowed 'Trans proline' 0 N--CA 1.439 -1.734 0 C-N-CA 121.898 1.732 . . . . 70.23 110.959 -178.021 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -101.81 155.63 18.02 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 114.258 -1.337 . . . . 74.01 109.92 -175.811 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.603 ' HA ' ' O ' ' B' ' 125' ' ' GLU . 7.6 p -117.65 130.71 72.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.474 0.655 . . . . 75.43 111.104 -177.707 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 52.0 m -104.7 122.05 44.85 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.401 -0.818 . . . . 65.42 109.996 178.636 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 47.3 mt -87.09 108.03 17.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 116.145 -0.479 . . . . 54.52 111.443 -174.783 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -101.15 170.73 8.06 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.469 -0.567 . . . . 54.25 109.469 175.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -142.76 138.76 30.7 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.782 0.325 . . . . 75.11 110.786 175.532 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -135.52 104.58 5.87 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.638 -0.71 . . . . 75.11 109.754 176.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.62 -110.14 3.31 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.908 -0.663 . . . . 51.11 111.898 -177.263 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.615 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 9.5 m-20 -97.06 -19.33 18.79 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.705 0.288 . . . . 74.2 110.977 -179.147 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.533 ' HB3' ' HA ' ' B' ' 139' ' ' PRO . 49.3 pttt -100.88 141.75 33.33 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.6 0.714 . . . . 71.25 112.503 -170.088 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 122' ' ' THR . . . . . 0.594 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 47.9 m -91.77 138.43 31.56 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 114.828 -1.078 . . . . 73.41 109.646 176.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 65.9 mt -124.89 106.56 16.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 120.984 0.421 . . . . 71.43 110.276 -178.709 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.56 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 67.1 mt-30 -96.91 117.19 30.57 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.918 0.39 . . . . 64.25 111.092 -176.081 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 125' ' ' GLU . . . . . 0.603 ' O ' ' HA ' ' B' ' 113' ' ' VAL . 43.2 mt-10 -83.02 114.15 21.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.736 -0.665 . . . . 74.23 110.947 179.299 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 126' ' ' TYR . . . . . 0.444 ' HB2' ' O ' ' B' ' 134' ' ' ALA . 41.2 m-85 -92.75 97.33 10.71 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.493 -0.558 . . . . 53.43 109.493 170.815 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 127' ' ' ARG . . . . . 0.439 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 21.8 mtm105 -121.08 127.41 51.63 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.803 -0.635 . . . . 74.04 110.071 179.375 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.745 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 6.0 p -87.97 -37.5 10.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.097 0.475 . . . . 71.54 110.834 -176.541 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -160.27 62.86 0.33 Allowed 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.292 0.568 . . . . 72.23 109.69 -178.464 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.0 -26.57 6.63 Favored Glycine 0 N--CA 1.446 -0.664 0 CA-C-N 115.404 -0.816 . . . . 62.31 112.734 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -99.12 130.81 45.46 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.014 0.435 . . . . 72.13 110.56 -175.342 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.783 HD11 HG13 ' B' ' 135' ' ' ILE . 3.2 tm? -78.06 118.62 20.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.263 -0.881 . . . . 72.41 109.615 178.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 133' ' ' TYR . . . . . 0.415 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 51.4 p90 -109.3 -22.27 12.14 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 120.748 -0.381 . . . . 72.34 111.34 178.24 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 134' ' ' ALA . . . . . 0.444 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -156.14 147.81 22.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.39 . . . . 54.25 111.12 179.517 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.783 HG13 HD11 ' B' ' 132' ' ' LEU . 75.4 mt -125.47 130.68 72.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.152 -0.476 . . . . 55.23 109.723 175.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.56 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 46.6 tttp -106.46 106.82 17.52 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.383 -0.599 . . . . 64.14 109.383 174.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.685 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.0 t -91.51 136.05 25.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 N-CA-C 109.024 -0.732 . . . . 70.34 109.024 178.583 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.594 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 22.0 t -121.85 73.33 34.29 Favored Pre-proline 0 C--N 1.318 -0.762 0 N-CA-C 109.483 -0.562 . . . . 75.11 109.483 173.298 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.576 ' HD3' HG12 ' B' ' 137' ' ' VAL . 53.2 Cg_endo -78.52 134.64 12.57 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 122.183 1.922 . . . . 72.23 112.931 176.601 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 140' ' ' LYS . . . . . 0.615 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 30.8 mtpp -62.94 -30.93 71.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.638 0.732 . . . . 71.43 109.547 174.222 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 72.8 m-70 -112.99 89.89 3.2 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.043 -0.981 . . . . 75.12 109.392 176.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 138.7 -21.52 3.04 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.621 -0.8 . . . . 75.3 112.328 -178.207 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 33.4 mmtp 69.59 150.8 0.13 Allowed Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 123.2 0.6 . . . . 65.32 111.524 178.484 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.685 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 19.3 Cg_endo -59.8 140.3 92.6 Favored 'Trans proline' 0 C--O 1.235 0.336 0 C-N-CA 122.575 2.183 . . . . 75.54 113.278 -177.244 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 38.9 p90 -155.33 151.06 27.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.924 -0.58 . . . . 74.31 110.307 178.441 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.522 ' HB2' ' HB2' ' B' ' 160' ' ' SER . 87.2 m-85 -95.35 139.32 31.82 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.171 -0.468 . . . . 75.14 111.166 179.453 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.419 ' HB3' ' CD2' ' B' ' 157' ' ' PHE . 39.5 mt -116.27 110.29 18.55 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.634 -0.712 . . . . 73.32 109.693 170.316 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 41.7 t -95.23 132.91 37.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.579 -0.282 . . . . 70.45 110.953 -178.622 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 149' ' ' ARG . . . . . 0.415 ' HG2' HH11 ' B' ' 149' ' ' ARG . 17.0 tpp85 -70.46 113.63 7.77 Favored 'General case' 0 N--CA 1.452 -0.338 0 N-CA-C 109.895 -0.409 . . . . 74.04 109.895 175.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.65 155.44 35.91 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 116.094 -0.503 . . . . 74.24 111.202 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 151' ' ' ASP . . . . . 0.516 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 3.4 p-10 -56.9 138.79 53.31 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.551 -0.749 . . . . 72.0 112.132 -177.418 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 93.74 -11.24 71.46 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.213 -0.903 . . . . 62.13 112.648 176.705 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 2.3 t 57.58 50.33 11.19 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-O 121.692 0.758 . . . . 62.01 109.391 -177.618 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -73.51 -8.45 55.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 114.885 -1.052 . . . . 72.45 111.876 -175.037 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 90.96 18.32 47.66 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.5 -0.857 . . . . 33.12 111.175 -174.089 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -119.88 137.47 54.0 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.914 -0.643 . . . . 73.4 110.058 -178.322 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 157' ' ' PHE . . . . . 0.419 ' CD2' ' HB3' ' B' ' 147' ' ' LEU . 42.3 m-85 -113.56 159.93 19.07 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.167 -0.469 . . . . 75.44 110.166 177.666 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 158' ' ' ILE . . . . . 0.693 HD11 HD23 ' B' ' 166' ' ' LEU . 45.7 mm -121.9 119.07 57.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 109.442 -0.577 . . . . 75.31 109.442 175.061 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.418 ' HB3' ' H ' ' B' ' 161' ' ' ASP . 36.2 mtt180 -71.14 140.16 50.49 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.213 -0.448 . . . . 44.23 110.09 176.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 160' ' ' SER . . . . . 0.522 ' HB2' ' HB2' ' B' ' 146' ' ' PHE . 7.4 t -80.82 1.06 32.21 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.617 -0.883 . . . . 64.55 108.617 169.702 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 161' ' ' ASP . . . . . 0.418 ' H ' ' HB3' ' B' ' 159' ' ' ARG . 0.2 OUTLIER -98.53 -23.12 15.65 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.561 -1.199 . . . . 73.22 109.884 174.567 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -144.71 67.83 14.24 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 115.099 -0.955 . . . . 72.13 109.559 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -75.34 -12.97 20.86 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 123.162 2.575 . . . . 73.32 113.346 -173.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -87.89 -12.5 44.6 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.581 0.705 . . . . 65.52 109.504 178.418 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 48.8 mtpt -105.46 170.45 7.88 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.406 -0.815 . . . . 71.41 111.459 -177.779 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 166' ' ' LEU . . . . . 0.693 HD23 HD11 ' B' ' 158' ' ' ILE . 17.8 mt -117.48 125.46 50.93 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.423 -0.954 . . . . 71.22 108.423 177.21 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 167' ' ' ILE . . . . . 0.542 ' CG2' ' HB3' ' B' ' 171' ' ' GLU . 36.5 mm -80.95 116.37 62.01 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-O 121.275 0.56 . . . . 72.32 111.835 -169.798 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 168' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.53 -179.46 2.82 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.58 2.853 . . . . 74.24 112.781 -178.227 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 169' ' ' GLN . . . . . 0.804 ' HA ' HG12 ' B' ' 172' ' ' ILE . 28.3 tt0 -79.23 -32.35 43.87 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.07 -0.514 . . . . 52.41 111.386 -170.367 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 11.4 p90 -68.21 -17.09 64.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.088 0.471 . . . . 73.14 110.231 178.09 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.542 ' HB3' ' CG2' ' B' ' 167' ' ' ILE . 1.2 tm-20 -91.12 -43.69 9.73 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.577 -0.738 . . . . 62.13 110.211 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.804 HG12 ' HA ' ' B' ' 169' ' ' GLN . 44.1 pt -68.61 -25.35 30.62 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.168 -0.469 . . . . 55.44 111.06 -179.395 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 173' ' ' PHE . . . . . 0.42 ' C ' ' H ' ' B' ' 175' ' ' TRP . 30.9 m-85 -111.14 30.45 6.88 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.18 0.514 . . . . 72.34 110.563 176.617 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 25.1 t -79.03 22.44 0.39 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.866 -0.607 . . . . 73.04 110.652 178.558 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 175' ' ' TRP . . . . . 0.42 ' H ' ' C ' ' B' ' 173' ' ' PHE . 12.9 m95 . . . . . 0 C--O 1.248 1.018 0 CA-C-O 118.271 -0.871 . . . . 73.41 110.509 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.622 0 N-CA-C 112.043 -0.423 . . . . 71.33 112.043 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -157.18 123.54 4.92 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.806 0.303 . . . . 61.53 111.255 -178.567 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 33.4 t70 74.43 -49.84 0.67 Allowed 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 123.868 0.867 . . . . 62.53 111.999 174.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -78.4 109.76 12.84 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.808 -0.441 . . . . 71.02 109.808 177.908 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.617 ' O ' ' HD3' ' A' ' 7' ' ' PRO . 24.1 m-20 -87.57 -163.26 0.91 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.459 -0.337 . . . . 71.53 110.659 179.673 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.5 96.15 13.35 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-O 120.753 0.311 . . . . 61.11 111.686 -176.225 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.617 ' HD3' ' O ' ' A' ' 5' ' ' ASP . 12.4 Cg_endo -92.38 117.38 0.4 Allowed 'Trans proline' 0 N--CA 1.45 -1.066 0 C-N-CA 123.301 2.667 . . . . 71.12 112.209 177.0 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 20.3 m -71.35 119.35 15.36 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.567 -0.531 . . . . 25.51 109.567 174.804 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.456 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 95.42 70.19 1.06 Allowed Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 110.53 -1.028 . . . . 74.5 110.53 -173.129 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLU . . . . . 0.415 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 11.9 pt-20 -98.48 102.65 15.12 Favored Pre-proline 0 C--N 1.325 -0.482 0 N-CA-C 109.348 -0.612 . . . . 64.42 109.348 -177.321 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.554 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 53.4 Cg_endo -91.14 97.24 0.23 Allowed 'Trans proline' 0 N--CA 1.441 -1.571 0 C-N-CA 122.572 2.181 . . . . 64.0 112.135 -175.008 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -103.05 114.18 28.27 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-N 115.365 -0.834 . . . . 74.11 109.859 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.634 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 9.1 p -77.1 127.12 38.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 CA-C-N 115.681 -0.69 . . . . 72.53 109.97 179.478 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.643 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 24.5 m -84.22 103.1 13.14 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.848 -0.614 . . . . 71.24 110.078 -178.063 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 65.5 mt -90.84 107.95 19.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.06 -0.518 . . . . 71.53 110.571 -176.055 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.507 ' HG2' ' O ' ' A' ' 23' ' ' ILE . 12.7 ptm180 -121.96 174.4 6.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.871 -0.604 . . . . 75.3 109.786 179.066 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -133.08 104.38 6.49 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 116.223 -0.444 . . . . 72.54 110.089 -177.567 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 58.5 mm-40 -103.49 80.1 1.77 Allowed 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 120.969 0.414 . . . . 75.1 110.205 -178.814 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 78.35 -106.16 2.27 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.797 -0.716 . . . . 54.42 112.428 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.859 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 6.9 m-20 -108.63 34.88 3.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.792 0.329 . . . . 73.11 110.831 -178.249 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.844 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 20.5 pttm -154.2 124.04 6.73 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.157 0.503 . . . . 75.13 111.46 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.446 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 62.3 m -82.02 105.89 13.49 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.624 -0.716 . . . . 74.34 109.36 174.036 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.599 HG12 HG13 ' A' ' 37' ' ' VAL . 61.1 mt -97.59 113.68 32.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.046 0.45 . . . . 54.42 110.687 -176.484 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.687 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 65.7 mt-30 -100.58 109.19 21.26 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.738 -0.664 . . . . 71.23 110.329 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.643 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.1 mt-10 -91.69 104.25 16.74 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.064 -0.517 . . . . 74.33 110.853 -178.912 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.539 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 54.0 m-85 -73.26 106.73 5.22 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.174 -0.467 . . . . 74.23 110.753 179.463 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.454 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 59.9 mtt180 -129.24 133.7 47.64 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.552 -0.536 . . . . 74.23 109.552 177.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 6.4 p -104.34 -41.47 6.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 121.272 0.558 . . . . 55.44 110.721 -179.105 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 54.5 m-20 -140.94 56.83 1.56 Allowed 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.708 -0.678 . . . . 71.43 109.626 178.463 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.21 -32.67 4.04 Favored Glycine 0 N--CA 1.451 -0.322 0 CA-C-N 115.385 -0.825 . . . . 72.43 113.242 177.614 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -90.32 132.2 35.69 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.001 0.429 . . . . 74.41 110.654 -174.092 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.555 HD13 ' HB3' ' A' ' 25' ' ' GLU . 33.2 tp -77.92 114.3 16.64 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.395 -0.82 . . . . 63.43 110.599 179.306 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' TYR . . . . . 0.527 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 35.4 p90 -106.34 -6.64 18.18 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.774 -0.37 . . . . 62.32 111.809 -178.376 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -171.84 142.91 1.57 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.842 0.353 . . . . 74.44 111.256 -178.747 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.459 HD12 HD23 ' A' ' 47' ' ' LEU . 61.9 mt -117.77 127.4 75.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.249 -0.432 . . . . 71.02 110.179 176.089 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.687 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.8 tttt -111.65 103.48 11.79 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 109.446 -0.576 . . . . 72.42 109.446 175.036 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.731 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 3.7 t -96.77 134.52 34.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 N-CA-C 109.309 -0.626 . . . . 53.31 109.309 -178.551 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.649 HG22 ' HB3' ' A' ' 44' ' ' PRO . 21.7 t -114.22 74.21 2.8 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 109.317 -0.623 . . . . 75.3 109.317 170.759 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.465 ' HD3' HG12 ' A' ' 37' ' ' VAL . 42.4 Cg_endo -74.0 142.81 31.79 Favored 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 122.039 1.826 . . . . 73.12 112.764 179.118 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.859 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 61.0 mtpt -64.39 -17.13 63.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.134 -0.939 . . . . 54.12 110.913 176.72 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -128.99 88.3 2.69 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.662 -0.699 . . . . 74.54 110.215 -178.643 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.403 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 135.23 -16.06 4.18 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.288 -0.958 . . . . 74.43 113.203 179.202 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.541 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 99.5 mttt 71.79 160.03 0.16 Allowed Pre-proline 0 N--CA 1.472 0.626 0 C-N-CA 122.755 0.422 . . . . 74.32 111.469 179.507 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.731 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 26.2 Cg_endo -63.57 141.62 80.82 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 122.491 2.127 . . . . 64.34 113.716 -176.48 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -145.71 155.23 42.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.717 -0.674 . . . . 75.13 110.212 177.671 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -99.72 132.91 44.76 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.305 -0.407 . . . . 74.12 110.994 178.144 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.459 HD23 HD12 ' A' ' 35' ' ' ILE . 40.1 tp -121.07 98.81 6.16 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.686 -0.688 . . . . 64.32 109.345 176.171 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 25.0 t -87.98 146.99 5.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.396 -0.366 . . . . 62.25 111.358 -172.205 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 10.0 tpt180 -81.23 122.92 28.01 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.848 -0.427 . . . . 73.32 109.848 177.659 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.426 ' HB3' ' OD1' ' A' ' 56' ' ' ASN . . . -74.86 161.94 29.1 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.208 -0.451 . . . . 73.23 110.862 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -66.78 145.54 55.4 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.135 0.493 . . . . 72.44 110.957 -177.6 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 88.67 -25.17 9.94 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.863 -0.608 . . . . 64.54 112.487 177.6 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 57.2 p 47.75 43.9 17.29 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.459 0.704 . . . . 74.42 112.058 -179.737 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -68.0 -33.0 73.79 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.453 0.644 . . . . 72.23 110.919 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 147.99 41.58 0.04 OUTLIER Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.582 -1.007 . . . . 61.41 110.582 -178.393 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ASN . . . . . 0.426 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 11.5 p30 -140.52 152.65 45.73 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.18 0.514 . . . . 75.05 111.078 -172.805 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 36.3 m-85 -134.23 157.5 46.11 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.511 -0.768 . . . . 74.01 109.566 175.444 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.809 HD11 HD23 ' A' ' 66' ' ' LEU . 45.2 mm -115.23 108.07 24.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.253 0.549 . . . . 62.25 109.668 176.324 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.592 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 50.2 ttp180 -89.31 133.37 34.51 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.811 -0.631 . . . . 62.44 109.952 -177.057 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.1 p -58.21 -25.57 61.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.15 0.5 . . . . 74.22 111.168 178.644 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.592 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 0.6 OUTLIER -59.55 -39.13 83.0 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.508 -0.769 . . . . 75.23 111.379 174.275 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 21.5 tp60 -147.91 79.68 9.16 Favored Pre-proline 0 C--N 1.326 -0.454 0 N-CA-C 109.827 -0.434 . . . . 33.55 109.827 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -73.8 -8.0 20.81 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.381 2.054 . . . . 75.23 111.52 179.553 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.05 3.06 36.24 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.118 -0.946 . . . . 62.43 110.084 178.382 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -139.37 140.06 37.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.043 -0.526 . . . . 72.31 111.022 -174.291 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.809 HD23 HD11 ' A' ' 58' ' ' ILE . 38.1 mt -82.08 113.1 19.72 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 108.581 -0.896 . . . . 75.03 108.581 171.807 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.508 HG13 ' HB2' ' A' ' 59' ' ' ARG . 50.1 mm -65.34 122.76 81.78 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 116.271 -0.422 . . . . 73.11 110.964 -175.566 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.496 ' O ' HG23 ' A' ' 72' ' ' ILE . 72.8 Cg_endo -73.27 175.12 11.0 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 123.106 2.537 . . . . 72.1 113.014 -177.695 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' GLN . . . . . 0.726 ' HA ' HG12 ' A' ' 72' ' ' ILE . 6.7 tt0 -74.65 -29.5 61.28 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.693 -0.685 . . . . 53.02 112.323 -168.07 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 33.6 p90 -74.45 -16.23 60.87 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.598 -0.441 . . . . 74.51 110.23 178.53 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.476 ' HA ' ' HB2' ' A' ' 74' ' ' SER . 8.3 mm-40 -100.0 -29.29 12.63 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.727 -0.67 . . . . 72.4 111.615 -178.86 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.726 HG12 ' HA ' ' A' ' 69' ' ' GLN . 42.0 pt -68.22 -29.44 44.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.148 0.499 . . . . 73.14 110.595 177.188 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 48.5 m-85 -118.82 38.69 3.71 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.735 -0.666 . . . . 70.2 109.267 174.27 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.476 ' HB2' ' HA ' ' A' ' 71' ' ' GLU . 6.1 t -62.49 -36.38 82.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.35 -0.841 . . . . 74.24 110.461 -178.758 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' TRP . . . . . 0.844 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 6.1 p-90 . . . . . 0 C--N 1.326 -0.443 0 CA-C-N 115.93 -0.577 . . . . 65.32 110.948 177.289 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.282 0 N-CA-C 112.22 -0.352 . . . . 64.05 112.22 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -132.14 157.22 44.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.717 0.294 . . . . 74.23 110.776 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -87.41 37.58 0.79 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.081 0.467 . . . . 74.43 110.968 -178.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -97.16 151.24 20.0 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.77 -0.65 . . . . 70.43 109.977 -179.453 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -144.98 48.94 1.29 Allowed 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.246 0.546 . . . . 51.12 109.968 -179.47 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -65.94 127.01 92.85 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.653 -0.703 . . . . 70.24 111.877 -177.863 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -91.41 -178.84 1.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.487 0 C-N-CA 123.237 2.624 . . . . 63.23 112.355 177.493 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 35.0 m -81.77 83.43 7.14 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.605 0.717 . . . . 74.44 109.128 174.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 109' ' ' GLY . . . . . 0.403 ' O ' ' HD3' ' B' ' 111' ' ' PRO . . . 140.07 78.08 0.06 OUTLIER Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 109.965 -1.254 . . . . 42.13 109.965 -172.108 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -109.72 94.77 17.71 Favored Pre-proline 0 C--N 1.322 -0.6 0 N-CA-C 109.693 -0.484 . . . . 64.32 109.693 -172.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.57 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 54.9 Cg_endo -77.36 79.01 3.29 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 C-N-CA 121.538 1.492 . . . . 72.23 111.031 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -100.24 156.37 17.26 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 114.747 -1.115 . . . . 74.4 109.184 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.716 HG21 ' HB3' ' B' ' 124' ' ' GLN . 8.8 p -112.94 127.76 70.02 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.812 0 CA-C-O 121.72 0.771 . . . . 74.11 111.738 -175.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 114' ' ' THR . . . . . 0.54 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.3 m -92.01 106.94 18.85 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.022 -0.99 . . . . 75.13 109.529 175.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.8 mt -90.8 115.5 30.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 120.699 0.285 . . . . 54.34 111.274 -175.234 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 41.4 mtm180 -115.39 165.81 12.56 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.178 -0.465 . . . . 72.14 110.712 175.126 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 96.8 mt-30 -129.44 108.79 10.55 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.197 -0.456 . . . . 74.3 110.18 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 118' ' ' GLU . . . . . 0.463 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 45.8 mm-40 -108.4 89.88 3.13 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.551 -0.536 . . . . 55.41 109.551 -178.441 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 83.68 -102.95 2.5 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 110.929 -0.869 . . . . 72.13 110.929 -172.75 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.58 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 30.8 m-20 -117.73 -18.17 9.69 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.756 0.312 . . . . 74.23 110.784 175.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.463 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 23.4 pttm -78.36 126.73 31.19 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.257 0.551 . . . . 71.11 110.861 -175.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 122' ' ' THR . . . . . 0.585 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 22.8 m -84.72 106.34 16.19 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.502 -0.772 . . . . 72.43 109.468 178.085 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 123' ' ' ILE . . . . . 0.449 HG12 HG13 ' B' ' 137' ' ' VAL . 28.4 mt -101.42 110.37 28.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 121.374 0.607 . . . . 74.32 110.631 -174.685 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.716 ' HB3' HG21 ' B' ' 113' ' ' VAL . 69.0 mt-30 -102.29 111.54 23.87 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.354 -0.839 . . . . 73.15 111.144 -175.511 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 125' ' ' GLU . . . . . 0.541 ' HB3' HD13 ' B' ' 132' ' ' LEU . 43.0 mt-10 -89.79 107.84 19.34 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.13 -0.486 . . . . 61.34 110.948 179.764 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 126' ' ' TYR . . . . . 0.457 ' HE1' ' HB2' ' B' ' 136' ' ' LYS . 58.3 m-85 -84.44 110.9 19.0 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.767 0.318 . . . . 74.3 110.338 177.553 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 69.6 mtt180 -123.42 116.13 22.73 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.844 0.354 . . . . 72.42 110.31 -178.803 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.57 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.4 p -82.83 -45.71 19.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.065 -0.516 . . . . 61.53 111.904 -177.434 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -158.99 74.08 0.63 Allowed 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 120.742 -0.383 . . . . 74.24 110.319 -174.243 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 64.2 23.81 68.36 Favored Glycine 0 C--N 1.33 0.232 0 C-N-CA 121.028 -0.606 . . . . 41.24 112.065 -178.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -145.91 124.93 12.78 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.876 -0.416 . . . . 70.04 109.876 -179.236 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.541 HD13 ' HB3' ' B' ' 125' ' ' GLU . 50.0 tp -83.06 113.01 20.31 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.791 -0.64 . . . . 72.1 109.569 175.781 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -103.12 -13.73 16.69 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.32 -0.552 . . . . 62.0 111.728 -175.793 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -164.94 139.81 5.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.087 0.47 . . . . 74.5 111.397 -175.716 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.405 ' CG1' HD21 ' B' ' 132' ' ' LEU . 63.6 mt -118.02 117.85 56.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.693 -0.685 . . . . 63.54 109.846 175.882 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.618 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 81.3 tttt -93.62 103.92 16.06 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.184 -0.673 . . . . 63.33 109.184 175.481 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.65 HG12 ' HD3' ' B' ' 139' ' ' PRO . 3.5 t -89.12 126.51 42.12 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 N-CA-C 108.785 -0.82 . . . . 62.43 108.785 177.299 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.585 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.5 t -113.67 74.47 2.38 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 109.543 -0.54 . . . . 61.42 109.543 171.647 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.65 ' HD3' HG12 ' B' ' 137' ' ' VAL . 43.3 Cg_endo -77.17 130.01 10.85 Favored 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.105 1.87 . . . . 75.0 111.892 175.815 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 140' ' ' LYS . . . . . 0.58 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 59.2 mtpt -58.36 -38.58 77.53 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.661 -0.699 . . . . 62.14 109.776 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 70.3 m-70 -111.81 90.32 3.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.282 -0.872 . . . . 71.02 109.385 175.163 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 142' ' ' GLY . . . . . 0.418 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 151.98 -22.71 0.89 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.54 -0.838 . . . . 53.11 112.704 -178.587 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 143' ' ' LYS . . . . . 0.418 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 95.2 mttt 76.48 144.65 0.1 Allowed Pre-proline 0 N--CA 1.472 0.638 0 C-N-CA 123.419 0.688 . . . . 75.34 111.258 179.177 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.613 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 55.5 Cg_endo -70.57 139.05 36.56 Favored 'Trans proline' 0 N--CA 1.463 -0.285 0 C-N-CA 122.865 2.376 . . . . 74.43 112.983 -177.059 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 45.4 p90 -152.39 160.03 43.34 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.895 -0.593 . . . . 75.32 110.322 179.114 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.666 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 96.5 m-85 -100.59 133.29 45.26 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.192 -0.458 . . . . 71.14 109.959 177.786 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.502 ' HG ' ' HB3' ' B' ' 157' ' ' PHE . 14.1 tp -115.46 100.84 8.37 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.386 -0.598 . . . . 72.2 109.386 175.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 49.1 t -92.55 140.56 16.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 116.061 -0.518 . . . . 72.52 111.347 -173.185 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -80.37 116.37 20.4 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.549 -0.296 . . . . 63.53 110.261 177.376 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.56 157.55 32.04 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-N 116.218 -0.447 . . . . 71.32 111.201 -179.423 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 151' ' ' ASP . . . . . 0.539 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 3.8 p-10 -57.45 143.48 40.28 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.96 -0.564 . . . . 74.33 110.855 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.43 -33.73 4.03 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.773 -0.727 . . . . 75.11 111.373 -175.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 50.8 m 57.3 33.17 22.91 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 123.008 0.523 . . . . 54.12 111.919 177.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -53.81 -68.77 0.15 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 115.712 -0.676 . . . . 72.41 111.145 -178.707 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . -173.43 30.58 0.1 OUTLIER Glycine 0 CA--C 1.505 -0.579 0 C-N-CA 120.338 -0.934 . . . . 73.03 112.456 178.601 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 79.5 m-20 -133.32 145.83 50.78 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.784 0.326 . . . . 52.34 110.799 -177.166 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 157' ' ' PHE . . . . . 0.502 ' HB3' ' HG ' ' B' ' 147' ' ' LEU . 32.6 m-85 -118.34 157.03 27.87 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.875 -0.602 . . . . 73.33 110.034 176.201 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.1 mm -113.91 122.66 68.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 109.676 -0.49 . . . . 74.43 109.676 178.499 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 159' ' ' ARG . . . . . . . . . . . . . 44.8 ttp180 -86.36 135.92 33.33 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.028 -0.36 . . . . 73.24 110.028 -178.386 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 160' ' ' SER . . . . . 0.666 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 23.5 p -56.97 -34.78 68.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.064 0.459 . . . . 65.22 111.118 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -69.39 -37.93 77.75 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.448 -0.796 . . . . 70.31 111.346 177.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 8.6 tp60 -134.03 83.6 45.35 Favored Pre-proline 0 C--N 1.324 -0.527 0 C-N-CA 121.04 -0.264 . . . . 74.51 110.715 -176.297 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -77.59 0.27 9.96 Favored 'Trans proline' 0 C--O 1.234 0.282 0 C-N-CA 122.577 2.184 . . . . 60.13 111.616 177.15 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -79.19 -33.31 43.99 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.178 -0.919 . . . . 43.13 110.768 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -116.64 138.13 51.67 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.857 -0.61 . . . . 70.34 111.173 -172.528 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.5 mp -85.27 121.31 27.83 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 108.795 -0.817 . . . . 75.01 108.795 175.083 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 50.3 mm -71.24 117.7 59.16 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 116.129 -0.487 . . . . 74.42 109.778 -177.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.521 ' O ' HG23 ' B' ' 172' ' ' ILE . 59.6 Cg_endo -70.39 173.61 11.28 Favored 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 122.843 2.362 . . . . 73.52 113.008 -175.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 169' ' ' GLN . . . . . 0.449 ' HA ' HG12 ' B' ' 172' ' ' ILE . 5.4 tt0 -74.95 -17.66 60.51 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.524 -0.762 . . . . 65.35 112.224 -168.156 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 42.4 p90 -90.24 -10.1 45.55 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.122 0.487 . . . . 74.31 110.013 176.374 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.579 ' O ' ' HB2' ' B' ' 174' ' ' SER . 19.6 mm-40 -109.42 -12.63 14.7 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.736 -0.665 . . . . 70.44 111.708 -178.282 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.521 HG23 ' O ' ' B' ' 168' ' ' PRO . 26.1 pt -72.7 -12.35 15.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.254 0.549 . . . . 71.42 110.435 176.177 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -115.9 32.76 5.89 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.442 -0.799 . . . . 62.14 109.148 175.094 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 174' ' ' SER . . . . . 0.579 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 3.0 t -66.97 -25.22 66.22 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 114.915 -1.039 . . . . 72.51 110.575 -177.657 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 7.1 p-90 . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.295 -0.86 . . . . 75.23 110.788 -179.936 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.683 0 N-CA-C 111.987 -0.445 . . . . 64.02 111.987 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.9 112.89 20.97 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.036 -0.357 . . . . 73.12 110.036 179.08 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 60.97 79.85 0.24 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.679 -0.691 . . . . 75.24 111.019 -177.68 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -104.06 -162.68 0.91 Allowed 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 108.615 -0.883 . . . . 70.13 108.615 178.804 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -138.57 -30.07 0.78 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 121.039 0.447 . . . . 73.12 111.031 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -171.0 97.12 0.42 Allowed Pre-proline 0 C--N 1.316 -0.869 0 CA-C-N 115.416 -0.811 . . . . 32.31 111.203 -177.081 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -89.2 97.63 0.34 Allowed 'Trans proline' 0 N--CA 1.449 -1.115 0 C-N-CA 122.812 2.341 . . . . 62.31 111.361 175.285 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.7 p -84.17 94.2 8.33 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.269 0.557 . . . . 72.43 110.513 178.11 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 136.63 106.28 0.8 Allowed Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 111.12 -0.792 . . . . 53.33 111.12 -174.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -124.3 97.29 40.29 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-O 121.357 0.599 . . . . 44.22 110.113 -175.301 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.599 ' HA ' ' O ' ' A' ' 27' ' ' ARG . 9.9 Cg_endo -85.17 93.97 0.66 Allowed 'Trans proline' 0 N--CA 1.444 -1.421 0 C-N-CA 122.867 2.378 . . . . 71.24 111.817 -178.102 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -116.72 153.96 31.45 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.952 -1.022 . . . . 61.14 109.373 -179.276 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.503 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 13.4 p -119.42 130.35 74.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.497 0.665 . . . . 74.42 111.639 -177.782 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.528 ' O ' ' HA ' ' A' ' 24' ' ' GLN . 9.3 m -90.68 111.85 23.36 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.369 -0.832 . . . . 71.31 109.693 176.372 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.429 HG12 ' HG2' ' A' ' 24' ' ' GLN . 60.9 mt -106.74 107.33 22.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.791 0.329 . . . . 63.54 110.865 -176.23 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -125.51 166.02 17.41 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.178 -0.465 . . . . 74.21 110.594 178.252 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -118.52 108.63 15.22 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.768 0.318 . . . . 72.53 110.761 -179.322 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.453 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 25.7 mm-40 -108.42 99.54 8.92 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.162 -0.472 . . . . 72.44 109.97 178.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 71.09 -114.27 5.15 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.786 -0.721 . . . . 42.4 112.298 -179.611 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ASP . . . . . 0.409 ' HB3' ' HD2' ' A' ' 40' ' ' LYS . 13.6 m-20 -106.43 13.33 28.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.771 0.32 . . . . 61.32 110.476 -178.735 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.453 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 14.2 ptmt -133.29 123.18 25.03 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.464 0.649 . . . . 74.21 111.949 -176.049 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.441 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 25.6 m -83.07 115.31 21.81 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.36 -0.836 . . . . 75.25 109.675 176.517 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 68.3 mt -100.77 120.43 50.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 120.716 0.293 . . . . 53.13 110.65 -175.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLN . . . . . 0.528 ' HA ' ' O ' ' A' ' 14' ' ' THR . 63.5 mt-30 -112.05 111.77 22.92 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.102 -0.499 . . . . 54.53 110.723 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -90.08 109.59 20.63 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.222 -0.444 . . . . 75.24 110.312 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 73.4 m-85 -87.68 110.55 20.5 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.763 0.315 . . . . 74.41 110.374 177.854 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ARG . . . . . 0.599 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 65.5 mtt180 -116.91 139.91 50.08 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.508 -0.553 . . . . 71.35 109.508 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.581 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 14.2 p -112.83 -11.96 11.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.509 0.671 . . . . 54.13 111.002 -177.641 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -166.77 38.4 0.04 OUTLIER 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 108.757 -0.831 . . . . 75.42 108.757 -177.918 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 85.17 -28.73 4.53 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.308 -0.86 . . . . 72.22 111.824 -174.926 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.418 ' CD2' HG21 ' B' ' 128' ' ' VAL . 15.4 t80 -88.24 125.85 34.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.106 0.479 . . . . 71.42 110.29 -177.055 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.662 HD11 HG13 ' A' ' 35' ' ' ILE . 3.3 tm? -68.24 134.27 50.15 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.201 -0.909 . . . . 74.21 110.141 178.74 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' TYR . . . . . 0.504 ' CE1' ' HB ' ' A' ' 28' ' ' VAL . 53.3 p90 -128.55 -24.56 3.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.594 -0.276 . . . . 70.22 111.584 176.275 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -149.54 139.82 22.26 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.815 0.34 . . . . 33.32 110.895 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.662 HG13 HD11 ' A' ' 32' ' ' LEU . 78.4 mt -122.72 122.35 65.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 116.17 -0.468 . . . . 70.44 110.239 178.07 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.512 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.4 tttt -101.18 102.05 12.89 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.406 -0.591 . . . . 70.14 109.406 174.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.572 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.7 p -99.39 124.44 52.71 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.98 0 CA-C-O 121.163 0.506 . . . . 64.35 110.005 176.485 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.633 HG22 ' HB3' ' A' ' 44' ' ' PRO . 40.0 t -106.91 85.01 1.72 Allowed Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 115.096 -0.956 . . . . 71.12 109.873 179.199 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.572 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 85.4 Cg_endo -91.08 144.01 3.33 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 122.762 2.308 . . . . 64.34 112.41 179.206 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' LYS . . . . . 0.409 ' HD2' ' HB3' ' A' ' 20' ' ' ASP . 97.0 mttt -60.46 -27.02 67.21 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.186 0.517 . . . . 71.51 110.128 173.784 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 6.5 m-70 -118.99 85.4 2.36 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.568 -0.742 . . . . 74.43 109.947 -174.203 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 139.15 -18.76 3.1 Favored Glycine 0 N--CA 1.449 -0.444 0 CA-C-N 115.876 -0.602 . . . . 71.01 111.982 -176.373 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 42.5 mtpt 69.4 150.86 0.13 Allowed Pre-proline 0 N--CA 1.469 0.48 0 C-N-CA 123.727 0.811 . . . . 61.32 112.235 -179.035 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.633 ' HB3' HG22 ' A' ' 38' ' ' VAL . 16.0 Cg_endo -59.7 123.64 13.71 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.878 2.385 . . . . 74.15 112.474 -179.647 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' TYR . . . . . 0.523 ' CE1' HG13 ' A' ' 37' ' ' VAL . 16.4 p90 -142.28 151.18 41.77 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.865 -0.607 . . . . 74.14 110.258 179.551 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -90.74 125.0 35.55 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.17 -0.468 . . . . 72.3 109.981 176.085 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.406 HD11 HG13 ' A' ' 67' ' ' ILE . 18.9 tp -103.34 100.91 10.81 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 108.42 -0.956 . . . . 73.4 108.42 174.502 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.3 t -90.75 132.27 35.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.979 -0.555 . . . . 70.12 111.029 -173.675 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -86.04 121.16 28.26 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.069 -0.715 . . . . 73.52 109.069 178.84 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.11 174.78 9.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.924 0.392 . . . . 44.02 111.574 -173.598 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.585 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 7.0 p-10 -68.94 135.66 51.34 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.301 -0.409 . . . . 75.11 110.405 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.439 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 94.54 146.05 19.66 Favored Glycine 0 N--CA 1.433 -1.562 0 C-N-CA 120.422 -0.895 . . . . 45.4 112.042 179.067 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 27.8 t -80.57 28.55 0.33 Allowed 'General case' 0 C--N 1.312 -1.05 0 CA-C-O 121.436 0.636 . . . . 71.23 109.866 175.468 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.439 ' H ' ' C ' ' A' ' 52' ' ' GLY . 30.0 t70 -63.89 -32.43 73.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.159 -0.928 . . . . 64.15 111.26 -177.629 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.86 37.49 4.42 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.41 -0.9 . . . . 63.32 113.138 177.426 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -126.06 139.53 53.33 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.05 0.452 . . . . 74.11 110.052 176.429 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -117.47 155.16 30.18 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.711 -0.677 . . . . 62.24 109.864 179.207 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 44.9 mm -113.86 116.59 53.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.137 -0.483 . . . . 64.12 109.7 177.341 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ARG . . . . . 0.519 ' HB2' HD11 ' A' ' 67' ' ' ILE . 55.5 ttt180 -83.82 124.06 30.54 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.121 -0.49 . . . . 75.24 109.846 -178.791 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 30.9 t -63.71 -8.3 9.97 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.342 -0.39 . . . . 61.13 111.615 -177.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.487 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 15.6 t70 -70.03 -36.0 74.72 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.231 0.538 . . . . 71.53 109.701 175.578 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 61.6 tt0 -159.08 88.87 2.1 Favored Pre-proline 0 N--CA 1.451 -0.383 0 CA-C-N 115.515 -0.766 . . . . 54.3 109.589 -177.492 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.453 ' HG3' ' OG ' ' B' ' 160' ' ' SER . 35.7 Cg_exo -58.98 -16.42 32.36 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 123.335 2.69 . . . . 64.42 112.699 178.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -66.62 -22.43 66.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.899 -0.591 . . . . 70.35 111.255 179.454 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.16 141.12 48.56 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 121.404 0.621 . . . . 53.4 111.892 -177.077 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.7 mp -88.54 141.43 28.53 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.689 -1.142 . . . . 71.33 109.306 174.365 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ILE . . . . . 0.755 HG23 ' HB3' ' A' ' 71' ' ' GLU . 25.2 mm -83.41 121.87 76.84 Favored Pre-proline 0 C--N 1.317 -0.818 0 CA-C-N 116.167 -0.47 . . . . 74.44 111.709 -176.77 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.51 ' O ' HG23 ' A' ' 72' ' ' ILE . 68.2 Cg_endo -74.05 179.45 5.74 Favored 'Trans proline' 0 C--O 1.233 0.264 0 C-N-CA 123.211 2.607 . . . . 75.1 112.488 178.631 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' GLN . . . . . 0.719 ' HA ' HG12 ' A' ' 72' ' ' ILE . 33.2 tt0 -71.99 -33.11 67.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.171 -0.468 . . . . 75.41 111.701 -168.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 7.2 p90 -69.23 -16.97 63.72 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.411 -0.516 . . . . 75.23 110.799 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.755 ' HB3' HG23 ' A' ' 67' ' ' ILE . 2.6 mm-40 -103.44 -20.22 14.13 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.329 -0.396 . . . . 63.22 111.233 -178.882 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.719 HG12 ' HA ' ' A' ' 69' ' ' GLN . 42.6 pt -75.61 -24.17 16.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 121.162 0.506 . . . . 72.1 109.922 174.752 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -103.69 39.21 1.65 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.467 -0.788 . . . . 53.24 109.371 173.353 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.506 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 11.5 t -71.17 -20.03 62.34 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.293 -0.867 . . . . 64.12 110.94 -177.141 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' TRP . . . . . 0.575 ' HZ2' HD13 ' A' ' 35' ' ' ILE . 69.6 p-90 . . . . . 0 C--O 1.235 0.312 0 CA-C-O 120.861 0.362 . . . . 73.45 110.835 177.6 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.508 0 N-CA-C 111.854 -0.498 . . . . 74.15 111.854 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -84.59 159.42 20.64 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 110.544 -0.169 . . . . 73.11 110.544 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 64.94 89.16 0.1 Allowed 'General case' 0 C--O 1.234 0.263 0 O-C-N 123.859 0.725 . . . . 75.42 111.309 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -123.02 169.53 11.08 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.448 -0.796 . . . . 62.24 109.899 178.364 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -97.26 -47.48 5.72 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.827 0.822 . . . . 73.54 109.844 178.198 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -161.35 144.1 9.28 Favored Pre-proline 0 C--N 1.309 -1.155 0 CA-C-N 114.125 -1.398 . . . . 73.31 109.609 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -70.97 95.74 0.67 Allowed 'Trans proline' 0 N--CA 1.463 -0.295 0 C-N-CA 122.147 1.898 . . . . 52.54 111.892 176.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 8.6 p -75.57 100.58 4.62 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.26 0.552 . . . . 74.43 110.594 179.06 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 92.25 116.29 2.25 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 111.063 -0.815 . . . . 61.21 111.063 -174.708 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -119.87 93.33 47.62 Favored Pre-proline 0 C--N 1.319 -0.739 0 CA-C-O 121.14 0.495 . . . . 71.41 110.58 -175.137 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 111' ' ' PRO . . . . . 0.684 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 55.7 Cg_endo -77.44 68.45 7.52 Favored 'Trans proline' 0 N--CA 1.449 -1.115 0 C-N-CA 121.943 1.762 . . . . 74.32 110.891 176.086 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -91.05 157.46 17.24 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 114.411 -1.268 . . . . 53.24 109.553 -178.723 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 113' ' ' VAL . . . . . 0.679 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 12.4 p -122.78 127.25 74.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-O 121.477 0.656 . . . . 73.25 111.19 -178.419 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 114' ' ' THR . . . . . 0.442 ' O ' ' HA ' ' B' ' 124' ' ' GLN . 13.7 m -84.61 111.26 19.38 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.435 -0.802 . . . . 72.34 109.439 178.749 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.6 mt -99.09 116.45 42.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 120.955 0.407 . . . . 75.14 111.527 -172.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 45.7 mtt180 -126.87 170.64 12.01 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.947 -0.57 . . . . 74.21 110.606 175.501 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 69.7 mt-30 -132.54 98.23 4.3 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.18 0.514 . . . . 61.02 110.204 176.536 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 118' ' ' GLU . . . . . 0.591 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 20.9 mm-40 -96.66 100.8 12.34 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.657 -0.701 . . . . 53.14 109.317 -178.433 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 73.37 -117.89 6.03 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.434 -0.889 . . . . 74.42 111.36 -175.44 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 120' ' ' ASP . . . . . 0.507 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 5.2 m-20 -104.26 11.58 34.7 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.94 0.37 . . . . 71.04 110.493 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 121' ' ' LYS . . . . . 0.591 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 10.1 ptmt -124.96 121.59 34.89 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.567 0.699 . . . . 62.24 111.73 -175.456 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 122' ' ' THR . . . . . 0.842 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 35.9 m -76.96 104.15 7.29 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.243 -0.89 . . . . 63.1 109.798 175.387 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 46.6 mt -94.01 119.89 42.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.218 0.532 . . . . 72.13 110.301 -179.311 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 124' ' ' GLN . . . . . 0.679 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 77.7 mt-30 -115.23 113.06 23.4 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.322 -0.854 . . . . 63.4 110.914 -177.043 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -88.16 111.98 22.21 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.173 -0.467 . . . . 72.13 110.678 -179.505 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 126' ' ' TYR . . . . . 0.585 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 29.1 m-85 -88.65 112.73 23.44 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.938 0.399 . . . . 73.43 111.07 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 127' ' ' ARG . . . . . 0.519 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 89.6 mtm180 -132.22 128.67 38.42 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.071 -0.513 . . . . 73.04 110.109 -179.218 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 128' ' ' VAL . . . . . 0.684 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 9.7 p -99.86 -27.84 3.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.071 0.462 . . . . 61.51 111.862 -174.367 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -152.74 47.61 0.72 Allowed 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.574 -0.528 . . . . 71.43 109.574 -179.032 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.19 -21.33 12.69 Favored Glycine 0 CA--C 1.518 0.235 0 CA-C-N 115.567 -0.742 . . . . 63.52 112.731 -178.447 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 131' ' ' PHE . . . . . 0.46 ' HD2' HG21 ' A' ' 28' ' ' VAL . 26.5 t80 -98.22 130.12 44.95 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.712 0.291 . . . . 72.41 110.374 -176.584 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 132' ' ' LEU . . . . . 0.519 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 3.1 tm? -71.0 132.55 45.32 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.812 -0.631 . . . . 74.5 109.967 179.214 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 133' ' ' TYR . . . . . 0.407 ' N ' HD13 ' B' ' 132' ' ' LEU . 46.1 p90 -129.32 -15.55 4.1 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.582 -0.447 . . . . 75.41 112.04 177.715 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.31 149.97 17.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.719 0.295 . . . . 60.3 111.079 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 135' ' ' ILE . . . . . 0.415 HG13 HD11 ' B' ' 132' ' ' LEU . 67.5 mt -130.69 125.42 58.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.963 -0.384 . . . . 62.2 109.963 176.863 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 136' ' ' LYS . . . . . 0.627 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 85.5 tttt -104.11 114.55 28.87 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.107 -0.331 . . . . 72.42 110.107 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 137' ' ' VAL . . . . . 0.589 HG12 ' HD3' ' B' ' 139' ' ' PRO . 3.4 t -96.49 130.94 44.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.126 -0.694 . . . . 55.1 109.126 175.577 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 138' ' ' VAL . . . . . 0.842 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 24.1 t -115.65 74.65 4.77 Favored Pre-proline 0 C--N 1.318 -0.798 0 N-CA-C 109.875 -0.417 . . . . 62.53 109.875 171.723 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 139' ' ' PRO . . . . . 0.589 ' HD3' HG12 ' B' ' 137' ' ' VAL . 37.1 Cg_endo -74.22 131.89 15.84 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.186 1.924 . . . . 54.01 112.276 176.445 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 140' ' ' LYS . . . . . 0.507 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 59.2 mtpt -60.63 -19.49 58.18 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.399 -0.818 . . . . 72.55 111.111 178.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 80.8 m-70 -130.72 105.4 7.78 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.703 -0.68 . . . . 63.14 109.379 178.492 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 142' ' ' GLY . . . . . 0.425 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 125.36 -11.02 7.65 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.75 -0.738 . . . . 61.14 112.432 -177.142 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 143' ' ' LYS . . . . . 0.463 ' HB3' ' HE2' ' B' ' 143' ' ' LYS . 45.7 mtpt 72.77 150.84 0.14 Allowed Pre-proline 0 N--CA 1.468 0.433 0 C-N-CA 123.603 0.761 . . . . 74.32 112.353 179.105 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 144' ' ' PRO . . . . . 0.58 ' HB3' HG13 ' B' ' 138' ' ' VAL . 44.3 Cg_endo -68.76 137.75 39.34 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.795 2.33 . . . . 60.31 112.552 178.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -143.75 147.99 34.99 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 120.954 0.407 . . . . 73.3 110.638 179.114 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 146' ' ' PHE . . . . . 0.408 ' HB2' ' HB2' ' B' ' 160' ' ' SER . 69.6 m-85 -90.47 129.27 36.66 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.88 -0.6 . . . . 74.44 110.032 175.506 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 147' ' ' LEU . . . . . 0.451 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 25.5 tp -108.59 93.27 4.43 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.621 -0.881 . . . . 74.41 108.621 173.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 40.3 t -83.53 135.91 23.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.602 -0.727 . . . . 74.23 110.499 -174.395 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 3.0 tmm_? -89.25 120.83 30.96 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 108.573 -0.899 . . . . 72.31 108.573 178.616 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -76.16 -173.94 2.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.978 0.418 . . . . 62.34 111.655 -173.123 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -75.33 146.26 41.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.369 -0.378 . . . . 71.4 110.288 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 91.63 136.8 7.26 Favored Glycine 0 N--CA 1.44 -1.076 0 C-N-CA 120.571 -0.823 . . . . 50.31 111.823 -177.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 18.4 t -87.22 35.67 0.71 Allowed 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.226 0.536 . . . . 52.12 110.212 178.425 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -74.68 -47.49 31.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.513 -0.767 . . . . 64.24 111.185 -178.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 123.08 36.6 0.65 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.868 -0.682 . . . . 24.11 111.97 -176.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 156' ' ' ASN . . . . . 0.401 ' OD1' ' HB3' ' B' ' 166' ' ' LEU . 6.8 t30 -119.73 126.75 51.84 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.974 0.416 . . . . 75.42 110.596 -178.322 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 157' ' ' PHE . . . . . 0.451 ' CD2' ' HG ' ' B' ' 147' ' ' LEU . 13.4 m-85 -109.97 164.0 13.02 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.196 -0.456 . . . . 71.41 110.487 179.541 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.7 mm -121.79 109.22 24.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.789 -0.819 . . . . 73.33 108.789 173.128 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 159' ' ' ARG . . . . . 0.543 ' HE ' ' HB3' ' B' ' 161' ' ' ASP . 43.3 ttp180 -75.07 125.94 29.98 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 109.027 -0.731 . . . . 72.15 109.027 178.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 160' ' ' SER . . . . . 0.453 ' OG ' ' HG3' ' A' ' 63' ' ' PRO . 23.8 t -58.64 -22.06 55.55 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.187 0.518 . . . . 32.33 110.755 -178.75 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 161' ' ' ASP . . . . . 0.543 ' HB3' ' HE ' ' B' ' 159' ' ' ARG . 1.5 t70 -68.81 -30.24 68.76 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.797 -0.638 . . . . 73.4 111.104 175.547 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 7.1 tp60 -140.95 81.34 16.31 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.271 -0.422 . . . . 71.14 110.409 -174.198 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.41 -8.67 17.36 Favored 'Trans proline' 0 C--N 1.343 0.264 0 C-N-CA 122.498 2.132 . . . . 72.15 112.318 -178.598 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -81.87 -21.52 37.45 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.665 -0.698 . . . . 62.04 110.502 178.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 19.1 ttmm -114.57 134.32 55.13 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.017 -0.538 . . . . 73.21 110.894 -175.006 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 166' ' ' LEU . . . . . 0.401 ' HB3' ' OD1' ' B' ' 156' ' ' ASN . 5.1 mp -82.98 129.31 35.02 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.22 -1.03 . . . . 75.4 108.22 171.449 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 45.2 mm -87.84 110.31 34.05 Favored Pre-proline 0 C--N 1.321 -0.651 0 N-CA-C 110.177 -0.305 . . . . 63.41 110.177 -174.21 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 168' ' ' PRO . . . . . 0.49 ' O ' HG23 ' B' ' 172' ' ' ILE . 42.9 Cg_endo -66.57 172.89 8.59 Favored 'Trans proline' 0 N--CA 1.462 -0.332 0 C-N-CA 122.94 2.426 . . . . 73.24 112.768 -175.595 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 34.8 tt0 -75.44 -5.44 45.01 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.304 -0.862 . . . . 62.24 111.665 -169.097 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -96.04 -13.24 23.87 Favored 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 120.495 -0.482 . . . . 71.53 110.73 176.471 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 171' ' ' GLU . . . . . 0.614 ' O ' ' HB2' ' B' ' 174' ' ' SER . 1.5 mm-40 -107.24 -9.61 16.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.988 0.423 . . . . 72.32 110.817 -178.386 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 172' ' ' ILE . . . . . 0.49 HG23 ' O ' ' B' ' 168' ' ' PRO . 47.9 pt -68.08 -19.15 24.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.423 0.63 . . . . 64.14 110.262 176.365 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -99.45 39.24 1.32 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.293 -0.867 . . . . 71.05 108.823 175.757 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 174' ' ' SER . . . . . 0.614 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 1.7 t -72.84 -15.31 61.62 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.358 -0.837 . . . . 60.42 110.305 -178.375 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 65.4 p-90 . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.817 -0.611 . . . . 71.3 109.371 174.38 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.3 p . . . . . 0 C--O 1.233 0.223 0 CA-C-O 121.525 0.679 . . . . 70.120000000000005 111.333 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 150.45 -76.48 0.24 Allowed Glycine 0 N--CA 1.443 -0.879 0 N-CA-C 110.521 -1.032 . . . . 72.030000000000001 110.521 -175.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 56.35 75.5 0.57 Allowed Pre-proline 0 N--CA 1.469 0.492 0 O-C-N 124.185 0.58 . . . . 70.5 112.473 173.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.619 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 71.6 Cg_endo -87.0 116.53 1.27 Allowed 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.507 2.138 . . . . 72.219999999999999 112.544 177.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -139.21 167.21 22.58 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.485 -0.561 . . . . 64.049999999999997 109.485 176.074 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.542 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 11.3 p -114.46 124.03 70.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.505 0.669 . . . . 64.340000000000003 111.502 -175.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.7 m -89.83 106.14 18.27 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.6 -0.727 . . . . 71.230000000000004 109.249 174.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.481 HG23 ' HG2' ' A' ' 24' ' ' GLN . 57.6 mt -93.89 107.84 19.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 120.908 0.385 . . . . 64.299999999999997 111.0 -175.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.41 HH11 ' HD3' ' A' ' 16' ' ' ARG . 4.8 mtm180 -116.13 174.77 5.87 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.225 -0.443 . . . . 75.109999999999999 110.537 177.114 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -129.98 104.87 7.61 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.782 -0.644 . . . . 62.350000000000001 109.823 175.508 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -97.32 83.56 3.31 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.563 -0.744 . . . . 52.329999999999998 109.338 -177.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.72 -115.17 4.12 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.429 -0.891 . . . . 73.310000000000002 111.413 -176.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.989 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 23.0 m-20 -110.73 24.95 12.31 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.099 0.476 . . . . 72.5 110.267 178.548 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.5 pttm -132.3 118.52 19.56 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 121.297 0.57 . . . . 71.340000000000003 110.782 178.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.433 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 35.8 m -80.06 101.42 8.71 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.421 -0.809 . . . . 54.43 109.374 177.047 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.554 HG12 HG23 ' A' ' 37' ' ' VAL . 16.4 mt -98.53 113.31 32.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.236 0.541 . . . . 72.25 110.388 -174.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.542 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 21.4 mt-30 -96.5 110.18 22.62 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.404 -0.816 . . . . 71.430000000000007 110.552 -178.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 30.0 mt-10 -84.3 103.24 13.32 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.681 -0.691 . . . . 65.400000000000006 110.828 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.426 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 85.2 m-85 -83.4 97.48 8.97 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.521 -0.548 . . . . 62.450000000000003 109.521 174.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 94.0 mtt180 -110.44 129.59 55.74 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.869 -0.605 . . . . 72.409999999999997 109.744 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.88 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.7 p -91.98 -82.7 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 C-N-CA 120.322 -0.551 . . . . 65.150000000000006 109.812 175.182 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.88 ' H ' HG13 ' A' ' 28' ' ' VAL . 5.6 t-20 -123.36 77.7 1.51 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.023 0.439 . . . . 73.5 110.325 -176.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 70.72 20.51 77.46 Favored Glycine 0 N--CA 1.448 -0.528 0 CA-C-N 115.456 -0.793 . . . . 61.450000000000003 113.144 177.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.48 ' CD2' HG21 ' B' ' 128' ' ' VAL . 32.2 t80 -148.12 129.3 14.62 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.125 0.488 . . . . 62.219999999999999 110.42 177.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.969 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -69.51 116.69 10.21 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 114.945 -1.025 . . . . 75.219999999999999 109.174 175.427 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . 0.426 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 36.7 p90 -105.1 -20.49 13.5 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.299 -0.56 . . . . 73.329999999999998 111.562 -178.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -157.43 143.41 17.61 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.947 0.403 . . . . 71.049999999999997 111.13 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.969 HG13 HD11 ' A' ' 32' ' ' LEU . 72.4 mt -120.86 120.25 61.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.171 -0.468 . . . . 61.200000000000003 110.148 175.377 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.417 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 86.6 tttt -103.04 97.78 7.83 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.849 -0.797 . . . . 71.140000000000001 108.849 171.103 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.554 HG23 HG12 ' A' ' 23' ' ' ILE . 2.1 p -100.2 128.61 51.99 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 CA-C-N 116.112 -0.495 . . . . 75.319999999999993 110.18 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.597 HG22 ' HB3' ' A' ' 44' ' ' PRO . 34.7 t -107.93 87.16 3.54 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 115.428 -0.805 . . . . 73.319999999999993 109.646 178.417 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 66.9 Cg_endo -83.48 132.9 6.01 Favored 'Trans proline' 0 N--CA 1.448 -1.171 0 C-N-CA 122.206 1.937 . . . . 73.239999999999995 111.905 178.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.989 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 58.6 mtpt -63.72 -24.0 67.6 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.648 -0.705 . . . . 61.539999999999999 109.93 176.35 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 59.3 m-70 -120.07 85.11 2.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.367 -0.833 . . . . 74.510000000000005 109.671 177.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 145.04 -20.07 1.95 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.286 -0.959 . . . . 74.349999999999994 113.205 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 94.0 mttt 73.42 144.42 0.1 Allowed Pre-proline 0 N--CA 1.474 0.743 0 C-N-CA 123.153 0.581 . . . . 65.319999999999993 111.373 178.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.597 ' HB3' HG22 ' A' ' 38' ' ' VAL . 41.7 Cg_endo -67.8 156.43 65.98 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.803 2.335 . . . . 52.439999999999998 113.361 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.421 ' CE2' ' HD2' ' A' ' 59' ' ' ARG . 6.8 p90 -165.3 167.16 18.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.581 -0.736 . . . . 71.030000000000001 109.516 178.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.543 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 64.4 m-85 -100.24 134.19 43.54 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.871 0.367 . . . . 74.409999999999997 110.591 176.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.429 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 20.2 tp -118.87 102.93 9.16 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.264 -0.643 . . . . 73.140000000000001 109.264 176.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.4 t -96.85 135.17 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.802 0.334 . . . . 72.219999999999999 111.663 -173.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.9 111.13 6.89 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.862 -0.608 . . . . 72.0 109.816 178.521 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.54 168.51 16.14 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.446 -0.343 . . . . 74.340000000000003 110.739 178.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -64.91 137.25 57.64 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.321 -0.4 . . . . 62.539999999999999 110.084 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 87.22 122.3 1.58 Allowed Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.705 -0.76 . . . . 74.129999999999995 111.239 -175.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.5 t -85.51 36.62 0.65 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.207 0.527 . . . . 70.409999999999997 110.277 -175.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -66.04 -48.44 71.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.504 -0.771 . . . . 75.450000000000003 110.753 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 134.46 49.75 0.08 OUTLIER Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.861 -0.685 . . . . 53.009999999999998 111.572 -177.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.831 HD21 ' HB3' ' A' ' 66' ' ' LEU . 41.1 t-20 -136.54 134.27 37.33 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.717 -0.475 . . . . 52.130000000000003 109.717 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.496 ' HD1' HG21 ' A' ' 72' ' ' ILE . 52.5 m-85 -123.53 159.71 28.56 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.139 -0.482 . . . . 74.340000000000003 110.784 -179.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 47.9 mm -117.49 129.96 73.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 109.501 -0.555 . . . . 42.340000000000003 109.501 175.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.946 ' HG3' HG13 ' A' ' 67' ' ' ILE . 18.0 mtm180 -95.79 153.63 17.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.827 0.346 . . . . 71.219999999999999 111.198 -176.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.543 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 59.5 p -71.53 -21.25 61.93 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.788 -0.642 . . . . 71.439999999999998 109.512 172.379 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -60.7 -44.0 97.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 114.833 -1.076 . . . . 73.030000000000001 110.858 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 9.8 tt0 -160.1 98.92 1.45 Allowed Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 115.8 -0.636 . . . . 64.450000000000003 109.908 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -73.03 -6.8 19.62 Favored 'Trans proline' 0 C--O 1.23 0.099 0 C-N-CA 122.777 2.318 . . . . 73.150000000000006 111.659 177.56 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -85.11 1.62 47.09 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.961 -1.018 . . . . 72.230000000000004 110.162 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 62.0 tttp -129.03 135.91 49.58 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.153 -0.476 . . . . 71.530000000000001 110.577 -177.651 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.831 ' HB3' HD21 ' A' ' 56' ' ' ASN . 5.0 mp -90.34 132.18 35.72 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.705 -0.85 . . . . 53.210000000000001 108.705 176.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.946 HG13 ' HG3' ' A' ' 59' ' ' ARG . 45.2 mm -106.15 110.52 64.05 Favored Pre-proline 0 C--N 1.317 -0.81 0 CA-C-O 121.021 0.438 . . . . 65.510000000000005 111.362 -172.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.536 ' O ' HG23 ' A' ' 72' ' ' ILE . 73.0 Cg_endo -76.44 -179.93 5.79 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 123.337 2.691 . . . . 74.040000000000006 112.297 177.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . 1.046 ' HA ' HG12 ' A' ' 72' ' ' ILE . 27.4 mt-30 -71.38 -32.69 68.76 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 113.489 0.922 . . . . 63.439999999999998 113.489 -169.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 25.2 p90 -70.13 -15.9 63.03 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.22 -0.592 . . . . 75.299999999999997 109.961 176.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.655 ' HB3' HG23 ' A' ' 67' ' ' ILE . 3.9 mm-40 -101.16 -30.31 11.63 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.776 -0.647 . . . . 74.200000000000003 111.186 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 1.046 HG12 ' HA ' ' A' ' 69' ' ' GLN . 44.8 pt -72.43 -32.77 43.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 121.099 0.476 . . . . 74.209999999999994 110.163 177.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -101.77 39.94 1.39 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.946 -0.57 . . . . 60.210000000000001 110.125 174.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.3 t -74.76 -16.12 60.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.355 -0.839 . . . . 73.519999999999996 109.762 179.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 8.6 p-90 . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 115.944 -0.571 . . . . 65.329999999999998 110.661 175.449 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 4.3 p . . . . . 0 N--CA 1.452 -0.342 0 CA-C-O 120.796 0.331 . . . . 73.109999999999999 110.473 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 100.43 84.45 1.8 Allowed Glycine 0 CA--C 1.504 -0.651 0 N-CA-C 110.992 -0.843 . . . . 73.400000000000006 110.992 -176.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -118.27 92.6 43.36 Favored Pre-proline 0 C--N 1.315 -0.934 0 CA-C-N 114.959 -0.621 . . . . 72.010000000000005 110.258 -174.401 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.827 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 40.5 Cg_endo -74.08 88.1 1.13 Allowed 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 121.781 1.654 . . . . 72.310000000000002 111.486 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -104.64 147.11 28.01 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.889 -1.05 . . . . 75.409999999999997 109.785 179.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.681 HG21 ' HB3' ' B' ' 124' ' ' GLN . 9.9 p -104.05 127.55 58.16 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-O 121.316 0.579 . . . . 62.520000000000003 111.073 -177.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . 0.67 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.4 m -83.9 102.65 12.55 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.607 -0.724 . . . . 71.010000000000005 109.364 175.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.1 mt -92.77 106.45 17.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.279 -0.419 . . . . 64.129999999999995 110.909 -174.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . 0.454 ' HG2' ' O ' ' B' ' 123' ' ' ILE . 13.3 ptm180 -118.25 171.47 8.1 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.335 -0.617 . . . . 72.109999999999999 109.335 176.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 89.7 mt-30 -139.55 113.49 8.73 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.32 0.581 . . . . 74.430000000000007 110.825 -179.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 17.9 mm-40 -101.26 97.73 8.2 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.335 -0.848 . . . . 71.219999999999999 109.569 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 70.24 -95.67 0.52 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.886 -0.673 . . . . 63.32 111.973 -177.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . 0.781 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 9.7 m-20 -127.54 26.71 5.91 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.849 0.357 . . . . 73.219999999999999 110.538 178.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.536 ' HE3' ' HE3' ' B' ' 175' ' ' TRP . 23.1 pttm -129.3 119.31 23.72 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.233 0.54 . . . . 53.240000000000002 110.88 175.113 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . 0.815 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 28.0 m -80.3 105.28 11.44 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.576 -0.738 . . . . 73.420000000000002 109.53 177.387 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . 0.473 HD11 ' HE2' ' B' ' 121' ' ' LYS . 24.2 mt -96.3 106.38 18.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-O 121.27 0.557 . . . . 75.209999999999994 110.097 -177.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.681 ' HB3' HG21 ' B' ' 113' ' ' VAL . 26.1 mt-30 -97.51 103.87 15.85 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.451 -0.795 . . . . 63.43 110.892 -176.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . 0.67 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 48.3 mt-10 -84.97 102.55 13.25 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.788 -0.642 . . . . 61.420000000000002 111.049 -179.214 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . 0.454 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 39.2 m-85 -78.38 107.09 10.75 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.931 0.396 . . . . 72.140000000000001 110.67 178.115 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 50.2 mtt180 -125.11 125.13 43.27 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.009 -0.542 . . . . 71.319999999999993 109.787 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.827 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 7.3 p -90.05 -25.6 5.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.202 0.525 . . . . 74.420000000000002 111.081 -174.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -165.94 56.35 0.1 Allowed 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.034 -0.728 . . . . 64.319999999999993 109.034 -179.244 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.68 -34.55 4.31 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.284 -0.871 . . . . 64.430000000000007 112.915 -178.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -94.54 133.47 38.13 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.204 0.526 . . . . 62.43 110.856 -173.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.709 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -73.95 125.82 29.08 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.983 -1.008 . . . . 73.150000000000006 110.17 179.289 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . 0.454 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 37.0 p90 -117.18 -16.97 10.35 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.617 -0.433 . . . . 71.25 111.384 177.457 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . 0.433 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -161.79 146.51 12.99 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.668 0.271 . . . . 72.340000000000003 110.87 178.029 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.709 HG13 HD11 ' B' ' 132' ' ' LEU . 71.1 mt -124.95 115.71 45.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 110.149 -0.315 . . . . 45.539999999999999 110.149 176.552 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.542 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.9 tttt -93.57 105.62 17.65 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.226 -0.657 . . . . 74.019999999999996 109.226 175.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.637 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.0 t -88.44 130.95 37.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.279 -0.637 . . . . 72.329999999999998 109.279 178.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.815 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 34.0 t -117.4 72.87 7.39 Favored Pre-proline 0 C--N 1.318 -0.795 0 CA-C-O 121.002 0.43 . . . . 42.43 109.863 173.152 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.597 ' HD3' HG12 ' B' ' 137' ' ' VAL . 44.4 Cg_endo -76.95 126.47 8.74 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.128 1.885 . . . . 71.140000000000001 112.473 176.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . 0.781 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 60.1 mtpt -66.04 -9.4 30.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.192 -0.913 . . . . 74.099999999999994 111.302 -179.046 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -129.92 21.81 5.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.772 -0.649 . . . . 72.099999999999994 110.298 -177.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . 0.497 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . -152.16 -9.21 0.1 OUTLIER Glycine 0 CA--C 1.521 0.416 0 C-N-CA 120.381 -0.914 . . . . 64.109999999999999 113.68 -178.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . 0.497 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 67.7 mmtt 75.69 143.98 0.1 Allowed Pre-proline 0 N--CA 1.472 0.67 0 CA-C-O 121.361 0.601 . . . . 72.450000000000003 112.128 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.637 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 59.8 Cg_endo -72.32 134.75 23.36 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 123.162 2.575 . . . . 72.219999999999999 112.887 -176.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -150.51 151.29 32.46 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.89 -0.595 . . . . 73.310000000000002 110.495 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.611 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 93.0 m-85 -89.51 128.1 35.94 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.31 -0.405 . . . . 73.340000000000003 110.103 176.403 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.561 ' HG ' ' CD1' ' B' ' 157' ' ' PHE . 16.0 tp -107.39 98.35 7.99 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.852 -0.796 . . . . 71.439999999999998 108.852 175.01 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 40.8 t -87.87 133.67 29.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.028 -0.533 . . . . 74.340000000000003 111.464 -172.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.03 108.13 8.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.803 -0.635 . . . . 52.020000000000003 110.476 178.064 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.12 155.72 33.94 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.876 -0.416 . . . . 60.329999999999998 109.876 173.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -62.31 139.21 58.53 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.885 0.374 . . . . 75.140000000000001 110.803 -177.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . 0.425 ' C ' ' H ' ' B' ' 154' ' ' ASP . . . 87.87 137.14 5.43 Favored Glycine 0 N--CA 1.44 -1.07 0 C-N-CA 120.433 -0.889 . . . . 44.43 111.689 -178.614 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 14.4 t -75.61 39.58 0.17 Allowed 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.616 0.722 . . . . 74.420000000000002 110.711 178.048 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . 0.425 ' H ' ' C ' ' B' ' 152' ' ' GLY . 21.3 t70 -67.29 -27.18 66.96 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.527 -0.761 . . . . 73.340000000000003 110.293 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 99.07 18.33 24.86 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.796 -0.716 . . . . 44.219999999999999 112.185 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . 1.011 HD21 ' HB3' ' B' ' 166' ' ' LEU . 18.5 t-20 -101.13 139.15 37.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.841 0.353 . . . . 71.450000000000003 110.375 -178.26 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . 0.561 ' CD1' ' HG ' ' B' ' 147' ' ' LEU . 29.3 m-85 -127.41 156.88 41.37 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.963 -0.562 . . . . 63.450000000000003 110.404 176.449 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.2 mm -122.69 130.19 74.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.563 -0.532 . . . . 72.329999999999998 109.563 177.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.456 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 11.0 mtm180 -93.3 145.35 24.52 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.818 -0.353 . . . . 75.040000000000006 110.076 179.748 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . 0.611 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 54.5 p -70.66 -16.71 62.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.26 -0.427 . . . . 64.209999999999994 111.383 -179.307 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -86.35 -25.13 25.54 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.972 0.415 . . . . 64.549999999999997 110.195 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 9.9 tt0 -151.72 79.54 6.46 Favored Pre-proline 0 N--CA 1.451 -0.411 0 CA-C-N 115.919 -0.582 . . . . 74.109999999999999 110.102 -177.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . 0.472 ' CG ' ' HB2' ' A' ' 60' ' ' SER . 16.1 Cg_exo -69.35 -9.57 26.6 Favored 'Trans proline' 0 C--O 1.233 0.247 0 C-N-CA 122.999 2.466 . . . . 74.439999999999998 111.398 177.081 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -78.01 -13.53 59.84 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.89 -1.05 . . . . 74.409999999999997 110.434 178.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 62.4 tttp -110.51 135.29 51.4 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.008 0.432 . . . . 73.519999999999996 110.938 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . 1.011 ' HB3' HD21 ' B' ' 156' ' ' ASN . 5.0 mp -97.85 126.22 43.11 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.616 -0.883 . . . . 61.130000000000003 108.616 175.104 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 51.2 mm -86.88 115.72 63.48 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-O 120.626 0.251 . . . . 73.120000000000005 110.611 -175.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.589 ' O ' HG23 ' B' ' 172' ' ' ILE . 49.3 Cg_endo -69.09 172.23 12.35 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.923 2.415 . . . . 43.109999999999999 112.172 178.61 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -84.49 8.8 15.28 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.926 -0.579 . . . . 71.030000000000001 111.968 -167.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . 0.54 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 31.8 p90 -108.33 -26.82 10.33 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.6 -0.519 . . . . 73.219999999999999 109.6 170.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.54 ' HG2' ' CD1' ' B' ' 170' ' ' TRP . 5.7 mm-40 -86.22 -13.49 46.74 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.932 -0.576 . . . . 60.100000000000001 111.549 -177.044 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.589 HG23 ' O ' ' B' ' 168' ' ' PRO . 24.0 pt -61.15 -27.9 42.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.568 -0.742 . . . . 72.420000000000002 111.554 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -110.15 44.01 1.29 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.299 0.571 . . . . 74.420000000000002 110.341 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 22.8 t -69.02 -22.96 64.03 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.569 -0.741 . . . . 50.409999999999997 110.446 178.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . 0.536 ' HE3' ' HE3' ' B' ' 121' ' ' LYS . 10.2 p-90 . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.383 -0.817 . . . . 70.439999999999998 110.965 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 24.8 m . . . . . 0 N--CA 1.451 -0.388 0 N-CA-C 109.825 -0.435 . . . . 73.209999999999994 109.825 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.47 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 102.93 52.85 0.93 Allowed Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 109.091 -1.604 . . . . 54.409999999999997 109.091 -168.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -88.51 103.49 5.42 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 114.233 -0.984 . . . . 71.430000000000007 109.722 -168.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.792 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 90.6 Cg_endo -87.18 101.36 0.52 Allowed 'Trans proline' 0 N--CA 1.443 -1.468 0 C-N-CA 122.539 2.16 . . . . 72.450000000000003 112.636 -172.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.13 149.74 20.96 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 116.067 -0.515 . . . . 74.109999999999999 109.98 -178.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.662 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 13.9 p -106.87 127.58 62.34 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.384 0.612 . . . . 75.540000000000006 110.61 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.455 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 25.3 m -91.77 112.33 24.21 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.833 -0.621 . . . . 71.299999999999997 109.44 176.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.409 HG12 ' HG2' ' A' ' 24' ' ' GLN . 62.9 mt -95.1 111.49 25.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.153 0.501 . . . . 53.25 111.54 -174.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 33.7 mmt180 -119.89 156.88 29.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.615 -0.72 . . . . 75.200000000000003 109.798 173.035 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -127.56 107.59 10.06 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.988 0.423 . . . . 74.25 110.795 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.446 ' HB2' ' HE2' ' A' ' 21' ' ' LYS . 54.9 mm-40 -97.57 81.72 2.98 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.012 -0.54 . . . . 73.230000000000004 109.595 178.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.47 -118.74 5.18 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.602 -0.808 . . . . 63.409999999999997 111.637 -176.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.707 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 42.7 m-20 -101.82 16.88 24.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.437 0.16 . . . . 64.099999999999994 110.962 179.048 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.492 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 23.1 pttm -123.49 122.52 38.43 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.269 0.557 . . . . 63.049999999999997 111.545 -179.261 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.403 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 36.2 m -83.73 103.98 13.47 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.273 -0.876 . . . . 61.299999999999997 109.577 174.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 51.0 mt -95.53 109.99 23.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.91 0.386 . . . . 65.340000000000003 110.03 -177.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.662 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 51.6 mt-30 -101.33 119.72 39.18 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.84 -0.618 . . . . 53.210000000000001 111.787 -175.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.455 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 29.0 mt-10 -89.77 99.98 12.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.619 -0.719 . . . . 71.019999999999996 110.36 175.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.441 ' CD2' ' HB3' ' B' ' 151' ' ' ASP . 68.3 m-85 -81.15 101.5 9.69 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.824 -0.436 . . . . 72.5 109.824 175.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.447 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 58.6 mtt180 -115.03 129.28 56.67 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.121 -0.49 . . . . 72.120000000000005 110.013 -179.064 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.792 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 2.4 p -90.0 -57.64 4.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-O 120.915 0.388 . . . . 55.299999999999997 111.541 -177.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.462 ' H ' HG13 ' A' ' 28' ' ' VAL . 5.1 t-20 -127.63 50.5 2.02 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 109.007 -0.738 . . . . 74.209999999999994 109.007 -179.246 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 92.42 -29.74 7.47 Favored Glycine 0 N--CA 1.45 -0.39 0 CA-C-N 115.484 -0.78 . . . . 71.200000000000003 112.292 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.574 ' CD2' HG21 ' B' ' 128' ' ' VAL . 57.1 t80 -92.35 134.43 34.92 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.113 0.482 . . . . 70.010000000000005 110.843 -176.247 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.864 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -72.84 118.81 16.23 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.225 -0.898 . . . . 55.530000000000001 109.965 177.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . 0.421 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 39.5 p90 -104.79 -25.54 12.61 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 120.3 -0.56 . . . . 74.400000000000006 111.263 179.528 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.427 ' O ' ' HB2' ' A' ' 26' ' ' TYR . . . -156.85 137.89 13.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.935 0.397 . . . . 73.219999999999999 111.102 178.622 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.864 HG13 HD11 ' A' ' 32' ' ' LEU . 76.4 mt -110.4 119.79 59.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.093 -0.503 . . . . 75.310000000000002 109.812 175.727 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -102.43 101.28 11.48 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.043 -0.663 . . . . 72.219999999999999 109.535 174.414 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.55 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.4 p -93.48 120.66 43.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 N-CA-C 109.525 -0.546 . . . . 73.420000000000002 109.525 176.361 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.595 HG13 ' HB3' ' A' ' 44' ' ' PRO . 41.7 t -107.34 86.25 2.57 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.365 -0.834 . . . . 73.400000000000006 109.858 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.55 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 62.3 Cg_endo -85.39 132.76 4.43 Favored 'Trans proline' 0 N--CA 1.445 -1.35 0 C-N-CA 122.347 2.031 . . . . 70.200000000000003 112.278 179.066 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.707 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 58.1 mtpt -62.61 -20.34 64.66 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.51 -0.768 . . . . 74.319999999999993 109.604 173.609 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 10.6 m-70 -123.6 96.94 5.16 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.216 -0.902 . . . . 50.149999999999999 108.942 177.067 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.467 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 133.64 -18.77 4.3 Favored Glycine 0 CA--C 1.52 0.373 0 C-N-CA 120.558 -0.83 . . . . 73.239999999999995 113.075 178.323 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 69.6 mmtt 75.31 136.6 0.05 OUTLIER Pre-proline 0 N--CA 1.47 0.556 0 C-N-CA 123.432 0.693 . . . . 73.530000000000001 112.39 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.595 ' HB3' HG13 ' A' ' 38' ' ' VAL . 21.8 Cg_endo -61.03 143.43 99.23 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 123.497 2.798 . . . . 73.219999999999999 113.334 -177.23 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.52 ' CE1' HG13 ' A' ' 37' ' ' VAL . 4.9 p90 -158.48 160.79 37.14 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.818 -0.628 . . . . 74.040000000000006 110.116 178.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.647 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 90.3 m-85 -100.03 142.0 32.1 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.294 -0.412 . . . . 75.430000000000007 111.073 -179.376 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 51.9 mt -113.98 103.05 10.77 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.791 -0.64 . . . . 75.209999999999994 109.367 168.455 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 43.0 t -86.34 133.58 29.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.129 -0.487 . . . . 75.409999999999997 110.287 -178.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . 0.427 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 33.8 tpt85 -76.71 115.54 16.57 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.958 -0.386 . . . . 72.319999999999993 109.958 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.14 154.79 18.68 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 116.094 -0.503 . . . . 71.030000000000001 111.406 -179.037 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -73.15 167.03 21.99 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.626 -0.715 . . . . 71.200000000000003 111.632 -176.022 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.54 10.22 86.08 Favored Glycine 0 N--CA 1.454 -0.131 0 CA-C-N 115.41 -0.814 . . . . 70.120000000000005 112.801 172.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.5 m 61.14 17.83 8.48 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 122.919 0.488 . . . . 72.040000000000006 111.745 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -50.39 -66.02 0.46 Allowed 'General case' 0 N--CA 1.468 0.451 0 O-C-N 123.607 0.567 . . . . 72.019999999999996 111.898 -178.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 137.4 -18.12 3.49 Favored Glycine 0 CA--C 1.508 -0.381 0 C-N-CA 120.591 -0.814 . . . . 71.230000000000004 111.759 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.428 ' ND2' ' HB3' ' A' ' 66' ' ' LEU . 13.8 t-20 -66.04 146.41 54.72 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.141 -0.53 . . . . 64.400000000000006 111.036 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.502 ' HB2' HG22 ' A' ' 72' ' ' ILE . 35.4 m-85 -119.35 141.46 49.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.256 -0.429 . . . . 73.219999999999999 110.082 175.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.404 ' CG2' ' HA ' ' A' ' 63' ' ' PRO . 49.6 mm -108.18 124.36 64.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.993 -0.549 . . . . 74.239999999999995 110.521 -177.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.436 HH11 ' HD3' ' A' ' 59' ' ' ARG . 42.4 mtp-105 -77.7 137.78 38.69 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.92 -0.4 . . . . 74.299999999999997 109.92 177.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.647 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 63.6 p -67.51 -23.95 65.52 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.403 0.62 . . . . 32.229999999999997 110.082 175.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -70.17 -43.08 71.54 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.217 -0.901 . . . . 64.400000000000006 110.569 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.9 mm100 -134.9 76.19 59.77 Favored Pre-proline 0 N--CA 1.441 -0.899 0 CA-C-N 115.95 -0.568 . . . . 63.450000000000003 111.193 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . 0.404 ' HA ' ' CG2' ' A' ' 58' ' ' ILE . 26.5 Cg_exo -63.47 -15.88 51.19 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 123.011 2.474 . . . . 74.420000000000002 112.533 177.019 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -75.24 -20.85 58.99 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.882 -0.599 . . . . 74.439999999999998 110.683 178.765 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 22.7 tptm -109.37 129.03 55.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.192 0.52 . . . . 71.040000000000006 111.495 -176.225 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.428 ' HB3' ' ND2' ' A' ' 56' ' ' ASN . 5.9 mp -89.93 128.8 36.3 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.43 -0.804 . . . . 74.519999999999996 109.965 176.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.405 HG13 ' HG3' ' A' ' 59' ' ' ARG . 50.5 mm -96.31 124.89 49.78 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 116.353 -0.385 . . . . 72.230000000000004 111.597 -173.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.56 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 38.1 Cg_endo -65.22 174.39 5.06 Favored 'Trans proline' 0 C--N 1.348 0.509 0 C-N-CA 123.13 2.553 . . . . 73.319999999999993 112.887 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 16.4 tt0 -83.82 -9.01 59.08 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.804 -0.635 . . . . 75.439999999999998 111.924 -168.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 38.4 p90 -96.88 -5.09 38.96 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.296 0.57 . . . . 72.140000000000001 109.927 175.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.56 ' HB2' ' HG2' ' A' ' 68' ' ' PRO . 4.8 mm-40 -115.63 10.76 15.62 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.42 -0.809 . . . . 75.329999999999998 111.145 -176.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.541 HG23 ' O ' ' A' ' 68' ' ' PRO . 18.9 pt -90.33 -11.25 9.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-O 121.096 0.474 . . . . 75.109999999999999 110.811 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 33.8 p90 -128.5 27.25 5.57 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.954 -0.566 . . . . 74.319999999999993 110.419 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 4.8 m -49.76 -41.33 43.8 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.692 -0.686 . . . . 73.030000000000001 111.041 -179.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . 0.492 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 10.3 p-90 . . . . . 0 C--N 1.326 -0.439 0 CA-C-N 115.787 -0.642 . . . . 75.120000000000005 111.043 175.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 42.7 m . . . . . 0 N--CA 1.454 -0.25 0 CA-C-O 120.994 0.426 . . . . 44.210000000000001 110.238 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 128.14 82.04 0.34 Allowed Glycine 0 N--CA 1.446 -0.65 0 N-CA-C 110.577 -1.009 . . . . 63.439999999999998 110.577 -173.035 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . 0.415 ' HA ' ' HD3' ' B' ' 111' ' ' PRO . 13.4 mt-10 -123.38 114.13 29.04 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-O 121.327 0.584 . . . . 74.299999999999997 109.975 -172.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.765 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 19.2 Cg_endo -89.01 102.29 0.38 Allowed 'Trans proline' 0 N--CA 1.438 -1.766 0 C-N-CA 122.832 2.355 . . . . 70.439999999999998 112.397 -176.241 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -101.57 115.28 30.16 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.188 -0.671 . . . . 71.340000000000003 109.188 178.274 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . . . . . . . . . 7.9 p -72.71 132.64 33.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.625 -0.716 . . . . 61.210000000000001 111.082 -176.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 27.4 m -93.22 99.17 11.78 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.464 -0.789 . . . . 71.239999999999995 109.742 174.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.608 HG23 ' HG2' ' B' ' 124' ' ' GLN . 71.3 mt -96.06 106.03 17.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.838 -0.619 . . . . 72.340000000000003 110.286 -177.252 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 39.1 mmt180 -118.75 149.6 41.19 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.192 0.52 . . . . 72.299999999999997 110.485 178.279 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -100.6 113.64 26.64 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-O 121.596 0.712 . . . . 75.450000000000003 110.865 -179.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . 0.517 ' HB3' ' HE2' ' B' ' 121' ' ' LYS . 0.7 OUTLIER -102.83 48.92 0.85 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.003 -0.999 . . . . 71.430000000000007 109.851 -176.785 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 97.74 -117.35 5.78 Favored Glycine 0 N--CA 1.446 -0.652 0 N-CA-C 111.223 -0.751 . . . . 63.130000000000003 111.223 -176.266 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . 0.497 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 3.6 m-20 -89.13 -3.32 58.67 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.037 0.446 . . . . 73.340000000000003 110.308 177.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.675 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 25.4 pttm -111.79 120.19 41.13 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.205 0.526 . . . . 75.530000000000001 111.303 -177.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . 0.474 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 5.5 m -84.03 111.96 19.77 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.908 -0.587 . . . . 72.400000000000006 109.611 175.146 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 51.4 mt -101.17 108.12 22.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-O 121.104 0.478 . . . . 72.239999999999995 110.368 -177.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.608 ' HG2' HG23 ' B' ' 115' ' ' ILE . 8.8 mt-30 -105.28 103.76 13.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.792 -0.64 . . . . 63.049999999999997 110.366 -178.427 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -88.4 108.82 19.56 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.234 -0.439 . . . . 73.430000000000007 110.766 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . 0.471 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 46.7 m-85 -82.37 106.39 14.21 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.218 -0.446 . . . . 74.400000000000006 110.47 177.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -120.86 125.31 47.16 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.508 -0.553 . . . . 62.25 109.508 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.765 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 3.5 p -93.65 -41.63 12.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 120.757 0.313 . . . . 73.510000000000005 111.497 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -158.6 70.37 0.52 Allowed 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.606 -0.438 . . . . 73.150000000000006 110.584 -175.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 78.87 -4.05 62.64 Favored Glycine 0 N--CA 1.454 -0.162 0 CA-C-N 115.692 -0.686 . . . . 65.319999999999993 113.574 175.218 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -130.0 129.32 43.57 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.097 0.475 . . . . 75.030000000000001 110.717 -178.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.892 HD11 HG13 ' B' ' 135' ' ' ILE . 3.5 tm? -73.5 118.35 16.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 114.875 -1.057 . . . . 74.230000000000004 109.462 175.223 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . 0.471 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 46.3 p90 -106.09 -23.77 12.53 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.66 -0.416 . . . . 75.450000000000003 111.528 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -158.99 134.55 8.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.806 0.336 . . . . 73.109999999999999 111.282 179.005 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.892 HG13 HD11 ' B' ' 132' ' ' LEU . 74.3 mt -114.07 130.73 67.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 N-CA-C 109.634 -0.506 . . . . 65.530000000000001 109.634 174.151 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -107.79 110.41 22.21 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.679 -0.489 . . . . 73.319999999999993 109.679 174.232 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.646 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.4 t -93.67 131.14 41.44 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 108.808 -0.812 . . . . 44.340000000000003 108.808 176.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.474 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 17.2 t -117.73 72.86 8.33 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 109.961 -0.385 . . . . 71.120000000000005 109.961 173.582 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.675 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 52.4 Cg_endo -78.48 134.73 12.69 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 122.367 2.044 . . . . 70.340000000000003 112.596 176.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . 0.497 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 48.6 mtpt -60.83 -33.21 72.69 Favored 'General case' 0 CA--C 1.518 -0.262 0 CA-C-O 121.416 0.627 . . . . 73.129999999999995 109.596 173.37 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 36.6 m-70 -110.52 82.58 1.62 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.252 -0.885 . . . . 74.349999999999994 109.2 177.038 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . 0.483 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 150.68 -26.73 1.06 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.357 -0.925 . . . . 73.549999999999997 113.054 -179.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . 0.483 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 70.7 mmtt 76.68 148.91 0.12 Allowed Pre-proline 0 N--CA 1.472 0.635 0 C-N-CA 123.283 0.633 . . . . 73.230000000000004 111.933 178.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.646 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 38.3 Cg_endo -66.27 127.6 17.79 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 123.069 2.513 . . . . 73.349999999999994 113.492 -176.098 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -143.91 150.48 38.47 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.79 -0.641 . . . . 72.049999999999997 110.734 179.327 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.666 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 77.8 m-85 -98.14 146.16 25.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.976 -0.556 . . . . 71.230000000000004 110.466 178.345 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 59.9 mt -122.73 100.55 6.97 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.826 -0.625 . . . . 73.030000000000001 109.555 171.156 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 61.4 t -92.84 130.34 42.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.054 -0.521 . . . . 74.140000000000001 110.677 -178.036 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . 0.544 HH11 ' HG3' ' B' ' 149' ' ' ARG . 0.3 OUTLIER -72.2 128.07 34.53 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.913 0.387 . . . . 74.239999999999995 111.689 -179.429 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.87 155.78 38.62 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 115.738 -0.664 . . . . 75.030000000000001 110.612 176.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . 0.441 ' HB3' ' CD2' ' A' ' 26' ' ' TYR . 3.9 p-10 -77.6 162.21 27.25 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.287 0.565 . . . . 73.530000000000001 111.736 -173.08 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.93 21.73 60.77 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.284 -0.871 . . . . 62.340000000000003 112.364 173.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . 0.433 ' H ' ' HD2' ' A' ' 11' ' ' PRO . 25.2 m 55.87 30.11 15.31 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-O 120.969 0.414 . . . . 75.319999999999993 110.384 -177.011 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -51.37 -64.39 0.83 Allowed 'General case' 0 N--CA 1.461 0.121 0 CA-C-N 114.851 -1.068 . . . . 64.219999999999999 111.068 -178.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 132.2 -36.36 2.21 Favored Glycine 0 CA--C 1.491 -1.458 0 C-N-CA 120.569 -0.824 . . . . 62.109999999999999 111.218 175.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . 0.607 ' OD1' ' HA ' ' B' ' 168' ' ' PRO . 75.6 m-20 -68.41 152.63 45.14 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 113.964 -1.118 . . . . 74.109999999999999 111.773 -179.424 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . 0.464 ' CE2' ' HG2' ' B' ' 149' ' ' ARG . 46.2 m-85 -112.32 157.7 20.66 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.54 -0.754 . . . . 61.200000000000003 110.248 176.285 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 49.1 mm -116.03 124.92 72.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 N-CA-C 109.596 -0.52 . . . . 73.349999999999994 109.596 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.491 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 30.2 ttt180 -85.51 137.72 32.7 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.4 -0.364 . . . . 74.200000000000003 110.165 -177.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . 0.666 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 6.5 p -57.18 -42.6 81.49 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.722 0.638 . . . . 64.409999999999997 112.722 -174.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -86.04 -1.06 57.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.979 0.419 . . . . 61.43 111.551 -174.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 10.9 tp60 -151.86 71.41 7.99 Favored Pre-proline 0 C--N 1.327 -0.401 0 N-CA-C 109.614 -0.513 . . . . 73.299999999999997 109.614 -178.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -67.47 -14.41 42.36 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 123.223 2.616 . . . . 63.450000000000003 113.13 -173.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -90.52 -6.39 54.81 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.169 -0.469 . . . . 64.430000000000007 110.549 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 23.1 tptm -104.74 126.17 51.55 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.163 0.506 . . . . 74.510000000000005 110.637 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.0 mp -95.19 124.68 39.36 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.326 -0.852 . . . . 62.43 109.789 178.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . 0.404 HG23 ' HB3' ' B' ' 171' ' ' GLU . 51.5 mm -93.17 111.58 52.44 Favored Pre-proline 0 C--N 1.32 -0.7 0 CA-C-N 116.122 -0.49 . . . . 74.120000000000005 109.827 179.029 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.607 ' HA ' ' OD1' ' B' ' 156' ' ' ASN . 60.2 Cg_endo -71.63 175.17 9.92 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.664 2.243 . . . . 71.150000000000006 113.025 -176.457 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . 0.415 ' O ' HG12 ' B' ' 172' ' ' ILE . 36.3 tt0 -78.92 -8.32 58.77 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.573 -0.739 . . . . 74.349999999999994 111.518 -170.341 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 10.3 p90 -94.23 -8.04 40.36 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.088 0.47 . . . . 71.400000000000006 110.081 174.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.476 ' O ' ' HB2' ' B' ' 174' ' ' SER . 0.1 OUTLIER -110.42 -4.63 15.47 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.891 -0.595 . . . . 54.409999999999997 110.717 -177.538 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.474 HG23 ' O ' ' B' ' 168' ' ' PRO . 36.6 pt -70.15 -18.68 21.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.231 -0.44 . . . . 74.340000000000003 111.197 -179.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -102.01 40.62 1.31 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.593 0.711 . . . . 74.439999999999998 109.678 176.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . 0.476 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 4.5 t -73.38 -11.13 60.37 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 114.9 -1.045 . . . . 64.400000000000006 110.211 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . 0.454 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 0.9 OUTLIER . . . . . 0 C--O 1.245 0.829 0 CA-C-O 118.353 -0.832 . . . . 74.230000000000004 110.9 179.008 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.5 p . . . . . 0 N--CA 1.449 -0.488 0 N-CA-C 109.749 -0.463 . . . . 75.430000000000007 109.749 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.03 66.33 0.53 Allowed Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.158 -1.177 . . . . 73.209999999999994 110.158 -173.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . 0.49 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -114.46 117.16 43.23 Favored Pre-proline 0 N--CA 1.44 -0.933 0 N-CA-C 107.995 -1.113 . . . . 72.310000000000002 107.995 -175.839 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.613 ' HG3' ' CZ ' ' B' ' 131' ' ' PHE . 24.7 Cg_endo -88.87 101.0 0.37 Allowed 'Trans proline' 0 N--CA 1.433 -2.049 0 C-N-CA 122.173 1.915 . . . . 73.219999999999999 111.693 -175.377 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -107.8 171.61 7.3 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 114.871 -1.059 . . . . 64.439999999999998 110.344 179.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.653 HG21 ' HB3' ' A' ' 24' ' ' GLN . 7.6 p -123.42 131.51 73.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 115.773 -0.649 . . . . 65.030000000000001 110.353 178.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.418 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 61.5 m -91.62 111.33 22.8 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.663 -0.699 . . . . 71.109999999999999 109.585 176.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 56.1 mt -88.66 103.76 14.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.942 -0.572 . . . . 63.25 110.967 -174.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.471 ' HA ' ' NE ' ' A' ' 16' ' ' ARG . 3.5 mmp_? -108.45 165.12 11.76 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.49 -0.777 . . . . 71.140000000000001 109.48 177.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -139.13 111.44 7.5 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.042 0.449 . . . . 73.340000000000003 110.502 174.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 30.9 mm-40 -103.77 100.57 10.38 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.448 -0.796 . . . . 75.319999999999993 109.002 178.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.25 -109.31 2.83 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.529 -0.843 . . . . 41.420000000000002 111.664 -175.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -111.02 8.46 21.91 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.788 0.294 . . . . 74.310000000000002 111.078 -177.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.705 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 0.3 OUTLIER -114.97 118.54 33.73 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.434 0.635 . . . . 72.349999999999994 111.463 179.484 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.739 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 20.7 m -76.59 98.33 4.65 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.19 -0.914 . . . . 31.350000000000001 109.618 175.213 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.427 HG12 HG13 ' A' ' 37' ' ' VAL . 38.3 mt -90.31 105.39 16.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.221 0.534 . . . . 74.329999999999998 110.234 -176.672 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.653 ' HB3' HG21 ' A' ' 13' ' ' VAL . 21.6 mt-30 -94.67 112.78 24.51 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.433 -0.803 . . . . 75.129999999999995 110.734 -177.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.418 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.6 mt-10 -91.99 108.85 20.23 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.03 -0.532 . . . . 65.219999999999999 110.736 -177.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.467 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 41.3 m-85 -84.72 106.06 15.98 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.349 -0.387 . . . . 75.329999999999998 110.687 178.173 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 71.3 mtm-85 -130.01 123.61 30.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.064 -0.516 . . . . 71.329999999999998 110.11 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.2 p -97.18 -41.99 11.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.313 -0.403 . . . . 75.099999999999994 111.48 -179.055 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 11.7 t-20 -153.65 73.37 0.95 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.006 0.432 . . . . 75.329999999999998 110.294 -176.087 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 67.03 18.53 69.0 Favored Glycine 0 C--N 1.33 0.207 0 CA-C-N 115.815 -0.63 . . . . 65.310000000000002 112.845 177.224 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.616 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 87.8 t80 -139.67 128.59 23.49 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.994 0.426 . . . . 64.450000000000003 111.042 -178.117 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.844 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -82.36 110.31 17.39 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.112 -0.949 . . . . 62.210000000000001 108.544 172.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . 0.467 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 45.5 p90 -103.92 -17.49 14.99 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.885 -0.326 . . . . 72.420000000000002 111.478 -178.39 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.456 ' O ' ' HB2' ' A' ' 26' ' ' TYR . . . -159.35 140.34 12.67 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.878 0.371 . . . . 31.109999999999999 111.105 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.844 HG13 HD11 ' A' ' 32' ' ' LEU . 66.9 mt -117.6 124.95 73.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 N-CA-C 109.653 -0.499 . . . . 54.420000000000002 109.653 174.326 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.623 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.9 tttt -106.01 103.77 13.33 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.533 -0.543 . . . . 73.409999999999997 109.533 176.11 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.725 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.6 t -88.7 127.24 41.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.839 -0.8 . . . . 73.340000000000003 108.839 177.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.739 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 22.0 t -115.14 74.0 3.64 Favored Pre-proline 0 C--N 1.318 -0.769 0 N-CA-C 109.55 -0.537 . . . . 53.450000000000003 109.55 172.492 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.705 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 39.4 Cg_endo -76.86 131.1 11.92 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.011 1.807 . . . . 45.100000000000001 112.242 177.003 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -54.83 -40.0 69.13 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.522 -0.763 . . . . 74.109999999999999 110.26 177.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -116.67 82.46 1.8 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.517 -0.765 . . . . 72.239999999999995 109.228 179.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.43 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 159.15 -29.48 0.41 Allowed Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.507 -0.769 . . . . 61.119999999999997 111.428 -175.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.43 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 71.6 mmtt 76.42 143.81 0.1 OUTLIER Pre-proline 0 N--CA 1.469 0.513 0 C-N-CA 123.738 0.815 . . . . 72.230000000000004 112.267 176.19 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.725 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 30.8 Cg_endo -64.03 132.7 35.37 Favored 'Trans proline' 0 C--N 1.347 0.469 0 C-N-CA 123.218 2.612 . . . . 73.549999999999997 113.61 -176.197 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 21.9 p90 -148.36 163.2 37.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.463 -0.79 . . . . 72.5 109.645 177.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.475 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 91.2 m-85 -107.76 137.79 45.14 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.842 0.353 . . . . 75.329999999999998 111.572 -176.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.407 ' HB3' ' CD2' ' A' ' 57' ' ' PHE . 34.7 mt -114.15 104.48 12.15 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.717 -0.674 . . . . 73.329999999999998 109.216 168.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 44.4 t -92.52 137.88 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.554 -0.294 . . . . 74.519999999999996 110.333 -178.198 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . 0.574 ' HG2' ' CE2' ' A' ' 57' ' ' PHE . 5.0 mmm180 -81.8 121.92 27.04 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.032 0.444 . . . . 72.219999999999999 110.885 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.45 167.03 19.16 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.337 -0.847 . . . . 74.230000000000004 111.22 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.463 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 9.8 p-10 -66.87 142.86 57.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.298 -0.41 . . . . 70.150000000000006 110.264 179.037 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.432 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 94.16 143.45 13.81 Favored Glycine 0 N--CA 1.433 -1.559 0 C-N-CA 120.588 -0.815 . . . . 53.130000000000003 111.566 -178.591 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 18.6 m -74.32 40.14 0.13 Allowed 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.174 0.511 . . . . 74.430000000000007 110.677 176.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.432 ' H ' ' C ' ' A' ' 52' ' ' GLY . 18.0 t70 -78.01 -39.86 40.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.779 -0.646 . . . . 53.310000000000002 110.357 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 112.02 -32.05 6.6 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.636 -0.792 . . . . 41.020000000000003 113.302 176.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -58.29 149.82 23.44 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 113.027 0.751 . . . . 71.349999999999994 113.027 -175.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.574 ' CE2' ' HG2' ' A' ' 49' ' ' ARG . 63.3 m-85 -115.5 168.3 10.12 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.096 -0.956 . . . . 72.25 110.697 -179.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 45.4 mm -128.27 132.16 68.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.995 -0.548 . . . . 75.540000000000006 109.649 174.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.789 ' HG3' HD11 ' A' ' 67' ' ' ILE . 70.7 mtt180 -78.59 147.88 33.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.809 0.337 . . . . 74.329999999999998 111.249 178.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.475 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 62.2 p -79.01 -29.86 43.92 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.681 -0.859 . . . . 54.32 108.681 165.812 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -70.27 -34.34 72.67 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.381 -1.281 . . . . 74.409999999999997 110.876 177.316 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . 0.6 ' HB3' ' HD2' ' A' ' 59' ' ' ARG . 9.9 tt0 -143.37 82.52 11.57 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 115.747 -0.66 . . . . 63.340000000000003 109.71 -174.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -79.58 -7.44 14.73 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.871 2.381 . . . . 63.009999999999998 113.13 -175.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -94.46 9.32 38.9 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.331 0.586 . . . . 73.439999999999998 110.165 178.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.4 tptt -125.63 128.23 47.56 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.85 -0.614 . . . . 74.150000000000006 110.429 -178.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.404 ' N ' HD12 ' A' ' 66' ' ' LEU . 5.2 mp -87.36 111.85 21.51 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 108.434 -0.95 . . . . 73.319999999999993 108.434 175.118 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.789 HD11 ' HG3' ' A' ' 59' ' ' ARG . 34.6 mm -67.24 117.33 45.42 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.146 -0.479 . . . . 74.140000000000001 111.27 -172.254 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.403 ' O ' HG23 ' A' ' 72' ' ' ILE . 55.8 Cg_endo -69.1 175.03 8.08 Favored 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.676 2.251 . . . . 72.140000000000001 112.038 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -84.36 -1.06 54.84 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.943 -0.572 . . . . 73.25 111.21 -169.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 16.5 p90 -98.89 -20.24 16.93 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.557 -0.457 . . . . 71.310000000000002 110.437 174.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.519 ' OE2' HD12 ' A' ' 67' ' ' ILE . 19.4 tt0 -90.55 -11.96 38.54 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 121.096 0.474 . . . . 72.109999999999999 110.536 -177.038 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.403 HG23 ' O ' ' A' ' 68' ' ' PRO . 45.6 pt -64.88 -19.26 25.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.095 -0.502 . . . . 62.140000000000001 110.975 178.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -117.6 29.32 7.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.951 -0.568 . . . . 71.299999999999997 110.289 176.121 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 23.0 t -63.72 -26.76 68.8 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.898 -0.592 . . . . 61.240000000000002 110.15 179.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 20.8 p-90 . . . . . 0 C--N 1.324 -0.528 0 CA-C-N 115.896 -0.593 . . . . 72.409999999999997 110.579 175.069 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 21.1 m . . . . . 0 C--O 1.236 0.389 0 CA-C-O 120.779 0.324 . . . . 74.409999999999997 110.558 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 99.72 83.24 1.72 Allowed Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 120.876 -0.678 . . . . 62.039999999999999 111.924 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 50.7 mt-10 -109.51 102.94 51.57 Favored Pre-proline 0 C--N 1.323 -0.545 0 N-CA-C 109.046 -0.724 . . . . 75.400000000000006 109.046 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.616 ' HG3' ' CZ ' ' A' ' 31' ' ' PHE . 66.2 Cg_endo -83.48 85.83 1.46 Allowed 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 122.036 1.824 . . . . 54.109999999999999 112.076 -176.21 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -96.05 133.47 40.25 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.049 -0.978 . . . . 71.120000000000005 109.359 178.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.521 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 14.7 p -92.92 127.55 44.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 121.438 0.637 . . . . 64.400000000000006 110.262 179.089 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 21.9 m -91.3 105.46 17.8 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.794 -0.639 . . . . 72.209999999999994 109.699 177.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 63.6 mt -84.36 106.13 14.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.024 -0.535 . . . . 65.450000000000003 110.899 -176.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 14.4 mtp180 -105.99 173.05 6.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.928 -0.578 . . . . 74.010000000000005 111.052 178.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -148.2 101.16 3.24 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.743 -0.662 . . . . 71.430000000000007 110.891 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . 0.607 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 3.8 mp0 -104.52 90.61 3.57 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.457 -0.792 . . . . 75.420000000000002 110.399 -178.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 76.85 -89.52 0.96 Allowed Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.775 -0.726 . . . . 72.049999999999997 112.486 179.282 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -127.57 14.57 7.06 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.458 0.129 . . . . 65.310000000000002 110.899 178.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.607 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 38.4 pttt -123.6 121.36 35.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.267 0.556 . . . . 72.150000000000006 111.181 -179.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . 0.519 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 20.8 m -84.13 98.31 9.83 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.488 -0.778 . . . . 73.420000000000002 109.748 176.412 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . 0.476 HG12 HG23 ' B' ' 137' ' ' VAL . 30.4 mt -89.68 107.52 18.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.174 0.511 . . . . 65.439999999999998 110.599 -177.231 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.521 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 20.8 mt-30 -97.95 107.6 20.12 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.783 -0.644 . . . . 54.310000000000002 110.515 -178.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -87.47 111.23 20.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.014 -0.539 . . . . 74.450000000000003 110.485 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . 0.463 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 78.5 m-85 -85.16 101.29 12.34 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.046 -0.353 . . . . 74.400000000000006 110.046 176.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 20.6 mtm180 -113.41 128.05 56.32 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.413 -0.358 . . . . 73.219999999999999 110.234 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.594 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -96.58 -50.6 11.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 C-N-CA 120.731 -0.388 . . . . 51.149999999999999 111.521 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -156.67 76.1 0.87 Allowed 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.622 -0.51 . . . . 71.340000000000003 109.622 -176.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 66.94 16.73 66.69 Favored Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.713 -0.676 . . . . 50.340000000000003 112.403 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.613 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 89.4 t80 -137.33 128.34 27.52 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.038 0.447 . . . . 71.310000000000002 110.791 -179.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.827 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -83.2 113.35 20.6 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.175 -0.92 . . . . 74.549999999999997 108.791 173.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . 0.421 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 50.9 p90 -104.88 -14.99 15.3 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.388 -0.525 . . . . 73.430000000000007 111.665 -178.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -159.9 143.01 13.93 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.897 0.38 . . . . 72.209999999999994 111.278 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.827 HG13 HD11 ' B' ' 132' ' ' LEU . 80.8 mt -120.93 127.09 75.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.931 -0.577 . . . . 73.329999999999998 109.889 174.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.443 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 82.6 tttt -116.69 101.12 8.31 Favored 'General case' 0 C--N 1.321 -0.63 0 N-CA-C 109.411 -0.588 . . . . 70.549999999999997 109.411 172.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.542 ' O ' ' HD3' ' B' ' 139' ' ' PRO . 4.9 p -101.95 129.38 53.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.978 0 C-N-CA 120.231 -0.588 . . . . 70.340000000000003 109.758 178.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.519 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 37.5 t -109.07 84.91 2.94 Favored Pre-proline 0 C--N 1.322 -0.591 0 CA-C-N 115.553 -0.748 . . . . 75.230000000000004 109.976 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.542 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 69.0 Cg_endo -87.86 133.46 3.02 Favored 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 122.506 2.138 . . . . 73.439999999999998 112.365 178.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -60.97 -20.31 62.2 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.94 -0.573 . . . . 75.099999999999994 110.304 174.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 5.6 m-70 -122.66 81.88 1.91 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.425 -0.807 . . . . 64.129999999999995 109.181 -175.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 140.0 -17.44 2.98 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.736 -0.745 . . . . 73.340000000000003 112.64 -178.082 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt 70.79 145.5 0.11 Allowed Pre-proline 0 N--CA 1.472 0.639 0 C-N-CA 123.41 0.684 . . . . 75.239999999999995 111.896 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.513 ' HB3' HG22 ' B' ' 138' ' ' VAL . 43.0 Cg_endo -67.95 149.1 77.36 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.62 2.213 . . . . 53.439999999999998 113.09 -177.342 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -158.71 156.7 30.37 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.848 -0.615 . . . . 73.129999999999995 109.695 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -102.29 134.34 45.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.647 0.261 . . . . 60.310000000000002 111.117 -179.221 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 46.0 mt -114.02 105.31 13.07 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.045 -0.525 . . . . 64.109999999999999 109.704 170.036 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 46.7 t -97.79 137.27 25.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.123 -0.49 . . . . 72.150000000000006 110.147 -178.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 2.8 mmt85 -75.68 131.64 40.02 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.99 0.424 . . . . 75.439999999999998 111.458 178.235 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -87.58 169.68 11.96 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.644 -0.707 . . . . 72.129999999999995 109.215 172.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . 0.449 ' H ' ' HE2' ' A' ' 26' ' ' TYR . 6.2 p-10 -69.99 125.52 26.99 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.374 0.606 . . . . 61.109999999999999 109.971 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 120.95 127.9 3.49 Favored Glycine 0 N--CA 1.442 -0.91 0 CA-C-N 115.505 -0.77 . . . . 73.209999999999994 112.12 -178.395 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 12.2 t -79.45 45.25 0.65 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.433 0.635 . . . . 53.43 110.08 178.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -84.88 -16.94 39.49 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.39 -0.823 . . . . 71.219999999999999 110.57 -178.339 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 86.39 23.56 43.25 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.825 -0.703 . . . . 70.150000000000006 111.666 -177.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 30.7 t30 -99.57 129.95 45.77 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.268 -0.466 . . . . 71.239999999999995 110.681 -177.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -116.59 151.08 36.94 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.815 -0.63 . . . . 61.020000000000003 110.004 178.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.7 mm -117.96 129.55 74.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 116.17 -0.468 . . . . 74.310000000000002 109.777 178.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.449 ' HG3' HD11 ' B' ' 167' ' ' ILE . 92.9 mtt180 -75.02 150.78 38.84 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.821 0.343 . . . . 74.510000000000005 111.136 179.362 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 64.7 p -81.29 -27.73 34.95 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 107.993 -1.114 . . . . 70.140000000000001 107.993 164.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -64.7 -35.61 81.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.019 -1.446 . . . . 65.519999999999996 110.94 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 9.3 tt0 -153.24 85.59 4.19 Favored Pre-proline 0 C--N 1.322 -0.589 0 CA-C-N 115.518 -0.764 . . . . 72.5 109.557 -177.137 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -79.14 8.87 3.6 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 123.106 2.537 . . . . 70.349999999999994 112.766 -176.299 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -107.4 3.9 25.73 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.214 0.531 . . . . 74.140000000000001 110.729 -178.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -125.23 130.65 52.51 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.855 -0.612 . . . . 73.140000000000001 110.484 -179.059 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . 0.44 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.7 mp -84.67 119.81 25.66 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.695 -0.854 . . . . 75.150000000000006 108.695 176.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . 0.449 HD11 ' HG3' ' B' ' 159' ' ' ARG . 36.4 mm -80.56 119.51 76.49 Favored Pre-proline 0 C--N 1.322 -0.614 0 CA-C-O 120.995 0.426 . . . . 72.450000000000003 111.177 -172.048 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.551 ' O ' HG23 ' B' ' 172' ' ' ILE . 58.1 Cg_endo -69.73 173.0 11.58 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.803 2.335 . . . . 72.329999999999998 112.098 178.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . 0.64 ' O ' HG12 ' B' ' 172' ' ' ILE . 5.5 tt0 -73.78 -33.11 64.11 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.734 -0.666 . . . . 64.530000000000001 111.362 -168.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 11.6 p90 -66.4 -17.72 64.94 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.437 -0.505 . . . . 72.040000000000006 110.714 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.614 ' HA ' ' HB2' ' B' ' 174' ' ' SER . 20.1 tt0 -102.46 -17.68 15.68 Favored 'General case' 0 N--CA 1.444 -0.727 0 CA-C-N 116.428 -0.351 . . . . 72.420000000000002 111.496 -177.024 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.64 HG12 ' O ' ' B' ' 169' ' ' GLN . 30.7 pt -70.18 -27.54 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.954 0.407 . . . . 72.219999999999999 110.509 178.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -118.22 36.25 4.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.517 0.675 . . . . 71.540000000000006 109.782 173.194 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . 0.614 ' HB2' ' HA ' ' B' ' 171' ' ' GLU . 45.3 t -62.39 -27.17 68.89 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.023 -0.99 . . . . 61.210000000000001 111.194 -179.307 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.246 0.916 0 CA-C-O 118.437 -0.792 . . . . 70.420000000000002 111.263 -179.675 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.0 p . . . . . 0 C--O 1.236 0.355 0 CA-C-O 120.853 0.359 . . . . 64.409999999999997 110.875 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.2 -73.34 2.63 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.77 -0.729 . . . . 72.420000000000002 111.467 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 60.4 74.87 0.51 Allowed Pre-proline 0 C--N 1.329 -0.285 0 C-N-CA 123.046 0.538 . . . . 65.099999999999994 110.152 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.856 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 12.2 Cg_endo -60.32 107.33 0.41 Allowed 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.597 2.198 . . . . 74.019999999999996 112.708 -178.806 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 23.7 m-20 -90.5 154.03 19.94 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.627 -0.715 . . . . 61.43 109.876 179.163 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.493 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 12.5 p -117.99 125.74 74.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-O 121.395 0.617 . . . . 64.329999999999998 110.549 176.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.6 m -98.53 111.45 23.81 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.548 -0.751 . . . . 73.030000000000001 110.062 179.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.8 mt -93.2 105.86 17.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.285 -0.416 . . . . 42.149999999999999 110.945 -176.374 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -120.48 167.42 12.39 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.014 -0.735 . . . . 64.0 109.014 177.244 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 91.6 mt-30 -127.35 119.0 25.24 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 120.929 0.395 . . . . 73.310000000000002 111.281 177.173 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.452 ' HG3' HD12 ' A' ' 23' ' ' ILE . 12.4 mm-40 -97.52 82.54 3.11 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.939 -0.763 . . . . 62.409999999999997 108.939 175.151 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 79.63 -107.03 2.51 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.3 -0.952 . . . . 62.340000000000003 111.351 -173.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.574 ' HB3' ' HB2' ' A' ' 40' ' ' LYS . 10.3 m-20 -108.85 0.41 20.27 Favored 'General case' 0 C--N 1.327 -0.38 0 O-C-N 122.615 -0.344 . . . . 72.430000000000007 111.114 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.81 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 22.1 pttm -101.74 113.03 25.84 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.443 0.64 . . . . 72.420000000000002 111.022 179.085 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.705 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 21.1 m -80.0 97.87 6.97 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.222 -0.899 . . . . 63.420000000000002 109.798 177.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.586 HG12 HG13 ' A' ' 37' ' ' VAL . 55.0 mt -90.85 112.23 24.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.035 0.445 . . . . 73.439999999999998 110.566 -176.544 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.588 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 17.1 mt-30 -95.67 108.33 20.61 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.961 -0.563 . . . . 72.349999999999994 109.956 178.21 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -84.82 102.81 13.36 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.78 -0.646 . . . . 64.420000000000002 110.346 -177.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.44 ' HE1' ' HB2' ' A' ' 36' ' ' LYS . 86.3 m-85 -82.12 102.38 11.02 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.162 0.506 . . . . 54.450000000000003 109.783 176.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 88.1 mtm180 -118.12 117.52 29.39 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.853 -0.612 . . . . 70.450000000000003 109.93 -179.382 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.892 HG11 HG11 ' B' ' 128' ' ' VAL . 2.6 p -69.4 -43.19 81.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.924 -0.58 . . . . 63.020000000000003 111.14 -174.356 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 33.9 t-20 -169.85 75.35 0.08 Allowed 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.644 -0.873 . . . . 65.400000000000006 108.644 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 85.22 -23.54 8.1 Favored Glycine 0 N--CA 1.45 -0.416 0 CA-C-N 115.443 -0.799 . . . . 34.130000000000003 112.676 -177.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 51.2 t80 -112.25 131.24 55.6 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.215 0.531 . . . . 60.229999999999997 110.749 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.505 HD21 ' CG1' ' A' ' 35' ' ' ILE . 27.2 tp -76.66 126.21 30.59 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 114.974 -1.012 . . . . 72.239999999999995 110.463 178.471 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . 0.425 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 49.6 p90 -115.23 -14.3 11.71 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.764 -0.374 . . . . 75.329999999999998 111.173 179.068 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.508 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -161.72 143.81 11.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.998 0.428 . . . . 74.310000000000002 111.142 -177.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.624 ' HB ' ' HB2' ' A' ' 47' ' ' LEU . 63.7 mt -121.84 121.35 64.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.992 -0.549 . . . . 52.240000000000002 109.87 176.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.588 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 88.2 tttt -102.19 99.62 9.76 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.244 -0.651 . . . . 75.430000000000007 109.244 172.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.69 HG12 ' HD3' ' A' ' 39' ' ' PRO . 3.5 t -86.18 126.63 40.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 108.568 -0.901 . . . . 71.239999999999995 108.568 178.132 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.705 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.6 t -115.73 72.87 4.19 Favored Pre-proline 0 C--N 1.318 -0.761 0 N-CA-C 109.753 -0.462 . . . . 64.099999999999994 109.753 172.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.81 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 43.2 Cg_endo -77.08 129.4 10.5 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 122.041 1.827 . . . . 75.120000000000005 112.413 177.179 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.574 ' HB2' ' HB3' ' A' ' 20' ' ' ASP . 55.7 mtpt -59.05 -32.13 69.47 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.043 -0.981 . . . . 43.539999999999999 110.285 176.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 67.9 m-70 -115.36 95.93 5.41 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.365 -0.834 . . . . 65.209999999999994 109.314 178.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 132.46 -23.06 4.08 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 121.009 -0.615 . . . . 71.439999999999998 111.99 -176.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.498 ' HD3' ' HA ' ' A' ' 43' ' ' LYS . 68.8 mmtt 72.99 148.94 0.12 Allowed Pre-proline 0 N--CA 1.467 0.389 0 C-N-CA 123.86 0.864 . . . . 74.340000000000003 112.651 177.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.646 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 27.9 Cg_endo -62.59 141.86 87.68 Favored 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 123.04 2.493 . . . . 62.340000000000003 113.921 -174.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.422 ' CE2' ' HG2' ' A' ' 59' ' ' ARG . 25.1 p90 -151.43 149.42 29.26 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-N 115.361 -0.836 . . . . 74.030000000000001 109.855 176.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.597 ' HB2' ' HB2' ' A' ' 60' ' ' SER . 88.6 m-85 -92.35 150.4 20.86 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.286 -0.416 . . . . 75.439999999999998 111.14 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.624 ' HB2' ' HB ' ' A' ' 35' ' ' ILE . 23.0 mt -123.37 96.46 4.99 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.711 -0.677 . . . . 43.340000000000003 109.674 171.252 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 45.8 t -90.16 122.24 41.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.438 -0.346 . . . . 55.439999999999998 110.519 -178.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -62.25 128.98 38.64 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 120.974 0.416 . . . . 74.510000000000005 111.303 176.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.9 152.33 19.44 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.452 -0.573 . . . . 74.420000000000002 109.452 172.601 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -57.85 144.07 40.12 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.332 -0.395 . . . . 71.400000000000006 110.58 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 118.45 148.31 8.46 Favored Glycine 0 N--CA 1.431 -1.684 0 C-N-CA 120.198 -1.001 . . . . 51.240000000000002 112.402 -179.664 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 16.6 m -76.67 -2.63 33.76 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 114.947 -0.626 . . . . 73.0 110.779 175.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -57.91 -43.66 86.34 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.142 -0.481 . . . . 70.319999999999993 112.048 -178.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 98.79 32.76 5.8 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.419 -0.896 . . . . 45.43 111.63 -179.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.842 HD21 HD22 ' A' ' 66' ' ' LEU . 32.1 t30 -87.06 132.82 33.7 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.367 -0.416 . . . . 74.299999999999997 110.417 -178.342 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -122.17 160.17 25.7 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.994 -0.548 . . . . 71.019999999999996 110.211 177.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.817 HD11 HD23 ' A' ' 66' ' ' LEU . 43.9 mm -120.22 115.32 46.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 116.279 -0.419 . . . . 74.439999999999998 109.972 177.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.676 ' HG3' HG13 ' A' ' 67' ' ' ILE . 18.7 mtp180 -75.95 130.1 37.94 Favored 'General case' 0 C--O 1.22 -0.492 0 CA-C-N 115.785 -0.643 . . . . 74.420000000000002 109.797 177.366 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.597 ' HB2' ' HB2' ' A' ' 46' ' ' PHE . 17.4 t -70.48 -17.53 62.97 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.894 0.854 . . . . 75.530000000000001 108.79 172.504 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -67.76 -27.38 66.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 114.384 -1.28 . . . . 61.210000000000001 110.453 173.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 -158.88 78.84 3.01 Favored Pre-proline 0 C--N 1.327 -0.404 0 CA-C-N 115.664 -0.698 . . . . 73.010000000000005 109.484 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_endo -78.76 -1.24 11.43 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.725 2.284 . . . . 71.129999999999995 112.375 -174.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -92.52 0.09 57.39 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.406 -0.816 . . . . 72.430000000000007 110.205 -178.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.429 ' HE3' ' O ' ' A' ' 66' ' ' LEU . 52.4 tptt -128.48 134.29 48.68 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.732 -0.667 . . . . 74.109999999999999 110.539 -179.078 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.842 HD22 HD21 ' A' ' 56' ' ' ASN . 26.2 mt -80.29 123.48 28.01 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.129 -0.693 . . . . 75.409999999999997 109.129 175.182 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.676 HG13 ' HG3' ' A' ' 59' ' ' ARG . 44.1 mm -92.43 113.76 60.32 Favored Pre-proline 0 C--N 1.32 -0.681 0 CA-C-O 120.941 0.401 . . . . 75.340000000000003 111.277 -173.08 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -72.62 177.99 6.82 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.887 2.392 . . . . 74.239999999999995 112.961 -177.288 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . 0.535 ' O ' HG12 ' A' ' 72' ' ' ILE . 19.4 tt0 -77.58 -17.14 58.13 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.493 -0.776 . . . . 73.340000000000003 112.067 -168.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 10.4 p90 -83.16 -18.32 39.83 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.251 -0.58 . . . . 74.329999999999998 110.281 176.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.553 ' HB3' HG23 ' A' ' 67' ' ' ILE . 1.4 tm-20 -90.35 -24.49 20.82 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 115.933 -0.576 . . . . 63.140000000000001 109.966 -178.304 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.535 HG12 ' O ' ' A' ' 69' ' ' GLN . 31.5 pt -70.28 -20.89 23.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 121.223 0.535 . . . . 62.439999999999998 110.396 177.766 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 46.2 m-85 -111.62 33.67 4.6 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.787 -0.642 . . . . 74.219999999999999 109.822 174.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 19.0 t -67.0 -33.17 74.98 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.384 -0.825 . . . . 62.210000000000001 110.171 178.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . 0.458 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 8.2 p-90 . . . . . 0 C--N 1.327 -0.398 0 CA-C-N 116.003 -0.544 . . . . 74.340000000000003 110.602 175.386 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 5.2 p . . . . . 0 N--CA 1.453 -0.289 0 CA-C-O 121.014 0.435 . . . . 63.020000000000003 111.065 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 108.75 -77.21 0.22 Allowed Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.588 -1.005 . . . . 73.329999999999998 110.588 -177.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 68.85 86.68 0.12 Allowed Pre-proline 0 CA--C 1.521 -0.171 0 CA-C-O 121.274 0.559 . . . . 70.019999999999996 110.558 173.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.668 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 3.0 Cg_exo -69.95 118.04 5.45 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 122.298 1.999 . . . . 74.439999999999998 111.731 -174.493 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -118.44 161.38 20.07 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.091 -0.958 . . . . 62.5 109.763 -174.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . . . . . . . . . 14.6 p -133.3 132.63 58.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.428 0.632 . . . . 61.130000000000003 111.5 -178.012 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 31.4 m -97.17 105.07 17.16 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.527 -0.76 . . . . 75.099999999999994 109.266 174.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 65.6 mt -95.59 104.66 16.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.369 0.604 . . . . 65.230000000000004 110.703 -176.369 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 57.1 mtm180 -123.55 176.06 6.42 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.247 -0.888 . . . . 54.340000000000003 109.354 176.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . 0.738 ' HG2' ' HA ' ' B' ' 122' ' ' THR . 37.7 mt-30 -134.17 139.73 46.05 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.411 0.624 . . . . 73.120000000000005 111.389 178.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . 0.565 ' HB3' ' HE2' ' B' ' 121' ' ' LYS . 0.9 OUTLIER -120.15 72.85 0.95 Allowed 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.954 -1.021 . . . . 73.329999999999998 109.679 -177.075 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 87.93 -108.87 3.44 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.611 -0.804 . . . . 71.209999999999994 111.703 -175.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . 0.687 ' HB3' ' HD2' ' B' ' 140' ' ' LYS . 39.5 m-20 -109.9 13.24 23.55 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.932 0.396 . . . . 75.140000000000001 110.616 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.573 ' HE3' ' HB2' ' B' ' 175' ' ' TRP . 23.7 pttm -120.02 116.49 25.85 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.868 -0.606 . . . . 74.129999999999995 110.664 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . 0.738 ' HA ' ' HG2' ' B' ' 117' ' ' GLN . 20.0 m -77.4 122.16 24.78 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.598 -0.728 . . . . 64.439999999999998 109.495 176.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 55.7 mt -112.4 107.79 23.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.328 0.585 . . . . 75.439999999999998 110.819 -176.356 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.509 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 12.4 mt-30 -100.5 102.9 14.19 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.724 -0.671 . . . . 75.430000000000007 109.935 178.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . 0.407 ' HB3' HD13 ' B' ' 132' ' ' LEU . 48.3 mt-10 -82.92 104.58 13.24 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.005 -0.543 . . . . 73.120000000000005 110.521 -179.612 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . 0.43 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 79.2 m-85 -82.15 108.9 15.98 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.165 0.507 . . . . 74.430000000000007 110.147 178.356 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 82.9 mtt180 -118.97 121.41 39.86 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.806 -0.634 . . . . 74.129999999999995 109.342 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.892 HG11 HG11 ' A' ' 28' ' ' VAL . 2.1 p -70.68 -46.44 69.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 C-N-CA 120.761 -0.376 . . . . 72.239999999999995 110.719 -178.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -158.34 56.96 0.46 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.482 0.658 . . . . 63.119999999999997 109.427 -177.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 98.04 -23.74 34.76 Favored Glycine 0 N--CA 1.449 -0.452 0 CA-C-N 115.589 -0.732 . . . . 72.349999999999994 112.86 -178.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -104.28 129.82 52.11 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 121.062 0.458 . . . . 72.219999999999999 110.46 -178.064 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.558 HD21 ' CG1' ' B' ' 135' ' ' ILE . 28.7 tp -74.46 120.86 20.6 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.107 -0.952 . . . . 72.140000000000001 110.6 177.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . 0.43 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 54.1 p90 -110.86 -12.96 14.21 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.845 -0.342 . . . . 74.510000000000005 111.204 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . 0.565 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -167.1 137.1 2.96 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.974 0.416 . . . . 65.450000000000003 111.141 -177.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.558 ' CG1' HD21 ' B' ' 132' ' ' LEU . 56.9 mt -114.58 122.78 69.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.02 -0.536 . . . . 73.200000000000003 109.821 175.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.509 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.3 tttt -96.0 101.51 13.19 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.089 -0.708 . . . . 51.439999999999998 109.089 172.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.681 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.0 t -91.62 125.84 44.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 108.493 -0.929 . . . . 72.209999999999994 108.493 177.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.536 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.3 t -115.48 72.91 3.81 Favored Pre-proline 0 C--N 1.316 -0.867 0 N-CA-C 109.672 -0.492 . . . . 54.25 109.672 173.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.611 ' HD3' HG12 ' B' ' 137' ' ' VAL . 56.8 Cg_endo -80.21 133.32 9.76 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 122.153 1.902 . . . . 64.310000000000002 112.005 175.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . 0.687 ' HD2' ' HB3' ' B' ' 120' ' ' ASP . 93.0 mttt -52.05 -40.93 61.88 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.527 0.68 . . . . 60.210000000000001 110.219 175.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 8.6 m-70 -112.26 91.9 3.82 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.108 -0.951 . . . . 75.530000000000001 109.429 -175.056 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 140.66 -21.65 2.7 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.819 -0.628 . . . . 51.200000000000003 111.832 -177.014 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt 75.3 150.62 0.13 Allowed Pre-proline 0 N--CA 1.469 0.491 0 C-N-CA 123.544 0.738 . . . . 54.329999999999998 111.708 178.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.681 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 36.5 Cg_endo -66.9 137.39 44.8 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 122.461 2.107 . . . . 62.140000000000001 112.791 -177.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . 0.413 ' CD2' ' HD2' ' B' ' 159' ' ' ARG . 50.8 p90 -149.51 150.28 32.06 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.751 -0.659 . . . . 72.040000000000006 110.352 179.276 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.534 ' O ' ' HA ' ' B' ' 159' ' ' ARG . 92.4 m-85 -95.74 130.35 42.68 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.778 -0.646 . . . . 73.140000000000001 110.375 176.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.565 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 15.0 mt -99.77 99.29 10.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.119 -0.491 . . . . 74.310000000000002 109.908 170.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.0 t -83.97 127.99 39.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 116.311 -0.404 . . . . 75.430000000000007 110.246 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.99 108.72 2.7 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.124 -0.695 . . . . 72.409999999999997 109.124 176.418 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.24 166.38 9.95 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.207 -0.451 . . . . 52.350000000000001 110.97 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -53.5 129.03 31.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.7 0.762 . . . . 75.450000000000003 112.52 -175.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 83.11 -115.99 4.13 Favored Glycine 0 N--CA 1.429 -1.816 0 CA-C-N 114.447 -1.251 . . . . 64.219999999999999 111.509 178.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 17.0 m -169.41 34.51 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 113.803 -1.198 . . . . 65.540000000000006 109.384 -178.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -78.79 35.7 0.25 Allowed 'General case' 0 CA--C 1.535 0.365 0 CA-C-N 115.4 -0.818 . . . . 72.25 111.405 -173.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 58.12 43.23 95.35 Favored Glycine 0 C--O 1.229 -0.212 0 CA-C-N 115.789 -0.641 . . . . 62.140000000000001 113.21 177.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 47.1 t30 -137.3 137.83 39.39 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.185 0.516 . . . . 74.319999999999993 111.085 -177.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . 0.527 ' HB3' HD22 ' B' ' 147' ' ' LEU . 39.0 m-85 -131.09 154.25 48.48 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.189 -0.914 . . . . 75.129999999999995 108.697 172.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 49.2 mm -120.65 122.79 68.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 N-CA-C 110.183 -0.303 . . . . 61.450000000000003 110.183 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.955 ' HG3' HG13 ' B' ' 167' ' ' ILE . 31.5 mtm-85 -88.9 137.28 32.46 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-N 116.338 -0.392 . . . . 72.439999999999998 110.126 178.067 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 35.1 t -64.69 -18.94 65.44 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.445 0.64 . . . . 73.319999999999993 109.334 171.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -59.37 -52.13 66.95 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 114.942 -1.027 . . . . 71.150000000000006 110.878 174.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 26.2 mt-30 -143.71 79.6 13.45 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 74.409999999999997 110.442 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -68.21 -0.58 5.87 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 123.292 2.661 . . . . 60.100000000000001 112.329 177.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -81.44 -18.48 45.16 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.639 -0.71 . . . . 64.25 110.233 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -119.95 140.11 51.42 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.856 -0.611 . . . . 61.340000000000003 110.885 -177.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.0 mp -81.87 126.87 32.4 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 107.898 -1.149 . . . . 74.319999999999993 107.898 171.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . 0.955 HG13 ' HG3' ' B' ' 159' ' ' ARG . 44.7 mm -87.81 119.66 70.63 Favored Pre-proline 0 C--N 1.318 -0.794 0 CA-C-O 120.882 0.372 . . . . 75.340000000000003 111.267 -170.425 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.449 ' O ' HG23 ' B' ' 172' ' ' ILE . 58.8 Cg_endo -71.09 174.3 10.85 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 123.27 2.647 . . . . 65.439999999999998 112.655 -179.187 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . 0.813 ' HA ' HG12 ' B' ' 172' ' ' ILE . 8.5 tt0 -72.75 -32.62 65.79 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.58 -0.736 . . . . 61.439999999999998 111.963 -168.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 36.9 p90 -73.56 -17.86 61.14 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.165 0.507 . . . . 74.329999999999998 110.326 178.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -94.28 -30.86 14.33 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.847 -0.615 . . . . 63.229999999999997 110.964 178.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.813 HG12 ' HA ' ' B' ' 169' ' ' GLN . 37.6 pt -74.45 -29.3 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.985 0.421 . . . . 73.129999999999995 110.381 176.312 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -104.76 37.86 2.04 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.184 0.516 . . . . 73.140000000000001 110.13 175.256 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 15.9 t -73.78 -22.88 59.69 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.827 -0.624 . . . . 65.299999999999997 110.262 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . 0.573 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 60.3 p-90 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.243 -0.884 . . . . 75.209999999999994 110.656 -178.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 28.5 p . . . . . 0 N--CA 1.452 -0.325 0 CA-C-O 120.883 0.373 . . . . 74.430000000000007 110.043 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.79 105.63 3.02 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 110.2 -1.16 . . . . 65.239999999999995 110.2 -173.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -116.76 95.74 47.06 Favored Pre-proline 0 C--N 1.317 -0.823 0 N-CA-C 109.516 -0.55 . . . . 74.409999999999997 109.516 -171.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.29 100.35 1.36 Allowed 'Trans proline' 0 N--CA 1.445 -1.372 0 C-N-CA 121.797 1.664 . . . . 43.049999999999997 111.422 -177.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -132.12 145.28 51.28 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.222 -0.899 . . . . 75.329999999999998 109.546 178.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.705 HG21 ' HB3' ' A' ' 24' ' ' GLN . 12.8 p -98.63 131.5 45.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 CA-C-O 121.297 0.57 . . . . 75.239999999999995 111.674 -172.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.49 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 25.0 m -83.69 103.79 13.28 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.686 -0.688 . . . . 75.219999999999999 109.211 176.527 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 61.3 mt -93.44 105.66 17.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 116.246 -0.434 . . . . 74.099999999999994 110.474 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 28.4 mmm180 -121.41 153.74 37.43 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.99 -0.55 . . . . 73.299999999999997 110.29 177.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 23.3 mp0 -113.49 107.66 16.12 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-O 121.355 0.598 . . . . 75.510000000000005 110.522 -178.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.653 ' HG3' HD12 ' A' ' 23' ' ' ILE . 24.1 mm-40 -106.21 88.4 2.78 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.204 -0.907 . . . . 62.109999999999999 109.8 -177.115 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 74.11 -109.57 2.83 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.702 -0.761 . . . . 64.340000000000003 112.201 -179.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.672 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 25.4 m-20 -109.31 22.4 15.87 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.752 0.311 . . . . 72.010000000000005 110.507 -177.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.56 ' HE2' HD11 ' A' ' 23' ' ' ILE . 22.2 pttm -138.41 127.05 23.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.307 0.575 . . . . 60.149999999999999 111.175 -178.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.591 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 26.4 m -85.13 103.9 14.54 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.623 -0.717 . . . . 62.329999999999998 109.232 174.423 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.653 HD12 ' HG3' ' A' ' 18' ' ' GLU . 41.7 mt -95.61 112.54 28.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.162 0.505 . . . . 72.420000000000002 110.294 -176.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.705 ' HB3' HG21 ' A' ' 13' ' ' VAL . 23.9 mt-30 -103.82 109.78 21.65 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.413 -0.812 . . . . 72.329999999999998 111.111 -176.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.49 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 24.7 mt-10 -94.61 106.67 18.66 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.032 -0.531 . . . . 72.340000000000003 111.137 -179.113 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.493 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 54.5 m-85 -76.69 109.52 10.53 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.276 -0.42 . . . . 52.530000000000001 110.508 178.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 74.7 mtt180 -124.06 140.49 52.92 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.337 -0.392 . . . . 74.109999999999999 110.115 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.505 HG21 ' CG ' ' B' ' 131' ' ' PHE . 12.3 p -109.03 -19.47 6.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.422 0.63 . . . . 72.530000000000001 111.28 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -159.82 24.54 0.18 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.237 -0.653 . . . . 72.450000000000003 109.237 -176.321 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 99.62 -31.18 8.65 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 110.984 -0.846 . . . . 75.319999999999993 110.984 -169.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 89.3 t80 -66.87 130.1 42.04 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.178 -0.511 . . . . 75.299999999999997 110.811 178.004 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.757 HD11 HG13 ' A' ' 35' ' ' ILE . 3.3 tm? -88.38 114.47 25.03 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.554 -0.748 . . . . 41.530000000000001 109.231 178.19 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . 0.493 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 43.2 p90 -110.98 -13.27 14.13 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.664 -0.414 . . . . 74.239999999999995 111.682 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -163.21 144.42 9.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.723 0.296 . . . . 65.010000000000005 111.34 179.588 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.757 HG13 HD11 ' A' ' 32' ' ' LEU . 71.3 mt -126.1 123.71 64.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.111 -0.495 . . . . 62.310000000000002 109.768 176.07 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.419 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 87.0 tttt -108.81 107.22 17.56 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.628 -0.508 . . . . 63.149999999999999 109.628 176.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.649 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.7 t -89.92 132.31 34.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.189 -0.671 . . . . 53.039999999999999 109.189 178.38 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.591 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 18.9 t -116.57 73.97 6.05 Favored Pre-proline 0 C--N 1.322 -0.623 0 N-CA-C 109.433 -0.58 . . . . 41.240000000000002 109.433 171.194 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.47 ' HD3' HG12 ' A' ' 37' ' ' VAL . 61.0 Cg_endo -78.71 145.87 20.69 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.642 2.228 . . . . 74.099999999999994 112.977 179.212 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.672 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 30.5 mtpp -68.07 -28.0 66.99 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.514 -0.766 . . . . 73.530000000000001 109.932 174.043 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 66.5 m-70 -122.52 96.2 4.94 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.55 -0.75 . . . . 54.439999999999998 109.745 178.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.418 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 139.51 -21.5 2.9 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.73 -0.747 . . . . 54.520000000000003 112.422 -179.649 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.422 ' HD3' ' HA ' ' A' ' 43' ' ' LYS . 69.4 mmtt 71.89 150.38 0.13 Allowed Pre-proline 0 N--CA 1.47 0.56 0 C-N-CA 123.201 0.6 . . . . 71.439999999999998 111.956 -179.593 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.649 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 39.4 Cg_endo -67.0 137.18 43.72 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.564 2.176 . . . . 73.530000000000001 112.683 -178.359 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 42.0 p90 -149.52 163.95 36.41 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.738 -0.664 . . . . 73.329999999999998 110.294 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.472 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 96.3 m-85 -108.22 126.44 52.81 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.484 -0.325 . . . . 72.530000000000001 111.429 -176.797 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.449 ' HB3' ' HD2' ' A' ' 57' ' ' PHE . 36.9 mt -107.22 100.14 9.62 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.131 -0.486 . . . . 72.510000000000005 109.977 171.253 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.6 t -84.74 126.72 40.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.245 -0.434 . . . . 73.349999999999994 109.901 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.45 111.39 18.43 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.236 -0.653 . . . . 73.420000000000002 109.236 -178.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.05 168.89 19.01 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.8 -0.636 . . . . 60.409999999999997 111.411 -172.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -64.14 145.19 56.37 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.765 -0.652 . . . . 74.329999999999998 109.904 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 113.83 135.95 6.26 Favored Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.452 -0.88 . . . . 44.299999999999997 112.373 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.2 m -79.24 19.68 0.56 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.931 0.396 . . . . 61.539999999999999 110.832 178.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -78.91 -42.61 26.7 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.026 0.441 . . . . 64.219999999999999 111.137 -177.313 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.84 36.4 2.99 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.698 -0.763 . . . . 75.319999999999993 111.919 -178.404 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.2 t30 -95.45 129.49 42.59 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.821 0.343 . . . . 74.049999999999997 110.539 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.449 ' HD2' ' HB3' ' A' ' 47' ' ' LEU . 34.7 m-85 -111.51 149.38 31.43 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.227 -0.442 . . . . 72.409999999999997 110.153 177.016 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 51.0 mm -121.57 125.73 73.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.22 -0.445 . . . . 72.120000000000005 109.98 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.581 ' HG3' HG13 ' A' ' 67' ' ' ILE . 27.4 mtp180 -81.6 141.08 34.05 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.438 -0.346 . . . . 72.120000000000005 110.66 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 33.7 t -70.0 -16.21 63.14 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.229 0.538 . . . . 74.140000000000001 109.894 176.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.46 ' OD1' ' HB3' ' A' ' 59' ' ' ARG . 0.4 OUTLIER -76.03 -34.41 59.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.4 -0.818 . . . . 73.310000000000002 109.945 178.169 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 47.7 mt-30 -143.26 70.36 18.01 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.443 -0.799 . . . . 74.329999999999998 109.786 -174.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -72.88 -2.35 11.83 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 123.325 2.684 . . . . 73.450000000000003 113.476 -175.067 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -94.06 -13.63 26.67 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.608 0.242 . . . . 71.450000000000003 111.332 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.419 ' HE2' ' HB2' ' A' ' 65' ' ' LYS . 0.0 OUTLIER -117.02 168.76 9.97 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-O 120.549 0.214 . . . . 73.049999999999997 110.943 -179.567 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.429 ' N ' HD12 ' A' ' 66' ' ' LEU . 4.1 mp -106.3 151.84 24.31 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 120.831 0.348 . . . . 74.109999999999999 111.032 -175.228 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.581 HG13 ' HG3' ' A' ' 59' ' ' ARG . 37.9 mm -119.54 104.98 44.43 Favored Pre-proline 0 C--N 1.325 -0.463 0 CA-C-N 116.192 -0.458 . . . . 52.049999999999997 109.98 177.519 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.558 ' O ' HG23 ' A' ' 72' ' ' ILE . 61.3 Cg_endo -73.77 177.42 8.11 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.822 2.348 . . . . 62.219999999999999 113.004 -178.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . 0.626 ' HA ' HG12 ' A' ' 72' ' ' ILE . 28.5 tt0 -65.32 -32.05 73.5 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 113.029 0.751 . . . . 64.120000000000005 113.029 -168.159 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 3.9 p90 -71.34 -18.95 62.36 Favored 'General case' 0 C--N 1.323 -0.545 0 O-C-N 121.517 -0.739 . . . . 74.430000000000007 110.592 178.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.47 ' HB3' HG23 ' A' ' 67' ' ' ILE . 4.8 tp10 -102.38 -17.76 15.7 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 115.749 -0.66 . . . . 72.349999999999994 110.549 -177.117 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.626 HG12 ' HA ' ' A' ' 69' ' ' GLN . 35.3 pt -74.26 -21.77 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.147 0 CA-C-O 121.256 0.55 . . . . 63.0 109.863 174.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -107.21 26.59 9.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.417 -0.81 . . . . 73.540000000000006 109.664 174.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.2 t -61.42 -29.84 70.19 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.197 -0.91 . . . . 65.540000000000006 110.234 179.295 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . 0.517 ' O ' ' HE3' ' A' ' 21' ' ' LYS . 28.3 p-90 . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.135 -0.484 . . . . 72.219999999999999 110.757 175.399 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 15.0 m . . . . . 0 C--O 1.233 0.236 0 CA-C-O 121.108 0.48 . . . . 72.430000000000007 110.737 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 124.49 -65.6 0.54 Allowed Glycine 0 N--CA 1.442 -0.953 0 N-CA-C 109.983 -1.247 . . . . 74.049999999999997 109.983 -174.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 66.82 86.4 0.13 Allowed Pre-proline 0 N--CA 1.463 0.178 0 O-C-N 124.334 0.667 . . . . 65.299999999999997 111.736 173.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.579 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 11.2 Cg_endo -77.58 97.16 1.13 Allowed 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 121.913 1.742 . . . . 72.549999999999997 110.775 177.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -128.81 150.82 50.15 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.407 -0.815 . . . . 75.310000000000002 109.67 -175.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.539 HG21 ' HB3' ' B' ' 124' ' ' GLN . 12.0 p -100.7 131.31 48.56 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 121.417 0.627 . . . . 75.109999999999999 111.748 -174.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . 0.587 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 15.6 m -87.77 102.43 14.66 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.5 -0.773 . . . . 73.150000000000006 109.772 175.585 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 55.1 mt -91.03 105.82 16.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-O 120.829 0.347 . . . . 73.510000000000005 110.495 -176.291 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 28.7 mmm180 -112.85 157.89 20.84 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.259 -0.428 . . . . 65.319999999999993 110.464 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -121.22 99.32 6.42 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.23 -0.441 . . . . 33.109999999999999 109.961 178.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 57.5 mm-40 -109.59 80.86 1.36 Allowed 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.981 -0.554 . . . . 65.409999999999997 110.515 -176.353 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 82.26 -121.43 5.43 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 121.008 -0.615 . . . . 73.209999999999994 112.32 -179.351 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . 0.493 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 5.9 m-20 -88.57 0.89 55.88 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.914 0.388 . . . . 74.109999999999999 110.527 -176.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.617 ' HE2' ' HB2' ' B' ' 175' ' ' TRP . 15.6 pttp -125.47 124.67 41.9 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.349 0.595 . . . . 75.120000000000005 112.373 -172.54 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . 0.454 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 33.4 m -83.97 109.7 17.84 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.044 -0.98 . . . . 75.25 108.595 172.114 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 53.2 mt -100.3 107.83 21.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.107 0.48 . . . . 61.509999999999998 110.627 -173.45 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.678 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 17.0 mt-30 -95.5 102.26 14.05 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.67 -0.695 . . . . 63.43 110.45 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . 0.587 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 43.3 mt-10 -86.87 102.31 14.2 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.265 -0.425 . . . . 71.230000000000004 110.365 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -78.54 104.83 9.4 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.122 0.487 . . . . 75.299999999999997 110.017 178.101 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . 0.513 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 82.6 mtm180 -126.14 136.76 53.26 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.653 -0.703 . . . . 71.519999999999996 110.141 -179.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.677 HG13 ' H ' ' B' ' 129' ' ' ASN . 2.4 p -84.81 -67.87 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 C-N-CA 120.32 -0.552 . . . . 61.329999999999998 109.658 175.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . 0.677 ' H ' HG13 ' B' ' 128' ' ' VAL . 2.2 t-20 -138.64 75.84 1.54 Allowed 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.56 -0.533 . . . . 71.299999999999997 109.56 178.332 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.7 -27.55 5.29 Favored Glycine 0 CA--C 1.518 0.231 0 CA-C-N 115.771 -0.65 . . . . 62.229999999999997 112.223 -178.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.505 ' CG ' HG21 ' A' ' 28' ' ' VAL . 82.9 t80 -86.19 124.75 32.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.902 0.382 . . . . 60.409999999999997 111.225 -177.176 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.857 HD11 HG13 ' B' ' 135' ' ' ILE . 3.5 tm? -85.6 119.38 25.88 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.893 -0.78 . . . . 52.25 108.893 175.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 44.1 p90 -112.94 -17.11 12.55 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.495 -0.482 . . . . 63.299999999999997 111.787 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.46 133.22 6.43 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.717 0.294 . . . . 63.219999999999999 111.059 178.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.857 HG13 HD11 ' B' ' 132' ' ' LEU . 69.8 mt -113.28 120.34 62.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.453 -0.339 . . . . 74.409999999999997 110.174 174.4 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.678 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.9 tttt -101.0 104.64 15.81 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.682 -0.488 . . . . 65.430000000000007 109.682 176.213 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.609 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 2.7 t -90.91 128.67 42.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 108.928 -0.767 . . . . 63.340000000000003 108.928 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.454 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 20.3 t -112.96 73.34 1.57 Allowed Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.771 -0.455 . . . . 75.450000000000003 109.771 171.253 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.491 ' HG3' ' HE1' ' B' ' 145' ' ' TYR . 72.9 Cg_endo -80.66 143.84 15.24 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 122.438 2.092 . . . . 71.340000000000003 112.76 178.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . 0.493 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 30.0 mtpp -65.75 -23.77 66.81 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.483 -0.78 . . . . 74.209999999999994 110.383 174.04 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 72.6 m-70 -115.91 95.07 4.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.574 -0.739 . . . . 54.039999999999999 110.025 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . 0.449 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 127.58 -9.93 6.83 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.178 -1.011 . . . . 51.409999999999997 113.638 177.093 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . 0.449 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 73.1 mmtt 70.64 155.9 0.15 Allowed Pre-proline 0 N--CA 1.472 0.644 0 CA-C-O 120.755 0.312 . . . . 44.020000000000003 111.164 -178.488 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.609 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 33.6 Cg_endo -66.48 135.13 38.17 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.192 1.928 . . . . 54.509999999999998 112.84 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . 0.491 ' HE1' ' HG3' ' B' ' 139' ' ' PRO . 14.7 p90 -146.4 161.28 40.71 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.768 -0.651 . . . . 73.099999999999994 110.205 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -106.75 138.46 42.88 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.27 -0.423 . . . . 72.439999999999998 111.758 -176.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.486 ' HB2' ' HB ' ' B' ' 135' ' ' ILE . 18.7 mt -110.38 95.73 5.76 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.447 -0.797 . . . . 75.299999999999997 109.72 168.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 41.6 t -82.14 126.39 39.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 109.692 -0.484 . . . . 72.409999999999997 109.692 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . 0.47 HH11 ' HG3' ' B' ' 149' ' ' ARG . 0.0 OUTLIER -80.86 114.66 19.89 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.439 -0.578 . . . . 62.109999999999999 109.439 -179.228 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.75 165.18 25.65 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.627 -0.715 . . . . 42.409999999999997 111.005 -174.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -70.44 147.57 49.32 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.581 -0.526 . . . . 71.420000000000002 109.581 178.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 105.01 131.26 7.03 Favored Glycine 0 N--CA 1.436 -1.347 0 C-N-CA 120.61 -0.805 . . . . 61.340000000000003 111.357 -175.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 21.6 m -82.77 17.8 1.75 Allowed 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.286 0.565 . . . . 75.010000000000005 110.587 -178.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -64.77 -52.96 54.14 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.488 -0.778 . . . . 61.43 110.958 -178.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 125.86 50.36 0.18 Allowed Glycine 0 CA--C 1.505 -0.588 0 C-N-CA 120.657 -0.782 . . . . 50.43 112.025 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 4.9 m120 -119.06 134.29 55.28 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.356 -0.422 . . . . 54.340000000000003 111.484 -177.305 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . 0.434 ' HB2' HG22 ' B' ' 172' ' ' ILE . 29.6 m-85 -117.31 159.19 23.1 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.541 -0.754 . . . . 63.229999999999997 109.735 174.357 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . 0.9 HD11 HD23 ' B' ' 166' ' ' LEU . 47.4 mm -120.7 122.79 68.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 116.256 -0.429 . . . . 74.5 110.008 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.627 ' HG3' HG13 ' B' ' 167' ' ' ILE . 52.2 mtp180 -87.81 147.18 25.26 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.375 -0.375 . . . . 73.209999999999994 110.379 178.028 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 33.8 t -67.38 -20.64 65.57 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.337 0.589 . . . . 74.450000000000003 109.466 174.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . 0.471 ' OD1' ' HB3' ' B' ' 159' ' ' ARG . 0.5 OUTLIER -71.93 -34.19 68.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.221 -0.9 . . . . 71.140000000000001 109.869 177.248 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -141.47 76.88 20.31 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.448 -0.796 . . . . 73.420000000000002 109.709 -174.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -82.18 4.53 6.99 Favored 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 122.746 2.297 . . . . 71.540000000000006 113.326 -173.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -109.07 -11.07 14.99 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.804 0.335 . . . . 73.349999999999994 111.084 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -122.93 137.25 55.0 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.75 0.31 . . . . 75.549999999999997 110.907 -176.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . 0.9 HD23 HD11 ' B' ' 158' ' ' ILE . 93.6 mt -73.96 130.65 40.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.018 -0.537 . . . . 74.340000000000003 109.986 177.122 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . 0.627 HG13 ' HG3' ' B' ' 159' ' ' ARG . 42.3 mm -81.48 128.5 69.54 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 116.366 -0.379 . . . . 73.219999999999999 110.393 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.527 ' O ' HG23 ' B' ' 172' ' ' ILE . 40.0 Cg_endo -65.75 173.01 7.37 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 123.163 2.575 . . . . 63.310000000000002 112.789 -179.344 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 33.8 tt0 -86.11 3.76 41.21 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.825 -0.625 . . . . 73.409999999999997 112.181 -168.271 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . 0.464 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 33.7 p90 -104.05 -18.89 14.38 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.377 -0.529 . . . . 73.420000000000002 109.872 172.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.464 ' HG2' ' CD1' ' B' ' 170' ' ' TRP . 2.8 mm-40 -97.65 -10.47 24.98 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.566 -0.743 . . . . 71.140000000000001 111.393 -176.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.527 HG23 ' O ' ' B' ' 168' ' ' PRO . 30.7 pt -71.68 -21.52 21.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.877 -0.601 . . . . 71.200000000000003 110.171 175.537 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -112.09 46.49 1.15 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.41 -0.814 . . . . 64.200000000000003 108.995 174.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . 0.464 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 2.1 t -74.89 -13.84 60.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.402 -0.817 . . . . 74.219999999999999 110.163 -178.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . 0.617 ' HB2' ' HE2' ' B' ' 121' ' ' LYS . 49.1 p-90 . . . . . 0 C--O 1.248 0.998 0 CA-C-N 115.502 -0.772 . . . . 74.129999999999995 109.85 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 41.6 m . . . . . 0 C--O 1.233 0.193 0 CA-C-O 121.112 0.482 . . . . 73.319999999999993 111.022 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -177.69 -38.72 0.06 OUTLIER Glycine 0 N--CA 1.446 -0.663 0 N-CA-C 110.71 -0.956 . . . . 54.240000000000002 110.71 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 54.05 66.29 4.52 Favored Pre-proline 0 N--CA 1.464 0.254 0 C-N-CA 123.556 0.742 . . . . 71.049999999999997 112.15 175.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 53.8 Cg_endo -76.97 137.49 17.53 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.169 1.912 . . . . 73.109999999999999 112.516 -178.317 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -141.4 155.83 45.86 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.968 -0.56 . . . . 71.5 109.738 179.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.8 p -110.88 129.75 65.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.273 0.559 . . . . 64.120000000000005 110.842 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.6 m -93.86 104.38 16.45 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.728 -0.669 . . . . 71.439999999999998 109.563 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 67.1 mt -90.1 106.82 17.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 116.301 -0.409 . . . . 72.409999999999997 110.351 -177.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 23.6 mmm180 -115.57 156.96 24.83 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.143 -0.48 . . . . 73.430000000000007 110.212 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 26.1 mp0 -121.58 127.17 50.64 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 121.098 0.475 . . . . 70.219999999999999 110.057 178.047 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -105.08 -60.58 1.59 Allowed 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.35 -0.841 . . . . 63.130000000000003 111.0 -172.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.519 ' C ' ' H ' ' A' ' 21' ' ' LYS . . . -156.95 76.58 0.2 Allowed Glycine 0 CA--C 1.507 -0.433 0 N-CA-C 110.353 -1.099 . . . . 51.420000000000002 110.353 178.741 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.538 ' HB3' ' HG3' ' A' ' 40' ' ' LYS . 19.2 m-20 70.07 -26.76 0.16 Allowed 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 123.519 0.728 . . . . 63.329999999999998 111.017 -170.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.519 ' H ' ' C ' ' A' ' 19' ' ' GLY . 22.7 pttm -83.42 120.21 25.61 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 121.198 0.523 . . . . 60.140000000000001 110.42 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.594 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 33.2 m -82.48 121.62 26.99 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.375 -0.83 . . . . 72.310000000000002 109.641 176.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 56.0 mt -111.33 106.77 21.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-O 121.036 0.446 . . . . 61.439999999999998 110.333 -178.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.67 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 19.2 mt-30 -100.53 111.04 23.24 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.788 -0.642 . . . . 55.100000000000001 110.756 -177.642 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 33.0 mt-10 -92.57 108.77 20.23 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.768 -0.651 . . . . 63.100000000000001 110.85 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.57 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 95.6 m-85 -83.0 104.65 13.37 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.968 0.414 . . . . 63.009999999999998 110.151 178.317 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -115.12 119.25 35.77 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.947 -0.569 . . . . 74.310000000000002 109.617 -179.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.781 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.7 p -73.26 -73.32 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 C-N-CA 120.786 -0.366 . . . . 61.32 110.879 -178.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.781 ' H ' HG13 ' A' ' 28' ' ' VAL . 7.6 t-20 -127.53 68.28 1.3 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.291 -0.633 . . . . 62.509999999999998 109.291 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 73.19 12.52 79.62 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.452 -0.795 . . . . 72.530000000000001 111.784 -175.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 29.5 t80 -129.33 124.08 33.42 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.818 0.342 . . . . 64.109999999999999 110.202 -175.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.419 HD11 HG13 ' A' ' 35' ' ' ILE . 3.2 tm? -72.41 132.76 44.35 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.611 -0.722 . . . . 74.409999999999997 109.781 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . 0.57 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 45.4 p90 -125.76 -22.81 4.13 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.127 0.417 . . . . 74.340000000000003 112.127 176.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.18 148.23 24.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.661 0.267 . . . . 75.230000000000004 111.022 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.419 HG13 HD11 ' A' ' 32' ' ' LEU . 61.6 mt -125.23 124.37 67.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 116.412 -0.358 . . . . 73.510000000000005 110.215 177.49 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.67 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.6 tttt -103.72 106.24 16.7 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.631 -0.507 . . . . 74.519999999999996 109.631 177.121 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.698 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.7 t -94.65 129.7 44.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 N-CA-C 109.226 -0.657 . . . . 34.5 109.226 177.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.594 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.4 t -117.6 72.57 7.81 Favored Pre-proline 0 C--N 1.317 -0.808 0 N-CA-C 109.845 -0.428 . . . . 45.43 109.845 173.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.581 ' HD3' HG12 ' A' ' 37' ' ' VAL . 54.1 Cg_endo -78.62 137.31 14.37 Favored 'Trans proline' 0 N--CA 1.456 -0.735 0 C-N-CA 122.197 1.932 . . . . 61.240000000000002 112.297 176.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.538 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 26.3 mtpp -68.76 -20.46 64.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.451 0.643 . . . . 44.039999999999999 109.868 178.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 84.7 m-70 -117.69 83.57 2.01 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.392 -0.822 . . . . 71.040000000000006 109.423 178.27 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.443 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 141.33 -22.0 2.58 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.945 -0.645 . . . . 52.399999999999999 112.339 -178.562 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.443 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 98.6 mttt 74.78 152.72 0.14 Allowed Pre-proline 0 N--CA 1.469 0.477 0 C-N-CA 123.579 0.752 . . . . 74.319999999999993 111.889 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.698 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 35.1 Cg_endo -66.73 136.37 41.9 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.651 2.234 . . . . 73.120000000000005 113.247 -178.139 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -142.33 162.32 35.77 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.511 -0.768 . . . . 62.140000000000001 109.589 176.505 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -106.11 123.19 47.63 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.397 -0.365 . . . . 72.349999999999994 110.244 178.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.465 HD11 HG13 ' A' ' 67' ' ' ILE . 28.5 tp -102.27 96.1 6.74 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 108.792 -0.818 . . . . 74.430000000000007 108.792 172.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.5 t -93.63 120.63 43.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.749 -0.659 . . . . 73.400000000000006 110.181 -175.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.7 tmm_? -77.88 121.47 24.18 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 109.065 -0.717 . . . . 74.150000000000006 109.065 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.15 -162.98 0.26 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.913 -0.585 . . . . 62.350000000000001 111.269 -173.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.404 ' OD2' ' HB2' ' A' ' 53' ' ' SER . 5.7 p-10 -73.76 154.78 39.43 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.161 0.505 . . . . 63.229999999999997 110.805 -177.443 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -65.29 -22.35 69.14 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.641 -0.709 . . . . 50.109999999999999 113.28 -177.422 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.404 ' HB2' ' OD2' ' A' ' 51' ' ' ASP . 14.5 m -73.52 -39.9 64.43 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.089 0.471 . . . . 40.030000000000001 109.958 178.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.521 ' OD2' ' HB3' ' A' ' 56' ' ' ASN . 31.2 t70 -71.66 -39.76 70.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.506 -0.77 . . . . 54.240000000000002 109.835 175.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 58.95 63.49 5.15 Favored Glycine 0 C--N 1.336 0.557 0 CA-C-N 115.78 -0.646 . . . . 74.430000000000007 111.663 178.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.521 ' HB3' ' OD2' ' A' ' 54' ' ' ASP . 14.6 t30 -165.36 155.76 13.51 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.685 -0.257 . . . . 72.120000000000005 110.331 -168.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.572 ' HB2' ' HB ' ' A' ' 67' ' ' ILE . 2.4 m-85 -108.68 143.11 38.2 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.162 -0.681 . . . . 75.439999999999998 109.162 174.448 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 48.1 mm -113.53 127.46 70.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.436 0.636 . . . . 74.549999999999997 110.319 177.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.469 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 58.5 ttt180 -93.63 124.09 37.39 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.309 -0.86 . . . . 73.0 109.685 -176.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 87.9 p -59.67 -26.77 65.82 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.242 0.544 . . . . 41.119999999999997 110.788 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.469 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 16.5 t70 -60.22 -39.71 87.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.211 -0.904 . . . . 62.450000000000003 110.711 177.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 29.3 mt-30 -144.67 89.01 6.85 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 115.947 -0.569 . . . . 71.109999999999999 109.863 -179.018 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -62.58 -24.71 75.22 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 123.1 2.533 . . . . 75.129999999999995 113.261 -175.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -78.84 -14.27 59.34 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 120.747 0.308 . . . . 73.510000000000005 110.73 178.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.2 tptm -93.71 123.42 37.02 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.459 0.647 . . . . 52.509999999999998 110.892 -177.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.412 ' N ' HD12 ' A' ' 66' ' ' LEU . 5.5 mp -90.24 128.48 36.41 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 114.798 -1.092 . . . . 61.399999999999999 108.688 175.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.757 HG23 ' HB3' ' A' ' 71' ' ' GLU . 47.0 mm -87.9 112.67 50.6 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-O 120.854 0.359 . . . . 72.209999999999994 111.373 -172.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.571 ' O ' HG23 ' A' ' 72' ' ' ILE . 60.0 Cg_endo -71.44 174.97 10.07 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.833 2.355 . . . . 53.140000000000001 112.036 179.163 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -79.15 1.85 22.96 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 112.987 0.736 . . . . 64.319999999999993 112.987 -166.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 42.4 p90 -107.04 -19.62 13.56 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.437 0.637 . . . . 70.420000000000002 109.953 172.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.757 ' HB3' HG23 ' A' ' 67' ' ' ILE . 2.8 mm-40 -87.41 -17.46 32.23 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.462 -0.79 . . . . 74.299999999999997 110.332 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.571 HG23 ' O ' ' A' ' 68' ' ' PRO . 42.3 pt -63.23 -28.39 44.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.885 -0.598 . . . . 65.209999999999994 111.412 -179.005 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.477 ' HD1' HG13 ' A' ' 72' ' ' ILE . 41.0 p90 -117.25 42.77 2.47 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.581 0.705 . . . . 74.319999999999993 109.584 175.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.424 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 4.7 t -59.27 -25.2 63.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.05 -0.977 . . . . 64.540000000000006 110.801 -179.567 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 26.6 p-90 . . . . . 0 C--N 1.327 -0.397 0 CA-C-N 115.925 -0.579 . . . . 70.150000000000006 111.267 177.479 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 57.1 m . . . . . 0 C--O 1.234 0.268 0 CA-C-O 121.451 0.643 . . . . 63.420000000000002 111.089 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 125.24 -60.8 0.62 Allowed Glycine 0 N--CA 1.44 -1.073 0 N-CA-C 109.129 -1.588 . . . . 61.219999999999999 109.129 -169.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 61.08 88.34 0.12 Allowed Pre-proline 0 CA--C 1.52 -0.209 0 O-C-N 124.322 0.66 . . . . 73.310000000000002 111.27 171.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.888 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 7.3 Cg_endo -76.41 102.83 1.66 Allowed 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.173 1.915 . . . . 74.230000000000004 111.098 -178.497 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -102.89 150.36 23.59 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.037 -0.528 . . . . 61.43 109.838 -177.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.644 HG21 ' HB3' ' B' ' 124' ' ' GLN . 14.9 p -113.05 131.58 64.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 121.401 0.62 . . . . 61.43 111.617 -175.153 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 48.1 m -89.46 118.86 29.42 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.314 -0.857 . . . . 61.100000000000001 109.373 174.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 63.5 mt -92.54 105.25 16.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.07 0.462 . . . . 74.319999999999993 111.175 -174.519 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . 0.562 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 11.0 mmm180 -99.12 153.0 19.23 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.952 -0.567 . . . . 74.409999999999997 110.459 177.224 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 76.0 mt-30 -134.81 99.19 4.24 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.537 -0.912 . . . . 75.120000000000005 108.537 176.163 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . 0.49 ' HG3' HD12 ' B' ' 123' ' ' ILE . 43.2 mm-40 -103.6 9.25 37.47 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.125 -0.489 . . . . 64.040000000000006 112.205 -169.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 109.45 100.81 2.64 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.37 -0.919 . . . . 64.129999999999995 111.92 -178.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . 0.573 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 9.5 m-20 66.66 -9.57 0.33 Allowed 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 124.085 0.954 . . . . 73.549999999999997 111.672 -176.515 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.491 ' HA ' ' O ' ' B' ' 138' ' ' VAL . 27.1 pttt -131.56 115.71 16.47 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 121.243 0.544 . . . . 75.010000000000005 112.074 -176.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 59.4 m -82.39 114.03 20.57 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.08 -0.964 . . . . 72.5 109.243 172.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . 0.708 HG12 HG13 ' B' ' 137' ' ' VAL . 49.8 mt -101.51 105.94 18.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 CA-C-O 121.326 0.584 . . . . 74.519999999999996 110.377 -176.114 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.644 ' HB3' HG21 ' B' ' 113' ' ' VAL . 49.7 mt-30 -96.01 106.89 19.11 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.444 -0.798 . . . . 71.230000000000004 110.974 -176.571 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -90.06 106.09 18.24 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.841 -0.618 . . . . 74.109999999999999 110.631 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -85.1 107.06 17.01 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.994 0.426 . . . . 75.200000000000003 110.698 -179.586 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . 0.502 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 79.0 mtm180 -120.39 120.52 36.22 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.137 0.494 . . . . 61.200000000000003 110.204 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.888 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -76.79 -62.5 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.893 -0.594 . . . . 72.219999999999999 111.021 -178.177 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . 0.574 ' H ' HG13 ' B' ' 128' ' ' VAL . 1.2 t-20 -149.21 76.82 1.34 Allowed 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.638 -0.504 . . . . 64.010000000000005 109.638 -178.54 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.75 -7.34 66.11 Favored Glycine 0 CA--C 1.521 0.438 0 CA-C-N 115.817 -0.629 . . . . 45.43 113.058 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.407 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 54.4 t80 -122.31 123.25 40.98 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.151 0.5 . . . . 71.450000000000003 111.27 -176.625 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.703 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -76.6 117.84 18.64 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.09 -0.959 . . . . 63.539999999999999 108.888 173.431 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -108.06 -22.85 12.23 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.478 -0.489 . . . . 71.049999999999997 111.525 -178.233 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -157.62 143.05 17.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.929 0.395 . . . . 75.0 111.329 -178.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.703 HG13 HD11 ' B' ' 132' ' ' LEU . 76.5 mt -121.77 121.75 65.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 115.895 -0.593 . . . . 65.549999999999997 110.067 176.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.467 ' HD2' ' CZ ' ' B' ' 146' ' ' PHE . 82.2 tttt -102.79 105.06 15.41 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.928 0.394 . . . . 70.200000000000003 109.99 177.373 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.708 HG13 HG12 ' B' ' 123' ' ' ILE . 5.0 t -90.46 132.37 35.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 108.653 -0.869 . . . . 74.420000000000002 108.653 176.08 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.511 HG13 ' HB3' ' B' ' 144' ' ' PRO . 20.6 t -114.21 71.73 2.21 Favored Pre-proline 0 C--N 1.317 -0.822 0 N-CA-C 109.907 -0.405 . . . . 64.030000000000001 109.907 173.345 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.534 ' HD3' HG12 ' B' ' 137' ' ' VAL . 74.3 Cg_endo -81.13 134.42 9.24 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.082 1.855 . . . . 73.420000000000002 113.243 178.534 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . 0.573 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 28.8 mtpp -60.04 -26.85 66.45 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.291 -0.868 . . . . 65.019999999999996 109.84 171.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 89.4 m-70 -116.8 89.5 3.12 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.282 -0.872 . . . . 73.420000000000002 109.492 177.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 138.36 -19.14 3.23 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.482 -0.866 . . . . 54.130000000000003 112.536 -179.294 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 47.0 mtmt 71.62 147.21 0.12 Allowed Pre-proline 0 N--CA 1.469 0.522 0 C-N-CA 123.309 0.643 . . . . 64.519999999999996 111.637 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.697 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 29.6 Cg_endo -64.8 125.81 15.48 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.584 2.189 . . . . 53.219999999999999 112.626 -179.356 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 25.7 p90 -139.88 160.29 40.23 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.076 -0.511 . . . . 71.329999999999998 110.383 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.467 ' CZ ' ' HD2' ' B' ' 136' ' ' LYS . 70.4 m-85 -104.54 122.18 45.02 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.091 -0.504 . . . . 73.019999999999996 110.04 178.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 26.0 tp -97.86 93.33 6.28 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 108.248 -1.019 . . . . 73.030000000000001 108.248 171.329 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.6 t -95.39 129.11 45.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.755 -0.657 . . . . 74.319999999999993 110.55 -173.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . 0.598 HH11 ' HG3' ' B' ' 149' ' ' ARG . 0.0 OUTLIER -79.45 123.22 27.33 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 116.217 -0.447 . . . . 75.510000000000005 109.871 177.462 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -77.41 -168.32 1.12 Allowed 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.815 -0.63 . . . . 72.400000000000006 110.034 177.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -56.94 147.13 24.63 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.174 -0.466 . . . . 52.130000000000003 110.792 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -75.14 -10.32 84.2 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.541 -0.838 . . . . 60.240000000000002 112.745 -177.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 1.6 m -67.67 -38.33 83.59 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.888 0.851 . . . . 71.349999999999994 108.729 172.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 15.1 t0 -80.36 -42.08 23.56 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.335 -1.302 . . . . 74.140000000000001 109.627 175.36 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 69.38 18.8 73.78 Favored Glycine 0 C--N 1.331 0.27 0 CA-C-N 115.17 -0.923 . . . . 72.340000000000003 112.139 -177.132 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 39.2 t30 -104.63 155.43 18.86 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 122.453 0.301 . . . . 62.310000000000002 111.656 -169.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . 0.662 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 8.3 m-85 -110.28 146.63 35.35 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.922 -0.77 . . . . 63.439999999999998 108.922 173.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.7 mm -118.31 133.39 65.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.038 0.447 . . . . 54.020000000000003 110.341 178.308 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.525 ' HD2' HD11 ' B' ' 167' ' ' ILE . 9.5 ttt180 -88.69 122.24 31.91 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.208 -0.664 . . . . 72.019999999999996 109.208 -179.001 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 66.5 p -57.66 -30.56 65.53 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 112.141 0.423 . . . . 61.240000000000002 112.141 -174.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -69.66 -40.45 76.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.068 0.461 . . . . 60.200000000000003 111.244 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 12.4 tt0 -130.33 88.84 46.41 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-N 116.139 -0.482 . . . . 73.219999999999999 110.178 -175.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -67.8 -12.76 36.49 Favored 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.917 2.411 . . . . 63.0 112.29 -179.083 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -84.58 -6.32 59.36 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.735 -0.666 . . . . 64.209999999999994 110.144 176.473 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 22.2 tptm -109.26 123.67 49.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.547 0.689 . . . . 73.219999999999999 110.998 -177.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . 0.471 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.0 mp -91.21 135.2 33.95 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 114.731 -1.122 . . . . 75.129999999999995 108.204 175.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . 0.662 ' HB ' ' HB2' ' B' ' 157' ' ' PHE . 48.1 mm -95.93 113.11 61.46 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-O 121.037 0.446 . . . . 74.120000000000005 111.303 -173.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.497 ' O ' HG23 ' B' ' 172' ' ' ILE . 55.9 Cg_endo -69.91 177.95 5.17 Favored 'Trans proline' 0 N--CA 1.464 -0.253 0 C-N-CA 123.15 2.566 . . . . 73.329999999999998 112.479 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -85.86 6.39 28.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.976 -0.557 . . . . 70.109999999999999 112.269 -168.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 30.4 p90 -107.7 -25.32 11.35 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.207 0.527 . . . . 75.239999999999995 110.007 171.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.415 ' HA ' ' HB2' ' B' ' 174' ' ' SER . 21.0 mm-40 -80.77 -14.7 57.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.753 -0.658 . . . . 64.319999999999993 110.9 -179.051 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.526 HG13 ' CD2' ' B' ' 173' ' ' PHE . 26.5 pt -72.64 -12.02 15.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.86 -0.609 . . . . 72.420000000000002 112.291 -176.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . 0.526 ' CD2' HG13 ' B' ' 172' ' ' ILE . 88.4 m-85 -126.83 21.03 7.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.44 0.638 . . . . 62.340000000000003 109.785 176.323 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . 0.415 ' HB2' ' HA ' ' B' ' 171' ' ' GLU . 7.8 t -95.76 28.77 2.91 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.115 -0.948 . . . . 60.5 110.925 -175.16 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 6.3 m0 . . . . . 0 C--O 1.244 0.794 0 CA-C-O 118.201 -0.904 . . . . 73.409999999999997 111.679 -176.671 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 18.2 m . . . . . 0 C--O 1.234 0.266 0 CA-C-O 120.908 0.385 . . . . 73.299999999999997 111.256 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 83.34 -60.54 4.87 Favored Glycine 0 N--CA 1.447 -0.619 0 N-CA-C 110.763 -0.935 . . . . 73.120000000000005 110.763 -173.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 60.19 88.35 0.12 Allowed Pre-proline 0 N--CA 1.463 0.214 0 C-N-CA 123.818 0.847 . . . . 74.129999999999995 112.235 176.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.608 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 37.5 Cg_endo -83.75 102.31 0.97 Allowed 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.344 2.03 . . . . 73.049999999999997 111.145 175.537 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.52 ' HA ' ' HB2' ' B' ' 151' ' ' ASP . 5.8 p-10 -130.06 140.91 50.77 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.186 0.517 . . . . 52.329999999999998 110.026 179.09 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.669 HG21 ' HB3' ' A' ' 24' ' ' GLN . 14.1 p -85.05 130.8 35.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.864 -0.607 . . . . 75.340000000000003 110.958 -176.392 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 34.3 m -88.26 105.07 17.3 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 109.674 -0.491 . . . . 73.349999999999994 109.674 177.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 72.2 mt -87.82 111.24 21.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.938 -0.574 . . . . 55.420000000000002 110.51 -177.091 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.476 ' HG2' ' O ' ' A' ' 23' ' ' ILE . 12.9 ptm180 -126.4 173.78 9.1 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.438 -0.578 . . . . 74.549999999999997 109.438 178.15 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -138.3 101.23 4.33 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.834 0.349 . . . . 72.209999999999994 110.222 -176.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.604 ' HG3' HD12 ' A' ' 23' ' ' ILE . 11.3 mm-40 -97.83 90.17 4.86 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.793 -0.64 . . . . 72.239999999999995 109.969 -176.278 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 75.51 -92.78 0.89 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.788 -0.72 . . . . 64.319999999999993 112.183 -178.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.588 ' HB2' ' HB2' ' A' ' 40' ' ' LYS . 7.3 p-10 -102.85 -36.73 8.14 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.438 0.637 . . . . 65.299999999999997 110.592 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.436 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 5.8 pttm -92.94 127.27 38.39 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.602 -0.727 . . . . 70.230000000000004 112.38 -167.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.467 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 46.6 m -82.67 96.01 8.0 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 114.771 -1.104 . . . . 62.329999999999998 108.326 174.162 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.742 HG12 HG23 ' A' ' 37' ' ' VAL . 48.5 mt -86.37 112.25 22.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.854 -0.612 . . . . 70.430000000000007 110.349 -175.336 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.669 ' HB3' HG21 ' A' ' 13' ' ' VAL . 47.7 mt-30 -94.01 104.63 16.67 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.738 -0.664 . . . . 73.219999999999999 110.464 179.456 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.486 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 26.7 mt-10 -87.48 100.6 12.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.673 -0.694 . . . . 71.109999999999999 110.868 -178.256 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -75.33 97.83 3.68 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.812 -0.44 . . . . 74.310000000000002 109.812 176.212 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.472 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 71.8 mtm180 -120.49 127.02 51.81 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.158 -0.474 . . . . 61.539999999999999 109.882 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.608 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 2.5 p -83.08 -64.26 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.643 -0.423 . . . . 75.209999999999994 110.843 178.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.578 ' H ' HG13 ' A' ' 28' ' ' VAL . 4.8 t-20 -142.72 69.25 1.31 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.175 0.512 . . . . 72.219999999999999 110.292 -176.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 88.18 1.87 81.14 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.562 -0.745 . . . . 54.549999999999997 113.474 176.223 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.408 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 60.7 t80 -131.24 127.01 36.97 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 117.151 0.476 . . . . 75.540000000000006 111.356 179.861 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.842 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -72.48 120.27 17.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.284 -0.871 . . . . 73.230000000000004 109.545 174.379 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -111.88 -19.51 12.37 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.396 -0.522 . . . . 73.150000000000006 111.746 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.44 141.56 18.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.832 0.349 . . . . 70.239999999999995 111.216 178.209 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.842 HG13 HD11 ' A' ' 32' ' ' LEU . 93.7 mt -119.73 117.36 53.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.36 -0.382 . . . . 72.310000000000002 110.723 176.706 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.495 ' HA ' ' O ' ' A' ' 45' ' ' TYR . 85.7 tttt -102.14 100.23 10.44 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.536 -0.913 . . . . 60.0 108.536 172.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.742 HG23 HG12 ' A' ' 23' ' ' ILE . 8.4 p -95.38 131.57 41.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 CA-C-N 116.174 -0.466 . . . . 74.439999999999998 110.045 -176.679 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.66 HG13 ' HG3' ' A' ' 44' ' ' PRO . 40.7 t -108.05 88.54 4.75 Favored Pre-proline 0 C--N 1.323 -0.559 0 N-CA-C 109.496 -0.557 . . . . 63.039999999999999 109.496 175.057 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.417 ' HA ' ' HB3' ' A' ' 21' ' ' LYS . 73.7 Cg_endo -82.39 141.26 11.23 Favored 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 122.51 2.14 . . . . 70.340000000000003 112.314 -178.395 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.588 ' HB2' ' HB2' ' A' ' 20' ' ' ASP . 27.9 mtpp -77.92 -14.93 59.38 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.346 0.593 . . . . 61.130000000000003 109.935 179.301 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 -116.43 25.63 10.48 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.342 -0.844 . . . . 62.130000000000003 110.203 -176.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -164.41 -148.64 5.51 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.28 -0.873 . . . . 44.219999999999999 111.128 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.1 pttp -131.9 142.63 45.87 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 117.238 0.519 . . . . 73.209999999999994 110.081 175.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.66 ' HG3' HG13 ' A' ' 38' ' ' VAL . 50.2 Cg_exo -53.15 135.53 59.67 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 123.55 2.833 . . . . 64.040000000000006 112.926 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.495 ' O ' ' HA ' ' A' ' 36' ' ' LYS . 4.6 p90 -142.32 160.44 40.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.163 -0.471 . . . . 72.299999999999997 110.69 177.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.656 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 92.0 m-85 -99.97 121.87 42.01 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.862 -0.608 . . . . 65.129999999999995 109.416 173.695 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 18.1 tp -108.36 97.43 7.11 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.913 -0.773 . . . . 74.349999999999994 108.913 175.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.47 HG21 HG21 ' B' ' 148' ' ' VAL . 38.4 t -93.94 135.41 28.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.255 -0.429 . . . . 73.299999999999997 111.282 -172.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . 0.627 HH21 ' HA ' ' A' ' 53' ' ' SER . 13.3 tpt180 -73.1 124.59 25.86 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.876 -0.602 . . . . 52.439999999999998 111.112 176.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.42 174.47 10.79 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.884 -0.598 . . . . 64.519999999999996 109.928 173.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -70.65 145.27 50.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.764 0.316 . . . . 52.399999999999999 110.596 -178.194 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.448 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 86.27 158.45 31.29 Favored Glycine 0 N--CA 1.428 -1.868 0 CA-C-O 122.133 0.852 . . . . 63.109999999999999 112.844 175.57 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.627 ' HA ' HH21 ' A' ' 49' ' ' ARG . 49.5 m -80.65 26.71 0.39 Allowed 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 114.604 -0.798 . . . . 72.420000000000002 110.113 170.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.448 ' H ' ' C ' ' A' ' 52' ' ' GLY . 22.6 t70 -56.77 -39.24 73.68 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.123 -0.944 . . . . 52.5 111.611 -178.149 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.48 16.41 20.32 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.511 -0.852 . . . . 52.229999999999997 113.068 176.325 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -112.63 148.39 34.71 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.049 0.452 . . . . 72.299999999999997 110.31 177.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -124.1 163.06 22.27 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.739 -0.664 . . . . 63.130000000000003 109.656 176.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.79 HD11 HD23 ' A' ' 66' ' ' LEU . 46.1 mm -121.27 123.81 70.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 N-CA-C 109.538 -0.541 . . . . 73.209999999999994 109.538 177.211 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.675 ' HD2' ' HB3' ' A' ' 61' ' ' ASP . 11.6 ttm180 -92.2 145.63 24.35 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.806 -0.442 . . . . 73.25 109.806 -176.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.777 ' HB2' ' HB3' ' B' ' 163' ' ' PRO . 23.8 p -61.13 -39.89 91.76 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.573 0.702 . . . . 61.420000000000002 110.133 174.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.675 ' HB3' ' HD2' ' A' ' 59' ' ' ARG . 27.7 t70 -68.34 -28.28 67.0 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 114.808 -1.087 . . . . 71.209999999999994 110.817 178.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . 0.46 ' HB3' ' HB3' ' A' ' 65' ' ' LYS . 86.7 mm-40 -133.52 73.14 73.46 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.022 -0.535 . . . . 44.43 110.254 -175.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -75.81 -17.2 18.01 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.568 2.179 . . . . 71.129999999999995 112.703 -174.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -101.62 7.32 42.19 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.03 -0.532 . . . . 71.310000000000002 110.697 -178.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.46 ' HB3' ' HB3' ' A' ' 62' ' ' GLN . 83.4 tttt -123.32 135.27 54.12 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.013 -0.539 . . . . 71.310000000000002 110.74 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.79 HD23 HD11 ' A' ' 58' ' ' ILE . 40.7 mt -84.75 112.21 20.29 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.882 -0.784 . . . . 72.150000000000006 108.882 175.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 51.4 mm -70.68 117.85 59.36 Favored Pre-proline 0 C--N 1.322 -0.629 0 CA-C-N 116.142 -0.481 . . . . 52.219999999999999 110.841 -176.211 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.91 178.62 6.99 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 123.28 2.653 . . . . 74.510000000000005 112.86 -178.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . 0.623 ' HA ' HG12 ' A' ' 72' ' ' ILE . 27.7 tt0 -74.76 -34.62 62.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.853 -0.612 . . . . 72.5 111.521 -170.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 16.0 p90 -67.66 -20.51 65.32 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.39 -0.524 . . . . 72.219999999999999 110.279 178.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -91.4 -28.42 17.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.334 -0.394 . . . . 60.109999999999999 111.404 -179.177 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.623 HG12 ' HA ' ' A' ' 69' ' ' GLN . 37.4 pt -74.81 -23.49 17.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.103 0.478 . . . . 71.430000000000007 110.274 176.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.514 ' HE2' HE21 ' A' ' 69' ' ' GLN . 38.1 m-85 -105.33 29.51 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.006 -0.543 . . . . 73.530000000000001 110.637 176.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 22.8 t -82.25 32.25 0.39 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.261 0.553 . . . . 54.439999999999998 110.863 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 54.3 m0 . . . . . 0 C--N 1.323 -0.552 0 CA-C-N 116.128 -0.487 . . . . 72.349999999999994 110.852 179.923 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 5.2 p . . . . . 0 C--O 1.234 0.282 0 CA-C-O 121.305 0.574 . . . . 75.540000000000006 111.534 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 100.98 -73.48 0.39 Allowed Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 109.999 -1.24 . . . . 74.140000000000001 109.999 -172.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 54.17 74.47 0.74 Allowed Pre-proline 0 C--N 1.329 -0.317 0 O-C-N 124.154 0.561 . . . . 73.200000000000003 111.259 175.459 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.928 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 18.0 Cg_endo -63.01 99.47 0.22 Allowed 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 122.106 1.871 . . . . 35.219999999999999 110.594 178.339 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -106.81 155.04 20.14 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.335 -0.848 . . . . 63.240000000000002 110.635 -173.217 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.624 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 12.4 p -111.54 124.68 68.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 CA-C-O 121.557 0.694 . . . . 73.319999999999993 110.421 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . 0.572 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 26.2 m -87.47 105.03 17.01 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.591 -0.731 . . . . 64.230000000000004 110.094 178.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.7 mt -83.48 106.07 13.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.955 -0.566 . . . . 72.010000000000005 110.375 -178.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . 0.437 ' HG3' HG22 ' B' ' 114' ' ' THR . 44.0 mtm105 -124.09 -178.9 4.22 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.403 -0.362 . . . . 74.230000000000004 110.465 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 64.0 mt-30 -144.76 115.21 7.61 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.205 -0.452 . . . . 72.209999999999994 111.056 -178.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . 0.461 ' O ' ' HE2' ' B' ' 121' ' ' LYS . 76.7 mm-40 -101.52 81.98 2.24 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.563 -0.532 . . . . 65.519999999999996 109.563 175.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 91.11 -110.83 3.88 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.657 -0.782 . . . . 61.409999999999997 111.4 -175.506 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . 0.79 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 18.2 m-20 -115.06 24.01 12.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.786 0.327 . . . . 74.030000000000001 110.488 178.178 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.496 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 22.5 pttt -124.55 120.1 30.98 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.232 0.539 . . . . 60.210000000000001 110.833 178.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 49.1 m -79.38 104.9 10.31 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.414 -0.812 . . . . 53.25 109.588 177.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . 0.439 HD13 ' CE3' ' B' ' 175' ' ' TRP . 52.8 mt -97.52 112.54 29.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.122 0.487 . . . . 73.519999999999996 110.408 -176.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.624 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 51.2 mt-30 -92.29 105.7 17.85 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.449 -0.796 . . . . 73.209999999999994 110.552 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . 0.572 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 41.7 mt-10 -88.3 100.78 13.27 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.774 -0.648 . . . . 63.32 110.421 -178.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . 0.474 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 63.4 m-85 -78.25 110.28 13.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.528 -0.305 . . . . 61.240000000000002 110.538 179.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' B' ' 131' ' ' PHE . 84.6 mtm180 -132.99 120.23 21.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.295 -0.411 . . . . 73.109999999999999 110.258 -179.622 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.928 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.5 p -83.51 -54.37 9.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.234 -0.439 . . . . 74.120000000000005 111.181 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 32.8 t-20 -150.08 79.25 1.36 Allowed 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.958 -0.386 . . . . 73.230000000000004 109.958 -175.136 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.65 30.36 74.55 Favored Glycine 0 N--CA 1.452 -0.234 0 CA-C-N 115.537 -0.756 . . . . 64.329999999999998 112.867 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.43 ' O ' ' HA ' ' B' ' 127' ' ' ARG . 87.2 t80 -147.86 127.22 13.09 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.856 0.36 . . . . 70.519999999999996 111.256 179.594 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.743 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -81.25 111.47 17.69 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.467 -0.788 . . . . 75.439999999999998 108.948 174.758 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . 0.474 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 51.6 p90 -106.98 -15.53 14.67 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.68 -0.408 . . . . 73.450000000000003 111.57 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . 0.51 ' HB1' ' CE2' ' B' ' 146' ' ' PHE . . . -159.07 145.18 16.61 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.947 0.403 . . . . 61.240000000000002 111.576 -178.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.743 HG13 HD11 ' B' ' 132' ' ' LEU . 75.7 mt -125.47 123.66 65.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.936 -0.574 . . . . 45.119999999999997 110.162 176.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.452 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 88.5 tttt -116.15 102.32 9.5 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.396 -0.594 . . . . 74.319999999999993 109.396 174.374 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.51 HG13 ' CE1' ' B' ' 145' ' ' TYR . 0.9 OUTLIER -102.36 127.07 56.31 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.088 0.471 . . . . 73.030000000000001 110.947 -177.603 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.816 HG22 ' HB3' ' B' ' 144' ' ' PRO . 22.8 t -112.55 88.83 11.74 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 115.235 -0.893 . . . . 71.099999999999994 109.73 -179.309 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.496 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 67.0 Cg_endo -77.95 134.54 13.31 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.137 1.891 . . . . 60.32 112.717 178.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . 0.79 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 58.2 mtpt -62.75 -28.18 69.79 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.577 -0.738 . . . . 64.120000000000005 110.251 173.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -96.43 43.84 1.07 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.996 -1.002 . . . . 75.420000000000002 110.187 -177.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 164.2 -146.71 11.75 Favored Glycine 0 N--CA 1.446 -0.645 0 CA-C-N 115.531 -0.759 . . . . 72.519999999999996 111.766 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 34.1 mmtp -126.68 150.0 69.87 Favored Pre-proline 0 C--N 1.322 -0.63 0 N-CA-C 110.206 -0.294 . . . . 73.200000000000003 110.206 177.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.816 ' HB3' HG22 ' B' ' 138' ' ' VAL . 18.6 Cg_endo -61.37 145.16 98.51 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.827 2.351 . . . . 74.319999999999993 112.22 178.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . 0.51 ' CE1' HG13 ' B' ' 137' ' ' VAL . 12.6 p90 -148.89 164.05 35.63 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.205 -0.452 . . . . 75.409999999999997 110.15 177.11 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.51 ' CE2' ' HB1' ' B' ' 134' ' ' ALA . 0.8 OUTLIER -113.14 142.13 46.12 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.901 -0.591 . . . . 75.340000000000003 111.17 -172.437 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.444 ' HB3' ' CD2' ' B' ' 157' ' ' PHE . 20.7 mt -126.65 108.74 11.37 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.972 -0.558 . . . . 75.040000000000006 109.659 170.074 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . 0.47 HG21 HG21 ' A' ' 48' ' ' VAL . 38.8 t -90.86 130.59 39.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.262 -0.426 . . . . 75.340000000000003 110.274 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . 0.463 ' HD3' ' CZ ' ' B' ' 157' ' ' PHE . 45.5 tpt85 -85.1 104.38 14.95 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.53 -0.544 . . . . 60.409999999999997 109.53 179.134 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.1 -178.85 0.85 Allowed 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.049 -0.523 . . . . 63.509999999999998 110.496 179.096 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . 0.52 ' HB2' ' HA ' ' A' ' 12' ' ' ASP . 2.2 p-10 -84.21 158.62 21.22 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.846 -0.427 . . . . 73.019999999999996 109.846 179.343 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 96.68 139.19 10.41 Favored Glycine 0 N--CA 1.439 -1.152 0 C-N-CA 120.049 -1.072 . . . . 70.200000000000003 112.609 176.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 16.3 m -77.6 43.12 0.39 Allowed 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.357 0.599 . . . . 62.229999999999997 110.97 176.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -89.15 -28.35 20.09 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.522 -0.763 . . . . 72.129999999999995 110.467 -178.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 88.79 31.39 12.73 Favored Glycine 0 N--CA 1.451 -0.36 0 N-CA-C 111.067 -0.813 . . . . 64.310000000000002 111.067 -174.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . 0.771 HD21 HD22 ' B' ' 166' ' ' LEU . 26.9 t30 -100.46 130.94 46.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.147 -0.526 . . . . 74.209999999999994 111.606 -172.571 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . 0.463 ' CZ ' ' HD3' ' B' ' 149' ' ' ARG . 29.2 m-85 -121.02 160.61 23.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.639 -0.71 . . . . 73.519999999999996 109.572 175.134 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . 0.8 HD11 HD23 ' B' ' 166' ' ' LEU . 46.0 mm -119.74 118.27 56.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.492 -0.558 . . . . 65.219999999999999 109.492 174.206 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.59 ' HG2' ' H ' ' B' ' 161' ' ' ASP . 20.0 ttm-85 -84.09 142.38 30.44 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 110.034 -0.358 . . . . 75.340000000000003 110.034 -177.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 42.3 p -63.08 -29.16 70.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.174 0.512 . . . . 70.400000000000006 110.836 178.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . 0.59 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 16.1 t70 -77.76 -27.49 50.36 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.477 -0.783 . . . . 72.230000000000004 110.81 178.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . 0.596 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 28.0 mm-40 -135.35 68.98 68.61 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 115.889 -0.596 . . . . 70.0 110.185 -177.608 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . 0.777 ' HB3' ' HB2' ' A' ' 60' ' ' SER . 12.9 Cg_exo -70.1 -26.33 26.1 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.71 2.274 . . . . 73.450000000000003 112.191 -177.479 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -84.0 1.31 44.38 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.451 -0.795 . . . . 72.510000000000005 110.27 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . 0.596 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 57.8 tttp -116.9 134.94 54.14 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.814 -0.63 . . . . 72.219999999999999 110.82 -177.498 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . 0.8 HD23 HD11 ' B' ' 158' ' ' ILE . 39.0 mt -89.53 115.4 26.91 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.643 -0.873 . . . . 74.400000000000006 108.643 175.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . 0.581 HG23 ' HB3' ' B' ' 171' ' ' GLU . 43.0 mm -75.04 123.87 89.14 Favored Pre-proline 0 C--N 1.32 -0.705 0 CA-C-N 116.147 -0.479 . . . . 74.540000000000006 110.896 -172.537 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.414 ' O ' HG23 ' B' ' 172' ' ' ILE . 72.5 Cg_endo -72.75 173.65 13.08 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.825 2.35 . . . . 74.329999999999998 112.225 -178.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . 0.444 ' O ' HG12 ' B' ' 172' ' ' ILE . 30.4 tt0 -77.79 -8.22 57.7 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.665 -0.698 . . . . 75.109999999999999 111.811 -169.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 8.4 p90 -95.33 -12.23 26.46 Favored 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 120.457 -0.497 . . . . 71.209999999999994 110.583 176.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.581 ' HB3' HG23 ' B' ' 167' ' ' ILE . 12.9 tt0 -104.07 -1.87 26.75 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 121.039 0.447 . . . . 65.450000000000003 110.409 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.444 HG12 ' O ' ' B' ' 169' ' ' GLN . 46.8 pt -71.75 -24.5 23.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.017 0.437 . . . . 63.530000000000001 110.689 179.399 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -104.85 35.93 2.62 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.42 0.629 . . . . 70.150000000000006 109.745 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 23.2 t -63.74 -20.4 65.72 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 114.993 -1.003 . . . . 53.25 110.792 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . 0.439 ' CE3' HD13 ' B' ' 123' ' ' ILE . 8.9 p-90 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.255 -0.879 . . . . 73.430000000000007 110.388 174.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 57.8 m . . . . . 0 C--O 1.234 0.279 0 CA-C-O 121.732 0.777 . . . . 75.319999999999993 112.361 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 138.64 -74.62 0.39 Allowed Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 109.197 -1.561 . . . . 71.439999999999998 109.197 -171.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 33.3 mt-10 58.68 92.49 0.06 OUTLIER Pre-proline 0 N--CA 1.463 0.197 0 CA-C-O 121.539 0.685 . . . . 72.409999999999997 112.052 170.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 9.6 Cg_endo -80.46 136.31 11.05 Favored 'Trans proline' 0 N--CA 1.451 -1.001 0 C-N-CA 122.833 2.355 . . . . 55.240000000000002 112.604 -173.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -124.8 170.84 10.64 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.173 -0.677 . . . . 73.519999999999996 109.173 177.069 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.471 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 14.0 p -127.72 124.29 62.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 121.481 0.657 . . . . 75.430000000000007 110.76 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.586 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 76.4 m -87.9 104.25 16.43 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.629 -0.714 . . . . 72.340000000000003 109.664 177.27 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 52.3 mt -98.45 117.66 43.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.064 -0.516 . . . . 65.129999999999995 110.388 -175.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -141.4 178.23 7.57 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.707 -0.679 . . . . 73.319999999999993 110.273 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 17.4 mp0 -133.45 126.15 30.56 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.922 0.392 . . . . 70.310000000000002 110.828 -178.131 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 52.0 mm-40 -95.58 -16.1 22.34 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.851 -0.613 . . . . 72.099999999999994 111.493 -178.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.43 104.91 1.3 Allowed Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.619 -0.8 . . . . 54.229999999999997 111.468 -176.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 1.093 ' HB3' ' HG3' ' A' ' 40' ' ' LYS . 35.3 m-20 61.81 13.89 5.8 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 123.226 0.61 . . . . 73.219999999999999 111.482 -175.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.428 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 40.2 pttt -154.52 114.97 3.9 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.229 0.538 . . . . 64.129999999999995 110.907 176.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 34.1 m -83.08 117.74 23.07 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.375 -0.83 . . . . 63.240000000000002 109.298 174.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.461 HG12 HG23 ' A' ' 37' ' ' VAL . 24.9 mt -108.61 120.33 59.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 120.906 0.384 . . . . 71.049999999999997 110.633 -174.13 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.471 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 20.1 mt-30 -105.27 111.31 24.01 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.819 -0.628 . . . . 74.209999999999994 110.758 -179.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.586 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 31.6 mt-10 -89.62 102.55 15.23 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.62 -0.718 . . . . 72.129999999999995 110.673 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.452 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 80.6 m-85 -79.38 108.19 12.71 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.965 0.412 . . . . 72.349999999999994 109.957 177.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.427 HH21 ' CD ' ' A' ' 25' ' ' GLU . 90.1 mtt180 -116.98 126.56 53.09 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.979 -0.555 . . . . 61.32 109.852 -178.449 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.68 HG11 HG11 ' B' ' 128' ' ' VAL . 3.7 p -78.77 -35.96 18.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.326 0.584 . . . . 41.219999999999999 110.027 179.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -168.92 64.68 0.06 Allowed 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.31 -0.996 . . . . 60.43 108.31 -179.045 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.76 -29.75 3.29 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-N 115.477 -0.783 . . . . 64.129999999999995 112.036 -174.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -86.26 130.92 34.36 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.941 0.401 . . . . 72.340000000000003 110.455 -176.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.888 HD11 HG13 ' A' ' 35' ' ' ILE . 3.2 tm? -81.96 119.21 23.67 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.436 -0.802 . . . . 74.439999999999998 109.847 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . 0.452 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 54.8 p90 -112.9 -17.54 12.47 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.937 -0.305 . . . . 74.200000000000003 111.218 177.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.544 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -157.28 142.21 16.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.812 0.339 . . . . 75.450000000000003 111.181 179.327 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.888 HG13 HD11 ' A' ' 32' ' ' LEU . 78.8 mt -125.14 120.21 57.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 116.329 -0.396 . . . . 63.32 110.01 175.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.469 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 86.0 tttt -108.53 101.15 10.33 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 120.381 -0.528 . . . . 63.340000000000003 109.697 173.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.565 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.8 p -101.02 131.78 48.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.973 0 CA-C-N 116.243 -0.435 . . . . 73.040000000000006 109.917 175.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.829 HG22 ' HB3' ' A' ' 44' ' ' PRO . 29.6 t -106.0 84.85 1.4 Allowed Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.396 -0.82 . . . . 73.219999999999999 109.51 177.469 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.565 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 97.3 Cg_endo -87.65 151.21 7.5 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.615 2.21 . . . . 72.319999999999993 113.143 -177.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 1.093 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 1.0 OUTLIER -55.06 -38.53 68.14 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.202 -0.908 . . . . 74.409999999999997 110.578 173.715 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 95.1 m-70 -123.56 120.9 34.21 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.814 -0.63 . . . . 71.530000000000001 110.181 179.428 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 117.46 -32.63 5.31 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.002 -0.839 . . . . 52.149999999999999 111.002 -173.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.469 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 67.0 mttm 67.97 155.61 0.14 Allowed Pre-proline 0 N--CA 1.465 0.282 0 C-N-CA 123.39 0.676 . . . . 74.409999999999997 111.97 178.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.829 ' HB3' HG22 ' A' ' 38' ' ' VAL . 11.4 Cg_endo -54.57 126.43 22.3 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 123.136 2.557 . . . . 71.230000000000004 113.179 -174.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.516 ' CE1' HG13 ' A' ' 37' ' ' VAL . 5.8 p90 -144.51 151.76 39.61 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.009 -0.541 . . . . 63.520000000000003 110.543 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.625 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 86.8 m-85 -96.18 133.27 40.69 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.097 -0.501 . . . . 72.439999999999998 110.804 178.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.544 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 21.2 mt -101.69 93.41 5.32 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.59 -0.522 . . . . 64.219999999999999 109.59 167.884 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.42 128.96 38.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 116.168 -0.469 . . . . 73.140000000000001 109.799 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . 0.474 HH21 ' HA ' ' A' ' 53' ' ' SER . 15.6 tpt180 -63.05 127.23 30.3 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.21 0.529 . . . . 74.540000000000006 111.87 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.05 113.84 21.31 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.114 -1.069 . . . . 74.519999999999996 108.114 166.281 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.556 ' OD2' ' HA ' ' B' ' 126' ' ' TYR . 37.8 m-20 -49.07 142.54 6.67 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.216 0.531 . . . . 72.329999999999998 111.715 -176.832 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.23 133.61 8.16 Favored Glycine 0 N--CA 1.437 -1.257 0 N-CA-C 110.508 -1.037 . . . . 54.210000000000001 110.508 -169.15 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.474 ' HA ' HH21 ' A' ' 49' ' ' ARG . 19.6 m -84.87 43.16 0.97 Allowed 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.128 0.49 . . . . 74.25 110.997 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -73.41 -33.95 65.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.682 -0.69 . . . . 73.420000000000002 109.769 -179.523 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 113.46 38.97 1.15 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.911 -0.661 . . . . 45.130000000000003 113.089 176.022 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -135.31 146.42 48.46 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.209 0.528 . . . . 70.049999999999997 111.688 -176.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.566 ' HB2' HG22 ' A' ' 72' ' ' ILE . 31.5 m-85 -127.74 167.04 17.04 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.318 -0.856 . . . . 63.200000000000003 109.494 175.499 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.898 HD11 HD23 ' A' ' 66' ' ' LEU . 39.4 mm -122.83 123.22 67.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 109.981 -0.378 . . . . 74.0 109.981 179.111 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.978 ' HG3' HG13 ' A' ' 67' ' ' ILE . 28.8 mtm180 -88.89 140.06 29.82 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.124 -0.324 . . . . 72.219999999999999 110.124 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 7.2 p -60.8 -20.95 62.58 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.222 0.534 . . . . 65.340000000000003 110.933 177.211 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -76.0 -31.43 58.95 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.422 -0.808 . . . . 75.530000000000001 110.67 178.256 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 82.0 mm-40 -141.75 71.21 24.92 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.346 -0.388 . . . . 71.430000000000007 110.433 -175.102 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo -71.14 -11.58 29.14 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 122.771 2.314 . . . . 72.510000000000005 112.427 -178.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -89.54 -14.56 34.87 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.699 -0.682 . . . . 72.5 110.799 -178.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -112.0 133.8 53.95 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.919 0.39 . . . . 70.340000000000003 110.86 -178.207 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.898 HD23 HD11 ' A' ' 58' ' ' ILE . 85.2 mt -80.74 110.18 16.0 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.114 -0.699 . . . . 72.430000000000007 109.114 176.101 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.978 HG13 ' HG3' ' A' ' 59' ' ' ARG . 50.6 mm -72.32 116.77 52.53 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 115.986 -0.552 . . . . 70.209999999999994 110.502 -175.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.462 ' O ' HG23 ' A' ' 72' ' ' ILE . 58.6 Cg_endo -70.39 177.56 5.89 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 123.315 2.676 . . . . 64.409999999999997 112.881 -177.491 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . 0.67 ' HA ' HG12 ' A' ' 72' ' ' ILE . 25.3 tt0 -73.5 -30.66 63.27 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.903 -0.589 . . . . 72.219999999999999 111.654 -171.013 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 21.5 p90 -73.06 -15.68 61.5 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.168 0.509 . . . . 73.219999999999999 110.234 177.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.459 ' HB3' HG23 ' A' ' 67' ' ' ILE . 3.2 mm-40 -103.08 -16.14 15.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.649 -0.705 . . . . 71.439999999999998 111.808 -176.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.67 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.4 pt -80.91 -20.26 11.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.179 0.514 . . . . 65.140000000000001 110.262 176.647 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -107.88 22.79 15.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.601 -0.727 . . . . 75.430000000000007 109.678 174.134 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.1 t -61.26 -34.08 74.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.195 -0.911 . . . . 75.209999999999994 110.622 -178.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 65.9 p-90 . . . . . 0 C--N 1.327 -0.372 0 CA-C-N 116.352 -0.385 . . . . 74.439999999999998 110.608 177.217 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 13.9 m . . . . . 0 N--CA 1.452 -0.374 0 CA-C-O 121.078 0.466 . . . . 75.329999999999998 111.05 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.65 -45.88 1.25 Allowed Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 110.249 -1.141 . . . . 71.140000000000001 110.249 -175.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 40.3 83.14 0.21 Allowed Pre-proline 0 N--CA 1.47 0.564 0 C-N-CA 124.755 1.222 . . . . 73.329999999999998 113.473 170.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.6 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 43.5 Cg_endo -90.56 124.58 1.06 Allowed 'Trans proline' 0 N--CA 1.446 -1.323 0 C-N-CA 123.009 2.473 . . . . 55.450000000000003 111.667 178.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -122.87 127.87 49.59 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.475 0.655 . . . . 53.310000000000002 110.008 -178.586 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.495 ' HB ' ' HB2' ' A' ' 51' ' ' ASP . 7.3 p -79.45 127.82 38.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-O 121.508 0.67 . . . . 52.240000000000002 110.459 -178.311 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . 0.907 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 25.8 m -80.62 101.69 9.36 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 115.386 -0.824 . . . . 74.420000000000002 109.605 178.676 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 51.1 mt -91.02 103.83 14.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.033 -0.53 . . . . 52.350000000000001 110.445 -175.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . 0.483 ' HG2' ' O ' ' B' ' 123' ' ' ILE . 14.0 ptm180 -124.94 178.87 5.28 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.949 -0.76 . . . . 73.239999999999995 108.949 178.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -138.88 158.74 43.67 Favored 'General case' 0 CA--C 1.502 -0.886 0 CA-C-O 122.189 0.995 . . . . 74.120000000000005 112.661 -178.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . 0.591 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 26.5 mt-10 -135.44 168.62 18.88 Favored 'General case' 0 N--CA 1.432 -1.365 0 CA-C-N 112.968 -1.924 . . . . 75.239999999999995 107.166 159.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . -42.29 107.92 0.12 Allowed Glycine 0 CA--C 1.526 0.722 0 O-C-N 123.718 0.636 . . . . 61.149999999999999 114.34 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 43.3 m-20 61.67 24.62 14.69 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.893 0.877 . . . . 53.100000000000001 112.508 176.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.591 ' HE3' ' HB2' ' B' ' 118' ' ' GLU . 58.7 pttt -147.81 115.02 6.21 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.616 0.722 . . . . 44.310000000000002 111.286 174.312 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 23.4 m -80.03 117.11 20.57 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.404 -0.817 . . . . 74.25 109.374 175.003 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . 0.517 HG12 HG13 ' B' ' 137' ' ' VAL . 40.2 mt -105.53 108.96 26.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.25 0.548 . . . . 63.329999999999998 110.457 -175.744 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.481 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 13.6 mt-30 -103.13 109.52 21.12 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.658 -0.701 . . . . 53.439999999999998 110.538 -176.21 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . 0.907 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 70.8 mt-10 -88.9 98.74 11.91 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.014 -0.539 . . . . 74.239999999999995 110.43 178.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . 0.556 ' HA ' ' OD2' ' A' ' 51' ' ' ASP . 67.7 m-85 -71.32 114.34 9.29 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.045 0.45 . . . . 73.200000000000003 110.295 179.18 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . 0.569 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 59.1 mtt-85 -135.36 131.12 35.97 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.709 -0.678 . . . . 72.340000000000003 110.989 -173.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.68 HG11 HG11 ' A' ' 28' ' ' VAL . 14.0 p -85.39 -132.76 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 108.689 -0.856 . . . . 71.530000000000001 108.689 172.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . 0.629 ' H ' HG22 ' B' ' 128' ' ' VAL . 2.3 t-20 -80.62 65.87 5.92 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.164 0.506 . . . . 63.119999999999997 110.812 -177.445 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.65 26.63 22.18 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.756 -0.735 . . . . 41.039999999999999 113.285 174.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 62.1 t80 -142.11 126.74 17.95 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 117.262 0.531 . . . . 72.409999999999997 111.31 175.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.569 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 3.5 tm? -77.15 117.49 18.75 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.992 -0.744 . . . . 72.230000000000004 108.992 175.505 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 39.6 p90 -119.15 -6.3 10.42 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.257 -0.577 . . . . 75.319999999999993 112.261 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . 0.525 ' HB3' ' HB2' ' B' ' 126' ' ' TYR . . . -164.21 143.35 7.54 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.699 0.285 . . . . 74.200000000000003 111.031 177.697 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.442 HG13 HD11 ' B' ' 132' ' ' LEU . 61.9 mt -122.84 121.06 62.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 109.924 -0.398 . . . . 53.310000000000002 109.924 175.403 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.485 ' CB ' ' HE1' ' B' ' 126' ' ' TYR . 83.6 tttt -107.84 107.03 17.59 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.835 -0.431 . . . . 74.200000000000003 109.835 177.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.762 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.5 t -94.81 131.6 41.16 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 N-CA-C 108.641 -0.874 . . . . 74.099999999999994 108.641 176.585 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.553 HG22 ' HB3' ' B' ' 144' ' ' PRO . 18.0 t -114.72 72.7 2.78 Favored Pre-proline 0 C--N 1.318 -0.769 0 N-CA-C 109.78 -0.452 . . . . 73.120000000000005 109.78 172.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.524 ' HD3' HG12 ' B' ' 137' ' ' VAL . 94.1 Cg_endo -83.2 142.16 10.67 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.235 1.957 . . . . 60.530000000000001 112.563 177.105 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 49.6 mttp -54.56 -44.56 73.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.596 0.712 . . . . 70.109999999999999 110.348 173.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 26.1 m-70 -102.8 92.1 4.45 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.836 -1.074 . . . . 72.150000000000006 109.474 -174.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 132.54 -27.35 3.56 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.357 -0.838 . . . . 64.450000000000003 111.712 -176.294 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . 0.51 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 71.2 mttt 69.1 159.66 0.15 Allowed Pre-proline 0 N--CA 1.464 0.255 0 C-N-CA 123.622 0.769 . . . . 72.209999999999994 112.367 -178.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.762 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 21.6 Cg_endo -61.09 134.5 53.16 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 122.873 2.382 . . . . 71.239999999999995 113.525 -177.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -143.32 147.21 34.37 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.68 -0.691 . . . . 74.109999999999999 110.291 175.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.65 ' HB2' ' HB2' ' B' ' 160' ' ' SER . 86.0 m-85 -93.61 125.93 38.49 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.231 -0.441 . . . . 61.509999999999998 110.392 176.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.507 HD11 HG21 ' B' ' 167' ' ' ILE . 25.0 tp -109.12 97.44 7.06 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.64 -0.874 . . . . 50.520000000000003 108.64 172.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.7 t -91.77 139.3 18.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.155 -0.475 . . . . 52.409999999999997 111.311 -172.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . 0.427 ' HD3' ' CZ ' ' B' ' 157' ' ' PHE . 42.4 tpt85 -80.36 113.73 18.75 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.278 -0.638 . . . . 74.140000000000001 109.278 176.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.89 175.6 6.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.825 0.345 . . . . 75.329999999999998 111.104 -176.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -71.47 147.8 47.46 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.163 -0.471 . . . . 74.120000000000005 110.94 -178.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . 0.492 ' C ' ' H ' ' B' ' 154' ' ' ASP . . . 89.85 145.4 12.74 Favored Glycine 0 N--CA 1.436 -1.365 0 C-N-CA 120.723 -0.751 . . . . 74.140000000000001 112.561 175.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 44.9 m -72.59 21.93 0.06 Allowed 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 121.022 0.439 . . . . 74.010000000000005 111.083 173.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . 0.492 ' H ' ' C ' ' B' ' 152' ' ' GLY . 14.5 t70 -60.86 -35.82 77.56 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.777 -0.647 . . . . 73.329999999999998 110.618 177.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 97.92 17.13 31.12 Favored Glycine 0 CA--C 1.507 -0.451 0 CA-C-N 115.734 -0.666 . . . . 75.310000000000002 111.89 -179.383 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -90.97 137.52 32.3 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.019 -0.59 . . . . 55.539999999999999 111.566 -175.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . 0.427 ' CZ ' ' HD3' ' B' ' 149' ' ' ARG . 39.0 m-85 -118.21 154.04 32.87 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.751 -0.658 . . . . 74.409999999999997 109.533 174.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.3 mm -121.46 119.91 60.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.817 -0.438 . . . . 65.530000000000001 109.817 177.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.727 ' HE ' ' HB3' ' B' ' 161' ' ' ASP . 37.2 ttp180 -85.02 129.05 34.86 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.444 -0.576 . . . . 74.329999999999998 109.444 -179.706 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . 0.65 ' HB2' ' HB2' ' B' ' 146' ' ' PHE . 36.6 t -59.84 -18.34 43.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.774 0.321 . . . . 54.310000000000002 111.318 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . 0.727 ' HB3' ' HE ' ' B' ' 159' ' ' ARG . 22.8 t70 -69.24 -39.77 78.31 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.031 -0.531 . . . . 74.319999999999993 110.29 176.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . 0.427 ' HG2' ' OD2' ' B' ' 161' ' ' ASP . 84.1 mm-40 -133.53 86.33 40.37 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 115.674 -0.693 . . . . 61.539999999999999 109.692 179.546 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.01 -14.37 40.86 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.56 2.173 . . . . 73.329999999999998 112.47 -178.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -100.49 21.09 13.76 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.817 -0.628 . . . . 72.150000000000006 110.421 178.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -133.3 136.06 45.24 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.365 -0.38 . . . . 74.049999999999997 110.732 -179.487 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . 0.435 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.6 mp -90.54 134.94 34.02 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.027 -0.731 . . . . 71.519999999999996 109.027 176.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . 0.538 HG23 ' HB3' ' B' ' 171' ' ' GLU . 46.2 mm -94.15 117.02 67.11 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-O 120.917 0.389 . . . . 74.319999999999993 111.771 -172.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.409 ' O ' HG23 ' B' ' 172' ' ' ILE . 59.5 Cg_endo -72.37 -179.55 4.14 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.305 2.67 . . . . 74.430000000000007 112.615 177.084 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . 0.59 ' HA ' HG12 ' B' ' 172' ' ' ILE . 33.0 tt0 -77.1 -36.09 55.94 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.258 -0.428 . . . . 65.430000000000007 112.136 -170.211 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . 0.409 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 35.9 p90 -66.99 -21.16 65.97 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 121.648 -0.658 . . . . 74.430000000000007 109.622 177.251 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.538 ' HB3' HG23 ' B' ' 167' ' ' ILE . 9.3 mm-40 -88.22 -26.05 22.57 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 115.156 -0.929 . . . . 75.129999999999995 111.647 -178.078 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.59 HG12 ' HA ' ' B' ' 169' ' ' GLN . 40.9 pt -77.97 -17.42 13.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.146 0.498 . . . . 74.530000000000001 109.971 177.118 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -108.05 34.61 3.5 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.574 -0.739 . . . . 70.319999999999993 109.748 174.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.9 t -65.13 -35.27 80.58 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.203 -0.908 . . . . 71.019999999999996 111.03 -179.182 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 25.6 p-90 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.018 -0.991 . . . . 73.099999999999994 111.023 -178.133 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 39.8 m . . . . . 0 N--CA 1.453 -0.312 0 N-CA-C 109.947 -0.39 . . . . 70.319999999999993 109.947 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 87.27 -34.01 3.72 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 110.977 -0.849 . . . . 50.32 110.977 -173.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 55.37 63.69 6.31 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 123.998 0.919 . . . . 62.439999999999998 111.73 177.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.699 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 18.2 Cg_endo -78.95 121.65 5.06 Favored 'Trans proline' 0 N--CA 1.45 -1.064 0 C-N-CA 122.091 1.861 . . . . 73.219999999999999 111.584 -179.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -148.36 122.42 9.47 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.654 0.74 . . . . 72.140000000000001 110.357 177.515 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.8 p -82.65 129.16 37.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-N 114.366 -1.288 . . . . 51.140000000000001 110.682 -178.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 59.2 m -93.64 102.51 14.69 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.592 -0.731 . . . . 53.109999999999999 109.735 178.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.1 mt -90.63 104.06 14.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.967 -0.561 . . . . 74.109999999999999 110.037 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -122.83 174.07 7.37 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.533 -0.758 . . . . 72.219999999999999 109.734 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -122.98 133.36 54.37 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 121.285 0.564 . . . . 74.430000000000007 111.059 -177.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.527 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 1.0 OUTLIER -115.81 84.9 2.19 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.318 -0.855 . . . . 64.420000000000002 109.336 -179.411 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 80.88 -106.11 2.51 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 110.827 -0.909 . . . . 73.450000000000003 110.827 -172.481 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.434 ' HB3' ' HG3' ' A' ' 40' ' ' LYS . 11.7 m-20 -110.49 -14.47 14.09 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.761 0.315 . . . . 71.409999999999997 110.93 176.323 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.527 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 24.6 pttm -89.41 136.57 32.95 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.98 0.419 . . . . 74.010000000000005 110.918 -176.28 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 13.0 m -83.8 130.33 34.93 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.781 -0.645 . . . . 73.510000000000005 110.205 178.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 26.4 mm -116.65 106.82 21.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 120.93 0.395 . . . . 75.5 110.128 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 16.1 mt-30 -100.02 102.5 13.87 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.225 -0.443 . . . . 73.510000000000005 109.828 178.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.417 ' HB3' HD13 ' A' ' 32' ' ' LEU . 26.4 mt-10 -89.67 100.68 13.43 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.519 -0.764 . . . . 65.450000000000003 110.937 -176.302 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.622 ' HD2' ' HB2' ' B' ' 151' ' ' ASP . 44.2 m-85 -75.41 100.21 4.39 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.086 -0.507 . . . . 74.519999999999996 110.32 179.257 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 51.2 mtm180 -115.89 124.45 50.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.311 -0.404 . . . . 71.109999999999999 110.418 178.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.849 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.9 p -87.24 -93.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 C-N-CA 120.564 -0.454 . . . . 70.510000000000005 110.091 175.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.849 ' H ' HG13 ' A' ' 28' ' ' VAL . 3.4 t-20 -107.49 70.07 0.77 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 121.562 -0.712 . . . . 64.329999999999998 109.997 -176.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 77.57 9.08 87.09 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.714 -0.755 . . . . 75.230000000000004 112.344 179.128 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 85.6 t80 -127.55 123.06 34.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.676 0.274 . . . . 73.430000000000007 110.643 -177.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.537 HD21 HD11 ' A' ' 35' ' ' ILE . 27.6 tp -78.65 115.5 18.4 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.025 -0.534 . . . . 72.329999999999998 109.762 173.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -103.51 -14.68 16.11 Favored 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 120.253 -0.579 . . . . 61.43 111.481 -176.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.446 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -167.61 146.34 4.81 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.889 0.376 . . . . 71.310000000000002 111.475 -177.206 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.537 HD11 HD21 ' A' ' 32' ' ' LEU . 71.4 mt -122.59 131.4 73.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 116.084 -0.507 . . . . 71.129999999999995 109.77 175.167 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -104.49 100.75 10.43 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.948 -0.76 . . . . 72.340000000000003 108.948 170.195 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 0.9 OUTLIER -97.75 123.56 50.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 115.663 -0.699 . . . . 64.319999999999993 110.283 -179.483 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.731 HG22 ' HB3' ' A' ' 44' ' ' PRO . 22.0 t -113.73 87.65 12.55 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 115.384 -0.825 . . . . 73.530000000000001 110.3 -178.489 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.489 ' HD3' HG22 ' A' ' 37' ' ' VAL . 74.5 Cg_endo -77.83 141.71 19.46 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.406 2.071 . . . . 62.43 111.33 176.568 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.434 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 35.2 mtmt -58.89 -32.95 69.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.197 0.523 . . . . 63.340000000000003 110.603 179.346 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -130.6 100.51 5.34 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.74 -0.664 . . . . 74.150000000000006 109.297 177.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 149.54 -16.0 1.1 Allowed Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.884 -0.674 . . . . 45.340000000000003 112.277 -177.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.5 mttt 72.76 140.84 0.08 OUTLIER Pre-proline 0 N--CA 1.467 0.393 0 C-N-CA 123.383 0.673 . . . . 74.219999999999999 112.237 178.29 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.731 ' HB3' HG22 ' A' ' 38' ' ' VAL . 29.1 Cg_endo -64.18 133.6 38.77 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 123.103 2.535 . . . . 71.120000000000005 112.476 179.04 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 11.2 p90 -144.15 156.18 44.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.107 -0.497 . . . . 70.129999999999995 110.57 -179.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.492 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 20.0 m-85 -99.54 142.38 31.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.084 -0.507 . . . . 75.430000000000007 111.484 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.446 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 72.0 mt -124.88 104.51 8.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.608 -0.724 . . . . 74.510000000000005 109.747 171.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 43.2 t -93.24 136.36 25.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.184 -0.462 . . . . 74.420000000000002 110.047 -178.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . 0.562 HH11 ' HG3' ' A' ' 49' ' ' ARG . 0.5 OUTLIER -76.06 132.06 39.87 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.94 0.4 . . . . 71.430000000000007 111.621 -178.504 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.12 158.31 35.98 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.565 -0.743 . . . . 74.25 111.707 179.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -79.18 171.86 14.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.647 -0.706 . . . . 72.209999999999994 111.771 -176.265 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 70.33 21.49 77.35 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.657 -0.701 . . . . 70.409999999999997 113.035 171.147 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.9 m 57.28 30.66 18.83 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.024 0.44 . . . . 73.319999999999993 110.526 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -55.98 -63.93 1.02 Allowed 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.468 -0.787 . . . . 74.129999999999995 111.501 -179.278 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 131.1 -39.2 1.81 Allowed Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.273 -0.965 . . . . 74.349999999999994 112.794 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -68.57 164.55 21.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.43 0.633 . . . . 64.219999999999999 111.507 -176.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.43 ' CE2' ' HG2' ' A' ' 49' ' ' ARG . 67.9 m-85 -113.29 155.28 25.41 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.209 -0.905 . . . . 74.209999999999994 109.587 175.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.624 HD11 HD23 ' A' ' 66' ' ' LEU . 27.5 mm -113.27 119.87 61.8 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 108.883 -0.784 . . . . 75.299999999999997 108.883 177.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.571 ' HB2' HG13 ' A' ' 67' ' ' ILE . 8.1 ttm180 -82.7 149.43 27.32 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.951 -0.3 . . . . 75.420000000000002 110.403 -175.273 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.492 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 4.3 p -62.82 -27.14 69.11 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.282 -0.417 . . . . 61.240000000000002 111.452 178.266 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.449 ' HB2' ' HD2' ' A' ' 59' ' ' ARG . 1.3 m-20 -64.41 -29.13 70.19 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.131 -0.486 . . . . 72.040000000000006 111.537 -179.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.9 tp-100 -150.79 93.0 3.79 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-O 121.034 0.445 . . . . 71.239999999999995 109.992 -179.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . 0.481 ' HB2' ' HD2' ' B' ' 146' ' ' PHE . 72.7 Cg_endo -74.35 15.06 0.67 Allowed 'Trans proline' 0 C--O 1.233 0.24 0 C-N-CA 123.396 2.73 . . . . 72.349999999999994 113.151 -176.429 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -128.25 8.33 6.04 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.161 0.505 . . . . 74.140000000000001 110.338 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 12.5 mmmt -121.75 145.43 48.04 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.101 -0.5 . . . . 65.099999999999994 111.925 -177.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.624 HD23 HD11 ' A' ' 58' ' ' ILE . 65.6 mt -92.41 109.11 20.49 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.342 -0.844 . . . . 64.239999999999995 109.754 178.071 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.571 HG13 ' HB2' ' A' ' 59' ' ' ARG . 46.6 mm -72.67 119.54 75.77 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 116.323 -0.398 . . . . 72.299999999999997 110.408 -178.697 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.53 178.95 3.91 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 123.274 2.649 . . . . 74.530000000000001 113.363 -177.184 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . 0.822 ' HA ' HG12 ' A' ' 72' ' ' ILE . 34.9 tt0 -75.19 -34.58 61.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.513 -0.767 . . . . 74.209999999999994 111.515 -170.486 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 3.7 p90 -64.32 -23.89 67.46 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.349 -0.541 . . . . 75.340000000000003 110.916 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.483 ' HA ' ' HB2' ' A' ' 74' ' ' SER . 4.2 tp10 -92.99 -27.79 16.8 Favored 'General case' 0 N--CA 1.438 -1.052 0 CA-C-N 116.086 -0.507 . . . . 72.409999999999997 110.639 -176.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.822 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.3 pt -80.14 -16.95 12.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.039 0.447 . . . . 70.549999999999997 110.66 177.547 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.452 ' CD1' HG13 ' A' ' 72' ' ' ILE . 46.5 m-85 -108.37 15.37 24.04 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.825 -0.625 . . . . 73.439999999999998 110.118 174.04 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.483 ' HB2' ' HA ' ' A' ' 71' ' ' GLU . 8.3 t -74.43 -28.81 61.23 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.755 -0.657 . . . . 71.109999999999999 110.396 -177.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . 0.405 ' O ' ' HE3' ' A' ' 21' ' ' LYS . 65.3 p-90 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.515 -0.311 . . . . 72.530000000000001 110.935 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 35.0 m . . . . . 0 N--CA 1.453 -0.295 0 CA-C-O 121.087 0.47 . . . . 64.030000000000001 110.861 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.49 -68.3 0.22 Allowed Glycine 0 N--CA 1.446 -0.691 0 N-CA-C 111.595 -0.602 . . . . 63.5 111.595 -177.408 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 57.8 mm-40 69.21 77.12 0.24 Allowed Pre-proline 0 N--CA 1.468 0.463 0 C-N-CA 123.537 0.735 . . . . 74.439999999999998 111.807 -178.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.617 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 10.8 Cg_endo -80.93 85.22 1.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.087 0 C-N-CA 122.455 2.103 . . . . 52.130000000000003 111.049 174.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -97.01 150.52 20.69 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.208 0.528 . . . . 61.210000000000001 110.448 -178.218 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.434 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 13.5 p -105.46 123.75 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.906 0 CA-C-N 115.653 -0.703 . . . . 54.049999999999997 109.417 174.282 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . 0.528 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 19.6 m -89.22 99.52 12.49 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 115.658 -0.701 . . . . 61.219999999999999 109.472 177.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 59.8 mt -88.86 106.19 16.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.919 -0.582 . . . . 52.310000000000002 110.093 -177.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 32.1 mtp-105 -122.28 -174.36 2.88 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.408 -0.815 . . . . 75.239999999999995 110.34 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 23.6 mp0 -136.16 132.55 36.13 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.839 -0.619 . . . . 74.5 110.431 179.201 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . 0.48 ' HG2' HG13 ' B' ' 123' ' ' ILE . 79.4 mm-40 -112.56 82.26 1.61 Allowed 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.062 -0.718 . . . . 75.430000000000007 109.062 173.687 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 81.05 -92.06 1.45 Allowed Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.743 -0.741 . . . . 75.450000000000003 111.387 -175.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 29.9 m-20 -117.61 -20.49 8.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.767 0.318 . . . . 70.329999999999998 111.205 178.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.745 ' HE3' ' HE3' ' B' ' 175' ' ' TRP . 23.6 pttt -86.62 126.0 34.21 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.273 0.559 . . . . 72.140000000000001 111.076 -177.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 43.9 m -80.72 124.32 28.93 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.502 -0.772 . . . . 70.140000000000001 109.986 178.592 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . 0.48 HG13 ' HG2' ' B' ' 118' ' ' GLU . 27.3 mm -108.98 108.59 25.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.552 -0.295 . . . . 72.010000000000005 110.393 -175.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.434 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 16.5 mt-30 -100.65 100.52 11.24 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.917 0.389 . . . . 73.519999999999996 110.254 178.256 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . 0.528 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 43.7 mt-10 -86.77 107.43 18.26 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.034 -0.53 . . . . 72.5 111.116 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . 0.487 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 78.0 m-85 -86.99 113.39 22.71 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.976 0.417 . . . . 74.109999999999999 110.422 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . 0.423 ' O ' ' HA ' ' B' ' 111' ' ' PRO . 60.5 mtm180 -117.22 178.7 4.27 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.124 -0.489 . . . . 71.310000000000002 109.957 179.145 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.624 HG13 ' H ' ' B' ' 129' ' ' ASN . 2.6 p -140.58 -65.21 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 116.279 -0.419 . . . . 64.519999999999996 110.884 173.055 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . 0.624 ' H ' HG13 ' B' ' 128' ' ' VAL . 3.7 t-20 -141.79 75.99 1.52 Allowed 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.438 -0.505 . . . . 61.149999999999999 110.194 -179.64 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.04 25.75 73.32 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.346 -0.843 . . . . 74.340000000000003 111.782 -179.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 67.7 t80 -146.01 121.7 10.5 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.685 -0.487 . . . . 73.019999999999996 109.685 -179.498 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.465 HD21 HD11 ' B' ' 135' ' ' ILE . 24.5 tp -80.14 123.93 28.33 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.724 -0.671 . . . . 75.519999999999996 109.318 176.048 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . 0.487 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 37.2 p90 -108.85 -15.72 14.32 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.969 -0.692 . . . . 75.310000000000002 111.849 -176.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . 0.41 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -168.03 148.85 5.07 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.928 0.394 . . . . 75.319999999999993 111.6 -178.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.465 HD11 HD21 ' B' ' 132' ' ' LEU . 62.9 mt -125.39 126.18 70.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.118 -0.492 . . . . 43.149999999999999 109.842 174.337 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.434 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 88.6 tttt -105.04 101.19 10.77 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.957 -0.757 . . . . 62.350000000000001 108.957 172.254 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.568 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 1.4 p -99.23 133.64 41.22 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.855 -0.611 . . . . 72.140000000000001 110.196 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.883 HG22 ' HB3' ' B' ' 144' ' ' PRO . 24.4 t -107.85 84.61 2.11 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 115.384 -0.826 . . . . 75.420000000000002 109.536 177.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.415 ' HG3' ' HE1' ' B' ' 145' ' ' TYR . 92.3 Cg_endo -79.86 150.01 20.78 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 122.407 2.072 . . . . 55.149999999999999 111.969 -179.175 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 4.1 mmpt? -62.2 -35.71 79.7 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.77 -0.65 . . . . 62.439999999999998 110.123 177.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 86.2 m-70 -124.73 90.67 3.29 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 115.789 -0.642 . . . . 72.310000000000002 109.913 -178.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 150.49 -29.18 1.07 Allowed Glycine 0 N--CA 1.448 -0.549 0 CA-C-N 115.191 -0.913 . . . . 70.25 111.675 -176.035 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . 0.446 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 87.0 mttt 70.34 155.73 0.15 Allowed Pre-proline 0 N--CA 1.467 0.421 0 C-N-CA 123.427 0.691 . . . . 74.140000000000001 112.01 -178.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.883 ' HB3' HG22 ' B' ' 138' ' ' VAL . 18.9 Cg_endo -58.25 124.07 15.06 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 123.224 2.616 . . . . 71.209999999999994 113.47 -175.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . 0.511 ' CE1' HG13 ' B' ' 137' ' ' VAL . 5.1 p90 -139.65 168.23 20.3 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.636 -0.711 . . . . 72.219999999999999 110.137 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.481 ' HD2' ' HB2' ' A' ' 63' ' ' PRO . 1.2 m-85 -108.84 139.32 43.83 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.954 0.407 . . . . 73.420000000000002 111.882 -176.506 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.41 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 25.6 mt -118.75 101.28 7.97 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.448 -0.796 . . . . 75.219999999999999 109.653 169.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 42.7 t -86.46 137.91 20.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 116.225 -0.443 . . . . 73.409999999999997 110.077 -179.101 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 5.1 mmt85 -74.85 130.38 39.32 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.884 0.373 . . . . 72.239999999999995 111.285 178.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -71.03 122.14 19.5 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.769 -0.65 . . . . 34.520000000000003 111.08 177.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . 0.622 ' HB2' ' HD2' ' A' ' 26' ' ' TYR . 15.7 t70 -61.31 140.0 58.06 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.648 -0.705 . . . . 73.239999999999995 110.981 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 73.47 -56.61 2.03 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.955 -0.566 . . . . 71.400000000000006 113.237 179.323 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . 0.433 ' O ' ' HB3' ' B' ' 154' ' ' ASP . 19.7 m -61.2 -46.07 91.96 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 122.43 0.292 . . . . 73.409999999999997 110.868 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . 0.433 ' HB3' ' O ' ' B' ' 153' ' ' SER . 18.0 t70 71.47 -48.27 0.67 Allowed 'General case' 0 N--CA 1.464 0.237 0 C-N-CA 123.743 0.817 . . . . 74.329999999999998 111.859 178.107 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . -88.13 50.07 3.84 Favored Glycine 0 N--CA 1.448 -0.502 0 CA-C-N 116.122 -0.49 . . . . 54.43 112.601 -178.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . 0.503 HD21 ' HB3' ' B' ' 166' ' ' LEU . 25.9 t-20 -162.54 144.59 10.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.457 -0.571 . . . . 75.549999999999997 109.457 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . 0.506 ' HB2' HG22 ' B' ' 172' ' ' ILE . 72.4 m-85 -118.99 150.71 39.48 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.909 0.385 . . . . 74.040000000000006 110.463 178.108 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.0 mm -113.43 114.44 46.86 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 N-CA-C 108.82 -0.807 . . . . 64.140000000000001 108.82 175.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.535 ' HB2' HG13 ' B' ' 167' ' ' ILE . 15.0 ttp180 -88.03 146.92 25.24 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 110.046 -0.353 . . . . 72.340000000000003 110.046 -174.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 4.0 p -60.03 -36.31 76.99 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 112.779 0.659 . . . . 61.109999999999999 112.779 -174.101 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -78.28 -14.65 59.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.973 0.416 . . . . 70.120000000000005 110.908 -177.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . 0.838 ' HG3' ' HB2' ' B' ' 165' ' ' LYS . 5.4 tp-100 -138.03 72.02 47.57 Favored Pre-proline 0 N--CA 1.45 -0.438 0 CA-C-N 116.219 -0.446 . . . . 54.310000000000002 110.894 -177.334 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -85.09 -1.57 9.38 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.674 2.249 . . . . 72.530000000000001 111.775 179.18 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -91.74 -17.99 24.59 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.25 -0.886 . . . . 75.200000000000003 110.14 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . 0.838 ' HB2' ' HG3' ' B' ' 162' ' ' GLN . 0.7 OUTLIER -122.79 158.83 29.35 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.124 -0.944 . . . . 72.420000000000002 111.134 -175.133 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . 0.503 ' HB3' HD21 ' B' ' 156' ' ' ASN . 5.1 mp -94.74 134.02 37.79 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.064 -1.087 . . . . 55.140000000000001 108.064 172.577 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . 0.535 HG13 ' HB2' ' B' ' 159' ' ' ARG . 50.2 mm -84.69 125.11 72.07 Favored Pre-proline 0 C--N 1.32 -0.695 0 C-N-CA 120.91 -0.316 . . . . 73.430000000000007 111.041 -171.552 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.455 ' HG2' ' HB2' ' B' ' 171' ' ' GLU . 49.6 Cg_endo -67.7 172.77 10.02 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.762 2.308 . . . . 74.299999999999997 112.429 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . 0.516 ' HA ' HG12 ' B' ' 172' ' ' ILE . 20.4 tt0 -79.56 -16.93 55.05 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.766 -0.652 . . . . 74.540000000000006 111.626 -167.464 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . 0.417 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 24.4 p90 -86.75 -8.01 57.76 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.234 0.54 . . . . 62.5 110.019 176.043 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.55 ' O ' ' HB2' ' B' ' 174' ' ' SER . 1.9 mm-40 -113.32 -11.89 13.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.816 -0.629 . . . . 73.120000000000005 111.961 -176.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.516 HG12 ' HA ' ' B' ' 169' ' ' GLN . 31.8 pt -76.82 -16.87 14.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 121.264 0.554 . . . . 70.5 110.277 175.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -109.14 39.09 2.13 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.356 -0.838 . . . . 75.219999999999999 108.874 174.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . 0.55 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 0.5 OUTLIER -70.15 -14.48 62.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 114.981 -1.009 . . . . 60.340000000000003 110.916 -176.181 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . 0.745 ' HE3' ' HE3' ' B' ' 121' ' ' LYS . 59.7 p-90 . . . . . 0 C--O 1.245 0.842 0 CA-C-O 118.286 -0.864 . . . . 64.239999999999995 110.204 177.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 15.0 m . . . . . 0 N--CA 1.453 -0.286 0 N-CA-C 109.03 -0.73 . . . . 75.219999999999999 109.03 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 116.17 102.8 2.33 Favored Glycine 0 N--CA 1.439 -1.111 0 N-CA-C 108.79 -1.724 . . . . 74.439999999999998 108.79 -166.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . 0.476 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 10.1 pt-20 -141.03 113.99 6.96 Favored Pre-proline 0 N--CA 1.437 -1.12 0 N-CA-C 108.089 -1.078 . . . . 63.409999999999997 108.089 -167.773 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.476 ' HD3' ' HA ' ' A' ' 10' ' ' GLU . 4.9 Cg_exo -77.12 81.47 2.61 Favored 'Trans proline' 0 N--CA 1.437 -1.803 0 C-N-CA 121.873 1.715 . . . . 73.120000000000005 110.531 -176.451 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -86.26 155.37 20.71 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.564 -1.198 . . . . 72.120000000000005 109.869 -177.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.592 HG21 ' HB3' ' A' ' 24' ' ' GLN . 10.1 p -121.23 123.79 70.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 CA-C-O 121.512 0.673 . . . . 64.420000000000002 111.143 -178.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.558 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 88.8 m -86.03 104.21 15.43 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.521 -0.763 . . . . 71.0 108.944 177.011 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.3 mt -91.44 105.5 16.61 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 CA-C-N 116.093 -0.503 . . . . 44.43 110.598 -175.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.405 HH21 ' CD ' ' A' ' 25' ' ' GLU . 62.3 mtm180 -117.86 172.99 7.02 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.787 -0.642 . . . . 72.540000000000006 109.993 177.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.499 ' HG2' ' HA ' ' A' ' 22' ' ' THR . 82.6 mt-30 -136.93 122.17 19.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.172 0.51 . . . . 64.519999999999996 111.024 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.469 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 31.5 mm-40 -106.96 87.35 2.49 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.398 -0.819 . . . . 75.430000000000007 110.018 178.188 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 79.17 -95.13 1.4 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.633 -0.794 . . . . 74.430000000000007 111.678 -178.26 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -124.09 12.5 8.97 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.83 0.347 . . . . 72.420000000000002 110.871 -179.228 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.714 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 21.3 pttm -117.27 117.29 29.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.019 0.438 . . . . 74.549999999999997 110.987 178.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.702 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 23.6 m -79.25 101.91 8.27 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.736 -0.665 . . . . 72.030000000000001 109.679 176.047 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.469 HG12 HG13 ' A' ' 37' ' ' VAL . 57.0 mt -92.64 106.85 18.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 120.996 0.427 . . . . 63.43 110.14 -176.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.604 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 20.2 mt-30 -91.4 110.7 22.01 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.801 -0.636 . . . . 75.120000000000005 110.3 178.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.622 ' HB3' HD13 ' A' ' 32' ' ' LEU . 26.4 mt-10 -93.83 103.48 15.6 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.469 -0.787 . . . . 62.329999999999998 111.109 -177.142 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.413 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 86.8 m-85 -77.83 109.13 11.58 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.985 0.421 . . . . 73.519999999999996 110.228 178.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 31' ' ' PHE . 83.8 mtt180 -127.58 127.3 43.65 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.581 -0.736 . . . . 74.420000000000002 109.459 -179.681 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.604 HG21 ' CD2' ' B' ' 131' ' ' PHE . 11.9 p -90.49 -28.25 4.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 C-N-CA 120.37 -0.532 . . . . 61.020000000000003 110.628 -177.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -172.26 68.06 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.707 -0.679 . . . . 73.109999999999999 109.631 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 95.77 -37.97 3.26 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.773 -0.727 . . . . 62.32 113.414 178.262 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.416 ' CD2' HG21 ' B' ' 128' ' ' VAL . 80.1 t80 -94.82 133.5 38.46 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.239 0.542 . . . . 71.150000000000006 111.405 -174.058 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.622 HD13 ' HB3' ' A' ' 25' ' ' GLU . 50.1 tp -82.38 112.86 19.73 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.941 -1.027 . . . . 54.100000000000001 110.156 174.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . 0.455 ' O ' ' HB2' ' A' ' 49' ' ' ARG . 44.3 p90 -108.62 -4.99 16.65 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.895 -0.322 . . . . 73.400000000000006 111.72 -176.614 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.405 ' HB3' ' HB2' ' A' ' 26' ' ' TYR . . . -168.3 136.97 2.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.891 0.377 . . . . 71.420000000000002 110.889 -176.141 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.414 ' CG1' HD21 ' A' ' 32' ' ' LEU . 61.4 mt -118.97 126.12 75.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.0 -0.546 . . . . 75.319999999999993 110.542 178.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.604 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 83.1 tttt -108.69 100.78 9.98 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.003 -0.74 . . . . 62.25 109.003 171.366 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.706 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.8 t -87.91 128.79 40.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 109.153 -0.684 . . . . 63.32 109.153 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.817 HG13 ' HG3' ' A' ' 44' ' ' PRO . 24.2 t -115.74 72.71 4.16 Favored Pre-proline 0 C--N 1.32 -0.709 0 N-CA-C 109.75 -0.463 . . . . 65.049999999999997 109.75 172.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.714 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 57.1 Cg_endo -78.76 134.43 12.09 Favored 'Trans proline' 0 N--CA 1.458 -0.615 0 C-N-CA 122.18 1.92 . . . . 63.109999999999999 112.433 176.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 9.4 mtpm? -59.78 -33.06 71.21 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-O 121.29 0.566 . . . . 74.200000000000003 109.948 175.275 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 62.4 m-70 -115.77 103.58 10.8 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.244 -0.889 . . . . 54.299999999999997 109.148 178.009 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 130.11 -25.18 4.39 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.943 -0.646 . . . . 31.440000000000001 112.096 -177.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.0 mttm 69.57 147.79 0.12 Allowed Pre-proline 0 N--CA 1.466 0.363 0 C-N-CA 123.342 0.657 . . . . 73.430000000000007 112.323 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.817 ' HG3' HG13 ' A' ' 38' ' ' VAL . 31.0 Cg_exo -58.51 145.97 92.59 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 123.222 2.615 . . . . 74.349999999999994 113.561 -177.03 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 30.6 p90 -156.39 164.91 37.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.314 -0.857 . . . . 74.310000000000002 109.304 174.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.557 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 85.1 m-85 -106.62 136.44 46.4 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.021 0.438 . . . . 72.120000000000005 110.7 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 16.9 tp -125.14 98.96 5.88 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.695 -0.854 . . . . 54.299999999999997 108.695 176.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.438 HG21 HG21 ' B' ' 148' ' ' VAL . 28.7 t -96.32 140.59 16.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.421 -0.354 . . . . 74.239999999999995 111.548 -171.036 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . 0.455 ' HB2' ' O ' ' A' ' 33' ' ' TYR . 0.7 OUTLIER -66.85 122.38 17.57 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.213 -0.449 . . . . 72.349999999999994 111.32 176.66 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.44 172.39 13.7 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.921 -0.581 . . . . 72.439999999999998 109.503 172.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -68.04 125.04 25.07 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.22 0.533 . . . . 71.510000000000005 109.781 176.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.41 125.57 5.49 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.783 -0.723 . . . . 63.229999999999997 111.899 -176.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.5 t -87.45 23.1 1.99 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.347 0.594 . . . . 74.349999999999994 110.24 -177.027 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -58.12 -60.43 3.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.432 -0.804 . . . . 54.509999999999998 110.206 177.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 156.61 21.87 0.03 OUTLIER Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 115.546 -0.752 . . . . 72.349999999999994 112.453 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.485 ' OD1' ' HB3' ' A' ' 66' ' ' LEU . 7.4 t30 -102.91 137.18 41.44 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.963 0.411 . . . . 65.340000000000003 110.867 -176.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -123.56 174.42 7.43 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.942 -0.572 . . . . 72.109999999999999 110.47 177.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 49.8 mm -123.97 122.08 63.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.893 -0.78 . . . . 42.409999999999997 108.893 171.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.668 ' HB2' HG13 ' A' ' 67' ' ' ILE . 74.6 ttt180 -93.34 131.97 38.0 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.07 -0.514 . . . . 71.150000000000006 110.309 -175.386 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.557 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 67.9 p -62.8 -22.77 66.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.86 0.362 . . . . 74.349999999999994 111.343 -178.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.468 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 16.4 t70 -64.23 -46.37 84.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.778 -0.647 . . . . 64.340000000000003 109.981 178.479 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 78.0 mm-40 -132.14 82.66 58.1 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.479 -0.782 . . . . 71.319999999999993 109.383 178.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -76.34 30.9 0.4 Allowed 'Trans proline' 0 CA--C 1.529 0.254 0 C-N-CA 123.28 2.653 . . . . 62.140000000000001 112.5 -177.052 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -119.57 -39.89 2.83 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.433 -0.803 . . . . 72.219999999999999 110.462 -177.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.7 pttt -97.53 160.22 14.45 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.999 -0.546 . . . . 74.530000000000001 110.501 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.485 ' HB3' ' OD1' ' A' ' 56' ' ' ASN . 5.4 mp -92.96 140.25 29.67 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.668 -0.696 . . . . 71.140000000000001 109.335 179.214 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.711 HG23 ' HB3' ' A' ' 71' ' ' GLU . 47.1 mm -96.84 109.03 46.79 Favored Pre-proline 0 C--N 1.322 -0.593 0 CA-C-O 121.235 0.54 . . . . 75.310000000000002 111.307 -176.453 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.49 ' O ' HG23 ' A' ' 72' ' ' ILE . 93.0 Cg_endo -81.61 -176.92 3.3 Favored 'Trans proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.505 2.803 . . . . 61.140000000000001 111.983 177.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . 0.651 ' O ' HG12 ' A' ' 72' ' ' ILE . 6.3 tt0 -67.99 -40.42 83.09 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.225 0.454 . . . . 72.420000000000002 112.225 -171.122 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . 0.644 ' HA ' ' CZ ' ' A' ' 73' ' ' PHE . 17.4 p90 -63.38 -17.76 62.95 Favored 'General case' 0 C--N 1.326 -0.441 0 O-C-N 121.723 -0.61 . . . . 72.349999999999994 110.981 -178.591 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.711 ' HB3' HG23 ' A' ' 67' ' ' ILE . 2.5 mm-40 -94.45 -18.45 21.49 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.041 -0.527 . . . . 71.030000000000001 111.117 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.651 HG12 ' O ' ' A' ' 69' ' ' GLN . 39.9 pt -83.61 -36.03 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 C-N-CA 120.723 -0.391 . . . . 53.299999999999997 111.625 -177.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.644 ' CZ ' ' HA ' ' A' ' 70' ' ' TRP . 10.7 p90 -90.82 26.09 2.18 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.262 0.554 . . . . 75.109999999999999 110.722 178.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.3 t -78.72 9.03 4.49 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.767 -0.652 . . . . 73.420000000000002 111.102 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . 0.681 ' HB3' ' HE3' ' A' ' 21' ' ' LYS . 38.8 m0 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.459 -0.337 . . . . 72.519999999999996 111.176 177.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 31.8 m . . . . . 0 C--O 1.233 0.221 0 CA-C-O 121.154 0.502 . . . . 72.239999999999995 110.366 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 122.61 42.89 0.4 Allowed Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 110.491 -1.043 . . . . 63.049999999999997 110.491 -170.397 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -106.59 100.56 31.25 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-O 121.658 0.742 . . . . 74.340000000000003 109.286 -179.463 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 58.0 Cg_endo -79.43 121.04 4.61 Favored 'Trans proline' 0 N--CA 1.448 -1.148 0 C-N-CA 122.382 2.054 . . . . 54.130000000000003 113.195 -169.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -122.84 144.19 49.36 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.814 -1.084 . . . . 74.340000000000003 108.599 174.583 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.75 HG21 ' HB3' ' B' ' 124' ' ' GLN . 7.9 p -92.37 132.01 37.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-O 121.396 0.617 . . . . 75.0 111.543 -172.112 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . 0.747 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.4 m -82.84 103.39 12.28 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.167 -0.924 . . . . 71.409999999999997 109.177 174.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 59.2 mt -88.67 104.61 14.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.096 0.474 . . . . 72.430000000000007 111.066 -176.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . 0.434 HH21 ' CD ' ' B' ' 125' ' ' GLU . 38.1 mtm180 -108.88 167.86 9.78 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.721 -0.672 . . . . 72.219999999999999 109.627 174.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 91.5 mt-30 -139.55 112.03 7.73 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.068 0.461 . . . . 74.340000000000003 110.585 177.447 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 81.6 mm-40 -108.48 85.35 2.09 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.669 -0.696 . . . . 74.099999999999994 110.384 -178.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 88.38 -111.94 3.84 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.624 -0.798 . . . . 51.420000000000002 111.589 -178.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . 0.507 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 4.3 m-20 -116.0 23.24 12.37 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.059 0.457 . . . . 42.229999999999997 110.041 177.141 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.962 ' HE3' ' HB3' ' B' ' 175' ' ' TRP . 21.2 pttm -127.5 115.56 19.04 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.236 0.541 . . . . 63.310000000000002 110.307 177.311 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . 0.747 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 62.5 m -76.22 113.0 13.29 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.611 -0.722 . . . . 73.239999999999995 109.675 177.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 14.2 mm -92.8 102.51 13.7 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-N 115.948 -0.569 . . . . 75.129999999999995 109.999 -178.222 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.776 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 15.5 mt-30 -94.77 102.89 14.79 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.093 0.473 . . . . 63.130000000000003 110.327 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . 0.747 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 38.9 mt-10 -84.62 102.72 13.13 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.556 -0.747 . . . . 71.120000000000005 110.603 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . 0.493 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 41.4 m-85 -78.8 106.0 10.51 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.137 0.494 . . . . 55.109999999999999 110.377 178.061 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 65.6 mtt-85 -124.08 134.55 53.36 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.61 -0.723 . . . . 74.099999999999994 109.468 -178.367 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 5.6 p -96.08 -30.91 3.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-O 120.966 0.412 . . . . 54.020000000000003 111.407 -176.374 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -160.45 45.99 0.22 Allowed 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.872 -0.788 . . . . 72.340000000000003 108.872 -176.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 95.54 -32.08 6.58 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.425 -0.807 . . . . 23.510000000000002 112.186 -177.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.604 ' CD2' HG21 ' A' ' 28' ' ' VAL . 38.2 t80 -86.49 133.6 33.74 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.99 0.424 . . . . 74.310000000000002 110.445 -177.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.449 HD21 HD11 ' B' ' 135' ' ' ILE . 41.4 tp -82.83 120.5 25.73 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.354 -0.839 . . . . 62.210000000000001 110.645 179.328 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . 0.493 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 36.2 p90 -110.4 -10.43 14.58 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.498 -0.481 . . . . 74.019999999999996 111.658 -179.101 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -170.14 148.13 3.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.806 0.336 . . . . 44.210000000000001 110.913 -178.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.449 HD11 HD21 ' B' ' 132' ' ' LEU . 63.5 mt -122.44 125.89 73.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.332 -0.395 . . . . 71.109999999999999 110.17 177.456 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.776 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 75.9 tttt -102.43 102.39 12.7 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 109.07 -0.715 . . . . 72.129999999999995 109.07 173.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.589 HG12 ' HD3' ' B' ' 139' ' ' PRO . 3.4 t -86.52 128.94 39.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 N-CA-C 108.559 -0.904 . . . . 70.409999999999997 108.559 178.151 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.747 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.5 t -115.35 72.1 3.39 Favored Pre-proline 0 C--N 1.317 -0.841 0 N-CA-C 109.956 -0.387 . . . . 75.120000000000005 109.956 173.525 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.589 ' HD3' HG12 ' B' ' 137' ' ' VAL . 45.1 Cg_endo -77.12 130.5 11.23 Favored 'Trans proline' 0 N--CA 1.455 -0.754 0 C-N-CA 121.992 1.794 . . . . 64.109999999999999 111.868 176.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . 0.507 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 22.9 mtpp -64.76 -27.43 68.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.442 -0.799 . . . . 73.450000000000003 110.199 177.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -114.43 86.57 2.46 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.132 -0.94 . . . . 73.019999999999996 109.149 176.293 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 140.96 -13.88 2.85 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.593 -0.813 . . . . 60.520000000000003 112.678 -177.576 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 67.1 mttm 70.03 149.01 0.12 Allowed Pre-proline 0 N--CA 1.469 0.525 0 C-N-CA 123.134 0.574 . . . . 74.209999999999994 112.183 178.266 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.554 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 56.3 Cg_endo -70.64 143.1 45.7 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.674 2.249 . . . . 74.219999999999999 113.146 -178.279 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 44.7 p90 -150.99 154.77 37.72 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.789 -0.641 . . . . 74.230000000000004 110.199 178.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.636 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 93.4 m-85 -96.64 130.5 43.84 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.838 -0.43 . . . . 75.25 109.838 177.255 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.402 HD11 HG13 ' B' ' 167' ' ' ILE . 15.7 tp -117.21 98.81 6.64 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.134 -0.691 . . . . 73.439999999999998 109.134 176.479 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . 0.438 HG21 HG21 ' A' ' 48' ' ' VAL . 39.0 t -83.92 135.73 24.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.05 -0.523 . . . . 72.140000000000001 110.837 -175.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.29 119.44 24.59 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.58 -0.526 . . . . 64.349999999999994 109.58 -177.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.14 166.75 22.88 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 121.321 0.581 . . . . 71.209999999999994 111.74 -174.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . 0.404 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 5.6 p-10 -67.77 157.59 34.38 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 114.964 -1.017 . . . . 71.239999999999995 111.99 -175.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.41 -8.93 57.24 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.301 -0.863 . . . . 52.219999999999999 113.28 173.179 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 23.3 t 59.3 31.1 20.9 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-O 121.513 0.673 . . . . 71.209999999999994 110.007 -178.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -64.43 -26.18 68.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.597 -0.729 . . . . 64.329999999999998 111.841 -178.139 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 106.15 25.17 6.53 Favored Glycine 0 CA--C 1.506 -0.525 0 N-CA-C 111.169 -0.772 . . . . 62.229999999999997 111.169 -175.044 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . 0.444 HD21 HD23 ' B' ' 166' ' ' LEU . 38.0 t30 -111.95 144.26 41.59 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.461 -0.57 . . . . 75.109999999999999 109.461 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . 0.531 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 55.8 m-85 -130.62 149.56 52.22 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.305 -0.407 . . . . 75.450000000000003 110.083 179.587 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.2 mm -112.44 117.19 54.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.444 -0.576 . . . . 72.150000000000006 109.444 176.306 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.443 ' HG2' ' H ' ' B' ' 161' ' ' ASP . 46.1 ttt180 -85.95 135.05 33.82 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.48 -0.782 . . . . 74.010000000000005 110.075 -175.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . 0.636 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 61.3 p -60.46 -33.07 72.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.406 0.622 . . . . 74.200000000000003 110.412 178.66 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . 0.443 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 26.6 t70 -75.94 -24.59 55.51 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.15 -0.932 . . . . 71.310000000000002 110.921 178.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . 0.453 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 84.3 mm-40 -139.98 70.97 35.44 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 71.319999999999993 110.197 -175.235 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -73.11 -15.37 25.8 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.431 2.087 . . . . 72.230000000000004 112.007 -178.032 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -89.2 -7.2 56.06 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.41 -0.814 . . . . 72.140000000000001 109.641 177.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . 0.453 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 51.3 tptt -110.68 123.98 51.06 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.444 -0.798 . . . . 75.099999999999994 110.447 -176.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . 0.444 HD23 HD21 ' B' ' 156' ' ' ASN . 5.3 mp -89.64 117.5 28.56 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.515 -0.766 . . . . 62.409999999999997 108.989 177.096 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . 0.531 ' HB ' ' HB2' ' B' ' 157' ' ' PHE . 49.3 mm -77.73 119.56 77.91 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.185 -0.462 . . . . 72.25 111.272 -171.31 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.481 ' O ' HG23 ' B' ' 172' ' ' ILE . 73.7 Cg_endo -73.3 177.26 8.1 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 123.049 2.5 . . . . 73.409999999999997 111.998 178.492 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 -84.25 0.88 47.2 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.347 -0.388 . . . . 71.319999999999993 111.468 -172.127 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 7.8 p90 -100.46 -18.89 16.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.987 0.423 . . . . 73.549999999999997 110.89 175.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.418 ' HB2' ' HG2' ' B' ' 168' ' ' PRO . 2.0 mm-40 -94.29 -11.43 30.15 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.194 -0.457 . . . . 74.519999999999996 110.76 -177.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.481 HG23 ' O ' ' B' ' 168' ' ' PRO . 37.0 pt -65.56 -29.65 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.991 -0.55 . . . . 75.219999999999999 111.432 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . 0.458 ' C ' ' H ' ' B' ' 175' ' ' TRP . 33.8 p90 -107.79 43.96 1.15 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.525 0.678 . . . . 71.140000000000001 110.447 178.742 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . 0.418 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 1.9 t -78.59 21.97 0.37 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.05 -0.977 . . . . 71.349999999999994 110.036 178.183 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . 0.962 ' HB3' ' HE3' ' B' ' 121' ' ' LYS . 39.3 m0 . . . . . 0 C--O 1.25 1.129 0 CA-C-N 115.223 -0.898 . . . . 75.209999999999994 110.928 -176.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.6 m . . . . . 0 C--O 1.233 0.22 0 N-CA-C 109.518 -0.549 . . . . 65.109999999999999 109.518 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.663 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 74.03 73.02 0.95 Allowed Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.02 -1.086 . . . . 52.329999999999998 110.621 -173.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . 0.432 ' H ' ' HG2' ' A' ' 10' ' ' GLU . 7.6 pt-20 -96.22 99.1 4.77 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-O 121.417 0.627 . . . . 63.049999999999997 110.667 -174.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.673 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 98.2 Cg_endo -93.73 94.72 0.14 Allowed 'Trans proline' 0 N--CA 1.445 -1.368 0 C-N-CA 122.926 2.417 . . . . 64.040000000000006 112.747 -176.524 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -86.96 147.1 25.89 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 108.932 -0.766 . . . . 60.210000000000001 108.932 177.069 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.623 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 8.1 p -90.63 122.41 41.98 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 CA-C-O 121.629 0.728 . . . . 65.129999999999995 110.261 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.628 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 21.6 m -83.31 102.59 12.08 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.264 -0.88 . . . . 72.400000000000006 109.196 179.226 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 53.2 mt -84.72 103.98 12.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-N 115.978 -0.555 . . . . 74.340000000000003 110.308 -175.449 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -108.8 161.24 15.3 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.621 -0.718 . . . . 64.310000000000002 109.32 176.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -137.87 98.25 3.61 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-O 121.351 0.596 . . . . 71.129999999999995 110.232 176.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -93.88 96.84 9.99 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 114.982 -1.008 . . . . 75.420000000000002 109.849 -177.313 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 71.06 -101.84 1.0 Allowed Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.837 -0.697 . . . . 63.439999999999998 112.077 -178.105 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.745 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 16.5 m-20 -120.76 30.42 6.91 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.635 0.255 . . . . 62.43 110.951 -178.364 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 48.0 pttt -143.55 127.69 17.58 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.382 0.61 . . . . 75.25 111.624 175.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.447 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 75.0 m -81.66 107.18 14.2 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.189 -0.914 . . . . 71.340000000000003 109.936 177.073 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 50.2 mt -94.63 104.35 15.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.088 -0.505 . . . . 72.310000000000002 109.721 178.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.623 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 24.0 mt-30 -95.15 106.38 18.39 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.871 -0.604 . . . . 74.299999999999997 110.654 -177.725 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.628 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.7 mt-10 -89.86 104.51 17.06 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.874 -0.603 . . . . 53.149999999999999 111.355 -177.437 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.568 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 71.7 m-85 -76.94 103.57 6.95 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.393 -0.595 . . . . 74.340000000000003 109.393 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.43 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 55.5 mtt180 -120.39 128.05 52.86 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.259 -0.428 . . . . 73.549999999999997 110.362 -177.312 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.685 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.3 p -93.49 -66.73 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.543 -0.298 . . . . 72.450000000000003 111.232 179.58 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.685 ' H ' HG13 ' A' ' 28' ' ' VAL . 74.2 m-20 -133.53 77.5 1.73 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.85 0.357 . . . . 71.010000000000005 110.158 179.513 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 69.21 13.49 67.38 Favored Glycine 0 C--N 1.331 0.267 0 CA-C-N 115.792 -0.64 . . . . 74.209999999999994 112.868 179.042 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.614 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 83.3 t80 -129.86 128.04 41.45 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.888 0.375 . . . . 72.120000000000005 111.12 -175.431 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.74 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -85.98 116.25 24.09 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.559 -0.746 . . . . 72.120000000000005 109.327 173.571 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -110.89 -19.71 12.71 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.622 -0.431 . . . . 74.040000000000006 111.729 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -156.08 141.21 17.39 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.656 0.265 . . . . 61.009999999999998 111.031 -179.338 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.74 HG13 HD11 ' A' ' 32' ' ' LEU . 77.0 mt -124.31 125.9 71.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 116.055 -0.521 . . . . 72.319999999999993 110.612 176.867 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.444 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 82.1 tttt -102.99 102.56 12.61 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.104 -0.702 . . . . 72.299999999999997 109.104 170.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 22' ' ' THR . 0.5 OUTLIER -101.84 119.93 50.78 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 116.119 -0.491 . . . . 70.510000000000005 110.337 -179.538 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.571 HG13 ' HB3' ' A' ' 44' ' ' PRO . 22.3 t -109.17 89.71 7.19 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.445 -0.798 . . . . 73.439999999999998 110.135 -179.826 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.417 ' HD3' HG22 ' A' ' 37' ' ' VAL . 63.6 Cg_endo -79.37 135.92 12.24 Favored 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 122.282 1.988 . . . . 73.019999999999996 112.133 178.001 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.745 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 56.5 mtpt -63.43 -36.27 83.19 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.362 0.601 . . . . 71.329999999999998 109.518 174.622 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -97.81 92.63 5.94 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.222 -0.899 . . . . 63.299999999999997 109.114 177.269 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 126.0 -151.39 17.82 Favored Glycine 0 N--CA 1.448 -0.549 0 N-CA-C 111.478 -0.649 . . . . 63.119999999999997 111.478 -176.529 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -129.29 143.76 50.11 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.801 0.301 . . . . 73.420000000000002 110.601 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.571 ' HB3' HG13 ' A' ' 38' ' ' VAL . 32.1 Cg_endo -65.29 128.94 21.49 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.679 2.253 . . . . 74.129999999999995 112.077 177.758 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -133.86 156.73 47.54 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.267 -0.424 . . . . 74.120000000000005 110.343 -178.151 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -95.71 131.62 41.77 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.778 -0.647 . . . . 74.140000000000001 109.792 177.514 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.569 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 17.0 tp -115.63 94.11 4.56 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.827 -0.805 . . . . 72.010000000000005 108.827 178.102 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.7 t -87.29 138.27 19.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.064 -0.517 . . . . 63.25 110.872 -174.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . 0.461 ' HE ' ' HA ' ' A' ' 53' ' ' SER . 0.0 OUTLIER -100.89 121.6 42.0 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.926 -0.398 . . . . 74.319999999999993 109.926 -177.3 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.431 ' HB3' ' OD1' ' A' ' 56' ' ' ASN . . . -76.98 172.06 13.79 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.01 0.433 . . . . 71.299999999999997 112.076 -173.387 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.437 ' HB3' ' CD2' ' B' ' 126' ' ' TYR . 4.3 p-10 -72.13 167.73 19.64 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 115.793 -0.64 . . . . 74.310000000000002 111.09 -175.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 81.2 -17.17 13.42 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.831 -0.622 . . . . 50.43 112.798 177.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.461 ' HA ' ' HE ' ' A' ' 49' ' ' ARG . 20.9 t 61.64 33.46 18.13 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-O 120.894 0.378 . . . . 63.530000000000001 110.148 -178.075 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -55.89 -42.02 75.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.714 -0.675 . . . . 73.319999999999993 111.363 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 119.17 25.52 2.7 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.834 -0.698 . . . . 72.109999999999999 111.392 -177.167 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.431 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 11.2 p30 -118.74 147.24 44.07 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.178 0.513 . . . . 74.140000000000001 110.633 -177.368 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.569 ' CD2' ' HG ' ' A' ' 47' ' ' LEU . 46.6 m-85 -128.17 154.33 45.91 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.684 -0.689 . . . . 75.400000000000006 110.501 -178.729 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 45.3 mm -113.1 122.89 68.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.987 -0.551 . . . . 73.409999999999997 109.519 177.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.491 ' HB3' ' HB3' ' A' ' 61' ' ' ASP . 67.2 mtt180 -86.17 144.79 27.3 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.56 -0.291 . . . . 71.420000000000002 110.61 178.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 77.6 p -76.02 -21.85 56.41 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.407 -0.961 . . . . 75.299999999999997 108.407 166.396 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.491 ' HB3' ' HB3' ' A' ' 59' ' ' ARG . 19.2 t70 -57.62 -49.17 77.33 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.519 -1.219 . . . . 74.349999999999994 110.092 172.746 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 24.1 mm-40 -144.78 86.38 7.9 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.151 -0.932 . . . . 63.200000000000003 110.25 178.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_endo -78.79 13.0 2.03 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.89 2.394 . . . . 75.439999999999998 112.24 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -83.65 -30.7 26.65 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.418 -0.81 . . . . 71.099999999999994 110.529 -178.59 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.434 ' HE3' HD11 ' A' ' 67' ' ' ILE . 0.0 OUTLIER -126.25 178.1 6.02 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-O 121.196 0.522 . . . . 72.349999999999994 111.614 -176.664 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.5 mp -111.16 138.19 47.91 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.206 -0.906 . . . . 75.409999999999997 109.607 177.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.434 HD11 ' HE3' ' A' ' 65' ' ' LYS . 33.7 mm -76.55 124.86 87.95 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 116.448 -0.342 . . . . 75.430000000000007 110.145 178.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.411 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 44.3 Cg_endo -66.98 173.84 7.72 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.903 2.402 . . . . 75.010000000000005 112.759 -177.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 19.5 tt0 -88.63 -1.44 58.07 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.54 -0.755 . . . . 74.109999999999999 111.907 -168.684 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . 0.586 ' HA ' ' CE2' ' A' ' 73' ' ' PHE . 33.4 p90 -97.39 -22.61 16.51 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.265 0.555 . . . . 74.530000000000001 109.727 172.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.414 ' HA ' ' OG ' ' A' ' 74' ' ' SER . 4.4 mm-40 -84.25 -12.71 54.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.448 -0.796 . . . . 44.409999999999997 111.522 -176.745 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 31.9 pt -77.67 -15.88 14.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.125 -0.489 . . . . 64.400000000000006 111.875 -177.496 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CE2' ' HA ' ' A' ' 70' ' ' TRP . 42.4 p90 -119.45 23.83 11.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.42 0.629 . . . . 74.420000000000002 110.189 177.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.414 ' OG ' ' HA ' ' A' ' 71' ' ' GLU . 56.2 m -80.23 -1.34 40.25 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.712 -0.676 . . . . 65.420000000000002 110.875 177.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . 0.553 ' HH2' HG21 ' A' ' 35' ' ' ILE . 0.3 OUTLIER . . . . . 0 C--N 1.327 -0.38 0 CA-C-N 116.149 -0.478 . . . . 73.129999999999995 110.58 178.275 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 58.8 m . . . . . 0 N--CA 1.45 -0.449 0 N-CA-C 109.292 -0.632 . . . . 75.340000000000003 109.292 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.45 52.66 0.55 Allowed Glycine 0 N--CA 1.445 -0.715 0 N-CA-C 110.551 -1.02 . . . . 73.230000000000004 110.551 -170.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . 0.407 ' O ' ' HG3' ' B' ' 110' ' ' GLU . 10.1 pt-20 -97.92 105.33 26.84 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.365 -0.976 . . . . 73.239999999999995 108.365 -179.316 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.614 ' HG3' ' CZ ' ' A' ' 31' ' ' PHE . 73.7 Cg_endo -83.11 113.42 2.11 Favored 'Trans proline' 0 N--CA 1.443 -1.489 0 C-N-CA 122.143 1.895 . . . . 72.549999999999997 112.418 -170.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 16.5 p-10 -109.72 133.46 53.1 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 115.066 -0.97 . . . . 75.409999999999997 109.444 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.626 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 11.7 p -83.55 127.89 39.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 121.42 0.629 . . . . 65.040000000000006 110.734 -177.396 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . 0.646 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 27.0 m -81.72 108.85 15.6 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.456 -0.793 . . . . 71.129999999999995 109.964 179.349 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.487 HG12 ' HG2' ' B' ' 124' ' ' GLN . 66.4 mt -93.26 106.05 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.074 0.464 . . . . 61.32 110.907 -176.439 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . 0.485 ' HA ' ' NE ' ' B' ' 116' ' ' ARG . 3.5 mmp_? -116.24 164.98 13.69 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.657 -0.701 . . . . 73.120000000000005 109.457 176.824 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -138.39 107.46 6.03 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.099 0.476 . . . . 72.219999999999999 110.962 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -100.36 97.29 8.07 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.584 -0.734 . . . . 71.239999999999995 110.297 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 74.89 -97.01 0.98 Allowed Glycine 0 N--CA 1.444 -0.797 0 C-N-CA 121.011 -0.614 . . . . 74.209999999999994 112.256 178.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . 0.746 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 5.8 m-20 -125.06 32.07 5.48 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.702 0.287 . . . . 72.109999999999999 110.664 -178.702 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . . . . . . . . . 41.9 pttt -145.83 125.43 13.28 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.273 0.559 . . . . 55.409999999999997 111.806 177.754 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 59.8 m -79.91 107.74 12.93 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.073 -0.967 . . . . 71.209999999999994 109.828 175.413 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 42.6 mt -100.13 109.46 24.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-O 121.209 0.528 . . . . 61.439999999999998 110.096 -178.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.626 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 55.0 mt-30 -96.19 111.23 23.34 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.573 -0.74 . . . . 74.010000000000005 111.135 -178.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . 0.646 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 42.9 mt-10 -90.0 104.94 17.46 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.874 -0.603 . . . . 74.439999999999998 110.669 177.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . 0.437 ' CD2' ' HB3' ' A' ' 51' ' ' ASP . 56.8 m-85 -76.82 110.8 11.72 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.486 -0.324 . . . . 74.019999999999996 110.487 178.002 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . 0.613 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 48.0 mtt180 -130.93 137.7 49.41 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.971 -0.381 . . . . 74.040000000000006 109.971 178.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.5 p -98.8 -41.21 9.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.273 0.558 . . . . 54.020000000000003 110.797 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 -157.36 72.92 0.71 Allowed 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.848 -0.797 . . . . 75.299999999999997 108.848 -177.751 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.47 -38.16 2.77 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.819 -0.628 . . . . 53.149999999999999 112.889 -178.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -88.97 132.62 34.64 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.039 0.447 . . . . 75.219999999999999 111.573 -172.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.613 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 45.1 tp -85.16 117.96 24.43 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.317 -0.856 . . . . 53.119999999999997 110.085 175.091 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -109.67 -9.39 14.86 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.428 -0.509 . . . . 75.209999999999994 111.948 -177.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -167.51 141.52 3.61 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.735 0.302 . . . . 52.310000000000002 111.294 -177.188 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 57.9 mt -118.13 126.29 74.85 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 116.271 -0.422 . . . . 71.140000000000001 110.121 176.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.466 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 84.7 tttt -112.7 101.19 9.31 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.367 -0.605 . . . . 72.310000000000002 109.367 174.453 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.511 HG13 ' CE1' ' B' ' 145' ' ' TYR . 0.7 OUTLIER -103.57 126.46 58.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 CA-C-O 121.03 0.443 . . . . 72.030000000000001 110.715 -178.844 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.809 HG22 ' HB3' ' B' ' 144' ' ' PRO . 21.9 t -110.2 89.53 8.54 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.366 -0.834 . . . . 64.129999999999995 109.62 178.748 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -77.35 136.52 15.94 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 122.508 2.139 . . . . 74.25 112.701 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . 0.746 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 56.2 mtpt -61.13 -38.08 85.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.6 0.714 . . . . 51.409999999999997 109.62 171.598 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 94.9 m-70 -99.3 84.25 2.97 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.832 -1.076 . . . . 75.140000000000001 108.889 177.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 130.59 -162.55 23.33 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 110.322 -1.111 . . . . 73.450000000000003 110.322 -172.316 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -138.83 153.24 71.82 Favored Pre-proline 0 C--N 1.321 -0.652 0 CA-C-N 117.336 0.568 . . . . 75.310000000000002 110.715 178.169 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.809 ' HB3' HG22 ' B' ' 138' ' ' VAL . 21.8 Cg_endo -60.47 140.72 92.93 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 123.226 2.617 . . . . 55.240000000000002 113.29 -174.235 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . 0.511 ' CE1' HG13 ' B' ' 137' ' ' VAL . 23.3 p90 -143.44 155.67 44.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.53 -0.759 . . . . 74.120000000000005 109.481 177.84 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.463 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 96.4 m-85 -97.22 133.14 42.25 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.754 0.312 . . . . 64.230000000000004 110.431 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.528 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 17.5 tp -122.29 98.53 5.97 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.864 -0.791 . . . . 72.409999999999997 108.864 177.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 39.0 t -99.31 144.72 11.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.431 -0.349 . . . . 24.039999999999999 111.186 -172.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 5.2 mmt85 -76.91 145.25 38.36 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-O 120.962 0.41 . . . . 75.409999999999997 111.932 179.194 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.96 169.95 12.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.807 -0.633 . . . . 64.319999999999993 109.823 171.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . 0.568 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 6.2 p-10 -67.64 157.23 34.99 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.373 0.606 . . . . 74.510000000000005 112.155 -174.479 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 84.76 -5.68 81.09 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.481 -0.781 . . . . 71.129999999999995 113.268 174.384 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . 0.413 ' HB2' ' CD ' ' A' ' 11' ' ' PRO . 3.5 t 62.22 27.99 16.78 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.487 0.66 . . . . 41.43 109.664 -177.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -56.59 -27.56 58.29 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 114.782 -1.099 . . . . 65.540000000000006 111.885 -178.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 112.09 -22.11 18.96 Favored Glycine 0 CA--C 1.498 -1.0 0 C-N-CA 120.617 -0.802 . . . . 73.230000000000004 111.19 -178.593 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . 1.038 HD21 HD22 ' B' ' 166' ' ' LEU . 52.2 t30 -63.8 132.96 52.51 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 114.203 -0.998 . . . . 72.530000000000001 111.507 179.446 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . 0.528 ' CD2' ' HG ' ' B' ' 147' ' ' LEU . 27.2 m-85 -115.0 159.17 21.09 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.828 -0.623 . . . . 72.25 110.538 178.04 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . 0.831 HD11 HD23 ' B' ' 166' ' ' LEU . 48.6 mm -127.75 132.71 68.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.992 -0.549 . . . . 73.409999999999997 109.558 174.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.502 ' HB2' ' HB2' ' B' ' 162' ' ' GLN . 70.2 mtt180 -85.26 156.89 20.76 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.885 0.374 . . . . 73.109999999999999 111.249 -179.829 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . 0.463 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 49.4 p -80.01 -19.48 47.64 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.885 0.85 . . . . 60.549999999999997 108.777 166.37 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . 0.409 ' H ' ' HB3' ' B' ' 159' ' ' ARG . 3.7 t70 -86.84 -26.04 24.23 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 114.461 -1.245 . . . . 63.219999999999999 110.46 176.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . 0.502 ' HB2' ' HB2' ' B' ' 159' ' ' ARG . 25.4 mm-40 -136.68 74.94 51.27 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.518 -0.764 . . . . 74.519999999999996 109.346 -179.691 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -89.24 11.68 2.89 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.897 2.398 . . . . 61.539999999999999 113.183 -176.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -107.87 -45.42 3.99 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 120.992 -0.283 . . . . 74.230000000000004 111.013 -178.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.25 172.79 7.89 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.029 0.442 . . . . 70.349999999999994 111.26 178.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . 1.038 HD22 HD21 ' B' ' 156' ' ' ASN . 15.8 mt -105.35 150.27 25.36 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.851 -0.613 . . . . 72.140000000000001 109.948 -175.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 40.8 mm -101.31 111.67 63.98 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 116.389 -0.369 . . . . 72.219999999999999 110.183 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.602 ' O ' HG23 ' B' ' 172' ' ' ILE . 59.7 Cg_endo -70.05 174.52 9.64 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 123.075 2.516 . . . . 73.010000000000005 112.593 -178.511 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . 0.625 ' O ' HG12 ' B' ' 172' ' ' ILE . 6.3 tt0 -72.45 -35.7 68.35 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.877 -0.601 . . . . 72.430000000000007 111.969 -167.816 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 33.4 p90 -69.02 -14.66 63.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.168 0.509 . . . . 65.420000000000002 110.222 177.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.467 ' HA ' ' HB2' ' B' ' 174' ' ' SER . 7.0 mm-40 -96.51 -29.54 13.83 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.569 -0.741 . . . . 71.150000000000006 111.671 -178.029 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.625 HG12 ' O ' ' B' ' 169' ' ' GLN . 43.4 pt -67.66 -26.21 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 N-CA-C 111.876 0.324 . . . . 71.200000000000003 111.876 -175.309 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -124.09 36.3 4.65 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.353 0.597 . . . . 71.409999999999997 110.256 176.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . 0.467 ' HB2' ' HA ' ' B' ' 171' ' ' GLU . 22.1 t -85.66 10.73 12.56 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.342 -0.845 . . . . 71.219999999999999 111.369 -176.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 11.9 p-90 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.619 -0.705 . . . . 72.5 111.599 -178.364 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 25.3 p . . . . . 0 N--CA 1.451 -0.389 0 N-CA-C 110.342 -0.244 . . . . 75.040000000000006 110.342 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 145.07 -53.16 0.57 Allowed Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.848 -0.691 . . . . 54.450000000000003 111.622 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 64.6 100.96 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.542 0.686 . . . . 65.209999999999994 111.624 177.041 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.646 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 18.8 Cg_endo -91.62 122.05 0.67 Allowed 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 123.58 2.853 . . . . 74.340000000000003 112.595 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -139.62 138.58 36.26 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.148 -0.478 . . . . 73.129999999999995 109.749 178.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.543 ' HB ' ' HB2' ' B' ' 151' ' ' ASP . 13.7 p -101.94 132.8 47.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.331 0.586 . . . . 74.129999999999995 111.215 -171.594 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.7 m -92.77 104.06 16.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.738 -0.665 . . . . 72.140000000000001 109.722 176.055 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 66.4 mt -94.23 107.83 19.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.167 -0.469 . . . . 71.040000000000006 110.5 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.9 mtp180 -115.83 -179.2 3.59 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.242 -0.435 . . . . 64.209999999999994 110.505 177.065 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 70.9 mt-30 -140.1 106.24 5.23 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.937 -0.574 . . . . 64.040000000000006 110.763 178.211 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -99.62 107.08 19.13 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.912 -0.585 . . . . 75.129999999999995 109.846 176.716 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 62.61 -111.15 3.8 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.752 -0.737 . . . . 71.439999999999998 112.215 -178.323 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.506 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 7.7 m-20 -105.81 7.62 32.43 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 111.49 0.181 . . . . 74.340000000000003 111.49 -177.847 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.641 ' HE3' ' HE3' ' A' ' 75' ' ' TRP . 0.0 OUTLIER -121.06 131.68 54.42 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 119.951 -0.7 . . . . 73.230000000000004 112.259 179.951 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.526 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 6.2 m -80.68 124.08 28.71 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.162 -0.926 . . . . 72.209999999999994 109.313 174.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.415 HD11 ' HG3' ' A' ' 21' ' ' LYS . 23.7 mm -108.45 107.32 22.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 110.141 -0.318 . . . . 64.219999999999999 110.141 -175.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 14.6 mt-30 -102.23 105.26 15.9 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.91 0.386 . . . . 64.150000000000006 110.273 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.417 ' HB3' HD23 ' A' ' 32' ' ' LEU . 29.7 mt-10 -88.92 100.38 13.14 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.447 -0.797 . . . . 63.340000000000003 110.606 -178.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.558 ' HA ' ' OD2' ' B' ' 151' ' ' ASP . 96.3 m-85 -76.22 118.39 18.9 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.011 -0.541 . . . . 75.200000000000003 110.3 179.561 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.461 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 50.6 mtt180 -139.2 121.17 15.6 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.161 0.505 . . . . 75.200000000000003 112.014 -173.174 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.646 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 3.8 p -97.45 120.5 46.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 108.751 -0.833 . . . . 75.400000000000006 108.751 169.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 73.85 -34.39 0.28 Allowed 'General case' 0 N--CA 1.47 0.562 0 O-C-N 123.456 0.473 . . . . 64.219999999999999 111.085 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.406 ' H ' ' C ' ' A' ' 28' ' ' VAL . . . 157.32 -16.39 0.34 Allowed Glycine 0 N--CA 1.45 -0.431 0 N-CA-C 111.859 -0.496 . . . . 72.0 111.859 178.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.438 ' O ' ' HA ' ' A' ' 27' ' ' ARG . 81.3 t80 -79.47 125.73 29.94 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.69 0.281 . . . . 74.219999999999999 111.003 -177.782 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.686 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -73.21 112.33 9.15 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.281 -0.637 . . . . 74.030000000000001 109.281 175.821 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 25.7 p90 -111.66 -14.3 13.64 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 120.402 -0.519 . . . . 74.519999999999996 111.83 -178.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -159.54 142.86 14.37 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.732 0.301 . . . . 73.299999999999997 110.94 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.686 HG13 HD11 ' A' ' 32' ' ' LEU . 68.2 mt -123.91 122.86 65.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.233 -0.44 . . . . 73.430000000000007 110.14 175.521 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.437 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 53.2 tttp -107.66 106.57 16.98 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.003 -0.74 . . . . 55.329999999999998 109.003 172.152 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.578 HG23 ' HB2' ' A' ' 21' ' ' LYS . 1.5 p -102.58 126.85 56.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-N 116.111 -0.495 . . . . 71.140000000000001 110.26 178.28 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.716 HG22 ' HB3' ' A' ' 44' ' ' PRO . 23.5 t -109.3 85.66 3.66 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.273 -0.876 . . . . 64.030000000000001 109.99 178.397 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.518 ' HD2' ' C ' ' A' ' 43' ' ' LYS . 36.6 Cg_endo -86.36 132.9 3.79 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 122.572 2.182 . . . . 75.25 112.557 179.539 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.506 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 56.2 mtpt -60.35 -26.01 66.28 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.619 0.724 . . . . 74.209999999999994 109.884 175.188 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -122.54 88.25 2.9 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 115.194 -0.912 . . . . 74.349999999999994 108.818 176.414 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 145.28 -34.7 1.5 Allowed Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.442 -0.799 . . . . 42.109999999999999 111.702 -175.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.518 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 97.4 mttt 72.22 145.97 0.11 Allowed Pre-proline 0 N--CA 1.468 0.451 0 C-N-CA 123.565 0.746 . . . . 53.149999999999999 112.152 176.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.716 ' HB3' HG22 ' A' ' 38' ' ' VAL . 34.3 Cg_endo -63.25 137.49 61.31 Favored 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 123.454 2.769 . . . . 55.409999999999997 114.362 -170.019 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.404 ' CE1' HG13 ' A' ' 37' ' ' VAL . 8.6 p90 -148.21 165.96 29.37 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.577 -0.738 . . . . 72.219999999999999 109.243 174.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.74 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 38.6 m-85 -104.93 134.19 48.46 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.904 0.383 . . . . 74.510000000000005 110.774 177.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.523 HD21 HG22 ' A' ' 72' ' ' ILE . 16.6 tp -120.41 102.7 8.64 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.574 -0.899 . . . . 75.439999999999998 108.574 172.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.4 t -97.61 138.68 21.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.143 -0.481 . . . . 62.420000000000002 110.886 -173.148 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . 0.424 HH11 ' HD3' ' A' ' 49' ' ' ARG . 7.4 tpt180 -66.57 128.02 34.62 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.89 -0.595 . . . . 72.340000000000003 110.131 175.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.09 116.84 18.85 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.736 -0.468 . . . . 62.420000000000002 109.736 174.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.618 ' HB2' ' CD2' ' B' ' 126' ' ' TYR . 0.4 OUTLIER -53.38 138.74 32.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.969 -0.56 . . . . 72.239999999999995 110.165 177.325 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 109.39 -32.48 6.78 Favored Glycine 0 N--CA 1.442 -0.963 0 N-CA-C 110.453 -1.059 . . . . 64.310000000000002 110.453 -171.623 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.4 t 56.99 50.36 12.28 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-O 121.253 0.549 . . . . 71.519999999999996 110.838 176.445 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -92.46 18.29 8.73 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.206 -0.452 . . . . 70.209999999999994 111.012 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.97 52.62 4.25 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.752 -0.737 . . . . 54.420000000000002 111.507 -176.591 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 30.2 t30 -147.76 141.81 25.99 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.804 0.335 . . . . 62.399999999999999 110.999 -174.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -129.42 147.1 51.2 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.898 -0.592 . . . . 74.040000000000006 109.529 175.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 43.7 mm -111.16 137.0 45.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.041 0.448 . . . . 75.010000000000005 110.394 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.743 ' HB2' HG13 ' A' ' 67' ' ' ILE . 24.0 ttt180 -103.22 142.18 34.61 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.826 -0.624 . . . . 73.519999999999996 110.5 -172.351 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.74 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 76.9 p -70.11 -30.81 68.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.41 0.624 . . . . 41.240000000000002 110.157 176.011 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.412 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 0.8 OUTLIER -70.81 -27.86 64.2 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 114.845 -1.07 . . . . 73.230000000000004 110.631 176.969 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . 0.699 ' HG2' ' HB3' ' A' ' 65' ' ' LYS . 5.5 tt0 -146.05 77.04 12.2 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.685 -0.689 . . . . 70.230000000000004 109.598 -175.241 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.2 -35.38 8.72 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.836 2.357 . . . . 65.040000000000006 113.842 -172.175 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -95.07 41.02 1.1 Allowed 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.888 0.851 . . . . 63.439999999999998 109.953 -177.657 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.699 ' HB3' ' HG2' ' A' ' 62' ' ' GLN . 22.9 tptm -150.46 128.38 11.78 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.185 -0.916 . . . . 70.540000000000006 109.93 175.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.511 ' H ' HD12 ' A' ' 66' ' ' LEU . 4.5 mp -73.32 120.35 18.82 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.324 -0.853 . . . . 65.540000000000006 109.045 176.654 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.743 HG13 ' HB2' ' A' ' 59' ' ' ARG . 47.4 mm -85.75 125.39 69.12 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-O 120.861 0.362 . . . . 62.310000000000002 110.639 -176.265 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -66.54 175.73 4.87 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.876 2.384 . . . . 72.310000000000002 112.778 -178.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 16.4 tt0 -93.9 14.35 19.82 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.588 -0.733 . . . . 70.019999999999996 111.834 -168.506 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 18.7 p90 -109.24 -26.35 10.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.147 0.499 . . . . 72.510000000000005 110.151 173.246 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -81.12 -11.89 59.37 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.998 -0.546 . . . . 64.340000000000003 110.672 -178.653 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.523 HG22 HD21 ' A' ' 47' ' ' LEU . 44.9 pt -69.59 -22.84 25.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.915 -0.584 . . . . 51.409999999999997 110.91 177.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -112.6 25.26 11.64 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-N 115.808 -0.633 . . . . 62.299999999999997 109.822 -178.587 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 4.5 t -60.22 -37.78 81.37 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.873 -1.058 . . . . 60.509999999999998 109.906 -179.222 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . 0.641 ' HE3' ' HE3' ' A' ' 21' ' ' LYS . 43.2 p-90 . . . . . 0 C--N 1.326 -0.434 0 CA-C-N 115.884 -0.598 . . . . 65.219999999999999 110.454 176.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 55.0 m . . . . . 0 N--CA 1.452 -0.326 0 CA-C-O 120.904 0.383 . . . . 55.340000000000003 110.542 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . 0.402 ' HA2' HD22 ' B' ' 129' ' ' ASN . . . 117.06 -63.25 0.38 Allowed Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 110.524 -1.031 . . . . 42.219999999999999 110.524 -175.741 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 62.3 88.19 0.12 Allowed Pre-proline 0 C--O 1.232 0.138 0 C-N-CA 123.157 0.583 . . . . 60.140000000000001 111.056 175.032 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.633 ' HB3' ' HA ' ' B' ' 128' ' ' VAL . 56.4 Cg_endo -86.67 140.08 5.94 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.982 2.454 . . . . 72.340000000000003 112.713 -176.701 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -148.13 122.42 9.62 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.751 -0.659 . . . . 73.140000000000001 109.28 177.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.462 ' N ' ' HB3' ' A' ' 51' ' ' ASP . 7.5 p -71.6 134.21 30.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.391 0.615 . . . . 70.129999999999995 111.739 -172.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 85.1 m -95.04 104.78 16.66 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.474 -0.785 . . . . 72.010000000000005 109.854 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 65.2 mt -88.19 106.56 16.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.893 -0.594 . . . . 72.219999999999999 110.143 -177.642 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 25.3 mtp-105 -108.75 171.59 7.34 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.166 0.508 . . . . 75.010000000000005 111.569 -178.241 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 70.4 mt-30 -132.34 114.7 14.7 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.581 -0.736 . . . . 62.530000000000001 109.989 176.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . 0.68 ' HG3' HD12 ' B' ' 123' ' ' ILE . 22.1 mm-40 -99.61 23.25 9.75 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.94 -0.573 . . . . 73.430000000000007 110.672 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 123.45 -90.47 0.42 Allowed Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.692 -0.563 . . . . 43.530000000000001 111.692 -178.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . 0.668 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 72.0 m-20 -105.35 -16.51 14.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.14 0.495 . . . . 64.219999999999999 110.077 177.51 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.676 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 27.4 pttt -99.96 120.09 39.26 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.434 0.635 . . . . 74.329999999999998 111.15 -178.761 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . 0.464 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 25.0 m -83.22 104.29 13.28 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.376 -0.829 . . . . 64.25 109.193 174.471 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . 0.68 HD12 ' HG3' ' B' ' 118' ' ' GLU . 23.4 mt -98.39 107.26 20.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.181 0.515 . . . . 73.239999999999995 110.887 -174.118 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.586 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 17.9 mt-30 -93.62 107.07 18.98 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.431 -0.804 . . . . 64.430000000000007 110.061 179.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -87.95 111.08 21.09 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.097 -0.501 . . . . 65.0 110.687 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . 0.618 ' CD2' ' HB2' ' A' ' 51' ' ' ASP . 37.8 m-85 -86.4 113.6 22.49 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.013 -0.54 . . . . 64.420000000000002 110.131 177.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . 0.638 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 63.7 mtt180 -138.12 132.95 32.78 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.663 -0.699 . . . . 72.340000000000003 109.675 -176.791 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.633 ' HA ' ' HB3' ' B' ' 111' ' ' PRO . 2.7 p -96.32 -39.39 9.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 120.944 0.402 . . . . 31.239999999999998 110.991 -178.341 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . 0.402 HD22 ' HA2' ' B' ' 109' ' ' GLY . 4.4 t-20 -153.1 64.79 0.77 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.322 -0.622 . . . . 75.040000000000006 109.322 -179.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.07 -36.01 3.35 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.489 -0.778 . . . . 72.310000000000002 112.597 -179.261 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.475 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 80.8 t80 -83.84 124.79 31.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.084 0.468 . . . . 72.310000000000002 111.233 -173.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.799 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -77.12 115.6 17.05 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.312 -0.858 . . . . 71.519999999999996 109.251 175.169 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 22.5 p90 -109.11 -19.03 13.5 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.268 -0.573 . . . . 72.519999999999996 111.901 -178.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -155.98 141.47 17.72 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.024 0.44 . . . . 73.0 111.057 179.065 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.799 HG13 HD11 ' B' ' 132' ' ' LEU . 81.8 mt -119.2 123.82 72.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.859 -0.609 . . . . 73.150000000000006 110.286 177.127 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.586 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.6 tttt -105.62 99.68 9.27 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.274 -0.639 . . . . 71.530000000000001 109.274 172.007 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.463 HG23 ' HB2' ' B' ' 121' ' ' LYS . 2.0 p -101.4 121.8 52.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-O 121.194 0.521 . . . . 74.439999999999998 110.361 -178.602 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.841 HG22 ' HB3' ' B' ' 144' ' ' PRO . 24.6 t -109.03 85.51 3.29 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 115.086 -0.961 . . . . 55.450000000000003 110.21 179.614 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.676 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 71.6 Cg_endo -84.3 134.08 5.73 Favored 'Trans proline' 0 N--CA 1.451 -0.979 0 C-N-CA 122.375 2.05 . . . . 64.030000000000001 112.545 179.525 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . 0.668 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 57.8 mtpt -57.92 -31.56 66.91 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.448 0.642 . . . . 61.329999999999998 109.889 174.436 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 82.7 m-70 -111.14 83.18 1.72 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.201 -0.909 . . . . 62.240000000000002 109.292 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . 0.41 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 148.71 -32.03 1.21 Allowed Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.684 -0.77 . . . . 63.210000000000001 112.785 -178.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . 0.45 ' C ' ' HD2' ' B' ' 139' ' ' PRO . 98.9 mttt 73.44 151.43 0.14 Allowed Pre-proline 0 N--CA 1.471 0.604 0 C-N-CA 123.452 0.701 . . . . 45.25 111.704 -178.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.841 ' HB3' HG22 ' B' ' 138' ' ' VAL . 26.7 Cg_endo -62.0 135.24 54.04 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 123.197 2.598 . . . . 70.510000000000005 113.952 -171.129 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . 0.429 ' CE1' HG13 ' B' ' 137' ' ' VAL . 6.2 p90 -150.99 152.19 33.17 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.356 -0.838 . . . . 74.409999999999997 109.852 176.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.681 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 50.7 m-85 -97.29 141.89 29.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.475 -0.33 . . . . 74.349999999999994 111.366 -178.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.457 HD23 ' HA ' ' B' ' 147' ' ' LEU . 15.3 mt -124.42 101.78 7.33 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.45 -0.795 . . . . 74.219999999999999 109.208 166.543 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . 0.433 HG13 ' HB ' ' B' ' 158' ' ' ILE . 6.0 p -104.65 139.2 26.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.724 -0.671 . . . . 73.409999999999997 111.015 -175.766 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 19.4 tpt180 -63.65 136.8 57.77 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.551 -0.75 . . . . 75.310000000000002 111.754 -178.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -90.19 123.95 34.43 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.275 -0.639 . . . . 74.109999999999999 109.275 169.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . 0.558 ' OD2' ' HA ' ' A' ' 26' ' ' TYR . 72.2 m-20 -57.33 142.91 41.79 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.285 0.564 . . . . 60.43 111.159 -178.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 109.91 -29.11 9.64 Favored Glycine 0 N--CA 1.444 -0.827 0 N-CA-C 110.468 -1.053 . . . . 64.329999999999998 110.468 -170.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 5.4 t 65.05 37.4 6.77 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-O 121.231 0.538 . . . . 64.530000000000001 111.009 174.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -65.11 -14.4 60.43 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.798 -0.637 . . . . 72.209999999999994 111.326 178.542 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 98.11 23.69 12.7 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 110.634 -0.986 . . . . 62.109999999999999 110.634 -173.405 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 42.1 t30 -110.71 140.18 45.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.916 -0.642 . . . . 70.219999999999999 110.494 -176.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -121.36 160.35 24.21 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.797 -0.638 . . . . 74.409999999999997 109.574 175.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . 0.433 ' HB ' HG13 ' B' ' 148' ' ' VAL . 46.2 mm -116.66 121.15 67.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 109.405 -0.591 . . . . 74.129999999999995 109.405 174.694 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.504 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 73.0 ttt180 -92.2 127.47 37.69 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.699 -0.682 . . . . 74.549999999999997 109.82 -177.61 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . 0.681 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 80.4 p -65.88 -9.22 27.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.513 -0.312 . . . . 71.450000000000003 111.78 -175.06 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . 0.457 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 21.1 t70 -64.06 -42.67 96.92 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.325 -0.621 . . . . 75.319999999999993 109.325 174.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . 0.423 ' HA ' ' HD2' ' B' ' 163' ' ' PRO . 23.1 mt-30 -141.86 92.6 7.79 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 115.146 -0.933 . . . . 71.209999999999994 108.766 177.518 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' B' ' 162' ' ' GLN . 36.6 Cg_endo -64.0 -10.59 23.58 Favored 'Trans proline' 0 N--CA 1.475 0.441 0 C-N-CA 123.767 2.978 . . . . 62.030000000000001 114.103 -172.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -98.39 -6.18 31.16 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.088 0.471 . . . . 75.109999999999999 109.925 179.066 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 24.4 tptm -97.21 127.94 43.63 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.743 -0.662 . . . . 73.0 110.872 -175.216 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . 0.445 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.7 mp -86.68 134.66 33.58 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.565 -0.743 . . . . 71.310000000000002 109.107 177.439 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . 0.906 HG23 ' HB3' ' B' ' 171' ' ' GLU . 27.3 mm -91.71 118.94 68.59 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-O 121.149 0.5 . . . . 43.039999999999999 112.052 -172.519 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.499 ' O ' HG23 ' B' ' 172' ' ' ILE . 74.5 Cg_endo -74.71 -179.39 4.84 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 123.451 2.767 . . . . 64.150000000000006 112.284 177.15 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . 0.612 ' HA ' HG12 ' B' ' 172' ' ' ILE . 34.6 tt0 -73.56 -30.95 63.36 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.873 0.368 . . . . 73.219999999999999 111.761 -170.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 22.7 p90 -75.74 -7.3 54.05 Favored 'General case' 0 C--N 1.324 -0.525 0 O-C-N 121.886 -0.509 . . . . 73.239999999999995 110.15 177.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.906 ' HB3' HG23 ' B' ' 167' ' ' ILE . 3.2 mm-40 -109.74 -18.81 13.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.791 -0.641 . . . . 70.219999999999999 111.472 -179.47 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.612 HG12 ' HA ' ' B' ' 169' ' ' GLN . 42.5 pt -73.51 -28.59 25.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.292 0.568 . . . . 73.299999999999997 109.932 176.329 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 62.1 m-85 -101.63 39.75 1.4 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.509 -0.769 . . . . 70.540000000000006 109.364 173.708 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . 0.603 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 5.7 t -66.7 -29.22 69.16 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.134 -0.939 . . . . 73.0 110.827 -176.39 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 20.8 p-90 . . . . . 0 C--O 1.242 0.677 0 CA-C-O 118.916 -0.564 . . . . 74.340000000000003 110.217 178.206 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 25.0 m . . . . . 0 C--O 1.234 0.25 0 CA-C-O 121.306 0.574 . . . . 74.109999999999999 111.034 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 157.33 40.89 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.727 0 N-CA-C 111.218 -0.753 . . . . 72.040000000000006 111.218 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . 0.405 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -114.99 101.59 54.59 Favored Pre-proline 0 N--CA 1.445 -0.681 0 N-CA-C 108.208 -1.034 . . . . 75.099999999999994 108.208 179.493 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.61 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 11.3 Cg_endo -79.32 104.65 1.78 Allowed 'Trans proline' 0 N--CA 1.44 -1.635 0 C-N-CA 122.064 1.843 . . . . 73.120000000000005 111.69 -171.552 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -123.13 149.59 44.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.502 -0.772 . . . . 74.450000000000003 109.21 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.653 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 9.3 p -99.74 126.97 53.04 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-O 121.595 0.712 . . . . 74.310000000000002 111.772 -172.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.54 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 7.0 m -83.36 103.51 12.79 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.513 -0.767 . . . . 75.310000000000002 109.334 176.706 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.5 mt -94.14 108.79 21.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 120.932 0.396 . . . . 71.25 111.127 -174.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 19.1 mmt180 -120.72 159.32 25.61 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.202 -0.454 . . . . 54.109999999999999 109.826 175.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -117.58 124.88 49.72 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.331 0.586 . . . . 71.239999999999995 110.677 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -111.42 59.67 0.62 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.9 -1.046 . . . . 72.030000000000001 110.061 -174.225 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 83.47 -107.67 2.95 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.843 -0.694 . . . . 55.450000000000003 111.943 -178.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -94.85 20.21 9.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.886 0.374 . . . . 74.209999999999994 110.652 -177.286 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.746 ' HD2' HD11 ' A' ' 23' ' ' ILE . 4.0 pttp -143.93 134.38 24.7 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.228 0.537 . . . . 74.019999999999996 111.89 -178.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 27.3 m -94.06 107.98 19.85 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.055 -0.72 . . . . 75.329999999999998 109.055 172.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.746 HD11 ' HD2' ' A' ' 21' ' ' LYS . 19.8 mt -101.61 113.54 38.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.269 0.556 . . . . 73.319999999999993 110.353 -175.098 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.653 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 23.2 mt-30 -104.89 117.86 35.1 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.497 -0.774 . . . . 52.240000000000002 111.356 -175.162 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.54 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 25.2 mt-10 -90.52 103.01 15.75 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.051 -0.522 . . . . 71.109999999999999 110.983 177.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 -81.27 103.5 11.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.897 0.379 . . . . 75.310000000000002 110.051 175.199 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.508 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 53.2 mtt180 -120.25 138.11 53.84 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.916 -0.402 . . . . 74.540000000000006 109.916 178.083 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.61 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 11.8 p -105.79 -27.89 2.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.288 0.566 . . . . 62.229999999999997 110.947 -175.82 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -162.64 59.05 0.21 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.758 -0.83 . . . . 73.549999999999997 108.758 -177.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.93 -36.95 3.23 Favored Glycine 0 N--CA 1.45 -0.427 0 CA-C-N 115.355 -0.839 . . . . 65.109999999999999 112.635 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.56 ' CD2' HG21 ' B' ' 128' ' ' VAL . 50.4 t80 -90.28 133.74 34.75 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.145 0.498 . . . . 74.519999999999996 110.723 -173.658 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.902 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -76.11 116.13 16.5 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.229 -0.896 . . . . 73.209999999999994 109.317 176.656 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 40.0 p90 -106.93 -17.8 14.09 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.431 -0.508 . . . . 71.329999999999998 111.218 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.45 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -157.58 137.9 12.76 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.014 0.435 . . . . 63.43 111.532 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.902 HG13 HD11 ' A' ' 32' ' ' LEU . 73.2 mt -118.02 117.08 53.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.159 -0.473 . . . . 72.140000000000001 110.102 175.262 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 84.9 tttt -100.69 101.53 12.43 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.022 -0.733 . . . . 53.240000000000002 109.022 173.296 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.671 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.5 p -102.77 124.5 56.84 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 N-CA-C 109.777 -0.453 . . . . 74.230000000000004 109.777 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.647 HG22 ' HB3' ' A' ' 44' ' ' PRO . 35.9 t -105.27 84.9 1.18 Allowed Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.206 -0.907 . . . . 55.119999999999997 109.525 177.391 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.671 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 89.2 Cg_endo -95.93 147.05 1.26 Allowed 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 123.04 2.493 . . . . 72.329999999999998 113.279 -178.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -68.73 -11.11 59.89 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.519 -0.764 . . . . 70.420000000000002 109.623 170.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 80.6 m-70 -121.85 92.85 3.83 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 115.022 -0.99 . . . . 74.140000000000001 109.468 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 121.54 -19.76 8.46 Favored Glycine 0 CA--C 1.519 0.338 0 C-N-CA 120.757 -0.735 . . . . 55.140000000000001 113.176 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.432 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 99.3 mttt 68.9 151.61 0.13 Allowed Pre-proline 0 N--CA 1.473 0.69 0 C-N-CA 123.026 0.53 . . . . 54.119999999999997 110.943 -178.166 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.647 ' HB3' HG22 ' A' ' 38' ' ' VAL . 18.3 Cg_endo -59.88 133.05 48.36 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.364 2.043 . . . . 74.439999999999998 112.816 -175.047 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.536 ' CE1' HG13 ' A' ' 37' ' ' VAL . 5.4 p90 -150.32 155.9 40.53 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.655 -0.702 . . . . 63.100000000000001 110.432 -179.072 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.452 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 87.7 m-85 -99.75 127.64 45.88 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.076 -0.511 . . . . 73.239999999999995 110.901 -179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 53.1 mt -102.12 97.35 7.67 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.146 -0.479 . . . . 64.439999999999998 109.761 171.052 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 60.8 t -90.58 137.43 21.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.065 -0.516 . . . . 74.140000000000001 110.578 -178.046 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 5.3 mmt180 -79.13 119.6 22.47 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.984 0.421 . . . . 75.230000000000004 111.108 175.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -72.15 167.22 20.74 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.603 -0.726 . . . . 43.25 109.555 172.722 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -69.74 128.92 38.12 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.416 0.627 . . . . 75.450000000000003 109.577 178.615 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.22 116.04 3.87 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 111.105 -0.798 . . . . 62.409999999999997 111.105 -171.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 39.1 p -78.02 36.7 0.23 Allowed 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.05 0.452 . . . . 75.439999999999998 111.311 -176.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -63.33 -29.6 70.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.801 -0.636 . . . . 65.450000000000003 111.588 -175.423 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 131.01 -13.21 5.53 Favored Glycine 0 CA--C 1.508 -0.404 0 C-N-CA 120.318 -0.944 . . . . 71.239999999999995 113.214 177.504 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -83.63 138.82 33.17 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.144 0.497 . . . . 75.409999999999997 111.544 -173.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.449 ' CD1' ' HB3' ' A' ' 47' ' ' LEU . 38.2 m-85 -109.38 162.46 14.32 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.762 -0.654 . . . . 64.299999999999997 110.02 174.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.4 mm -120.64 123.86 71.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.35 -0.611 . . . . 71.219999999999999 109.35 175.762 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.791 ' HG3' HG13 ' A' ' 67' ' ' ILE . 53.7 mtm180 -88.34 149.77 23.58 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.221 0.534 . . . . 73.200000000000003 111.826 -177.79 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 5.7 p -69.12 -24.53 64.12 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.379 -0.828 . . . . 72.319999999999993 109.84 171.365 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.73 -37.46 84.29 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-N 115.517 -0.765 . . . . 61.100000000000001 110.152 176.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -156.64 96.91 2.17 Favored Pre-proline 0 N--CA 1.451 -0.4 0 CA-C-N 115.835 -0.62 . . . . 74.200000000000003 110.612 -175.421 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.19 -10.07 23.94 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.433 2.089 . . . . 72.310000000000002 111.233 175.51 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -81.22 -15.86 54.4 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 114.895 -1.048 . . . . 72.209999999999994 110.774 178.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.6 tptt -114.9 132.34 56.57 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.2 -0.454 . . . . 70.25 111.252 -175.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.6 mp -90.31 125.79 35.64 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.333 -0.617 . . . . 63.240000000000002 109.333 174.218 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.791 HG13 ' HG3' ' A' ' 59' ' ' ARG . 49.4 mm -84.78 112.59 43.82 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 116.111 -0.495 . . . . 42.439999999999998 110.491 -177.25 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -74.63 179.69 5.71 Favored 'Trans proline' 0 N--CA 1.464 -0.264 0 C-N-CA 123.289 2.659 . . . . 61.210000000000001 112.937 -177.155 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . 0.463 ' CG ' HD11 ' A' ' 72' ' ' ILE . 31.4 tt0 -80.86 -4.27 54.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.581 -0.736 . . . . 72.349999999999994 112.519 -171.083 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 15.9 p90 -96.24 -19.97 18.91 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.234 -0.586 . . . . 75.430000000000007 110.312 175.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -99.99 8.04 44.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.93 -0.577 . . . . 72.200000000000003 111.042 -177.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.463 HD11 ' CG ' ' A' ' 69' ' ' GLN . 21.6 pt -98.71 -7.06 9.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.249 0.547 . . . . 74.219999999999999 110.21 175.251 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -104.91 16.17 26.43 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.632 -0.713 . . . . 71.420000000000002 109.486 177.041 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 12.9 m -73.59 -7.78 53.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.185 -0.916 . . . . 70.109999999999999 111.309 -178.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 57.9 p-90 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.442 -0.344 . . . . 73.400000000000006 110.459 176.222 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 44.3 m . . . . . 0 C--O 1.233 0.22 0 CA-C-O 121.021 0.439 . . . . 61.310000000000002 110.046 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 121.1 102.34 1.81 Allowed Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.914 -0.66 . . . . 61.409999999999997 111.764 -178.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -122.15 92.57 48.86 Favored Pre-proline 0 C--N 1.324 -0.532 0 N-CA-C 109.382 -0.599 . . . . 75.310000000000002 109.382 -178.081 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.474 ' HA ' ' O ' ' B' ' 127' ' ' ARG . 8.4 Cg_endo -77.98 82.85 2.32 Favored 'Trans proline' 0 N--CA 1.443 -1.451 0 C-N-CA 121.917 1.745 . . . . 73.430000000000007 111.633 -178.559 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -108.71 141.84 40.11 Favored 'General case' 0 CA--C 1.51 -0.566 0 CA-C-N 115.194 -0.912 . . . . 65.409999999999997 109.558 177.649 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.508 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 10.3 p -101.84 125.7 55.91 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 CA-C-N 115.627 -0.715 . . . . 73.409999999999997 110.807 -176.637 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 10.1 m -88.55 103.57 16.01 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.34 -0.846 . . . . 74.040000000000006 109.609 177.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.502 HG12 ' HG2' ' B' ' 124' ' ' GLN . 54.6 mt -94.59 105.94 17.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 116.164 -0.471 . . . . 70.540000000000006 110.358 -176.568 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 27.0 mmm180 -122.27 153.44 38.9 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.242 -0.435 . . . . 74.099999999999994 110.541 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -111.19 103.09 11.49 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.002 0.43 . . . . 61.299999999999997 110.701 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 49.8 mm-40 -99.67 81.51 2.49 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.778 -0.646 . . . . 73.430000000000007 109.294 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 81.94 -128.69 8.6 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.805 -0.712 . . . . 71.25 111.382 -174.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . 0.579 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 67.8 m-20 -91.84 9.92 30.79 Favored 'General case' 0 C--N 1.328 -0.349 0 O-C-N 122.699 -0.295 . . . . 73.239999999999995 111.088 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.517 ' HE2' HD11 ' B' ' 123' ' ' ILE . 24.6 pttm -119.27 116.58 26.55 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.576 0.703 . . . . 75.120000000000005 111.073 179.371 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 26.1 m -84.97 108.43 17.58 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.292 -0.867 . . . . 64.5 109.502 176.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . 0.517 HD11 ' HE2' ' B' ' 121' ' ' LYS . 52.1 mt -101.14 117.12 45.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.973 -0.558 . . . . 73.5 110.604 -173.788 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.529 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 23.0 mt-30 -102.61 104.49 14.87 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.649 -0.705 . . . . 74.319999999999993 110.35 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -85.27 107.25 17.21 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.06 -0.518 . . . . 71.430000000000007 111.071 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 59.6 m-85 -80.71 103.67 10.72 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.947 0.403 . . . . 74.209999999999994 109.945 175.333 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . 0.474 ' O ' ' HA ' ' B' ' 111' ' ' PRO . 65.5 mtt180 -114.14 152.78 30.62 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.857 -0.611 . . . . 70.200000000000003 109.389 178.587 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.56 HG21 ' CD2' ' A' ' 31' ' ' PHE . 7.0 p -120.36 -37.41 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.078 0.466 . . . . 72.239999999999995 111.73 179.385 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -140.83 35.8 1.78 Allowed 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.035 -0.728 . . . . 54.140000000000001 109.035 -178.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 98.26 -29.5 11.25 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 114.992 -1.004 . . . . 44.119999999999997 111.746 -177.498 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.524 ' HD2' HG21 ' A' ' 28' ' ' VAL . 26.9 t80 -93.39 132.86 37.23 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.917 0.389 . . . . 62.520000000000003 110.261 -176.19 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.784 HD11 HG13 ' B' ' 135' ' ' ILE . 3.3 tm? -69.49 134.44 48.91 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.104 -0.953 . . . . 71.329999999999998 110.43 179.042 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . 0.426 ' N ' HD13 ' B' ' 132' ' ' LEU . 42.6 p90 -124.24 -23.51 4.51 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 121.026 -0.27 . . . . 64.150000000000006 111.361 174.608 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -149.92 143.19 25.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.784 0.326 . . . . 71.109999999999999 111.055 179.068 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.784 HG13 HD11 ' B' ' 132' ' ' LEU . 77.5 mt -125.08 129.56 73.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.507 -0.315 . . . . 75.530000000000001 110.804 178.648 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.529 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.2 tttt -112.69 102.51 10.56 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.128 -0.693 . . . . 73.25 109.128 172.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.458 HG21 ' HB3' ' B' ' 175' ' ' TRP . 1.8 p -106.52 127.99 61.47 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-O 121.271 0.558 . . . . 43.439999999999998 110.744 -177.665 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.893 HG22 ' HB3' ' B' ' 144' ' ' PRO . 22.6 t -113.21 87.72 11.4 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.138 -0.937 . . . . 62.539999999999999 110.282 -179.299 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.48 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 73.5 Cg_endo -83.66 134.87 6.62 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.283 1.988 . . . . 63.030000000000001 112.309 176.127 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . 0.579 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 56.2 mtpt -67.62 -9.48 43.44 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.773 -0.649 . . . . 71.219999999999999 110.954 176.668 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 31.6 m-70 -126.68 54.14 1.62 Allowed 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.574 -0.739 . . . . 64.310000000000002 109.524 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 167.45 -17.09 0.08 OUTLIER Glycine 0 CA--C 1.52 0.391 0 C-N-CA 120.59 -0.815 . . . . 73.400000000000006 113.39 -177.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 93.6 mttt 71.59 150.88 0.14 Allowed Pre-proline 0 N--CA 1.473 0.688 0 C-N-CA 123.235 0.614 . . . . 74.239999999999995 111.438 179.428 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.893 ' HB3' HG22 ' B' ' 138' ' ' VAL . 24.5 Cg_endo -62.42 140.68 83.56 Favored 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.77 2.313 . . . . 73.219999999999999 113.357 -176.154 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . 0.448 ' CE1' HG13 ' B' ' 137' ' ' VAL . 8.7 p90 -150.59 155.26 39.06 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.655 -0.702 . . . . 75.200000000000003 109.969 177.107 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.569 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 83.6 m-85 -101.56 141.29 34.66 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.286 -0.415 . . . . 73.439999999999998 111.37 -177.503 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 27.6 mt -124.88 95.74 4.62 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.559 -0.746 . . . . 62.0 109.885 169.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 48.9 t -94.02 122.81 45.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.02 -0.733 . . . . 73.400000000000006 109.02 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 15.6 ttm-85 -67.94 143.54 55.61 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.468 0.651 . . . . 64.349999999999994 111.975 -174.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.03 175.4 10.67 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.664 -1.153 . . . . 64.430000000000007 110.586 176.128 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -84.94 138.27 32.6 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 109.01 -0.737 . . . . 75.219999999999999 109.01 173.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 110.07 132.07 6.24 Favored Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 120.654 -0.784 . . . . 71.430000000000007 111.655 -177.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 18.8 m -82.33 30.5 0.4 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.921 0.391 . . . . 74.109999999999999 110.983 -177.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -73.59 -47.29 41.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.052 0.453 . . . . 72.450000000000003 110.56 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 121.38 46.75 0.31 Allowed Glycine 0 CA--C 1.503 -0.714 0 C-N-CA 120.774 -0.727 . . . . 54.549999999999997 112.417 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 -122.17 135.53 54.79 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 120.964 0.411 . . . . 71.439999999999998 110.705 -179.178 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -113.01 159.4 19.17 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.764 -0.653 . . . . 73.5 109.381 173.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . 0.807 HD11 HD23 ' B' ' 166' ' ' LEU . 48.7 mm -114.34 115.84 50.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 N-CA-C 109.341 -0.614 . . . . 73.25 109.341 176.079 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.513 ' HG2' ' H ' ' B' ' 161' ' ' ASP . 40.2 ttm180 -85.39 145.16 27.61 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.75 -0.659 . . . . 74.129999999999995 110.376 -174.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . 0.569 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 5.2 p -58.89 -31.87 68.99 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.447 0.641 . . . . 72.340000000000003 110.862 178.211 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . 0.513 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 3.5 m-20 -76.03 -31.26 58.79 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.192 -0.913 . . . . 72.230000000000004 110.902 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . 0.677 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 13.9 mm100 -132.37 71.07 79.66 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 115.944 -0.571 . . . . 52.25 110.808 -176.358 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . 0.405 ' HA ' ' CG2' ' B' ' 158' ' ' ILE . 59.2 Cg_endo -73.37 -12.79 25.29 Favored 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.187 1.925 . . . . 73.319999999999993 111.432 178.462 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -93.24 -4.91 51.07 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.012 -0.995 . . . . 73.409999999999997 110.253 179.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . 0.677 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 60.7 tptt -122.72 126.54 47.74 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.918 -0.583 . . . . 64.430000000000007 111.074 -174.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . 0.807 HD23 HD11 ' B' ' 158' ' ' ILE . 61.0 mt -74.41 110.43 8.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.398 -0.819 . . . . 71.25 109.087 174.477 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . 0.438 HG13 ' HB2' ' B' ' 159' ' ' ARG . 43.3 mm -70.56 116.37 44.74 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 109.92 -0.4 . . . . 73.349999999999994 109.92 -176.569 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.505 ' O ' HG23 ' B' ' 172' ' ' ILE . 38.3 Cg_endo -64.95 172.57 7.01 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 123.251 2.634 . . . . 71.420000000000002 113.416 -174.231 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -76.98 -9.9 59.0 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.92 -1.036 . . . . 74.409999999999997 111.978 -168.142 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 31.8 p90 -96.22 -10.8 27.16 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.461 0.648 . . . . 74.099999999999994 109.924 175.079 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.478 ' HB2' ' HG2' ' B' ' 168' ' ' PRO . 6.8 mm-40 -106.58 -7.06 17.6 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.454 -0.794 . . . . 71.129999999999995 111.215 -176.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.505 HG23 ' O ' ' B' ' 168' ' ' PRO . 29.0 pt -71.04 -30.01 39.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.121 -0.491 . . . . 64.109999999999999 110.723 178.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -102.32 41.54 1.22 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.304 0.574 . . . . 74.040000000000006 109.772 174.263 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 31.1 t -55.08 -31.86 61.52 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.992 -1.004 . . . . 74.299999999999997 110.847 179.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . 0.515 ' HB2' ' HD2' ' B' ' 121' ' ' LYS . 4.0 p-90 . . . . . 0 C--O 1.251 1.169 0 CA-C-O 118.044 -0.979 . . . . 75.349999999999994 110.462 176.765 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.8 m . . . . . 0 N--CA 1.453 -0.309 0 N-CA-C 109.896 -0.409 . . . . 72.450000000000003 109.896 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.493 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 95.27 63.52 0.98 Allowed Glycine 0 N--CA 1.442 -0.918 0 C-N-CA 120.664 -0.779 . . . . 35.219999999999999 111.191 -175.489 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -100.3 98.94 8.55 Favored Pre-proline 0 C--N 1.324 -0.537 0 N-CA-C 108.845 -0.798 . . . . 73.420000000000002 108.845 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.613 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 88.5 Cg_endo -80.25 102.8 1.46 Allowed 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.247 1.964 . . . . 73.230000000000004 112.29 -173.669 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -80.88 141.5 34.53 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.062 -0.972 . . . . 71.430000000000007 109.939 -178.45 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.447 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 11.2 p -103.3 120.29 53.04 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 CA-C-O 121.638 0.732 . . . . 65.030000000000001 109.88 179.461 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.4 m -93.47 103.11 15.34 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 115.449 -0.796 . . . . 65.299999999999997 109.564 -179.547 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.536 HG23 ' HG2' ' A' ' 24' ' ' GLN . 63.9 mt -85.61 105.2 14.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.82 -0.627 . . . . 73.019999999999996 110.517 -175.297 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -101.61 160.92 14.04 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.681 -0.69 . . . . 73.109999999999999 110.565 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -127.11 98.04 5.16 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.617 -0.512 . . . . 73.540000000000006 109.617 175.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.642 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 43.6 mm-40 -103.49 93.32 4.88 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.819 -0.628 . . . . 64.439999999999998 109.618 -178.064 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 66.06 -106.36 1.56 Allowed Glycine 0 N--CA 1.444 -0.83 0 C-N-CA 120.764 -0.731 . . . . 43.130000000000003 111.832 -176.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.655 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 4.0 m-20 -102.05 -5.34 24.67 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.566 0.222 . . . . 73.319999999999993 110.819 -177.197 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.642 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 12.3 ptmt -110.77 121.03 44.33 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 121.471 0.653 . . . . 64.299999999999997 111.934 -173.449 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.4 m -82.41 97.56 8.43 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.276 -0.875 . . . . 74.310000000000002 109.212 174.434 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.409 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 54.1 mt -93.99 106.88 18.57 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-O 121.117 0.485 . . . . 70.319999999999993 110.812 -175.574 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.536 ' HG2' HG23 ' A' ' 15' ' ' ILE . 12.7 mt-30 -94.55 109.39 21.29 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.019 -0.537 . . . . 63.409999999999997 110.029 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.439 ' HB3' HD23 ' A' ' 32' ' ' LEU . 27.5 mt-10 -89.2 111.38 22.15 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.134 -0.484 . . . . 74.129999999999995 110.84 -178.539 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.504 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 50.5 m-85 -84.59 103.88 14.09 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.635 -0.506 . . . . 72.450000000000003 109.635 176.268 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -116.04 133.72 55.72 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.062 -0.517 . . . . 61.409999999999997 109.923 -179.552 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.613 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 3.4 p -92.05 -60.37 2.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 C-N-CA 120.272 -0.571 . . . . 45.350000000000001 110.443 176.684 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.554 ' H ' HG13 ' A' ' 28' ' ' VAL . 88.5 m-20 -138.47 72.6 1.41 Allowed 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.045 0.45 . . . . 74.549999999999997 110.213 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 90.46 -27.94 8.09 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.914 -0.585 . . . . 74.400000000000006 113.676 175.248 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.491 ' HD2' HG21 ' B' ' 128' ' ' VAL . 35.8 t80 -112.08 134.52 53.58 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.376 0.608 . . . . 73.400000000000006 111.469 -173.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.881 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -67.21 123.64 20.87 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.495 -1.229 . . . . 53.219999999999999 110.441 176.268 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . 0.481 ' CD1' ' HB2' ' B' ' 133' ' ' TYR . 24.2 p90 -108.23 -24.82 11.35 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.369 -0.533 . . . . 71.430000000000007 111.345 177.172 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -156.19 142.72 18.56 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.685 0.278 . . . . 64.0 110.965 179.342 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.881 HG13 HD11 ' A' ' 32' ' ' LEU . 81.4 mt -120.8 132.41 70.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.537 -0.301 . . . . 72.140000000000001 110.589 178.062 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.49 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 88.3 tttt -115.16 100.43 8.15 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 108.953 -0.758 . . . . 73.239999999999995 108.953 169.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.569 HG23 ' HB2' ' A' ' 21' ' ' LYS . 1.1 p -98.39 126.17 51.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 116.092 -0.503 . . . . 74.319999999999993 110.124 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.56 HG22 ' HB3' ' A' ' 44' ' ' PRO . 25.0 t -111.64 88.28 9.24 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 115.544 -0.753 . . . . 72.209999999999994 110.109 -179.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.534 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 57.8 Cg_endo -73.67 142.42 32.35 Favored 'Trans proline' 0 N--CA 1.457 -0.663 0 C-N-CA 122.48 2.12 . . . . 64.010000000000005 111.975 177.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.655 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 28.9 mtpp -70.09 -10.55 59.11 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.944 -0.571 . . . . 73.219999999999999 110.978 176.329 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 38.7 m-70 -131.04 80.64 1.95 Allowed 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.848 -0.615 . . . . 71.140000000000001 109.78 -178.532 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 151.3 -117.23 0.81 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.128 -0.558 . . . . 73.340000000000003 112.306 179.499 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 14.3 ptpt -152.79 151.76 27.18 Favored Pre-proline 0 C--N 1.328 -0.344 0 N-CA-C 110.179 -0.304 . . . . 72.329999999999998 110.179 178.467 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.56 ' HB3' HG22 ' A' ' 38' ' ' VAL . 48.5 Cg_endo -74.28 124.09 8.73 Favored 'Trans proline' 0 N--CA 1.46 -0.492 0 C-N-CA 122.262 1.975 . . . . 73.120000000000005 110.987 170.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.516 ' CE1' HG13 ' A' ' 37' ' ' VAL . 11.4 p90 -139.86 158.57 43.88 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.803 0.335 . . . . 72.099999999999994 110.988 -175.185 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.519 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 73.1 m-85 -103.93 141.64 35.81 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.828 -0.624 . . . . 53.219999999999999 111.258 -176.498 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 83.8 mt -123.71 105.02 9.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.535 -0.757 . . . . 75.510000000000005 109.907 172.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.593 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 43.8 t -85.79 139.66 17.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.098 -0.501 . . . . 64.140000000000001 109.917 179.355 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . 0.417 HH11 ' HD3' ' A' ' 49' ' ' ARG . 4.5 tpt180 -75.06 115.09 14.31 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.846 -0.428 . . . . 73.310000000000002 109.846 179.222 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.33 149.83 41.14 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.023 -0.535 . . . . 73.040000000000006 111.399 -178.204 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.58 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 4.9 p-10 -57.44 132.07 52.01 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.269 0.557 . . . . 73.340000000000003 110.981 -178.265 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.57 -24.13 24.76 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.41 -0.814 . . . . 72.409999999999997 111.86 -179.025 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.5 t 58.15 37.57 26.34 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 121.192 0.52 . . . . 43.539999999999999 109.985 -176.56 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -53.57 -38.61 64.05 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.425 -0.807 . . . . 74.420000000000002 111.44 -179.03 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 150.44 24.4 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.365 -0.921 . . . . 64.450000000000003 113.261 176.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.456 ' OD1' ' HA ' ' A' ' 68' ' ' PRO . 93.5 m-20 -134.79 162.7 31.62 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.79 0.329 . . . . 74.409999999999997 110.579 -176.764 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 73.2 m-85 -121.73 158.57 28.47 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.078 -0.51 . . . . 75.549999999999997 110.15 177.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.593 ' HB ' ' HB ' ' A' ' 48' ' ' VAL . 39.5 mm -106.74 110.54 32.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 N-CA-C 109.35 -0.611 . . . . 62.420000000000002 109.35 175.566 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.627 ' HG2' ' H ' ' A' ' 61' ' ' ASP . 74.3 ttt180 -83.99 140.42 31.9 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.276 -0.42 . . . . 73.109999999999999 110.682 -176.253 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.519 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 9.7 p -64.08 -25.06 67.94 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.901 -0.59 . . . . 64.140000000000001 112.204 -177.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.627 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 5.5 m-20 -72.78 -24.99 61.01 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.768 0.318 . . . . 71.439999999999998 111.649 -178.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.5 tp60 -155.0 88.36 3.21 Favored Pre-proline 0 C--N 1.327 -0.399 0 CA-C-O 120.73 0.3 . . . . 71.530000000000001 110.616 -176.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -82.05 6.5 5.66 Favored 'Trans proline' 0 C--O 1.233 0.231 0 C-N-CA 122.915 2.41 . . . . 55.240000000000002 112.455 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -62.34 -44.22 96.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.646 -0.706 . . . . 75.409999999999997 111.059 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.55 -178.37 4.9 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-N 115.6 -0.727 . . . . 61.210000000000001 111.458 -176.054 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.0 mp -95.51 135.04 37.66 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.078 -0.964 . . . . 62.43 108.846 177.424 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.429 HG13 ' HB2' ' A' ' 59' ' ' ARG . 41.0 mm -78.64 112.85 29.85 Favored Pre-proline 0 C--N 1.319 -0.743 0 N-CA-C 109.85 -0.426 . . . . 65.0 109.85 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.463 ' O ' HG23 ' A' ' 72' ' ' ILE . 46.6 Cg_endo -67.1 174.48 6.89 Favored 'Trans proline' 0 CA--C 1.519 -0.268 0 C-N-CA 123.188 2.592 . . . . 63.439999999999998 113.311 -173.336 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . 0.732 ' HA ' HG12 ' A' ' 72' ' ' ILE . 9.5 tt0 -68.16 -42.39 80.11 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.516 -0.765 . . . . 71.430000000000007 111.567 -170.624 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . 0.792 ' HA ' ' CZ ' ' A' ' 73' ' ' PHE . 29.6 p90 -63.19 -16.38 59.95 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.339 0.59 . . . . 74.319999999999993 110.395 -179.117 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 16.0 mm-40 -94.94 -28.75 15.01 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.527 -0.76 . . . . 72.049999999999997 111.579 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.732 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.0 pt -76.63 -38.6 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.148 0 N-CA-C 111.882 0.327 . . . . 72.150000000000006 111.882 -178.199 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.792 ' CZ ' ' HA ' ' A' ' 70' ' ' TRP . 6.6 p90 -85.67 30.65 0.63 Allowed 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.727 0.775 . . . . 75.140000000000001 110.847 179.55 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 32.5 t -74.23 -11.77 60.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.103 -0.953 . . . . 23.300000000000001 108.64 170.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . 0.437 ' HH2' HD13 ' A' ' 35' ' ' ILE . 36.6 m0 . . . . . 0 C--O 1.233 0.218 0 CA-C-N 115.465 -0.789 . . . . 72.549999999999997 110.6 173.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 33.1 m . . . . . 0 N--CA 1.455 -0.185 0 CA-C-O 121.06 0.457 . . . . 61.210000000000001 109.774 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 112.5 95.0 2.19 Favored Glycine 0 N--CA 1.441 -0.985 0 N-CA-C 110.838 -0.905 . . . . 52.229999999999997 110.838 -172.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -110.43 98.33 35.83 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-O 121.424 0.631 . . . . 73.319999999999993 109.899 -178.322 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.718 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 82.7 Cg_endo -81.83 76.57 4.25 Favored 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 122.484 2.123 . . . . 65.120000000000005 112.68 -175.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -91.38 149.86 21.53 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.092 -0.707 . . . . 73.129999999999995 109.092 176.536 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.669 HG21 ' HB3' ' B' ' 124' ' ' GLN . 7.2 p -102.96 130.52 52.93 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-O 121.555 0.693 . . . . 71.299999999999997 111.307 -176.085 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . 0.454 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 30.4 m -91.84 111.2 22.64 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.234 -0.894 . . . . 45.509999999999998 109.139 176.027 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.6 mt -88.69 107.69 18.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 120.957 0.408 . . . . 72.400000000000006 111.06 -174.148 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . 0.502 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 20.2 mmt180 -94.84 160.46 14.59 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.447 -0.575 . . . . 55.439999999999998 109.447 175.619 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -136.99 86.84 2.24 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 115.774 -0.648 . . . . 62.439999999999998 109.574 174.138 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -100.35 87.81 3.51 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.475 -0.784 . . . . 74.420000000000002 109.395 -173.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 78.97 -111.56 3.27 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.791 -0.719 . . . . 63.399999999999999 111.968 -177.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . 0.61 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 20.4 m-20 -109.11 12.16 25.24 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.855 0.36 . . . . 75.299999999999997 111.189 -177.572 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.95 ' HE3' ' HB3' ' B' ' 175' ' ' TRP . 20.8 pttm -125.27 123.24 39.06 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.483 0.659 . . . . 75.420000000000002 111.481 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 65.9 m -81.75 103.31 11.35 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.249 -0.887 . . . . 70.299999999999997 109.472 174.629 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . 0.502 ' HB ' ' HB2' ' B' ' 116' ' ' ARG . 64.7 mt -93.58 105.87 17.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.076 0.465 . . . . 73.219999999999999 110.378 -177.284 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.669 ' HB3' HG21 ' B' ' 113' ' ' VAL . 21.1 mt-30 -96.23 109.72 22.14 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.167 -0.47 . . . . 54.200000000000003 110.897 -177.467 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . 0.454 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 45.8 mt-10 -86.47 106.48 17.51 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.778 -0.647 . . . . 71.450000000000003 110.799 179.471 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . 0.58 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 21.6 m-85 -82.07 106.36 13.92 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.88 -0.415 . . . . 74.439999999999998 109.88 174.297 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . 0.424 ' O ' ' HA ' ' B' ' 111' ' ' PRO . 95.2 mtt180 -119.97 126.38 50.7 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.842 -0.429 . . . . 74.25 109.842 179.735 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.718 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 3.0 p -99.0 -34.77 4.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.32 0.581 . . . . 74.299999999999997 111.268 -177.422 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -143.15 40.71 1.49 Allowed 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.596 0.712 . . . . 54.210000000000001 109.166 -175.43 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.15 -23.69 10.82 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.324 -0.853 . . . . 74.420000000000002 111.83 -176.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 58.3 t80 -93.83 132.26 38.4 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.98 0.419 . . . . 72.310000000000002 110.435 -177.647 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.861 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -70.66 117.29 12.0 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.359 -0.837 . . . . 74.129999999999995 109.261 176.368 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . 0.557 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 41.9 p90 -105.39 -24.69 12.61 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.384 -0.527 . . . . 73.329999999999998 111.18 179.533 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . 0.483 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -156.56 134.96 11.43 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.762 0.315 . . . . 72.019999999999996 110.734 179.224 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.861 HG13 HD11 ' B' ' 132' ' ' LEU . 74.3 mt -107.71 125.7 64.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 N-CA-C 110.031 -0.359 . . . . 73.299999999999997 110.031 175.492 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.548 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.9 tttt -107.53 99.92 9.38 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.038 -0.727 . . . . 62.43 109.038 174.142 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.539 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 1.1 p -103.85 124.45 58.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-O 121.074 0.464 . . . . 71.510000000000005 110.356 -178.519 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.777 HG22 ' HB3' ' B' ' 144' ' ' PRO . 21.2 t -108.89 88.12 5.18 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 115.224 -0.898 . . . . 65.040000000000006 109.732 179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 72.4 Cg_endo -83.13 135.96 7.67 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.539 2.159 . . . . 74.400000000000006 112.459 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . 0.61 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 59.1 mtpt -60.32 -34.53 73.93 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.605 -0.725 . . . . 71.439999999999998 110.088 173.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -102.09 77.06 1.65 Allowed 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.461 -0.79 . . . . 64.230000000000004 108.925 177.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 144.38 -158.14 27.4 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.215 -0.902 . . . . 65.349999999999994 110.988 -174.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -131.13 150.03 75.39 Favored Pre-proline 0 C--N 1.324 -0.515 0 N-CA-C 110.026 -0.361 . . . . 73.540000000000006 110.026 177.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.777 ' HB3' HG22 ' B' ' 138' ' ' VAL . 17.7 Cg_endo -61.58 122.88 11.71 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.426 2.084 . . . . 65.209999999999994 112.124 178.064 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . 0.48 ' CE1' HG13 ' B' ' 137' ' ' VAL . 5.7 p90 -136.49 152.86 51.0 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.144 -0.48 . . . . 75.099999999999994 110.964 -177.005 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.541 ' O ' ' HA ' ' B' ' 159' ' ' ARG . 88.2 m-85 -101.97 138.33 39.08 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.88 -0.6 . . . . 72.230000000000004 111.114 -178.268 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.471 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 56.9 mt -117.5 104.19 10.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.992 -0.549 . . . . 65.030000000000001 109.965 172.016 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . 0.507 ' HB ' ' HB ' ' B' ' 158' ' ' ILE . 49.1 t -91.33 128.02 43.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 116.339 -0.391 . . . . 65.129999999999995 110.888 -177.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 23.8 tpt180 -63.11 120.45 11.48 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 116.47 -0.332 . . . . 74.530000000000001 110.975 176.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.09 154.62 37.35 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-N 115.987 -0.551 . . . . 63.32 110.933 177.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . 0.504 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 8.0 p-10 -59.64 147.06 38.78 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.83 -0.623 . . . . 70.120000000000005 111.574 -176.667 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 73.63 2.59 60.83 Favored Glycine 0 N--CA 1.452 -0.247 0 CA-C-N 115.389 -0.823 . . . . 71.340000000000003 112.391 178.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 7.9 t 59.73 49.2 8.4 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 109.137 -0.69 . . . . 75.030000000000001 109.137 -175.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -48.64 -43.74 36.8 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 114.84 -1.073 . . . . 72.510000000000005 111.251 -179.326 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 131.13 -18.38 5.02 Favored Glycine 0 CA--C 1.492 -1.346 0 N-CA-C 110.718 -0.953 . . . . 71.230000000000004 110.718 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 -97.89 166.78 11.29 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 113.719 -1.241 . . . . 65.540000000000006 110.816 -176.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -121.22 153.39 37.67 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.817 -0.629 . . . . 72.120000000000005 110.206 178.314 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . 0.507 ' HB ' ' HB ' ' B' ' 148' ' ' VAL . 48.5 mm -106.31 114.77 46.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 N-CA-C 109.266 -0.642 . . . . 75.430000000000007 109.266 176.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.541 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 68.0 ttt180 -89.33 138.58 31.31 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.25 -0.432 . . . . 64.150000000000006 110.87 -175.505 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 5.6 p -62.59 -22.4 66.34 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.821 -0.627 . . . . 64.420000000000002 112.301 -177.191 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . 0.52 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 5.5 m-20 -76.22 -16.95 59.72 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.731 0.301 . . . . 62.020000000000003 111.237 -177.772 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 21.9 tp60 -166.06 84.81 0.97 Allowed Pre-proline 0 C--N 1.328 -0.34 0 N-CA-C 109.44 -0.578 . . . . 75.019999999999996 109.44 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . 0.512 ' HG2' ' HB2' ' A' ' 60' ' ' SER . 23.7 Cg_exo -64.86 -9.36 20.96 Favored 'Trans proline' 0 N--CA 1.474 0.337 0 C-N-CA 123.16 2.573 . . . . 63.25 112.929 -178.682 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -90.6 -5.63 55.66 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.962 -0.563 . . . . 74.409999999999997 110.768 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.8 tptt -114.83 123.29 48.81 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.25 0.548 . . . . 73.340000000000003 110.419 -178.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.3 mp -85.34 113.57 21.76 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.169 -0.923 . . . . 74.150000000000006 109.229 177.777 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . 0.543 HG23 ' HB3' ' B' ' 171' ' ' GLU . 50.5 mm -64.41 110.58 4.15 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 123.608 0.567 . . . . 74.209999999999994 110.681 -177.347 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.564 ' O ' HG23 ' B' ' 172' ' ' ILE . 80.5 Cg_endo -76.06 176.81 9.55 Favored 'Trans proline' 0 N--CA 1.461 -0.386 0 C-N-CA 122.933 2.422 . . . . 60.43 112.472 -176.711 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -76.26 -5.42 46.89 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.711 -0.677 . . . . 61.25 112.707 -170.453 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 27.9 p90 -97.64 -12.88 21.93 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.497 -0.481 . . . . 64.340000000000003 110.254 173.395 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.543 ' HB3' HG23 ' B' ' 167' ' ' ILE . 1.7 mm-40 -105.95 -15.05 15.01 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.37 -0.377 . . . . 53.420000000000002 111.465 -177.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.564 HG23 ' O ' ' B' ' 168' ' ' PRO . 43.1 pt -66.73 -21.28 28.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.083 0.468 . . . . 75.140000000000001 110.693 177.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -88.87 41.88 1.05 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.797 -0.638 . . . . 71.299999999999997 109.99 177.43 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 22.8 t -86.1 17.22 3.7 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.393 -0.821 . . . . 75.230000000000004 110.247 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . 0.95 ' HB3' ' HE3' ' B' ' 121' ' ' LYS . 45.9 m0 . . . . . 0 C--O 1.246 0.921 0 CA-C-O 118.471 -0.776 . . . . 72.519999999999996 110.421 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 20.9 m . . . . . 0 C--O 1.235 0.319 0 CA-C-O 120.643 0.258 . . . . 71.010000000000005 110.543 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 80.22 -86.77 1.29 Allowed Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 110.903 -0.879 . . . . 61.530000000000001 110.903 -176.164 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 70.87 97.94 0.04 OUTLIER Pre-proline 0 CA--C 1.516 -0.347 0 C-N-CA 123.138 0.575 . . . . 74.340000000000003 110.89 175.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.55 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 5.5 Cg_endo -78.82 85.03 1.92 Allowed 'Trans proline' 0 N--CA 1.443 -1.451 0 C-N-CA 122.378 2.052 . . . . 50.310000000000002 110.041 178.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -95.7 152.05 18.81 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.284 -0.871 . . . . 73.510000000000005 110.179 -175.372 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.722 HG21 ' HB3' ' A' ' 24' ' ' GLN . 7.3 p -121.67 131.52 72.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-O 121.378 0.609 . . . . 70.310000000000002 111.158 -176.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.2 m -92.05 115.55 28.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.437 -0.801 . . . . 54.32 109.488 176.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 50.3 mt -94.13 107.73 19.7 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.101 0.477 . . . . 53.520000000000003 111.344 -173.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.724 ' HB2' ' HB ' ' A' ' 23' ' ' ILE . 33.5 mmt180 -100.41 169.31 9.18 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.701 -0.681 . . . . 71.329999999999998 109.424 175.688 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 69.2 mt-30 -139.61 102.78 4.53 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.878 0.37 . . . . 55.109999999999999 110.301 175.537 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 60.2 mm-40 -101.51 80.15 2.03 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.031 -0.532 . . . . 72.310000000000002 110.18 -178.39 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.41 -111.06 3.49 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.794 -0.717 . . . . 42.299999999999997 111.51 -176.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.587 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 5.8 m-20 -112.47 4.23 17.33 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.239 0.542 . . . . 44.200000000000003 109.837 178.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 23.9 pttm -107.08 119.99 40.88 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.492 0.663 . . . . 74.0 110.379 175.581 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.694 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 8.5 m -80.21 127.15 32.01 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.499 -0.773 . . . . 63.329999999999998 109.488 177.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.724 ' HB ' ' HB2' ' A' ' 16' ' ' ARG . 26.0 mm -108.08 104.99 17.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 120.677 0.275 . . . . 74.200000000000003 110.296 -175.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.755 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 16.2 mt-30 -99.35 109.34 21.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.887 0.375 . . . . 52.420000000000002 110.827 -178.109 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -91.69 110.9 22.24 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.978 -0.556 . . . . 60.200000000000003 110.311 -179.161 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.531 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 28.1 m-85 -88.69 108.91 19.72 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.877 0.37 . . . . 73.519999999999996 111.531 -178.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 46.4 mtm105 -121.44 123.68 42.67 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.713 -0.477 . . . . 64.0 109.713 175.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.55 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.4 p -91.83 -27.88 4.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 121.11 0.481 . . . . 65.25 110.728 -177.719 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -172.3 72.5 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.015 -0.539 . . . . 73.340000000000003 109.905 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.31 -24.97 4.52 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.795 -0.639 . . . . 55.409999999999997 113.202 177.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -108.17 130.11 55.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.969 0.384 . . . . 72.340000000000003 111.097 -174.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.514 HD11 HG13 ' A' ' 35' ' ' ILE . 3.1 tm? -74.51 112.76 11.02 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.345 -0.843 . . . . 74.450000000000003 109.037 175.031 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -105.44 -16.33 14.76 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.614 -0.434 . . . . 61.439999999999998 111.696 -177.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -160.47 145.75 14.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.032 0.444 . . . . 34.210000000000001 111.522 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.514 HG13 HD11 ' A' ' 32' ' ' LEU . 63.6 mt -118.32 125.68 74.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 115.909 -0.587 . . . . 64.219999999999999 109.461 174.084 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.755 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 82.6 tttt -109.78 105.66 14.97 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.881 -0.415 . . . . 71.150000000000006 109.881 179.163 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.631 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 3.5 t -89.52 134.38 28.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 108.965 -0.754 . . . . 74.140000000000001 108.965 178.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.694 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.4 t -120.32 73.22 20.61 Favored Pre-proline 0 C--N 1.317 -0.839 0 N-CA-C 109.731 -0.47 . . . . 73.109999999999999 109.731 173.693 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.618 ' HD3' HG12 ' A' ' 37' ' ' VAL . 49.6 Cg_endo -76.96 132.46 12.9 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.286 1.991 . . . . 75.109999999999999 111.489 175.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.587 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 21.9 mtpp -57.77 -34.41 69.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 65.510000000000005 111.11 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -119.11 109.69 16.19 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.331 -0.618 . . . . 73.109999999999999 109.331 175.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 128.53 -27.6 4.4 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 110.79 -0.924 . . . . 31.100000000000001 110.79 -173.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 58.6 mtmt 70.97 152.0 0.14 Allowed Pre-proline 0 CA--C 1.532 0.255 0 C-N-CA 123.593 0.757 . . . . 62.329999999999998 112.496 175.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.631 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 43.3 Cg_endo -67.63 145.2 69.15 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.138 2.559 . . . . 73.439999999999998 114.159 -174.434 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 29.2 p90 -148.93 158.92 44.54 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.497 -0.774 . . . . 74.319999999999993 109.801 176.363 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.548 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 72.7 m-85 -101.71 129.14 47.81 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.276 -0.42 . . . . 73.120000000000005 110.701 178.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.58 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 29.7 tp -109.67 96.2 6.11 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.898 -0.779 . . . . 73.319999999999993 108.898 173.034 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 32.3 t -94.61 142.38 13.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 116.239 -0.437 . . . . 64.140000000000001 111.293 -172.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . 0.453 HH11 ' HZ ' ' A' ' 57' ' ' PHE . 1.6 mmt-85 -66.93 137.57 56.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.962 -0.563 . . . . 63.329999999999998 111.046 177.075 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.73 153.84 21.04 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.056 -0.52 . . . . 55.100000000000001 109.701 172.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.409 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 4.3 p-10 -60.64 130.37 46.17 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.264 0.554 . . . . 64.340000000000003 111.289 -177.793 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 81.17 -15.0 24.94 Favored Glycine 0 CA--C 1.518 0.257 0 CA-C-N 115.637 -0.711 . . . . 63.43 112.39 -178.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.7 p 43.52 72.46 0.18 Allowed 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 123.721 0.808 . . . . 73.329999999999998 112.503 -175.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -80.09 42.08 0.55 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.612 0.72 . . . . 64.319999999999993 109.435 177.164 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 62.35 37.16 94.14 Favored Glycine 0 N--CA 1.451 -0.362 0 N-CA-C 110.359 -1.097 . . . . 75.340000000000003 110.359 -170.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.924 HD21 HD22 ' A' ' 66' ' ' LEU . 51.1 t30 -133.08 141.68 48.34 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.937 0.399 . . . . 72.450000000000003 110.766 -169.397 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.58 ' CD2' ' HG ' ' A' ' 47' ' ' LEU . 29.7 m-85 -132.09 168.36 18.12 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.767 -0.651 . . . . 73.530000000000001 109.879 177.03 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.891 HD11 HD23 ' A' ' 66' ' ' LEU . 42.4 mm -129.16 120.79 52.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.482 -0.562 . . . . 44.439999999999998 109.482 174.679 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.615 ' HG3' HG13 ' A' ' 67' ' ' ILE . 41.6 mtp180 -88.03 150.66 23.28 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.271 -0.422 . . . . 62.43 110.655 -179.085 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.672 ' HB2' ' HB3' ' B' ' 163' ' ' PRO . 34.2 p -66.71 -30.43 70.66 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.283 0.564 . . . . 45.240000000000002 110.363 177.082 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.51 ' OD1' ' HB3' ' A' ' 59' ' ' ARG . 4.2 p-10 -78.51 -23.23 46.42 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.709 -0.678 . . . . 72.310000000000002 110.971 177.048 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -137.33 70.58 54.29 Favored Pre-proline 0 C--N 1.316 -0.868 0 CA-C-N 115.719 -0.673 . . . . 73.319999999999993 110.808 -172.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . 0.467 ' HG3' ' HB2' ' B' ' 160' ' ' SER . 84.2 Cg_endo -84.47 -19.83 4.22 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.662 2.242 . . . . 74.019999999999996 112.587 -178.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 14.7 p-10 -90.61 3.76 53.2 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.935 -0.575 . . . . 74.409999999999997 109.975 -179.337 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 81.5 tttt -127.04 137.39 53.05 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.412 -0.813 . . . . 75.430000000000007 109.972 179.018 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.924 HD22 HD21 ' A' ' 56' ' ' ASN . 48.1 mt -86.22 116.54 24.46 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.916 -0.772 . . . . 74.129999999999995 108.916 176.08 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.673 HG23 ' HB3' ' A' ' 71' ' ' GLU . 41.5 mm -69.71 120.15 75.69 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 115.905 -0.589 . . . . 62.299999999999997 111.2 -172.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.537 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 51.3 Cg_endo -68.82 172.98 10.78 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.561 2.174 . . . . 62.140000000000001 112.574 -178.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 10.9 tt0 -80.1 -4.03 51.19 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.503 -0.771 . . . . 61.109999999999999 112.091 -166.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 39.1 p90 -100.78 -17.86 16.72 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.196 0.522 . . . . 72.400000000000006 110.214 174.002 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.673 ' HB3' HG23 ' A' ' 67' ' ' ILE . 1.2 mm-40 -90.73 -13.1 34.71 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.682 -0.69 . . . . 74.329999999999998 110.037 -178.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.531 HG23 ' O ' ' A' ' 68' ' ' PRO . 41.2 pt -70.34 -21.49 23.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.738 -0.665 . . . . 53.509999999999998 110.218 176.514 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -108.0 38.42 2.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.643 -0.708 . . . . 64.120000000000005 109.211 175.029 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.558 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 7.7 t -62.85 -32.77 74.06 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.192 -0.913 . . . . 64.019999999999996 111.187 -175.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 66.9 p-90 . . . . . 0 C--N 1.327 -0.383 0 CA-C-O 120.887 0.375 . . . . 74.040000000000006 110.838 179.19 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 14.1 m . . . . . 0 C--O 1.236 0.352 0 CA-C-O 120.937 0.398 . . . . 55.25 110.699 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.9 -58.28 4.98 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.72 -0.752 . . . . 73.219999999999999 111.362 -178.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 58.43 77.11 0.42 Allowed Pre-proline 0 C--N 1.329 -0.298 0 C-N-CA 122.941 0.497 . . . . 73.140000000000001 111.363 177.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.651 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 46.3 Cg_endo -72.84 80.12 1.84 Allowed 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 121.914 1.743 . . . . 73.129999999999995 110.745 175.159 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -97.77 164.33 12.44 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.197 -0.911 . . . . 75.349999999999994 110.255 -176.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.632 HG21 ' HB3' ' B' ' 124' ' ' GLN . 9.7 p -125.09 132.7 70.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-O 121.395 0.617 . . . . 62.350000000000001 111.195 -177.622 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . 0.58 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 21.6 m -93.4 110.48 22.04 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.469 -0.787 . . . . 64.129999999999995 109.534 175.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.5 mt -84.37 105.35 13.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.062 0.458 . . . . 75.400000000000006 111.051 -176.039 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . 0.758 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 30.2 mmt180 -100.81 171.93 7.37 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.733 -0.667 . . . . 75.030000000000001 109.551 176.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 -145.59 125.18 13.25 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.512 0.672 . . . . 54.140000000000001 110.49 172.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.13 61.27 0.81 Allowed 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 115.008 -0.996 . . . . 63.340000000000003 110.223 -175.178 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 94.14 -111.94 4.25 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.685 -0.769 . . . . 53.539999999999999 111.638 -179.035 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -100.23 9.45 42.73 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.036 0.446 . . . . 73.040000000000006 109.837 178.215 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.715 ' HD2' ' HB2' ' B' ' 175' ' ' TRP . 25.0 pttm -123.81 119.59 30.15 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.9 -0.591 . . . . 74.200000000000003 110.791 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . 0.635 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 35.0 m -80.07 133.38 36.11 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.755 -0.657 . . . . 74.109999999999999 109.543 175.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . 0.758 ' HB ' ' HB2' ' B' ' 116' ' ' ARG . 32.5 mm -114.89 103.39 15.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 120.753 0.311 . . . . 43.43 110.41 -177.403 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.751 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 14.5 mt-30 -95.7 105.69 17.72 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 120.644 -0.422 . . . . 73.030000000000001 110.452 -178.055 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . 0.58 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 41.1 mt-10 -81.63 101.7 10.19 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.865 -0.607 . . . . 75.510000000000005 110.831 179.137 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . 0.472 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 55.6 m-85 -81.03 105.72 12.46 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.916 0.388 . . . . 72.430000000000007 110.253 176.362 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . 0.479 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 86.8 mtm180 -127.67 118.03 23.08 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.956 -0.566 . . . . 73.439999999999998 110.262 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.733 HG13 ' H ' ' B' ' 129' ' ' ASN . 2.4 p -84.44 -72.06 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-N 116.114 -0.494 . . . . 73.099999999999994 110.246 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . 0.733 ' H ' HG13 ' B' ' 128' ' ' VAL . 18.3 t-20 -122.28 69.44 0.96 Allowed 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.122 0.487 . . . . 70.409999999999997 110.252 -177.091 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.79 -18.74 37.41 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.501 -0.772 . . . . 32.530000000000001 113.684 175.359 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.477 ' CD2' HG21 ' A' ' 28' ' ' VAL . 38.0 t80 -114.68 132.13 56.5 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.138 0.494 . . . . 70.040000000000006 111.189 -171.721 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.774 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -73.24 113.6 10.5 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.967 -1.015 . . . . 55.109999999999999 109.358 174.668 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . 0.472 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 52.5 p90 -106.01 -20.04 13.54 Favored 'General case' 0 C--N 1.326 -0.415 0 C-N-CA 120.72 -0.392 . . . . 71.099999999999994 111.456 -179.072 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -157.44 142.11 16.6 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.816 0.341 . . . . 75.310000000000002 111.361 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.774 HG13 HD11 ' B' ' 132' ' ' LEU . 73.5 mt -119.14 117.44 54.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 116.145 -0.48 . . . . 64.230000000000004 109.958 175.028 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.751 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 78.9 tttt -93.8 104.64 16.71 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.399 -0.593 . . . . 73.019999999999996 109.399 175.611 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.685 HG12 ' HD3' ' B' ' 139' ' ' PRO . 4.1 t -88.71 131.04 37.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 N-CA-C 108.985 -0.746 . . . . 63.210000000000001 108.985 177.529 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.635 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.4 t -118.18 73.03 9.76 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.703 -0.481 . . . . 71.120000000000005 109.703 173.016 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.685 ' HD3' HG12 ' B' ' 137' ' ' VAL . 61.2 Cg_endo -81.27 134.04 8.9 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 122.047 1.831 . . . . 75.400000000000006 112.161 175.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 63.4 mttm -57.07 -42.91 81.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.592 0.71 . . . . 62.140000000000001 110.083 174.659 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 18.0 m-70 -98.95 83.77 2.97 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.088 -0.96 . . . . 73.109999999999999 109.406 -173.165 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 136.28 -21.5 3.46 Favored Glycine 0 N--CA 1.45 -0.372 0 CA-C-N 115.51 -0.768 . . . . 52.549999999999997 111.848 -177.402 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . 0.503 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 53.7 mtmt 72.46 154.88 0.15 Allowed Pre-proline 0 N--CA 1.466 0.354 0 C-N-CA 123.682 0.793 . . . . 53.409999999999997 111.893 179.639 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.514 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 36.4 Cg_endo -65.49 146.85 86.06 Favored 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 123.017 2.478 . . . . 72.109999999999999 114.12 -174.334 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 27.3 p90 -151.19 171.26 17.67 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.402 -0.817 . . . . 75.439999999999998 109.472 175.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -111.67 126.54 55.14 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.94 0.4 . . . . 65.439999999999998 111.163 -179.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.427 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 26.7 tp -107.79 99.18 8.67 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.601 -0.727 . . . . 64.120000000000005 109.121 175.503 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 39.2 t -99.87 138.06 25.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 120.805 0.336 . . . . 64.409999999999997 111.152 -174.389 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . 0.473 ' HD3' ' CE2' ' B' ' 157' ' ' PHE . 0.4 OUTLIER -65.46 123.77 20.51 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 121.049 0.452 . . . . 72.120000000000005 111.469 174.509 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.05 156.54 37.37 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.228 -0.897 . . . . 54.420000000000002 110.705 177.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . 0.531 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 5.7 p-10 -64.51 133.85 53.25 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.144 0.497 . . . . 74.420000000000002 110.427 -179.364 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 89.72 -30.76 5.58 Favored Glycine 0 N--CA 1.453 -0.217 0 CA-C-N 115.831 -0.622 . . . . 50.140000000000001 111.808 -175.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 59.8 p 46.21 56.4 6.26 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.126 0.97 . . . . 75.230000000000004 113.13 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -77.64 40.79 0.31 Allowed 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.837 0.827 . . . . 71.530000000000001 110.417 176.623 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 73.08 28.73 65.91 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 111.362 -0.695 . . . . 51.100000000000001 111.362 -173.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . 0.524 ' ND2' HD23 ' B' ' 166' ' ' LEU . 34.0 t30 -122.02 141.57 51.22 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.393 -0.403 . . . . 45.240000000000002 110.364 -175.424 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . 0.473 ' CE2' ' HD3' ' B' ' 149' ' ' ARG . 43.1 m-85 -125.93 162.63 24.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.026 -0.533 . . . . 63.039999999999999 110.025 179.283 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 46.4 mm -122.07 130.14 74.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 109.088 -0.708 . . . . 73.129999999999995 109.088 175.382 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.512 ' HB3' ' OD1' ' B' ' 161' ' ' ASP . 23.6 mtp180 -104.92 158.79 16.29 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.193 0.52 . . . . 71.040000000000006 111.382 -175.762 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . 0.467 ' HB2' ' HG3' ' A' ' 63' ' ' PRO . 11.5 p -74.86 -26.06 59.42 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.907 -0.588 . . . . 52.32 110.689 178.808 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . 0.512 ' OD1' ' HB3' ' B' ' 159' ' ' ARG . 11.3 p-10 -86.68 -15.4 39.69 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.883 -0.598 . . . . 54.329999999999998 110.428 177.274 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . 0.436 ' OE1' ' HD3' ' B' ' 165' ' ' LYS . 39.4 mt-30 -143.24 74.45 17.48 Favored Pre-proline 0 C--N 1.319 -0.718 0 CA-C-N 115.243 -0.89 . . . . 74.239999999999995 109.38 -176.095 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . 0.672 ' HB3' ' HB2' ' A' ' 60' ' ' SER . 74.0 Cg_endo -83.05 -44.23 0.07 OUTLIER 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.966 2.444 . . . . 74.219999999999999 114.133 -172.155 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -80.8 -6.8 59.01 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.443 0.64 . . . . 72.540000000000006 109.631 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . 0.436 ' HD3' ' OE1' ' B' ' 162' ' ' GLN . 88.1 tttt -103.92 135.98 44.43 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.18 -0.918 . . . . 71.319999999999993 110.27 -178.04 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . 0.524 HD23 ' ND2' ' B' ' 156' ' ' ASN . 5.3 mp -87.41 124.21 33.16 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 108.994 -0.743 . . . . 51.140000000000001 108.994 178.374 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 46.5 mm -83.44 117.73 69.47 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.114 -0.494 . . . . 74.219999999999999 111.686 -170.635 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.522 ' O ' HG23 ' B' ' 172' ' ' ILE . 70.4 Cg_endo -72.95 175.93 9.74 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.957 2.438 . . . . 62.009999999999998 112.874 -178.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -82.75 15.16 2.77 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.45 -0.795 . . . . 61.109999999999999 112.944 -168.469 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 26.3 p90 -115.67 -14.98 11.41 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.144 0.497 . . . . 74.430000000000007 110.424 171.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -107.32 0.81 23.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.967 -0.561 . . . . 72.340000000000003 111.017 -176.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.522 HG23 ' O ' ' B' ' 168' ' ' PRO . 21.6 pt -80.79 -31.3 12.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.914 -0.585 . . . . 74.420000000000002 111.217 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -111.5 39.4 2.34 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.422 0.63 . . . . 71.230000000000004 110.376 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.9 t -61.19 -26.03 67.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.378 -0.828 . . . . 74.019999999999996 110.933 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . 0.715 ' HB2' ' HD2' ' B' ' 121' ' ' LYS . 4.0 p-90 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.126 -0.94 . . . . 72.239999999999995 110.981 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 14.6 m . . . . . 0 C--O 1.235 0.325 0 N-CA-C 110.213 -0.291 . . . . 71.540000000000006 110.213 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.512 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 85.43 87.69 0.94 Allowed Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 110.437 -1.065 . . . . 73.129999999999995 110.437 -171.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -106.06 101.91 36.68 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-O 120.834 0.35 . . . . 72.420000000000002 110.938 -169.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.664 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 71.7 Cg_endo -92.07 122.41 0.62 Allowed 'Trans proline' 0 N--CA 1.445 -1.363 0 C-N-CA 122.864 2.376 . . . . 72.0 112.314 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -128.19 111.56 13.57 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.526 0.679 . . . . 71.510000000000005 110.321 176.508 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.599 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 9.1 p -67.33 130.0 32.31 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.085 0 CA-C-N 114.723 -1.126 . . . . 73.349999999999994 110.806 179.412 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.544 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 51.8 m -86.23 103.34 14.76 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.671 -0.695 . . . . 75.219999999999999 109.561 175.763 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 63.5 mt -86.8 104.47 14.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.159 -0.473 . . . . 73.530000000000001 110.482 -177.427 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 10.1 mmm-85 -106.0 156.34 18.49 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.682 -0.69 . . . . 63.109999999999999 110.766 -178.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -129.23 98.21 4.83 Favored 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 108.873 -0.788 . . . . 72.219999999999999 108.873 173.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.592 ' HG3' HD12 ' A' ' 23' ' ' ILE . 8.0 mm-40 -91.47 15.7 11.8 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.475 -0.784 . . . . 74.310000000000002 110.723 -171.773 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.41 -98.96 0.64 Allowed Glycine 0 N--CA 1.445 -0.727 0 C-N-CA 120.998 -0.62 . . . . 52.140000000000001 111.899 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.451 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 11.5 p-10 -85.45 4.57 35.02 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.632 0.253 . . . . 72.540000000000006 111.568 -178.129 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.622 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 14.1 pttm -148.44 130.54 15.41 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 112.664 0.616 . . . . 44.350000000000001 112.664 -176.553 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.8 m -84.87 103.31 13.82 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 114.925 -1.034 . . . . 74.519999999999996 108.997 172.401 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.592 HD12 ' HG3' ' A' ' 18' ' ' GLU . 55.7 mt -100.33 112.23 32.36 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.013 0.435 . . . . 72.209999999999994 110.393 -175.264 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.599 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 21.4 mt-30 -101.43 117.36 34.78 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.96 -0.564 . . . . 75.140000000000001 111.576 -177.16 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.544 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.1 mt-10 -91.05 100.5 13.34 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.551 -0.75 . . . . 24.300000000000001 110.322 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.554 ' CD2' ' HB2' ' B' ' 151' ' ' ASP . 63.2 m-85 -78.12 104.73 8.88 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.676 0.274 . . . . 74.140000000000001 110.682 179.327 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 94.0 mtt180 -122.69 132.9 54.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.313 -0.403 . . . . 75.340000000000003 110.687 -178.423 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.81 HG13 ' H ' ' A' ' 29' ' ' ASN . 3.0 p -98.59 -73.98 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 C-N-CA 120.725 -0.39 . . . . 63.530000000000001 110.898 176.222 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.81 ' H ' HG13 ' A' ' 28' ' ' VAL . 7.4 m-20 -128.38 68.62 1.36 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.05 0.453 . . . . 73.140000000000001 110.51 -177.308 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 77.42 12.56 84.44 Favored Glycine 0 N--CA 1.451 -0.331 0 CA-C-N 115.679 -0.691 . . . . 71.310000000000002 112.019 -179.052 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 79.9 t80 -130.07 127.36 39.72 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.921 0.391 . . . . 75.450000000000003 110.785 -176.183 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 30.2 tp -85.91 114.8 23.1 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.393 -0.821 . . . . 72.510000000000005 109.413 174.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . 0.483 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 50.8 p90 -104.47 -10.3 17.78 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.669 -0.412 . . . . 75.540000000000006 111.938 -176.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -167.44 145.05 4.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.081 0.467 . . . . 63.310000000000002 111.361 -177.825 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 66.9 mt -121.14 115.77 47.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.872 -0.604 . . . . 72.010000000000005 109.615 174.3 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.455 ' CB ' ' HE1' ' A' ' 26' ' ' TYR . 83.5 tttt -104.69 105.25 15.26 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.666 -0.494 . . . . 30.440000000000001 109.666 177.326 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.543 HG13 ' CE1' ' A' ' 45' ' ' TYR . 1.6 p -104.24 127.05 58.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.996 0.427 . . . . 74.129999999999995 110.512 178.3 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.827 HG22 ' HB3' ' A' ' 44' ' ' PRO . 16.1 t -103.0 88.01 1.41 Allowed Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 115.312 -0.858 . . . . 74.120000000000005 109.463 175.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.511 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 90.0 Cg_endo -81.65 150.09 16.57 Favored 'Trans proline' 0 N--CA 1.461 -0.423 0 C-N-CA 122.714 2.276 . . . . 65.409999999999997 113.432 -176.734 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.451 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 29.0 mtpp -74.36 -10.48 59.63 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.368 -0.833 . . . . 75.5 110.556 174.175 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 52.9 m-70 -113.43 21.01 15.58 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.766 -0.652 . . . . 74.150000000000006 110.277 -173.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.26 -155.85 15.33 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 115.675 -0.693 . . . . 42.100000000000001 111.661 -178.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -112.09 150.53 42.57 Favored Pre-proline 0 C--N 1.324 -0.506 0 N-CA-C 109.89 -0.411 . . . . 72.329999999999998 109.89 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.827 ' HB3' HG22 ' A' ' 38' ' ' VAL . 19.8 Cg_endo -60.18 121.03 9.15 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.37 2.046 . . . . 64.349999999999994 111.8 175.774 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.543 ' CE1' HG13 ' A' ' 37' ' ' VAL . 9.4 p90 -136.53 155.73 49.56 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.0 -0.546 . . . . 71.340000000000003 111.039 -176.227 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -99.7 137.07 38.69 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.621 -0.718 . . . . 64.239999999999995 110.787 -179.805 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 31.8 mt -104.7 98.13 7.92 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.865 -0.791 . . . . 71.040000000000006 108.865 164.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 39.7 t -83.54 129.12 38.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.117 -0.492 . . . . 72.150000000000006 110.083 -176.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.19 125.64 29.65 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.303 -0.408 . . . . 64.129999999999995 110.435 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.43 135.72 53.58 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 120.953 0.406 . . . . 65.25 110.899 178.181 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.709 ' OD1' ' HB2' ' B' ' 111' ' ' PRO . 31.3 t0 -80.01 168.58 19.0 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.594 -0.73 . . . . 74.209999999999994 110.942 -174.743 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.65 24.51 45.88 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.269 -0.732 . . . . 75.510000000000005 111.269 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 14.2 m 58.66 28.01 16.61 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.118 0.485 . . . . 74.530000000000001 110.592 -177.054 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.4 ' OD1' ' HB3' ' A' ' 56' ' ' ASN . 17.5 t70 -60.09 -47.95 83.75 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 115.349 -0.841 . . . . 74.329999999999998 111.325 -177.213 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 101.34 -36.73 4.01 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.679 -0.772 . . . . 63.340000000000003 112.946 176.386 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.4 ' HB3' ' OD1' ' A' ' 54' ' ' ASP . 7.4 t30 -70.93 150.95 45.2 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.967 0.413 . . . . 65.140000000000001 111.619 -175.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.45 ' CD1' HG21 ' A' ' 72' ' ' ILE . 37.7 m-85 -108.95 148.88 30.02 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.271 -0.422 . . . . 74.420000000000002 110.685 179.429 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 50.2 mm -111.26 129.07 67.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 109.641 -0.503 . . . . 74.430000000000007 109.641 176.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.415 ' HG2' ' H ' ' A' ' 61' ' ' ASP . 43.2 ttm180 -89.91 135.69 33.49 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.541 -0.299 . . . . 74.340000000000003 110.59 -176.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.405 ' HB3' ' HB2' ' A' ' 45' ' ' TYR . 35.0 t -63.2 -33.27 75.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.33 -0.396 . . . . 73.340000000000003 111.704 -178.194 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.415 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 4.6 m-20 -62.3 -42.64 99.53 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.248 0.547 . . . . 45.549999999999997 110.5 178.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 62.4 mt-30 -135.04 89.6 23.68 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 115.491 -0.777 . . . . 64.140000000000001 110.355 -174.015 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -68.97 -6.19 17.58 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.892 2.395 . . . . 72.109999999999999 112.416 -178.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -95.7 -8.44 34.6 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.086 -0.506 . . . . 71.219999999999999 110.241 178.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.3 tptt -105.84 123.12 47.45 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.869 -0.605 . . . . 45.009999999999998 110.737 -177.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.413 ' N ' HD12 ' A' ' 66' ' ' LEU . 5.1 mp -90.45 119.64 30.9 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.108 -0.951 . . . . 74.530000000000001 109.075 177.787 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 49.6 mm -90.07 113.92 58.97 Favored Pre-proline 0 C--N 1.323 -0.573 0 CA-C-N 116.263 -0.426 . . . . 75.310000000000002 110.729 -175.612 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.449 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 56.9 Cg_endo -69.43 174.03 9.81 Favored 'Trans proline' 0 N--CA 1.46 -0.5 0 C-N-CA 122.498 2.132 . . . . 71.530000000000001 112.371 -179.304 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 29.4 tt0 -83.14 -5.17 59.02 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.806 -0.633 . . . . 74.409999999999997 111.857 -168.233 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 35.7 p90 -100.45 -2.02 34.33 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.287 0.565 . . . . 73.329999999999998 109.902 176.468 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.449 ' HB2' ' HG2' ' A' ' 68' ' ' PRO . 2.8 mm-40 -121.72 17.02 11.12 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.391 -0.822 . . . . 71.299999999999997 111.03 -177.016 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.45 HG21 ' CD1' ' A' ' 57' ' ' PHE . 12.1 pt -98.18 -22.55 4.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.944 -0.571 . . . . 72.430000000000007 111.457 -179.569 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -113.58 20.78 15.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.185 0.517 . . . . 71.549999999999997 110.427 -178.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.1 m -57.75 -32.69 67.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.246 -0.888 . . . . 71.409999999999997 111.489 -177.011 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . 0.622 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 10.2 p-90 . . . . . 0 C--N 1.325 -0.467 0 CA-C-N 116.23 -0.441 . . . . 75.439999999999998 111.088 176.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 26.3 m . . . . . 0 N--CA 1.45 -0.437 0 CA-C-O 121.369 0.604 . . . . 70.209999999999994 109.763 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . 0.433 ' O ' ' HD3' ' B' ' 111' ' ' PRO . . . 151.59 54.14 0.01 OUTLIER Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 110.485 -1.046 . . . . 70.219999999999999 110.485 -175.058 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . 0.414 ' HA ' ' HD3' ' B' ' 111' ' ' PRO . 11.0 mt-10 -92.41 104.03 10.07 Favored Pre-proline 0 C--N 1.323 -0.578 0 CA-C-N 115.182 -0.509 . . . . 64.200000000000003 109.851 -176.065 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.722 ' HB3' ' HB ' ' B' ' 128' ' ' VAL . 68.4 Cg_endo -98.61 158.37 0.73 Allowed 'Trans proline' 0 N--CA 1.444 -1.437 0 C-N-CA 123.156 2.571 . . . . 73.450000000000003 112.768 -174.621 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -156.26 126.28 6.49 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 115.544 -0.753 . . . . 71.099999999999994 109.766 177.151 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.455 ' HB ' ' HB3' ' A' ' 51' ' ' ASP . 5.4 p -84.88 132.79 30.82 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 CA-C-N 114.979 -1.01 . . . . 74.439999999999998 110.801 -174.124 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . 0.592 HG22 ' HG3' ' B' ' 116' ' ' ARG . 28.6 m -95.78 104.76 16.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.463 -0.79 . . . . 53.32 110.184 179.077 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.495 HG12 ' HG2' ' B' ' 124' ' ' GLN . 60.7 mt -90.64 102.98 13.92 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 116.073 -0.512 . . . . 74.019999999999996 109.928 -179.593 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . 0.592 ' HG3' HG22 ' B' ' 114' ' ' THR . 71.7 mtm180 -121.24 169.71 10.3 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.162 -0.472 . . . . 74.430000000000007 110.847 -178.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -125.24 117.49 23.95 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.045 -0.525 . . . . 75.109999999999999 110.537 179.016 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . 0.611 ' HG3' HD12 ' B' ' 123' ' ' ILE . 22.8 mm-40 -95.36 25.66 4.26 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.577 -0.738 . . . . 74.549999999999997 110.911 -177.225 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 121.45 -107.95 1.28 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.897 -0.668 . . . . 33.539999999999999 111.638 -177.379 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . 0.522 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 28.4 m-20 -95.39 29.21 2.61 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.911 0.386 . . . . 62.409999999999997 110.027 179.519 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . . . . . . . . . 20.7 pttm -151.88 127.52 10.14 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.032 0.444 . . . . 75.219999999999999 111.292 179.121 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 21.7 m -90.14 113.24 24.96 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.599 -0.728 . . . . 74.400000000000006 109.19 174.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . 0.611 HD12 ' HG3' ' B' ' 118' ' ' GLU . 51.8 mt -109.84 114.79 47.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.198 0.523 . . . . 61.43 110.634 -173.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.523 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 19.6 mt-30 -95.3 105.89 17.88 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.552 -0.749 . . . . 73.519999999999996 109.569 178.067 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . 0.424 ' CD ' HH21 ' B' ' 116' ' ' ARG . 28.8 mt-10 -84.53 98.82 10.34 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.541 -0.754 . . . . 71.120000000000005 110.34 -177.482 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . 0.62 ' CD2' ' HB2' ' A' ' 51' ' ' ASP . 6.5 m-85 -76.51 103.3 6.43 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.595 -0.52 . . . . 71.239999999999995 109.595 178.361 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 56.9 mtt-85 -132.43 126.34 32.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.108 0.48 . . . . 64.219999999999999 111.553 -172.725 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.722 ' HB ' ' HB3' ' B' ' 111' ' ' PRO . 4.3 p -115.7 119.44 61.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.675 -0.693 . . . . 51.240000000000002 109.827 175.105 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 60.29 27.14 16.66 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.284 -0.416 . . . . 74.5 111.545 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.36 21.13 52.92 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.509 -0.853 . . . . 71.519999999999996 112.576 179.544 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.468 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 90.0 t80 -122.27 119.43 31.16 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.933 0.396 . . . . 65.400000000000006 110.235 175.443 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.536 HD21 HD11 ' B' ' 135' ' ' ILE . 24.4 tp -83.06 114.24 21.16 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.694 -0.684 . . . . 72.540000000000006 109.928 178.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 45.6 p90 -110.06 -6.93 15.0 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.618 -0.433 . . . . 65.310000000000002 111.296 -178.107 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -165.83 146.88 6.89 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.027 0.441 . . . . 72.140000000000001 111.207 -177.148 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.536 HD11 HD21 ' B' ' 132' ' ' LEU . 59.3 mt -130.57 118.05 41.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.932 -0.576 . . . . 64.209999999999994 109.946 177.582 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.523 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.1 tttt -101.3 98.32 8.72 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 120.092 -0.643 . . . . 73.140000000000001 109.477 172.354 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.53 HG13 ' CE1' ' B' ' 145' ' ' TYR . 1.9 p -101.4 125.38 55.43 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.125 0.488 . . . . 73.310000000000002 110.537 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.671 HG22 ' HB3' ' B' ' 144' ' ' PRO . 23.2 t -104.98 88.67 2.48 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.169 -0.923 . . . . 72.219999999999999 109.451 175.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.482 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 72.6 Cg_endo -83.51 132.69 5.92 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.54 2.16 . . . . 75.099999999999994 112.708 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . 0.522 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 29.1 mtpp -56.65 -33.38 66.28 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.454 -0.794 . . . . 72.140000000000001 111.006 176.742 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -97.11 17.42 17.14 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.705 -0.679 . . . . 73.140000000000001 111.029 -174.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . -155.76 -149.99 5.48 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 121.001 -0.619 . . . . 52.329999999999998 111.742 178.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -119.08 147.42 42.66 Favored Pre-proline 0 C--N 1.327 -0.395 0 N-CA-C 109.611 -0.514 . . . . 71.310000000000002 109.611 176.495 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.671 ' HB3' HG22 ' B' ' 138' ' ' VAL . 25.3 Cg_endo -64.29 123.85 12.47 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.362 2.041 . . . . 61.210000000000001 111.492 175.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . 0.53 ' CE1' HG13 ' B' ' 137' ' ' VAL . 5.8 p90 -144.88 151.79 39.25 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.874 0.368 . . . . 70.329999999999998 111.418 -175.614 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.478 ' HB2' ' OG ' ' B' ' 160' ' ' SER . 74.9 m-85 -96.83 136.81 36.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.675 -0.693 . . . . 72.030000000000001 110.393 177.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.506 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 56.9 mt -109.53 102.62 11.46 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.163 -0.471 . . . . 64.129999999999995 109.884 169.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.9 t -81.83 130.35 35.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 109.836 -0.431 . . . . 44.009999999999998 109.836 178.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . 0.589 ' NH1' ' HA ' ' B' ' 153' ' ' SER . 0.0 OUTLIER -81.31 128.06 33.41 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.703 -0.226 . . . . 71.510000000000005 110.447 -177.149 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -68.58 150.7 47.7 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 120.963 0.411 . . . . 74.409999999999997 110.631 176.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . 0.554 ' HB2' ' CD2' ' A' ' 26' ' ' TYR . 22.7 t70 -70.77 165.88 22.14 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.598 -0.728 . . . . 71.299999999999997 111.115 -175.148 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.08 0.66 70.97 Favored Glycine 0 C--N 1.331 0.3 0 CA-C-N 116.206 -0.452 . . . . 72.540000000000006 112.34 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . 0.589 ' HA ' ' NH1' ' B' ' 149' ' ' ARG . 5.9 t 60.6 31.91 20.29 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.078 0.466 . . . . 61.229999999999997 109.836 -176.441 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -52.39 -49.4 64.53 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.126 -0.943 . . . . 64.230000000000004 111.54 -179.521 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 124.61 -17.87 7.28 Favored Glycine 0 CA--C 1.499 -0.918 0 C-N-CA 120.762 -0.732 . . . . 73.120000000000005 111.565 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -70.33 140.35 52.21 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 114.851 -0.675 . . . . 63.520000000000003 111.281 178.037 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . 0.521 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 53.9 m-85 -118.28 151.47 37.61 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.071 -0.513 . . . . 73.120000000000005 109.673 174.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 46.7 mm -119.35 121.91 67.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 N-CA-C 109.743 -0.465 . . . . 64.219999999999999 109.743 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.592 ' HB3' ' H ' ' B' ' 162' ' ' GLN . 54.5 mtt180 -76.2 137.07 39.78 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.318 -0.401 . . . . 71.019999999999996 110.941 179.434 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . 0.478 ' OG ' ' HB2' ' B' ' 146' ' ' PHE . 19.9 m -80.88 -13.68 58.7 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.252 -1.018 . . . . 74.239999999999995 108.252 165.096 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -73.66 -45.85 50.13 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.251 -1.34 . . . . 75.319999999999993 109.859 173.033 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . 0.592 ' H ' ' HB3' ' B' ' 159' ' ' ARG . 77.6 mt-30 -137.63 86.19 19.28 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-N 115.364 -0.835 . . . . 74.400000000000006 109.444 176.456 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -68.19 -13.99 39.39 Favored 'Trans proline' 0 N--CA 1.473 0.282 0 C-N-CA 122.905 2.403 . . . . 72.450000000000003 112.936 -176.436 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -92.29 10.68 28.67 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.976 0.417 . . . . 64.439999999999998 110.453 -179.028 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -127.09 125.81 41.91 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.33 0.586 . . . . 75.319999999999993 111.075 -179.589 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . 0.429 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.9 mp -87.87 125.06 34.27 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.036 -0.984 . . . . 55.409999999999997 108.93 176.573 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . 0.837 HG23 ' HB3' ' B' ' 171' ' ' GLU . 39.4 mm -87.26 117.43 68.58 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 116.18 -0.463 . . . . 64.120000000000005 111.64 -172.396 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.454 ' HG2' ' HB2' ' B' ' 171' ' ' GLU . 72.4 Cg_endo -75.59 -179.75 5.42 Favored 'Trans proline' 0 N--CA 1.463 -0.287 0 C-N-CA 123.088 2.525 . . . . 61.130000000000003 112.043 175.539 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . 0.761 ' O ' HG12 ' B' ' 172' ' ' ILE . 35.4 tt0 -76.34 -29.51 57.28 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.727 -0.389 . . . . 62.130000000000003 111.68 -172.261 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 36.5 p90 -75.06 -14.11 60.56 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 119.92 -0.712 . . . . 74.450000000000003 110.313 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.837 ' HB3' HG23 ' B' ' 167' ' ' ILE . 0.8 OUTLIER -89.68 -21.1 22.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.885 -0.598 . . . . 73.150000000000006 110.185 -179.257 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.761 HG12 ' O ' ' B' ' 169' ' ' GLN . 21.9 pt -73.59 -18.44 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 121.27 0.557 . . . . 74.200000000000003 110.24 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 80.0 m-85 -93.65 15.23 16.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.663 -0.699 . . . . 72.439999999999998 110.168 176.217 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.7 t -56.96 -37.06 71.04 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-N 115.817 -0.629 . . . . 72.019999999999996 109.777 175.782 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 54.7 p-90 . . . . . 0 C--O 1.247 0.927 0 CA-C-O 118.203 -0.903 . . . . 74.420000000000002 109.828 175.02 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 19.6 m . . . . . 0 N--CA 1.45 -0.461 0 N-CA-C 109.504 -0.554 . . . . 71.430000000000007 109.504 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 72.41 74.78 0.74 Allowed Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 110.005 -1.238 . . . . 64.510000000000005 110.005 -168.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . 0.446 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 7.1 pt-20 -112.31 107.74 55.26 Favored Pre-proline 0 C--N 1.317 -0.809 0 CA-C-O 121.375 0.607 . . . . 73.430000000000007 109.712 -169.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.578 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 32.5 Cg_endo -84.67 108.94 1.28 Allowed 'Trans proline' 0 N--CA 1.442 -1.541 0 C-N-CA 122.445 2.097 . . . . 62.439999999999998 112.371 -174.006 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -118.79 164.2 15.75 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.127 -0.942 . . . . 50.25 109.674 -179.437 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.604 HG21 ' HB3' ' A' ' 24' ' ' GLN . 13.1 p -115.34 131.24 68.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.237 0.541 . . . . 64.430000000000007 111.41 -177.315 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 52.9 m -93.16 107.09 18.96 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.244 -0.65 . . . . 63.530000000000001 109.244 174.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 53.5 mt -92.09 107.96 19.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 120.963 0.411 . . . . 71.209999999999994 111.217 -174.559 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 66.7 mtt180 -103.65 167.85 9.53 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.736 -0.665 . . . . 72.150000000000006 110.252 176.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 62.6 mt-30 -134.16 97.31 3.82 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.438 -0.579 . . . . 72.219999999999999 109.438 170.317 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 22.1 mm-40 -96.29 82.42 3.42 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.823 -0.626 . . . . 74.209999999999994 110.093 -175.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.86 -109.02 3.31 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.798 -0.715 . . . . 62.200000000000003 111.927 -178.506 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.903 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 7.1 m-20 -111.22 17.53 20.2 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.899 0.381 . . . . 65.239999999999995 110.326 -179.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.599 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 22.9 pttm -130.84 123.79 29.84 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.294 0.569 . . . . 74.120000000000005 111.398 -179.151 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.474 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 24.5 m -82.83 109.75 17.24 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.603 -0.726 . . . . 33.329999999999998 109.682 176.265 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 48.7 mt -102.55 112.83 37.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-O 121.117 0.484 . . . . 71.239999999999995 110.654 -176.335 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.604 ' HB3' HG21 ' A' ' 13' ' ' VAL . 25.2 mt-30 -102.48 110.92 23.02 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.67 -0.695 . . . . 74.310000000000002 110.996 -177.562 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -92.26 107.51 19.27 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.795 -0.639 . . . . 73.019999999999996 110.837 -178.42 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -84.87 112.42 20.54 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.893 0.378 . . . . 74.019999999999996 110.599 178.392 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.466 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 87.9 mtt180 -117.39 137.56 52.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.924 -0.58 . . . . 71.019999999999996 109.905 178.756 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.578 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 6.2 p -96.82 -34.82 5.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-O 121.346 0.593 . . . . 72.239999999999995 110.489 177.714 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 30.9 t-20 -161.78 59.8 0.26 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.641 -0.874 . . . . 61.0 108.641 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.07 -34.69 3.36 Favored Glycine 0 CA--C 1.519 0.297 0 CA-C-N 115.482 -0.781 . . . . 61.039999999999999 112.058 -176.162 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.56 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 81.9 t80 -78.28 129.25 34.82 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.021 0.438 . . . . 64.420000000000002 111.047 -177.328 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.781 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -81.44 114.04 19.91 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.196 -0.911 . . . . 72.340000000000003 109.094 174.59 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 52.1 p90 -107.86 -19.4 13.53 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.634 -0.426 . . . . 74.129999999999995 111.682 -179.057 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -154.85 136.15 14.05 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.785 0.326 . . . . 51.439999999999998 111.244 -179.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.781 HG13 HD11 ' A' ' 32' ' ' LEU . 75.0 mt -116.26 122.81 70.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 116.064 -0.516 . . . . 75.450000000000003 109.91 175.378 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.4 tmtp? -110.21 114.49 28.02 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 108.732 -0.84 . . . . 65.430000000000007 108.732 173.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.571 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 0.9 OUTLIER -120.46 129.72 75.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 CA-C-N 115.796 -0.638 . . . . 74.549999999999997 110.692 -174.011 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.765 HG22 ' HB3' ' A' ' 44' ' ' PRO . 21.2 t -112.8 86.96 9.38 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.313 -0.858 . . . . 75.400000000000006 110.097 -179.378 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.469 ' HD2' ' C ' ' A' ' 43' ' ' LYS . 70.4 Cg_endo -86.49 134.45 4.05 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 122.503 2.135 . . . . 64.329999999999998 112.496 176.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.903 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 59.4 mtpt -56.31 -31.19 63.46 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.664 -0.698 . . . . 71.209999999999994 110.168 174.149 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 61.4 m-70 -116.95 91.18 3.51 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.338 -0.846 . . . . 73.340000000000003 109.156 176.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 141.31 -31.31 2.16 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.837 -0.619 . . . . 65.329999999999998 111.977 -177.019 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.469 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 98.5 mttt 70.52 151.12 0.13 Allowed Pre-proline 0 N--CA 1.469 0.477 0 C-N-CA 123.508 0.723 . . . . 72.329999999999998 111.872 178.577 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.765 ' HB3' HG22 ' A' ' 38' ' ' VAL . 18.8 Cg_endo -59.26 139.44 90.09 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 123.013 2.476 . . . . 74.010000000000005 113.798 -174.01 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.544 ' CE1' HG13 ' A' ' 37' ' ' VAL . 22.5 p90 -152.34 163.65 39.04 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.62 -0.718 . . . . 71.209999999999994 109.548 176.594 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . 0.472 ' HB2' ' HB2' ' A' ' 60' ' ' SER . 60.1 m-85 -107.6 120.66 42.84 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.704 0.288 . . . . 74.120000000000005 110.712 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 28.1 tp -107.15 99.14 8.7 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.16 -0.681 . . . . 44.149999999999999 109.16 176.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 37.3 t -95.38 140.76 16.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.26 -0.427 . . . . 63.409999999999997 111.436 -173.52 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . 0.498 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 43.8 tpt85 -81.82 110.97 17.61 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.495 -0.557 . . . . 73.109999999999999 109.495 178.23 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.457 ' HB2' HG12 ' A' ' 58' ' ' ILE . . . -70.03 -177.96 1.48 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.994 -0.548 . . . . 73.519999999999996 111.111 -177.286 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.752 ' HB2' ' HA ' ' B' ' 112' ' ' ASP . 9.1 p-10 -79.01 148.42 32.53 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.154 -0.475 . . . . 72.049999999999997 110.17 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 103.27 140.16 10.69 Favored Glycine 0 N--CA 1.439 -1.16 0 C-N-CA 120.571 -0.823 . . . . 64.010000000000005 112.675 174.026 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 20.7 m -69.13 -4.93 19.3 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.675 -0.262 . . . . 52.130000000000003 110.919 174.708 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -43.03 -48.07 5.97 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 123.556 0.743 . . . . 73.0 112.012 176.711 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.25 53.86 1.32 Allowed Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.608 -0.806 . . . . 43.310000000000002 112.46 178.275 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -127.17 148.96 50.17 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.095 0.474 . . . . 65.319999999999993 110.538 176.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.498 ' CZ ' ' HD3' ' A' ' 49' ' ' ARG . 40.2 m-85 -117.75 152.64 34.87 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.594 -0.73 . . . . 73.019999999999996 110.322 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.457 HG12 ' HB2' ' A' ' 50' ' ' ALA . 50.6 mm -121.26 127.07 75.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 109.914 -0.402 . . . . 73.230000000000004 109.914 179.753 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 65.0 mtp180 -78.55 139.2 38.64 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 110.144 -0.317 . . . . 70.319999999999993 110.144 175.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.472 ' HB2' ' HB2' ' A' ' 46' ' ' PHE . 63.2 m -73.05 -23.19 60.55 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.495 -0.321 . . . . 60.310000000000002 110.448 176.109 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.46 ' OD1' ' HB2' ' A' ' 45' ' ' TYR . 0.8 OUTLIER -61.79 -60.58 3.44 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 121.74 0.781 . . . . 64.450000000000003 109.414 175.918 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 -122.65 88.62 49.85 Favored Pre-proline 0 N--CA 1.445 -0.724 0 CA-C-N 114.538 -1.21 . . . . 75.120000000000005 109.817 -179.524 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.84 -9.19 20.24 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 123.165 2.577 . . . . 65.239999999999995 112.626 -178.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -78.37 -24.84 46.19 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.926 -0.579 . . . . 73.219999999999999 110.599 177.393 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' A' ' 65' ' ' LYS . 42.6 tptt -91.82 122.92 34.8 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.388 0.613 . . . . 61.409999999999997 111.395 -175.14 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.5 mp -96.59 119.38 34.98 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.09 -0.959 . . . . 71.239999999999995 109.642 176.243 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 50.7 mm -88.11 111.42 42.85 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 116.273 -0.421 . . . . 73.409999999999997 110.023 178.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.428 ' O ' HG23 ' A' ' 72' ' ' ILE . 72.7 Cg_endo -74.16 176.72 9.18 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.563 2.175 . . . . 74.299999999999997 112.367 -177.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 28.4 tt0 -80.41 -6.24 57.76 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.859 -0.61 . . . . 54.549999999999997 111.334 -169.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -95.24 -12.14 26.76 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.409 -0.516 . . . . 62.5 110.433 176.367 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -103.12 -7.6 21.17 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.839 0.352 . . . . 52.439999999999998 110.795 -178.167 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.428 HG23 ' O ' ' A' ' 68' ' ' PRO . 45.7 pt -67.72 -27.74 39.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.846 0.355 . . . . 75.230000000000004 111.573 -178.24 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 24.3 p90 -101.27 34.49 2.54 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.372 0.605 . . . . 74.129999999999995 110.528 178.101 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 42.4 t -64.75 -26.98 68.59 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.43 -0.805 . . . . 52.130000000000003 110.212 176.161 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . 0.599 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 26.0 p-90 . . . . . 0 C--O 1.235 0.327 0 CA-C-N 116.436 -0.347 . . . . 65.319999999999993 111.048 177.309 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 16.9 m . . . . . 0 C--O 1.233 0.223 0 CA-C-O 120.833 0.349 . . . . 64.409999999999997 110.072 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 114.58 85.05 1.28 Allowed Glycine 0 N--CA 1.443 -0.864 0 C-N-CA 120.578 -0.82 . . . . 63.340000000000003 111.437 -176.8 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . 0.462 ' HA ' ' HD3' ' B' ' 111' ' ' PRO . 11.1 pt-20 -124.08 110.73 28.99 Favored Pre-proline 0 C--N 1.322 -0.618 0 CA-C-O 121.322 0.582 . . . . 72.049999999999997 109.558 -176.384 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.695 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 19.1 Cg_endo -89.52 131.35 2.01 Favored 'Trans proline' 0 N--CA 1.444 -1.4 0 C-N-CA 122.63 2.22 . . . . 60.219999999999999 112.604 -176.393 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . 0.752 ' HA ' ' HB2' ' A' ' 51' ' ' ASP . 4.2 p-10 -144.9 171.17 14.82 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.188 -0.671 . . . . 72.329999999999998 109.188 175.272 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.544 HG21 ' HB3' ' B' ' 124' ' ' GLN . 10.9 p -118.44 131.6 70.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.653 0.739 . . . . 72.450000000000003 112.096 -172.461 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 30.3 m -94.86 103.44 15.32 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.435 -0.802 . . . . 55.039999999999999 109.31 173.161 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.468 HG23 ' HG2' ' B' ' 124' ' ' GLN . 65.2 mt -90.57 106.44 17.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.245 -0.434 . . . . 72.099999999999994 110.823 -176.15 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -113.74 165.08 12.91 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.126 -0.488 . . . . 72.439999999999998 110.603 177.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -133.14 105.57 7.11 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.094 0.474 . . . . 63.450000000000003 110.468 178.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -109.85 88.75 2.82 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.904 -0.589 . . . . 71.340000000000003 110.191 -178.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 88.47 -119.8 5.47 Favored Glycine 0 N--CA 1.445 -0.734 0 CA-C-N 115.439 -0.8 . . . . 52.43 111.742 -177.377 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . 0.508 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 90.5 m-20 -101.37 6.29 42.57 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.73 0.3 . . . . 63.340000000000003 110.573 178.84 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.706 ' HE3' ' HB2' ' B' ' 175' ' ' TRP . 25.1 pttm -117.42 120.69 38.92 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.47 0.652 . . . . 72.420000000000002 111.692 -177.806 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . 0.586 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 69.7 m -84.86 105.0 15.31 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.163 -0.926 . . . . 73.140000000000001 109.478 174.183 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . 0.655 HD11 ' HE2' ' B' ' 121' ' ' LYS . 33.2 mt -95.02 108.08 20.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 121.049 0.452 . . . . 71.109999999999999 110.531 -176.366 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.544 ' HB3' HG21 ' B' ' 113' ' ' VAL . 22.1 mt-30 -98.65 105.15 17.26 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.825 -0.625 . . . . 72.120000000000005 110.319 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -87.37 112.77 22.46 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.125 -0.488 . . . . 65.409999999999997 110.926 -179.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -90.09 111.14 22.16 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.205 -0.452 . . . . 72.230000000000004 110.028 176.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . 0.403 ' HD3' ' O ' ' B' ' 130' ' ' GLY . 52.8 mtt-85 -128.33 138.1 52.23 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.313 -0.403 . . . . 75.340000000000003 110.346 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.695 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -101.86 -56.17 5.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.065 0.459 . . . . 71.510000000000005 111.201 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . 0.449 ' H ' HG13 ' B' ' 128' ' ' VAL . 6.7 t-20 -122.66 42.03 3.28 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.761 0.791 . . . . 64.310000000000002 109.103 -178.029 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . 0.403 ' O ' ' HD3' ' B' ' 127' ' ' ARG . . . 92.31 -28.72 8.51 Favored Glycine 0 N--CA 1.448 -0.563 0 CA-C-N 115.086 -0.961 . . . . 64.319999999999993 112.099 -178.087 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 33.8 t80 -84.59 135.57 34.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.934 0.397 . . . . 72.329999999999998 110.318 -175.627 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.843 HD11 HG13 ' B' ' 135' ' ' ILE . 3.3 tm? -76.75 117.59 18.53 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.327 -0.851 . . . . 75.140000000000001 109.966 179.068 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 40.0 p90 -112.26 -14.96 13.27 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.521 -0.471 . . . . 72.010000000000005 111.571 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.11 141.61 12.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.848 0.356 . . . . 51.210000000000001 111.169 178.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.843 HG13 HD11 ' B' ' 132' ' ' LEU . 75.3 mt -125.14 121.61 61.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.188 -0.46 . . . . 72.129999999999995 109.935 175.713 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.407 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 83.7 tttt -104.37 98.5 8.28 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 108.821 -0.807 . . . . 73.010000000000005 108.821 171.512 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.55 ' O ' ' HD3' ' B' ' 139' ' ' PRO . 3.5 p -98.21 128.67 49.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-O 121.142 0.496 . . . . 74.120000000000005 109.916 179.374 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.586 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 40.8 t -108.03 84.82 2.28 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.31 -0.859 . . . . 72.129999999999995 109.69 179.083 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.55 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 62.5 Cg_endo -88.7 132.33 2.45 Favored 'Trans proline' 0 N--CA 1.443 -1.464 0 C-N-CA 122.459 2.106 . . . . 75.140000000000001 111.885 178.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . 0.508 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 55.0 mtpt -65.37 -15.81 62.96 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.701 -0.681 . . . . 54.329999999999998 109.808 176.229 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 64.4 m-70 -117.47 89.52 3.13 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-N 115.174 -0.921 . . . . 63.240000000000002 109.289 178.413 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 127.87 -18.35 5.94 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.724 -0.751 . . . . 63.25 112.555 -178.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 89.1 mttt 72.98 148.94 0.12 Allowed Pre-proline 0 N--CA 1.472 0.649 0 C-N-CA 123.557 0.743 . . . . 73.299999999999997 111.736 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.545 ' HB3' HG22 ' B' ' 138' ' ' VAL . 34.9 Cg_endo -65.12 149.26 89.24 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.936 2.424 . . . . 74.400000000000006 113.375 -176.433 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . 0.43 ' HE2' HD13 ' B' ' 147' ' ' LEU . 3.9 p90 -160.3 160.43 32.51 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.534 -0.757 . . . . 71.230000000000004 109.59 178.178 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.547 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 55.0 m-85 -94.55 128.84 41.42 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.457 -0.338 . . . . 74.439999999999998 110.216 176.687 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.43 HD13 ' HE2' ' B' ' 145' ' ' TYR . 15.8 tp -110.36 99.8 8.76 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 108.931 -0.766 . . . . 74.420000000000002 108.931 174.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.3 t -93.77 139.28 18.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.988 -0.551 . . . . 73.5 111.047 -173.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 11.6 tpt180 -72.02 131.06 42.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.199 -0.455 . . . . 72.319999999999993 111.245 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -93.34 162.22 14.08 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.372 -0.603 . . . . 75.140000000000001 109.372 171.306 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -68.69 138.24 54.78 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.966 0.412 . . . . 72.299999999999997 110.537 -177.548 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.1 147.45 15.01 Favored Glycine 0 N--CA 1.437 -1.28 0 C-N-CA 120.491 -0.861 . . . . 72.25 112.048 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 11.1 t -87.0 23.88 1.66 Allowed 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 121.253 0.549 . . . . 63.140000000000001 110.015 175.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -65.17 -29.45 70.28 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.571 -0.74 . . . . 72.150000000000006 110.59 179.01 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 94.44 37.92 5.18 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.891 -0.671 . . . . 71.049999999999997 111.641 -177.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . 0.943 HD21 HD22 ' B' ' 166' ' ' LEU . 40.7 t30 -110.85 130.51 55.56 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.836 0.351 . . . . 65.109999999999999 110.69 -177.457 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . 0.428 ' HB3' ' HG ' ' B' ' 147' ' ' LEU . 27.1 m-85 -126.71 161.0 29.15 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.002 -0.545 . . . . 72.239999999999995 110.269 178.198 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . 0.775 HD11 HD23 ' B' ' 166' ' ' LEU . 39.9 mm -118.38 141.05 39.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.458 -0.337 . . . . 73.120000000000005 110.603 -179.63 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.817 ' HD2' HD11 ' B' ' 167' ' ' ILE . 34.1 mtp-105 -96.23 145.68 25.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.394 -0.366 . . . . 75.400000000000006 110.925 -178.098 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . 0.547 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 25.8 p -74.96 -15.16 60.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.26 0.552 . . . . 74.239999999999995 110.679 175.098 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -78.66 -30.79 46.47 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.118 -0.492 . . . . 72.530000000000001 110.38 177.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -159.19 98.02 1.63 Allowed Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.781 -0.645 . . . . 75.420000000000002 110.224 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . 0.418 ' HA ' HG23 ' B' ' 158' ' ' ILE . 48.6 Cg_endo -69.62 -13.03 34.41 Favored 'Trans proline' 0 CA--C 1.529 0.231 0 C-N-CA 122.991 2.461 . . . . 61.039999999999999 112.844 -179.343 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -77.66 -19.38 55.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.86 0.362 . . . . 62.539999999999999 111.022 177.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 51.7 tptt -94.07 122.61 36.76 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.409 0.623 . . . . 71.120000000000005 111.132 -177.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . 0.943 HD22 HD21 ' B' ' 156' ' ' ASN . 20.4 mt -90.57 128.02 36.45 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.598 -1.183 . . . . 73.400000000000006 108.832 176.734 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . 0.817 HD11 ' HD2' ' B' ' 159' ' ' ARG . 46.1 mm -98.77 112.08 61.89 Favored Pre-proline 0 C--N 1.318 -0.778 0 CA-C-O 120.65 0.262 . . . . 70.310000000000002 110.832 -178.151 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.539 ' O ' HG23 ' B' ' 172' ' ' ILE . 68.6 Cg_endo -73.5 175.23 10.94 Favored 'Trans proline' 0 N--CA 1.464 -0.263 0 C-N-CA 122.775 2.317 . . . . 75.340000000000003 112.611 -179.421 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . 0.517 ' O ' HG12 ' B' ' 172' ' ' ILE . 28.0 tt0 -69.65 -25.48 63.94 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.703 -0.681 . . . . 73.319999999999993 112.325 -168.488 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 30.6 p90 -81.09 -12.07 59.36 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 120.182 -0.607 . . . . 74.420000000000002 110.303 178.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.548 ' HB3' HG23 ' B' ' 167' ' ' ILE . 3.9 mt-10 -106.79 -19.27 13.7 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.157 -0.474 . . . . 71.329999999999998 111.892 -178.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.539 HG23 ' O ' ' B' ' 168' ' ' PRO . 43.6 pt -64.51 -26.36 40.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.244 0.545 . . . . 72.129999999999995 110.681 177.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -105.3 48.56 0.83 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.612 -0.722 . . . . 70.439999999999998 109.782 174.4 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 16.6 t -71.06 -15.39 62.54 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.806 -0.634 . . . . 73.409999999999997 110.17 179.379 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . 0.706 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 4.5 p-90 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.249 -0.882 . . . . 73.120000000000005 110.519 178.305 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 27.0 m . . . . . 0 C--O 1.23 0.059 0 CA-C-O 121.66 0.743 . . . . 53.119999999999997 110.374 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -135.18 102.99 0.45 Allowed Glycine 0 N--CA 1.442 -0.957 0 N-CA-C 110.108 -1.197 . . . . 75.109999999999999 110.108 177.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -119.99 94.71 48.81 Favored Pre-proline 0 C--N 1.319 -0.743 0 CA-C-O 121.261 0.553 . . . . 74.329999999999998 110.401 -175.069 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.848 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 51.6 Cg_endo -77.56 81.79 2.57 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 121.913 1.742 . . . . 73.120000000000005 111.265 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -100.48 168.26 9.85 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.339 -0.615 . . . . 73.450000000000003 109.339 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.673 HG21 ' HB3' ' A' ' 24' ' ' GLN . 8.3 p -125.65 131.41 72.06 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-O 121.253 0.549 . . . . 44.450000000000003 111.387 -175.177 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.5 m -89.51 121.14 31.44 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.679 -0.691 . . . . 71.150000000000006 109.423 176.34 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 52.9 mt -91.58 109.09 20.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 120.834 0.349 . . . . 71.430000000000007 111.161 -175.382 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 38.3 mmt180 -105.51 165.7 10.96 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 72.109999999999999 109.867 176.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 40.1 mt-30 -138.95 122.57 17.43 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.768 0.318 . . . . 75.349999999999994 111.147 177.007 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -124.97 96.93 5.05 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.793 -0.639 . . . . 73.040000000000006 109.524 176.212 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.24 -106.49 1.8 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.476 -0.869 . . . . 75.349999999999994 111.719 -178.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.588 ' HB3' ' HB2' ' A' ' 40' ' ' LYS . 7.0 m-20 -111.35 6.26 20.31 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 121.156 -0.217 . . . . 41.310000000000002 111.537 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.652 ' HB3' ' HB3' ' A' ' 39' ' ' PRO . 0.0 OUTLIER -110.94 122.49 48.01 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 119.917 -0.713 . . . . 72.030000000000001 111.472 177.422 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.448 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 42.4 m -83.42 101.28 11.26 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 114.961 -1.018 . . . . 61.409999999999997 108.983 173.174 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.475 HG12 HG13 ' A' ' 37' ' ' VAL . 61.3 mt -90.82 109.86 21.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.153 0.502 . . . . 71.439999999999998 110.291 -175.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.673 ' HB3' HG21 ' A' ' 13' ' ' VAL . 14.6 mt-30 -99.78 119.45 38.18 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.787 -0.642 . . . . 73.219999999999999 111.021 -175.562 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -94.31 108.73 20.6 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.825 -0.625 . . . . 74.239999999999995 110.559 -178.001 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.516 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 33.5 m-85 -86.62 114.82 23.65 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.923 0.392 . . . . 75.120000000000005 111.051 -179.587 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.427 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 68.3 mtm180 -131.03 126.64 36.43 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.018 -0.537 . . . . 73.120000000000005 110.416 179.295 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.848 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.3 p -91.07 -28.83 4.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.063 -0.517 . . . . 70.109999999999999 111.242 -176.52 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -173.61 69.68 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.626 -0.509 . . . . 62.310000000000002 109.626 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.98 -24.59 5.19 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.817 -0.629 . . . . 63.119999999999997 112.642 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.645 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 88.4 t80 -97.26 128.43 44.11 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.869 0.366 . . . . 75.25 111.057 -176.2 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.622 HD11 HG13 ' A' ' 35' ' ' ILE . 3.2 tm? -79.24 109.73 13.85 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.803 -0.814 . . . . 54.109999999999999 108.803 175.194 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 41.7 p90 -106.0 -13.87 15.35 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.513 -0.475 . . . . 63.32 111.467 -176.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -162.11 149.49 14.12 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.069 0.461 . . . . 31.210000000000001 111.62 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.622 HG13 HD11 ' A' ' 32' ' ' LEU . 70.1 mt -126.07 128.12 71.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.659 -0.701 . . . . 72.510000000000005 109.681 174.669 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.622 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 81.5 tttt -112.01 105.15 13.47 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.306 -0.406 . . . . 74.530000000000001 110.084 179.159 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.696 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 4.4 t -89.64 126.71 42.55 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 108.765 -0.828 . . . . 62.229999999999997 108.765 177.379 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.448 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 20.1 t -114.43 73.98 2.91 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 109.883 -0.414 . . . . 73.219999999999999 109.883 172.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.679 ' HD3' HG12 ' A' ' 37' ' ' VAL . 39.8 Cg_endo -77.52 132.11 11.99 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.094 1.862 . . . . 65.420000000000002 112.648 176.377 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.588 ' HB2' ' HB3' ' A' ' 20' ' ' ASP . 50.4 mtpt -60.76 -28.22 68.55 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.535 -0.757 . . . . 70.200000000000003 110.316 175.24 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 74.2 m-70 -118.03 94.63 4.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.325 -0.852 . . . . 74.530000000000001 108.763 178.026 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.413 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 134.04 -31.22 2.84 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.492 -0.776 . . . . 73.319999999999993 111.544 -175.038 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.472 ' HA ' ' HD3' ' A' ' 43' ' ' LYS . 31.5 mmtp 74.23 153.65 0.15 Allowed Pre-proline 0 N--CA 1.469 0.501 0 C-N-CA 123.557 0.743 . . . . 60.210000000000001 112.254 177.243 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.696 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 28.3 Cg_endo -62.86 132.52 37.54 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 123.074 2.516 . . . . 74.340000000000003 114.2 -173.485 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -140.0 154.55 47.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.456 -0.793 . . . . 72.129999999999995 109.884 175.364 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -107.01 136.98 45.95 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-O 120.763 0.316 . . . . 73.420000000000002 111.574 -175.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.585 HD23 ' HA ' ' A' ' 59' ' ' ARG . 47.7 mt -118.38 107.78 14.25 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.851 -0.613 . . . . 60.140000000000001 109.858 171.431 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 47.3 t -95.46 134.92 31.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.628 -0.26 . . . . 61.5 110.398 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . 0.656 ' HD2' ' HA ' ' A' ' 53' ' ' SER . 16.1 tpp85 -68.7 122.04 17.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.808 0.337 . . . . 75.140000000000001 110.123 177.211 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -73.6 158.35 34.95 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.136 -0.483 . . . . 72.230000000000004 110.784 179.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -53.49 143.55 19.26 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 115.765 -0.652 . . . . 63.140000000000001 111.194 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.28 -33.84 5.36 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.772 -0.728 . . . . 73.219999999999999 111.99 -178.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.656 ' HA ' ' HD2' ' A' ' 49' ' ' ARG . 17.4 t 63.02 38.3 11.06 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-O 121.009 0.433 . . . . 75.129999999999995 110.992 178.776 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -76.44 -3.67 38.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.526 0.679 . . . . 73.349999999999994 110.815 -178.468 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 111.54 2.53 27.46 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.617 -0.801 . . . . 54.200000000000003 111.692 -179.038 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -85.89 134.59 33.89 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.051 0.453 . . . . 73.219999999999999 110.497 178.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -116.04 144.19 44.45 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.82 -0.627 . . . . 70.450000000000003 110.109 176.095 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.2 mm -105.75 105.43 18.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 CA-C-O 121.564 0.697 . . . . 73.219999999999999 109.368 176.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.719 ' HB2' HG13 ' A' ' 67' ' ' ILE . 24.0 ttt180 -69.56 119.78 14.34 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 114.631 -1.168 . . . . 71.540000000000006 109.461 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.5 t -63.05 -18.56 63.49 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.396 0.617 . . . . 71.219999999999999 110.404 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.696 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 24.7 t70 -73.96 -28.42 61.48 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.449 -0.796 . . . . 74.5 110.489 175.61 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -142.79 68.5 19.09 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-N 115.424 -0.807 . . . . 65.140000000000001 109.191 -177.328 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_exo -71.06 -11.5 29.18 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 123.256 2.637 . . . . 53.329999999999998 112.998 -171.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -95.47 4.76 52.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.493 0.663 . . . . 72.510000000000005 109.758 -178.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -131.96 137.35 47.88 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.6 -0.727 . . . . 63.329999999999998 110.753 -178.038 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.488 ' N ' HD12 ' A' ' 66' ' ' LEU . 4.5 mp -85.02 131.44 34.46 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.049 -0.523 . . . . 61.030000000000001 109.65 179.678 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.719 HG13 ' HB2' ' A' ' 59' ' ' ARG . 40.6 mm -89.71 129.1 47.95 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-O 120.933 0.397 . . . . 71.510000000000005 111.305 -174.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -76.28 176.59 9.86 Favored 'Trans proline' 0 N--CA 1.459 -0.505 0 C-N-CA 122.862 2.374 . . . . 71.439999999999998 112.514 178.15 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . 0.685 ' HA ' HG12 ' A' ' 72' ' ' ILE . 6.4 tt0 -79.41 -31.62 42.72 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.61 -0.723 . . . . 64.329999999999998 112.184 -170.653 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 28.3 p90 -69.42 -19.39 63.8 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 120.184 -0.607 . . . . 71.530000000000001 110.384 178.421 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -84.84 -35.45 22.26 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.852 -0.613 . . . . 70.099999999999994 110.179 178.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.685 HG12 ' HA ' ' A' ' 69' ' ' GLN . 41.2 pt -76.24 -21.79 15.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.116 0 CA-C-O 120.965 0.412 . . . . 64.439999999999998 110.878 179.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 31.4 m-85 -103.63 28.47 6.52 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.077 -0.511 . . . . 74.120000000000005 110.926 176.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 11.1 t -84.93 45.22 1.14 Allowed 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.864 0.84 . . . . 71.219999999999999 109.616 178.352 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 11.3 m0 . . . . . 0 C--N 1.324 -0.521 0 CA-C-N 115.124 -0.944 . . . . 73.329999999999998 110.729 -178.83 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 6.3 p . . . . . 0 N--CA 1.452 -0.358 0 CA-C-O 121.041 0.448 . . . . 74.420000000000002 109.998 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 128.05 76.89 0.21 Allowed Glycine 0 N--CA 1.445 -0.701 0 N-CA-C 110.891 -0.884 . . . . 74.049999999999997 110.891 -175.555 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -110.16 105.77 57.47 Favored Pre-proline 0 C--N 1.32 -0.703 0 N-CA-C 109.138 -0.69 . . . . 71.040000000000006 109.138 -175.371 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.745 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 46.1 Cg_endo -82.23 86.35 1.54 Allowed 'Trans proline' 0 N--CA 1.439 -1.734 0 C-N-CA 121.898 1.732 . . . . 70.230000000000004 110.959 -178.021 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -101.81 155.63 18.02 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 114.258 -1.337 . . . . 74.010000000000005 109.92 -175.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.603 ' HA ' ' O ' ' B' ' 125' ' ' GLU . 7.6 p -117.65 130.71 72.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.474 0.655 . . . . 75.430000000000007 111.104 -177.707 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 52.0 m -104.7 122.05 44.85 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.401 -0.818 . . . . 65.420000000000002 109.996 178.636 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 47.3 mt -87.09 108.03 17.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 116.145 -0.479 . . . . 54.520000000000003 111.443 -174.783 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -101.15 170.73 8.06 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.469 -0.567 . . . . 54.25 109.469 175.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -142.76 138.76 30.7 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.782 0.325 . . . . 75.109999999999999 110.786 175.532 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -135.52 104.58 5.87 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.638 -0.71 . . . . 75.109999999999999 109.754 176.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.62 -110.14 3.31 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.908 -0.663 . . . . 51.109999999999999 111.898 -177.263 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . 0.615 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 9.5 m-20 -97.06 -19.33 18.79 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.705 0.288 . . . . 74.200000000000003 110.977 -179.147 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.533 ' HB3' ' HA ' ' B' ' 139' ' ' PRO . 49.3 pttt -100.88 141.75 33.33 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.6 0.714 . . . . 71.25 112.503 -170.088 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . 0.594 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 47.9 m -91.77 138.43 31.56 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 114.828 -1.078 . . . . 73.409999999999997 109.646 176.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 65.9 mt -124.89 106.56 16.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 120.984 0.421 . . . . 71.430000000000007 110.276 -178.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.56 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 18.7 mt-30 -96.91 117.19 30.57 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.918 0.39 . . . . 64.25 111.092 -176.081 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . 0.603 ' O ' ' HA ' ' B' ' 113' ' ' VAL . 43.2 mt-10 -83.02 114.15 21.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.736 -0.665 . . . . 74.230000000000004 110.947 179.299 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . 0.444 ' HB2' ' O ' ' B' ' 134' ' ' ALA . 41.2 m-85 -92.75 97.33 10.71 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.493 -0.558 . . . . 53.43 109.493 170.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . 0.439 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 21.8 mtm105 -121.08 127.41 51.63 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.803 -0.635 . . . . 74.040000000000006 110.071 179.375 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.745 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 6.0 p -87.97 -37.5 10.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.097 0.475 . . . . 71.540000000000006 110.834 -176.541 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -160.27 62.86 0.33 Allowed 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.292 0.568 . . . . 72.230000000000004 109.69 -178.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.0 -26.57 6.63 Favored Glycine 0 N--CA 1.446 -0.664 0 CA-C-N 115.404 -0.816 . . . . 62.310000000000002 112.734 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -99.12 130.81 45.46 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.014 0.435 . . . . 72.129999999999995 110.56 -175.342 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.783 HD11 HG13 ' B' ' 135' ' ' ILE . 3.2 tm? -78.06 118.62 20.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.263 -0.881 . . . . 72.409999999999997 109.615 178.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . 0.415 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 51.4 p90 -109.3 -22.27 12.14 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 120.748 -0.381 . . . . 72.340000000000003 111.34 178.24 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . 0.444 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -156.14 147.81 22.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.39 . . . . 54.25 111.12 179.517 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.783 HG13 HD11 ' B' ' 132' ' ' LEU . 75.4 mt -125.47 130.68 72.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.152 -0.476 . . . . 55.229999999999997 109.723 175.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.56 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 46.6 tttp -106.46 106.82 17.52 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.383 -0.599 . . . . 64.140000000000001 109.383 174.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.685 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.0 t -91.51 136.05 25.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 N-CA-C 109.024 -0.732 . . . . 70.340000000000003 109.024 178.583 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.594 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 22.0 t -121.85 73.33 34.29 Favored Pre-proline 0 C--N 1.318 -0.762 0 N-CA-C 109.483 -0.562 . . . . 75.109999999999999 109.483 173.298 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.576 ' HD3' HG12 ' B' ' 137' ' ' VAL . 53.2 Cg_endo -78.52 134.64 12.57 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 122.183 1.922 . . . . 72.230000000000004 112.931 176.601 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . 0.615 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 30.8 mtpp -62.94 -30.93 71.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.638 0.732 . . . . 71.430000000000007 109.547 174.222 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 72.8 m-70 -112.99 89.89 3.2 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.043 -0.981 . . . . 75.120000000000005 109.392 176.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 138.7 -21.52 3.04 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.621 -0.8 . . . . 75.299999999999997 112.328 -178.207 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 33.4 mmtp 69.59 150.8 0.13 Allowed Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 123.2 0.6 . . . . 65.319999999999993 111.524 178.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.685 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 19.3 Cg_endo -59.8 140.3 92.6 Favored 'Trans proline' 0 C--O 1.235 0.336 0 C-N-CA 122.575 2.183 . . . . 75.540000000000006 113.278 -177.244 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 38.9 p90 -155.33 151.06 27.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.924 -0.58 . . . . 74.310000000000002 110.307 178.441 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.522 ' HB2' ' HB2' ' B' ' 160' ' ' SER . 87.2 m-85 -95.35 139.32 31.82 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.171 -0.468 . . . . 75.140000000000001 111.166 179.453 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.419 ' HB3' ' CD2' ' B' ' 157' ' ' PHE . 39.5 mt -116.27 110.29 18.55 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.634 -0.712 . . . . 73.319999999999993 109.693 170.316 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 41.7 t -95.23 132.91 37.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.579 -0.282 . . . . 70.450000000000003 110.953 -178.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . 0.415 HH11 ' HG2' ' B' ' 149' ' ' ARG . 17.0 tpp85 -70.46 113.63 7.77 Favored 'General case' 0 N--CA 1.452 -0.338 0 N-CA-C 109.895 -0.409 . . . . 74.040000000000006 109.895 175.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.65 155.44 35.91 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 116.094 -0.503 . . . . 74.239999999999995 111.202 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . 0.516 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 3.4 p-10 -56.9 138.79 53.31 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.551 -0.749 . . . . 72.0 112.132 -177.418 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 93.74 -11.24 71.46 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.213 -0.903 . . . . 62.130000000000003 112.648 176.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 2.3 t 57.58 50.33 11.19 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-O 121.692 0.758 . . . . 62.009999999999998 109.391 -177.618 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -73.51 -8.45 55.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 114.885 -1.052 . . . . 72.450000000000003 111.876 -175.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 90.96 18.32 47.66 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.5 -0.857 . . . . 33.119999999999997 111.175 -174.089 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . 0.694 HD21 HD22 ' B' ' 166' ' ' LEU . 36.5 t30 -119.88 137.47 54.0 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.914 -0.643 . . . . 73.400000000000006 110.058 -178.322 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . 0.419 ' CD2' ' HB3' ' B' ' 147' ' ' LEU . 42.3 m-85 -113.56 159.93 19.07 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.167 -0.469 . . . . 75.439999999999998 110.166 177.666 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . 0.693 HD11 HD23 ' B' ' 166' ' ' LEU . 45.7 mm -121.9 119.07 57.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 109.442 -0.577 . . . . 75.310000000000002 109.442 175.061 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.418 ' HB3' ' H ' ' B' ' 161' ' ' ASP . 36.2 mtt180 -71.14 140.16 50.49 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.213 -0.448 . . . . 44.229999999999997 110.09 176.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . 0.522 ' HB2' ' HB2' ' B' ' 146' ' ' PHE . 7.4 t -80.82 1.06 32.21 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.617 -0.883 . . . . 64.549999999999997 108.617 169.702 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . 0.418 ' H ' ' HB3' ' B' ' 159' ' ' ARG . 0.2 OUTLIER -98.53 -23.12 15.65 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.561 -1.199 . . . . 73.219999999999999 109.884 174.567 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -144.71 67.83 14.24 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 115.099 -0.955 . . . . 72.129999999999995 109.559 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -75.34 -12.97 20.86 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 123.162 2.575 . . . . 73.319999999999993 113.346 -173.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -87.89 -12.5 44.6 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.581 0.705 . . . . 65.519999999999996 109.504 178.418 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 48.8 mtpt -105.46 170.45 7.88 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.406 -0.815 . . . . 71.409999999999997 111.459 -177.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . 0.694 HD22 HD21 ' B' ' 156' ' ' ASN . 17.8 mt -117.48 125.46 50.93 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.423 -0.954 . . . . 71.219999999999999 108.423 177.21 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . 0.542 ' CG2' ' HB3' ' B' ' 171' ' ' GLU . 36.5 mm -80.95 116.37 62.01 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-O 121.275 0.56 . . . . 72.319999999999993 111.835 -169.798 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.53 -179.46 2.82 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.58 2.853 . . . . 74.239999999999995 112.781 -178.227 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . 0.804 ' HA ' HG12 ' B' ' 172' ' ' ILE . 3.7 tt0 -79.23 -32.35 43.87 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.07 -0.514 . . . . 52.409999999999997 111.386 -170.367 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 11.4 p90 -68.21 -17.09 64.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.088 0.471 . . . . 73.140000000000001 110.231 178.09 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.542 ' HB3' ' CG2' ' B' ' 167' ' ' ILE . 1.2 tm-20 -91.12 -43.69 9.73 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.577 -0.738 . . . . 62.130000000000003 110.211 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.804 HG12 ' HA ' ' B' ' 169' ' ' GLN . 44.1 pt -68.61 -25.35 30.62 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.168 -0.469 . . . . 55.439999999999998 111.06 -179.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . 0.42 ' C ' ' H ' ' B' ' 175' ' ' TRP . 30.9 m-85 -111.14 30.45 6.88 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.18 0.514 . . . . 72.340000000000003 110.563 176.617 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 25.1 t -79.03 22.44 0.39 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.866 -0.607 . . . . 73.040000000000006 110.652 178.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . 0.42 ' H ' ' C ' ' B' ' 173' ' ' PHE . 12.9 m95 . . . . . 0 C--O 1.248 1.018 0 CA-C-O 118.271 -0.871 . . . . 73.409999999999997 110.509 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 20.3 m . . . . . 0 N--CA 1.453 -0.319 0 N-CA-C 109.567 -0.531 . . . . 25.510000000000002 109.567 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.456 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 95.42 70.19 1.06 Allowed Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 110.53 -1.028 . . . . 74.5 110.53 -173.129 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . 0.415 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 11.9 pt-20 -98.48 102.65 15.12 Favored Pre-proline 0 C--N 1.325 -0.482 0 N-CA-C 109.348 -0.612 . . . . 64.420000000000002 109.348 -177.321 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.554 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 53.4 Cg_endo -91.14 97.24 0.23 Allowed 'Trans proline' 0 N--CA 1.441 -1.571 0 C-N-CA 122.572 2.181 . . . . 64.0 112.135 -175.008 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -103.05 114.18 28.27 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-N 115.365 -0.834 . . . . 74.109999999999999 109.859 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.634 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 9.1 p -77.1 127.12 38.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 CA-C-N 115.681 -0.69 . . . . 72.530000000000001 109.97 179.478 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.643 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 24.5 m -84.22 103.1 13.14 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.848 -0.614 . . . . 71.239999999999995 110.078 -178.063 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 65.5 mt -90.84 107.95 19.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.06 -0.518 . . . . 71.530000000000001 110.571 -176.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.507 ' HG2' ' O ' ' A' ' 23' ' ' ILE . 12.7 ptm180 -121.96 174.4 6.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.871 -0.604 . . . . 75.299999999999997 109.786 179.066 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -133.08 104.38 6.49 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 116.223 -0.444 . . . . 72.540000000000006 110.089 -177.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 58.5 mm-40 -103.49 80.1 1.77 Allowed 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 120.969 0.414 . . . . 75.099999999999994 110.205 -178.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 78.35 -106.16 2.27 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.797 -0.716 . . . . 54.420000000000002 112.428 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.859 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 6.9 m-20 -108.63 34.88 3.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.792 0.329 . . . . 73.109999999999999 110.831 -178.249 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.844 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 20.5 pttm -154.2 124.04 6.73 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.157 0.503 . . . . 75.129999999999995 111.46 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.446 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 62.3 m -82.02 105.89 13.49 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.624 -0.716 . . . . 74.340000000000003 109.36 174.036 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.599 HG12 HG13 ' A' ' 37' ' ' VAL . 61.1 mt -97.59 113.68 32.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.046 0.45 . . . . 54.420000000000002 110.687 -176.484 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.687 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 17.9 mt-30 -100.58 109.19 21.26 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.738 -0.664 . . . . 71.230000000000004 110.329 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.643 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.1 mt-10 -91.69 104.25 16.74 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.064 -0.517 . . . . 74.329999999999998 110.853 -178.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.539 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 54.0 m-85 -73.26 106.73 5.22 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.174 -0.467 . . . . 74.230000000000004 110.753 179.463 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.454 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 59.9 mtt180 -129.24 133.7 47.64 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.552 -0.536 . . . . 74.230000000000004 109.552 177.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 6.4 p -104.34 -41.47 6.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 121.272 0.558 . . . . 55.439999999999998 110.721 -179.105 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 54.5 m-20 -140.94 56.83 1.56 Allowed 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.708 -0.678 . . . . 71.430000000000007 109.626 178.463 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.21 -32.67 4.04 Favored Glycine 0 N--CA 1.451 -0.322 0 CA-C-N 115.385 -0.825 . . . . 72.430000000000007 113.242 177.614 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -90.32 132.2 35.69 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.001 0.429 . . . . 74.409999999999997 110.654 -174.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.555 HD13 ' HB3' ' A' ' 25' ' ' GLU . 33.2 tp -77.92 114.3 16.64 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.395 -0.82 . . . . 63.43 110.599 179.306 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . 0.527 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 35.4 p90 -106.34 -6.64 18.18 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.774 -0.37 . . . . 62.32 111.809 -178.376 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -171.84 142.91 1.57 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.842 0.353 . . . . 74.439999999999998 111.256 -178.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.459 HD12 HD23 ' A' ' 47' ' ' LEU . 61.9 mt -117.77 127.4 75.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.249 -0.432 . . . . 71.019999999999996 110.179 176.089 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.687 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.8 tttt -111.65 103.48 11.79 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 109.446 -0.576 . . . . 72.420000000000002 109.446 175.036 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.731 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 3.7 t -96.77 134.52 34.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 N-CA-C 109.309 -0.626 . . . . 53.310000000000002 109.309 -178.551 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.649 HG22 ' HB3' ' A' ' 44' ' ' PRO . 21.7 t -114.22 74.21 2.8 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 109.317 -0.623 . . . . 75.299999999999997 109.317 170.759 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.465 ' HD3' HG12 ' A' ' 37' ' ' VAL . 42.4 Cg_endo -74.0 142.81 31.79 Favored 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 122.039 1.826 . . . . 73.120000000000005 112.764 179.118 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.859 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 61.0 mtpt -64.39 -17.13 63.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.134 -0.939 . . . . 54.119999999999997 110.913 176.72 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -128.99 88.3 2.69 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.662 -0.699 . . . . 74.540000000000006 110.215 -178.643 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.403 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 135.23 -16.06 4.18 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.288 -0.958 . . . . 74.430000000000007 113.203 179.202 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.541 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 99.5 mttt 71.79 160.03 0.16 Allowed Pre-proline 0 N--CA 1.472 0.626 0 C-N-CA 122.755 0.422 . . . . 74.319999999999993 111.469 179.507 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.731 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 26.2 Cg_endo -63.57 141.62 80.82 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 122.491 2.127 . . . . 64.340000000000003 113.716 -176.48 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -145.71 155.23 42.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.717 -0.674 . . . . 75.129999999999995 110.212 177.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -99.72 132.91 44.76 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.305 -0.407 . . . . 74.120000000000005 110.994 178.144 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.459 HD23 HD12 ' A' ' 35' ' ' ILE . 40.1 tp -121.07 98.81 6.16 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.686 -0.688 . . . . 64.319999999999993 109.345 176.171 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 25.0 t -87.98 146.99 5.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.396 -0.366 . . . . 62.25 111.358 -172.205 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 10.0 tpt180 -81.23 122.92 28.01 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.848 -0.427 . . . . 73.319999999999993 109.848 177.659 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.426 ' HB3' ' OD1' ' A' ' 56' ' ' ASN . . . -74.86 161.94 29.1 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.208 -0.451 . . . . 73.230000000000004 110.862 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -66.78 145.54 55.4 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.135 0.493 . . . . 72.439999999999998 110.957 -177.6 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 88.67 -25.17 9.94 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.863 -0.608 . . . . 64.540000000000006 112.487 177.6 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 57.2 p 47.75 43.9 17.29 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.459 0.704 . . . . 74.420000000000002 112.058 -179.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -68.0 -33.0 73.79 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.453 0.644 . . . . 72.230000000000004 110.919 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 147.99 41.58 0.04 OUTLIER Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.582 -1.007 . . . . 61.409999999999997 110.582 -178.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . 0.426 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 11.5 p30 -140.52 152.65 45.73 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.18 0.514 . . . . 75.049999999999997 111.078 -172.805 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 36.3 m-85 -134.23 157.5 46.11 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.511 -0.768 . . . . 74.010000000000005 109.566 175.444 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.809 HD11 HD23 ' A' ' 66' ' ' LEU . 45.2 mm -115.23 108.07 24.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.253 0.549 . . . . 62.25 109.668 176.324 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.592 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 50.2 ttp180 -89.31 133.37 34.51 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.811 -0.631 . . . . 62.439999999999998 109.952 -177.057 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.1 p -58.21 -25.57 61.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.15 0.5 . . . . 74.219999999999999 111.168 178.644 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.592 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 0.6 OUTLIER -59.55 -39.13 83.0 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.508 -0.769 . . . . 75.230000000000004 111.379 174.275 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 21.5 tp60 -147.91 79.68 9.16 Favored Pre-proline 0 C--N 1.326 -0.454 0 N-CA-C 109.827 -0.434 . . . . 33.549999999999997 109.827 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -73.8 -8.0 20.81 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.381 2.054 . . . . 75.230000000000004 111.52 179.553 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.05 3.06 36.24 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.118 -0.946 . . . . 62.43 110.084 178.382 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -139.37 140.06 37.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.043 -0.526 . . . . 72.310000000000002 111.022 -174.291 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.809 HD23 HD11 ' A' ' 58' ' ' ILE . 38.1 mt -82.08 113.1 19.72 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 108.581 -0.896 . . . . 75.030000000000001 108.581 171.807 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.508 HG13 ' HB2' ' A' ' 59' ' ' ARG . 50.1 mm -65.34 122.76 81.78 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 116.271 -0.422 . . . . 73.109999999999999 110.964 -175.566 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.496 ' O ' HG23 ' A' ' 72' ' ' ILE . 72.8 Cg_endo -73.27 175.12 11.0 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 123.106 2.537 . . . . 72.099999999999994 113.014 -177.695 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . 0.726 ' HA ' HG12 ' A' ' 72' ' ' ILE . 6.7 tt0 -74.65 -29.5 61.28 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.693 -0.685 . . . . 53.020000000000003 112.323 -168.07 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 33.6 p90 -74.45 -16.23 60.87 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.598 -0.441 . . . . 74.510000000000005 110.23 178.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.476 ' HA ' ' HB2' ' A' ' 74' ' ' SER . 8.3 mm-40 -100.0 -29.29 12.63 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.727 -0.67 . . . . 72.400000000000006 111.615 -178.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.726 HG12 ' HA ' ' A' ' 69' ' ' GLN . 42.0 pt -68.22 -29.44 44.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.148 0.499 . . . . 73.140000000000001 110.595 177.188 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 48.5 m-85 -118.82 38.69 3.71 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.735 -0.666 . . . . 70.200000000000003 109.267 174.27 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.476 ' HB2' ' HA ' ' A' ' 71' ' ' GLU . 6.1 t -62.49 -36.38 82.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.35 -0.841 . . . . 74.239999999999995 110.461 -178.758 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . 0.844 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 6.1 p-90 . . . . . 0 C--N 1.326 -0.443 0 CA-C-N 115.93 -0.577 . . . . 65.319999999999993 110.948 177.289 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 35.0 m . . . . . 0 N--CA 1.454 -0.251 0 CA-C-O 121.605 0.717 . . . . 74.439999999999998 109.128 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . 0.403 ' O ' ' HD3' ' B' ' 111' ' ' PRO . . . 140.07 78.08 0.06 OUTLIER Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 109.965 -1.254 . . . . 42.130000000000003 109.965 -172.108 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -109.72 94.77 17.71 Favored Pre-proline 0 C--N 1.322 -0.6 0 N-CA-C 109.693 -0.484 . . . . 64.319999999999993 109.693 -172.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.57 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 54.9 Cg_endo -77.36 79.01 3.29 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 C-N-CA 121.538 1.492 . . . . 72.230000000000004 111.031 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -100.24 156.37 17.26 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 114.747 -1.115 . . . . 74.400000000000006 109.184 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.716 HG21 ' HB3' ' B' ' 124' ' ' GLN . 8.8 p -112.94 127.76 70.02 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.812 0 CA-C-O 121.72 0.771 . . . . 74.109999999999999 111.738 -175.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . 0.54 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.3 m -92.01 106.94 18.85 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.022 -0.99 . . . . 75.129999999999995 109.529 175.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.8 mt -90.8 115.5 30.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 120.699 0.285 . . . . 54.340000000000003 111.274 -175.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 41.4 mtm180 -115.39 165.81 12.56 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.178 -0.465 . . . . 72.140000000000001 110.712 175.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 96.8 mt-30 -129.44 108.79 10.55 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.197 -0.456 . . . . 74.299999999999997 110.18 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . 0.463 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 45.8 mm-40 -108.4 89.88 3.13 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.551 -0.536 . . . . 55.409999999999997 109.551 -178.441 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 83.68 -102.95 2.5 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 110.929 -0.869 . . . . 72.129999999999995 110.929 -172.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . 0.58 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 30.8 m-20 -117.73 -18.17 9.69 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.756 0.312 . . . . 74.230000000000004 110.784 175.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.463 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 23.4 pttm -78.36 126.73 31.19 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.257 0.551 . . . . 71.109999999999999 110.861 -175.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . 0.585 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 22.8 m -84.72 106.34 16.19 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.502 -0.772 . . . . 72.430000000000007 109.468 178.085 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . 0.449 HG12 HG13 ' B' ' 137' ' ' VAL . 28.4 mt -101.42 110.37 28.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 121.374 0.607 . . . . 74.319999999999993 110.631 -174.685 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.716 ' HB3' HG21 ' B' ' 113' ' ' VAL . 19.9 mt-30 -102.29 111.54 23.87 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.354 -0.839 . . . . 73.150000000000006 111.144 -175.511 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . 0.541 ' HB3' HD13 ' B' ' 132' ' ' LEU . 43.0 mt-10 -89.79 107.84 19.34 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.13 -0.486 . . . . 61.340000000000003 110.948 179.764 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . 0.457 ' HE1' ' HB2' ' B' ' 136' ' ' LYS . 58.3 m-85 -84.44 110.9 19.0 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.767 0.318 . . . . 74.299999999999997 110.338 177.553 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 69.6 mtt180 -123.42 116.13 22.73 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.844 0.354 . . . . 72.420000000000002 110.31 -178.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.57 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.4 p -82.83 -45.71 19.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.065 -0.516 . . . . 61.530000000000001 111.904 -177.434 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -158.99 74.08 0.63 Allowed 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 120.742 -0.383 . . . . 74.239999999999995 110.319 -174.243 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 64.2 23.81 68.36 Favored Glycine 0 C--N 1.33 0.232 0 C-N-CA 121.028 -0.606 . . . . 41.240000000000002 112.065 -178.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -145.91 124.93 12.78 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.876 -0.416 . . . . 70.040000000000006 109.876 -179.236 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.541 HD13 ' HB3' ' B' ' 125' ' ' GLU . 50.0 tp -83.06 113.01 20.31 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.791 -0.64 . . . . 72.099999999999994 109.569 175.781 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -103.12 -13.73 16.69 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.32 -0.552 . . . . 62.0 111.728 -175.793 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -164.94 139.81 5.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.087 0.47 . . . . 74.5 111.397 -175.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.405 ' CG1' HD21 ' B' ' 132' ' ' LEU . 63.6 mt -118.02 117.85 56.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.693 -0.685 . . . . 63.539999999999999 109.846 175.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.618 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 81.3 tttt -93.62 103.92 16.06 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.184 -0.673 . . . . 63.329999999999998 109.184 175.481 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.65 HG12 ' HD3' ' B' ' 139' ' ' PRO . 3.5 t -89.12 126.51 42.12 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 N-CA-C 108.785 -0.82 . . . . 62.43 108.785 177.299 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.585 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.5 t -113.67 74.47 2.38 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 109.543 -0.54 . . . . 61.420000000000002 109.543 171.647 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.65 ' HD3' HG12 ' B' ' 137' ' ' VAL . 43.3 Cg_endo -77.17 130.01 10.85 Favored 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.105 1.87 . . . . 75.0 111.892 175.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . 0.58 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 59.2 mtpt -58.36 -38.58 77.53 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.661 -0.699 . . . . 62.140000000000001 109.776 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 70.3 m-70 -111.81 90.32 3.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.282 -0.872 . . . . 71.019999999999996 109.385 175.163 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . 0.418 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 151.98 -22.71 0.89 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.54 -0.838 . . . . 53.109999999999999 112.704 -178.587 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . 0.418 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 95.2 mttt 76.48 144.65 0.1 Allowed Pre-proline 0 N--CA 1.472 0.638 0 C-N-CA 123.419 0.688 . . . . 75.340000000000003 111.258 179.177 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.613 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 55.5 Cg_endo -70.57 139.05 36.56 Favored 'Trans proline' 0 N--CA 1.463 -0.285 0 C-N-CA 122.865 2.376 . . . . 74.430000000000007 112.983 -177.059 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 45.4 p90 -152.39 160.03 43.34 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.895 -0.593 . . . . 75.319999999999993 110.322 179.114 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.666 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 96.5 m-85 -100.59 133.29 45.26 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.192 -0.458 . . . . 71.140000000000001 109.959 177.786 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.502 ' HG ' ' HB3' ' B' ' 157' ' ' PHE . 14.1 tp -115.46 100.84 8.37 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.386 -0.598 . . . . 72.200000000000003 109.386 175.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 49.1 t -92.55 140.56 16.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 116.061 -0.518 . . . . 72.519999999999996 111.347 -173.185 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -80.37 116.37 20.4 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.549 -0.296 . . . . 63.530000000000001 110.261 177.376 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.56 157.55 32.04 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-N 116.218 -0.447 . . . . 71.319999999999993 111.201 -179.423 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . 0.539 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 3.8 p-10 -57.45 143.48 40.28 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.96 -0.564 . . . . 74.329999999999998 110.855 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.43 -33.73 4.03 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.773 -0.727 . . . . 75.109999999999999 111.373 -175.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 50.8 m 57.3 33.17 22.91 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 123.008 0.523 . . . . 54.119999999999997 111.919 177.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -53.81 -68.77 0.15 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 115.712 -0.676 . . . . 72.409999999999997 111.145 -178.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . -173.43 30.58 0.1 OUTLIER Glycine 0 CA--C 1.505 -0.579 0 C-N-CA 120.338 -0.934 . . . . 73.030000000000001 112.456 178.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 79.5 m-20 -133.32 145.83 50.78 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.784 0.326 . . . . 52.340000000000003 110.799 -177.166 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . 0.502 ' HB3' ' HG ' ' B' ' 147' ' ' LEU . 32.6 m-85 -118.34 157.03 27.87 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.875 -0.602 . . . . 73.329999999999998 110.034 176.201 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.1 mm -113.91 122.66 68.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 109.676 -0.49 . . . . 74.430000000000007 109.676 178.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . . . . . . . . . 44.8 ttp180 -86.36 135.92 33.33 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.028 -0.36 . . . . 73.239999999999995 110.028 -178.386 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . 0.666 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 23.5 p -56.97 -34.78 68.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.064 0.459 . . . . 65.219999999999999 111.118 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -69.39 -37.93 77.75 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.448 -0.796 . . . . 70.310000000000002 111.346 177.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 8.6 tp60 -134.03 83.6 45.35 Favored Pre-proline 0 C--N 1.324 -0.527 0 C-N-CA 121.04 -0.264 . . . . 74.510000000000005 110.715 -176.297 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -77.59 0.27 9.96 Favored 'Trans proline' 0 C--O 1.234 0.282 0 C-N-CA 122.577 2.184 . . . . 60.130000000000003 111.616 177.15 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -79.19 -33.31 43.99 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.178 -0.919 . . . . 43.130000000000003 110.768 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -116.64 138.13 51.67 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.857 -0.61 . . . . 70.340000000000003 111.173 -172.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.5 mp -85.27 121.31 27.83 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 108.795 -0.817 . . . . 75.010000000000005 108.795 175.083 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 50.3 mm -71.24 117.7 59.16 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 116.129 -0.487 . . . . 74.420000000000002 109.778 -177.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.521 ' O ' HG23 ' B' ' 172' ' ' ILE . 59.6 Cg_endo -70.39 173.61 11.28 Favored 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 122.843 2.362 . . . . 73.519999999999996 113.008 -175.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . 0.449 ' HA ' HG12 ' B' ' 172' ' ' ILE . 5.4 tt0 -74.95 -17.66 60.51 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.524 -0.762 . . . . 65.349999999999994 112.224 -168.156 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 42.4 p90 -90.24 -10.1 45.55 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.122 0.487 . . . . 74.310000000000002 110.013 176.374 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.579 ' O ' ' HB2' ' B' ' 174' ' ' SER . 19.6 mm-40 -109.42 -12.63 14.7 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.736 -0.665 . . . . 70.439999999999998 111.708 -178.282 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.521 HG23 ' O ' ' B' ' 168' ' ' PRO . 26.1 pt -72.7 -12.35 15.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.254 0.549 . . . . 71.420000000000002 110.435 176.177 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -115.9 32.76 5.89 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.442 -0.799 . . . . 62.140000000000001 109.148 175.094 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . 0.579 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 3.0 t -66.97 -25.22 66.22 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 114.915 -1.039 . . . . 72.510000000000005 110.575 -177.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 7.1 p-90 . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.295 -0.86 . . . . 75.230000000000004 110.788 -179.936 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.7 p . . . . . 0 N--CA 1.454 -0.265 0 CA-C-O 121.269 0.557 . . . . 72.430000000000007 110.513 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 136.63 106.28 0.8 Allowed Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 111.12 -0.792 . . . . 53.329999999999998 111.12 -174.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -124.3 97.29 40.29 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-O 121.357 0.599 . . . . 44.219999999999999 110.113 -175.301 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.599 ' HA ' ' O ' ' A' ' 27' ' ' ARG . 9.9 Cg_endo -85.17 93.97 0.66 Allowed 'Trans proline' 0 N--CA 1.444 -1.421 0 C-N-CA 122.867 2.378 . . . . 71.239999999999995 111.817 -178.102 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -116.72 153.96 31.45 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.952 -1.022 . . . . 61.140000000000001 109.373 -179.276 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.503 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 13.4 p -119.42 130.35 74.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.497 0.665 . . . . 74.420000000000002 111.639 -177.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.528 ' O ' ' HA ' ' A' ' 24' ' ' GLN . 9.3 m -90.68 111.85 23.36 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.369 -0.832 . . . . 71.310000000000002 109.693 176.372 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.429 HG12 ' HG2' ' A' ' 24' ' ' GLN . 60.9 mt -106.74 107.33 22.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.791 0.329 . . . . 63.539999999999999 110.865 -176.23 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -125.51 166.02 17.41 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.178 -0.465 . . . . 74.209999999999994 110.594 178.252 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -118.52 108.63 15.22 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.768 0.318 . . . . 72.530000000000001 110.761 -179.322 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.453 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 25.7 mm-40 -108.42 99.54 8.92 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.162 -0.472 . . . . 72.439999999999998 109.97 178.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 71.09 -114.27 5.15 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.786 -0.721 . . . . 42.399999999999999 112.298 -179.611 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.409 ' HB3' ' HD2' ' A' ' 40' ' ' LYS . 13.6 m-20 -106.43 13.33 28.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.771 0.32 . . . . 61.32 110.476 -178.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.453 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 14.2 ptmt -133.29 123.18 25.03 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.464 0.649 . . . . 74.209999999999994 111.949 -176.049 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' THR . . . . . 0.441 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 25.6 m -83.07 115.31 21.81 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.36 -0.836 . . . . 75.25 109.675 176.517 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 68.3 mt -100.77 120.43 50.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 120.716 0.293 . . . . 53.130000000000003 110.65 -175.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLN . . . . . 0.528 ' HA ' ' O ' ' A' ' 14' ' ' THR . 16.7 mt-30 -112.05 111.77 22.92 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.102 -0.499 . . . . 54.530000000000001 110.723 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -90.08 109.59 20.63 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.222 -0.444 . . . . 75.239999999999995 110.312 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 73.4 m-85 -87.68 110.55 20.5 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.763 0.315 . . . . 74.409999999999997 110.374 177.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ARG . . . . . 0.599 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 65.5 mtt180 -116.91 139.91 50.08 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.508 -0.553 . . . . 71.349999999999994 109.508 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.581 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 14.2 p -112.83 -11.96 11.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.509 0.671 . . . . 54.130000000000003 111.002 -177.641 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -166.77 38.4 0.04 OUTLIER 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 108.757 -0.831 . . . . 75.420000000000002 108.757 -177.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 85.17 -28.73 4.53 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.308 -0.86 . . . . 72.219999999999999 111.824 -174.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.418 ' CD2' HG21 ' B' ' 128' ' ' VAL . 15.4 t80 -88.24 125.85 34.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.106 0.479 . . . . 71.420000000000002 110.29 -177.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.662 HD11 HG13 ' A' ' 35' ' ' ILE . 3.3 tm? -68.24 134.27 50.15 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.201 -0.909 . . . . 74.209999999999994 110.141 178.74 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' TYR . . . . . 0.504 ' CE1' ' HB ' ' A' ' 28' ' ' VAL . 53.3 p90 -128.55 -24.56 3.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.594 -0.276 . . . . 70.219999999999999 111.584 176.275 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -149.54 139.82 22.26 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.815 0.34 . . . . 33.32 110.895 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.662 HG13 HD11 ' A' ' 32' ' ' LEU . 78.4 mt -122.72 122.35 65.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 116.17 -0.468 . . . . 70.439999999999998 110.239 178.07 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.512 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.4 tttt -101.18 102.05 12.89 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.406 -0.591 . . . . 70.140000000000001 109.406 174.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.572 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.7 p -99.39 124.44 52.71 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.98 0 CA-C-O 121.163 0.506 . . . . 64.349999999999994 110.005 176.485 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.633 HG22 ' HB3' ' A' ' 44' ' ' PRO . 40.0 t -106.91 85.01 1.72 Allowed Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 115.096 -0.956 . . . . 71.120000000000005 109.873 179.199 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.572 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 85.4 Cg_endo -91.08 144.01 3.33 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 122.762 2.308 . . . . 64.340000000000003 112.41 179.206 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . 0.409 ' HD2' ' HB3' ' A' ' 20' ' ' ASP . 97.0 mttt -60.46 -27.02 67.21 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.186 0.517 . . . . 71.510000000000005 110.128 173.784 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 6.5 m-70 -118.99 85.4 2.36 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.568 -0.742 . . . . 74.430000000000007 109.947 -174.203 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 139.15 -18.76 3.1 Favored Glycine 0 N--CA 1.449 -0.444 0 CA-C-N 115.876 -0.602 . . . . 71.010000000000005 111.982 -176.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 42.5 mtpt 69.4 150.86 0.13 Allowed Pre-proline 0 N--CA 1.469 0.48 0 C-N-CA 123.727 0.811 . . . . 61.32 112.235 -179.035 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.633 ' HB3' HG22 ' A' ' 38' ' ' VAL . 16.0 Cg_endo -59.7 123.64 13.71 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.878 2.385 . . . . 74.150000000000006 112.474 -179.647 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' TYR . . . . . 0.523 ' CE1' HG13 ' A' ' 37' ' ' VAL . 16.4 p90 -142.28 151.18 41.77 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.865 -0.607 . . . . 74.140000000000001 110.258 179.551 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -90.74 125.0 35.55 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.17 -0.468 . . . . 72.299999999999997 109.981 176.085 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.406 HD11 HG13 ' A' ' 67' ' ' ILE . 18.9 tp -103.34 100.91 10.81 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 108.42 -0.956 . . . . 73.400000000000006 108.42 174.502 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.3 t -90.75 132.27 35.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.979 -0.555 . . . . 70.120000000000005 111.029 -173.675 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -86.04 121.16 28.26 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.069 -0.715 . . . . 73.519999999999996 109.069 178.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.11 174.78 9.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.924 0.392 . . . . 44.020000000000003 111.574 -173.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.585 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 7.0 p-10 -68.94 135.66 51.34 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.301 -0.409 . . . . 75.109999999999999 110.405 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.439 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 94.54 146.05 19.66 Favored Glycine 0 N--CA 1.433 -1.562 0 C-N-CA 120.422 -0.895 . . . . 45.399999999999999 112.042 179.067 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 27.8 t -80.57 28.55 0.33 Allowed 'General case' 0 C--N 1.312 -1.05 0 CA-C-O 121.436 0.636 . . . . 71.230000000000004 109.866 175.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.439 ' H ' ' C ' ' A' ' 52' ' ' GLY . 30.0 t70 -63.89 -32.43 73.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.159 -0.928 . . . . 64.150000000000006 111.26 -177.629 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.86 37.49 4.42 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.41 -0.9 . . . . 63.32 113.138 177.426 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -126.06 139.53 53.33 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.05 0.452 . . . . 74.109999999999999 110.052 176.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -117.47 155.16 30.18 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.711 -0.677 . . . . 62.240000000000002 109.864 179.207 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 44.9 mm -113.86 116.59 53.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.137 -0.483 . . . . 64.120000000000005 109.7 177.341 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . 0.519 ' HB2' HD11 ' A' ' 67' ' ' ILE . 55.5 ttt180 -83.82 124.06 30.54 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.121 -0.49 . . . . 75.239999999999995 109.846 -178.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 30.9 t -63.71 -8.3 9.97 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.342 -0.39 . . . . 61.130000000000003 111.615 -177.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . 0.487 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 15.6 t70 -70.03 -36.0 74.72 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.231 0.538 . . . . 71.530000000000001 109.701 175.578 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -159.08 88.87 2.1 Favored Pre-proline 0 N--CA 1.451 -0.383 0 CA-C-N 115.515 -0.766 . . . . 54.299999999999997 109.589 -177.492 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . 0.453 ' HG3' ' OG ' ' B' ' 160' ' ' SER . 35.7 Cg_exo -58.98 -16.42 32.36 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 123.335 2.69 . . . . 64.420000000000002 112.699 178.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -66.62 -22.43 66.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.899 -0.591 . . . . 70.349999999999994 111.255 179.454 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.16 141.12 48.56 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 121.404 0.621 . . . . 53.399999999999999 111.892 -177.077 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.7 mp -88.54 141.43 28.53 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.689 -1.142 . . . . 71.329999999999998 109.306 174.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ILE . . . . . 0.755 HG23 ' HB3' ' A' ' 71' ' ' GLU . 25.2 mm -83.41 121.87 76.84 Favored Pre-proline 0 C--N 1.317 -0.818 0 CA-C-N 116.167 -0.47 . . . . 74.439999999999998 111.709 -176.77 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.51 ' O ' HG23 ' A' ' 72' ' ' ILE . 68.2 Cg_endo -74.05 179.45 5.74 Favored 'Trans proline' 0 C--O 1.233 0.264 0 C-N-CA 123.211 2.607 . . . . 75.099999999999994 112.488 178.631 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' GLN . . . . . 0.719 ' HA ' HG12 ' A' ' 72' ' ' ILE . 4.2 tt0 -71.99 -33.11 67.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.171 -0.468 . . . . 75.409999999999997 111.701 -168.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 7.2 p90 -69.23 -16.97 63.72 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.411 -0.516 . . . . 75.230000000000004 110.799 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.755 ' HB3' HG23 ' A' ' 67' ' ' ILE . 2.6 mm-40 -103.44 -20.22 14.13 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.329 -0.396 . . . . 63.219999999999999 111.233 -178.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.719 HG12 ' HA ' ' A' ' 69' ' ' GLN . 42.6 pt -75.61 -24.17 16.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 121.162 0.506 . . . . 72.099999999999994 109.922 174.752 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -103.69 39.21 1.65 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.467 -0.788 . . . . 53.240000000000002 109.371 173.353 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.506 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 11.5 t -71.17 -20.03 62.34 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.293 -0.867 . . . . 64.120000000000005 110.94 -177.141 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' TRP . . . . . 0.575 ' HZ2' HD13 ' A' ' 35' ' ' ILE . 69.6 p-90 . . . . . 0 C--O 1.235 0.312 0 CA-C-O 120.861 0.362 . . . . 73.450000000000003 110.835 177.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 8.6 p . . . . . 0 N--CA 1.452 -0.332 0 CA-C-O 121.26 0.552 . . . . 74.430000000000007 110.594 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 92.25 116.29 2.25 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 111.063 -0.815 . . . . 61.210000000000001 111.063 -174.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -119.87 93.33 47.62 Favored Pre-proline 0 C--N 1.319 -0.739 0 CA-C-O 121.14 0.495 . . . . 71.409999999999997 110.58 -175.137 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 111' ' ' PRO . . . . . 0.684 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 55.7 Cg_endo -77.44 68.45 7.52 Favored 'Trans proline' 0 N--CA 1.449 -1.115 0 C-N-CA 121.943 1.762 . . . . 74.319999999999993 110.891 176.086 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -91.05 157.46 17.24 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 114.411 -1.268 . . . . 53.240000000000002 109.553 -178.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 113' ' ' VAL . . . . . 0.679 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 12.4 p -122.78 127.25 74.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-O 121.477 0.656 . . . . 73.25 111.19 -178.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 114' ' ' THR . . . . . 0.442 ' O ' ' HA ' ' B' ' 124' ' ' GLN . 13.7 m -84.61 111.26 19.38 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.435 -0.802 . . . . 72.340000000000003 109.439 178.749 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.6 mt -99.09 116.45 42.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 120.955 0.407 . . . . 75.140000000000001 111.527 -172.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 45.7 mtt180 -126.87 170.64 12.01 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.947 -0.57 . . . . 74.209999999999994 110.606 175.501 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 69.7 mt-30 -132.54 98.23 4.3 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.18 0.514 . . . . 61.020000000000003 110.204 176.536 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 118' ' ' GLU . . . . . 0.591 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 20.9 mm-40 -96.66 100.8 12.34 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.657 -0.701 . . . . 53.140000000000001 109.317 -178.433 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 73.37 -117.89 6.03 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.434 -0.889 . . . . 74.420000000000002 111.36 -175.44 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 120' ' ' ASP . . . . . 0.507 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 5.2 m-20 -104.26 11.58 34.7 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.94 0.37 . . . . 71.040000000000006 110.493 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 121' ' ' LYS . . . . . 0.591 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 10.1 ptmt -124.96 121.59 34.89 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.567 0.699 . . . . 62.240000000000002 111.73 -175.456 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 122' ' ' THR . . . . . 0.842 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 35.9 m -76.96 104.15 7.29 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.243 -0.89 . . . . 63.100000000000001 109.798 175.387 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 46.6 mt -94.01 119.89 42.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.218 0.532 . . . . 72.129999999999995 110.301 -179.311 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 124' ' ' GLN . . . . . 0.679 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 25.4 mt-30 -115.23 113.06 23.4 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.322 -0.854 . . . . 63.399999999999999 110.914 -177.043 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -88.16 111.98 22.21 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.173 -0.467 . . . . 72.129999999999995 110.678 -179.505 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 126' ' ' TYR . . . . . 0.585 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 29.1 m-85 -88.65 112.73 23.44 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.938 0.399 . . . . 73.430000000000007 111.07 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 127' ' ' ARG . . . . . 0.519 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 89.6 mtm180 -132.22 128.67 38.42 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.071 -0.513 . . . . 73.040000000000006 110.109 -179.218 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 128' ' ' VAL . . . . . 0.684 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 9.7 p -99.86 -27.84 3.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.071 0.462 . . . . 61.509999999999998 111.862 -174.367 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -152.74 47.61 0.72 Allowed 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.574 -0.528 . . . . 71.430000000000007 109.574 -179.032 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.19 -21.33 12.69 Favored Glycine 0 CA--C 1.518 0.235 0 CA-C-N 115.567 -0.742 . . . . 63.520000000000003 112.731 -178.447 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 131' ' ' PHE . . . . . 0.46 ' HD2' HG21 ' A' ' 28' ' ' VAL . 26.5 t80 -98.22 130.12 44.95 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.712 0.291 . . . . 72.409999999999997 110.374 -176.584 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 132' ' ' LEU . . . . . 0.519 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 3.1 tm? -71.0 132.55 45.32 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.812 -0.631 . . . . 74.5 109.967 179.214 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 133' ' ' TYR . . . . . 0.407 ' N ' HD13 ' B' ' 132' ' ' LEU . 46.1 p90 -129.32 -15.55 4.1 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.582 -0.447 . . . . 75.409999999999997 112.04 177.715 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.31 149.97 17.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.719 0.295 . . . . 60.299999999999997 111.079 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 135' ' ' ILE . . . . . 0.415 HG13 HD11 ' B' ' 132' ' ' LEU . 67.5 mt -130.69 125.42 58.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.963 -0.384 . . . . 62.200000000000003 109.963 176.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 136' ' ' LYS . . . . . 0.627 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 85.5 tttt -104.11 114.55 28.87 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.107 -0.331 . . . . 72.420000000000002 110.107 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 137' ' ' VAL . . . . . 0.589 HG12 ' HD3' ' B' ' 139' ' ' PRO . 3.4 t -96.49 130.94 44.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.126 -0.694 . . . . 55.100000000000001 109.126 175.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 138' ' ' VAL . . . . . 0.842 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 24.1 t -115.65 74.65 4.77 Favored Pre-proline 0 C--N 1.318 -0.798 0 N-CA-C 109.875 -0.417 . . . . 62.530000000000001 109.875 171.723 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 139' ' ' PRO . . . . . 0.589 ' HD3' HG12 ' B' ' 137' ' ' VAL . 37.1 Cg_endo -74.22 131.89 15.84 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.186 1.924 . . . . 54.009999999999998 112.276 176.445 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 140' ' ' LYS . . . . . 0.507 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 59.2 mtpt -60.63 -19.49 58.18 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.399 -0.818 . . . . 72.549999999999997 111.111 178.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 80.8 m-70 -130.72 105.4 7.78 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.703 -0.68 . . . . 63.140000000000001 109.379 178.492 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 142' ' ' GLY . . . . . 0.425 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 125.36 -11.02 7.65 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.75 -0.738 . . . . 61.140000000000001 112.432 -177.142 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 143' ' ' LYS . . . . . 0.463 ' HB3' ' HE2' ' B' ' 143' ' ' LYS . 45.7 mtpt 72.77 150.84 0.14 Allowed Pre-proline 0 N--CA 1.468 0.433 0 C-N-CA 123.603 0.761 . . . . 74.319999999999993 112.353 179.105 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 144' ' ' PRO . . . . . 0.58 ' HB3' HG13 ' B' ' 138' ' ' VAL . 44.3 Cg_endo -68.76 137.75 39.34 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.795 2.33 . . . . 60.310000000000002 112.552 178.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -143.75 147.99 34.99 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 120.954 0.407 . . . . 73.299999999999997 110.638 179.114 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 146' ' ' PHE . . . . . 0.408 ' HB2' ' HB2' ' B' ' 160' ' ' SER . 69.6 m-85 -90.47 129.27 36.66 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.88 -0.6 . . . . 74.439999999999998 110.032 175.506 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 147' ' ' LEU . . . . . 0.451 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 25.5 tp -108.59 93.27 4.43 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.621 -0.881 . . . . 74.409999999999997 108.621 173.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 40.3 t -83.53 135.91 23.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.602 -0.727 . . . . 74.230000000000004 110.499 -174.395 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 3.0 tmm_? -89.25 120.83 30.96 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 108.573 -0.899 . . . . 72.310000000000002 108.573 178.616 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -76.16 -173.94 2.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.978 0.418 . . . . 62.340000000000003 111.655 -173.123 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -75.33 146.26 41.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.369 -0.378 . . . . 71.400000000000006 110.288 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 91.63 136.8 7.26 Favored Glycine 0 N--CA 1.44 -1.076 0 C-N-CA 120.571 -0.823 . . . . 50.310000000000002 111.823 -177.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 18.4 t -87.22 35.67 0.71 Allowed 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.226 0.536 . . . . 52.119999999999997 110.212 178.425 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -74.68 -47.49 31.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.513 -0.767 . . . . 64.239999999999995 111.185 -178.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 123.08 36.6 0.65 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.868 -0.682 . . . . 24.109999999999999 111.97 -176.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 156' ' ' ASN . . . . . 0.401 ' OD1' ' HB3' ' B' ' 166' ' ' LEU . 6.8 t30 -119.73 126.75 51.84 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.974 0.416 . . . . 75.420000000000002 110.596 -178.322 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 157' ' ' PHE . . . . . 0.451 ' CD2' ' HG ' ' B' ' 147' ' ' LEU . 13.4 m-85 -109.97 164.0 13.02 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.196 -0.456 . . . . 71.409999999999997 110.487 179.541 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.7 mm -121.79 109.22 24.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.789 -0.819 . . . . 73.329999999999998 108.789 173.128 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 159' ' ' ARG . . . . . 0.543 ' HE ' ' HB3' ' B' ' 161' ' ' ASP . 43.3 ttp180 -75.07 125.94 29.98 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 109.027 -0.731 . . . . 72.150000000000006 109.027 178.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 160' ' ' SER . . . . . 0.453 ' OG ' ' HG3' ' A' ' 63' ' ' PRO . 23.8 t -58.64 -22.06 55.55 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.187 0.518 . . . . 32.329999999999998 110.755 -178.75 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 161' ' ' ASP . . . . . 0.543 ' HB3' ' HE ' ' B' ' 159' ' ' ARG . 1.5 t70 -68.81 -30.24 68.76 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.797 -0.638 . . . . 73.400000000000006 111.104 175.547 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 162' ' ' GLN . . . . . 0.69 HE21 ' HA ' ' B' ' 162' ' ' GLN . 0.0 OUTLIER -140.95 81.34 16.31 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.271 -0.422 . . . . 71.140000000000001 110.409 -174.198 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.41 -8.67 17.36 Favored 'Trans proline' 0 C--N 1.343 0.264 0 C-N-CA 122.498 2.132 . . . . 72.150000000000006 112.318 -178.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -81.87 -21.52 37.45 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.665 -0.698 . . . . 62.039999999999999 110.502 178.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 19.1 ttmm -114.57 134.32 55.13 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.017 -0.538 . . . . 73.209999999999994 110.894 -175.006 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 166' ' ' LEU . . . . . 0.401 ' HB3' ' OD1' ' B' ' 156' ' ' ASN . 5.1 mp -82.98 129.31 35.02 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.22 -1.03 . . . . 75.400000000000006 108.22 171.449 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 45.2 mm -87.84 110.31 34.05 Favored Pre-proline 0 C--N 1.321 -0.651 0 N-CA-C 110.177 -0.305 . . . . 63.409999999999997 110.177 -174.21 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 168' ' ' PRO . . . . . 0.49 ' O ' HG23 ' B' ' 172' ' ' ILE . 42.9 Cg_endo -66.57 172.89 8.59 Favored 'Trans proline' 0 N--CA 1.462 -0.332 0 C-N-CA 122.94 2.426 . . . . 73.239999999999995 112.768 -175.595 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 5.1 tt0 -75.44 -5.44 45.01 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.304 -0.862 . . . . 62.240000000000002 111.665 -169.097 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -96.04 -13.24 23.87 Favored 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 120.495 -0.482 . . . . 71.530000000000001 110.73 176.471 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 171' ' ' GLU . . . . . 0.614 ' O ' ' HB2' ' B' ' 174' ' ' SER . 1.5 mm-40 -107.24 -9.61 16.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.988 0.423 . . . . 72.319999999999993 110.817 -178.386 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 172' ' ' ILE . . . . . 0.49 HG23 ' O ' ' B' ' 168' ' ' PRO . 47.9 pt -68.08 -19.15 24.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.423 0.63 . . . . 64.140000000000001 110.262 176.365 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -99.45 39.24 1.32 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.293 -0.867 . . . . 71.049999999999997 108.823 175.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 174' ' ' SER . . . . . 0.614 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 1.7 t -72.84 -15.31 61.62 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.358 -0.837 . . . . 60.420000000000002 110.305 -178.375 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 65.4 p-90 . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.817 -0.611 . . . . 71.299999999999997 109.371 174.38 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.682 0 N-CA-C 111.635 -0.586 . . . . 61.520000000000003 111.635 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -74.32 -71.9 0.31 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.139 0.495 . . . . 73.120000000000005 110.143 176.485 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -99.98 153.46 19.17 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.712 -0.676 . . . . 73.420000000000002 109.591 176.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -134.0 151.97 51.66 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.766 0.317 . . . . 73.239999999999995 110.822 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -153.19 83.4 1.2 Allowed 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.067 -0.716 . . . . 73.209999999999994 109.067 177.704 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -80.41 135.44 53.61 Favored Pre-proline 0 C--N 1.322 -0.608 0 CA-C-N 115.862 -0.608 . . . . 53.009999999999998 111.274 -175.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -73.96 175.34 10.96 Favored 'Trans proline' 0 CA--C 1.527 0.174 0 C-N-CA 122.798 2.332 . . . . 72.109999999999999 112.06 177.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.3 p -57.32 107.43 0.43 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.525 0.679 . . . . 70.120000000000005 111.333 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 150.45 -76.48 0.24 Allowed Glycine 0 N--CA 1.443 -0.879 0 N-CA-C 110.521 -1.032 . . . . 72.030000000000001 110.521 -175.022 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 56.35 75.5 0.57 Allowed Pre-proline 0 N--CA 1.469 0.492 0 O-C-N 124.185 0.58 . . . . 70.5 112.473 173.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.619 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 71.6 Cg_endo -87.0 116.53 1.27 Allowed 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.507 2.138 . . . . 72.219999999999999 112.544 177.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -139.21 167.21 22.58 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.485 -0.561 . . . . 64.049999999999997 109.485 176.074 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.542 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 11.3 p -114.46 124.03 70.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.505 0.669 . . . . 64.340000000000003 111.502 -175.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 27.7 m -89.83 106.14 18.27 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.6 -0.727 . . . . 71.230000000000004 109.249 174.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.481 HG23 ' HG2' ' A' ' 24' ' ' GLN . 57.6 mt -93.89 107.84 19.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-O 120.908 0.385 . . . . 64.299999999999997 111.0 -175.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.41 HH11 ' HD3' ' A' ' 16' ' ' ARG . 4.8 mtm180 -116.13 174.77 5.87 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.225 -0.443 . . . . 75.109999999999999 110.537 177.114 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 92.9 mt-30 -129.98 104.87 7.61 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.782 -0.644 . . . . 62.350000000000001 109.823 175.508 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -97.32 83.56 3.31 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.563 -0.744 . . . . 52.329999999999998 109.338 -177.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.72 -115.17 4.12 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.429 -0.891 . . . . 73.310000000000002 111.413 -176.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.989 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 23.0 m-20 -110.73 24.95 12.31 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.099 0.476 . . . . 72.5 110.267 178.548 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 22.5 pttm -132.3 118.52 19.56 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 121.297 0.57 . . . . 71.340000000000003 110.782 178.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.433 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 35.8 m -80.06 101.42 8.71 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.421 -0.809 . . . . 54.43 109.374 177.047 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.554 HG12 HG23 ' A' ' 37' ' ' VAL . 16.4 mt -98.53 113.31 32.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.236 0.541 . . . . 72.25 110.388 -174.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.542 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 21.4 mt-30 -96.5 110.18 22.62 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.404 -0.816 . . . . 71.430000000000007 110.552 -178.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 30.0 mt-10 -84.3 103.24 13.32 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.681 -0.691 . . . . 65.400000000000006 110.828 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.426 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 85.2 m-85 -83.4 97.48 8.97 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.521 -0.548 . . . . 62.450000000000003 109.521 174.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 94.0 mtt180 -110.44 129.59 55.74 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.869 -0.605 . . . . 72.409999999999997 109.744 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.88 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.7 p -91.98 -82.7 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 C-N-CA 120.322 -0.551 . . . . 65.150000000000006 109.812 175.182 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.88 ' H ' HG13 ' A' ' 28' ' ' VAL . 5.6 t-20 -123.36 77.7 1.51 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.023 0.439 . . . . 73.5 110.325 -176.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 70.72 20.51 77.46 Favored Glycine 0 N--CA 1.448 -0.528 0 CA-C-N 115.456 -0.793 . . . . 61.450000000000003 113.144 177.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.48 ' CD2' HG21 ' B' ' 128' ' ' VAL . 32.2 t80 -148.12 129.3 14.62 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.125 0.488 . . . . 62.219999999999999 110.42 177.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.969 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -69.51 116.69 10.21 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 114.945 -1.025 . . . . 75.219999999999999 109.174 175.427 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . 0.426 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 36.7 p90 -105.1 -20.49 13.5 Favored 'General case' 0 C--N 1.327 -0.39 0 C-N-CA 120.299 -0.56 . . . . 73.329999999999998 111.562 -178.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -157.43 143.41 17.61 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.947 0.403 . . . . 71.049999999999997 111.13 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.969 HG13 HD11 ' A' ' 32' ' ' LEU . 72.4 mt -120.86 120.25 61.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.171 -0.468 . . . . 61.200000000000003 110.148 175.377 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.417 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 86.6 tttt -103.04 97.78 7.83 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.849 -0.797 . . . . 71.140000000000001 108.849 171.103 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.554 HG23 HG12 ' A' ' 23' ' ' ILE . 2.1 p -100.2 128.61 51.99 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 CA-C-N 116.112 -0.495 . . . . 75.319999999999993 110.18 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.597 HG22 ' HB3' ' A' ' 44' ' ' PRO . 34.7 t -107.93 87.16 3.54 Favored Pre-proline 0 C--N 1.322 -0.613 0 CA-C-N 115.428 -0.805 . . . . 73.319999999999993 109.646 178.417 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 66.9 Cg_endo -83.48 132.9 6.01 Favored 'Trans proline' 0 N--CA 1.448 -1.171 0 C-N-CA 122.206 1.937 . . . . 73.239999999999995 111.905 178.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.989 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 58.6 mtpt -63.72 -24.0 67.6 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.648 -0.705 . . . . 61.539999999999999 109.93 176.35 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 59.3 m-70 -120.07 85.11 2.33 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.367 -0.833 . . . . 74.510000000000005 109.671 177.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 145.04 -20.07 1.95 Allowed Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.286 -0.959 . . . . 74.349999999999994 113.205 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 94.0 mttt 73.42 144.42 0.1 Allowed Pre-proline 0 N--CA 1.474 0.743 0 C-N-CA 123.153 0.581 . . . . 65.319999999999993 111.373 178.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.597 ' HB3' HG22 ' A' ' 38' ' ' VAL . 41.7 Cg_endo -67.8 156.43 65.98 Favored 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.803 2.335 . . . . 52.439999999999998 113.361 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.421 ' CE2' ' HD2' ' A' ' 59' ' ' ARG . 6.8 p90 -165.3 167.16 18.15 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.581 -0.736 . . . . 71.030000000000001 109.516 178.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.543 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 64.4 m-85 -100.24 134.19 43.54 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.871 0.367 . . . . 74.409999999999997 110.591 176.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.429 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 20.2 tp -118.87 102.93 9.16 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.264 -0.643 . . . . 73.140000000000001 109.264 176.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.4 t -96.85 135.17 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.802 0.334 . . . . 72.219999999999999 111.663 -173.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.9 111.13 6.89 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.862 -0.608 . . . . 72.0 109.816 178.521 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.54 168.51 16.14 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.446 -0.343 . . . . 74.340000000000003 110.739 178.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -64.91 137.25 57.64 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.321 -0.4 . . . . 62.539999999999999 110.084 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 87.22 122.3 1.58 Allowed Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.705 -0.76 . . . . 74.129999999999995 111.239 -175.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 2.5 t -85.51 36.62 0.65 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.207 0.527 . . . . 70.409999999999997 110.277 -175.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -66.04 -48.44 71.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.504 -0.771 . . . . 75.450000000000003 110.753 179.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 134.46 49.75 0.08 OUTLIER Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.861 -0.685 . . . . 53.009999999999998 111.572 -177.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.831 HD21 ' HB3' ' A' ' 66' ' ' LEU . 41.1 t-20 -136.54 134.27 37.33 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.717 -0.475 . . . . 52.130000000000003 109.717 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.496 ' HD1' HG21 ' A' ' 72' ' ' ILE . 52.5 m-85 -123.53 159.71 28.56 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.139 -0.482 . . . . 74.340000000000003 110.784 -179.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 47.9 mm -117.49 129.96 73.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 109.501 -0.555 . . . . 42.340000000000003 109.501 175.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.946 ' HG3' HG13 ' A' ' 67' ' ' ILE . 18.0 mtm180 -95.79 153.63 17.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.827 0.346 . . . . 71.219999999999999 111.198 -176.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.543 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 59.5 p -71.53 -21.25 61.93 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.788 -0.642 . . . . 71.439999999999998 109.512 172.379 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -60.7 -44.0 97.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 114.833 -1.076 . . . . 73.030000000000001 110.858 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 9.8 tt0 -160.1 98.92 1.45 Allowed Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 115.8 -0.636 . . . . 64.450000000000003 109.908 -179.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -73.03 -6.8 19.62 Favored 'Trans proline' 0 C--O 1.23 0.099 0 C-N-CA 122.777 2.318 . . . . 73.150000000000006 111.659 177.56 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -85.11 1.62 47.09 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 114.961 -1.018 . . . . 72.230000000000004 110.162 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 62.0 tttp -129.03 135.91 49.58 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.153 -0.476 . . . . 71.530000000000001 110.577 -177.651 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.831 ' HB3' HD21 ' A' ' 56' ' ' ASN . 5.0 mp -90.34 132.18 35.72 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 108.705 -0.85 . . . . 53.210000000000001 108.705 176.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.946 HG13 ' HG3' ' A' ' 59' ' ' ARG . 45.2 mm -106.15 110.52 64.05 Favored Pre-proline 0 C--N 1.317 -0.81 0 CA-C-O 121.021 0.438 . . . . 65.510000000000005 111.362 -172.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.536 ' O ' HG23 ' A' ' 72' ' ' ILE . 73.0 Cg_endo -76.44 -179.93 5.79 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 123.337 2.691 . . . . 74.040000000000006 112.297 177.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . 1.046 ' HA ' HG12 ' A' ' 72' ' ' ILE . 27.4 mt-30 -71.38 -32.69 68.76 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 113.489 0.922 . . . . 63.439999999999998 113.489 -169.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 25.2 p90 -70.13 -15.9 63.03 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.22 -0.592 . . . . 75.299999999999997 109.961 176.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.655 ' HB3' HG23 ' A' ' 67' ' ' ILE . 3.9 mm-40 -101.16 -30.31 11.63 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.776 -0.647 . . . . 74.200000000000003 111.186 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 1.046 HG12 ' HA ' ' A' ' 69' ' ' GLN . 44.8 pt -72.43 -32.77 43.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 121.099 0.476 . . . . 74.209999999999994 110.163 177.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -101.77 39.94 1.39 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.946 -0.57 . . . . 60.210000000000001 110.125 174.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.3 t -74.76 -16.12 60.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.355 -0.839 . . . . 73.519999999999996 109.762 179.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 8.6 p-90 . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 115.944 -0.571 . . . . 65.329999999999998 110.661 175.449 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.384 0 N-CA-C 112.174 -0.37 . . . . 64.439999999999998 112.174 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -157.7 -41.3 0.07 Allowed 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.808 0.337 . . . . 72.420000000000002 111.327 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -92.12 37.45 0.98 Allowed 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 112.171 0.434 . . . . 61.299999999999997 112.171 -173.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -88.91 33.42 0.78 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.251 0.548 . . . . 75.150000000000006 110.482 175.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -54.34 132.45 43.98 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.054 -0.975 . . . . 73.109999999999999 111.862 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -90.24 120.13 69.17 Favored Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.1 -0.5 . . . . 65.0 110.502 178.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.32 -166.29 0.34 Allowed 'Trans proline' 0 N--CA 1.464 -0.264 0 C-N-CA 123.171 2.581 . . . . 62.020000000000003 112.581 -178.613 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 4.3 p -72.75 117.03 13.95 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.802 -0.635 . . . . 73.109999999999999 110.473 178.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 100.43 84.45 1.8 Allowed Glycine 0 CA--C 1.504 -0.651 0 N-CA-C 110.992 -0.843 . . . . 73.400000000000006 110.992 -176.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -118.27 92.6 43.36 Favored Pre-proline 0 C--N 1.315 -0.934 0 CA-C-N 114.959 -0.621 . . . . 72.010000000000005 110.258 -174.401 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.827 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 40.5 Cg_endo -74.08 88.1 1.13 Allowed 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 121.781 1.654 . . . . 72.310000000000002 111.486 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -104.64 147.11 28.01 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.889 -1.05 . . . . 75.409999999999997 109.785 179.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.681 HG21 ' HB3' ' B' ' 124' ' ' GLN . 9.9 p -104.05 127.55 58.16 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-O 121.316 0.579 . . . . 62.520000000000003 111.073 -177.757 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . 0.67 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.4 m -83.9 102.65 12.55 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.607 -0.724 . . . . 71.010000000000005 109.364 175.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.1 mt -92.77 106.45 17.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 116.279 -0.419 . . . . 64.129999999999995 110.909 -174.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . 0.454 ' HG2' ' O ' ' B' ' 123' ' ' ILE . 13.3 ptm180 -118.25 171.47 8.1 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.335 -0.617 . . . . 72.109999999999999 109.335 176.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 89.7 mt-30 -139.55 113.49 8.73 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.32 0.581 . . . . 74.430000000000007 110.825 -179.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 17.9 mm-40 -101.26 97.73 8.2 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.335 -0.848 . . . . 71.219999999999999 109.569 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 70.24 -95.67 0.52 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.886 -0.673 . . . . 63.32 111.973 -177.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.781 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 9.7 m-20 -127.54 26.71 5.91 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.849 0.357 . . . . 73.219999999999999 110.538 178.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.536 ' HE3' ' HE3' ' B' ' 175' ' ' TRP . 23.1 pttm -129.3 119.31 23.72 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-O 121.233 0.54 . . . . 53.240000000000002 110.88 175.113 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . 0.815 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 28.0 m -80.3 105.28 11.44 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.576 -0.738 . . . . 73.420000000000002 109.53 177.387 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . 0.473 HD11 ' HE2' ' B' ' 121' ' ' LYS . 24.2 mt -96.3 106.38 18.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-O 121.27 0.557 . . . . 75.209999999999994 110.097 -177.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.681 ' HB3' HG21 ' B' ' 113' ' ' VAL . 26.1 mt-30 -97.51 103.87 15.85 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.451 -0.795 . . . . 63.43 110.892 -176.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . 0.67 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 48.3 mt-10 -84.97 102.55 13.25 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.788 -0.642 . . . . 61.420000000000002 111.049 -179.214 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . 0.454 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 39.2 m-85 -78.38 107.09 10.75 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.931 0.396 . . . . 72.140000000000001 110.67 178.115 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 50.2 mtt180 -125.11 125.13 43.27 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.009 -0.542 . . . . 71.319999999999993 109.787 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.827 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 7.3 p -90.05 -25.6 5.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.202 0.525 . . . . 74.420000000000002 111.081 -174.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -165.94 56.35 0.1 Allowed 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.034 -0.728 . . . . 64.319999999999993 109.034 -179.244 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.68 -34.55 4.31 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.284 -0.871 . . . . 64.430000000000007 112.915 -178.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -94.54 133.47 38.13 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.204 0.526 . . . . 62.43 110.856 -173.524 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.709 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -73.95 125.82 29.08 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 114.983 -1.008 . . . . 73.150000000000006 110.17 179.289 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . 0.454 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 37.0 p90 -117.18 -16.97 10.35 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 120.617 -0.433 . . . . 71.25 111.384 177.457 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . 0.433 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -161.79 146.51 12.99 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.668 0.271 . . . . 72.340000000000003 110.87 178.029 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.709 HG13 HD11 ' B' ' 132' ' ' LEU . 71.1 mt -124.95 115.71 45.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 110.149 -0.315 . . . . 45.539999999999999 110.149 176.552 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.542 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.9 tttt -93.57 105.62 17.65 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.226 -0.657 . . . . 74.019999999999996 109.226 175.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.637 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.0 t -88.44 130.95 37.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 109.279 -0.637 . . . . 72.329999999999998 109.279 178.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.815 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 34.0 t -117.4 72.87 7.39 Favored Pre-proline 0 C--N 1.318 -0.795 0 CA-C-O 121.002 0.43 . . . . 42.43 109.863 173.152 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.597 ' HD3' HG12 ' B' ' 137' ' ' VAL . 44.4 Cg_endo -76.95 126.47 8.74 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.128 1.885 . . . . 71.140000000000001 112.473 176.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . 0.781 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 60.1 mtpt -66.04 -9.4 30.21 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.192 -0.913 . . . . 74.099999999999994 111.302 -179.046 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 83.8 m-70 -129.92 21.81 5.39 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.772 -0.649 . . . . 72.099999999999994 110.298 -177.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . 0.497 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . -152.16 -9.21 0.1 OUTLIER Glycine 0 CA--C 1.521 0.416 0 C-N-CA 120.381 -0.914 . . . . 64.109999999999999 113.68 -178.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . 0.497 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 67.7 mmtt 75.69 143.98 0.1 Allowed Pre-proline 0 N--CA 1.472 0.67 0 CA-C-O 121.361 0.601 . . . . 72.450000000000003 112.128 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.637 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 59.8 Cg_endo -72.32 134.75 23.36 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 123.162 2.575 . . . . 72.219999999999999 112.887 -176.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -150.51 151.29 32.46 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.89 -0.595 . . . . 73.310000000000002 110.495 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.611 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 93.0 m-85 -89.51 128.1 35.94 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.31 -0.405 . . . . 73.340000000000003 110.103 176.403 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.561 ' HG ' ' CD1' ' B' ' 157' ' ' PHE . 16.0 tp -107.39 98.35 7.99 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 108.852 -0.796 . . . . 71.439999999999998 108.852 175.01 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 40.8 t -87.87 133.67 29.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.028 -0.533 . . . . 74.340000000000003 111.464 -172.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.03 108.13 8.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.803 -0.635 . . . . 52.020000000000003 110.476 178.064 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.12 155.72 33.94 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 109.876 -0.416 . . . . 60.329999999999998 109.876 173.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -62.31 139.21 58.53 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.885 0.374 . . . . 75.140000000000001 110.803 -177.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . 0.425 ' C ' ' H ' ' B' ' 154' ' ' ASP . . . 87.87 137.14 5.43 Favored Glycine 0 N--CA 1.44 -1.07 0 C-N-CA 120.433 -0.889 . . . . 44.43 111.689 -178.614 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 14.4 t -75.61 39.58 0.17 Allowed 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.616 0.722 . . . . 74.420000000000002 110.711 178.048 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . 0.425 ' H ' ' C ' ' B' ' 152' ' ' GLY . 21.3 t70 -67.29 -27.18 66.96 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.527 -0.761 . . . . 73.340000000000003 110.293 179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 99.07 18.33 24.86 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.796 -0.716 . . . . 44.219999999999999 112.185 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . 1.011 HD21 ' HB3' ' B' ' 166' ' ' LEU . 18.5 t-20 -101.13 139.15 37.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.841 0.353 . . . . 71.450000000000003 110.375 -178.26 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . 0.561 ' CD1' ' HG ' ' B' ' 147' ' ' LEU . 29.3 m-85 -127.41 156.88 41.37 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.963 -0.562 . . . . 63.450000000000003 110.404 176.449 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.2 mm -122.69 130.19 74.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.563 -0.532 . . . . 72.329999999999998 109.563 177.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.456 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 11.0 mtm180 -93.3 145.35 24.52 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 120.818 -0.353 . . . . 75.040000000000006 110.076 179.748 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . 0.611 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 54.5 p -70.66 -16.71 62.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.26 -0.427 . . . . 64.209999999999994 111.383 -179.307 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -86.35 -25.13 25.54 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.972 0.415 . . . . 64.549999999999997 110.195 -178.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 9.9 tt0 -151.72 79.54 6.46 Favored Pre-proline 0 N--CA 1.451 -0.411 0 CA-C-N 115.919 -0.582 . . . . 74.109999999999999 110.102 -177.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . 0.472 ' CG ' ' HB2' ' A' ' 60' ' ' SER . 16.1 Cg_exo -69.35 -9.57 26.6 Favored 'Trans proline' 0 C--O 1.233 0.247 0 C-N-CA 122.999 2.466 . . . . 74.439999999999998 111.398 177.081 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -78.01 -13.53 59.84 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.89 -1.05 . . . . 74.409999999999997 110.434 178.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 62.4 tttp -110.51 135.29 51.4 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.008 0.432 . . . . 73.519999999999996 110.938 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . 1.011 ' HB3' HD21 ' B' ' 156' ' ' ASN . 5.0 mp -97.85 126.22 43.11 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.616 -0.883 . . . . 61.130000000000003 108.616 175.104 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 51.2 mm -86.88 115.72 63.48 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-O 120.626 0.251 . . . . 73.120000000000005 110.611 -175.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.589 ' O ' HG23 ' B' ' 172' ' ' ILE . 49.3 Cg_endo -69.09 172.23 12.35 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.923 2.415 . . . . 43.109999999999999 112.172 178.61 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -84.49 8.8 15.28 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.926 -0.579 . . . . 71.030000000000001 111.968 -167.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . 0.54 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 31.8 p90 -108.33 -26.82 10.33 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.6 -0.519 . . . . 73.219999999999999 109.6 170.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.54 ' HG2' ' CD1' ' B' ' 170' ' ' TRP . 5.7 mm-40 -86.22 -13.49 46.74 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.932 -0.576 . . . . 60.100000000000001 111.549 -177.044 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.589 HG23 ' O ' ' B' ' 168' ' ' PRO . 24.0 pt -61.15 -27.9 42.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.568 -0.742 . . . . 72.420000000000002 111.554 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 61.5 m-85 -110.15 44.01 1.29 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.299 0.571 . . . . 74.420000000000002 110.341 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 22.8 t -69.02 -22.96 64.03 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.569 -0.741 . . . . 50.409999999999997 110.446 178.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . 0.536 ' HE3' ' HE3' ' B' ' 121' ' ' LYS . 10.2 p-90 . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.383 -0.817 . . . . 70.439999999999998 110.965 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.796 0 N-CA-C 111.848 -0.501 . . . . 73.200000000000003 111.848 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -83.68 92.5 7.71 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.043 0.449 . . . . 72.420000000000002 110.221 176.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -123.47 123.72 41.28 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.989 -0.55 . . . . 73.299999999999997 110.605 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -158.37 -166.81 2.01 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.532 -0.914 . . . . 73.120000000000005 108.532 178.021 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -82.54 110.7 17.87 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.824 0.345 . . . . 74.409999999999997 110.326 179.289 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -68.1 120.83 77.13 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.014 -0.539 . . . . 63.420000000000002 111.253 -177.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_endo -78.38 174.88 11.75 Favored 'Trans proline' 0 C--O 1.233 0.252 0 C-N-CA 122.998 2.465 . . . . 74.319999999999993 112.461 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 24.8 m -77.72 141.63 39.2 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.176 -0.466 . . . . 73.209999999999994 109.825 178.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.47 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 102.93 52.85 0.93 Allowed Glycine 0 N--CA 1.445 -0.723 0 N-CA-C 109.091 -1.604 . . . . 54.409999999999997 109.091 -168.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -88.51 103.49 5.42 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-N 114.233 -0.984 . . . . 71.430000000000007 109.722 -168.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.792 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 90.6 Cg_endo -87.18 101.36 0.52 Allowed 'Trans proline' 0 N--CA 1.443 -1.468 0 C-N-CA 122.539 2.16 . . . . 72.450000000000003 112.636 -172.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -95.13 149.74 20.96 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 116.067 -0.515 . . . . 74.109999999999999 109.98 -178.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.662 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 13.9 p -106.87 127.58 62.34 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.384 0.612 . . . . 75.540000000000006 110.61 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.455 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 25.3 m -91.77 112.33 24.21 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.833 -0.621 . . . . 71.299999999999997 109.44 176.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.409 HG12 ' HG2' ' A' ' 24' ' ' GLN . 62.9 mt -95.1 111.49 25.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.153 0.501 . . . . 53.25 111.54 -174.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 33.7 mmt180 -119.89 156.88 29.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.615 -0.72 . . . . 75.200000000000003 109.798 173.035 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -127.56 107.59 10.06 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.988 0.423 . . . . 74.25 110.795 178.219 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.446 ' HB2' ' HE2' ' A' ' 21' ' ' LYS . 54.9 mm-40 -97.57 81.72 2.98 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.012 -0.54 . . . . 73.230000000000004 109.595 178.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 88.47 -118.74 5.18 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.602 -0.808 . . . . 63.409999999999997 111.637 -176.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.707 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 42.7 m-20 -101.82 16.88 24.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.437 0.16 . . . . 64.099999999999994 110.962 179.048 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.492 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 23.1 pttm -123.49 122.52 38.43 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.269 0.557 . . . . 63.049999999999997 111.545 -179.261 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.403 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 36.2 m -83.73 103.98 13.47 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.273 -0.876 . . . . 61.299999999999997 109.577 174.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 51.0 mt -95.53 109.99 23.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.91 0.386 . . . . 65.340000000000003 110.03 -177.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.662 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 51.6 mt-30 -101.33 119.72 39.18 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.84 -0.618 . . . . 53.210000000000001 111.787 -175.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.455 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 29.0 mt-10 -89.77 99.98 12.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.619 -0.719 . . . . 71.019999999999996 110.36 175.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.441 ' CD2' ' HB3' ' B' ' 151' ' ' ASP . 68.3 m-85 -81.15 101.5 9.69 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 109.824 -0.436 . . . . 72.5 109.824 175.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.447 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 58.6 mtt180 -115.03 129.28 56.67 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.121 -0.49 . . . . 72.120000000000005 110.013 -179.064 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.792 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 2.4 p -90.0 -57.64 4.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-O 120.915 0.388 . . . . 55.299999999999997 111.541 -177.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.462 ' H ' HG13 ' A' ' 28' ' ' VAL . 5.1 t-20 -127.63 50.5 2.02 Favored 'General case' 0 C--N 1.319 -0.733 0 N-CA-C 109.007 -0.738 . . . . 74.209999999999994 109.007 -179.246 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 92.42 -29.74 7.47 Favored Glycine 0 N--CA 1.45 -0.39 0 CA-C-N 115.484 -0.78 . . . . 71.200000000000003 112.292 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.574 ' CD2' HG21 ' B' ' 128' ' ' VAL . 57.1 t80 -92.35 134.43 34.92 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.113 0.482 . . . . 70.010000000000005 110.843 -176.247 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.864 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -72.84 118.81 16.23 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.225 -0.898 . . . . 55.530000000000001 109.965 177.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . 0.421 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 39.5 p90 -104.79 -25.54 12.61 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 120.3 -0.56 . . . . 74.400000000000006 111.263 179.528 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.427 ' O ' ' HB2' ' A' ' 26' ' ' TYR . . . -156.85 137.89 13.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.935 0.397 . . . . 73.219999999999999 111.102 178.622 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.864 HG13 HD11 ' A' ' 32' ' ' LEU . 76.4 mt -110.4 119.79 59.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 116.093 -0.503 . . . . 75.310000000000002 109.812 175.727 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -102.43 101.28 11.48 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.043 -0.663 . . . . 72.219999999999999 109.535 174.414 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.55 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.4 p -93.48 120.66 43.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 N-CA-C 109.525 -0.546 . . . . 73.420000000000002 109.525 176.361 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.595 HG13 ' HB3' ' A' ' 44' ' ' PRO . 41.7 t -107.34 86.25 2.57 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.365 -0.834 . . . . 73.400000000000006 109.858 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.55 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 62.3 Cg_endo -85.39 132.76 4.43 Favored 'Trans proline' 0 N--CA 1.445 -1.35 0 C-N-CA 122.347 2.031 . . . . 70.200000000000003 112.278 179.066 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.707 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 58.1 mtpt -62.61 -20.34 64.66 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.51 -0.768 . . . . 74.319999999999993 109.604 173.609 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 10.6 m-70 -123.6 96.94 5.16 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 115.216 -0.902 . . . . 50.149999999999999 108.942 177.067 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.467 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 133.64 -18.77 4.3 Favored Glycine 0 CA--C 1.52 0.373 0 C-N-CA 120.558 -0.83 . . . . 73.239999999999995 113.075 178.323 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 69.6 mmtt 75.31 136.6 0.05 OUTLIER Pre-proline 0 N--CA 1.47 0.556 0 C-N-CA 123.432 0.693 . . . . 73.530000000000001 112.39 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.595 ' HB3' HG13 ' A' ' 38' ' ' VAL . 21.8 Cg_endo -61.03 143.43 99.23 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 123.497 2.798 . . . . 73.219999999999999 113.334 -177.23 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.52 ' CE1' HG13 ' A' ' 37' ' ' VAL . 4.9 p90 -158.48 160.79 37.14 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.818 -0.628 . . . . 74.040000000000006 110.116 178.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.647 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 90.3 m-85 -100.03 142.0 32.1 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.294 -0.412 . . . . 75.430000000000007 111.073 -179.376 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 51.9 mt -113.98 103.05 10.77 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.791 -0.64 . . . . 75.209999999999994 109.367 168.455 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 43.0 t -86.34 133.58 29.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.129 -0.487 . . . . 75.409999999999997 110.287 -178.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.427 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 33.8 tpt85 -76.71 115.54 16.57 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.958 -0.386 . . . . 72.319999999999993 109.958 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.14 154.79 18.68 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 116.094 -0.503 . . . . 71.030000000000001 111.406 -179.037 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -73.15 167.03 21.99 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.626 -0.715 . . . . 71.200000000000003 111.632 -176.022 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 79.54 10.22 86.08 Favored Glycine 0 N--CA 1.454 -0.131 0 CA-C-N 115.41 -0.814 . . . . 70.120000000000005 112.801 172.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.5 m 61.14 17.83 8.48 Favored 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 122.919 0.488 . . . . 72.040000000000006 111.745 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -50.39 -66.02 0.46 Allowed 'General case' 0 N--CA 1.468 0.451 0 O-C-N 123.607 0.567 . . . . 72.019999999999996 111.898 -178.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 137.4 -18.12 3.49 Favored Glycine 0 CA--C 1.508 -0.381 0 C-N-CA 120.591 -0.814 . . . . 71.230000000000004 111.759 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.428 ' ND2' ' HB3' ' A' ' 66' ' ' LEU . 13.8 t-20 -66.04 146.41 54.72 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.141 -0.53 . . . . 64.400000000000006 111.036 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.502 ' HB2' HG22 ' A' ' 72' ' ' ILE . 35.4 m-85 -119.35 141.46 49.01 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.256 -0.429 . . . . 73.219999999999999 110.082 175.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.404 ' CG2' ' HA ' ' A' ' 63' ' ' PRO . 49.6 mm -108.18 124.36 64.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 115.993 -0.549 . . . . 74.239999999999995 110.521 -177.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.436 HH11 ' HD3' ' A' ' 59' ' ' ARG . 42.4 mtp-105 -77.7 137.78 38.69 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 109.92 -0.4 . . . . 74.299999999999997 109.92 177.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.647 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 63.6 p -67.51 -23.95 65.52 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.403 0.62 . . . . 32.229999999999997 110.082 175.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -70.17 -43.08 71.54 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.217 -0.901 . . . . 64.400000000000006 110.569 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 7.9 mm100 -134.9 76.19 59.77 Favored Pre-proline 0 N--CA 1.441 -0.899 0 CA-C-N 115.95 -0.568 . . . . 63.450000000000003 111.193 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.404 ' HA ' ' CG2' ' A' ' 58' ' ' ILE . 26.5 Cg_exo -63.47 -15.88 51.19 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 123.011 2.474 . . . . 74.420000000000002 112.533 177.019 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -75.24 -20.85 58.99 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.882 -0.599 . . . . 74.439999999999998 110.683 178.765 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 22.7 tptm -109.37 129.03 55.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.192 0.52 . . . . 71.040000000000006 111.495 -176.225 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.428 ' HB3' ' ND2' ' A' ' 56' ' ' ASN . 5.9 mp -89.93 128.8 36.3 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.43 -0.804 . . . . 74.519999999999996 109.965 176.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.405 HG13 ' HG3' ' A' ' 59' ' ' ARG . 50.5 mm -96.31 124.89 49.78 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 116.353 -0.385 . . . . 72.230000000000004 111.597 -173.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.56 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 38.1 Cg_endo -65.22 174.39 5.06 Favored 'Trans proline' 0 C--N 1.348 0.509 0 C-N-CA 123.13 2.553 . . . . 73.319999999999993 112.887 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 16.4 tt0 -83.82 -9.01 59.08 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.804 -0.635 . . . . 75.439999999999998 111.924 -168.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 38.4 p90 -96.88 -5.09 38.96 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 121.296 0.57 . . . . 72.140000000000001 109.927 175.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.56 ' HB2' ' HG2' ' A' ' 68' ' ' PRO . 4.8 mm-40 -115.63 10.76 15.62 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.42 -0.809 . . . . 75.329999999999998 111.145 -176.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.541 HG23 ' O ' ' A' ' 68' ' ' PRO . 18.9 pt -90.33 -11.25 9.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-O 121.096 0.474 . . . . 75.109999999999999 110.811 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 33.8 p90 -128.5 27.25 5.57 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.954 -0.566 . . . . 74.319999999999993 110.419 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 4.8 m -49.76 -41.33 43.8 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.692 -0.686 . . . . 73.030000000000001 111.041 -179.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . 0.492 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 10.3 p-90 . . . . . 0 C--N 1.326 -0.439 0 CA-C-N 115.787 -0.642 . . . . 75.120000000000005 111.043 175.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.434 0 N-CA-C 112.334 -0.307 . . . . 64.519999999999996 112.334 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -86.19 144.14 27.62 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.881 -0.414 . . . . 52.409999999999997 109.881 176.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -100.12 110.22 22.5 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.866 0.841 . . . . 73.409999999999997 111.664 -176.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -127.65 127.83 44.44 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 107.166 -1.42 . . . . 74.109999999999999 107.166 169.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -48.28 107.32 0.12 Allowed 'General case' 0 N--CA 1.468 0.471 0 O-C-N 123.678 0.611 . . . . 70.519999999999996 112.115 -170.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . 0.427 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -107.07 148.55 37.21 Favored Pre-proline 0 C--N 1.32 -0.689 0 CA-C-N 115.328 -0.851 . . . . 44.140000000000001 110.351 -179.122 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 24.8 Cg_exo -64.95 175.86 3.46 Favored 'Trans proline' 0 C--O 1.233 0.252 0 C-N-CA 122.943 2.429 . . . . 72.109999999999999 112.352 177.018 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 42.7 m -60.32 129.51 42.05 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.197 -0.456 . . . . 44.210000000000001 110.238 176.607 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 128.14 82.04 0.34 Allowed Glycine 0 N--CA 1.446 -0.65 0 N-CA-C 110.577 -1.009 . . . . 63.439999999999998 110.577 -173.035 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . 0.415 ' HA ' ' HD3' ' B' ' 111' ' ' PRO . 13.4 mt-10 -123.38 114.13 29.04 Favored Pre-proline 0 C--N 1.32 -0.683 0 CA-C-O 121.327 0.584 . . . . 74.299999999999997 109.975 -172.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.765 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 19.2 Cg_endo -89.01 102.29 0.38 Allowed 'Trans proline' 0 N--CA 1.438 -1.766 0 C-N-CA 122.832 2.355 . . . . 70.439999999999998 112.397 -176.241 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -101.57 115.28 30.16 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.188 -0.671 . . . . 71.340000000000003 109.188 178.274 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . . . . . . . . . 7.9 p -72.71 132.64 33.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 115.625 -0.716 . . . . 61.210000000000001 111.082 -176.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 27.4 m -93.22 99.17 11.78 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.464 -0.789 . . . . 71.239999999999995 109.742 174.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.608 HG23 ' HG2' ' B' ' 124' ' ' GLN . 71.3 mt -96.06 106.03 17.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.838 -0.619 . . . . 72.340000000000003 110.286 -177.252 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 39.1 mmt180 -118.75 149.6 41.19 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.192 0.52 . . . . 72.299999999999997 110.485 178.279 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -100.6 113.64 26.64 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-O 121.596 0.712 . . . . 75.450000000000003 110.865 -179.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . 0.517 ' HB3' ' HE2' ' B' ' 121' ' ' LYS . 0.7 OUTLIER -102.83 48.92 0.85 Allowed 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.003 -0.999 . . . . 71.430000000000007 109.851 -176.785 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 97.74 -117.35 5.78 Favored Glycine 0 N--CA 1.446 -0.652 0 N-CA-C 111.223 -0.751 . . . . 63.130000000000003 111.223 -176.266 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.497 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 3.6 m-20 -89.13 -3.32 58.67 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.037 0.446 . . . . 73.340000000000003 110.308 177.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.675 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 25.4 pttm -111.79 120.19 41.13 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.205 0.526 . . . . 75.530000000000001 111.303 -177.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . 0.474 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 5.5 m -84.03 111.96 19.77 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.908 -0.587 . . . . 72.400000000000006 109.611 175.146 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 51.4 mt -101.17 108.12 22.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-O 121.104 0.478 . . . . 72.239999999999995 110.368 -177.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.608 ' HG2' HG23 ' B' ' 115' ' ' ILE . 8.8 mt-30 -105.28 103.76 13.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.792 -0.64 . . . . 63.049999999999997 110.366 -178.427 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -88.4 108.82 19.56 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.234 -0.439 . . . . 73.430000000000007 110.766 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . 0.471 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 46.7 m-85 -82.37 106.39 14.21 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.218 -0.446 . . . . 74.400000000000006 110.47 177.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -120.86 125.31 47.16 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.508 -0.553 . . . . 62.25 109.508 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.765 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 3.5 p -93.65 -41.63 12.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 120.757 0.313 . . . . 73.510000000000005 111.497 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -158.6 70.37 0.52 Allowed 'General case' 0 C--N 1.323 -0.586 0 C-N-CA 120.606 -0.438 . . . . 73.150000000000006 110.584 -175.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 78.87 -4.05 62.64 Favored Glycine 0 N--CA 1.454 -0.162 0 CA-C-N 115.692 -0.686 . . . . 65.319999999999993 113.574 175.218 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -130.0 129.32 43.57 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.097 0.475 . . . . 75.030000000000001 110.717 -178.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.892 HD11 HG13 ' B' ' 135' ' ' ILE . 3.5 tm? -73.5 118.35 16.35 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 114.875 -1.057 . . . . 74.230000000000004 109.462 175.223 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . 0.471 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 46.3 p90 -106.09 -23.77 12.53 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.66 -0.416 . . . . 75.450000000000003 111.528 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -158.99 134.55 8.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.806 0.336 . . . . 73.109999999999999 111.282 179.005 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.892 HG13 HD11 ' B' ' 132' ' ' LEU . 74.3 mt -114.07 130.73 67.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 N-CA-C 109.634 -0.506 . . . . 65.530000000000001 109.634 174.151 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -107.79 110.41 22.21 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.679 -0.489 . . . . 73.319999999999993 109.679 174.232 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.646 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.4 t -93.67 131.14 41.44 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 108.808 -0.812 . . . . 44.340000000000003 108.808 176.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.474 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 17.2 t -117.73 72.86 8.33 Favored Pre-proline 0 C--N 1.32 -0.71 0 N-CA-C 109.961 -0.385 . . . . 71.120000000000005 109.961 173.582 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.675 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 52.4 Cg_endo -78.48 134.73 12.69 Favored 'Trans proline' 0 N--CA 1.454 -0.801 0 C-N-CA 122.367 2.044 . . . . 70.340000000000003 112.596 176.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . 0.497 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 48.6 mtpt -60.83 -33.21 72.69 Favored 'General case' 0 CA--C 1.518 -0.262 0 CA-C-O 121.416 0.627 . . . . 73.129999999999995 109.596 173.37 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 36.6 m-70 -110.52 82.58 1.62 Allowed 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.252 -0.885 . . . . 74.349999999999994 109.2 177.038 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . 0.483 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 150.68 -26.73 1.06 Allowed Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.357 -0.925 . . . . 73.549999999999997 113.054 -179.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . 0.483 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 70.7 mmtt 76.68 148.91 0.12 Allowed Pre-proline 0 N--CA 1.472 0.635 0 C-N-CA 123.283 0.633 . . . . 73.230000000000004 111.933 178.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.646 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 38.3 Cg_endo -66.27 127.6 17.79 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 123.069 2.513 . . . . 73.349999999999994 113.492 -176.098 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -143.91 150.48 38.47 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.79 -0.641 . . . . 72.049999999999997 110.734 179.327 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.666 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 77.8 m-85 -98.14 146.16 25.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.976 -0.556 . . . . 71.230000000000004 110.466 178.345 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.464 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 59.9 mt -122.73 100.55 6.97 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.826 -0.625 . . . . 73.030000000000001 109.555 171.156 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 61.4 t -92.84 130.34 42.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.054 -0.521 . . . . 74.140000000000001 110.677 -178.036 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . 0.544 HH11 ' HG3' ' B' ' 149' ' ' ARG . 0.3 OUTLIER -72.2 128.07 34.53 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.913 0.387 . . . . 74.239999999999995 111.689 -179.429 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.87 155.78 38.62 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 115.738 -0.664 . . . . 75.030000000000001 110.612 176.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . 0.441 ' HB3' ' CD2' ' A' ' 26' ' ' TYR . 3.9 p-10 -77.6 162.21 27.25 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.287 0.565 . . . . 73.530000000000001 111.736 -173.08 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.93 21.73 60.77 Favored Glycine 0 N--CA 1.449 -0.495 0 CA-C-N 115.284 -0.871 . . . . 62.340000000000003 112.364 173.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . 0.433 ' H ' ' HD2' ' A' ' 11' ' ' PRO . 25.2 m 55.87 30.11 15.31 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-O 120.969 0.414 . . . . 75.319999999999993 110.384 -177.011 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -51.37 -64.39 0.83 Allowed 'General case' 0 N--CA 1.461 0.121 0 CA-C-N 114.851 -1.068 . . . . 64.219999999999999 111.068 -178.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 132.2 -36.36 2.21 Favored Glycine 0 CA--C 1.491 -1.458 0 C-N-CA 120.569 -0.824 . . . . 62.109999999999999 111.218 175.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . 0.607 ' OD1' ' HA ' ' B' ' 168' ' ' PRO . 75.6 m-20 -68.41 152.63 45.14 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 113.964 -1.118 . . . . 74.109999999999999 111.773 -179.424 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . 0.464 ' CE2' ' HG2' ' B' ' 149' ' ' ARG . 46.2 m-85 -112.32 157.7 20.66 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.54 -0.754 . . . . 61.200000000000003 110.248 176.285 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 49.1 mm -116.03 124.92 72.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 N-CA-C 109.596 -0.52 . . . . 73.349999999999994 109.596 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.491 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 30.2 ttt180 -85.51 137.72 32.7 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.4 -0.364 . . . . 74.200000000000003 110.165 -177.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . 0.666 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 6.5 p -57.18 -42.6 81.49 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.722 0.638 . . . . 64.409999999999997 112.722 -174.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -86.04 -1.06 57.01 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.979 0.419 . . . . 61.43 111.551 -174.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 10.9 tp60 -151.86 71.41 7.99 Favored Pre-proline 0 C--N 1.327 -0.401 0 N-CA-C 109.614 -0.513 . . . . 73.299999999999997 109.614 -178.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -67.47 -14.41 42.36 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 123.223 2.616 . . . . 63.450000000000003 113.13 -173.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -90.52 -6.39 54.81 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.169 -0.469 . . . . 64.430000000000007 110.549 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 23.1 tptm -104.74 126.17 51.55 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.163 0.506 . . . . 74.510000000000005 110.637 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.0 mp -95.19 124.68 39.36 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.326 -0.852 . . . . 62.43 109.789 178.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . 0.404 HG23 ' HB3' ' B' ' 171' ' ' GLU . 51.5 mm -93.17 111.58 52.44 Favored Pre-proline 0 C--N 1.32 -0.7 0 CA-C-N 116.122 -0.49 . . . . 74.120000000000005 109.827 179.029 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.607 ' HA ' ' OD1' ' B' ' 156' ' ' ASN . 60.2 Cg_endo -71.63 175.17 9.92 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.664 2.243 . . . . 71.150000000000006 113.025 -176.457 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . 0.415 ' O ' HG12 ' B' ' 172' ' ' ILE . 36.3 tt0 -78.92 -8.32 58.77 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.573 -0.739 . . . . 74.349999999999994 111.518 -170.341 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 10.3 p90 -94.23 -8.04 40.36 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.088 0.47 . . . . 71.400000000000006 110.081 174.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.476 ' O ' ' HB2' ' B' ' 174' ' ' SER . 0.1 OUTLIER -110.42 -4.63 15.47 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.891 -0.595 . . . . 54.409999999999997 110.717 -177.538 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.474 HG23 ' O ' ' B' ' 168' ' ' PRO . 36.6 pt -70.15 -18.68 21.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.231 -0.44 . . . . 74.340000000000003 111.197 -179.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -102.01 40.62 1.31 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.593 0.711 . . . . 74.439999999999998 109.678 176.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . 0.476 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 4.5 t -73.38 -11.13 60.37 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 114.9 -1.045 . . . . 64.400000000000006 110.211 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . 0.454 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 0.9 OUTLIER . . . . . 0 C--O 1.245 0.829 0 CA-C-O 118.353 -0.832 . . . . 74.230000000000004 110.9 179.008 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.609 0 N-CA-C 111.987 -0.445 . . . . 72.329999999999998 111.987 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -135.69 -39.4 0.72 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.744 0.306 . . . . 64.200000000000003 111.262 -178.051 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -100.83 17.76 21.27 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.425 -0.352 . . . . 63.130000000000003 111.258 -177.132 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -64.5 131.09 46.13 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.244 -0.435 . . . . 65.140000000000001 110.653 177.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 61.61 68.18 0.72 Allowed 'General case' 0 C--N 1.329 -0.318 0 O-C-N 123.856 0.723 . . . . 64.340000000000003 110.752 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -109.85 149.54 40.12 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 115.325 -0.852 . . . . 72.109999999999999 110.302 -179.123 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -78.46 153.56 27.23 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.384 2.056 . . . . 74.329999999999998 112.546 179.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.5 p -94.53 119.06 32.63 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.965 -0.561 . . . . 75.430000000000007 109.749 175.025 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.03 66.33 0.53 Allowed Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.158 -1.177 . . . . 73.209999999999994 110.158 -173.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . 0.49 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 0.1 OUTLIER -114.46 117.16 43.23 Favored Pre-proline 0 N--CA 1.44 -0.933 0 N-CA-C 107.995 -1.113 . . . . 72.310000000000002 107.995 -175.839 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.613 ' HG3' ' CZ ' ' B' ' 131' ' ' PHE . 24.7 Cg_endo -88.87 101.0 0.37 Allowed 'Trans proline' 0 N--CA 1.433 -2.049 0 C-N-CA 122.173 1.915 . . . . 73.219999999999999 111.693 -175.377 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -107.8 171.61 7.3 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 114.871 -1.059 . . . . 64.439999999999998 110.344 179.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.653 HG21 ' HB3' ' A' ' 24' ' ' GLN . 7.6 p -123.42 131.51 73.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 CA-C-N 115.773 -0.649 . . . . 65.030000000000001 110.353 178.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.418 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 61.5 m -91.62 111.33 22.8 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.663 -0.699 . . . . 71.109999999999999 109.585 176.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 56.1 mt -88.66 103.76 14.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.942 -0.572 . . . . 63.25 110.967 -174.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.471 ' HA ' ' NE ' ' A' ' 16' ' ' ARG . 3.5 mmp_? -108.45 165.12 11.76 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.49 -0.777 . . . . 71.140000000000001 109.48 177.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -139.13 111.44 7.5 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.042 0.449 . . . . 73.340000000000003 110.502 174.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 30.9 mm-40 -103.77 100.57 10.38 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.448 -0.796 . . . . 75.319999999999993 109.002 178.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.25 -109.31 2.83 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.529 -0.843 . . . . 41.420000000000002 111.664 -175.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -111.02 8.46 21.91 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.788 0.294 . . . . 74.310000000000002 111.078 -177.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.705 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 0.3 OUTLIER -114.97 118.54 33.73 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.434 0.635 . . . . 72.349999999999994 111.463 179.484 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.739 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 20.7 m -76.59 98.33 4.65 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.19 -0.914 . . . . 31.350000000000001 109.618 175.213 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.427 HG12 HG13 ' A' ' 37' ' ' VAL . 38.3 mt -90.31 105.39 16.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.221 0.534 . . . . 74.329999999999998 110.234 -176.672 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.653 ' HB3' HG21 ' A' ' 13' ' ' VAL . 21.6 mt-30 -94.67 112.78 24.51 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.433 -0.803 . . . . 75.129999999999995 110.734 -177.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.418 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.6 mt-10 -91.99 108.85 20.23 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.03 -0.532 . . . . 65.219999999999999 110.736 -177.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.467 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 41.3 m-85 -84.72 106.06 15.98 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.349 -0.387 . . . . 75.329999999999998 110.687 178.173 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 71.3 mtm-85 -130.01 123.61 30.99 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.064 -0.516 . . . . 71.329999999999998 110.11 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.2 p -97.18 -41.99 11.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.313 -0.403 . . . . 75.099999999999994 111.48 -179.055 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 11.7 t-20 -153.65 73.37 0.95 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.006 0.432 . . . . 75.329999999999998 110.294 -176.087 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 67.03 18.53 69.0 Favored Glycine 0 C--N 1.33 0.207 0 CA-C-N 115.815 -0.63 . . . . 65.310000000000002 112.845 177.224 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.616 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 87.8 t80 -139.67 128.59 23.49 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.994 0.426 . . . . 64.450000000000003 111.042 -178.117 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.844 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -82.36 110.31 17.39 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.112 -0.949 . . . . 62.210000000000001 108.544 172.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . 0.467 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 45.5 p90 -103.92 -17.49 14.99 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.885 -0.326 . . . . 72.420000000000002 111.478 -178.39 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.456 ' O ' ' HB2' ' A' ' 26' ' ' TYR . . . -159.35 140.34 12.67 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 120.878 0.371 . . . . 31.109999999999999 111.105 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.844 HG13 HD11 ' A' ' 32' ' ' LEU . 66.9 mt -117.6 124.95 73.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 N-CA-C 109.653 -0.499 . . . . 54.420000000000002 109.653 174.326 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.623 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.9 tttt -106.01 103.77 13.33 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.533 -0.543 . . . . 73.409999999999997 109.533 176.11 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.725 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.6 t -88.7 127.24 41.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 108.839 -0.8 . . . . 73.340000000000003 108.839 177.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.739 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 22.0 t -115.14 74.0 3.64 Favored Pre-proline 0 C--N 1.318 -0.769 0 N-CA-C 109.55 -0.537 . . . . 53.450000000000003 109.55 172.492 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.705 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 39.4 Cg_endo -76.86 131.1 11.92 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.011 1.807 . . . . 45.100000000000001 112.242 177.003 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 29.2 mtpp -54.83 -40.0 69.13 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.522 -0.763 . . . . 74.109999999999999 110.26 177.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -116.67 82.46 1.8 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.517 -0.765 . . . . 72.239999999999995 109.228 179.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.43 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 159.15 -29.48 0.41 Allowed Glycine 0 N--CA 1.45 -0.402 0 CA-C-N 115.507 -0.769 . . . . 61.119999999999997 111.428 -175.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.43 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 71.6 mmtt 76.42 143.81 0.1 OUTLIER Pre-proline 0 N--CA 1.469 0.513 0 C-N-CA 123.738 0.815 . . . . 72.230000000000004 112.267 176.19 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.725 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 30.8 Cg_endo -64.03 132.7 35.37 Favored 'Trans proline' 0 C--N 1.347 0.469 0 C-N-CA 123.218 2.612 . . . . 73.549999999999997 113.61 -176.197 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 21.9 p90 -148.36 163.2 37.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.463 -0.79 . . . . 72.5 109.645 177.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.475 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 91.2 m-85 -107.76 137.79 45.14 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.842 0.353 . . . . 75.329999999999998 111.572 -176.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.407 ' HB3' ' CD2' ' A' ' 57' ' ' PHE . 34.7 mt -114.15 104.48 12.15 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.717 -0.674 . . . . 73.329999999999998 109.216 168.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 44.4 t -92.52 137.88 21.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.554 -0.294 . . . . 74.519999999999996 110.333 -178.198 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.574 ' HG2' ' CE2' ' A' ' 57' ' ' PHE . 5.0 mmm180 -81.8 121.92 27.04 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.032 0.444 . . . . 72.219999999999999 110.885 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.45 167.03 19.16 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.337 -0.847 . . . . 74.230000000000004 111.22 -179.183 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.463 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 9.8 p-10 -66.87 142.86 57.17 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.298 -0.41 . . . . 70.150000000000006 110.264 179.037 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.432 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 94.16 143.45 13.81 Favored Glycine 0 N--CA 1.433 -1.559 0 C-N-CA 120.588 -0.815 . . . . 53.130000000000003 111.566 -178.591 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 18.6 m -74.32 40.14 0.13 Allowed 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.174 0.511 . . . . 74.430000000000007 110.677 176.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.432 ' H ' ' C ' ' A' ' 52' ' ' GLY . 18.0 t70 -78.01 -39.86 40.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.779 -0.646 . . . . 53.310000000000002 110.357 -179.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 112.02 -32.05 6.6 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.636 -0.792 . . . . 41.020000000000003 113.302 176.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 -58.29 149.82 23.44 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 113.027 0.751 . . . . 71.349999999999994 113.027 -175.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.574 ' CE2' ' HG2' ' A' ' 49' ' ' ARG . 63.3 m-85 -115.5 168.3 10.12 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.096 -0.956 . . . . 72.25 110.697 -179.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 45.4 mm -128.27 132.16 68.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.995 -0.548 . . . . 75.540000000000006 109.649 174.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.789 ' HG3' HD11 ' A' ' 67' ' ' ILE . 70.7 mtt180 -78.59 147.88 33.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.809 0.337 . . . . 74.329999999999998 111.249 178.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.475 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 62.2 p -79.01 -29.86 43.92 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.681 -0.859 . . . . 54.32 108.681 165.812 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -70.27 -34.34 72.67 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.381 -1.281 . . . . 74.409999999999997 110.876 177.316 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . 0.6 ' HB3' ' HD2' ' A' ' 59' ' ' ARG . 9.9 tt0 -143.37 82.52 11.57 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 115.747 -0.66 . . . . 63.340000000000003 109.71 -174.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -79.58 -7.44 14.73 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.871 2.381 . . . . 63.009999999999998 113.13 -175.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -94.46 9.32 38.9 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.331 0.586 . . . . 73.439999999999998 110.165 178.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 54.4 tptt -125.63 128.23 47.56 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.85 -0.614 . . . . 74.150000000000006 110.429 -178.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.404 ' N ' HD12 ' A' ' 66' ' ' LEU . 5.2 mp -87.36 111.85 21.51 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 108.434 -0.95 . . . . 73.319999999999993 108.434 175.118 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.789 HD11 ' HG3' ' A' ' 59' ' ' ARG . 34.6 mm -67.24 117.33 45.42 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.146 -0.479 . . . . 74.140000000000001 111.27 -172.254 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.403 ' O ' HG23 ' A' ' 72' ' ' ILE . 55.8 Cg_endo -69.1 175.03 8.08 Favored 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 122.676 2.251 . . . . 72.140000000000001 112.038 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -84.36 -1.06 54.84 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.943 -0.572 . . . . 73.25 111.21 -169.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 16.5 p90 -98.89 -20.24 16.93 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.557 -0.457 . . . . 71.310000000000002 110.437 174.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.519 ' OE2' HD12 ' A' ' 67' ' ' ILE . 19.4 tt0 -90.55 -11.96 38.54 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 121.096 0.474 . . . . 72.109999999999999 110.536 -177.038 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.403 HG23 ' O ' ' A' ' 68' ' ' PRO . 45.6 pt -64.88 -19.26 25.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.095 -0.502 . . . . 62.140000000000001 110.975 178.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -117.6 29.32 7.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.951 -0.568 . . . . 71.299999999999997 110.289 176.121 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 23.0 t -63.72 -26.76 68.8 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.898 -0.592 . . . . 61.240000000000002 110.15 179.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 20.8 p-90 . . . . . 0 C--N 1.324 -0.528 0 CA-C-N 115.896 -0.593 . . . . 72.409999999999997 110.579 175.069 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.163 -0.375 . . . . 74.510000000000005 112.163 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -92.13 -31.34 15.54 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.343 0.592 . . . . 62.229999999999997 110.19 178.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -120.71 166.43 13.72 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.416 -0.811 . . . . 74.510000000000005 109.968 179.593 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -137.86 104.14 5.19 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.261 -0.427 . . . . 63.240000000000002 109.978 178.106 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 38.9 t70 67.28 97.13 0.06 Allowed 'General case' 0 N--CA 1.465 0.296 0 O-C-N 123.936 0.772 . . . . 73.420000000000002 110.709 -177.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . 0.441 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -68.29 133.49 91.36 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 115.332 -0.849 . . . . 70.549999999999997 111.693 -174.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 8.0 Cg_exo -72.68 155.87 53.9 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 123.246 2.631 . . . . 74.319999999999993 112.109 178.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 21.1 m -72.72 107.71 5.32 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.385 -0.371 . . . . 74.409999999999997 110.558 178.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 99.72 83.24 1.72 Allowed Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 120.876 -0.678 . . . . 62.039999999999999 111.924 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 50.7 mt-10 -109.51 102.94 51.57 Favored Pre-proline 0 C--N 1.323 -0.545 0 N-CA-C 109.046 -0.724 . . . . 75.400000000000006 109.046 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.616 ' HG3' ' CZ ' ' A' ' 31' ' ' PHE . 66.2 Cg_endo -83.48 85.83 1.46 Allowed 'Trans proline' 0 N--CA 1.447 -1.215 0 C-N-CA 122.036 1.824 . . . . 54.109999999999999 112.076 -176.21 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 37.4 m-20 -96.05 133.47 40.25 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.049 -0.978 . . . . 71.120000000000005 109.359 178.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.521 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 14.7 p -92.92 127.55 44.96 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 121.438 0.637 . . . . 64.400000000000006 110.262 179.089 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 21.9 m -91.3 105.46 17.8 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.794 -0.639 . . . . 72.209999999999994 109.699 177.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 63.6 mt -84.36 106.13 14.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.024 -0.535 . . . . 65.450000000000003 110.899 -176.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 14.4 mtp180 -105.99 173.05 6.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.928 -0.578 . . . . 74.010000000000005 111.052 178.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -148.2 101.16 3.24 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.743 -0.662 . . . . 71.430000000000007 110.891 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . 0.607 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 3.8 mp0 -104.52 90.61 3.57 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.457 -0.792 . . . . 75.420000000000002 110.399 -178.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 76.85 -89.52 0.96 Allowed Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.775 -0.726 . . . . 72.049999999999997 112.486 179.282 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -127.57 14.57 7.06 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.458 0.129 . . . . 65.310000000000002 110.899 178.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.607 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 38.4 pttt -123.6 121.36 35.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.267 0.556 . . . . 72.150000000000006 111.181 -179.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . 0.519 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 20.8 m -84.13 98.31 9.83 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.488 -0.778 . . . . 73.420000000000002 109.748 176.412 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . 0.476 HG12 HG23 ' B' ' 137' ' ' VAL . 30.4 mt -89.68 107.52 18.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.174 0.511 . . . . 65.439999999999998 110.599 -177.231 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.521 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 20.8 mt-30 -97.95 107.6 20.12 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.783 -0.644 . . . . 54.310000000000002 110.515 -178.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -87.47 111.23 20.95 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.014 -0.539 . . . . 74.450000000000003 110.485 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . 0.463 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 78.5 m-85 -85.16 101.29 12.34 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.046 -0.353 . . . . 74.400000000000006 110.046 176.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 20.6 mtm180 -113.41 128.05 56.32 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.413 -0.358 . . . . 73.219999999999999 110.234 179.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.594 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -96.58 -50.6 11.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 C-N-CA 120.731 -0.388 . . . . 51.149999999999999 111.521 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -156.67 76.1 0.87 Allowed 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.622 -0.51 . . . . 71.340000000000003 109.622 -176.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 66.94 16.73 66.69 Favored Glycine 0 N--CA 1.451 -0.307 0 CA-C-N 115.713 -0.676 . . . . 50.340000000000003 112.403 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.613 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 89.4 t80 -137.33 128.34 27.52 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.038 0.447 . . . . 71.310000000000002 110.791 -179.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.827 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -83.2 113.35 20.6 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.175 -0.92 . . . . 74.549999999999997 108.791 173.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . 0.421 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 50.9 p90 -104.88 -14.99 15.3 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.388 -0.525 . . . . 73.430000000000007 111.665 -178.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -159.9 143.01 13.93 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.897 0.38 . . . . 72.209999999999994 111.278 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.827 HG13 HD11 ' B' ' 132' ' ' LEU . 80.8 mt -120.93 127.09 75.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.931 -0.577 . . . . 73.329999999999998 109.889 174.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.443 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 82.6 tttt -116.69 101.12 8.31 Favored 'General case' 0 C--N 1.321 -0.63 0 N-CA-C 109.411 -0.588 . . . . 70.549999999999997 109.411 172.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.542 ' O ' ' HD3' ' B' ' 139' ' ' PRO . 4.9 p -101.95 129.38 53.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.978 0 C-N-CA 120.231 -0.588 . . . . 70.340000000000003 109.758 178.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.519 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 37.5 t -109.07 84.91 2.94 Favored Pre-proline 0 C--N 1.322 -0.591 0 CA-C-N 115.553 -0.748 . . . . 75.230000000000004 109.976 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.542 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 69.0 Cg_endo -87.86 133.46 3.02 Favored 'Trans proline' 0 N--CA 1.447 -1.222 0 C-N-CA 122.506 2.138 . . . . 73.439999999999998 112.365 178.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -60.97 -20.31 62.2 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.94 -0.573 . . . . 75.099999999999994 110.304 174.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 5.6 m-70 -122.66 81.88 1.91 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.425 -0.807 . . . . 64.129999999999995 109.181 -175.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 140.0 -17.44 2.98 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.736 -0.745 . . . . 73.340000000000003 112.64 -178.082 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 74.4 mmtt 70.79 145.5 0.11 Allowed Pre-proline 0 N--CA 1.472 0.639 0 C-N-CA 123.41 0.684 . . . . 75.239999999999995 111.896 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.513 ' HB3' HG22 ' B' ' 138' ' ' VAL . 43.0 Cg_endo -67.95 149.1 77.36 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.62 2.213 . . . . 53.439999999999998 113.09 -177.342 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -158.71 156.7 30.37 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.848 -0.615 . . . . 73.129999999999995 109.695 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -102.29 134.34 45.73 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.647 0.261 . . . . 60.310000000000002 111.117 -179.221 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 46.0 mt -114.02 105.31 13.07 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.045 -0.525 . . . . 64.109999999999999 109.704 170.036 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 46.7 t -97.79 137.27 25.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.123 -0.49 . . . . 72.150000000000006 110.147 -178.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 2.8 mmt85 -75.68 131.64 40.02 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.99 0.424 . . . . 75.439999999999998 111.458 178.235 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -87.58 169.68 11.96 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.644 -0.707 . . . . 72.129999999999995 109.215 172.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . 0.449 ' H ' ' HE2' ' A' ' 26' ' ' TYR . 6.2 p-10 -69.99 125.52 26.99 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.374 0.606 . . . . 61.109999999999999 109.971 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 120.95 127.9 3.49 Favored Glycine 0 N--CA 1.442 -0.91 0 CA-C-N 115.505 -0.77 . . . . 73.209999999999994 112.12 -178.395 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 12.2 t -79.45 45.25 0.65 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.433 0.635 . . . . 53.43 110.08 178.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -84.88 -16.94 39.49 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.39 -0.823 . . . . 71.219999999999999 110.57 -178.339 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 86.39 23.56 43.25 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.825 -0.703 . . . . 70.150000000000006 111.666 -177.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 30.7 t30 -99.57 129.95 45.77 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.268 -0.466 . . . . 71.239999999999995 110.681 -177.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -116.59 151.08 36.94 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.815 -0.63 . . . . 61.020000000000003 110.004 178.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.7 mm -117.96 129.55 74.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 116.17 -0.468 . . . . 74.310000000000002 109.777 178.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.449 ' HG3' HD11 ' B' ' 167' ' ' ILE . 92.9 mtt180 -75.02 150.78 38.84 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.821 0.343 . . . . 74.510000000000005 111.136 179.362 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 64.7 p -81.29 -27.73 34.95 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 107.993 -1.114 . . . . 70.140000000000001 107.993 164.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -64.7 -35.61 81.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 114.019 -1.446 . . . . 65.519999999999996 110.94 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 9.3 tt0 -153.24 85.59 4.19 Favored Pre-proline 0 C--N 1.322 -0.589 0 CA-C-N 115.518 -0.764 . . . . 72.5 109.557 -177.137 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -79.14 8.87 3.6 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 123.106 2.537 . . . . 70.349999999999994 112.766 -176.299 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -107.4 3.9 25.73 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.214 0.531 . . . . 74.140000000000001 110.729 -178.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.7 tptt -125.23 130.65 52.51 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.855 -0.612 . . . . 73.140000000000001 110.484 -179.059 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . 0.44 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.7 mp -84.67 119.81 25.66 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.695 -0.854 . . . . 75.150000000000006 108.695 176.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . 0.449 HD11 ' HG3' ' B' ' 159' ' ' ARG . 36.4 mm -80.56 119.51 76.49 Favored Pre-proline 0 C--N 1.322 -0.614 0 CA-C-O 120.995 0.426 . . . . 72.450000000000003 111.177 -172.048 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.551 ' O ' HG23 ' B' ' 172' ' ' ILE . 58.1 Cg_endo -69.73 173.0 11.58 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 122.803 2.335 . . . . 72.329999999999998 112.098 178.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . 0.64 ' O ' HG12 ' B' ' 172' ' ' ILE . 5.5 tt0 -73.78 -33.11 64.11 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.734 -0.666 . . . . 64.530000000000001 111.362 -168.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 11.6 p90 -66.4 -17.72 64.94 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 120.437 -0.505 . . . . 72.040000000000006 110.714 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.614 ' HA ' ' HB2' ' B' ' 174' ' ' SER . 20.1 tt0 -102.46 -17.68 15.68 Favored 'General case' 0 N--CA 1.444 -0.727 0 CA-C-N 116.428 -0.351 . . . . 72.420000000000002 111.496 -177.024 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.64 HG12 ' O ' ' B' ' 169' ' ' GLN . 30.7 pt -70.18 -27.54 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.954 0.407 . . . . 72.219999999999999 110.509 178.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -118.22 36.25 4.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.517 0.675 . . . . 71.540000000000006 109.782 173.194 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . 0.614 ' HB2' ' HA ' ' B' ' 171' ' ' GLU . 45.3 t -62.39 -27.17 68.89 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.023 -0.99 . . . . 61.210000000000001 111.194 -179.307 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.246 0.916 0 CA-C-O 118.437 -0.792 . . . . 70.420000000000002 111.263 -179.675 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.669 0 N-CA-C 112.076 -0.41 . . . . 54.329999999999998 112.076 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -90.45 -22.84 21.21 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.73 0.3 . . . . 63.439999999999998 111.242 -176.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 14.3 p-10 -83.77 -44.44 14.4 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.467 -0.333 . . . . 43.219999999999999 110.497 -178.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -166.24 -167.25 1.01 Allowed 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.094 -0.706 . . . . 73.239999999999995 109.094 175.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -126.09 111.78 15.08 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.905 0.383 . . . . 73.319999999999993 110.5 -178.374 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -98.91 115.1 65.95 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 115.989 -0.551 . . . . 64.109999999999999 111.142 -177.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -84.37 -160.25 0.11 Allowed 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 123.053 2.502 . . . . 53.409999999999997 112.228 177.092 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.0 p -79.41 178.05 8.4 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.305 -0.407 . . . . 64.409999999999997 110.875 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.2 -73.34 2.63 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.77 -0.729 . . . . 72.420000000000002 111.467 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 60.4 74.87 0.51 Allowed Pre-proline 0 C--N 1.329 -0.285 0 C-N-CA 123.046 0.538 . . . . 65.099999999999994 110.152 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.856 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 12.2 Cg_endo -60.32 107.33 0.41 Allowed 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.597 2.198 . . . . 74.019999999999996 112.708 -178.806 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 23.7 m-20 -90.5 154.03 19.94 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.627 -0.715 . . . . 61.43 109.876 179.163 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.493 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 12.5 p -117.99 125.74 74.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-O 121.395 0.617 . . . . 64.329999999999998 110.549 176.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.6 m -98.53 111.45 23.81 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.548 -0.751 . . . . 73.030000000000001 110.062 179.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.8 mt -93.2 105.86 17.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.285 -0.416 . . . . 42.149999999999999 110.945 -176.374 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 22.5 mtt180 -120.48 167.42 12.39 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.014 -0.735 . . . . 64.0 109.014 177.244 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 91.6 mt-30 -127.35 119.0 25.24 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 120.929 0.395 . . . . 73.310000000000002 111.281 177.173 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.452 ' HG3' HD12 ' A' ' 23' ' ' ILE . 12.4 mm-40 -97.52 82.54 3.11 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.939 -0.763 . . . . 62.409999999999997 108.939 175.151 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 79.63 -107.03 2.51 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.3 -0.952 . . . . 62.340000000000003 111.351 -173.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.574 ' HB3' ' HB2' ' A' ' 40' ' ' LYS . 10.3 m-20 -108.85 0.41 20.27 Favored 'General case' 0 C--N 1.327 -0.38 0 O-C-N 122.615 -0.344 . . . . 72.430000000000007 111.114 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.81 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 22.1 pttm -101.74 113.03 25.84 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.443 0.64 . . . . 72.420000000000002 111.022 179.085 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.705 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 21.1 m -80.0 97.87 6.97 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.222 -0.899 . . . . 63.420000000000002 109.798 177.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.586 HG12 HG13 ' A' ' 37' ' ' VAL . 55.0 mt -90.85 112.23 24.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.035 0.445 . . . . 73.439999999999998 110.566 -176.544 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.588 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 17.1 mt-30 -95.67 108.33 20.61 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.961 -0.563 . . . . 72.349999999999994 109.956 178.21 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -84.82 102.81 13.36 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.78 -0.646 . . . . 64.420000000000002 110.346 -177.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.44 ' HE1' ' HB2' ' A' ' 36' ' ' LYS . 86.3 m-85 -82.12 102.38 11.02 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.162 0.506 . . . . 54.450000000000003 109.783 176.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 88.1 mtm180 -118.12 117.52 29.39 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.853 -0.612 . . . . 70.450000000000003 109.93 -179.382 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.892 HG11 HG11 ' B' ' 128' ' ' VAL . 2.6 p -69.4 -43.19 81.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.924 -0.58 . . . . 63.020000000000003 111.14 -174.356 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 33.9 t-20 -169.85 75.35 0.08 Allowed 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.644 -0.873 . . . . 65.400000000000006 108.644 -179.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 85.22 -23.54 8.1 Favored Glycine 0 N--CA 1.45 -0.416 0 CA-C-N 115.443 -0.799 . . . . 34.130000000000003 112.676 -177.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 51.2 t80 -112.25 131.24 55.6 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.215 0.531 . . . . 60.229999999999997 110.749 -176.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.505 HD21 ' CG1' ' A' ' 35' ' ' ILE . 27.2 tp -76.66 126.21 30.59 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 114.974 -1.012 . . . . 72.239999999999995 110.463 178.471 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . 0.425 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 49.6 p90 -115.23 -14.3 11.71 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 120.764 -0.374 . . . . 75.329999999999998 111.173 179.068 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.508 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -161.72 143.81 11.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.998 0.428 . . . . 74.310000000000002 111.142 -177.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.624 ' HB ' ' HB2' ' A' ' 47' ' ' LEU . 63.7 mt -121.84 121.35 64.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.992 -0.549 . . . . 52.240000000000002 109.87 176.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.588 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 88.2 tttt -102.19 99.62 9.76 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.244 -0.651 . . . . 75.430000000000007 109.244 172.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.69 HG12 ' HD3' ' A' ' 39' ' ' PRO . 3.5 t -86.18 126.63 40.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 N-CA-C 108.568 -0.901 . . . . 71.239999999999995 108.568 178.132 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.705 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.6 t -115.73 72.87 4.19 Favored Pre-proline 0 C--N 1.318 -0.761 0 N-CA-C 109.753 -0.462 . . . . 64.099999999999994 109.753 172.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.81 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 43.2 Cg_endo -77.08 129.4 10.5 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 122.041 1.827 . . . . 75.120000000000005 112.413 177.179 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.574 ' HB2' ' HB3' ' A' ' 20' ' ' ASP . 55.7 mtpt -59.05 -32.13 69.47 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.043 -0.981 . . . . 43.539999999999999 110.285 176.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 67.9 m-70 -115.36 95.93 5.41 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.365 -0.834 . . . . 65.209999999999994 109.314 178.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 132.46 -23.06 4.08 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 121.009 -0.615 . . . . 71.439999999999998 111.99 -176.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.498 ' HD3' ' HA ' ' A' ' 43' ' ' LYS . 68.8 mmtt 72.99 148.94 0.12 Allowed Pre-proline 0 N--CA 1.467 0.389 0 C-N-CA 123.86 0.864 . . . . 74.340000000000003 112.651 177.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.646 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 27.9 Cg_endo -62.59 141.86 87.68 Favored 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 123.04 2.493 . . . . 62.340000000000003 113.921 -174.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.422 ' CE2' ' HG2' ' A' ' 59' ' ' ARG . 25.1 p90 -151.43 149.42 29.26 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-N 115.361 -0.836 . . . . 74.030000000000001 109.855 176.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.597 ' HB2' ' HB2' ' A' ' 60' ' ' SER . 88.6 m-85 -92.35 150.4 20.86 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.286 -0.416 . . . . 75.439999999999998 111.14 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.624 ' HB2' ' HB ' ' A' ' 35' ' ' ILE . 23.0 mt -123.37 96.46 4.99 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.711 -0.677 . . . . 43.340000000000003 109.674 171.252 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 45.8 t -90.16 122.24 41.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.438 -0.346 . . . . 55.439999999999998 110.519 -178.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -62.25 128.98 38.64 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 120.974 0.416 . . . . 74.510000000000005 111.303 176.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -92.9 152.33 19.44 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.452 -0.573 . . . . 74.420000000000002 109.452 172.601 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -57.85 144.07 40.12 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.332 -0.395 . . . . 71.400000000000006 110.58 -179.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 118.45 148.31 8.46 Favored Glycine 0 N--CA 1.431 -1.684 0 C-N-CA 120.198 -1.001 . . . . 51.240000000000002 112.402 -179.664 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 16.6 m -76.67 -2.63 33.76 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 114.947 -0.626 . . . . 73.0 110.779 175.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -57.91 -43.66 86.34 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.142 -0.481 . . . . 70.319999999999993 112.048 -178.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 98.79 32.76 5.8 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.419 -0.896 . . . . 45.43 111.63 -179.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.842 HD21 HD22 ' A' ' 66' ' ' LEU . 32.1 t30 -87.06 132.82 33.7 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.367 -0.416 . . . . 74.299999999999997 110.417 -178.342 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -122.17 160.17 25.7 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.994 -0.548 . . . . 71.019999999999996 110.211 177.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.817 HD11 HD23 ' A' ' 66' ' ' LEU . 43.9 mm -120.22 115.32 46.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 116.279 -0.419 . . . . 74.439999999999998 109.972 177.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.676 ' HG3' HG13 ' A' ' 67' ' ' ILE . 18.7 mtp180 -75.95 130.1 37.94 Favored 'General case' 0 C--O 1.22 -0.492 0 CA-C-N 115.785 -0.643 . . . . 74.420000000000002 109.797 177.366 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.597 ' HB2' ' HB2' ' A' ' 46' ' ' PHE . 17.4 t -70.48 -17.53 62.97 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.894 0.854 . . . . 75.530000000000001 108.79 172.504 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -67.76 -27.38 66.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 114.384 -1.28 . . . . 61.210000000000001 110.453 173.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 9.7 tt0 -158.88 78.84 3.01 Favored Pre-proline 0 C--N 1.327 -0.404 0 CA-C-N 115.664 -0.698 . . . . 73.010000000000005 109.484 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 81.8 Cg_endo -78.76 -1.24 11.43 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.725 2.284 . . . . 71.129999999999995 112.375 -174.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -92.52 0.09 57.39 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.406 -0.816 . . . . 72.430000000000007 110.205 -178.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.429 ' HE3' ' O ' ' A' ' 66' ' ' LEU . 52.4 tptt -128.48 134.29 48.68 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.732 -0.667 . . . . 74.109999999999999 110.539 -179.078 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.842 HD22 HD21 ' A' ' 56' ' ' ASN . 26.2 mt -80.29 123.48 28.01 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.129 -0.693 . . . . 75.409999999999997 109.129 175.182 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.676 HG13 ' HG3' ' A' ' 59' ' ' ARG . 44.1 mm -92.43 113.76 60.32 Favored Pre-proline 0 C--N 1.32 -0.681 0 CA-C-O 120.941 0.401 . . . . 75.340000000000003 111.277 -173.08 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -72.62 177.99 6.82 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.887 2.392 . . . . 74.239999999999995 112.961 -177.288 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . 0.535 ' O ' HG12 ' A' ' 72' ' ' ILE . 19.4 tt0 -77.58 -17.14 58.13 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.493 -0.776 . . . . 73.340000000000003 112.067 -168.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 10.4 p90 -83.16 -18.32 39.83 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.251 -0.58 . . . . 74.329999999999998 110.281 176.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.553 ' HB3' HG23 ' A' ' 67' ' ' ILE . 1.4 tm-20 -90.35 -24.49 20.82 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 115.933 -0.576 . . . . 63.140000000000001 109.966 -178.304 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.535 HG12 ' O ' ' A' ' 69' ' ' GLN . 31.5 pt -70.28 -20.89 23.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 121.223 0.535 . . . . 62.439999999999998 110.396 177.766 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 46.2 m-85 -111.62 33.67 4.6 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.787 -0.642 . . . . 74.219999999999999 109.822 174.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 19.0 t -67.0 -33.17 74.98 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.384 -0.825 . . . . 62.210000000000001 110.171 178.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . 0.458 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 8.2 p-90 . . . . . 0 C--N 1.327 -0.398 0 CA-C-N 116.003 -0.544 . . . . 74.340000000000003 110.602 175.386 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.405 0 N-CA-C 112.186 -0.366 . . . . 71.109999999999999 112.186 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -78.59 -39.31 37.79 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.198 0.523 . . . . 61.200000000000003 110.368 178.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . 0.425 ' O ' ' HB3' ' B' ' 104' ' ' ASP . 6.4 p-10 -109.14 117.34 33.89 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.079 -0.711 . . . . 74.329999999999998 109.079 173.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . 0.425 ' HB3' ' O ' ' B' ' 103' ' ' ASP . 8.4 t70 70.18 136.59 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 121.522 0.677 . . . . 64.409999999999997 111.615 -177.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -121.4 128.65 52.42 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.829 -0.623 . . . . 72.129999999999995 110.991 -178.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . 0.505 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -115.36 135.09 22.52 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.199 -0.455 . . . . 71.209999999999994 110.516 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . 0.505 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 15.1 Cg_endo -90.71 -161.25 0.1 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 123.408 2.739 . . . . 64.319999999999993 112.698 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 5.2 p -73.37 162.33 29.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.777 -0.647 . . . . 63.020000000000003 111.065 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 108.75 -77.21 0.22 Allowed Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.588 -1.005 . . . . 73.329999999999998 110.588 -177.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 68.85 86.68 0.12 Allowed Pre-proline 0 CA--C 1.521 -0.171 0 CA-C-O 121.274 0.559 . . . . 70.019999999999996 110.558 173.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.668 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 3.0 Cg_exo -69.95 118.04 5.45 Favored 'Trans proline' 0 N--CA 1.451 -0.972 0 C-N-CA 122.298 1.999 . . . . 74.439999999999998 111.731 -174.493 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -118.44 161.38 20.07 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.091 -0.958 . . . . 62.5 109.763 -174.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . . . . . . . . . 14.6 p -133.3 132.63 58.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.428 0.632 . . . . 61.130000000000003 111.5 -178.012 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 31.4 m -97.17 105.07 17.16 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.527 -0.76 . . . . 75.099999999999994 109.266 174.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 65.6 mt -95.59 104.66 16.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.369 0.604 . . . . 65.230000000000004 110.703 -176.369 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 57.1 mtm180 -123.55 176.06 6.42 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.247 -0.888 . . . . 54.340000000000003 109.354 176.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . 0.738 ' HG2' ' HA ' ' B' ' 122' ' ' THR . 37.7 mt-30 -134.17 139.73 46.05 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.411 0.624 . . . . 73.120000000000005 111.389 178.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . 0.565 ' HB3' ' HE2' ' B' ' 121' ' ' LYS . 0.9 OUTLIER -120.15 72.85 0.95 Allowed 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.954 -1.021 . . . . 73.329999999999998 109.679 -177.075 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 87.93 -108.87 3.44 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.611 -0.804 . . . . 71.209999999999994 111.703 -175.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.687 ' HB3' ' HD2' ' B' ' 140' ' ' LYS . 39.5 m-20 -109.9 13.24 23.55 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.932 0.396 . . . . 75.140000000000001 110.616 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.573 ' HE3' ' HB2' ' B' ' 175' ' ' TRP . 23.7 pttm -120.02 116.49 25.85 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.868 -0.606 . . . . 74.129999999999995 110.664 179.151 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . 0.738 ' HA ' ' HG2' ' B' ' 117' ' ' GLN . 20.0 m -77.4 122.16 24.78 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.598 -0.728 . . . . 64.439999999999998 109.495 176.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 55.7 mt -112.4 107.79 23.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.328 0.585 . . . . 75.439999999999998 110.819 -176.356 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.509 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 12.4 mt-30 -100.5 102.9 14.19 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.724 -0.671 . . . . 75.430000000000007 109.935 178.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . 0.407 ' HB3' HD13 ' B' ' 132' ' ' LEU . 48.3 mt-10 -82.92 104.58 13.24 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.005 -0.543 . . . . 73.120000000000005 110.521 -179.612 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . 0.43 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 79.2 m-85 -82.15 108.9 15.98 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.165 0.507 . . . . 74.430000000000007 110.147 178.356 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 82.9 mtt180 -118.97 121.41 39.86 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.806 -0.634 . . . . 74.129999999999995 109.342 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.892 HG11 HG11 ' A' ' 28' ' ' VAL . 2.1 p -70.68 -46.44 69.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 C-N-CA 120.761 -0.376 . . . . 72.239999999999995 110.719 -178.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 6.1 t-20 -158.34 56.96 0.46 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.482 0.658 . . . . 63.119999999999997 109.427 -177.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 98.04 -23.74 34.76 Favored Glycine 0 N--CA 1.449 -0.452 0 CA-C-N 115.589 -0.732 . . . . 72.349999999999994 112.86 -178.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 64.0 t80 -104.28 129.82 52.11 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 121.062 0.458 . . . . 72.219999999999999 110.46 -178.064 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.558 HD21 ' CG1' ' B' ' 135' ' ' ILE . 28.7 tp -74.46 120.86 20.6 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.107 -0.952 . . . . 72.140000000000001 110.6 177.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . 0.43 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 54.1 p90 -110.86 -12.96 14.21 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 120.845 -0.342 . . . . 74.510000000000005 111.204 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . 0.565 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -167.1 137.1 2.96 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.974 0.416 . . . . 65.450000000000003 111.141 -177.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.558 ' CG1' HD21 ' B' ' 132' ' ' LEU . 56.9 mt -114.58 122.78 69.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.02 -0.536 . . . . 73.200000000000003 109.821 175.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.509 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.3 tttt -96.0 101.51 13.19 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.089 -0.708 . . . . 51.439999999999998 109.089 172.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.681 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.0 t -91.62 125.84 44.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 N-CA-C 108.493 -0.929 . . . . 72.209999999999994 108.493 177.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.536 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.3 t -115.48 72.91 3.81 Favored Pre-proline 0 C--N 1.316 -0.867 0 N-CA-C 109.672 -0.492 . . . . 54.25 109.672 173.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.611 ' HD3' HG12 ' B' ' 137' ' ' VAL . 56.8 Cg_endo -80.21 133.32 9.76 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 122.153 1.902 . . . . 64.310000000000002 112.005 175.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . 0.687 ' HD2' ' HB3' ' B' ' 120' ' ' ASP . 93.0 mttt -52.05 -40.93 61.88 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-O 121.527 0.68 . . . . 60.210000000000001 110.219 175.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 8.6 m-70 -112.26 91.9 3.82 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.108 -0.951 . . . . 75.530000000000001 109.429 -175.056 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 140.66 -21.65 2.7 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.819 -0.628 . . . . 51.200000000000003 111.832 -177.014 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt 75.3 150.62 0.13 Allowed Pre-proline 0 N--CA 1.469 0.491 0 C-N-CA 123.544 0.738 . . . . 54.329999999999998 111.708 178.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.681 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 36.5 Cg_endo -66.9 137.39 44.8 Favored 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 122.461 2.107 . . . . 62.140000000000001 112.791 -177.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . 0.413 ' CD2' ' HD2' ' B' ' 159' ' ' ARG . 50.8 p90 -149.51 150.28 32.06 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.751 -0.659 . . . . 72.040000000000006 110.352 179.276 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.534 ' O ' ' HA ' ' B' ' 159' ' ' ARG . 92.4 m-85 -95.74 130.35 42.68 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.778 -0.646 . . . . 73.140000000000001 110.375 176.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.565 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 15.0 mt -99.77 99.29 10.08 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.119 -0.491 . . . . 74.310000000000002 109.908 170.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.0 t -83.97 127.99 39.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 116.311 -0.404 . . . . 75.430000000000007 110.246 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.99 108.72 2.7 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.124 -0.695 . . . . 72.409999999999997 109.124 176.418 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.24 166.38 9.95 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.207 -0.451 . . . . 52.350000000000001 110.97 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -53.5 129.03 31.06 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.7 0.762 . . . . 75.450000000000003 112.52 -175.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 83.11 -115.99 4.13 Favored Glycine 0 N--CA 1.429 -1.816 0 CA-C-N 114.447 -1.251 . . . . 64.219999999999999 111.509 178.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 17.0 m -169.41 34.51 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 113.803 -1.198 . . . . 65.540000000000006 109.384 -178.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -78.79 35.7 0.25 Allowed 'General case' 0 CA--C 1.535 0.365 0 CA-C-N 115.4 -0.818 . . . . 72.25 111.405 -173.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 58.12 43.23 95.35 Favored Glycine 0 C--O 1.229 -0.212 0 CA-C-N 115.789 -0.641 . . . . 62.140000000000001 113.21 177.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 47.1 t30 -137.3 137.83 39.39 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.185 0.516 . . . . 74.319999999999993 111.085 -177.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . 0.527 ' HB3' HD22 ' B' ' 147' ' ' LEU . 39.0 m-85 -131.09 154.25 48.48 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.189 -0.914 . . . . 75.129999999999995 108.697 172.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 49.2 mm -120.65 122.79 68.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 N-CA-C 110.183 -0.303 . . . . 61.450000000000003 110.183 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.955 ' HG3' HG13 ' B' ' 167' ' ' ILE . 31.5 mtm-85 -88.9 137.28 32.46 Favored 'General case' 0 CA--C 1.517 -0.326 0 CA-C-N 116.338 -0.392 . . . . 72.439999999999998 110.126 178.067 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 35.1 t -64.69 -18.94 65.44 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.445 0.64 . . . . 73.319999999999993 109.334 171.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -59.37 -52.13 66.95 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 114.942 -1.027 . . . . 71.150000000000006 110.878 174.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 26.2 mt-30 -143.71 79.6 13.45 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 74.409999999999997 110.442 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -68.21 -0.58 5.87 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 123.292 2.661 . . . . 60.100000000000001 112.329 177.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -81.44 -18.48 45.16 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.639 -0.71 . . . . 64.25 110.233 178.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -119.95 140.11 51.42 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.856 -0.611 . . . . 61.340000000000003 110.885 -177.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.0 mp -81.87 126.87 32.4 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 107.898 -1.149 . . . . 74.319999999999993 107.898 171.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . 0.955 HG13 ' HG3' ' B' ' 159' ' ' ARG . 44.7 mm -87.81 119.66 70.63 Favored Pre-proline 0 C--N 1.318 -0.794 0 CA-C-O 120.882 0.372 . . . . 75.340000000000003 111.267 -170.425 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.449 ' O ' HG23 ' B' ' 172' ' ' ILE . 58.8 Cg_endo -71.09 174.3 10.85 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 123.27 2.647 . . . . 65.439999999999998 112.655 -179.187 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . 0.813 ' HA ' HG12 ' B' ' 172' ' ' ILE . 8.5 tt0 -72.75 -32.62 65.79 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.58 -0.736 . . . . 61.439999999999998 111.963 -168.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 36.9 p90 -73.56 -17.86 61.14 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.165 0.507 . . . . 74.329999999999998 110.326 178.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -94.28 -30.86 14.33 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.847 -0.615 . . . . 63.229999999999997 110.964 178.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.813 HG12 ' HA ' ' B' ' 169' ' ' GLN . 37.6 pt -74.45 -29.3 23.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.985 0.421 . . . . 73.129999999999995 110.381 176.312 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -104.76 37.86 2.04 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.184 0.516 . . . . 73.140000000000001 110.13 175.256 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 15.9 t -73.78 -22.88 59.69 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.827 -0.624 . . . . 65.299999999999997 110.262 179.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . 0.573 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 60.3 p-90 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.243 -0.884 . . . . 75.209999999999994 110.656 -178.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.84 0 N-CA-C 112.195 -0.362 . . . . 72.230000000000004 112.195 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -144.72 79.74 1.61 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.719 0.295 . . . . 61.32 110.801 179.398 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 62.11 20.87 11.98 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.721 -0.672 . . . . 72.299999999999997 111.963 178.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.1 p30 -95.62 155.35 16.78 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.146 0.498 . . . . 75.109999999999999 110.588 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 34.8 t70 -93.29 133.1 36.87 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.768 -0.651 . . . . 63.539999999999999 110.972 -177.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -87.63 138.23 31.74 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-N 115.845 -0.616 . . . . 70.329999999999998 111.096 -177.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -82.24 179.46 5.49 Favored 'Trans proline' 0 N--CA 1.464 -0.261 0 C-N-CA 122.954 2.436 . . . . 74.140000000000001 112.938 -177.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 28.5 p -72.42 110.43 6.82 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-N 116.135 -0.484 . . . . 74.430000000000007 110.043 176.122 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.79 105.63 3.02 Favored Glycine 0 N--CA 1.443 -0.845 0 N-CA-C 110.2 -1.16 . . . . 65.239999999999995 110.2 -173.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -116.76 95.74 47.06 Favored Pre-proline 0 C--N 1.317 -0.823 0 N-CA-C 109.516 -0.55 . . . . 74.409999999999997 109.516 -171.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.29 100.35 1.36 Allowed 'Trans proline' 0 N--CA 1.445 -1.372 0 C-N-CA 121.797 1.664 . . . . 43.049999999999997 111.422 -177.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -132.12 145.28 51.28 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 115.222 -0.899 . . . . 75.329999999999998 109.546 178.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.705 HG21 ' HB3' ' A' ' 24' ' ' GLN . 12.8 p -98.63 131.5 45.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 CA-C-O 121.297 0.57 . . . . 75.239999999999995 111.674 -172.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.49 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 25.0 m -83.69 103.79 13.28 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.686 -0.688 . . . . 75.219999999999999 109.211 176.527 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 61.3 mt -93.44 105.66 17.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 116.246 -0.434 . . . . 74.099999999999994 110.474 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 28.4 mmm180 -121.41 153.74 37.43 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.99 -0.55 . . . . 73.299999999999997 110.29 177.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 23.3 mp0 -113.49 107.66 16.12 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-O 121.355 0.598 . . . . 75.510000000000005 110.522 -178.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.653 ' HG3' HD12 ' A' ' 23' ' ' ILE . 24.1 mm-40 -106.21 88.4 2.78 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.204 -0.907 . . . . 62.109999999999999 109.8 -177.115 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 74.11 -109.57 2.83 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.702 -0.761 . . . . 64.340000000000003 112.201 -179.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.672 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 25.4 m-20 -109.31 22.4 15.87 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.752 0.311 . . . . 72.010000000000005 110.507 -177.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.56 ' HE2' HD11 ' A' ' 23' ' ' ILE . 22.2 pttm -138.41 127.05 23.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.307 0.575 . . . . 60.149999999999999 111.175 -178.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.591 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 26.4 m -85.13 103.9 14.54 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.623 -0.717 . . . . 62.329999999999998 109.232 174.423 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.653 HD12 ' HG3' ' A' ' 18' ' ' GLU . 41.7 mt -95.61 112.54 28.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.162 0.505 . . . . 72.420000000000002 110.294 -176.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.705 ' HB3' HG21 ' A' ' 13' ' ' VAL . 23.9 mt-30 -103.82 109.78 21.65 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.413 -0.812 . . . . 72.329999999999998 111.111 -176.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.49 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 24.7 mt-10 -94.61 106.67 18.66 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.032 -0.531 . . . . 72.340000000000003 111.137 -179.113 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.493 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 54.5 m-85 -76.69 109.52 10.53 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 116.276 -0.42 . . . . 52.530000000000001 110.508 178.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 74.7 mtt180 -124.06 140.49 52.92 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.337 -0.392 . . . . 74.109999999999999 110.115 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.505 HG21 ' CG ' ' B' ' 131' ' ' PHE . 12.3 p -109.03 -19.47 6.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-O 121.422 0.63 . . . . 72.530000000000001 111.28 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -159.82 24.54 0.18 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.237 -0.653 . . . . 72.450000000000003 109.237 -176.321 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 99.62 -31.18 8.65 Favored Glycine 0 N--CA 1.45 -0.429 0 N-CA-C 110.984 -0.846 . . . . 75.319999999999993 110.984 -169.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 89.3 t80 -66.87 130.1 42.04 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.178 -0.511 . . . . 75.299999999999997 110.811 178.004 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.757 HD11 HG13 ' A' ' 35' ' ' ILE . 3.3 tm? -88.38 114.47 25.03 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.554 -0.748 . . . . 41.530000000000001 109.231 178.19 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . 0.493 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 43.2 p90 -110.98 -13.27 14.13 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 120.664 -0.414 . . . . 74.239999999999995 111.682 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -163.21 144.42 9.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.723 0.296 . . . . 65.010000000000005 111.34 179.588 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.757 HG13 HD11 ' A' ' 32' ' ' LEU . 71.3 mt -126.1 123.71 64.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.111 -0.495 . . . . 62.310000000000002 109.768 176.07 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.419 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 87.0 tttt -108.81 107.22 17.56 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.628 -0.508 . . . . 63.149999999999999 109.628 176.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.649 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.7 t -89.92 132.31 34.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.189 -0.671 . . . . 53.039999999999999 109.189 178.38 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.591 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 18.9 t -116.57 73.97 6.05 Favored Pre-proline 0 C--N 1.322 -0.623 0 N-CA-C 109.433 -0.58 . . . . 41.240000000000002 109.433 171.194 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.47 ' HD3' HG12 ' A' ' 37' ' ' VAL . 61.0 Cg_endo -78.71 145.87 20.69 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.642 2.228 . . . . 74.099999999999994 112.977 179.212 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.672 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 30.5 mtpp -68.07 -28.0 66.99 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.514 -0.766 . . . . 73.530000000000001 109.932 174.043 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 66.5 m-70 -122.52 96.2 4.94 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.55 -0.75 . . . . 54.439999999999998 109.745 178.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.418 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 139.51 -21.5 2.9 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 120.73 -0.747 . . . . 54.520000000000003 112.422 -179.649 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.422 ' HD3' ' HA ' ' A' ' 43' ' ' LYS . 69.4 mmtt 71.89 150.38 0.13 Allowed Pre-proline 0 N--CA 1.47 0.56 0 C-N-CA 123.201 0.6 . . . . 71.439999999999998 111.956 -179.593 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.649 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 39.4 Cg_endo -67.0 137.18 43.72 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 122.564 2.176 . . . . 73.530000000000001 112.683 -178.359 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 42.0 p90 -149.52 163.95 36.41 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.738 -0.664 . . . . 73.329999999999998 110.294 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.472 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 96.3 m-85 -108.22 126.44 52.81 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.484 -0.325 . . . . 72.530000000000001 111.429 -176.797 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.449 ' HB3' ' HD2' ' A' ' 57' ' ' PHE . 36.9 mt -107.22 100.14 9.62 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.131 -0.486 . . . . 72.510000000000005 109.977 171.253 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.6 t -84.74 126.72 40.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.245 -0.434 . . . . 73.349999999999994 109.901 178.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.45 111.39 18.43 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.236 -0.653 . . . . 73.420000000000002 109.236 -178.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -79.05 168.89 19.01 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.8 -0.636 . . . . 60.409999999999997 111.411 -172.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -64.14 145.19 56.37 Favored 'General case' 0 C--O 1.236 0.39 0 CA-C-N 115.765 -0.652 . . . . 74.329999999999998 109.904 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 113.83 135.95 6.26 Favored Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.452 -0.88 . . . . 44.299999999999997 112.373 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 13.2 m -79.24 19.68 0.56 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.931 0.396 . . . . 61.539999999999999 110.832 178.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 21.6 t70 -78.91 -42.61 26.7 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.026 0.441 . . . . 64.219999999999999 111.137 -177.313 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.84 36.4 2.99 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.698 -0.763 . . . . 75.319999999999993 111.919 -178.404 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 26.2 t30 -95.45 129.49 42.59 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.821 0.343 . . . . 74.049999999999997 110.539 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.449 ' HD2' ' HB3' ' A' ' 47' ' ' LEU . 34.7 m-85 -111.51 149.38 31.43 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.227 -0.442 . . . . 72.409999999999997 110.153 177.016 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 51.0 mm -121.57 125.73 73.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.22 -0.445 . . . . 72.120000000000005 109.98 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.581 ' HG3' HG13 ' A' ' 67' ' ' ILE . 27.4 mtp180 -81.6 141.08 34.05 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.438 -0.346 . . . . 72.120000000000005 110.66 179.376 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 33.7 t -70.0 -16.21 63.14 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.229 0.538 . . . . 74.140000000000001 109.894 176.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.46 ' OD1' ' HB3' ' A' ' 59' ' ' ARG . 0.4 OUTLIER -76.03 -34.41 59.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.4 -0.818 . . . . 73.310000000000002 109.945 178.169 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 47.7 mt-30 -143.26 70.36 18.01 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 115.443 -0.799 . . . . 74.329999999999998 109.786 -174.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -72.88 -2.35 11.83 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 123.325 2.684 . . . . 73.450000000000003 113.476 -175.067 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -94.06 -13.63 26.67 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.608 0.242 . . . . 71.450000000000003 111.332 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.419 ' HE2' ' HB2' ' A' ' 65' ' ' LYS . 0.0 OUTLIER -117.02 168.76 9.97 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-O 120.549 0.214 . . . . 73.049999999999997 110.943 -179.567 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.429 ' N ' HD12 ' A' ' 66' ' ' LEU . 4.1 mp -106.3 151.84 24.31 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 120.831 0.348 . . . . 74.109999999999999 111.032 -175.228 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.581 HG13 ' HG3' ' A' ' 59' ' ' ARG . 37.9 mm -119.54 104.98 44.43 Favored Pre-proline 0 C--N 1.325 -0.463 0 CA-C-N 116.192 -0.458 . . . . 52.049999999999997 109.98 177.519 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.558 ' O ' HG23 ' A' ' 72' ' ' ILE . 61.3 Cg_endo -73.77 177.42 8.11 Favored 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.822 2.348 . . . . 62.219999999999999 113.004 -178.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . 0.626 ' HA ' HG12 ' A' ' 72' ' ' ILE . 28.5 tt0 -65.32 -32.05 73.5 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 113.029 0.751 . . . . 64.120000000000005 113.029 -168.159 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 3.9 p90 -71.34 -18.95 62.36 Favored 'General case' 0 C--N 1.323 -0.545 0 O-C-N 121.517 -0.739 . . . . 74.430000000000007 110.592 178.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.47 ' HB3' HG23 ' A' ' 67' ' ' ILE . 4.8 tp10 -102.38 -17.76 15.7 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 115.749 -0.66 . . . . 72.349999999999994 110.549 -177.117 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.626 HG12 ' HA ' ' A' ' 69' ' ' GLN . 35.3 pt -74.26 -21.77 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.147 0 CA-C-O 121.256 0.55 . . . . 63.0 109.863 174.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -107.21 26.59 9.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.417 -0.81 . . . . 73.540000000000006 109.664 174.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.2 t -61.42 -29.84 70.19 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.197 -0.91 . . . . 65.540000000000006 110.234 179.295 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . 0.517 ' O ' ' HE3' ' A' ' 21' ' ' LYS . 28.3 p-90 . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.135 -0.484 . . . . 72.219999999999999 110.757 175.399 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 N-CA-C 112.128 -0.389 . . . . 73.230000000000004 112.128 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -140.67 -59.99 0.51 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.086 0.469 . . . . 75.219999999999999 110.117 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -139.08 81.84 1.86 Allowed 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 108.703 -0.851 . . . . 71.409999999999997 108.703 173.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -173.21 177.92 2.57 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.468 -0.787 . . . . 71.510000000000005 110.208 -172.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -114.95 161.97 17.58 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.113 -0.494 . . . . 74.439999999999998 110.832 -177.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -118.21 139.18 26.39 Favored Pre-proline 0 C--N 1.321 -0.638 0 CA-C-N 115.652 -0.704 . . . . 73.409999999999997 109.428 172.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.2 148.95 87.84 Favored 'Trans proline' 0 C--O 1.236 0.39 0 C-N-CA 122.451 2.101 . . . . 72.420000000000002 111.798 178.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 15.0 m -51.5 130.27 27.3 Favored 'General case' 0 C--O 1.233 0.236 0 CA-C-O 121.108 0.48 . . . . 72.430000000000007 110.737 -178.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 124.49 -65.6 0.54 Allowed Glycine 0 N--CA 1.442 -0.953 0 N-CA-C 109.983 -1.247 . . . . 74.049999999999997 109.983 -174.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 66.82 86.4 0.13 Allowed Pre-proline 0 N--CA 1.463 0.178 0 O-C-N 124.334 0.667 . . . . 65.299999999999997 111.736 173.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.579 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 11.2 Cg_endo -77.58 97.16 1.13 Allowed 'Trans proline' 0 N--CA 1.447 -1.257 0 C-N-CA 121.913 1.742 . . . . 72.549999999999997 110.775 177.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -128.81 150.82 50.15 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.407 -0.815 . . . . 75.310000000000002 109.67 -175.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.539 HG21 ' HB3' ' B' ' 124' ' ' GLN . 12.0 p -100.7 131.31 48.56 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-O 121.417 0.627 . . . . 75.109999999999999 111.748 -174.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . 0.587 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 15.6 m -87.77 102.43 14.66 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.5 -0.773 . . . . 73.150000000000006 109.772 175.585 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 55.1 mt -91.03 105.82 16.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-O 120.829 0.347 . . . . 73.510000000000005 110.495 -176.291 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 28.7 mmm180 -112.85 157.89 20.84 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.259 -0.428 . . . . 65.319999999999993 110.464 -179.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -121.22 99.32 6.42 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.23 -0.441 . . . . 33.109999999999999 109.961 178.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 57.5 mm-40 -109.59 80.86 1.36 Allowed 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.981 -0.554 . . . . 65.409999999999997 110.515 -176.353 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 82.26 -121.43 5.43 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 121.008 -0.615 . . . . 73.209999999999994 112.32 -179.351 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.493 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 5.9 m-20 -88.57 0.89 55.88 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 120.914 0.388 . . . . 74.109999999999999 110.527 -176.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.617 ' HE2' ' HB2' ' B' ' 175' ' ' TRP . 15.6 pttp -125.47 124.67 41.9 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.349 0.595 . . . . 75.120000000000005 112.373 -172.54 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . 0.454 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 33.4 m -83.97 109.7 17.84 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.044 -0.98 . . . . 75.25 108.595 172.114 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 53.2 mt -100.3 107.83 21.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 CA-C-O 121.107 0.48 . . . . 61.509999999999998 110.627 -173.45 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.678 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 17.0 mt-30 -95.5 102.26 14.05 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.67 -0.695 . . . . 63.43 110.45 -179.208 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . 0.587 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 43.3 mt-10 -86.87 102.31 14.2 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.265 -0.425 . . . . 71.230000000000004 110.365 179.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 74.5 m-85 -78.54 104.83 9.4 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.122 0.487 . . . . 75.299999999999997 110.017 178.101 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . 0.513 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 82.6 mtm180 -126.14 136.76 53.26 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.653 -0.703 . . . . 71.519999999999996 110.141 -179.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.677 HG13 ' H ' ' B' ' 129' ' ' ASN . 2.4 p -84.81 -67.87 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 C-N-CA 120.32 -0.552 . . . . 61.329999999999998 109.658 175.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . 0.677 ' H ' HG13 ' B' ' 128' ' ' VAL . 2.2 t-20 -138.64 75.84 1.54 Allowed 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.56 -0.533 . . . . 71.299999999999997 109.56 178.332 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.7 -27.55 5.29 Favored Glycine 0 CA--C 1.518 0.231 0 CA-C-N 115.771 -0.65 . . . . 62.229999999999997 112.223 -178.462 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.505 ' CG ' HG21 ' A' ' 28' ' ' VAL . 82.9 t80 -86.19 124.75 32.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.902 0.382 . . . . 60.409999999999997 111.225 -177.176 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.857 HD11 HG13 ' B' ' 135' ' ' ILE . 3.5 tm? -85.6 119.38 25.88 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.893 -0.78 . . . . 52.25 108.893 175.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 44.1 p90 -112.94 -17.11 12.55 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 120.495 -0.482 . . . . 63.299999999999997 111.787 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.46 133.22 6.43 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.717 0.294 . . . . 63.219999999999999 111.059 178.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.857 HG13 HD11 ' B' ' 132' ' ' LEU . 69.8 mt -113.28 120.34 62.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.453 -0.339 . . . . 74.409999999999997 110.174 174.4 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.678 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.9 tttt -101.0 104.64 15.81 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.682 -0.488 . . . . 65.430000000000007 109.682 176.213 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.609 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 2.7 t -90.91 128.67 42.59 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 N-CA-C 108.928 -0.767 . . . . 63.340000000000003 108.928 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.454 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 20.3 t -112.96 73.34 1.57 Allowed Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.771 -0.455 . . . . 75.450000000000003 109.771 171.253 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.491 ' HG3' ' HE1' ' B' ' 145' ' ' TYR . 72.9 Cg_endo -80.66 143.84 15.24 Favored 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 122.438 2.092 . . . . 71.340000000000003 112.76 178.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . 0.493 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 30.0 mtpp -65.75 -23.77 66.81 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.483 -0.78 . . . . 74.209999999999994 110.383 174.04 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 72.6 m-70 -115.91 95.07 4.94 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.574 -0.739 . . . . 54.039999999999999 110.025 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . 0.449 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 127.58 -9.93 6.83 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.178 -1.011 . . . . 51.409999999999997 113.638 177.093 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . 0.449 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 73.1 mmtt 70.64 155.9 0.15 Allowed Pre-proline 0 N--CA 1.472 0.644 0 CA-C-O 120.755 0.312 . . . . 44.020000000000003 111.164 -178.488 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.609 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 33.6 Cg_endo -66.48 135.13 38.17 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.192 1.928 . . . . 54.509999999999998 112.84 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . 0.491 ' HE1' ' HG3' ' B' ' 139' ' ' PRO . 14.7 p90 -146.4 161.28 40.71 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.768 -0.651 . . . . 73.099999999999994 110.205 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -106.75 138.46 42.88 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.27 -0.423 . . . . 72.439999999999998 111.758 -176.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.486 ' HB2' ' HB ' ' B' ' 135' ' ' ILE . 18.7 mt -110.38 95.73 5.76 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.447 -0.797 . . . . 75.299999999999997 109.72 168.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 41.6 t -82.14 126.39 39.93 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 109.692 -0.484 . . . . 72.409999999999997 109.692 -179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . 0.47 HH11 ' HG3' ' B' ' 149' ' ' ARG . 0.0 OUTLIER -80.86 114.66 19.89 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 109.439 -0.578 . . . . 62.109999999999999 109.439 -179.228 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.75 165.18 25.65 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.627 -0.715 . . . . 42.409999999999997 111.005 -174.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -70.44 147.57 49.32 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.581 -0.526 . . . . 71.420000000000002 109.581 178.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 105.01 131.26 7.03 Favored Glycine 0 N--CA 1.436 -1.347 0 C-N-CA 120.61 -0.805 . . . . 61.340000000000003 111.357 -175.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 21.6 m -82.77 17.8 1.75 Allowed 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.286 0.565 . . . . 75.010000000000005 110.587 -178.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -64.77 -52.96 54.14 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.488 -0.778 . . . . 61.43 110.958 -178.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 125.86 50.36 0.18 Allowed Glycine 0 CA--C 1.505 -0.588 0 C-N-CA 120.657 -0.782 . . . . 50.43 112.025 -178.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 4.9 m120 -119.06 134.29 55.28 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.356 -0.422 . . . . 54.340000000000003 111.484 -177.305 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . 0.434 ' HB2' HG22 ' B' ' 172' ' ' ILE . 29.6 m-85 -117.31 159.19 23.1 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.541 -0.754 . . . . 63.229999999999997 109.735 174.357 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . 0.9 HD11 HD23 ' B' ' 166' ' ' LEU . 47.4 mm -120.7 122.79 68.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 116.256 -0.429 . . . . 74.5 110.008 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.627 ' HG3' HG13 ' B' ' 167' ' ' ILE . 52.2 mtp180 -87.81 147.18 25.26 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.375 -0.375 . . . . 73.209999999999994 110.379 178.028 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 33.8 t -67.38 -20.64 65.57 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.337 0.589 . . . . 74.450000000000003 109.466 174.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . 0.471 ' OD1' ' HB3' ' B' ' 159' ' ' ARG . 0.5 OUTLIER -71.93 -34.19 68.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.221 -0.9 . . . . 71.140000000000001 109.869 177.248 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -141.47 76.88 20.31 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 115.448 -0.796 . . . . 73.420000000000002 109.709 -174.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -82.18 4.53 6.99 Favored 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 122.746 2.297 . . . . 71.540000000000006 113.326 -173.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -109.07 -11.07 14.99 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.804 0.335 . . . . 73.349999999999994 111.084 -177.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 38.2 ttpt -122.93 137.25 55.0 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.75 0.31 . . . . 75.549999999999997 110.907 -176.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . 0.9 HD23 HD11 ' B' ' 158' ' ' ILE . 93.6 mt -73.96 130.65 40.29 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.018 -0.537 . . . . 74.340000000000003 109.986 177.122 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . 0.627 HG13 ' HG3' ' B' ' 159' ' ' ARG . 42.3 mm -81.48 128.5 69.54 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 116.366 -0.379 . . . . 73.219999999999999 110.393 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.527 ' O ' HG23 ' B' ' 172' ' ' ILE . 40.0 Cg_endo -65.75 173.01 7.37 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 123.163 2.575 . . . . 63.310000000000002 112.789 -179.344 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 33.8 tt0 -86.11 3.76 41.21 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.825 -0.625 . . . . 73.409999999999997 112.181 -168.271 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . 0.464 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 33.7 p90 -104.05 -18.89 14.38 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.377 -0.529 . . . . 73.420000000000002 109.872 172.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.464 ' HG2' ' CD1' ' B' ' 170' ' ' TRP . 2.8 mm-40 -97.65 -10.47 24.98 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.566 -0.743 . . . . 71.140000000000001 111.393 -176.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.527 HG23 ' O ' ' B' ' 168' ' ' PRO . 30.7 pt -71.68 -21.52 21.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 115.877 -0.601 . . . . 71.200000000000003 110.171 175.537 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -112.09 46.49 1.15 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.41 -0.814 . . . . 64.200000000000003 108.995 174.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . 0.464 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 2.1 t -74.89 -13.84 60.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.402 -0.817 . . . . 74.219999999999999 110.163 -178.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . 0.617 ' HB2' ' HE2' ' B' ' 121' ' ' LYS . 49.1 p-90 . . . . . 0 C--O 1.248 0.998 0 CA-C-N 115.502 -0.772 . . . . 74.129999999999995 109.85 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.798 0 N-CA-C 111.607 -0.597 . . . . 62.200000000000003 111.607 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -75.3 -54.75 6.57 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.201 -0.666 . . . . 72.420000000000002 109.201 175.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 44.5 m-20 52.4 68.59 0.8 Allowed 'General case' 0 C--O 1.232 0.149 0 CA-C-N 115.286 -0.87 . . . . 74.120000000000005 111.49 174.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -132.96 161.8 33.34 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.477 -0.783 . . . . 74.230000000000004 109.521 178.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -87.46 116.47 25.59 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.342 -0.39 . . . . 72.530000000000001 110.415 -179.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -89.05 156.12 49.3 Favored Pre-proline 0 C--N 1.32 -0.703 0 CA-C-N 116.109 -0.496 . . . . 41.43 109.889 178.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.453 ' HB2' ' HD1' ' B' ' 131' ' ' PHE . 51.9 Cg_exo -53.68 150.07 29.97 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.643 2.229 . . . . 73.319999999999993 112.186 178.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 41.6 m -60.93 115.63 3.86 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.112 0.482 . . . . 73.319999999999993 111.022 -177.089 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -177.69 -38.72 0.06 OUTLIER Glycine 0 N--CA 1.446 -0.663 0 N-CA-C 110.71 -0.956 . . . . 54.240000000000002 110.71 -179.441 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 54.05 66.29 4.52 Favored Pre-proline 0 N--CA 1.464 0.254 0 C-N-CA 123.556 0.742 . . . . 71.049999999999997 112.15 175.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 53.8 Cg_endo -76.97 137.49 17.53 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.169 1.912 . . . . 73.109999999999999 112.516 -178.317 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -141.4 155.83 45.86 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.968 -0.56 . . . . 71.5 109.738 179.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.8 p -110.88 129.75 65.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 121.273 0.559 . . . . 64.120000000000005 110.842 -177.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 10.6 m -93.86 104.38 16.45 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.728 -0.669 . . . . 71.439999999999998 109.563 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 67.1 mt -90.1 106.82 17.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 116.301 -0.409 . . . . 72.409999999999997 110.351 -177.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 23.6 mmm180 -115.57 156.96 24.83 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.143 -0.48 . . . . 73.430000000000007 110.212 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 26.1 mp0 -121.58 127.17 50.64 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 121.098 0.475 . . . . 70.219999999999999 110.057 178.047 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -105.08 -60.58 1.59 Allowed 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.35 -0.841 . . . . 63.130000000000003 111.0 -172.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.519 ' C ' ' H ' ' A' ' 21' ' ' LYS . . . -156.95 76.58 0.2 Allowed Glycine 0 CA--C 1.507 -0.433 0 N-CA-C 110.353 -1.099 . . . . 51.420000000000002 110.353 178.741 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.538 ' HB3' ' HG3' ' A' ' 40' ' ' LYS . 19.2 m-20 70.07 -26.76 0.16 Allowed 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 123.519 0.728 . . . . 63.329999999999998 111.017 -170.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.519 ' H ' ' C ' ' A' ' 19' ' ' GLY . 22.7 pttm -83.42 120.21 25.61 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 121.198 0.523 . . . . 60.140000000000001 110.42 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.594 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 33.2 m -82.48 121.62 26.99 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.375 -0.83 . . . . 72.310000000000002 109.641 176.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 56.0 mt -111.33 106.77 21.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 CA-C-O 121.036 0.446 . . . . 61.439999999999998 110.333 -178.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.67 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 19.2 mt-30 -100.53 111.04 23.24 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.788 -0.642 . . . . 55.100000000000001 110.756 -177.642 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 33.0 mt-10 -92.57 108.77 20.23 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.768 -0.651 . . . . 63.100000000000001 110.85 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.57 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 95.6 m-85 -83.0 104.65 13.37 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.968 0.414 . . . . 63.009999999999998 110.151 178.317 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -115.12 119.25 35.77 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.947 -0.569 . . . . 74.310000000000002 109.617 -179.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.781 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.7 p -73.26 -73.32 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 C-N-CA 120.786 -0.366 . . . . 61.32 110.879 -178.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.781 ' H ' HG13 ' A' ' 28' ' ' VAL . 7.6 t-20 -127.53 68.28 1.3 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.291 -0.633 . . . . 62.509999999999998 109.291 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 73.19 12.52 79.62 Favored Glycine 0 N--CA 1.448 -0.505 0 CA-C-N 115.452 -0.795 . . . . 72.530000000000001 111.784 -175.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.79 ' HE1' ' HB2' ' B' ' 107' ' ' PRO . 29.5 t80 -129.33 124.08 33.42 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.818 0.342 . . . . 64.109999999999999 110.202 -175.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.419 HD11 HG13 ' A' ' 35' ' ' ILE . 3.2 tm? -72.41 132.76 44.35 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.611 -0.722 . . . . 74.409999999999997 109.781 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . 0.57 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 45.4 p90 -125.76 -22.81 4.13 Favored 'General case' 0 CA--C 1.531 0.236 0 N-CA-C 112.127 0.417 . . . . 74.340000000000003 112.127 176.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.18 148.23 24.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.661 0.267 . . . . 75.230000000000004 111.022 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.419 HG13 HD11 ' A' ' 32' ' ' LEU . 61.6 mt -125.23 124.37 67.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-N 116.412 -0.358 . . . . 73.510000000000005 110.215 177.49 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.67 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.6 tttt -103.72 106.24 16.7 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.631 -0.507 . . . . 74.519999999999996 109.631 177.121 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.698 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.7 t -94.65 129.7 44.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 N-CA-C 109.226 -0.657 . . . . 34.5 109.226 177.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.594 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.4 t -117.6 72.57 7.81 Favored Pre-proline 0 C--N 1.317 -0.808 0 N-CA-C 109.845 -0.428 . . . . 45.43 109.845 173.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.581 ' HD3' HG12 ' A' ' 37' ' ' VAL . 54.1 Cg_endo -78.62 137.31 14.37 Favored 'Trans proline' 0 N--CA 1.456 -0.735 0 C-N-CA 122.197 1.932 . . . . 61.240000000000002 112.297 176.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.538 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 26.3 mtpp -68.76 -20.46 64.37 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.451 0.643 . . . . 44.039999999999999 109.868 178.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 84.7 m-70 -117.69 83.57 2.01 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.392 -0.822 . . . . 71.040000000000006 109.423 178.27 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.443 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 141.33 -22.0 2.58 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.945 -0.645 . . . . 52.399999999999999 112.339 -178.562 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.443 ' HB2' ' O ' ' A' ' 42' ' ' GLY . 98.6 mttt 74.78 152.72 0.14 Allowed Pre-proline 0 N--CA 1.469 0.477 0 C-N-CA 123.579 0.752 . . . . 74.319999999999993 111.889 179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.698 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 35.1 Cg_endo -66.73 136.37 41.9 Favored 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.651 2.234 . . . . 73.120000000000005 113.247 -178.139 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -142.33 162.32 35.77 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.511 -0.768 . . . . 62.140000000000001 109.589 176.505 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -106.11 123.19 47.63 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.397 -0.365 . . . . 72.349999999999994 110.244 178.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.465 HD11 HG13 ' A' ' 67' ' ' ILE . 28.5 tp -102.27 96.1 6.74 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 108.792 -0.818 . . . . 74.430000000000007 108.792 172.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 42.5 t -93.63 120.63 43.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.749 -0.659 . . . . 73.400000000000006 110.181 -175.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 3.7 tmm_? -77.88 121.47 24.18 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 109.065 -0.717 . . . . 74.150000000000006 109.065 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.15 -162.98 0.26 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.913 -0.585 . . . . 62.350000000000001 111.269 -173.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.404 ' OD2' ' HB2' ' A' ' 53' ' ' SER . 5.7 p-10 -73.76 154.78 39.43 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.161 0.505 . . . . 63.229999999999997 110.805 -177.443 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -65.29 -22.35 69.14 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.641 -0.709 . . . . 50.109999999999999 113.28 -177.422 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.404 ' HB2' ' OD2' ' A' ' 51' ' ' ASP . 14.5 m -73.52 -39.9 64.43 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.089 0.471 . . . . 40.030000000000001 109.958 178.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.521 ' OD2' ' HB3' ' A' ' 56' ' ' ASN . 31.2 t70 -71.66 -39.76 70.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.506 -0.77 . . . . 54.240000000000002 109.835 175.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 58.95 63.49 5.15 Favored Glycine 0 C--N 1.336 0.557 0 CA-C-N 115.78 -0.646 . . . . 74.430000000000007 111.663 178.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.521 ' HB3' ' OD2' ' A' ' 54' ' ' ASP . 14.6 t30 -165.36 155.76 13.51 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.685 -0.257 . . . . 72.120000000000005 110.331 -168.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.572 ' HB2' ' HB ' ' A' ' 67' ' ' ILE . 2.4 m-85 -108.68 143.11 38.2 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.162 -0.681 . . . . 75.439999999999998 109.162 174.448 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 48.1 mm -113.53 127.46 70.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 121.436 0.636 . . . . 74.549999999999997 110.319 177.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.469 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 58.5 ttt180 -93.63 124.09 37.39 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.309 -0.86 . . . . 73.0 109.685 -176.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 87.9 p -59.67 -26.77 65.82 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.242 0.544 . . . . 41.119999999999997 110.788 -179.339 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.469 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 16.5 t70 -60.22 -39.71 87.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.211 -0.904 . . . . 62.450000000000003 110.711 177.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 29.3 mt-30 -144.67 89.01 6.85 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 115.947 -0.569 . . . . 71.109999999999999 109.863 -179.018 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -62.58 -24.71 75.22 Favored 'Trans proline' 0 C--N 1.347 0.494 0 C-N-CA 123.1 2.533 . . . . 75.129999999999995 113.261 -175.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -78.84 -14.27 59.34 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 120.747 0.308 . . . . 73.510000000000005 110.73 178.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.2 tptm -93.71 123.42 37.02 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.459 0.647 . . . . 52.509999999999998 110.892 -177.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.412 ' N ' HD12 ' A' ' 66' ' ' LEU . 5.5 mp -90.24 128.48 36.41 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 114.798 -1.092 . . . . 61.399999999999999 108.688 175.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.757 HG23 ' HB3' ' A' ' 71' ' ' GLU . 47.0 mm -87.9 112.67 50.6 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-O 120.854 0.359 . . . . 72.209999999999994 111.373 -172.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.571 ' O ' HG23 ' A' ' 72' ' ' ILE . 60.0 Cg_endo -71.44 174.97 10.07 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.833 2.355 . . . . 53.140000000000001 112.036 179.163 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -79.15 1.85 22.96 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 112.987 0.736 . . . . 64.319999999999993 112.987 -166.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 42.4 p90 -107.04 -19.62 13.56 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.437 0.637 . . . . 70.420000000000002 109.953 172.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.757 ' HB3' HG23 ' A' ' 67' ' ' ILE . 2.8 mm-40 -87.41 -17.46 32.23 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.462 -0.79 . . . . 74.299999999999997 110.332 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.571 HG23 ' O ' ' A' ' 68' ' ' PRO . 42.3 pt -63.23 -28.39 44.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.885 -0.598 . . . . 65.209999999999994 111.412 -179.005 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.477 ' HD1' HG13 ' A' ' 72' ' ' ILE . 41.0 p90 -117.25 42.77 2.47 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.581 0.705 . . . . 74.319999999999993 109.584 175.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.424 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 4.7 t -59.27 -25.2 63.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.05 -0.977 . . . . 64.540000000000006 110.801 -179.567 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 26.6 p-90 . . . . . 0 C--N 1.327 -0.397 0 CA-C-N 115.925 -0.579 . . . . 70.150000000000006 111.267 177.479 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.435 0 N-CA-C 112.346 -0.302 . . . . 62.399999999999999 112.346 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -132.44 -62.18 0.84 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.564 0.221 . . . . 31.129999999999999 110.479 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 62.98 22.22 13.34 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 115.696 -0.684 . . . . 72.409999999999997 112.703 176.327 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -105.09 160.96 14.65 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.716 0.294 . . . . 75.040000000000006 110.324 178.319 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -75.35 134.02 41.09 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.185 -0.461 . . . . 73.310000000000002 111.229 -177.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . 0.449 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -82.11 130.41 60.16 Favored Pre-proline 0 C--N 1.322 -0.63 0 CA-C-N 115.902 -0.59 . . . . 63.229999999999997 109.798 174.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . 0.79 ' HB2' ' HE1' ' A' ' 31' ' ' PHE . 34.3 Cg_exo -59.69 147.07 93.62 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.746 2.297 . . . . 74.530000000000001 112.101 -178.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 57.1 m -54.53 144.4 21.47 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-O 121.451 0.643 . . . . 63.420000000000002 111.089 -179.197 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 125.24 -60.8 0.62 Allowed Glycine 0 N--CA 1.44 -1.073 0 N-CA-C 109.129 -1.588 . . . . 61.219999999999999 109.129 -169.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 61.08 88.34 0.12 Allowed Pre-proline 0 CA--C 1.52 -0.209 0 O-C-N 124.322 0.66 . . . . 73.310000000000002 111.27 171.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.888 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 7.3 Cg_endo -76.41 102.83 1.66 Allowed 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.173 1.915 . . . . 74.230000000000004 111.098 -178.497 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -102.89 150.36 23.59 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.037 -0.528 . . . . 61.43 109.838 -177.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.644 HG21 ' HB3' ' B' ' 124' ' ' GLN . 14.9 p -113.05 131.58 64.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-O 121.401 0.62 . . . . 61.43 111.617 -175.153 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 48.1 m -89.46 118.86 29.42 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.314 -0.857 . . . . 61.100000000000001 109.373 174.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 63.5 mt -92.54 105.25 16.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.07 0.462 . . . . 74.319999999999993 111.175 -174.519 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . 0.562 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 11.0 mmm180 -99.12 153.0 19.23 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.952 -0.567 . . . . 74.409999999999997 110.459 177.224 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 76.0 mt-30 -134.81 99.19 4.24 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.537 -0.912 . . . . 75.120000000000005 108.537 176.163 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . 0.49 ' HG3' HD12 ' B' ' 123' ' ' ILE . 43.2 mm-40 -103.6 9.25 37.47 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.125 -0.489 . . . . 64.040000000000006 112.205 -169.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 109.45 100.81 2.64 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.37 -0.919 . . . . 64.129999999999995 111.92 -178.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.573 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 9.5 m-20 66.66 -9.57 0.33 Allowed 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 124.085 0.954 . . . . 73.549999999999997 111.672 -176.515 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.491 ' HA ' ' O ' ' B' ' 138' ' ' VAL . 27.1 pttt -131.56 115.71 16.47 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 121.243 0.544 . . . . 75.010000000000005 112.074 -176.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 59.4 m -82.39 114.03 20.57 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.08 -0.964 . . . . 72.5 109.243 172.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . 0.708 HG12 HG13 ' B' ' 137' ' ' VAL . 49.8 mt -101.51 105.94 18.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 CA-C-O 121.326 0.584 . . . . 74.519999999999996 110.377 -176.114 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.644 ' HB3' HG21 ' B' ' 113' ' ' VAL . 49.7 mt-30 -96.01 106.89 19.11 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.444 -0.798 . . . . 71.230000000000004 110.974 -176.571 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -90.06 106.09 18.24 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.841 -0.618 . . . . 74.109999999999999 110.631 179.171 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 89.0 m-85 -85.1 107.06 17.01 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.994 0.426 . . . . 75.200000000000003 110.698 -179.586 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . 0.502 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 79.0 mtm180 -120.39 120.52 36.22 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.137 0.494 . . . . 61.200000000000003 110.204 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.888 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -76.79 -62.5 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.893 -0.594 . . . . 72.219999999999999 111.021 -178.177 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . 0.574 ' H ' HG13 ' B' ' 128' ' ' VAL . 1.2 t-20 -149.21 76.82 1.34 Allowed 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.638 -0.504 . . . . 64.010000000000005 109.638 -178.54 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.75 -7.34 66.11 Favored Glycine 0 CA--C 1.521 0.438 0 CA-C-N 115.817 -0.629 . . . . 45.43 113.058 -179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.453 ' HD1' ' HB2' ' A' ' 7' ' ' PRO . 54.4 t80 -122.31 123.25 40.98 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.151 0.5 . . . . 71.450000000000003 111.27 -176.625 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.703 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -76.6 117.84 18.64 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.09 -0.959 . . . . 63.539999999999999 108.888 173.431 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -108.06 -22.85 12.23 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 120.478 -0.489 . . . . 71.049999999999997 111.525 -178.233 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -157.62 143.05 17.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.929 0.395 . . . . 75.0 111.329 -178.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.703 HG13 HD11 ' B' ' 132' ' ' LEU . 76.5 mt -121.77 121.75 65.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 115.895 -0.593 . . . . 65.549999999999997 110.067 176.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.467 ' HD2' ' CZ ' ' B' ' 146' ' ' PHE . 82.2 tttt -102.79 105.06 15.41 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.928 0.394 . . . . 70.200000000000003 109.99 177.373 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.708 HG13 HG12 ' B' ' 123' ' ' ILE . 5.0 t -90.46 132.37 35.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 108.653 -0.869 . . . . 74.420000000000002 108.653 176.08 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.511 HG13 ' HB3' ' B' ' 144' ' ' PRO . 20.6 t -114.21 71.73 2.21 Favored Pre-proline 0 C--N 1.317 -0.822 0 N-CA-C 109.907 -0.405 . . . . 64.030000000000001 109.907 173.345 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.534 ' HD3' HG12 ' B' ' 137' ' ' VAL . 74.3 Cg_endo -81.13 134.42 9.24 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.082 1.855 . . . . 73.420000000000002 113.243 178.534 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . 0.573 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 28.8 mtpp -60.04 -26.85 66.45 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.291 -0.868 . . . . 65.019999999999996 109.84 171.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 89.4 m-70 -116.8 89.5 3.12 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.282 -0.872 . . . . 73.420000000000002 109.492 177.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 138.36 -19.14 3.23 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.482 -0.866 . . . . 54.130000000000003 112.536 -179.294 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 47.0 mtmt 71.62 147.21 0.12 Allowed Pre-proline 0 N--CA 1.469 0.522 0 C-N-CA 123.309 0.643 . . . . 64.519999999999996 111.637 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.697 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 29.6 Cg_endo -64.8 125.81 15.48 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.584 2.189 . . . . 53.219999999999999 112.626 -179.356 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 25.7 p90 -139.88 160.29 40.23 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.076 -0.511 . . . . 71.329999999999998 110.383 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.467 ' CZ ' ' HD2' ' B' ' 136' ' ' LYS . 70.4 m-85 -104.54 122.18 45.02 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 116.091 -0.504 . . . . 73.019999999999996 110.04 178.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 26.0 tp -97.86 93.33 6.28 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 108.248 -1.019 . . . . 73.030000000000001 108.248 171.329 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.6 t -95.39 129.11 45.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.755 -0.657 . . . . 74.319999999999993 110.55 -173.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . 0.598 HH11 ' HG3' ' B' ' 149' ' ' ARG . 0.0 OUTLIER -79.45 123.22 27.33 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 116.217 -0.447 . . . . 75.510000000000005 109.871 177.462 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -77.41 -168.32 1.12 Allowed 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.815 -0.63 . . . . 72.400000000000006 110.034 177.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -56.94 147.13 24.63 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.174 -0.466 . . . . 52.130000000000003 110.792 -179.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -75.14 -10.32 84.2 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 120.541 -0.838 . . . . 60.240000000000002 112.745 -177.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 1.6 m -67.67 -38.33 83.59 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.888 0.851 . . . . 71.349999999999994 108.729 172.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 15.1 t0 -80.36 -42.08 23.56 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.335 -1.302 . . . . 74.140000000000001 109.627 175.36 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 69.38 18.8 73.78 Favored Glycine 0 C--N 1.331 0.27 0 CA-C-N 115.17 -0.923 . . . . 72.340000000000003 112.139 -177.132 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 39.2 t30 -104.63 155.43 18.86 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 122.453 0.301 . . . . 62.310000000000002 111.656 -169.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . 0.662 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 8.3 m-85 -110.28 146.63 35.35 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.922 -0.77 . . . . 63.439999999999998 108.922 173.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.7 mm -118.31 133.39 65.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.038 0.447 . . . . 54.020000000000003 110.341 178.308 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.525 ' HD2' HD11 ' B' ' 167' ' ' ILE . 9.5 ttt180 -88.69 122.24 31.91 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.208 -0.664 . . . . 72.019999999999996 109.208 -179.001 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 66.5 p -57.66 -30.56 65.53 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 112.141 0.423 . . . . 61.240000000000002 112.141 -174.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -69.66 -40.45 76.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.068 0.461 . . . . 60.200000000000003 111.244 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 12.4 tt0 -130.33 88.84 46.41 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-N 116.139 -0.482 . . . . 73.219999999999999 110.178 -175.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -67.8 -12.76 36.49 Favored 'Trans proline' 0 C--N 1.343 0.269 0 C-N-CA 122.917 2.411 . . . . 63.0 112.29 -179.083 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -84.58 -6.32 59.36 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.735 -0.666 . . . . 64.209999999999994 110.144 176.473 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 22.2 tptm -109.26 123.67 49.64 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.547 0.689 . . . . 73.219999999999999 110.998 -177.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . 0.471 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.0 mp -91.21 135.2 33.95 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 114.731 -1.122 . . . . 75.129999999999995 108.204 175.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . 0.662 ' HB ' ' HB2' ' B' ' 157' ' ' PHE . 48.1 mm -95.93 113.11 61.46 Favored Pre-proline 0 C--N 1.32 -0.686 0 CA-C-O 121.037 0.446 . . . . 74.120000000000005 111.303 -173.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.497 ' O ' HG23 ' B' ' 172' ' ' ILE . 55.9 Cg_endo -69.91 177.95 5.17 Favored 'Trans proline' 0 N--CA 1.464 -0.253 0 C-N-CA 123.15 2.566 . . . . 73.329999999999998 112.479 178.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -85.86 6.39 28.49 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.976 -0.557 . . . . 70.109999999999999 112.269 -168.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 30.4 p90 -107.7 -25.32 11.35 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.207 0.527 . . . . 75.239999999999995 110.007 171.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.415 ' HA ' ' HB2' ' B' ' 174' ' ' SER . 21.0 mm-40 -80.77 -14.7 57.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.753 -0.658 . . . . 64.319999999999993 110.9 -179.051 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.526 HG13 ' CD2' ' B' ' 173' ' ' PHE . 26.5 pt -72.64 -12.02 15.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.86 -0.609 . . . . 72.420000000000002 112.291 -176.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . 0.526 ' CD2' HG13 ' B' ' 172' ' ' ILE . 88.4 m-85 -126.83 21.03 7.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.44 0.638 . . . . 62.340000000000003 109.785 176.323 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . 0.415 ' HB2' ' HA ' ' B' ' 171' ' ' GLU . 7.8 t -95.76 28.77 2.91 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.115 -0.948 . . . . 60.5 110.925 -175.16 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 6.3 m0 . . . . . 0 C--O 1.244 0.794 0 CA-C-O 118.201 -0.904 . . . . 73.409999999999997 111.679 -176.671 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.596 0 N-CA-C 111.865 -0.494 . . . . 53.539999999999999 111.865 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -108.03 85.9 2.2 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.129 0.49 . . . . 70.430000000000007 110.524 178.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -134.75 -41.02 0.77 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.674 -0.693 . . . . 73.540000000000006 110.063 179.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -76.06 153.62 36.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.974 -0.557 . . . . 64.400000000000006 109.89 179.248 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -84.83 129.67 34.78 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 120.849 0.357 . . . . 72.430000000000007 111.208 -174.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.468 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -79.49 140.48 55.87 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.944 -0.571 . . . . 63.039999999999999 110.902 -178.757 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.468 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 17.0 Cg_exo -67.35 179.21 2.58 Favored 'Trans proline' 0 CA--C 1.531 0.334 0 C-N-CA 123.048 2.499 . . . . 75.030000000000001 112.594 179.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 18.2 m -63.9 169.78 3.96 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.139 -0.482 . . . . 73.299999999999997 111.256 -179.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 83.34 -60.54 4.87 Favored Glycine 0 N--CA 1.447 -0.619 0 N-CA-C 110.763 -0.935 . . . . 73.120000000000005 110.763 -173.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 60.19 88.35 0.12 Allowed Pre-proline 0 N--CA 1.463 0.214 0 C-N-CA 123.818 0.847 . . . . 74.129999999999995 112.235 176.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.608 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 37.5 Cg_endo -83.75 102.31 0.97 Allowed 'Trans proline' 0 N--CA 1.446 -1.28 0 C-N-CA 122.344 2.03 . . . . 73.049999999999997 111.145 175.537 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.52 ' HA ' ' HB2' ' B' ' 151' ' ' ASP . 5.8 p-10 -130.06 140.91 50.77 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.186 0.517 . . . . 52.329999999999998 110.026 179.09 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.669 HG21 ' HB3' ' A' ' 24' ' ' GLN . 14.1 p -85.05 130.8 35.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.864 -0.607 . . . . 75.340000000000003 110.958 -176.392 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 34.3 m -88.26 105.07 17.3 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 109.674 -0.491 . . . . 73.349999999999994 109.674 177.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 72.2 mt -87.82 111.24 21.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.938 -0.574 . . . . 55.420000000000002 110.51 -177.091 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.476 ' HG2' ' O ' ' A' ' 23' ' ' ILE . 12.9 ptm180 -126.4 173.78 9.1 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.438 -0.578 . . . . 74.549999999999997 109.438 178.15 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -138.3 101.23 4.33 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.834 0.349 . . . . 72.209999999999994 110.222 -176.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.604 ' HG3' HD12 ' A' ' 23' ' ' ILE . 11.3 mm-40 -97.83 90.17 4.86 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.793 -0.64 . . . . 72.239999999999995 109.969 -176.278 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 75.51 -92.78 0.89 Allowed Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.788 -0.72 . . . . 64.319999999999993 112.183 -178.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.588 ' HB2' ' HB2' ' A' ' 40' ' ' LYS . 7.3 p-10 -102.85 -36.73 8.14 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.438 0.637 . . . . 65.299999999999997 110.592 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.436 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 5.8 pttm -92.94 127.27 38.39 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.602 -0.727 . . . . 70.230000000000004 112.38 -167.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.467 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 46.6 m -82.67 96.01 8.0 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 114.771 -1.104 . . . . 62.329999999999998 108.326 174.162 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.742 HG12 HG23 ' A' ' 37' ' ' VAL . 48.5 mt -86.37 112.25 22.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 115.854 -0.612 . . . . 70.430000000000007 110.349 -175.336 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.669 ' HB3' HG21 ' A' ' 13' ' ' VAL . 47.7 mt-30 -94.01 104.63 16.67 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.738 -0.664 . . . . 73.219999999999999 110.464 179.456 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.486 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 26.7 mt-10 -87.48 100.6 12.88 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.673 -0.694 . . . . 71.109999999999999 110.868 -178.256 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 76.0 m-85 -75.33 97.83 3.68 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.812 -0.44 . . . . 74.310000000000002 109.812 176.212 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.472 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 71.8 mtm180 -120.49 127.02 51.81 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.158 -0.474 . . . . 61.539999999999999 109.882 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.608 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 2.5 p -83.08 -64.26 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.643 -0.423 . . . . 75.209999999999994 110.843 178.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.578 ' H ' HG13 ' A' ' 28' ' ' VAL . 4.8 t-20 -142.72 69.25 1.31 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.175 0.512 . . . . 72.219999999999999 110.292 -176.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 88.18 1.87 81.14 Favored Glycine 0 N--CA 1.45 -0.394 0 CA-C-N 115.562 -0.745 . . . . 54.549999999999997 113.474 176.223 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.408 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 60.7 t80 -131.24 127.01 36.97 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 117.151 0.476 . . . . 75.540000000000006 111.356 179.861 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.842 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -72.48 120.27 17.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.284 -0.871 . . . . 73.230000000000004 109.545 174.379 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -111.88 -19.51 12.37 Favored 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 120.396 -0.522 . . . . 73.150000000000006 111.746 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -155.44 141.56 18.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.832 0.349 . . . . 70.239999999999995 111.216 178.209 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.842 HG13 HD11 ' A' ' 32' ' ' LEU . 93.7 mt -119.73 117.36 53.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.36 -0.382 . . . . 72.310000000000002 110.723 176.706 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.495 ' HA ' ' O ' ' A' ' 45' ' ' TYR . 85.7 tttt -102.14 100.23 10.44 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.536 -0.913 . . . . 60.0 108.536 172.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.742 HG23 HG12 ' A' ' 23' ' ' ILE . 8.4 p -95.38 131.57 41.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.943 0 CA-C-N 116.174 -0.466 . . . . 74.439999999999998 110.045 -176.679 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.66 HG13 ' HG3' ' A' ' 44' ' ' PRO . 40.7 t -108.05 88.54 4.75 Favored Pre-proline 0 C--N 1.323 -0.559 0 N-CA-C 109.496 -0.557 . . . . 63.039999999999999 109.496 175.057 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.417 ' HA ' ' HB3' ' A' ' 21' ' ' LYS . 73.7 Cg_endo -82.39 141.26 11.23 Favored 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 122.51 2.14 . . . . 70.340000000000003 112.314 -178.395 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.588 ' HB2' ' HB2' ' A' ' 20' ' ' ASP . 27.9 mtpp -77.92 -14.93 59.38 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.346 0.593 . . . . 61.130000000000003 109.935 179.301 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 -116.43 25.63 10.48 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.342 -0.844 . . . . 62.130000000000003 110.203 -176.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -164.41 -148.64 5.51 Favored Glycine 0 N--CA 1.451 -0.339 0 CA-C-N 115.28 -0.873 . . . . 44.219999999999999 111.128 177.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.1 pttp -131.9 142.63 45.87 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 117.238 0.519 . . . . 73.209999999999994 110.081 175.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.66 ' HG3' HG13 ' A' ' 38' ' ' VAL . 50.2 Cg_exo -53.15 135.53 59.67 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 123.55 2.833 . . . . 64.040000000000006 112.926 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.495 ' O ' ' HA ' ' A' ' 36' ' ' LYS . 4.6 p90 -142.32 160.44 40.26 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.163 -0.471 . . . . 72.299999999999997 110.69 177.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.656 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 92.0 m-85 -99.97 121.87 42.01 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.862 -0.608 . . . . 65.129999999999995 109.416 173.695 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 18.1 tp -108.36 97.43 7.11 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.913 -0.773 . . . . 74.349999999999994 108.913 175.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.47 HG21 HG21 ' B' ' 148' ' ' VAL . 38.4 t -93.94 135.41 28.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.255 -0.429 . . . . 73.299999999999997 111.282 -172.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.627 HH21 ' HA ' ' A' ' 53' ' ' SER . 13.3 tpt180 -73.1 124.59 25.86 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 115.876 -0.602 . . . . 52.439999999999998 111.112 176.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -77.42 174.47 10.79 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.884 -0.598 . . . . 64.519999999999996 109.928 173.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -70.65 145.27 50.74 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.764 0.316 . . . . 52.399999999999999 110.596 -178.194 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.448 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 86.27 158.45 31.29 Favored Glycine 0 N--CA 1.428 -1.868 0 CA-C-O 122.133 0.852 . . . . 63.109999999999999 112.844 175.57 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.627 ' HA ' HH21 ' A' ' 49' ' ' ARG . 49.5 m -80.65 26.71 0.39 Allowed 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 114.604 -0.798 . . . . 72.420000000000002 110.113 170.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.448 ' H ' ' C ' ' A' ' 52' ' ' GLY . 22.6 t70 -56.77 -39.24 73.68 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.123 -0.944 . . . . 52.5 111.611 -178.149 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.48 16.41 20.32 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.511 -0.852 . . . . 52.229999999999997 113.068 176.325 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -112.63 148.39 34.71 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.049 0.452 . . . . 72.299999999999997 110.31 177.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -124.1 163.06 22.27 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.739 -0.664 . . . . 63.130000000000003 109.656 176.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.79 HD11 HD23 ' A' ' 66' ' ' LEU . 46.1 mm -121.27 123.81 70.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 N-CA-C 109.538 -0.541 . . . . 73.209999999999994 109.538 177.211 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.675 ' HD2' ' HB3' ' A' ' 61' ' ' ASP . 11.6 ttm180 -92.2 145.63 24.35 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.806 -0.442 . . . . 73.25 109.806 -176.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.777 ' HB2' ' HB3' ' B' ' 163' ' ' PRO . 23.8 p -61.13 -39.89 91.76 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.573 0.702 . . . . 61.420000000000002 110.133 174.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.675 ' HB3' ' HD2' ' A' ' 59' ' ' ARG . 27.7 t70 -68.34 -28.28 67.0 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 114.808 -1.087 . . . . 71.209999999999994 110.817 178.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . 0.46 ' HB3' ' HB3' ' A' ' 65' ' ' LYS . 86.7 mm-40 -133.52 73.14 73.46 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-N 116.022 -0.535 . . . . 44.43 110.254 -175.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -75.81 -17.2 18.01 Favored 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.568 2.179 . . . . 71.129999999999995 112.703 -174.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.4 m-20 -101.62 7.32 42.19 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.03 -0.532 . . . . 71.310000000000002 110.697 -178.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.46 ' HB3' ' HB3' ' A' ' 62' ' ' GLN . 83.4 tttt -123.32 135.27 54.12 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.013 -0.539 . . . . 71.310000000000002 110.74 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.79 HD23 HD11 ' A' ' 58' ' ' ILE . 40.7 mt -84.75 112.21 20.29 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 108.882 -0.784 . . . . 72.150000000000006 108.882 175.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 51.4 mm -70.68 117.85 59.36 Favored Pre-proline 0 C--N 1.322 -0.629 0 CA-C-N 116.142 -0.481 . . . . 52.219999999999999 110.841 -176.211 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.91 178.62 6.99 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 123.28 2.653 . . . . 74.510000000000005 112.86 -178.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . 0.623 ' HA ' HG12 ' A' ' 72' ' ' ILE . 27.7 tt0 -74.76 -34.62 62.52 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.853 -0.612 . . . . 72.5 111.521 -170.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 16.0 p90 -67.66 -20.51 65.32 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.39 -0.524 . . . . 72.219999999999999 110.279 178.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -91.4 -28.42 17.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.334 -0.394 . . . . 60.109999999999999 111.404 -179.177 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.623 HG12 ' HA ' ' A' ' 69' ' ' GLN . 37.4 pt -74.81 -23.49 17.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.103 0.478 . . . . 71.430000000000007 110.274 176.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.514 ' HE2' HE21 ' A' ' 69' ' ' GLN . 38.1 m-85 -105.33 29.51 6.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.006 -0.543 . . . . 73.530000000000001 110.637 176.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 22.8 t -82.25 32.25 0.39 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.261 0.553 . . . . 54.439999999999998 110.863 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 54.3 m0 . . . . . 0 C--N 1.323 -0.552 0 CA-C-N 116.128 -0.487 . . . . 72.349999999999994 110.852 179.923 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.492 0 N-CA-C 111.993 -0.443 . . . . 60.340000000000003 111.993 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -81.45 76.0 8.39 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.103 0.478 . . . . 63.149999999999999 110.998 -179.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -98.9 4.18 47.37 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.035 -0.529 . . . . 65.219999999999999 110.942 178.132 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -142.57 148.23 37.19 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.441 -0.345 . . . . 74.549999999999997 110.157 -178.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -82.22 147.06 29.17 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.198 -0.455 . . . . 74.420000000000002 111.132 -176.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -105.78 133.04 20.39 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 120.873 0.368 . . . . 54.25 111.989 -175.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -73.15 -176.17 2.3 Favored 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 123.059 2.506 . . . . 72.25 112.132 176.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 5.2 p -62.83 158.43 18.91 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-O 121.305 0.574 . . . . 75.540000000000006 111.534 -178.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 100.98 -73.48 0.39 Allowed Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 109.999 -1.24 . . . . 74.140000000000001 109.999 -172.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 54.17 74.47 0.74 Allowed Pre-proline 0 C--N 1.329 -0.317 0 O-C-N 124.154 0.561 . . . . 73.200000000000003 111.259 175.459 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.928 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 18.0 Cg_endo -63.01 99.47 0.22 Allowed 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 122.106 1.871 . . . . 35.219999999999999 110.594 178.339 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -106.81 155.04 20.14 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.335 -0.848 . . . . 63.240000000000002 110.635 -173.217 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.624 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 12.4 p -111.54 124.68 68.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 CA-C-O 121.557 0.694 . . . . 73.319999999999993 110.421 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . 0.572 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 26.2 m -87.47 105.03 17.01 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.591 -0.731 . . . . 64.230000000000004 110.094 178.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.7 mt -83.48 106.07 13.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.955 -0.566 . . . . 72.010000000000005 110.375 -178.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . 0.437 ' HG3' HG22 ' B' ' 114' ' ' THR . 44.0 mtm105 -124.09 -178.9 4.22 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.403 -0.362 . . . . 74.230000000000004 110.465 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 64.0 mt-30 -144.76 115.21 7.61 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.205 -0.452 . . . . 72.209999999999994 111.056 -178.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . 0.461 ' O ' ' HE2' ' B' ' 121' ' ' LYS . 76.7 mm-40 -101.52 81.98 2.24 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.563 -0.532 . . . . 65.519999999999996 109.563 175.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 91.11 -110.83 3.88 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.657 -0.782 . . . . 61.409999999999997 111.4 -175.506 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.79 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 18.2 m-20 -115.06 24.01 12.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.786 0.327 . . . . 74.030000000000001 110.488 178.178 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.496 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 22.5 pttt -124.55 120.1 30.98 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.232 0.539 . . . . 60.210000000000001 110.833 178.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 49.1 m -79.38 104.9 10.31 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.414 -0.812 . . . . 53.25 109.588 177.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . 0.439 HD13 ' CE3' ' B' ' 175' ' ' TRP . 52.8 mt -97.52 112.54 29.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.122 0.487 . . . . 73.519999999999996 110.408 -176.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.624 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 51.2 mt-30 -92.29 105.7 17.85 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.449 -0.796 . . . . 73.209999999999994 110.552 179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . 0.572 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 41.7 mt-10 -88.3 100.78 13.27 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.774 -0.648 . . . . 63.32 110.421 -178.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . 0.474 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 63.4 m-85 -78.25 110.28 13.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.528 -0.305 . . . . 61.240000000000002 110.538 179.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' B' ' 131' ' ' PHE . 84.6 mtm180 -132.99 120.23 21.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.295 -0.411 . . . . 73.109999999999999 110.258 -179.622 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.928 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.5 p -83.51 -54.37 9.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.234 -0.439 . . . . 74.120000000000005 111.181 179.599 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 32.8 t-20 -150.08 79.25 1.36 Allowed 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 109.958 -0.386 . . . . 73.230000000000004 109.958 -175.136 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 61.65 30.36 74.55 Favored Glycine 0 N--CA 1.452 -0.234 0 CA-C-N 115.537 -0.756 . . . . 64.329999999999998 112.867 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.43 ' O ' ' HA ' ' B' ' 127' ' ' ARG . 87.2 t80 -147.86 127.22 13.09 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.856 0.36 . . . . 70.519999999999996 111.256 179.594 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.743 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -81.25 111.47 17.69 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.467 -0.788 . . . . 75.439999999999998 108.948 174.758 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . 0.474 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 51.6 p90 -106.98 -15.53 14.67 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.68 -0.408 . . . . 73.450000000000003 111.57 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . 0.51 ' HB1' ' CE2' ' B' ' 146' ' ' PHE . . . -159.07 145.18 16.61 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.947 0.403 . . . . 61.240000000000002 111.576 -178.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.743 HG13 HD11 ' B' ' 132' ' ' LEU . 75.7 mt -125.47 123.66 65.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.936 -0.574 . . . . 45.119999999999997 110.162 176.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.452 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 88.5 tttt -116.15 102.32 9.5 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.396 -0.594 . . . . 74.319999999999993 109.396 174.374 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.51 HG13 ' CE1' ' B' ' 145' ' ' TYR . 0.9 OUTLIER -102.36 127.07 56.31 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.088 0.471 . . . . 73.030000000000001 110.947 -177.603 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.816 HG22 ' HB3' ' B' ' 144' ' ' PRO . 22.8 t -112.55 88.83 11.74 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 115.235 -0.893 . . . . 71.099999999999994 109.73 -179.309 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.496 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 67.0 Cg_endo -77.95 134.54 13.31 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.137 1.891 . . . . 60.32 112.717 178.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . 0.79 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 58.2 mtpt -62.75 -28.18 69.79 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.577 -0.738 . . . . 64.120000000000005 110.251 173.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -96.43 43.84 1.07 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.996 -1.002 . . . . 75.420000000000002 110.187 -177.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 164.2 -146.71 11.75 Favored Glycine 0 N--CA 1.446 -0.645 0 CA-C-N 115.531 -0.759 . . . . 72.519999999999996 111.766 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 34.1 mmtp -126.68 150.0 69.87 Favored Pre-proline 0 C--N 1.322 -0.63 0 N-CA-C 110.206 -0.294 . . . . 73.200000000000003 110.206 177.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.816 ' HB3' HG22 ' B' ' 138' ' ' VAL . 18.6 Cg_endo -61.37 145.16 98.51 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.827 2.351 . . . . 74.319999999999993 112.22 178.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . 0.51 ' CE1' HG13 ' B' ' 137' ' ' VAL . 12.6 p90 -148.89 164.05 35.63 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.205 -0.452 . . . . 75.409999999999997 110.15 177.11 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.51 ' CE2' ' HB1' ' B' ' 134' ' ' ALA . 0.8 OUTLIER -113.14 142.13 46.12 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.901 -0.591 . . . . 75.340000000000003 111.17 -172.437 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.444 ' HB3' ' CD2' ' B' ' 157' ' ' PHE . 20.7 mt -126.65 108.74 11.37 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.972 -0.558 . . . . 75.040000000000006 109.659 170.074 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . 0.47 HG21 HG21 ' A' ' 48' ' ' VAL . 38.8 t -90.86 130.59 39.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.262 -0.426 . . . . 75.340000000000003 110.274 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . 0.463 ' HD3' ' CZ ' ' B' ' 157' ' ' PHE . 45.5 tpt85 -85.1 104.38 14.95 Favored 'General case' 0 N--CA 1.449 -0.498 0 N-CA-C 109.53 -0.544 . . . . 60.409999999999997 109.53 179.134 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.1 -178.85 0.85 Allowed 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.049 -0.523 . . . . 63.509999999999998 110.496 179.096 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . 0.52 ' HB2' ' HA ' ' A' ' 12' ' ' ASP . 2.2 p-10 -84.21 158.62 21.22 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.846 -0.427 . . . . 73.019999999999996 109.846 179.343 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 96.68 139.19 10.41 Favored Glycine 0 N--CA 1.439 -1.152 0 C-N-CA 120.049 -1.072 . . . . 70.200000000000003 112.609 176.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 16.3 m -77.6 43.12 0.39 Allowed 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.357 0.599 . . . . 62.229999999999997 110.97 176.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -89.15 -28.35 20.09 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.522 -0.763 . . . . 72.129999999999995 110.467 -178.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 88.79 31.39 12.73 Favored Glycine 0 N--CA 1.451 -0.36 0 N-CA-C 111.067 -0.813 . . . . 64.310000000000002 111.067 -174.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . 0.771 HD21 HD22 ' B' ' 166' ' ' LEU . 26.9 t30 -100.46 130.94 46.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.147 -0.526 . . . . 74.209999999999994 111.606 -172.571 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . 0.463 ' CZ ' ' HD3' ' B' ' 149' ' ' ARG . 29.2 m-85 -121.02 160.61 23.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.639 -0.71 . . . . 73.519999999999996 109.572 175.134 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . 0.8 HD11 HD23 ' B' ' 166' ' ' LEU . 46.0 mm -119.74 118.27 56.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.492 -0.558 . . . . 65.219999999999999 109.492 174.206 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.59 ' HG2' ' H ' ' B' ' 161' ' ' ASP . 20.0 ttm-85 -84.09 142.38 30.44 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 110.034 -0.358 . . . . 75.340000000000003 110.034 -177.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 42.3 p -63.08 -29.16 70.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.174 0.512 . . . . 70.400000000000006 110.836 178.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . 0.59 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 16.1 t70 -77.76 -27.49 50.36 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.477 -0.783 . . . . 72.230000000000004 110.81 178.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . 0.596 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 28.0 mm-40 -135.35 68.98 68.61 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 115.889 -0.596 . . . . 70.0 110.185 -177.608 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . 0.777 ' HB3' ' HB2' ' A' ' 60' ' ' SER . 12.9 Cg_exo -70.1 -26.33 26.1 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.71 2.274 . . . . 73.450000000000003 112.191 -177.479 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -84.0 1.31 44.38 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.451 -0.795 . . . . 72.510000000000005 110.27 179.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . 0.596 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 57.8 tttp -116.9 134.94 54.14 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.814 -0.63 . . . . 72.219999999999999 110.82 -177.498 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . 0.8 HD23 HD11 ' B' ' 158' ' ' ILE . 39.0 mt -89.53 115.4 26.91 Favored 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 108.643 -0.873 . . . . 74.400000000000006 108.643 175.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . 0.581 HG23 ' HB3' ' B' ' 171' ' ' GLU . 43.0 mm -75.04 123.87 89.14 Favored Pre-proline 0 C--N 1.32 -0.705 0 CA-C-N 116.147 -0.479 . . . . 74.540000000000006 110.896 -172.537 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.414 ' O ' HG23 ' B' ' 172' ' ' ILE . 72.5 Cg_endo -72.75 173.65 13.08 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.825 2.35 . . . . 74.329999999999998 112.225 -178.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . 0.444 ' O ' HG12 ' B' ' 172' ' ' ILE . 30.4 tt0 -77.79 -8.22 57.7 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.665 -0.698 . . . . 75.109999999999999 111.811 -169.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 8.4 p90 -95.33 -12.23 26.46 Favored 'General case' 0 C--N 1.325 -0.469 0 C-N-CA 120.457 -0.497 . . . . 71.209999999999994 110.583 176.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.581 ' HB3' HG23 ' B' ' 167' ' ' ILE . 12.9 tt0 -104.07 -1.87 26.75 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 121.039 0.447 . . . . 65.450000000000003 110.409 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.444 HG12 ' O ' ' B' ' 169' ' ' GLN . 46.8 pt -71.75 -24.5 23.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-O 121.017 0.437 . . . . 63.530000000000001 110.689 179.399 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -104.85 35.93 2.62 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.42 0.629 . . . . 70.150000000000006 109.745 175.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 23.2 t -63.74 -20.4 65.72 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 114.993 -1.003 . . . . 53.25 110.792 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . 0.439 ' CE3' HD13 ' B' ' 123' ' ' ILE . 8.9 p-90 . . . . . 0 C--O 1.246 0.905 0 CA-C-O 118.255 -0.879 . . . . 73.430000000000007 110.388 174.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 2.007 0 N-CA-C 112.414 -0.275 . . . . 31.010000000000002 112.414 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.493 ' O ' ' HA ' ' B' ' 154' ' ' ASP . . . -138.08 155.26 48.95 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.89 0.376 . . . . 42.549999999999997 110.048 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 10.1 p-10 -135.32 104.38 5.85 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.568 0.699 . . . . 71.109999999999999 111.094 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -133.78 -168.67 2.15 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 107.806 -1.183 . . . . 53.100000000000001 107.806 173.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -121.61 140.73 51.88 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.025 0.441 . . . . 73.010000000000005 110.853 -176.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -119.95 164.08 24.28 Favored Pre-proline 0 C--N 1.32 -0.692 0 CA-C-N 115.882 -0.599 . . . . 62.32 110.198 -177.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_exo -60.36 164.28 13.24 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.419 2.079 . . . . 63.299999999999997 111.961 175.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 57.8 m -56.91 142.95 39.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.732 0.777 . . . . 75.319999999999993 112.361 -175.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 138.64 -74.62 0.39 Allowed Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 109.197 -1.561 . . . . 71.439999999999998 109.197 -171.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 33.3 mt-10 58.68 92.49 0.06 OUTLIER Pre-proline 0 N--CA 1.463 0.197 0 CA-C-O 121.539 0.685 . . . . 72.409999999999997 112.052 170.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 9.6 Cg_endo -80.46 136.31 11.05 Favored 'Trans proline' 0 N--CA 1.451 -1.001 0 C-N-CA 122.833 2.355 . . . . 55.240000000000002 112.604 -173.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -124.8 170.84 10.64 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.173 -0.677 . . . . 73.519999999999996 109.173 177.069 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.471 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 14.0 p -127.72 124.29 62.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-O 121.481 0.657 . . . . 75.430000000000007 110.76 179.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.586 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 76.4 m -87.9 104.25 16.43 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.629 -0.714 . . . . 72.340000000000003 109.664 177.27 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 52.3 mt -98.45 117.66 43.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.064 -0.516 . . . . 65.129999999999995 110.388 -175.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -141.4 178.23 7.57 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.707 -0.679 . . . . 73.319999999999993 110.273 -179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 17.4 mp0 -133.45 126.15 30.56 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.922 0.392 . . . . 70.310000000000002 110.828 -178.131 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 52.0 mm-40 -95.58 -16.1 22.34 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.851 -0.613 . . . . 72.099999999999994 111.493 -178.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 127.43 104.91 1.3 Allowed Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.619 -0.8 . . . . 54.229999999999997 111.468 -176.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 1.093 ' HB3' ' HG3' ' A' ' 40' ' ' LYS . 35.3 m-20 61.81 13.89 5.8 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 123.226 0.61 . . . . 73.219999999999999 111.482 -175.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.428 ' HA ' ' O ' ' A' ' 38' ' ' VAL . 40.2 pttt -154.52 114.97 3.9 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.229 0.538 . . . . 64.129999999999995 110.907 176.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 34.1 m -83.08 117.74 23.07 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.375 -0.83 . . . . 63.240000000000002 109.298 174.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.461 HG12 HG23 ' A' ' 37' ' ' VAL . 24.9 mt -108.61 120.33 59.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 120.906 0.384 . . . . 71.049999999999997 110.633 -174.13 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.471 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 20.1 mt-30 -105.27 111.31 24.01 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.819 -0.628 . . . . 74.209999999999994 110.758 -179.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.586 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 31.6 mt-10 -89.62 102.55 15.23 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.62 -0.718 . . . . 72.129999999999995 110.673 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.452 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 80.6 m-85 -79.38 108.19 12.71 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.965 0.412 . . . . 72.349999999999994 109.957 177.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.427 HH21 ' CD ' ' A' ' 25' ' ' GLU . 90.1 mtt180 -116.98 126.56 53.09 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.979 -0.555 . . . . 61.32 109.852 -178.449 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.68 HG11 HG11 ' B' ' 128' ' ' VAL . 3.7 p -78.77 -35.96 18.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.326 0.584 . . . . 41.219999999999999 110.027 179.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -168.92 64.68 0.06 Allowed 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 108.31 -0.996 . . . . 60.43 108.31 -179.045 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.76 -29.75 3.29 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-N 115.477 -0.783 . . . . 64.129999999999995 112.036 -174.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -86.26 130.92 34.36 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.941 0.401 . . . . 72.340000000000003 110.455 -176.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.888 HD11 HG13 ' A' ' 35' ' ' ILE . 3.2 tm? -81.96 119.21 23.67 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.436 -0.802 . . . . 74.439999999999998 109.847 -179.613 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . 0.452 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 54.8 p90 -112.9 -17.54 12.47 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 120.937 -0.305 . . . . 74.200000000000003 111.218 177.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.544 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -157.28 142.21 16.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.812 0.339 . . . . 75.450000000000003 111.181 179.327 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.888 HG13 HD11 ' A' ' 32' ' ' LEU . 78.8 mt -125.14 120.21 57.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 116.329 -0.396 . . . . 63.32 110.01 175.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.469 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 86.0 tttt -108.53 101.15 10.33 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 120.381 -0.528 . . . . 63.340000000000003 109.697 173.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.565 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.8 p -101.02 131.78 48.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.973 0 CA-C-N 116.243 -0.435 . . . . 73.040000000000006 109.917 175.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.829 HG22 ' HB3' ' A' ' 44' ' ' PRO . 29.6 t -106.0 84.85 1.4 Allowed Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.396 -0.82 . . . . 73.219999999999999 109.51 177.469 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.565 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 97.3 Cg_endo -87.65 151.21 7.5 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.615 2.21 . . . . 72.319999999999993 113.143 -177.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 1.093 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 1.0 OUTLIER -55.06 -38.53 68.14 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.202 -0.908 . . . . 74.409999999999997 110.578 173.715 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 95.1 m-70 -123.56 120.9 34.21 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.814 -0.63 . . . . 71.530000000000001 110.181 179.428 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 117.46 -32.63 5.31 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.002 -0.839 . . . . 52.149999999999999 111.002 -173.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.469 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 67.0 mttm 67.97 155.61 0.14 Allowed Pre-proline 0 N--CA 1.465 0.282 0 C-N-CA 123.39 0.676 . . . . 74.409999999999997 111.97 178.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.829 ' HB3' HG22 ' A' ' 38' ' ' VAL . 11.4 Cg_endo -54.57 126.43 22.3 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 123.136 2.557 . . . . 71.230000000000004 113.179 -174.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.516 ' CE1' HG13 ' A' ' 37' ' ' VAL . 5.8 p90 -144.51 151.76 39.61 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.009 -0.541 . . . . 63.520000000000003 110.543 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.625 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 86.8 m-85 -96.18 133.27 40.69 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.097 -0.501 . . . . 72.439999999999998 110.804 178.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.544 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 21.2 mt -101.69 93.41 5.32 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.59 -0.522 . . . . 64.219999999999999 109.59 167.884 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 39.3 t -84.42 128.96 38.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 116.168 -0.469 . . . . 73.140000000000001 109.799 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.474 HH21 ' HA ' ' A' ' 53' ' ' SER . 15.6 tpt180 -63.05 127.23 30.3 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.21 0.529 . . . . 74.540000000000006 111.87 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -84.05 113.84 21.31 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.114 -1.069 . . . . 74.519999999999996 108.114 166.281 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.556 ' OD2' ' HA ' ' B' ' 126' ' ' TYR . 37.8 m-20 -49.07 142.54 6.67 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.216 0.531 . . . . 72.329999999999998 111.715 -176.832 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 99.23 133.61 8.16 Favored Glycine 0 N--CA 1.437 -1.257 0 N-CA-C 110.508 -1.037 . . . . 54.210000000000001 110.508 -169.15 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.474 ' HA ' HH21 ' A' ' 49' ' ' ARG . 19.6 m -84.87 43.16 0.97 Allowed 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.128 0.49 . . . . 74.25 110.997 -179.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -73.41 -33.95 65.24 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.682 -0.69 . . . . 73.420000000000002 109.769 -179.523 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 113.46 38.97 1.15 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.911 -0.661 . . . . 45.130000000000003 113.089 176.022 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -135.31 146.42 48.46 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.209 0.528 . . . . 70.049999999999997 111.688 -176.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.566 ' HB2' HG22 ' A' ' 72' ' ' ILE . 31.5 m-85 -127.74 167.04 17.04 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.318 -0.856 . . . . 63.200000000000003 109.494 175.499 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.898 HD11 HD23 ' A' ' 66' ' ' LEU . 39.4 mm -122.83 123.22 67.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 109.981 -0.378 . . . . 74.0 109.981 179.111 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.978 ' HG3' HG13 ' A' ' 67' ' ' ILE . 28.8 mtm180 -88.89 140.06 29.82 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 110.124 -0.324 . . . . 72.219999999999999 110.124 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 7.2 p -60.8 -20.95 62.58 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.222 0.534 . . . . 65.340000000000003 110.933 177.211 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -76.0 -31.43 58.95 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.422 -0.808 . . . . 75.530000000000001 110.67 178.256 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 82.0 mm-40 -141.75 71.21 24.92 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 116.346 -0.388 . . . . 71.430000000000007 110.433 -175.102 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo -71.14 -11.58 29.14 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 122.771 2.314 . . . . 72.510000000000005 112.427 -178.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 25.8 t70 -89.54 -14.56 34.87 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.699 -0.682 . . . . 72.5 110.799 -178.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -112.0 133.8 53.95 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.919 0.39 . . . . 70.340000000000003 110.86 -178.207 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.898 HD23 HD11 ' A' ' 58' ' ' ILE . 85.2 mt -80.74 110.18 16.0 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.114 -0.699 . . . . 72.430000000000007 109.114 176.101 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.978 HG13 ' HG3' ' A' ' 59' ' ' ARG . 50.6 mm -72.32 116.77 52.53 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 115.986 -0.552 . . . . 70.209999999999994 110.502 -175.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.462 ' O ' HG23 ' A' ' 72' ' ' ILE . 58.6 Cg_endo -70.39 177.56 5.89 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 123.315 2.676 . . . . 64.409999999999997 112.881 -177.491 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . 0.67 ' HA ' HG12 ' A' ' 72' ' ' ILE . 25.3 tt0 -73.5 -30.66 63.27 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.903 -0.589 . . . . 72.219999999999999 111.654 -171.013 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 21.5 p90 -73.06 -15.68 61.5 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.168 0.509 . . . . 73.219999999999999 110.234 177.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.459 ' HB3' HG23 ' A' ' 67' ' ' ILE . 3.2 mm-40 -103.08 -16.14 15.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.649 -0.705 . . . . 71.439999999999998 111.808 -176.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.67 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.4 pt -80.91 -20.26 11.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 121.179 0.514 . . . . 65.140000000000001 110.262 176.647 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -107.88 22.79 15.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.601 -0.727 . . . . 75.430000000000007 109.678 174.134 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.1 t -61.26 -34.08 74.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.195 -0.911 . . . . 75.209999999999994 110.622 -178.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 65.9 p-90 . . . . . 0 C--N 1.327 -0.372 0 CA-C-N 116.352 -0.385 . . . . 74.439999999999998 110.608 177.217 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.103 -0.399 . . . . 60.25 112.103 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -146.02 156.55 43.56 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 110.225 -0.287 . . . . 45.420000000000002 110.225 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -162.0 131.78 4.65 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.427 0.632 . . . . 70.239999999999995 110.793 176.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -152.41 151.92 31.39 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 107.269 -1.382 . . . . 73.040000000000006 107.269 173.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -62.08 127.01 29.34 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 120.473 -0.491 . . . . 72.439999999999998 110.442 -174.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . 0.43 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -59.92 118.57 33.53 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 115.667 -0.697 . . . . 72.329999999999998 111.998 -173.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 7.4 Cg_exo -73.63 176.75 8.92 Favored 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 123.102 2.535 . . . . 64.120000000000005 111.938 178.722 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 13.9 m -71.88 157.44 37.86 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.905 -0.588 . . . . 75.329999999999998 111.05 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.65 -45.88 1.25 Allowed Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 110.249 -1.141 . . . . 71.140000000000001 110.249 -175.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 40.3 83.14 0.21 Allowed Pre-proline 0 N--CA 1.47 0.564 0 C-N-CA 124.755 1.222 . . . . 73.329999999999998 113.473 170.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.6 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 43.5 Cg_endo -90.56 124.58 1.06 Allowed 'Trans proline' 0 N--CA 1.446 -1.323 0 C-N-CA 123.009 2.473 . . . . 55.450000000000003 111.667 178.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -122.87 127.87 49.59 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.475 0.655 . . . . 53.310000000000002 110.008 -178.586 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.495 ' HB ' ' HB2' ' A' ' 51' ' ' ASP . 7.3 p -79.45 127.82 38.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-O 121.508 0.67 . . . . 52.240000000000002 110.459 -178.311 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . 0.907 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 25.8 m -80.62 101.69 9.36 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 115.386 -0.824 . . . . 74.420000000000002 109.605 178.676 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 51.1 mt -91.02 103.83 14.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.033 -0.53 . . . . 52.350000000000001 110.445 -175.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . 0.483 ' HG2' ' O ' ' B' ' 123' ' ' ILE . 14.0 ptm180 -124.94 178.87 5.28 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.949 -0.76 . . . . 73.239999999999995 108.949 178.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -138.88 158.74 43.67 Favored 'General case' 0 CA--C 1.502 -0.886 0 CA-C-O 122.189 0.995 . . . . 74.120000000000005 112.661 -178.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . 0.591 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 26.5 mt-10 -135.44 168.62 18.88 Favored 'General case' 0 N--CA 1.432 -1.365 0 CA-C-N 112.968 -1.924 . . . . 75.239999999999995 107.166 159.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . -42.29 107.92 0.12 Allowed Glycine 0 CA--C 1.526 0.722 0 O-C-N 123.718 0.636 . . . . 61.149999999999999 114.34 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 43.3 m-20 61.67 24.62 14.69 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 123.893 0.877 . . . . 53.100000000000001 112.508 176.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.591 ' HE3' ' HB2' ' B' ' 118' ' ' GLU . 58.7 pttt -147.81 115.02 6.21 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.616 0.722 . . . . 44.310000000000002 111.286 174.312 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 23.4 m -80.03 117.11 20.57 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.404 -0.817 . . . . 74.25 109.374 175.003 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . 0.517 HG12 HG13 ' B' ' 137' ' ' VAL . 40.2 mt -105.53 108.96 26.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 121.25 0.548 . . . . 63.329999999999998 110.457 -175.744 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.481 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 13.6 mt-30 -103.13 109.52 21.12 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.658 -0.701 . . . . 53.439999999999998 110.538 -176.21 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . 0.907 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 70.8 mt-10 -88.9 98.74 11.91 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.014 -0.539 . . . . 74.239999999999995 110.43 178.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . 0.556 ' HA ' ' OD2' ' A' ' 51' ' ' ASP . 67.7 m-85 -71.32 114.34 9.29 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.045 0.45 . . . . 73.200000000000003 110.295 179.18 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . 0.569 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 59.1 mtt-85 -135.36 131.12 35.97 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.709 -0.678 . . . . 72.340000000000003 110.989 -173.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.68 HG11 HG11 ' A' ' 28' ' ' VAL . 14.0 p -85.39 -132.76 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 N-CA-C 108.689 -0.856 . . . . 71.530000000000001 108.689 172.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . 0.629 ' H ' HG22 ' B' ' 128' ' ' VAL . 2.3 t-20 -80.62 65.87 5.92 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.164 0.506 . . . . 63.119999999999997 110.812 -177.445 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.65 26.63 22.18 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.756 -0.735 . . . . 41.039999999999999 113.285 174.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 62.1 t80 -142.11 126.74 17.95 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 117.262 0.531 . . . . 72.409999999999997 111.31 175.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.569 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 3.5 tm? -77.15 117.49 18.75 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 108.992 -0.744 . . . . 72.230000000000004 108.992 175.505 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 39.6 p90 -119.15 -6.3 10.42 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.257 -0.577 . . . . 75.319999999999993 112.261 -178.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . 0.525 ' HB3' ' HB2' ' B' ' 126' ' ' TYR . . . -164.21 143.35 7.54 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.699 0.285 . . . . 74.200000000000003 111.031 177.697 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.442 HG13 HD11 ' B' ' 132' ' ' LEU . 61.9 mt -122.84 121.06 62.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 109.924 -0.398 . . . . 53.310000000000002 109.924 175.403 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.485 ' CB ' ' HE1' ' B' ' 126' ' ' TYR . 83.6 tttt -107.84 107.03 17.59 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 109.835 -0.431 . . . . 74.200000000000003 109.835 177.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.762 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.5 t -94.81 131.6 41.16 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 N-CA-C 108.641 -0.874 . . . . 74.099999999999994 108.641 176.585 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.553 HG22 ' HB3' ' B' ' 144' ' ' PRO . 18.0 t -114.72 72.7 2.78 Favored Pre-proline 0 C--N 1.318 -0.769 0 N-CA-C 109.78 -0.452 . . . . 73.120000000000005 109.78 172.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.524 ' HD3' HG12 ' B' ' 137' ' ' VAL . 94.1 Cg_endo -83.2 142.16 10.67 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.235 1.957 . . . . 60.530000000000001 112.563 177.105 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 49.6 mttp -54.56 -44.56 73.04 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.596 0.712 . . . . 70.109999999999999 110.348 173.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 26.1 m-70 -102.8 92.1 4.45 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.836 -1.074 . . . . 72.150000000000006 109.474 -174.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 132.54 -27.35 3.56 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.357 -0.838 . . . . 64.450000000000003 111.712 -176.294 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . 0.51 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 71.2 mttt 69.1 159.66 0.15 Allowed Pre-proline 0 N--CA 1.464 0.255 0 C-N-CA 123.622 0.769 . . . . 72.209999999999994 112.367 -178.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.762 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 21.6 Cg_endo -61.09 134.5 53.16 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 122.873 2.382 . . . . 71.239999999999995 113.525 -177.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -143.32 147.21 34.37 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.68 -0.691 . . . . 74.109999999999999 110.291 175.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.65 ' HB2' ' HB2' ' B' ' 160' ' ' SER . 86.0 m-85 -93.61 125.93 38.49 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.231 -0.441 . . . . 61.509999999999998 110.392 176.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.507 HD11 HG21 ' B' ' 167' ' ' ILE . 25.0 tp -109.12 97.44 7.06 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.64 -0.874 . . . . 50.520000000000003 108.64 172.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.7 t -91.77 139.3 18.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.155 -0.475 . . . . 52.409999999999997 111.311 -172.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . 0.427 ' HD3' ' CZ ' ' B' ' 157' ' ' PHE . 42.4 tpt85 -80.36 113.73 18.75 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.278 -0.638 . . . . 74.140000000000001 109.278 176.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.89 175.6 6.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.825 0.345 . . . . 75.329999999999998 111.104 -176.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -71.47 147.8 47.46 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.163 -0.471 . . . . 74.120000000000005 110.94 -178.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . 0.492 ' C ' ' H ' ' B' ' 154' ' ' ASP . . . 89.85 145.4 12.74 Favored Glycine 0 N--CA 1.436 -1.365 0 C-N-CA 120.723 -0.751 . . . . 74.140000000000001 112.561 175.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 44.9 m -72.59 21.93 0.06 Allowed 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 121.022 0.439 . . . . 74.010000000000005 111.083 173.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . 0.493 ' HA ' ' O ' ' A' ' 2' ' ' ALA . 14.5 t70 -60.86 -35.82 77.56 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.777 -0.647 . . . . 73.329999999999998 110.618 177.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 97.92 17.13 31.12 Favored Glycine 0 CA--C 1.507 -0.451 0 CA-C-N 115.734 -0.666 . . . . 75.310000000000002 111.89 -179.383 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -90.97 137.52 32.3 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.019 -0.59 . . . . 55.539999999999999 111.566 -175.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . 0.427 ' CZ ' ' HD3' ' B' ' 149' ' ' ARG . 39.0 m-85 -118.21 154.04 32.87 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.751 -0.658 . . . . 74.409999999999997 109.533 174.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.3 mm -121.46 119.91 60.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.747 0 N-CA-C 109.817 -0.438 . . . . 65.530000000000001 109.817 177.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.727 ' HE ' ' HB3' ' B' ' 161' ' ' ASP . 37.2 ttp180 -85.02 129.05 34.86 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.444 -0.576 . . . . 74.329999999999998 109.444 -179.706 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . 0.65 ' HB2' ' HB2' ' B' ' 146' ' ' PHE . 36.6 t -59.84 -18.34 43.37 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.774 0.321 . . . . 54.310000000000002 111.318 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . 0.727 ' HB3' ' HE ' ' B' ' 159' ' ' ARG . 22.8 t70 -69.24 -39.77 78.31 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.031 -0.531 . . . . 74.319999999999993 110.29 176.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . 0.427 ' HG2' ' OD2' ' B' ' 161' ' ' ASP . 84.1 mm-40 -133.53 86.33 40.37 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 115.674 -0.693 . . . . 61.539999999999999 109.692 179.546 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.01 -14.37 40.86 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.56 2.173 . . . . 73.329999999999998 112.47 -178.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -100.49 21.09 13.76 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.817 -0.628 . . . . 72.150000000000006 110.421 178.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -133.3 136.06 45.24 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.365 -0.38 . . . . 74.049999999999997 110.732 -179.487 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . 0.435 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.6 mp -90.54 134.94 34.02 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.027 -0.731 . . . . 71.519999999999996 109.027 176.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . 0.538 HG23 ' HB3' ' B' ' 171' ' ' GLU . 46.2 mm -94.15 117.02 67.11 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-O 120.917 0.389 . . . . 74.319999999999993 111.771 -172.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.409 ' O ' HG23 ' B' ' 172' ' ' ILE . 59.5 Cg_endo -72.37 -179.55 4.14 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 123.305 2.67 . . . . 74.430000000000007 112.615 177.084 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . 0.59 ' HA ' HG12 ' B' ' 172' ' ' ILE . 33.0 tt0 -77.1 -36.09 55.94 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.258 -0.428 . . . . 65.430000000000007 112.136 -170.211 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . 0.409 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 35.9 p90 -66.99 -21.16 65.97 Favored 'General case' 0 C--N 1.325 -0.489 0 O-C-N 121.648 -0.658 . . . . 74.430000000000007 109.622 177.251 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.538 ' HB3' HG23 ' B' ' 167' ' ' ILE . 9.3 mm-40 -88.22 -26.05 22.57 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 115.156 -0.929 . . . . 75.129999999999995 111.647 -178.078 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.59 HG12 ' HA ' ' B' ' 169' ' ' GLN . 40.9 pt -77.97 -17.42 13.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 121.146 0.498 . . . . 74.530000000000001 109.971 177.118 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -108.05 34.61 3.5 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.574 -0.739 . . . . 70.319999999999993 109.748 174.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.9 t -65.13 -35.27 80.58 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.203 -0.908 . . . . 71.019999999999996 111.03 -179.182 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 25.6 p-90 . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.018 -0.991 . . . . 73.099999999999994 111.023 -178.133 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.855 0 N-CA-C 112.152 -0.379 . . . . 52.43 112.152 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.74 131.71 38.83 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 110.289 -0.263 . . . . 74.319999999999993 110.289 178.251 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -59.05 -48.19 82.5 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.96 0.41 . . . . 73.340000000000003 110.406 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -157.87 139.61 13.92 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.95 -0.759 . . . . 73.329999999999998 108.95 171.764 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 26.9 t0 -169.13 137.71 2.0 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 110.158 -0.312 . . . . 63.399999999999999 110.158 -178.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -83.35 125.56 73.92 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.485 -0.325 . . . . 72.340000000000003 110.504 178.086 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -82.91 -160.01 0.12 Allowed 'Trans proline' 0 N--CA 1.463 -0.285 0 C-N-CA 123.063 2.508 . . . . 73.519999999999996 112.426 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 39.8 m -131.35 168.71 17.1 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.947 -0.39 . . . . 70.319999999999993 109.947 176.012 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 87.27 -34.01 3.72 Favored Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 110.977 -0.849 . . . . 50.32 110.977 -173.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 55.37 63.69 6.31 Favored Pre-proline 0 C--N 1.329 -0.289 0 C-N-CA 123.998 0.919 . . . . 62.439999999999998 111.73 177.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.699 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 18.2 Cg_endo -78.95 121.65 5.06 Favored 'Trans proline' 0 N--CA 1.45 -1.064 0 C-N-CA 122.091 1.861 . . . . 73.219999999999999 111.584 -179.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -148.36 122.42 9.47 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.654 0.74 . . . . 72.140000000000001 110.357 177.515 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.8 p -82.65 129.16 37.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-N 114.366 -1.288 . . . . 51.140000000000001 110.682 -178.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 59.2 m -93.64 102.51 14.69 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.592 -0.731 . . . . 53.109999999999999 109.735 178.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.1 mt -90.63 104.06 14.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.967 -0.561 . . . . 74.109999999999999 110.037 -179.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 94.5 mtt180 -122.83 174.07 7.37 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.533 -0.758 . . . . 72.219999999999999 109.734 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 24.7 mp0 -122.98 133.36 54.37 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 121.285 0.564 . . . . 74.430000000000007 111.059 -177.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.527 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 1.0 OUTLIER -115.81 84.9 2.19 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.318 -0.855 . . . . 64.420000000000002 109.336 -179.411 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 80.88 -106.11 2.51 Favored Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 110.827 -0.909 . . . . 73.450000000000003 110.827 -172.481 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.434 ' HB3' ' HG3' ' A' ' 40' ' ' LYS . 11.7 m-20 -110.49 -14.47 14.09 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.761 0.315 . . . . 71.409999999999997 110.93 176.323 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.527 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 24.6 pttm -89.41 136.57 32.95 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.98 0.419 . . . . 74.010000000000005 110.918 -176.28 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 13.0 m -83.8 130.33 34.93 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.781 -0.645 . . . . 73.510000000000005 110.205 178.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 26.4 mm -116.65 106.82 21.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 120.93 0.395 . . . . 75.5 110.128 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 16.1 mt-30 -100.02 102.5 13.87 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.225 -0.443 . . . . 73.510000000000005 109.828 178.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.417 ' HB3' HD13 ' A' ' 32' ' ' LEU . 26.4 mt-10 -89.67 100.68 13.43 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.519 -0.764 . . . . 65.450000000000003 110.937 -176.302 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.622 ' HD2' ' HB2' ' B' ' 151' ' ' ASP . 44.2 m-85 -75.41 100.21 4.39 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.086 -0.507 . . . . 74.519999999999996 110.32 179.257 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 51.2 mtm180 -115.89 124.45 50.66 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.311 -0.404 . . . . 71.109999999999999 110.418 178.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.849 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.9 p -87.24 -93.25 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 C-N-CA 120.564 -0.454 . . . . 70.510000000000005 110.091 175.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.849 ' H ' HG13 ' A' ' 28' ' ' VAL . 3.4 t-20 -107.49 70.07 0.77 Allowed 'General case' 0 C--N 1.325 -0.488 0 O-C-N 121.562 -0.712 . . . . 64.329999999999998 109.997 -176.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 77.57 9.08 87.09 Favored Glycine 0 C--N 1.331 0.251 0 C-N-CA 120.714 -0.755 . . . . 75.230000000000004 112.344 179.128 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 85.6 t80 -127.55 123.06 34.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.676 0.274 . . . . 73.430000000000007 110.643 -177.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.537 HD21 HD11 ' A' ' 35' ' ' ILE . 27.6 tp -78.65 115.5 18.4 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.025 -0.534 . . . . 72.329999999999998 109.762 173.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -103.51 -14.68 16.11 Favored 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 120.253 -0.579 . . . . 61.43 111.481 -176.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.446 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -167.61 146.34 4.81 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.889 0.376 . . . . 71.310000000000002 111.475 -177.206 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.537 HD11 HD21 ' A' ' 32' ' ' LEU . 71.4 mt -122.59 131.4 73.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 116.084 -0.507 . . . . 71.129999999999995 109.77 175.167 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -104.49 100.75 10.43 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.948 -0.76 . . . . 72.340000000000003 108.948 170.195 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 0.9 OUTLIER -97.75 123.56 50.25 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 115.663 -0.699 . . . . 64.319999999999993 110.283 -179.483 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.731 HG22 ' HB3' ' A' ' 44' ' ' PRO . 22.0 t -113.73 87.65 12.55 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 115.384 -0.825 . . . . 73.530000000000001 110.3 -178.489 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.489 ' HD3' HG22 ' A' ' 37' ' ' VAL . 74.5 Cg_endo -77.83 141.71 19.46 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 122.406 2.071 . . . . 62.43 111.33 176.568 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.434 ' HG3' ' HB3' ' A' ' 20' ' ' ASP . 35.2 mtmt -58.89 -32.95 69.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.197 0.523 . . . . 63.340000000000003 110.603 179.346 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -130.6 100.51 5.34 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.74 -0.664 . . . . 74.150000000000006 109.297 177.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 149.54 -16.0 1.1 Allowed Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.884 -0.674 . . . . 45.340000000000003 112.277 -177.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.5 mttt 72.76 140.84 0.08 OUTLIER Pre-proline 0 N--CA 1.467 0.393 0 C-N-CA 123.383 0.673 . . . . 74.219999999999999 112.237 178.29 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.731 ' HB3' HG22 ' A' ' 38' ' ' VAL . 29.1 Cg_endo -64.18 133.6 38.77 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 123.103 2.535 . . . . 71.120000000000005 112.476 179.04 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 11.2 p90 -144.15 156.18 44.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.107 -0.497 . . . . 70.129999999999995 110.57 -179.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.492 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 20.0 m-85 -99.54 142.38 31.1 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.084 -0.507 . . . . 75.430000000000007 111.484 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.446 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 72.0 mt -124.88 104.51 8.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.608 -0.724 . . . . 74.510000000000005 109.747 171.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 43.2 t -93.24 136.36 25.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 116.184 -0.462 . . . . 74.420000000000002 110.047 -178.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.562 HH11 ' HG3' ' A' ' 49' ' ' ARG . 0.5 OUTLIER -76.06 132.06 39.87 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.94 0.4 . . . . 71.430000000000007 111.621 -178.504 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -70.12 158.31 35.98 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.565 -0.743 . . . . 74.25 111.707 179.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -79.18 171.86 14.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.647 -0.706 . . . . 72.209999999999994 111.771 -176.265 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 70.33 21.49 77.35 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.657 -0.701 . . . . 70.409999999999997 113.035 171.147 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 15.9 m 57.28 30.66 18.83 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.024 0.44 . . . . 73.319999999999993 110.526 -177.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -55.98 -63.93 1.02 Allowed 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.468 -0.787 . . . . 74.129999999999995 111.501 -179.278 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 131.1 -39.2 1.81 Allowed Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.273 -0.965 . . . . 74.349999999999994 112.794 177.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 54.9 m-80 -68.57 164.55 21.1 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.43 0.633 . . . . 64.219999999999999 111.507 -176.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.43 ' CE2' ' HG2' ' A' ' 49' ' ' ARG . 67.9 m-85 -113.29 155.28 25.41 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.209 -0.905 . . . . 74.209999999999994 109.587 175.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.624 HD11 HD23 ' A' ' 66' ' ' LEU . 27.5 mm -113.27 119.87 61.8 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 108.883 -0.784 . . . . 75.299999999999997 108.883 177.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.571 ' HB2' HG13 ' A' ' 67' ' ' ILE . 8.1 ttm180 -82.7 149.43 27.32 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.951 -0.3 . . . . 75.420000000000002 110.403 -175.273 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.492 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 4.3 p -62.82 -27.14 69.11 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.282 -0.417 . . . . 61.240000000000002 111.452 178.266 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.449 ' HB2' ' HD2' ' A' ' 59' ' ' ARG . 1.3 m-20 -64.41 -29.13 70.19 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.131 -0.486 . . . . 72.040000000000006 111.537 -179.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.9 tp-100 -150.79 93.0 3.79 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-O 121.034 0.445 . . . . 71.239999999999995 109.992 -179.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.481 ' HB2' ' HD2' ' B' ' 146' ' ' PHE . 72.7 Cg_endo -74.35 15.06 0.67 Allowed 'Trans proline' 0 C--O 1.233 0.24 0 C-N-CA 123.396 2.73 . . . . 72.349999999999994 113.151 -176.429 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 31.2 t70 -128.25 8.33 6.04 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.161 0.505 . . . . 74.140000000000001 110.338 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 12.5 mmmt -121.75 145.43 48.04 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.101 -0.5 . . . . 65.099999999999994 111.925 -177.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.624 HD23 HD11 ' A' ' 58' ' ' ILE . 65.6 mt -92.41 109.11 20.49 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.342 -0.844 . . . . 64.239999999999995 109.754 178.071 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.571 HG13 ' HB2' ' A' ' 59' ' ' ARG . 46.6 mm -72.67 119.54 75.77 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 116.323 -0.398 . . . . 72.299999999999997 110.408 -178.697 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -69.53 178.95 3.91 Favored 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 123.274 2.649 . . . . 74.530000000000001 113.363 -177.184 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . 0.822 ' HA ' HG12 ' A' ' 72' ' ' ILE . 34.9 tt0 -75.19 -34.58 61.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.513 -0.767 . . . . 74.209999999999994 111.515 -170.486 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 3.7 p90 -64.32 -23.89 67.46 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.349 -0.541 . . . . 75.340000000000003 110.916 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.483 ' HA ' ' HB2' ' A' ' 74' ' ' SER . 4.2 tp10 -92.99 -27.79 16.8 Favored 'General case' 0 N--CA 1.438 -1.052 0 CA-C-N 116.086 -0.507 . . . . 72.409999999999997 110.639 -176.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.822 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.3 pt -80.14 -16.95 12.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.039 0.447 . . . . 70.549999999999997 110.66 177.547 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.452 ' CD1' HG13 ' A' ' 72' ' ' ILE . 46.5 m-85 -108.37 15.37 24.04 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.825 -0.625 . . . . 73.439999999999998 110.118 174.04 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.483 ' HB2' ' HA ' ' A' ' 71' ' ' GLU . 8.3 t -74.43 -28.81 61.23 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.755 -0.657 . . . . 71.109999999999999 110.396 -177.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . 0.405 ' O ' ' HE3' ' A' ' 21' ' ' LYS . 65.3 p-90 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.515 -0.311 . . . . 72.530000000000001 110.935 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.45 0 N-CA-C 111.67 -0.572 . . . . 43.020000000000003 111.67 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -99.58 116.29 31.37 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.1 0.476 . . . . 71.219999999999999 111.118 -176.23 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 12.8 m-20 -101.83 -52.74 3.12 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.449 0.643 . . . . 72.040000000000006 109.463 177.34 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -136.49 26.4 3.13 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 107.79 -1.189 . . . . 73.420000000000002 107.79 174.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -87.32 91.09 8.6 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 114.257 -1.338 . . . . 71.439999999999998 110.611 -173.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -90.5 116.28 66.04 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.194 -0.457 . . . . 70.010000000000005 111.02 -178.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -68.28 176.49 5.52 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.902 2.401 . . . . 62.25 111.805 178.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 35.0 m -107.56 159.22 16.6 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.087 0.47 . . . . 64.030000000000001 110.861 -179.508 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.49 -68.3 0.22 Allowed Glycine 0 N--CA 1.446 -0.691 0 N-CA-C 111.595 -0.602 . . . . 63.5 111.595 -177.408 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 57.8 mm-40 69.21 77.12 0.24 Allowed Pre-proline 0 N--CA 1.468 0.463 0 C-N-CA 123.537 0.735 . . . . 74.439999999999998 111.807 -178.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.617 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 10.8 Cg_endo -80.93 85.22 1.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.087 0 C-N-CA 122.455 2.103 . . . . 52.130000000000003 111.049 174.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -97.01 150.52 20.69 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.208 0.528 . . . . 61.210000000000001 110.448 -178.218 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.434 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 13.5 p -105.46 123.75 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.906 0 CA-C-N 115.653 -0.703 . . . . 54.049999999999997 109.417 174.282 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . 0.528 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 19.6 m -89.22 99.52 12.49 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 115.658 -0.701 . . . . 61.219999999999999 109.472 177.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 59.8 mt -88.86 106.19 16.56 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.919 -0.582 . . . . 52.310000000000002 110.093 -177.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 32.1 mtp-105 -122.28 -174.36 2.88 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.408 -0.815 . . . . 75.239999999999995 110.34 179.286 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 23.6 mp0 -136.16 132.55 36.13 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.839 -0.619 . . . . 74.5 110.431 179.201 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . 0.48 ' HG2' HG13 ' B' ' 123' ' ' ILE . 79.4 mm-40 -112.56 82.26 1.61 Allowed 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 109.062 -0.718 . . . . 75.430000000000007 109.062 173.687 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 81.05 -92.06 1.45 Allowed Glycine 0 N--CA 1.446 -0.667 0 C-N-CA 120.743 -0.741 . . . . 75.450000000000003 111.387 -175.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 29.9 m-20 -117.61 -20.49 8.95 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.767 0.318 . . . . 70.329999999999998 111.205 178.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.745 ' HE3' ' HE3' ' B' ' 175' ' ' TRP . 23.6 pttt -86.62 126.0 34.21 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.273 0.559 . . . . 72.140000000000001 111.076 -177.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 43.9 m -80.72 124.32 28.93 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.502 -0.772 . . . . 70.140000000000001 109.986 178.592 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . 0.48 HG13 ' HG2' ' B' ' 118' ' ' GLU . 27.3 mm -108.98 108.59 25.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 116.552 -0.295 . . . . 72.010000000000005 110.393 -175.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.434 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 16.5 mt-30 -100.65 100.52 11.24 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.917 0.389 . . . . 73.519999999999996 110.254 178.256 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . 0.528 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 43.7 mt-10 -86.77 107.43 18.26 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.034 -0.53 . . . . 72.5 111.116 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . 0.487 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 78.0 m-85 -86.99 113.39 22.71 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.976 0.417 . . . . 74.109999999999999 110.422 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . 0.423 ' O ' ' HA ' ' B' ' 111' ' ' PRO . 60.5 mtm180 -117.22 178.7 4.27 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.124 -0.489 . . . . 71.310000000000002 109.957 179.145 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.624 HG13 ' H ' ' B' ' 129' ' ' ASN . 2.6 p -140.58 -65.21 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 116.279 -0.419 . . . . 64.519999999999996 110.884 173.055 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . 0.624 ' H ' HG13 ' B' ' 128' ' ' VAL . 3.7 t-20 -141.79 75.99 1.52 Allowed 'General case' 0 C--N 1.324 -0.536 0 C-N-CA 120.438 -0.505 . . . . 61.149999999999999 110.194 -179.64 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 67.04 25.75 73.32 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.346 -0.843 . . . . 74.340000000000003 111.782 -179.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 67.7 t80 -146.01 121.7 10.5 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.685 -0.487 . . . . 73.019999999999996 109.685 -179.498 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.465 HD21 HD11 ' B' ' 135' ' ' ILE . 24.5 tp -80.14 123.93 28.33 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.724 -0.671 . . . . 75.519999999999996 109.318 176.048 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . 0.487 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 37.2 p90 -108.85 -15.72 14.32 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 119.969 -0.692 . . . . 75.310000000000002 111.849 -176.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . 0.41 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -168.03 148.85 5.07 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.928 0.394 . . . . 75.319999999999993 111.6 -178.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.465 HD11 HD21 ' B' ' 132' ' ' LEU . 62.9 mt -125.39 126.18 70.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 116.118 -0.492 . . . . 43.149999999999999 109.842 174.337 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.434 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 88.6 tttt -105.04 101.19 10.77 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.957 -0.757 . . . . 62.350000000000001 108.957 172.254 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.568 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 1.4 p -99.23 133.64 41.22 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 CA-C-N 115.855 -0.611 . . . . 72.140000000000001 110.196 179.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.883 HG22 ' HB3' ' B' ' 144' ' ' PRO . 24.4 t -107.85 84.61 2.11 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 115.384 -0.826 . . . . 75.420000000000002 109.536 177.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.415 ' HG3' ' HE1' ' B' ' 145' ' ' TYR . 92.3 Cg_endo -79.86 150.01 20.78 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 122.407 2.072 . . . . 55.149999999999999 111.969 -179.175 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 4.1 mmpt? -62.2 -35.71 79.7 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.77 -0.65 . . . . 62.439999999999998 110.123 177.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 86.2 m-70 -124.73 90.67 3.29 Favored 'General case' 0 N--CA 1.447 -0.612 0 CA-C-N 115.789 -0.642 . . . . 72.310000000000002 109.913 -178.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 150.49 -29.18 1.07 Allowed Glycine 0 N--CA 1.448 -0.549 0 CA-C-N 115.191 -0.913 . . . . 70.25 111.675 -176.035 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . 0.446 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 87.0 mttt 70.34 155.73 0.15 Allowed Pre-proline 0 N--CA 1.467 0.421 0 C-N-CA 123.427 0.691 . . . . 74.140000000000001 112.01 -178.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.883 ' HB3' HG22 ' B' ' 138' ' ' VAL . 18.9 Cg_endo -58.25 124.07 15.06 Favored 'Trans proline' 0 C--N 1.349 0.579 0 C-N-CA 123.224 2.616 . . . . 71.209999999999994 113.47 -175.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . 0.511 ' CE1' HG13 ' B' ' 137' ' ' VAL . 5.1 p90 -139.65 168.23 20.3 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.636 -0.711 . . . . 72.219999999999999 110.137 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.481 ' HD2' ' HB2' ' A' ' 63' ' ' PRO . 1.2 m-85 -108.84 139.32 43.83 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.954 0.407 . . . . 73.420000000000002 111.882 -176.506 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.41 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 25.6 mt -118.75 101.28 7.97 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.448 -0.796 . . . . 75.219999999999999 109.653 169.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 42.7 t -86.46 137.91 20.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 116.225 -0.443 . . . . 73.409999999999997 110.077 -179.101 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 5.1 mmt85 -74.85 130.38 39.32 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.884 0.373 . . . . 72.239999999999995 111.285 178.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -71.03 122.14 19.5 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.769 -0.65 . . . . 34.520000000000003 111.08 177.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . 0.622 ' HB2' ' HD2' ' A' ' 26' ' ' TYR . 15.7 t70 -61.31 140.0 58.06 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.648 -0.705 . . . . 73.239999999999995 110.981 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 73.47 -56.61 2.03 Favored Glycine 0 CA--C 1.522 0.478 0 CA-C-N 115.955 -0.566 . . . . 71.400000000000006 113.237 179.323 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . 0.433 ' O ' ' HB3' ' B' ' 154' ' ' ASP . 19.7 m -61.2 -46.07 91.96 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 122.43 0.292 . . . . 73.409999999999997 110.868 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . 0.433 ' HB3' ' O ' ' B' ' 153' ' ' SER . 18.0 t70 71.47 -48.27 0.67 Allowed 'General case' 0 N--CA 1.464 0.237 0 C-N-CA 123.743 0.817 . . . . 74.329999999999998 111.859 178.107 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . -88.13 50.07 3.84 Favored Glycine 0 N--CA 1.448 -0.502 0 CA-C-N 116.122 -0.49 . . . . 54.43 112.601 -178.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . 0.503 HD21 ' HB3' ' B' ' 166' ' ' LEU . 25.9 t-20 -162.54 144.59 10.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.457 -0.571 . . . . 75.549999999999997 109.457 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . 0.506 ' HB2' HG22 ' B' ' 172' ' ' ILE . 72.4 m-85 -118.99 150.71 39.48 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.909 0.385 . . . . 74.040000000000006 110.463 178.108 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 50.0 mm -113.43 114.44 46.86 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 N-CA-C 108.82 -0.807 . . . . 64.140000000000001 108.82 175.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.535 ' HB2' HG13 ' B' ' 167' ' ' ILE . 15.0 ttp180 -88.03 146.92 25.24 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 110.046 -0.353 . . . . 72.340000000000003 110.046 -174.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 4.0 p -60.03 -36.31 76.99 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 112.779 0.659 . . . . 61.109999999999999 112.779 -174.101 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -78.28 -14.65 59.34 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.973 0.416 . . . . 70.120000000000005 110.908 -177.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . 0.838 ' HG3' ' HB2' ' B' ' 165' ' ' LYS . 5.4 tp-100 -138.03 72.02 47.57 Favored Pre-proline 0 N--CA 1.45 -0.438 0 CA-C-N 116.219 -0.446 . . . . 54.310000000000002 110.894 -177.334 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -85.09 -1.57 9.38 Favored 'Trans proline' 0 C--N 1.348 0.506 0 C-N-CA 122.674 2.249 . . . . 72.530000000000001 111.775 179.18 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -91.74 -17.99 24.59 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.25 -0.886 . . . . 75.200000000000003 110.14 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . 0.838 ' HB2' ' HG3' ' B' ' 162' ' ' GLN . 0.7 OUTLIER -122.79 158.83 29.35 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.124 -0.944 . . . . 72.420000000000002 111.134 -175.133 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . 0.503 ' HB3' HD21 ' B' ' 156' ' ' ASN . 5.1 mp -94.74 134.02 37.79 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.064 -1.087 . . . . 55.140000000000001 108.064 172.577 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . 0.535 HG13 ' HB2' ' B' ' 159' ' ' ARG . 50.2 mm -84.69 125.11 72.07 Favored Pre-proline 0 C--N 1.32 -0.695 0 C-N-CA 120.91 -0.316 . . . . 73.430000000000007 111.041 -171.552 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.455 ' HG2' ' HB2' ' B' ' 171' ' ' GLU . 49.6 Cg_endo -67.7 172.77 10.02 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.762 2.308 . . . . 74.299999999999997 112.429 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . 0.516 ' HA ' HG12 ' B' ' 172' ' ' ILE . 20.4 tt0 -79.56 -16.93 55.05 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.766 -0.652 . . . . 74.540000000000006 111.626 -167.464 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . 0.417 ' CD1' ' HG2' ' B' ' 171' ' ' GLU . 24.4 p90 -86.75 -8.01 57.76 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.234 0.54 . . . . 62.5 110.019 176.043 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.55 ' O ' ' HB2' ' B' ' 174' ' ' SER . 1.9 mm-40 -113.32 -11.89 13.11 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.816 -0.629 . . . . 73.120000000000005 111.961 -176.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.516 HG12 ' HA ' ' B' ' 169' ' ' GLN . 31.8 pt -76.82 -16.87 14.75 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 121.264 0.554 . . . . 70.5 110.277 175.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -109.14 39.09 2.13 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.356 -0.838 . . . . 75.219999999999999 108.874 174.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . 0.55 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 0.5 OUTLIER -70.15 -14.48 62.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 114.981 -1.009 . . . . 60.340000000000003 110.916 -176.181 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . 0.745 ' HE3' ' HE3' ' B' ' 121' ' ' LYS . 59.7 p-90 . . . . . 0 C--O 1.245 0.842 0 CA-C-O 118.286 -0.864 . . . . 64.239999999999995 110.204 177.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.659 0 N-CA-C 111.328 -0.709 . . . . 63.32 111.328 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -78.74 73.56 5.28 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 121.447 0.641 . . . . 73.010000000000005 110.518 175.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -121.17 131.39 54.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.31 -0.859 . . . . 73.409999999999997 109.909 178.096 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -82.05 -60.89 2.07 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.88 -0.6 . . . . 62.310000000000002 111.964 -173.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -83.77 111.88 19.58 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.272 -0.422 . . . . 72.400000000000006 111.124 -175.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -86.97 131.36 45.14 Favored Pre-proline 0 C--N 1.322 -0.62 0 CA-C-N 115.677 -0.692 . . . . 74.030000000000001 109.798 176.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -68.69 165.68 28.68 Favored 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.671 2.248 . . . . 63.439999999999998 112.386 -178.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 15.0 m -81.03 111.58 17.64 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.03 -0.73 . . . . 75.219999999999999 109.03 175.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 116.17 102.8 2.33 Favored Glycine 0 N--CA 1.439 -1.111 0 N-CA-C 108.79 -1.724 . . . . 74.439999999999998 108.79 -166.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . 0.476 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 10.1 pt-20 -141.03 113.99 6.96 Favored Pre-proline 0 N--CA 1.437 -1.12 0 N-CA-C 108.089 -1.078 . . . . 63.409999999999997 108.089 -167.773 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.476 ' HD3' ' HA ' ' A' ' 10' ' ' GLU . 4.9 Cg_exo -77.12 81.47 2.61 Favored 'Trans proline' 0 N--CA 1.437 -1.803 0 C-N-CA 121.873 1.715 . . . . 73.120000000000005 110.531 -176.451 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -86.26 155.37 20.71 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 114.564 -1.198 . . . . 72.120000000000005 109.869 -177.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.592 HG21 ' HB3' ' A' ' 24' ' ' GLN . 10.1 p -121.23 123.79 70.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 CA-C-O 121.512 0.673 . . . . 64.420000000000002 111.143 -178.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.558 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 88.8 m -86.03 104.21 15.43 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.521 -0.763 . . . . 71.0 108.944 177.011 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.3 mt -91.44 105.5 16.61 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.895 0 CA-C-N 116.093 -0.503 . . . . 44.43 110.598 -175.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.405 HH21 ' CD ' ' A' ' 25' ' ' GLU . 62.3 mtm180 -117.86 172.99 7.02 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.787 -0.642 . . . . 72.540000000000006 109.993 177.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.499 ' HG2' ' HA ' ' A' ' 22' ' ' THR . 82.6 mt-30 -136.93 122.17 19.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.172 0.51 . . . . 64.519999999999996 111.024 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.469 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 31.5 mm-40 -106.96 87.35 2.49 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.398 -0.819 . . . . 75.430000000000007 110.018 178.188 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 79.17 -95.13 1.4 Allowed Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.633 -0.794 . . . . 74.430000000000007 111.678 -178.26 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -124.09 12.5 8.97 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.83 0.347 . . . . 72.420000000000002 110.871 -179.228 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.714 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 21.3 pttm -117.27 117.29 29.12 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.019 0.438 . . . . 74.549999999999997 110.987 178.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.702 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 23.6 m -79.25 101.91 8.27 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.736 -0.665 . . . . 72.030000000000001 109.679 176.047 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.469 HG12 HG13 ' A' ' 37' ' ' VAL . 57.0 mt -92.64 106.85 18.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 120.996 0.427 . . . . 63.43 110.14 -176.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.604 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 20.2 mt-30 -91.4 110.7 22.01 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.801 -0.636 . . . . 75.120000000000005 110.3 178.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.622 ' HB3' HD13 ' A' ' 32' ' ' LEU . 26.4 mt-10 -93.83 103.48 15.6 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.469 -0.787 . . . . 62.329999999999998 111.109 -177.142 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.413 ' HB3' ' CZ ' ' A' ' 33' ' ' TYR . 86.8 m-85 -77.83 109.13 11.58 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.985 0.421 . . . . 73.519999999999996 110.228 178.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 31' ' ' PHE . 83.8 mtt180 -127.58 127.3 43.65 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.581 -0.736 . . . . 74.420000000000002 109.459 -179.681 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.604 HG21 ' CD2' ' B' ' 131' ' ' PHE . 11.9 p -90.49 -28.25 4.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 C-N-CA 120.37 -0.532 . . . . 61.020000000000003 110.628 -177.754 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -172.26 68.06 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.707 -0.679 . . . . 73.109999999999999 109.631 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 95.77 -37.97 3.26 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.773 -0.727 . . . . 62.32 113.414 178.262 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.416 ' CD2' HG21 ' B' ' 128' ' ' VAL . 80.1 t80 -94.82 133.5 38.46 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.239 0.542 . . . . 71.150000000000006 111.405 -174.058 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.622 HD13 ' HB3' ' A' ' 25' ' ' GLU . 50.1 tp -82.38 112.86 19.73 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.941 -1.027 . . . . 54.100000000000001 110.156 174.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . 0.455 ' O ' ' HB2' ' A' ' 49' ' ' ARG . 44.3 p90 -108.62 -4.99 16.65 Favored 'General case' 0 C--N 1.325 -0.487 0 C-N-CA 120.895 -0.322 . . . . 73.400000000000006 111.72 -176.614 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.405 ' HB3' ' HB2' ' A' ' 26' ' ' TYR . . . -168.3 136.97 2.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.891 0.377 . . . . 71.420000000000002 110.889 -176.141 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.414 ' CG1' HD21 ' A' ' 32' ' ' LEU . 61.4 mt -118.97 126.12 75.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.0 -0.546 . . . . 75.319999999999993 110.542 178.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.604 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 83.1 tttt -108.69 100.78 9.98 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 109.003 -0.74 . . . . 62.25 109.003 171.366 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.706 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 2.8 t -87.91 128.79 40.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 109.153 -0.684 . . . . 63.32 109.153 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.817 HG13 ' HG3' ' A' ' 44' ' ' PRO . 24.2 t -115.74 72.71 4.16 Favored Pre-proline 0 C--N 1.32 -0.709 0 N-CA-C 109.75 -0.463 . . . . 65.049999999999997 109.75 172.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.714 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 57.1 Cg_endo -78.76 134.43 12.09 Favored 'Trans proline' 0 N--CA 1.458 -0.615 0 C-N-CA 122.18 1.92 . . . . 63.109999999999999 112.433 176.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 9.4 mtpm? -59.78 -33.06 71.21 Favored 'General case' 0 CA--C 1.516 -0.335 0 CA-C-O 121.29 0.566 . . . . 74.200000000000003 109.948 175.275 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 62.4 m-70 -115.77 103.58 10.8 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.244 -0.889 . . . . 54.299999999999997 109.148 178.009 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 130.11 -25.18 4.39 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.943 -0.646 . . . . 31.440000000000001 112.096 -177.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.0 mttm 69.57 147.79 0.12 Allowed Pre-proline 0 N--CA 1.466 0.363 0 C-N-CA 123.342 0.657 . . . . 73.430000000000007 112.323 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.817 ' HG3' HG13 ' A' ' 38' ' ' VAL . 31.0 Cg_exo -58.51 145.97 92.59 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 123.222 2.615 . . . . 74.349999999999994 113.561 -177.03 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 30.6 p90 -156.39 164.91 37.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.314 -0.857 . . . . 74.310000000000002 109.304 174.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.557 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 85.1 m-85 -106.62 136.44 46.4 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.021 0.438 . . . . 72.120000000000005 110.7 -179.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 16.9 tp -125.14 98.96 5.88 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.695 -0.854 . . . . 54.299999999999997 108.695 176.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.438 HG21 HG21 ' B' ' 148' ' ' VAL . 28.7 t -96.32 140.59 16.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.421 -0.354 . . . . 74.239999999999995 111.548 -171.036 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.455 ' HB2' ' O ' ' A' ' 33' ' ' TYR . 0.7 OUTLIER -66.85 122.38 17.57 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.213 -0.449 . . . . 72.349999999999994 111.32 176.66 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.44 172.39 13.7 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.921 -0.581 . . . . 72.439999999999998 109.503 172.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -68.04 125.04 25.07 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.22 0.533 . . . . 71.510000000000005 109.781 176.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.41 125.57 5.49 Favored Glycine 0 N--CA 1.446 -0.68 0 C-N-CA 120.783 -0.723 . . . . 63.229999999999997 111.899 -176.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.5 t -87.45 23.1 1.99 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.347 0.594 . . . . 74.349999999999994 110.24 -177.027 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -58.12 -60.43 3.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.432 -0.804 . . . . 54.509999999999998 110.206 177.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 156.61 21.87 0.03 OUTLIER Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 115.546 -0.752 . . . . 72.349999999999994 112.453 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.485 ' OD1' ' HB3' ' A' ' 66' ' ' LEU . 7.4 t30 -102.91 137.18 41.44 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.963 0.411 . . . . 65.340000000000003 110.867 -176.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -123.56 174.42 7.43 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.942 -0.572 . . . . 72.109999999999999 110.47 177.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 49.8 mm -123.97 122.08 63.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.893 -0.78 . . . . 42.409999999999997 108.893 171.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.668 ' HB2' HG13 ' A' ' 67' ' ' ILE . 74.6 ttt180 -93.34 131.97 38.0 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.07 -0.514 . . . . 71.150000000000006 110.309 -175.386 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.557 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 67.9 p -62.8 -22.77 66.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.86 0.362 . . . . 74.349999999999994 111.343 -178.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.468 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 16.4 t70 -64.23 -46.37 84.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.778 -0.647 . . . . 64.340000000000003 109.981 178.479 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 78.0 mm-40 -132.14 82.66 58.1 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 115.479 -0.782 . . . . 71.319999999999993 109.383 178.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -76.34 30.9 0.4 Allowed 'Trans proline' 0 CA--C 1.529 0.254 0 C-N-CA 123.28 2.653 . . . . 62.140000000000001 112.5 -177.052 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -119.57 -39.89 2.83 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.433 -0.803 . . . . 72.219999999999999 110.462 -177.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.7 pttt -97.53 160.22 14.45 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.999 -0.546 . . . . 74.530000000000001 110.501 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.485 ' HB3' ' OD1' ' A' ' 56' ' ' ASN . 5.4 mp -92.96 140.25 29.67 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.668 -0.696 . . . . 71.140000000000001 109.335 179.214 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.711 HG23 ' HB3' ' A' ' 71' ' ' GLU . 47.1 mm -96.84 109.03 46.79 Favored Pre-proline 0 C--N 1.322 -0.593 0 CA-C-O 121.235 0.54 . . . . 75.310000000000002 111.307 -176.453 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.49 ' O ' HG23 ' A' ' 72' ' ' ILE . 93.0 Cg_endo -81.61 -176.92 3.3 Favored 'Trans proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.505 2.803 . . . . 61.140000000000001 111.983 177.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . 0.651 ' O ' HG12 ' A' ' 72' ' ' ILE . 6.3 tt0 -67.99 -40.42 83.09 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.225 0.454 . . . . 72.420000000000002 112.225 -171.122 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . 0.644 ' HA ' ' CZ ' ' A' ' 73' ' ' PHE . 17.4 p90 -63.38 -17.76 62.95 Favored 'General case' 0 C--N 1.326 -0.441 0 O-C-N 121.723 -0.61 . . . . 72.349999999999994 110.981 -178.591 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.711 ' HB3' HG23 ' A' ' 67' ' ' ILE . 2.5 mm-40 -94.45 -18.45 21.49 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.041 -0.527 . . . . 71.030000000000001 111.117 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.651 HG12 ' O ' ' A' ' 69' ' ' GLN . 39.9 pt -83.61 -36.03 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 C-N-CA 120.723 -0.391 . . . . 53.299999999999997 111.625 -177.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.644 ' CZ ' ' HA ' ' A' ' 70' ' ' TRP . 10.7 p90 -90.82 26.09 2.18 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 121.262 0.554 . . . . 75.109999999999999 110.722 178.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.3 t -78.72 9.03 4.49 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.767 -0.652 . . . . 73.420000000000002 111.102 -179.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . 0.681 ' HB3' ' HE3' ' A' ' 21' ' ' LYS . 38.8 m0 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.459 -0.337 . . . . 72.519999999999996 111.176 177.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 N-CA-C 111.876 -0.49 . . . . 54.200000000000003 111.876 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -103.66 0.36 30.56 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.228 0.537 . . . . 72.239999999999995 110.319 178.163 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -88.94 168.38 12.44 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.679 -0.692 . . . . 60.340000000000003 110.456 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -81.94 -48.25 11.71 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.145 0.498 . . . . 71.140000000000001 110.612 178.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -114.03 134.68 54.7 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.611 -0.722 . . . . 73.239999999999995 110.528 -178.215 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -120.75 128.58 25.71 Favored Pre-proline 0 C--N 1.319 -0.747 0 CA-C-N 115.883 -0.599 . . . . 72.140000000000001 109.979 177.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -52.89 144.08 46.14 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.833 2.355 . . . . 73.209999999999994 112.183 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 31.8 m -58.77 115.72 3.26 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.872 -0.603 . . . . 72.239999999999995 110.366 -179.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 122.61 42.89 0.4 Allowed Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 110.491 -1.043 . . . . 63.049999999999997 110.491 -170.397 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -106.59 100.56 31.25 Favored Pre-proline 0 C--N 1.324 -0.517 0 CA-C-O 121.658 0.742 . . . . 74.340000000000003 109.286 -179.463 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 58.0 Cg_endo -79.43 121.04 4.61 Favored 'Trans proline' 0 N--CA 1.448 -1.148 0 C-N-CA 122.382 2.054 . . . . 54.130000000000003 113.195 -169.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -122.84 144.19 49.36 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.814 -1.084 . . . . 74.340000000000003 108.599 174.583 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.75 HG21 ' HB3' ' B' ' 124' ' ' GLN . 7.9 p -92.37 132.01 37.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-O 121.396 0.617 . . . . 75.0 111.543 -172.112 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . 0.747 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.4 m -82.84 103.39 12.28 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.167 -0.924 . . . . 71.409999999999997 109.177 174.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 59.2 mt -88.67 104.61 14.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.096 0.474 . . . . 72.430000000000007 111.066 -176.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . 0.434 HH21 ' CD ' ' B' ' 125' ' ' GLU . 38.1 mtm180 -108.88 167.86 9.78 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.721 -0.672 . . . . 72.219999999999999 109.627 174.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 91.5 mt-30 -139.55 112.03 7.73 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.068 0.461 . . . . 74.340000000000003 110.585 177.447 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 81.6 mm-40 -108.48 85.35 2.09 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.669 -0.696 . . . . 74.099999999999994 110.384 -178.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 88.38 -111.94 3.84 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.624 -0.798 . . . . 51.420000000000002 111.589 -178.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.507 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 4.3 m-20 -116.0 23.24 12.37 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.059 0.457 . . . . 42.229999999999997 110.041 177.141 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.962 ' HE3' ' HB3' ' B' ' 175' ' ' TRP . 21.2 pttm -127.5 115.56 19.04 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.236 0.541 . . . . 63.310000000000002 110.307 177.311 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . 0.747 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 62.5 m -76.22 113.0 13.29 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.611 -0.722 . . . . 73.239999999999995 109.675 177.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 14.2 mm -92.8 102.51 13.7 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-N 115.948 -0.569 . . . . 75.129999999999995 109.999 -178.222 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.776 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 15.5 mt-30 -94.77 102.89 14.79 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.093 0.473 . . . . 63.130000000000003 110.327 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . 0.747 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 38.9 mt-10 -84.62 102.72 13.13 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.556 -0.747 . . . . 71.120000000000005 110.603 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . 0.493 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 41.4 m-85 -78.8 106.0 10.51 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.137 0.494 . . . . 55.109999999999999 110.377 178.061 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 65.6 mtt-85 -124.08 134.55 53.36 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.61 -0.723 . . . . 74.099999999999994 109.468 -178.367 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 5.6 p -96.08 -30.91 3.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-O 120.966 0.412 . . . . 54.020000000000003 111.407 -176.374 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -160.45 45.99 0.22 Allowed 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.872 -0.788 . . . . 72.340000000000003 108.872 -176.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 95.54 -32.08 6.58 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.425 -0.807 . . . . 23.510000000000002 112.186 -177.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.604 ' CD2' HG21 ' A' ' 28' ' ' VAL . 38.2 t80 -86.49 133.6 33.74 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.99 0.424 . . . . 74.310000000000002 110.445 -177.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.449 HD21 HD11 ' B' ' 135' ' ' ILE . 41.4 tp -82.83 120.5 25.73 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.354 -0.839 . . . . 62.210000000000001 110.645 179.328 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . 0.493 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 36.2 p90 -110.4 -10.43 14.58 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 120.498 -0.481 . . . . 74.019999999999996 111.658 -179.101 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -170.14 148.13 3.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.806 0.336 . . . . 44.210000000000001 110.913 -178.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.449 HD11 HD21 ' B' ' 132' ' ' LEU . 63.5 mt -122.44 125.89 73.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.332 -0.395 . . . . 71.109999999999999 110.17 177.456 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.776 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 75.9 tttt -102.43 102.39 12.7 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 109.07 -0.715 . . . . 72.129999999999995 109.07 173.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.589 HG12 ' HD3' ' B' ' 139' ' ' PRO . 3.4 t -86.52 128.94 39.08 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 N-CA-C 108.559 -0.904 . . . . 70.409999999999997 108.559 178.151 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.747 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.5 t -115.35 72.1 3.39 Favored Pre-proline 0 C--N 1.317 -0.841 0 N-CA-C 109.956 -0.387 . . . . 75.120000000000005 109.956 173.525 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.589 ' HD3' HG12 ' B' ' 137' ' ' VAL . 45.1 Cg_endo -77.12 130.5 11.23 Favored 'Trans proline' 0 N--CA 1.455 -0.754 0 C-N-CA 121.992 1.794 . . . . 64.109999999999999 111.868 176.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . 0.507 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 22.9 mtpp -64.76 -27.43 68.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.442 -0.799 . . . . 73.450000000000003 110.199 177.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -114.43 86.57 2.46 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.132 -0.94 . . . . 73.019999999999996 109.149 176.293 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 140.96 -13.88 2.85 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.593 -0.813 . . . . 60.520000000000003 112.678 -177.576 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 67.1 mttm 70.03 149.01 0.12 Allowed Pre-proline 0 N--CA 1.469 0.525 0 C-N-CA 123.134 0.574 . . . . 74.209999999999994 112.183 178.266 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.554 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 56.3 Cg_endo -70.64 143.1 45.7 Favored 'Trans proline' 0 C--N 1.346 0.397 0 C-N-CA 122.674 2.249 . . . . 74.219999999999999 113.146 -178.279 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 44.7 p90 -150.99 154.77 37.72 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.789 -0.641 . . . . 74.230000000000004 110.199 178.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.636 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 93.4 m-85 -96.64 130.5 43.84 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.838 -0.43 . . . . 75.25 109.838 177.255 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.402 HD11 HG13 ' B' ' 167' ' ' ILE . 15.7 tp -117.21 98.81 6.64 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.134 -0.691 . . . . 73.439999999999998 109.134 176.479 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . 0.438 HG21 HG21 ' A' ' 48' ' ' VAL . 39.0 t -83.92 135.73 24.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.05 -0.523 . . . . 72.140000000000001 110.837 -175.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.29 119.44 24.59 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.58 -0.526 . . . . 64.349999999999994 109.58 -177.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.14 166.75 22.88 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 121.321 0.581 . . . . 71.209999999999994 111.74 -174.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . 0.404 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 5.6 p-10 -67.77 157.59 34.38 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 114.964 -1.017 . . . . 71.239999999999995 111.99 -175.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 81.41 -8.93 57.24 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.301 -0.863 . . . . 52.219999999999999 113.28 173.179 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 23.3 t 59.3 31.1 20.9 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-O 121.513 0.673 . . . . 71.209999999999994 110.007 -178.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -64.43 -26.18 68.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.597 -0.729 . . . . 64.329999999999998 111.841 -178.139 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 106.15 25.17 6.53 Favored Glycine 0 CA--C 1.506 -0.525 0 N-CA-C 111.169 -0.772 . . . . 62.229999999999997 111.169 -175.044 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . 0.444 HD21 HD23 ' B' ' 166' ' ' LEU . 38.0 t30 -111.95 144.26 41.59 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.461 -0.57 . . . . 75.109999999999999 109.461 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . 0.531 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 55.8 m-85 -130.62 149.56 52.22 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.305 -0.407 . . . . 75.450000000000003 110.083 179.587 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.2 mm -112.44 117.19 54.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 109.444 -0.576 . . . . 72.150000000000006 109.444 176.306 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.443 ' HG2' ' H ' ' B' ' 161' ' ' ASP . 46.1 ttt180 -85.95 135.05 33.82 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.48 -0.782 . . . . 74.010000000000005 110.075 -175.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . 0.636 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 61.3 p -60.46 -33.07 72.03 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.406 0.622 . . . . 74.200000000000003 110.412 178.66 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . 0.443 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 26.6 t70 -75.94 -24.59 55.51 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.15 -0.932 . . . . 71.310000000000002 110.921 178.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . 0.453 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 84.3 mm-40 -139.98 70.97 35.44 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-N 116.153 -0.476 . . . . 71.319999999999993 110.197 -175.235 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -73.11 -15.37 25.8 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.431 2.087 . . . . 72.230000000000004 112.007 -178.032 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -89.2 -7.2 56.06 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.41 -0.814 . . . . 72.140000000000001 109.641 177.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . 0.453 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 51.3 tptt -110.68 123.98 51.06 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.444 -0.798 . . . . 75.099999999999994 110.447 -176.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . 0.444 HD23 HD21 ' B' ' 156' ' ' ASN . 5.3 mp -89.64 117.5 28.56 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.515 -0.766 . . . . 62.409999999999997 108.989 177.096 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . 0.531 ' HB ' ' HB2' ' B' ' 157' ' ' PHE . 49.3 mm -77.73 119.56 77.91 Favored Pre-proline 0 C--N 1.322 -0.603 0 CA-C-N 116.185 -0.462 . . . . 72.25 111.272 -171.31 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.481 ' O ' HG23 ' B' ' 172' ' ' ILE . 73.7 Cg_endo -73.3 177.26 8.1 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 123.049 2.5 . . . . 73.409999999999997 111.998 178.492 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 4.7 tt0 -84.25 0.88 47.2 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 116.347 -0.388 . . . . 71.319999999999993 111.468 -172.127 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 7.8 p90 -100.46 -18.89 16.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.987 0.423 . . . . 73.549999999999997 110.89 175.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.418 ' HB2' ' HG2' ' B' ' 168' ' ' PRO . 2.0 mm-40 -94.29 -11.43 30.15 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.194 -0.457 . . . . 74.519999999999996 110.76 -177.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.481 HG23 ' O ' ' B' ' 168' ' ' PRO . 37.0 pt -65.56 -29.65 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.991 -0.55 . . . . 75.219999999999999 111.432 -179.003 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . 0.458 ' C ' ' H ' ' B' ' 175' ' ' TRP . 33.8 p90 -107.79 43.96 1.15 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.525 0.678 . . . . 71.140000000000001 110.447 178.742 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . 0.418 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 1.9 t -78.59 21.97 0.37 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.05 -0.977 . . . . 71.349999999999994 110.036 178.183 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . 0.962 ' HB3' ' HE3' ' B' ' 121' ' ' LYS . 39.3 m0 . . . . . 0 C--O 1.25 1.129 0 CA-C-N 115.223 -0.898 . . . . 75.209999999999994 110.928 -176.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.884 0 N-CA-C 112.028 -0.429 . . . . 45.030000000000001 112.028 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -154.0 95.74 1.89 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.627 0.251 . . . . 61.310000000000002 110.681 -179.195 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -96.46 75.48 2.88 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.447 0.642 . . . . 73.430000000000007 109.318 178.296 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -116.83 112.82 21.65 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.282 -0.872 . . . . 74.349999999999994 110.278 -176.618 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -103.7 154.81 19.12 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.675 0.274 . . . . 74.209999999999994 110.482 -179.318 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.426 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -99.74 130.55 26.33 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-N 116.239 -0.437 . . . . 52.130000000000003 110.692 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 16.7 Cg_exo -68.13 171.42 12.62 Favored 'Trans proline' 0 CA--C 1.529 0.242 0 C-N-CA 122.955 2.436 . . . . 71.010000000000005 112.369 -179.513 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.6 m -65.67 143.25 57.69 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.518 -0.549 . . . . 65.109999999999999 109.518 176.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.663 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 74.03 73.02 0.95 Allowed Glycine 0 N--CA 1.445 -0.765 0 C-N-CA 120.02 -1.086 . . . . 52.329999999999998 110.621 -173.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . 0.432 ' H ' ' HG2' ' A' ' 10' ' ' GLU . 7.6 pt-20 -96.22 99.1 4.77 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-O 121.417 0.627 . . . . 63.049999999999997 110.667 -174.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.673 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 98.2 Cg_endo -93.73 94.72 0.14 Allowed 'Trans proline' 0 N--CA 1.445 -1.368 0 C-N-CA 122.926 2.417 . . . . 64.040000000000006 112.747 -176.524 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -86.96 147.1 25.89 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 108.932 -0.766 . . . . 60.210000000000001 108.932 177.069 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.623 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 8.1 p -90.63 122.41 41.98 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 CA-C-O 121.629 0.728 . . . . 65.129999999999995 110.261 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.628 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 21.6 m -83.31 102.59 12.08 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.264 -0.88 . . . . 72.400000000000006 109.196 179.226 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 53.2 mt -84.72 103.98 12.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.84 0 CA-C-N 115.978 -0.555 . . . . 74.340000000000003 110.308 -175.449 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -108.8 161.24 15.3 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.621 -0.718 . . . . 64.310000000000002 109.32 176.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -137.87 98.25 3.61 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-O 121.351 0.596 . . . . 71.129999999999995 110.232 176.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -93.88 96.84 9.99 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 114.982 -1.008 . . . . 75.420000000000002 109.849 -177.313 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 71.06 -101.84 1.0 Allowed Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.837 -0.697 . . . . 63.439999999999998 112.077 -178.105 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.745 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 16.5 m-20 -120.76 30.42 6.91 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.635 0.255 . . . . 62.43 110.951 -178.364 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 48.0 pttt -143.55 127.69 17.58 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.382 0.61 . . . . 75.25 111.624 175.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.447 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 75.0 m -81.66 107.18 14.2 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.189 -0.914 . . . . 71.340000000000003 109.936 177.073 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 50.2 mt -94.63 104.35 15.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.088 -0.505 . . . . 72.310000000000002 109.721 178.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.623 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 24.0 mt-30 -95.15 106.38 18.39 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.871 -0.604 . . . . 74.299999999999997 110.654 -177.725 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.628 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.7 mt-10 -89.86 104.51 17.06 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.874 -0.603 . . . . 53.149999999999999 111.355 -177.437 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.568 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 71.7 m-85 -76.94 103.57 6.95 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 109.393 -0.595 . . . . 74.340000000000003 109.393 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.43 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 55.5 mtt180 -120.39 128.05 52.86 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.259 -0.428 . . . . 73.549999999999997 110.362 -177.312 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.685 HG13 ' H ' ' A' ' 29' ' ' ASN . 2.3 p -93.49 -66.73 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.543 -0.298 . . . . 72.450000000000003 111.232 179.58 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.685 ' H ' HG13 ' A' ' 28' ' ' VAL . 74.2 m-20 -133.53 77.5 1.73 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.85 0.357 . . . . 71.010000000000005 110.158 179.513 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 69.21 13.49 67.38 Favored Glycine 0 C--N 1.331 0.267 0 CA-C-N 115.792 -0.64 . . . . 74.209999999999994 112.868 179.042 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.614 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 83.3 t80 -129.86 128.04 41.45 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.888 0.375 . . . . 72.120000000000005 111.12 -175.431 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.74 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -85.98 116.25 24.09 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.559 -0.746 . . . . 72.120000000000005 109.327 173.571 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -110.89 -19.71 12.71 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.622 -0.431 . . . . 74.040000000000006 111.729 -179.583 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -156.08 141.21 17.39 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.656 0.265 . . . . 61.009999999999998 111.031 -179.338 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.74 HG13 HD11 ' A' ' 32' ' ' LEU . 77.0 mt -124.31 125.9 71.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 116.055 -0.521 . . . . 72.319999999999993 110.612 176.867 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.444 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 82.1 tttt -102.99 102.56 12.61 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.104 -0.702 . . . . 72.299999999999997 109.104 170.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 22' ' ' THR . 0.5 OUTLIER -101.84 119.93 50.78 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 116.119 -0.491 . . . . 70.510000000000005 110.337 -179.538 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.571 HG13 ' HB3' ' A' ' 44' ' ' PRO . 22.3 t -109.17 89.71 7.19 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.445 -0.798 . . . . 73.439999999999998 110.135 -179.826 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.417 ' HD3' HG22 ' A' ' 37' ' ' VAL . 63.6 Cg_endo -79.37 135.92 12.24 Favored 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 122.282 1.988 . . . . 73.019999999999996 112.133 178.001 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.745 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 56.5 mtpt -63.43 -36.27 83.19 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.362 0.601 . . . . 71.329999999999998 109.518 174.622 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 79.0 m-70 -97.81 92.63 5.94 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.222 -0.899 . . . . 63.299999999999997 109.114 177.269 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 126.0 -151.39 17.82 Favored Glycine 0 N--CA 1.448 -0.549 0 N-CA-C 111.478 -0.649 . . . . 63.119999999999997 111.478 -176.529 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -129.29 143.76 50.11 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.801 0.301 . . . . 73.420000000000002 110.601 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.571 ' HB3' HG13 ' A' ' 38' ' ' VAL . 32.1 Cg_endo -65.29 128.94 21.49 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 122.679 2.253 . . . . 74.129999999999995 112.077 177.758 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -133.86 156.73 47.54 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.267 -0.424 . . . . 74.120000000000005 110.343 -178.151 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -95.71 131.62 41.77 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.778 -0.647 . . . . 74.140000000000001 109.792 177.514 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.569 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 17.0 tp -115.63 94.11 4.56 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.827 -0.805 . . . . 72.010000000000005 108.827 178.102 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.7 t -87.29 138.27 19.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.064 -0.517 . . . . 63.25 110.872 -174.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.461 ' HE ' ' HA ' ' A' ' 53' ' ' SER . 0.0 OUTLIER -100.89 121.6 42.0 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.926 -0.398 . . . . 74.319999999999993 109.926 -177.3 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.431 ' HB3' ' OD1' ' A' ' 56' ' ' ASN . . . -76.98 172.06 13.79 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.01 0.433 . . . . 71.299999999999997 112.076 -173.387 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.437 ' HB3' ' CD2' ' B' ' 126' ' ' TYR . 4.3 p-10 -72.13 167.73 19.64 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 115.793 -0.64 . . . . 74.310000000000002 111.09 -175.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 81.2 -17.17 13.42 Favored Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 115.831 -0.622 . . . . 50.43 112.798 177.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.461 ' HA ' ' HE ' ' A' ' 49' ' ' ARG . 20.9 t 61.64 33.46 18.13 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-O 120.894 0.378 . . . . 63.530000000000001 110.148 -178.075 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -55.89 -42.02 75.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.714 -0.675 . . . . 73.319999999999993 111.363 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 119.17 25.52 2.7 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.834 -0.698 . . . . 72.109999999999999 111.392 -177.167 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.431 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 11.2 p30 -118.74 147.24 44.07 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.178 0.513 . . . . 74.140000000000001 110.633 -177.368 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.569 ' CD2' ' HG ' ' A' ' 47' ' ' LEU . 46.6 m-85 -128.17 154.33 45.91 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.684 -0.689 . . . . 75.400000000000006 110.501 -178.729 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 45.3 mm -113.1 122.89 68.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.987 -0.551 . . . . 73.409999999999997 109.519 177.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.491 ' HB3' ' HB3' ' A' ' 61' ' ' ASP . 67.2 mtt180 -86.17 144.79 27.3 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.56 -0.291 . . . . 71.420000000000002 110.61 178.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 77.6 p -76.02 -21.85 56.41 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.407 -0.961 . . . . 75.299999999999997 108.407 166.396 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.491 ' HB3' ' HB3' ' A' ' 59' ' ' ARG . 19.2 t70 -57.62 -49.17 77.33 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.519 -1.219 . . . . 74.349999999999994 110.092 172.746 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 24.1 mm-40 -144.78 86.38 7.9 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.151 -0.932 . . . . 63.200000000000003 110.25 178.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_endo -78.79 13.0 2.03 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.89 2.394 . . . . 75.439999999999998 112.24 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 17.6 t70 -83.65 -30.7 26.65 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.418 -0.81 . . . . 71.099999999999994 110.529 -178.59 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.434 ' HE3' HD11 ' A' ' 67' ' ' ILE . 0.0 OUTLIER -126.25 178.1 6.02 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-O 121.196 0.522 . . . . 72.349999999999994 111.614 -176.664 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.5 mp -111.16 138.19 47.91 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.206 -0.906 . . . . 75.409999999999997 109.607 177.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.434 HD11 ' HE3' ' A' ' 65' ' ' LYS . 33.7 mm -76.55 124.86 87.95 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 116.448 -0.342 . . . . 75.430000000000007 110.145 178.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.411 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 44.3 Cg_endo -66.98 173.84 7.72 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.903 2.402 . . . . 75.010000000000005 112.759 -177.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 19.5 tt0 -88.63 -1.44 58.07 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.54 -0.755 . . . . 74.109999999999999 111.907 -168.684 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . 0.586 ' HA ' ' CE2' ' A' ' 73' ' ' PHE . 33.4 p90 -97.39 -22.61 16.51 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.265 0.555 . . . . 74.530000000000001 109.727 172.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.414 ' HA ' ' OG ' ' A' ' 74' ' ' SER . 4.4 mm-40 -84.25 -12.71 54.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.448 -0.796 . . . . 44.409999999999997 111.522 -176.745 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 31.9 pt -77.67 -15.88 14.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.125 -0.489 . . . . 64.400000000000006 111.875 -177.496 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CE2' ' HA ' ' A' ' 70' ' ' TRP . 42.4 p90 -119.45 23.83 11.01 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.42 0.629 . . . . 74.420000000000002 110.189 177.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.414 ' OG ' ' HA ' ' A' ' 71' ' ' GLU . 56.2 m -80.23 -1.34 40.25 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.712 -0.676 . . . . 65.420000000000002 110.875 177.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . 0.553 ' HH2' HG21 ' A' ' 35' ' ' ILE . 0.3 OUTLIER . . . . . 0 C--N 1.327 -0.38 0 CA-C-N 116.149 -0.478 . . . . 73.129999999999995 110.58 178.275 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.253 0 N-CA-C 112.093 -0.403 . . . . 32.310000000000002 112.093 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -94.71 155.4 16.86 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.48 0.181 . . . . 43.210000000000001 110.595 179.592 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -135.3 95.85 3.36 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.142 0.496 . . . . 72.439999999999998 110.576 -179.281 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -118.18 118.89 33.08 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.08 -0.711 . . . . 71.25 109.08 177.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -71.97 127.15 31.65 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.154 0.502 . . . . 65.129999999999995 110.184 -178.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . 0.406 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -107.9 109.3 62.1 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 115.755 -0.657 . . . . 55.439999999999998 110.757 -177.718 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 22.8 Cg_exo -65.48 161.87 36.35 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 123.178 2.585 . . . . 24.399999999999999 112.256 -179.583 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 58.8 m -71.12 111.34 6.4 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.292 -0.632 . . . . 75.340000000000003 109.292 175.088 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 111.45 52.66 0.55 Allowed Glycine 0 N--CA 1.445 -0.715 0 N-CA-C 110.551 -1.02 . . . . 73.230000000000004 110.551 -170.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . 0.407 ' O ' ' HG3' ' B' ' 110' ' ' GLU . 10.1 pt-20 -97.92 105.33 26.84 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.365 -0.976 . . . . 73.239999999999995 108.365 -179.316 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.614 ' HG3' ' CZ ' ' A' ' 31' ' ' PHE . 73.7 Cg_endo -83.11 113.42 2.11 Favored 'Trans proline' 0 N--CA 1.443 -1.489 0 C-N-CA 122.143 1.895 . . . . 72.549999999999997 112.418 -170.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 16.5 p-10 -109.72 133.46 53.1 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 115.066 -0.97 . . . . 75.409999999999997 109.444 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.626 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 11.7 p -83.55 127.89 39.31 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 121.42 0.629 . . . . 65.040000000000006 110.734 -177.396 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . 0.646 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 27.0 m -81.72 108.85 15.6 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.456 -0.793 . . . . 71.129999999999995 109.964 179.349 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.487 HG12 ' HG2' ' B' ' 124' ' ' GLN . 66.4 mt -93.26 106.05 17.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 121.074 0.464 . . . . 61.32 110.907 -176.439 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . 0.485 ' HA ' ' NE ' ' B' ' 116' ' ' ARG . 3.5 mmp_? -116.24 164.98 13.69 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.657 -0.701 . . . . 73.120000000000005 109.457 176.824 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 90.9 mt-30 -138.39 107.46 6.03 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.099 0.476 . . . . 72.219999999999999 110.962 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -100.36 97.29 8.07 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.584 -0.734 . . . . 71.239999999999995 110.297 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 74.89 -97.01 0.98 Allowed Glycine 0 N--CA 1.444 -0.797 0 C-N-CA 121.011 -0.614 . . . . 74.209999999999994 112.256 178.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.746 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 5.8 m-20 -125.06 32.07 5.48 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.702 0.287 . . . . 72.109999999999999 110.664 -178.702 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . . . . . . . . . 41.9 pttt -145.83 125.43 13.28 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.273 0.559 . . . . 55.409999999999997 111.806 177.754 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 59.8 m -79.91 107.74 12.93 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.073 -0.967 . . . . 71.209999999999994 109.828 175.413 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 42.6 mt -100.13 109.46 24.99 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-O 121.209 0.528 . . . . 61.439999999999998 110.096 -178.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.626 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 55.0 mt-30 -96.19 111.23 23.34 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.573 -0.74 . . . . 74.010000000000005 111.135 -178.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . 0.646 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 42.9 mt-10 -90.0 104.94 17.46 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.874 -0.603 . . . . 74.439999999999998 110.669 177.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . 0.437 ' CD2' ' HB3' ' A' ' 51' ' ' ASP . 56.8 m-85 -76.82 110.8 11.72 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.486 -0.324 . . . . 74.019999999999996 110.487 178.002 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . 0.613 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 48.0 mtt180 -130.93 137.7 49.41 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.971 -0.381 . . . . 74.040000000000006 109.971 178.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.573 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.5 p -98.8 -41.21 9.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 121.273 0.558 . . . . 54.020000000000003 110.797 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 -157.36 72.92 0.71 Allowed 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 108.848 -0.797 . . . . 75.299999999999997 108.848 -177.751 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.47 -38.16 2.77 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.819 -0.628 . . . . 53.149999999999999 112.889 -178.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 73.8 t80 -88.97 132.62 34.64 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.039 0.447 . . . . 75.219999999999999 111.573 -172.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.613 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 45.1 tp -85.16 117.96 24.43 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.317 -0.856 . . . . 53.119999999999997 110.085 175.091 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -109.67 -9.39 14.86 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 120.428 -0.509 . . . . 75.209999999999994 111.948 -177.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -167.51 141.52 3.61 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.735 0.302 . . . . 52.310000000000002 111.294 -177.188 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . . . . . . . . . 57.9 mt -118.13 126.29 74.85 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 116.271 -0.422 . . . . 71.140000000000001 110.121 176.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.466 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 84.7 tttt -112.7 101.19 9.31 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.367 -0.605 . . . . 72.310000000000002 109.367 174.453 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.511 HG13 ' CE1' ' B' ' 145' ' ' TYR . 0.7 OUTLIER -103.57 126.46 58.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 CA-C-O 121.03 0.443 . . . . 72.030000000000001 110.715 -178.844 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.809 HG22 ' HB3' ' B' ' 144' ' ' PRO . 21.9 t -110.2 89.53 8.54 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 115.366 -0.834 . . . . 64.129999999999995 109.62 178.748 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -77.35 136.52 15.94 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 122.508 2.139 . . . . 74.25 112.701 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . 0.746 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 56.2 mtpt -61.13 -38.08 85.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.6 0.714 . . . . 51.409999999999997 109.62 171.598 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 94.9 m-70 -99.3 84.25 2.97 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.832 -1.076 . . . . 75.140000000000001 108.889 177.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 130.59 -162.55 23.33 Favored Glycine 0 N--CA 1.446 -0.698 0 N-CA-C 110.322 -1.111 . . . . 73.450000000000003 110.322 -172.316 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -138.83 153.24 71.82 Favored Pre-proline 0 C--N 1.321 -0.652 0 CA-C-N 117.336 0.568 . . . . 75.310000000000002 110.715 178.169 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.809 ' HB3' HG22 ' B' ' 138' ' ' VAL . 21.8 Cg_endo -60.47 140.72 92.93 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 123.226 2.617 . . . . 55.240000000000002 113.29 -174.235 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . 0.511 ' CE1' HG13 ' B' ' 137' ' ' VAL . 23.3 p90 -143.44 155.67 44.44 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.53 -0.759 . . . . 74.120000000000005 109.481 177.84 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.463 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 96.4 m-85 -97.22 133.14 42.25 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.754 0.312 . . . . 64.230000000000004 110.431 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.528 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 17.5 tp -122.29 98.53 5.97 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 108.864 -0.791 . . . . 72.409999999999997 108.864 177.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 39.0 t -99.31 144.72 11.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.431 -0.349 . . . . 24.039999999999999 111.186 -172.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 5.2 mmt85 -76.91 145.25 38.36 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-O 120.962 0.41 . . . . 75.409999999999997 111.932 179.194 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.96 169.95 12.77 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.807 -0.633 . . . . 64.319999999999993 109.823 171.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . 0.568 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 6.2 p-10 -67.64 157.23 34.99 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.373 0.606 . . . . 74.510000000000005 112.155 -174.479 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 84.76 -5.68 81.09 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.481 -0.781 . . . . 71.129999999999995 113.268 174.384 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . 0.413 ' HB2' ' CD ' ' A' ' 11' ' ' PRO . 3.5 t 62.22 27.99 16.78 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.487 0.66 . . . . 41.43 109.664 -177.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -56.59 -27.56 58.29 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 114.782 -1.099 . . . . 65.540000000000006 111.885 -178.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 112.09 -22.11 18.96 Favored Glycine 0 CA--C 1.498 -1.0 0 C-N-CA 120.617 -0.802 . . . . 73.230000000000004 111.19 -178.593 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . 1.038 HD21 HD22 ' B' ' 166' ' ' LEU . 52.2 t30 -63.8 132.96 52.51 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 114.203 -0.998 . . . . 72.530000000000001 111.507 179.446 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . 0.528 ' CD2' ' HG ' ' B' ' 147' ' ' LEU . 27.2 m-85 -115.0 159.17 21.09 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.828 -0.623 . . . . 72.25 110.538 178.04 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . 0.831 HD11 HD23 ' B' ' 166' ' ' LEU . 48.6 mm -127.75 132.71 68.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.992 -0.549 . . . . 73.409999999999997 109.558 174.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.502 ' HB2' ' HB2' ' B' ' 162' ' ' GLN . 70.2 mtt180 -85.26 156.89 20.76 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.885 0.374 . . . . 73.109999999999999 111.249 -179.829 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . 0.463 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 49.4 p -80.01 -19.48 47.64 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.885 0.85 . . . . 60.549999999999997 108.777 166.37 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . 0.409 ' H ' ' HB3' ' B' ' 159' ' ' ARG . 3.7 t70 -86.84 -26.04 24.23 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 114.461 -1.245 . . . . 63.219999999999999 110.46 176.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . 0.502 ' HB2' ' HB2' ' B' ' 159' ' ' ARG . 25.4 mm-40 -136.68 74.94 51.27 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 115.518 -0.764 . . . . 74.519999999999996 109.346 -179.691 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -89.24 11.68 2.89 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.897 2.398 . . . . 61.539999999999999 113.183 -176.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -107.87 -45.42 3.99 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 120.992 -0.283 . . . . 74.230000000000004 111.013 -178.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.25 172.79 7.89 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.029 0.442 . . . . 70.349999999999994 111.26 178.581 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . 1.038 HD22 HD21 ' B' ' 156' ' ' ASN . 15.8 mt -105.35 150.27 25.36 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.851 -0.613 . . . . 72.140000000000001 109.948 -175.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 40.8 mm -101.31 111.67 63.98 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 116.389 -0.369 . . . . 72.219999999999999 110.183 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.602 ' O ' HG23 ' B' ' 172' ' ' ILE . 59.7 Cg_endo -70.05 174.52 9.64 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 123.075 2.516 . . . . 73.010000000000005 112.593 -178.511 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . 0.625 ' O ' HG12 ' B' ' 172' ' ' ILE . 6.3 tt0 -72.45 -35.7 68.35 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.877 -0.601 . . . . 72.430000000000007 111.969 -167.816 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 33.4 p90 -69.02 -14.66 63.17 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.168 0.509 . . . . 65.420000000000002 110.222 177.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.467 ' HA ' ' HB2' ' B' ' 174' ' ' SER . 7.0 mm-40 -96.51 -29.54 13.83 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.569 -0.741 . . . . 71.150000000000006 111.671 -178.029 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.625 HG12 ' O ' ' B' ' 169' ' ' GLN . 43.4 pt -67.66 -26.21 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 N-CA-C 111.876 0.324 . . . . 71.200000000000003 111.876 -175.309 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -124.09 36.3 4.65 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.353 0.597 . . . . 71.409999999999997 110.256 176.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . 0.467 ' HB2' ' HA ' ' B' ' 171' ' ' GLU . 22.1 t -85.66 10.73 12.56 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.342 -0.845 . . . . 71.219999999999999 111.369 -176.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 11.9 p-90 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.619 -0.705 . . . . 72.5 111.599 -178.364 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.886 0 N-CA-C 111.72 -0.552 . . . . 73.030000000000001 111.72 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -98.97 -45.93 5.79 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.627 -0.508 . . . . 75.400000000000006 109.627 176.381 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -132.0 130.84 41.93 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.434 -0.803 . . . . 75.439999999999998 109.526 176.591 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . 0.406 ' CG ' ' H ' ' A' ' 5' ' ' ASP . 3.6 p-10 -112.7 -93.09 0.47 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.705 -0.225 . . . . 74.519999999999996 111.348 -177.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.406 ' H ' ' CG ' ' A' ' 4' ' ' ASP . 32.7 t70 -154.06 124.09 6.84 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.914 0.388 . . . . 74.239999999999995 110.567 -178.491 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.467 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -133.71 134.68 23.73 Favored Pre-proline 0 C--N 1.323 -0.565 0 CA-C-N 115.937 -0.574 . . . . 74.010000000000005 110.106 179.406 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.467 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 19.4 Cg_exo -66.04 110.2 1.68 Allowed 'Trans proline' 0 N--CA 1.462 -0.327 0 C-N-CA 122.745 2.296 . . . . 54.240000000000002 112.281 -179.429 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 25.3 p -103.56 156.12 18.02 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.099 -0.501 . . . . 75.040000000000006 110.342 177.502 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 145.07 -53.16 0.57 Allowed Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.848 -0.691 . . . . 54.450000000000003 111.622 -179.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 64.6 100.96 0.04 OUTLIER Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.542 0.686 . . . . 65.209999999999994 111.624 177.041 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.646 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 18.8 Cg_endo -91.62 122.05 0.67 Allowed 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 123.58 2.853 . . . . 74.340000000000003 112.595 -179.837 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -139.62 138.58 36.26 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.148 -0.478 . . . . 73.129999999999995 109.749 178.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.543 ' HB ' ' HB2' ' B' ' 151' ' ' ASP . 13.7 p -101.94 132.8 47.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-O 121.331 0.586 . . . . 74.129999999999995 111.215 -171.594 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.7 m -92.77 104.06 16.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.738 -0.665 . . . . 72.140000000000001 109.722 176.055 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 66.4 mt -94.23 107.83 19.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 116.167 -0.469 . . . . 71.040000000000006 110.5 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 62.9 mtp180 -115.83 -179.2 3.59 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.242 -0.435 . . . . 64.209999999999994 110.505 177.065 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 70.9 mt-30 -140.1 106.24 5.23 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.937 -0.574 . . . . 64.040000000000006 110.763 178.211 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.5 mm-40 -99.62 107.08 19.13 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.912 -0.585 . . . . 75.129999999999995 109.846 176.716 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 62.61 -111.15 3.8 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.752 -0.737 . . . . 71.439999999999998 112.215 -178.323 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.506 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 7.7 m-20 -105.81 7.62 32.43 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 111.49 0.181 . . . . 74.340000000000003 111.49 -177.847 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.641 ' HE3' ' HE3' ' A' ' 75' ' ' TRP . 0.0 OUTLIER -121.06 131.68 54.42 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 119.951 -0.7 . . . . 73.230000000000004 112.259 179.951 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.526 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 6.2 m -80.68 124.08 28.71 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.162 -0.926 . . . . 72.209999999999994 109.313 174.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.415 HD11 ' HG3' ' A' ' 21' ' ' LYS . 23.7 mm -108.45 107.32 22.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 110.141 -0.318 . . . . 64.219999999999999 110.141 -175.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . . . . . . . . . 14.6 mt-30 -102.23 105.26 15.9 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.91 0.386 . . . . 64.150000000000006 110.273 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.417 ' HB3' HD23 ' A' ' 32' ' ' LEU . 29.7 mt-10 -88.92 100.38 13.14 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.447 -0.797 . . . . 63.340000000000003 110.606 -178.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.558 ' HA ' ' OD2' ' B' ' 151' ' ' ASP . 96.3 m-85 -76.22 118.39 18.9 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.011 -0.541 . . . . 75.200000000000003 110.3 179.561 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.461 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 50.6 mtt180 -139.2 121.17 15.6 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 121.161 0.505 . . . . 75.200000000000003 112.014 -173.174 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.646 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 3.8 p -97.45 120.5 46.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 108.751 -0.833 . . . . 75.400000000000006 108.751 169.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 18.3 t-20 73.85 -34.39 0.28 Allowed 'General case' 0 N--CA 1.47 0.562 0 O-C-N 123.456 0.473 . . . . 64.219999999999999 111.085 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.406 ' H ' ' C ' ' A' ' 28' ' ' VAL . . . 157.32 -16.39 0.34 Allowed Glycine 0 N--CA 1.45 -0.431 0 N-CA-C 111.859 -0.496 . . . . 72.0 111.859 178.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.438 ' O ' ' HA ' ' A' ' 27' ' ' ARG . 81.3 t80 -79.47 125.73 29.94 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.69 0.281 . . . . 74.219999999999999 111.003 -177.782 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.686 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -73.21 112.33 9.15 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.281 -0.637 . . . . 74.030000000000001 109.281 175.821 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 25.7 p90 -111.66 -14.3 13.64 Favored 'General case' 0 C--N 1.326 -0.417 0 C-N-CA 120.402 -0.519 . . . . 74.519999999999996 111.83 -178.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -159.54 142.86 14.37 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.732 0.301 . . . . 73.299999999999997 110.94 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.686 HG13 HD11 ' A' ' 32' ' ' LEU . 68.2 mt -123.91 122.86 65.6 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.233 -0.44 . . . . 73.430000000000007 110.14 175.521 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.437 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 53.2 tttp -107.66 106.57 16.98 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.003 -0.74 . . . . 55.329999999999998 109.003 172.152 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.578 HG23 ' HB2' ' A' ' 21' ' ' LYS . 1.5 p -102.58 126.85 56.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 CA-C-N 116.111 -0.495 . . . . 71.140000000000001 110.26 178.28 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.716 HG22 ' HB3' ' A' ' 44' ' ' PRO . 23.5 t -109.3 85.66 3.66 Favored Pre-proline 0 C--N 1.324 -0.508 0 CA-C-N 115.273 -0.876 . . . . 64.030000000000001 109.99 178.397 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.518 ' HD2' ' C ' ' A' ' 43' ' ' LYS . 36.6 Cg_endo -86.36 132.9 3.79 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 122.572 2.182 . . . . 75.25 112.557 179.539 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.506 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 56.2 mtpt -60.35 -26.01 66.28 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.619 0.724 . . . . 74.209999999999994 109.884 175.188 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -122.54 88.25 2.9 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 115.194 -0.912 . . . . 74.349999999999994 108.818 176.414 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 145.28 -34.7 1.5 Allowed Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.442 -0.799 . . . . 42.109999999999999 111.702 -175.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.518 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 97.4 mttt 72.22 145.97 0.11 Allowed Pre-proline 0 N--CA 1.468 0.451 0 C-N-CA 123.565 0.746 . . . . 53.149999999999999 112.152 176.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.716 ' HB3' HG22 ' A' ' 38' ' ' VAL . 34.3 Cg_endo -63.25 137.49 61.31 Favored 'Trans proline' 0 C--N 1.345 0.39 0 C-N-CA 123.454 2.769 . . . . 55.409999999999997 114.362 -170.019 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.404 ' CE1' HG13 ' A' ' 37' ' ' VAL . 8.6 p90 -148.21 165.96 29.37 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.577 -0.738 . . . . 72.219999999999999 109.243 174.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.74 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 38.6 m-85 -104.93 134.19 48.46 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.904 0.383 . . . . 74.510000000000005 110.774 177.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.523 HD21 HG22 ' A' ' 72' ' ' ILE . 16.6 tp -120.41 102.7 8.64 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.574 -0.899 . . . . 75.439999999999998 108.574 172.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.4 t -97.61 138.68 21.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.143 -0.481 . . . . 62.420000000000002 110.886 -173.148 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.424 HH11 ' HD3' ' A' ' 49' ' ' ARG . 7.4 tpt180 -66.57 128.02 34.62 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.89 -0.595 . . . . 72.340000000000003 110.131 175.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -78.09 116.84 18.85 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.736 -0.468 . . . . 62.420000000000002 109.736 174.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.618 ' HB2' ' CD2' ' B' ' 126' ' ' TYR . 0.4 OUTLIER -53.38 138.74 32.22 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.969 -0.56 . . . . 72.239999999999995 110.165 177.325 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 109.39 -32.48 6.78 Favored Glycine 0 N--CA 1.442 -0.963 0 N-CA-C 110.453 -1.059 . . . . 64.310000000000002 110.453 -171.623 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 8.4 t 56.99 50.36 12.28 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-O 121.253 0.549 . . . . 71.519999999999996 110.838 176.445 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -92.46 18.29 8.73 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.206 -0.452 . . . . 70.209999999999994 111.012 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 80.97 52.62 4.25 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.752 -0.737 . . . . 54.420000000000002 111.507 -176.591 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 30.2 t30 -147.76 141.81 25.99 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.804 0.335 . . . . 62.399999999999999 110.999 -174.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -129.42 147.1 51.2 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.898 -0.592 . . . . 74.040000000000006 109.529 175.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 43.7 mm -111.16 137.0 45.51 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.041 0.448 . . . . 75.010000000000005 110.394 178.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.743 ' HB2' HG13 ' A' ' 67' ' ' ILE . 24.0 ttt180 -103.22 142.18 34.61 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.826 -0.624 . . . . 73.519999999999996 110.5 -172.351 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.74 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 76.9 p -70.11 -30.81 68.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.41 0.624 . . . . 41.240000000000002 110.157 176.011 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.412 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 0.8 OUTLIER -70.81 -27.86 64.2 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 114.845 -1.07 . . . . 73.230000000000004 110.631 176.969 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . 0.699 ' HG2' ' HB3' ' A' ' 65' ' ' LYS . 5.5 tt0 -146.05 77.04 12.2 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-N 115.685 -0.689 . . . . 70.230000000000004 109.598 -175.241 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -71.2 -35.38 8.72 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.836 2.357 . . . . 65.040000000000006 113.842 -172.175 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -95.07 41.02 1.1 Allowed 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.888 0.851 . . . . 63.439999999999998 109.953 -177.657 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.699 ' HB3' ' HG2' ' A' ' 62' ' ' GLN . 22.9 tptm -150.46 128.38 11.78 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.185 -0.916 . . . . 70.540000000000006 109.93 175.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.511 ' H ' HD12 ' A' ' 66' ' ' LEU . 4.5 mp -73.32 120.35 18.82 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.324 -0.853 . . . . 65.540000000000006 109.045 176.654 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.743 HG13 ' HB2' ' A' ' 59' ' ' ARG . 47.4 mm -85.75 125.39 69.12 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-O 120.861 0.362 . . . . 62.310000000000002 110.639 -176.265 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -66.54 175.73 4.87 Favored 'Trans proline' 0 N--CA 1.463 -0.293 0 C-N-CA 122.876 2.384 . . . . 72.310000000000002 112.778 -178.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 16.4 tt0 -93.9 14.35 19.82 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.588 -0.733 . . . . 70.019999999999996 111.834 -168.506 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 18.7 p90 -109.24 -26.35 10.13 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.147 0.499 . . . . 72.510000000000005 110.151 173.246 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -81.12 -11.89 59.37 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.998 -0.546 . . . . 64.340000000000003 110.672 -178.653 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.523 HG22 HD21 ' A' ' 47' ' ' LEU . 44.9 pt -69.59 -22.84 25.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.915 -0.584 . . . . 51.409999999999997 110.91 177.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -112.6 25.26 11.64 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-N 115.808 -0.633 . . . . 62.299999999999997 109.822 -178.587 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 4.5 t -60.22 -37.78 81.37 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 114.873 -1.058 . . . . 60.509999999999998 109.906 -179.222 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . 0.641 ' HE3' ' HE3' ' A' ' 21' ' ' LYS . 43.2 p-90 . . . . . 0 C--N 1.326 -0.434 0 CA-C-N 115.884 -0.598 . . . . 65.219999999999999 110.454 176.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.404 0 N-CA-C 112.155 -0.378 . . . . 41.130000000000003 112.155 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -119.55 -1.67 10.62 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.938 0.399 . . . . 73.010000000000005 110.623 179.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -131.4 117.07 18.36 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.002 -0.544 . . . . 73.409999999999997 111.107 -177.722 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 -108.36 -71.64 0.75 Allowed 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.258 -0.645 . . . . 71.420000000000002 109.258 173.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -160.6 139.95 10.72 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.315 -0.857 . . . . 71.349999999999994 109.238 178.096 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . 0.474 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -137.37 126.99 15.39 Favored Pre-proline 0 C--N 1.32 -0.688 0 N-CA-C 110.176 -0.305 . . . . 53.140000000000001 110.176 179.173 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . 0.474 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 5.2 Cg_exo -79.38 69.16 8.05 Favored 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 123.041 2.494 . . . . 72.519999999999996 112.069 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 55.0 m -76.18 158.89 31.22 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.18 -0.464 . . . . 55.340000000000003 110.542 178.274 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . 0.402 ' HA2' HD22 ' B' ' 129' ' ' ASN . . . 117.06 -63.25 0.38 Allowed Glycine 0 N--CA 1.445 -0.72 0 N-CA-C 110.524 -1.031 . . . . 42.219999999999999 110.524 -175.741 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 62.3 88.19 0.12 Allowed Pre-proline 0 C--O 1.232 0.138 0 C-N-CA 123.157 0.583 . . . . 60.140000000000001 111.056 175.032 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.633 ' HB3' ' HA ' ' B' ' 128' ' ' VAL . 56.4 Cg_endo -86.67 140.08 5.94 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.982 2.454 . . . . 72.340000000000003 112.713 -176.701 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -148.13 122.42 9.62 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.751 -0.659 . . . . 73.140000000000001 109.28 177.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.462 ' N ' ' HB3' ' A' ' 51' ' ' ASP . 7.5 p -71.6 134.21 30.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.391 0.615 . . . . 70.129999999999995 111.739 -172.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 85.1 m -95.04 104.78 16.66 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.474 -0.785 . . . . 72.010000000000005 109.854 176.218 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 65.2 mt -88.19 106.56 16.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 115.893 -0.594 . . . . 72.219999999999999 110.143 -177.642 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 25.3 mtp-105 -108.75 171.59 7.34 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.166 0.508 . . . . 75.010000000000005 111.569 -178.241 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 70.4 mt-30 -132.34 114.7 14.7 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.581 -0.736 . . . . 62.530000000000001 109.989 176.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . 0.68 ' HG3' HD12 ' B' ' 123' ' ' ILE . 22.1 mm-40 -99.61 23.25 9.75 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.94 -0.573 . . . . 73.430000000000007 110.672 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 123.45 -90.47 0.42 Allowed Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.692 -0.563 . . . . 43.530000000000001 111.692 -178.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.668 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 72.0 m-20 -105.35 -16.51 14.73 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.14 0.495 . . . . 64.219999999999999 110.077 177.51 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.676 ' HA ' ' HA ' ' B' ' 139' ' ' PRO . 27.4 pttt -99.96 120.09 39.26 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 121.434 0.635 . . . . 74.329999999999998 111.15 -178.761 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . 0.464 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 25.0 m -83.22 104.29 13.28 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.376 -0.829 . . . . 64.25 109.193 174.471 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . 0.68 HD12 ' HG3' ' B' ' 118' ' ' GLU . 23.4 mt -98.39 107.26 20.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.181 0.515 . . . . 73.239999999999995 110.887 -174.118 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.586 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 17.9 mt-30 -93.62 107.07 18.98 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.431 -0.804 . . . . 64.430000000000007 110.061 179.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -87.95 111.08 21.09 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.097 -0.501 . . . . 65.0 110.687 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . 0.618 ' CD2' ' HB2' ' A' ' 51' ' ' ASP . 37.8 m-85 -86.4 113.6 22.49 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.013 -0.54 . . . . 64.420000000000002 110.131 177.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . 0.638 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 63.7 mtt180 -138.12 132.95 32.78 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.663 -0.699 . . . . 72.340000000000003 109.675 -176.791 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.633 ' HA ' ' HB3' ' B' ' 111' ' ' PRO . 2.7 p -96.32 -39.39 9.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 120.944 0.402 . . . . 31.239999999999998 110.991 -178.341 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . 0.402 HD22 ' HA2' ' B' ' 109' ' ' GLY . 4.4 t-20 -153.1 64.79 0.77 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 109.322 -0.622 . . . . 75.040000000000006 109.322 -179.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.07 -36.01 3.35 Favored Glycine 0 N--CA 1.447 -0.577 0 CA-C-N 115.489 -0.778 . . . . 72.310000000000002 112.597 -179.261 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.475 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 80.8 t80 -83.84 124.79 31.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.084 0.468 . . . . 72.310000000000002 111.233 -173.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.799 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -77.12 115.6 17.05 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.312 -0.858 . . . . 71.519999999999996 109.251 175.169 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 22.5 p90 -109.11 -19.03 13.5 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.268 -0.573 . . . . 72.519999999999996 111.901 -178.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -155.98 141.47 17.72 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.024 0.44 . . . . 73.0 111.057 179.065 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.799 HG13 HD11 ' B' ' 132' ' ' LEU . 81.8 mt -119.2 123.82 72.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.859 -0.609 . . . . 73.150000000000006 110.286 177.127 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.586 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 87.6 tttt -105.62 99.68 9.27 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.274 -0.639 . . . . 71.530000000000001 109.274 172.007 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.463 HG23 ' HB2' ' B' ' 121' ' ' LYS . 2.0 p -101.4 121.8 52.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-O 121.194 0.521 . . . . 74.439999999999998 110.361 -178.602 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.841 HG22 ' HB3' ' B' ' 144' ' ' PRO . 24.6 t -109.03 85.51 3.29 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 115.086 -0.961 . . . . 55.450000000000003 110.21 179.614 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.676 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 71.6 Cg_endo -84.3 134.08 5.73 Favored 'Trans proline' 0 N--CA 1.451 -0.979 0 C-N-CA 122.375 2.05 . . . . 64.030000000000001 112.545 179.525 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . 0.668 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 57.8 mtpt -57.92 -31.56 66.91 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.448 0.642 . . . . 61.329999999999998 109.889 174.436 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 82.7 m-70 -111.14 83.18 1.72 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.201 -0.909 . . . . 62.240000000000002 109.292 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . 0.41 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 148.71 -32.03 1.21 Allowed Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.684 -0.77 . . . . 63.210000000000001 112.785 -178.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . 0.45 ' C ' ' HD2' ' B' ' 139' ' ' PRO . 98.9 mttt 73.44 151.43 0.14 Allowed Pre-proline 0 N--CA 1.471 0.604 0 C-N-CA 123.452 0.701 . . . . 45.25 111.704 -178.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.841 ' HB3' HG22 ' B' ' 138' ' ' VAL . 26.7 Cg_endo -62.0 135.24 54.04 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 123.197 2.598 . . . . 70.510000000000005 113.952 -171.129 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . 0.429 ' CE1' HG13 ' B' ' 137' ' ' VAL . 6.2 p90 -150.99 152.19 33.17 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.356 -0.838 . . . . 74.409999999999997 109.852 176.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.681 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 50.7 m-85 -97.29 141.89 29.84 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.475 -0.33 . . . . 74.349999999999994 111.366 -178.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.457 HD23 ' HA ' ' B' ' 147' ' ' LEU . 15.3 mt -124.42 101.78 7.33 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.45 -0.795 . . . . 74.219999999999999 109.208 166.543 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . 0.433 HG13 ' HB ' ' B' ' 158' ' ' ILE . 6.0 p -104.65 139.2 26.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-N 115.724 -0.671 . . . . 73.409999999999997 111.015 -175.766 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 19.4 tpt180 -63.65 136.8 57.77 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.551 -0.75 . . . . 75.310000000000002 111.754 -178.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -90.19 123.95 34.43 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.275 -0.639 . . . . 74.109999999999999 109.275 169.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . 0.558 ' OD2' ' HA ' ' A' ' 26' ' ' TYR . 72.2 m-20 -57.33 142.91 41.79 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.285 0.564 . . . . 60.43 111.159 -178.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 109.91 -29.11 9.64 Favored Glycine 0 N--CA 1.444 -0.827 0 N-CA-C 110.468 -1.053 . . . . 64.329999999999998 110.468 -170.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 5.4 t 65.05 37.4 6.77 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-O 121.231 0.538 . . . . 64.530000000000001 111.009 174.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -65.11 -14.4 60.43 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 115.798 -0.637 . . . . 72.209999999999994 111.326 178.542 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 98.11 23.69 12.7 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 110.634 -0.986 . . . . 62.109999999999999 110.634 -173.405 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 42.1 t30 -110.71 140.18 45.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.916 -0.642 . . . . 70.219999999999999 110.494 -176.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -121.36 160.35 24.21 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.797 -0.638 . . . . 74.409999999999997 109.574 175.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . 0.433 ' HB ' HG13 ' B' ' 148' ' ' VAL . 46.2 mm -116.66 121.15 67.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 N-CA-C 109.405 -0.591 . . . . 74.129999999999995 109.405 174.694 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.504 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 73.0 ttt180 -92.2 127.47 37.69 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.699 -0.682 . . . . 74.549999999999997 109.82 -177.61 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . 0.681 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 80.4 p -65.88 -9.22 27.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.513 -0.312 . . . . 71.450000000000003 111.78 -175.06 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . 0.457 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 21.1 t70 -64.06 -42.67 96.92 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.325 -0.621 . . . . 75.319999999999993 109.325 174.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . 0.423 ' HA ' ' HD2' ' B' ' 163' ' ' PRO . 23.1 mt-30 -141.86 92.6 7.79 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 115.146 -0.933 . . . . 71.209999999999994 108.766 177.518 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' B' ' 162' ' ' GLN . 36.6 Cg_endo -64.0 -10.59 23.58 Favored 'Trans proline' 0 N--CA 1.475 0.441 0 C-N-CA 123.767 2.978 . . . . 62.030000000000001 114.103 -172.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -98.39 -6.18 31.16 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.088 0.471 . . . . 75.109999999999999 109.925 179.066 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 24.4 tptm -97.21 127.94 43.63 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.743 -0.662 . . . . 73.0 110.872 -175.216 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . 0.445 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.7 mp -86.68 134.66 33.58 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.565 -0.743 . . . . 71.310000000000002 109.107 177.439 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . 0.906 HG23 ' HB3' ' B' ' 171' ' ' GLU . 27.3 mm -91.71 118.94 68.59 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-O 121.149 0.5 . . . . 43.039999999999999 112.052 -172.519 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.499 ' O ' HG23 ' B' ' 172' ' ' ILE . 74.5 Cg_endo -74.71 -179.39 4.84 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 123.451 2.767 . . . . 64.150000000000006 112.284 177.15 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . 0.612 ' HA ' HG12 ' B' ' 172' ' ' ILE . 34.6 tt0 -73.56 -30.95 63.36 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 120.873 0.368 . . . . 73.219999999999999 111.761 -170.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 22.7 p90 -75.74 -7.3 54.05 Favored 'General case' 0 C--N 1.324 -0.525 0 O-C-N 121.886 -0.509 . . . . 73.239999999999995 110.15 177.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.906 ' HB3' HG23 ' B' ' 167' ' ' ILE . 3.2 mm-40 -109.74 -18.81 13.36 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.791 -0.641 . . . . 70.219999999999999 111.472 -179.47 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.612 HG12 ' HA ' ' B' ' 169' ' ' GLN . 42.5 pt -73.51 -28.59 25.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.292 0.568 . . . . 73.299999999999997 109.932 176.329 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 62.1 m-85 -101.63 39.75 1.4 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.509 -0.769 . . . . 70.540000000000006 109.364 173.708 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . 0.603 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 5.7 t -66.7 -29.22 69.16 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.134 -0.939 . . . . 73.0 110.827 -176.39 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 20.8 p-90 . . . . . 0 C--O 1.242 0.677 0 CA-C-O 118.916 -0.564 . . . . 74.340000000000003 110.217 178.206 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.723 0 N-CA-C 111.515 -0.634 . . . . 70.329999999999998 111.515 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -77.76 129.35 35.37 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.699 -0.482 . . . . 75.040000000000006 109.699 176.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -65.54 136.91 56.99 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 121.067 0.461 . . . . 63.119999999999997 111.163 -176.666 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -95.08 -30.19 14.2 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.551 -0.749 . . . . 61.229999999999997 111.857 -174.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -88.66 68.94 8.74 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.153 0.501 . . . . 73.340000000000003 110.599 -175.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.437 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -163.02 138.7 5.36 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 115.76 -0.655 . . . . 53.140000000000001 110.367 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 6.8 Cg_exo -73.82 -170.64 0.72 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 123.184 2.59 . . . . 73.430000000000007 112.083 178.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 25.0 m -70.37 92.5 0.81 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.306 0.574 . . . . 74.109999999999999 111.034 -179.481 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 157.33 40.89 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.727 0 N-CA-C 111.218 -0.753 . . . . 72.040000000000006 111.218 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . 0.405 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -114.99 101.59 54.59 Favored Pre-proline 0 N--CA 1.445 -0.681 0 N-CA-C 108.208 -1.034 . . . . 75.099999999999994 108.208 179.493 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.61 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 11.3 Cg_endo -79.32 104.65 1.78 Allowed 'Trans proline' 0 N--CA 1.44 -1.635 0 C-N-CA 122.064 1.843 . . . . 73.120000000000005 111.69 -171.552 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -123.13 149.59 44.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.502 -0.772 . . . . 74.450000000000003 109.21 -179.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.653 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 9.3 p -99.74 126.97 53.04 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-O 121.595 0.712 . . . . 74.310000000000002 111.772 -172.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.54 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 7.0 m -83.36 103.51 12.79 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.513 -0.767 . . . . 75.310000000000002 109.334 176.706 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 64.5 mt -94.14 108.79 21.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 120.932 0.396 . . . . 71.25 111.127 -174.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 19.1 mmt180 -120.72 159.32 25.61 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.202 -0.454 . . . . 54.109999999999999 109.826 175.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -117.58 124.88 49.72 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.331 0.586 . . . . 71.239999999999995 110.677 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -111.42 59.67 0.62 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.9 -1.046 . . . . 72.030000000000001 110.061 -174.225 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 83.47 -107.67 2.95 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.843 -0.694 . . . . 55.450000000000003 111.943 -178.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -94.85 20.21 9.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.886 0.374 . . . . 74.209999999999994 110.652 -177.286 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.746 ' HD2' HD11 ' A' ' 23' ' ' ILE . 4.0 pttp -143.93 134.38 24.7 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.228 0.537 . . . . 74.019999999999996 111.89 -178.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 27.3 m -94.06 107.98 19.85 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.055 -0.72 . . . . 75.329999999999998 109.055 172.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.746 HD11 ' HD2' ' A' ' 21' ' ' LYS . 19.8 mt -101.61 113.54 38.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.269 0.556 . . . . 73.319999999999993 110.353 -175.098 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.653 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 23.2 mt-30 -104.89 117.86 35.1 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.497 -0.774 . . . . 52.240000000000002 111.356 -175.162 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.54 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 25.2 mt-10 -90.52 103.01 15.75 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.051 -0.522 . . . . 71.109999999999999 110.983 177.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 53.7 m-85 -81.27 103.5 11.09 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.897 0.379 . . . . 75.310000000000002 110.051 175.199 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.508 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 53.2 mtt180 -120.25 138.11 53.84 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.916 -0.402 . . . . 74.540000000000006 109.916 178.083 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.61 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 11.8 p -105.79 -27.89 2.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.288 0.566 . . . . 62.229999999999997 110.947 -175.82 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -162.64 59.05 0.21 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.758 -0.83 . . . . 73.549999999999997 108.758 -177.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.93 -36.95 3.23 Favored Glycine 0 N--CA 1.45 -0.427 0 CA-C-N 115.355 -0.839 . . . . 65.109999999999999 112.635 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.56 ' CD2' HG21 ' B' ' 128' ' ' VAL . 50.4 t80 -90.28 133.74 34.75 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.145 0.498 . . . . 74.519999999999996 110.723 -173.658 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.902 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -76.11 116.13 16.5 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.229 -0.896 . . . . 73.209999999999994 109.317 176.656 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 40.0 p90 -106.93 -17.8 14.09 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 120.431 -0.508 . . . . 71.329999999999998 111.218 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.45 ' HA ' ' O ' ' A' ' 47' ' ' LEU . . . -157.58 137.9 12.76 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.014 0.435 . . . . 63.43 111.532 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.902 HG13 HD11 ' A' ' 32' ' ' LEU . 73.2 mt -118.02 117.08 53.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.159 -0.473 . . . . 72.140000000000001 110.102 175.262 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 84.9 tttt -100.69 101.53 12.43 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.022 -0.733 . . . . 53.240000000000002 109.022 173.296 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.671 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.5 p -102.77 124.5 56.84 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 N-CA-C 109.777 -0.453 . . . . 74.230000000000004 109.777 177.338 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.647 HG22 ' HB3' ' A' ' 44' ' ' PRO . 35.9 t -105.27 84.9 1.18 Allowed Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 115.206 -0.907 . . . . 55.119999999999997 109.525 177.391 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.671 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 89.2 Cg_endo -95.93 147.05 1.26 Allowed 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 123.04 2.493 . . . . 72.329999999999998 113.279 -178.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -68.73 -11.11 59.89 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.519 -0.764 . . . . 70.420000000000002 109.623 170.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 80.6 m-70 -121.85 92.85 3.83 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 115.022 -0.99 . . . . 74.140000000000001 109.468 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 121.54 -19.76 8.46 Favored Glycine 0 CA--C 1.519 0.338 0 C-N-CA 120.757 -0.735 . . . . 55.140000000000001 113.176 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.432 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 99.3 mttt 68.9 151.61 0.13 Allowed Pre-proline 0 N--CA 1.473 0.69 0 C-N-CA 123.026 0.53 . . . . 54.119999999999997 110.943 -178.166 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.647 ' HB3' HG22 ' A' ' 38' ' ' VAL . 18.3 Cg_endo -59.88 133.05 48.36 Favored 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 122.364 2.043 . . . . 74.439999999999998 112.816 -175.047 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.536 ' CE1' HG13 ' A' ' 37' ' ' VAL . 5.4 p90 -150.32 155.9 40.53 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.655 -0.702 . . . . 63.100000000000001 110.432 -179.072 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.452 ' O ' ' HA ' ' A' ' 59' ' ' ARG . 87.7 m-85 -99.75 127.64 45.88 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.076 -0.511 . . . . 73.239999999999995 110.901 -179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.45 ' O ' ' HA ' ' A' ' 34' ' ' ALA . 53.1 mt -102.12 97.35 7.67 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.146 -0.479 . . . . 64.439999999999998 109.761 171.052 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 60.8 t -90.58 137.43 21.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.065 -0.516 . . . . 74.140000000000001 110.578 -178.046 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 5.3 mmt180 -79.13 119.6 22.47 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.984 0.421 . . . . 75.230000000000004 111.108 175.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -72.15 167.22 20.74 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.603 -0.726 . . . . 43.25 109.555 172.722 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -69.74 128.92 38.12 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.416 0.627 . . . . 75.450000000000003 109.577 178.615 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 100.22 116.04 3.87 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 111.105 -0.798 . . . . 62.409999999999997 111.105 -171.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 39.1 p -78.02 36.7 0.23 Allowed 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.05 0.452 . . . . 75.439999999999998 111.311 -176.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -63.33 -29.6 70.89 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.801 -0.636 . . . . 65.450000000000003 111.588 -175.423 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 131.01 -13.21 5.53 Favored Glycine 0 CA--C 1.508 -0.404 0 C-N-CA 120.318 -0.944 . . . . 71.239999999999995 113.214 177.504 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -83.63 138.82 33.17 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.144 0.497 . . . . 75.409999999999997 111.544 -173.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.449 ' CD1' ' HB3' ' A' ' 47' ' ' LEU . 38.2 m-85 -109.38 162.46 14.32 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.762 -0.654 . . . . 64.299999999999997 110.02 174.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.4 mm -120.64 123.86 71.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.35 -0.611 . . . . 71.219999999999999 109.35 175.762 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.791 ' HG3' HG13 ' A' ' 67' ' ' ILE . 53.7 mtm180 -88.34 149.77 23.58 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.221 0.534 . . . . 73.200000000000003 111.826 -177.79 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 5.7 p -69.12 -24.53 64.12 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.379 -0.828 . . . . 72.319999999999993 109.84 171.365 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.73 -37.46 84.29 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-N 115.517 -0.765 . . . . 61.100000000000001 110.152 176.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -156.64 96.91 2.17 Favored Pre-proline 0 N--CA 1.451 -0.4 0 CA-C-N 115.835 -0.62 . . . . 74.200000000000003 110.612 -175.421 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.19 -10.07 23.94 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.433 2.089 . . . . 72.310000000000002 111.233 175.51 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -81.22 -15.86 54.4 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 114.895 -1.048 . . . . 72.209999999999994 110.774 178.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 45.6 tptt -114.9 132.34 56.57 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.2 -0.454 . . . . 70.25 111.252 -175.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.6 mp -90.31 125.79 35.64 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.333 -0.617 . . . . 63.240000000000002 109.333 174.218 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.791 HG13 ' HG3' ' A' ' 59' ' ' ARG . 49.4 mm -84.78 112.59 43.82 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 116.111 -0.495 . . . . 42.439999999999998 110.491 -177.25 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -74.63 179.69 5.71 Favored 'Trans proline' 0 N--CA 1.464 -0.264 0 C-N-CA 123.289 2.659 . . . . 61.210000000000001 112.937 -177.155 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . 0.463 ' CG ' HD11 ' A' ' 72' ' ' ILE . 31.4 tt0 -80.86 -4.27 54.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.581 -0.736 . . . . 72.349999999999994 112.519 -171.083 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 15.9 p90 -96.24 -19.97 18.91 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.234 -0.586 . . . . 75.430000000000007 110.312 175.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 7.9 mm-40 -99.99 8.04 44.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.93 -0.577 . . . . 72.200000000000003 111.042 -177.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.463 HD11 ' CG ' ' A' ' 69' ' ' GLN . 21.6 pt -98.71 -7.06 9.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 121.249 0.547 . . . . 74.219999999999999 110.21 175.251 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -104.91 16.17 26.43 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.632 -0.713 . . . . 71.420000000000002 109.486 177.041 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 12.9 m -73.59 -7.78 53.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.185 -0.916 . . . . 70.109999999999999 111.309 -178.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 57.9 p-90 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.442 -0.344 . . . . 73.400000000000006 110.459 176.222 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 N-CA-C 112.116 -0.394 . . . . 62.109999999999999 112.116 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -159.07 124.66 4.32 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.677 0.275 . . . . 71.409999999999997 110.617 179.757 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -138.31 129.21 26.86 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.216 -0.447 . . . . 55.43 109.92 176.569 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -85.34 -16.45 39.93 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.449 0.642 . . . . 54.32 110.247 -177.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -88.83 11.07 18.91 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.598 -0.728 . . . . 61.420000000000002 110.536 178.764 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . 0.4 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -63.8 138.58 97.43 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.15 -0.477 . . . . 33.409999999999997 110.822 179.054 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 81.1 Cg_endo -90.1 -164.14 0.15 Allowed 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 123.037 2.491 . . . . 75.310000000000002 112.261 178.467 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 44.3 m -75.22 99.24 3.96 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.021 0.439 . . . . 61.310000000000002 110.046 176.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 121.1 102.34 1.81 Allowed Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.914 -0.66 . . . . 61.409999999999997 111.764 -178.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -122.15 92.57 48.86 Favored Pre-proline 0 C--N 1.324 -0.532 0 N-CA-C 109.382 -0.599 . . . . 75.310000000000002 109.382 -178.081 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.474 ' HA ' ' O ' ' B' ' 127' ' ' ARG . 8.4 Cg_endo -77.98 82.85 2.32 Favored 'Trans proline' 0 N--CA 1.443 -1.451 0 C-N-CA 121.917 1.745 . . . . 73.430000000000007 111.633 -178.559 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -108.71 141.84 40.11 Favored 'General case' 0 CA--C 1.51 -0.566 0 CA-C-N 115.194 -0.912 . . . . 65.409999999999997 109.558 177.649 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.508 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 10.3 p -101.84 125.7 55.91 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 CA-C-N 115.627 -0.715 . . . . 73.409999999999997 110.807 -176.637 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 10.1 m -88.55 103.57 16.01 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.34 -0.846 . . . . 74.040000000000006 109.609 177.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.502 HG12 ' HG2' ' B' ' 124' ' ' GLN . 54.6 mt -94.59 105.94 17.53 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 116.164 -0.471 . . . . 70.540000000000006 110.358 -176.568 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 27.0 mmm180 -122.27 153.44 38.9 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.242 -0.435 . . . . 74.099999999999994 110.541 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -111.19 103.09 11.49 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.002 0.43 . . . . 61.299999999999997 110.701 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 49.8 mm-40 -99.67 81.51 2.49 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.778 -0.646 . . . . 73.430000000000007 109.294 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 81.94 -128.69 8.6 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 120.805 -0.712 . . . . 71.25 111.382 -174.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.579 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 67.8 m-20 -91.84 9.92 30.79 Favored 'General case' 0 C--N 1.328 -0.349 0 O-C-N 122.699 -0.295 . . . . 73.239999999999995 111.088 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.517 ' HE2' HD11 ' B' ' 123' ' ' ILE . 24.6 pttm -119.27 116.58 26.55 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.576 0.703 . . . . 75.120000000000005 111.073 179.371 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 26.1 m -84.97 108.43 17.58 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.292 -0.867 . . . . 64.5 109.502 176.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . 0.517 HD11 ' HE2' ' B' ' 121' ' ' LYS . 52.1 mt -101.14 117.12 45.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.973 -0.558 . . . . 73.5 110.604 -173.788 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.529 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 23.0 mt-30 -102.61 104.49 14.87 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.649 -0.705 . . . . 74.319999999999993 110.35 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -85.27 107.25 17.21 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.06 -0.518 . . . . 71.430000000000007 111.071 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 59.6 m-85 -80.71 103.67 10.72 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.947 0.403 . . . . 74.209999999999994 109.945 175.333 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . 0.474 ' O ' ' HA ' ' B' ' 111' ' ' PRO . 65.5 mtt180 -114.14 152.78 30.62 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.857 -0.611 . . . . 70.200000000000003 109.389 178.587 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.56 HG21 ' CD2' ' A' ' 31' ' ' PHE . 7.0 p -120.36 -37.41 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.078 0.466 . . . . 72.239999999999995 111.73 179.385 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -140.83 35.8 1.78 Allowed 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 109.035 -0.728 . . . . 54.140000000000001 109.035 -178.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 98.26 -29.5 11.25 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 114.992 -1.004 . . . . 44.119999999999997 111.746 -177.498 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.524 ' HD2' HG21 ' A' ' 28' ' ' VAL . 26.9 t80 -93.39 132.86 37.23 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.917 0.389 . . . . 62.520000000000003 110.261 -176.19 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.784 HD11 HG13 ' B' ' 135' ' ' ILE . 3.3 tm? -69.49 134.44 48.91 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.104 -0.953 . . . . 71.329999999999998 110.43 179.042 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . 0.426 ' N ' HD13 ' B' ' 132' ' ' LEU . 42.6 p90 -124.24 -23.51 4.51 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 121.026 -0.27 . . . . 64.150000000000006 111.361 174.608 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -149.92 143.19 25.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.784 0.326 . . . . 71.109999999999999 111.055 179.068 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.784 HG13 HD11 ' B' ' 132' ' ' LEU . 77.5 mt -125.08 129.56 73.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.507 -0.315 . . . . 75.530000000000001 110.804 178.648 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.529 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.2 tttt -112.69 102.51 10.56 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.128 -0.693 . . . . 73.25 109.128 172.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.458 HG21 ' HB3' ' B' ' 175' ' ' TRP . 1.8 p -106.52 127.99 61.47 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-O 121.271 0.558 . . . . 43.439999999999998 110.744 -177.665 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.893 HG22 ' HB3' ' B' ' 144' ' ' PRO . 22.6 t -113.21 87.72 11.4 Favored Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 115.138 -0.937 . . . . 62.539999999999999 110.282 -179.299 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.48 ' HA ' ' HA ' ' B' ' 121' ' ' LYS . 73.5 Cg_endo -83.66 134.87 6.62 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.283 1.988 . . . . 63.030000000000001 112.309 176.127 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . 0.579 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 56.2 mtpt -67.62 -9.48 43.44 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.773 -0.649 . . . . 71.219999999999999 110.954 176.668 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 31.6 m-70 -126.68 54.14 1.62 Allowed 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.574 -0.739 . . . . 64.310000000000002 109.524 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 167.45 -17.09 0.08 OUTLIER Glycine 0 CA--C 1.52 0.391 0 C-N-CA 120.59 -0.815 . . . . 73.400000000000006 113.39 -177.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 93.6 mttt 71.59 150.88 0.14 Allowed Pre-proline 0 N--CA 1.473 0.688 0 C-N-CA 123.235 0.614 . . . . 74.239999999999995 111.438 179.428 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.893 ' HB3' HG22 ' B' ' 138' ' ' VAL . 24.5 Cg_endo -62.42 140.68 83.56 Favored 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.77 2.313 . . . . 73.219999999999999 113.357 -176.154 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . 0.448 ' CE1' HG13 ' B' ' 137' ' ' VAL . 8.7 p90 -150.59 155.26 39.06 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.655 -0.702 . . . . 75.200000000000003 109.969 177.107 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.569 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 83.6 m-85 -101.56 141.29 34.66 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.286 -0.415 . . . . 73.439999999999998 111.37 -177.503 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . . . . . . . . . 27.6 mt -124.88 95.74 4.62 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.559 -0.746 . . . . 62.0 109.885 169.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 48.9 t -94.02 122.81 45.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.02 -0.733 . . . . 73.400000000000006 109.02 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 15.6 ttm-85 -67.94 143.54 55.61 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.468 0.651 . . . . 64.349999999999994 111.975 -174.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.03 175.4 10.67 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.664 -1.153 . . . . 64.430000000000007 110.586 176.128 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -84.94 138.27 32.6 Favored 'General case' 0 N--CA 1.448 -0.562 0 N-CA-C 109.01 -0.737 . . . . 75.219999999999999 109.01 173.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 110.07 132.07 6.24 Favored Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 120.654 -0.784 . . . . 71.430000000000007 111.655 -177.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 18.8 m -82.33 30.5 0.4 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 120.921 0.391 . . . . 74.109999999999999 110.983 -177.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -73.59 -47.29 41.5 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.052 0.453 . . . . 72.450000000000003 110.56 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 121.38 46.75 0.31 Allowed Glycine 0 CA--C 1.503 -0.714 0 C-N-CA 120.774 -0.727 . . . . 54.549999999999997 112.417 179.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 -122.17 135.53 54.79 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 120.964 0.411 . . . . 71.439999999999998 110.705 -179.178 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -113.01 159.4 19.17 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.764 -0.653 . . . . 73.5 109.381 173.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . 0.807 HD11 HD23 ' B' ' 166' ' ' LEU . 48.7 mm -114.34 115.84 50.79 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.976 0 N-CA-C 109.341 -0.614 . . . . 73.25 109.341 176.079 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.513 ' HG2' ' H ' ' B' ' 161' ' ' ASP . 40.2 ttm180 -85.39 145.16 27.61 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.75 -0.659 . . . . 74.129999999999995 110.376 -174.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . 0.569 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 5.2 p -58.89 -31.87 68.99 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.447 0.641 . . . . 72.340000000000003 110.862 178.211 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . 0.513 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 3.5 m-20 -76.03 -31.26 58.79 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.192 -0.913 . . . . 72.230000000000004 110.902 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . 0.677 ' HB3' ' HB3' ' B' ' 165' ' ' LYS . 13.9 mm100 -132.37 71.07 79.66 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 115.944 -0.571 . . . . 52.25 110.808 -176.358 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . 0.405 ' HA ' ' CG2' ' B' ' 158' ' ' ILE . 59.2 Cg_endo -73.37 -12.79 25.29 Favored 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 122.187 1.925 . . . . 73.319999999999993 111.432 178.462 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -93.24 -4.91 51.07 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.012 -0.995 . . . . 73.409999999999997 110.253 179.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . 0.677 ' HB3' ' HB3' ' B' ' 162' ' ' GLN . 60.7 tptt -122.72 126.54 47.74 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.918 -0.583 . . . . 64.430000000000007 111.074 -174.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . 0.807 HD23 HD11 ' B' ' 158' ' ' ILE . 61.0 mt -74.41 110.43 8.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.398 -0.819 . . . . 71.25 109.087 174.477 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . 0.438 HG13 ' HB2' ' B' ' 159' ' ' ARG . 43.3 mm -70.56 116.37 44.74 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 109.92 -0.4 . . . . 73.349999999999994 109.92 -176.569 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.505 ' O ' HG23 ' B' ' 172' ' ' ILE . 38.3 Cg_endo -64.95 172.57 7.01 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 123.251 2.634 . . . . 71.420000000000002 113.416 -174.231 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 20.7 tt0 -76.98 -9.9 59.0 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 114.92 -1.036 . . . . 74.409999999999997 111.978 -168.142 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 31.8 p90 -96.22 -10.8 27.16 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.461 0.648 . . . . 74.099999999999994 109.924 175.079 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.478 ' HB2' ' HG2' ' B' ' 168' ' ' PRO . 6.8 mm-40 -106.58 -7.06 17.6 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.454 -0.794 . . . . 71.129999999999995 111.215 -176.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.505 HG23 ' O ' ' B' ' 168' ' ' PRO . 29.0 pt -71.04 -30.01 39.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.121 -0.491 . . . . 64.109999999999999 110.723 178.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 16.7 p90 -102.32 41.54 1.22 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.304 0.574 . . . . 74.040000000000006 109.772 174.263 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 31.1 t -55.08 -31.86 61.52 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 114.992 -1.004 . . . . 74.299999999999997 110.847 179.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . 0.515 ' HB2' ' HD2' ' B' ' 121' ' ' LYS . 4.0 p-90 . . . . . 0 C--O 1.251 1.169 0 CA-C-O 118.044 -0.979 . . . . 75.349999999999994 110.462 176.765 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.624 0 N-CA-C 112.116 -0.393 . . . . 64.230000000000004 112.116 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -72.99 -62.05 1.6 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.687 0.28 . . . . 65.319999999999993 111.172 -178.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -83.67 119.94 25.39 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.42 -0.355 . . . . 72.129999999999995 110.295 -178.413 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -114.37 153.29 30.09 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.249 0.547 . . . . 74.109999999999999 111.041 -177.236 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -146.05 90.32 1.96 Allowed 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.389 -0.823 . . . . 74.140000000000001 109.222 175.019 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.22 128.37 84.75 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 116.156 -0.475 . . . . 35.340000000000003 111.597 -175.234 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -80.64 179.21 6.25 Favored 'Trans proline' 0 N--CA 1.461 -0.398 0 C-N-CA 122.865 2.377 . . . . 63.329999999999998 111.985 176.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.8 m -71.9 120.72 17.89 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.896 -0.409 . . . . 72.450000000000003 109.896 177.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.493 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 95.27 63.52 0.98 Allowed Glycine 0 N--CA 1.442 -0.918 0 C-N-CA 120.664 -0.779 . . . . 35.219999999999999 111.191 -175.489 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -100.3 98.94 8.55 Favored Pre-proline 0 C--N 1.324 -0.537 0 N-CA-C 108.845 -0.798 . . . . 73.420000000000002 108.845 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.613 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 88.5 Cg_endo -80.25 102.8 1.46 Allowed 'Trans proline' 0 N--CA 1.447 -1.251 0 C-N-CA 122.247 1.964 . . . . 73.230000000000004 112.29 -173.669 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -80.88 141.5 34.53 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.062 -0.972 . . . . 71.430000000000007 109.939 -178.45 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.447 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 11.2 p -103.3 120.29 53.04 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 CA-C-O 121.638 0.732 . . . . 65.030000000000001 109.88 179.461 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 22.4 m -93.47 103.11 15.34 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 115.449 -0.796 . . . . 65.299999999999997 109.564 -179.547 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.536 HG23 ' HG2' ' A' ' 24' ' ' GLN . 63.9 mt -85.61 105.2 14.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.82 -0.627 . . . . 73.019999999999996 110.517 -175.297 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 35.4 mmt180 -101.61 160.92 14.04 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.681 -0.69 . . . . 73.109999999999999 110.565 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -127.11 98.04 5.16 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.617 -0.512 . . . . 73.540000000000006 109.617 175.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.642 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 43.6 mm-40 -103.49 93.32 4.88 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.819 -0.628 . . . . 64.439999999999998 109.618 -178.064 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 66.06 -106.36 1.56 Allowed Glycine 0 N--CA 1.444 -0.83 0 C-N-CA 120.764 -0.731 . . . . 43.130000000000003 111.832 -176.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.655 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 4.0 m-20 -102.05 -5.34 24.67 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.566 0.222 . . . . 73.319999999999993 110.819 -177.197 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.642 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 12.3 ptmt -110.77 121.03 44.33 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 121.471 0.653 . . . . 64.299999999999997 111.934 -173.449 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.4 m -82.41 97.56 8.43 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.276 -0.875 . . . . 74.310000000000002 109.212 174.434 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.409 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 54.1 mt -93.99 106.88 18.57 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-O 121.117 0.485 . . . . 70.319999999999993 110.812 -175.574 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.536 ' HG2' HG23 ' A' ' 15' ' ' ILE . 12.7 mt-30 -94.55 109.39 21.29 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.019 -0.537 . . . . 63.409999999999997 110.029 179.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.439 ' HB3' HD23 ' A' ' 32' ' ' LEU . 27.5 mt-10 -89.2 111.38 22.15 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.134 -0.484 . . . . 74.129999999999995 110.84 -178.539 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.504 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 50.5 m-85 -84.59 103.88 14.09 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.635 -0.506 . . . . 72.450000000000003 109.635 176.268 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 93.6 mtt180 -116.04 133.72 55.72 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.062 -0.517 . . . . 61.409999999999997 109.923 -179.552 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.613 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 3.4 p -92.05 -60.37 2.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 C-N-CA 120.272 -0.571 . . . . 45.350000000000001 110.443 176.684 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.554 ' H ' HG13 ' A' ' 28' ' ' VAL . 88.5 m-20 -138.47 72.6 1.41 Allowed 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.045 0.45 . . . . 74.549999999999997 110.213 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 90.46 -27.94 8.09 Favored Glycine 0 N--CA 1.45 -0.417 0 CA-C-N 115.914 -0.585 . . . . 74.400000000000006 113.676 175.248 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.491 ' HD2' HG21 ' B' ' 128' ' ' VAL . 35.8 t80 -112.08 134.52 53.58 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.376 0.608 . . . . 73.400000000000006 111.469 -173.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.881 HD11 HG13 ' A' ' 35' ' ' ILE . 3.5 tm? -67.21 123.64 20.87 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.495 -1.229 . . . . 53.219999999999999 110.441 176.268 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . 0.481 ' CD1' ' HB2' ' B' ' 133' ' ' TYR . 24.2 p90 -108.23 -24.82 11.35 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.369 -0.533 . . . . 71.430000000000007 111.345 177.172 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -156.19 142.72 18.56 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.685 0.278 . . . . 64.0 110.965 179.342 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.881 HG13 HD11 ' A' ' 32' ' ' LEU . 81.4 mt -120.8 132.41 70.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.537 -0.301 . . . . 72.140000000000001 110.589 178.062 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.49 ' HD2' ' CZ ' ' A' ' 46' ' ' PHE . 88.3 tttt -115.16 100.43 8.15 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 108.953 -0.758 . . . . 73.239999999999995 108.953 169.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.569 HG23 ' HB2' ' A' ' 21' ' ' LYS . 1.1 p -98.39 126.17 51.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 116.092 -0.503 . . . . 74.319999999999993 110.124 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.56 HG22 ' HB3' ' A' ' 44' ' ' PRO . 25.0 t -111.64 88.28 9.24 Favored Pre-proline 0 C--N 1.326 -0.434 0 CA-C-N 115.544 -0.753 . . . . 72.209999999999994 110.109 -179.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.534 ' HA ' ' HA ' ' A' ' 21' ' ' LYS . 57.8 Cg_endo -73.67 142.42 32.35 Favored 'Trans proline' 0 N--CA 1.457 -0.663 0 C-N-CA 122.48 2.12 . . . . 64.010000000000005 111.975 177.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.655 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 28.9 mtpp -70.09 -10.55 59.11 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.944 -0.571 . . . . 73.219999999999999 110.978 176.329 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 38.7 m-70 -131.04 80.64 1.95 Allowed 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.848 -0.615 . . . . 71.140000000000001 109.78 -178.532 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 151.3 -117.23 0.81 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.128 -0.558 . . . . 73.340000000000003 112.306 179.499 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 14.3 ptpt -152.79 151.76 27.18 Favored Pre-proline 0 C--N 1.328 -0.344 0 N-CA-C 110.179 -0.304 . . . . 72.329999999999998 110.179 178.467 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.56 ' HB3' HG22 ' A' ' 38' ' ' VAL . 48.5 Cg_endo -74.28 124.09 8.73 Favored 'Trans proline' 0 N--CA 1.46 -0.492 0 C-N-CA 122.262 1.975 . . . . 73.120000000000005 110.987 170.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.516 ' CE1' HG13 ' A' ' 37' ' ' VAL . 11.4 p90 -139.86 158.57 43.88 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.803 0.335 . . . . 72.099999999999994 110.988 -175.185 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.519 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 73.1 m-85 -103.93 141.64 35.81 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.828 -0.624 . . . . 53.219999999999999 111.258 -176.498 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 83.8 mt -123.71 105.02 9.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.535 -0.757 . . . . 75.510000000000005 109.907 172.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.593 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 43.8 t -85.79 139.66 17.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.098 -0.501 . . . . 64.140000000000001 109.917 179.355 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.417 HH11 ' HD3' ' A' ' 49' ' ' ARG . 4.5 tpt180 -75.06 115.09 14.31 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.846 -0.428 . . . . 73.310000000000002 109.846 179.222 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.33 149.83 41.14 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.023 -0.535 . . . . 73.040000000000006 111.399 -178.204 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.58 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 4.9 p-10 -57.44 132.07 52.01 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.269 0.557 . . . . 73.340000000000003 110.981 -178.265 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 92.57 -24.13 24.76 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.41 -0.814 . . . . 72.409999999999997 111.86 -179.025 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 10.5 t 58.15 37.57 26.34 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 121.192 0.52 . . . . 43.539999999999999 109.985 -176.56 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -53.57 -38.61 64.05 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.425 -0.807 . . . . 74.420000000000002 111.44 -179.03 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 150.44 24.4 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.365 -0.921 . . . . 64.450000000000003 113.261 176.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.456 ' OD1' ' HA ' ' A' ' 68' ' ' PRO . 93.5 m-20 -134.79 162.7 31.62 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.79 0.329 . . . . 74.409999999999997 110.579 -176.764 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 73.2 m-85 -121.73 158.57 28.47 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.078 -0.51 . . . . 75.549999999999997 110.15 177.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.593 ' HB ' ' HB ' ' A' ' 48' ' ' VAL . 39.5 mm -106.74 110.54 32.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 N-CA-C 109.35 -0.611 . . . . 62.420000000000002 109.35 175.566 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.627 ' HG2' ' H ' ' A' ' 61' ' ' ASP . 74.3 ttt180 -83.99 140.42 31.9 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.276 -0.42 . . . . 73.109999999999999 110.682 -176.253 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.519 ' HB3' ' HB2' ' A' ' 46' ' ' PHE . 9.7 p -64.08 -25.06 67.94 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.901 -0.59 . . . . 64.140000000000001 112.204 -177.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.627 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 5.5 m-20 -72.78 -24.99 61.01 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.768 0.318 . . . . 71.439999999999998 111.649 -178.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 5.5 tp60 -155.0 88.36 3.21 Favored Pre-proline 0 C--N 1.327 -0.399 0 CA-C-O 120.73 0.3 . . . . 71.530000000000001 110.616 -176.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -82.05 6.5 5.66 Favored 'Trans proline' 0 C--O 1.233 0.231 0 C-N-CA 122.915 2.41 . . . . 55.240000000000002 112.455 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -62.34 -44.22 96.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.646 -0.706 . . . . 75.409999999999997 111.059 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.55 -178.37 4.9 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-N 115.6 -0.727 . . . . 61.210000000000001 111.458 -176.054 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.0 mp -95.51 135.04 37.66 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.078 -0.964 . . . . 62.43 108.846 177.424 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.429 HG13 ' HB2' ' A' ' 59' ' ' ARG . 41.0 mm -78.64 112.85 29.85 Favored Pre-proline 0 C--N 1.319 -0.743 0 N-CA-C 109.85 -0.426 . . . . 65.0 109.85 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.463 ' O ' HG23 ' A' ' 72' ' ' ILE . 46.6 Cg_endo -67.1 174.48 6.89 Favored 'Trans proline' 0 CA--C 1.519 -0.268 0 C-N-CA 123.188 2.592 . . . . 63.439999999999998 113.311 -173.336 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . 0.732 ' HA ' HG12 ' A' ' 72' ' ' ILE . 9.5 tt0 -68.16 -42.39 80.11 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.516 -0.765 . . . . 71.430000000000007 111.567 -170.624 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . 0.792 ' HA ' ' CZ ' ' A' ' 73' ' ' PHE . 29.6 p90 -63.19 -16.38 59.95 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.339 0.59 . . . . 74.319999999999993 110.395 -179.117 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 16.0 mm-40 -94.94 -28.75 15.01 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.527 -0.76 . . . . 72.049999999999997 111.579 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.732 HG12 ' HA ' ' A' ' 69' ' ' GLN . 39.0 pt -76.63 -38.6 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.148 0 N-CA-C 111.882 0.327 . . . . 72.150000000000006 111.882 -178.199 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.792 ' CZ ' ' HA ' ' A' ' 70' ' ' TRP . 6.6 p90 -85.67 30.65 0.63 Allowed 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.727 0.775 . . . . 75.140000000000001 110.847 179.55 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 32.5 t -74.23 -11.77 60.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.103 -0.953 . . . . 23.300000000000001 108.64 170.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . 0.437 ' HH2' HD13 ' A' ' 35' ' ' ILE . 36.6 m0 . . . . . 0 C--O 1.233 0.218 0 CA-C-N 115.465 -0.789 . . . . 72.549999999999997 110.6 173.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.255 0 N-CA-C 112.329 -0.309 . . . . 64.219999999999999 112.329 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -158.79 -54.35 0.06 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.097 0.475 . . . . 72.420000000000002 110.435 -178.731 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -141.99 116.4 9.58 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.701 -0.681 . . . . 62.549999999999997 109.851 179.258 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -118.99 145.58 45.71 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.185 -0.672 . . . . 71.420000000000002 109.185 178.014 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -134.27 123.19 23.82 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.914 0.388 . . . . 63.140000000000001 111.594 -174.471 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -106.37 134.41 19.8 Favored Pre-proline 0 C--N 1.322 -0.625 0 CA-C-N 115.778 -0.646 . . . . 60.520000000000003 110.688 178.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -80.84 -160.77 0.13 Allowed 'Trans proline' 0 C--O 1.235 0.354 0 C-N-CA 122.955 2.437 . . . . 75.439999999999998 112.156 179.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 33.1 m -65.41 96.91 0.26 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.06 0.457 . . . . 61.210000000000001 109.774 174.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 112.5 95.0 2.19 Favored Glycine 0 N--CA 1.441 -0.985 0 N-CA-C 110.838 -0.905 . . . . 52.229999999999997 110.838 -172.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -110.43 98.33 35.83 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-O 121.424 0.631 . . . . 73.319999999999993 109.899 -178.322 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.718 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 82.7 Cg_endo -81.83 76.57 4.25 Favored 'Trans proline' 0 N--CA 1.45 -1.041 0 C-N-CA 122.484 2.123 . . . . 65.120000000000005 112.68 -175.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -91.38 149.86 21.53 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.092 -0.707 . . . . 73.129999999999995 109.092 176.536 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.669 HG21 ' HB3' ' B' ' 124' ' ' GLN . 7.2 p -102.96 130.52 52.93 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-O 121.555 0.693 . . . . 71.299999999999997 111.307 -176.085 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . 0.454 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 30.4 m -91.84 111.2 22.64 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.234 -0.894 . . . . 45.509999999999998 109.139 176.027 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.6 mt -88.69 107.69 18.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 120.957 0.408 . . . . 72.400000000000006 111.06 -174.148 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . 0.502 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 20.2 mmt180 -94.84 160.46 14.59 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.447 -0.575 . . . . 55.439999999999998 109.447 175.619 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -136.99 86.84 2.24 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 115.774 -0.648 . . . . 62.439999999999998 109.574 174.138 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 8.6 mm-40 -100.35 87.81 3.51 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-N 115.475 -0.784 . . . . 74.420000000000002 109.395 -173.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 78.97 -111.56 3.27 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.791 -0.719 . . . . 63.399999999999999 111.968 -177.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.61 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 20.4 m-20 -109.11 12.16 25.24 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.855 0.36 . . . . 75.299999999999997 111.189 -177.572 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.95 ' HE3' ' HB3' ' B' ' 175' ' ' TRP . 20.8 pttm -125.27 123.24 39.06 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.483 0.659 . . . . 75.420000000000002 111.481 179.505 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 65.9 m -81.75 103.31 11.35 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.249 -0.887 . . . . 70.299999999999997 109.472 174.629 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . 0.502 ' HB ' ' HB2' ' B' ' 116' ' ' ARG . 64.7 mt -93.58 105.87 17.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-O 121.076 0.465 . . . . 73.219999999999999 110.378 -177.284 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.669 ' HB3' HG21 ' B' ' 113' ' ' VAL . 21.1 mt-30 -96.23 109.72 22.14 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.167 -0.47 . . . . 54.200000000000003 110.897 -177.467 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . 0.454 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 45.8 mt-10 -86.47 106.48 17.51 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.778 -0.647 . . . . 71.450000000000003 110.799 179.471 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . 0.58 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 21.6 m-85 -82.07 106.36 13.92 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.88 -0.415 . . . . 74.439999999999998 109.88 174.297 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . 0.424 ' O ' ' HA ' ' B' ' 111' ' ' PRO . 95.2 mtt180 -119.97 126.38 50.7 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.842 -0.429 . . . . 74.25 109.842 179.735 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.718 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 3.0 p -99.0 -34.77 4.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 121.32 0.581 . . . . 74.299999999999997 111.268 -177.422 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -143.15 40.71 1.49 Allowed 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.596 0.712 . . . . 54.210000000000001 109.166 -175.43 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.15 -23.69 10.82 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.324 -0.853 . . . . 74.420000000000002 111.83 -176.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 58.3 t80 -93.83 132.26 38.4 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.98 0.419 . . . . 72.310000000000002 110.435 -177.647 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.861 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -70.66 117.29 12.0 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.359 -0.837 . . . . 74.129999999999995 109.261 176.368 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . 0.557 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 41.9 p90 -105.39 -24.69 12.61 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.384 -0.527 . . . . 73.329999999999998 111.18 179.533 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . 0.483 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -156.56 134.96 11.43 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.762 0.315 . . . . 72.019999999999996 110.734 179.224 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.861 HG13 HD11 ' B' ' 132' ' ' LEU . 74.3 mt -107.71 125.7 64.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 N-CA-C 110.031 -0.359 . . . . 73.299999999999997 110.031 175.492 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.548 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.9 tttt -107.53 99.92 9.38 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.038 -0.727 . . . . 62.43 109.038 174.142 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.539 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 1.1 p -103.85 124.45 58.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-O 121.074 0.464 . . . . 71.510000000000005 110.356 -178.519 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.777 HG22 ' HB3' ' B' ' 144' ' ' PRO . 21.2 t -108.89 88.12 5.18 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 115.224 -0.898 . . . . 65.040000000000006 109.732 179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 72.4 Cg_endo -83.13 135.96 7.67 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 122.539 2.159 . . . . 74.400000000000006 112.459 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . 0.61 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 59.1 mtpt -60.32 -34.53 73.93 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-N 115.605 -0.725 . . . . 71.439999999999998 110.088 173.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -102.09 77.06 1.65 Allowed 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.461 -0.79 . . . . 64.230000000000004 108.925 177.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 144.38 -158.14 27.4 Favored Glycine 0 N--CA 1.445 -0.753 0 CA-C-N 115.215 -0.902 . . . . 65.349999999999994 110.988 -174.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 96.6 mttt -131.13 150.03 75.39 Favored Pre-proline 0 C--N 1.324 -0.515 0 N-CA-C 110.026 -0.361 . . . . 73.540000000000006 110.026 177.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.777 ' HB3' HG22 ' B' ' 138' ' ' VAL . 17.7 Cg_endo -61.58 122.88 11.71 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.426 2.084 . . . . 65.209999999999994 112.124 178.064 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . 0.48 ' CE1' HG13 ' B' ' 137' ' ' VAL . 5.7 p90 -136.49 152.86 51.0 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.144 -0.48 . . . . 75.099999999999994 110.964 -177.005 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.541 ' O ' ' HA ' ' B' ' 159' ' ' ARG . 88.2 m-85 -101.97 138.33 39.08 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.88 -0.6 . . . . 72.230000000000004 111.114 -178.268 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.471 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 56.9 mt -117.5 104.19 10.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.992 -0.549 . . . . 65.030000000000001 109.965 172.016 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . 0.507 ' HB ' ' HB ' ' B' ' 158' ' ' ILE . 49.1 t -91.33 128.02 43.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 116.339 -0.391 . . . . 65.129999999999995 110.888 -177.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 23.8 tpt180 -63.11 120.45 11.48 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 116.47 -0.332 . . . . 74.530000000000001 110.975 176.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.09 154.62 37.35 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-N 115.987 -0.551 . . . . 63.32 110.933 177.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . 0.504 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 8.0 p-10 -59.64 147.06 38.78 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.83 -0.623 . . . . 70.120000000000005 111.574 -176.667 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 73.63 2.59 60.83 Favored Glycine 0 N--CA 1.452 -0.247 0 CA-C-N 115.389 -0.823 . . . . 71.340000000000003 112.391 178.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 7.9 t 59.73 49.2 8.4 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 109.137 -0.69 . . . . 75.030000000000001 109.137 -175.259 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -48.64 -43.74 36.8 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 114.84 -1.073 . . . . 72.510000000000005 111.251 -179.326 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 131.13 -18.38 5.02 Favored Glycine 0 CA--C 1.492 -1.346 0 N-CA-C 110.718 -0.953 . . . . 71.230000000000004 110.718 178.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 87.5 m-20 -97.89 166.78 11.29 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 113.719 -1.241 . . . . 65.540000000000006 110.816 -176.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -121.22 153.39 37.67 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.817 -0.629 . . . . 72.120000000000005 110.206 178.314 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . 0.507 ' HB ' ' HB ' ' B' ' 148' ' ' VAL . 48.5 mm -106.31 114.77 46.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 N-CA-C 109.266 -0.642 . . . . 75.430000000000007 109.266 176.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.541 ' HA ' ' O ' ' B' ' 146' ' ' PHE . 68.0 ttt180 -89.33 138.58 31.31 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.25 -0.432 . . . . 64.150000000000006 110.87 -175.505 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . . . . . . . . . 5.6 p -62.59 -22.4 66.34 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.821 -0.627 . . . . 64.420000000000002 112.301 -177.191 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . 0.52 ' H ' ' HG2' ' B' ' 159' ' ' ARG . 5.5 m-20 -76.22 -16.95 59.72 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.731 0.301 . . . . 62.020000000000003 111.237 -177.772 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 21.9 tp60 -166.06 84.81 0.97 Allowed Pre-proline 0 C--N 1.328 -0.34 0 N-CA-C 109.44 -0.578 . . . . 75.019999999999996 109.44 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . 0.512 ' HG2' ' HB2' ' A' ' 60' ' ' SER . 23.7 Cg_exo -64.86 -9.36 20.96 Favored 'Trans proline' 0 N--CA 1.474 0.337 0 C-N-CA 123.16 2.573 . . . . 63.25 112.929 -178.682 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -90.6 -5.63 55.66 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.962 -0.563 . . . . 74.409999999999997 110.768 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.8 tptt -114.83 123.29 48.81 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.25 0.548 . . . . 73.340000000000003 110.419 -178.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.3 mp -85.34 113.57 21.76 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.169 -0.923 . . . . 74.150000000000006 109.229 177.777 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . 0.543 HG23 ' HB3' ' B' ' 171' ' ' GLU . 50.5 mm -64.41 110.58 4.15 Favored Pre-proline 0 C--N 1.325 -0.48 0 O-C-N 123.608 0.567 . . . . 74.209999999999994 110.681 -177.347 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.564 ' O ' HG23 ' B' ' 172' ' ' ILE . 80.5 Cg_endo -76.06 176.81 9.55 Favored 'Trans proline' 0 N--CA 1.461 -0.386 0 C-N-CA 122.933 2.422 . . . . 60.43 112.472 -176.711 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -76.26 -5.42 46.89 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.711 -0.677 . . . . 61.25 112.707 -170.453 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 27.9 p90 -97.64 -12.88 21.93 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.497 -0.481 . . . . 64.340000000000003 110.254 173.395 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.543 ' HB3' HG23 ' B' ' 167' ' ' ILE . 1.7 mm-40 -105.95 -15.05 15.01 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.37 -0.377 . . . . 53.420000000000002 111.465 -177.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.564 HG23 ' O ' ' B' ' 168' ' ' PRO . 43.1 pt -66.73 -21.28 28.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 121.083 0.468 . . . . 75.140000000000001 110.693 177.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -88.87 41.88 1.05 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.797 -0.638 . . . . 71.299999999999997 109.99 177.43 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 22.8 t -86.1 17.22 3.7 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.393 -0.821 . . . . 75.230000000000004 110.247 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . 0.95 ' HB3' ' HE3' ' B' ' 121' ' ' LYS . 45.9 m0 . . . . . 0 C--O 1.246 0.921 0 CA-C-O 118.471 -0.776 . . . . 72.519999999999996 110.421 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.718 0 N-CA-C 111.809 -0.517 . . . . 72.510000000000005 111.809 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 64.91 15.19 9.78 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 123.348 0.659 . . . . 75.409999999999997 111.854 177.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -103.64 105.31 15.51 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.936 0.398 . . . . 65.129999999999995 110.004 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -145.89 -43.24 0.21 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.045 -0.525 . . . . 64.25 110.382 -178.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -89.9 113.23 24.81 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.907 -0.588 . . . . 71.140000000000001 109.938 -178.692 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.477 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -83.26 124.59 75.92 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 116.095 -0.502 . . . . 55.329999999999998 112.009 -175.107 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.477 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 6.7 Cg_exo -74.7 172.68 15.76 Favored 'Trans proline' 0 C--O 1.235 0.338 0 C-N-CA 123.317 2.678 . . . . 64.430000000000007 112.098 176.794 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 20.9 m -89.15 -178.72 5.73 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.391 -0.368 . . . . 71.010000000000005 110.543 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 80.22 -86.77 1.29 Allowed Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 110.903 -0.879 . . . . 61.530000000000001 110.903 -176.164 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 70.87 97.94 0.04 OUTLIER Pre-proline 0 CA--C 1.516 -0.347 0 C-N-CA 123.138 0.575 . . . . 74.340000000000003 110.89 175.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.55 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 5.5 Cg_endo -78.82 85.03 1.92 Allowed 'Trans proline' 0 N--CA 1.443 -1.451 0 C-N-CA 122.378 2.052 . . . . 50.310000000000002 110.041 178.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -95.7 152.05 18.81 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.284 -0.871 . . . . 73.510000000000005 110.179 -175.372 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.722 HG21 ' HB3' ' A' ' 24' ' ' GLN . 7.3 p -121.67 131.52 72.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-O 121.378 0.609 . . . . 70.310000000000002 111.158 -176.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 24.2 m -92.05 115.55 28.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.437 -0.801 . . . . 54.32 109.488 176.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 50.3 mt -94.13 107.73 19.7 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.101 0.477 . . . . 53.520000000000003 111.344 -173.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.724 ' HB2' ' HB ' ' A' ' 23' ' ' ILE . 33.5 mmt180 -100.41 169.31 9.18 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.701 -0.681 . . . . 71.329999999999998 109.424 175.688 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 69.2 mt-30 -139.61 102.78 4.53 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.878 0.37 . . . . 55.109999999999999 110.301 175.537 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 60.2 mm-40 -101.51 80.15 2.03 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.031 -0.532 . . . . 72.310000000000002 110.18 -178.39 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.41 -111.06 3.49 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.794 -0.717 . . . . 42.299999999999997 111.51 -176.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.587 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 5.8 m-20 -112.47 4.23 17.33 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.239 0.542 . . . . 44.200000000000003 109.837 178.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 39' ' ' PRO . 23.9 pttm -107.08 119.99 40.88 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.492 0.663 . . . . 74.0 110.379 175.581 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.694 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 8.5 m -80.21 127.15 32.01 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.499 -0.773 . . . . 63.329999999999998 109.488 177.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.724 ' HB ' ' HB2' ' A' ' 16' ' ' ARG . 26.0 mm -108.08 104.99 17.95 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-O 120.677 0.275 . . . . 74.200000000000003 110.296 -175.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.755 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 16.2 mt-30 -99.35 109.34 21.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.887 0.375 . . . . 52.420000000000002 110.827 -178.109 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 25.3 mt-10 -91.69 110.9 22.24 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.978 -0.556 . . . . 60.200000000000003 110.311 -179.161 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.531 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 28.1 m-85 -88.69 108.91 19.72 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.877 0.37 . . . . 73.519999999999996 111.531 -178.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 46.4 mtm105 -121.44 123.68 42.67 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.713 -0.477 . . . . 64.0 109.713 175.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.55 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.4 p -91.83 -27.88 4.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-O 121.11 0.481 . . . . 65.25 110.728 -177.719 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -172.3 72.5 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.015 -0.539 . . . . 73.340000000000003 109.905 -179.17 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.31 -24.97 4.52 Favored Glycine 0 N--CA 1.45 -0.411 0 CA-C-N 115.795 -0.639 . . . . 55.409999999999997 113.202 177.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -108.17 130.11 55.15 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.969 0.384 . . . . 72.340000000000003 111.097 -174.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.514 HD11 HG13 ' A' ' 35' ' ' ILE . 3.1 tm? -74.51 112.76 11.02 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.345 -0.843 . . . . 74.450000000000003 109.037 175.031 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -105.44 -16.33 14.76 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.614 -0.434 . . . . 61.439999999999998 111.696 -177.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -160.47 145.75 14.74 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.032 0.444 . . . . 34.210000000000001 111.522 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.514 HG13 HD11 ' A' ' 32' ' ' LEU . 63.6 mt -118.32 125.68 74.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 115.909 -0.587 . . . . 64.219999999999999 109.461 174.084 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.755 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 82.6 tttt -109.78 105.66 14.97 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.881 -0.415 . . . . 71.150000000000006 109.881 179.163 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.631 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 3.5 t -89.52 134.38 28.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 108.965 -0.754 . . . . 74.140000000000001 108.965 178.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.694 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 21.4 t -120.32 73.22 20.61 Favored Pre-proline 0 C--N 1.317 -0.839 0 N-CA-C 109.731 -0.47 . . . . 73.109999999999999 109.731 173.693 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.618 ' HD3' HG12 ' A' ' 37' ' ' VAL . 49.6 Cg_endo -76.96 132.46 12.9 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.286 1.991 . . . . 75.109999999999999 111.489 175.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.587 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 21.9 mtpp -57.77 -34.41 69.54 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 65.510000000000005 111.11 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -119.11 109.69 16.19 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.331 -0.618 . . . . 73.109999999999999 109.331 175.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 128.53 -27.6 4.4 Favored Glycine 0 N--CA 1.444 -0.79 0 N-CA-C 110.79 -0.924 . . . . 31.100000000000001 110.79 -173.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 58.6 mtmt 70.97 152.0 0.14 Allowed Pre-proline 0 CA--C 1.532 0.255 0 C-N-CA 123.593 0.757 . . . . 62.329999999999998 112.496 175.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.631 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 43.3 Cg_endo -67.63 145.2 69.15 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.138 2.559 . . . . 73.439999999999998 114.159 -174.434 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 29.2 p90 -148.93 158.92 44.54 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.497 -0.774 . . . . 74.319999999999993 109.801 176.363 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.548 ' HB2' ' HB3' ' A' ' 60' ' ' SER . 72.7 m-85 -101.71 129.14 47.81 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.276 -0.42 . . . . 73.120000000000005 110.701 178.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.58 ' HG ' ' CD2' ' A' ' 57' ' ' PHE . 29.7 tp -109.67 96.2 6.11 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.898 -0.779 . . . . 73.319999999999993 108.898 173.034 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 32.3 t -94.61 142.38 13.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 116.239 -0.437 . . . . 64.140000000000001 111.293 -172.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.453 HH11 ' HZ ' ' A' ' 57' ' ' PHE . 1.6 mmt-85 -66.93 137.57 56.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.962 -0.563 . . . . 63.329999999999998 111.046 177.075 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -87.73 153.84 21.04 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.056 -0.52 . . . . 55.100000000000001 109.701 172.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.409 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 4.3 p-10 -60.64 130.37 46.17 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.264 0.554 . . . . 64.340000000000003 111.289 -177.793 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 81.17 -15.0 24.94 Favored Glycine 0 CA--C 1.518 0.257 0 CA-C-N 115.637 -0.711 . . . . 63.43 112.39 -178.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 19.7 p 43.52 72.46 0.18 Allowed 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 123.721 0.808 . . . . 73.329999999999998 112.503 -175.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -80.09 42.08 0.55 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.612 0.72 . . . . 64.319999999999993 109.435 177.164 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 62.35 37.16 94.14 Favored Glycine 0 N--CA 1.451 -0.362 0 N-CA-C 110.359 -1.097 . . . . 75.340000000000003 110.359 -170.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.924 HD21 HD22 ' A' ' 66' ' ' LEU . 51.1 t30 -133.08 141.68 48.34 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.937 0.399 . . . . 72.450000000000003 110.766 -169.397 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.58 ' CD2' ' HG ' ' A' ' 47' ' ' LEU . 29.7 m-85 -132.09 168.36 18.12 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.767 -0.651 . . . . 73.530000000000001 109.879 177.03 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.891 HD11 HD23 ' A' ' 66' ' ' LEU . 42.4 mm -129.16 120.79 52.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.482 -0.562 . . . . 44.439999999999998 109.482 174.679 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.615 ' HG3' HG13 ' A' ' 67' ' ' ILE . 41.6 mtp180 -88.03 150.66 23.28 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.271 -0.422 . . . . 62.43 110.655 -179.085 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.672 ' HB2' ' HB3' ' B' ' 163' ' ' PRO . 34.2 p -66.71 -30.43 70.66 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.283 0.564 . . . . 45.240000000000002 110.363 177.082 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.51 ' OD1' ' HB3' ' A' ' 59' ' ' ARG . 4.2 p-10 -78.51 -23.23 46.42 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.709 -0.678 . . . . 72.310000000000002 110.971 177.048 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -137.33 70.58 54.29 Favored Pre-proline 0 C--N 1.316 -0.868 0 CA-C-N 115.719 -0.673 . . . . 73.319999999999993 110.808 -172.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.467 ' HG3' ' HB2' ' B' ' 160' ' ' SER . 84.2 Cg_endo -84.47 -19.83 4.22 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.662 2.242 . . . . 74.019999999999996 112.587 -178.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 14.7 p-10 -90.61 3.76 53.2 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.935 -0.575 . . . . 74.409999999999997 109.975 -179.337 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 81.5 tttt -127.04 137.39 53.05 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.412 -0.813 . . . . 75.430000000000007 109.972 179.018 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.924 HD22 HD21 ' A' ' 56' ' ' ASN . 48.1 mt -86.22 116.54 24.46 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.916 -0.772 . . . . 74.129999999999995 108.916 176.08 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.673 HG23 ' HB3' ' A' ' 71' ' ' GLU . 41.5 mm -69.71 120.15 75.69 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-N 115.905 -0.589 . . . . 62.299999999999997 111.2 -172.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.537 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 51.3 Cg_endo -68.82 172.98 10.78 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.561 2.174 . . . . 62.140000000000001 112.574 -178.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 10.9 tt0 -80.1 -4.03 51.19 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.503 -0.771 . . . . 61.109999999999999 112.091 -166.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 39.1 p90 -100.78 -17.86 16.72 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 121.196 0.522 . . . . 72.400000000000006 110.214 174.002 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.673 ' HB3' HG23 ' A' ' 67' ' ' ILE . 1.2 mm-40 -90.73 -13.1 34.71 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.682 -0.69 . . . . 74.329999999999998 110.037 -178.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.531 HG23 ' O ' ' A' ' 68' ' ' PRO . 41.2 pt -70.34 -21.49 23.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.738 -0.665 . . . . 53.509999999999998 110.218 176.514 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -108.0 38.42 2.2 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.643 -0.708 . . . . 64.120000000000005 109.211 175.029 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.558 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 7.7 t -62.85 -32.77 74.06 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.192 -0.913 . . . . 64.019999999999996 111.187 -175.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 66.9 p-90 . . . . . 0 C--N 1.327 -0.383 0 CA-C-O 120.887 0.375 . . . . 74.040000000000006 110.838 179.19 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.469 0 N-CA-C 111.975 -0.45 . . . . 72.329999999999998 111.975 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -139.5 123.27 17.54 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.564 0.221 . . . . 73.340000000000003 110.59 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -91.61 129.58 37.56 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 109.53 -0.545 . . . . 73.209999999999994 109.53 178.234 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -96.35 3.7 52.75 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.19 0.441 . . . . 72.25 112.19 -170.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -78.08 137.41 38.21 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.877 0.37 . . . . 75.540000000000006 111.068 -178.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . 0.453 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -112.98 117.36 46.19 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 115.879 -0.601 . . . . 71.230000000000004 110.216 178.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 2.9 Cg_exo -75.27 165.45 30.89 Favored 'Trans proline' 0 N--CA 1.462 -0.329 0 C-N-CA 123.302 2.668 . . . . 75.230000000000004 112.845 -178.003 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 14.1 m -77.6 179.19 6.72 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.826 -0.625 . . . . 55.25 110.699 178.412 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 84.9 -58.28 4.98 Favored Glycine 0 N--CA 1.449 -0.497 0 C-N-CA 120.72 -0.752 . . . . 73.219999999999999 111.362 -178.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 58.43 77.11 0.42 Allowed Pre-proline 0 C--N 1.329 -0.298 0 C-N-CA 122.941 0.497 . . . . 73.140000000000001 111.363 177.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.651 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 46.3 Cg_endo -72.84 80.12 1.84 Allowed 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 121.914 1.743 . . . . 73.129999999999995 110.745 175.159 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -97.77 164.33 12.44 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.197 -0.911 . . . . 75.349999999999994 110.255 -176.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.632 HG21 ' HB3' ' B' ' 124' ' ' GLN . 9.7 p -125.09 132.7 70.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-O 121.395 0.617 . . . . 62.350000000000001 111.195 -177.622 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . 0.58 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 21.6 m -93.4 110.48 22.04 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.469 -0.787 . . . . 64.129999999999995 109.534 175.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.5 mt -84.37 105.35 13.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.062 0.458 . . . . 75.400000000000006 111.051 -176.039 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . 0.758 ' HB2' ' HB ' ' B' ' 123' ' ' ILE . 30.2 mmt180 -100.81 171.93 7.37 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.733 -0.667 . . . . 75.030000000000001 109.551 176.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 -145.59 125.18 13.25 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.512 0.672 . . . . 54.140000000000001 110.49 172.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -119.13 61.27 0.81 Allowed 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 115.008 -0.996 . . . . 63.340000000000003 110.223 -175.178 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 94.14 -111.94 4.25 Favored Glycine 0 N--CA 1.444 -0.786 0 C-N-CA 120.685 -0.769 . . . . 53.539999999999999 111.638 -179.035 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . . . . . . . . . 80.6 m-20 -100.23 9.45 42.73 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.036 0.446 . . . . 73.040000000000006 109.837 178.215 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.715 ' HD2' ' HB2' ' B' ' 175' ' ' TRP . 25.0 pttm -123.81 119.59 30.15 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.9 -0.591 . . . . 74.200000000000003 110.791 -179.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . 0.635 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 35.0 m -80.07 133.38 36.11 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.755 -0.657 . . . . 74.109999999999999 109.543 175.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . 0.758 ' HB ' ' HB2' ' B' ' 116' ' ' ARG . 32.5 mm -114.89 103.39 15.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-O 120.753 0.311 . . . . 43.43 110.41 -177.403 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.751 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 14.5 mt-30 -95.7 105.69 17.72 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 120.644 -0.422 . . . . 73.030000000000001 110.452 -178.055 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . 0.58 ' HB2' ' HB ' ' B' ' 114' ' ' THR . 41.1 mt-10 -81.63 101.7 10.19 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.865 -0.607 . . . . 75.510000000000005 110.831 179.137 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . 0.472 ' HB3' ' CZ ' ' B' ' 133' ' ' TYR . 55.6 m-85 -81.03 105.72 12.46 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.916 0.388 . . . . 72.430000000000007 110.253 176.362 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . 0.479 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 86.8 mtm180 -127.67 118.03 23.08 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.956 -0.566 . . . . 73.439999999999998 110.262 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.733 HG13 ' H ' ' B' ' 129' ' ' ASN . 2.4 p -84.44 -72.06 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-N 116.114 -0.494 . . . . 73.099999999999994 110.246 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . 0.733 ' H ' HG13 ' B' ' 128' ' ' VAL . 18.3 t-20 -122.28 69.44 0.96 Allowed 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.122 0.487 . . . . 70.409999999999997 110.252 -177.091 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.79 -18.74 37.41 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.501 -0.772 . . . . 32.530000000000001 113.684 175.359 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.477 ' CD2' HG21 ' A' ' 28' ' ' VAL . 38.0 t80 -114.68 132.13 56.5 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-O 121.138 0.494 . . . . 70.040000000000006 111.189 -171.721 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.774 HD11 HG13 ' B' ' 135' ' ' ILE . 3.4 tm? -73.24 113.6 10.5 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.967 -1.015 . . . . 55.109999999999999 109.358 174.668 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . 0.472 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 52.5 p90 -106.01 -20.04 13.54 Favored 'General case' 0 C--N 1.326 -0.415 0 C-N-CA 120.72 -0.392 . . . . 71.099999999999994 111.456 -179.072 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -157.44 142.11 16.6 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.816 0.341 . . . . 75.310000000000002 111.361 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.774 HG13 HD11 ' B' ' 132' ' ' LEU . 73.5 mt -119.14 117.44 54.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 116.145 -0.48 . . . . 64.230000000000004 109.958 175.028 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.751 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 78.9 tttt -93.8 104.64 16.71 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.399 -0.593 . . . . 73.019999999999996 109.399 175.611 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.685 HG12 ' HD3' ' B' ' 139' ' ' PRO . 4.1 t -88.71 131.04 37.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 N-CA-C 108.985 -0.746 . . . . 63.210000000000001 108.985 177.529 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.635 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.4 t -118.18 73.03 9.76 Favored Pre-proline 0 C--N 1.319 -0.754 0 N-CA-C 109.703 -0.481 . . . . 71.120000000000005 109.703 173.016 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.685 ' HD3' HG12 ' B' ' 137' ' ' VAL . 61.2 Cg_endo -81.27 134.04 8.9 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 122.047 1.831 . . . . 75.400000000000006 112.161 175.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . . . . . . . . . 63.4 mttm -57.07 -42.91 81.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.592 0.71 . . . . 62.140000000000001 110.083 174.659 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 18.0 m-70 -98.95 83.77 2.97 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.088 -0.96 . . . . 73.109999999999999 109.406 -173.165 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 136.28 -21.5 3.46 Favored Glycine 0 N--CA 1.45 -0.372 0 CA-C-N 115.51 -0.768 . . . . 52.549999999999997 111.848 -177.402 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . 0.503 ' HB3' ' HD2' ' B' ' 144' ' ' PRO . 53.7 mtmt 72.46 154.88 0.15 Allowed Pre-proline 0 N--CA 1.466 0.354 0 C-N-CA 123.682 0.793 . . . . 53.409999999999997 111.893 179.639 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.514 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 36.4 Cg_endo -65.49 146.85 86.06 Favored 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 123.017 2.478 . . . . 72.109999999999999 114.12 -174.334 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 27.3 p90 -151.19 171.26 17.67 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.402 -0.817 . . . . 75.439999999999998 109.472 175.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -111.67 126.54 55.14 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.94 0.4 . . . . 65.439999999999998 111.163 -179.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.427 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 26.7 tp -107.79 99.18 8.67 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.601 -0.727 . . . . 64.120000000000005 109.121 175.503 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 39.2 t -99.87 138.06 25.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 120.805 0.336 . . . . 64.409999999999997 111.152 -174.389 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . 0.473 ' HD3' ' CE2' ' B' ' 157' ' ' PHE . 0.4 OUTLIER -65.46 123.77 20.51 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 121.049 0.452 . . . . 72.120000000000005 111.469 174.509 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -74.05 156.54 37.37 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.228 -0.897 . . . . 54.420000000000002 110.705 177.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . 0.531 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 5.7 p-10 -64.51 133.85 53.25 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.144 0.497 . . . . 74.420000000000002 110.427 -179.364 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 89.72 -30.76 5.58 Favored Glycine 0 N--CA 1.453 -0.217 0 CA-C-N 115.831 -0.622 . . . . 50.140000000000001 111.808 -175.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 59.8 p 46.21 56.4 6.26 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.126 0.97 . . . . 75.230000000000004 113.13 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -77.64 40.79 0.31 Allowed 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.837 0.827 . . . . 71.530000000000001 110.417 176.623 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 73.08 28.73 65.91 Favored Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 111.362 -0.695 . . . . 51.100000000000001 111.362 -173.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . 0.524 ' ND2' HD23 ' B' ' 166' ' ' LEU . 34.0 t30 -122.02 141.57 51.22 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.393 -0.403 . . . . 45.240000000000002 110.364 -175.424 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . 0.473 ' CE2' ' HD3' ' B' ' 149' ' ' ARG . 43.1 m-85 -125.93 162.63 24.78 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.026 -0.533 . . . . 63.039999999999999 110.025 179.283 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 46.4 mm -122.07 130.14 74.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 109.088 -0.708 . . . . 73.129999999999995 109.088 175.382 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.512 ' HB3' ' OD1' ' B' ' 161' ' ' ASP . 23.6 mtp180 -104.92 158.79 16.29 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.193 0.52 . . . . 71.040000000000006 111.382 -175.762 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . 0.467 ' HB2' ' HG3' ' A' ' 63' ' ' PRO . 11.5 p -74.86 -26.06 59.42 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.907 -0.588 . . . . 52.32 110.689 178.808 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . 0.512 ' OD1' ' HB3' ' B' ' 159' ' ' ARG . 11.3 p-10 -86.68 -15.4 39.69 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.883 -0.598 . . . . 54.329999999999998 110.428 177.274 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . 0.436 ' OE1' ' HD3' ' B' ' 165' ' ' LYS . 39.4 mt-30 -143.24 74.45 17.48 Favored Pre-proline 0 C--N 1.319 -0.718 0 CA-C-N 115.243 -0.89 . . . . 74.239999999999995 109.38 -176.095 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . 0.672 ' HB3' ' HB2' ' A' ' 60' ' ' SER . 74.0 Cg_endo -83.05 -44.23 0.07 OUTLIER 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.966 2.444 . . . . 74.219999999999999 114.133 -172.155 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -80.8 -6.8 59.01 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.443 0.64 . . . . 72.540000000000006 109.631 -179.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . 0.436 ' HD3' ' OE1' ' B' ' 162' ' ' GLN . 88.1 tttt -103.92 135.98 44.43 Favored 'General case' 0 N--CA 1.446 -0.666 0 CA-C-N 115.18 -0.918 . . . . 71.319999999999993 110.27 -178.04 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . 0.524 HD23 ' ND2' ' B' ' 156' ' ' ASN . 5.3 mp -87.41 124.21 33.16 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 108.994 -0.743 . . . . 51.140000000000001 108.994 178.374 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 46.5 mm -83.44 117.73 69.47 Favored Pre-proline 0 C--N 1.322 -0.607 0 CA-C-N 116.114 -0.494 . . . . 74.219999999999999 111.686 -170.635 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.522 ' O ' HG23 ' B' ' 172' ' ' ILE . 70.4 Cg_endo -72.95 175.93 9.74 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.957 2.438 . . . . 62.009999999999998 112.874 -178.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -82.75 15.16 2.77 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.45 -0.795 . . . . 61.109999999999999 112.944 -168.469 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 26.3 p90 -115.67 -14.98 11.41 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.144 0.497 . . . . 74.430000000000007 110.424 171.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -107.32 0.81 23.34 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.967 -0.561 . . . . 72.340000000000003 111.017 -176.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.522 HG23 ' O ' ' B' ' 168' ' ' PRO . 21.6 pt -80.79 -31.3 12.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.914 -0.585 . . . . 74.420000000000002 111.217 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -111.5 39.4 2.34 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.422 0.63 . . . . 71.230000000000004 110.376 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.9 t -61.19 -26.03 67.44 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.378 -0.828 . . . . 74.019999999999996 110.933 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . 0.715 ' HB2' ' HD2' ' B' ' 121' ' ' LYS . 4.0 p-90 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.126 -0.94 . . . . 72.239999999999995 110.981 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.63 0 N-CA-C 111.712 -0.555 . . . . 74.549999999999997 111.712 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -139.42 133.5 31.1 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.922 0.392 . . . . 62.219999999999999 111.192 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -86.2 97.96 10.65 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.119 -0.697 . . . . 64.239999999999995 109.119 174.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -144.06 -171.85 3.64 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.489 -0.323 . . . . 73.340000000000003 110.764 -175.757 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -107.83 113.68 27.09 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.395 -0.366 . . . . 44.549999999999997 111.347 -173.333 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.529 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -72.33 122.5 87.6 Favored Pre-proline 0 C--N 1.326 -0.454 0 CA-C-N 116.202 -0.454 . . . . 73.340000000000003 110.572 176.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.529 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 1.6 Cg_endo -83.26 -153.03 0.04 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.454 0 C-N-CA 123.341 2.694 . . . . 74.319999999999993 112.279 -179.084 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 14.6 m -66.81 143.96 56.58 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 116.083 -0.508 . . . . 71.540000000000006 110.213 178.192 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.512 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 85.43 87.69 0.94 Allowed Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 110.437 -1.065 . . . . 73.129999999999995 110.437 -171.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -106.06 101.91 36.68 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-O 120.834 0.35 . . . . 72.420000000000002 110.938 -169.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.664 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 71.7 Cg_endo -92.07 122.41 0.62 Allowed 'Trans proline' 0 N--CA 1.445 -1.363 0 C-N-CA 122.864 2.376 . . . . 72.0 112.314 -179.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -128.19 111.56 13.57 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.526 0.679 . . . . 71.510000000000005 110.321 176.508 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.599 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 9.1 p -67.33 130.0 32.31 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.085 0 CA-C-N 114.723 -1.126 . . . . 73.349999999999994 110.806 179.412 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.544 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 51.8 m -86.23 103.34 14.76 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.671 -0.695 . . . . 75.219999999999999 109.561 175.763 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 63.5 mt -86.8 104.47 14.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.159 -0.473 . . . . 73.530000000000001 110.482 -177.427 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 10.1 mmm-85 -106.0 156.34 18.49 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.682 -0.69 . . . . 63.109999999999999 110.766 -178.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -129.23 98.21 4.83 Favored 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 108.873 -0.788 . . . . 72.219999999999999 108.873 173.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.592 ' HG3' HD12 ' A' ' 23' ' ' ILE . 8.0 mm-40 -91.47 15.7 11.8 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.475 -0.784 . . . . 74.310000000000002 110.723 -171.773 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 122.41 -98.96 0.64 Allowed Glycine 0 N--CA 1.445 -0.727 0 C-N-CA 120.998 -0.62 . . . . 52.140000000000001 111.899 -179.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.451 ' O ' ' HG3' ' A' ' 40' ' ' LYS . 11.5 p-10 -85.45 4.57 35.02 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.632 0.253 . . . . 72.540000000000006 111.568 -178.129 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.622 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 14.1 pttm -148.44 130.54 15.41 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 112.664 0.616 . . . . 44.350000000000001 112.664 -176.553 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 17.8 m -84.87 103.31 13.82 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 114.925 -1.034 . . . . 74.519999999999996 108.997 172.401 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.592 HD12 ' HG3' ' A' ' 18' ' ' GLU . 55.7 mt -100.33 112.23 32.36 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.013 0.435 . . . . 72.209999999999994 110.393 -175.264 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.599 ' HB3' ' CG2' ' A' ' 13' ' ' VAL . 21.4 mt-30 -101.43 117.36 34.78 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.96 -0.564 . . . . 75.140000000000001 111.576 -177.16 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.544 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.1 mt-10 -91.05 100.5 13.34 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.551 -0.75 . . . . 24.300000000000001 110.322 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.554 ' CD2' ' HB2' ' B' ' 151' ' ' ASP . 63.2 m-85 -78.12 104.73 8.88 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.676 0.274 . . . . 74.140000000000001 110.682 179.327 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . . . . . . . . . 94.0 mtt180 -122.69 132.9 54.47 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.313 -0.403 . . . . 75.340000000000003 110.687 -178.423 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.81 HG13 ' H ' ' A' ' 29' ' ' ASN . 3.0 p -98.59 -73.98 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 C-N-CA 120.725 -0.39 . . . . 63.530000000000001 110.898 176.222 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.81 ' H ' HG13 ' A' ' 28' ' ' VAL . 7.4 m-20 -128.38 68.62 1.36 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.05 0.453 . . . . 73.140000000000001 110.51 -177.308 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 77.42 12.56 84.44 Favored Glycine 0 N--CA 1.451 -0.331 0 CA-C-N 115.679 -0.691 . . . . 71.310000000000002 112.019 -179.052 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 79.9 t80 -130.07 127.36 39.72 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 120.921 0.391 . . . . 75.450000000000003 110.785 -176.183 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 30.2 tp -85.91 114.8 23.1 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.393 -0.821 . . . . 72.510000000000005 109.413 174.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . 0.483 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 50.8 p90 -104.47 -10.3 17.78 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.669 -0.412 . . . . 75.540000000000006 111.938 -176.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -167.44 145.05 4.6 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.081 0.467 . . . . 63.310000000000002 111.361 -177.825 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 66.9 mt -121.14 115.77 47.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.872 -0.604 . . . . 72.010000000000005 109.615 174.3 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.455 ' CB ' ' HE1' ' A' ' 26' ' ' TYR . 83.5 tttt -104.69 105.25 15.26 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.666 -0.494 . . . . 30.440000000000001 109.666 177.326 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.543 HG13 ' CE1' ' A' ' 45' ' ' TYR . 1.6 p -104.24 127.05 58.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.996 0.427 . . . . 74.129999999999995 110.512 178.3 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.827 HG22 ' HB3' ' A' ' 44' ' ' PRO . 16.1 t -103.0 88.01 1.41 Allowed Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 115.312 -0.858 . . . . 74.120000000000005 109.463 175.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.511 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 90.0 Cg_endo -81.65 150.09 16.57 Favored 'Trans proline' 0 N--CA 1.461 -0.423 0 C-N-CA 122.714 2.276 . . . . 65.409999999999997 113.432 -176.734 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.451 ' HG3' ' O ' ' A' ' 20' ' ' ASP . 29.0 mtpp -74.36 -10.48 59.63 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.368 -0.833 . . . . 75.5 110.556 174.175 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 52.9 m-70 -113.43 21.01 15.58 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.766 -0.652 . . . . 74.150000000000006 110.277 -173.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.26 -155.85 15.33 Favored Glycine 0 N--CA 1.448 -0.525 0 CA-C-N 115.675 -0.693 . . . . 42.100000000000001 111.661 -178.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -112.09 150.53 42.57 Favored Pre-proline 0 C--N 1.324 -0.506 0 N-CA-C 109.89 -0.411 . . . . 72.329999999999998 109.89 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.827 ' HB3' HG22 ' A' ' 38' ' ' VAL . 19.8 Cg_endo -60.18 121.03 9.15 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.37 2.046 . . . . 64.349999999999994 111.8 175.774 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.543 ' CE1' HG13 ' A' ' 37' ' ' VAL . 9.4 p90 -136.53 155.73 49.56 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.0 -0.546 . . . . 71.340000000000003 111.039 -176.227 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -99.7 137.07 38.69 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.621 -0.718 . . . . 64.239999999999995 110.787 -179.805 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 31.8 mt -104.7 98.13 7.92 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.865 -0.791 . . . . 71.040000000000006 108.865 164.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 39.7 t -83.54 129.12 38.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.117 -0.492 . . . . 72.150000000000006 110.083 -176.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.19 125.64 29.65 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.303 -0.408 . . . . 64.129999999999995 110.435 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -67.43 135.72 53.58 Favored 'General case' 0 C--O 1.237 0.433 0 CA-C-O 120.953 0.406 . . . . 65.25 110.899 178.181 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.709 ' OD1' ' HB2' ' B' ' 111' ' ' PRO . 31.3 t0 -80.01 168.58 19.0 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.594 -0.73 . . . . 74.209999999999994 110.942 -174.743 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.65 24.51 45.88 Favored Glycine 0 N--CA 1.446 -0.681 0 N-CA-C 111.269 -0.732 . . . . 75.510000000000005 111.269 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 14.2 m 58.66 28.01 16.61 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-O 121.118 0.485 . . . . 74.530000000000001 110.592 -177.054 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.4 ' OD1' ' HB3' ' A' ' 56' ' ' ASN . 17.5 t70 -60.09 -47.95 83.75 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 115.349 -0.841 . . . . 74.329999999999998 111.325 -177.213 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 101.34 -36.73 4.01 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.679 -0.772 . . . . 63.340000000000003 112.946 176.386 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.4 ' HB3' ' OD1' ' A' ' 54' ' ' ASP . 7.4 t30 -70.93 150.95 45.2 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 120.967 0.413 . . . . 65.140000000000001 111.619 -175.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.45 ' CD1' HG21 ' A' ' 72' ' ' ILE . 37.7 m-85 -108.95 148.88 30.02 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.271 -0.422 . . . . 74.420000000000002 110.685 179.429 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 50.2 mm -111.26 129.07 67.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 N-CA-C 109.641 -0.503 . . . . 74.430000000000007 109.641 176.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.415 ' HG2' ' H ' ' A' ' 61' ' ' ASP . 43.2 ttm180 -89.91 135.69 33.49 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.541 -0.299 . . . . 74.340000000000003 110.59 -176.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.405 ' HB3' ' HB2' ' A' ' 45' ' ' TYR . 35.0 t -63.2 -33.27 75.13 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.33 -0.396 . . . . 73.340000000000003 111.704 -178.194 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.415 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 4.6 m-20 -62.3 -42.64 99.53 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 121.248 0.547 . . . . 45.549999999999997 110.5 178.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 62.4 mt-30 -135.04 89.6 23.68 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 115.491 -0.777 . . . . 64.140000000000001 110.355 -174.015 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -68.97 -6.19 17.58 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.892 2.395 . . . . 72.109999999999999 112.416 -178.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 20.3 m-20 -95.7 -8.44 34.6 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.086 -0.506 . . . . 71.219999999999999 110.241 178.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.3 tptt -105.84 123.12 47.45 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.869 -0.605 . . . . 45.009999999999998 110.737 -177.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.413 ' N ' HD12 ' A' ' 66' ' ' LEU . 5.1 mp -90.45 119.64 30.9 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.108 -0.951 . . . . 74.530000000000001 109.075 177.787 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 49.6 mm -90.07 113.92 58.97 Favored Pre-proline 0 C--N 1.323 -0.573 0 CA-C-N 116.263 -0.426 . . . . 75.310000000000002 110.729 -175.612 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.449 ' HG2' ' HB2' ' A' ' 71' ' ' GLU . 56.9 Cg_endo -69.43 174.03 9.81 Favored 'Trans proline' 0 N--CA 1.46 -0.5 0 C-N-CA 122.498 2.132 . . . . 71.530000000000001 112.371 -179.304 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 29.4 tt0 -83.14 -5.17 59.02 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.806 -0.633 . . . . 74.409999999999997 111.857 -168.233 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 35.7 p90 -100.45 -2.02 34.33 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.287 0.565 . . . . 73.329999999999998 109.902 176.468 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.449 ' HB2' ' HG2' ' A' ' 68' ' ' PRO . 2.8 mm-40 -121.72 17.02 11.12 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.391 -0.822 . . . . 71.299999999999997 111.03 -177.016 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.45 HG21 ' CD1' ' A' ' 57' ' ' PHE . 12.1 pt -98.18 -22.55 4.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.944 -0.571 . . . . 72.430000000000007 111.457 -179.569 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -113.58 20.78 15.69 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.185 0.517 . . . . 71.549999999999997 110.427 -178.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 3.1 m -57.75 -32.69 67.72 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.246 -0.888 . . . . 71.409999999999997 111.489 -177.011 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . 0.622 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 10.2 p-90 . . . . . 0 C--N 1.325 -0.467 0 CA-C-N 116.23 -0.441 . . . . 75.439999999999998 111.088 176.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.419 0 N-CA-C 112.039 -0.424 . . . . 25.219999999999999 112.039 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -98.58 78.69 2.4 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 120.903 0.383 . . . . 73.230000000000004 110.691 -179.278 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -74.11 140.84 45.53 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.713 -0.476 . . . . 74.409999999999997 109.713 179.226 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -145.73 179.65 7.3 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.122 -0.325 . . . . 54.210000000000001 110.122 -176.008 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 24.7 t70 -98.67 113.32 25.34 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.934 -0.395 . . . . 75.120000000000005 109.934 179.587 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -70.15 123.67 89.27 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.99 -0.55 . . . . 70.430000000000007 110.811 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_endo -77.31 -155.34 0.05 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.281 0 C-N-CA 122.792 2.328 . . . . 61.140000000000001 111.435 176.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 26.3 m -74.62 90.78 2.29 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.369 0.604 . . . . 70.209999999999994 109.763 177.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . 0.433 ' O ' ' HD3' ' B' ' 111' ' ' PRO . . . 151.59 54.14 0.01 OUTLIER Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 110.485 -1.046 . . . . 70.219999999999999 110.485 -175.058 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . 0.414 ' HA ' ' HD3' ' B' ' 111' ' ' PRO . 11.0 mt-10 -92.41 104.03 10.07 Favored Pre-proline 0 C--N 1.323 -0.578 0 CA-C-N 115.182 -0.509 . . . . 64.200000000000003 109.851 -176.065 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.722 ' HB3' ' HB ' ' B' ' 128' ' ' VAL . 68.4 Cg_endo -98.61 158.37 0.73 Allowed 'Trans proline' 0 N--CA 1.444 -1.437 0 C-N-CA 123.156 2.571 . . . . 73.450000000000003 112.768 -174.621 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -156.26 126.28 6.49 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 115.544 -0.753 . . . . 71.099999999999994 109.766 177.151 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.455 ' HB ' ' HB3' ' A' ' 51' ' ' ASP . 5.4 p -84.88 132.79 30.82 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 CA-C-N 114.979 -1.01 . . . . 74.439999999999998 110.801 -174.124 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . 0.592 HG22 ' HG3' ' B' ' 116' ' ' ARG . 28.6 m -95.78 104.76 16.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.463 -0.79 . . . . 53.32 110.184 179.077 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.495 HG12 ' HG2' ' B' ' 124' ' ' GLN . 60.7 mt -90.64 102.98 13.92 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 116.073 -0.512 . . . . 74.019999999999996 109.928 -179.593 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . 0.592 ' HG3' HG22 ' B' ' 114' ' ' THR . 71.7 mtm180 -121.24 169.71 10.3 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.162 -0.472 . . . . 74.430000000000007 110.847 -178.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -125.24 117.49 23.95 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.045 -0.525 . . . . 75.109999999999999 110.537 179.016 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . 0.611 ' HG3' HD12 ' B' ' 123' ' ' ILE . 22.8 mm-40 -95.36 25.66 4.26 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.577 -0.738 . . . . 74.549999999999997 110.911 -177.225 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 121.45 -107.95 1.28 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.897 -0.668 . . . . 33.539999999999999 111.638 -177.379 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.522 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 28.4 m-20 -95.39 29.21 2.61 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.911 0.386 . . . . 62.409999999999997 110.027 179.519 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . . . . . . . . . 20.7 pttm -151.88 127.52 10.14 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.032 0.444 . . . . 75.219999999999999 111.292 179.121 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . . . . . . . . . 21.7 m -90.14 113.24 24.96 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.599 -0.728 . . . . 74.400000000000006 109.19 174.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . 0.611 HD12 ' HG3' ' B' ' 118' ' ' GLU . 51.8 mt -109.84 114.79 47.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 121.198 0.523 . . . . 61.43 110.634 -173.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.523 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 19.6 mt-30 -95.3 105.89 17.88 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.552 -0.749 . . . . 73.519999999999996 109.569 178.067 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . 0.424 ' CD ' HH21 ' B' ' 116' ' ' ARG . 28.8 mt-10 -84.53 98.82 10.34 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.541 -0.754 . . . . 71.120000000000005 110.34 -177.482 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . 0.62 ' CD2' ' HB2' ' A' ' 51' ' ' ASP . 6.5 m-85 -76.51 103.3 6.43 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.595 -0.52 . . . . 71.239999999999995 109.595 178.361 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 56.9 mtt-85 -132.43 126.34 32.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.108 0.48 . . . . 64.219999999999999 111.553 -172.725 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.722 ' HB ' ' HB3' ' B' ' 111' ' ' PRO . 4.3 p -115.7 119.44 61.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 115.675 -0.693 . . . . 51.240000000000002 109.827 175.105 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 60.29 27.14 16.66 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 116.284 -0.416 . . . . 74.5 111.545 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.36 21.13 52.92 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.509 -0.853 . . . . 71.519999999999996 112.576 179.544 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.468 ' CZ ' ' HG3' ' A' ' 11' ' ' PRO . 90.0 t80 -122.27 119.43 31.16 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.933 0.396 . . . . 65.400000000000006 110.235 175.443 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.536 HD21 HD11 ' B' ' 135' ' ' ILE . 24.4 tp -83.06 114.24 21.16 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.694 -0.684 . . . . 72.540000000000006 109.928 178.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 45.6 p90 -110.06 -6.93 15.0 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.618 -0.433 . . . . 65.310000000000002 111.296 -178.107 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' B' ' 147' ' ' LEU . . . -165.83 146.88 6.89 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.027 0.441 . . . . 72.140000000000001 111.207 -177.148 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.536 HD11 HD21 ' B' ' 132' ' ' LEU . 59.3 mt -130.57 118.05 41.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.932 -0.576 . . . . 64.209999999999994 109.946 177.582 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.523 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 86.1 tttt -101.3 98.32 8.72 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 120.092 -0.643 . . . . 73.140000000000001 109.477 172.354 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.53 HG13 ' CE1' ' B' ' 145' ' ' TYR . 1.9 p -101.4 125.38 55.43 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-O 121.125 0.488 . . . . 73.310000000000002 110.537 179.03 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.671 HG22 ' HB3' ' B' ' 144' ' ' PRO . 23.2 t -104.98 88.67 2.48 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 115.169 -0.923 . . . . 72.219999999999999 109.451 175.896 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.482 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 72.6 Cg_endo -83.51 132.69 5.92 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.54 2.16 . . . . 75.099999999999994 112.708 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . 0.522 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 29.1 mtpp -56.65 -33.38 66.28 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.454 -0.794 . . . . 72.140000000000001 111.006 176.742 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -97.11 17.42 17.14 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.705 -0.679 . . . . 73.140000000000001 111.029 -174.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . -155.76 -149.99 5.48 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 121.001 -0.619 . . . . 52.329999999999998 111.742 178.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -119.08 147.42 42.66 Favored Pre-proline 0 C--N 1.327 -0.395 0 N-CA-C 109.611 -0.514 . . . . 71.310000000000002 109.611 176.495 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.671 ' HB3' HG22 ' B' ' 138' ' ' VAL . 25.3 Cg_endo -64.29 123.85 12.47 Favored 'Trans proline' 0 N--CA 1.464 -0.257 0 C-N-CA 122.362 2.041 . . . . 61.210000000000001 111.492 175.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . 0.53 ' CE1' HG13 ' B' ' 137' ' ' VAL . 5.8 p90 -144.88 151.79 39.25 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.874 0.368 . . . . 70.329999999999998 111.418 -175.614 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.478 ' HB2' ' OG ' ' B' ' 160' ' ' SER . 74.9 m-85 -96.83 136.81 36.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.675 -0.693 . . . . 72.030000000000001 110.393 177.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.506 ' O ' ' HA ' ' B' ' 134' ' ' ALA . 56.9 mt -109.53 102.62 11.46 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.163 -0.471 . . . . 64.129999999999995 109.884 169.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 44.9 t -81.83 130.35 35.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 109.836 -0.431 . . . . 44.009999999999998 109.836 178.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . 0.589 ' NH1' ' HA ' ' B' ' 153' ' ' SER . 0.0 OUTLIER -81.31 128.06 33.41 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.703 -0.226 . . . . 71.510000000000005 110.447 -177.149 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -68.58 150.7 47.7 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 120.963 0.411 . . . . 74.409999999999997 110.631 176.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . 0.554 ' HB2' ' CD2' ' A' ' 26' ' ' TYR . 22.7 t70 -70.77 165.88 22.14 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.598 -0.728 . . . . 71.299999999999997 111.115 -175.148 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 77.08 0.66 70.97 Favored Glycine 0 C--N 1.331 0.3 0 CA-C-N 116.206 -0.452 . . . . 72.540000000000006 112.34 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . 0.589 ' HA ' ' NH1' ' B' ' 149' ' ' ARG . 5.9 t 60.6 31.91 20.29 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.078 0.466 . . . . 61.229999999999997 109.836 -176.441 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -52.39 -49.4 64.53 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.126 -0.943 . . . . 64.230000000000004 111.54 -179.521 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 124.61 -17.87 7.28 Favored Glycine 0 CA--C 1.499 -0.918 0 C-N-CA 120.762 -0.732 . . . . 73.120000000000005 111.565 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -70.33 140.35 52.21 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 114.851 -0.675 . . . . 63.520000000000003 111.281 178.037 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . 0.521 ' HB2' ' HB ' ' B' ' 167' ' ' ILE . 53.9 m-85 -118.28 151.47 37.61 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.071 -0.513 . . . . 73.120000000000005 109.673 174.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 46.7 mm -119.35 121.91 67.69 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 N-CA-C 109.743 -0.465 . . . . 64.219999999999999 109.743 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.592 ' HB3' ' H ' ' B' ' 162' ' ' GLN . 54.5 mtt180 -76.2 137.07 39.78 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.318 -0.401 . . . . 71.019999999999996 110.941 179.434 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . 0.478 ' OG ' ' HB2' ' B' ' 146' ' ' PHE . 19.9 m -80.88 -13.68 58.7 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.252 -1.018 . . . . 74.239999999999995 108.252 165.096 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -73.66 -45.85 50.13 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 114.251 -1.34 . . . . 75.319999999999993 109.859 173.033 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . 0.592 ' H ' ' HB3' ' B' ' 159' ' ' ARG . 77.6 mt-30 -137.63 86.19 19.28 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-N 115.364 -0.835 . . . . 74.400000000000006 109.444 176.456 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -68.19 -13.99 39.39 Favored 'Trans proline' 0 N--CA 1.473 0.282 0 C-N-CA 122.905 2.403 . . . . 72.450000000000003 112.936 -176.436 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 31.3 m-20 -92.29 10.68 28.67 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.976 0.417 . . . . 64.439999999999998 110.453 -179.028 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 56.0 tptt -127.09 125.81 41.91 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.33 0.586 . . . . 75.319999999999993 111.075 -179.589 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . 0.429 HD12 ' N ' ' B' ' 166' ' ' LEU . 4.9 mp -87.87 125.06 34.27 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.036 -0.984 . . . . 55.409999999999997 108.93 176.573 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . 0.837 HG23 ' HB3' ' B' ' 171' ' ' GLU . 39.4 mm -87.26 117.43 68.58 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 116.18 -0.463 . . . . 64.120000000000005 111.64 -172.396 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.454 ' HG2' ' HB2' ' B' ' 171' ' ' GLU . 72.4 Cg_endo -75.59 -179.75 5.42 Favored 'Trans proline' 0 N--CA 1.463 -0.287 0 C-N-CA 123.088 2.525 . . . . 61.130000000000003 112.043 175.539 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . 0.761 ' O ' HG12 ' B' ' 172' ' ' ILE . 35.4 tt0 -76.34 -29.51 57.28 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 120.727 -0.389 . . . . 62.130000000000003 111.68 -172.261 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 36.5 p90 -75.06 -14.11 60.56 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 119.92 -0.712 . . . . 74.450000000000003 110.313 179.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.837 ' HB3' HG23 ' B' ' 167' ' ' ILE . 0.8 OUTLIER -89.68 -21.1 22.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.885 -0.598 . . . . 73.150000000000006 110.185 -179.257 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.761 HG12 ' O ' ' B' ' 169' ' ' GLN . 21.9 pt -73.59 -18.44 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 121.27 0.557 . . . . 74.200000000000003 110.24 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 80.0 m-85 -93.65 15.23 16.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.663 -0.699 . . . . 72.439999999999998 110.168 176.217 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 32.7 t -56.96 -37.06 71.04 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-N 115.817 -0.629 . . . . 72.019999999999996 109.777 175.782 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 54.7 p-90 . . . . . 0 C--O 1.247 0.927 0 CA-C-O 118.203 -0.903 . . . . 74.420000000000002 109.828 175.02 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.565 0 N-CA-C 111.912 -0.475 . . . . 34.409999999999997 111.912 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -142.4 -75.13 0.28 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.941 0.401 . . . . 73.129999999999995 110.002 178.505 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -155.75 126.92 7.1 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.833 -0.622 . . . . 73.329999999999998 109.524 176.501 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -138.0 111.41 8.04 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.909 -0.587 . . . . 75.019999999999996 110.943 -177.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -95.98 107.51 19.8 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.002 -0.545 . . . . 74.439999999999998 110.488 178.31 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -83.84 149.33 56.41 Favored Pre-proline 0 C--N 1.324 -0.506 0 CA-C-N 115.923 -0.581 . . . . 64.409999999999997 110.27 177.553 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 67.8 Cg_endo -74.58 178.85 6.56 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.418 2.079 . . . . 74.040000000000006 112.138 178.454 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 19.6 m -72.09 167.24 20.64 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.504 -0.554 . . . . 71.430000000000007 109.504 175.425 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 72.41 74.78 0.74 Allowed Glycine 0 N--CA 1.448 -0.565 0 N-CA-C 110.005 -1.238 . . . . 64.510000000000005 110.005 -168.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . 0.446 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 7.1 pt-20 -112.31 107.74 55.26 Favored Pre-proline 0 C--N 1.317 -0.809 0 CA-C-O 121.375 0.607 . . . . 73.430000000000007 109.712 -169.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.578 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 32.5 Cg_endo -84.67 108.94 1.28 Allowed 'Trans proline' 0 N--CA 1.442 -1.541 0 C-N-CA 122.445 2.097 . . . . 62.439999999999998 112.371 -174.006 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -118.79 164.2 15.75 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.127 -0.942 . . . . 50.25 109.674 -179.437 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.604 HG21 ' HB3' ' A' ' 24' ' ' GLN . 13.1 p -115.34 131.24 68.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.237 0.541 . . . . 64.430000000000007 111.41 -177.315 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 52.9 m -93.16 107.09 18.96 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 109.244 -0.65 . . . . 63.530000000000001 109.244 174.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 53.5 mt -92.09 107.96 19.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 120.963 0.411 . . . . 71.209999999999994 111.217 -174.559 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 66.7 mtt180 -103.65 167.85 9.53 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.736 -0.665 . . . . 72.150000000000006 110.252 176.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 62.6 mt-30 -134.16 97.31 3.82 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.438 -0.579 . . . . 72.219999999999999 109.438 170.317 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 22.1 mm-40 -96.29 82.42 3.42 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.823 -0.626 . . . . 74.209999999999994 110.093 -175.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 85.86 -109.02 3.31 Favored Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.798 -0.715 . . . . 62.200000000000003 111.927 -178.506 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.903 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 7.1 m-20 -111.22 17.53 20.2 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.899 0.381 . . . . 65.239999999999995 110.326 -179.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.599 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 22.9 pttm -130.84 123.79 29.84 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.294 0.569 . . . . 74.120000000000005 111.398 -179.151 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.474 ' O ' ' HA ' ' A' ' 37' ' ' VAL . 24.5 m -82.83 109.75 17.24 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.603 -0.726 . . . . 33.329999999999998 109.682 176.265 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 48.7 mt -102.55 112.83 37.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-O 121.117 0.484 . . . . 71.239999999999995 110.654 -176.335 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.604 ' HB3' HG21 ' A' ' 13' ' ' VAL . 25.2 mt-30 -102.48 110.92 23.02 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.67 -0.695 . . . . 74.310000000000002 110.996 -177.562 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -92.26 107.51 19.27 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.795 -0.639 . . . . 73.019999999999996 110.837 -178.42 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -84.87 112.42 20.54 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 120.893 0.378 . . . . 74.019999999999996 110.599 178.392 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.466 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 87.9 mtt180 -117.39 137.56 52.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.924 -0.58 . . . . 71.019999999999996 109.905 178.756 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.578 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 6.2 p -96.82 -34.82 5.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-O 121.346 0.593 . . . . 72.239999999999995 110.489 177.714 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 30.9 t-20 -161.78 59.8 0.26 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.641 -0.874 . . . . 61.0 108.641 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 86.07 -34.69 3.36 Favored Glycine 0 CA--C 1.519 0.297 0 CA-C-N 115.482 -0.781 . . . . 61.039999999999999 112.058 -176.162 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.56 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 81.9 t80 -78.28 129.25 34.82 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.021 0.438 . . . . 64.420000000000002 111.047 -177.328 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.781 HD11 HG13 ' A' ' 35' ' ' ILE . 3.4 tm? -81.44 114.04 19.91 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.196 -0.911 . . . . 72.340000000000003 109.094 174.59 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 52.1 p90 -107.86 -19.4 13.53 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.634 -0.426 . . . . 74.129999999999995 111.682 -179.057 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -154.85 136.15 14.05 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 120.785 0.326 . . . . 51.439999999999998 111.244 -179.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.781 HG13 HD11 ' A' ' 32' ' ' LEU . 75.0 mt -116.26 122.81 70.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 116.064 -0.516 . . . . 75.450000000000003 109.91 175.378 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 1.4 tmtp? -110.21 114.49 28.02 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 108.732 -0.84 . . . . 65.430000000000007 108.732 173.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.571 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 0.9 OUTLIER -120.46 129.72 75.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 CA-C-N 115.796 -0.638 . . . . 74.549999999999997 110.692 -174.011 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.765 HG22 ' HB3' ' A' ' 44' ' ' PRO . 21.2 t -112.8 86.96 9.38 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.313 -0.858 . . . . 75.400000000000006 110.097 -179.378 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.469 ' HD2' ' C ' ' A' ' 43' ' ' LYS . 70.4 Cg_endo -86.49 134.45 4.05 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 122.503 2.135 . . . . 64.329999999999998 112.496 176.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.903 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 59.4 mtpt -56.31 -31.19 63.46 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.664 -0.698 . . . . 71.209999999999994 110.168 174.149 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 61.4 m-70 -116.95 91.18 3.51 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.338 -0.846 . . . . 73.340000000000003 109.156 176.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 141.31 -31.31 2.16 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.837 -0.619 . . . . 65.329999999999998 111.977 -177.019 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.469 ' C ' ' HD2' ' A' ' 39' ' ' PRO . 98.5 mttt 70.52 151.12 0.13 Allowed Pre-proline 0 N--CA 1.469 0.477 0 C-N-CA 123.508 0.723 . . . . 72.329999999999998 111.872 178.577 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.765 ' HB3' HG22 ' A' ' 38' ' ' VAL . 18.8 Cg_endo -59.26 139.44 90.09 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 123.013 2.476 . . . . 74.010000000000005 113.798 -174.01 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.544 ' CE1' HG13 ' A' ' 37' ' ' VAL . 22.5 p90 -152.34 163.65 39.04 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.62 -0.718 . . . . 71.209999999999994 109.548 176.594 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . 0.472 ' HB2' ' HB2' ' A' ' 60' ' ' SER . 60.1 m-85 -107.6 120.66 42.84 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.704 0.288 . . . . 74.120000000000005 110.712 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 28.1 tp -107.15 99.14 8.7 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.16 -0.681 . . . . 44.149999999999999 109.16 176.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 37.3 t -95.38 140.76 16.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.26 -0.427 . . . . 63.409999999999997 111.436 -173.52 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.498 ' HD3' ' CZ ' ' A' ' 57' ' ' PHE . 43.8 tpt85 -81.82 110.97 17.61 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 109.495 -0.557 . . . . 73.109999999999999 109.495 178.23 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.457 ' HB2' HG12 ' A' ' 58' ' ' ILE . . . -70.03 -177.96 1.48 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.994 -0.548 . . . . 73.519999999999996 111.111 -177.286 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.752 ' HB2' ' HA ' ' B' ' 112' ' ' ASP . 9.1 p-10 -79.01 148.42 32.53 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.154 -0.475 . . . . 72.049999999999997 110.17 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 103.27 140.16 10.69 Favored Glycine 0 N--CA 1.439 -1.16 0 C-N-CA 120.571 -0.823 . . . . 64.010000000000005 112.675 174.026 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 20.7 m -69.13 -4.93 19.3 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.675 -0.262 . . . . 52.130000000000003 110.919 174.708 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -43.03 -48.07 5.97 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 123.556 0.743 . . . . 73.0 112.012 176.711 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.25 53.86 1.32 Allowed Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.608 -0.806 . . . . 43.310000000000002 112.46 178.275 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -127.17 148.96 50.17 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.095 0.474 . . . . 65.319999999999993 110.538 176.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.498 ' CZ ' ' HD3' ' A' ' 49' ' ' ARG . 40.2 m-85 -117.75 152.64 34.87 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.594 -0.73 . . . . 73.019999999999996 110.322 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.457 HG12 ' HB2' ' A' ' 50' ' ' ALA . 50.6 mm -121.26 127.07 75.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 109.914 -0.402 . . . . 73.230000000000004 109.914 179.753 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 65.0 mtp180 -78.55 139.2 38.64 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 110.144 -0.317 . . . . 70.319999999999993 110.144 175.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.472 ' HB2' ' HB2' ' A' ' 46' ' ' PHE . 63.2 m -73.05 -23.19 60.55 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.495 -0.321 . . . . 60.310000000000002 110.448 176.109 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.46 ' OD1' ' HB2' ' A' ' 45' ' ' TYR . 0.8 OUTLIER -61.79 -60.58 3.44 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 121.74 0.781 . . . . 64.450000000000003 109.414 175.918 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 -122.65 88.62 49.85 Favored Pre-proline 0 N--CA 1.445 -0.724 0 CA-C-N 114.538 -1.21 . . . . 75.120000000000005 109.817 -179.524 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.84 -9.19 20.24 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 123.165 2.577 . . . . 65.239999999999995 112.626 -178.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -78.37 -24.84 46.19 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.926 -0.579 . . . . 73.219999999999999 110.599 177.393 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' A' ' 65' ' ' LYS . 42.6 tptt -91.82 122.92 34.8 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.388 0.613 . . . . 61.409999999999997 111.395 -175.14 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.5 mp -96.59 119.38 34.98 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.09 -0.959 . . . . 71.239999999999995 109.642 176.243 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . . . . . . . . . 50.7 mm -88.11 111.42 42.85 Favored Pre-proline 0 C--N 1.322 -0.599 0 CA-C-N 116.273 -0.421 . . . . 73.409999999999997 110.023 178.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.428 ' O ' HG23 ' A' ' 72' ' ' ILE . 72.7 Cg_endo -74.16 176.72 9.18 Favored 'Trans proline' 0 N--CA 1.462 -0.343 0 C-N-CA 122.563 2.175 . . . . 74.299999999999997 112.367 -177.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . . . . . . . . . 28.4 tt0 -80.41 -6.24 57.76 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.859 -0.61 . . . . 54.549999999999997 111.334 -169.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 12.7 p90 -95.24 -12.14 26.76 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.409 -0.516 . . . . 62.5 110.433 176.367 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 12.9 tt0 -103.12 -7.6 21.17 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.839 0.352 . . . . 52.439999999999998 110.795 -178.167 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.428 HG23 ' O ' ' A' ' 68' ' ' PRO . 45.7 pt -67.72 -27.74 39.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.846 0.355 . . . . 75.230000000000004 111.573 -178.24 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 24.3 p90 -101.27 34.49 2.54 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.372 0.605 . . . . 74.129999999999995 110.528 178.101 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 42.4 t -64.75 -26.98 68.59 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.43 -0.805 . . . . 52.130000000000003 110.212 176.161 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . 0.599 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 26.0 p-90 . . . . . 0 C--O 1.235 0.327 0 CA-C-N 116.436 -0.347 . . . . 65.319999999999993 111.048 177.309 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.249 0 N-CA-C 112.689 -0.164 . . . . 43.340000000000003 112.689 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -167.87 -78.68 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.048 0.452 . . . . 52.530000000000001 110.417 178.093 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -147.52 130.99 16.7 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.731 -0.668 . . . . 64.329999999999998 109.821 179.688 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -156.56 155.97 32.81 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.021 -0.536 . . . . 74.420000000000002 110.119 -179.592 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -92.16 146.82 23.42 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.01 -0.541 . . . . 71.099999999999994 111.377 -177.041 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . 0.487 ' HA ' ' HD3' ' B' ' 107' ' ' PRO . . . -90.63 129.94 42.97 Favored Pre-proline 0 C--N 1.321 -0.633 0 CA-C-N 115.531 -0.759 . . . . 71.540000000000006 110.203 178.43 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . 0.487 ' HD3' ' HA ' ' B' ' 106' ' ' ALA . 7.6 Cg_exo -73.33 171.03 18.49 Favored 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.736 2.291 . . . . 54.25 111.643 177.429 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 16.9 m -60.27 109.3 0.95 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.414 -0.357 . . . . 64.409999999999997 110.072 175.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 114.58 85.05 1.28 Allowed Glycine 0 N--CA 1.443 -0.864 0 C-N-CA 120.578 -0.82 . . . . 63.340000000000003 111.437 -176.8 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . 0.462 ' HA ' ' HD3' ' B' ' 111' ' ' PRO . 11.1 pt-20 -124.08 110.73 28.99 Favored Pre-proline 0 C--N 1.322 -0.618 0 CA-C-O 121.322 0.582 . . . . 72.049999999999997 109.558 -176.384 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.695 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 19.1 Cg_endo -89.52 131.35 2.01 Favored 'Trans proline' 0 N--CA 1.444 -1.4 0 C-N-CA 122.63 2.22 . . . . 60.219999999999999 112.604 -176.393 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . 0.752 ' HA ' ' HB2' ' A' ' 51' ' ' ASP . 4.2 p-10 -144.9 171.17 14.82 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.188 -0.671 . . . . 72.329999999999998 109.188 175.272 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.544 HG21 ' HB3' ' B' ' 124' ' ' GLN . 10.9 p -118.44 131.6 70.73 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-O 121.653 0.739 . . . . 72.450000000000003 112.096 -172.461 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 30.3 m -94.86 103.44 15.32 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.435 -0.802 . . . . 55.039999999999999 109.31 173.161 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.468 HG23 ' HG2' ' B' ' 124' ' ' GLN . 65.2 mt -90.57 106.44 17.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.245 -0.434 . . . . 72.099999999999994 110.823 -176.15 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 58.6 mtm180 -113.74 165.08 12.91 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.126 -0.488 . . . . 72.439999999999998 110.603 177.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -133.14 105.57 7.11 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.094 0.474 . . . . 63.450000000000003 110.468 178.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -109.85 88.75 2.82 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.904 -0.589 . . . . 71.340000000000003 110.191 -178.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 88.47 -119.8 5.47 Favored Glycine 0 N--CA 1.445 -0.734 0 CA-C-N 115.439 -0.8 . . . . 52.43 111.742 -177.377 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.508 ' HB3' ' HB2' ' B' ' 140' ' ' LYS . 90.5 m-20 -101.37 6.29 42.57 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.73 0.3 . . . . 63.340000000000003 110.573 178.84 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.706 ' HE3' ' HB2' ' B' ' 175' ' ' TRP . 25.1 pttm -117.42 120.69 38.92 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.47 0.652 . . . . 72.420000000000002 111.692 -177.806 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . 0.586 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 69.7 m -84.86 105.0 15.31 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.163 -0.926 . . . . 73.140000000000001 109.478 174.183 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . 0.655 HD11 ' HE2' ' B' ' 121' ' ' LYS . 33.2 mt -95.02 108.08 20.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-O 121.049 0.452 . . . . 71.109999999999999 110.531 -176.366 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.544 ' HB3' HG21 ' B' ' 113' ' ' VAL . 22.1 mt-30 -98.65 105.15 17.26 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.825 -0.625 . . . . 72.120000000000005 110.319 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -87.37 112.77 22.46 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.125 -0.488 . . . . 65.409999999999997 110.926 -179.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -90.09 111.14 22.16 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.205 -0.452 . . . . 72.230000000000004 110.028 176.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . 0.403 ' HD3' ' O ' ' B' ' 130' ' ' GLY . 52.8 mtt-85 -128.33 138.1 52.23 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.313 -0.403 . . . . 75.340000000000003 110.346 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.695 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.6 p -101.86 -56.17 5.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.065 0.459 . . . . 71.510000000000005 111.201 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . 0.449 ' H ' HG13 ' B' ' 128' ' ' VAL . 6.7 t-20 -122.66 42.03 3.28 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.761 0.791 . . . . 64.310000000000002 109.103 -178.029 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . 0.403 ' O ' ' HD3' ' B' ' 127' ' ' ARG . . . 92.31 -28.72 8.51 Favored Glycine 0 N--CA 1.448 -0.563 0 CA-C-N 115.086 -0.961 . . . . 64.319999999999993 112.099 -178.087 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 33.8 t80 -84.59 135.57 34.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.934 0.397 . . . . 72.329999999999998 110.318 -175.627 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.843 HD11 HG13 ' B' ' 135' ' ' ILE . 3.3 tm? -76.75 117.59 18.53 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.327 -0.851 . . . . 75.140000000000001 109.966 179.068 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 40.0 p90 -112.26 -14.96 13.27 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 120.521 -0.471 . . . . 72.010000000000005 111.571 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.11 141.61 12.6 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.848 0.356 . . . . 51.210000000000001 111.169 178.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.843 HG13 HD11 ' B' ' 132' ' ' LEU . 75.3 mt -125.14 121.61 61.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.188 -0.46 . . . . 72.129999999999995 109.935 175.713 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.407 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 83.7 tttt -104.37 98.5 8.28 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 108.821 -0.807 . . . . 73.010000000000005 108.821 171.512 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.55 ' O ' ' HD3' ' B' ' 139' ' ' PRO . 3.5 p -98.21 128.67 49.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 CA-C-O 121.142 0.496 . . . . 74.120000000000005 109.916 179.374 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.586 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 40.8 t -108.03 84.82 2.28 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 115.31 -0.859 . . . . 72.129999999999995 109.69 179.083 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.55 ' HD3' ' O ' ' B' ' 137' ' ' VAL . 62.5 Cg_endo -88.7 132.33 2.45 Favored 'Trans proline' 0 N--CA 1.443 -1.464 0 C-N-CA 122.459 2.106 . . . . 75.140000000000001 111.885 178.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . 0.508 ' HB2' ' HB3' ' B' ' 120' ' ' ASP . 55.0 mtpt -65.37 -15.81 62.96 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.701 -0.681 . . . . 54.329999999999998 109.808 176.229 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 64.4 m-70 -117.47 89.52 3.13 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-N 115.174 -0.921 . . . . 63.240000000000002 109.289 178.413 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 127.87 -18.35 5.94 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.724 -0.751 . . . . 63.25 112.555 -178.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 89.1 mttt 72.98 148.94 0.12 Allowed Pre-proline 0 N--CA 1.472 0.649 0 C-N-CA 123.557 0.743 . . . . 73.299999999999997 111.736 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.545 ' HB3' HG22 ' B' ' 138' ' ' VAL . 34.9 Cg_endo -65.12 149.26 89.24 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.936 2.424 . . . . 74.400000000000006 113.375 -176.433 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . 0.43 ' HE2' HD13 ' B' ' 147' ' ' LEU . 3.9 p90 -160.3 160.43 32.51 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.534 -0.757 . . . . 71.230000000000004 109.59 178.178 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.547 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 55.0 m-85 -94.55 128.84 41.42 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.457 -0.338 . . . . 74.439999999999998 110.216 176.687 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.43 HD13 ' HE2' ' B' ' 145' ' ' TYR . 15.8 tp -110.36 99.8 8.76 Favored 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 108.931 -0.766 . . . . 74.420000000000002 108.931 174.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 38.3 t -93.77 139.28 18.59 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.988 -0.551 . . . . 73.5 111.047 -173.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 11.6 tpt180 -72.02 131.06 42.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.199 -0.455 . . . . 72.319999999999993 111.245 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -93.34 162.22 14.08 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 109.372 -0.603 . . . . 75.140000000000001 109.372 171.306 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 8.2 p-10 -68.69 138.24 54.78 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.966 0.412 . . . . 72.299999999999997 110.537 -177.548 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 106.1 147.45 15.01 Favored Glycine 0 N--CA 1.437 -1.28 0 C-N-CA 120.491 -0.861 . . . . 72.25 112.048 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 11.1 t -87.0 23.88 1.66 Allowed 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 121.253 0.549 . . . . 63.140000000000001 110.015 175.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -65.17 -29.45 70.28 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.571 -0.74 . . . . 72.150000000000006 110.59 179.01 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 94.44 37.92 5.18 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.891 -0.671 . . . . 71.049999999999997 111.641 -177.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . 0.943 HD21 HD22 ' B' ' 166' ' ' LEU . 40.7 t30 -110.85 130.51 55.56 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.836 0.351 . . . . 65.109999999999999 110.69 -177.457 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . 0.428 ' HB3' ' HG ' ' B' ' 147' ' ' LEU . 27.1 m-85 -126.71 161.0 29.15 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.002 -0.545 . . . . 72.239999999999995 110.269 178.198 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . 0.775 HD11 HD23 ' B' ' 166' ' ' LEU . 39.9 mm -118.38 141.05 39.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.458 -0.337 . . . . 73.120000000000005 110.603 -179.63 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.817 ' HD2' HD11 ' B' ' 167' ' ' ILE . 34.1 mtp-105 -96.23 145.68 25.35 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.394 -0.366 . . . . 75.400000000000006 110.925 -178.098 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . 0.547 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 25.8 p -74.96 -15.16 60.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.26 0.552 . . . . 74.239999999999995 110.679 175.098 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 22.7 t70 -78.66 -30.79 46.47 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.118 -0.492 . . . . 72.530000000000001 110.38 177.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -159.19 98.02 1.63 Allowed Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.781 -0.645 . . . . 75.420000000000002 110.224 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . 0.418 ' HA ' HG23 ' B' ' 158' ' ' ILE . 48.6 Cg_endo -69.62 -13.03 34.41 Favored 'Trans proline' 0 CA--C 1.529 0.231 0 C-N-CA 122.991 2.461 . . . . 61.039999999999999 112.844 -179.343 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -77.66 -19.38 55.5 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.86 0.362 . . . . 62.539999999999999 111.022 177.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 51.7 tptt -94.07 122.61 36.76 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.409 0.623 . . . . 71.120000000000005 111.132 -177.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . 0.943 HD22 HD21 ' B' ' 156' ' ' ASN . 20.4 mt -90.57 128.02 36.45 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.598 -1.183 . . . . 73.400000000000006 108.832 176.734 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . 0.817 HD11 ' HD2' ' B' ' 159' ' ' ARG . 46.1 mm -98.77 112.08 61.89 Favored Pre-proline 0 C--N 1.318 -0.778 0 CA-C-O 120.65 0.262 . . . . 70.310000000000002 110.832 -178.151 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.539 ' O ' HG23 ' B' ' 172' ' ' ILE . 68.6 Cg_endo -73.5 175.23 10.94 Favored 'Trans proline' 0 N--CA 1.464 -0.263 0 C-N-CA 122.775 2.317 . . . . 75.340000000000003 112.611 -179.421 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . 0.517 ' O ' HG12 ' B' ' 172' ' ' ILE . 28.0 tt0 -69.65 -25.48 63.94 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.703 -0.681 . . . . 73.319999999999993 112.325 -168.488 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 30.6 p90 -81.09 -12.07 59.36 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 120.182 -0.607 . . . . 74.420000000000002 110.303 178.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.548 ' HB3' HG23 ' B' ' 167' ' ' ILE . 3.9 mt-10 -106.79 -19.27 13.7 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.157 -0.474 . . . . 71.329999999999998 111.892 -178.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.539 HG23 ' O ' ' B' ' 168' ' ' PRO . 43.6 pt -64.51 -26.36 40.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.244 0.545 . . . . 72.129999999999995 110.681 177.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -105.3 48.56 0.83 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.612 -0.722 . . . . 70.439999999999998 109.782 174.4 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 16.6 t -71.06 -15.39 62.54 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.806 -0.634 . . . . 73.409999999999997 110.17 179.379 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . 0.706 ' HB2' ' HE3' ' B' ' 121' ' ' LYS . 4.5 p-90 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.249 -0.882 . . . . 73.120000000000005 110.519 178.305 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.661 0 N-CA-C 112.198 -0.361 . . . . 74.349999999999994 112.198 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -91.21 90.25 7.7 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.164 0.507 . . . . 72.319999999999993 109.933 178.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -156.56 134.62 11.19 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.534 -0.757 . . . . 74.109999999999999 109.667 -177.414 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -136.63 100.39 4.32 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.076 0.465 . . . . 73.129999999999995 112.031 -178.55 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -128.27 136.03 50.46 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 108.19 -1.041 . . . . 73.340000000000003 108.19 169.356 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.436 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . . . -146.54 142.78 17.75 Favored Pre-proline 0 C--N 1.319 -0.724 0 C-N-CA 121.011 -0.275 . . . . 73.120000000000005 111.335 -174.803 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 6' ' ' ALA . 18.8 Cg_exo -67.25 172.67 9.72 Favored 'Trans proline' 0 CA--C 1.53 0.306 0 C-N-CA 122.841 2.361 . . . . 62.439999999999998 112.239 178.269 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 27.0 m -89.68 11.47 19.76 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.66 0.743 . . . . 53.119999999999997 110.374 179.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -135.18 102.99 0.45 Allowed Glycine 0 N--CA 1.442 -0.957 0 N-CA-C 110.108 -1.197 . . . . 75.109999999999999 110.108 177.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -119.99 94.71 48.81 Favored Pre-proline 0 C--N 1.319 -0.743 0 CA-C-O 121.261 0.553 . . . . 74.329999999999998 110.401 -175.069 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.848 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 51.6 Cg_endo -77.56 81.79 2.57 Favored 'Trans proline' 0 N--CA 1.448 -1.182 0 C-N-CA 121.913 1.742 . . . . 73.120000000000005 111.265 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -100.48 168.26 9.85 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.339 -0.615 . . . . 73.450000000000003 109.339 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.673 HG21 ' HB3' ' A' ' 24' ' ' GLN . 8.3 p -125.65 131.41 72.06 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-O 121.253 0.549 . . . . 44.450000000000003 111.387 -175.177 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.5 m -89.51 121.14 31.44 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.679 -0.691 . . . . 71.150000000000006 109.423 176.34 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 52.9 mt -91.58 109.09 20.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 120.834 0.349 . . . . 71.430000000000007 111.161 -175.382 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 38.3 mmt180 -105.51 165.7 10.96 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 72.109999999999999 109.867 176.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 40.1 mt-30 -138.95 122.57 17.43 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 120.768 0.318 . . . . 75.349999999999994 111.147 177.007 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -124.97 96.93 5.05 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.793 -0.639 . . . . 73.040000000000006 109.524 176.212 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.24 -106.49 1.8 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.476 -0.869 . . . . 75.349999999999994 111.719 -178.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.588 ' HB3' ' HB2' ' A' ' 40' ' ' LYS . 7.0 m-20 -111.35 6.26 20.31 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 121.156 -0.217 . . . . 41.310000000000002 111.537 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.652 ' HB3' ' HB3' ' A' ' 39' ' ' PRO . 0.0 OUTLIER -110.94 122.49 48.01 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 119.917 -0.713 . . . . 72.030000000000001 111.472 177.422 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.448 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 42.4 m -83.42 101.28 11.26 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 114.961 -1.018 . . . . 61.409999999999997 108.983 173.174 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.475 HG12 HG13 ' A' ' 37' ' ' VAL . 61.3 mt -90.82 109.86 21.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.153 0.502 . . . . 71.439999999999998 110.291 -175.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.673 ' HB3' HG21 ' A' ' 13' ' ' VAL . 14.6 mt-30 -99.78 119.45 38.18 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.787 -0.642 . . . . 73.219999999999999 111.021 -175.562 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -94.31 108.73 20.6 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.825 -0.625 . . . . 74.239999999999995 110.559 -178.001 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.516 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 33.5 m-85 -86.62 114.82 23.65 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.923 0.392 . . . . 75.120000000000005 111.051 -179.587 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.427 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 68.3 mtm180 -131.03 126.64 36.43 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.018 -0.537 . . . . 73.120000000000005 110.416 179.295 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.848 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 7.3 p -91.07 -28.83 4.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.063 -0.517 . . . . 70.109999999999999 111.242 -176.52 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -173.61 69.68 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 109.626 -0.509 . . . . 62.310000000000002 109.626 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 82.98 -24.59 5.19 Favored Glycine 0 N--CA 1.451 -0.31 0 CA-C-N 115.817 -0.629 . . . . 63.119999999999997 112.642 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.645 ' CZ ' ' HG3' ' B' ' 111' ' ' PRO . 88.4 t80 -97.26 128.43 44.11 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.869 0.366 . . . . 75.25 111.057 -176.2 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.622 HD11 HG13 ' A' ' 35' ' ' ILE . 3.2 tm? -79.24 109.73 13.85 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.803 -0.814 . . . . 54.109999999999999 108.803 175.194 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . . . . . . . . . 41.7 p90 -106.0 -13.87 15.35 Favored 'General case' 0 C--N 1.327 -0.391 0 C-N-CA 120.513 -0.475 . . . . 63.32 111.467 -176.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -162.11 149.49 14.12 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.069 0.461 . . . . 31.210000000000001 111.62 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.622 HG13 HD11 ' A' ' 32' ' ' LEU . 70.1 mt -126.07 128.12 71.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.659 -0.701 . . . . 72.510000000000005 109.681 174.669 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.622 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 81.5 tttt -112.01 105.15 13.47 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.306 -0.406 . . . . 74.530000000000001 110.084 179.159 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.696 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 4.4 t -89.64 126.71 42.55 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 108.765 -0.828 . . . . 62.229999999999997 108.765 177.379 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.448 ' HB ' ' HB ' ' A' ' 22' ' ' THR . 20.1 t -114.43 73.98 2.91 Favored Pre-proline 0 C--N 1.32 -0.678 0 N-CA-C 109.883 -0.414 . . . . 73.219999999999999 109.883 172.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.679 ' HD3' HG12 ' A' ' 37' ' ' VAL . 39.8 Cg_endo -77.52 132.11 11.99 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.094 1.862 . . . . 65.420000000000002 112.648 176.377 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.588 ' HB2' ' HB3' ' A' ' 20' ' ' ASP . 50.4 mtpt -60.76 -28.22 68.55 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.535 -0.757 . . . . 70.200000000000003 110.316 175.24 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 74.2 m-70 -118.03 94.63 4.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.325 -0.852 . . . . 74.530000000000001 108.763 178.026 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.413 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 134.04 -31.22 2.84 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.492 -0.776 . . . . 73.319999999999993 111.544 -175.038 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.472 ' HA ' ' HD3' ' A' ' 43' ' ' LYS . 31.5 mmtp 74.23 153.65 0.15 Allowed Pre-proline 0 N--CA 1.469 0.501 0 C-N-CA 123.557 0.743 . . . . 60.210000000000001 112.254 177.243 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.696 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 28.3 Cg_endo -62.86 132.52 37.54 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 123.074 2.516 . . . . 74.340000000000003 114.2 -173.485 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -140.0 154.55 47.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.456 -0.793 . . . . 72.129999999999995 109.884 175.364 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -107.01 136.98 45.95 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-O 120.763 0.316 . . . . 73.420000000000002 111.574 -175.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.585 HD23 ' HA ' ' A' ' 59' ' ' ARG . 47.7 mt -118.38 107.78 14.25 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.851 -0.613 . . . . 60.140000000000001 109.858 171.431 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 47.3 t -95.46 134.92 31.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.628 -0.26 . . . . 61.5 110.398 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.656 ' HD2' ' HA ' ' A' ' 53' ' ' SER . 16.1 tpp85 -68.7 122.04 17.72 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.808 0.337 . . . . 75.140000000000001 110.123 177.211 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -73.6 158.35 34.95 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.136 -0.483 . . . . 72.230000000000004 110.784 179.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -53.49 143.55 19.26 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 115.765 -0.652 . . . . 63.140000000000001 111.194 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 96.28 -33.84 5.36 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 120.772 -0.728 . . . . 73.219999999999999 111.99 -178.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.656 ' HA ' ' HD2' ' A' ' 49' ' ' ARG . 17.4 t 63.02 38.3 11.06 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-O 121.009 0.433 . . . . 75.129999999999995 110.992 178.776 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -76.44 -3.67 38.39 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.526 0.679 . . . . 73.349999999999994 110.815 -178.468 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 111.54 2.53 27.46 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.617 -0.801 . . . . 54.200000000000003 111.692 -179.038 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -85.89 134.59 33.89 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.051 0.453 . . . . 73.219999999999999 110.497 178.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -116.04 144.19 44.45 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.82 -0.627 . . . . 70.450000000000003 110.109 176.095 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 46.2 mm -105.75 105.43 18.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 CA-C-O 121.564 0.697 . . . . 73.219999999999999 109.368 176.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.719 ' HB2' HG13 ' A' ' 67' ' ' ILE . 24.0 ttt180 -69.56 119.78 14.34 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 114.631 -1.168 . . . . 71.540000000000006 109.461 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 9.5 t -63.05 -18.56 63.49 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.396 0.617 . . . . 71.219999999999999 110.404 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.696 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 24.7 t70 -73.96 -28.42 61.48 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.449 -0.796 . . . . 74.5 110.489 175.61 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 23.9 mt-30 -142.79 68.5 19.09 Favored Pre-proline 0 C--N 1.326 -0.417 0 CA-C-N 115.424 -0.807 . . . . 65.140000000000001 109.191 -177.328 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_exo -71.06 -11.5 29.18 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 123.256 2.637 . . . . 53.329999999999998 112.998 -171.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -95.47 4.76 52.95 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.493 0.663 . . . . 72.510000000000005 109.758 -178.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -131.96 137.35 47.88 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.6 -0.727 . . . . 63.329999999999998 110.753 -178.038 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.488 ' N ' HD12 ' A' ' 66' ' ' LEU . 4.5 mp -85.02 131.44 34.46 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.049 -0.523 . . . . 61.030000000000001 109.65 179.678 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.719 HG13 ' HB2' ' A' ' 59' ' ' ARG . 40.6 mm -89.71 129.1 47.95 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-O 120.933 0.397 . . . . 71.510000000000005 111.305 -174.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -76.28 176.59 9.86 Favored 'Trans proline' 0 N--CA 1.459 -0.505 0 C-N-CA 122.862 2.374 . . . . 71.439999999999998 112.514 178.15 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . 0.685 ' HA ' HG12 ' A' ' 72' ' ' ILE . 6.4 tt0 -79.41 -31.62 42.72 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.61 -0.723 . . . . 64.329999999999998 112.184 -170.653 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 28.3 p90 -69.42 -19.39 63.8 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 120.184 -0.607 . . . . 71.530000000000001 110.384 178.421 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -84.84 -35.45 22.26 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.852 -0.613 . . . . 70.099999999999994 110.179 178.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.685 HG12 ' HA ' ' A' ' 69' ' ' GLN . 41.2 pt -76.24 -21.79 15.43 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.116 0 CA-C-O 120.965 0.412 . . . . 64.439999999999998 110.878 179.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 31.4 m-85 -103.63 28.47 6.52 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.077 -0.511 . . . . 74.120000000000005 110.926 176.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 11.1 t -84.93 45.22 1.14 Allowed 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.864 0.84 . . . . 71.219999999999999 109.616 178.352 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . . . . . . . . . 11.3 m0 . . . . . 0 C--N 1.324 -0.521 0 CA-C-N 115.124 -0.944 . . . . 73.329999999999998 110.729 -178.83 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.483 0 N-CA-C 112.439 -0.264 . . . . 65.209999999999994 112.439 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -86.78 96.67 10.26 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 120.698 0.285 . . . . 71.340000000000003 111.099 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -73.89 110.91 8.56 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.75 -0.463 . . . . 53.219999999999999 109.75 175.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -100.72 32.86 2.96 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.598 0.713 . . . . 63.020000000000003 110.828 -174.507 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -84.75 95.55 8.98 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.191 -0.67 . . . . 72.230000000000004 109.191 176.146 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -108.68 111.13 61.23 Favored Pre-proline 0 C--N 1.323 -0.559 0 CA-C-O 120.926 0.393 . . . . 64.120000000000005 111.329 -175.199 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 96.5 Cg_endo -83.8 159.08 14.04 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.638 2.225 . . . . 65.349999999999994 111.61 176.171 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 6.3 p -75.75 96.47 3.65 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.041 0.448 . . . . 74.420000000000002 109.998 176.721 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 128.05 76.89 0.21 Allowed Glycine 0 N--CA 1.445 -0.701 0 N-CA-C 110.891 -0.884 . . . . 74.049999999999997 110.891 -175.555 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -110.16 105.77 57.47 Favored Pre-proline 0 C--N 1.32 -0.703 0 N-CA-C 109.138 -0.69 . . . . 71.040000000000006 109.138 -175.371 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.745 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 46.1 Cg_endo -82.23 86.35 1.54 Allowed 'Trans proline' 0 N--CA 1.439 -1.734 0 C-N-CA 121.898 1.732 . . . . 70.230000000000004 110.959 -178.021 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -101.81 155.63 18.02 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 114.258 -1.337 . . . . 74.010000000000005 109.92 -175.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.603 ' HA ' ' O ' ' B' ' 125' ' ' GLU . 7.6 p -117.65 130.71 72.11 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-O 121.474 0.655 . . . . 75.430000000000007 111.104 -177.707 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . . . . . . . . . 52.0 m -104.7 122.05 44.85 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.401 -0.818 . . . . 65.420000000000002 109.996 178.636 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 47.3 mt -87.09 108.03 17.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 116.145 -0.479 . . . . 54.520000000000003 111.443 -174.783 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -101.15 170.73 8.06 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.469 -0.567 . . . . 54.25 109.469 175.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -142.76 138.76 30.7 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.782 0.325 . . . . 75.109999999999999 110.786 175.532 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . . . . . . . . . 32.0 mm-40 -135.52 104.58 5.87 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.638 -0.71 . . . . 75.109999999999999 109.754 176.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 66.62 -110.14 3.31 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.908 -0.663 . . . . 51.109999999999999 111.898 -177.263 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.615 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 9.5 m-20 -97.06 -19.33 18.79 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.705 0.288 . . . . 74.200000000000003 110.977 -179.147 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.533 ' HB3' ' HA ' ' B' ' 139' ' ' PRO . 49.3 pttt -100.88 141.75 33.33 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.6 0.714 . . . . 71.25 112.503 -170.088 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . 0.594 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 47.9 m -91.77 138.43 31.56 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 114.828 -1.078 . . . . 73.409999999999997 109.646 176.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 65.9 mt -124.89 106.56 16.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 120.984 0.421 . . . . 71.430000000000007 110.276 -178.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.56 ' HB2' ' HB3' ' B' ' 136' ' ' LYS . 18.7 mt-30 -96.91 117.19 30.57 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.918 0.39 . . . . 64.25 111.092 -176.081 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . 0.603 ' O ' ' HA ' ' B' ' 113' ' ' VAL . 43.2 mt-10 -83.02 114.15 21.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.736 -0.665 . . . . 74.230000000000004 110.947 179.299 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . 0.444 ' HB2' ' O ' ' B' ' 134' ' ' ALA . 41.2 m-85 -92.75 97.33 10.71 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.493 -0.558 . . . . 53.43 109.493 170.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . 0.439 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 21.8 mtm105 -121.08 127.41 51.63 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.803 -0.635 . . . . 74.040000000000006 110.071 179.375 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.745 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 6.0 p -87.97 -37.5 10.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-O 121.097 0.475 . . . . 71.540000000000006 110.834 -176.541 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -160.27 62.86 0.33 Allowed 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.292 0.568 . . . . 72.230000000000004 109.69 -178.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.0 -26.57 6.63 Favored Glycine 0 N--CA 1.446 -0.664 0 CA-C-N 115.404 -0.816 . . . . 62.310000000000002 112.734 179.714 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 30.3 t80 -99.12 130.81 45.46 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.014 0.435 . . . . 72.129999999999995 110.56 -175.342 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.783 HD11 HG13 ' B' ' 135' ' ' ILE . 3.2 tm? -78.06 118.62 20.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.263 -0.881 . . . . 72.409999999999997 109.615 178.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . 0.415 ' CZ ' ' HB3' ' B' ' 126' ' ' TYR . 51.4 p90 -109.3 -22.27 12.14 Favored 'General case' 0 C--N 1.329 -0.316 0 C-N-CA 120.748 -0.381 . . . . 72.340000000000003 111.34 178.24 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . 0.444 ' O ' ' HB2' ' B' ' 126' ' ' TYR . . . -156.14 147.81 22.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.39 . . . . 54.25 111.12 179.517 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.783 HG13 HD11 ' B' ' 132' ' ' LEU . 75.4 mt -125.47 130.68 72.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.152 -0.476 . . . . 55.229999999999997 109.723 175.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.56 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 46.6 tttp -106.46 106.82 17.52 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.383 -0.599 . . . . 64.140000000000001 109.383 174.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.685 ' O ' ' HA ' ' B' ' 144' ' ' PRO . 3.0 t -91.51 136.05 25.38 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 N-CA-C 109.024 -0.732 . . . . 70.340000000000003 109.024 178.583 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.594 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 22.0 t -121.85 73.33 34.29 Favored Pre-proline 0 C--N 1.318 -0.762 0 N-CA-C 109.483 -0.562 . . . . 75.109999999999999 109.483 173.298 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.576 ' HD3' HG12 ' B' ' 137' ' ' VAL . 53.2 Cg_endo -78.52 134.64 12.57 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 122.183 1.922 . . . . 72.230000000000004 112.931 176.601 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . 0.615 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 30.8 mtpp -62.94 -30.93 71.94 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.638 0.732 . . . . 71.430000000000007 109.547 174.222 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 72.8 m-70 -112.99 89.89 3.2 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.043 -0.981 . . . . 75.120000000000005 109.392 176.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . . . . . . . . . . . 138.7 -21.52 3.04 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.621 -0.8 . . . . 75.299999999999997 112.328 -178.207 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . . . . . . . . . 33.4 mmtp 69.59 150.8 0.13 Allowed Pre-proline 0 N--CA 1.472 0.67 0 C-N-CA 123.2 0.6 . . . . 65.319999999999993 111.524 178.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.685 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 19.3 Cg_endo -59.8 140.3 92.6 Favored 'Trans proline' 0 C--O 1.235 0.336 0 C-N-CA 122.575 2.183 . . . . 75.540000000000006 113.278 -177.244 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 38.9 p90 -155.33 151.06 27.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.924 -0.58 . . . . 74.310000000000002 110.307 178.441 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.522 ' HB2' ' HB2' ' B' ' 160' ' ' SER . 87.2 m-85 -95.35 139.32 31.82 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.171 -0.468 . . . . 75.140000000000001 111.166 179.453 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.419 ' HB3' ' CD2' ' B' ' 157' ' ' PHE . 39.5 mt -116.27 110.29 18.55 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.634 -0.712 . . . . 73.319999999999993 109.693 170.316 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 41.7 t -95.23 132.91 37.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.579 -0.282 . . . . 70.450000000000003 110.953 -178.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . 0.415 HH11 ' HG2' ' B' ' 149' ' ' ARG . 17.0 tpp85 -70.46 113.63 7.77 Favored 'General case' 0 N--CA 1.452 -0.338 0 N-CA-C 109.895 -0.409 . . . . 74.040000000000006 109.895 175.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.65 155.44 35.91 Favored 'General case' 0 C--O 1.236 0.386 0 CA-C-N 116.094 -0.503 . . . . 74.239999999999995 111.202 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . 0.516 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 3.4 p-10 -56.9 138.79 53.31 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.551 -0.749 . . . . 72.0 112.132 -177.418 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 93.74 -11.24 71.46 Favored Glycine 0 N--CA 1.446 -0.685 0 CA-C-N 115.213 -0.903 . . . . 62.130000000000003 112.648 176.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 2.3 t 57.58 50.33 11.19 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-O 121.692 0.758 . . . . 62.009999999999998 109.391 -177.618 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -73.51 -8.45 55.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 114.885 -1.052 . . . . 72.450000000000003 111.876 -175.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 90.96 18.32 47.66 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.5 -0.857 . . . . 33.119999999999997 111.175 -174.089 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . 0.694 HD21 HD22 ' B' ' 166' ' ' LEU . 36.5 t30 -119.88 137.47 54.0 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.914 -0.643 . . . . 73.400000000000006 110.058 -178.322 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . 0.419 ' CD2' ' HB3' ' B' ' 147' ' ' LEU . 42.3 m-85 -113.56 159.93 19.07 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 116.167 -0.469 . . . . 75.439999999999998 110.166 177.666 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . 0.693 HD11 HD23 ' B' ' 166' ' ' LEU . 45.7 mm -121.9 119.07 57.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 109.442 -0.577 . . . . 75.310000000000002 109.442 175.061 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.418 ' HB3' ' H ' ' B' ' 161' ' ' ASP . 36.2 mtt180 -71.14 140.16 50.49 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.213 -0.448 . . . . 44.229999999999997 110.09 176.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . 0.522 ' HB2' ' HB2' ' B' ' 146' ' ' PHE . 7.4 t -80.82 1.06 32.21 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.617 -0.883 . . . . 64.549999999999997 108.617 169.702 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . 0.418 ' H ' ' HB3' ' B' ' 159' ' ' ARG . 0.2 OUTLIER -98.53 -23.12 15.65 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.561 -1.199 . . . . 73.219999999999999 109.884 174.567 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 37.3 mt-30 -144.71 67.83 14.24 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 115.099 -0.955 . . . . 72.129999999999995 109.559 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -75.34 -12.97 20.86 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 123.162 2.575 . . . . 73.319999999999993 113.346 -173.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -87.89 -12.5 44.6 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.581 0.705 . . . . 65.519999999999996 109.504 178.418 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 48.8 mtpt -105.46 170.45 7.88 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.406 -0.815 . . . . 71.409999999999997 111.459 -177.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . 0.694 HD22 HD21 ' B' ' 156' ' ' ASN . 17.8 mt -117.48 125.46 50.93 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.423 -0.954 . . . . 71.219999999999999 108.423 177.21 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . 0.542 ' CG2' ' HB3' ' B' ' 171' ' ' GLU . 36.5 mm -80.95 116.37 62.01 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-O 121.275 0.56 . . . . 72.319999999999993 111.835 -169.798 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.53 -179.46 2.82 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.58 2.853 . . . . 74.239999999999995 112.781 -178.227 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . 0.804 ' HA ' HG12 ' B' ' 172' ' ' ILE . 3.7 tt0 -79.23 -32.35 43.87 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.07 -0.514 . . . . 52.409999999999997 111.386 -170.367 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 11.4 p90 -68.21 -17.09 64.23 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.088 0.471 . . . . 73.140000000000001 110.231 178.09 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.542 ' HB3' ' CG2' ' B' ' 167' ' ' ILE . 1.2 tm-20 -91.12 -43.69 9.73 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.577 -0.738 . . . . 62.130000000000003 110.211 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.804 HG12 ' HA ' ' B' ' 169' ' ' GLN . 44.1 pt -68.61 -25.35 30.62 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 CA-C-N 116.168 -0.469 . . . . 55.439999999999998 111.06 -179.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . 0.42 ' C ' ' H ' ' B' ' 175' ' ' TRP . 30.9 m-85 -111.14 30.45 6.88 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.18 0.514 . . . . 72.340000000000003 110.563 176.617 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . . . . . . . . . 25.1 t -79.03 22.44 0.39 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.866 -0.607 . . . . 73.040000000000006 110.652 178.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . 0.42 ' H ' ' C ' ' B' ' 173' ' ' PHE . 12.9 m95 . . . . . 0 C--O 1.248 1.018 0 CA-C-O 118.271 -0.871 . . . . 73.409999999999997 110.509 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.622 0 N-CA-C 112.043 -0.423 . . . . 71.329999999999998 112.043 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -157.18 123.54 4.92 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.806 0.303 . . . . 61.530000000000001 111.255 -178.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 33.4 t70 74.43 -49.84 0.67 Allowed 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 123.868 0.867 . . . . 62.530000000000001 111.999 174.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -78.4 109.76 12.84 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 109.808 -0.441 . . . . 71.019999999999996 109.808 177.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.617 ' O ' ' HD3' ' A' ' 7' ' ' PRO . 24.1 m-20 -87.57 -163.26 0.91 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.459 -0.337 . . . . 71.530000000000001 110.659 179.673 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -106.5 96.15 13.35 Favored Pre-proline 0 C--N 1.324 -0.502 0 CA-C-O 120.753 0.311 . . . . 61.109999999999999 111.686 -176.225 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.617 ' HD3' ' O ' ' A' ' 5' ' ' ASP . 12.4 Cg_endo -92.38 117.38 0.4 Allowed 'Trans proline' 0 N--CA 1.45 -1.066 0 C-N-CA 123.301 2.667 . . . . 71.120000000000005 112.209 177.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 20.3 m -71.35 119.35 15.36 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.567 -0.531 . . . . 25.510000000000002 109.567 174.804 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.456 ' O ' ' HD3' ' A' ' 11' ' ' PRO . . . 95.42 70.19 1.06 Allowed Glycine 0 N--CA 1.443 -0.886 0 N-CA-C 110.53 -1.028 . . . . 74.5 110.53 -173.129 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . 0.415 ' HA ' ' HD3' ' A' ' 11' ' ' PRO . 11.9 pt-20 -98.48 102.65 15.12 Favored Pre-proline 0 C--N 1.325 -0.482 0 N-CA-C 109.348 -0.612 . . . . 64.420000000000002 109.348 -177.321 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.554 ' HA ' ' HA ' ' A' ' 28' ' ' VAL . 53.4 Cg_endo -91.14 97.24 0.23 Allowed 'Trans proline' 0 N--CA 1.441 -1.571 0 C-N-CA 122.572 2.181 . . . . 64.0 112.135 -175.008 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 39.6 m-20 -103.05 114.18 28.27 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-N 115.365 -0.834 . . . . 74.109999999999999 109.859 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.634 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 9.1 p -77.1 127.12 38.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 CA-C-N 115.681 -0.69 . . . . 72.530000000000001 109.97 179.478 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.643 ' HB ' ' HB2' ' A' ' 25' ' ' GLU . 24.5 m -84.22 103.1 13.14 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.848 -0.614 . . . . 71.239999999999995 110.078 -178.063 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 65.5 mt -90.84 107.95 19.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.06 -0.518 . . . . 71.530000000000001 110.571 -176.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.507 ' HG2' ' O ' ' A' ' 23' ' ' ILE . 12.7 ptm180 -121.96 174.4 6.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.871 -0.604 . . . . 75.299999999999997 109.786 179.066 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -133.08 104.38 6.49 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 116.223 -0.444 . . . . 72.540000000000006 110.089 -177.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 58.5 mm-40 -103.49 80.1 1.77 Allowed 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 120.969 0.414 . . . . 75.099999999999994 110.205 -178.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 78.35 -106.16 2.27 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.797 -0.716 . . . . 54.420000000000002 112.428 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.859 ' HB3' ' HD3' ' A' ' 40' ' ' LYS . 6.9 m-20 -108.63 34.88 3.42 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.792 0.329 . . . . 73.109999999999999 110.831 -178.249 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.844 ' HE3' ' HB2' ' A' ' 75' ' ' TRP . 20.5 pttm -154.2 124.04 6.73 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.157 0.503 . . . . 75.129999999999995 111.46 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.446 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 62.3 m -82.02 105.89 13.49 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.624 -0.716 . . . . 74.340000000000003 109.36 174.036 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.599 HG12 HG13 ' A' ' 37' ' ' VAL . 61.1 mt -97.59 113.68 32.73 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-O 121.046 0.45 . . . . 54.420000000000002 110.687 -176.484 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.687 ' HB2' ' HB3' ' A' ' 36' ' ' LYS . 17.9 mt-30 -100.58 109.19 21.26 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.738 -0.664 . . . . 71.230000000000004 110.329 -179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.643 ' HB2' ' HB ' ' A' ' 14' ' ' THR . 27.1 mt-10 -91.69 104.25 16.74 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.064 -0.517 . . . . 74.329999999999998 110.853 -178.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.539 ' CE2' ' HB3' ' B' ' 151' ' ' ASP . 54.0 m-85 -73.26 106.73 5.22 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.174 -0.467 . . . . 74.230000000000004 110.753 179.463 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.454 ' HG2' ' HA ' ' A' ' 32' ' ' LEU . 59.9 mtt180 -129.24 133.7 47.64 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 109.552 -0.536 . . . . 74.230000000000004 109.552 177.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 6.4 p -104.34 -41.47 6.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-O 121.272 0.558 . . . . 55.439999999999998 110.721 -179.105 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 54.5 m-20 -140.94 56.83 1.56 Allowed 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.708 -0.678 . . . . 71.430000000000007 109.626 178.463 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 87.21 -32.67 4.04 Favored Glycine 0 N--CA 1.451 -0.322 0 CA-C-N 115.385 -0.825 . . . . 72.430000000000007 113.242 177.614 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 38.1 t80 -90.32 132.2 35.69 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.001 0.429 . . . . 74.409999999999997 110.654 -174.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.555 HD13 ' HB3' ' A' ' 25' ' ' GLU . 33.2 tp -77.92 114.3 16.64 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.395 -0.82 . . . . 63.43 110.599 179.306 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . 0.527 ' CZ ' ' HB3' ' A' ' 26' ' ' TYR . 35.4 p90 -106.34 -6.64 18.18 Favored 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 120.774 -0.37 . . . . 62.32 111.809 -178.376 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -171.84 142.91 1.57 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.842 0.353 . . . . 74.439999999999998 111.256 -178.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.459 HD12 HD23 ' A' ' 47' ' ' LEU . 61.9 mt -117.77 127.4 75.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 116.249 -0.432 . . . . 71.019999999999996 110.179 176.089 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.687 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.8 tttt -111.65 103.48 11.79 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 109.446 -0.576 . . . . 72.420000000000002 109.446 175.036 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.731 ' O ' ' HA ' ' A' ' 44' ' ' PRO . 3.7 t -96.77 134.52 34.13 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 N-CA-C 109.309 -0.626 . . . . 53.310000000000002 109.309 -178.551 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.649 HG22 ' HB3' ' A' ' 44' ' ' PRO . 21.7 t -114.22 74.21 2.8 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 109.317 -0.623 . . . . 75.299999999999997 109.317 170.759 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.465 ' HD3' HG12 ' A' ' 37' ' ' VAL . 42.4 Cg_endo -74.0 142.81 31.79 Favored 'Trans proline' 0 N--CA 1.457 -0.632 0 C-N-CA 122.039 1.826 . . . . 73.120000000000005 112.764 179.118 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.859 ' HD3' ' HB3' ' A' ' 20' ' ' ASP . 61.0 mtpt -64.39 -17.13 63.46 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.134 -0.939 . . . . 54.119999999999997 110.913 176.72 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 85.7 m-70 -128.99 88.3 2.69 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.662 -0.699 . . . . 74.540000000000006 110.215 -178.643 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.403 ' O ' ' HB2' ' A' ' 43' ' ' LYS . . . 135.23 -16.06 4.18 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.288 -0.958 . . . . 74.430000000000007 113.203 179.202 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.541 ' HB3' ' HD2' ' A' ' 44' ' ' PRO . 99.5 mttt 71.79 160.03 0.16 Allowed Pre-proline 0 N--CA 1.472 0.626 0 C-N-CA 122.755 0.422 . . . . 74.319999999999993 111.469 179.507 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.731 ' HA ' ' O ' ' A' ' 37' ' ' VAL . 26.2 Cg_endo -63.57 141.62 80.82 Favored 'Trans proline' 0 C--N 1.35 0.64 0 C-N-CA 122.491 2.127 . . . . 64.340000000000003 113.716 -176.48 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -145.71 155.23 42.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.717 -0.674 . . . . 75.129999999999995 110.212 177.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -99.72 132.91 44.76 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.305 -0.407 . . . . 74.120000000000005 110.994 178.144 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.459 HD23 HD12 ' A' ' 35' ' ' ILE . 40.1 tp -121.07 98.81 6.16 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.686 -0.688 . . . . 64.319999999999993 109.345 176.171 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 25.0 t -87.98 146.99 5.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 116.396 -0.366 . . . . 62.25 111.358 -172.205 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 10.0 tpt180 -81.23 122.92 28.01 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.848 -0.427 . . . . 73.319999999999993 109.848 177.659 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.426 ' HB3' ' OD1' ' A' ' 56' ' ' ASN . . . -74.86 161.94 29.1 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.208 -0.451 . . . . 73.230000000000004 110.862 -179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -66.78 145.54 55.4 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.135 0.493 . . . . 72.439999999999998 110.957 -177.6 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 88.67 -25.17 9.94 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.863 -0.608 . . . . 64.540000000000006 112.487 177.6 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 57.2 p 47.75 43.9 17.29 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.459 0.704 . . . . 74.420000000000002 112.058 -179.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -68.0 -33.0 73.79 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.453 0.644 . . . . 72.230000000000004 110.919 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 147.99 41.58 0.04 OUTLIER Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.582 -1.007 . . . . 61.409999999999997 110.582 -178.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . 0.426 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 11.5 p30 -140.52 152.65 45.73 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.18 0.514 . . . . 75.049999999999997 111.078 -172.805 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 36.3 m-85 -134.23 157.5 46.11 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.511 -0.768 . . . . 74.010000000000005 109.566 175.444 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.809 HD11 HD23 ' A' ' 66' ' ' LEU . 45.2 mm -115.23 108.07 24.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.253 0.549 . . . . 62.25 109.668 176.324 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.592 ' HG2' ' HB3' ' A' ' 61' ' ' ASP . 50.2 ttp180 -89.31 133.37 34.51 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 115.811 -0.631 . . . . 62.439999999999998 109.952 -177.057 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.1 p -58.21 -25.57 61.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.15 0.5 . . . . 74.219999999999999 111.168 178.644 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.592 ' HB3' ' HG2' ' A' ' 59' ' ' ARG . 0.6 OUTLIER -59.55 -39.13 83.0 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.508 -0.769 . . . . 75.230000000000004 111.379 174.275 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 21.5 tp60 -147.91 79.68 9.16 Favored Pre-proline 0 C--N 1.326 -0.454 0 N-CA-C 109.827 -0.434 . . . . 33.549999999999997 109.827 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -73.8 -8.0 20.81 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.381 2.054 . . . . 75.230000000000004 111.52 179.553 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.05 3.06 36.24 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.118 -0.946 . . . . 62.43 110.084 178.382 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 86.4 tttt -139.37 140.06 37.37 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.043 -0.526 . . . . 72.310000000000002 111.022 -174.291 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.809 HD23 HD11 ' A' ' 58' ' ' ILE . 38.1 mt -82.08 113.1 19.72 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 108.581 -0.896 . . . . 75.030000000000001 108.581 171.807 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.508 HG13 ' HB2' ' A' ' 59' ' ' ARG . 50.1 mm -65.34 122.76 81.78 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 116.271 -0.422 . . . . 73.109999999999999 110.964 -175.566 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.496 ' O ' HG23 ' A' ' 72' ' ' ILE . 72.8 Cg_endo -73.27 175.12 11.0 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 123.106 2.537 . . . . 72.099999999999994 113.014 -177.695 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . 0.726 ' HA ' HG12 ' A' ' 72' ' ' ILE . 6.7 tt0 -74.65 -29.5 61.28 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.693 -0.685 . . . . 53.020000000000003 112.323 -168.07 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 33.6 p90 -74.45 -16.23 60.87 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.598 -0.441 . . . . 74.510000000000005 110.23 178.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.476 ' HA ' ' HB2' ' A' ' 74' ' ' SER . 8.3 mm-40 -100.0 -29.29 12.63 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.727 -0.67 . . . . 72.400000000000006 111.615 -178.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.726 HG12 ' HA ' ' A' ' 69' ' ' GLN . 42.0 pt -68.22 -29.44 44.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.148 0.499 . . . . 73.140000000000001 110.595 177.188 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 48.5 m-85 -118.82 38.69 3.71 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.735 -0.666 . . . . 70.200000000000003 109.267 174.27 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.476 ' HB2' ' HA ' ' A' ' 71' ' ' GLU . 6.1 t -62.49 -36.38 82.33 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.35 -0.841 . . . . 74.239999999999995 110.461 -178.758 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . 0.844 ' HB2' ' HE3' ' A' ' 21' ' ' LYS . 6.1 p-90 . . . . . 0 C--N 1.326 -0.443 0 CA-C-N 115.93 -0.577 . . . . 65.319999999999993 110.948 177.289 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.282 0 N-CA-C 112.22 -0.352 . . . . 64.049999999999997 112.22 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -132.14 157.22 44.82 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.717 0.294 . . . . 74.230000000000004 110.776 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -87.41 37.58 0.79 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.081 0.467 . . . . 74.430000000000007 110.968 -178.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -97.16 151.24 20.0 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.77 -0.65 . . . . 70.430000000000007 109.977 -179.453 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -144.98 48.94 1.29 Allowed 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.246 0.546 . . . . 51.119999999999997 109.968 -179.47 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -65.94 127.01 92.85 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 115.653 -0.703 . . . . 70.239999999999995 111.877 -177.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -91.41 -178.84 1.27 Allowed 'Trans proline' 0 N--CA 1.46 -0.487 0 C-N-CA 123.237 2.624 . . . . 63.229999999999997 112.355 177.493 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 35.0 m -81.77 83.43 7.14 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.605 0.717 . . . . 74.439999999999998 109.128 174.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . 0.403 ' O ' ' HD3' ' B' ' 111' ' ' PRO . . . 140.07 78.08 0.06 OUTLIER Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 109.965 -1.254 . . . . 42.130000000000003 109.965 -172.108 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 47.4 mt-10 -109.72 94.77 17.71 Favored Pre-proline 0 C--N 1.322 -0.6 0 N-CA-C 109.693 -0.484 . . . . 64.319999999999993 109.693 -172.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.57 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 54.9 Cg_endo -77.36 79.01 3.29 Favored 'Trans proline' 0 N--CA 1.443 -1.498 0 C-N-CA 121.538 1.492 . . . . 72.230000000000004 111.031 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -100.24 156.37 17.26 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 114.747 -1.115 . . . . 74.400000000000006 109.184 179.518 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.716 HG21 ' HB3' ' B' ' 124' ' ' GLN . 8.8 p -112.94 127.76 70.02 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.812 0 CA-C-O 121.72 0.771 . . . . 74.109999999999999 111.738 -175.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . 0.54 ' HB ' ' HB2' ' B' ' 125' ' ' GLU . 24.3 m -92.01 106.94 18.85 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.022 -0.99 . . . . 75.129999999999995 109.529 175.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 52.8 mt -90.8 115.5 30.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 120.699 0.285 . . . . 54.340000000000003 111.274 -175.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 41.4 mtm180 -115.39 165.81 12.56 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.178 -0.465 . . . . 72.140000000000001 110.712 175.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 96.8 mt-30 -129.44 108.79 10.55 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 116.197 -0.456 . . . . 74.299999999999997 110.18 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . 0.463 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 45.8 mm-40 -108.4 89.88 3.13 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.551 -0.536 . . . . 55.409999999999997 109.551 -178.441 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 83.68 -102.95 2.5 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 110.929 -0.869 . . . . 72.129999999999995 110.929 -172.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.58 ' HB3' ' HD3' ' B' ' 140' ' ' LYS . 30.8 m-20 -117.73 -18.17 9.69 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.756 0.312 . . . . 74.230000000000004 110.784 175.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.463 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 23.4 pttm -78.36 126.73 31.19 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.257 0.551 . . . . 71.109999999999999 110.861 -175.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . 0.585 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 22.8 m -84.72 106.34 16.19 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.502 -0.772 . . . . 72.430000000000007 109.468 178.085 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . 0.449 HG12 HG13 ' B' ' 137' ' ' VAL . 28.4 mt -101.42 110.37 28.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-O 121.374 0.607 . . . . 74.319999999999993 110.631 -174.685 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.716 ' HB3' HG21 ' B' ' 113' ' ' VAL . 19.9 mt-30 -102.29 111.54 23.87 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.354 -0.839 . . . . 73.150000000000006 111.144 -175.511 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . 0.541 ' HB3' HD13 ' B' ' 132' ' ' LEU . 43.0 mt-10 -89.79 107.84 19.34 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.13 -0.486 . . . . 61.340000000000003 110.948 179.764 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . 0.457 ' HE1' ' HB2' ' B' ' 136' ' ' LYS . 58.3 m-85 -84.44 110.9 19.0 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.767 0.318 . . . . 74.299999999999997 110.338 177.553 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . . . . . . . . . 69.6 mtt180 -123.42 116.13 22.73 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.844 0.354 . . . . 72.420000000000002 110.31 -178.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.57 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 2.4 p -82.83 -45.71 19.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-N 116.065 -0.516 . . . . 61.530000000000001 111.904 -177.434 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -158.99 74.08 0.63 Allowed 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 120.742 -0.383 . . . . 74.239999999999995 110.319 -174.243 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 64.2 23.81 68.36 Favored Glycine 0 C--N 1.33 0.232 0 C-N-CA 121.028 -0.606 . . . . 41.240000000000002 112.065 -178.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . . . . . . . . . 90.3 t80 -145.91 124.93 12.78 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 109.876 -0.416 . . . . 70.040000000000006 109.876 -179.236 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.541 HD13 ' HB3' ' B' ' 125' ' ' GLU . 50.0 tp -83.06 113.01 20.31 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.791 -0.64 . . . . 72.099999999999994 109.569 175.781 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -103.12 -13.73 16.69 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.32 -0.552 . . . . 62.0 111.728 -175.793 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -164.94 139.81 5.25 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.087 0.47 . . . . 74.5 111.397 -175.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.405 ' CG1' HD21 ' B' ' 132' ' ' LEU . 63.6 mt -118.02 117.85 56.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.693 -0.685 . . . . 63.539999999999999 109.846 175.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.618 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 81.3 tttt -93.62 103.92 16.06 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.184 -0.673 . . . . 63.329999999999998 109.184 175.481 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.65 HG12 ' HD3' ' B' ' 139' ' ' PRO . 3.5 t -89.12 126.51 42.12 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 N-CA-C 108.785 -0.82 . . . . 62.43 108.785 177.299 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.585 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 21.5 t -113.67 74.47 2.38 Favored Pre-proline 0 C--N 1.319 -0.733 0 N-CA-C 109.543 -0.54 . . . . 61.420000000000002 109.543 171.647 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.65 ' HD3' HG12 ' B' ' 137' ' ' VAL . 43.3 Cg_endo -77.17 130.01 10.85 Favored 'Trans proline' 0 N--CA 1.454 -0.841 0 C-N-CA 122.105 1.87 . . . . 75.0 111.892 175.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . 0.58 ' HD3' ' HB3' ' B' ' 120' ' ' ASP . 59.2 mtpt -58.36 -38.58 77.53 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.661 -0.699 . . . . 62.140000000000001 109.776 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 70.3 m-70 -111.81 90.32 3.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.282 -0.872 . . . . 71.019999999999996 109.385 175.163 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . 0.418 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 151.98 -22.71 0.89 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.54 -0.838 . . . . 53.109999999999999 112.704 -178.587 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . 0.418 ' HB2' ' O ' ' B' ' 142' ' ' GLY . 95.2 mttt 76.48 144.65 0.1 Allowed Pre-proline 0 N--CA 1.472 0.638 0 C-N-CA 123.419 0.688 . . . . 75.340000000000003 111.258 179.177 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.613 ' HA ' ' O ' ' B' ' 137' ' ' VAL . 55.5 Cg_endo -70.57 139.05 36.56 Favored 'Trans proline' 0 N--CA 1.463 -0.285 0 C-N-CA 122.865 2.376 . . . . 74.430000000000007 112.983 -177.059 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 45.4 p90 -152.39 160.03 43.34 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.895 -0.593 . . . . 75.319999999999993 110.322 179.114 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.666 ' HB2' ' HB3' ' B' ' 160' ' ' SER . 96.5 m-85 -100.59 133.29 45.26 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.192 -0.458 . . . . 71.140000000000001 109.959 177.786 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.502 ' HG ' ' HB3' ' B' ' 157' ' ' PHE . 14.1 tp -115.46 100.84 8.37 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.386 -0.598 . . . . 72.200000000000003 109.386 175.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 49.1 t -92.55 140.56 16.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 116.061 -0.518 . . . . 72.519999999999996 111.347 -173.185 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -80.37 116.37 20.4 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.549 -0.296 . . . . 63.530000000000001 110.261 177.376 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.56 157.55 32.04 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-N 116.218 -0.447 . . . . 71.319999999999993 111.201 -179.423 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . 0.539 ' HB3' ' CE2' ' A' ' 26' ' ' TYR . 3.8 p-10 -57.45 143.48 40.28 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.96 -0.564 . . . . 74.329999999999998 110.855 -179.04 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 88.43 -33.73 4.03 Favored Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 120.773 -0.727 . . . . 75.109999999999999 111.373 -175.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 50.8 m 57.3 33.17 22.91 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 123.008 0.523 . . . . 54.119999999999997 111.919 177.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -53.81 -68.77 0.15 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 115.712 -0.676 . . . . 72.409999999999997 111.145 -178.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . -173.43 30.58 0.1 OUTLIER Glycine 0 CA--C 1.505 -0.579 0 C-N-CA 120.338 -0.934 . . . . 73.030000000000001 112.456 178.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . . . . . . . . . 79.5 m-20 -133.32 145.83 50.78 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.784 0.326 . . . . 52.340000000000003 110.799 -177.166 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . 0.502 ' HB3' ' HG ' ' B' ' 147' ' ' LEU . 32.6 m-85 -118.34 157.03 27.87 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.875 -0.602 . . . . 73.329999999999998 110.034 176.201 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.1 mm -113.91 122.66 68.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 109.676 -0.49 . . . . 74.430000000000007 109.676 178.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . . . . . . . . . 44.8 ttp180 -86.36 135.92 33.33 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 110.028 -0.36 . . . . 73.239999999999995 110.028 -178.386 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . 0.666 ' HB3' ' HB2' ' B' ' 146' ' ' PHE . 23.5 p -56.97 -34.78 68.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.064 0.459 . . . . 65.219999999999999 111.118 179.377 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -69.39 -37.93 77.75 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.448 -0.796 . . . . 70.310000000000002 111.346 177.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . . . . . . . . . 8.6 tp60 -134.03 83.6 45.35 Favored Pre-proline 0 C--N 1.324 -0.527 0 C-N-CA 121.04 -0.264 . . . . 74.510000000000005 110.715 -176.297 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -77.59 0.27 9.96 Favored 'Trans proline' 0 C--O 1.234 0.282 0 C-N-CA 122.577 2.184 . . . . 60.130000000000003 111.616 177.15 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -79.19 -33.31 43.99 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.178 -0.919 . . . . 43.130000000000003 110.768 -179.78 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 80.4 tttt -116.64 138.13 51.67 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.857 -0.61 . . . . 70.340000000000003 111.173 -172.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . . . . . . . . . 5.5 mp -85.27 121.31 27.83 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 108.795 -0.817 . . . . 75.010000000000005 108.795 175.083 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 50.3 mm -71.24 117.7 59.16 Favored Pre-proline 0 C--N 1.323 -0.552 0 CA-C-N 116.129 -0.487 . . . . 74.420000000000002 109.778 -177.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.521 ' O ' HG23 ' B' ' 172' ' ' ILE . 59.6 Cg_endo -70.39 173.61 11.28 Favored 'Trans proline' 0 N--CA 1.462 -0.378 0 C-N-CA 122.843 2.362 . . . . 73.519999999999996 113.008 -175.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . 0.449 ' HA ' HG12 ' B' ' 172' ' ' ILE . 5.4 tt0 -74.95 -17.66 60.51 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.524 -0.762 . . . . 65.349999999999994 112.224 -168.156 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 42.4 p90 -90.24 -10.1 45.55 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.122 0.487 . . . . 74.310000000000002 110.013 176.374 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.579 ' O ' ' HB2' ' B' ' 174' ' ' SER . 19.6 mm-40 -109.42 -12.63 14.7 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.736 -0.665 . . . . 70.439999999999998 111.708 -178.282 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.521 HG23 ' O ' ' B' ' 168' ' ' PRO . 26.1 pt -72.7 -12.35 15.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 121.254 0.549 . . . . 71.420000000000002 110.435 176.177 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 49.9 m-85 -115.9 32.76 5.89 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.442 -0.799 . . . . 62.140000000000001 109.148 175.094 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . 0.579 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 3.0 t -66.97 -25.22 66.22 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 114.915 -1.039 . . . . 72.510000000000005 110.575 -177.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 7.1 p-90 . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.295 -0.86 . . . . 75.230000000000004 110.788 -179.936 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.683 0 N-CA-C 111.987 -0.445 . . . . 64.019999999999996 111.987 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.9 112.89 20.97 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 110.036 -0.357 . . . . 73.120000000000005 110.036 179.08 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 60.97 79.85 0.24 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.679 -0.691 . . . . 75.239999999999995 111.019 -177.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -104.06 -162.68 0.91 Allowed 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 108.615 -0.883 . . . . 70.129999999999995 108.615 178.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -138.57 -30.07 0.78 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 121.039 0.447 . . . . 73.120000000000005 111.031 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -171.0 97.12 0.42 Allowed Pre-proline 0 C--N 1.316 -0.869 0 CA-C-N 115.416 -0.811 . . . . 32.310000000000002 111.203 -177.081 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -89.2 97.63 0.34 Allowed 'Trans proline' 0 N--CA 1.449 -1.115 0 C-N-CA 122.812 2.341 . . . . 62.310000000000002 111.361 175.285 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.7 p -84.17 94.2 8.33 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.269 0.557 . . . . 72.430000000000007 110.513 178.11 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 136.63 106.28 0.8 Allowed Glycine 0 N--CA 1.446 -0.696 0 N-CA-C 111.12 -0.792 . . . . 53.329999999999998 111.12 -174.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -124.3 97.29 40.29 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-O 121.357 0.599 . . . . 44.219999999999999 110.113 -175.301 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.599 ' HA ' ' O ' ' A' ' 27' ' ' ARG . 9.9 Cg_endo -85.17 93.97 0.66 Allowed 'Trans proline' 0 N--CA 1.444 -1.421 0 C-N-CA 122.867 2.378 . . . . 71.239999999999995 111.817 -178.102 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -116.72 153.96 31.45 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.952 -1.022 . . . . 61.140000000000001 109.373 -179.276 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.503 ' CG2' ' HB3' ' A' ' 24' ' ' GLN . 13.4 p -119.42 130.35 74.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-O 121.497 0.665 . . . . 74.420000000000002 111.639 -177.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.528 ' O ' ' HA ' ' A' ' 24' ' ' GLN . 9.3 m -90.68 111.85 23.36 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.369 -0.832 . . . . 71.310000000000002 109.693 176.372 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.429 HG12 ' HG2' ' A' ' 24' ' ' GLN . 60.9 mt -106.74 107.33 22.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.791 0.329 . . . . 63.539999999999999 110.865 -176.23 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -125.51 166.02 17.41 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.178 -0.465 . . . . 74.209999999999994 110.594 178.252 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 74.8 mt-30 -118.52 108.63 15.22 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.768 0.318 . . . . 72.530000000000001 110.761 -179.322 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.453 ' O ' ' HG2' ' A' ' 21' ' ' LYS . 25.7 mm-40 -108.42 99.54 8.92 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.162 -0.472 . . . . 72.439999999999998 109.97 178.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 71.09 -114.27 5.15 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.786 -0.721 . . . . 42.399999999999999 112.298 -179.611 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.409 ' HB3' ' HD2' ' A' ' 40' ' ' LYS . 13.6 m-20 -106.43 13.33 28.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.771 0.32 . . . . 61.32 110.476 -178.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.453 ' HG2' ' O ' ' A' ' 18' ' ' GLU . 14.2 ptmt -133.29 123.18 25.03 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.464 0.649 . . . . 74.209999999999994 111.949 -176.049 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.441 ' HB ' ' HB ' ' A' ' 38' ' ' VAL . 25.6 m -83.07 115.31 21.81 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.36 -0.836 . . . . 75.25 109.675 176.517 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 68.3 mt -100.77 120.43 50.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 120.716 0.293 . . . . 53.130000000000003 110.65 -175.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLN . . . . . 0.528 ' HA ' ' O ' ' A' ' 14' ' ' THR . 16.7 mt-30 -112.05 111.77 22.92 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.102 -0.499 . . . . 54.530000000000001 110.723 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -90.08 109.59 20.63 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.222 -0.444 . . . . 75.239999999999995 110.312 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 73.4 m-85 -87.68 110.55 20.5 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.763 0.315 . . . . 74.409999999999997 110.374 177.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ARG . . . . . 0.599 ' O ' ' HA ' ' A' ' 11' ' ' PRO . 65.5 mtt180 -116.91 139.91 50.08 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 109.508 -0.553 . . . . 71.349999999999994 109.508 178.779 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.581 ' HA ' ' HA ' ' A' ' 11' ' ' PRO . 14.2 p -112.83 -11.96 11.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.509 0.671 . . . . 54.130000000000003 111.002 -177.641 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -166.77 38.4 0.04 OUTLIER 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 108.757 -0.831 . . . . 75.420000000000002 108.757 -177.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . 85.17 -28.73 4.53 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.308 -0.86 . . . . 72.219999999999999 111.824 -174.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.418 ' CD2' HG21 ' B' ' 128' ' ' VAL . 15.4 t80 -88.24 125.85 34.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.106 0.479 . . . . 71.420000000000002 110.29 -177.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.662 HD11 HG13 ' A' ' 35' ' ' ILE . 3.3 tm? -68.24 134.27 50.15 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.201 -0.909 . . . . 74.209999999999994 110.141 178.74 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' TYR . . . . . 0.504 ' CE1' ' HB ' ' A' ' 28' ' ' VAL . 53.3 p90 -128.55 -24.56 3.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.594 -0.276 . . . . 70.219999999999999 111.584 176.275 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -149.54 139.82 22.26 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.815 0.34 . . . . 33.32 110.895 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.662 HG13 HD11 ' A' ' 32' ' ' LEU . 78.4 mt -122.72 122.35 65.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 116.17 -0.468 . . . . 70.439999999999998 110.239 178.07 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.512 ' HB3' ' HB2' ' A' ' 24' ' ' GLN . 85.4 tttt -101.18 102.05 12.89 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.406 -0.591 . . . . 70.140000000000001 109.406 174.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.572 ' O ' ' HD3' ' A' ' 39' ' ' PRO . 1.7 p -99.39 124.44 52.71 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.98 0 CA-C-O 121.163 0.506 . . . . 64.349999999999994 110.005 176.485 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.633 HG22 ' HB3' ' A' ' 44' ' ' PRO . 40.0 t -106.91 85.01 1.72 Allowed Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 115.096 -0.956 . . . . 71.120000000000005 109.873 179.199 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.572 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 85.4 Cg_endo -91.08 144.01 3.33 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 122.762 2.308 . . . . 64.340000000000003 112.41 179.206 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . 0.409 ' HD2' ' HB3' ' A' ' 20' ' ' ASP . 97.0 mttt -60.46 -27.02 67.21 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.186 0.517 . . . . 71.510000000000005 110.128 173.784 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 6.5 m-70 -118.99 85.4 2.36 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.568 -0.742 . . . . 74.430000000000007 109.947 -174.203 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 139.15 -18.76 3.1 Favored Glycine 0 N--CA 1.449 -0.444 0 CA-C-N 115.876 -0.602 . . . . 71.010000000000005 111.982 -176.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 42.5 mtpt 69.4 150.86 0.13 Allowed Pre-proline 0 N--CA 1.469 0.48 0 C-N-CA 123.727 0.811 . . . . 61.32 112.235 -179.035 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.633 ' HB3' HG22 ' A' ' 38' ' ' VAL . 16.0 Cg_endo -59.7 123.64 13.71 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.878 2.385 . . . . 74.150000000000006 112.474 -179.647 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' TYR . . . . . 0.523 ' CE1' HG13 ' A' ' 37' ' ' VAL . 16.4 p90 -142.28 151.18 41.77 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.865 -0.607 . . . . 74.140000000000001 110.258 179.551 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -90.74 125.0 35.55 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.17 -0.468 . . . . 72.299999999999997 109.981 176.085 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.406 HD11 HG13 ' A' ' 67' ' ' ILE . 18.9 tp -103.34 100.91 10.81 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 108.42 -0.956 . . . . 73.400000000000006 108.42 174.502 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 40.3 t -90.75 132.27 35.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.979 -0.555 . . . . 70.120000000000005 111.029 -173.675 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -86.04 121.16 28.26 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.069 -0.715 . . . . 73.519999999999996 109.069 178.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -76.11 174.78 9.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.924 0.392 . . . . 44.020000000000003 111.574 -173.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.585 ' HB3' ' CE2' ' B' ' 126' ' ' TYR . 7.0 p-10 -68.94 135.66 51.34 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.301 -0.409 . . . . 75.109999999999999 110.405 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.439 ' C ' ' H ' ' A' ' 54' ' ' ASP . . . 94.54 146.05 19.66 Favored Glycine 0 N--CA 1.433 -1.562 0 C-N-CA 120.422 -0.895 . . . . 45.399999999999999 112.042 179.067 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . . . . . . . . . 27.8 t -80.57 28.55 0.33 Allowed 'General case' 0 C--N 1.312 -1.05 0 CA-C-O 121.436 0.636 . . . . 71.230000000000004 109.866 175.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.439 ' H ' ' C ' ' A' ' 52' ' ' GLY . 30.0 t70 -63.89 -32.43 73.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.159 -0.928 . . . . 64.150000000000006 111.26 -177.629 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.86 37.49 4.42 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.41 -0.9 . . . . 63.32 113.138 177.426 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -126.06 139.53 53.33 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.05 0.452 . . . . 74.109999999999999 110.052 176.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -117.47 155.16 30.18 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.711 -0.677 . . . . 62.240000000000002 109.864 179.207 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 44.9 mm -113.86 116.59 53.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.137 -0.483 . . . . 64.120000000000005 109.7 177.341 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . 0.519 ' HB2' HD11 ' A' ' 67' ' ' ILE . 55.5 ttt180 -83.82 124.06 30.54 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.121 -0.49 . . . . 75.239999999999995 109.846 -178.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 30.9 t -63.71 -8.3 9.97 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.342 -0.39 . . . . 61.130000000000003 111.615 -177.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.487 ' H ' ' HG2' ' A' ' 59' ' ' ARG . 15.6 t70 -70.03 -36.0 74.72 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.231 0.538 . . . . 71.530000000000001 109.701 175.578 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -159.08 88.87 2.1 Favored Pre-proline 0 N--CA 1.451 -0.383 0 CA-C-N 115.515 -0.766 . . . . 54.299999999999997 109.589 -177.492 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.453 ' HG3' ' OG ' ' B' ' 160' ' ' SER . 35.7 Cg_exo -58.98 -16.42 32.36 Favored 'Trans proline' 0 C--N 1.344 0.305 0 C-N-CA 123.335 2.69 . . . . 64.420000000000002 112.699 178.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -66.62 -22.43 66.12 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.899 -0.591 . . . . 70.349999999999994 111.255 179.454 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -116.16 141.12 48.56 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 121.404 0.621 . . . . 53.399999999999999 111.892 -177.077 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 5.7 mp -88.54 141.43 28.53 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.689 -1.142 . . . . 71.329999999999998 109.306 174.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ILE . . . . . 0.755 HG23 ' HB3' ' A' ' 71' ' ' GLU . 25.2 mm -83.41 121.87 76.84 Favored Pre-proline 0 C--N 1.317 -0.818 0 CA-C-N 116.167 -0.47 . . . . 74.439999999999998 111.709 -176.77 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.51 ' O ' HG23 ' A' ' 72' ' ' ILE . 68.2 Cg_endo -74.05 179.45 5.74 Favored 'Trans proline' 0 C--O 1.233 0.264 0 C-N-CA 123.211 2.607 . . . . 75.099999999999994 112.488 178.631 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' GLN . . . . . 0.719 ' HA ' HG12 ' A' ' 72' ' ' ILE . 4.2 tt0 -71.99 -33.11 67.85 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.171 -0.468 . . . . 75.409999999999997 111.701 -168.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' TRP . . . . . . . . . . . . . 7.2 p90 -69.23 -16.97 63.72 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.411 -0.516 . . . . 75.230000000000004 110.799 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.755 ' HB3' HG23 ' A' ' 67' ' ' ILE . 2.6 mm-40 -103.44 -20.22 14.13 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.329 -0.396 . . . . 63.219999999999999 111.233 -178.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.719 HG12 ' HA ' ' A' ' 69' ' ' GLN . 42.6 pt -75.61 -24.17 16.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-O 121.162 0.506 . . . . 72.099999999999994 109.922 174.752 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -103.69 39.21 1.65 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.467 -0.788 . . . . 53.240000000000002 109.371 173.353 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.506 ' HB2' ' O ' ' A' ' 71' ' ' GLU . 11.5 t -71.17 -20.03 62.34 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.293 -0.867 . . . . 64.120000000000005 110.94 -177.141 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' TRP . . . . . 0.575 ' HZ2' HD13 ' A' ' 35' ' ' ILE . 69.6 p-90 . . . . . 0 C--O 1.235 0.312 0 CA-C-O 120.861 0.362 . . . . 73.450000000000003 110.835 177.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 101' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.508 0 N-CA-C 111.854 -0.498 . . . . 74.150000000000006 111.854 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 102' ' ' ALA . . . . . . . . . . . . . . . -84.59 159.42 20.64 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 110.544 -0.169 . . . . 73.109999999999999 110.544 -179.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 103' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 64.94 89.16 0.1 Allowed 'General case' 0 C--O 1.234 0.263 0 O-C-N 123.859 0.725 . . . . 75.420000000000002 111.309 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 104' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -123.02 169.53 11.08 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.448 -0.796 . . . . 62.240000000000002 109.899 178.364 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 105' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -97.26 -47.48 5.72 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.827 0.822 . . . . 73.540000000000006 109.844 178.198 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 106' ' ' ALA . . . . . . . . . . . . . . . -161.35 144.1 9.28 Favored Pre-proline 0 C--N 1.309 -1.155 0 CA-C-N 114.125 -1.398 . . . . 73.310000000000002 109.609 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -70.97 95.74 0.67 Allowed 'Trans proline' 0 N--CA 1.463 -0.295 0 C-N-CA 122.147 1.898 . . . . 52.539999999999999 111.892 176.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 108' ' ' SER . . . . . . . . . . . . . 8.6 p -75.57 100.58 4.62 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.26 0.552 . . . . 74.430000000000007 110.594 179.06 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 92.25 116.29 2.25 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 111.063 -0.815 . . . . 61.210000000000001 111.063 -174.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -119.87 93.33 47.62 Favored Pre-proline 0 C--N 1.319 -0.739 0 CA-C-O 121.14 0.495 . . . . 71.409999999999997 110.58 -175.137 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 111' ' ' PRO . . . . . 0.684 ' HA ' ' HA ' ' B' ' 128' ' ' VAL . 55.7 Cg_endo -77.44 68.45 7.52 Favored 'Trans proline' 0 N--CA 1.449 -1.115 0 C-N-CA 121.943 1.762 . . . . 74.319999999999993 110.891 176.086 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 112' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -91.05 157.46 17.24 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 114.411 -1.268 . . . . 53.240000000000002 109.553 -178.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 113' ' ' VAL . . . . . 0.679 ' CG2' ' HB3' ' B' ' 124' ' ' GLN . 12.4 p -122.78 127.25 74.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-O 121.477 0.656 . . . . 73.25 111.19 -178.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 114' ' ' THR . . . . . 0.442 ' O ' ' HA ' ' B' ' 124' ' ' GLN . 13.7 m -84.61 111.26 19.38 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.435 -0.802 . . . . 72.340000000000003 109.439 178.749 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . . . . . . . . . 67.6 mt -99.09 116.45 42.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 120.955 0.407 . . . . 75.140000000000001 111.527 -172.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 116' ' ' ARG . . . . . . . . . . . . . 45.7 mtt180 -126.87 170.64 12.01 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.947 -0.57 . . . . 74.209999999999994 110.606 175.501 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 117' ' ' GLN . . . . . . . . . . . . . 69.7 mt-30 -132.54 98.23 4.3 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.18 0.514 . . . . 61.020000000000003 110.204 176.536 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 118' ' ' GLU . . . . . 0.591 ' O ' ' HG2' ' B' ' 121' ' ' LYS . 20.9 mm-40 -96.66 100.8 12.34 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.657 -0.701 . . . . 53.140000000000001 109.317 -178.433 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 119' ' ' GLY . . . . . . . . . . . . . . . 73.37 -117.89 6.03 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.434 -0.889 . . . . 74.420000000000002 111.36 -175.44 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 120' ' ' ASP . . . . . 0.507 ' O ' ' HG3' ' B' ' 140' ' ' LYS . 5.2 m-20 -104.26 11.58 34.7 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.94 0.37 . . . . 71.040000000000006 110.493 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 121' ' ' LYS . . . . . 0.591 ' HG2' ' O ' ' B' ' 118' ' ' GLU . 10.1 ptmt -124.96 121.59 34.89 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.567 0.699 . . . . 62.240000000000002 111.73 -175.456 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 122' ' ' THR . . . . . 0.842 ' HB ' ' HB ' ' B' ' 138' ' ' VAL . 35.9 m -76.96 104.15 7.29 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.243 -0.89 . . . . 63.100000000000001 109.798 175.387 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 123' ' ' ILE . . . . . . . . . . . . . 46.6 mt -94.01 119.89 42.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 121.218 0.532 . . . . 72.129999999999995 110.301 -179.311 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 124' ' ' GLN . . . . . 0.679 ' HB3' ' CG2' ' B' ' 113' ' ' VAL . 25.4 mt-30 -115.23 113.06 23.4 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.322 -0.854 . . . . 63.399999999999999 110.914 -177.043 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -88.16 111.98 22.21 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.173 -0.467 . . . . 72.129999999999995 110.678 -179.505 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 126' ' ' TYR . . . . . 0.585 ' CE2' ' HB3' ' A' ' 51' ' ' ASP . 29.1 m-85 -88.65 112.73 23.44 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.938 0.399 . . . . 73.430000000000007 111.07 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 127' ' ' ARG . . . . . 0.519 ' HG2' ' HA ' ' B' ' 132' ' ' LEU . 89.6 mtm180 -132.22 128.67 38.42 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.071 -0.513 . . . . 73.040000000000006 110.109 -179.218 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 128' ' ' VAL . . . . . 0.684 ' HA ' ' HA ' ' B' ' 111' ' ' PRO . 9.7 p -99.86 -27.84 3.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.071 0.462 . . . . 61.509999999999998 111.862 -174.367 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 129' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -152.74 47.61 0.72 Allowed 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.574 -0.528 . . . . 71.430000000000007 109.574 -179.032 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.19 -21.33 12.69 Favored Glycine 0 CA--C 1.518 0.235 0 CA-C-N 115.567 -0.742 . . . . 63.520000000000003 112.731 -178.447 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 131' ' ' PHE . . . . . 0.46 ' HD2' HG21 ' A' ' 28' ' ' VAL . 26.5 t80 -98.22 130.12 44.95 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.712 0.291 . . . . 72.409999999999997 110.374 -176.584 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 132' ' ' LEU . . . . . 0.519 ' HA ' ' HG2' ' B' ' 127' ' ' ARG . 3.1 tm? -71.0 132.55 45.32 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.812 -0.631 . . . . 74.5 109.967 179.214 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 133' ' ' TYR . . . . . 0.407 ' N ' HD13 ' B' ' 132' ' ' LEU . 46.1 p90 -129.32 -15.55 4.1 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.582 -0.447 . . . . 75.409999999999997 112.04 177.715 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 134' ' ' ALA . . . . . . . . . . . . . . . -160.31 149.97 17.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.719 0.295 . . . . 60.299999999999997 111.079 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 135' ' ' ILE . . . . . 0.415 HG13 HD11 ' B' ' 132' ' ' LEU . 67.5 mt -130.69 125.42 58.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 N-CA-C 109.963 -0.384 . . . . 62.200000000000003 109.963 176.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 136' ' ' LYS . . . . . 0.627 ' HB3' ' HB2' ' B' ' 124' ' ' GLN . 85.5 tttt -104.11 114.55 28.87 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.107 -0.331 . . . . 72.420000000000002 110.107 179.405 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 137' ' ' VAL . . . . . 0.589 HG12 ' HD3' ' B' ' 139' ' ' PRO . 3.4 t -96.49 130.94 44.43 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 109.126 -0.694 . . . . 55.100000000000001 109.126 175.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 138' ' ' VAL . . . . . 0.842 ' HB ' ' HB ' ' B' ' 122' ' ' THR . 24.1 t -115.65 74.65 4.77 Favored Pre-proline 0 C--N 1.318 -0.798 0 N-CA-C 109.875 -0.417 . . . . 62.530000000000001 109.875 171.723 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 139' ' ' PRO . . . . . 0.589 ' HD3' HG12 ' B' ' 137' ' ' VAL . 37.1 Cg_endo -74.22 131.89 15.84 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.186 1.924 . . . . 54.009999999999998 112.276 176.445 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 140' ' ' LYS . . . . . 0.507 ' HG3' ' O ' ' B' ' 120' ' ' ASP . 59.2 mtpt -60.63 -19.49 58.18 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.399 -0.818 . . . . 72.549999999999997 111.111 178.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 141' ' ' HIS . . . . . . . . . . . . . 80.8 m-70 -130.72 105.4 7.78 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.703 -0.68 . . . . 63.140000000000001 109.379 178.492 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 142' ' ' GLY . . . . . 0.425 ' O ' ' HB2' ' B' ' 143' ' ' LYS . . . 125.36 -11.02 7.65 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.75 -0.738 . . . . 61.140000000000001 112.432 -177.142 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 143' ' ' LYS . . . . . 0.463 ' HB3' ' HE2' ' B' ' 143' ' ' LYS . 45.7 mtpt 72.77 150.84 0.14 Allowed Pre-proline 0 N--CA 1.468 0.433 0 C-N-CA 123.603 0.761 . . . . 74.319999999999993 112.353 179.105 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 144' ' ' PRO . . . . . 0.58 ' HB3' HG13 ' B' ' 138' ' ' VAL . 44.3 Cg_endo -68.76 137.75 39.34 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.795 2.33 . . . . 60.310000000000002 112.552 178.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 145' ' ' TYR . . . . . . . . . . . . . 47.2 p90 -143.75 147.99 34.99 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 120.954 0.407 . . . . 73.299999999999997 110.638 179.114 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 146' ' ' PHE . . . . . 0.408 ' HB2' ' HB2' ' B' ' 160' ' ' SER . 69.6 m-85 -90.47 129.27 36.66 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.88 -0.6 . . . . 74.439999999999998 110.032 175.506 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 147' ' ' LEU . . . . . 0.451 ' HG ' ' CD2' ' B' ' 157' ' ' PHE . 25.5 tp -108.59 93.27 4.43 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.621 -0.881 . . . . 74.409999999999997 108.621 173.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 148' ' ' VAL . . . . . . . . . . . . . 40.3 t -83.53 135.91 23.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.602 -0.727 . . . . 74.230000000000004 110.499 -174.395 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 149' ' ' ARG . . . . . . . . . . . . . 3.0 tmm_? -89.25 120.83 30.96 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 108.573 -0.899 . . . . 72.310000000000002 108.573 178.616 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 150' ' ' ALA . . . . . . . . . . . . . . . -76.16 -173.94 2.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.978 0.418 . . . . 62.340000000000003 111.655 -173.123 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 151' ' ' ASP . . . . . . . . . . . . . 9.1 p-10 -75.33 146.26 41.09 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.369 -0.378 . . . . 71.400000000000006 110.288 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . 91.63 136.8 7.26 Favored Glycine 0 N--CA 1.44 -1.076 0 C-N-CA 120.571 -0.823 . . . . 50.310000000000002 111.823 -177.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 153' ' ' SER . . . . . . . . . . . . . 18.4 t -87.22 35.67 0.71 Allowed 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.226 0.536 . . . . 52.119999999999997 110.212 178.425 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 154' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -74.68 -47.49 31.4 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.513 -0.767 . . . . 64.239999999999995 111.185 -178.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 123.08 36.6 0.65 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.868 -0.682 . . . . 24.109999999999999 111.97 -176.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 156' ' ' ASN . . . . . 0.401 ' OD1' ' HB3' ' B' ' 166' ' ' LEU . 6.8 t30 -119.73 126.75 51.84 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.974 0.416 . . . . 75.420000000000002 110.596 -178.322 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 157' ' ' PHE . . . . . 0.451 ' CD2' ' HG ' ' B' ' 147' ' ' LEU . 13.4 m-85 -109.97 164.0 13.02 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.196 -0.456 . . . . 71.409999999999997 110.487 179.541 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 158' ' ' ILE . . . . . . . . . . . . . 48.7 mm -121.79 109.22 24.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.789 -0.819 . . . . 73.329999999999998 108.789 173.128 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 159' ' ' ARG . . . . . 0.543 ' HE ' ' HB3' ' B' ' 161' ' ' ASP . 43.3 ttp180 -75.07 125.94 29.98 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 109.027 -0.731 . . . . 72.150000000000006 109.027 178.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 160' ' ' SER . . . . . 0.453 ' OG ' ' HG3' ' A' ' 63' ' ' PRO . 23.8 t -58.64 -22.06 55.55 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.187 0.518 . . . . 32.329999999999998 110.755 -178.75 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 161' ' ' ASP . . . . . 0.543 ' HB3' ' HE ' ' B' ' 159' ' ' ARG . 1.5 t70 -68.81 -30.24 68.76 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.797 -0.638 . . . . 73.400000000000006 111.104 175.547 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 162' ' ' GLN . . . . . 0.69 HE21 ' HA ' ' B' ' 162' ' ' GLN . 0.0 OUTLIER -140.95 81.34 16.31 Favored Pre-proline 0 C--N 1.325 -0.487 0 CA-C-N 116.271 -0.422 . . . . 71.140000000000001 110.409 -174.198 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 163' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.41 -8.67 17.36 Favored 'Trans proline' 0 C--N 1.343 0.264 0 C-N-CA 122.498 2.132 . . . . 72.150000000000006 112.318 -178.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 164' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -81.87 -21.52 37.45 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.665 -0.698 . . . . 62.039999999999999 110.502 178.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 19.1 ttmm -114.57 134.32 55.13 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.017 -0.538 . . . . 73.209999999999994 110.894 -175.006 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 166' ' ' LEU . . . . . 0.401 ' HB3' ' OD1' ' B' ' 156' ' ' ASN . 5.1 mp -82.98 129.31 35.02 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.22 -1.03 . . . . 75.400000000000006 108.22 171.449 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 167' ' ' ILE . . . . . . . . . . . . . 45.2 mm -87.84 110.31 34.05 Favored Pre-proline 0 C--N 1.321 -0.651 0 N-CA-C 110.177 -0.305 . . . . 63.409999999999997 110.177 -174.21 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 168' ' ' PRO . . . . . 0.49 ' O ' HG23 ' B' ' 172' ' ' ILE . 42.9 Cg_endo -66.57 172.89 8.59 Favored 'Trans proline' 0 N--CA 1.462 -0.332 0 C-N-CA 122.94 2.426 . . . . 73.239999999999995 112.768 -175.595 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 169' ' ' GLN . . . . . . . . . . . . . 5.1 tt0 -75.44 -5.44 45.01 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.304 -0.862 . . . . 62.240000000000002 111.665 -169.097 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 170' ' ' TRP . . . . . . . . . . . . . 6.5 p90 -96.04 -13.24 23.87 Favored 'General case' 0 C--N 1.325 -0.493 0 C-N-CA 120.495 -0.482 . . . . 71.530000000000001 110.73 176.471 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 171' ' ' GLU . . . . . 0.614 ' O ' ' HB2' ' B' ' 174' ' ' SER . 1.5 mm-40 -107.24 -9.61 16.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.988 0.423 . . . . 72.319999999999993 110.817 -178.386 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 172' ' ' ILE . . . . . 0.49 HG23 ' O ' ' B' ' 168' ' ' PRO . 47.9 pt -68.08 -19.15 24.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.423 0.63 . . . . 64.140000000000001 110.262 176.365 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 173' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -99.45 39.24 1.32 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.293 -0.867 . . . . 71.049999999999997 108.823 175.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 174' ' ' SER . . . . . 0.614 ' HB2' ' O ' ' B' ' 171' ' ' GLU . 1.7 t -72.84 -15.31 61.62 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.358 -0.837 . . . . 60.420000000000002 110.305 -178.375 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 175' ' ' TRP . . . . . . . . . . . . . 65.4 p-90 . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.817 -0.611 . . . . 71.299999999999997 109.371 174.38 . . . . . . . . 0 0 . 1 stop_ save_